,id,ticker,title,category,content,date,provider,url,article_id
148493,370009,AMGN,Amgen Stock Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  Stock fell by 3 42  to trade at  218 37 by 09 30  14 30 GMT  on Friday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 204 03K  Amgen has traded in a range of  218 04 to  219 00 on the day 
The stock has traded at  237 0600 at its highest and  218 2200 at its lowest during the past seven days ",2020-01-31,Investing.com,https://www.investing.com/news/stock-market-news/amgen-stock-falls-3-2073009,2073009
148502,370018,AMGN,Amgen s Shares Slip on Soft Guidance  Time to Buy ,news,"Yesterday  Amgen  NASDAQ AMGN   a blue chip biotech  reported fourth quarter earnings  Although the biotech heavyweight topped Wall Street s consensus estimates for its bottom and top lines during the three month period  investors apparently weren t impressed  Amgen s shares immediately dropped by 3 16  in after hours trading on the heels of this overall positive earnings report 
What s the deal  The sore spot seems to be Amgen s  soft  revenue guidance for 2020  Specifically  the company said it expects 2020 revenue to come in between  25 0 billion to  25 6 billion  implying year over year top line growth of 9 4  on the high end of the range  Wall Street s prior forecast pegged the biotech s 2020 revenue at approximately  25 5 billion  So  it s not as though Amgen is calling for 2020 to be a complete disaster 

Should bargain hunters take advantage of this rather questionable sell off  Let s consider Amgen s strengths and weaknesses to find out 
Amgen  The bull and bear case
What s the biggest knock against Amgen s bull case  The most pressing concern among investors seems to be the biotech s ongoing battle against generic and biosimilar competition  Amgen has continually had to drop the net selling price for several key legacy products due to this issue  In fact  the biotech warned investors during this latest earnings call that further price erosion is likely to occur again this year 
To offset this pricing headwind  Amgen is banking on a healthy rise in sales volume across its growth portfolio in 2020  Fortunately  this stated goal does seem feasible thanks to the  13 4 billion acquisition of psoriasis medication Otezla last year  along with the strong commercial performance of multiple growth oriented brands such as osteoporosis treatment Prolia and migraine drug Aimovig  among others  
There are two inter related issues that should concern shareholders  though  First of all  the biotech s cash position dropped from  29 3 billion to  8 9 billion year over year  mainly due to the costly Otezla transaction in 2019  Secondly  Amgen decided to plow  7 6 billion into share repurchases last year  It also has a whopping  6 5 billion remaining in authorized buybacks under the current plan  Amgen s aggressive capital allocation strategy is a tad concerning in light of the biotech s enormous debt load of almost  30 billion 
Amgen should have ample free cash flow to service this debt without issue in 2020  However  a global economic downturn    perhaps one triggered by a pandemic    could put the biotech in a bind at some point  Put bluntly  Amgen might want to rethink its capital allocation strategy given the potentially severe economic ramifications of the deadly coronavirus currently ravaging important emerging markets such as China    
Amgen s bull case  though  is arguably far more compelling than the bear thesis right now  Apart from its healthy top line growth prospects in 2020 and beyond  Amgen s stock is presently trading at a mere 12 98 times next year s projected earnings  That s not exactly bargain territory for a large cap biotech stock  but it s also a far cry from where other biopharmas  such as AstraZeneca and Eli Lilly  are trading at right now  Moreover  Amgen recently boosted its dividend by a noteworthy 10   bringing its forward looking annualized yield to a respectable 2 82   That s slightly above average for its immediate peer group  
Time to buy 
It s hard to go wrong owning Amgen s stock for the long haul  This large cap biotech stock has been one of the absolute best investing vehicles over the past 10 years  There s also no overarching reason to believe this trend won t continue for the next 10 years  Bargain hunters may indeed want to capitalize on the market s puzzling reaction to Amgen s fourth quarter results ",2020-01-31,The Motley Fool,https://invst.ly/ppi5e,2073128
148503,370019,AMGN,Stock Market News  Amazon s Amazing  Amgen Falls Short,news,"Investors have been worried about the coronavirus outbreak as it spreads in China and across the world  and Friday morning s stock market action clearly reflected rising levels of fear  As the number of cases moved toward the 10 000 mark  market participants increasingly believe that the outbreak won t simply die out the way similar diseases have in the past  As of 11 a m  EST  the Dow Jones Industrial Average  DJINDICES  DJI  was down 387 points to 28 473  The S P 500  SNPINDEX  GSPC  fell 37 points to 3 246  and the Nasdaq Composite  NASDAQINDEX  IXIC  was lower by 83 points at 9 215 
Even with health worries overhanging the market  not all of the news was bad  Amazon com  NASDAQ AMZN  soared after a strong earnings report  Yet in the biotech realm  Amgen  NASDAQ AMGN  wasn t able to satisfy investors even after what looked like solid results in its most recent quarter 
A prime day for Amazon shares
Amazon com saw its stock jump 9  after the e commerce and cloud computing giant reported its fourth quarter financial results  Investors were generally impressed with the numbers and with Amazon s outlook for the future 

Amazon saw sales jump 21  year over year  with particularly strong results in the North American side of the e commerce business as well as Amazon Web Services  Earnings gains of 7  were somewhat less impressive  but that partially reflected all the investment in building out one day delivery capabilities  The number of Prime members topped the 150 million mark  Subscription and third party seller services were also notably strong from a growth standpoint 
Investors even seemed satisfied with predictions for falling operating income in the near future  Much of the change is tied to accounting treatment of server related depreciation  which few shareholders really follow all that closely 
Today s move pushed Amazon s market cap back above the  1 trillion mark and was particularly impressive on a sharply lower day on Wall Street  Right now  Amazon seems to have all the momentum it needs to sustain growth for the foreseeable future 
Amgen predicts a tough 2020
Elsewhere  shares of Amgen were down 6  following its release of its fourth quarter financial report  Despite better than expected numbers  investors weren t excited about future prospects for the biotech giant 
Amgen s results were somewhat mixed  Revenue in the fourth quarter of 2019 fell 1   as biosimilar and generic competition ramped up against some of its key products  That capped a year in which the top line dropped 2   Yet despite higher operating expenses  adjusted earnings per share were up 6  compared to the year earlier period  buoyed by stock buybacks that lowered outstanding share counts 
Yet what shareholders really seemed not to like was Amgen s guidance  The company expects total revenue of  25 billion to  25 6 billion in 2020  with adjusted earnings of  14 85 to  15 60 per share 
The real question facing Amgen is whether recent major acquisitions will pay off with higher sales and profits  If so  then an attractive valuation could make the biotech stock seem like a steal at current levels  But if those strategic moves fail to bear fruit  then it could cause even more problems for Amgen shareholders in the future ",2020-01-31,The Motley Fool,https://invst.ly/ppj0m,2073194
148504,370020,AMGN,Amgen Is Making 3 Big Bets    Will They Pay Off for Investors ,news,"Amgen  NASDAQ AMGN  beat Wall Street s earnings estimate with its fourth quarter results  But the big biotech s 2020 outlook underwhelmed  Amgen expects to deliver modest earnings growth and return to revenue growth  but it wasn t enough to impress investors 
During Amgen s quarterly conference call on Thursday  the company s management talked about plans to move past what they called the  transition year  of 2019  a reference to the challenges the company faced with several of its older drugs facing biosimilar and generic competition  Their comments focused to a large extent on three big bets that Amgen is making to drive future growth  What are these bets    and will they pay off for investors  

1  Acquisitions
Amgen acquired Otezla a few months ago  thanks to regulators requiring Celgene to sell the blockbuster drug to pave the way for its acquisition by Bristol Myers Squibb  If there was any doubt about how important this purchase was for Amgen  they should be erased by the biotech s 2020 outlook  The company expects revenue for its base business to be flat year over year  Amgen s return to revenue growth will be driven by Otezla 
The addition of the immunology drug will help Amgen in other ways  too  CEO Bob Bradway said that the company s Humira biosimilar  Amgevita   will benefit from our recent acquisition of Otezla   He thinks that Otezla will help Amgen build its business in China and Japan  Murdo Gordon  Amgen s executive vice president of global commercial operations  said the company is also  excited about potential synergies between Otezla and Enbrel  
More acquisitions could be on the way  At the J P  Morgan Healthcare Conference earlier this year  Amgen s executives hinted that the company could be interested in bolstering its nephrology pipeline  Bradway confirmed in Amgen s Q4 call that the company isn t  investing in discovery research in nephrology right now  but we are going to look for business development opportunities there  
2  Asia Pacific ventures
Amgen has great expectations for the Asia Pacific region  Bradway stated   Over the next decade  we expect this region to account for as much as 25  of Amgen s growth   And the key to unlocking that potential growth is the biotech s partnerships 
Bradway said that over two thirds of its Asia Pacific growth in Q4 stemmed from its joint venture with Astellas Pharma  OTC ALPMY  in Japan  However  Amgen will buy 49  of the shares in this joint venture currently held by Astellas on April 1  2020  for what CFO Peter Griffeth called  a nominal fee   This transaction will make the joint venture a wholly owned subsidiary of Amgen 
While Japan is the third largest pharmaceutical market in the world  China is second only to the U S  Amgen s collaboration deal in China with BeiGene  NASDAQ BGNE  closed in early January  giving Amgen a 20 5  stake in the Chinese biotech  BeiGene will market three of Amgen s cancer drugs    Xgeva  Kyprolis  and Blincyto    in China and work together on other experimental cancer drugs in Amgen s pipeline  Bradway said that  we re excited by what our two companies can achieve together  
3  Pipeline
Probably the biggest and most important bet that Amgen is making is on its pipeline  Bradway highlighted several key pipeline updates on the way this year  including data readouts for AMG 510 in treating solid tumors  tezepelumab in asthma  omecamtiv in heart failure  and Otezla in mild to moderate psoriasis 
While all but the AMG 510 results will be from late stage clinical studies  it s probably fair to say that none of these pipeline updates will be game changers for Amgen  For example  with respect to omecamtiv  David Reese  Amgen s head of research and development  acknowledged that  the heart failure treatment landscape is expected to change based on recent data from other drug classes   a reference to FDA approval for AstraZeneca s Farxiga in reducing the risk of hospitalization for heart failure in type 2 diabetes patients 
But Amgen does have some potential game changers in its pipeline  namely its bispecific T cell engager  BiTE  drugs in development  Reese said that the company  remain s  enthusiastic about our BiTE platform  and 2020 will be an important year   He also mentioned that Amgen has seen  the sort of pharmacodynamic activity and early suggestions of anti tumor activity that are reminiscent of the early days of Blincyto and that give s  us encouragement that we re on the right track   Amgen expects to provide updates for several of its BiTE clinical studies this year  
Paying off 
Will Amgen s big bets pay off for investors  The answer seems to be a resounding  yes  when it comes to the company s purchase of Otezla  My view is that Amgen s deals to strengthen its position in the Asia Pacific region are also good investments 
The jury is still out on Amgen s pipeline  though  It s possible that the company s BiTE drugs will be big winners  but there s a real chance that they won t be nearly as successful as Amgen hopes they ll be 
My view is that Amgen continues to be a solid dividend stock  In fact  Peter Griffeth stressed that the company is  committed to returning capital to shareholders in the form of growing dividends   I m not as bullish about Amgen s growth prospects in the near term  however  I think some of the biotech s big bets need to begin paying off in a more significant way before Amgen will return to strong growth ",2020-02-02,The Motley Fool,https://invst.ly/pp-ly,2073853
148505,370021,AMGN,Amgen Stock Rises 3 ,news,"Investing com   Amgen  NASDAQ AMGN  Stock rose by 3 02  to trade at  223 28 by 14 01  19 01 GMT  on Tuesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 1 21M  Amgen has traded in a range of  220 58 to  223 28 on the day 
The stock has traded at  228 6700 at its highest and  210 0500 at its lowest during the past seven days ",2020-02-04,Investing.com,https://www.investing.com/news/stock-market-news/amgen-stock-rises-3-2075823,2075823
148506,370022,AMGN,Amgen Stock Rises 6 ,news,"Investing com   Amgen  NASDAQ AMGN  Stock rose by 5 52  to trade at  234 04 by 14 02  19 02 GMT  on Wednesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 2 28M  Amgen has traded in a range of  224 76 to  234 21 on the day 
The stock has traded at  234 2100 at its highest and  210 0500 at its lowest during the past seven days ",2020-02-05,Investing.com,https://www.investing.com/news/stock-market-news/amgen-stock-rises-6-2077097,2077097
148509,370025,AMGN,Why Amgen Stock Dropped 10 4  in January,news,"What happened
Shares of Amgen  NASDAQ AMGN  fell 10 4  in January  according to data provided by S P Global Market Intelligence  after the stock rose 24  last year and reached an all time high in December 
This isn t simply a case of locking in profits  Investors may be concerned about a slowdown at the biotech giant as older drugs lose patent protection  In the third quarter presentation in October  Amgen reported declines in sales of bone marrow stimulants Neulasta and Neupogen  citing biosimilar competition  Both drugs help the body make white blood cells after cancer treatments 
Biosimilars are highly similar to an already approved biological treatment  Sales of Neulasta fell 32  in the quarter to  711 million  while Neupogen declined 36  to  54 million  Just a year earlier  quarterly revenue of Neulasta topped  1 billion 

While brighter news such as a 10  increase in the 2020 first quarter dividend and a Food and Drug Administration approval for Amgen s fourth biosimilar buoyed the shares late last year  as fourth quarter and full year earnings approached  some investors decided to lock in profits in anticipation of a further slowdown in the company s older products 
So what
Biotechs such as Amgen that have been around for years and have stellar revenue and profit thanks to blockbuster drugs are seeing many of those older drugs come off patent  That opens the door to competition  which weighs on profits from the original drug  Investors could count on Amgen  with more than 20 marketed products and annual sales topping  22 billion for the past four years 
Now what
Future growth at Amgen will depend its ability to replace yesterday s blockbuster with newer drugs  and whether it can introduce biosimilars to other successful drugs  And the need to expand through partnerships is also important 
In its fourth quarter earnings report  the company gave an update on AMG 510  its investigational cancer treatment  Data from a potentially pivotal Phase 2 monotherapy study in advanced non small cell lung cancer is expected this year 
Amgen recently submitted a biologics license application to the FDA for a biosimilar version of Rituxan  Biogen s  NASDAQ BIIB  and Genentech s cancer drug  And it just recently began its collaboration with BeiGene  NASDAQ BGNE  to increase its oncology presence in China  Will it be enough to lift shares meaningfully  We might have to wait for Amgen s next earnings report to find out ",2020-02-05,The Motley Fool,https://invst.ly/prn2j,2077362
148513,370029,AMGN,Is Amgen a Stock to Buy ,news,"Revenue growth is slowing at biotech giant Amgen  NASDAQ AMGN   and yet the shares are trading near a record high  The share price is a reflection of years of revenue  profit  and a portfolio of more than 20 products  In the world of biotech  where many companies are still in the clinical or pre clinical stage and any revenue source is years down the road  there is value in a portfolio the size of Amgen s  The biotech company has also steadily increased its dividend since 2011  And investors are clearly paying for that  But now the question is  Can the stock move higher from here 
Amgen focuses on diseases that affect large portions of the population  such as asthma  rheumatoid arthritis  and cardiovascular disease  to name a few  The company has about 45 drug candidates in clinical trials  and nearly half of them are in phase 3 studies  Amgen is also working in the up and coming area of biosimilars  or drugs that are highly similar to an already approved biological treatment  Amgen has four approved biosimilars and others in the pipeline 

Profitable for years
From a financial perspective  Amgen has been profitable for years  with blockbuster drugs Neulasta  a bone marrow stimulant for cancer patients  and Enbrel  approved for rheumatoid arthritis among other conditions  driving growth  Amgen won a patent case regarding Enbrel last year  although Sandoz  a company of Novartis  vowed to appeal the decision in order to bring its biosimilar to patients  In spite of that victory  competition has started to threaten some of the company s drugs  and that is showing in the latest earnings reports 
Though Amgen s adjusted earnings per share  that is  not using generally accepted accounting principles  increased 6  in the fourth quarter to  3 64  surpassing analysts  estimates  quarterly revenue has gone down on a year over year basis each of the past three quarters  As a result  the company reported a 1  decrease in revenue for the fourth quarter and a 2  decline for the year to  23 4 billion  Product sales fell 1  for the year  Neulasta  which used to generate more than  1 billion in a quarter  saw quarterly revenue fall to  665 million in this most recent earnings report  Sales of Neulasta slid 43   while sales of Neupogen  a second bone marrow stimulant  fell 17   Amgen cited competition as a reason for the declines in both drugs  Since the drugs came off patent in recent years  the U S  Food and Drug Administration has approved competing products such as Pfizer s Nivestym  a Neupogen biosimilar  and Coherus Biosciences  Udenyca  a Neulasta biosimilar  which have cut into revenue 
When a billion dollar drug no longer brings in billions
Now the question is how to boost revenue when a billion dollar drug no longer brings in billions  Though the obvious answer seems to be  through newer drugs   there is the possibility that the new products won t be as successful as older ones  As mentioned earlier  Amgen has a full pipeline  and the company expects data from various studies this year  including results from a phase 3 trial of heart failure drug omecamtiv mecarbil in the fourth quarter of this year  GlobalData expects the heart failure market to represent  16 1 billion by 2026  Though Amgen s executive vice president of research and development  David M  Reese  said during the earnings call that the heart failure treatment landscape is changing based on data from other drug classes  he considers there is still plenty of unmet need to be addressed 
In addition to clinical stage drugs  Amgen is also seeking to expand the use of already marketed drugs  like psoriasis treatment Otezla  The company expects an FDA decision on the expansion of prescribing information to include data from a scalp psoriasis study in April  Though Otezla only represented 3  of total product sales in the quarter  the psoriasis market isn t negligible  The global psoriasis market is expected to reach  46 6 billion by 2022  according to a report by The Business Research Company 
Another important step Amgen has taken is in the area of partnerships  and its recent one in China  a large and growing oncology market  is encouraging  The company announced late last year that it would collaborate with BeiGene to increase its oncology presence in China  and the two companies recently launched their work together  As part of the deal  BeiGene will commercialize three of Amgen s cancer drugs in China and the two companies will equally share profits and losses  The companies will also advance 20 of Amgen s oncology drug candidates globally  The agreement also involved Amgen taking a 20 5  stake in BeiGene  The oncology drug market in China  growing at a compound annual growth rate of 8 7   is expected to reach  12 7 billion by 2026  according to Allied Market Research 
Is Amgen a stock to buy 
Amgen shares are close to their highest ever  and Wall Street sees 6  upside from here  At the same time  the shares trade at about 18 times earnings  while peers such as Sanofi and Novo Nordisk each trade at about 26  Though Amgen shares may not gain in leaps and bounds  for a long term investor who wants a solid dividend paying stock  Amgen makes a good addition to a biotech portfolio  The company s efforts in the pipeline and partnerships indicate that the current earnings slowdown is transient  and as for dividends  the 2019 total dividend was  5 80 a share  for a yield around 3  with a well supported payout ratio around 45   The stock lost 10  in January  offering investors a decent entry point for shares they will want to hold on to for a long while ",2020-02-08,The Motley Fool,https://invst.ly/psre4,2079826
148522,370038,AMGN,Teva s Two Pivotal Studies On Ajovy In Japan Meet Goal,opinion,Teva Pharmaceutical Industries Limited   NYSE TEVA   announced positive results from two phase II III studies on its new migraine drug Ajovy in patients with chronic and episodic migraines in Japan The company has an exclusive license agreement with Otsuka for the development and sales of Ajovy in Japan  The medicine is being developed by Otsuka in the country Preliminary data from the studies showed that the primary endpoints were achieved with both clinical and statistical significance compared to placebo  The studies also met all the secondary endpoints by demonstrating statistically significant improvements compared to placebo Detailed results from the study will be presented at the upcoming medical conference Otsuka Teva will file regulatory applications seeking approval of Ajovy in Japan based on data from these studies Shares of Teva were up 7 2  following the above favorable news on Monday  However  the stock has declined 44 1  in the past year compared with the  decrease of 6 2  Ajovy for the prevention of chronic episodic migraine was approved by the FDA in September 2018 and in the EU in April 2019  The drug is the first and the only anti CGRP medicine offering both quarterly and monthly dosing options  In the first nine months of 2019  Ajovy recorded sales of  68 million Last week  the FDA approved an autoinjector device for Ajovy injection  which is expected to be available to patients in the coming months  During the third quarter conference call held last November  management informed that Ajovy saw a decline in new prescription shares  which was due to patients  preference for auto injectors while Ajovy is available as a subcutaneous injection  The approval for the autoinjector device for Ajovy could reignite growth for the drug in 2020 However  Ajovy faces intense competition from Amgen   NASDAQ AMGN     Novartis   NYSE NVS   and Lilly s   NYSE LLY   respective CGRPs of Aimovig and Emgality  Both were approved by the FDA in mid 2018  Both are also approved in the EU Zacks Rank Teva currently carries a zacks Rank  3  Hold   You can see  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 7  per year  So be sure to give these hand picked 7 your immediate attention ,2020-02-03,Zacks Investment Research,https://www.investing.com/analysis/tevas-two-pivotal-studies-on-ajovy-in-japan-meet-goal-200504459,200504459
148523,370039,AMGN,QIAGEN Launches CE Marked Breast Cancer Test Kit In Europe,opinion,"QIAGEN N V    NYSE QGEN   announced the receipt of CE Mark for its therascreen PIK3CA  phosphatidylinositol3 kinase catalytic subunit alpha  Rotor Gene Q  RGQ  PCR Kit and its subsequent Europe launch  The move is aimed to help detect breast cancer patients with a PIK3CA mutation  The test is the latest diagnostic assay for the detection of activating mutations in the PIK3CA gene Per the company  the therascreen PIK3CA is the first to enable testing of DNA from FFPE tissue or plasma specimens  Currently  all therascreen PIK3CA tests from the company are based on QIAGEN s global co exclusive license from Johns Hopkins University  The license is for PCR based companion diagnostics based on detection of mutations in the PIK3CA gene Notably  the therascreen PIK3CA test received FDA s clearance in 2019  It was launched as a companion diagnostic test for PIQRAY  alpelisib  in the United States  The therapy is developed and marketed by Novartis With the latest regulatory clearance and subsequent launch  QIAGEN aims to consolidate its position in the Molecular Diagnostics business on global scale 
 Significance of the Approval and LaunchPer current estimates  probability of developing breast cancer before the age of 85 is much higher  which makes it the most common type of cancer in women  Given the scenario  the company believes that expanding its therascreen portfolio of companion diagnostics  with the help of the PIK3CA Kit  will be an appropriate option for countering the advanced form of the disease Notably  the company is working toward making the test available in Europe s leading laboratories to realize its market potential Industry ProspectsPer a report by   the global molecular diagnostics market size was approximately  9 9 billion in 2018 and is expected to expand at a CAGR of 9 1  between 2019 and 2026  Technological advancements in molecular diagnostics is expected to be the primary driver behind the market s growth Given the market potential  the regulatory clearance and the subsequent launch is well timed Recent DevelopmentsOf late  QIAGEN is winning the headlines with a spree of developments across its business arms In January 2020  the company launched QIAGEN Clinical Insights  QCI  Precision Insights in Europe  with the inclusion of the European Society for Medical Oncology  ESMO  guidelines and European Medicines Agency  EMA  approved oncology drugs catalogue  Further  the company announced entering into a collaboration with Amgen  NASDAQ AMGN  to develop tissue based therascreen test  paired with investigational treatment AMG 510  to identify patients whose cancer have KRAS G12C mutation In November 2019  QIAGEN along with biotechnology major DiaSorin announced the commercial launch of QuantiFERON TB Gold Plus  QFT Plus  on DiaSorin s LIAISON platforms in the United States  following FDA clearance  The LIAISON QFT Plus Test developed by QIAGEN and DiaSorin will offer streamlined laboratory automation for latent tuberculosis  TB  screening In the same moth  QIAGEN inked an agreement with LabCorp to extend their existing QIAGEN Clinical Insights  QCI  license  It also announced an expansion of its QIAseq next generation sequencing  NGS  portfolio to offer a one day workflow for simultaneous preparation of DNA and RNA libraries using NGS technologies Price PerformanceShares of QIAGEN have dropped 5 2  in the past year compared with the  s 0 1  decline Zacks Rank   Key PicksCurrently  the company carries a Zacks Rank  4  Sell  Some better ranked stocks from the broader medical space are Perrigo Company plc   NYSE PRGO    Hill Rom Holdings  Inc    NYSE HRC   and Myomo  Inc    NYSE MYO    each currently carrying a Zacks Rank  2  Buy   You can see Perrigo Company has a projected long term earnings growth rate of 2  Hill Rom s long term earnings growth rate is estimated at 11 1  Myomo s long term earnings growth rate is estimated at 25  More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ",2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/qiagen-launches-cemarked-breast-cancer-test-kit-in-europe-200505413,200505413
148524,370040,AMGN,Sanofi  SNY  Q4 Earnings Top  Sales Miss  Dupixent Strong,opinion,"Sanofi  PA SASY    NASDAQ SNY   reported fourth quarter 2019 earnings of 74 cents per American depositary share  which beat the Zacks Consensus Estimate of 70 cents  Earnings increased 21 8  on a reported basis  At constant currency rates  CER   earnings rose 17 3  driven by higher revenues and lower costs Fourth quarter net sales of the French pharma giant rose 6 8  on a reported basis to  10 66 billion   9 6 billion   Exchange rate movements benefited sales by 2 1  driven by a strong dollar and Japanese yen  At CER  sales increased 4 7  year over year  Sales however missed the Zacks Consensus Estimate of  11 12 billion       Sales rose 11 8  at CER in the United States and 1 8  in the Emerging Markets  Sales were flat in Europe at CER but rose 0 6  in the Rest of the World  Japan  South Korea  Canada  Australia  New Zealand and Puerto Rico  All growth rates mentioned below are on a year on year basis and at CER Segmental PerformanceSanofi reports through five Global Business Units  GBUs    Sanofi Genzyme  Specialty Care   Primary Care  China   Emerging Markets  Consumer Healthcare and Vaccines At its Capital Markets Day held in December 2019  Sanofi announced plans to restructure the company s operations under three GBUs   Specialty Care  immunology  rare diseases  rare blood disorders  neurology and oncology   Vaccines and General Medicines  diabetes  cardiovascular  and established products   The company s Consumer Healthcare  CHC  will operate as a standalone business unit Pharmaceuticals sales  including the emerging markets  rose 2 4  in the fourth quarter to  6 55 billion driven by key eczema drug  Dupixent  which was partially offset by lower Diabetes and Established Rx products sales Sanofi Genzyme Specialty Care GBU sales  excluding the emerging markets  increased 19 7  to  2 53 billion  driven by Dupixent In the immunology franchise  Dupixent generated sales of  668 million in the quarter  up 133 1   Sales of the drug in the United States were  545 million  up 134 7  driven by continued growth in atopic dermatitis and rapid uptake in new asthma indication and launch in chronic rhinosinusitis with nasal polyposis in June 2019  Sales in Europe were  64 million  up 117 2  Kevzara recorded sales of  53 million in the quarter  up 64 5   Sanofi markets Dupixent and Kevzara in partnership with Regeneron Pharmaceuticals   NASDAQ REGN   Sales of rare disease drugs increased 0 8  to  661 million  Myozyme Lumizyme rose 2 1  to  197 million  Fabrazyme sales were  186 million  up 0 6   Cerezyme sales declined 6 3  to  121 million Oncology sales increased 12 6  to  333 million  Key cancer drug Jevtana s sales were up 10 1  to  123 million supported by higher sales in the United States Sales of multiple sclerosis drugs declined 3 8  to  517 million  Aubagio sales increased 3 9  to  465 million while sales of Lemtrada fell 42 5  to  52 million Rare blood disorders franchise  added to Sanofi s portfolio with the acquisition of Bioverativ in 2018  fetched sales of  293 million  down 2 4  year over year  New drug Cablivi  caplacizumab  generated sales of  16 million in the quarter  lower than  20 million in the previous quarter  primarily due to price adjustments in Europe and increased assistance program participation in the United States  Sales of another drug in the franchise  Eloctate declined 14 9  in the quarter due to the ongoing competitive pressure in the United States Primary Care GBU comprises the Diabetes and Cardiovascular and the Established Rx Products segments  Sales in the Primary Care GBU declined 8 7  to  2 33 billion hurt by lower sales in Diabetes and Established Products The Diabetes franchise  excluding the emerging markets  declined 15 5  to  861 million due to lower sales of key drugs   Lantus and Toujeo Sales of diabetes drugs in the United States declined 20 5  to  454 million due to pricing pressure and loss of Part D business  In Europe  it dropped 4 4  and in rest of the world  it declined 21 8  Lantus sales decreased 23 9  to  485 million in the quarter  Lantus sales plunged 26 9  in the United States due to lower average net price and change in coverage with respect to Sanofi s Part D business  In Europe  sales decreased 13 1  due to biosimilar competition and patient switching to Toujeo Toujeo generated sales of  186 million in the reported quarter  up 1 7   Sales rose 14 3  in Europe while it declined 7 4  in the United States Admelog  a rapid acting insulin  similar to Lilly s   NYSE LLY   Humalog  achieved sales worth  56  down 1 8  year over year In the cardiovascular franchise  Sanofi s anti PCSK9 therapy  Praluent  garnered worldwide sales of  68 million in the reported quarter  down 14 1   Sales in the United States declined due to significantly higher rebates offered by Sanofi and partner Regeneron to payers to improve access to the drug  Amgen   NASDAQ AMGN   is also facing similar issues with its PCSK9 inhibitor  Repatha  Sales of the other drug  Multaq  in this franchise rose 1 1  to  97 million Sales of Established Rx Products came in at  1 3 billion  down 4  mainly due to lower sales of Plavix and Aprovel in China due to anticipated price and inventory adjustments in the channel  Meanwhile  lower sales of Lovenox in Europe and generic competition for Renvela Renagel in the United Sales also hurt segment sales China and Emerging Markets GBU declined 1 9  to  1 7 billion Consumer Healthcare  CHC  GBU  including the emerging markets  sales were  1 15 billion  down 5 2  as higher sales in Emerging Markets were offset by lower sales in the United States and Europe  Sales declined 12 8  in the United States due to Sanofi s voluntary recall of its over the counter acid reflux medicine Zantac  which is sold by the generic name of ranitidine by many other companies Meanwhile  non core divestments and increased regulatory requirements  which resulted in product suspensions  also hurt the performance of the CHC segment Sanofi Pasteur  Vaccines  sales  including the emerging markets  rose 22  to  1 91 billion  U S  sales of vaccines rose 33 1  in the quarter  reflecting the majority of U S  influenza vaccine shipments in the fourth quarter  Sales also rose in Emerging Markets and Europe Costs DeclineSelling  general and administrative expenses declined 1 4  at CER in the quarter  reflecting cost control measures  Research and development expenses declined 0 7  at CER due to smart spending initiatives as well as portfolio prioritization 2020 GuidanceSanofi expects earnings to grow approximately 5  at CER in 2020  It now anticipates a positive currency impact of around 1  on earnings Our TakeFor the second quarter in a row  Sanofi s results were mixed as it beat estimates for earnings but missed the same for sales  Double digit growth in Specialty Care and Vaccines was offset by persistent sluggishness in Diabetes and Cardiovascular franchises and a weak performance in the CHC unit in the quarter  Its 2020 earnings outlook looked encouraging  Shares were up 3 4  in pre market trading on Thursday  Sanofi s shares have outperformed the industry in the past year  It has risen 13 1  in the said time frame compared with the  s increase of 11 9    Sanofi s Specialty Care segment is on a strong footing particularly with regular label expansion of Dupixent  The drug has  in a very short time  become the key top line driver for Sanofi  Importantly  Sanofi is discontinuing all its research activities in diabetes and cardiovascular area and will prioritize key growth drivers   Dupixent and vaccines  However  weak performance of the Diabetes unit  generic competition for many drugs and slower than expected uptake of core products like Praluent are headwinds Zacks Rank Sanofi currently carries a Zacks Rank  2  Buy   You can  Sanofi Price  Consensus and EPS Surprise
    
More Stock News  This Is Bigger than the iPhone                    It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ",2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/sanofi-sny-q4-earnings-top-sales-miss-dupixent-strong-200505300,200505300
148525,370041,AMGN,Bristol Myers   BMY  Q4 Earnings   Revenues Beat Estimates,opinion,"Bristol Myers Squibb Company   NYSE BMY   reported better than expected results for the fourth quarter of 2019 on stellar performance of its blood thinner drug  Eliquis  and addition of sales from Celgene s drugs  The numbers included Celgene s results  following its acquisition on Nov 20 
Shares were up 2 9  in pre market trading  following the earnings release  Bristol Myers  shares have increased 31 1  in the past year compared with the  s rise of 12 7  

 
Fourth quarter 2019 earnings of  1 22 per share easily beat the Zacks Consensus Estimate of 88 cents and increased from the year ago quarter s earnings of 94 cents 
Total revenues of  7 95 billion comprehensively beat the Zacks Consensus Estimate of  6 14 billion and increased 33  from  5 97 billion in the year ago period  Strong growth was mainly driven by addition of Celgene s products 
Full Year Results
Bristol Myers  adjusted earnings per share were  4 69 per share for the full year  up 18   Full year revenues rose 16  to approximately  26 1 billion 
Quarterly Details
Revenues were up 34  year over year when adjusted for foreign exchange impact  Revenues increased 42  to  4 8 billion in the United States and 21  outside the country  Ex U S  revenues were up 23  when adjusted for foreign exchange impact 
Eliquis witnessed strong growth and was the top revenue generator for the company yet again  Sales of the drug rose 19  to  2 billion  We note that Bristol Myers has a collaboration agreement with Pfizer   NYSE PFE   for Eliquis  Sales of Opdivo  which is approved for multiple cancer indications  were down 2  year over year to  1 76 billion  While sales of Eliquis rose 18   Opdivo sales were down 10  in the United States 
Leukemia drug  Sprycel  raked in sales of  549 million  up 2  year over year  Sales of rheumatoid arthritis drug  Orencia were up 8  to  792 million  Melanoma drug  Yervoy  contributed  385 million to the top line  flat year over year 
Multiple myeloma drug  Empliciti  recorded sales of  94 million  up 36  year over year 
The performance of key drugs in the Virology unit were disappointing  Sales of Baraclude declined 26  to  122 million  Sales of other brands  including Sustiva  Reyataz  Daklinza and all other products that have lost exclusivity in major markets  fell 39  year over year to  356 million 
Myeloma drug  Revlimid  added with Celgene s acquisition contributed  1 3 billion to the top line  Other key drugs from Celgene   Pomalyst and Abraxane   generated sales of  322 million and  166 million  respectively 
Adjusted research and development  R D  expenses in the quarter were up 44 4  to  1 96 billion  Adjusted marketing  selling and administrative expenses increased 27 3  to  1 7 billion 
Gross margin was 68 6  in the quarter compared with 72  in the year ago quarter 
Celgene Acquisition Update
In November  Bristol Myers completed the previously announced acquisition of biotech bigwig Celgene Corporation  NASDAQ CELG  for a whopping  74 billion  The acquisition added blockbuster oncology drug  Revlimid to Bristol Myers portfolio  Bristol Myers owns approximately 69  of the combined entity  while Celgene shareholders own approximately 31  
In November  Celgene sold its global rights to psoriasis drug  Otezla  to Amgen   NASDAQ AMGN   in connection with the regulatory approval process for Celgene s acquisition by Bristol Myers 
Pipeline Update
Bristol Myers recently withdrew its application in the European Union   EU   for the combination of Opdivo and Yervoy for the treatment of advanced non small cell lung cancer   NSCLC   based on data from CheckMate 227 
Though the Committee for Medicinal Products for Human Use acknowledged the integrity of the patient data  it determined that a full assessment of the application was not possible following the multiple protocol changes the company made in response to the rapidly evolving science and data  Consequently  Bristol Myers has no plans to resubmit this application in the EU 
In January 2020  the FDA granted a Priority Review status to the Opdivo Yervoy combination for the treatment of first line NSCLC 
The FDA accepted the supplemental Biologics License Application  sBLA  and granted Breakthrough Therapy designation to the combination for the treatment of patients with advanced hepatocellular carcinoma   HCC   previously treated with sorafenib  The FDA granted a Priority Review to the application  with a Prescription Drug User Fee Act   PDUFA   goal date of Mar 10  2020 
2020 Guidance
Bristol Myers provided guidance for revenues and adjusted earnings in 2020  The company projects earnings of  6 00  6 20 per share  The company expects revenues for 2020 in the range of  40 5 billion  42 5 billion  The Zacks Consensus Estimate for revenues and earnings is pegged at  42 11 billion and  6 04 per share  respectively 
The company expects adjusted earnings per share in 2021 to be between  7 15 and  7 45 
Our Take
Bristol Myers  performance in the fourth quarter was encouraging  Earnings and sales beat estimates primarily on addition of Celgene s drugs to its portfolio  However  weak growth in Opdivo sales is a concern  Withdrawal of regulatory application seeking label expansion of Opdivo as first line treatment for advanced NSCLC in Europe is also discouraging 
Potential approval for Opdivo s label expansion to include HCC patients and first line metastatic or recurrent NSCLC patients with no EGFR or ALK genomic tumor aberrations will likely boost sales of the drug  The drug faces stiff competition from Merck s   NYSE MRK   Keytruda and Roche s Tecentriq 
The acquisition of Celgene holds promise as it boosted Bristol Myers  oncology franchise and added diverse pipeline in the therapeutic areas of inflammatory  immunologic and cardiovascular diseases  Moreover  the deal is expected to be 40  accretive to the bottom line on a standalone basis in 2020  Bristol Myers expects to realize cost synergies of approximately  2 5 billion by 2022 Bristol Myers Squibb Company Price  Consensus and EPS Surprise
 

    
Zacks Rank
Bristol Myers currently carries a Zacks Rank  3  Hold   You can see  
More Stock News  This Is Bigger than the iPhone 
It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market 
Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ",2020-02-06,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-bmy-q4-earnings--revenues-beat-estimates-200505453,200505453
148526,370042,AMGN,Ligand  LGND  Q4 Earnings   Revenues Top Estimates  Stock Up,opinion,"Ligand Pharmaceuticals Incorporated   NASDAQ LGND   reported fourth quarter 2019 adjusted earnings of 71 cents per share  which beat the Zacks Consensus Estimate of 68 cents  The company had reported adjusted earnings of  1 70 in the year ago quarter  Fourth quarter adjusted earnings exclude the impact of non cash charge of  8 5 million related to Ligand s investment in Viking Therapeutics  stock based compensation and non cash charges Total revenues decreased to  27 million from  59 6 million in the year ago quarter mainly due to lower royalty revenues  However  the top line surpassed the Zacks Consensus Estimate of  24 9 million Shares of Ligand were up 2 4  in after hours trading on Feb 6  following the earnings release  The company s shares have declined 20 7  in the past year compared with the  s 0 1  decrease Quarterly HighlightsRoyalty revenues were  11 million in the fourth quarter compared with  40 2 million in the year ago quarter  Ligand primarily earns royalties on sales of Amgen s   NASDAQ AMGN   Kyprolis and CASI Pharmaceuticals    NASDAQ CASI   Evomela  which were developed using its Captisol technology  The significant decline in royalty revenues was due to loss of royalties from sales of Novartis    NYSE NVS   blockbuster drug  Promacta  In March 2019  Ligand sold Promacta rights  including royalty rights to worldwide net sales  to privately held Royalty Pharma for  827 million Please note that excluding Promacta royalties recorded in the year ago quarter  royalty revenues increased year over year in the fourth quarter License fees  milestones and other revenues were  8 8 million in the fourth quarter compared with  9 3 million a year ago  Material sales were  7 1 million  down 29 7  Full Year ResultsLigand s adjusted earnings per share were  3 09 per share for the full year compared with  7 15 per share in 2018  Full  year revenues declined 52 2  to approximately  120 3 billion Business DevelopmentsIn 2019  Ligand entered into nine agreements related to its OmniAb technology platform  Moreover  12 OmniAb based partnered drugs are in pivotal stage of development  Currently  the company has 13 approved partnered drugs developed using its Captisol technology  generating royalties for the company The company entered into worldwide OmniAb license agreement with privately held Pandion Therapeutics last month  In December 2019  it entered into another license agreement with France based pharma giant  Sanofi  PA SASY   related to use of OmniAb technology platform 2020 Guidance Ligand provided guidance for its sales and earnings for 2020  The company expects total revenues and earnings for 2020to be approximately  121 million and  3 40  indicating organic growth of 14  and 35   respectively  The Zacks Consensus Estimate for revenues and earnings is pegged at  118 59 million and  3 25 per share  respectively Guidance for total revenues includes approximately  38 million in royalties  approximately  35 million from material sales and license fees and milestones of approximately  48 million Ligand Pharmaceuticals Incorporated Price  Consensus and EPS Surprise
    Zacks RankLigand currently carries a Zacks Rank  5  Strong Sell  You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 7  per year These 7 were selected because of their superior potential for immediate breakout ",2020-02-06,Zacks Investment Research,https://www.investing.com/analysis/ligand-lgnd-q4-earnings--revenues-top-estimates-stock-up-200505727,200505727
148527,370043,AMGN,Top Stock Research Reports For Alphabet  Roche   Amgen,opinion,"Friday  February 7  2020The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Alphabet  NASDAQ GOOGL   GOOGL   Roche Holding  SIX ROG   RHHBY  and Amgen  AMGN   These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Alphabet s shares have outperformed the Zacks Internet Services industry in the past six months   21 8  vs   16 3    The Zacks analyst believes that Google s strong focus on innovation of AI techniques and the home automation space should aid business growth in the long term Alphabet reported weak fourth quarter earnings due to declining search advertising growth and lower than expected YouTube sales  Also  heavy investment in cloud computing and hardware businesses negatively impacted the results  However  Google s robust mobile search is a positive Notably  it has agreed to acquire Fitbit for roughly  2 1 billion  This deal will likely help the company to accelerate innovation in the wearables category  However  the company s growing expenses  litigation issues and competition might hurt profitability   You can  Shares of Roche have gained  28 7  over the past year against the Zacks Large Cap Pharmaceuticals industry s rise of  13 5   The Zacks analyst believes that Roche s dominant position in the breast cancer space continues to boost performance on label expansion of drugs Roche s performance in 2019 was impressive  propelled by solid sales of new drugs  Strong growth of Ocrevus  Perjeta  Tecentriq and Hemlibra countered biosimilar competition for Herceptin  MabThera and Avastin  Particularly  MS drug Ocrevus witnessed strong growth on increased demand Also  label expansion of blockbuster immune oncology drug Tecentriq into additional indications is a positive  The recent Spark acquisition will boost Roche s presence in the gene therapy space as well  However  most of the legacy drugs are facing biosimilar competition  Additionally  pipeline setbacks are concerns as well  You can  Amgen s shares have gained  9 9  over the past three months against the Zacks Biomedical and Genetics industry s rise of  4 7   The Zacks analyst believes that while Amgen s growth products like Prolia  Evenity  Repatha  Aimovig  Otezla and biosimilars will drive sales  increasing competition for its legacy products will continue to hurt the same this year Amgen boasts of a strong biosimilars portfolio  which can drive long term growth  Amgen is also progressing with its pipeline while regularly pursuing  external opportunities  such as the acquisition of Otezla and the recently acquired stake in China s BeiGene Amgen also expects several important clinical data readouts from its innovative pipeline in 2020  However  pricing and competitive pressure are concerns  You can  Other noteworthy reports we are featuring today include General Electric  GE   Sony  SNE  and Biogen  BIIB  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 7  per year These 7 were selected because of their superior potential for immediate breakout Sheraz MianDirector of ResearchNote  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Alphabet  GOOGL  Rides on Strong Mobile  Higher Expenses Ail


New Drugs Boost Roche  RHHBY  Amid Biosimilar Competition


Amgen  AMGN  Counts on Growth Drugs Amid Biosimilar Woes


Featured Reports
Restructuring Actions to Aid General Electric  GE   Tariff Woes Drag
Per a Zacks analyst  General Electric  GE  is poised to gain from its portfolio restructuring actions  aiming expansion in Power  Aviation and Renewable Energy segments 

Sony  SNE  Rides on Strong Financial Services and I SS Unit
Per the Zacks analyst  significant rise in revenues at Sony Life  coupled with growth in Imaging   Sensing Solutions  I SS  segment led by sales of image sensors for mobile products  is aiding Sony 

Biogen s  BIIB  Key Drugs Drive Sales Amid Stiff Competition
While Biogen s multiple sclerosis  MS  drug Tecfidera and spinal muscular atrophy  SMA  drug Spinraza are driving sales  competitive pressure is expected to rise in 2020 in both MS and SMA markets 

Diverse Revenue Mix Aids Moody s  MCO   Elevated Costs a Woe
Per the Zacks analyst  Moody s is poised for growth given its diverse revenue mix and low risk product portfolio 

Schlumberger  NYSE SLB  Gains From Robust Reservoir   Well Techs
Per the Zacks analyst  Schlumberger s attractive reservoir and well technologies help it to outperform its peers 

Solid Balance Sheet  Revenue Growth Aid MetLife  NYSE MET 
Per the Zacks analyst  the company s revenues have been increasing from sales growth  rise in premium  its strong capital position enables investment for long term growth 

Amid Choppy End Market  Global Presence Aid Eaton  NYSE ETN 
Per the Zacks analyst Eaton s presence in 175 countries widens its revenue base but weakness in end market conditions is expected to have an adverse impact on the company s organic revenue growth 

New Upgrades
Robust International Sales Aid Ralph Lauren s  NYSE RL  Revenues
Per the Zacks analyst  Ralph Lauren s top line gains from consistent strength in international markets  fueled by constant currency revenue growth of 5  and 5 4   respectively  in Europe and Asia 

Robust Product Portfolio   Deal Wins Aid Monolithic  MPWR 
Per the Zacks analyst  Monolithic is poised to gain from robust product portfolio  high demand for smart in car connectivity and infotainment systems  Also  design wins for high end servers bode well 

Sunoco  SUN  Grows on Extensive Fuel Distribution Operations
Per the Zacks analyst Sunoco is expected to generate stable cash flows from its lucrative motor fuel distribution business in the U S  wholesale market 

New Downgrades
Weak International Business   Cost Woes To Ail Ford  F 
Ebbing vehicle sales in the Middle East and China amid global slowdown are likely to hurt Ford s top line growth  The Zacks analyst is also worried of high costs related to new model launches 

Maintenance and Higher Input Costs Hurt LyondellBasell  LYB 
Per the Zacks analyst  planned maintenance activities will weigh on LyondellBasell s margins in 2020  It also faces headwind from elevated raw material and energy costs 

Unfavorable Pricing Impedes C H  Robinson s  CHRW  Growth
The Zacks Analyst is worried about the soft pricing across most transportation service lines  Deterioration in operating ratio due to tepid revenues is also concerning 
undefined undefined",2020-02-07,Zacks Investment Research,https://www.investing.com/analysis/top-stock-research-reports-for-alphabet-roche--amgen-200505830,200505830
148528,370044,AMGN,Stocks Jump On Feb  6  Setting Up For A Post Job Data Rip Higher,opinion,"S P 500  SPY  NYSE SPY  
Stocks jumped once again but seemed to hit a brick wall at 3 346 and managed to find support 3 341  on the S P 500 cash  It is creating what appears to be a bullish flag pattern that would suggest the index rises from its current levels  tomorrow 
I find it particularly interesting because other markets do not seem nearly as supportive of this increase  and I do not know what to make of it  But we have to follow the trends  and can t fight it  I guess  there is no other explanation 
Based on the pattern and its projection  it amounts to about a 1  increase to around 3 375  So we can all wait overnight and hold our breath as to what the next major move in the market is 






The nice thing about such a late write up is that we get a head start on tomorrow because the S P 500 futures are already breaking out of that pattern  as Japan trades higher by 25 bps  despite South Korea down 40 bps 







Tomorrow  of course  is the big job data and based on all of my extensive research  the number should be pretty healthy and likely better than expected  Jobless claims have fallen significantly on the 4 week moving average  and the ADP employment was much better than expected  Based on my math  which isn t always perfect  I came to a reading of around 320 000 jobs created in January  This number is a moving target  though  and nearly impossible to predict  because the numbers from previous months will be revised  I went through all most of the significant points in a video today  although I didn t go through my secret formula for my guesstimate  
Tesla  NASDAQ TSLA  






Tesla  NASDAQ TSLA  almost had an average day of trading  rising by just 2   But that doesn t tell the whole tale  because shares fell as low as  687 and traded as high as  795  Just a typical day of trading  with a more than  100 point trading range  Anyway  the stock seemed to find some support at the uptrend around  that s a plus 
Amgen  NASDAQ AMGN 
Another stock that has been trading all over the place is Amgen  NASDAQ AMGN   and this one seems almost impossible to figure out  The one thing that seems clear is that resistance appears to be at the upper downtrend  I think there is a good chance it trades down to  225 






Disney  DIS  
Disney seems like it is trending higher  and holding on to key support levels  but the stock doesn t seem to be acting the way we expected  The stock does have a nice double bottom in the chart  but I do not see any clear patterns or directions at this point  We are going to have to give this a few days to see how it settles out  or at least until we get some clear sense of direction 






Alpahbet  GOOGL 
It is nice to see that Alphabet  NASDAQ GOOGL  has started to come around after that post earnings drop  It looks like shares are consolidating and forming a symmetrical triangle  which could result in the stock breaking higher perhaps to  1 600  which is that level we have been looking to achieve for some time now  Free Article  






Microsoft  NASDAQ MSFT 






Finally  I have been seeing a lot of bullish betting ing Microsoft  NASDAQ MSFT  the last two days that suggests the stock still has much further to climb ",2020-02-07,Michael Kramer,https://www.investing.com/analysis/stocks-jump-on-feb-6-setting-up-for-a-post-job-data-rip-higher-200505553,200505553
148529,370045,AMGN,AbbVie s  ABBV  Q4 Earnings Beat  2020 View Solid  Stock Up,opinion,"AbbVie Inc    NYSE ABBV   reported earnings of  2 21 per share in the fourth quarter  marginally beating the Zacks Consensus Estimate of  2 20 as well as the company s guided range of  2 17  2 19  Earnings rose 16 3  year over year 
Meanwhile  the company s revenues of  8 70 billion matched the company s expectations and also came in line with the Zacks Consensus Estimate  Meanwhile  the top line improved 4 8  year over year 
Shares of AbbVie have gained 9 5  in the past year compared with the  rally of 13 6  

 
Quarter in Detail
Key drug Humira recorded sales increase of 0 5  on an operational basis with revenues from the same coming in at  4 92 billion  Sales in the United States climbed 9 8  to  3 97 billion  However  Humira sales in the ex U S  markets were down 25 4  on an operational basis and 27 3  on a reported basis to  948 million  International sales were severely affected by the launch of several direct biosimilar drugs in Europe by other pharma companies including Amgen  NASDAQ AMGN  Sandoz and Biogen  NASDAQ BIIB  
New immunology drugs Skyrizi and Rinvoq registered sales of  216 million and  33 million  respectively  In the previous quarter  Skyrizi and Rinvoq recorded sales of  91 million and  14 million  respectively 
While Skyrizi  risankizumab  was approved in the United States and Europe for plaque psoriasis in April 2019  Rinvoq  upadacitinib  won the FDA nod in August 2019 for moderate to severe rheumatoid arthritis  RA   Rinvoq was also approved in the EU during December 2019 
AbbVie s oncology hematology  including Imbruvica and Venclexta  sales surged 37 2  on an operational basis to  1 55 billion in the quarter  driven by strong growth of both Imbruvica and Venclexta 
Fourth quarter net revenues from Imbruvica were  1 3 billion  up 28 9  year over year  U S  sales of Imbruvica grossed  1 07 billion  up 28  from the year ago figure  International sales of the drug ascended 33 8  to  223 million  Notably  AbbVie shares international profits earned from Imbruvica with Johnson   Johnson   NYSE JNJ   
The company s leukemia drug Venclexta generated revenues of  251 million in the reported quarter  doubling year over year  AbbVie has partnership with Roche   OTC RHHBY   for Venclexta 
Other products that delivered an encouraging performance include Duodopa  which recorded revenue growth of 7 1  on an operational basis and 4 1   reportedly  While Creon generating sales only from U S  markets witnessed a revenue increase of 11 5  
Chronic hepatitis C virus products recognized sales worth  632 million  down 26 4  operationally year over year  Sales of Mavyret were  628 million  down 23 1  operationally 
Other drugs that recorded sales decline include Androgel  Kaletra and Sevoflurane  which fell 69 1   35 3  and 3 6   respectively  on operational basis during the quarter  Moreover  sales of Synthroid dipped 2 2   Synagis and Lupron sales decreased 1 2  and 6 6  each on an operational basis during the quarter 
Adjusted SG A expenses increased 5 5  to  1 9 billion while R D expenses were  1 33 billion in the fourth quarter  sliding 0 7  year over year  Adjusted operating margin represented 44 6  of sales 
Closing in on Allergan Acquisition
AbbVie is set to acquire Botox maker Allergan   NYSE AGN   in a cash and stock deal of  63 billion  Subject to necessary approvals  the deal is expected to close in the first quarter of 2020  Last month  Allergan and AbbVie announced a definitive agreement to divest the mid stage candidate  and marketed medicine Zenpep to AstraZeneca and Nestle  respectively  in connection with the pending merger 
2020 Guidance
AbbVie expects adjusted EPS to be in the range of  9 61  9 71 for 2020 for the standalone company which means excluding Allergan  The earnings guidance represents a year over year increase of 8 1  at the mid point  The Zacks Consensus Estimate for current year earnings per share is pegged at  8 93  The better than expected guidance resulted in shares to go up in pre market trading  Shares were up 3 1  in pre market trading 
The company also expects a standalone revenue growth approaching 8  on an operational basis 
AbbVie Inc  Price  Consensus and EPS Surprise
   
Zacks RankAbbVie currently carries a Zacks Rank  4  Sell  
You can see  
Just Released  Zacks  7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 7  per year These 7 were selected because of their superior potential for immediate breakout ",2020-02-07,Zacks Investment Research,https://www.investing.com/analysis/abbvies-abbv-q4-earnings-beat-2020-view-solid-stock-up-200505828,200505828
148557,370073,AMGN,Amgen Earnings  Revenue Beat in Q4,news,"Investing com   Amgen  NASDAQ AMGN  reported on Thursday fourth quarter earnings  that beat analysts  forecasts and revenue that topped expectations 
Amgen announced earnings per share of  3 64 on revenue of  6 20B  Analysts polled by Investing com anticipated EPS of  3 4 on revenue of  6 02B  That with comparison to EPS of  3 42 on revenue of  6 23B in the same period a year before  Amgen had reported EPS of  3 66 on revenue of  5 74B in the previous quarter  Analysts are expecting EPS of  3 88 and revenue of  6 06B in the upcoming quarter 
Amgen shares are down 6 21  from the beginning of the year and are trading at  225 00   still down 7 71  from its 52 week high of  244 99 set on December 17  2019  They are under performing the Nasdaq 100 which is up 3 79  year to date 
Amgen shares lost 0 49  in after hours trade after the report 
Amgen follows other major Healthcare sector earnings this monthAmgen s report follows an earnings beat by J J  on January 22  who reported EPS of  1 88 on revenue of  20 75B   compared to forecasts EPS of  1 87 on revenue of  20 8B 
Novartis ADR had beat expectations on Wednesday with fourth quarter EPS of  1 32 on revenue of  12 4B  compared to forecast for EPS of  1 31 on revenue of  12 33B 
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2020-01-30,Investing.com,https://www.investing.com/news/stock-market-news/amgen-earnings-revenue-beat-in-q4-2072244,2072244
148558,370074,AMGN,Amgen stock slips as quarter beats Street view but outlook doesn t,news,"Amgen Inc  

                            
                            
                                  
      
      
      
      
      
      
      
                                  
                                    AMGN   0 92 

                            
                                  
      
      
      
      
      
      
      
                                         shares ticked lower in the extended session Thursday after the biotech drug maker s quarterly results topped Wall Street estimates but its outlook came up short  Amgen shares declined 2  after hours  following a 0 4  decline in the regular session to close at  226 15  The company reported fourth quarter net income of  1 7 billion  or  2 85 a share  compared with  1 93 billion  or  3 01 a share  in the year ago period  Adjusted earnings were  3 64 a share  Revenue declined to  6 2 billion from  6 23 billion in the year ago quarter  Analysts surveyed by FactSet had forecast earnings of  3 41 on revenue of  6 03 billion  Amgen expects adjusted 2020 earnings of  14 85 to  15 60 a share on revenue of  25 billion to  25 6 billion  while analysts had forecast earnings of  16 19 a share on revenue of  25 51 billion for the year 




  div gpt ad 1569967089584 0   div   iframe   width  100   important   min width  300px  max width  800px   ",2020-01-30,MarketWatch,https://invst.ly/pp45d,2072282
148559,370075,AMGN,Amgen 2020 outlook falls short of Street estimates  shares down 3 ,news,"By Deena Beasley
 Reuters     Amgen Inc   O AMGN  on Thursday forecast 2020 earnings well short of current Wall Street estimates  sending shares of the largest U S  biotechnology company down 3  
For the full year  the company forecast earnings of  14 85 to  15 60 per share on revenue as high as  25 6 billion  Analysts had estimated 2020 adjusted earnings of  16 14 on revenue of  25 5 billion  according to Refinitiv IBES data 
A company official attributed the difference to lower interest income and Amgen s recently acquired 20 5  stake in China s  BeiGene Ltd   HK 6160   which is not yet profitable 
For the fourth quarter of last year  Amgen said its sales fell 2  from a year earlier due to competition from lower cost generic drugs and biosimilars  but share buybacks enabled the company to post a profit that topped Wall Street estimates 
Sales for the quarter totaled  5 88 billion  Total revenue fell 1  to  6 2 billion  which was ahead of the average analyst estimate of  6 06 billion 
Quarterly adjusted earnings per share rose 6  to  3 64  beating the average Wall Street estimate of  3 48 
Net earnings fell 5  to  2 85 per share due to higher operating costs partially offset by a lower share count 
Sales of older drugs such as white blood cell booster Neulasta and kidney drug Sensipar fell sharply due to competition from cheaper versions  Neulasta was down 43  at  665 million and Sensipar sales were off by 76  at  107 million 
Sales of newer drugs like cholesterol fighter Repatha and migraine drug Aimovig rose  Repatha was up by 26  to  200 million  while Aimovig rose 3  to  98 million in the quarter 
Amgen said it bought back around 6  of its outstanding shares last year 
Shares of the company were down  7 15  or 3 2   at  219 in after hours trading ",2020-01-30,Reuters,https://www.investing.com/news/stock-market-news/amgen-2020-outlook-falls-short-of-street-estimates-shares-down-3-2072383,2072383
148560,370076,AMGN,Amgen Revenue Slipped 1  in the Fourth Quarter,news,"Fourth quarter revenue for Amgen  NASDAQ AMGN  slipped 1  year over year to  6 2 billion as the company faced competition from biosimilar and generic competition for its older medications  Adjusted earnings per share increased 6  year over year  boosted by the company s repurchase of 40 2 million shares for  7 6 billion during 2019 
Sales of Parsabiv  which helps patients on hemodialysis  jumped 49  year over year  Cholesterol lowering Repatha saw sales increase 26  year over year as Amgen parlayed data from an outcomes study showing the drug reduces cardiovascular events  Sales of osteoporosis treatment Prolia and immune thrombocytopenia treatment Nplate both increased 15  year over year  Psoriasis and psoriatic arthritis treatment Otezla  which Amgen acquired to facilitate Bristol Myers Squibb s  NYSE BMY  closing of its deal with Celgene  added  178 million in revenue during the five weeks or so that Amgen owned the drug during the quarter 

While Amgen fights biosimilars to its branded drugs  it s also launching biosimilars of its own  including Avsola  a biosimilar to Johnson   Johnson s  NYSE JNJ  Remicade that gained Food and Drug Administration approval in December  The drugmaker also has a biosimilar to Biogen s  NASDAQ BIIB  and Roche s  OTC RHHBY  Rituxan that was submitted to the FDA in December 
Management guided for 2020 revenue of  25 0 billion to  25 6 billion  up 8 2  at the midpoint  Adjusted earnings per share are expected to fall in the  14 85 to  15 60 range  higher than the  14 82 Amgen recorded last year  but up just 2 7  at the midpoint  suggesting that the company plans to increase spending faster than revenue this year ",2020-01-30,The Motley Fool,https://invst.ly/pp6d6,2072503
148561,370077,AMGN,Amgen Inc  AMGN  Q4 2019 Earnings Call Transcript,news,"Amgen Inc  NASDAQ AMGN Q4 2019 Earnings CallJan 30  2020  5 00 p m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorMy name is Ian and I will be you conference facilitator today for Amgen s Fourth Quarter 2019 Financial Results Conference Call   Operator Instructions I would now like introduce Arvind Sood  Vice President of Investor Relations  Mr  Sood  you may now begin Arvind Sood    Vice President of Investor RelationsOkay  Thank you  Ian  Good afternoon  everybody  Thanks for joining us today  So  2019 was the year that we made significant progress on our strategy and took steps that position us well for what will surely be a special year in 2020 as we celebrate our 40th anniversary  What better gift to celebrate this important milestone than to get back to revenue growth So  our Chairman and CEO  Bob Bradway  will lead the discussion today  We are also joined today by our new CFO  Peter Griffith  who will provide a financial update on our results for Q4 and full year 2019 and provide guidance for 2020  Our Head of Global Commercial Operations  Murdo Gordon  will then review our product performance  followed by our Head of R D  Dave Reese  who will provide a pipeline update  We will use slides to guide our discussion today  and you should have received the link separately We ll also use non GAAP financial measures in today s presentation  and some of the statements will be forward looking statements  Our 10 K and subsequent filings identify factors that could cause our results  actual results to differ materially So with that  I would like to turn the call over to Bob  Bob Robert A  Bradway    Chairman and Chief Executive OfficerOkay  Thank you  Arvind  and good afternoon  everyone  and thank you for joining our call  Heading into 2020  we feel ready for the challenges of a new year and we re feeling encouraged by the progress we made in 2019  Once again  this past year  we met and exceeded our financial targets  We advanced key elements of our long term growth strategy and we served more patients around the world with our growing portfolio of medicines 2019 was the transition year  we had long been preparing for  as many of our off patent legacy products faced new competition  I believe we managed this transition well  as evidenced by the fact that we delivered earnings growth in 2019 and will return to top line growth in 2020 In 2019  drug prices in the US actually fell overall for the first time since 1974  In anticipation of this challenge  we repositioned the Company s expense base and embedded productivity initiatives over the past several years that are serving us well  In addition  we reshaped our product portfolio committing to medicines that can deliver growth for us primarily through volume increases rather than price increases  Products like Repatha  Aimovig  Prolia  EVENITY  and most recently Otezla In 2019  we delivered 3  volume growth globally and 19  volume growth outside the United States  We re seeing especially strong performance in our Asia Pacific region  albeit from a small base  Over the next decade  we expect this region to account for as much as 25  of Amgen s growth  For the full year in 2019  volume in the region grew 62   Over two thirds of that growth came from our joint venture with Astellas in Japan  the world s third largest pharmaceutical market  Just a reminder that this collaboration reverts fully to Amgen on April 1st  enabling us to do business in Japan through a wholly owned subsidiary for the first time Our strategic collaboration in China with BeiGene closed a few weeks ago and we re excited by what our two companies can achieve together in the world s second largest pharmaceutical market 2019 was also a watershed year for us  for our biosimilars business  We ve delivered our first several biosimilars to market on time and on budget and we believe we are in the early innings of what can be an important growth opportunity for us over time  Through the end of Q4  the business was already annualizing at over  1 billion and we will add to our portfolio later this year with the launch of AVSOLA  our biosimilar to Remicade  We also expect that AMGEVITA  our biosimilar to Humira in Europe and other parts of the world will benefit from our recent acquisition of Otezla A key pillar of our growth strategy continues to be bringing to market first in class or best in class medicines that deliver a large effect size for patients suffering from serious illnesses  The world is growing older  wealthier  and more urban  and these mega trends mean that the world will need more biopharmaceutical innovation  not less  We intend to be a leader in delivering that innovation We expect several important data readouts from our pipeline in 2020  We expect data for AMG 510 or KRAS G12C inhibitor  for tezepelumab in allergic and non allergic asthma  for omecamtiv and heart failure  and look for Otezla in mild to moderate psoriasis  In addition  we d expect to generate some important data across our BiTE portfolio in 2020 as well and Dave Reese will provide details on all of this shortly Last year  we also expanded our commitment to discovery research  strengthening our world leading human genetics capabilities through a number of collaborations while adding large scale proteomic data as well  We remain excited about how our approach is enabling us to identify and pursue new targets and the patients who stand to benefit most from them Everything we see in our Company and across the industry continues to make us feel that we re living in an incredible age of biotechnology innovation  Across diseases  we re seeing more and more reason to be optimistic about the next breakthrough for patients  At the same time  we know that governments and individuals are struggling with how to pay for these breakthroughs  We accept responsibility to be part of the solution  both in advancing innovation that really matters and in providing innovative ways for patients to get access to it In an election year  there is bound to be much discussion about healthcare and we look forward to engaging with other stakeholders to promote market based solutions that promotes innovative medicines and affordable access to them Just as we recognize that we need to be a constructive stakeholder to help sustain the robust ecosystem that exists for biotechnology innovation in the US  so too do we recognize and accept the need to be part of the process of addressing other environmental  social  and governance matters that are of concern in our communities today  To that end  several years ago  we set targets for reducing our carbon emissions and water consumption by the year 2020  Having hit those targets in 2019  a year earlier than planned  we are now developing a next set of goals that we will share later this year  These goals will include a further commitment to our next generation manufacturing technologies  which have a much smaller environmental footprint than traditional biologics manufacturing and enable us to operate at a lower cost  too Now  let me turn over the call to our new CFO  Peter Griffith  You ll recall that Peter joined us in October  and he ll take you through the details of our performance in 2019 and our outlook for 2020  Peter  over to you Peter Griffith    Executive Vice President and Chief Financial OfficerThanks  Bob  Let me begin by saying how happy I am to join Amgen at such an exciting time in the Company s 40 year history  I also want to take a moment to thank David Meline  the Amgen team  as well as many of you on the call who have helped me transition into the role  Over the last several months  I ve enjoyed meeting many of our investors  as well as members of the analyst community  and I look forward to the continued dialogue and engagement Now  let s turn to the fourth quarter financial results on Page six of the slide deck  Revenues at  6 2 billion decreased 1  year over year in the fourth quarter  In the quarter  we saw worldwide product sales declined 2  to  5 9 billion as our portfolio transitioned with declines in our mature products  substantially offset by our growth and launch products  We are particularly encouraged by the strong 21  volume driven growth from our ex US markets  which gives us confidence as we continue our global expansion including into China  which will also benefit from our collaboration with BeiGene  which closed earlier this month Foreign exchange had a 1  negative impact to fourth quarter worldwide sales on a year over year basis Other revenues at  316 million were up  87 million versus Q4 2018 Our Q4 non GAAP operating income at  2 6 billion decreased 4  from prior year  Non GAAP operating margin was 44 6  for the quarter  compared to 45 3  in Q4 of 2018  As previously indicated  our operating expenses reflected the typical underlining    underlying fourth quarter pattern  increased investment in our rapidly evolving oncology pipeline portfolio and additional operating expenses associated with the Otezla acquisition  which closed in Q4  These increases were partially offset by continued favorable expense impacts from our productivity initiatives across all operating expense categories Other income and expenses were a net  65 million expense in Q4  representing  132 million of year over year favorability  This favorability was driven by gains generated from liquidating bond investments to fund the Otezla and BeiGene transaction and favorable market value fluctuations of publicly traded securities held in our Ventures portfolio  partially offset by lower interest income due to reduced cash balances The non GAAP tax rate was 14 9  for the quarter  a 1 6 point increase versus Q4 2018  primarily due to a one time prior year tax benefit associated with intercompany sales under US Corporate Tax Reform Non GAAP net income was  2 2 billion and non GAAP earnings per share increased 6  year over year for the fourth quarter  supported by a 7  reduction in share count versus Q4 2018 Next  I will review our 2019  full year results on Page seven of the presentation  Our 2019  full year revenues decreased 2  to  23 4 billion  while our non GAAP earnings per share grew 3  to  14 82 per share  For the full year  we saw a 1  decline in worldwide product sales to  22 2 billion  Volume growth in markets outside the US was 19  year over year  Other revenues at  1 2 billion were down  56 million year over year For the full year  non GAAP operating income at  11 2 billion decreased 6  from the prior year  and our non GAAP operating margin was 50 2  for the year  down from 52 6  in 2018  In total  non GAAP operating expenses increased 3  year over year to  12 2 billion  This growth was driven by research and development investments  launch product support  and the addition of Otezla to our business  partially offset by our productivity program Other income and expenses were favorable by  250 million on a year over year basis due primarily to gains in 2019 from liquidating bonds to fund the Otezla and BeiGene transactions  partially offset by lower interest income resulting from reduced cash balances The non GAAP tax rate was 15  for the full year  up 1 5 points versus 2018  Again  primarily due to a one time prior year tax benefit associated with intercompany sales under US Corporate Tax Reform Turning next to cash flow in the balance sheet on Page eight  For the full year 2019  Amgen continued to generate strong cash flow  reflecting a diversified portfolio of products coupled with an industry leading cost structure  Free cash flow was  8 5 billion in 2019 versus  10 6 billion in 2018  The decline driven by lower net income  timing of working capital  and an advance tax deposit In 2019  we returned a total of  11 1 billion to shareholders through dividend payments totaling  3 5 billion and  7 6 billion used to repurchase 40 2 million shares at an average of  190 per share  And this follows the  21 4 billion return of capital to shareholders in 2018 Cash and investments totaled  8 9 billion at the end of 2019  a decrease of  20 4 billion from the end of 2018  This decrease was primarily driven by the Otezla transaction  cash return to shareholders in the form of dividends and share repurchases  as well as debt repayment  All partially offset by free cash flow generated during the period  Debt outstanding at year end totaled  29 9 billion and carries a weighted average interest rate of 3 7  with an average maturity of 12 years Now  turning to the outlook for the business for 2020 on Page nine  2020 will be another important year for Amgen  as we continue to invest in the pipeline to generate innovative and differentiated molecules  build out the global business  and support the growth of our new products  As previously discussed  in anticipation of this opportunity and continued downward pressure on net prices  we developed a productivity capability to enable us to fully invest from a position of strength Our 2020 revenue guidance is  25 0 billion to  25 6 billion and our non GAAP earnings per share guidance is  14 85 per share to  15 60 per share GAAP earnings per share guidance is  10 85 per share to  11 65 per share  which divergence from non GAAP EPS  primarily due to the amortization of intangibles related to our Otezla acquisition Our non GAAP tax rate guidance is 13 5  to 14 5  and once again  we expect capital expenditures of approximately  700 million this year  including our industry leading environmentally friendly next generation manufacturing facility in Rhode Island Let me mention several key assumptions embedded in our guidance  First  our revenue guidance range reflects continued strong worldwide growth from products including Prolia  EVENITY  Repatha  Aimovig  Otezla and our biosimilar portfolio  At the same time  we expect increasing competition against our filgrastim and ESA franchises  as well as Sensipar Next  with regard to net selling prices  we experienced a 5  decline globally in 2019  For 2020  we expect to again experience low  to middle single digit declines globally  We expect our volume growth to more than offset the net price declines  Overall  as previously stated  excluding Otezla  we expect our base business to be stable in 2020 on a year over year basis As you model revenue in 2020  note that historically the first quarter represents the lowest product sales quarter of the year  As a percent of the full year  product sales for the first quarter should look similar to the percentage we saw in Q1 of 2019  Murdo will explain further in his remarks With respect to other revenue  we expect about  1 1 billion for the full year 2020  as we anticipate increased competition against our royalty product portfolio From an operating expense perspective  overall we expect 2020 total non GAAP operating expenses to grow in the low double digit percentage range year over year on an absolute basis As previously communicated  we reiterate the following three assumptions  Non GAAP R D investment to increase as we invest in our advancing innovative pipeline programs and new Otezla indications  partially offset by R D recoveries received from our BeiGene collaboration Second  non GAAP SG A expense to increase due to the acquisition of Otezla  as well as modest incremental investment in support of our base business  as we continue to expand globally  including China and Japan  grow our biosimilars business and begin product launch preparation for our late stage pipeline Non GAAP cost of sales as a percent of product sales to be generally consistent with 2019  We expect all expense categories to continue to benefit from our productivity program We anticipate non GAAP other income and expense to be a net expense in a range between  1 2 billion and  1 4 billion  This is primarily driven by lower interest income as a result of cash used to fund the Otezla and BeiGene transactions  as well as our 20 5  share of BeiGene s results based on current publicly available consensus estimates  I note that our 20 5  share of BeiGene s results will be booked one quarter in arrears in accordance with the equity method of accounting and therefore  begins in Q2 2020 As you know  on April 1  2020  Amgen will purchase the 49  of shares in Amgen Astellas BioPharma that are held by Astellas for a nominal fee  making the company a wholly owned Amgen subsidiary  First  let me say how excited we are about this transition as it marks the achievement of a long term strategic objective  We look forward to further leveraging this platform as we seek to bring Amgen s new medicines to patients in the third largest pharmaceutical market  From a financial perspective  we anticipate limited near term financial impact resulting from this transition Now  with regard to capital deployment  Our actions will continue to reflect the following principles  First  we will invest in our business to expand our pipeline of innovative medicines and to seek to drive long term volume growth globally  We will also invest in prudent external business development opportunities Second  we remain committed to returning capital to shareholders in the form of growing dividends  including the 10  increase in the first quarter of 2020  Technical Issues   1 60  Phonetic  per share  as well as continued share repurchases  We will continue to take an opportunistic view toward the timing of share repurchases within  20  We expect share repurchases within a range of  3 billion to  5 billion and have an authorization outstanding in the amount of  6 5 billion And third  we remain committed to maintaining an optimal capital structure in order to minimize our weighted average cost to capital and retain our investment grade rating  Consistent with our usual practice  our guidance today does not include the impact of potential external business development activities So  in summary  we delivered another year of strong financial results in 2019  and we remain confident in the outlook for Amgen s success in 2020 and beyond This concludes the financial update  I will now turn the call over to Murdo Murdo Gordon    Executive Vice President  Global Commercial OperationsThanks  Peter  and good afternoon  everyone  I ll take a few minutes to reflect on 2019 and then review Q4 in greater detail  In the 40 years since incorporation  Amgen s product portfolio and geographical footprint has changed dramatically  On our 40th anniversary  we reflect on the pioneering innovative spirit of our early Amgen employees that transformed the treatment of disease  Our mission to serve patients remains unchanged and it motivates us every single day  Our accomplishments on behalf of patients in 2019 give us further confidence about our future as we enter 2020 To summarize 2019  for the full year  we grew volume by 3   The growing proportion of our portfolio posted 35  year over year volume increases  This portfolio is diverse and includes products such as Prolia  EVENITY  Repatha  Aimovig  Otezla  AMGEVITA  our six hematology and oncology brands  as well as MVASI and KANJINTI Finally  our international business contributed 19  volume growth in 2019  Notably  year over year revenues for our businesses in China and Japan grew nearly eight fold  These markets are long term growth engines for Amgen and our collaboration with BeiGene  along with our acquisition of Otezla will accelerate our expansions in the second and third largest pharmaceutical markets Now  moving to fourth quarter results  Volumes grew by 3  year over year  In Q4  net selling prices declined 4  year over year  resulting in reported net sales declining by 2   As Peter mentioned  we have a stable outlook for our base business for 2020 and with the addition of Otezla  we expect revenue growth this year despite projecting continued declines in net selling price on a portfolio basis Now  getting into product details  Prolia delivered 15  growth year over year  driven by higher volume from increasing rates of new patient growth and strong repeat injection rates  Recall that given twice a year dosing  Prolia experiences consistent seasonal trends  EVENITY posted  85 million in the fourth quarter  driven by strong uptake in both Japan and the US  Every year  worldwide 8 9 million fractures occur due to osteoporosis  That s one fracture every three seconds  and only 20  of women who experienced a fracture are treated with a bone building medicine  Given the under penetrated nature of this market  we continue to focus on ensuring postmenopausal women receive appropriate screening  diagnosis  and treatment  With Prolia and EVENITY  we have excellent treatment options to offer these patients On to Repatha  Q4 sales grew by 26  year over year  as we continue to be the leader in the PCSK9 class  Worldwide unit growth was 67  year over year  And new to brand US prescriptions are steadily improving growing at 61  year over year  We ve taken significant steps and have made major progress in improving access and affordability for Repatha  We removed the original list price offering  We simplified and improved prescription approval rates and commercial plans and we have increased the percentage of Medicare patients up to 70  that can access Repatha at a more affordable co pay  Although the blended net price of Repatha in the US declined in Q4 versus the previous year  net selling price was relatively stable sequentially  For 2020  we expect a step down in Repatha s net selling price in Q1 based on our contracting to obtain broader access with stabilization thereafter Now  onto Aimovig on Slide 16  On a year over year basis  volume grew 27   while net sales grew 3   As a reminder  Q4 2018 benefited from  20 million of favorable changes in accounting estimates impacting the year over year comparison on a quarter over quarter basis  Unit volume grew 9   To date  almost 300 000 patients have been prescribed Aimovig by more than 33 000 prescribers  Considering that there are 4 million migraine patients in the US who are eligible for CGRP treatment  Aimovig has significant potential remaining to penetrate this market  and we expect to drive volume growth over the course of 2020 Aimovig leads in both new to CGRP prescriptions and total prescriptions  which exited Q4 with a 48  TRx share  Aimovig has exceptional access with over 80  of prescriptions paid and over 92  of lives covered  As a result of this broader access  we expect net price to decline slightly on a full year basis for 2020  when compared to the full year 2019  Additionally  Q1 has lower sales in subsequent quarters due to the impact of benefit plan changes  insurance reverifications  and greater co pay expenses as patients work through their deductibles We ll move to Parsabiv on Slide 17  which grew by 49  year over year in the fourth quarter  Independent and midsize dialysis providers already utilize Parsabiv for a majority of their calcimimetic patients  while FMC and DaVita continue to increase adoption Next  onto Otezla  With the help of the dedicated professionals that have joined our team from Celgene  we will continue to drive strong sales growth and launch potential new indications for Otezla  During the period since acquisition close  prescription momentum continued with 13  year over year growth  Our seamless integration efforts  combined with planned  label and geographic expansion gives us confidence in our ability to grow Otezla at low double digit compound annual growth rate over the next five years  For the approximately five weeks post closing in 2019  Otezla sales were  178 million  We expect first quarter sales to be proportionally lower than in the remaining quarters of the year  The quarterly pattern for Otezla in 2020 should approximate the historical pattern over the last number of years Moving onto Enbrel  Sales increased 2  year over year  driven by a  66 million favorable change in accounting estimates and increases in net selling price  partially offset by unit volume declines  Volume trends in 2020 are expected to be similar to those in 2019  As for net selling price  we project limited benefit in 2020 versus 2019 due to less favorable contract terms With two highly complementary products  targeting psoriasis and psoriatic arthritis  we see an opportunity to strengthen their positions in the market  More broadly  we re increasing our focus in inflammation through our broad portfolio  which includes our biosimilars  AMGEVITA  and AVSOLA  Our late stage asset tezepelumab and a number of other earlier assets in the R D pipeline Now  to our hematology and oncology business  which is highly integrated with our oncology biosimilars that I ll discuss later  Our innovative portfolio of six brands XGEVA  KYPROLIS  Nplate  Vectibix  BLINCYTO  and IMLYGIC collectively totaled  1 2 billion in the quarter  growing 10  year over year As for some of the larger brands within this portfolio  XGEVA grew 7  in Q4 year over year  driven by 4  volume growth  KYPROLIS grew 6  year over year  driven by volume led by a 12  increase in the US    in US sales  Nplate grew 15  year over year  driven by volume  Our investments in R D for Nplate have resulted in two innovations  First  we recently launched a smaller presentation at 125 micrograms in support of in Nplate s pediatric indication  as the product is administered with weight based dosing  This new presentation will also help to minimize general product wastage for ITP patients across all indications  Second  Nplate received approval in October for the treatment of early ITP  which gives us the chance to serve patients earlier in the course of their disease and provides the opportunity for treatment free remission Now  onto our more mature brands  in Q4  Neulasta sales declined 43  year over year  with a 42  decline in the US  Recall that Q4 of 2018 benefited from a  55 million BARDA order  which did not repeat in Q4 of 2019  Coinciding with the emergence of US biosimilar competition  the most recent CMS published ASP for Neulasta reflects a 10  reduction  Bear in mind that ASP is calculated two quarters in arrears On a volume basis in Q4  US Neulasta retained an exit share of 74  of the long acting segment with Onpro holding an exit share of 55   We are encouraged by Onpro s durability demonstrating confidence that our customers have  in the reliability and quality of our supply  along with our broader customer services  We now face a third biosimilar competitor in the US and other potential competitors remain in development  As you model Neulasta sales for the first quarter  recall that Q1 2019 benefited from a  98 million BARDA order that we do not project to recur in 2020 Finally  outside the US  sales declined 48  in Q4 and we expect those trends to continue  Switching to Nephrology  starting on Slide 25  Q4 EPOGEN sales declined 20  primarily due to lower net selling price from our contractual commitments with DaVita  which calls for a further price reduction in 2020  Meanwhile  Aranesp declined 10  year over year driven by lower volume due to increased competition Regarding Sensipar  recall that in the US  there were several at risk generic launches in 2019 that resulted in year over year sales declining 76  to  107 million in the quarter  In 2020  supplemental patent protection certificates for cinacalcet expire in France  Germany  Italy  Spain  and the United Kingdom  which will likely result in a significant decline in ex US sales in 2020 I ll close the product section with our biosimilar portfolio  which is highly integrated with our innovative business throughout the Company  As examples  a majority of these products were made with the same manufacturing network as our innovative brands  We also leverage the same supply chain for distribution  And on the commercial side  we continue to identify synergies in commercializing our biosimilars alongside our innovative products  making it a highly efficient selling model  and allowing us to rapidly apply learnings across our portfolio We also offer the same provider and patient services as with our innovative portfolio  These advantages are increasingly important as we now face additional biosimilar competition to KANJINTI and MVASI and expect other competitors to enter during 2020  Our Q4 biosimilar portfolio comprised of KANJINTI and MVASI in the US and AMGEVITA  KANJINTI and MVASI outside of the US recorded sales of  258 million In the US  KANJINTI and MVASI each recorded  79 million of sales  and we ve seen very encouraging adoption rates in the clinic segment and hospital adoption is accelerating  Given the early stage of launch  there is also some inventory stocking during the quarter  Ex US sales from our biosimilars where  100 million led by AMGEVITA  We continue to see important differences between products and markets in terms of uptake and price erosion with some markets experiencing strong uptake at more discounted pricing levels  while other larger markets  including Germany and France exhibit a more balanced and sustainable opportunity  Here again  we re able to leverage our expertise and footprint in oncology  while AMGEVITA efforts synergized nicely with Otezla In summary  2019 was a solid year given the evolution of our product portfolio  In 2020  we plan to drive volume uptake of our growth portfolio of products  now including Otezla while defending our mature brands Let me now turn it over to Dave Reese David M  Reese    Executive Vice President  Research and DevelopmentThanks  Murdo  and good afternoon  everyone  As we enter 2020  we are looking forward to important clinical data from programs across our three therapeutic areas  inflammation  oncology  and cardiovascular disease  I ll say more about oncology in a moment  but I d like to take the opportunity upfront to express our enthusiasm for the BeiGene collaboration  We re off to a good start and look forward to working together to advance the global development of our pipeline of innovative oncology molecules I ll now begin my quarterly review in inflammation  We expect Otezla data this year from a Phase 3 study in over 500 patients with mild to moderate psoriasis that have failed topical therapy  This patient population has no approved oral therapy available and we are confident that Otezla may provide a much needed treatment option  We re working with the CHMP toward a Behcet s indication in Europe and with the FDA on inclusion of the scalp psoriasis data in the US label this year  There are also ongoing studies for new indications  including pediatric psoriasis and we re evaluating additional studies to expand the opportunity for Otezla I ll also remind you that later this year  we expect Phase 3 data from our TSLP antibody  tezepelumab in development with AstraZeneca in severe uncontrolled asthma In bone health  along with UCB  we were pleased to receive European approval for EVENITY for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture  EVENITY is the first new osteoporosis medicine approved in Europe in the last decade  a testament to the need for a new therapy that can rapidly build bone Turning to oncology and hematology  we continue to rapidly advance the development program for AMG 510  our first in class KRAS G12C inhibitor  We enrolled the potentially pivotal Phase 2 monotherapy study in advanced non small cell lung cancer in approximately three months and look forward to sharing data later this year when we have at least six months follow up on all patients  I previously mentioned that we had enrolled a cohort of advanced colorectal cancer patients in our Phase 2 monotherapy study  Based on the data we have generated to date  we have opened the study to further enrollment and we ll assess our potential development path in colorectal cancer as additional data become available We also expect to present additional data later this year from our first in human monotherapy study in solid tumors  where we will have more information on duration of therapy  as well as data in tumor types other than lung and colon cancer  We also expect initial data from our Phase 1 combination study with KEYTRUDA in advanced non small cell lung cancer We are enrolling advanced colorectal and non small cell lung cancer patients in our MEK inhibitor combination study  as well as treatment naive non small cell lung cancer patients in our ongoing Phase 1 monotherapy study  We continue to plan additional studies primarily combination trials and we ll provide updates as the program progresses We remain enthusiastic about our BiTE platform  and 2020 will be an important year  Based on emerging evidence of anti tumor activity in both hematologic malignancies and solid tumors  we are growing increasingly confident in the half life extended format  As we advance our BiTE clinical programs in different tumor settings  we are gaining important insights into dose and schedule and management of adverse events  such as cytokine release syndrome  These insights will guide customized development approaches  depending on the target and underlying disease biology  Over the course of the year  we anticipate sharing data from some of these programs and I ll provide further guidance on expected data presentations as these molecules advance We are now pursuing two half life extended BiTE programs for gastric cancer and recently initiated a first in human study for AMG 199  which is directed against MUC17  a target widely expressed in gastric cancer  Gastric cancer  as you know  is highly prevalent in East Asia  where we have a growing presence through our impending Japan subsidiary and collaboration with BeiGene As I previously discussed  we intend to present the data for AMG 701  or half life extended BCMA BiTE when we have a meaningful dataset  most likely in the second half of this year We ve also made several regulatory submissions in oncology  including the KYPROLIS CANDOR study in the US  KYPROLIS plus dexamethasone in China for relapse and refractory multiple myeloma and BLINCYTO in China for relapsed refractory AOL  We look forward to working with BeiGene to advance these important medicines In cardiovascular disease  along with Cytokinetics  we look forward to the data from the omecamtiv mecarbil Phase 3 outcome study in the fourth quarter of this year  While the heart failure treatment landscape is expected to change based on recent data from other drug classes  we believe significant residual unmet medical need remains in this global epidemic  Also  in cardiovascular disease  our Lp a  siRNA  AMG 890 continues to advance and we expect to initiate Phase 2 development in the first half of the year Finally  on biosimilars  we re pleased to receive US approval for AVSOLA  our biosimilar Remicade and to make our US regulatory submission for ABP 798  our biosimilar Rituxan  I m also pleased to announce that we are initiating a Phase 3 study with our 7th biosimilar ABP 938  our biosimilar aflibercept or EYLEA Bob Robert A  Bradway    Chairman and Chief Executive OfficerOkay  Thanks  Dave  Ian  why don t we open the lines up for questions now and please remind our callers of the process Questions and Answers Operator Operator Instructions  Our first question is from the line of Jay Olson from Oppenheimer   Company  Jay Jay Olson    Oppenheimer   Co     AnalystOh  hi  Congrats on the quarter and thanks for taking the question  You talked a little bit about net pricing dynamics for Aimovig  Could you maybe elaborate a little bit on how you expect the competitive dynamic to shape up in the CGRP space and any long term data you could potentially leverage there  Thank you Murdo Gordon    Executive Vice President  Global Commercial OperationsThanks for the question  Jay  it s Murdo here  We re very pleased with Aimovig s market access position now with over 92  of covered lives  having access to Aimovig at a very affordable co pay  We re also pleased with the addition this year of CVS  Last year  we did not have CVS as a benefit    with Aimovig as a benefit and we do  as of the beginning of this year  and we ve already seen an acceleration in our new patient uptake  We are happy that the percentage of patients that are receiving paid prescriptions now of Aimovig is above 80  and that bodes well for the future growth of this category because we ve got highly effective medicines that have an impact    a significant impact on the reduction of migraine days on migraine sufferers and we have a lot of them  there is 4 million eligible patients out there in the US and they re able to access Aimovig at a very affordable co pay  So that s good for the future outlook of the category Obviously  because we did contract to secure that additional access  there will be a reduction in our net selling price that you ll see in Q1  and then we expect it to be relatively stable over time  Now  because this is a retail benefit product  you do see some fluctuations as you make true ups in the mix of your product that comes through Medicaid commercial or to some extent Medicare Part D  But overall  we would expect post Q1 stability in net selling price Robert A  Bradway    Chairman and Chief Executive OfficerAll right  Let s go to the next question  Ian OperatorAnd our next question is from the line of Michael Yee from Jefferies  Michael Michael Yee    Jefferies   Company    AnalystGreat  Thanks for the question  I had a R D question for David  Of course  there is a lot of attention on AMG 510  You made a lot of great comments about how you quickly enrolled the study and we re going to get data later this year  One of the things I picked up on was your comments about first line lung  can you just maybe make a comment about how that advances or how that progresses or how you go about a first line strategy that s  obviously  a huge opportunity  So  maybe just comment about where that monotherapy study goes and where you can go with first line  Thank you David M  Reese    Executive Vice President  Research and DevelopmentYeah  Thanks  Michael  That is intended to provide a potential treatment option for patients who are not eligible for other first line lung therapies or unwilling to take such therapies  I think it will provide incredibly valuable clinical information on response to the drug in a previously untreated population  We ve just started enrolling that in the    so    over the course of the year as we generate data  we ll provide guidance as to when we may have some things to share OperatorAnd our next question is from the line of Chris Raymond from Piper Sandler  Chris Christopher Raymond    Piper Sandler    AnalystHey  thanks for taking the question  Just on M A priorities  So Bob  I was kind of struck a couple of weeks ago in San Francisco  You guys talked about renal as maybe an area of interest in terms of building out the pipeline  And you re offering  and obviously  augmenting what is a pretty formidable business now  But I think the wording that I heard you say  Bob was that  any asset you bring in  would have to be game changing  So maybe two parts  can you talk about the reasoning for this sort of focus on renal or at least articulating that to us  And then what are you really looking for in terms of the game changing therapy  Thanks Robert A  Bradway    Chairman and Chief Executive OfficerYeah  So  Chris  just to remind you  we have six commercial franchise areas  of which nephrology is one  Obviously  that was our first  We ve been a leader in that area now for several decades  We have a number of important products for nephrologists today and we intend to continue to serve the needs of patients and physicians and providers  etc   in that community  We have not found in our own discovery research efforts that we ve been able to find the kinds of game changing innovation that we want to invest in from a discovery standpoint  So we re not investing in discovery research in nephrology right now  but we are going to look for business development opportunities there  And in general  our strategy when it comes to the business development  is to look for medicines that make a big difference for patients suffering from these diseases  So we ll look for innovation and large effect size  I don t know that I use the word game changer  But if I did  that s what I was intending to reflect the notion of large effect size innovative medicines So  to the extent  there are some in the industry or otherwise medicines  where again we think  because of the historical investment we ve had it  with this community patients that we can add real value  we ll look OperatorAnd our next question is from line of Brian Skorney from Robert W  Baird   Company  Brian Brian Skorney    Robert W  Baird   Co     AnalystHey  good afternoon  guys  Thanks for taking the question  One quick one    actually two quick ones on housekeeping  just it looks like compared to last quarter  you saw a 6  decline in Neulasta market share  Could you just breakout how much of that was Onpro loss  And can you also talk about how Onpro price has been impacted by the biosimilars have been able to maintain price so far or have you taken greater discounts to maintain that share  Thanks Robert A  Bradway    Chairman and Chief Executive OfficerOkay  Those are good questions for Murdo  Why don t you go ahead  Murdo Murdo Gordon    Executive Vice President  Global Commercial OperationsYeah  Thanks  Brian  The majority of the share decline is from the prefilled syringe  Onpro exited at a 55  share of long acting filgrastim and continues to hold up well in terms of share  We have had a contract out there that provides some discount to Onpro  but it s a more modest discount  then you would see on the prefilled syringe OperatorAnd our next question is from the line of Evan Seigerman from Credit Suisse  Evan Evan Seigerman    Credit Suisse    AnalystHi  all  Thank you for taking my questions  One on biosimilars  so what are some gating factors to achieve  I think it s multi billion or you had at one point said greater than  3 billion in sales across the franchise  And if there were to be implementation of an international pricing index for most favored nation clause for Medicare Part B  how would this potentially impact your biosimilars business  Thank you  guys Robert A  Bradway    Chairman and Chief Executive OfficerI can take a stab at the first part of your question and Murdo  I invite you to jump in  But since we made those undertakings before you were part of the team  Murdo  the notion that we articulated was that we were going to advance the portfolio of up to 10 biosimilars that we expected that these could be an attractive growth opportunity for the Company and we re off to a good start  as you heard me say earlier  At the end of the fourth quarter  we were annualizing in excess of  1 billion  So  we re off to a good start  We re on time  We re on budget with these programs and the gating item is simply product approvals and product launches  So  we remain enthusiastic about our chance to earn a return from these products and it adds to the specifics of IPI  just to say in general  We  obviously  would be concerned we think quite a few other stakeholder groups would as well about the disruption that IPI would represent to the innovative biopharmaceutical industry  And we think there are better ways to evolve our system in a way that ensures patients have access to medicines at affordable prices But Murdo  feel free if you want to add anything specific about IPI in biosimilar landscape Murdo Gordon    Executive Vice President  Global Commercial OperationsNothing on IPI  Bob  I think you summarized it well  And on the biosimilars  the only thing I would say is  I m thankful to have inherited this portfolio and for the decisions that were made prior to my arrival  I think this is a strong business opportunity  It s been one  we ve been able to realize very good competitive share in Europe and we re off to a very good start in our early launch in the US  And I look forward to being able to launch more products OperatorAnd our next question is from the line of Kennen MacKay from RBC Capital Markets  Kennen Kennen MacKay    RBC Capital Markets    AnalystHey  Thanks so much for taking the question and congrats on the end of the year in 2019  I totally agree it was transformative  Maybe for Murdo  I was wondering if you could talk a little bit about the synergies you re seeing or expecting between selling of both Otezla and Enbrel  And whether there were any tailwinds there to year end formulary rebating or contracting negotiations we should think about in pricing or access in the year ahead Murdo Gordon    Executive Vice President  Global Commercial OperationsThanks for the question  Kennen  Yeah  We re excited about potential synergies between Otezla and Enbrel  and quite frankly  by extension our biosimilars business coming into the inflammation category  Too early to comment on specifics  but we continue to work through our contracting strategy  promotional strategy  even things as simple as possibly expanding into primary care promotion because we have a fairly large primary care footprint  And then  clearly  our international geographic expansion is augmented by having Otezla joining our portfolio with potential new markets where perhaps Otezla was slated to be launched by distributors when we have a full blown affiliate in some of those markets And then the last piece is  of course  synergies as we go into some of the new indication areas  So I m excited about building those out  Our teams are working hard to realize those synergies  and I feel optimistic that we ll be able to be more specific in upcoming quarters OperatorAnd our next question is from the line of Umer Raffat from Evercore ISI  Umer Umer Raffat    Evercore ISI    AnalystHi  Thanks so much for taking my question  I am just extraordinarily confused today on the guidance  but I ll limit my question two specific things perhaps  First  Peter on the OI E line  if you can bear with me for a second  you mentioned  1 2 billion to  1 4 billion  And I was trying to think it through and I thought to myself  30 billion debt at just above 3  rate  so that s  1 billion as an interest expense  minus about  100 million of the interest income  So that s  900 million  so when you guide to  1 2 billion to  1 4 billion  that s effectively implying  300 million to  500 million for BeiGene  But my understanding was you re only booking 20   and I m just trying to understand  is BeiGene s implied net income  1 5 billion to  2 5 billion  or am I thinking about that wrong  because that sounds so much higher than what BeiGene does  That s number one And secondly on revenues  I noticed    I know the business is being implied flat year over year outside Otezla  so I just want to understand better what the pushes and the pulls are there  And perhaps also  I think it mentions biosimilars doing  1 billion in 2020  annual 4Q  19 alone was north of  1 billion run rate  So just trying to understand all this  Thank you very much Robert A  Bradway    Chairman and Chief Executive OfficerOkay  Umer  Let s try and go through that  I think there were three questions there  So  Murdo  you want to take the first two on the revenue  just clarify what we said  and then Pete  you can help clarify the other interest and expense line item Murdo Gordon    Executive Vice President  Global Commercial OperationsSure  So  yes  we ve guided that our base business will be stable year over year  Obviously  there are a range of outcomes on that portfolio  and we continue to work hard across a number of opportunities to do as we ve done historically and that is to outperform  I would say that Otezla has come in and we have seen very good seamless integration of that team and that performance of that product and the growth trajectory continues without any interruption through the fourth quarter and we re seeing strong weeks early in the New Year On biosimilars  it s very early in the launch of those two products  where we are annualizing  as you pointed out  at over  1 billion based on fourth quarter and we expect to be able to continue to accelerate that business Peter Griffith    Executive Vice President and Chief Financial OfficerUmer  Peter here  Thanks for your question  I would take you to the fact that our total debt at the interest rate I talked about in my remarks at 3 7  average maturity 12 years  by the way  I mentioned that too  That plus the 20 5  of BeiGene s results for 2020  the publicly available consensus estimates are what we re guiding to  So  when you work through those two  you should get pretty close to our  1 2 billion to  1 4 billion for 2020 OperatorAnd our next question is from the line of Robyn Karnauskas from SunTrust Robinson Humphrey  Robyn Robyn Karnauskas    SunTrust Robinson Humphrey    AnalystHi  I don t want to beat a dead horse  but I guess  I m confused  too  just by this lack of growth  given that your slides have outlined  in your last    you ve lost like half Onpro s holding  you re growing like a bunch of different products  So  what is the one thing you think that is going to prevent you from growing more this year and not just having a stable business year over year  Like that s sort of what I m struggling with the most  Just help me understand that  because the way you describe  it looks like more growth of the top line  Thank you Robert A  Bradway    Chairman and Chief Executive OfficerSorry  Robyn  repeat the last piece of your question   Speech Overlap Robyn Karnauskas    SunTrust Robinson Humphrey    AnalystSure  Just like    the way you re describing our your businesses in your slide performance basically is that  you re growing many parts of the business and the part that is declining is Neulasta  it seems to be potentially stabilizing with Onpro  So  what is preventing you from growing beyond what you re guiding  Is there one particular thing  I think most of us are sitting there saying  why can t you grow more than what you ve outlined given the picture that you painted of the business being actually quite strong Murdo Gordon    Executive Vice President  Global Commercial OperationsSo  I would agree with your last comment  the picture of the business does look quite strong  We re pleased with what we ve been able to achieve  particularly in the back half of last year  As I mentioned earlier  some of the Neulasta stability with Onpro has been at the expense of contracted terms  which lowered the net price of that total portfolio inclusive of Onpro  and we would expect with additional competitors against Neulasta in the biosimilar space that there will be further net price erosion in the long acting filgrastim category  And  of course  overall in our total portfolio worldwide  we would expect single digit net price declines for the year Now  that goes up against what I talked about throughout the call is  we have a number of really strong growth drivers in a young portfolio  very diverse products  and we have guided a wide range on revenue and it s my hope that the strong execution we saw in the back half of last year continues into this year and we can achieve a good growth profile  not just in Otezla but in the base business OperatorAnd our next question is from the line of Terence Flynn from Goldman Sachs  Terence Terence Flynn    Goldman Sachs    AnalystHi  Thanks for taking the question  Omecamtiv is a product you guys haven t talked a lot about recently  obviously  some Phase 3 data coming later this year  Dave  you mentioned it in your remarks as well in terms of kind of the change in treatment landscape  But just curious if you could remind us of the puts and takes for the program  as we think about the probability of success here  And what would really get you guys excited that type of data  Thank you David M  Reese    Executive Vice President  Research and DevelopmentYeah  Sure  Terence  This is Dave  I m happy to address that  I mean  as I mentioned in my remarks  heart failure is a global epidemic  what makes us continue to have excitement in omecamtiv  it s a first in class mechanism of action  it s the only drug ever introduced that actually acts directly on the heart cell to improve contractility or the heart s pumping function  And we re conducting what ll will be a definitive 8 200 patient  give or take  trial in patients with advanced heart failure  It s a fairly sick population  where we re going to be looking for mortality benefit and a variety of other clinical outcome measures that improve  So  I think there is a large amount of residual unmet medical need and  obviously  where this fits in a train    changing treatment landscape will depend on the profile that emerges from that Phase 3 trial OperatorAnd our next question is from the line of Ronny Gal from Bernstein Research  Ronny Ronny Gal    Sanford C  Bernstein    AnalystGood afternoon and congratulations on the nice 2019  And got one housekeeping and one question  The quick one is  I was wondering if you could give us your comment on the Medicaid block grant that just was announced today  Does that has any relevance to you  And then generally  where do you expect it will impact the drug industry And second  David  I was wondering if you could give me your view on the Memorial Sloan Kettering paper suggesting the targeting the active GDP bound form of KRAS is better than trapping the GDP KRAS in the inactive form in terms of preventing tumors    tumor resistance to those agents Robert A  Bradway    Chairman and Chief Executive OfficerGood  Well  let me    I ll knock off the Medicaid piece first  Ronny  For those who are on the call who aren t aware  CMS released some guidance earlier today  so we and others are still chewing through it  I think it ll have very limited impact at first read of it for us  But it s likely to be relevant for those states that didn t opt into the ACA in the first instance and we ll go through it  as well  I m sure others in our industry  more closely to see whether there are any specific issues for our business  But it didn t seem to me  Ronny  that that was going to be a concern for us in 2020 Dave  you want to tackle the Sloan reference  Speech Overlap  David M  Reese    Executive Vice President  Research and DevelopmentYeah  I m sure you don t want to address that one  Bob  So  for those who aren t familiar  Ronny is referring to a paper that came out within the last month or so that suggests that also targeting the GDP bound form of KRAS G12C would be required for signaling inhibition  We read the paper with interest  of course  I ll make a couple of observations  First  I would say our own data with AMG 510 suggests that at the appropriate doses and doses that we can achieve clinically  we can completely suppress signaling throughout a dosing interval  It is also my understanding or belief that the G12C inhibitor used in that paper may have been a little less potent  And one thing that we ve learned over 40 years in oncology is that  if you incompletely inhibit a target you very quickly breed resistance  So  I would say  I feel very confident based on the preclinical data that we ve generated with AMG 510  We re  of course  profiling tumors across our clinical program to try to generate signatures of response and resistance  This is the sort of thing that we ll look at  But I don t see anything in the literature as of yet that dissuades me from the approach we re currently taking OperatorAnd our next question is from the line of Mohit Bansal from Citi  Mohit Mohit Bansal    Citigroup    AnalystGreat  Thanks for taking my question  And a quick question on Otezla in mild to moderate psoriasis  it seems like you ll have data later this year  But given that net of tax rate is kind of a standard of care in that particular market and is a generic  what sort of challenge do you anticipate placing Otezla in that market and how do you think about navigating those challenges there  Thank you David M  Reese    Executive Vice President  Research and DevelopmentYeah  Well  let me start  Mohit  and then I ll ask Murdo to jump in  So  in mild to moderate psoriasis  there are currently no approved oral therapies  The only thing really available to patients right now is topical therapy  many of them will not ultimately experience disease control with those topical therapies  And so  we think there is a real opportunity for Otezla in that area  There are up to nearly 6 million patients with mild to moderate psoriasis in the United States alone  So that gives you a sense of the size of this opportunity and actually the prevalence of the disease  Murdo Murdo Gordon    Executive Vice President  Global Commercial OperationsYeah  And  Mohit  the only thing I would add is  yes  there is some methotrexate used there  but it s largely a topical business as Dave described and it s largely a patient population that gives very little relief  And this is really a patient population that is in the sweet spot for Otezla The other thing I have to say is that  our new colleagues when building out their positioning strategy for Otezla and their payor strategy have done a very  very nice job of positioning the access and reimbursement for Otezla as a post topical pre biologic option  So  I think for the mild to moderate population  if we re successful in securing that indication  that same payor strategy will be continued  So  I feel confident that we re in good shape there for another source of growth for Otezla going forward Robert A  Bradway    Chairman and Chief Executive OfficerSo  Ian  I know we ve got several calls or several questions still queued up  so we ll try to get through those  Apologies that we re beyond the top of the hour here  but let s go onto the next question OperatorCertainly  Our next question is from the line of Matthew Harrison from Morgan Stanley  Matthew Matthew Harrison    Morgan Stanley    AnalystGood afternoon  Thanks for taking the question  I just wanted to follow up on a comment that Dave made earlier in the call  suggesting I think that maybe you re seeing some activity in HLE BiTEs in both solid tumors and liquid tumors  Maybe you could just characterize for us what data you have internally that gave you the confidence to make that statement  Thanks David M  Reese    Executive Vice President  Research and DevelopmentYeah  Thanks  Matt  And I assume that someone would pick up on that statement  So  what I would say is  I m not ready to declare victory in any indication yet  but we re seeing the sort of pharmacodynamic activity and early suggestions of anti tumor activity that are reminiscent of the early days of BLINCYTO and that give us encouragement that we re on the right track I d also point out that we undoubtedly have the largest experience in the world in development of bispecific T cell engagers  As I noted in my remarks  we ve learned an enormous amount about dosing and scheduling appropriate management of adverse events  and I think all of that is starting to come to bear right now  And we re starting to see some of these hints in that in the HLE or half life extended format  So  again  I m not ready to declare a victory  but we re seeing signs of encouragement and we ll be ready to share some of those data as the year goes on OperatorAnd our next question is from the line of Do Kim from BMO Capital Markets  Do Do Kim    BMO Capital Markets    AnalystGreat  Thanks for taking my question  Just one on Aimovig  you ve talked previously about expanding the primary care prescribing base  How would you go about doing that and could you do it with your current sales force Murdo Gordon    Executive Vice President  Global Commercial OperationsYes  Thanks  Do  We are doing it with our current sales force  I think I talked about the 33 000 prescribing base  And I think we re seeing some encouraging results  Right now in the CGRP class  you see about 7 000 new patients coming into the class  and into the category that are receiving a CGRP therapy and it s our goal to broaden that  Given that there are so many patients  who are persisting on oral therapies and older therapies that are just not as effective and in fact  we see very high drop off and very low persistency on these older oral meds like topiramate  And we are trying to change that care continue on that pathway in the way physicians treat chronic migraine sufferers  And I think we re having some success So the 7 000 patient per week number that we re seeing is one that we re looking to grow  And we are applying all the right efforts  both in our digital campaigns  as well as our personal selling teams in the primary care community right now  So yes  the answer is  we have all the resources required to do that OperatorAnd our next question is from the line of Yaron Werber from Cowen   Company  Yaron Yaron Werber    Cowen   Company    AnalystYeah  Great  Thanks so much  If you don t mind  Dave  just have a quick housekeeping and then a question for Murdo  On the housekeeping side  omecamtiv  can you just let us know  is there one more final DSMB look before you look at the event rate  And then for Murdo  just curious about Repatha  it looks like it s beginning to grow now  But now  what s your expectation given that 70  of patients now have access to the new price    the new formulation  Thank you David M  Reese    Executive Vice President  Research and DevelopmentYeah  Yaron  So I ll take the omecamtiv question  There is an    as we ve previously discussed  there is an interim analysis for efficacy that will occur  that has a very  very high bar  a very high bar in terms of the statistical stopping rule  So  our expectation is that  the trial will continue through to the primary analysis toward the end of the year Murdo Gordon    Executive Vice President  Global Commercial OperationsYes  And Yaron  on Repatha  just a reminder  a 100  of patients are accessing the low list price because we pulled the original list price off the market in December  And we ve been able to  throughout the course of 2019  open up the commercial access  where the majority of patients receive Repatha by their physicians prescribing it without the need for paperwork and utilization management criteria  so physician attestation only in commercial is the majority condition for how they can prescribe Repatha And then in the Medicare Part D space  obviously  that s a new event for us  because we were mid cycle when we lowered the price with the introduction of the low list price  So  it s really something we re excited about as an accelerating potential for Repatha  as was mentioned  roughly 70  of Medicare Part D lives now have access to Repatha at an affordable co pay  So  we re looking forward to seeing sustained growth going forward  Our teams are ready  and I was just with our sales forces in Dallas and everybody is pretty excited about being able to treat more patients quite frankly the way they should have been treated all along OperatorAnd our next question is from the line of Geoffrey Porges from SVB Leerink  Geoffrey Geoffrey Porges    SVB Leerink    AnalystThank you very much for taking the question  A quick housekeeping and then one for Murdo  First  could you just give us an update  Dave  on where the C5 biosimilar program is  Is that still active  And then for Murdo  I m impressed with the EVENITY number  you re annualizing it sort of  350 million already  which I think is better than most of us anticipated  Could you talk a little bit about the reception you re receiving and whether you really think this can become FORTEO s  obviously  losing its exclusivity  can it become a FORTEO like brand given what you re seeing already  Thanks David M  Reese    Executive Vice President  Research and DevelopmentYeah  Geoff  so I ll take the first part of that question relating to ABP 959 or Soliris biosimilar  the Phase 3 is actively enrolling and we ll provide guidance as we come to the conclusion of that trial when you can expect to see data Murdo Gordon    Executive Vice President  Global Commercial OperationsYeah  And Geoffrey  thanks for the question on of EVENITY  We are pleased with the launch trajectory on EVENITY  it s reflective really of two markets  Japan and US primarily  The Japanese launch has been nothing short of a resounding success out there with our partners  Astellas and UCB  I think physician reception has been excellent  We positioned the product for post fracture high risk patients  And I think that that s gone really well and it s where the risk benefit equation seems to be one that most physicians are accepting off  And we ve done the same thing in the US  our launch is a little younger in the US  but nonetheless the trajectory has exceeded our own expectations as well We just recently got our permanent J code in the US and that s opening up the prescriber base as well  So  I do think that we will have a very successful franchise on our hands and  of course  UCB will be commercializing with some help from us across Europe  thanks to the approval with the EMA there So overall  whether    will it be as big as a FORTEO  that remains to be seen  We are    I will remind you slightly less expensive 30  on the low end  as much as 70  on the high end than our competitors in the category  It s a 12 month duration  so it s not a product that you take for multiple years  it s a 12 month duration  but the new patient acquisition is clearly exciting OperatorAnd our next question is from the line of Alethia Young from Cantor Fitzgerald  Alethia Alethia Young    Cantor Fitzgerald    AnalystHey  guys  Thanks for taking my question  I guess  Parsabiv is another drug that s been doing quite well in spite of Sensipar  So maybe can you talk about  should we expect continued kind of unit demand growth  I know you probably had some contracting  obviously  over the prior 12 months  But just maybe help us frame how to think about the next 12 months for Parsabiv  Thanks Murdo Gordon    Executive Vice President  Global Commercial OperationsYeah  Thanks  Alethia  The Parsabiv performance last year was fantastic  There are a number of patients who are benefiting from it  There is a change in reimbursement for Parsabiv going into    coming into 2020 that may slow the rate of growth a little  but the range of possible outcomes is broad and it s really too early to call Robert A  Bradway    Chairman and Chief Executive OfficerOkay  Ian  I think we ve got two more calls  Why don t we try to get them and then we ll wrap up OperatorVery well  Our next question is from the line of Salim Syed from Mizuho Securities  Salim Salim Syed    Mizuho Securities    AnalystYes  Hi  Thanks  guys  for taking the question  Just one for me on omecamtiv  David  you mentioned that the landscape will be changing  you believe  based on some of the recent data  And  I guess  what I was looking for some clarity on  when I presume you re talking about the SGLT2 space  specifically dapagliflozin  And then from the commentary you provide  are you envisioning this to be    omecamtiv to be on top of SGLT2s or competing at the head  And if there is any SGLT2 patients actually getting enrolled in the trial  Thank you David M  Reese    Executive Vice President  Research and DevelopmentYeah  Thanks  Salim  Yeah  So I was making reference to the SGLT2s  in particular  Our sense is that  the patients treated in those studies were probably a somewhat less sick population  So that may be a point of differentiation  And then as we have intended all along with omecamtiv  given the lack of drug drug interactions that we ve seen now in the mechanism of action  it is intended to be an add on to other therapies  Of course  in the Phase 3 trial  we will look at number of patients who are receiving things such as SGLT2s in the study Robert A  Bradway    Chairman and Chief Executive OfficerOkay  Let s get the last question OperatorAnd our final question is from the line of Cory Kasimov from J P  Morgan  Cory Gavin Scott    J P  Morgan    AnalystHi  this is Gavin on for Cory  Thanks for fitting us in  And I apologize if you answered this  but we are wondering what your assumptions are going into the double digit growth for Otezla  Does this imply label expansion or is this just with the existing label and or any comment on competitive concerns Robert A  Bradway    Chairman and Chief Executive OfficerAnd I think we ve addressed that  But why don t we just reiterate for you  Gavin  what we think is behind that Murdo Gordon    Executive Vice President  Global Commercial OperationsYeah  So we are assuming that we would secure additional indications in our assumption for double digit going forward  We re also using historical growth rate and where we re sourcing new patients right now  So I think that s pretty clear Robert A  Bradway    Chairman and Chief Executive OfficerOkay  everyone  thanks for your patience  Sorry  we went a little bit past the allotted hour  But let me just conclude by saying that we feel good about where we ended in 2019  managing through what was always going to be a transition year for us  and we think we re on the cusp now of a period of new product revenue growth  So we look forward to that  And we look forward as well to the important clinical data that is expected  particularly toward the second half of this year So  I d be remiss if I didn t just take a moment to thank  as well the Amgen staff around the world  who continue to work so hard every day to deliver on our mission to serve patients  So  thank you to them  And we look forward to having a chance to talk to all of you in April after the first quarter  Thanks Arvind Sood    Vice President of Investor RelationsThanks  Bob  Thanks  everybody  for your participation  If you have any other questions you would like to cover  of course  myself  and the rest of the IR team will be around for several hours  Have a good day Operator Operator Closing Remarks Duration  77 minutesCall participants Arvind Sood    Vice President of Investor RelationsRobert A  Bradway    Chairman and Chief Executive OfficerPeter Griffith    Executive Vice President and Chief Financial OfficerMurdo Gordon    Executive Vice President  Global Commercial OperationsDavid M  Reese    Executive Vice President  Research and DevelopmentJay Olson    Oppenheimer   Co     AnalystMichael Yee    Jefferies   Company    AnalystChristopher Raymond    Piper Sandler    AnalystBrian Skorney    Robert W  Baird   Co     AnalystEvan Seigerman    Credit Suisse    AnalystKennen MacKay    RBC Capital Markets    AnalystUmer Raffat    Evercore ISI    AnalystRobyn Karnauskas    SunTrust Robinson Humphrey    AnalystTerence Flynn    Goldman Sachs    AnalystRonny Gal    Sanford C  Bernstein    AnalystMohit Bansal    Citigroup    AnalystMatthew Harrison    Morgan Stanley    AnalystDo Kim    BMO Capital Markets    AnalystYaron Werber    Cowen   Company    AnalystGeoffrey Porges    SVB Leerink    AnalystAlethia Young    Cantor Fitzgerald    AnalystSalim Syed    Mizuho Securities    AnalystGavin Scott    J P  Morgan    Analyst
More AMGN analysis
All earnings call transcripts",2020-01-31,The Motley Fool,https://invst.ly/ppbmz,2072673
148562,370078,AMGN,Stocks   U S  Futures Lower  Virus Fears Weigh as Earnings Continue,news,"By Peter Nurse  
Investing com   U S  stock markets are set to open lower  as the deadly coronavirus in China continues to weigh on sentiment  overshadowing strong earnings from retail giant Amazon com  NASDAQ AMZN  
At 7 10 AM ET  1210 GMT   futures for the S P 500 traded 14 points  or 0 4   lower  futures for the Nasdaqdown 36 points  or 0 4   while theDJI futures contract fell 125 points  or 0 4   These are on track for a second straight down week  but January is still likely to be a positive month  the fifth in a row 
The nationwide death toll in China s coronavirus outbreak has climbed above 200  with nearly 10 000 infected  prompting the World Health Organization to declare the coronavirus a global health emergency  
The organization stopped short of recommending travel and trade restrictions with China  and also backed the efforts of the world s second largest economy to contain the outbreak 
Goldman Sachs  NYSE GS  has taken a stab at putting some estimates on the impact on growth from the efforts to control the spread of the virus  
The investment banking giant revised down its estimate for China s GDP growth in 2020 to 5 5  from 5 9  previously  It also estimated that U S  GDP growth would be hit by 0 4  in the first quarter 
On Thursday official data showed the U S  economy grew by 2 1  in the fourth quarter  resulting in full year growth of 2 3  in 2019 
Looking at the corporate sector  Amazon  NASDAQ AMZN  is set to be today s standout performer after the e commerce giant reported sales soared over the holiday season  rising 21  from the previous year  Shares traded over 8  higher premarket 
  IBM    NYSE IBM  will also be in the spotlight after the information technology company announced CEO Ginni Rometty will retire at the end of 2020 after almost 40 years with the company  to be replaced by Arvind Krishna 
Shares in Visa  NYSE V  fell premarket after the world s largest payment network posted disappointing numbers for its first quarter and said it sees muted revenue growth this year  while Amgen  NASDAQ AMGN  shares also dropped after the biotech drug maker disappointed with its 2020 outlook 
  Caterpillar    NYSE CAT  reported better than expected fourth quarter earnings Friday  but this result was based largely on successful cost cutting as revenue  fell short of expectations  as did 2020 guidance 
Economic data due for release Friday include core PCE price and personal spending data at 8 30 AM ET  1330 GMT   Michigan consumer sentiment numbers at 10 00 AM ET  1500 GMT  and Baker Hughes total rig count at 1 00 PM ET  1800 GMT  
AT 07 10 AM ET  1210 GMT   U S  crude futures rose 0 6  to  52 45 and the international benchmark Brent contract climbed 0 3  to  57 48 
Gold futures fell 0 3  and the dollar index  which tracks the greenback against a basket of developed market peers  fell 0 1  ",2020-01-31,Investing.com,https://www.investing.com/news/stock-market-news/stocks--us-futures-lower-virus-fears-weigh-as-earnings-continue-2072829,2072829
148563,370079,AMGN,Baird downgrades Amgen on soft guidance in premarket analyst action,news,"AdaptHealth  NASDAQ AHCO  initiated with Buy rating and  17  31  upside  price target at Stifel 
DURECT  NASDAQ DRRX  initiated with Buy rating and  5  158  upside  price target at B  Riley FBR  Shares up 6  premarket 
InMed Pharmaceuticals  IN CN  initiated with Buy rating and C 1 50  341  upside  price target at Maxim Group  OTCQX IMLFF  
Neptune Wellness Solutions  NEPT CN  initiated with Market Perform rating and C 3 75  14  upside   NASDAQ NEPT  
Phreesia  NYSE PHR  initiated with Overweight rating and  36  15  upside  price target at KeyBanc 
Arena Pharmaceuticals  NASDAQ ARNA  upgraded to Overweight with a  58  32  upside  price target at JPMorgan  Shares up 2  premarket 
United Therapeutics  NASDAQ UTHR  upgraded to Overweight with a  120  25  upside  price target at JPMorgan 
Amgen  NASDAQ AMGN  downgraded to Underperform with a  185  18  downside risk  price target at Baird on soft 2020 guidance  Shares down 3  premarket 
Global Blood Therapeutics  NASDAQ GBT  downgraded to Hold with a  75  10  upside  price target at SunTrust Robinson Humphrey 
Intra Cellular Therapies  NASDAQ ITCI  downgraded to Neutral with a  26  13  upside  price target at JPMorgan  Shares down 9  premarket 
ResMed  NYSE RMD  downgraded to Neutral at UBS after FQ2 results 
Rubius Therapeutics  NASDAQ RUBY  downgraded to Neutral with a  9  17  upside  price target at JPMorgan  Shares down 5  premarket ",2020-01-31,Seeking Alpha,https://invst.ly/ppfxs,2072937
148567,370083,AMGN,What Lies Ahead For Healthcare ETFs In Q4 Earnings ,opinion,The healthcare sector made a strong bounce back in the fourth quarter and continued its solid performance to start 2020  Positive news pertaining to trial results  deal activities and better than expected earnings fueled optimism in the space The ultra popular ETF  Health Care Select Sector SPDR Fund   Vanguard Health Care ETF   ASX VHT    iShares U S  Healthcare ETF  and Fidelity MSCI Health Care Index ETF  were up at least 14 0  each in the past 13 weeks  The price movement of the fund depends on earnings releases of some big names like Pfizer   NYSE PFE    Merck   NYSE MRK    Amgen   NASDAQ AMGN    AbbVie   NYSE ABBV    Gilead Sciences   NASDAQ GILD   and Bristol Myers Squibb   NYSE BMY   that dominate their returns  read    These firms are lined up to report their earnings in the coming weeks  All these stocks collectively account for 24 5  share in XLV  22 7  in IYH  21 6  in VHT and 20 9  in FHLC  Let s dig deeper into the earnings picture of these companies  which will drive the performance of the above mentioned funds in the coming days According to our methodology  the combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Inside Our Surprise Prediction for These StocksPfizer has a Zacks Rank  1 and an Earnings ESP of  1 02   indicating a lower chance of beating estimates this quarter  The stock saw no earnings estimate revision for the to be reported quarter over the past 30 days  It delivered positive earnings surprise of 4 63   on average  in the past four quarters and has a VGM Score of D  Pfizer is scheduled to report earnings on Jan 28  before the opening bell Merck is expected to report results on Feb 5 before market open  It has a Zacks Rank  3 and an Earnings ESP of  1 05   indicating reasonable chances of beating estimates  The stock delivered a positive earnings surprise in the last four quarters  with the average beat being 12 51   It witnessed no earnings estimate revision over the past 30 days for the to be reported quarter  Merck has a VGM Score of A  read    Amgen carries a Zacks Rank  3 and has an Earnings ESP of  1 55   The earnings surprise track over the past four quarters is strong  with the positive surprise being 5 82   on average  Amgen has witnessed negative earnings estimate revision of a penny over the past 30 days for the quarter to be reported  The stock has a VGM Score of B  Amgen will report earnings on Jan 30 after market close AbbVie has a Zacks Rank  3 and an Earnings ESP of  1 96   The company delivered a positive earnings surprise in the last four quarters  with the average beat being 1 71   However  it saw negative earnings estimate revision of three cents over the past month for the to be reported quarter  The stock has a top VGM Score of A  The company is scheduled to report on Feb 7 before the opening bell     Gilead is expected to release earnings on Feb 4 after market close  It has a Zacks Rank  2 and an Earnings ESP of  4 45   Gilead s negative earnings surprise was 0 66   on average  over the last four quarters  It saw no earnings estimate revision over the past month for the to be reported quarter  Gilead has a VGM Score of B  see    Bristol Myers will likely report earnings on Feb 6 before the opening bell  It has a Zacks Rank  2 and an Earnings ESP of  2 64   The stock delivered an average positive earnings surprise of 8 30  over the past four quarters  and saw no earnings estimate revision for the to be reported quarter in a month  It has a VGM Score of A Summing UpWith earnings surprise in the cards  the healthcare sector is expected to witness substantial earnings growth of  in the fourth quarter  suggesting some room for potential upside for healthcare ETFs  In particular  FHLC has a Zacks ETF Rank  3 while the remaining three have a Zacks ETF Rank  2 Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2020-01-23,Zacks Investment Research,https://www.investing.com/analysis/what-lies-ahead-for-healthcare-etfs-in-q4-earnings-200501480,200501480
148568,370084,AMGN,Lilly  LLY  Q4 Earnings And Sales Top Estimates  Stock Up,opinion,"Eli Lilly   Company   NYSE LLY   reported fourth quarter 2019 adjusted earnings per share of  1 73  which comprehensively beat the Zacks Consensus Estimate of  1 52  Earnings rose 31  year over year as higher operating costs were offset by higher revenues  lower tax rate and reduction in shares outstanding due to buybacks Quarter in DetailRevenues of  6 11 billion beat the Zacks Consensus Estimate of  6 07 billion  Sales grew 8  year over year  backed by strong volume trends for its newer drugs  namely Trulicity  Taltz  Jardiance  Basaglar  Emgality  and Verzenio  which compensated for lower sales of older products like Cialis and Forteo and the impact of Lartruvo s product withdrawal  Lilly suspended promotion of its advanced soft tissue sarcoma drug  Lartruvo due to the failure of the ANNOUNCE confirmatory study Lower realized prices had a negative impact of 1  on sales due to rebates and legislated increases in Medicare Part D cost sharing in the United States and price cuts in some international markets  Volumes rose 10  New pharma products  products launched since 2014  drove 14  of revenue growth and represented nearly 46  total revenues  up from 44  in the previous quarter  U S  revenues rose 7 to  3 52 billion while ex U S  revenues rose 10  to  2 6billion Among the established products  Forteo sales declined 18 to  360 2million  Alimta declined 5 to  530 7million  Humalog sales dropped 1  to  763 4million  Humulin sales rose 3  to  348 0million Cialis sales declined 44  to  197 8 million as U S  sales were hurt by entry of generic products  Outside U S  sales were hurt by currency headwinds  which offset the impact of higher realized prices Among the new products  Trulicity generated revenues of  1 21 billion  up 31  year over year driven by higher demand in the United States and higher volumes in ex U S  markets  which offset the impact of lower realized prices and changes in segment mix Cyramza revenues were  245 1 million  up 11  year over year driven by higher sales in both U S  and international markets Jardiance sales rose 39  to  268 0 million  driven by increased demand trends within the SGLT2 class of diabetes medicines in the United States and increased volume outside the United States  which offset the negative impact of currency Basaglar recorded revenues of  307 2 million  up 32  year over year  In the United States  sales rose 34   benefiting from higher demand and the impact of higher realized prices  Outside U S  sales growth of 28  was driven by increased volume Taltz brought in sales of  420 1 million  up 37  year over year as U S  sales gained from higher demand  which offset the impact of lower realized prices due to changes in estimates for rebates and discounts  Ex U S  sales were driven by increased volume from launches in new countries New rheumatoid arthritis drug  Olumiant generated sales of  127 8 million in the quarter compared with  114 6 million in the previous quarter backed by increased demand in international markets  In the United States  Olumiant recorded sales of  13 0 million compared with  12 1 million in the previous quarter  Revenues outside the United States were  114 9 million compared with  102 5 million in the previous quarter New advanced breast cancer treatment medicine  Verzenio generated sales of  179 1 million in the quarter  up from  157 2 million in the previous quarter driven by increased demand in the United States New CGRP antibody  Emgality generated revenues of  66 3 million in the quarter compared with  47 7 million in the previous quarter  In the United States  Emgality sales were  63 1 million compared with  45 8 million in the previous quarter  Emgality was launched in some international markets in the first quarter  which brought sales of  3 2 million in the fourth quarter Amgen s   NASDAQ AMGN   Aimovig and Teva s   NYSE TEVA   Ajovy were two other CGRP antibodies launched last year  which pose strong competition to Emgality Adjusted gross margin of 79 9  in the quarter was down 70 basis points  Operating income rose 10  year over year to  1 61 billion 2019 ResultsFull year 2019 sales rose 4  to  22 32 billion  beating the Zacks Consensus Estimate of  22 29 billion by a slight margin  However  sales were within the guided range of  22 0 billion    22 5 billionAdjusted earnings of  6 04 per share beat Zacks Consensus Estimate of  5 80 and came ahead of the guided range of  5 75 to  5 85  Earnings rose 11  year over year 2020 Guidance Lilly re affirmed its 2020 adjusted earnings guidance in the range of  6 70  6 80 per share  which it had issued in December last year  The earnings guidance represents growth in the range of 11  13   However  the company slightly raised its 2020 revenue guidance from a range of  23 6 billion  24 1 billion to  23 7 billion  24 2 billion  Lilly expects new products to help it achieve the sales growth target as the headwind from Cialis LOE and Lartruvo will abate in 2020 Gross margin guidance was maintained at approximately 81   Adjusted tax rate is expected to be approximately 15   Adjusted operating margin is expected to be 31  in 2020  maintained  Marketing  selling and administrative expense are expected to be in the range of  6 2 to  6 4 billion compared with  6 1 billion to  6 3 billion previously  Research and development expense is still expected to be in the range of  5 6 billion to  5 9 billion Our TakeLilly reported strong fourth quarter results  beating estimates on both counts  The stock was up more than 1  in pre market trading  In the past year  Lilly s stock has risen 19 6  compared with the  increase of 14    Going forward  Lilly s revenue growth is expected to be driven by higher demand for its newer drugs including Trulicity  Jardiance  Taltz  Verzenio  Basaglar  Emgality as well as newly launched glucagon nasal powder  Baqsimi and potential launch of newly approved oral tablets to treat acute migraine  Reyvow  However  generic competition for several drugs including the expected generic entry of Forteo  rising pricing pressure in the United States due to rebates and legislated increases in Medicare Part D cost sharing  and price cuts in some international markets like China  Japan and Europe are some top line headwinds expected in 2020  In the United States  prices are expected to decline in a low single digit range Nonetheless  Lilly is making significant pipeline progress with several positive late stage data readouts  multiple approvals and regulatory submissions scheduled for 2020 Lilly is also regularly adding promising new pipeline assets through business development deals  Earlier this month  Lilly announced a definitive deal to buy dermatology company  Dermira   NASDAQ DERM   for  18 75 per share in cash or approximately  1 1 billion  The deal will add Dermira s promising interleukin inhibitor in late stage development for atopic dermatitis eczema  lebrikizumab  thereby expanding Lilly s immunology pipeline Zacks RankLilly currently carries a Zacks Rank  2  Buy   You can see  Eli Lilly and Company Price  Consensus and EPS Surprise
    
 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ",2020-01-29,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-q4-earnings-and-sales-top-estimates-stock-up-200503166,200503166
148569,370085,AMGN,Amgen  AMGN  Q4 Earnings And Revenues Surpass Estimates,opinion,"Amgen  AMGN  came out with quarterly earnings of  3 64 per share  beating the Zacks Consensus Estimate of  3 44 per share  This compares to earnings of  3 42 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 5 81   A quarter ago  it was expected that this world s largest biotech drugmaker would post earnings of  3 51 per share when it actually produced earnings of  3 66  delivering a surprise of 4 27  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Amgen  which belongs to the Zacks Medical   Biomedical and Genetics industry  posted revenues of  6 20 billion for the quarter ended December 2019  surpassing the Zacks Consensus Estimate by 3 18   This compares to year ago revenues of  6 23 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Amgen shares have lost about 5 8  since the beginning of the year versus the S P 500 s gain of 1 3  
What s Next for Amgen 
While Amgen has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Amgen was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  3 90 on  6 01 billion in revenues for the coming quarter and  15 98 on  25 33 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Biomedical and Genetics is currently in the top 29  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-q4-earnings-and-revenues-surpass-estimates-200503369,200503369
148570,370086,AMGN,Amazon Beats Big On Q4 Bottom Line  Plus V  AMGN,opinion,"Amazon   NASDAQ AMZN   shares climbed more than 13  immediately following its Q4 2019 earnings release  whereby earnings per share blew away estimates     6 47 per share versus  3 98 expected  on  87 44 billion in revenues than outpaced the  86 00 billion anticipated  Expectations for Q4 earnings were on the low side  both at Zacks and on the street  so take this giant bottom line beat with a grain of salt Guidance for Q1 revenues were a range of  69 billion to  73 billion  which puts the current Zacks consensus on  71 34 squarely in the middle  North America revenues reached  53 7 billion  while AWS outperformed expectations to  9 95 billion for the quarter  Online sales grew 15  in the all important holiday shopping season  Also  consider that Amazon had been the worst performing of the Big Tech players of late  trading down year to date until today s after market Visa   NYSE V   met earnings projections of  1 46 per share on  6 05 billion in quarterly revenues  which was a smidge below forecasts  The company s Q1 Payments Volume grew 8  year over year  and it has announced a  9 5 billion share buyback program  That said  Visa shares are down more than 1  in late trading Thursday  not only did the credit card giant post a slight sales miss  but this is a company that has never once posted a negative earnings surprise    so just meeting estimates must feel a bit strange  Biotech major Amgen   NASDAQ AMGN    however  posted better than expected results on both top and bottom lines Thursday afternoon     3 64 per share easily surpassed the  3 47 expected and the  3 42 per share from the year ago quarter  and revenues of  6 2 billion pushed comfortably above expectations of  6 01 billion  Full year 2020 guidance also moved higher than the initial Zacks consensus figures   14 85   15 60 is now expected for full year earnings on sales of between  25   25 6 billion  as opposed to the  14 63 and  23 18 billion analysts were looking for  respectively  Yet shares are down 2 7  in the late session  and down year to date 
Just Released  5 Stocks Set to Double
Four Zacks experts each announce their single favorite pick with potential to gain  100  and more in the months ahead  Today  download the private Special Report that names these stocks and spotlights why their upside is so exceptional  See Stocks Now   ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/amazon-beats-big-on-q4-bottom-line-plus-v-amgn-200503359,200503359
148571,370087,AMGN,Amgen  AMGN  Stock Down Despite Q4 Earnings   Revenue Beat ,opinion,"Amgen   NASDAQ AMGN   reported fourth quarter 2019 earnings of  3 64 per share  which beat the Zacks Consensus Estimate of  3 44  Earnings rose 6  year over year as lower revenues and higher R D costs were offset by a lower share count Total revenues of  6 2 billion in the quarter beat the Zacks Consensus Estimate of  6 0 billion  However  total revenues declined 1  year over year Amgen shares have risen 20 9  in the past year against 5 6  decrease registered by the  during this period   Quarter in DetailTotal product revenues decreased 2  from the year ago quarter to  5 88 billion  U S    4 37 billion  ex U S    1 51 billion   Increasing demand of Amgen s growth and launch drugs like Prolia  Repatha   Aimovig  Parsabiv and others and strong sales of  biosimilar products and in ex U S  markets was offset by the erosion of mature brands from biosimilar new competition  Product sales growth was mostly driven by higher volumes  up 3   as prices were lower for several drugs  Net selling prices declined 4  year over year in the quarter  which resulted in the decline in total revenues Other revenues of  316 million rose 38  in the quarter Prolia revenues came in at  752 million  up 15  from the year ago quarter  driven by volume increases resulting from new patient growth as well as strong repeat rates Xgeva delivered revenues of  489 million  up 7  from the year ago quarter mainly due to higher demand  which drove volumes up 4  Kyprolis recorded sales of  266 million  up 6  year over year driven primarily by 12  volume growth in the United States Blincyto sales increased 27  from the year ago period to  80 million Repatha generated revenues of  200 million  up 26  year over year  as higher volume was partially offset by lower prices Vectibix revenues came in at  182 million  up 8  year over year  Nplate sales rose 15  to  210 million Parsabiv recorded sales of  179 million  up 49  as higher demand offset the impact of lower selling prices Amgen s new migraine drug  Aimovig recorded sales of  98 million in the quarter  higher than  66 million in the previous quarter as higher demand was partially offset by unfavorable changes in accounting estimates Newly launched osteoporosis drug  Evenity recorded sales of  85 million in the quarter compared with  59 million in the previous quarter  driven by strong uptake in both Japan and the United States where the product has been launched  In the United States  where Evenity was launched in April 2019  sales were  27 million while international sales were  58 million  Evenity was approved in Europe in December 2019 Amgen recorded total biosimilars revenues of  258 million in the quarter  Amgen markets Kanjinti  a biosimilar of Roche s   OTC RHHBY   Herceptin  and Mvasi  biosimilar of Roche s Avastin  in the United States and Amgevita  biosimilar of AbbVie s   NYSE ABBV   Humira   Kanjinti and Mvasi outside of the United States  Amjevita sales were  71 million in the quarter  Sales of Kanjinti and Mvasi were  103 million and  84 million  respectively  Kanjinti and Mvasi were launched in the United States in July 2019  On the call  Amgen mentioned that it now faces additional biosimilar competition for Kanjinti and Mvasi and expects other competitors to enter the market in 2020 Amgen expects more biosimilars to gain approval this year and contribute to total revenues  especially as drug pricing issues increase demand for lower cost treatment options  In December  the FDA granted approval to Avsola  ABP 710   Amgen s biosimilar version of J J Merck s blockbuster immunology medicine  Remicade  It also filed a biologics license application  BLA  to the FDA for ABP 798  a biosimilar candidate to Roche s Rituxan in the same month In November  Amgen completed the previously announced acquisition of Celgene s blockbuster psoriasis drug  Otezla  which the latter had to divest in order to complete its merger with Bristol Myers   NYSE BMY    Sales of Otezla were  178 million for the approximately five weeks post closing in 2019 However  Amgen s mature drugs like Enbrel  Aranesp  Epogen  Neupogen and Neulasta are facing an array of branded and generic competitors Aranesp revenues declined 10  from the prior year quarter to  427 million on lower volume due to increased competitive pressure  Meanwhile  lower net selling price as well as unfavorable changes in inventory hurt sales Revenues of the other ESA  Epogen  declined 20  to  210 million due to lower selling prices and demand with the category becoming extremely competitive Neulasta revenues declined 43  from the year ago period to  665 million due to lower selling prices and biosimilar competition Neupogen recorded 17  decline in sales to  62 million in the quarter  Enbrel delivered revenues of  1 35 billion  up 2  from the year ago quarter  driven primarily by favorable changes in inventory along with a slight price increase  which offset volume declines due to continued competition Sensipar Mimpara revenues declined 76  to  107 million due to several at risk generic launches  Other product sales rose 19  to  87 million Operating Margins DecreaseAdjusted operating margin declined 70 basis points  bps  to 44 6   Adjusted operating expenses rose 2  year over year in the quarter to  3 58 billion  SG A spend decreased 2  to  1 5 billion on cost control  which offset the impact of Otezla related expenses  R D expenses rose 11  year over year to  1 29 due to higher spending on Amgen s early  and late stage oncology pipeline 2019 ResultsFull year 2019 sales declined 2  to  23 36 billion  beating the Zacks Consensus Estimate of  23 18 billion  Sales slightly topped the guided range of  23 1  23 3 billion  Product sales declined 1  Adjusted earnings for 2019 of  14 82 per share were also above the Zacks Consensus Estimate of  14 63 as well as the guided range of  14 50  14 70  Earnings rose 3  year over year 2020 OutlookAmgen issued its financial guidance for 2020  In the year  it expects revenues in the range of  25 0 billion  25 6 billion which indicates an increase from 2019 levels  In 2020  Amgen s base business  excluding Otezla  is expected to be stable  The Zacks Consensus Estimate for revenues stands at  25 33 billion Importantly  Amgen s net selling price for its drugs fell 5  globally in 2019 and is expected to decline in 2020 at a low to mid single digit rate Adjusted earnings per share are anticipated in the range of  14 85  15 60  The Zacks Consensus Estimate was pegged much higher at  15 98 per share Adjusted operating costs are expected to grow in a low double digit percentage range year over year in 2020 Amgen plans to spend approximately  700 million for capital expenditures in 2020 Our TakeAmgen s stock was down 2 5  in after hours trading despite announcing strong fourth quarter results  This is because its 2020 earnings guidance fell well short of expectations In 2020  while Amgen s growth products like Prolia  Evenity  Repatha  Aimovig  Otezla will drive sales  increasing competition for its legacy products will continue to create pressure on sales  However  biosimilars and international expansion provide incremental growth opportunities  Amgen boasts a strong biosimilars portfolio  which can drive long term growth  Amgen is also progressing with its pipeline while regularly pursuing  external opportunities   such as the acquisition of Otezla and the recently acquired acquired 20 5  stake in China s BeiGene Ltd  Amgen also expects several important clinical data readouts from its innovative pipeline this year Amgen currently carries a Zacks Rank  3  Hold   You can see  Amgen Inc  Price  Consensus and EPS Surprise 
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year  ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-stock-down-despite-q4-earnings--revenue-beat-200503531,200503531
148600,370116,AMGN,Bristol Myers reports positive data on cancer treatment acquired in Celgene deal,news,"By Michael Erman and Carl O Donnell
 Reuters    Bristol Myers Squibb  NYSE BMY  Co on Saturday said that an experimental cancer therapy it acquired as part of its  74 billion deal for  Celgene Corp   NASDAQ CELG  produced positive results in a clinical trial 
The company said it will apply for U S  approval for the treatment for a type of advanced blood cancer by the end of the year 
The treatment  liso cel  is a newer type of immunotherapy known as CAR T cell therapy  that takes immune cells from a patient  engineers them to better recognize and attack cancer and infuses them back into the patient 
The study tested three dose levels of liso cel in the 269 patients with relapsed or refractory large B cell lymphoma 
Nearly three quarters of the patients responded to the one time treatment  with 53  experiencing a complete response  meaning no detectable sign of the cancer  according to data presented at American Society of Hematology Conference in Orlando 
The data marks a win for Bristol Myers after its purchase of Celgene met resistance from some investors who thought that it was overpaying for the cancer focused biotech 
It is also a positive sign for Celgene investors  who are entitled to received a contingent value right  or CVR  payment of  9 a share if three treatments in development  including liso cel  achieve timely approvals 
Celgene had forecast annual sales reaching  3 billion for the immunotherapy  If approved  it would lessen some of Bristol Myers  dependence on its immunotherapy Opdivo  which has faced stiff competition from Merck   Co s market leading rival drug Keytruda 
Liso cel would compete with already approved CAR T therapies Kymriah from Novartis AG s Gilead Sciences  NASDAQ GILD  Inc s Yescarta  Several other companies are also developing CAR T cell therapies 
Bristol Myers closed its deal for Celgene in November  after anti trust regulators approved it on the condition it divest Celgene s psoriasis drug Otezla   Amgen Inc   NASDAQ AMGN  agreed to purchase Otezla for  13 4 billion in August 
Bristol Myers managed to win investor approval for the deal despite resistance from investors Starboard Value LP and Wellington Management  who pushed other investors to vote against it ",2019-12-07,Reuters,https://www.investing.com/news/general/bristolmyers-reports-positive-data-on-cancer-treatment-acquired-in-celgene-deal-2036286,2036286
148601,370117,AMGN,Amgen Stock Rises 3 ,news,"Investing com   Amgen  NASDAQ AMGN  Stock rose by 3 04  to trade at  243 93 by 11 19  16 19 GMT  on Monday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 666 80K  Amgen has traded in a range of  239 50 to  243 93 on the day 
The stock has traded at  243 9300 at its highest and  231 5100 at its lowest during the past seven days ",2019-12-16,Investing.com,https://www.investing.com/news/stock-market-news/amgen-stock-rises-3-2042171,2042171
148602,370118,AMGN,Amgen prevails in appeal of adverse patent ruling on Sensipar,news,"The U S  Court of Appeals for the Federal Circuit has vacated a lower court ruling clearing Amneal Pharmaceuticals  AMRX  3 6   of infringing on an Amgen  AMGN  0 8   patent covering Sensipar  cinacalcet  and has sent the case back to the Delaware district court for further action 
The appeals court found that Zydus Pharmaceuticals  generic offering infringes while Piramal Pharma Solutions  does not ",2020-01-07,Seeking Alpha,https://invst.ly/pexdf,2054068
148603,370119,AMGN,Guardant Health teams up with Amgen to develop CDx test,news,"Guardant Health  GH  2 2   will collaborate with Amgen  AMGN  1   on developing a blood based companion diagnostic  CDx  test for candidate AMG 510 
GH will pursue regulatory approvals in the U S   Europe and Japan for its Guardant360 CDx for this use in metastatic non small cell lung cancer ",2020-01-13,Seeking Alpha,https://invst.ly/phdyg,2058038
148604,370120,AMGN,Better Buy  Amgen vs  Gilead Sciences,news,"Gilead Sciences  NASDAQ GILD  has been struggling recently as the company s hepatitis C drug business is no longer performing as well as it used to  Last year  the pharma stock gained a meager 3 88  in part due to its declining hepatitis C Virus  HCV  drug sales 
By contrast  Amgen s  NASDAQ AMGN  stock gained a healthy 23 84  last year  despite some of the company s products    such as Neulasta  which treats a lack of white blood cells caused by chemotherapy    encountering stiff competition from biosimilars  Will Amgen continue to outperform Gilead Sciences moving forward  
Product lineup
Though Gilead Sciences  HCV revenue is declining  this segment still includes products such as Harvoni and Epclusa  which generate decent sales  However  Gilead Sciences makes the bulk of its revenue from its HIV lineup  In particular  the company s HIV prevention medicine Biktarvy has been performing well  Gilead Sciences HIV products also include Genvoya  Descovy  and Truvada  But the U S  government filed a lawsuit against Gilead Sciences last year alleging that Descovy and Truvada infringe on patents held by the U S  Department of Health and Human Services  DHHS   Not much has come of this lawsuit yet  

Amgen s top selling product is Enbrel  which treats several conditions  including rheumatoid arthritis  RA   The company also boasts several other drugs with growing sales  including Prolia  a medicine used to treat osteoporosis in postmenopausal women  Lastly  Amgen can count on sales of Xgeva  which treats giant cell bone tumors  and its cancer medicine Kyprolis  
Financial results
During the third quarter  Gilead Sciences posted total revenue of  5 6 billion  which was flat compared to the same period the year prior  The company s HCV business posted revenue of  674 million  down from  902 million during the prior year quarter  Meanwhile  the company s HIV sales were  4 2 billion  a 13 5  year over year increase  Further  Gilead posted an operating loss of  1 5 billion as its expenses soared by 138  year over year  The company also posted a loss per share of  0 92  compared to its earnings per share  EPS  of  1 62 in the same quarter the year before  
Amgen s performance during the third quarter wasn t particularly stellar either  The company s revenue of  5 7 billion decreased by 3  year over year  mostly as a result of competition from biosimilars for  key products  such as Neulasta  However  the company recorded a generally accepted accounting principles  GAAP  operating income of  2 5 billion  up 7  year over year  and a GAAP EPS of  3 27  up 14  year over year  
Pipeline
Gilead Sciences boasts several potential medicines in its late stage pipeline  Most notably  the company s product Filgotinib is being evaluated for several conditions  including psoriatic arthritis  rheumatoid arthritis  and Crohn s disease  This product could become highly successful if it passes the appropriate clinical and regulatory hurdles  
Amgen recently completed its acquisition of psoriatic arthritis drug Otezla from Bristol Myers Squibb  This product will bolster the company s pipeline as it is being evaluated for several other conditions including a rare inflammatory disorder called Behcet s disease  Amgen s late stage pipeline includes other products such as Tezepelumab  a potential treatment for severe asthma  
Which is the better buy 
Investors looking for stocks that will provide strong revenue growth will have to look elsewhere  these two pharma giants are unlikely to deliver that  at least for now 
However  I think Amgen wins this matchup for three reasons  First  Amgen is more attractively valued when taking into account future earnings growth  Amgen s price to earnings growth  PEG  is 2 07  while Gilead Sciences  PEG ratio is 5 27  Second  Amgen is a better dividend stock  The company offers a dividend yield of 2 66  and a payout ratio of 43 55   With Amgen raising its quarterly dividends by 83 5  over the past five years  investors can expect more in the future  Gilead Sciences  juicy yield of 4  isn t backed by a conservative payout ratio  currently at 116  
Lastly  Amgen s recent acquisition of Otezla will help boost the company s sales  This is why Amgen is  in my view  the better buy at the moment ",2020-01-24,The Motley Fool,https://invst.ly/pmcqh,2066973
148605,370121,AMGN,Amgen Stock Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  Stock fell by 3 02  to trade at  227 95 by 10 32  15 32 GMT  on Friday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 1 25M  Amgen has traded in a range of  227 95 to  235 88 on the day 
The stock has traded at  243 8500 at its highest and  227 8900 at its lowest during the past seven days ",2020-01-24,Investing.com,https://www.investing.com/news/stock-market-news/amgen-stock-falls-3-2067228,2067228
148606,370122,AMGN,Which Big Biotech Has the Safer Dividend    Amgen or Gilead Sciences ,news,"You can count the number of big biotechs that pay dividends without even using all of your fingers  Two of the best dividends belong to Amgen  NASDAQ AMGN  and Gilead Sciences  NASDAQ GILD   Amgen s dividend currently yields nearly 2 7   while Gilead s yield stands right at 4  
Neither company has had any problems whatsoever in the past funding its dividend program  But that doesn t mean the future won t hold any bumps in the road  Which of these big biotechs has a safer dividend  

What the numbers say
One of the most important metrics to look at when evaluating the health of a given company s dividend is the payout ratio  This number provides a quick assessment of what percentage of a company s earnings are being used to fund dividends 
Amgen s payout ratio of 43 6  indicates that the biotech should be able to easily keep its dividends flowing without breaking a sweat  On the other hand  Gilead s payout ratio of 116  appears to be more concerning  No company can pay out more in dividends than it makes in profits for very long 
But before we immediately give the safer dividend prize to Amgen  let s dive deeper into Gilead s financial position  The company reported a net loss of  1 17 billion in the third quarter and shelled out  2 4 billion in dividend payments during the period  This performance weighed heavily on Gilead s payout ratio 
There s more to the story  though  Gilead s Q3 loss resulted from the company s  3 92 billion upfront payment that was part of its expanded collaboration agreement with Galapagos  Before the paper loss in the third quarter  Gilead s payout ratio was around 52   Although that s a little higher than Amgen s number  it s still quite healthy 
Looking to the future
An even more critical factor to consider is how strong Amgen s and Gilead s cash flows are  A company with solid cash flow can fund a dividend program even if its earnings are low 
Amgen s operating cash flow over the last 12 months was  9 8 billion with a free cash flow of  6 4 billion  Gilead s operating cash flow during the same period was  8 9 billion with a free cash flow of  3 3 billion  While Amgen pays out a little more than Gilead does in dividends each quarter   2 6 billion  compared to  2 4 billion in Q3   its stronger cash flow appears to give it more flexibility in funding future dividends  
But cash flows can decline over time  Amgen faces significant competition for several of its top selling drugs  Sales continue to plunge for Neulasta and Sensipar  especially  Meanwhile  the worst days for Gilead s hepatitis C virus  HCV  franchise appear to be in the past  setting the stage for the company to deliver stronger cash flow going forward with its HIV drugs and a potential winner in immunology with filgotinib 
Still  though  Wall Street analysts project that Amgen will increase its earnings by an average of nearly 8  annually over the next five years  The biotech s newer products such as migraine drug Aimovig and immunology drug Otezla  which Amgen picked up with Bristol Myers Squibb s acquisition of Celgene  should fuel revenue and earnings growth  Analysts think Gilead will return to earnings growth over the next five years but will be able to increase earnings by less than 2  annually  
The safer dividend
My view is that both Amgen and Gilead Sciences are solid dividend stocks  I don t think either company will run into problems paying dividends  But if I had to pick only one of these stocks based solely on how safe its dividend is  I d have to go with Amgen because of its lower payout ratio and stronger cash flow 
I think the jury is still out on earnings growth  though  My hunch is that Gilead will beat analysts  earnings growth projections if it wins regulatory approvals for filgotinib and its HCV franchise sales stabilize more than they ve done so far  I also expect Gilead to continue offering a higher yield than Amgen does  even if Amgen dramatically increases its dividend  which I think is very likely  
But a higher dividend yield doesn t translate to a safer dividend  I believe Amgen still has the edge on that front ",2020-01-26,The Motley Fool,https://invst.ly/pmzqg,2067890
148613,370129,AMGN,Know These 3 Facts To Avoid Paying Half Your Retirement Income To The IRS   January 13  2020,opinion,"If you do not make a required minimum distribution  RMD  from your own or an inherited IRA by the specified deadline  the IRS could hit you with a big penalty   50   For example  if you were required to withdraw a minimum of  4 000 and you did not  you would be obliged to pay  2 000  Plus  beginning January 1  2020  the rules concerning RMDs were updated 
In case you re like most investors  you re probably trying to build a financial portfolio that is solid enough to guarantee a comfortable retirement  Among retirement financial planners  this is known as the  accumulation phase   In this stage  your objective is to carefully invest by selecting stocks with long term potential for your retirement nest egg  For example  you might choose Amgen  AMGN   which is a current top ranked dividend stock 
There is also a second phase of retirement planning that gets less focus   despite the fact that it s the more interesting part  It s the  distribution phase   which essentially means spending the wealth you ve worked hard to amass 
Planning for the distribution phase is the time where you may make decisions about where you ll want to live in retirement  whether you ll want to travel  hobbies you may pursue  and other decisions that will affect your retirement spending 
Along with those choices  you need to be mindful of the RMD  because it applies to the majority of retirement accounts  This IRS rule requires you to withdraw a specific minimum amount from any qualified accounts you have when you reach a certain age  previously it was 70 1 2  but beginning in 2020  it is 72 
Why does the IRS require these distributions  It s straightforward   they need to ensure they get their tax  In the event that this standard didn t exist  individuals could live off other pay and never pay tax on their retirement investment returns  So  that cash could be left to family or companions as an inheritance without the IRS getting any taxes from you 
The Most Important Things to Know About RMDs
What types of retirement accounts have RMDs  Qualified retirement accounts such as IRA accounts  401 k s  457 plans and other tax deferred retirement savings plans like a TSP  403 b   TSA  SEP  or SIMPLE IRA plan require withdrawals in retirement 
When do I need to begin withdrawals  For most accounts  you should take your first distribution by April 1 of the year following the calendar year in which you turn 72  If you retire after 72  you must withdraw your first RMD from your 401 k   profit sharing  403 b   or other defined contribution plan by April 1 of the year following the calendar year that you retire 
Every year after your start date  you are required to take your RMD by December 31  Remember  for Roth IRAs you do not have to take an RMD because you paid taxes before contributing  However  other types of Roth accounts do require RMDs  but you may be able to avoid them  for instance  by rolling your Roth 401 k  into your Roth IRA  
What happens if I don t take my RMD  The penalty for not taking a required minimum distribution  or not taking a large enough distribution  is a 50  tax on the amount not withdrawn in time 
How much money do I have to withdraw  To calculate a specific RMD  you must divide your prior year s December 31st retirement account balance by a  distribution period  factor based on your age 
Example  Ann is 71 and must take her first RMD in the year that she reaches age 72  Her year end IRA balance the prior year was  100 000  Her  distribution period  factor is 27 4  The result of dividing  100 000 by 27 4 is  3 649 63   the amount of the RMD that Ann must withdraw for the calendar year in which she turns 72 
Learning about the  distribution phase  is just one aspect of preparing for your nest egg years 
To learn more about the tax implications of retirement spending   and much more about retirement planning   download our free guide  Retirement Made Easy You ll find useful  detailed steps to help you navigate both the accumulation and distribution phases of retirement planning  Get Your FREE Guide Now",2020-01-12,Zacks Investment Research,https://www.investing.com/analysis/know-these-3-facts-to-avoid-paying-half-your-retirement-income-to-the-irs--january-13-2020-200498261,200498261
148614,370130,AMGN,Should Value Investors Consider Amgen  AMGN  Stock Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value  One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Amgen Inc    NASDAQ AMGN   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Amgen has a trailing twelve months PE ratio of 16 54  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 20 53  If we focus on the long term PE trend  Amgen s current PE level puts it above its midpoint of 14 32 over the past five years  Moreover  the current level stands well below the highs for the stock  suggesting that it can be a solid entry point Further  the stock s PE also compares favorably with the Zacks Medical sector s trailing twelve months PE ratio  which stands at 23 48  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Amgen has a forward PE ratio  price relative to this year s earnings  of just 15 03  so it is fair to say that a slightly more value oriented path may be ahead for Amgen stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings  Right now  Amgen has a P S ratio of about 6 22  This is a bit lower than the S P 500 average  which comes in at 3 56x right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  this suggests some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  Amgen currently has a Value Score of B  putting it into the top 40  of all stocks we cover from this look  This makes Amgen a solid choice for value investors  and some of its other key metrics make this pretty clear too  What About the Stock Overall Though Amgen might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of D and a Momentum Score of A  This gives AMGN a Zacks VGM score   or its overarching fundamental grade   of B   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been solid at best  The current quarter has seen eight estimates go higher in the past sixty days compared to none lower  while the full year estimate has seen eight up and none down in the same time period  This has had a positive impact on the consensus estimate though as the current quarter consensus estimate has risen by 5 8  in the past two months  while the full year estimate has inched higher by 1 4   You can see the consensus estimate trend and recent price action for the stock in the chart below Amgen Inc  Price and Consensus   This somewhat bullish trend is why the stock has just a Zacks Rank  2  Buy  and why we are looking for outperformance from the company in the near term  Bottom LineAmgen is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Further  a strong industry rank  among Top 34  of more than 250 industries  instills our confidence  However  over the past two years  the Zacks Medical   Biomedical and Genetics industry has clearly underperformed the broader market  as you can see below So  value investors might want to wait for analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2020-01-15,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-consider-amgen-amgn-stock-now-200499314,200499314
148615,370131,AMGN,Biotech Stock Roundup  Updates From HZNP   CLVS  BioNTech To Acquire Neon,opinion,"This week  a few biotech companies came out with pipeline and regulatory updates  Horizon Therapeutics   NASDAQ HZNP   got a significant boost with the FDA approval of its thyroid eye disease  TED  drug  The FDA also accepted Clovis Oncology  Inc  s   NASDAQ CLVS   application for Rubraca  rucaparib  as a monotherapy treatment of adult patients with BRCA1 2 mutant recurrent  metastatic castrate resistant prostate cancer Recap of the Week s Most Important Stories FDA Approves Horizon s Thyroid Eye Disease Drug   Horizon Therapeutics plc announced that the FDA approved Tepezza  teprotumumab trbw  for the treatment of TED  Tepezza is a fully human monoclonal antibody  mAb  and a targeted inhibitor of the insulin like growth factor 1 receptor  IGF 1R  that is administered to patients once every three weeks for a total of eight infusions  The FDA approval of the drug comes ahead of the Prescription Drug User Fee Act  PDUFA  goal date of Mar 8  2020   The approval was based on statistically significant  positive results from the phase II study as well as the phase III confirmatory clinical study  OPTIC Clovis  sNDA for Rubraca Gets Priority Review Status   Clovis Oncology  Inc  announced that the FDA accepted its supplemental New Drug Application  sNDA  for Rubraca  rucaparib   The agency granted Priority Review status to the application  with a PDUFA date of May 15  2020  Clovis submitted the sNDA for Rubraca as a monotherapy treatment of adult patients with BRCA1 2 mutant recurrent  metastatic castrate resistant prostate cancer in November 2019 A Priority Review designation is granted to proposed medicines that the FDA has found to have the potential to offer a significant improvement in the safety or effectiveness of the treatment  prevention or diagnosis of a serious condition  The designation shortens the review period from the standard 10 months to six months Clovis currently carries a Zacks Rank  2  Buy   You can see  Kala Pharmaceuticals Completes Enrollment in Phase III  Kala Pharmaceuticals  Inc    NASDAQ KALA   announced the completion of enrollment in its STRIDE 3  Short Term Relief In Dry Eye  phase III study for KPI 121 0 25   its product candidate for the short term treatment of dry eye disease  Upon approval  the company plans to commercialize KPI 121 0 25  under the brand name Eysuvis  It also plans to report top line results from the study during the first quarter of 2020  Additionally  the company targets to resubmit its New Drug Application  NDA  to the FDA in the first half of 2020 BioNTech to Acquire Neon Therapeutics  BioNTech   NASDAQ BNTX   announced that it will acquire biotechnology company  Neon Therapeutics  Inc    NASDAQ NTGN    in an all stock transaction  valued at approximately  67 0 million  Neon is developing novel neoantigen based T cell therapies  Upon closing  it will operate as a subsidiary of BioNTech  a global clinical stage biotechnology company focused on patient specific immunotherapies for the treatment of cancer and other serious diseases  The transaction is expected to close in the second quarter of 2020 and will strengthen BioNTech s immunotherapy pipeline Performance    Medical   Biomedical and Genetics Industry 5YR   Return
  
The Nasdaq Biotechnology index lost 0 48  in the last four trading sessions  Among the biotech giants  Regeneron lost 6 17  in the period  Over the past six months  shares of Amgen  NASDAQ AMGN  have gained 36 95    See the last biotech stock roundup here    What s Next in Biotech Stay tuned for more pipeline updates Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ",2020-01-21,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-updates-from-hznp--clvs-biontech-to-acquire-neon-200500630,200500630
148616,370132,AMGN,Amgen  AMGN  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"Wall Street expects a year over year increase in earnings on lower revenues when Amgen  AMGN  reports results for the quarter ended December 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on January 30  2020  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This world s largest biotech drugmaker is expected to post quarterly earnings of  3 48 per share in its upcoming report  which represents a year over year change of  1 8  
Revenues are expected to be  6 01 billion  down 3 5  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Amgen 
For Amgen  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  1 55  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Amgen will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Amgen would post earnings of  3 51 per share when it actually produced earnings of  3 66  delivering a surprise of  4 27  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Amgen doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2020-01-23,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-reports-next-week-wall-street-expects-earnings-growth-200501147,200501147
148617,370133,AMGN,Will Pfizer s  PFE  BioPharma Unit Boost Its Q4 Earnings ,opinion,"Pfizer  Inc    NYSE PFE   Biopharmaceuticals Group comprises six business units   Oncology  Inflammation   Immunology  Rare Disease  Hospital  Vaccines and Internal Medicine  It is the company s key top line driver Within the Biopharma group  oncology sales are likely to have risen in the fourth quarter  driven by higher sales of Ibrance  Inlyta  Xalkori and alliance revenues from Astellas for Xtandi Continued strong uptake in international markets and consistent growth in the United States are likely to have driven Ibrance s sales  Importantly  U S  sales of Inlyta rose significantly in the third quarter  gaining from FDA approvals in 2019 for the combination of Inlyta plus Pfizer s Bavencio and Inlyta plus Merck s   NYSE MRK   Keytruda in first line treatment of advanced renal cell carcinoma patients  The trend is expected to have continued in the fourth quarter In non oncology area  sales of drugs like Xeljanz  alliance revenues from Bristol Myers   NYSE BMY   for Eliquis and Chantix are likely to have provided top line support  Regarding Xeljanz  continued growth in rheumatoid arthritis  RA  revenues and contributions from launches in new indications  psoriatic arthritis and ulcerative colitis  UC  are likely to have driven sales In July 2019  Xeljanz s prescribing information in the United States was updated by the FDA to include two additional boxed warnings as well as changes to the indication and dosing for UC following review of a post marketing study  Regarding this update  Pfizer mentioned on the third quarter conference call that it was not sure how the label update will affect prescribing trends of the drug in the future quarters  An update is expected on the fourth  quarter call The Zacks Consensus Estimate for sales of Ibrance  worldwide  and alliance revenues from Eliquis is  1 36 billion and  1 05 billion  respectively  The Zacks Consensus Estimate for Inlyta and Xeljanz s sales is pegged at  150 million and  616 million  respectively Pfizer s shares have declined 0 6  in the past year against an increase of 16 8  for the  Importantly  new drug Vyndaqel  which was launched in the United States in May 2019 for the treatment of the transthyretin amyloid cardiomyopathy  recorded sequentially higher sales in the third quarter  a trend likely to have continued in the to be reported quarter However  sales of some key drugs like of Prevnar 13 Prevenar 13 and Enbrel declined in the past two quarters  While sales of Prevnar 13 Prevenar suffered as a result of decreased government purchases for the pediatric indication and continued decline in revenues for the adult indication in the United States  Enbrel revenues in key European markets declined due to continued biosimilar competition  It remains to be seen if sales of these drugs have improved this time around  Pfizer has exclusive rights to Amgen s   NASDAQ AMGN   blockbuster RA drug  Enbrel  outside the United States and Canada The Zacks Consensus Estimate for sales of Enbrel and Prevnar is  439 million and  1 5 billion  respectively Overall  in the fourth quarter  higher sales of the Biopharma segment and strong emerging markets sales are likely to have made up for lower sales in the Upjohn group   Read More   Pfizer currently sports a Zacks Rank  1  Strong Buy   You can see  Pfizer Inc  Price and Consensus
    Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020 Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ",2020-01-23,Zacks Investment Research,https://www.investing.com/analysis/will-pfizers-pfe-biopharma-unit-boost-its-q4-earnings-200501371,200501371
148641,370157,AMGN,U S  judge rules for Regeneron  Sanofi in Amgen cholesterol drug patent fight,news,By Jan Wolfe  Reuters    A U S  judge on Wednesday set aside a jury verdict that found  Amgen Inc   O AMGN  patents on its cholesterol drug Repatha were valid  handing a victory to Regeneron Pharmaceuticals Inc  O REGN  and Sanofi SA  PA SASY   which sells a rival drug  The ruling from U S  District Judge Richard Andrews in Wilmington  Delaware was the latest reversal of fortune in a long running lawsuit in which Amgen is seeking to stop French drugmaker Sanofi and U S  biotech Regeneron from selling their drug Praluent  Repatha and Praluent won U S  approval about two weeks apart in July of 2016  Both drugs dramatically lower  bad  LDL cholesterol by blocking a protein known as PCSK9 that prevents LDL removal from the blood  The injected drugs were later shown to also cut the risk of heart attacks   The judge  in setting aside the jury s verdict reached in February  said some patent claims by Amgen relating to antibodies targeting PCSK9 were invalid because they did not sufficiently disclose the Thousand Oaks  California based company s claimed innovations    It has been our longstanding belief that all of Amgen s asserted U S  PCSK9 patent claims are invalid  and we are pleased that today s decision reaffirms this   Sanofi and Regeneron said in a statement   California based Amgen said in a statement that it disagreed with aspects of the court s decision and will seek review by the appellate court   Protecting intellectual property is critical to our business since it allows for our investment in the research and development of new medicines   Amgen said   Consequently  we are disappointed with today s decision  and we look forward to presenting our case to uphold the jury s verdict   Despite initial forecasts for multibillion dollar sales  restrictions placed by insurers on use of the potent but expensive drugs have severely limited patient access and sales  Repatha had worldwide sales of  152 million in the second quarter of 2019  while Regeneron reported Praluent sales of  73 7 million for the period ,2019-08-28,Reuters,https://www.investing.com/news/stock-market-news/us-judge-rules-for-regeneron-sanofi-in-amgen-cholesterol-drug-patent-fight-1965755,1965755
148642,370158,AMGN,Amgen Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3 22  to trade at  201 11 by 09 32  13 32 GMT  on Monday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 207 14K  Amgen has traded in a range of  201 00 to  202 94 on the day 
The stock has traded at  210 9700 at its highest and  201 0100 at its lowest during the past seven days ",2019-09-09,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-3-1973450,1973450
148643,370159,AMGN,Amgen Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3 16  to trade at  195 92 by 10 53  14 53 GMT  on Tuesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 1 30M  Amgen has traded in a range of  195 93 to  201 75 on the day 
The stock has traded at  210 9700 at its highest and  195 9200 at its lowest during the past seven days ",2019-09-10,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-3-1974585,1974585
148644,370160,AMGN,U S  charges six investment bankers over insider trading scheme,news,"By Chris Prentice
NEW YORK  Reuters    U S  prosecutors said on Tuesday they had charged six members of an insider trading ring who worked for firms including  Goldman Sachs Group   N GS   Moelis and Centerview Partners and allegedly booked tens of millions of dollars in illicit profits 
The U S  Attorney s Office for the Southern  NYSE SO  District of New York has arrested three members of the international ring and unsealed four separate indictments in recent days 
The bankers and others all booked trading profits off nonpublic information related to deals including acquisitions  the prosecutors said in a statement 
They said Benjamin Taylor  formerly an employee of investment banking firm Moelis  and Darina Windsor  a former employee of boutique investment bank Centerview Partners  obtained and leaked nonpublic information about publicly traded companies to securities dealers 
The bankers shared in the profits from the trades beginning in at least January 2013  authorities said in an indictment unsealed on Monday 
That included profits from buying shares of biotech firm InterMune Inc ahead of a 2014 announcement of an  8 3 billion acquisition by Roche Holding AG  S ROG   profits from shares of Onyx Pharmaceuticals before news reports in June 2013 that it would be purchased by Amgen  O AMGN  for  10 4 billion  and profits off shares of Pharmacyclics ahead of an announcement it would be purchased by  AbbVie Inc   N ABBV  for  21 billion in 2015 
Windsor and Taylor  who were romantically involved   repeatedly accessed internal electronic files  of their employees  including files relating to business deals on which they were not involved  the authorities said 
A Moelis spokeswoman confirmed Taylor had been a  junior employee   A Centerview spokesman said Windsor  also a  junior employee   was terminated nearly four years ago for misconduct 
Securities trader Joseph El Khouri was arrested on Monday in the United Kingdom  He allegedly received leaked information from Windsor and Taylor  which he then passed along to journalists 
El Khouri and an unnamed trader built up long positions in companies targeted for acquisition  court documents said  El Khouri realized over  2 million in illicit gains trading securities of at least six different companies  according to the documents 
Bryan Cohen  a banker who worked for Goldman Sachs  was arrested on Friday 
Cohen shared inside information with a securities trader named Georgios Nikas  who is also an owner of a chain of Greek restaurants in New York  prosecutors said 
From December 2012 through 2017  Nikas and another trader obtained information from Taylor  Windsor and Cohen  prosecutors said 
They said Nikas also received information from Telemaque Lavidas  the son of a member of the board of directors at Ariad Pharmaceuticals Inc  Lavidas was arrested on Friday 
The U S  Securities and Exchange Commission said in a separate statement on Tuesday it had obtained an order freezing Nikas s assets  The SEC had filed an emergency action charging Cohen and Nikas on Oct  18 
Nikas  Taylor and Windsor remain at large  the U S  Attorney s office said  None of the defendants could be reached immediately for comment ",2019-10-22,Reuters,https://www.investing.com/news/stock-market-news/us-charges-six-investment-bankers-over-insider-trading-scheme-2001714,2001714
148645,370161,AMGN,Amgen Rises 3 ,news,"Investing com   Amgen  NASDAQ AMGN  rose by 3 01  to trade at  211 17 by 14 15  18 15 GMT  on Tuesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 2 37M  Amgen has traded in a range of  204 95 to  211 21 on the day 
The stock has traded at  211 2100 at its highest and  200 7800 at its lowest during the past seven days ",2019-10-29,Investing.com,https://www.investing.com/news/stock-market-news/amgen-rises-3-2006839,2006839
148646,370162,AMGN,Amgen Earnings  Revenue Beat in Q3,news,"Investing com   Amgen  NASDAQ AMGN  reported third quarter earnings  that beat analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  3 66 on revenue of  5 74B  Analysts polled by Investing com expected EPS of  3 53 on revenue of  5 64B  That compared to EPS of  3 69 on revenue of  5 9B in the same period a year earlier  The company had reported EPS of  3 97 on revenue of  5 87B in the previous quarter 
Amgen shares gained 2 42  to trade at  214 00 in after hours trade following the report 
Amgen follows other major Healthcare sector earnings this monthOn October 15  J J reported third quarter EPS of  2 12 on revenue of  20 73B  compared to forecasts of EPS of  2 01 on revenue of  20 08B 
Merck Co earnings beat analysts  expectations on Tuesday  with third quarter EPS of  1 51 on revenue of  12 4B  Investing com analysts expected EPS of  1 24 on revenue of  11 65B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-10-29,Investing.com,https://www.investing.com/news/stock-market-news/amgen-earnings-revenue-beat-in-q3-2006946,2006946
148647,370163,AMGN,Biotech for hire PeptiDream charts new path and becomes short target,news,By Rocky Swift TOKYO  Reuters    The promise of PeptiDream Inc s drug discovery technology and its lucrative research for hire contracts have made it a darling of the Tokyo stock market  Now  those gains have made it a target for short seller Muddy Waters   The company  which has seen its market value jump fivefold to  6 billion over the past four years  is now pivoting its strategy to in house research  using its technology that allows it to create libraries of peptide chemicals that can bind drugs to cells   Muddy Waters Capital LLC says that the biotech company s new  and traditional  businesses are flawed and is betting its shares will fall back to earth as a result   Since its listing in 2013  PeptiDream has grown from a lab start up into a company with the highest profit margins in the Japanese pharmaceutical industry   without ever having brought a drug to market  Its technology has attracted a bevy of partners including Novartis AG  Merck   Co and Shionogi   Co    We re on the cusp of over the next 1 5 years of introducing a multitude of drugs into the clinic through our big pharma and strategic partnerships   PeptiDream President Patrick Reid told Reuters in an interview    We d rather get 5  of 100 drugs than get 100  of five drugs   he said  He estimates that around half of all drugs being worked on by PeptiDream partners are cancer drugs   PeptiDream s rocketing market value has been helped by its traditional fees for collaborating in R D and licensing deals to use its libraries  Its operating profit margin is 50   the highest of all 37 members in the Tokyo market s pharma index  where the average is 14    MUDDY WATERS DEALS DISPUTE However the shares of the Kawasaki based company fell 4 percent on the Nov  7 release of Muddy Water s report  which doubted the viability of many of its existing partnerships and said investors were  deluded as to its potential for commercializing drugs    There s real technology there  but it s the usefulness of the technology that we question   Muddy Waters founder Carson Block said in an interview with Reuters   It s cool  but so far it s been unable to yield anything that s meaningful   PeptiDream was now  massively overvalued   Block said  adding that  many of these partnerships that are the basis of this valuation seem inactive    PeptiDream s Reid declined to comment on the Muddy Waters report  referring to a company statement that  completely rejects  the short seller s assertions  The company says it has 19 discovery and development partners  predominantly big to mid pharma firms  Among its 101 programs in progress  compared with 60 in 2017  two are cancer related compounds being developed with Bristol Myers Squibb  NYSE BMY  now in phase 1 clinical studies  Twelve of PeptiDream s partners told Reuters their partnerships were active and ongoing  including pharma giants Bristol Myers  Merck  Novartis   Bayer AG   DE BAYGN  and  Amgen Inc   NASDAQ AMGN   Japan s Mitsubishi Tanabe Pharma Corp declined to comment on the status of its relationship  The other six companies did not respond to multiple requests for comment   Block declined to name a price target for PeptiDream or the size of its short strategy  which pays off when a stock falls  PeptiDream s shares are trading about 5  lower than before the release of Block s report  PeptiDream is the second short play in Japan for Muddy Waters  which became famous for its bearish calls on Chinese companies  Muddy Waters announced a short bet on Nidec Corp in December 2016  Shares in the maker of precision motors have since risen more than 60    It s a bunt single  and that s better than a strikeout   Block said of PeptiDream s share fall  referring by bunt single to a baseball play that sees a batter eke out a small gain   Japan s potentially interesting  We might look to come back and hit some more bunt singles and see if we can build up a brand   PROTEIN HULA HOOPS PeptiDream s research partners do the heavy lifting in bringing drugs through clinical trials to market   allowing the company to avoid much of the large development costs and risks   Even so  as the company increasingly looks to keep some ownership of its research  it will still receive future milestone payments and royalties   On top of its research partnerships  it also has seven license agreements for its library or drug discovery platform  PeptiDream concentrates on  constrained peptides   particularly macrocyclic peptides   hula hoops of natural and non natural amino acids that can carry various cargoes to specific types of cells   such as cancer or inflamed tissue  Founded in 2006  the company sprang out of the research of University of Tokyo professor Hiroaki Suga  Suga looked to Reid  then an associate professor at the university  to help forge the connections to big pharma  As discoveries related to antibody and small molecule treatments dwindle  peptide based compounds are likely to become increasingly important as a class of drugs  said Bernstein analyst Shen He  who has an  outperform  on the stock    PeptiDream is one of the best technology platforms out there to solve this   He said   But it s not an overnight journey    Japan Pharma Stock Performance   ,2019-11-13,Reuters,https://www.investing.com/news/stock-market-news/biotechforhire-peptidream-charts-new-path-and-becomes-short-target-2019785,2019785
148648,370164,AMGN,Bristol Myers Squibb wins antitrust approval to buy Celgene  but must divest psoriasis drug,news,"WASHINGTON  Reuters    Bristol Myers Squibb Co  N BMY  and  Celgene Corp   O CELG  have won U S  antitrust approval for their merger on condition that they sell Celgene s psoriasis drug Otezla  the Federal Trade Commission said in a statement on Friday 
Bristol Myers Squibb said the decision meant it had all the needed regulatory approvals and would close the acquisition on Wednesday 
Amgen  NASDAQ AMGN  has agreed to buy Celgene s Otezla business  the company said in a statement  The Otezla sale was valued at  13 4 billion 
Bristol Myers Squibb announced in January it would buy Celgene Corp in a cash and stock deal for about  74 billion  combining two of the world s largest cancer drug businesses in the biggest pharmaceutical deal ever 
The proposed divestiture is the largest that the FTC or the U S  Department of Justice have ever required in a merger enforcement matter  the FTC said in its statement 
 The Commission has ordered BMS to divest Otezla to preserve BMS s incentive to continue developing its own oral product for treating moderate to severe psoriasis   FTC Chairman Joseph Simons said in a statement 
The five members of the FTC split along party lines on whether to approve the proposed merger  with the three Republicans in favor and two Democrats opposed 
Rebecca Slaughter  who voted to oppose the deal  argued that the FTC s approach of demanding divestitures only if the two companies sell treatments for the same ailment was  too narrow  
 The commission should more broadly consider whether any pharmaceutical merger is likely to exacerbate anticompetitive conduct by the merged firm or to hinder innovation   she said in a dissenting statement ",2019-11-15,Reuters,https://www.investing.com/news/stock-market-news/bristolmyers-squibb-wins-antitrust-approval-to-buy-celgene-but-must-divest-psoriasis-drug-2021921,2021921
148652,370168,AMGN,3 Investing Facts About Required Minimum Distributions You Need To Know   December 20  2019,opinion,"Failing to withdraw a required minimum distribution  RMD  from your own or an inherited IRA by the deadline results in a big tax code penalty  50   That s right  If you were supposed to take out a minimum of  4 000 and  oops   did not do so  you have the privilege of writing the IRS a check for  2 000 
Like many investors  you re likely aiming to build a comfortable nest egg to ensure a comfortable retirement  Among retirement financial planners  this is called the  accumulation phase   In this phase  your goal is to invest wisely by choosing stocks with long term potential for your retirement portfolio  such as Amgen  AMGN   a current top ranked dividend stock 
There is also a second phase of retirement planning that gets less focus   despite the fact that it s the more interesting part  It s the  distribution phase   which essentially means spending the wealth you ve worked hard to amass 
Making plans for the distribution stage involves deciding where you ll live in retirement  whether you ll travel  your proposed leisure activities  and more decisions that will affect your spending during your golden years 
Along with these aspects  it is important to consider the required minimum distribution  RMD  that applies to most retirement accounts  Essentially  the IRS requires you to withdraw a specific sum from your qualified retirement accounts once you hit age 72 
Why does the IRS requires you to start taking your money out  It s simple   they want to make sure they get their tax  If this rule didn t exist  people could live off other income and never pay tax on their retirement investment gains  Then  that money could be left to family or friends as an inheritance without the IRS collecting any taxes from you 
What You Need to Know About RMDs
Which types of retirement accounts have RMDs  Qualified retirement accounts like IRA accounts  401 k s  457 plans and other tax deferred retirement savings plans like a TSP  403 b   TSA  SEP  or SIMPLE IRA plan require withdrawals in retirement 
When do I have to start taking distributions  For most accounts  you must take your first distribution by April 1 of the year following the calendar year in which you reach age 72 
Every year after your start date  you are required to take your RMD by December 31  Remember  for Roth IRAs you do not have to take an RMD because you paid taxes before contributing  However  other types of Roth accounts do require RMDs  but you may be able to avoid them  for instance  by rolling your Roth 401 k  into your Roth IRA  
What happens if don t take my RMD  The penalty for not taking a required minimum distribution  or if the distribution is not large enough  is a 50  tax on the amount not withdrawn in time 
How much money do I have to withdraw  To calculate a specific RMD  you must divide your prior year s December 31st retirement account balance by a  distribution period  factor based on your age 
Here s an example to give you an idea of the amount  Ann is 70 and will take her first RMD in the year she turns 72  Her IRA balance at the end of the prior year was  100 000  Her  distribution period  factor is 27 4  Dividing  100 000 by 27 4 equals  3 649 63  This is how much Ann is required to withdraw for the calendar year in which she turns 72 
Learning about the  distribution phase  is just one aspect of preparing for your nest egg years 
To learn more about the tax implications of retirement spending   and much more about retirement planning   download our free guide  Retirement Made Easy You   ll find useful  detailed steps to help you navigate both the accumulation and distribution phases of retirement planning  Get Your FREE Guide Now",2019-12-19,Zacks Investment Research,https://www.investing.com/analysis/3-investing-facts-about-required-minimum-distributions-you-need-to-know--december-20-2019-200494077,200494077
148653,370169,AMGN,Amgen  AMGN  Upgraded To Buy  Here s What You Should Know,opinion,"Investors might want to bet on Amgen  AMGN   as it has been recently upgraded to a Zacks Rank  2  Buy   This upgrade is essentially a reflection of an upward trend in earnings estimates    one of the most powerful forces impacting stock prices 
The Zacks rating relies solely on a company s changing earnings picture  It tracks EPS estimates for the current and following years from the sell side analysts covering the stock through a consensus measure    the Zacks Consensus Estimate 
The power of a changing earnings picture in determining near term stock price movements makes the Zacks rating system highly useful for individual investors  since it can be difficult to make decisions based on rating upgrades by Wall Street analysts  These are mostly driven by subjective factors that are hard to see and measure in real time 
Therefore  the Zacks rating upgrade for Amgen basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  and the near term price movement of its stock are proven to be strongly correlated  That s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their bulk investment action then leads to price movement for the stock 
For Amgen  rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company s underlying business  And investors  appreciation of this improving business trend should push the stock higher 
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  so it could be truly rewarding if such revisions are tracked for making an investment decision  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for Amgen
This world s largest biotech drugmaker is expected to earn  14 60 per share for the fiscal year ending December  2019  which represents a year over year change of 1 4  
Analysts have been steadily raising their estimates for Amgen  Over the past three months  the Zacks Consensus Estimate for the company has increased 1 9  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of Amgen to a Zacks Rank  2 positions it in the top 20  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2020-01-01,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-upgraded-to-buy-heres-what-you-should-know-200495803,200495803
148654,370170,AMGN,Merck s Keytruda Misses One Of Two Goals In Lung Cancer Study,opinion,Merck   Co   Inc  s   NYSE MRK   late stage study  evaluating its blockbuster PD L1 inhibitor Keytruda as first line treatment for extensive stage small cell lung cancer  SCLC   failed to meet one of the two primary endpoints While the phase III KEYNOTE 604 study evaluating Keytruda plus chemotherapy for the above indication met one of its dual primary endpoints of progression free survival  PFS   it failed to meet the other endpoint of overall survival  OS   The data showed that treatment with Keytruda plus chemotherapy  etoposide plus cisplatin or carboplatin  led to a statistically significant improvement in PFS compared to chemotherapy alone  However  while the combination showed an improvement in OS  the OS results did not meet statistical significanceMerck s shares were down more than 1  in after hours trading in response  Merck s shares have risen 21 5  in the past year compared with the  s increase of 12 2    Keytruda  Merck s biggest product  is already approved for use in 20 indications across 12 different tumor types in the United States Keytruda generated sales of almost  8 billion in the first nine months of 2019  up around 63  year over year  While the drug s sales are being driven by the launch of new indications globally  Keytruda s sales are particularly benefitting from lung cancer indications  Keytruda is presently approved for five indications in lung cancer  mostly non small cell lung cancer  NSCLC which is the most common form of lung cancer   Small cell lung cancer  SCLC  is quite rare and accounts for about 10 to 15  of all lung cancers  Keytruda is approved for previously treated metastatic SCLC  The latest setback will hurt the company s growth prospects in lung cancer Keytruda is being studied for more than 30 types of cancer in above 1000 studies including 600 plus combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte  NASDAQ INCY   Glaxo   NYSE GSK   and Pfizer   NYSE PFE   separately for the evaluation of Keytruda in combination with other regimens  In a separate press release  Merck announced an exclusive global research licensing deal with Japan s Taiho Pharmaceutical and Astex Pharmaceuticals  UK   a wholly owned subsidiary of Japan s Otsuka Pharmaceutical  Per the deal  Merck will get an exclusive global license to Taiho and Astex  s small molecule inhibitor candidates for an upfront payment of  50 million  Taiho and Astex are developing small molecule inhibitors against several drug targets  including the KRAS oncogene  which is among the most frequently mutated oncogenes in cancer  In addition to the upfront amount  Merck will also be entitled to make approximately  2 5 billion of potential milestone payments as well as tiered royalties on sales  if any drug emerges from the deal  Merck will take care of the R D funding and will be responsible for commercialization of any product that receives regulatory approval Merck currently carries a Zacks Rank  3  Hold   You can see Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2020-01-06,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-misses-one-of-two-goals-in-lung-cancer-study-200496966,200496966
148655,370171,AMGN,Biotech Stock Roundup  Updates From INCY   EXEL  APLS   LIFE Surge On Positive Data ,opinion,"This week  a few biotech companies came up with pipeline and regulatory updates  Incyte   NASDAQ INCY   suffered a setback with its pipeline candidate and consequently  shares fell  Meanwhile  Apellis   NASDAQ APLS   and aTyr Pharma   NASDAQ LIFE   soared on positive pipeline updates Recap of the Week s Most Important Stories Pipeline Update From Incyte  Incyte announced disappointing results from a late stage study on pipeline candidate itacitinib  INCB039110   a novel and selective JAK1 inhibitor The phase III randomized  double blind  placebo controlled GRAVITAS 301 study was evaluating itacitinib in combination with corticosteroids in patients with treatment na ve  first line  acute graft versus host disease  GVHD   The primary endpoint was overall response rate  ORR  at day 28  defined as the proportion of subjects demonstrating a complete response  very good partial response  or partial response  The key secondary endpoint is non relapse mortality  NRM  at month 6  defined as the proportion of subjects who died due to causes other than malignancy relapse However  the study did not meet the primary endpoint of ORR improvement at day 28 compared to placebo plus corticosteroids  74 0  vs  66 4   p 0 08  respectively   While itacitinib added to corticosteroids improved the ORR in patients with treatment na ve acute GVHD  the difference observed versus placebo plus corticosteroids was not statistically significant  Additionally  there was no difference observed in NRM at month 6 between the treatment and placebo arms Additionally  Incyte announced that its Marketing Authorization Application  MAA  for pemigatinib for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2  FGFR2  fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy has been validated by the European Medicines Agency  EMA  Exelixis Expands Oncology Study  Exelixis  Inc    NASDAQ EXEL   announced that it plans to further expand the metastatic castration resistant prostate cancer  CRPC  cohort of COSMIC 021  the phase Ib study of lead drug Cabometyx in combination with Tecentriq in patients with locally advanced or metastatic solid tumors  based on continued encouraging efficacy and safety data  The cohort  which was previously expanded from 30 to 80 patients in July 2019  will now include up to 130 patients  Exelixis expects the expansion of the cohort by an additional 50 patients to further document how the combination may benefit this patient population  The company is assessing its regulatory plans for the combination and preparing to initiate a phase III pivotal trial Exelixis currently carries a Zacks Rank  2  Buy   You can see  Apellis Soars on Encouraging PNH Study Results  Apellis Pharmaceuticals  Inc  surged after it announced positive results from the phase III PEGASUS study  evaluating pegcetacoplan  APL 2  in adults with paroxysmal nocturnal hemoglobinuria  PNH   Pegcetacoplan met the study s primary efficacy endpoint  demonstrating superiority to Soliris with a statistically significant improvement in adjusted means of 3 8 g dL of hemoglobin at week 16  p 0 0001   At week 16  pegcetacoplan treated patients had an adjusted mean hemoglobin increase of 2 4 g dL from a baseline of 8 7 g dL compared to eculizumab treated patients  n 39  who had a change of  1 5 g dL from the baseline aTyr Surges on Collaboration Deal With Kyorin Pharma   aTyr Pharma surged more than 43  after it announced a collaboration and license agreement with Kyorin Pharmaceutical Co   Ltd   a wholly owned subsidiary of Kyorin Holdings  Inc Both companies have entered into a collaboration for the development and commercialization of aTyr s lead candidate  ATYR1923  for interstitial lung diseases  ILDs  in Japan  Per the agreement  the company will receive an  8 million upfront payment and is eligible to receive up to an additional  167 million in milestone payments as well as tiered royalties on net sales in Japan  Kyorin  a leading respiratory focused pharmaceutical company in Japan  will receive the exclusive right to develop and commercialize ATYR1923 in Japan for ILDs and will be responsible for funding all research  development  regulatory  marketing and commercialization activities  Meanwhile  aTyr will supply all drug products for Japan and support development activities as the global development leader for ATYR1923 Performance    Medical   Biomedical and Genetics Industry 5YR   Return
 The Nasdaq Biotechnology index lost 1 09  in the last four trading sessions  Among the biotech giants  Incyte lost 11 66  in the period  Over the past six months  shares of Amgen  NASDAQ AMGN  have gained 32 42    See the last biotech stock roundup here   What s Next in Biotech Stay tuned for more pipeline updates The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2020-01-07,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-updates-from-incy--exel-apls--life-surge-on-positive-data-200497231,200497231
148656,370172,AMGN,Merck s Keytruda Gets FDA Nod For High Risk Bladder Cancer,opinion,Merck   Co   Inc    NYSE MRK   announced that the FDA has granted approval to its blockbuster PD L1 inhibitor  Keytruda for a bladder cancer indication  The latest approval allows use of Keytruda as a monotherapy to treat patients with high risk non muscle invasive bladder cancer  NMIBC   unresponsive to Bacillus Calmette Guerin  BCG    a therapy widely used in the management of bladder cancer  These patients have carcinoma in situ  CIS  with or without papillary tumors and are ineligible for or have elected not to undergo cystectomy The approval was expected as in December the FDA s Oncologic Drugs Advisory Committee  ODAC  had voted 9 4 in favor of approving Keytruda for the indication  The FDA approval was based on data from the phase II KEYNOTE 057 study In bladder cancer  Keytruda is already approved for first  as well as second line treatment of certain patients with locally advanced or metastatic urothelial carcinoma  a type of bladder cancer Merck s shares have risen 17 5  this year so far compared with the  s increase of 11 4    Keytruda  Merck s biggest product  is already approved for use in 20 indications across 12 different tumor types in the United States Keytruda generated sales of almost  8 billion in the first nine months of 2019  up around 63  year over year  The drug s sales were driven by the launch of new indications globally  Keytruda sales are benefiting from strong momentum in the indication of first line lung cancer The Keytruda development program is also progressing well with Merck spending billions on research and development of this medicine to secure more approvals in earlier lines of treatment  The drug is being studied for more than 30 types of cancer in over 1000 studies including 600 plus combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte  NASDAQ INCY   Glaxo   NYSE GSK   and Pfizer   NYSE PFE   separately for the evaluation of Keytruda in combination with other regimens  Undoubtedly  Keytruda s solid growth prospects are based on increased utilization approval for new indications and expectation of additional approvals worldwide Merck currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2020-01-08,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-gets-fda-nod-for-highrisk-bladder-cancer-200497617,200497617
148657,370173,AMGN,Bet On Favorite Sector ETFs   Stocks This Earnings Season,opinion,Like the first three quarters of 2019  the earnings picture looks weak for Q4 thanks to tough comparisons and moderating economic growth The S P 500 s earnings are expected to decline  year over year despite 3 4  higher revenues  This would follow 1 7  deceleration in the third quarter  0 6  growth in the second quarter and a flat showing in the first quarter  Earnings growth is expected to be negative for 10 of the 16 Zacks sectors  autos and energy being the biggest drags with expected earnings decline of 56 5  and 42 1   respectively  read    Given this dismal picture  investors could place their bet on sectors that are expected to post earnings growth  Utilities is expected to record strong earnings growth of 17 9   followed by business services  9 6    finance  7 5    construction  5 5   and medical  3 5   Given this  we have highlighted one ETF and one stock from some of these sectors that could make great plays as the earnings season unfolds  These ETFs and stocks have a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   For stocks  we have added the extra criteria of a VGM Score of B or better and a positive   Stocks with a Zacks Rank  3 or better and a positive ESP have 70  chance of beating estimates You can uncover the best stocks to buy or sell before they re reported with our  UtilitiesUtilities Select Sector SPDR   With AUM of  10 7 billion  this fund provides exposure to a small basket of 28 securities by tracking the Utilities Select Sector Index  Electric utilities take the top spot in terms of sectors at 61 6   closely followed by multi utilities  31 8    The product charges 13 bps in annual fees and sees heavy volume of around 16 5 million shares on average  It has a Zacks ETF Rank  2  Buy  with a Medium risk outlook  read    Algonquin Power   Utilities Corp    TSX AQN    This renewable energy and regulated utility company is engaged in the ownership of power generation facilities  and water and energy utilities primarily in North America  It has a Zacks Rank  3 and an Earnings ESP of  4 35   The stock saw no earnings estimate revision for the to be reported quarter over the past three months and has an expected earnings growth of 21 4   However  its trailing four quarter negative earnings surprise is 3 41   on average  The company is slated to release earnings results on Feb 27 FinancialsFinancial Select Sector SPDR Fund   This fund follows the Financial Select Sector Index and holds 66 stocks in its basket  Banks dominate the fund s portfolio with 43  while capital markets  insurance and diversified financial services round off the next three spots  The fund has accumulated nearly  25 3 billion in AUM and charges investors 13 bps in annual fees  It trades in volumes of 47 1 million shares on average per day and has a Zacks ETF Rank  2 with a Medium risk outlook  read    E TRADE Financial Corporation   NASDAQ ETFC    This company provides online brokerage and related products and services primarily to individual retail investors  under the brand name of  E TRADE Financial  worldwide  The stock has a Zacks Rank  2 and an Earnings ESP of  1 22   It saw negative earnings estimate revision of 9 cents over the past 90 days for the to be reported quarter and has an estimated year over year decline rate of 22 6   The company s trailing four quarter earnings surprise is 6 68   on average  It is slated to release earnings on Jan 23 ConstructionSPDR S P Homebuilders  NYSE XHB  ETF   The most popular choice in the homebuilding space  XHB  follows the S P Homebuilders Select Industry Index  The fund holds about 35 securities in its basket with equal weighted exposure of around 5   It has AUM of  750 million and trades in volume of almost 1 8 million shares  The fund charges 35 bps in annual fees and carries a Zacks ETF Rank  3 with a High risk outlook  read    Patrick Industries Inc    NASDAQ PATK    It is a major manufacturer of component products and distributor of building products and materials for the Recreational Vehicle  Manufactured Housing and Marine industries  The stock has a Zacks Rank  2 and an Earnings ESP of  12 83   The Zacks Consensus Estimate for the to be reported quarter has been revised downward by 23 cents over the past 90 days and represents a substantial 21 9  earnings decline  Additionally  the company delivered a positive four quarter earnings surprise of 7 91   on average  and is scheduled to report earnings on Feb 13  You can see  MedicalVanguard Health Care ETF   ASX VHT    This ETF tracks the MSCI US Investable Market Health Care 25 50 Index and holds 403 stocks in its basket  Pharma takes the largest share at 27 7   while health care equipment and biotech round off the top three spots  VHT is also one of the popular and liquid ETFs with AUM of  10 1 billion and average daily volume of about 187 000 shares  It charges 10 bps in annual fees and has a Zacks ETF Rank  2 with a Medium risk outlook  read    Amgen Inc    NASDAQ AMGN    It is one of the leading biotechnology companies in the world  with extensive manufacturing  distribution and sales facilities  The stock has a Zacks Rank  2 and an Earnings ESP of  0 29   The Zacks Consensus Estimate for the to be reported quarter has been revised upward by 12 cents over the past three months and its earnings are estimated to grow 1 5   The company s trailing four quarter positive earnings surprise is 2 86   on average  The company is slated to release earnings results on Feb 4 Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2020-01-09,Zacks Investment Research,https://www.investing.com/analysis/bet-on-favorite-sector-etfs--stocks-this-earnings-season-200497995,200497995
148677,370193,AMGN,Amgen Rises 3 ,news,"Investing com   Amgen  NASDAQ AMGN  rose by 3 04  to trade at  205 10 by 10 46  14 46 GMT  on Monday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 1 08M  Amgen has traded in a range of  199 67 to  205 25 on the day 
The stock has traded at  206 5000 at its highest and  198 2600 at its lowest during the past seven days ",2019-08-26,Investing.com,https://www.investing.com/news/stock-market-news/amgen-rises-3-1963500,1963500
148678,370194,AMGN,Amgen to buy Celgene psoriasis drug Otezla for  13 4 billion,news,By Michael Erman and Manas Mishra  Reuters     Amgen Inc   NASDAQ AMGN  will buy Celgene  NASDAQ CELG  Corp s psoriasis drug Otezla for  13 4 billion in cash  clearing the way for Bristol Myers Squibb  NYSE BMY  to go ahead with its  74 billion deal for Celgene by the end of the year  Amgen  which announced the deal on Monday  is paying a hefty price for the drug  according to analysts and investors  Still  Otezla  which brought in sales of  1 61 billion last year  will deliver growth for Amgen right away  and its shares rose around 3 percent in afternoon trading  Bristol Myers and Celgene s shares were both also up around 3 percent  New York based Bristol Myers said in June that it would sell Otezla to allay concerns raised by the U S  Federal Trade Commission because of a competing treatment that it is developing  Analysts said at the time that they were expecting Otezla to sell for around  8 billion to  10 billion  Bristol Myers said in a statement that there was significant interest from multiple potential buyers from early on in the process  Thousand Oaks  California based Amgen said that it expects Otezla s sales to grow at least in the low double digits over the next five years  It also said it expects the drug s patents to protect its exclusivity in the United States until 2028  For an interactive on Otezla sales click   Jeff Jonas  healthcare portfolio manager at Gabelli funds  said that a number of Amgen s current drugs face loss of patent protection and competition from biosimilar drugs  so the growth from Otezla would be welcome   This is an attractive product for them that fits more or less with their current portfolio   Jonas said   It s an approved product with a good safety profile  so there s not a lot of risk   Still  Jonas expressed some skepticism about Amgen s growth forecast for the drug  noting that new competitors  including Bristol Myers  drug in development  are likely to eat into its market share  Amgen said it expects the deal to produce tax benefits with a present cash value of  2 2 billion  reducing the actual deal total to  11 2 billion  With respect to possible antitrust concerns about the purchase  Amgen said on a conference call that it feels very confident that it will be able to close the deal  Bristol Myers said most of the proceeds from the sale will go to pay down debt from the deal with Summit  New Jersey based Celgene  It also increased a previously planned  5 billion accelerated share buyback to  7 billion ,2019-08-26,Reuters,https://www.investing.com/news/stock-market-news/amgen-to-buy-celgenes-psoriasis-drug-otezla-for-134-billion-in-cash-1963261,1963261
148684,370200,AMGN,Amarin Gains On FDA Approval Of Vascepa Label Expansion,opinion,Shares of Amarin Corporation   NASDAQ AMRN   gained after the company announced that the FDA approved a label expansion for Vascepa Vascepa is now approved as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction  stroke  coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride  TG  levels   150 mg dL  and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease The approval was based on the results of the REDUCE IT cardiovascular outcomes study  Last month  the FDA s Endocrinologic and Metabolic Drugs Advisory Committee  EMDAC  voted unanimously  16 0  to approve the label expansion for Vascepa  icosapent ethyl  capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL C  bad cholesterol  The label expansion should significantly boost Vascepa as  per estimates  millions of high risk patients in the United States could benefit from this one of a kind prescription therapy  Vascepa will be a new FDA approved treatment option to reduce the persistent cardiovascular risk faced by many patients despite the use of statins with other contemporary standard of care therapies We remind investors that the drug was initially approved by the FDA as an adjunct to diet to reduce triglyceride levels in adult patients with severe   500 mg dL  hypertriglyceridemia Amarin will launch the drug in the United States immediately  given its strong sales force  which it had doubled toward the beginning of 2019   It will double the size of its sales force again to a total of 800 sales representatives in the beginning of 2020   We expect the initial uptake of the drug to be strong and boost the top line  given the market potential Shares of Amarin have soared 77 2  so far this year compared with the  s growth of 7 2   Concurrently  Amarin updated its guidance for 2019 and issued the same for 2020  The company now expects net revenues of  410  425 million compared to the earlier estimated range of  380  420 million For 2020  Amarin projects total net revenues of  650  700 million  mostly from sales of Vascepa in the United States Earlier this month  the European Medicines Agency  EMA  validated the marketing authorization application  MAA  seeking approval of Vascepa as a treatment to reduce the risk of cardiovascular events in high risk patients who have their cholesterol levels controlled with statin treatment but have elevated triglycerides  135 mg dL or above  and other cardiovascular risk factors Key players in this space are Sanofi   NASDAQ SNY   Regeneron   NASDAQ REGN   s Praluent and Amgen s   NASDAQ AMGN   Repatha Amarin is currently a Zacks Rank  2  Buy  stock  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-12-15,Zacks Investment Research,https://www.investing.com/analysis/amarin-gains-on-fda-approval-of-vascepa-label-expansion-200492782,200492782
148685,370201,AMGN,4 Drug Biotech Outperformers That May Lose Steam In 2020,opinion,The drug and biotech industry has done relatively well this year  particularly picking up steam in the past three monthsThe chart below shows that the   Bio Med    and the  have risen 11 9   10 3  and 8 5   respectively while the S P Zacks S P 500 composite has gone up 26 1    A strong third quarter earnings season  bullish outlook for the rest of 2019 and 2020 and a flurry of M A deal announcements this year were the primary reasons for the industry s strong performance  Demand driven growth in sales of new products  success of key pipeline candidates in clinical studies  product line extensions of blockbuster drugs in important therapeutic areas  successful innovation resulting in new drug approvals  and continued strong performance of key products are some other factors boosting this industry s growth There has been a flurry of M A deal announcements this year in the biotech drug industry  Apart from the two mega merger announcements of Bristol Myers Celgene and AbbVie Allergan  smaller biotech research firms  investigating new therapies or interesting pipeline candidates  garnered attention of bigger players this year  Oncology and gene therapy have mainly been the focus areas of M A activities Headwinds for the industry include government scrutiny of high drug prices  pricing and competitive pressure  slowdown in sales of some of the most high profile older drugs and most importantly major pipeline setbacks  Nonetheless  we believe that pipeline success  cost cutting measures  regulatory approvals for new drugs and line extension  product launches  ramped up M A and collaboration activities and appropriate utilization of cash should keep the sector afloat in 2020 Though it would be prudent to add a few stocks from this growing sector to your portfolio  you need to watch out for a few stocks  which  despite performing well this year  may lose momentum next year  In this article  we discuss four stocks whose prices shot up this year but these might not prove to be good buys for 2020  These stocks carry a Zacks Rank  4  Sell  or  5  Strong Sell  and have seen their earnings estimates for 2020 decline in the past 60 days Immunomedics  Inc    NASDAQ IMMU  Immunomedics stock is up 41 3  this year so far  outperforming the Bio Med industry s increase of 8 5  as it made significant progress against important manufacturing and clinical milestones  related to its most advanced candidate  sacituzumab govitecan   Sacituzumab govitecan is presently under review with the FDA for metastatic triple negative breast cancer   mTNBC   in the third line setting  Though the company received a complete response letter   CRL   from the FDA for its biologics license application   BLA   in January 2019  the CRL did not require any new study to be conducted  In December 2019  the company resubmitted the BLA to the FDA  Meanwhile  sacituzumab govitecan is being evaluated in several label expansion studies including earlier line settings for breast cancer as well as other cancer indications However  the stock currently carries a Zacks Rank  4 and its estimates for 2020 have widened from a loss of  1 41 per share to  1 59 in the past 60 days  Rising competitive pressure in the breast cancer market is a concern  In September  sacituzumab govitecan showed a response rate in a bladder cancer study  which was lower than that of a competitor s candidate  The data was presented at the European Society for Medical Oncology meeting in BarcelonaANI Pharmaceuticals  Inc    NASDAQ ANIP  ANI Pharmaceuticals  shares are up 42 1  this year so far  also outperforming the Bio Med industry  driven by decent sales and profits in a challenging U S  generics drug market   However  competitive pressure hit sales of some of its generic drugs in the third quarter  leading management to lower its 2019 sales and earnings outlook on expectations of intensified pressure on base generics business  This explains the company s Zacks Rank of 5 and negative estimate revision of 7 9  for 2020 over the past 60 days Mirati Therapeutics  Inc    NASDAQ MRTX  Mirati Therapeutics  stock has risen 165 1  this year  outperforming the Bio Med industry  mainly on positive data on its KRAS G12C inhibitor  MRTX849  which showed that treatment with the candidate can result in clinical responses at well tolerated doses  Earlier this year  Amgen  NASDAQ AMGN  presented initial results from a study on its KRAS inhibitor  AMG 510  which were impressive and pushed up Mirati s stock in the process   Mirati s lead drug candidate  sitravatinib  is being evaluated in a registration enabling phase III study in combination with a checkpoint inhibitor in non small cell lung cancer  NSCLC   It is also developing novel inhibitors of KRAS mutations including MRTX849 However  loss estimates of this  4 Ranked stock have widened from  5 67 per share to  5 99 per share for 2020 in the past 60 days PTC Therapeutics  Inc    NASDAQ PTCT  Shares of PTC Therapeutics were up 39 9  this year  outperforming the 11 9  increase for the Medical Drugs industry   PTC markets two drugs for treating Duchenne muscular dystrophy  DMD   Translarna and Emflaza  It will launch Tegsedi  inotersen  in Brazil in 2020   Meanwhile  it is evaluating several drug candidates across rare diseases and oncology and exploring line extensions of its marketed drug products  PTC  new drug application  NDA  for lead candidate risdiplam  RG7916  for the treatment of spinal muscular atrophy  SMA  was granted priority review by the FDA last month  PTC is looking for approval for a broader SMA patient population  including type 1  type 2 and type 3 SMA patients However  the stock has a Zacks Rank of 4 and has seen its loss estimates for 2020 widen from  1 43 per share to  1 47 per share in the past 60 days  This is due to investor concerns over rising costs to support new launches and its vast pipeline Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 top tickers for the entirety of 2020 These 10 are painstakingly hand picked from over 4 000 companies covered by the Zacks Rank  They are our primary picks to buy and hold ,2019-12-18,Zacks Investment Research,https://www.investing.com/analysis/4-drugbiotech-outperformers-that-may-lose-steam-in-2020-200493817,200493817
148703,370219,AMGN,France s Sanofi bets on new CEO to drive sluggish drug sales,news,"By John Miller ZURICH  Reuters    In veteran drug salesman Paul Hudson  Sanofi s 100 000 plus employees are getting a new chief executive who relishes a good commercial fight  The French firm said on Friday it had poached 51 year old Hudson from Novartis  betting on him to rejuvenate a business hit by sluggish cholesterol drug sales and a diabetes unit facing growing competition for its top seller   Hudson  the latest of several Novartis executives to exit the Swiss firm  has nearly 30 years of industry experience  including a stint as AstraZeneca s top U S  manager  The Englishman  a skilled public speaker and fan of his hometown soccer team Manchester United  will replace Olivier Brandicourt  63  who is retiring in September  At Novartis  Hudson kick started sales of heart failure medicine Entresto that the firm expected to generate  5 billion but whose sales began at a glacial pace after its 2015 launch  After heavy marketing investment and a sales push  Hudson turned the drug into a Novartis blockbuster   We re now starting to see the fruits of all the effort we put in   Hudson told analysts on a Novartis call in April   Will it continue  We believe it does continue   At Sanofi  PA SASY   one of Hudson s challenges will be to turn around the fortunes of Praluent  a cholesterol medicine that has failed to meet original expectations due to concerns about its price and a bitter patent dispute with rival Amgen  NASDAQ AMGN    The departure of Paul Hudson is regrettable for Novartis  due to his industry experience in the United States   said Michael Nawrath from Zuercher Kantonalbank  But his knowledge of the world s biggest drugs market will be Sanofi s gain   Hudson  awarded an honorary doctorate at his alma mater Manchester Metropolitan University  also has to defend Sanofi s patent expired insulin Lantus  a top earner at 3 6 billion euros   4 billion  even after a 20 percent drop in sales  Competition will come from Mylan s generics and even Novartis  which in 2018 signed a deal with China s Gan   Lee to make Lantus copies  Hudson has proved a tenacious salesman at Novartis  winning approval for the world s costliest medicine  gene therapy Zolgensma for spinal muscular atrophy  at  2 1 million per patient  Novartis said Hudson s replacement would be Marie France Tschudin  48  who has led the Swiss firm s European cancer unit after joining the company in 2017  She previously worked at Celgene s cancer business  It marks another change at the top of Novartis  where most of its executive committee was appointed in the last two years   The turn over at the Novartis executive committee continues at high speed   Bank Vontobel analyst Stefan Schneider said  This week  Samit Hirawat  head of oncology drug development  left for Bristol Myers Squibb  NYSE BMY   while Novartis s cancer chief  Susanne Schaffert  has only been in her post since January  In March  the Swiss firm hired a new generics head  Richard Saynor  from GlaxoSmithKline  
A Novartis spokesman said Novartis had a deep bench of global experts to fill talent gaps left by Hudson and others ",2019-06-07,Reuters,https://www.investing.com/news/stock-market-news/frances-sanofi-bets-on-new-ceo-to-drive-sluggish-drug-sales-1891692,1891692
148704,370220,AMGN,U S  judge halts rule requiring drug prices in TV ads,news,"By Tina Bellon and Nate Raymond  Reuters    A federal judge on Monday dealt a blow to the Trump administration by striking down a new rule that would have forced pharmaceutical companies to include the wholesale prices of their drugs in television advertising  U S  District Judge Amit Mehta in Washington sided with drugmakers Merck   Co Inc  Eli Lilly  NYSE LLY  and Co and  Amgen Inc   NASDAQ AMGN  by halting the U S  Department of Health and Human Services  HHS  rule from taking effect on Tuesday as planned  Mehta in his ruling set aside the entire rule as invalid  saying the HHS lacked authority from the U S  Congress to compel drug manufacturers to disclose list prices   It is outrageous that an Obama appointed judge sided with big PhRMA to keep high drug prices secret from the American people  leaving patients and families as the real victims   White House spokesman Judd Deere said in a statement  referring to President Donald Trump s Democratic predecessor  Barack Obama  PhRMA  the Pharmaceutical Research and Manufacturers of America  is the largest industry lobbying group  HHS Secretary Alex Azar announced the rule on May 8  saying that forcing drugmakers to disclose their prices in direct to consumer TV advertising could help drive down skyrocketing prescription drug costs if the companies were embarrassed by them or afraid they would scare away customers  The rule was originally suggested in May 2018 as part of Trump s  blueprint  to lower prescription drug costs for U S  consumers   The judge said such disclosures could well be an effective tool in halting the rising cost of prescription drugs   But no matter how vexing the problem of spiraling drug costs may be  HHS cannot do more than what Congress has authorized   Mehta concluded  Under the rule  the wholesale  or list  price would be included if it was  35 or more for a month s supply or the usual course of therapy  HHS said the 10 most commonly advertised drugs had list prices of  488 to  16 938 per month or for a usual course of therapy   Many drugmakers have opposed the rule  PhRMA said the list prices could be confusing for patients and discourage them from seeking medical care  Merck  Eli Lilly and Amgen filed their lawsuit alongside the Association Of National Advertisers trade group on June 14  arguing the rule would confuse consumers by forcing them to disclose a price irrelevant to patients with insurance  Drugmakers have long argued that list prices do not reflect the actual cost of drugs as they do not take into account discounts and rebates negotiated with health insurers and pharmacy benefit managers to ensure patient access to the medicines   The lawsuit alleged that HHS lacked authority to issue the rule and that it violated their free speech rights under the First Amendment of the U S  Constitution  
The U S  Justice Department defended the rule in court  saying it met a standard the U S  Supreme Court set in 1985  when it held the government could force advertisers to disclose factual  non controversial information ",2019-07-08,Reuters,https://www.investing.com/news/stock-market-news/us-judge-halts-rule-requiring-drug-prices-in-tv-ads-1917964,1917964
148705,370221,AMGN,Amgen Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3 30  to trade at  176 27 by 10 44  14 44 GMT  on Thursday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 872 72K  Amgen has traded in a range of  176 26 to  181 00 on the day 
The stock has traded at  189 4100 at its highest and  176 2700 at its lowest during the past seven days ",2019-07-11,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-3-1921099,1921099
148706,370222,AMGN,Amgen quarterly results beat estimates  but revenue dips 3 ,news,"By Deena Beasley  Reuters     Amgen Inc   O AMGN  on Tuesday said its second quarter revenue fell 3  due to more competition for its older off patent drugs  but rising sales of newer medicines helped its results exceed Wall Street forecasts   Amgen also said its experimental cancer drug AMG510 has shown activity in patients with colorectal and appendiceal cancer  helping to boost the company s shares by nearly 3  to  181 in extended trading  The U S  biotechnology company  which presented data in June showing that AMG510 also appeared to be effective against lung cancer  said it may begin a trial later this year that could serve as the basis for a U S  regulatory application seeking approval  AMG510 is part of a growing trend of precision medicines that target gene mutations driving cancer regardless of in which organ the disease originated    I m very impressed with the emerging safety profile that we are seeing with AMG510   David Reese  Amgen s head of research and development  said on a conference call on Tuesday  Amgen said second quarter adjusted earnings per share rose 4  to  3 97  topping analysts  average expectations by 41 cents  according to IBES data from Refinitiv  A lower number of outstanding shares contributed to the earnings beat  Total revenue of  5 87 billion  while lower than a year ago  topped analysts  estimates of  5 66 billion   Amgen had a good quarter all around   said Jefferies analyst Michael Yee   They tightened up guidance to the higher end of the range  which is where the Street is at   The company raised the lower end of its full year outlook and now expects adjusted earnings of  13 75 to  14 30 per share on revenue of  22 4 billion to  22 9 billion  It had previously forecast  13 25 to  14 30 per share on revenue of  22 billion to  22 9 billion  Sales of potent cholesterol fighter Repatha rose 3  to  152 million  below Wall Street estimates of  157 million  Sales of Amgen s new migraine drug Aimovig  which competes with similar new treatments from Eli Lilly  N LLY  and Teva  TA TEVA   totaled  83 million for the quarter  beating the  77 4 million projected by analysts   But sales of Neulasta  which fights infections by boosting white blood cells  fell 25  to  824 million  while sales of kidney drug Sensipar plunged 71  to  122 million as competition from cheaper generics and biosimilars increased  
Amgen reported a net profit of  2 17 billion  or  3 57 per share  for the quarter  compared with a profit of  2 29 billion  or  3 50 per share  a year ago ",2019-07-30,Reuters,https://www.investing.com/news/stock-market-news/amgen-quarterly-results-beat-estimates-but-revenue-dips-3-1939683,1939683
148707,370223,AMGN,Amgen Rises 3 ,news,"Investing com   Amgen  NASDAQ AMGN  rose by 3 09  to trade at  181 91 by 09 44  13 44 GMT  on Wednesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 454 96K  Amgen has traded in a range of  177 90 to  181 97 on the day 
The stock has traded at  181 9100 at its highest and  173 1200 at its lowest during the past seven days ",2019-07-31,Investing.com,https://www.investing.com/news/stock-market-news/amgen-rises-3-1940661,1940661
148708,370224,AMGN,Amgen Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3 02  to trade at  181 69 by 14 31  18 31 GMT  on Monday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 1 87M  Amgen has traded in a range of  181 53 to  185 96 on the day 
The stock has traded at  189 4600 at its highest and  173 1200 at its lowest during the past seven days ",2019-08-05,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-3-1945933,1945933
148709,370225,AMGN,Amgen Rises 3 ,news,"Investing com   Amgen  NASDAQ AMGN  rose by 3 05  to trade at  190 88 by 15 34  19 34 GMT  on Friday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 0  Amgen has traded in a range of  182 82 to  191 49 on the day 
The stock has traded at  191 4800 at its highest and  179 6100 at its lowest during the past seven days ",2019-08-09,Investing.com,https://www.investing.com/news/stock-market-news/amgen-rises-3-1951591,1951591
148710,370226,AMGN,Amgen Rises 5 ,news,"Investing com   Amgen  NASDAQ AMGN  rose by 4 68  to trade at  205 44 by 09 32  13 32 GMT  on Monday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 445 94K  Amgen has traded in a range of  197 26 to  205 72 on the day 
The stock has traded at  205 6200 at its highest and  179 6100 at its lowest during the past seven days ",2019-08-12,Investing.com,https://www.investing.com/news/stock-market-news/amgen-rises-5-1952645,1952645
148713,370229,AMGN,Merck s Keytruda Gets FDA s Priority Tag In Bladder Cancer,opinion,Merck   Co   Inc    NYSE MRK   announced that the FDA has granted priority review status to yet another supplemental new drug application  sNDA  for its blockbuster PD L1 inhibitor  Keytruda  The sNDA is seeking approval of Keytruda  as a monotherapy  to treat patients with high risk non muscle invasive bladder cancer  NMIBC   unresponsive to Bacillus Calmette Guerin  BCG  therapy   a therapy widely used in the management of bladder cancer The sNDA was based on data from the phase II KEYNOTE 057 study wherein Keytruda led to a complete response rate of nearly 40   Meanwhile  FDA s Oncologic Drugs Advisory Committee  ODAC  is due to discuss this sNDA at its Dec 17 meeting  With the FDA granting priority review  Merck expects a decision is in January 2020Merck s shares have risen 13 9  this year so far compared with the  s increase of 6 4    Keytruda  Merck s biggest product  is already approved for use in 20 indications across 12 different tumor types in the United States Keytruda generated sales of almost  8 billion in the first nine months of 2019  up around 63  year over year  The drug s sales were driven by the launch of new indications globally  Keytruda sales are benefiting from strong momentum in the indication of first line lung cancer The Keytruda development program is also progressing well with Merck spending billions on research and development of this medicine to secure more approvals in earlier lines of treatment  The drug is being studied for more than 30 types of cancer in above 1000 studies including 600 plus combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte  NASDAQ INCY   Glaxo   NYSE GSK   and Pfizer   NYSE PFE   separately for the evaluation of Keytruda in combination with other regimens  Undoubtedly  Keytruda s solid growth prospects are based on increased utilization  approval for new indications and expectation of additional approvals worldwide Merck currently carries a Zacks Rank  2  Buy   You can see  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-12-02,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-gets-fdas-priority-tag-in-bladder-cancer-200489674,200489674
148714,370230,AMGN,Why Is Ligand  LGND  Up 5 3  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Ligand Pharmaceuticals  LGND   Shares have added about 5 3  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Ligand due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Ligand Misses on Q3 Earnings   SalesLigand reported third quarter 2019 adjusted earnings of 49 cents per share  which missed the Zacks Consensus Estimate of 65 cents  The company had reported adjusted earnings of  1 32 in the year ago quarter  Third quarter adjusted earnings exclude the impact of non cash charge of  10 5 million related to Ligand s investment in Viking Therapeutics  stock based compensation and non cash charges Total revenues in the quarter decreased to  24 8 million from  45 7 million in the year ago period  However  the top line surpassed the Zacks Consensus Estimate of  23 16 million Quarterly HighlightsRoyalty revenues were  9 8 million in the reported quarter compared with  36 1 million in the year ago quarter  Ligand primarily earns royalties on sales of Kyprolis and Evomela  which were developed using its Captisol technology  The significant decline in royalty revenues was due to loss of royalties from sales of Novartis  Promacta Please note that excluding Promacta royalties recorded in the year ago quarter  royalty revenues increased almost 39  year over year in the third quarter  The growth was driven by higher royalty rate on Kyprolis sales as the drug s sales reached higher royalty rate tier and higher sales of Evomela following its launch in China CASI Pharmaceuticals launched Evomela in China in August 2019 License fees  milestones and other revenues were  8 2 million in the third quarter compared with  2 5 million in the year ago period  Material sales were  6 8 million  down 2 9  year over year General and administrative expense was  9 5 million in the third quarter  down 1 1  from the year ago quarter  Research and development expense more than 150  year over year to  13 7 million Business DevelopmentsLigand inked new OmniAb license agreements with six companies including Takeda Pharmaceutical  It also entered into agreements related to its Captisol technology with several companies during the quarter In September  Amgen  NASDAQ AMGN  announced successful completion of a phase III study evaluating Kyprolis in combination with dexamethasone and J J s cancer drug  Darzalex  The company also signed an agreement to commercialize Kyprolis in China  In July  Sage Therapeutics announced the launch of its postpartum depression drug  Zulresso Meanwhile  Ligand is actively repurchasing its shares since November 2018  The company has  500 million share repurchase program  and it has utilized about  91 million so far   2019 Guidance Ligand continues to expect sales for 2019 to be  118 million  However  it lowered adjusted earnings estimate from  3 20 per share to  3 00 for 2019  which reflects certain changes in tax expense  especially related to sale of Promacta royalty right 
How Have Estimates Been Moving Since Then 
It turns out  estimates revision have trended downward during the past month  The consensus estimate has shifted  10 64  due to these changes 
VGM Scores
At this time  Ligand has a poor Growth Score of F  however its Momentum Score is doing a lot better with a B  Following the exact same course  the stock was allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision has been net zero  Notably  Ligand has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-04,Zacks Investment Research,https://www.investing.com/analysis/why-is-ligand-lgnd-up-53-since-last-earnings-report-200490349,200490349
148715,370231,AMGN,Healthpeak Amends   Extends Lease With Amgen In San Francisco,opinion,Healthpeak Properties  Inc    NYSE PEAK   recently announced a lease amendment and extension with Amgen   NASDAQ AMGN   on the Britannia Oyster Point   BOP   campus of the former in South San Francisco  The move marks the company s efforts to continue its strategic relationships with existing tenants as well as address future tenants looking for space at this property Presently  Amgen leases spaces across the BOP campus in seven buildings  These include 1130   1150 Veterans Blvd  331   333 Oyster Point Blvd  as well as 1100  1120 and 1140 Veterans Blvd With the lease amendment  Amgen has the flexible right to carry on its occupancy at three of its currently leased buildings through 2029  At the same time  Amgen has flexibility to end its occupancy in these buildings at prior dates  which is conditional on advance notice requirements Located in a thriving development area  the BOP campus has 10 buildings aggregating more than 900 000 square feet of Class A life sciences spaces  It is positioned directly neighboring to Healthpeak s transformative 1 million square foot development   The Cove at Oyster Point Notably  over the past years  Healthpeak has made concerted efforts to reposition its portfolio  As part of these  the company has recycled capital through non core dispositions to its solid investment and development pipeline  The strategic expansion of its life science and medical office building  MOB  portfolio footprint and selective buyouts of high quality senior housing assets in high barrier to entry markets has renewed the company s growth opportunities Increasing life expectancy of the U S  population and bio pharma drug development growth opportunities have boosted the institutional life science and medical real estate market fundamentals  Amid these  Healthpeak has adopted a cluster strategy in three premier life science epicenters   San Diego  San Francisco and Boston   aimed at assembling assets through acquisitions  developments and redevelopments  On the back of these  the company is gaining scale and is well poised to meet the growing demand of life science tenants Healthpeak currently carries a Zacks Rank  3  Hold   In the past six months  shares of this REIT have gained 8 4   as against its  s increase of 2 3  Stocks to ConsiderPrologis  Inc  s   NYSE PLD   currently sports a Zacks Rank of 1  Strong Buy   The company s funds from operations  FFO  per share estimate for 2019 has been revised 1 2  upward to  3 31 in two months  time  The stock has rallied 10 8  in three months  time  You can see  Cousins Properties Incorporated s   NYSE CUZ   Zacks Consensus Estimate for the current year FFO per share moved 2 1  north to  2 96 over the past two months  Shares of this Zacks Rank  2  Buy  company have gained 12  over the past three months Note  Anything related to earnings presented in this write up represents funds from operations  FFO    a widely used metric to gauge the performance of REITs Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-12-09,Zacks Investment Research,https://www.investing.com/analysis/healthpeak-amends--extends-lease-with-amgen-in-san-francisco-200491526,200491526
148739,370255,AMGN,Amgen Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3 01  to trade at  183 16 by 12 41  17 41 GMT  on Wednesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 1 81M  Amgen has traded in a range of  183 09 to  189 37 on the day 
The stock has traded at  192 1900 at its highest and  183 0800 at its lowest during the past seven days ",2019-03-06,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-3-1799658,1799658
148740,370256,AMGN,Amgen Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3 05  to trade at  182 35 by 14 05  18 05 GMT  on Wednesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 2 59M  Amgen has traded in a range of  182 32 to  188 68 on the day 
The stock has traded at  195 0000 at its highest and  182 3200 at its lowest during the past seven days ",2019-04-17,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-3-1838930,1838930
148741,370257,AMGN,Drugmakers Astellas  Amgen to pay  125 million in U S  charity kickback probe,news,"By Nate Raymond BOSTON  Reuters    Two drugmakers will pay nearly  125 million to settle claims they used charities that help cover Medicare patients  out of pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their medications  the U S  Justice Department said on Thursday  The department said Astellas Pharma and  Amgen Inc   NASDAQ AMGN  were the latest pharmaceutical companies to settle claims stemming from an industry wide probe of drugmakers  financial support of patient assistance charities  Astellas will pay  100 million while Amgen will pay  24 75 million  the department said  Neither company admitted wrongdoing or responded immediately to requests for comment  The investigation  led by the U S  Attorney s Office in Boston  came amid growing attention to soaring U S  drug prices  Copays are partly meant to serve as a check on healthcare expenses by exposing patients to some of a drug s cost  Drug companies are prohibited from subsidizing copayments for patients enrolled in the government s Medicare healthcare program for those aged 65 and older  Companies may donate to non profits providing copay assistance as long as they are independent  
But the government alleged that the drugmakers used such charities as conduits to improperly pay the copay obligations of Medicare patients using their drugs  in violation of the Anti Kickback Statute ",2019-04-25,Reuters,https://www.investing.com/news/stock-market-news/drugmakers-astellas-amgen-to-pay-125-million-in-us-charity-kickback-probe-1846200,1846200
148742,370258,AMGN,Amgen Earnings  Revenue Beat in Q1,news,"Investing com   Amgen  NASDAQ AMGN  reported first quarter earnings  that Beat analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  3 56 on revenue of  5 56B  Analysts polled by Investing com expected EPS of  3 48 on revenue of  5 53B  That compared to EPS of  3 47 on revenue of  5 55B in the same period a year earlier  The company had reported EPS of  3 42 on revenue of  6 23B in the previous quarter 
Amgen shares lost 0 18  to trade at  179 00 in after hours trade following the report 
Amgen follows other major Healthcare sector earnings this month
 On April 16  J J reported first quarter EPS of  2 1 on revenue of  20 02B  compared to forecasts of EPS of  2 04 on revenue of  19 61B 
Pfizer earnings Beat analysts  expectations on Tuesday  with first quarter EPS of  0 85 on revenue of  13 12B  Investing com analysts expected EPS of  0 75 on revenue of  13B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-04-30,Investing.com,https://www.investing.com/news/stock-market-news/amgen-earnings-revenue-beat-in-q1-1851251,1851251
148743,370259,AMGN,Amgen Falls 4 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3 52  to trade at  173 00 by 09 47  13 47 GMT  on Wednesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 596 67K  Amgen has traded in a range of  172 85 to  178 50 on the day 
The stock has traded at  182 4700 at its highest and  172 6200 at its lowest during the past seven days ",2019-05-01,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-4-1852435,1852435
148744,370260,AMGN,Amgen Rises 3 ,news,"Investing com   Amgen  NASDAQ AMGN  rose by 3 18  to trade at  172 00 by 09 31  13 31 GMT  on Monday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 114 89K  Amgen has traded in a range of  171 21 to  172 06 on the day 
The stock has traded at  173 7700 at its highest and  166 6800 at its lowest during the past seven days ",2019-06-03,Investing.com,https://www.investing.com/news/stock-market-news/amgen-rises-3-1886126,1886126
148749,370265,AMGN,Pharma Stock Roundup  FDA Nod To NVS    AZN s Drugs  BMY CELG Merger Closes,opinion,"This week  the FDA approved Novartis    NYSE NVS   sickle cell disease  SCD  candidate Adakveo  crizanlizumab   AstraZeneca s   NYSE AZN   leukemia drug Calquence for a new indication   chronic lymphocytic leukemia  CLL  and Pfizer s   NYSE PFE   Abrilada  a biosimilar version of AbbVie s   NYSE ABBV   Humira  Meanwhile  Bristol Myers   NYSE BMY   closed the long pending  74 billion acquisition of Celgene  NASDAQ CELG   While Merck s   NYSE MRK   late stage study on heart failure candidate vericiguat met its goal  Bristol Myers  late stage melanoma study on Opdivo plus Yervoy combination failed to meet the primary endpoint Recap of the Week s Most Important Stories FDA Approves Novartis SCD Drug and AstraZeneca s Calquence for CLL  The FDA approved Novartis  to reduce the frequency of vaso occlusive crises  VOCs  or pain crises in patients suffering sickle cell disease  SCD   The drug will be marketed by the trade name Adakveo  The regulatory agency s approval was based on results from the 52 week  randomized  placebo controlled SUSTAIN study  The nod comes approximately two months ahead of the FDA s priority review action date The FDA also granted approval to AstraZeneca s BTK inhibitor Calquence for a new indication  chronic lymphocytic leukemia  CLL  or small lymphocytic lymphoma  SLL  in frontline and in the relapsed recurrent disease setting  Calquence is presently marketed for the previously treated mantle cell lymphoma  MCL    The approval for the CLL indication was based on two phase III studies  namely ELEVATE TN and ASCEND  Data from the studies demonstrated superior progression free survival post treatment with Calquence across multiple settings while maintaining favourable tolerability  With the approval for this much larger indication  AstraZeneca can gain access to a broader patient population and boost sales of this promising drug Bristol Myers   Celgene Merger Closes  The U S  Federal Trade Commission finally allowed completion of the  of Celgene with Bristol Myers after the former agreed to divest its blockbuster psoriasis drug Otezla to Amgen  NASDAQ AMGN  in August  As a result  Bristol Myers fulfilled all the regulatory requirements under the merger agreement to complete the acquisition of Celgene  which was concluded on Nov 20  2019 Meanwhile  Bristol Myers  phase III study evaluating a combination of  plus Yervoy in patients with resected high risk melanoma failed to show a statistically significant benefit for the co primary endpoint of recurrence free survival  RFS   The study was recommended to be continued unmodified by the Data Monitoring Committee FDA Approves Pfizer s Humira Biosimilar  Abrilada  Pfizer s biosimilar version of AbbVie s blockbuster drug Humira was approved by the FDA to treat multiple inflammatory conditions  The biosimilar will be marketed by the trade name   Pfizer has a non exclusive licensing deal with AbbVie under which it can launch Abrilada in the United States on Nov 20  2023  In the EU  Pfizer can launch Humira biosimilar when it gets an approval from the European Medicines Agency Merck Bayer s Heart Failure Candidate Meets Study Endpoint  Merck and Bayer s investigational drug  met the primary endpoint in the phase III VICTORIA study of patients with worsening chronic heart failure with reduced ejection fraction  HFrEF    Data from the study showed that vericiguat lowered the risk of composite endpoint of heart failure  hospitalization or cardiovascular death in such patients compared to placebo when given in combination with available heart failure therapies Meanwhile  the European Commission approved Merck s PD L1 inhibitor  for first line treatment of metastatic or unresectable  recurrent head and neck squamous cell cancer  HNSCC  as monotherapy  or in combination with chemotherapy in patients whose tumors express PD L1  The sBLA was based on data from the phase III KEYNOTE 048 study  A similar approval was granted by the FDA in the United States in June 2019 CHMP Nod to Roche   Novartis  Drugs  The European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  recommended EU approval of Roche s   OTC RHHBY    for the adjuvant treatment of people with HER2 positive early breast cancer with residual invasive disease after neoadjuvant treatment  The agency also recommended conditional EU nod to Roche s Polivy for people with previously treated aggressive lymphoma  Polivy was approved in the United States in June this year  Novartis  Mayzent  siponimod  also got a positive CHMP opinion for the treatment of adult patients with active secondary progressive multiple sclerosis  SPMS    Mayzent was approved by the FDA earlier in March Novo Nordisk  CSE NOVOb    AbbVie s New Deals  Novo Nordisk announced a collaboration deal with Massachusetts based  Pharmaceuticals to discover and develop RNAi therapies for liver related cardio metabolic diseases using Dicerna s proprietary GalXC RNAi platform  The companies will discover molecules for targets that may yield multiple potential treatments across disease areas  such as diabetes  obesity  cardiovascular and NASH  Per the deal  Dicerna will get an upfront payment of  175 million while Novo Nordisk will make an equity investment worth  50 million in its stock  Dicerna will also be eligible to receive additional milestone fees and potential royalties on product sales AbbVie signed a license and option collaboration contract with Harpoon Therapeutics to advance Harpoon s pre clinical candidate HPN217  BCMA   a TriTAC for the treatment of multiple myeloma  Per the deal  Harpoon granted AbbVie an option to license worldwide exclusive rights to HPN217  Harpoon plans to file an IND application this year to begin a phase I II study on HPN217 for multiple myeloma  Harpoon will take care of the phase I II development after completion of which AbbVie can exercise the option  The companies also expanded their existing TriTAC discovery collaboration  formed in October 2017  for up to six additional targets selected by AbbVie  For the two deals  AbbVie will pay Harpoon  50 million upfront and up to  50 million in a contingent milestone payment for the first patient treated with HPN217 in a study The NYSE ARCA Pharmaceutical Index rose 1 4  in the last five trading sessions  Large Cap Pharmaceuticals Industry 5YR   Return
  
Here is how the seven major stocks performed in the last five trading sessions 
 Last week  all the stocks were in the green except Bristol Myers  which declined 2 8   J J  NYSE JNJ  rose the most  4 2   In the past six months  AstraZeneca has risen the most  23 2   while Pfizer lost the maximum  10 0    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week The Hottest Tech Mega Trend of All                 Last year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2019-11-21,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-fda-nod-to-nvs--azns-drugs-bmycelg-merger-closes-200487702,200487702
148750,370266,AMGN,Novartis  NVS  To Acquire The Medicines Company For  9 7B,opinion,Swiss pharma giant Novartis   NYSE NVS   is the latest company to join the ongoing M A wave in the pharma biotech sector The company announced that it entered an agreement to acquire U S  based biopharmaceutical company  The Medicines Company   NASDAQ MDCO    for  85 per share in cash or a total valuation of  9 7 billion  and add a potentially transformational investigational cholesterol lowering therapy Financial Terms of the AcquisitionPer the terms  the offer price represents a premium of approximately 41  over The Medicines Company s 30 day  to November 22  2019  volume weighted average price of  60 33 and approximately 24  premium over the closing share price of  68 55 on Nov 22  which represented a fully diluted equity value of approximately  7 7 billion The transaction  expected to close in the first quarter of 2020  has been unanimously approved by the boards of both companies The acquisition is expected to modestly dilute core earnings per share Value of the DealThe acquisition will add a potentially first in class siRNA inhibitor targeting PCSK9  inclisiran  to Novartis  pipeline  The Medicines Company recently announced data from its late stage program consisting of three phase III studies  ORION 9  10 and 11  on inclisiran for the treatment of atherosclerotic cardiovascular disease  ASCVD  and familial hypercholesterolemia  FH   Inclisiran demonstrated potent and durable LDL C reduction with an excellent safety and tolerability profile  The candidate s twice yearly dosing schedule allows administration during patients  routine visits to their healthcare professionals and will likely improve patient adherence and sustain lower LDL C levels Additionally  an ongoing clinical trial  ORION 4  will evaluate the cardiovascular morbidity and mortality benefits of inclisiran The Medicines Company expects to file regulatory submissions in the United States in the fourth quarter of 2019 and Europe in the first quarter of 2020  The Medicines Company has a partnership with Alnylam Pharmaceuticals for the development of PCSK9 inhibitor  inclisiran Our TakeThe planned acquisition will add a promising candidate to Novartis  cardiovascular portfolio  which includes Entresto  With regulatory applications planned shortly  inclisiran represents a near term product launch opportunity and is expected to contribute to sales from 2021  The twice yearly dosing schedule provides a great advantage to the candidate over the existing treatments in the market Though the targeted market holds significant potential  competition is stiff from the likes of Amgen s   NASDAQ AMGN   Repatha and Regeneron and Sanofi s   NASDAQ SNY   Praluent  While Praluent and Repatha are approved with once every two weeks or once a month dosing  inclisiran has been developed for twice a year dosing Shares of the company have gained 5 5  year to date compared with the  s growth of 5 2   Novartis has been making prudent acquisitions in recent times to diversify its portfolio  as its legacy drugs are facing generic competition  Earlier  the company acquired Endocyte to expand expertise in radiopharmaceuticals and transformational therapeutic platforms  In 2018  it acquired U S  based  clinical stage  gene therapy company  AveXis  Inc  which focuses on developing novel treatments for patients suffering from rare and life threatening neurological genetic diseases  The company spun off its ophthalmology division  Alcon  into a separately traded  standalone company in order to grow as a medicines company solely We are positive about the impending acquisition and expect Novartis to witness significant growth in sales once inclisiran obtains approval Zacks RankNovartis currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-11-24,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-to-acquire-the-medicines-company-for-97b-200487664,200487664
148751,370267,AMGN,Merck s Keytruda Gets Nod In China For Difficult Lung Cancer,opinion,Merck   Co   Inc    NYSE MRK   announced that the National Medical Products Administration  NMPA  in China has approved yet another label expansion of its blockbuster PD 1 inhibitor Keytruda  pembrolizumab   The drug is now approved in combination with chemotherapy  carboplatin and paclitaxel  for the first line treatment of patients with metastatic squamous non small cell lung cancer  NSCLC   a difficult to treat lung cancer population Following this recent nod  Keytruda in combination with chemotherapy is now approved for the first line treatment of squamous and nonsquamous NSCLC in China  It is also approved as a monotherapy in the first line setting for appropriate NSCLC patients with tumor proportion score  1  The approval for squamous NSCLC patients was based on data from the phase III KEYNOTE 407 study including interim data from an extension of the global study in Chinese patients  Data from the study showed that the combination of Keytruda plus chemotherapy led to a significant improvement in both overall survival  OS  and progression free survival rates compared with patients receiving only chemotherapy in the given indication A similar label expansion was approved in the United States and Europe in October 2018 and March 2019  respectively  This nod will help Merck gain access to a broader lung cancer patient population in China Shares of Merck have rallied 14 3  so far this year  outperforming the increase of 5 9  Notably  Keytruda is Merck s biggest product and already approved for 20 indications across 12 different tumor types in the United States The drug generated sales of almost  8 billion in the first nine months 2019  up approximately 63  year over year  Sales were driven by the launch of new indications globally  Keytruda sales are benefiting from a strong momentum in the indication of first line lung cancer Moreover  Keytruda development program is progressing well and the drug is being studied for more than 30 types of cancer in above 1000 studies including 600 plus combination studies Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte   NASDAQ INCY    Glaxo and Pfizer   NYSE PFE   separately for the evaluation of Keytruda in combination with other regimens Zacks RankMerck currently carries a Zacks Rank  2  Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-11-26,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-gets-nod-in-china-for-difficult-lung-cancer-200488346,200488346
148752,370268,AMGN,Here s Why Merck s  MRK  Shares Are Up This Year ,opinion,Shares of Merck   Co   Inc    NYSE MRK   have rallied 11 7  this year so far compared with the  s increase of 6 2    Its earnings estimates have risen almost 4 9  for 2019 and 2  for 2020 over the past 60 days What s Behind the Rally A significant part of Merck s outperformance this year has been owing to strong performance and positive regulatory updates related to its PD 1 inhibitor Keytruda  The medicine is Merck s biggest product now  It is already approved for use in 20 indications across 12 different tumor types in the United States  Keytruda generated sales of almost  8 billion in the first nine months 2019  up around 63  year over year  The drug s sales are driven by the launch of new indications globally and a strong momentum in the indication of first line lung cancer The drug gained several label expansion approvals from the FDA this year so far  These are as an adjuvant therapy for high risk stage III melanoma  first line head neck cancer  previously treated advanced small cell lung cancer  advanced esophageal cancer  as a Keytruda Lenvima combo for endometrial carcinoma and Keytruda   Inlyta combo for first line advanced renal cell carcinoma  RCC  Keytruda also won the nod for five new cancer line extensions in Japan  first line advanced non small cell lung cancer  NSCLC  in China and first line head neck cancer andas Keytruda   Inlyta combo for first line advanced RCC in the EU  All these label expansion approvals are boosting the product sales higher with the trend expected to continue in 2020 Several regulatory decisions for new indications in the United States as well as in Europe are pending in 2020  which if approved  can further improve sales The Keytruda development program is also progressing well with Merck spending billions on research and development of this medicine to secure more approvals in earlier lines of treatment  The drug is being studied for more than 30 types of cancer in above 1000 studies including 600 plus combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte  NASDAQ INCY   Glaxo and Pfizer   NYSE PFE   separately for the evaluation of Keytruda in combination with other regimens  Undoubtedly  Keytruda s solid growth prospects are based on increased utilization  approval for new indications and expectation of additional approvals worldwide This apart  Merck clinched FDA nod for its new combination antibacterial injection  Recarbrio  MK 7655A   a fixed combination of relebactam with imipenem cilastatin  and a new indication   two types of pneumonia infections   for its antibacterial medicine  Zerbaxa  It also received several label expansion approvals for PARP inhibitor Lynparza  which it shares with partner AstraZeneca s   NYSE AZN   including front line ovarian cancer in the EU and Japan as well as for advanced breast cancer in the EU  Merck s investigational vaccine V920 for Ebola Zaire disease was also approved in the EU this month Merck has also been on a firm footing as far as collaborations and M A activity are concerned  This year  the company bought small cancer focused biotech Immune Design and privately held Europe s animal health technology provider Antelliq Group  It also purchased small private biotechs Peloton  NASDAQ PTON  Therapeutics and Tilos Therapeutics  All these acquisitions strengthened its pipeline ConclusionMerck  which carries a Zacks Rank  2  Buy   has its share of challenges in the form of generic competition for several drugs  pricing pressure and increased competitive pressure on its diabetes franchise and products like Isentress  HIV  and Zepatier  HCV  Nonetheless  new products  namely Keytruda  Lynparza and Bridion should continue to contribute meaningfully to the company s top line going forward  Animal health and vaccine products are also witnessing a solid uptake and remain core growth drivers for Merck Also  the company can gain approval for V920 and MEK 1 2 inhibitor selumetinib to treat pediatric neurofibromatosis type 1 in the United States and further line extensions for Keytruda and Lynparza in 2020  Also  Merck is expected to maintain its cost cutting initiatives  which would drive its bottom line You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-11-27,Zacks Investment Research,https://www.investing.com/analysis/heres-why-mercks-mrk-shares-are-up-this-year-200488800,200488800
148753,370269,AMGN,The Zacks Analyst Blog Highlights  Intercept  CymaBay  Amgen  Global Blood Therapeutics And ChemoCentryx,opinion,For Immediate ReleaseChicago  IL  November 29  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Intercept Pharmaceuticals   NASDAQ ICPT    CymaBay   NASDAQ CBAY    Amgen   NASDAQ AMGN    Global Blood Therapeutics   NASDAQ GBT   and ChemoCentryx   NASDAQ CCXI   Here are highlights from Wednesday s Analyst Blog Biotech Stock Roundup  CBAY  CCXI  AMGN and MoreIt was a busy week for the biotech sector with updates from quite a few companies  While Intercept Pharmaceuticals obtained Priority Review for its New Drug Application  NDA  for NASH drug  CymaBay plunged on termination of NASH study  Amgen upped its guidance after buying Otezla whereas Global Blood Therapeutics obtained FDA approval for its SCD drug   Meanwhile  ChemoCentryx soared after it announced positive data from a late stage study on its rare disease candidate Recap of the Week s Most Important Stories Intercept NDA for NASK Drug Gets Priority Review   Intercept Pharmaceuticals  that the FDA has accepted its New Drug Application  NDA  for obeticholic acid  OCA  seeking accelerated nod for the treatment of fibrosis due to nonalcoholic steatohepatitis  NASH   The agency also granted a Priority Review to the same  Notably  the regulatory authority generally grants priority review to drugs with potential to treat a serious condition and if approved  would provide a significant improvement in safety or effectiveness  The FDA set a Prescription Drug User Fee Act  PDUFA  target action date of Mar 26  2020  for the NDA  The agency indicated that it currently plans to hold an advisory committee meeting to discuss the application  However  the date for the meet has not been finalized and the timeline for the NDA review is subject to change CymaBay Plunges on Termination of NASH Study  Shares of CymaBay plummeted significantly after the company announced that it was terminating its phase IIb study of seladelpar in patients with NASH and its recently initiated phase II study of the drug in patients with primary sclerosing cholangitis  PSC   Moreover  it is putting a hold on all studies of seladelpar in patients with primary biliary cholangitis  PBC   The decision to terminate these studies was based on initial histological findings observed in the phase IIb study of seladelpar for NASH after data showed some patients experiencing some liver damage  These planned  blinded  histological assessments of the first tranche of liver biopsies in the study showed atypical histological findings including histology characterized as an interface hepatitis presentation with or without biliary injury You can see Amgen Buys Otezla  Lifts Outlook  Amgen that it has completed the previously declared acquisition of Celgene s blockbuster psoriasis drug Otezla  which the latter had to divest in order to complete its merger with Bristol Myers   Amgen had to pay Celgene  NASDAQ CELG   13 4 billion in cash or approximately  11 2 billion net of anticipated future cash tax benefits for Otezla and certain related assets and liabilities  Otezla is approved to treat psoriasis  psoriatic arthritis and oral ulcers associated with Beh et s diseaseFollowing this buyout  the company raised its overall guidance for 2019  Amgen now expects total revenues in the range of  23 1  23 3 billion  previously expected within  22 8  23 0 billion  Adjusted EPS is expected in the band of  14 5   14 7 compared with the previous range of  14 20 14 45 Global Blood Gets FDA Approval for SCD Drug   Global Blood Therapeutics that the FDA has approved its lead product candidate Oxbryta  voxelotor  as an oral  once daily treatment for sickle cell disease  SCD  in patients aged 12 years and above  The approval comes almost three months ahead of the scheduled action date of Feb 26  2020   SCD is a chronic  inherited blood disorder that affects hemoglobin levels  Following this nod  Oxbryta became the first approved therapy that directly inhibits sickle hemoglobin polymerization  a major cause for SCD ChemoCentryx Gains on Study Results  ChemoCentryx surged significantly after it announced encouraging top line data from the phase III study ADVOCATE evaluating its orally administered selective complement 5a receptor inhibitor  avacopan  The pivotal study evaluated avacopan in patients with anti neutrophil cytoplasmic antibody associated vasculitis  ANCA vasculitis   a rare disease affecting small blood vessels  Data from the study showed that patients in the study treated with avacopan achieved both primary endpoints of clinical remission at weeks 26 and 52   Clinical remission was statistically superior in the avacopan arm compared to SOC at 52 weeks  The company is planning to file a regulatory application seeking approval for avacopan to treat ANCA vasculitis in the United States and Europe next year Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-11-28,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-intercept-cymabay-amgen-global-blood-therapeutics-and-chemocentryx-200489000,200489000
148754,370270,AMGN,A Guide To Biotech ETF Investing,opinion,The biotech industry has kept its promise of solid returns so far  The rally in some major biotechnology indexes reflects the same  In this context  the has returned 23 1  year to date  Following the trend   has returned around 29 5   read    With time  biotechnology is emerging as a favored sector for investors with some risk appetite Trends Favoring Biotech Increasing mergers and acquisition  M A  deals  growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market  The sector has been benefitting from a flurry of positive news  including trial results and deal activities M As are dominating the sector as sluggishness in mature products has forced companies to explore acquisitions to bolster their pipelines Several other large cap pharma as well as bigger biotech companies are entering collaboration deals with smaller ones to boost their pipeline  Furthermore  in licensing deals are consistently rising with bigwigs partnering with smaller and mid sized players that own promising mid to late stage pipeline candidates or interesting technology  Amgen  NASDAQ AMGN  recently completed the buyout of psoriasis and psoriatic arthritis drug Otezla from Celgene for  13 4 billion in cash or around  11 2 billion net of anticipated future cash tax benefits  Moreover  Bristol Myers Squibb  NYSE BMY  has completed the acquisition of Celgene Corp  NASDAQ CELG  for  74 billion in a cash and stock deal  It is considered to be one of the biotech industry s largest deal of the past decade  Furthermore  Swiss drugmaker Novartis AG recently announced plans to buy cholesterol drug developer  The Medicines Company  for  9 7 billion  The acquisition will give Novartis access to Medicines Co  s near to market heart drug   inclisiran The companies within the biotech sector gain majorly from positive pipeline related advancements  The space has seen a series of developments so far in 2019  Moreover  biotech bigwigs are increasingly focusing on a few drug categories like biosimilars  neurological disorders  autoimmune diseases and gene therapies  In fact  per an article on   the FDA is increasingly encouraging companies to adopt means to develop gene therapy related products Here  we have highlighted the 10 most popular biotech ETFs for investors seeking to benefit from the strengthening biotechnology market iSharesNasdaq Biotechnology ETF This fund seeks to provide exposure to U S  biotechnology stocks and tracks the NASDAQ Biotechnology Index  It comprises 215 holdings  It has AUM of  7 83 billion and charges a fee of 47 basis points a year  The fund trades in average daily trading volume of 2 4 million shares and has gained 23  year to date  read    SPDR S P Biotech  NYSE XBI  ETF The fund seeks daily investment results  before fees and expenses  which match the S P Biotechnology Select Industry Index  It holds about 115 securities in its basket  Its AUM is  4 34 billion and expense ratio  0 35   The fund trades in average daily trading volume of 4 4 million shares and has gained 28 3  year to date  read    First Trust Amex Biotechnology Index The fund measures the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services  It holds about 31 securities in its basket  Its AUM is around  1 78 billion and expense ratio is 0 57   The fund trades in average daily trading volume of around 172 000 shares and has gained 17 1  year to date ARK Genomic Revolution Multi Sector ETF This is an actively managed ETF focusing on companies likely to benefit from the extension and enhancement of the quality of human and other life by incorporating technological and scientific developments plus improvements and advancements in genomics into their business  The fund holds 38 stocks in its basket  It charges 0 75  in expense ratio and has accumulated  465 6 million in its asset base  The fund trades in average daily trading volume of around 120 000 shares and has gained 44 7  year to date  read    VanEck Vectors Biotech ETF   LON BBH  The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production  marketing and sales of drugs based on genetic analysis and diagnostic equipment  It holds about 24 securities in its basket  Its AUM is  371 9 million and expense ratio is 0 35   The fund trades in average daily trading volume of around 14 000 shares and has gained 27 5  year to date Invesco Dynamic Biotechnology   Genome ETF This fund follows the Dynamic Biotech   Genome Intellidex Index  The index comprises companies that are majorly engaged in the research  development  manufacturing and marketing plus distribution of various biotechnological products  services and processes and companies that gain significantly from scientific and technological advances in biotechnology and genetic engineering and research  The fund holds 28 stocks in its basket  It has managed  234 3 million in its asset base  Expense ratio is at 0 57   The fund trades in average daily trading volume of around 12 000 shares and has gained 17 8  year to date ALPS Medical Breakthroughs ETF   SI SBIO  The fund seeks investment results that correspond  before fees and expenses  generally to the performance of its underlying index  the S Network Medical Breakthroughs Index  The product charges 50 basis points in fees per year from investors and holds 77 stocks in its basket  It has AUM of  193 million in its asset base  The fund trades in average daily trading volume of around 34 000 shares and has gained 40 4  year to date  read    Principal Healthcare Innovators Index ETF This fund offers access to early phase companies developing treatments for conditions like migraines  Crohn s disease  multiple sclerosis  diabetes and other illnesses by tracking the Nasdaq Healthcare Innovators Index  It holds 188 stocks in its basket  BTEC charges 42 bps in annual fees  The product has accumulated  59 3 million in its asset base  The fund trades in average daily trading volume of around 1 900 shares and has gained 35 7  year to date  read    The Cancer Immunotherapy ETF This ETF offers exposure to a basket of companies that develop therapies to treat cancer by harnessing the body s own immune system  Holding 26 stocks in its basket  it has AUM of  38 million  The product charges 79 bps in annual fees  The fund trades in average daily trading volume of around 9 400 shares and has gained 23 7  year to date  read    Virtus LifeSci Biotech Products ETF   BS BBP  The ETF follows the LifeSci Biotechnology Products Index  which measures the performance of biotechnology companies with at least one drug therapy approved by the FDA  Holding 39 stocks  the product has moderate concentration across components  The product has accumulated AUM of about  28 3 million and charges 79 bps in fees per year  The fund trades in average daily trading volume of around 3 100 shares and has gained 26  year to date Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-12-02,Zacks Investment Research,https://www.investing.com/analysis/a-guide-to-biotech-etf-investing-200489393,200489393
148773,370289,AMGN,Amgen quarterly profit tops Street view  2019 forecast falls short,news,By Deena Beasley  Reuters     Amgen Inc   NASDAQ AMGN  on Tuesday reported higher than expected fourth quarter profit as sales rose and tax expense fell  but competition for older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates  For the full year  Amgen projected adjusted earnings of  13 10 to  14 30 per share on revenue of  21 8 billion to  22 9 billion  Wall Street analysts  on average  had forecast  14 61 per share on revenue  22 9 billion  according to IBES data from Refinitiv  The world s largest biotechnology company posted a net profit of  1 93 billion  or  3 01 per share  compared with a net loss of  4 26 billion  or  5 89 per share  a year ago  when it took a large charge related to changes in U S  corporate tax laws  Excluding items  Amgen said it had adjusted earnings for the quarter of  3 42 per share  Analysts  on average  expected  3 27 per share  Total revenue for the quarter rose 7 percent to  6 23 billion  beating the average analyst estimate of  5 84 billion   The rise in sales was driven largely by increased demand for medicines such as cancer drug Kyprolis  cholesterol fighter Repatha and osteoporosis treatment Prolia ,2019-01-29,Reuters,https://www.investing.com/news/stock-market-news/amgen-quarterly-profit-tops-street-view-2019-forecast-falls-short-1762131,1762131
148774,370290,AMGN,Amgen Falls 5 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 4 97  to trade at  182 57 by 10 16  15 16 GMT  on Wednesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 1 76M  Amgen has traded in a range of  182 49 to  189 76 on the day 
The stock has traded at  203 9500 at its highest and  182 5400 at its lowest during the past seven days ",2019-01-30,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-5-1763375,1763375
148775,370291,AMGN,Amgen Falls 5 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 5 18  to trade at  182 16 by 10 17  15 17 GMT  on Wednesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 1 79M  Amgen has traded in a range of  182 13 to  189 76 on the day 
The stock has traded at  203 9500 at its highest and  182 1600 at its lowest during the past seven days ",2019-01-30,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-5-1763378,1763378
148776,370292,AMGN,Exclusive  Facing crackdown in Canada  drugmakers offered billions in price cuts,news,By Allison Martell and Anna Mehler Paperny TORONTO  Reuters    Canadian pharmaceutical industry lobby groups  in an effort to head off a planned crackdown on prescription drug prices  offered to give up C 8 6 billion   6 6 billion  in revenue over 10 years  freeze prices or reduce the cost of treating rare diseases  according to interviews and documents seen by Reuters  Those industry offers did not impress federal officials  coming last year as Canada prepared to expand the powers of a little known federal watchdog called the Patented Medicine Prices Review Board  PMPRB  to reduce the cost of prescription drugs  The government proposals would change the countries Canada compares its prices to  dropping the United States where they are highest  and set a formula to assess cost effectiveness of medicines  Announced in 2017  the new rules were scheduled to come into effect last month but have been delayed as the government reviews feedback  which has some wondering if they will ever be implemented   The delay is a setback for supporters of the changes  But documents detailing counter offers from lobby groups Innovative Medicines Canada and BIOTECanada show an industry struggling to win over federal officials  Unlike other countries with universal healthcare  Canada s government funded healthcare system does not cover prescription drugs  Most Canadians rely on an expensive patchwork of public and private insurance plans for that  Among industrialized nations  only the United States and Switzerland spend more on prescriptions per capita  Declan Hamill  a vice president at Innovative Medicines Canada  said the proposed regulations go too far and could hurt patient access to new drugs in Canada  But his group recognizes that the Canadian government wants to make drugs more affordable  he said    We d like to help the government out with that  and we ve been trying to have discussions with them   Hamill said   Lower prices in Canada could eventually hit drugmakers in the most lucrative U S  market  as Washington evaluates a proposal to base drug prices paid under the government s Medicare program on the cost of medicines in other developed nations  including Canada  Global drugmakers  including Johnson   Johnson  NYSE JNJ   Merck   Co   Amgen Inc   NASDAQ AMGN  and others  have argued against the Canadian proposal  They referred questions back to Innovative Medicines Canada   WOULD NOT ACHIEVE THE GOAL  With major drugmakers united in their condemnation of proposed regulations to rein in prices  Health Canada hired former Bank of Canada governor David Dodge and health economist  ke Blomqvist to assess the government proposal  Their review  completed in August 2018  broadly endorsed the government s plan  documents seen by Reuters showed  Prime Minister Justin Trudeau s senior ministers will eventually decide how to proceed  PMPRB Executive Director Douglas Clark told Reuters the new regime could be running by early 2020   People have a tendency to presume that the sky is falling   Clark said   I think it s a little early for people to panic and lament the demise of this policy initiative    Health Canada said the industry s offers do not address drug price problems created by outdated rules   The non regulatory counter proposals that Innovative Medicines Canada and BIOTECanada jointly submitted to the government would not achieve the goal of ensuring appropriate consumer protection in these circumstances   the ministry said in an emailed statement  One offer was to  secure a price reduction target of C 8 6 billion  in net present value terms  according to a letter from officials seen by Reuters   Hamill said the C 8 6 billion figure was borrowed from a government estimate of how much the PMPRB reforms would reduce revenue and would have been spread over 10 years  He did not say exactly how it would have worked  Total patented medicine sales were C 16 8 billion   12 8 billion  in 2017  according to the PMPRB  Health Canada also rejected an offer to freeze prescription drug prices  saying it would not meet its objective of lowering prices  Health Canada said the industry had also committed to improving access for patients with rare diseases  but that proposal would not help those who have drug plans  Meanwhile  ahead of a fall election  Trudeau s government is preparing to announce a limited expansion of the nation s universal healthcare system to cover part of the cost of prescription medicines  as drug plans grapple with the extremely high cost of newer specialty drugs   WE DON T WANT TO SHUT THAT DOOR  The PMPRB caps prices of drugs still under patent protection  If new regulations are adopted  it would change the list of countries whose drug pricing it uses to decide whether costs are excessive  dropping the United States and adding countries with lower prices  The regulator would also consider for the first time a type of value based pricing  measuring how cost effective drugs are in terms of quality adjusted life years  and force drug companies to privately disclose some confidential discounts  It is not entirely clear how the PMPRB would use its new powers  In documents posted online  the agency said it could apply new rules to drugs already on the market  But Health Canada said the regime would not apply to those  Andrew Casey  president of BIOTECanada  would like  a more rigorous sit down  with the government   I fear the consequences when you do something without really working with industry   he said   We don t want to shut that door  ,2019-02-06,Reuters,https://www.investing.com/news/stock-market-news/exclusive-facing-crackdown-in-canada-drugmakers-offered-billions-in-price-cuts-1770433,1770433
148777,370293,AMGN,Amgen Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3 09  to trade at  184 86 by 10 51  15 51 GMT  on Thursday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 932 51K  Amgen has traded in a range of  184 86 to  190 53 on the day 
The stock has traded at  191 8700 at its highest and  179 6500 at its lowest during the past seven days ",2019-02-07,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-3-1772336,1772336
148778,370294,AMGN,FDA chief tough on e cigs steps down in surprise resignation,news,By Yasmeen Abutaleb WASHINGTON  Reuters    U S  Food and Drug Administration Commissioner Scott Gottlieb said on Tuesday that he plans to step down next month  a sudden resignation that calls into question how the agency will handle issues such as surging e cigarette use among teens and efforts to increase competition in prescription drugs   Gottlieb was well regarded by public health advocates and won bipartisan support for his efforts to curb use of flavored e cigarettes by youths  speed approval times for cheap generic medicines to increase competition and bring down drug prices  and boost the use of cheaper versions of expensive biotech medicines called biosimilars  Unlike his predecessors  who said drug pricing was not the purview of the FDA  Gottlieb waded into the intensifying debate about the high cost of medicines for U S  consumers and had the agency actively looking into possible solutions    Scott s leadership inspired historic results from the FDA team  which delivered record approvals of both innovative treatments and affordable generic drugs  while advancing important policies to confront opioid addiction  tobacco and youth e cigarette use   Health and Human Services  HHS  Secretary Alex Azar said in a statement   Gottlieb  who said he wanted to spend more time with his wife and three young children in Connecticut  was nominated by President Donald Trump in part to aid in Trump s anti regulation agenda  But Gottlieb took an aggressive stance toward e cigarette makers  such as Juul Labs Inc  On Monday  he confronted 15 retailers including Walgreens Boots Alliance  NASDAQ WBA   Kroger  NYSE KR  Co and Walmart  NYSE WMT  Inc  for illegally selling tobacco products to children  In early February  the FDA pursued enforcement actions against some Walgreen and Circle K locations   But Gottlieb ran into fierce opposition from anti regulation groups  such as Americans for Tax Reform  and former FDA officials  who said the agency s regulatory efforts would destroy thousands of jobs   A coalition of these groups wrote Trump last month asking him to  immediately halt the Food and Drug Administration s aggressive regulatory assault  on e cigarette businesses   Following news of Gottlieb s resignation  the Nasdaq Biotechnology Index turned negative  It closed down 0 5 percent as shares of  Amgen Inc   NASDAQ AMGN  erased gains and  Gilead Sciences Inc   NASDAQ GILD  shares fell further  Shares of  British American Tobacco   LON BATS  Plc rose after the news on Gottlieb  who had signaled his intention to also go after menthol and other flavored cigarette products   He made proposals that were unprecedented in their breadth  scope and  if they were adopted  likely impact   said Matthew Myers  president of the Campaign for Tobacco Free Kids   But they were just proposals    E CIG  EPIDEMIC   Gottlieb s campaign against flavored e cigarettes followed preliminary federal data showing teenage use had surged by more than 75 percent since last year  which the FDA described as an  epidemic    Under Gottlieb  the FDA proposed a ban on the sale of fruit  and candy flavored electronic cigarettes in convenience stores and gas stations  The FDA also proposed stricter age verification requirements for online sales of e cigarettes    Scott has helped us to lower drug prices  get a record number of generic drugs approved and onto the market  and so many other things  He and his talents will be greatly missed   Trump said on Twitter on Tuesday  Trump picked Gottlieb to lead the agency in March 2017 and he was confirmed by the Senate in May of that year   The Washington Post first reported on Tuesday that Gottlieb planned to resign    There s perhaps nothing that could pull me away from this role other than the challenge of being apart from my family for these past two years   Gottlieb wrote in a note to FDA staff  In his resignation letter  Gottlieb touted several agency initiatives  including efforts to curb tobacco use  decrease the rate of opioid addiction  speed up approval of generic drugs and streamline the process to bring to market novel medical technologies  such as gene therapy  Gottlieb  46  a conservative and former physician  was deputy FDA commissioner under Republican President George W  Bush  Before taking over at FDA  he was a healthcare investor and consultant who sat on multiple company boards  He surprised critics who worried about his ties to the pharmaceutical industry by speaking out about rising drug prices and drug company tactics to keep competitors off the market   In all my years of public service  I ve never worked with a more talented  forthright  and effective agency leader than Dr  Scott Gottlieb   Republican Congressman Greg Walden said in a statement   He worked effectively with Congress to find solutions and to improve the quality of life for all of us   Gottlieb often touted that the agency had approved more than 1 000 generic drugs as evidence that it was helping to curb prescription drug prices  a priority of Trump s administration  Among those seen as possible successors  according to the Wall Street Journal  are Norman Sharpless  director of the National Cancer Institute  and Brett Giroir  assistant secretary at HHS  Giroir has been the senior adviser to Azar for HHS efforts to fight the opioid crisis  In January  Gottlieb said in a tweet that he did not plan to leave the agency after speculation that he was preparing to step down   We ve got a lot of important policy we ll advance this year   he wrote in the January tweet ,2019-03-05,Reuters,https://www.investing.com/news/stock-market-news/fda-chief-gottlieb-resigning-1798503,1798503
148783,370299,AMGN,Merck s Keytruda Wins EU Nod For First Line Head Neck Cancer ,opinion,Merck   Co   Inc    NYSE MRK   announced that the European Commission granted approval to two new regimens of its blockbuster PD L1 inhibitor Keytruda for the first line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma  HNSCC  With this latest nod  Keytruda can be prescribed to previously untreated patients with metastatic or unresectable  recurrent HNSCC as monotherapy or in combination with chemotherapy in patients whose tumors express PD L1 CPS  combined proportion score   1   The approval was expected as last month  the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  gave a positive opinion recommending the same The approval was based on data from the phase III KEYNOTE 048 study wherein Keytruda as a monotherapy and in combination with platinum and 5 fluorouracil  5 FU  chemotherapy demonstrated significant improvement in overall survival compared to the standard of care in the given patient population   A similar nod came in from the FDA in the United States in June Merck s shares have risen 11 6  this year so far compared with the  s increase of 4 8    Keytruda  Merck s biggest product  is already approved for use in 20 indications across 12 different tumor types in the United States Keytruda generated sales of almost  8 billion in the first nine months 2019  up around 63  year over year  The drug s sales are driven by the launch of new indications globally  Keytruda sales are benefiting from strong momentum in the indication of first line lung cancer Other than first line HNSCC in the United States and now in Europe  Keytruda has gained several label expansion approvals from the FDA this year so far  These are as an adjuvant therapy for high risk stage III melanoma  previously treated advanced small cell lung cancer  SCLC   Keytruda Lenvima combo for endometrial carcinoma  Keytruda   Inlyta combo for first line advanced renal cell carcinoma  RCC  and advanced esophageal cancer Keytruda was also approved for five new cancer line extensions in Japan  first line advanced non small cell lung cancer  NSCLC  in China and as Keytruda   Inlyta combo in the EU for first line advanced RCC  All these label expansion approvals are boosting sales of Keytruda higher with the trend expected to continue in 2020 In fact  the Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in above 1000 studies including 600 plus combination studies  Several regulatory decisions for new indications in the United States as well as in Europe are pending in 2020  which if approved  can further improve sales Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte   NASDAQ INCY    Glaxo and Pfizer   NYSE PFE   separately for the evaluation of Keytruda in combination with other regimens Undoubtedly  Keytruda s solid growth prospects are based on increased utilization  approval for new indications and expectation of additional approvals worldwide Merck currently carries a Zacks Rank  2  Buy   You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 5  per year These 7 were selected because of their superior potential for immediate breakout ,2019-11-20,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-wins-eu-nod-for-firstline-headneck-cancer-200487014,200487014
148784,370300,AMGN,Bristol Myers  Melanoma Study Misses Goal  Closes Celgene Deal,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that the phase III study evaluating a combination of Opdivo plus Yervoy in patients with resected high risk melanoma missed one of the co primary endpoints 
The double blind  randomized CheckMate 915 study evaluated the Opdivo Yervoy combination versus Opdivo as a monotherapy for the adjuvant treatment of patients  who have had a complete surgical removal of stage IIIb c d or stage IV  no evidence of disease  melanoma 
The study did not meet one of the co primary endpoints of recurrence free survival  RFS  as statistically significant benefit was not reached in patients whose tumors expressed PD L1  1  
The Data Monitoring Committee recommended to continue the study unchanged 
Shares of Bristol Myers have rallied 8 5  so far this year  outperforming the  rise of 4 9  

 
We note that Opdivo is currently approved in several countries including the United States  the EU and Japan for several cancer indications 
The company continues to evaluate Opdivo alone or in combination therapies with Yervoy and other anti cancer agents  The drug generated sales of  5 4 billion in the first nine months of 2019  reflecting an increase of 10  year over year 
Label expansion of Opdivo into additional indications would lend the product access to a higher patient population and increase its commercial potential significantly  However  a key study failure like CheckMate 915 can hurt the growth prospects of Opdivo 
In a separate press release  Bristol Myers announced that it has closed the long impending acquisition of Celgene Corp    NASDAQ CELG   for a whopping  74 billion  Last week  the U S  Federal Trade Commission   FTC    to close the merger of Bristol Myers with Celgene after the latter agreed to divest its blockbuster psoriasis drug Otezla to Amgen   NASDAQ AMGN   in August 
As a result  Bristol Myers met all the regulatory requirements under the merger agreement to complete the buyout of Celgene and completed the transaction 
The acquisition is likely to boost Bristol Myers  oncology portfolio  given the stiff competition for Opdivo from the likes of Merck s   NYSE MRK   PD L1 inhibitor Keytruda 
We remind investors that in January 2019  Bristol Myers announced that it will acquire Celgene  Following several roadblocks  the acquisition was finally given a green signal in April  In July  the merger was granted unconditional approval by the European Commission 
Zacks Rank
Bristol Myers currently carries a Zacks Rank  2  Buy   You can see  
Just Released  Zacks  7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 5  per year These 7 were selected because of their superior potential for immediate breakout ",2019-11-21,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-melanoma-study-misses-goal-closes-celgene-deal-200487203,200487203
148804,370320,AMGN,Amgen Rises 3 ,news,"Investing com   Amgen  NASDAQ AMGN  rose by 3 08  to trade at  194 79 by 10 27  15 27 GMT  on Friday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 648 91K  Amgen has traded in a range of  190 84 to  194 80 on the day 
The stock has traded at  195 8000 at its highest and  178 8800 at its lowest during the past seven days ",2019-01-04,Investing.com,https://www.investing.com/news/stock-market-news/amgen-rises-3-1737626,1737626
148805,370321,AMGN,U S  lawmaker launches investigation into pharma drug pricing,news,"By Yasmeen Abutaleb WASHINGTON  Reuters    A top U S  lawmaker launched an investigation into pharmaceutical industry pricing practices on Monday  less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices   Representative Elijah Cummings  who chairs the House Oversight Committee  sent letters to 12 drugmakers seeking information on price increases  investment in research and development  and corporate strategies to preserve market share and pricing power  his office said in a statement    AbbVie Inc   NYSE ABBV    Amgen Inc   NASDAQ AMGN   AstraZeneca PLC   Celgene Corp   NASDAQ CELG   Eli Lilly  NYSE LLY  and Co  Johnson   Johnson  NYSE JNJ    Mallinckrodt   NYSE MNK  PLC  Novartis AG   Novo Nordisk   CO NOVOb    Pfizer  Inc  NYSE PFE   Sanofi  PA SASY  and Teva Pharmaceutical  NYSE TEVA  all received letters seeking information about their pricing practices   Novo Nordisk  Amgen  Celgene  and Novartis said they were reviewing the request  The other drug companies did not immediately respond to requests for comment  Cummings  letters focused on drugs that are the costliest to Medicare Part D  a program that helps beneficiaries of the federal health insurance program for the elderly and disabled pay for self administered medicines like those purchased at drugstores  as well as drugs that have had the largest price increases over a five year period   They include AbbVie s Humira  the world s top selling medicine that had a price increase at the start of the year  Johnson   Johnson s blockbuster cancer drug Imbruvica and several diabetes medications   President Donald Trump made high prescription drug prices a top issue in the 2016 U S  presidential campaign and said that drug companies were  getting away with murder   The U S  Department of Health and Human Services  HHS  last year rolled out a plan to lower drug prices and has introduced several modest proposals to curb medicine costs  but Democrats have said Trump and his administration are not doing enough   Several pharmaceutical companies temporarily froze prices on select drugs last year after being criticized by Trump on Twitter  But drugmakers raised prices on more than 250 prescription drugs to begin 2019  Cummings  along with U S  Senator Bernie Sanders  an independent who caucuses with Democrats  introduced three bills last week aimed at lowering drug prices  
That legislation would peg U S  prescription drug prices to the median price from five countries   Canada  Britain  France  Germany and Japan   where drug costs are typically far lower because of government price controls  It would also allow Americans to import medication from Canada and other countries  as well as allow the HHS secretary to negotiate prices in Medicare Part D ",2019-01-14,Reuters,https://www.investing.com/news/politics-news/us-lawmaker-launches-investigation-into-pharma-drug-pricing-1746631,1746631
148806,370322,AMGN,Amgen Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3 05  to trade at  192 71 by 09 44  14 44 GMT  on Monday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 329 39K  Amgen has traded in a range of  192 67 to  194 97 on the day 
The stock has traded at  204 3300 at its highest and  192 7100 at its lowest during the past seven days ",2019-01-28,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-3-1759687,1759687
148807,370323,AMGN,Amgen Earnings  Revenue beat in Q4,news,"Investing com   Amgen  NASDAQ AMGN  reported fourth quarter earnings  that beat analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  3 42 on revenue of  6 23B  Analysts polled by Investing com forecast EPS of  3 28 on revenue of  5 86B  That compared to EPS of  2 89 on revenue of  5 80B in the same period a year earlier  The company had reported EPS of  3 69 on revenue of  5 9B in the previous quarter 
Amgen shares lost 2 92  to trade at  186 50 in after hours trade following the report 
Amgen follows other major Healthcare sector earnings this month
 On January 22  J J reported fourth quarter EPS of  1 97 on revenue of  20 39B  compared to forecasts of EPS of  1 95 on revenue of  20 2B 
Pfizer earnings matched analyst s expectations on Tuesday  with fourth quarter EPS of  0 64 on revenue of  13 98B  Investing com analysts expected EPS of  0 64 on revenue of  13 96B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-01-29,Investing.com,https://www.investing.com/news/stock-market-news/amgen-earnings-revenue-beat-in-q4-1762120,1762120
148813,370329,AMGN,Ligand s  LGND  Q3 Earnings Miss Estimates  EPS View Down,opinion,"Ligand Pharmaceuticals Incorporated   NASDAQ LGND   reported third quarter 2019 adjusted earnings of 49 cents per share  which missed the Zacks Consensus Estimate of 65 cents  The company had reported adjusted earnings of  1 32 in the year ago quarter  Third quarter adjusted earnings exclude the impact of non cash charge of  10 5 million related to Ligand s investment in Viking Therapeutics  stock based compensation and non cash charges Total revenues decreased to  24 8 million from  45 7 million in the year ago quarter due to lower royalty revenues  However  the top line surpassed the Zacks Consensus Estimate of  23 16 million Shares of Ligand have declined 17 6  so far this year against the  s 0 7  increase Quarterly HighlightsRoyalty revenues were  9 8 million in the third quarter compared with  36 1 million in the year ago quarter  Ligand primarily earns royalties on sales of Amgen s   NASDAQ AMGN   Kyprolis and CASI Pharmaceuticals    NASDAQ CASI   Evomela  which were developed using its Captisol technology  The significant decline in royalty revenues was due to loss of royalties from sales of Novartis    NYSE NVS   blockbuster drug  Promacta  In March  Ligand sold Promacta rights  including royalty rights to worldwide net sales  to privately held Royalty Pharma for  827 million Please note that  excluding Promacta royalties recorded in the year ago quarter  royalty revenues increased almost 39  year over year in the third quarter  The growth was driven by higher royalties on Kyprolis as the drug s sales reachedhigher royalty rate tier and higher sales of Evomela following its launch in China  CASI Pharmaceuticals launched Evomela in China in August License fees  milestones and other revenues were  8 2 million in the third quarter compared with  2 5 million a year ago  Material sales were  6 8 million  down 2 9  Adjusted general and administrative expense was  5 6 million in the third quarter  down 11 1  from the year ago quarter  Adjusted research and development expense doubled year over year to  6 2 million Business DevelopmentsIn July 2019  Ligand acquired privately held Ab Initio and added antigen discovery platform to its portfolio  The company also inked new OmniAb license agreements with six companies  including Japanese pharma company  Takeda Pharmaceutical  It entered into agreements related to its Captisol technology with several companies during the quarter In September  Amgen announced successful completion of a phase III study evaluating Kyprolis in combination with dexamethasone and J J s cancer drug  Darzalex  The company also signed an agreement to commercialize Kyprolis in China  In July  Ligand s partner Sage Therapeutics announced the launch of its postpartum depression drug  Zulresso 2019 Guidance Ligand reiterated its sales guidance for 2019 of approximately  118 million  However  it lowered adjusted earnings view from  3 20 per share to  3 00 for 2019  which reflects certain changes in tax expense  especially related to sale of Promacta royalty right  The Zacks Consensus Estimate for revenues and earnings are pegged at  118 59 million and  3 25 per share  respectively Ligand Pharmaceuticals Incorporated Price  Consensus and EPS Surprise
    Zacks RankLigand currently carries a Zacks Rank  3  Hold   You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 5  per year These 7 were selected because of their superior potential for immediate breakout ",2019-11-05,Zacks Investment Research,https://www.investing.com/analysis/ligands-lgnd-q3-earnings-miss-estimates-eps-view-down-200482835,200482835
148814,370330,AMGN,Radius  RDUS  Q3 Earnings Beat Estimates On Tymlos Strength ,opinion,Radius Health  Inc    NASDAQ RDUS   reported encouraging results for the third quarter of 2019  wherein loss was narrower than expected and sales surpassed estimates Shares of Radius have surged 70 4  in the year so far  outperforming the  s growth of 4 2  The company incurred a loss of 65 cents per share in the third quarter  narrower than the year ago quarter s loss of  1 09 and the Zacks Consensus Estimate of a loss of 80 cents  The year over year improvement was backed by increased revenues The company reported revenues of  46 8 million  marginally surpassing the Zacks Consensus Estimate of  46 million and increasing from  27 6 million in the year ago quarter Quarter in DetailWe remind investors that Radius obtained the FDA approval for Tymlos  abaloparatide  injection in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk of fracture  The company began shipments of the drug to wholesalers at the end of May 2017 Tymlos gained traction in the third quarter of 2019  Radius increased its market share with Tymlos capturing 38  of the U S  anabolic osteoporosis market  based on Patient Months on Therapy  TRx PMOT   on average  in the third quarter  In October  Tymlos achieved 50  NBRx share  on average  and its total market TRx share increased to 40   The anabolic market grew 4  in the third quarter from the prior year quarter Research   development expenses for the reported quarter were  31 8 million  up 18 6  year over year  General   administrative expenses decreased 18 4  to  35 6 million Pipeline UpdatesThe pipeline includes abaloparatide injection for potential use in the treatment of men with osteoporosis  abaloparatide patch for potential use in osteoporosis and elacestrant  RAD1901  for potential use in hormone receptor positive breast cancer Enrollment is ongoing in the EMERALD phase III monotherapy study of elacestrant  with completion of recruitment targeted in the third quarter of 2020   However  Radius is evaluating all strategic options for its oncology assets to maximize their potential and does not plan to initiate further clinical trials for elacestrant or RAD140 beyond the ongoing EMERALD study In August  the first patient was randomized in the phase III wearABLe clinical trial  assessing the safety and efficacy of abaloparatide patch in postmenopausal patients with osteoporosis at high risk for fracture  However  patient enrollment has been slower than expected due to a higher than anticipated screen failure rate  A revised enrollment plan is being implemented that includes identified measures to improve site recruitment efforts  including adding sites outside the United States  Top line data from the study is expected in the second half of 2021 2019 Sales GuidanceRadius now expects Tymlos net revenues to be  168  172 million  the previous guidance was  165  170 million  for 2019 Our TakeThe narrower than expected loss in the third quarter was encouraging as Tymlos continued to gain traction   Effective Jan 1  2020  Tymlos  coverage will expand to approximately 290 million U S  insured lives  representing approximately 99  of U S  commercial and 79  of Medicare insured lives  This is likely to drive revenues for the company  However  the drug is expected to face significant competition from Eli Lilly   Co s   NYSE LLY   Forteo and Amgen s   NASDAQ AMGN   Prolia Zacks Rank   A Stock to ConsiderRadius currently carries a Zacks Rank  3  Hold  A better ranked stock in this space is Lannett Inc    NYSE LCI    which sports a Zacks Rank  1  Strong Buy   You can see  Lannett s earnings per share estimates have increased to  1 25 from  1 18 in the past 60 days Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 5  per year These 7 were selected because of their superior potential for immediate breakout ,2019-11-05,Zacks Investment Research,https://www.investing.com/analysis/radius-rdus-q3-earnings-beat-estimates-on-tymlos-strength-200482977,200482977
148839,370355,AMGN,Amgen s BiTE candidate AMG 420 shows positive action in early stage blood cancer study but AMG 330 lags,news,Initial data from two separate Phase 1 dose escalation studies evaluating Amgen s  NASDAQ AMGN  BiTE immunotherapies AMG 420 and AMG 330 showed encouraging action for the former and not so encouraging action for the latter  The results were presented at ASH in San Diego  Results from the study evaluating a range of doses of Fast Track tagged AMG 420 in patients with relapsed refractory multiple myeloma who had received at least two prior lines of treatment showed a 31   n 13 42  response rate  including seven complete responders  The response rate in patients receiving 400  g d was 70   n 7 10  with 86   n 6 7  of the responders maintaining their responses for up to 7 5 months  One dose limiting toxicity  peripheral polyneuropathy  was observed in the 400  g d arm which improved to baseline after IV immunoglobulin and corticosteroid treatment  On the safety front  48   n 20 42  of treated patients experienced serious adverse events  AEs   including 17   n 7 42  who required hospitalization  four prolonged   Treatment related serious AEs included two cases of polyneuropathy and one case of edema  Cytokine release syndrome was observed in 16 patients  but only one case was serious  The 800  g d dose was determined to be intolerable  Two patients died during the study  neither related to treatment  Results from the study assessing a range of doses of AMG 330 in patients with relapsed refractory acute myeloid leukemia  AML  showed a complete response rate of 10   n 4 40  at two doses  240  g d and 120  g d  but the complete responses were not sustained beyond one cycle of treatment  The majority of patients discontinued treatment due to cancer progression  Serious treatment related adverse events were observed in 43   n 17 40  of patients  According to Amgen  a BiTE  Bispecific T cell engager  antibody construct can be engineered to target any tumor antigen expressed by any type of cancer   ASH18 Now read ,2018-12-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgens-bite-candidate-amg-420-shows-positive-action-in-earlystage-blood-cancer-study-but-amg-330-lags-1710031,1710031
148840,370356,AMGN,Spectrum Pharma s Rolontis on par with Amgen s Neulasta in late stage breast cancer study,news,Results from a Phase 3 clinical trial  RECOVER  evaluating  Spectrum Pharmaceuticals    SPPI  2 4   ROLONTIS  eflapegrastim  for reducing the duration of severe neutropenia  low levels of a type of white blood cell called neutrophils  in breast cancer patients receiving chemo showed its non inferiority  no worse than  to Amgen s  AMGN  0 8   NEULASTA  pegfilgrastim   The data were presented at the San Antonio Breast Cancer Symposium The non inferiority of ROLONTIS was maintained across all four treatment cycles  The incidences of severe neutropenia in the eflapegrastim and pegfilgrastim arms were 20  and 24   respectively  with 14  less relative risk for the former RECOVER is the second late stage study to demonstrate the non inferiority of eflapegrastim to pegfilgrastim  Results from ADVANCE were announced at ASCO in June Eflapegrastim a long acting granulocyte colony stimulating factor  G CSF  The company plans to file its U S  marketing application by year end Now read ,2018-12-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/spectrum-pharmas-rolontis-on-par-with-amgens-neulasta-in-latestage-breast-cancer-study-1713482,1713482
148841,370357,AMGN,BeyondSpring s lead candidate on par with Amgen s Neulasta in late stage study  shares ahead 3 ,news,Ultra thinly traded BeyondSpring  BYSI  3 2   is up on almost double normal volume  albeit on turnover of only 12K shares  on the heels of its announcement of positive results evaluating lead candidate Plinabulin in patients receiving docetaxel chemotherapy The study met the primary endpoint of demonstrating the non inferiority  no worse than  of Plinabulin compared to Amgen s  AMGN  1 7   NEULASTA  pegfilgrastim  in reducing the duration of severe neutropenia  low levels of a type of white blood cell called neutrophils  in the first cycle of chemo The company plans to file a marketing applications in China and the U S  seeking approval for Plinabulin for the treatment of chemo induced neutropenia The company acquired global rights to Plinabulin  a small molecule synthetic analogue of a marine microbial product  from San Diego based Nereus Pharmaceuticals in 2013 Now read ,2018-12-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/beyondsprings-lead-candidate-on-par-with-amgens-neulasta-in-latestage-study-shares-ahead-3-1713566,1713566
148842,370358,AMGN,Amgen Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3 14  to trade at  192 76 by 12 33  17 33 GMT  on Friday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 1 11M  Amgen has traded in a range of  192 76 to  198 39 on the day 
The stock has traded at  208 9900 at its highest and  192 6800 at its lowest during the past seven days ",2018-12-07,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-3-1715122,1715122
148843,370359,AMGN,Amgen Rises 3 ,news,"Investing com   Amgen  NASDAQ AMGN  rose by 3 03  to trade at  183 81 by 12 07  17 07 GMT  on Wednesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 817 79K  Amgen has traded in a range of  179 04 to  183 84 on the day 
The stock has traded at  194 4500 at its highest and  178 4000 at its lowest during the past seven days ",2018-12-26,Investing.com,https://www.investing.com/news/stock-market-news/amgen-rises-3-1730996,1730996
148844,370360,AMGN,Teva  Amgen end dispute over generic Cinacalcet HCl tablets,news," Reuters    Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  said on Thursday it will pay an undisclosed amount to settle an ongoing dispute with  Amgen Inc   O AMGN  over its generic Cinacalcet HCl product  The Israel based drugmaker has also agreed to stop selling the generic product until its license date in mid year 2021  or earlier under certain circumstances   Teva said it recently received approval for the generic product and launched it in the United States  
Cinacalcet hydrochloride is approved for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on dialysis and for the treatment of higher levels of calcium in adults with parathyroid carcinoma ",2019-01-02,Reuters,https://www.investing.com/news/stock-market-news/teva-amgen-end-dispute-over-generic-cinacalcet-hcl-tablets-1735690,1735690
148848,370364,AMGN,Amgen  AMGN  Beats On Q3 Earnings  Ends Neuroscience R D  ,opinion,"Amgen   NASDAQ AMGN   reported third quarter 2019 earnings of  3 66 per share  which beat the Zacks Consensus Estimate of  3 51  Earnings declined 1  year over year due to lower revenues and operating profits Total revenues of  5 74 billion in the quarter beat the Zacks Consensus Estimate of  5 63 billion  However  total revenues declined 3  year over year Amgen shares have risen 7 3  this year so far against 1 5  decrease registered by the  during this period   Quarter in DetailTotal product revenues decreased 1  from the year ago quarter to  5 46 billion  U S    4 03 billion  ex U S    1 43 billion  as increasing demand for newer products like Prolia and strong performance of the newly launched biosimilar products   Kanjinti and Mvasi in the United States   was offset by the erosion of mature brands from biosimilar competition  Product sales growth was mostly driven by higher volumes  up 3   as prices were lower for several drugs  Net selling prices declined 4  year over year in the quarter  which resulted in the decline in total revenues Other revenues of  274 million declined 30 5  in the quarter due to a milestone payment received in the prior year quarterProlia revenues came in at  630 million  up 18  from the year ago quarter  driven by volume increases resulting from new patient growth as well as strong repeat rates Xgeva delivered revenues of  476 million  up 10  from the year ago quarter mainly due to higher demand  which drove volumes Kyprolis recorded sales of  266 million  up 15  year over year driven primarily by 12  volume growth in the United States Blincyto sales increased 47  from the year ago period to  85 million  reflecting rise in demand Repatha generated revenues of  168 million  up 40  year over year  as higher volume was offset by lower prices Sales of Amgen s PCSK9 inhibitor  Repatha have suffered since launch due to payer restrictions  Despite Amgen s efforts to improve access to Repatha  patients face significant hurdles due to high co pay expenses  In response  Amgen announced a cut in the U S  list price of Repatha by 60  to improve access and affordability of Repatha Vectibix revenues came in at  196 million  up 8  year over year  Nplate sales rose 10  to  195 million Parsabiv  launched in several markets including the United States in 2018  recorded sales of  157 million  which was lower than  168 million in the previous quarter  While Parsabiv sales are gaining from higher demand  sales declined sequentially as trends were impacted by purchasing patterns  which included a larger purchase in the second quarter Amgen s new migraine drug  Aimovig recorded sales of  66 million in the quarter  lower than  83 million in the previous quarter due to unfavorable changes in accounting estimates for sales discounts in prior periods Newly launched osteoporosis drug  Evenity recorded sales of  59 million in the quarter compared with  28 million in the previous quarter  In the United States  where Evenity was launched in April this year  sales were  12 million while international sales were  47 million Amgen recorded biosimilar revenues of  173 million in the quarter  much higher than  82 million in the previous quarter driven by the launches of Kanjinti  a biosimilar of Roche s Herceptin  and Mvasi  biosimilar of Roche s   OTC RHHBY   Avastin in the United States in July 2019  Total sales comprised sales of  81 million in the United States and  92 million in international markets  In EU  Amgen markets Amjevita  biosimilar of AbbVie s Humira  and Kanjinti since 2018 Amgen expects more biosimilars to gain approval this year and contribute to total revenues  especially as drug pricing issues increase demand for lower cost treatment options However  Amgen s mature drugs like Enbrel  Aranesp  Epogen  Neupogen and Neulasta are facing an array of branded and generic competitors Aranesp revenues declined 5  from the prior year quarter to  452 million on lower volume due to increased competitive pressure Revenues of the other ESA  Epogen  declined 15  to  215 million due to lower selling prices as the category has become extremely competitive Neulasta revenues declined 32  from the year ago period to  711 million due to lower selling prices and biosimilar competition Neupogen recorded 36  decline in sales to  54 million in the quarter due to unfavorable changes in accounting estimates and biosimilar competition in the United States  which hurt demand and prices Enbrel delivered revenues of  1 37 billion  up 6  from the year ago quarter  driven primarily by favorable changes in inventory along with a slight price increase  which offset the 2  decline in volumes due to continued competition Sensipar Mimpara revenues declined 73  to  109 million due to at risk small molecule generic launches  Other product sales rose 25  to  85 million Operating Margins DecreaseAdjusted operating margin declined 280 basis points  bps  to 51 1   Adjusted operating expenses were flat year over year in the third quarter  SG A spend decreased 5  to  1 21 billion on cost control  R D expenses rose 8  year over year to  977 million due to higher spending on Amgen s early  and late stage oncology pipeline 2019 Guidance UppedAmgen slightly raised its previously issued sales guidance while increasing the earnings range significantly  The company expects revenues in the range of  22 8  23 billion versus  22 4  22 9 billion expected previously  Adjusted earnings per share are anticipated in the range of  14 20  14 45 versus  13 75  14 30 expected previously  The guidance excludes the impact of the Otezla acquisition In August  Amgen entered into an agreement to acquire global commercial rights to Celgene s   NASDAQ CELG   blockbuster psoriasis drug  Otezla  which the latter has to divest to complete its impending merger with Bristol Myers   NYSE BMY    Amgen agreed to pay Celgene  13 4 billion in cash or approximately  11 2 billion net of anticipated future cash tax benefits for Otezla and certain related assets and liabilities  The acquisition of Otezla is expected to close before the end of the fourth quarter of the year Operating costs in 2019 are expected to be up slightly from 2018 level on an absolute basis versus prior expectation of remaining flat  Research and development costs are expected to rise in high single digit percentage terms in 2019  However  SG A expenses are expected to decline as launch expenses normalize  Adjusted tax rate is expected in the range of 14  to 15   maintained  Amgen plans to invest approximately  650 million in capital expenditures in 2019 versus prior expectation of  700 million Ends Neuroscience Research EffortsOn the call  the company announced that it is discontinuing its early neuroscience research efforts with the exception of programs centered on neuro inflammation  Amgen chief executive officer  Bob Bradway  said that the company wants to focus its research efforts in therapeutic areas like cardiovascular disease  inflammatory disease and oncology  where it thinks it can be successful  We remind investors that in July  Amgen and partner Novartis discontinued two pivotal late stage studies evaluating CNP520 to prevent or delay the symptoms of Alzheimer s disease in a high risk population Our TakeAmgen s third quarter results were strong as it beat estimates for both earnings and sales While Amgen s newer drugs   Prolia  Xgeva  Parsabiv  Blincyto  Kyprolis   will continue to drive sales  biosimilar and brand competition for its legacy products will continue to create pressure on sales  However  recently launched products including Aimovig and Evenity  biosimilars and international expansion provide incremental growth opportunities  Amgen boasts a strong biosimilars pipeline  which can drive long term growth  Amgen is also progressing with its pipeline while regularly pursuing  external opportunities   such as the pending acquisition of Otezla  The acquisition is expected to significantly strengthen its inflammation portfolio and boost long term growth Amgen currently carries a Zacks Rank  2  Buy   You can see  Amgen Inc  Price  Consensus and EPS Surprise
    Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-29,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-beats-on-q3-earnings-ends-neuroscience-rd-200480226,200480226
148849,370365,AMGN,Bristol Myers   BMY  Q3 Earnings   Revenues Beat Estimates,opinion,"Bristol Myers Squibb Company   NYSE BMY   reported better than expected results for the third quarter of 2019 on stellar performance of its blood thinner drug  Eliquis  However  sales growth of its PD 1 inhibitor  Opdivo  was weak Shares were down in pre market trading following the earnings release  Bristol Myers  shares have increased 9 4  in the year so far compared with the  s rise of 2 6  Third quarter 2019 earnings of  1 17 per share easily beat the Zacks Consensus Estimate of  1 06 and increased from the year ago quarter s earnings of  1 09 Total revenues of  6 billion comprehensively beat the Zacks Consensus Estimate of  5 8 billion and increased 6  from  5 69 billion in the year ago period  Strong sales of Eliquis  Sprycel and Orencia contributed to the company s top line in the reported quarter Quarterly DetailsRevenues were up 7  year over year when adjusted for foreign exchange impact  Revenues increased 7  to  3 5 billion in the United States and 3  outside the country  Ex U S  revenues were up 7  when adjusted for foreign exchange impact Eliquis witnessed strong growth and became the top revenue generator for the company yet again  Sales of the drug rose 22  to  1 93 billion  We note that Bristol Myers has a collaboration agreement with Pfizer   NYSE PFE   for Eliquis  Sales of Opdivo  which is approved for multiple cancer indications  were up 1  year over year to  1 8 billion  While sales of Eliquis rose 23   Opdivo sales were down 5  in the United States Leukemia drug  Sprycel  raked in sales of  558 million  up 14  year over year  Sales of rheumatoid arthritis drug  Orencia  were up 14  to  767 million  Melanoma drug  Yervoy  contributed  353 million to the top line  down 8  year over year Multiple myeloma drug  Empliciti  recorded sales of  89 million  up 51  year over year     The performance of key drugs in the Virology unit were disappointing  Sales of Baraclude declined 17  to  145 million  Sales of other brands  including Sustiva  Reyataz  Daklinza and all other products that have lost exclusivity in major markets  fell 35  year over year to  350 million Adjusted research and development  R D  expenses in the quarter were up 7 9  to  1 36 billion  Adjusted marketing  selling and administrative expenses decreased 4 4  to  1 1 billion Gross margin was 69 9  in the quarter compared with 71 1  in the year ago quarter Celgene Acquisition UpdateEarlier in the year  the company announced that it will acquire biotech bigwig Celgene Corporation   NASDAQ CELG   for a whopping  74 billion  The acquisition was finally given a green signal a few months back after it faced opposition from some of the shareholders  In July  the company s acquisition offer was granted unconditional approval by the European Commission   EC    In August  Celgene entered into an agreement with Amgen   NASDAQ AMGN   to sell its global rights to psoriasis drug  Otezla  The deal was announced following a concern raised by the U S  Federal Trade Commission about a possible overlap between Otezla and Bristol Myers  tyrosine kinase 2  TYK2  inhibitor  BMS 986165  which is being evaluated in several autoimmune diseases  including psoriasis  Bristol Myers now expects to conclude the merger by the end of 2019 Pipeline UpdateIn a major achievement  Bristol Myers announced earlier this month that the pivotal  phase III study   CheckMate 9LA   evaluating a combination regimen of Opdivo in first line advanced non small cell lung cancer  NSCLC  met its primary endpoint of superior overall survival at a pre specified interim analysis In October  the EC approved flexible dosing options of a flat dosing schedule of Opdivo 240 mg infused over 30 minutes every two weeks or 480 mg infused over 60 minutes every four weeks as an adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease having undergone complete resection 2019 Guidance UpdatedBristol Myers updated its adjusted earnings expectation for 2019  The company projects earnings of  4 25  4 35 per share  previous guidance   4 20  4 30   The Zacks Consensus Estimate for earnings is pegged at  4 28 Our TakeBristol Myers  performance in the third quarter was encouraging   Earnings and sales beat estimates primarily on robust sales of Eliquis and Sprycel  However  weak growth in Opdivo sales is a concern  Although successful completion of the CheckMate 9LA study is encouraging  pending detailed data from the study will be needed to access the actual benefit of the Opdivo regimen compared to other approved immuno oncology drugs as first line treatment for advanced NSCLC patients Bristol Myers Squibb Company Price  Consensus and EPS Surprise
    Zacks RankBristol Myers currently carries a Zacks Rank  2  Buy   You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-bmy-q3-earnings--revenues-beat-estimates-200480973,200480973
148874,370390,AMGN,BeyondSpring s Plinabulin shows positive effect in preventing chemo induced neutropenia,news,A Phase 2 clinical trial evaluating BeyondSpring s  BYSI  4   Plinabulin  combined with Amgen s  AMGN  1 9   Neulasta  pegfilgrastim   for the prevention of chemo induced neutropenia  CIN  low and bone pain demonstrated a treatment effect 50  of patients receiving high risk TAC  docetaxel  doxorubicin and cyclophosphamide  chemo who also received Plinabulin   Neulasta experienced grade 3  serious  or grade 4  life threatening  neutropenia compared to 81  who received Neulasta only  p 0 0456   Duration of grade 3 4 neutropenia was 0 94 days in the Plinabulin group compared to 1 38 days for the Neulasta only group 6  of patients receiving Plinabulin   Neulasta experienced at least one day of bone pain compared to 95  who received Neulasta alone  p 0 0001  Plinabulin is a marine derived small molecule that contributes to the prevention of neutropenia by activating a protein called GEF H1 that plays a key role in signaling pathways affecting the levels of neutrophils Neutropenia is an abnormally low level of neutrophils  a type of white blood cell that plays a key role in fighting infections  in the blood The current standard of care for treating CIN is G CSF agents like Neulasta or Neupogen  filgrastim   but they are associated with bone pain and do not eliminate the risk of grade 3 4 neutropenia Shares are down 4  but only on  7 300 shares Now read ,2018-10-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/beyondsprings-plinabulin-shows-positive-effect-in-preventing-chemoinduced-neutropenia-1655856,1655856
148875,370391,AMGN,Amgen Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3 17  to trade at  191 37 by 13 37  17 37 GMT  on Wednesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 1 38M  Amgen has traded in a range of  191 34 to  197 95 on the day 
The stock has traded at  205 1200 at its highest and  191 3400 at its lowest during the past seven days ",2018-10-24,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-3-1658075,1658075
148876,370392,AMGN,Amgen Earnings  Revenue beat in Q3,news,"Investing com   Amgen  NASDAQ AMGN  reported third quarter earnings  that beat analyst s expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  3 69 on revenue of  5 9B  Analysts polled by Investing com forecast EPS of  3 44 on revenue of  5 78B  That compared to EPS of  3 27 on revenue of  5 77B in the same period a year earlier  The company had reported EPS of  3 83 on revenue of  6 06B in the previous quarter 
For the year  Amgen shares are up 8 73   outperforming the Nasdaq which is up 3 23  year to date 
Amgen follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 05B 
 Pfizer   NYSE PFE  earnings beat analyst s expectations on Tuesday  with third quarter EPS of  0 78 on revenue of  13 3B  Investing com analysts expected EPS of  0 75 on revenue of  13 55B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-30,Investing.com,https://www.investing.com/news/stock-market-news/amgen-earnings-revenue-beat-in-q3-1666497,1666497
148877,370393,AMGN,Amgen Rises 3 ,news,"Investing com   Amgen  NASDAQ AMGN  rose by 3 07  to trade at  194 89 by 15 05  19 05 GMT  on Wednesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 2 88M  Amgen has traded in a range of  189 04 to  194 94 on the day 
The stock has traded at  199 0900 at its highest and  181 3100 at its lowest during the past seven days ",2018-10-31,Investing.com,https://www.investing.com/news/stock-market-news/amgen-rises-3-1668530,1668530
148878,370394,AMGN,Amgen Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3 04  to trade at  187 04 by 14 07  18 07 GMT  on Friday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 1 74M  Amgen has traded in a range of  186 94 to  195 35 on the day 
The stock has traded at  195 3400 at its highest and  181 3100 at its lowest during the past seven days ",2018-11-02,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-3-1672479,1672479
148879,370395,AMGN,Amgen Rises 3 ,news,"Investing com   Amgen  NASDAQ AMGN  rose by 3 06  to trade at  196 59 by 11 45  16 45 GMT  on Wednesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 841 50K  Amgen has traded in a range of  192 01 to  196 59 on the day 
The stock has traded at  196 5900 at its highest and  185 8200 at its lowest during the past seven days ",2018-11-07,Investing.com,https://www.investing.com/news/stock-market-news/amgen-rises-3-1678235,1678235
148880,370396,AMGN,Goldman bumps Novartis rating to Buy,news,"Novartis  NYSE NVS  has gotten an upgrade to Buy by Goldman Sachs  NYSE GS   from a previous Neutral rating 
Goldman added the stock to its Conviction Buy list  That makes for an even split among 30 covering analysts between Buy and Hold ratings  Bloomberg says  Shares are up 2 7  in late trading amid today s postmarket news  including approval for expanded use of the company s Promacta  Now read ",2018-11-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/goldman-bumps-novartis-rating-to-buy-1692473,1692473
148881,370397,AMGN,Jefferies  AWS headed for  71B in revenue,news,"Amazon  NASDAQ AMZN  Web Services revenue could reach  71B by 2022  according to Jefferies analyst Brent Thill after attending this year s re Invent conference 
The revenue total would give AWS a valuation of about  350B 
Thill says customers are  jumping in big with AWS  and increasing partner deal sizes by 3 5x last year  Commitments include Korean Air  an Oracle  ORCL  0 1   customer  committing to a 10 year deal to move all systems to AWS and Amgen  NASDAQ AMGN  moving over most of its cloud infrastructure 
Amazon shares are up 2 5  to  1 621 33  

Now read ",2018-11-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/jefferies-aws-headed-for-71b-in-revenue-1703445,1703445
148882,370398,AMGN,Amgen Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3 03  to trade at  201 94 by 13 35  18 35 GMT  on Monday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 2 05M  Amgen has traded in a range of  201 85 to  208 30 on the day 
The stock has traded at  208 9900 at its highest and  190 7700 at its lowest during the past seven days ",2018-12-03,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-3-1708933,1708933
148886,370402,AMGN,Factors Setting The Tone For Bristol Myers  BMY  Q3 Earnings,opinion,"Bristol Myers Squibb Company   NYSE BMY   is scheduled to report third quarter 2019 results on Oct 31  before market open The company s shares have gained 5 8  in the year so far compared with the  s growth of 0 9  Bristol Myers delivered average positive earnings surprise of 10 65  in the trailing four quarters  In the last reported quarter  the company delivered a positive surprise of 11 32  Let s see how things are shaping up for this quarter Why a Likely Positive Surprise Our proven model predicts an earnings beat for Bristol Myers this earnings season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Earnings ESP for Bristol Myers is  0 38  Zacks Rank  It currently carries a Zacks Rank  3 Bristol Myers Squibb Company Price  Consensus and EPS Surprise
  
   Factors Driving GrowthBristol Myers  key immuno oncology drug  Opdivo  is likely to have maintained its stellar performance in the to be reported quarter  The drug  which is approved for multiple indications  generated sales of  1 8 billion in the second quarter  increasing 12  year over year  The momentum is likely to have continued in the third quarter owing to demand resulting from the rapid commercial acceptance of the drug for several indications  including melanoma  renal cell carcinoma  hepatocellular carcinoma and second line non small cell lung cancer  NSCLC  Blood thinner drug  Eliquis  witnessed strong growth in the second quarter and was the top revenue generator  a trend that most likely continued in the third quarter propelled by market share increases Oncology drug  Sprycel  is also likely to have maintained momentum  Further  Orencia and Yervoy might have continued with their stellar performance in the third quarter However  the virology business has most likely declined in the third quarter Apart from the top and bottom line numbers  investors will focus on pipeline updates on label expansion of drugs  In August  the European Commission  EC  approved Empliciti plus pomalidomide and low dose dexamethasone  EPd  for the treatment of adult patients with relapsed and refractory multiple myeloma  who have received at least two prior therapies  including lenalidomide and a proteasome inhibitor  PI   and have demonstrated disease progression on the last therapy Earlier this month  the company announced that the pivotal  phase III study   CheckMate 9LA   evaluating a combination regimen of its PD 1 inhibitor  Opdivo  and Yervoy in first line advanced NSCLC met its primary endpoint of superior overall survival at a prespecified interim analysis  Investors will look forward to more updates on this as the combination regimen targets the lucrative first line lung cancer indication Key Anticipated UpdatesInvestors will also focus on further updates on the company s impending acquisition of Celgene Corp   NASDAQ CELG    In August  Celgene inked an agreement with Amgen  NASDAQ AMGN   whereby the latter would acquire the global rights to Otezla for  13 4 billion in cash  The decision to divest Otezla was taken in connection with the ongoing regulatory approval process for Bristol Myers  pending merger with Celgene  The EC has granted unconditional approval to this acquisition  The transaction is currently expected to close by the end of 2019 or the beginning of 2020 Other Stocks to ConsiderHere are some other stocks you may want to consider  as our model shows that these too have the right combination of elements to post an earnings beat this quarter GlaxoSmithKline plc   NYSE GSK   has an Earnings ESP of  3 03  and a Zacks Rank  2  It is scheduled to release earnings on Oct 30  You can see  Merck   Co   NYSE MRK   currently carries a Zacks Rank  3 and an Earnings ESP of  0 16   It is scheduled to release earnings on Oct 29 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-10-28,Zacks Investment Research,https://www.investing.com/analysis/factors-setting-the-tone-for-bristolmyers-bmy-q3-earnings-200479185,200479185
148887,370403,AMGN,Pfizer  PFE  Rises On Q3 Earnings   Sales Beat  Ups EPS View,opinion,"Pfizer  Inc    NYSE PFE   reported third quarter 2019 adjusted earnings per share of 75 cents  which beat the Zacks Consensus Estimate of 63 cents  Earnings however declined 2  year over year due to lower revenues and higher taxes  which offset the impact of lower costs in the quarter The pharma heavyweight recorded revenues of  12 68 billion  which beat the Zacks Consensus Estimate of  12 15 billion  Revenues declined 5  from the year ago quarter on a reported basis  On an operational basis  excluding the 2  negative impact of currency  revenues declined 3  year over year as higher sales of some key brands in Pfizer s Biopharmaceuticals group was offset by decline of revenues in the Upjohn segment  The segment was hurt mainly by the loss of Lyrica exclusivity in July 2019 in the United States Importantly  excluding the spin off of the Consumer Healthcare unit  third quarter revenues were flat operationally  We remind investors that on Aug 1  Pfizer merged its Consumer Healthcare unit with Glaxo s   NYSE GSK   Consumer unit to form a new joint venture  JV   Pfizer owns a stake of 32  in the JV and Glaxo owns the remaining 68  International revenues declined 2  to  6 83 billion  However  on an operational basis  international sales rose 2  in the quarter  U S  revenues declined 8  to  5 85 billion Adjusted selling  informational and administrative  SI A  expenses declined 7   operationally  in the quarter to  3 2 billion  Adjusted R D expenses declined 2  to  1 94 billion Segment DiscussionIn 2018  Pfizer s reporting segments were Pfizer Innovative Health  IH  and Pfizer Essential Health  EH  Beginning the first quarter of 2019  Pfizer started reporting under three new business units   Pfizer Biopharmaceuticals Group  previous IH unit except Consumer Healthcare   Upjohn  previous EH unit  and Consumer Healthcare  In July 2019  Pfizer announced a definitive agreement to spin off the Upjohn unit and combine it with generic drugmaker Mylan   NASDAQ MYL   in a Reverse Morris Trust transaction to create a new generic pharmaceutical company Pfizer Biopharma sales grew 7  on a reported basis  up 9  an operational basis  from the year ago period to  10 1 billion  Higher sales of brands like Eliquis  Ibrance  Inlyta and Xeljanz  and a strong emerging markets performance  up 15   drove this segment s sales growth  Weaker sales of Prevnar 13 Prevenar 13 and Enbrel internationally offset the increase Within the Biopharma group  Oncology revenues increased 30   on an operational basis  to  2 35 billion  Vaccine revenues declined 1  to  1 81 billion  Internal Medicine rose 3  to  2 21 billion  The Inflammation   Immunology franchise rose 6  to  1 23 billion  The portfolio of Rare Disease rose 16  to  601 million  The newly added Hospital sub segment s sales rose 6  to  1 92 billion  The Hospital segment comprises Pfizer s global portfolio of sterile injectable and anti infective medicines Pfizer s Upjohn group s sales declined 28   down 26  on an operational basis  to  2 2 billion mainly due to U S  loss of exclusivity of Lyrica in July 2019 Revenues from the Consumer Healthcare unit declined 55   54  on an operational basis  to  377 million as a result of the completion of the JV transaction with Glaxo Performance of Key DrugsIbrance revenues rose 27  year over year to  1 28 billion on continued strong uptake in international markets and consistent growth in the United States Xeljanz sales rose 40  to  599 million driven by continued growth in rheumatoid arthritis  RA  revenues and contributions from the drug s 2018 launches for psoriatic arthritis and ulcerative colitis in the United States and only ulcerative colitis indication in certain developed markets Inlyta revenues increased 98  to  139 million driven mainly by 240  growth in the United States  U S  sales gained from FDA approval of Inlyta in combination with Merck s PD L1 inhibitor Keytruda for first line treatment advanced renal cell carcinoma  RCC   the most common type of kidney cancer  in April this year Global Prevnar 13 Prevenar 13 revenues declined 3  to  1 60 billion  Prevnar 13 revenues declined 7  in the United States  reflecting decreased government purchases for the pediatric indication and continued decline in revenues for the adult indication  Prevenar 13 revenues rose 7  in international markets Enbrel revenues declined 19  to  415 million in key European markets due to continued biosimilar competition  Pfizer has exclusive rights to Amgen s   NASDAQ AMGN   blockbuster RA drug  Enbrel  outside the United States and Canada Xalkori sales rose 5  to  130 million  Sutent sales declined 7  to  224 million  Eliquis alliance revenues and direct sales rose 20  to  1 03 billion  Chantix sales rose 7  to  276 million in the quarter  Xtandi recorded alliance revenues of  225 million in the quarter  up 25  year over year Importantly  new drug Vyndaqel which was launched in May 2019 for the treatment of the transthyretin amyloid cardiomyopathy  recorded sales of  156 million in the quarter Total biosimilar revenues were  236 million  up 22  year over year In the Upjohn segment  sales of key drug Lyrica declined 57  to  527 million due to generic erosion  Viagra sales declined 11  to  120 million due to generic competition that began in December 2017 2019 Guidance Pfizer raised its previously issued 2019 guidance for earnings while tightening its range for revenues Revenues are expected in the range of  51 2 billion to  52 2 billion compared with  50 5 billion to  52 5 billion expected previously  Adjusted earnings per share are expected in the range of  2 94  3 00 versus the previous expectation of  2 76  2 86 Research and development expense is expected in the range of  7 7  8 1 billion versus  7 9  8 3 billion while SI A spending is projected in the range of  13 5  14 0 billion versus  13 0  14 0 billion expected earlier  Adjusted tax rate is still expected to be approximately 16  in 2019 Our TakePfizer s third quarter 2019 performance was better than the second quarter  It beat estimates for both earnings and sales while raising its outlook for earnings and tightening the revenue outlook  Pfizer s shares were up more than 3  in pre market trading  Pfizer s shares have declined 14 6  this year so far compared with an increase of 0 8  for the    We believe the Consumer Healthcare joint venture with Glaxo  the Array acquisition  July 2019  and the pending merger of Upjohn unit with Mylan  if successful  will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines  The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff goes away  Pfizer expects strong growth of key brands like Ibrance and Eliquis to continue to drive sales  Pfizer is also strengthening its pipeline and hopes to launch innovative medicines in the next five years  which can drive long term growth  However  Lyrica generic erosion  currency headwinds  weak sales in the sterile injectables portfolio and pricing pressure are the key near term top line headwinds Pfizer currently carries a Zacks Rank  3  Hold   You can see   Pfizer Inc  Price  Consensus and EPS Surprise
    
 
 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-10-28,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-rises-on-q3-earnings--sales-beat-ups-eps-view-200479738,200479738
148888,370404,AMGN,Is A Beat In Store For Amarin  AMRN  This Earnings Season ,opinion,"We expect Amarin Corporation PLC   NASDAQ AMRN   to beat expectations when it reports third quarter 2019 results on Nov 7  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 300 00  Shares of Amarin have outperformed the  in the year so far  The stock has gained 21 6  against the industry s decrease of 2 8  Notably  Amarin s earnings history is decent with the pharmaceuticals company outpacing estimates in three out of the last four quarters with the average beat being 67 5  Factors at PlayAmarin s Vascepa demonstrated solid sales on the back of strong demand and an expanded sales force promoting awareness for the drug in the first half of 2019  The drug is approved as an adjunct to diet to reduce triglyceride levels in severe hypertriglyceridemia patients  We expect the momentum to have continued in the third quarter  The Zacks Consensus Estimate for product sales  primarily comprising Vascepa  stands at  111 million The company earns fees from its licensed partners related to commercialization of Vascepa outside the United States  which is expected to have increased in the soon to be reported quarter  The Zacks Consensus Estimate for licensing revenues for the quarter is  0 53 million In a major development  the company announced in August that the FDA is planning to hold an advisory committee meeting regarding the review of its pending supplemental new drug application  sNDA  for the label expansion of Vascepa to include data from REDUCE IT cardiovascular outcomes study  The regulatory authority has set a tentative date of Nov 14 against the previously announced PDUFA date of Sep 28 for the sNDA  With the AdCom meeting being scheduled in November  the action date will now be postponed  Investors will likely ask questions on details related to the advisory committee meeting and impact of the delay in approval of Vascepa s sNDA on the company s outlook on the third quarter earnings call Investor focus will be on updates on payer coverage for Vascepa  expansion in Canada and Europe  and the impact of competition from other approved drugs  especially Sanofi   NASDAQ SNY   and Amgen s   NASDAQ AMGN   PCSK9 inhibitors  Praluent and Repatha  respectively on the third quarter call Amarin has been actively hiring sales personnel to support the launch of Vascepa in the expanded label  following its approval  We expect this activity to have driven operating expenses higher in the soon to be reported quarter Why a Likely Positive Surprise Our proven model predicts an earnings beat for Amarin this time around   The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate  breakeven  and the Zacks Consensus Estimate  loss of 1 cent   stands at  100 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Amarin has a Zacks Rank  3 Amarin Corporation PLC Price and Consensus
    Another Stock That Warrants a LookHere is a biotech stock that you may also want to consider  as our model shows that it has the right combination of elements to deliver an earnings beat in its upcoming release AMAG Pharmaceuticals  Inc    NASDAQ AMAG   has an Earnings ESP of  9 76  and a Zacks Rank  2  The company is scheduled to release third quarter results on Nov 1  You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-10-28,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-amarin-amrn-this-earnings-season-200479710,200479710
148889,370405,AMGN,Exelixis  EXEL  To Report Q3 Earnings  What s In The Cards ,opinion,"Exelixis  Inc    NASDAQ EXEL   is scheduled to report third quarter 2019 results on Oct 30  after market close The company s shares have lost 12 4  in the year so far compared with the  s decline of 1 6   Exelixis has an excellent earnings surprise history  having surpassed expectations in the trailing four quarters  with average positive surprise of 46 25   In the last reported quarter  the company beat expectations by 8 70  Factors Likely to Impact Q3 ResultsStrong sales of Exelixis  lead drug Cabometyx boosted the company s second quarter 2019 results despite stiff competition  The upside was driven by continued growth in demand in the United States for the treatment of advanced renal cell carcinoma  a trend that most likely continued in the third quarter  Moreover  Cabometyx received another FDA approval for the treatment of patients with hepatocellular carcinoma in January and the demand is likely to have picked up well for the same in the to be reported quarter However  expenses are likely to have increased in the third quarter due to higher expenses associated with the company s collaboration with Aurigene  In July  Exelixis announced an exclusive option and license agreement with Aurigene  a biotechnology company based in India focused on oncology and inflammatory disorders  Per the agreement  Exelixis will in license up to six oncology programs from Aurigene Research and development expenses increased significantly in the second quarter  owing to high clinical trial costs  license and other collaborations  and the same is likely to have continued in the third quarter Meanwhile  investors are expected to focus on pipeline development  In July  Exelixis announced that two original cohorts are being expanded and four new cohorts are being added to the protocol for COSMIC 021  the phase Ib trial of Cabometyx in combination with Roche s   OTC RHHBY   Tecentriq in patients with locally advanced or metastatic solid tumors Apart from Cabometyx  Exelixis has other sources of revenues  In January  partner Daiichi Sankyo announced that Minnebro  esaxerenone  tablets were approved by the Japanese Ministry of Health  Labour and Welfare as a treatment for patients with hypertension  The compound was identified during the prior research collaboration between Exelixis and Daiichi Sankyo and has been subsequently developed by the latter  In May  Daiichi Sankyo launched Minnebro tablets in Japan and hence Exelixis will earn royalties on the sales of the same Earnings WhispersOur proven model does not conclusively predict an earnings beat for Exelixis this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  Unfortunately  that is not the case here  as you will see below  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Earnings ESP for Exelixis is 0 00  as both the Zacks Consensus Estimate and the Most Accurate Estimate stand at 20 cents Zacks Rank  The company currently carries a Zacks Rank  4  Sell  Exelixis  Inc  Price  Consensus and EPS Surprise
    
Stocks to ConsiderHere are some companies you may consider  as our model shows that these have the right combination of elements to deliver a beat this quarter United Therapeutics Corporation   NASDAQ UTHR   has a Zacks Rank  1 and an Earnings ESP of  38 18   The company is scheduled to release third quarter results on Oct 30  You can see  Amgen  Inc    NASDAQ AMGN   has an Earnings ESP of  0 04  and a Zacks Rank of 2  The company is scheduled to release third quarter results on Oct 29 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-10-28,Zacks Investment Research,https://www.investing.com/analysis/exelixis-exel-to-report-q3-earnings-whats-in-the-cards-200479521,200479521
148890,370406,AMGN,Will Opdivo   Eliquis Drive Bristol Myers  BMY  Q3 Earnings ,opinion,Bristol Myers    NYSE BMY   immuno oncology drug  Opdivo  which is approved for multiple oncology indications fueled the top line in the second quarter  The uptake of the drug continued to be strong in metastatic and adjuvant melanoma  and first line renal cell carcinoma in the United States and the trend most likely continued in the third quarter  However  the size of the eligible pool of second line lung cancer patients declined in the second quarter  which impacted demand sequentially  and the same most likely prevailed in the third quarter In international markets  Opdivo recorded growth for first line renal cell carcinoma in the second quarter and the third quarter top line is likely to have benefited from the same  However  Opdivo is likely to have faced competition from Merck s   NYSE MRK   Keytruda in the adjuvant melanoma indication Apart from the drug s sales  investors will look forward to key pipeline updates on the ongoing trials of the drug  The part 1a of the phase III Checkmate 227 study  evaluating Opdivo plus low dose Yervoy versus chemotherapy  met the co primary endpoint of overall survival in first line non small cell lung cancer  NSCLC  patients Most recently  a pivotal  phase III study  CheckMate 9LA  evaluating a combination regimen of the company s PD 1 inhibitor  Opdivo  and Yervoy in first line advanced NSCLC  met its primary endpoint of superior overall survival at a prespecified interim analysis  The regimen targets the lucrative first line lung cancer space Eliquis delivered a stellar performance during the first half of the year  propelled by increased share in the novel oral anticoagulant  NOAC  market  a trend that most likely continued in the third quarter  Eliquis  demand grew more than 30  year over year in the United States during the second quarter Oncology drug  Sprycel  might also have contributed to the top line  driven by recent label expansions  Additionally  multiple myeloma drug  Empliciti  is likely to have contributed significantly to the top line on recent label expansions The Zacks Consensus Estimate for third quarter sales and earnings is pegged at  5 80 billion and  1 06  respectively Bristol Myers  shares have gained 7 7  in the year so far compared with the  s growth of 1 6  Apart from these  investors will focus on further updates on the company s impending acquisition of Celgene Corp   NASDAQ CELG    In August  Celgene inked an agreement with Amgen  NASDAQ AMGN   whereby the latter would acquire the global rights to Otezla for  13 4 billion in cash  The decision to divest Otezla was taken in connection with the ongoing regulatory approval process for Bristol Myers  pending merger with Celgene  The EC has granted unconditional approval to this acquisition  The transaction is currently expected to close by the end of 2019 or the beginning of 2020 Zacks Rank   A Stock to ConsiderBristol Myers currently carries a Zacks Rank  3  Hold   A better ranked stock in the same space is Novartis   NYSE NVS    which carries a Zacks Rank  2  Buy   You can see  Novartis  earnings estimates have increased to  5 16 from  5 11 in the past seven days Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-10-29,Zacks Investment Research,https://www.investing.com/analysis/will-opdivo--eliquis-drive-bristolmyers-bmy-q3-earnings-200479670,200479670
148891,370407,AMGN,Amgen  AMGN  Q3 Earnings And Revenues Top Estimates,opinion,"Amgen  AMGN  came out with quarterly earnings of  3 66 per share  beating the Zacks Consensus Estimate of  3 51 per share  This compares to earnings of  3 69 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 4 27   A quarter ago  it was expected that this world s largest biotech drugmaker would post earnings of  3 58 per share when it actually produced earnings of  3 97  delivering a surprise of 10 89  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Amgen  which belongs to the Zacks Medical   Biomedical and Genetics industry  posted revenues of  5 74 billion for the quarter ended September 2019  surpassing the Zacks Consensus Estimate by 1 82   This compares to year ago revenues of  5 90 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Amgen shares have added about 5 3  since the beginning of the year versus the S P 500 s gain of 21 3  
What s Next for Amgen 
While Amgen has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Amgen was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  3 37 on  5 81 billion in revenues for the coming quarter and  14 35 on  22 84 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Biomedical and Genetics is currently in the top 27  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-10-29,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-q3-earnings-and-revenues-top-estimates-200479810,200479810
148911,370427,AMGN,Impatient patients turn to online  buyers club  for new drugs,news,By Ben Hirschler LONDON  Reuters    Frustrated by delays in new medicines reaching their own country  a small but growing number of patients are turning to an online broker that bills itself as a legal version of the Dallas Buyers Club  While regulators warn of the risk of buying drugs online  the Amsterdam based Social Medwork sees its network of trusted suppliers as filling a gap in the market for the latest drugs against diseases such as cancer  migraine and multiple sclerosis  Now it is looking to raise its profile and expand  by signing up former EU Commissioner Neelie Kroes to its supervisory board and securing 1 5 million euros   1 73 million  in new funding from the Social Impact Ventures capital fund  Like Ron Woodroof  the 1980s AIDS patient in the movie  Dallas Buyers Club   patients who cannot get the drugs they want through local healthcare systems are using the organization to self import medicines from abroad  But while Woodroof had to smuggle drugs across the Mexican border  the Social Medwork s customers can place orders online legally  as long as they have a prescription and a doctor s letter stating that the drug is strictly for personal use  In the past 18 months  the group  which is registered with the Dutch Ministry of Health as a medicines intermediary  has supplied more than 3 000 patients  They include British migraine sufferer Senty Bera  43  who recently used the system to buy Aimovig  a new monthly migraine injection from Amgen  NASDAQ AMGN  and Novartis  the first in an improved class of drugs that target a chemical involved in triggering attacks   My quality of life was so poor I thought it was worth trying and it is working brilliantly   Bera said  As yet  Aimovig is not approved for use within Britain s state health service   though Bera hopes it will be soon   but its reputation means it is one of Social Medwork s top sellers  despite a price tag of 698 euros for two autoinjectors  A spokeswoman for Britain s Medicines and Healthcare products Regulatory Agency confirmed there were no formal restrictions on importing such medicines for personal use  In the past  informal drug buying networks  have helped supply cheap generic versions of treatments for HIV and hepatitis C  But the Dutch group  which charges a fee of around 6 percent  claims to be the only organization focused on newly approved branded drugs  With customers in 70 countries  its line up includes new cancer drugs that are U S  approved but not yet available elsewhere  as well as medicines for chronic disorders  such as Roche s new multiple sclerosis treatment Ocrevus  Founder Sjaak Vink says the Internet means patients are increasingly aware they may be waiting months or even years for novel drugs following a first approval elsewhere   We really need to bridge this gap because this situation is ridiculous   he said in an interview  Vink said he was inspired to found the organization by delays in European availability of Merck   Co s innovative cancer immunotherapy Keytruda  Today  his group has customers in Australia  the Middle East and Asia  as well as major European markets such as France  Italy  Germany and Britain  where drug delays could worsen if Brexit disrupts supply lines  Given relatively speedy U S  approvals  there are currently fewer customers in America  although there was a spike in U S  demand last year for Mitsubishi Tanabe Pharma s amyotrophic lateral sclerosis drug Radicut Radicava  which was approved first in Japan ,2018-10-03,Reuters,https://www.investing.com/news/stock-market-news/impatient-patients-turn-to-online-buyers-club-for-new-drugs-1632908,1632908
148912,370428,AMGN,Amgen Falls 3 ,news,"Investing com   Amgen  NASDAQ AMGN  fell by 3  to trade at  194 79 by 11 13  15 13 GMT  on Thursday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 1 15M  Amgen has traded in a range of  194 28 to  202 59 on the day 
The stock has traded at  208 25 at its highest and  194 55 at its lowest during the past seven days ",2018-10-11,Investing.com,https://www.investing.com/news/stock-market-news/amgen-falls-3-1640833,1640833
148913,370429,AMGN,Abbvie settles Humira patent disputes with Novartis unit,news," Reuters    Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG  granting it a non exclusive license to manufacture and sell a copycat version of blockbuster drug  Humira  Abbvie  however  did not disclose details regarding the royalties it will receive from Novartis generics unit  Sandoz  as part of the agreement  Shares of Abbvie rose 2 39 percent to  92 87 in after market trading   The license period will begin on Sept  30  2023 in the United States and on Oct  16 in most countries in the European Union  Abbvie said in a statement  Sandoz received marketing approval for its Humira biosimilar from the European Commission in July and had submitted its application to the U S  health regulator early this year  Last year  Abbvie reached a settlement with  Amgen Inc   NASDAQ AMGN   delaying Amgen s cheaper biosimilar version of Humira until Jan  31  2023  Humira is the world s best selling prescription medicine and has long buoyed AbbVie s business  raking in  5 19 billion in second quarter sales  
But as cheaper biosimilar versions come closer to entering the market  the company has been trying to grow sales from its other medicines  including cancer treatment Imbruvica ",2018-10-11,Reuters,https://www.investing.com/news/stock-market-news/abbvie-settles-humira-patent-disputes-with-novartis-unit-1641452,1641452
148914,370430,AMGN,Intra Cellular Therapies appoints Mark Neumann as Executive VP  Chief Commercial Officer,news,Intra Cellular Therapies  NASDAQ ITCI  appoints Mark Neumann as Executive Vice President  Chief Commercial Officer  Most recently  Mr  Neumann was Vice President  Global Marketing with leadership of nephrology  inflammation  and bone health at Amgen  NASDAQ AMGN   Now read ,2018-10-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/intracellular-therapies-appoints-mark-neumann-as-executive-vp-chief-commercial-officer-1646076,1646076
148915,370431,AMGN,Amgen Rises 3 ,news,"Investing com   Amgen  NASDAQ AMGN  rose by 3 10  to trade at  201 66 by 14 31  18 31 GMT  on Tuesday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was 1 14M  Amgen has traded in a range of  196 46 to  201 67 on the day 
The stock has traded at  208 0800 at its highest and  192 3800 at its lowest during the past seven days ",2018-10-16,Investing.com,https://www.investing.com/news/stock-market-news/amgen-rises-3-1646674,1646674
148916,370432,AMGN,Can Merck  MRK  Keep The Earnings Beat Streak Alive In Q3 ,opinion,"We expect Merck   Co   Inc    NYSE MRK   to beat estimates when it reports third quarter 2019 results on Oct 29 before market open  In the last reported quarter  the company delivered a positive earnings surprise of 12 07  Merck s performance has been pretty impressive  with the company exceeding earnings expectations in all the trailing four quarters  The average four quarter positive earnings surprise was 7 96  Merck   Co   Inc  Price and EPS Surprise
    Merck s shares have risen 8 4  in the year so far against 0 3  decrease for the  
 Let s see how things are shaping up for this announcement Factors to ConsiderMerck s new products like cancer drug Keytruda  Gardasil vaccine and Bridion injection are likely to have driven the top line in the to be reported quarter driven by strong demand trends  Alliance revenues from Lynparza and Lenvima may have contributed to higher oncology sales  Please note that Merck markets Lynparza in partnership with AstraZeneca   NYSE AZN   However  the top line is expected to reflect the impact of loss of exclusivity   LOE   for some products  biosimilar competition for Remicade in Merck s marketing territories and competitive pressure for the diabetes franchise  Januvia Janumet  and currency headwinds Keytruda sales once again must have been driven by the launch of new indications globally  Keytruda sales are gaining from strong momentum in first line lung cancer indication and recent launch in newer indications   renal cell carcinoma and adjuvant melanoma This year so far  Keytruda has gained several label expansion approvals  It includes FDA approval as an adjuvant therapy for high risk stage III melanoma  first line advanced renal cell carcinoma  RDCC   first line recurrent or metastatic head and neck squamous cell cancer  HNSCC   previously treated advanced small cell lung cancer  SCLC  and advanced esophageal cancer  Keytruda was also approved for five new cancer line extensions in Japan and Keytruda   Inlyta combo was approved in EU for first line advanced RCC  All these label expansion approvals should drive sales of Keytruda higher in the future quarters of 2019 Strong demand in most markets is driving sales of Bridion  sugammadex  Injection   a trend that most likely continued in the third quarter  Meanwhile  ongoing commercial launch in China and higher demand in Europe might have driven sales of Gardasil Gardasil 9 vaccine  Importantly  sales of the vaccine improved in the United States in the second quarter due to favorable public sector buying patterns and greater demand in adolescent cohorts  It remains to be seen if the improved U S  sales trends of Gardasil continued in the third quarter Animal health franchise sales recovered in the second quarter from softer growth in the first quarter  We expect the improving trend to have continued in the third quarter Meanwhile  adjusted gross margin is expected to have been roughly flat year over year as an improved product mix is likely to have been offset by headwinds like lower prices  royalty payments  currency fluctuations and continued amortization of collaboration milestones Earnings WhispersOur proven model predicts an earnings beat for Merck in the soon to be reported quarter because it has the right combination of two key ingredients  A stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise Earnings ESP  Merck s Earnings ESP is  0 16   The Zacks Consensus Estimate stands at  1 25 per share  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Merck has a Zacks Rank  3 Other Stocks to Consider Here are some other large drug biotech stocks that have the right combination of elements to beat on earnings this time around GlaxoSmithKline plc   NYSE GSK   has an Earnings ESP of  3 03  and a Zacks Rank  2  The company is scheduled to release results on Oct 30  You can see  Amgen  Inc    NASDAQ AMGN   has an Earnings ESP of  0 50  and a Zacks Rank  3  The company is scheduled to release results on Oct 29 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/can-merck-mrk-keep-the-earnings-beat-streak-alive-in-q3-200477461,200477461
148917,370433,AMGN,Pfizer  PFE  To Report Q3 Earnings  What s In The Cards ,opinion,"Pfizer  Inc    NYSE PFE   will report its third quarter 2019 results on Oct 29  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 3 90  This pharma giant s earnings surpassed expectations in each of the last four quarters  delivering an average positive surprise of 4 63   Pfizer Inc  Price and Consensus
    Pfizer s shares have declined 15 8  this year so far compared with a decline of 0 3  for the  
 Factors at PlayHigher sales of Pfizer s key brands  Eliquis and Ibrance in the Biopharma segment  biosimilars and strong emerging markets sales are likely to have made up for lower sales in the Upjohn group  Continued strong uptake in developed Europe and Japan as well as in certain emerging markets and consistent growth in the United States are likely to have driven Ibrance s sales  Meanwhile  higher sales from Xalkori and Chantix and alliance revenues from Astellas for Xtandi are likely to have aided top line The Zacks Consensus Estimate for sales of Ibrance  worldwide  and alliance revenues from Eliquis is  1 21 billion and  1 01 billion  respectively However  sales of some key drugs like of Prevnar 13 Prevenar 13 and Enbrel declined in the second quarter  It remains to be seen if sales of these drugs have improved this time around  The Zacks Consensus Estimate for sales of Enbrel and Prevnar is  469 million and  1 59 billion  respectively In the Upjohn segment  sales of key drug Lyrica are likely to have declined as the drug lost exclusivity in July  Viagra sales are likely to have declined due to generic competition that began in December 2017 We remind investors that in July  along with its second quarter earnings release  Pfizer lowered its previously issued sales and earnings guidance for 2019 to reflect the formation of the Consumer Healthcare joint venture with Glaxo   NYSE GSK   and the Array BioPharma acquisition Other than this business development activity  an incremental negative impact of foreign exchange and unfavorable product developments in case of Prevnar  vaccine and Xeljanz  autoimmune diseases  led to the guidance cut  These negative developments are expected to have weighed on sales of Prevnar and Xeljanz In July  Xeljanz s prescribing information in the United States was updated by the FDA to include two additional boxed warnings as well as changes to the indication and dosing for ulcerative colitis indication following review of a post marketing study  Pfizer had stated on the second quarter call that the label update may affect prescribing and sales in the future quarters  The Zacks Consensus Estimate for sales of Xeljanz is  564 million Meanwhile  due to some unfavorable revisions in Advisory Committee on Immunization Practices   ACIP  pneumococcal vaccination guidelines for Prevnar 13 in adults across the United States  Pfizer  back then  had said that it expects some decline in demand for Prevnar  which can weaken sales in the future quarters Investors will be keen to know the impact of these unfavorable product developments on third quarter sales of Prevnar and XeljanzMeanwhile  Pfizer s sterile injectables portfolio has been seeing lower revenues since the last few quarters due to persistent legacy Hospira product shortages in the United States  The company is facing supply scarcity for sterile injectable products  mainly due to capacity constraints and technical issues  The trend is expected to have continued in the third quarterImportantly  in July  Pfizer announced a definitive agreement stating that it will spin off its Upjohn unit and combine it with generic drugmaker Mylan   NASDAQ MYL   in a Reverse Morris Trust transaction to create a generic pharmaceutical company  An update is expected on the conference call     What Our Model IndicatesOur proven model does not conclusively predict an earnings beat for Pfizer this time around  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But that s not the case here Earnings ESP  Its Earnings ESP is  0 79   The Zacks Consensus Estimate stands at 63 cents per share  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Pfizer carries a Zacks Rank  3 Stocks to Consider Here are some large drug biotech stocks that have the right combination of elements to beat on earnings in their upcoming release Glaxo has an Earnings ESP of  3 03  and a Zacks Rank  2  The company is scheduled to release results on Oct 30  You can see  Amgen  Inc    NASDAQ AMGN   has an Earnings ESP of  0 50  and a Zacks Rank  3  The company is scheduled to release results on Oct 29 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-to-report-q3-earnings-whats-in-the-cards-200477825,200477825
148918,370434,AMGN,Acorda  ACOR  To Post Q3 Earnings  What s In The Cards ,opinion,Acorda Therapeutics  Inc    NASDAQ ACOR   is scheduled to report third quarter 2019 results on Nov 4  after the market closes Acorda has an excellent earnings surprise history  surpassing expectations in each of the trailing four quarters  the average being 69 68   In the last reported quarter  the company delivered a positive surprise of 48 11  Shares of Acorda have plummeted 84 4  so far this year underperforming the  decrease of 2 8  Factors to ConsiderAcorda s lead multiple sclerosis  MS  drug Ampyra is facing generic competition in the United States  During the first half of 2019  sales of Ampyra tanked significantly year over year due to generic launches  This sales erosion induced by generic competition is likely to have hurt the company s third quarter top line  Though Ampyra sales recorded a surprising sequential increase in the second quarter  management had then guided that this will see a sharp decline in the upcoming quarters of 2019 On Oct 23  the company provided Ampyra s sales figure for the third quarter of 2019  The drug generated sales of  37 6 million in the third quarter  reflecting a 72 7  plunge year over year and a 14 9  decline on a sequential basis Notably  last September  Ampyra lost its exclusivity as generics entered the market including Mylan s   NASDAQ MYL   authorized generic version Acorda s Parkinson s disease drug Inbrija was launched in the United States in February and is off to a strong start on high demand both from doctors and patients  On Wednesday  management reported that the drug recorded sales worth of  4 9 million in the third quarter of 2019  reflecting a surge of 63 3  sequentially Inbrija is also under review in Europe with a decision expected by the end of 2019  Investor will be keen to get an update on the same during the earnings call as a potential approval in the EU will boost sales of the drug in the future quarters Key Recent DevelopmentsAlong with providing the sales numbers of Inbrija and Ampyra on Wednesday  Acorda also announced a corporate restructuring and updated its 2019 financial outlook as well as renewed 2020 financial guidance As part of its corporate strategy  management stated to trim workforce by almost 25   The company expects to realize estimated annualized cost savings of approximately  21 million beginning next year due to headcount reduction Acorda lowered its previously issued research and development  R D  expenses and selling  general and administrative  SG A  expenses  excluding share based compensation expenses  for the full year  The company now expects R D expenses in the range of  55  60 million compared with the previous expectation of  70  80 million  SG A expenses are expected in the  185  190 million range compared with  200  210 million expected earlier For 2020  R D expenses are expected in the range of  20  25 million while SG A expenses are anticipated in the  160  165 million band Earnings WhispersOur proven model does not conclusively predict an earnings beat for Acorda this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But this is not the case here  You can uncover the best stocks to buy or sell before they re reported with our Earnings ESP  Acorda has an Earnings ESP of  1 27  Zacks Rank  Acorda carries a Zacks Rank  2  which increases the predictive power of ESP  However  its negative ESP leaves surprise prediction inconclusive Acorda Therapeutics  Inc  Price and EPS Surprise   Stocks That Warrant a LookHere are a few healthcare stocks worth considering as our model shows that these have the right mix of elements to beat estimates this time around Incyte Corporation   NASDAQ INCY   has an Earnings ESP of  1 15  and a Zacks Rank of 1  The company is scheduled to release results on Oct 29  You can see  Amgen  Inc    NASDAQ AMGN   has an Earnings ESP of  0 50  and a Zacks Rank of 3  The company is scheduled to release results on Oct 29 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/acorda-acor-to-post-q3-earnings-whats-in-the-cards-200477756,200477756
148919,370435,AMGN,Amgen  AMGN  To Report Q3 Earnings  What s In The Cards ,opinion,"We expect Amgen Inc    NASDAQ AMGN   to beat expectations when it reports third quarter 2019 results on Oct 29 after market close  Amgen delivered positive earnings surprise of 10 89  in the last reported quarter Amgen shares rose 4 3  this year so far against 2 5  decrease registered by the during this period  Amgen s performance has been impressive  with the company delivering a positive surprise in each of the trailing four quarters with the average being 6 72  Amgen Inc  Price and EPS Surprise
    Factors at PlayHigher sales of products like Prolia  Xgeva  Kyprolis and Blincyto are expected to have made up for lower sales of Amgen s mature drugs like Enbrel  Aranesp  Epogen  Neupogen  Neulasta and Sensipar that face an array of branded and generic competitors  The Zacks Consensus Estimate for Enbrel sales is  1 27 billion Sales of Prolia  Xgeva  Blincyto  Parsabiv  Kyprolis and Nplate are likely to have been driven by higher demand trends once again The respective Zacks Consensus Estimate for Prolia  Xgeva  Blincyto  Parsabiv and Kyprolis sales is pegged at  638 million   484 million   75 million   178 million and  270 million Biosimilars may have once again being an important contributor to top line growth  Kanjinti  Amgen s biosimilar of Roche s Herceptin  and Mvasi  biosimilar of Roche s Avastin  were launched in the United States in July  which are likely to have contributed to third quarter sales Though Repatha sales are expected to have gained on higher unit demand  lower prices are likely to have acted as an offsetting factor  The Zacks Consensus Estimate for Repatha sales stands at  169 million Amgen s new migraine drug  Aimovig  recorded sequentially improved sales in the second quarter driven by an increase in the percentage of paid volume as the company sees improvement in conversion of free to paid patients  We expect the positive trend to have continued in the third quarter Another important drug  Evenity was launched in the United States and Japan this year for the treatment of osteoporosis in postmenopausal women at high risk of fracture  Investors will be keen to know how Aimovig and Evenity performed in the third quarter In August  Amgen entered into an agreement to acquire global commercial rights to Celgene s   NASDAQ CELG   blockbuster psoriasis drug  Otezla  which the latter had to divest to complete its impending merger with Bristol Myers   NYSE BMY    Amgen agreed to pay Celgene  13 4 billion in cash or approximately  11 2 billion net of anticipated future cash tax benefits for Otezla and certain related assets and liabilities  An update is expected at the call Earnings WhispersOur proven model predicts an earnings beat for Amgen in the soon to be reported quarter because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise Earnings ESP  Amgen s Earnings ESP is  0 50  as the Zacks Consensus Estimate of  3 50 is lower than the Most Accurate Estimate of  3 51  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Amgen has a Zacks Rank  3 Another Stock to Consider Here s another large biotech stock that has the right combination of elements to beat on earnings this time around Regeneron Pharmaceuticals   NASDAQ REGN   with an Earnings ESP of  5 65  and a Zacks Rank  3  The company is scheduled to release results on Nov 5  You can see  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-to-report-q3-earnings-whats-in-the-cards-200478495,200478495
148920,370436,AMGN,Should You Buy Amgen  AMGN  Ahead Of Earnings ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Amgen Inc    NASDAQ AMGN   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Amgen is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for AMGN in this report In fact  the Most Accurate Estimate for the current quarter is currently higher than the broader Zacks Consensus Estimate of  3 51 per share  This suggests that analysts have very recently bumped up their estimates for AMGN  giving the stock a Zacks Earnings ESP of  0 04  heading into earnings season Amgen Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that AMGN has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see Clearly  recent earnings estimate revisions suggest that good things are ahead for Amgen  and that a beat might be in the cards for the upcoming report Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-10-27,Zacks Investment Research,https://www.investing.com/analysis/should-you-buy-amgen-amgn-ahead-of-earnings-200479155,200479155
148937,370453,AMGN,Amgen profit beats Street view  will not raise prices again in 2018,news,By Michael Erman and Robin Respaut  Reuters     Amgen Inc   O AMGN  on Thursday reported a better than expected second quarter profit and raised its full year earnings forecast  and its chief executive pledged not to raise drug prices again this year  Amgen joined several drugmakers that have vowed to limit or delay price increases under intensifying pressure from the Trump administration to cut health care costs for U S  consumers  The world s largest biotechnology company also announced replacements for its head of research and development and retiring global commercial operations chief  The company said on a conference call that it decided in May to forego list price increases it had planned for July  although it did not say which drugs it had targeted for price hikes   We have no plans to change that for the balance of the year   CEO Robert Bradway said   Amgen posted adjusted earnings of  3 83 per share  topping analysts  average expectations by 29 cents  according to Thomson Reuters I B E S  Growth of newer drugs like cholesterol fighter Repatha and osteoporosis drug Prolia offset weakness in older products  the company said  The company increased its 2018 earnings forecast to  13 30 to  14 per share  up from its previous view of  12 80 to  13 70  Amgen shares rose 1 percent in extended trading to  196   Overall revenue for the quarter revenue rose 4 percent to  6 06 billion  Sales of rheumatoid arthritis drug Enbrel fell 11 percent to  1 3 billion   Sales of the potent but expensive cholesterol drug Repatha have begun to take off  increasing 78 percent to  148 million  They have been held back since the drug s 2015 approval by an unwillingness of insurers and pharmacy benefit managers to authorize its use for most patients   Prolia sales rose 21 percent to  610 million  Amgen did not report early sales of Aimovig  the new migraine preventer that won U S  approval in May  Amgen offered all new patients two free months of the medicine  The company is trying to get around barriers large insurers are setting for patients prescribed the costly new headache treatment  Amgen said it had already negotiated contracts with payers covering around 30 percent of commercially insured patients in the United States  Amgen announced that longtime research chief Sean Harper is stepping down and will be replaced by David Reese  currently head of translational sciences and oncology at the company  Murdo Gordon  who left his role as Bristol Myers Squibb s  N BMY  chief commercial officer earlier this week  will replace Tony Hooper as executive vice president of global commercial operations in September  the company said ,2018-07-26,Reuters,https://www.investing.com/news/stock-market-news/amgen-quarterly-profit-beats-wall-street-view-on-new-product-sales-1547741,1547741
148938,370454,AMGN,Amgen Rises 3 01  As Investors Eye Earnings,news,Investing com   Amgen  NASDAQ AMGN  rose by 3 01  to trade at  196 37 by 12 28  16 28 GMT  on Tuesday on the NASDAQ exchange  up 3 01  on the day  The volume of Amgen  shares traded since the start of the session was 1 23M Amgen has traded in a range of  190 87 to  196 43 on the day  The stock has traded at  196 42 at its highest and  189 16 at its lowest during the past seven days ,2018-07-31,Investing.com,https://www.investing.com/news/stock-market-news/amgen-rises-301-as-investors-eye-earnings-1553535,1553535
148939,370455,AMGN,German Stock Exchange approves delisting request of Precision Therapeutics,news,Precision Therapeutics  NASDAQ AIPT  has received confirmation from the B rse Stuttgart Stock Exchange for delistingPrecision Therapeutics  stock  traded under the symbol  S1K1  in Germany  with the last day of trading to be September 6  Dr  Carl Schwartz  Chief Executive Officer of Precision Therapeutics  commented   We did not request or consent to any listing on any exchange outside of the NASDAQ Capital Market in the U S  and are pleased the Stuttgart Stock Exchange swiftly responded to our request to delist from its exchange  AIPT  8  premarket  Now read ,2018-08-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/german-stock-exchange-approves-delisting-request-of-precision-therapeutics-1556902,1556902
148940,370456,AMGN,Radius Health beats by  0 36  beats on revenue,news,Radius Health  NASDAQ RDUS   Q2 EPS of   0 99 beats by  0 36 Revenue of  22 63M   2209 2  Y Y  beats by  2 17M Press ReleaseNow read ,2018-08-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/radius-health-beats-by-036-beats-on-revenue-1563085,1563085
148941,370457,AMGN,Amgen Rises 3 09 ,news,"Investing com   Amgen  NASDAQ AMGN  rose by 3 09  to trade at  202 36 by 12 45  16 45 GMT  on Monday on the NASDAQ exchange 
The volume of Amgen shares traded since the start of the session was  1 51M  Amgen has traded in a range of  196 56 to  202 43 on the day 
The stock has traded at  202 39 at its highest and  194 75 at its lowest during the past seven days ",2018-09-10,Investing.com,https://www.investing.com/news/stock-market-news/amgen-rises-309-1604478,1604478
148943,370459,AMGN,Can New Drugs Help Lilly  LLY  To Deliver Solid Q3 Earnings ,opinion,"Eli Lilly and Company   NYSE LLY   will report third quarter 2019 results on Oct 23  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 2 74  Lilly s shares have declined 6 7  this year so far against the  s increase of 0 2    Lilly s earnings performance has been mixed  Its earnings beat expectations in three of the last four quarters  with the average positive surprise being 0 69  Eli Lilly and Company Price and EPS Surprise
  
   Let s see how things are shaping up for this announcement Factors to ConsiderLike the previous few quarters  strong demand for new products namely Trulicity  Taltz  Jardiance  Basaglar  Olumiant and Verzenio as well as new migraine drug  Emgality are likely to have driven sales in the third quarter  making up for the decline in sales of established products like Cialis due to loss of exclusivity and the impact of Lartruvo s impending product withdrawal  Lilly has suspended promotion of its advanced soft tissue sarcoma drug  Lartruvo due to the failure of the ANNOUNCE confirmatory study Among the new drugs  in August  Taltz gained FDA approval for its third indication   active ankylosing spondylitis  which expanded the drug s eligible patient population and might have driven sales higher in the third quarter However  rising pricing pressure in the United States due to rebates and legislated increases in Medicare Part D cost sharing  price cuts in some international markets  currency headwinds are expected to have negatively impacted the top line in the third quarter of 2019 Also  competitive pressure and loss of exclusivity in certain countries are hurting Alimta sales particularly international sales   a trend that most likely continued in the third quarter Investors will be keen to know the sales numbers of Lilly s new CGRP antibody Emgality  Emgality generated sales of  34 3 million in the second quarter  We expect sales to have been much higher in the third quarter In July 2019  Lilly gained FDA approval for Baqsimi  its glucagon nasal powder to treat severe hypoglycemia in diabetes patients  Baqsim is the first and only nasally administered glucagon to be approved by the FDA  Investors will be keen to know about the initial sales uptake of this product on the third quarter conference call Key Recent DevelopmentsEarlier this week  Lilly announced that a late stage study  SEQUOIA  evaluating its pipeline candidate  pegilodecakin plus Folfox  to treat patients with metastatic pancreatic cancer did not meet primary endpoint of overall survival  Pegilodecakin  a PEGylated IL 10  was added to Lilly s portfolio with the June 2018 acquisition of ARMO BioSciences Last week  the FDA granted approval to Lilly s lasmiditan oral tablets to treat acute migraine  with or without aura  in adults  Lasmiditan will be marketed by the trade name of  and will be available in doses of 50 mg  100 mg  and 200 mg  once launched Earnings WhispersOur proven model does not conclusively predict an earnings beat for Lilly this time around  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But that is not the case here Earnings ESP   Its Earnings ESP is  1 61  as the Zacks Consensus Estimate of  1 44 is higher than the Most Accurate Estimate of  1 42  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Lilly carries a Zacks Rank  3 Stocks to ConsiderHere are some large drug biotech stocks that have the right combination of elements to beat on earnings this time around Pfizer  Inc    NYSE PFE   has an Earnings ESP of  0 26  and a Zacks Rank  2  The company is scheduled to release results on Oct 29 Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  1 04  and a Zacks Rank  3  The company is scheduled to release results on Oct 24  You can see  Amgen  Inc    NASDAQ AMGN   has an Earnings ESP of  1 31  and a Zacks Rank  3  The company is scheduled to release results on Oct 29 7 Best Stocks for the Next 30 Days                                               Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ",2019-10-16,Zacks Investment Research,https://www.investing.com/analysis/can-new-drugs-help-lilly-lly-to-deliver-solid-q3-earnings-200474588,200474588
148944,370460,AMGN,Roche Posts Solid Sales For First 9 Months Of  19  Ups View,opinion,Roche Holding  SIX ROG  AG   OTC RHHBY   posted strong sales for the nine months of 2019  propelled by demand for new drugs amid biosimilar competition for legacy drugs  Consequently  the company also raised its guidance for 2019 Roche s stock has gained 15  in the year so far compared with the  s growth of 0 2   The company reported sales of CHF 46 1 billion in the first nine months of 2019  up 10  from the year ago quarter The company reports results under two divisions   Pharmaceuticals and Diagnostics  All growth rates mentioned below are on a year over year basis and at constant exchange rates Sales at the Pharmaceuticals division increased 12   driven by strong growth of Ocrevus  Hemlibra  Tecentriq  Perjeta and Avastin  The strong uptake of the newly introduced drugs more than offset lower sales of Herceptin and MabThera Rituxan  The Diagnostics division sales climbed 4   owing to its immunodiagnostic testing portfolio Results in DetailHerceptin sales fell 9  owing to biosimilar competition  Perjeta sales jumped 34   owing to increased demand for adjuvant early breast cancer therapy Sales of Ocrevus  the drug used to treat two forms of multiple sclerosis  surged 57  on continued global growth Immuno oncology drug  Tecentriq  for advanced bladder cancer and advanced lung cancer  recorded 146  year over year growth in sales  driven by the inclusion of new indications   extensive stage small cell lung cancer and triple negative breast cancer Sales of lung cancer drug  Alecensa  surged 50  on solid growth across all regions  Oncology drug  Avastin  recorded 8  year over year growth Performance of the immunology franchise was driven by 9  growth in Actemra RoActemra sales and 2  in Xolair sales  Gazyva Gazyvaro sales jumped 40  Sales of ophthalmology drug  Lucentis  grew 9   Roche has a collaboration agreement with Novartis   NYSE NVS   for this drug However  sales of Rituxan MabThera declined 3  due to the entry of biosimilars in Europe Revenues at the Diagnostics division rose 4   owing to 7  growth in Molecular Diagnostics  Centralized and Point of Care Solutions grew on the back of the immunodiagnostics business 2019 Outlook RaisedSales in 2019 are expected to increase high single digits as compared to the previous guidance of mid single digit growth  The company expects core earnings to grow in line with sales Pipeline Progress   Roche made encouraging pipeline progress in the third quarter  In particular  label expansions of immuno oncology drug  Tecentriq  obtained approvals for various indications  The European Commission  EC  approved Tecentriq plus chemotherapy  nab paclitaxel  for the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer  Tecentriq in combination with chemotherapy  carboplatin and etoposide  was also approved in Europe for the initial  first line  treatment of adults with extensive stage small cell lung cancer  The EC also approved the drug in combination with chemotherapy  nab paclitaxel  for the initial treatment of adults with metastatic non squamous non small cell lung cancer  NSCLC   who do not have EGFR mutant or ALK positive NSCLC The FDA approved Rozlytrek for the treatment of adults with ROS1  positive  metastatic NSCLC The FDA granted Breakthrough Therapy Designation to Gazyva in adults with lupus nephritis and to Cotellic in patients with histiocytic neoplasms  who do not harbor the BRAF V600 mutation The FDA approved MabThera Rituxan in combination with glucocorticoids for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in pediatric patients aged two years or older Update on Spark AcquisitionIn February  Roche announced that it had entered a definitive merger agreement to acquire Spark Therapeutics   NASDAQ ONCE    However  a regulatory review of the transaction is ongoing and the transaction will close by the end of this year Our TakeRoche s performance in the first nine months was impressive  as strong growth in Ocrevus  Perjeta  Tecentriq and Hemlibra countered biosimilar competition in Europe for Herceptin and MabThera from the likes of Amgen   NASDAQ AMGN   The increase in guidance is impressive as well and reflects strong underlying growth from newly launched drugs Meanwhile  the company continues to progress with its pipeline  as it looks to restructure the portfolio beyond oncology into MS and hemophilia  among others  The approvals of Polivy and Rozlytrek should further drive sales Roche currently carries a Zacks Rank  3  Hold   You can see  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-16,Zacks Investment Research,https://www.investing.com/analysis/roche-posts-solid-sales-for-first-9-months-of-19-ups-view-200474762,200474762
148945,370461,AMGN,What s In Store For Healthcare ETFs In Q3 Earnings ,opinion,The healthcare space stood tall well over the past three months amid rounds of broad market sell off  This is primarily thanks to the dual tailwinds of encouraging industry fundamentals  including M A  and the sector s defensive tilt The ultra popular ETF  Health Care Select Sector SPDR Fund   gained 0 4  while other popular ETFs like Vanguard Health Care ETF   ASX VHT    iShares U S  Healthcare ETF  and Fidelity MSCI Health Care Index ETF  were down 0 6   0 2  and 0 5   respectively  The price movement of the fund depends on the earnings releases of some big names like Pfizer   NYSE PFE    Merck   NYSE MRK    Amgen   NASDAQ AMGN    AbbVie   NYSE ABBV    Gilead Sciences   NASDAQ GILD   and Bristol Myers Squibb   NYSE BMY   that dominate their returns These firms are lined up to report their earnings this week and in the next  All these stocks collectively account for 23 7  share in XLV  21 9  in IYH  20 5  in FHLC and 20 1  in VHT  Let s dig deeper into the earnings picture of these companies  which will drive the performance of the above mentioned funds in the coming days  read    According to our methodology  the combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Inside Our Surprise Prediction for These StocksPfizer has a Zacks Rank  3 and an Earnings ESP of  0 79   indicating a lower chance of beating estimates this quarter  The stock saw no earnings estimate revision for to be reported quarter over the past 30 days  It delivered an average positive earnings surprise of 4 63  for the past four quarters and has a VGM Score of B  Pfizer is scheduled to report earnings on Oct 29  before the opening bell Merck is expected to report results on Oct 29 before market open  It has a Zacks Rank  3 and an Earnings ESP of  0 16   indicating reasonable chances of beating estimates  The stock delivered a positive earnings surprise in the last four quarters  with the average beat being 7 96   It witnessed no earnings estimate revision over the past 30 days for the to be reported quarter  Merck has a VGM Score of A Amgen carries a Zacks Rank  3 and has an Earnings ESP of  0 50   The earnings surprise track over the past four quarters is strong  with the average positive surprise being 6 72   Amgen has witnessed positive earnings estimate revision of three cents over the past 30 days for the quarter to be reported  The stock has a VGM Score of B  Amgen will report earnings on Oct 29 after market close AbbVie has a Zacks Rank  3 and an Earnings ESP of  2 62   The company delivered a positive earnings surprise in the last four quarters  with the average beat being 2 89   It saw positive earnings estimate revision by a couple of cents over the past month for the to be reported quarter  The stock has a top VGM Score of A  The company is scheduled to report on Nov 1 before the opening bell  see        Gilead is expected to release earnings on Oct 24 after market close  It has a Zacks Rank  3 and an Earnings ESP of  0 91   Gilead delivered average positive earnings surprise of 2 20  over the last four quarters and saw no earnings estimate revision over the past month for the to be reported quarter  It has a VGM Score of A Bristol Myers will likely report earnings on Oct 31 before the opening bell  It has a Zacks Rank  3 and an Earnings ESP of  0 38   The stock delivered an average positive earnings surprise of 10 65  over the past four quarters  and saw no earnings estimate revision for the to be reported quarter in a month  It has a VGM Score of B Summing UpWith earnings surprise in the cards  the healthcare sector is expected to witness modest earnings growth of  in the third quarter  suggesting some room for potential upside for healthcare ETFs  In particular  FHLC has a Zacks ETF Rank  3 while the remaining  three have a Zacks ETF Rank  2  read    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-10-20,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-healthcare-etfs-in-q3-earnings-200475704,200475704
148946,370462,AMGN,Lilly  LLY  Q3 Earnings Top Estimates  Sales Lag  Stock Down,opinion,"Eli Lilly   Company   NYSE LLY   reported third quarter 2019 adjusted earnings per share of  1 48  which beat the Zacks Consensus Estimate of  1 43  Earnings rose 10  year over year as higher operating costs were partially offset by slightly higher revenues  a lower tax rate and reduction in shares outstanding due to buybacks Quarter in DetailRevenues of  5 48 billion missed the Zacks Consensus Estimate of  5 56 billion  Sales however grew 3  year over year  backed by strong volume trends for its newer drugs  namely Trulicity  Taltz  Jardiance  Basaglar  Emgality  and Verzenio  which compensated for lower sales of older products like Cialis due to the loss of U S  exclusivity and the impact of Lartruvo s product withdrawal  Lilly has suspended promotion of its advanced soft tissue sarcoma drug  Lartruvo due to the failure of the ANNOUNCE confirmatory study Foreign exchange hurt sales growth by 1  in the quarter  Also  lower realized prices had a negative impact of 4  on sales due to rebates and legislated increases in Medicare Part D cost sharing in the United States and price cuts in some international markets  Volumes rose 8  New pharma products  products launched since 2014  drove 12  of volume growth and represented nearly 44  total revenues  up from 43  in the previous quarter  U S  revenues were flat at  3 06 billion while ex U S  revenues rose 8  to  2 42 billion Among the established products  Forteo sales declined 5 to  370 7million  Alimta declined 2 to  508 2million  Humalog sales dropped 2  to  648 9million  Humulin sales were flat at  321 8million Cialis sales declined 61  to  184 3 million as U S  sales were hurt by entry of generic products  Outside U S  sales were also hurt by generic competition  lower realized prices and currency headwinds Among the new products  Trulicity generated revenues of  1 01 billion  up 24  year over year driven by higher demand in the United States and higher volumes in ex U S  markets  which offset the impact of lower realized prices and changes in segment mix Cyramza revenues were  240 0 million  up 21  year over year driven by higher sales in both U S  and international markets Jardiance sales surged 44  to  240 7 million  driven by increased demand trends within the SGLT2 class of diabetes medicines in the United States and increased volume outside the United States  which offset the negative impact of currency Basaglar recorded revenues of  263 2 million  up 31  year over year  In the United States  sales rose 29   benefiting from higher demand and the impact of higher realized prices  Outside U S  sales growth of 39  was driven by increased volume Taltz brought in sales of  340 0 million  up 29  year over year as U S  sales gained from higher demand  which offset the impact of lower realized prices due to changes in estimates for rebates and discounts  Ex U S  sales were driven by increased volume from launches in new countries  In August  Taltz gained FDA approval for its third indication   active ankylosing spondylitis  which expanded the drug s eligible patient population New rheumatoid arthritis drug  Olumiant generated sales of  114 6 million in the quarter compared with  102 4 million in the previous quarter backed by increased demand in international markets  In the United States  Olumiant recorded sales of  12 1 million  higher than  10 7 million in the previous quarter New advanced breast cancer treatment medicine  Verzenio generated sales of  157 2 million in the quarter  up from  133 9 million in the previous quarter  This was because of increased demand and higher realized prices in the United States The newly launched CGRP antibody  Emgality generated revenues of  47 7 million in the quarter compared with  34 3 million in the previous quarter  In the United States  Emgality sales were  45 8 million compared with  33 8 million in the previous quarter  Emgality was launched in some international markets in the first quarter  which brought sales of  1 9 million in the third quarter Amgen s   NASDAQ AMGN   Aimovig and Teva s   NYSE TEVA   Ajovy were two other CGRP antibodies launched last year  which pose strong competition to Emgality Adjusted gross margin of 79 6  in the quarter was down 60 basis points  Operating income rose 3  year over year to  1 57 billion 2019 Earnings GuidanceLilly raised its expectations for full year earnings while keeping its revenue guidance intact   The earnings forecast was increased from a range of  5 67 to  5 77 per share to  5 75 to  5 85 taking into account a lower tax rate The revenue guidance was maintained in the range of  22 0 billion    22 5 billion  which indicates 5  growth  at mid point  over 2018 level on a constant currency basis Gross margin is still expected to be approximately 80   Adjusted tax rate is expected to be in the range of 12  13  versus 13  14  expected previously Marketing  selling and administrative expense are expected to be in the range of  5 9 billion to  6 1 billion  Research and development expense is still expected to be in the range of  5 5 billion to  5 7 billion Our TakeJust like the second quarter  Lilly beat estimates for third quarter earnings but missed the same for sales  The stock was down more than 3  in pre market trading probably due to Lilly s lukewarm sales performance in the quarter and absence of an increase in sales guidance  In fact  so far this year  shares of Lilly have declined 5 1  against the  decrease of 0 3    Going forward  Lilly s revenue growth is expected to be driven by higher demand for its newer drugs including Trulicity  Jardiance  Taltz  Verzenio  Basaglar  Emgality as well as newly launched glucagon nasal powder  Baqsimi  However  competitive pressure on Lilly s drugs is rising  Generic competition for several drugs including Cialis  rising pricing pressure in the United States due to rebates and legislated increases in Medicare Part D cost sharing  price cuts in some international markets  currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line Nonetheless  Lilly has made significant pipeline progress in the past year with several positive late stage data readouts  multiple approvals and regulatory submissions  Earlier this month  the FDA granted approval to Lilly s lasmiditan oral tablets to treat acute migraine  with or without aura  in adults  Lasmiditan will be marketed by the trade name of  and will be available in doses of 50 mg  100 mg  and 200 mg  once launched  Lilly regularly adds promising new pipeline assets through business development deals Zacks RankLilly currently carries a Zacks Rank  3  Hold   You can see  A better ranked large cap pharma stock is GlaxoSmithKline   NYSE GSK    which has a Zacks Rank  2  Buy   Glaxo s earnings estimates for 2019 have gone up 2 8  while that for 2020 have increased 1  over the past 60 days  Glaxo stock has rallied 11 3  so far in 2019  Eli Lilly and Company Price and Consensus
    Wall Street s Next Amazon  NASDAQ AMZN 
 Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-10-22,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-q3-earnings-top-estimates-sales-lag-stock-down-200476943,200476943
148947,370463,AMGN,Will Strong Jakafi Sales Drive Incyte s  INCY  Q3 Earnings ,opinion,"Incyte Corporation   NASDAQ INCY   is scheduled to report third quarter 2019 results on Oct 29  before market open In the last reported quarter  the company beat earnings estimates by a whopping 53 06   It beat earnings expectations twice over the last four quarters  delivering average positive surprise of 25 01  Incyte Corporation Price  Consensus and EPS Surprise
    Why a Likely Earnings Beat Our proven model predicts an earnings beat for Incyte this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Incyte has an Earnings ESP of  1 15  as the Zacks Consensus Estimate is pegged at 65 cents and the Most Accurate Estimate stands at 66 cents Zacks Rank  The company has a Zacks Rank  1  You can see  Factors Driving GrowthIncyte s lead drug  Jakafi  a first in class JAK1 JAK2 inhibitor  which is approved for the treatment of patients with polycythemia vera  and those with intermediate or high risk myelofibrosis  drove second quarter results  a trend that most likely continued in the third quarter  Jakafi sales grew 18  in the second quarter Moreover  the FDA approved a label expansion of Jakafi for the treatment of steroid refractory acute graft versus host disease in adult and pediatric patients 12 years or older in May 2019 and hence this is the first full quarter when the benefit of this expanded label was realized  Hence  sales of the drug for this indication are likely to have boosted the top line in the third quarter The company also earns product royalty revenues from Novartis AG   NYSE NVS   for the commercialization of Jakafi in ex U S  markets  Novartis recorded 17  growth in sales in the third quarter and hence Incyte must have received higher royalties for the same period We remind investors that while Jakafi sales and royalties are key catalysts for the company s revenue growth  Iclusig sales and Olumiant royalties also contribute to the top line  Hence  these are likely to have contributed significantly to the company s revenues in the third quarter Apart from the regular top and bottom line numbers  we expect investors to focus on the company s pipeline updates on the label expansion of Jakafi into additional indications  Last month  Incyte announced that the first patient has been treated in the TRuE V clinical program  evaluating the cream formulation of ruxolitinib as monotherapy for vitiligo  Earlier this month  the company announced positive 52 week results from its randomized  double blind  dose ranging  phase II study  evaluating ruxolitinib cream in adult patients with vitiligo  In September  Incyte announced positive updated results from the phase II study of pemigatinib in patients with previously treated  advanced cholangiocarcinoma Share Price PerformanceIncyte s stock has rallied 23 5  in the year so far against the  s decline of 4 6  Other Stocks That Warrant a LookHere are a few other healthcare stocks worth considering as our model shows that these too have the right mix of elements to beat estimates this time around Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  0 91  and a Zacks Rank  3  The company is scheduled to release results on Oct 24 Amgen  Inc    NASDAQ AMGN   has an Earnings ESP of  0 50  and a Zacks Rank of 3  The company is scheduled to release results on Oct 29 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-10-22,Zacks Investment Research,https://www.investing.com/analysis/will-strong-jakafi-sales-drive-incytes-incy-q3-earnings-200476936,200476936
148959,370475,AMGN,Biotechs perk up ahead of ASCO abstract drop,news,The SPDR S P Biotech  MX XBI  ETF  XBI  1 1   is up 1  as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology  ASCO  Annual Meeting in Chicago  June 1   5 The abstracts should be released at 5 00 pm ET today Virtually all companies with any presence at all in cancer will have data presented Selected tickers   CELG  BLUE  0 2   LOXO  1 4   OTCQX RHHBY  0 5   BMY  0 3   MRK  0 8   AZN  0 6   ABBV  0 8   DVAX  1 3   GTHX  5   IDRA  4 2   EPZM  0 6   FGEN  1 4   IMGN  3   GILD  1 3   PFE  0 3   LLY  0 6   JNJ  0 5   AMGN  0 9   CLVS  2 2   TSRO  0 9  Now read ,2018-05-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/biotechs-perk-up-ahead-of-asco-abstract-drop-1450379,1450379
148961,370477,AMGN,Novartis readies anti sexism message for migraine drug,news,"By John Miller ZURICH  Reuters    With women hardest hit by migraine headaches  Swiss drugmaker Novartis is gearing up its marketing message to counteract sexism that it worries might become a barrier to adoption of its new medicine Aimovig    The injectable monoclonal antibody that Novartis has developed with Amgen  NASDAQ AMGN  won approval in the United States this month and on Friday bagged a recommendation from a key European panel  clearing the way for likely approval on the continent  The drug is expected to be high priced  though countries negotiate their own terms with the company  In the United States  the drug is priced at  6 900 a year  Novartis is also considering new pricing models for Aimovig  Novartis s top neuroscience developer Dan Bar Zohar said he is keenly aware that most migraine sufferers are women  The Basel based company has data to combat scepticism about the severity of migraines in women   We are tailoring quite a lot of our messages to this relevant population  We are extremely aware of this gender bias   Bar Zohar said in an interview with Reuters    We have science based evidence to show this is not just a headache   To reflect the community of migraine suffers  Novartis said that about 85 percent of those who took part in its clinical trials were women  The European Medicines Agency s Committee for Medicinal Products for Human Use  CHMP  on Friday recommended the drug for treating migraine headaches in adults  The European Commission s backing usually follows in just a couple of months   The medicine  also called erenumab or AMG334  is the first in a new class of treatments designed to prevent migraine by interfering with calcitonin gene related peptide  CGRP   which is involved in the processes that kick off the severe headaches  such as dilation of blood vessels in the brain  In the United States  Amgen and Novartis are pricing the self injection drug at  575 a month  before discounts   There  prescription benefits managers had taken aim at the drug  announcing in advance that they saw it as a test case to help rein in prices  Bar Zohar did not give details on potential pricing in Europe  where cost can differ widely from country to country  But he did say that Novartis is considering a variety of models    including an approach in which it would quickly identify patients who respond to the treatment    to help determine reimbursement levels   We are exploring some innovative methods in order to price it right   he said  adding Novartis wants to avoid the traditional  pay  fire and forget  model where it is reimbursed by the pill  in favor of an approach that delivers more value to health care systems and patients  Studies of the Amgen Novartis drug included patients who were new to migraine treatments  as well as patients who had tried other therapies unsuccessfully before abandoning them   A late stage trial of Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments   These people live literally in the dark   Bar Zohar said   This is a breakthrough   Though Aimovig has a head start  competition from makers of would be rival medicines could eventually become fierce   Companies including Teva Pharmaceutical Industries  NYSE TEVA    Eli Lilly   Co and Alder Biopharmaceuticals Inc are developing similar treatments   Analysts  on average  have forecast annual Aimovig sales of nearly  1 billion by 2022  according to Thomson Reuters I B E S  with Novartis sharing a smaller piece of the proceeds  
Novartis and Amgen are selling Aimovig in the United States  Amgen has commercialization rights in Japan  while Novartis has the rights elsewhere ",2018-06-01,Reuters,https://www.investing.com/news/stock-market-news/novartis-readies-antisexism-message-for-migraine-drug-1477631,1477631
148962,370478,AMGN,Biotech s Soon Shiong hiring bankers for Nant cancer drug IPO,news,"By Deena Beasley
LOS ANGELES  Reuters    Billionaire Patrick Soon Shiong plans to take an experimental cancer treatment company public this year and has begun hiring bankers  the biotechnology entrepreneur told Reuters 
The former surgeon said in a recent interview that the new company  to be called Nant  would use most of the money raised from the initial public offering to develop a pipeline of cancer drugs  although the amount of financing has yet to be determined 
Soon Shiong made billions by founding and selling an injectable drugmaker  followed by a company that developed a way to make a chemotherapy drug more effective 
Later  he founded Culver City  California based NantWorks  from which he has spun off two publicly traded companies   cancer testing company NantHealth Inc  O NH  and immunotherapy developer  NantKwest  Inc  N NK  
Shares of both have fallen sharply and losses have mounted amid questions over whether funds from his charitable foundation have been used to drive sales  Soon Shiong called allegations of donations being tied to sales of a cancer diagnostic test  completely untrue  
Earlier this year  he agreed to buy the Los Angeles Times and other California newspapers for  500 million  but the deal has not yet closed 
 Credit Suisse   SIX CSGN  has been hired to work on the Nant IPO  and Soon Shiong said he was in talks with two other investment banks  Credit Suisse declined comment 
Nant s portfolio includes six compounds in clinical trials against nine tumor types  The pipeline includes versions of existing chemotherapy drugs designed to make tumors more recognizable to the immune system  methods of delivering cancer fighting cells to tumors  and immunotherapies 
Soon Shiong believes a multi drug regimen could help cancer patients achieve long term remission 
 Everybody is focusing on one little piece of the puzzle   he said   But the tumor is too smart  It has too many fail safes  We need to attack the entire tumor system  
At least two of Nant s drugs are in late stage trials  Ganitumab  an antibody licensed from  Amgen Inc   O AMGN   blocks a receptor linked to cell growth and is being tested in combination with chemotherapy for advanced sarcoma patients 
Another compound  N 803  targets a protein involved in activating immune system cells and is in late stage development for bladder cancer 
NANTHEALTH AND NANTKWEST
Shares of NantHealth have fallen to  3 41 from their IPO price of  14 in 2015  The company reported a first quarter loss of around  22 million 
NantKwest trades at  3 66  down from  25 when it debuted in 2016  and reported a quarterly net loss near  27 million 
Jefferies analyst Biren Amin rates shares of NantKwest as  hold   Citi Research has a  sell  rating on NantKwest and estimates the company has enough cash for two years of operations  Soon Shiong said NantKwest was exploring  strategic partnerships  to fund clinical trials  He owns controlling stakes and holds the chief executive office of both companies  and will be a majority shareholder in Nant 
Health news website STAT reported last year that Soon Shiong and his charitable foundations in 2014 gave the University of Utah  12 million for disease research  and the university later paid NantHealth  10 million for testing services 
Utah s legislature determined that the university should have sought competitive bids for the testing  but said the donation was not tied to the purchase 
Soon Shiong said of the Utah case   That was a donation our foundation made to the University of Utah  They had an opportunity to go to any vendor  and they came to us  ",2018-06-11,Reuters,https://www.investing.com/news/stock-market-news/biotechs-soonshiong-hiring-bankers-for-nant-cancer-drug-ipo-1487673,1487673
148963,370479,AMGN,Early stage study of Advaxis  cancer candidate ADXS NEO underway,news,The first patient has been dosed in a Phase 1 clinical trial assessing Advaxis   ADXS  ADXS NEO  a personalized immunotherapy targeting cancer neoantigens  in patients with metastatic non small cell lung cancer  NSCLC   metastatic microsatellite stable colon cancer and metastatic squamous head and neck cancer Participants will undergo a biopsy  Advaxis will then manufacture a customized treatment based on an analysis of their tumor neoantigen mutations  a process that takes  eight weeks According to ClinicalTrials gov  the estimated primary completion date is September 2019 The company is co developing ADXS NEO with Amgen  AMGN  0 6    with Advaxis leading development through proof of concept Now read ,2018-06-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/earlystage-study-of-advaxis-cancer-candidate-adxsneo-underway-1488100,1488100
148964,370480,AMGN,Drugmakers try evasion  tougher negotiations to fight new U S  insurer tactic,news,"By Michael Erman and Caroline Humer NEW YORK  Reuters    In the escalating battle over U S  prescription drug prices  major pharmaceutical companies are scrambling to limit the economic damage from a new U S  insurer tactic that coaxes patients away from expensive drugs   The latest move by insurers   which effectively forces drug companies to pay more to assist patients with their copays   is causing a decline in real U S  drug prices this year  and is expected to become more widely adopted in 2019   That reality is forcing drugmakers to devise their own response in the near term  according to interviews with pharmaceutical and insurance industry executives and consultants  Among major drugmakers   AbbVie Inc   NYSE ABBV  and  Amgen Inc   NASDAQ AMGN  have said the most so far about the new tactic  and more drugmakers will likely face questions about it during quarterly earnings calls in July  In recent years  insurers have tried to guide patients toward less expensive treatments by making them pay a higher portion of a drug s costs  Drugmakers responded by dramatically raising the financial aid they offer  in the form of  copay assistance  cards   similar to a debit card   that reduce what consumers need to pay when they place their pharmacy order  Express Scripts Holding Co and CVS Health  NYSE CVS   which manage prescription drug coverage for large U S  employers  say these payments shield consumers from drug costs  making it easier for manufacturers to raise those prices  Insurers have to make up the difference  This year  Express Scripts and others introduced a new  copay accumulator  approach for its corporate customers  The programs prevent copay card funds from counting toward a patient s required out of pocket spending before insurance kicks in on expensive specialty drugs  such as arthritis and HIV treatments   As an example  a patient whose medicine costs  1 000 per month might be required to pay that amount until they reach a deductible of  2 000 set by their insurer  A copay card from the drugmaker would cover most  or all  of those costs for the patient and it would count towards the deductible   When the deductible is reached  the insurance begins to pay  But if the insurance plan is using an accumulator  the patient could still have to pay the  2 000 out of pocket when their copay card expires or runs out of money  Some more aggressive accumulator programs will also draw more money than a drugmaker expected to pay off a copay card when the card is detected    These tactics could force the drugmaker to keep paying the out of pocket costs  Otherwise the patient could move to an equivalent drug if one is available or abandon their prescription because it is too expensive  PHARMA FIGHTS BACK Drugmakers are working on ways to counter copay accumulator programs  fearing that more employer health plans will adopt them in 2019    They include new payment options to evade detection by the pharmacy benefits managers  PBMs  so that a patient still benefits from the financial aid  said Matthew Turner  who is working with drugmakers as director of patient affordability at TrialCard  which operates copay cards for companies  He would not provide details of how those arrangements work  Larger drugmakers may have the financial flexibility to monitor how these accumulator programs affect revenue over time  while those reliant on a small number of drugs may not be able to wait it out  Turner said   Drugmakers are also taking a tougher stance when negotiating prices or new discounts for payers  according to insurance industry executives and pharmaceutical consultants   They have reason for concern  A survey by the National Business Group on Health  NBGH   which represents large corporate employers  showed that 17 percent of respondents said they were currently using a copay accumulator program  Another 18 percent of respondents are considering using one next year or in 2020   Real U S  drug prices  including discounts and rebates  fell 5 6 percent in the first quarter of this year  mostly due to copay accumulator programs  according to Sector and Sovereign Research  Amgen has said that it altered copay assistance cards for arthritis drug Enbrel to work only if the funds are applied to a patient s deductible  The company would not say how it responds when a patient is affected by an accumulator  adding the information was proprietary  AbbVie in April said that about 4 percent of patients taking rival arthritis drug Humira were exposed to accumulators  but that they had no material effect on company profits   Belgium s UCB  which makes a competing drug called Cimzia  said in February that it was reaching out to patients affected by the programs to help them stay on the medication  Savings can be substantial for employers when accumulators coax patients to switch to a drug for which they receive the highest rebate  For instance  rebates to PBMs for Humira and Enbrel can differ by as much as  1 000 per prescription  according to Michael Rea  CEO of Rx Savings Solutions  At CVS Health  accumulator programs help reduce specialty drug spending by about 5 percent for its customers  health plans  spokeswoman Christine Cramer said  Express Scripts and UnitedHealth Group Inc  NYSE UNH   told Reuters they expect the programs to expand   UnitedHealth tracks copay assistance payments at its mail order specialty pharmacy BriovaRx and wants to introduce them to other specialty pharmacies it works with  Chief Medical Officer Dr  Sam Ho said   UnitedHealth calls patients to tell them their copay cards will no longer count towards deductibles  and suggests switching to a less pricey drug  if available  or provides information on charity assistance  he said   When asked how drugmakers have responded to UnitedHealth s program  Dr  Ho said the manufacturers are taking a tough stance in new price negotiations  Kevin Cast  a partner at pharmaceutical consulting firm Archbow Consulting  said drugmakers may be better off providing greater discounts to the PBMs in exchange for ending the copay accumulator  Concocting an alternative payment method is only a temporary fix  he said  
 As soon as a copay card company makes a slight adjustment  they ll figure it out   he said ",2018-07-05,Reuters,https://www.investing.com/news/stock-market-news/drugmakers-try-evasion-tougher-negotiations-to-fight-new-us-insurer-tactic-1518584,1518584
148969,370485,AMGN,Has Amgen  AMGN  Outpaced Other Medical Stocks This Year ,opinion,"For those looking to find strong Medical stocks  it is prudent to search for companies in the group that are outperforming their peers  Amgen  AMGN  is a stock that can certainly grab the attention of many investors  but do its recent returns compare favorably to the sector as a whole  One simple way to answer this question is to take a look at the year to date performance of AMGN and the rest of the Medical group s stocks 
Amgen is one of 889 companies in the Medical group  The Medical group currently sits at  2 within the Zacks Sector Rank  The Zacks Sector Rank considers 16 different sector groups  The average Zacks Rank of the individual stocks within the groups is measured  and the sectors are listed from best to worst 
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks  This system has a long record of success  and these stocks tend to be on track to beat the market over the next one to three months  AMGN is currently sporting a Zacks Rank of  2  Buy  
Over the past three months  the Zacks Consensus Estimate for AMGN s full year earnings has moved 2 81  higher  This is a sign of improving analyst sentiment and a positive earnings outlook trend 
Our latest available data shows that AMGN has returned about 0 47  since the start of the calendar year  Meanwhile  the Medical sector has returned an average of  0 28  on a year to date basis  This shows that Amgen is outperforming its peers so far this year 
Breaking things down more  AMGN is a member of the Medical   Biomedical and Genetics industry  which includes 377 individual companies and currently sits at  79 in the Zacks Industry Rank  Stocks in this group have lost about 6 05  so far this year  so AMGN is performing better this group in terms of year to date returns 
Investors with an interest in Medical stocks should continue to track AMGN  The stock will be looking to continue its solid performance ",2019-10-06,Zacks Investment Research,https://www.investing.com/analysis/has-amgen-amgn-outpaced-other-medical-stocks-this-year-200471103,200471103
148970,370486,AMGN,Roche Announces Positive Late Stage Data On Rituxan In PV,opinion,Roche   OTC RHHBY   announced that the late stage study  PEMPHIX  on its rheumatoid arthritis  RA  drug  MabThera Rituxan for the indication of pemphigus vulgaris  PV  was successful We note that Rituxan became the first biologic therapy for PV after being approved by the FDA in June 2018 and the European Commission in March 2019 The phase III study was designed to evaluate the efficacy and safety of Rituxan compared with mycophenolate mofetil  MMF  in patients with moderate to severe active PV requiring 60 120 mg day oral prednisone  or equivalent  The study met the primary endpoint at week 52 and demonstrated that Rituxan is superior to MMF  In the study  40 3  of patients treated with Rituxan achieved sustained complete remission  CR  without the use of steroids for 16 consecutive weeks or more compared to 9 5  in the MMF arm The PEMPHIX study provided additional clinical evidence of the effectiveness of Rituxan for PV  a rare autoimmune condition characterized by blistering of the skin and mucous membranes Meanwhile  the study is ongoing  with patients participating in a 48 week safety follow up period after treatment completion or discontinuation Notably  the drug is indicated for the treatment of four autoimmune conditions  Rituxan in combination with glucocorticoids is also indicated for the treatment of granulomatosis with polyangiitis  Wegener s granulomatosis  GPA  and microscopic polyangiitis  MPA  in adults In fact  MabThera Rituxan is one of Roche s legacy drugs  However  the drug is facing biosimilar competition in Europe  which is adversely impacting sales Apart from Rituxan  Roche s rheumatology portfolio has a first in class anti IL 6 receptor therapy  Actemra RoActemra  It is approved for RA  polyarticular and systemic juvenile idiopathic arthritis  giant cell arteritis and chimeric antigen receptor T cell induced cytokine release syndrome Roche s stock has gained 16 3  in the year so far against the  s decline of 0 8  The company s performance so far this year has been impressive  propelled by solid sales of new drugs  Strong growth of Ocrevus  Perjeta  Tecentriq  Alecensa and Hemlibra combated biosimilar competition in Europe for Herceptin and MabThera from the likes of Novartis   NYSE NVS   and Amgen   NASDAQ AMGN   Zacks Rank   Stock to ConsiderRoche currently carries a Zacks Rank  4  Sell  A better ranked stock in the healthcare sector is Bristol Myers Squibb   NYSE BMY    which carries a Zacks Rank  2  Buy   You can see  Bristol Myers  earnings per share estimates increased from  4 24 to  4 29 for 2019 over the past 60 days Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-10-13,Zacks Investment Research,https://www.investing.com/analysis/roche-announces-positive-latestage-data-on-rituxan-in-pv-200473147,200473147
148971,370487,AMGN,Lilly Gets FDA Approval For New Oral Tablets For Migraine ,opinion,Eli Lilly   Company   NYSE LLY   announced that the FDA has approved lasmiditan for the treatment of acute migraine headaches  with or without aura  in adults  Lasmiditan  an oral 5 HT1F agonist  is the first and only FDA approved medicine in this class of migraine drugs  Lasmiditan will be marketed by the trade name of Reyvow and will be available in oral doses of 50 mg  100 mg  and 200 mg  once launched The new drug application for Reyvow was based on data from two phase III studies  SAMURAI and SPARTAN  Both the studies met the efficacy endpoints  Data from the studies showed that treatment with Reyvow led to pain freedom and freedom from most bothersome symptoms of migraine at two hours after administration of Reyvow compared to placebo Please note that lasmiditan was added to Lilly s portfolio with the 2017 acquisition of CoLucid Pharmaceuticals Year to date  Lilly s shares have declined 6 3  compared with the  s decrease of 0 8    Reyvow s approval has boosted Lilly s portfolio of pain medicines  which also includes recently launched  Emgality  its CGRP antibody  for the preventive treatment of migraine   Emgality was launched in the United States in September last year  Emgality was approved in the United States for another indication  episodic cluster headache in June 2019  Emgality  a once monthly  self administered  subcutaneous 120 mg injection  could emerge as a significant contributor to long term growth at Lilly  However  it faces strong competition from Teva   NYSE TEVA   and Amgen s   NASDAQ AMGN   CGRPs  Ajovy and Aimovig  respectively  which were also approved in 2018 Lilly s pain portfolio also includes tanezumab  which is being evaluated  in collaboration with Pfizer  Inc    NYSE PFE    Lilly expects to file a NDA for tanezumab for treating osteoarthritis pain next year Lilly currently carries a Zacks Rank  3  Hold  You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-10-13,Zacks Investment Research,https://www.investing.com/analysis/lilly-gets-fda-approval-for-new-oral-tablets-for-migraine-200473197,200473197
148973,370489,AMGN,JNJ Beats  Ups View  Healthcare ETFs To Buy,opinion,Johnson   Johnson   NYSE JNJ   set the ball rolling for pharma earnings when it reported second quarter results on Oct 15  before the opening bell  The world s biggest healthcare products maker continued its long streak of earnings beat and outpaced revenue estimates  It also raised its guidance for the full year Earnings per share came in at  2 12  12 cents ahead of the Zacks Consensus Estimate and 3 4  higher than the year ago quarter  Revenues grew 1 9  year over year to  20 7 billion and edged past the Zacks Consensus Estimate of  20 1 billion  The stronger performance was driven by higher demand for its cancer drug Darzalex and Imbruvica as well as psoriasis drug Stelara For 2019  Johnson   Johnson raised its sales forecast from  81 8  82 3 billion to  80 8  81 6 billion  which represents 0 2  0 7  year over year growth  on robust demand for its cancer drugs  It also upped its earnings per share outlook to  8 62  8 67 from  8 53  8 63  representing year over year growth of 5 4 6   read    The strong results pushed shares of JNJ up by 1 6  at the close  Currently  the stock has a Zacks Rank  4  Sell  and VGM Score of B  However  Johnson   Johnson belongs to a top ranked Zacks industry Rank     suggesting smooth trading in the days ahead ETFs in FocusGiven this  investors should closely watch the movement of the stock and keep a close eye on ETFs having double digit allocation to this diversified drug maker  Below we have highlighted them  see    iShares U S  Pharmaceuticals ETF This ETF provides exposure to 45 companies that manufacture prescription or over the counter drugs or vaccines by tracking the Dow Jones U S  Select Pharmaceuticals Index  Of these  Johnson and Johnson takes the top spot  accounting for 23  share  The product has  321 3 million in AUM and charges 42 bps in fees and expenses  Volume is lower as it exchanges about 16 000 shares a day  The fund has a Zacks ETF Rank  3  Hold  with a High risk outlook iShares Evolved U S  Innovative Healthcare ETF This actively managed ETF employs data science techniques to identify companies with exposure to the innovative healthcare sector  Holding 220 stocks in its basket  JNJ is the top firm with 10 8  allocation  The product has accumulated  4 9 million in its asset base and trades in a meager volume of 2 000 shares per day on average  It charges 18 bps in annual fees  read    Health Care Select Sector SPDR Fund The most popular healthcare ETF  XLV follows the Health Care Select Sector Index  This fund manages nearly  17 billion in its asset base and trades in heavy volume of around 11 million shares  Expense ratio comes in at 0 13   In total  the fund holds 61 securities in its basket  with JNJ taking the top spot at 10 2  of the assets  Pharma accounts for 31 9  share from a sector look  while healthcare equipment and supplies  healthcare providers and services  and biotech have a double digit exposure each  It has a Zacks ETF Rank  2  Buy  with a Medium risk outlook  read    iShares U S  Healthcare ETF This fund offers exposure to 122 securities by tracking the Dow Jones U S  Health Care Index  Here again  Johnson   Johnson dominates the fund s returns with 9 5  of the total assets  In terms of industrial exposure  pharma takes the top spot at 30 2   followed by healthcare equipment  24 7   and biotech  17 9    The product has amassed nearly  2 billion in its asset base and charges 43 bps in annual fees  It trades in a good volume of around 74 000 shares a day and has a Zacks ETF Rank  2 with a Medium risk outlook Vanguard Health Care ETF   ASX VHT  This ETF tracks the MSCI US Investable Market Health Care 25 50 Index and holds 389 stocks in its basket  Of these  Johnson   Johnson occupies the top position with 8 7  allocation  Pharma takes the largest share at 28 5   while healthcare equipment and biotech round off the top three spots  VHT is also one of the popular and liquid ETFs with AUM of  8 6 billion and average daily volume of about 203 000 shares  It charges 10 bps in annual fees and has a Zacks ETF Rank  2 with a Medium risk outlook Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-10-15,Zacks Investment Research,https://www.investing.com/analysis/jnj-beats-ups-view-healthcare-etfs-to-buy-200474157,200474157
148988,370504,AMGN,New Novartis CEO feels heat on U S  generics business,news,"By John Miller ZURICH  Reuters    Swiss drugmaker Novartis   S NOVN  first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U S  generics unit  The stock declined 1 9 percent at 0910 GMT  more than double the fall of the broader European Healthcare index  SXDP  after the company released first quarter earnings  While Narasimhan confirmed 2018 growth targets  his Cosentyx drug for psoriasis and arthritis missed analyst expectations by more than  50 million   And though price pressure on Novartis s Sandoz U S  generics business is no secret  the 18 percent sales decline in the world s biggest market underscores the company s uphill struggle in the U S  to market cheap  copycat pills amid intense competition and buyers seeking to cut costs  Sandoz s U S  business is under review for a possible disposal  but the relentless price battle could make finding a buyer more difficult  especially one willing to pay a reasonable price   At Sandoz  times are tough   said Berenberg analyst Laura Sutcliffe  who has a  hold  rating on the shares   The biggest surprise is that psoriasis drug Cosentyx delivered sales that are a 9 percent miss versus consensus    It is possible we are starting to see the effects of a more competitive landscape in psoriasis   Cosentyx  a pillar for replacing plunging revenue from Novartis s patent expired Gleevec blood cancer drug  boosted revenue by 35 percent to  580 million  Still  that trailed the average analyst forecast of  636 million   Novartis  blamed the impacts on Cosentyx sales on destocking at the specialty pharmacy level  and price concessions it made to help the drug win business in earlier treatment  MIXED BAG Overall  core net income rose 4 percent to  2 98 billion  the Basel based company said  equaling analyst forecasts in a Reuters poll  Sales rose 4 percent in constant currencies to  12 7 billion  beating forecasts for  12 3 billion  Narasimhan  who took over Feb  1  has other reasons for encouragement  His cancer drugs portfolio enjoyed 6 percent growth in the first three months of 2018  while a resurgent Alcon eye care unit profited from demand for products like implantable lenses  Alcon s  1 8 billion sales  up 7 percent  beat analysts   1 6 billion forecast and could increase Novartis s options as it considers spinning off the unit to shareholders to focus on prescription drugs   A spin off could come as early as first half 2019  Novartis said   Operationally  we drove solid growth across all financial metrics  strong performance across our key growth brands  and continued Alcon s strong recovery   Narasimhan said in a statement  He also announced that he had poached Amgen s  O AMGN  John Tsai as his new chief drug developer  Novartis is on track for 2018 core operating profit to rise by a mid to high single digit percentage  it said  Even so  Narasimhan  a U S  citizen and Harvard trained doctor  is not there yet  First quarter core operating profit rose only 4 percent to  3 34 billion  so improvements are needed by year s end   To start 2018  Narasimhan has been aggressively managing his portfolio  unloading a consumer health venture to GlaxoSmithKline  L GSK  and adding gene therapy hopeful AveXis  O AVXS  for  8 7 billion  
The deal for AveXis  whose top spinal muscular atrophy prospect is expected to have multiple billion dollar annual sales potential  shows Narasimhan is hunting for targets that could run to  10 billion ",2018-04-19,Reuters,https://www.investing.com/news/stock-market-news/novartis-confirms-2018-targets-as-alcon-recovery-gains-steam-1402621,1402621
148991,370507,AMGN,Incyte Treats First Patient In Phase III Vitiligo Study ,opinion,Incyte   NASDAQ INCY   announced that the first patient has been treated in the TRuE V clinical program evaluating the cream formulation of ruxolitinib as monotherapy for vitiligo The TRuE V clinical program includes two phase III studies   TRuE V1  NCT04052425  and TRuE V2  NCT04057573    evaluating the safety and efficacy of ruxolitinib cream in patients with vitiligo  a chronic autoimmune disease Both studies will enroll approximately 300 patients  age either 12 years or above  who have been diagnosed with non segmental vitiligo and have depigmented areas including at least 0 5  of the body surface area  BSA  on the face with a facial vitiligo area severity index  F VASI  score of equal or greater than 0 5   The patients who will be enrolled should also have at least 3  BSA on non facial areas  a total body Vitiligo Area Scoring Index score of equal to or greater than 3 and total BSA involvement  facial and nonfacial  of up to 10  We note that ruxolitinib  an oral JAK1 and JAK2 inhibitor  is marketed as tablets under the brand name  Jakafi  for the treatment of adults with myelofibrosis  adults with polycythemia vera  who have had an inadequate response to or are intolerant of hydroxyurea  and adult and pediatric patients aged 12 years or older suffering from steroid refractory acute graft versus host disease  GVHD  The cream formulation is currently in phase III development for the treatment of patients with mild to moderate atopic dermatitis  TRuE AD   with initial results expected in the first half of 2020  It is also being evaluated for the treatment of adolescents and adults with vitiligo  TRuE V  There are currently no approved treatments in the United States and Europe for the treatment of vitiligo and potential label expansion will drive the top line Shares of the company have gained 18 1  in the year so far against the  s 3 8  decline Jakafi is Incyte s lead drug  The company has a collaboration agreement with Novartis   NYSE NVS   for the same  It has a second JAK1 and JAK2 inhibitor  baricitinib  in collaboration with Eli Lilly   NYSE LLY    Per the terms  Lilly owns exclusive worldwide development and commercialization rights to the compound for inflammatory and autoimmune diseases The company s efforts to diversify its revenue base are impressive  but pipeline setbacks are a concern Zacks Rank   Stock to ConsiderIncyte currently carries a Zacks Rank  3  Hold  A better ranked stock in the biotech sector is Amgen  Inc    NASDAQ AMGN    which carries a Zacks Rank  2  Buy   You can see  Earnings estimates for Amgen have increased 40 cents for 2019 in the past sixty days Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-09-25,Zacks Investment Research,https://www.investing.com/analysis/incyte-treats-first-patient-in-phase-iii-vitiligo-study-200468347,200468347
148992,370508,AMGN,Cutting Rates 50 Bps  Smart  Dumb  Not Enough ,opinion," 0 15    Fed Rate Cut Again  What Does This Mean  1 55    Is There A Recession On The Horizon  2 50    John Blank s Top Stock PicksPodcast Zacks comAs was anticipated  the Fed cut the Fed Funds rate a quarter point  But for our Chief Equity Strategist and Economist  John Blank  it s hard to say what the real justification for this was  He joins me now 
1  What s your rationale here John 
2  Many investors considered this an underwhelming decision  Should there have been a deeper cut 
3  So was this the right move at this point 
4  Do you think the central bank is preparing to act more often in 2020 
5  Do you see an imminent U S  economic downturn coming 
6  What do you think other central banks will do in light of this move by the Fed 
7  Stocks on your radar currently include Amgen  AMGN   Tokyo Electron  TOELY  and Kinross Gold  KGC   Why these 
Chief Equity Strategist   Economist  John Blank  on interest rates and the Global Markets  With John  I m Terry Ruffolo 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana       Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-09-26,Zacks Investment Research,https://www.investing.com/analysis/cutting-rates-50-bps-smart-dumb-not-enough-200468527,200468527
148993,370509,AMGN,Amgen  AMGN  Stock Moves  0 23   What You Should Know,opinion,"Amgen  AMGN  closed at  194 94 in the latest trading session  marking a  0 23  move from the prior day  This move was narrower than the S P 500 s daily loss of 0 53   Elsewhere  the Dow lost 0 26   while the tech heavy Nasdaq lost 1 13  
Coming into today  shares of the world s largest biotech drugmaker had lost 5 6  in the past month  In that same time  the Medical sector lost 0 4   while the S P 500 gained 3 59  
Wall Street will be looking for positivity from AMGN as it approaches its next earnings report date  On that day  AMGN is projected to report earnings of  3 47 per share  which would represent a year over year decline of 5 96   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  5 63 billion  down 4 63  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  14 30 per share and revenue of  22 81 billion  which would represent changes of  0 69  and  3 96   respectively  from the prior year 
Investors should also note any recent changes to analyst estimates for AMGN  These revisions typically reflect the latest short term business trends  which can change frequently  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  The Zacks Consensus EPS estimate has moved 0 04  higher within the past month  AMGN is holding a Zacks Rank of  2  Buy  right now 
Valuation is also important  so investors should note that AMGN has a Forward P E ratio of 13 67 right now  This valuation marks a discount compared to its industry s average Forward P E of 28 16 
Meanwhile  AMGN s PEG ratio is currently 2 54  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  Medical   Biomedical and Genetics stocks are  on average  holding a PEG ratio of 1 66 based on yesterday s closing prices 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 86  putting it in the top 34  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-09-27,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-stock-moves-023-what-you-should-know-200468860,200468860
148994,370510,AMGN,Should Value Investors Buy Amgen  AMGN  Stock ,opinion,"Here at Zacks  our focus is on the proven Zacks Rank system  which emphasizes earnings estimates and estimate revisions to find great stocks  Nevertheless  we are always paying attention to the latest value  growth  and momentum trends to underscore strong picks 
Looking at the history of these trends  perhaps none is more beloved than value investing  This strategy simply looks to identify companies that are being undervalued by the broader market  Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large 
On top of the Zacks Rank  investors can also look at our innovative Style Scores system to find stocks with specific traits  For example  value investors will want to focus on the  Value  category  Stocks with high Zacks Ranks and  A  grades for Value will be some of the highest quality value stocks on the market today 
One company value investors might notice is Amgen  AMGN   AMGN is currently holding a Zacks Rank of  2  Buy  and a Value grade of A 
We also note that AMGN holds a PEG ratio of 2 40  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  AMGN s industry has an average PEG of 3 62 right now  AMGN s PEG has been as high as 2 43 and as low as 1 76  with a median of 2 12  all within the past year 
Value investors also use the P S ratio  The P S ratio is is calculated as price divided by sales  Some people prefer this metric because sales are harder to manipulate on an income statement  This means it could be a truer performance indicator  AMGN has a P S ratio of 4 93  This compares to its industry s average P S of 12 48 
Value investors will likely look at more than just these metrics  but the above data helps show that Amgen is likely undervalued currently  And when considering the strength of its earnings outlook  AMGN sticks out at as one of the market s strongest value stocks ",2019-09-30,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-buy-amgen-amgn-stock-200469626,200469626
148996,370512,AMGN,OSE Immunotherapeutics  R D Progress Triggers Milestone Payment Windfall,opinion,"OSE Immunotherapeutics  PA OSE  now has four clinical trials running  Interim results from its Phase III Atalante 1 trial with cancer vaccine Tedopi are a key catalyst and due in Q120  Another three trials were initiated over the last 12 months  which brought OSE a total of  27m in payments from partners  plus another  5 4m from Bpifrance   These trials include a Phase I study with OSE 127  partnered with Servier   a Phase I study with BI 765063  previously OSE 172  with Boehringer Ingelheim  BI  and a Phase II study with Tedopi in pancreatic cancer  GERCOR   We raise our valuation of OSE to  198m or  13 2 share  previously  190m  




Phase III Atalante 1 interim results in Q120
Although OSE has a broad and diversified R D pipeline  much of the focus until early 2020  Q120  will be on the Phase III Atalante 1 trial with a peptide cancer vaccine Tedopi for second  and third line treatment of non small cell lung cancer patients  NSCLC   OSE hosted a Tedopi focused KOL event in New York in May 2019  where the presenters provided a detailed overview of the cancer vaccine s development and of target indications NSCLC and pancreatic cancer 
Self sufficient R D
In addition to Phase III Atalante 1  funded by OSE   Tedopi is being tested in a Phase II trial in pancreatic cancer patients  which is run by OSE s partner GERCOR  a physician network   Another two trials were initiated earlier this year and both are financed by partners  These include a Phase I study with BI 765063  OSE 172   a SIRP  antagonist for solid tumours  which is run by OSE but funded by BI  which paid  15m in milestones on initiation of the trial  According to the terms of the licensing deal with BI  OSE is still eligible to receive up to  1 1bn in milestones plus royalties if certain conditions are met  Similarly  OSE initiated a Phase I trial with its OSE 127 IL 7R   CD127  antagonist for autoimmune diseases  which triggered a  12m payment  Servier exercised an option  total value of the deal  272m  of which  22m has been received  
Valuation   198m or  13 2 share
We have raised our valuation of OSE to  198m or  13 2 share from  190m or  12 8 share previously  which is due to a better cash position  rolling our model forward and increasing the probability of success to 10  for BI 765063  OSE 172  as the Phase I trial has been initiated  The milestone payments from Servier and BI had virtually no effect as we have already included them in our model  The interim results from the Phase III Atalante 1 trials are the main catalyst in the near term 
Business description
OSE Immunotherapeutics is an immunotherapy company based in Nantes and Paris  France  and listed on the Euronext Paris exchange  OSE is developing immunotherapies for the treatment of solid tumours and autoimmune diseases and has established several partnerships with large pharma companies 
Tedopi KOL event  interim Atalante 1 trial data in Q120
On 30 May 2019  OSE hosted a KOL day in New York  which focused on Tedopi  NSCLC and pancreatic cancer  The presentations provided more detailed background on the development of Tedopi and an overview of the target cancer indications  Overall  we view the update as in line with our discussions in our initiation report  Although OSE has a well balanced R D pipeline in terms of asset stages and technology types  the focus on Tedopi will prevail due to a combination of factors  It is the most advanced OSE asset in development and interim analysis will be carried out in Q120  which will also include some efficacy data  this makes it a substantial catalyst for OSE 
Atalante 1 is a Phase III trial with Tedopi as second  or third line treatment against standard of care  docetaxel or pemetrexed  in HLA A2 positive patients with locally advanced  IIIB   unsuitable for radiotherapy or metastatic  IV  NSCLC  Post checkpoint failure patients represent an area where no novel treatment has been approved yet  The trial aims to enrol 300 patients  Interim analysis is expected in Q120  which will include survival data from the first 84 patients  This is a significant catalyst for OSE  although the final results should come later in 2021  OSE presented case reports from three patients from the Atalante 1 trial at AACR in Atlanta on 31 March 2019  which we discussed in our last update report 
At the end of 2018  OSE s partner GERCOR  a physician network  initiated a Phase II trial with Tedopi as maintenance therapy alone or in combination with Opdivo or FOLFIRI in pancreatic cancer after induction therapy with FOLFIRINOX  Bristol Myers Squibb  NYSE BMY  is supporting the trial by providing Opdivo for free  Results are expected in 2022  Pancreatic cancer represents an unmet need with relatively little advance in treatment compared to most other cancers over the last decade  Pancreatic cancer is a  cold  tumour  so the rationale is to combine immune priming cancer vaccine Tedopi  stimulates specific T cell response  with checkpoint inhibitors  makes tumours  visible  to the immune system   OSE will evaluate options for further development and commercialisation depending on the results of this study 
Exhibit 1  OSE s pipeline




BI 765063  First patient enrolled in Ph I  milestone paid
OSE announced on 17 June 2019 that the first patient had been dosed in the Phase I study with BI 765063  OSE 172   a monoclonal antibody antagonist of SIRP   that OSE licensed to BI  This triggered the second part of the  15m milestone payment from BI as expected  we only adjusted the milestone with 95  probability in our model   OSE is still eligible to receive up to a further  1 1bn in milestones plus royalties if certain milestones are met 
The full clinical trial design is now available  Exhibit 2   It is an open label  dose finding Phase I study of BI 765063  OSE 172  as single agent and in combination with BI 754091  anti PD 1  to characterise safety  PK PD and preliminary efficacy in patients with advanced solid tumours  OSE is responsible for running the trial but BI bears the costs  according to the collaboration and licensing agreement  BI will take over the development after Phase I 
In total 116 patients with advanced metastatic tumours are expected to be enrolled  The study includes two steps and four cohorts  essentially two dose escalation cohorts and two expansion cohorts  BI 765063 standalone and BI 765063 in combination with BI s own anti PD 1   The dose escalation cohorts are enrolling patients with advanced metastatic primary or recurrent malignancies who failed or are not eligible to standard therapy  Then the expansion cohorts will be restricted to selected cancers  see Exhibit 2 notes for the list  




Combining BI 765063 with a PD 1 inhibitor is based on the complementary mechanisms of action of the two agents  That is  CD47 SIRP  inhibition should lead to phagocytosis of tumour cells by myeloid cells  this leads to tumour antigen uptake and presentation  which should activate the adaptive immune system  namely  T cells killing tumour cells  which in turn is facilitated by PD 1 PD L1 inhibition  OSE recently published an article describing the role of SIRP  in the induction and maintenance of immune tolerance and a poster presentation supporting the combination of a SIRP  monoclonal antibody and checkpoint inhibitor  anti PD L1 not anti PD 1 as in the Phase I study   These pre clinical studies add support to OSE s strategy  As with many Phase I cancer trials  the indications are quite broad at the moment but will focus on the most promising cancers in further trials 
BiCKI bispecific platform  PD 1   innovative targets
OSE presented its new BiCKI platform at the World Immunotherapy Congress in San Diego on 5 March 2019  This included some information about the bispecific fusion antibody platform and included a lot of information on the first potential bispecific candidate  BiCKI IL 7  While we do not include any new assets in our valuation  we conducted a more detailed review of the platform and the opportunities 
Bispecifics and other types of antibodies can bind multiple targets  BiCKI is a bispecific fusion antibody platform  Exhibit 3  that consists of 
A humanised high affinity anti PD 1 monoclonal antibody  blue Y in Exhibit 3   OSE has developed its own anti PD 1 antibody that forms the  backbone  of the bispecifics  So far there is limited information about this anti PD 1 but OSE indicated it was chosen due to its good yield in terms of manufacturing and productivity  in particular in bispecific format  This is an IgG antibody in that it has a normal structure with heavy and light chains  where the Fab region binds to the PD 1 receptor on T cells 
Engineered proteins attached to the Fc region  green circles in Exhibit 3   The silent Fc region of the antibody  base of the heavy chains  is the effector part of the molecule  It determines what effect the antibody has once it has bound to the antigen   usually an immune response  OSE plans to engineer different proteins to the Fc region  eg IL 7  through protein fusion to target novel receptors 




Exhibit 3  BiCKI platform  left  and BiCKI IL 7 mechanism of action on T cells  right 
OSE hopes these anti PD 1 bispecifics will help overcome the resistance  primary and secondary  depending on the second target  to anti PD 1 drugs by selecting targets that are involved in different stages of the immunity cycle and so are complementary  In particular  OSE is looking for targets that would have synergistic potential 
OSE s first candidate based on this platform is BiCKI IL 7  Exhibit 3   OSE is already working with the IL 7 receptor  IL 7R  from the OSE 703 and OSE 127 programmes  so has experience in this area with a cytotoxic agonist asset  OSE suggested a few mechanisms of action for BiCKI IL 7 during the BiCKI presentation in March 2019  but perhaps the most important is that IL 7R sustains the life of exhausted T cells  IL 7 is a cytokine that controls the proliferation  apoptosis and activation of CD4  and CD8  T cells in humans  IL 7R  expression is reduced in exhausted T cells  Activating the IL 7R  receptor with IL 7 should reduce T cell exhaustion  The main advantage of the bispecific drug  over a combination of two drugs  anti PD 1 with IL 7  is that BiCKI IL 7 synergistically increases TCR signalling and hence antigen specific T cells responses 
OSE presented the first preclinical data with its BiCKI IL 7 technology at the International Cancer Immunotherapy Conference  CICON  25 28 September  2019  in Paris  The company showed that the bifunctional anti PD1 IL 7 fusion protein potentiates effector function of exhausted T cells and disarms the suppressive activity of regulatory T cells 
Large biotech pharma are getting in early on bispecifics
Many players are trying to tackle the resistance to checkpoint inhibitors issue through developing combination therapies and bispecifics to solve the same problem  Some existing projects in the anti PD 1 bispecifics space are listed in Exhibit 4  The most advanced candidates are in Phase I  There are a few companies trying to use bispecifics to target multiple checkpoints  eg XmAb20717 targets both PD 1 and CTLA 4  with the aim of further reducing any T cell inhibition by tumour cells and promoting T cell activation 




The bispecifics field has recently become a popular area  There are three bispecific antibodies  they do not target checkpoint receptors  that have been approved   Blincyto  blinatumomab  Amgen  NASDAQ AMGN    Hemlibra  emicizumab  Roche  and Removab  catumaxomab  Fresenius now withdrawn   but there are many more in clinical stages  57 individual bispecifics according to EvaluatePharma   They are being developed for both oncology and immunology indications 




Most of the programmes are still very early stage therefore the existing deals are for bispecific platforms and pre clinical programmes  There have been several large deals  Exhibit 5   which is promising for OSE  Most of the pre clinical deals in Exhibit 5 include a collaboration based on the licensor s bispecific platform plus rights for their existing pre clinical bispecific programmes  These deals achieved between  45 150m in upfront payments and  180 1 700m in milestone payments  for platform plus existing programmes   depending on the number of candidates included in the deal  As there is an appetite for bispecifics platforms and bispecific candidates from pharma  OSE s decision to invest in BiCKI seems well founded 
Financials
OSE reported a top line of  16 0m in H119  which was mostly a milestone from BI  the rest is R D cost reimbursement to OSE   The milestone payment of  10m from Servier was booked as prepaid income  cash balanced with deferred income plus  2m in VAT received as OSE and Servier are both French companies   Total H119 operating expenses were  12 1m  of which R D costs and overhead expenses amounted to  9 2m and  2 9m respectively  resulting in an operating profit of  3 9m  R D costs are mainly associated with the Tedopi Phase III NSCLC study  Our full 2019 and 2020 estimated operating expenses were  19 6m and  19 7m  which we now revise to  22 7m and  22 8m 
As of end H119  OSE had cash  cash equivalents and financial assets of  26 5m  includes  current financial assets    The balance sheet also includes debt of  5 1m  which is mainly government loans  In September 2019  OSE announced it had received a  5 4m milestone payment from Bpifrance  the French public investment bank  in connection to the initiation of the Phase I trial with BI 765063   4 8m as a loan and  0 6m as income  as well  As part of a research consortium with the L on B rard cancer research centre  OSE also received a grant of  800k from the French National Research Agency  which will support preclinical research focused on validation of new targets linked to myeloid cells  Our model implies a comfortable cash reach to around end of 2020 
Valuation
We have raised our valuation of OSE to  198m or  13 2 share from  190m or  12 8 share previously  The increase is due to a better cash position and rolling our model forward  but is also a result of increased probability of success to a standard 10  for BI 765063  OSE 172  as the Phase I trial has now been initiated  previously we used a slightly discounted probability of 7 5    The milestone payment from Servier and BI had no effect as we have already included them in our model  now moved from respective projects to cash in Exhibit 6   We make no other changes to our assumptions  described in detail in our initiation report 




We include Tedopi NSCLC  FR104  OSE 127 and OSE 172 in our valuation  Although GERCOR has initiated the Phase II study with Tedopi in pancreatic cancer  we still do not include this indication in the valuation because its commercial strategy has not been confirmed   OSE will evaluate this based on the Phase II results  We do not include the new bispecific platform in the valuation because it is still in a pre clinical stage ",2019-10-01,Edison,https://www.investing.com/analysis/ose-immunotherapeutics-rd-progress-triggers-milestone-payment-windfall-200469407,200469407
148998,370514,AMGN,Why The Earnings Surprise Streak Could Continue For Amgen  AMGN ,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering Amgen  AMGN   which belongs to the Zacks Medical   Biomedical and Genetics industry 
This world s largest biotech drugmaker has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 7 04  
For the last reported quarter  Amgen came out with earnings of  3 97 per share versus the Zacks Consensus Estimate of  3 58 per share  representing a surprise of 10 89   For the previous quarter  the company was expected to post earnings of  3 45 per share and it actually produced earnings of  3 56 per share  delivering a surprise of 3 19  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for Amgen  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Amgen currently has an Earnings ESP of  2 31   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  2  Buy  indicates that another beat is possibly around the corner 
Investors should note  however  that a negative Earnings ESP reading is not indicative of an earnings miss  but a negative value does reduce the predictive power of this metric 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-10-01,Zacks Investment Research,https://www.investing.com/analysis/why-the-earnings-surprise-streak-could-continue-for-amgen-amgn-200469969,200469969
149012,370528,AMGN,Akebia and Otsuka tweak design of late stage vadadustat studies  marketing approval in Japan may be 2021  shares down 2 ,news,In an update to investors  Akebia Therapeutics  AKBA  1 6   announces that it and commercialization partner Mitsubishi Tanabe Pharma have changed the designs of two Japan based Phase 3 studies  FO2RWARD and TRILO2GY  evaluating vadadustat in patients with anemia associated with dialysis dependent chronic kidney disease   DD CKD   FO2RWARD will now include a broader dialysis population and larger sample size with once daily and 3x week dosing  It is designed to inform ESA  erythropoietin stimulating agent  switching protocols  The study will be initiated next quarter with top line data expected by year end early 2019 TRILO2GY will also include a larger sample size and once daily and 3x week dosing  It is designed to inform switching from Amgen  NASDAQ AMGN  s Epogen  epoetin alfa  and Aranesp  darbepoetin alfa  and Vifor Pharma s Mircera  methoxy PEG epoetin beta   The study will launch by year end early 2019 with top line results expected in early 2020 Akebia s two U S  Phase 3s  INNO2VATE and PRO2TECT  should hit their enrollment targets by year end  Top line data are expected in 2019 with market launch to follow on 2020 assuming positive results and the accrual of the required number of major adverse cardiac events  MACE  Previously  Akebia s vadadustat shows positive results in Japan based anemia study  Jan  4 Now read ,2018-02-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/akebia-and-otsuka-tweak-design-of-latestage-vadadustat-studies-marketing-approval-in-japan-may-be-2021-shares-down-2-1231752,1231752
149013,370529,AMGN,Tenax to reverse split stock 1 20  shares down 13  premarket,news,Aimed at regaining compliance with Nasdaq s  1 minimum bid price requirement  Tenax Therapeutics  NASDAQ TENX  will execute a 1 20 reverse split of its common stock after the close  Post split trading will commence on Monday  February 26 Shares are down 13  premarket on light volume Now read ,2018-02-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/tenax-to-reverse-split-stock-120-shares-down-13-premarket-1301867,1301867
149014,370530,AMGN,Amgen to acquire   10B in stock in tender offer,news,Preliminary results from Amgen s  AMGN  0 3   modified Dutch auction tender offer for shares of its common stock showed  54 3M shares were tendered at  192 per share The company expects to acquire  52 1M shares at  192 for a total of   10B  The number of shares represents  7 2  of its outstanding stock Now read ,2018-03-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgen-to-acquire-10b-in-stock-in-tender-offer-1327192,1327192
149015,370531,AMGN,Singapore pharma on recovery path after worst output in decades,news,By Masayuki Kitano and John Geddie SINGAPORE  Reuters    Singapore s pharmaceuticals business  among the pillars of the city state s manufacturing sector  is set to return to strength this year as big global drugmakers ramp up output and advance automation at their production sites across the country  A recovery from dismal 2017  which marked the sector s worst contraction in two decades  would underpin Singapore s economic growth  Pharmaceuticals is the No 2 contributor to the country s manufacturing output and accounts for 3 percent of its GDP  The sector will see a  robust  2018  Singapore s Economic Development Board  EDB  told Reuters   The opening of new sites like AbbVie s  N ABBV  biologics manufacturing facility and the ramp up of others including Amgen  O AMGN  and  Novartis   S NOVN  reflect strong fundamentals     we expect the manufacturing activity to remain robust for 2018   said Ho Weng Si  director of biomedical sciences for EDB   Outlook for the industry as a whole remains positive for the next few years   Ho added  citing the pace of new drug approvals by the U S  Food and Drug Administration that hit a 21 year high in 2017  Singapore is well placed to benefit from this uptick in approvals as it hosts facilities of eight of the world s top 10 drugmakers   such as Roche  S ROG   GlaxoSmithKline  L GSK    Pfizer   N PFE  and Sanofi  PA SASY    Sanofi  which in Singapore mainly produces ingredients for blood thinning drugs shipped globally  told Reuters it expects production  to be relatively stable to slightly increasing in coming years  as it invests to upgrade capacity  A quarterly EDB survey of the manufacturing sector shows the pharmaceuticals industry is the most optimistic about production over January March  with a net weighted balance of 56 percent of firms expecting output to rise from the preceding three months  EDB s Ho and the survey did not provide a specific forecast  Data for January shows pharmaceutical production dropped  albeit at a milder pace  Output shrank 15 6 percent in 2017  the largest annual contraction since at least 1993  Singapore s pharmaceutical output has risen more than three fold since the start of this century  with the sector generating S 17 billion   13 billion  worth of products last year    For a graphic on  Singapore s pharmaceuticals output coming off a weak year  click   ADVANCEMENTS IN TECHNOLOGY  AUTOMATION  The outlook for recovery  however  is not free of headwinds  Output in pharmaceuticals is inherently volatile because production happens in batches  which can take anywhere from a few days to weeks to make  But thanks to advancements in technology  industry players are hoping to achieve more consistent production levels  GSK  which has been manufacturing in Singapore for nearly 50 years  has been pioneering a technology called continuous manufacturing where instead of making products in batches  materials are constantly added and products removed   Last year  for the first time products were commercially made using this technology   The pharma industry has to progress on the technology front     to ensure we increase productivity   said Lim Hock Heng  a site director in Singapore for GSK  Mundipharma hopes to start commercial production of antiseptics at its new plant in Singapore as early as the fourth quarter of 2019   which according to CEO Raman Singh  will be the most automated plant in the world compared to any other competitors  ,2018-03-25,Reuters,https://www.investing.com/news/stock-market-news/singapore-pharma-on-recovery-path-after-worst-output-in-decades-1359115,1359115
149024,370540,AMGN,The Zacks Analyst Blog Highlights  Amgen  Tokyo Electron And Kinross Gold,opinion,For Immediate ReleaseChicago  IL   September 17  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Amgen   NASDAQ AMGN    Tokyo Electron   OTC TOELY   and Kinross Gold   NYSE KGC   Here are highlights from Monday s Analyst Blog  Why Cut the Fed Funds Rate Again  Global Week Ahead This is a Fed meeting week  On Wednesday  Fed Chair Powell is widely anticipated to cut the Fed Funds rate another 25 basis points With a U S  consensus forecast for a tad above 2 0  U S  real GDP growth rate  a core U S  CPI tracking near  2 0  in y y terms  and a U S  3 7  household unemployment rate  the Fed s statutory mandate of stable consumer prices and full employment is clearly and succinctly met For this economist  it is hard to say what is the real justification It could be to keep policy and risk free benchmark U S  Treasury rates in alignment with the ECB s easing last week  It could be to alleviate trade war uncertainty  It could be to assist in next year s U S  Presidential election Most likely  it is all of the above  I placed them in order of their likely emphasis  too Next  I have Reuters  five world market themes for the Global Week Ahead  leaving them in order of importance for equity market traders  Yes  the Fed Meeting leads  But don t forget about the many central bank meetings that conclude the following day  1  The Fed Meets Tuesday and WednesdayInvestors around the globe are bracing for a second rate cut from the U S  Federal Reserve at its policy setting Federal Open Market Committee on Sept  17 18 Fed Chair Jerome Powell recently said that the central bank remained committed to keeping the U S  economic expansion going  signaling he and his colleagues are likely to cut interest rates into 2020  But even so  President Donald Trump has made life a little harder for Powell Trump again lambasted the Fed following an European Central Bank rate cut Thursday that sent the euro lower  tweeting the ECB was  succeeding  in  depreciating the Euro against the VERY strong Dollar  hurting U S  exports  while the Fed  sits  and sits  and sits  Powell acknowledged  a range of views  among policymakers  his careful wording reflects a split within the U S  central bank about how best to respond to an economy where the job market and consumer spending are holding up but trade tensions between Beijing and Washington  Britain s possibly messy exit from the European Union and a broad global slowdown pose risks The Fed cut rates for the first time in more than a decade in July  Market pricing suggests that investors expect another quarter point reduction next week  2  Lots of Central Banks Will Follow Suit ThursdayAfter the European Central Bank s bazooka  the wait is on to see what the message is from other central banks  The Fed of course will cut rates by a quarter point on Wednesday  But Thursday brings policy meetings in Japan  Britain  Norway and Switzerland The Bank of Japan  sources say  will discuss further easing  it may even decide to act to head off further economic pain  a third of analysts in a Reuters poll predict  Upcoming trade and inflation data should show Japan s export slump deepening and inflation at two year lows  But its dilemma is the same as elsewhere  How to inject stimulus without hurting banks any further  and how to make it effective Switzerland  with a  0 75  interest rate  is quiet so far on the prospect of emulating ECB easing but will be concerned at the franc s surge to two year highs versus the euro  On the other hand  the relentless rise in SNB  sight deposits  is hardly tenable  These are at almost 600 billion francs as the SNB intervenes to tamp down the franc Brexit clouds the Bank of England s strategy but Norway  one of very few central banks still pressing on with rate rises  could hike again on Sept  19  But with easing gathering steam all around  it is very likely to mark the end of its tightening cycle There is excitement also in emerging markets  where Brazil is expected to cut 50 bps on Wednesday  South Africa s central bank also meets on Thursday  though is not expected to move  But these days  you never know  3  Can a Mini Trade Deal Be Struck in October Financial markets were quick to seize on recent conciliatory messages and measures between Beijing and Washington as a hopeful sign of an imminent deal in the protracted trade war  Yet that may be as much a symptom of fatigue   from the unremitting tweets and retorts   as genuine optimism A Reuters poll of 60 economists shows 80  expect relations between Beijing and the Trump administration to deteriorate or at best hold steady until end 2020 The week saw Beijing exempt some agricultural products from additional tariffs on U S  goods and Trump delay a tariff increase on certain Chinese goods by two weeks  Junior U S  and Chinese officials meet in the coming week  followed by talks between senior trade negotiators in early October Meanwhile  the IMF has issued dire warnings of a drop in global economic growth next year  China s neighbors are seeing growth rates slide as their exports to the mainland collapse Some are looking for upsides  Vietnam has been a beneficiary of businesses seeking to move or alter trade routes  Thailand just announced a package of tax incentives  investment zones and new legislation that would draw in companies from China  Japan  Taiwan and South Korea  But if tensions are shrinking the world trade pie  any feasting in Southeast Asia may be short lived China also reports industrial output and retails sales data for August on Monday  4  Brexit and Boris Johnson  The Same IssueBritain s never ending Brexit drama is set to reach fever pitch again   this time in the country s top court Prime Minister Boris Johnson will challenge a ruling of Scotland s highest court of appeal that his decision to suspend  or prorogue  parliament for five weeks was unlawful and should be annulled  Gina Miller will appeal a rejection of her challenge for a judicial review of Johnson s decision to prorogue parliament  Both cases are scheduled to be heard by U K  s Supreme Court on Tuesday Proroguing parliament until Oct  14 was seen by most as a tactical move from Johnson to make sure he maintains a strong negotiating hand with Brussels Johnson wanted to show he can deliver a no deal Brexit on Oct  31  Most investors believed him  sending the pound sharply lower at the start of the month  to levels not seen since 1985 But the tables seem to have turned for now  Parliament managed to pass a law that forces Johnson to extend Brexit if a deal isn t reached by Oct  19  Traders say this has definitely reduced the probability of a no deal Brexit on Oct  31  though the risks of a no deal Brexit down the road was still high  5  Will Emerging Markets Finally Be the Place to Be If the Fed goes big with its rate cut on Wednesday  the place to be will probably be the riskier parts of the world that still have interest rates you can see with the naked eye Low rates in the United States and sub zero ones in core Europe and Japan mean high yield bonds from places like Turkey  Ukraine  Ecuador  Egypt  Brazil or parts of sub Saharan Africa look ever more attractive There is a catch up factor in play too  August was a torrid month for these countries  assets  Argentina s slump into crisis made it worse  of course  but the underperformance between high yield emerging market sovereign debt and that the safer  investment grade   IG  emerging market countries  was one of the most severe ever   roughly  3  returns versus  3  for IG emerging markets debt Turkey s jumbo rate cut this week helped speed that catch up process but a dove bomb from the Fed on Wednesday as well as a big chop from Brazil and more soothing trade war sounds will all help it along nicely Top Zacks  1 Rank StocksAmgen  Health Care stocks have been overlooked in this rally  So far  This Zacks  1 Rank stock has a Zacks Value Score of B and a Growth score of D  2  Tokyo Electron  Japanese stocks have rallied recently  This premier chip stock is no exception  This is a  32B market cap stock with a  48 share price  It carries a Zacks Value Score of D and Growth Score of D  3  Kinross Gold  This is a  5 9B market cap gold miner  whose shares trade at  4 72  The Zacks Value Score is A  the Growth Score is A  and the Momentum Score is A What s wrong with that  Nothing  other than the price of gold may have already run up  and all the good news is fully priced in  As a cheap stock  though  there may be more to go Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-amgen-tokyo-electron-and-kinross-gold-200465394,200465394
149025,370541,AMGN,5 Safe Bets For A Rocky Market,opinion,"We don t need to regurgitate what s going on in the market to know that things just aren t too stable now  okay  that s an understatement   We have an ongoing trade war  we have border tensions  we have material price escalation  we have farmers complaining  and finally  we may have the onset of war in the Middle East 
So with all that going on and the president looking for negative interest rates  there s just so much you can do with your money  And yet  some people are better off than others  because they re going by certain principles of operation 
So  I don t know about you  but when I m confused about the best course of action  I tend to lean on experts  on people who know what they re doing  and have been relatively more consistent with what they deliver 
Yes  I m talking about good management  because maybe  just maybe  they ll be able to take you through this and also help you generate a small income 
So today  the stocks I ve picked on have a Zacks Rank  1  Strong Buy   Catch the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
They have a return on equity  ROE  of over 20   have delivered an average return on assets  ROA  of over 12  in the last 5 years  pay a dividend and have a current ratio of over 2  so there s no liquidity crisis  
Without further ado  let s see which ones they are 
Amgen Inc    NASDAQ AMGN  
Amgen discovers  develops and delivers innovative human therapeutics  A biotechnology pioneer  Amgen was one of the first companies to realize the new science s promise by bringing safe and effective medicines from the lab  to manufacturing plant  and to patients  Amgen therapeutics have changed the practice of medicine  helping millions of people around the world in the fight against cancer  kidney disease  rheumatoid arthritis  and other serious illnesses  With a deep and broad pipeline of potential new medicines  Amgen remains committed to advancing science to dramatically improve people s lives 
Zacks Rank  1
ROE 76 17 
ROA 11 74 
Dividend Yield 2 97 
Current Ratio 2 89X

Bristol Myers Squibb Company   NYSE BMY  
Bristol Myers Squibb is a differentiated company  led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm  They deliver innovative medicines in serious and life threatening disease areas such as oncology  cardiovascular  immunoscience and fibrosis  Through their R D organization  they have built a sustainable pipeline of potential therapies  and actively partner to access external innovation to broaden and accelerate their work 
Zacks Rank  1
ROE 47 63 
ROA 13 86 
Dividend Yield 3 29 
Current Ratio 3 88X

Marine Products Corporation   NYSE MPX  
Marine Products is the third largest distributor of sterndrive powerboats in the U S  The company designs  manufactures and distributes premium branded Chaparral sterndrive pleasure boats and Robalo outboard offshore fishing boats  Diversification of the product line through product innovation and strategic acquisition is also a strategy  With premium brands and a solid capital structure  Marine Products Corporation is prepared to capitalize on opportunities to increase its market share and to generate superior financial performance to build long term shareholder value 
Zacks Rank  1
ROE 37 19 
ROA 17 30 
Dividend Yield 3 19 
Current Ratio 3 15X

NewMarket Corporation   NYSE NEU  
NewMarket Corporation through its subsidiaries  Afton Chemical Corporation and Ethyl Corporation  develops  manufactures  blends  and delivers chemical additives that enhance the performance of petroleum products  From custom formulated chemical blends to market general additive components  the NewMarket family of companies provides the world with the technology to make fuels burn cleaner  engines run smoother and machines last longer 
Zacks Rank  1
ROE 47 25 
ROA 16 29 
Dividend Yield 1 66 
Current Ratio 2 93X

Xperi Corporation   NASDAQ XPER  
Xperi Corp  is a product and technology licensing company which manufactures semiconductors and related products  Its technologies and intellectual property are deployed  in areas such as premium audio  computational imaging  computer vision  mobile computing and communications  memory  data storage  3D semiconductor interconnect and packaging  Xperi Corporation was formerly known as Tessera Holding Corporation 
Zacks Rank  1
ROE 22 90 
ROA 13 46 
Dividend Yield 3 92 
Current Ratio 7 58X

 
Just Released  Zacks  7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year 
These 7 were selected because of their superior potential for immediate breakout ",2019-09-20,Zacks Investment Research,https://www.investing.com/analysis/5-safe-bets-for-a-rocky-market-200466730,200466730
149026,370542,AMGN,Bull Of The Day  Amgen  AMGN ,opinion,"Amgen  is literally one of the world s biotech pioneers  Founded in California in 1980 and going public three years later  the company   formerly known as American Molecular Genetics   has been on the cutting edge of genetic therapeutics  molecular biology and biochemistry for almost 40 years 
Following the 2009 acquisition of Genentech   an early competitor in recombinant DNA technology   by Roche  Amgen became the world s largest stand alone biotechnology research and development company 
Amgen s first blockbuster product was synthetic human erythropoietin that had been produced in cell culture using non human animal eggs  The technique was lauded as brilliantly creative at the time   as well as covered by extensive patent protection  Epogen was approved by the FDA in 1989 for the treatment of chronic anemia as a result of kidney disease  and approvals for use in cancer  HIV and other critical ill patients soon followed  By 2002 it was the single most paid for pharmaceutical by Medicare with reimbursements of over  2 billion annually 
Neupogen is still marketed by Amgen and also sold under the brand named  Procrit  through a licensing agreement with Johnson and Johnson   
In fact  Erythropoietin is so effective at helping the human body produce red blood cells under stressful conditions that Epogen was added to the World Anti Doping Agency s  banned  list and was the subject of many failed drug tests by healthy endurance athletes who had obtained it illegally and used it as a performance enhancing drug 
Amgen continued to use unique and creative techniques for developing precisely targeted therapeutic biologicals based on naturally occurring human compounds for a wide range of afflictions  including kidney failure  osteoporosis  migraines  auto immune disorders and many more serious illnesses 
Starting in 1994  Amgen also started making strategic acquisitions of smaller biotech companies who owned promising intellectual property that fit well into the Amgen stable of treatments  Among the 17 companies acquired in the past 25 years was Immunex  which was on the verge of approval for its rheumatoid arthritis drug Enbrel  now another Amgen blockbuster with annual sales of over  5 billion 
Current pharmaceutical offerings like Neulasta  Neupogen and Repatha headline a list of 18 drugs that are currently being sold by Amgen or its partners   producing  23 billion in annual revenues The company also continues to use state of the art science to investigate new treatments for serious illnesses  They currently have 24 compounds in Phase 1 trials  2 in Phase 2 and 5 in Phase 3   as well as countless experiments running on pre trial drug ideas 
It s exactly that combination of huge selling and profitable drugs and a full pipeline of candidates for the next generation of success stories that make Amgen such a compelling investment  The typical narrative for a small startup biotech is that they have a low number of potential drugs in development or even in trials  and with little or no revenues  significant costs and essentially infinate pricing multiples  investors are quick to unload shares at the first sign of any trouble 
Amgen is already so far past that stage that they look attractive on a valuation basis just based on current lines of business  The potential for new best selling drugs is just gravy for shareholders 
With a forward P E Ratio of just 13 7X and an annual dividend yield of 3   Amgen can be viewed simultaneously as a Value stock  a Growth stock and an Income stock  
Twelve upward analyst revisions in the past 60 days have brought the Zacks Consensus Earnings Estimate for 2019 from  13 90 share to  14 30 and help earn Amgen a Zacks Rank  1  Strong Buy   2020 estimates have been rising on a similar trajectory over the same period   from  14 78 to  15 42 share 
Pharmaceutical companies tend to be steady performers  producing sales gains even in difficult economic conditions  but with little chance of huge growth  Early stage Biotechs have explosive potential  but they also have a tendency to implode when things don t go as planned 
Owning Amgen shares allows a savvy investor to experience the best of both worlds 
5 Stocks Set to Double Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth  Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-09-20,Zacks Investment Research,https://www.investing.com/analysis/bull-of-the-day-amgen-amgn-200466526,200466526
149032,370548,AMGN,High Hopes for Fourth Quarter Earnings  ,news,Investing com   Even before Delta Air Lines  NYSE DAL    JP Morgan Chase   NYSE JPM  and other U S  companies beat earnings estimates for the fourth quarter  there was reason for optimism Earnings for the quarter are forecast to increase 10 5   according to Fact Set  the best performance since the first quarter of 2017 What s more  all 11 sectors in the S P 500 are expected to show gains  Leading the pack will be energy  The weakest sector will be be telecoms  One key element to look for is one time tax charges  resulting from the massive tax cut package signed into law late last year  Under the plan  U S  companies will pay a one time tax of 15 5  on profits held overseas  Chase  for one  elected to take advantage of the change  taking a  2 4 billion charge in its fourth quarter Other companies  such as Goldman Sachs  NYSE GS  and biotech giant Amgen  NASDAQ AMGN   have said they plan to do so,2018-01-17,Investing.com,https://www.investing.com/news/stock-market-news/high-hopes-for-fourthquarter-earnings-1113099,1113099
149033,370549,AMGN,J J takes  13 6 billion charge related to new U S  tax law,news,"By Michael Erman and Divya Grover  Reuters    Healthcare conglomerate Johnson   Johnson  NYSE JNJ  on Tuesday took a  13 6 billion charge related to the new U S  tax law and plans to bring back billions of dollars from overseas immediately  The company reported a quarterly loss due to the charge  but beat analysts  profit estimates excluding items  helped by growth in cancer drugs and treatments from its  30 billion purchase of Actelion last year  Still  J J shares fell 4 2 percent to  141 97 in afternoon trading as investors sold off after the shares closed just below their all time high on Monday   It s just kind of a low quality earnings beat   said Jeff Jonas  a portfolio manager at Gabelli Funds  He noted that the company s fourth quarter tax rate was only 9 percent   so maybe the beat wasn t as big as it looked on a headline basis   Also on Tuesday  U S  appeals court upheld a ruling that invalidated a crucial J J patent on its blockbuster rheumatoid arthritis drug Remicade  U S  President Donald Trump signed the new U S  tax law late last year  and many large U S  corporations and drugmakers have said they will take advantage of its new  lower tax rate on repatriated foreign earnings and cash  J J reported a year ago that it had  66 billion in undistributed international earnings and on Tuesday said it had  16 billion in cash outside the United States   The company  based in New Brunswick  New Jersey  plans to move  12 billion of that cash immediately  J J CFO Dominic Caruso said during a conference call with analysts  and will be used to fund U S  operations  primarily by paying down debt   Caruso also expects the new tax law to lower J J s 2018 tax rate by 1 5 percentage points to 2 5 percentage points  and forecast an effective tax rate of 16 5 percent to 18 percent   He said that money generated from lower taxes would primarily be funneled toward more research and development spending  J J s tax hit is the biggest announced for the pharmaceutical industry so far  Drugmaker  Amgen Inc   NASDAQ AMGN   for instance  said it would take a charge of more than  6 billion  while  Pfizer  Inc  NYSE PFE  has not yet given details on its tax plans  QUARTERLY LOSS International operations accounted for nearly half of J J s total fourth quarter sales of  20 20 billion  which were up 11 5 percent from a year earlier  Cancer drugs Darzalex  Imbruvica and Zytiga helped drive a 17 6 percent rise in pharmaceuticals sales to  9 68 billion   A U S  administrative court recently invalidated Zytiga s patent  but J J said it does not expect its competitors to launch a generic version of the drug this year  High margin treatments from Actelion  acquired by J J for  30 billion in 2016  accounted for about a quarter of the pharmaceutical unit s sales growth  Sales at J J s consumer products unit  which makes Band Aids  Neutrogena beauty products and Tylenol  rose 3 1 percent to  3 5 billion  Including the tax charge  J J lost  10 71 billion  or  3 99 per share  in the quarter  compared with a profit of  3 81 billion  or  1 38 per share  a year earlier  Excluding items  J J earned  1 74 per share  slightly above analysts  average estimate of  1 72 per share  according to Thomson Reuters I B E S  J J forecast an adjusted 2018 profit of  8 to  8 20 per share on revenue of  80 6 billion to  81 4 billion   
Analysts were expecting profit of  7 87 per share and revenue of  80 7 billion ",2018-01-23,Reuters,https://www.investing.com/news/stock-market-news/jj-posts-quarterly-loss-on-taxrelated-charge-1138125,1138125
149034,370550,AMGN,North Korea threats spur U S  search for new radiation therapies,news,By Divya Grover  Reuters    The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome   The hostility between the two nations reached a new height last November after Pyongyang fired an intercontinental ballistic missile capable of reaching the U S  mainland  Health officials in Washington say they have adequate stocks in the event of a nuclear attack and subsequent mass radiation poisonings  But statements by a handful of drug developers and partnerships the government have announced suggest the DoD is stepping up efforts to develop stronger treatments that could protect the military and civilians ahead of a nuclear attack   The DoD s budget allocated  3 9 million of its total funding to develop such medical countermeasures in 2018  an increase of  600 000 from a year ago   However  the numbers available on a handful of contracts issued to firms including Cleveland BioLabs Inc and privately held Humanetics Corp show funding of at least  13 million  suggesting that other departments of the military agency are investing in the area  The reward for a successful drug developer is high  in 2013  the government spent  157 million to stockpile Amgen  NASDAQ AMGN  Inc s nearly three decades old drug  Neupogen  but it and other stockpile drugs are limited as they only treat certain after effects of radiation exposure  Medical experts say that the increased  700 billion military budget signed into law by President Donald Trump last month could put more emphasis on programs to counter the North Korean threat and may allow a large outlay for new treatments  The new drugs in development for radiation exposure are designed to recover the loss of all three blood lineages   white and red blood cells  and platelets   without the need for multiple blood tests or prescreening   Israel based Pluristem Therapeutics Inc  Cleveland BioLabs and privately held Neumedicines Inc are all in the final stages of developing their treatments  while Humanetics is yet to initiate an early stage trial for its oral drug   Pluristem has been developing an injectable drug  which could prevent or reduce the severity of radiation poisoning if taken before exposure    Additional funding for the U S  military may support more rapid development of medical countermeasures   Pluristem s North America division s vice president Karine Kleinhaus said   Leukine  Neulasta  Neupogen each only targets recovery of a sub population of white blood cells  with no effect on the other two lineages  Pre determination of amount of radiation exposure and serial blood tests are     not required for PLX R18 administration  making PLX R18 more suitable in a mass casualty situation   Kleinhaus said of the company s experimental drug  The National Aeronautics and Space Administration  NASA  also entered into a partnership last August with the government s Biomedical Advanced Research and Development Authority  BARDA  to develop drugs  focusing on the radiation issues experienced by astronauts  NASA s radiology scientist Dr  Honglu Wu told Reuters there would certainly be interest in medicines that could be taken prior to the exposure of radiation   Neumedicines Chief Executive Lena Basile  whose developmental drug HemaMax is a post exposure therapy  said the pre exposure treatments would be undermined because they are limited to military personnel or first responders    You cannot give pre exposure drugs to the civilian population   she said  Pluristem is also planning to expand its treatment for the use in cancer patients  the company s co Chief Executive Yaky Yanay said  adding that the drug has a  1 billion market potential in revenue   If we are  going  to get to the chemotherapy market  we are looking at a much larger market  ,2018-01-31,Reuters,https://www.investing.com/news/world-news/north-korea-threats-spur-us-search-for-new-radiation-therapies-1178019,1178019
149035,370551,AMGN,Amgen Q4 top line off 3   non GAAP EPS flat  shares down 5  after hours,news,Amgen  NASDAQ AMGN  Q4 results   M   Revenues  5 802   2 7    Product sales  5 569   1 7   Net Loss   4 264    320 4    non GAAP net income  2 104   2 6    loss share   5 89    327 4    non GAAP EPS  2 89  flat  GAAP results were negatively impacted by the income tax effect from the Tax Cuts and Jobs Act Key product sales  Repatha  98   69 0    BLINCYTO  46   58 6    Prolia  574   24 0    KYPROLIS  227   24 0    Vectibix  159   11 2    Enbel  1 423   13 4   2018 Guidance  Revenues   21 8B   22 8B  EPS   11 18   12 36  non GAAP EPS   12 60   13 70 Shares are down 5  after hours Now read ,2018-02-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgen-q4-top-line-off-3-nongaap-eps-flat-shares-down-5-after-hours-1184829,1184829
149036,370552,AMGN,Spectrum Pharma s Rolontis on par with Neulasta in late stage study  shares ahead 7  premarket,news,A Phase 3 clinical trial  ADVANCE  evaluating  Spectrum Pharmaceuticals    NASDAQ SPPI  ROLONTIS  eflapegrastim  compared to Amgen s  NASDAQ AMGN  Neulasta  pegfilgrastim  in managing chemotherapy induced neutropenia in patients with early stage breast cancer met the primary endpoint of non inferiority The company says it expects to file its U S  marketing application in Q4 Spectrum licensed ROLONTIS from South Korea s Hanmi Pharmaceutical in January 2012 A second Phase 3  RECOVER  has completed enrollment Shares are up 7  premarket  albeit on only 502 shares Now read ,2018-02-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/spectrum-pharmas-rolontis-on-par-with-neulasta-in-latestage-study-shares-ahead-7-premarket-1196442,1196442
149044,370560,AMGN,Celgene s  CELG  Leukemia Candidate Meets Endpoints In Study,opinion,Celgene Corporation   NASDAQ CELG   announced top line results from the international phase III study  QUAZAR AML 001  The study evaluated the efficacy and safety of investigational CC 486  oral azacitidine as maintenance therapy in patients with newly diagnosed acute myeloid leukemia  AML   who achieved first complete response  CR  or complete response with incomplete blood count recovery  CRi  with induction chemotherapy The primary endpoint of the study was overall survival  The study results showed that maintenance treatment with CC 486 resulted in a highly statistically significant and clinically meaningful improvement in overall survival compared to placebo  The key secondary endpoint of relapse free survival  RFS  also showed a statistically significant improvement Shares of the company have surged 54 2  year to date against the  s decline of 1 3  CC 486 was well tolerated and there were no unexpected safety events in the QUAZAR AML 001 study  This is the first phase III study to show that the addition of maintenance therapy has the potential to extend OS in a broad population of patients with newly diagnosed AML  who have achieved remission with induction chemotherapy We note that  AML is a type of cancer in which the bone marrow makes abnormal blast cells that are supposed to grow into different types of blood cells  AML progresses rapidly and is typically fatal within weeks or months if left untreated Last month  the FDA approved  Inrebic  fedratinib  for the treatment of adult patients with intermediate 2 or high risk primary or secondary  post polycythemia vera or post essential thrombocythemia  myelofibrosis  Myelofibrosis is a serious and rare bone marrow disorder that disrupts the body s normal production of blood cells Celgene has been in the news since January 2019 due to a merger announcement with large cap pharma Bristol Myers Squibb Co    NYSE BMY   for a whopping  74 billion  Celgene Corporation Price    Zacks Rank   A Stock to ConsiderCurrently  Celgene is a Zacks Rank  3  Hold  stock Some better ranked stocks in the biotech sector are Amgen Inc    NASDAQ AMGN   and Acorda Therapeutics Inc    NASDAQ ACOR    Both these stocks sport Zacks Rank  1  Strong Buy   at present  You can see  Amgen s earnings per share estimates have increased from  13 92 to  14 30 for 2019  and from  14 76 to  15 42 for 2020  in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters  the average beat being 6 72      Acorda s loss per share estimates for the current year narrowed from  4 11 to  2 97 for 2019 and from  3 26 to  3 11 for 2020 over the past 60 days  The company recorded a positive earnings surprise in the preceding four quarters  the average beat being 155 36      Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-12,Zacks Investment Research,https://www.investing.com/analysis/celgenes-celg-leukemia-candidate-meets-endpoints-in-study-200464456,200464456
149045,370561,AMGN,REGENXBIO  RGNX  Catches Eye  Stock Jumps 5 8 ,opinion,REGENXBIO Inc    NASDAQ RGNX   was a big mover last session  as the company saw its shares rise nearly 6  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  31 84 to  37 54 in the past one month time frame The company has seen no changes when it comes to estimate revision over the past few weeks  while the Zacks Consensus Estimate for the current quarter has also remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future REGENXBIO currently has a Zacks Rank  3  Hold  while its  is 0 00  REGENXBIO Inc  Price   Investors interested in the Medical   Biomedical and Genetics industry may consider a better ranked stock like Amgen Inc    NASDAQ AMGN    which carries a Zacks Rank  1  Strong Buy   You can see  Is RGNX going up  Or down  Predict to see what others think Up or DownToday s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-13,Zacks Investment Research,https://www.investing.com/analysis/regenxbio-rgnx-catches-eye-stock-jumps-58-200464434,200464434
149046,370562,AMGN,Aimmune s Peanut Allergy Drug Gets FDA Committee s Support,opinion,Aimmune Therapeutics  Inc    NASDAQ AIMT   announced that the Allergenic Products Advisory Committee  APAC  convened by the FDA voted in favor of pipeline candidate  Palforzia The committee supported the use of Palforzia in children and teens with peanut allergy  The APAC voted in favor of the candidate s effectiveness in the ratio of 7 to 2  The committee also voted in the ratio of 8 to 1 in favor of the safety data in conjunction with additional safeguards  which are adequate to support the use of Palforzia We note that Palforzia  the proposed trade name of AR101  is a complex  biologic oral immunotherapy  OIT  candidate  which is designed to reduce the incidence and severity of allergic reactions  These include anaphylaxis after the accidental exposure to peanut in patients aged 4 17 years with a confirmed diagnosis of peanut allergy Aimmune s Biologics License Application  BLA  seeking approval for Palforzia for the treatment of children and adolescents with peanut allergy is currently under FDA review  with an action date in late January 2020  The BLA was submitted in December 2018  The agency had earlier granted the Fast Track and the Breakthrough Therapy designations to the candidate  Additionally  the European Medicines Agency  EMA  is also reviewing the company s Marketing Authorization Application  MAA  for the same  Both agencies have conditionally accepted Palforzia as the trade name for AR101 As part of its original BLA submission  Aimmune has proposed a number of risk management measures in line with the recent Advisory Committee discussion   the requirement for the initial dose escalation and first dose of each dose escalation level to be administered in a facility equipped to treat systemic allergic reactions  documentation of patients having a prescription for injectable epinephrine prior to the initiation of Palforzia  distribution of therapy through specialty pharmacies  and a purposefully designed packaging such that patients only receive their appropriate dose  Moreover  the company proposed a Black Box warning in the product labeling in the original BLA submission  consistent with immunotherapies indicated to treat allergic conditions Trading was halted on Sep 13  owing to the scheduled meeting of APAC  Shares of Aimmune gained in after hours trading  Meanwhile  shares of the company have gained 3 1  so far this year against the  s decline of 1 7  A potential approval will boost the growth prospects of this clinical stage biopharmaceutical company  Peanut allergy is one of the most common food allergies  which affects more than 1 6 million children and teens in the United States alone The candidate is also being evaluated in combination with Sanofi s   NASDAQ SNY   dupilumab in a phase II study for treating peanut allergy  The study was sponsored by Sanofi s partner Regeneron   NASDAQ REGN   Apart from Palforzia  Aimmune is also evaluating its second investigational  complex biologic product  AR201  for the treatment of egg allergy  The study was initiated in August 2019  The company is exploring another product candidate to treat multi tree nut allergy Zacks Rank   A Stock to ConsiderAimmune currently carries a Zacks Rank  3  Hold  A better ranked stock in the biotech sector is Amgen   NASDAQ AMGN    sporting a Zacks Rank  1  Strong Buy   You can see  Amgen s earnings per share estimates have increased from  13 89 to  14 30 for 2019  and from  14 72 to  15 42 for 2020  in the past 60 days 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/aimmunes-peanut-allergy-drug-gets-fda-committees-support-200465077,200465077
149047,370563,AMGN,Top Stock Picks For Week Of September 16  2019,opinion,"Amgen Inc    NASDAQ AMGN    discovers  develops and delivers innovative human therapeutics  Shares of this Zacks  1  Strong Buy have risen this year so far  compared with a decline for its industry  Acquisitions and Deals to drive growth and boost its pipeline  Amgen has several interesting candidates in its pipeline  which represent a significant commercial potential  The company boasts a strong biosimilars pipeline  which could be an important long term growth driver for it    
Alibaba Group Holding Limited   NYSE BABA    operates online and mobile marketplaces in retail and wholesale trade  as well as cloud computing and other services  Alibaba reported strong fiscal first quarter earnings driven by steady improvement in core commerce and cloud businesses  along with strong growth in metrics  Its strong momentum in both domestic as well as international market remains growth drivers  Further  Alibaba s strengthening cloud business with its expanding customer base continues to drive its performance  Its New Retail strategy is also gaining momentum in the market  And  Alibaba continues to witness increasing monetization rates    
7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/top-stock-picks-for-week-of-september-16-2019-200465102,200465102
149048,370564,AMGN,Amgen s Kyprolis Combo Improves PFS In Multiple Myeloma Study,opinion,Amgen Inc    NASDAQ AMGN   announced that a three drug combination regimen of its multiple myeloma  MM  drug Kyprolis improved progression free survival  PFS  in a phase III study The phase III CANDOR study evaluating Amgen s Kyprolis   dexamethasone and Johnson   Johnson s   NYSE JNJ   Darzalex in patients with relapsed or refractory multiple myeloma  met the primary endpoint of PFS compared to Kyprolis plus dexamethasone  Kd  alone In the study  treatment with the three drug Kyprolis combo  KdD  led to a reduction in the risk of progression or death by 37  in patients with relapsed or refractory MM The median PFS for patients who received Kd alone was 15 8 months  However  as of the cut off date  the median PFS has not been reached for patients in the KdD arm  Also  there were a higher number of adverse events like thrombocytopenia  anemia  diarrhea  hypertension among others reported in the KdD regimen compared to Kd Notably  this is the first phase III study  evaluating the combo of Kyprolis and Darzalex for treating the given patient population  The primary endpoint was PFS while the key secondary endpoints were overall response rate  minimal residual disease and overall survival The randomized  open label CANDOR study was initiated by Amgen as part of its collaboration agreement with Janssen  a subsidiary of J J  which is also co funding the study along with Amgen Amgen plans to present data from the above study at an upcoming medical conference  The company also plans to submit the results for regulatory approvals Shares of Amgen have inched up 0 4  so far this year against the  decline of 1 8  We remind investors that Kyprolis is already approved as a monotherapy as well as in combination with dexamethasone or Celgene Corporation s   NASDAQ CELG   Revlimid  lenalidomide  plus dexamethasone for the treatment of relapsed refractory MM in patients who have received one to three lines of therapy During the first half of 2019  Kyprolis generated sales of  512 million  reflecting an increase of 5 6  year over year  primarily driven by volume growth in the United States Zacks Rank   Another Key PickAmgen currently sports a Zacks Rank  1  Strong Buy   Another top ranked stock in the healthcare sector is NuCana PLC   NASDAQ NCNA    which has the same favorable Zacks Rank as Amgen  You can see  NuCana s loss per share estimates have been narrowed 17 5  for 2019 and 16 7  for 2020 over the past 60 days 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/amgens-kyprolis-combo-improves-pfs-in-multiple-myeloma-study-200464961,200464961
149049,370565,AMGN,Alder  ALDR  Stock Up On Acquisition Agreement With Lundbeck,opinion,Shares of clinical stage biopharmaceutical company  Alder BioPharmaceuticals   NASDAQ ALDR   skyrocketed 83 9  after it announced an acquisition agreement with Danish pharmaceutical company  Lundbeck A S  for  1 95 billion Notably  shares of the company have soared 80 5  in the year so far against the  s decline of 1 7   Per the agreement  Lundbeck will commence a tender offer for all outstanding shares of Alder for an upfront payment for  18 00 per share in cash  a 79  premium to the latter s share price of  10 06 on Sep 13  Additionally  Alder s shareholders will also receive one non tradeable Contingent Value Right  CVR  that entitles them to an additional  2 00 per share upon a potential approval of pipeline candidate eptinezumab by the European Medicines Agency  EMA   Hence  the total potential consideration comes to  20 per share Alder s board has unanimously approved the transaction and the deal is expected to close in the fourth quarter of 2019  subject to customary closing conditions We note that the company is developing eptinezumab  an investigational monoclonal antibody  mAb   for the preventive treatment of migraine in adults  Eptinezumab was designed for immediate and complete bioavailability with high specificity and strong binding for suppression of calcitonin gene related peptide  CGRP   Alder had submitted a Biologics License Application  BLA  to the FDA for the candidate in February 2019 and the agency has set an action date of Feb 21  2020  Per the company  a potential approval in the United States will make it the first IV CGRP therapy for migraine prevention  The company also expects to submit an application for the same to regulatory authorities in the European Union during 2020 Moreover  Alder plans to initiate a phase III clinical study evaluating the same as a treatment for acute migraine in the second half of 2019 Apart from eptinezumab  the company is also developing ALD1910  a mAb designed to inhibit pituitary adenylate cyclase activating polypeptide  PACAP  for migraine prevention The addition of eptinezumab will broaden Lundbeck s brain disease franchise  A potential approval and the U S  launch of the candidate for preventive treatment of episodic and chronic migraine in 2020 will diversify Lundbeck s portfolio  Moreover  Lundbeck will gain an early stage antibody  ALD1910  against a separate target for migraine and other pain syndromes  The transaction is expected to be accretive to the core bottom line in 2023  assuming FDA approval in the first quarter of 2020 followed by regulatory approvals in other regions  including Europe Lundbeck is a global pharmaceutical company  which specializes in brain diseases with drugs like Rexulti  depression and schizophrenia   Brintellix  depression  and Abilify Maintena  schizophrenia   The acquisition of Alder will solidify Lundbeck s position in the brain diseases space In May 2019  Lundbeck closed the acquisition of U S  biotech Abide Therapeutics Inc  which enables it to develop new classes of drugs for a broad spectrum of brain diseases based on the latter s world class discovery platform  The acquisition added ABX 1431  a first in class MAG Lipase inhibitor explored in clinical trials as a first of its kind compound for the treatment of Tourette Syndrome  exploratory phase IIa  and neuropathic pain  phase I   to Lundbeck s pipeline While the migraine market holds potential and approval of late stage candidate eptinezumab will be a significant boost for Lundbeck  competition is stiff in this space from the likes of Novartis   NYSE NVS   Amgen   NASDAQ AMGN   s Aimovig  Eli Lilly s   NYSE LLY   Emgality  and Teva s Ajovy  among others Alder currently carries a Zacks Rank  2  Buy   You can see  5 Stocks Set to DoubleZacks experts released their picks to gain  100  or more in 2020  One is a famous cutting edge food company that is  hiding in plain sight   Swamped with competitors and ignored by Wall Street  its stock price floundered  Now  suddenly  it acquired a company that gives it an advantage none of its peers have ,2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/alder-aldr-stock-up-on-acquisition-agreement-with-lundbeck-200465305,200465305
149052,370568,AMGN,Amgen estimates its U S  tax bill at over  6 billion as it repatriates cash,news,"NEW YORK  Reuters     Amgen Inc   O AMGN  said it expects to incur tax expenses of  6 billion to  6 5 billion over time as it repatriates cash it has accumulated around the world because of the new U S  tax law signed by President Donald Trump on Friday  Some of the expense is also due to the revaluation of its tax liabilities  the drugmaker said in a filing with the Securities and Exchange Commission  Amgen did not say how much of its  38 9 billion in cash and other holdings it plans to move back to the United States  To encourage U S  companies to bring home the more than  2 6 trillion now held overseas  the law sets a one time tax repatriation rate of 15 5 percent for cash and cash equivalents and 8 percent for illiquid assets  Amgen said its future U S  income generally will be taxed at the 21 percent U S  corporate income tax rate  while its income elsewhere will generally be taxed in the United States at 10 5 percent  reduced by foreign tax credits  
It said the tax expenses from moving its cash back to the United States will affect its current generally accepted accounting principles  GAAP  earnings forecast  but will not affect its non GAAP forecast ",2017-12-22,Reuters,https://www.investing.com/news/stock-market-news/amgen-estimates-its-us-tax-bill-at-over-6-billion-as-it-repatriates-cash-1025746,1025746
149069,370585,AMGN,Novartis Announces Positive Long Term Data On Migraine Drug,opinion,Novartis AG   NYSE NVS   announced 5 year open label treatment period  OLTP  data on migraine drug Aimovig The study is being conducted to evaluate its sustained efficacy and long term safety in patients taking 70mg and 140mg  Patients initially received 70mg of Aimovig monthly in the OLTP  The dose was increased to 140mg for the patients enrolled under the study after approximately 2 years  Of the 250 patients who switched from Aimovig 70mg to 140mg  221 patients  88   completed the OLTP or remained on 140mg at 4 5 years The interim analysis at 4 5 years showed that 77  of the patients who were still on treatment experienced at least a 50  reduction in monthly migraine days  MMD  at the last month of assessment  In addition  33  of patients who continued with the regimen achieved a 100  reduction while 56  achieved a 75  decrease in MMD This encouraging data strengthens Aimovig s position as the most prescribed anti CGRP with more than 250 000 patients recommended worldwide since its launch Aimovig is designed specifically to block the calcitonin gene related peptide receptor  CRGP   Per Novartis  Aimovig is the first FDA and EMA approved CGRP targeted therapy for the prevention of migraine in adults  Novartis and Amgen   NASDAQ AMGN   co commercialize the drug in the United States  While Amgen has the exclusive rights to commercialize the drug in Japan  Novartis has the exclusive commercialization rights in the rest of the world  Both companies were involved in a lawsuit regarding this agreement CRGP is a new class of drugs  designed to reduce the number of migraine attacks  Also  this category has fewer adverse reactions in clinical trials and lesser warnings plus precautions compared with other approved migraine therapeutics  Other drugs in this category are Teva s   NYSE TEVA   Ajovy and Eli Lilly s   NYSE LLY   Emgality Shares of Novartis have inched up 4 6  so far this year against the  decrease of 0 5   Novartis is looking to transform its business with focus on key therapeutic areas considering the weakness in the generic business and separation of eye care business Novartis currently carries a Zacks Rank  2  Buy    You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-08,Zacks Investment Research,https://www.investing.com/analysis/novartis-announces-positive-longterm-data-on-migraine-drug-200462992,200462992
149070,370586,AMGN,Ultragenyx To Submit SBLA For Label Expansion Of Crysvita,opinion,"Ultragenyx Pharmaceutical Inc    NASDAQ RARE   and partner Kyowa Kirin Co   Ltd   announced plans to submit a supplemental Biologics License Application  sBLA  to the FDA for the label expansion of Crysvita  burosumab   The sBLA will be submitted for the treatment of FGF23 related hypophosphatemia associated with phosphaturic mesenchymal tumors  tumor induced osteomalacia  TIO  that cannot be curatively resected or localized  The company decided to  to submit the sBLA after completing a pre sBLA meeting with the FDA and an agreement on the filing package  The submission of the sBLA is planned for the first half of 2020 The sBLA will be supported by data from two single arm phase II studies   a 144 week phase II study in 14 adult patients conducted by Ultragenyx in the United States and an 88 week phase II study in 13 adult patients conducted by Kyowa Kirin in Japan and South Korea  In both studies  Crysvita was associated with increases in serum phosphorus and serum 1 25 dihydroxyvitamin D levels  Increased phosphate levels led to improvements in osteomalacia  mobility  and vitality Shares of the company have inched up 0 9  year to date against the  s decline of 1 9  Crysvita  an antibody targeting fibroblast growth factor 23  FGF23   is approved in the United States for the treatment of X linked hypophosphatemia  XLH  in adult and pediatric patients  The drug received European conditional marketing authorization in February 2018 for the treatment of XLH with radiographic evidence of bone disease in children one year of age or older  and adolescents with growing skeletons The company also has some gene therapy candidates in its pipeline  These include DTX301  which is an adeno associated virus 8  AAV8  being evaluated for the treatment of patients with Ornithine transcarbamylase  OTC  deficiency  It reported data from the first two dose cohorts of DTX301 gene therapy in the same indication  DTX301 phase I II data from the third dose cohort are expected in the third quarter of 2019 DTX401 is an AAV8 gene therapy candidate being evaluated for the treatment of patients with glycogen storage disease type Ia  GSDIa   The company is developing DTX201 in its FVIII gene therapy program for the treatment of hemophilia A in collaboration with Bayer  DE BAYGN   BAYRY   The investigational new drug  IND  application was accepted by the FDA in the second quarter of 2018  Ultragenyx Pharmaceutical Inc  Price
    Zacks Rank   Stocks to ConsiderUltragenyx is currently a Zacks Rank  3  Hold  stock Some better ranked stocks in the biotech sector are Amgen Inc    NASDAQ AMGN    Acorda Therapeutics Inc    NASDAQ ACOR   and Celcuity Inc    NASDAQ CELC    All of these sport a Zacks Rank  1  Strong Buy   at present  You can see  Amgen s earnings per share estimates have increased from  13 90 to  14 30 for 2019  and from  14 78 to  15 42 for 2020  in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters  the average beat being 6 72      Acorda s loss per share estimates for the current year narrowed from  3 59 to  2 74 over the past 60 days  The company recorded a positive earnings surprise in the preceding four quarters  the average beat being 69 68      Celcuity s loss per share estimates narrowed from 81 cents to 70 cents for 2019 and from 96 cents to 71 cents for 2020  in the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  the average beat being 25 76      Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-09-10,Zacks Investment Research,https://www.investing.com/analysis/ultragenyx-to-submit-sbla-for-label-expansion-of-crysvita-200463753,200463753
149071,370587,AMGN,Puma Biotech s SNDA For Nerlynx Combo Gets FDA Acceptance,opinion,Puma Biotechnology  Inc    NASDAQ PBYI   announced that the FDA has accepted for review its supplemental New Drug Application  sNDA  of Nerlynx  neratinib   The sNDA is seeking approval of Nerlynx in combination with Roche s   OTC RHHBY   Xeloda  capecitabine  to treat HER2 positive metastatic breast cancer in patients who have failed two or more prior lines of treatments  The regulatory body will announce its decision on the sNDA on April  2020 The company stated that the FDA is not planning to hold an advisory committee meeting to discuss this application This sNDA was based on data from the phase III NALA study  which assessed the combination of Nerlynx   Xeloda compared to Xeloda plus Novartis    NYSE NVS   Tykerb  lapatinib  in the above mentioned advanced breast cancer patient population In July 2019   to the FDA for getting the Nerlynx combo approved for the given patient population Nerlynx is already approved for use as an extended adjuvant treatment of HER2 positive early stage breast cancer in adult patients  previously treated with Roche s Herceptin based adjuvant therapy  The drug was approved in Europe last September for the given indication Shares of Puma Biotech have plunged 41 6  so far this year  wider than the  decrease of 2 4  Notably  Nerlynx is the only marketed product in Puma Biotech s portfolio  The drug generated sales of  99 4 million in the first half of 2019  reflecting an increase of 14 5  year over year  If the company gets an approval to include the NALA study data on Nerlynx s label  it will be eligible to treat a broader set of breast cancer population  which can drive sales higher for the drug Meanwhile  several other studies on Nerlynx targeting different types of breast cancer subject compositions and in earlier line settings are currently underway Apart from the HER2 positive breast cancer indication  the company believes that Nerlynx holds great potential for the treatment of several cancers including NSCLC and other tumor types that over express or have a mutation in HER2 In April this year  Puma Biotech added two cohorts to the phase II SUMMIT basket study on Nerlynx  which is presently being conducted for treating solid tumors in patients with activating EGFR  HER2 or HER4 mutations  The company plans to report data from this SUMMIT study in the second half of 2019 and expects to meet the FDA authorities to discuss the regulatory strategy for the same later in the ongoing year Zacks Rank   Key PickPuma Biotech currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Amgen Inc    NASDAQ AMGN   which sports a Zacks Rank  1  Strong Buy   You can see  Amgen s earnings estimates have been revised 2 9  upward for 2019 and 4 3  for 2020 over the past 60 days  The stock has inched up 0 6  year to date Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-09-11,Zacks Investment Research,https://www.investing.com/analysis/puma-biotechs-snda-for-nerlynx-combo-gets-fda-acceptance-200464110,200464110
149072,370588,AMGN,Amgen declares  1 15 dividend,news,Amgen  NASDAQ AMGN  declares  1 15 share quarterly dividend  in line with previous Forward yield 2 55 Payable Dec  8  for shareholders of record Nov  17  ex div Nov  16 Now read ,2017-10-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgen-declares-115-dividend-546900,546900
149073,370589,AMGN,Amgen quarterly profit tops expectations despite sales decline,news,"By Bill Berkrot  Reuters     Amgen Inc   O AMGN  reported higher than expected third quarter profit on Wednesday as lower costs and improved operating margins helped offset sales declines in some of its most important products  The world s largest biotechnology company also raised its full year adjusted earnings forecast  but its shares fell in late trading as weaker than expected sales of a new drug and declines in sales of key blockbuster products may have spooked investors   Amgen boosted its earnings outlook to  12 50 to  12 70 per share from  12 15 to  12 65 despite taking a financial hit to Puerto Rico operations from Hurricane Maria  which devastated the island last month  Analysts on average were looking for 2017 earnings of  12 58 per share  according to Thomson Reuters data  The low end of Amgen s 2017 revenue forecast range was slightly raised to  22 7 billion with the top end still at  23 billion  Amgen shares  up 21 percent this year  fell 1 5 percent to  174 75  Repatha  which is a key new launch drug for Amgen  is disappointing   said Cowen and Co analyst Eric Schmidt about the expensive cholesterol drug struggling to reach patients being repeatedly denied by insurers  Repatha sales of  89 million were short of analyst estimates of  106 million   Improving patient access to Repatha remains a top priority   Chief Executive Robert Bradway said  In December  the company hopes U S  regulators will allow Amgen to begin promoting data showing Repatha cuts the risk of heart attacks and strokes  seen as key to unlocking its sales potential   Sales of Amgen s two biggest products  Enbrel for rheumatoid arthritis and Neulasta  which prevents infections in cancer patients  each fell 6 percent   Enbrel to  1 36 billion due to increased competition and Neulasta to  1 12 billion as use of chemotherapies that increase infection risk declined  Prolia for osteoporosis was a bright spot with sales up 22 percent at  464 million  Amgen estimated the Puerto Rico related cost to 2017 earnings would be 15 cents to 18 cents per share  with no expected disruption to product supply  It does not anticipate hurricane damage to significantly impact 2018 results  The company expects its Puerto Rico facilities to be fully operational by next week  while still using generators due to extensive damage to the island s electrical grid  Revenue declined 1 percent to  5 77 billion  about in line with analysts  estimates  But research and development spending  cost of sales and selling  general and administrative expenses were all lower  
Excluding items  Amgen said it earned  3 27 per share  topping analysts  average expectations by 16 cents ",2017-10-25,Reuters,https://www.investing.com/news/stock-market-news/amgen-quarterly-profit-tops-expectations-despite-sales-decline-547757,547757
149074,370590,AMGN,Avenue Therapeutics up 12  on start of late stage study of pain med IV tramadol,news,Thinly traded nano cap Avenue Therapeutics  ATXI  12 1   is up on average volume in response to its announcement that the first patient has been dosed in a Phase 3 clinical trial assessing IV tramadol for the management of moderate to moderately severe pain following bunionectomy surgery  Topline data should be available in Q2 2018 If approved  IV tramadol would be the only Schedule IV intravenous opioid available in the U S  The company says the product will potentially fill the pain treatment gap between IV acetaminophen and NSAIDS and conventional narcotics Schedule IV drugs  including Xanax  alprazolam   Valium  diazepam  and Halcion  triazolam   are considered to pose lower abuse potential than Schedule III drugs which include opioids such as Dilaudid  hydromorphone   OxyContin  oxycodone  and fentanyl Now read ,2017-10-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/avenue-therapeutics-up-12-on-start-of-latestage-study-of-pain-med-iv-tramadol-760286,760286
149075,370591,AMGN,Japan s Kirin cashes out of Amgen drug joint venture,news,"TOKYO  Reuters    Japan s Kirin Holdings Co Ltd  T 2503  said on Tuesday it would sell its share in a pharmaceutical research joint venture with California based drugmaker  Amgen Inc   O AMGN  for  780 million  The joint venture  Kirin Amgen  will buy the Japanese firm s 50 percent stake and will make further payments to Kirin for certain sales  the Japanese firm said in a statement  adding that the companies saw their collaboration as complete  Established in 1984 to fund the development of the kidney disease drug Epogen  the joint venture s scope grew to include  among others  the white blood cell boosting drugs Neupogen and Neulasta  used during chemotherapy treatment  Amgen said in a separate statement  Amgen will own product rights and the remaining cash held by the joint venture as the sole shareholder of the joint venture  the companies said  The venture s licensing agreements in certain Asian countries with Kyowa Hakko Kirin Co Ltd  T 4151   Kirin s pharmaceutical unit  will remain in place  Kirin  known primarily as a brewer  said its pharmaceuticals and bio chemicals business would remain core to the company and would not be affected by the termination of the joint venture agreement  It said the financial impact would be insignificant  The transaction is expected to close during either the fourth quarter of 2017 or the first quarter of 2018  Amgen said   
Goldman Sachs   Co  NYSE GS  LLC is acting as the exclusive financial advisor to Amgen on the deal ",2017-10-31,Reuters,https://www.investing.com/news/stock-market-news/japans-kirin-cashes-out-of-amgen-drug-joint-venture-760734,760734
149089,370605,AMGN,Amgen  AMGN  Up 11 2  Since Last Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Amgen  AMGN   Shares have added about 11 2  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Amgen due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Amgen Q2 Earnings   Sales Beat  New Drugs ShineAmgen reported second quarter 2019 earnings of  3 97 per share  which beat the Zacks Consensus Estimate of  3 58  Earnings increased 4  year over year helped by a lower share count Total revenues of  5 87 billion in the quarter beat the Zacks Consensus Estimate of  5 68 billion  However  total revenues declined 3  year over year Quarter in DetailTotal product revenues decreased 2  from the year ago quarter to  5 57 billion  U S    4 14 billion  ex U S    1 43 billion  as increasing demand for newer products was offset by the erosion of mature brands from biosimilar competition  Product sales growth was mostly driven by higher volumes as prices were lower for several drugs Other revenues of  297 million declined 21 8  in the quarter due to lower milestone payments than the prior year quarter Prolia revenues came in at  698 million  up 14  from the year ago quarter  attributable to 15  volume growth resulting from higher demand  Moreover  a seasonal sales pattern with second quarter sales being higher than the first quarter due to a six month dosing interval also benefited Prolia sales in the quarter Xgeva delivered revenues of  499 million  up 10  from the year ago quarter mainly due to higher demand  which drove volumes Kyprolis recorded sales of  267 million  up 2  year over year driven primarily by 13  volume growth in the United States Blincyto sales increased 30  from the year ago period to  78 million  reflecting rise in demand Repatha generated revenues of  152 million  up 3  year over year  as higher volume was offset by lower prices  Repatha volumes grew 59  globally and 66  in the United States Vectibix revenues came in at  196 million  up 13  year over year  Nplate sales rose 12  to  201 million Parsabiv  launched in several markets including United States in 2018  recorded sales of  168 million in the second quarter  higher than  126 million in the previous quarter  The increase was driven by higher demand in midsize dialysis centers  offset partially by lower prices Amgen s new migraine drug  Aimovig recorded sales of  83 million in the quarter  higher than  59 million in the previous quarter driven by an increase in the percentage of paid volume as the company sees improvement in conversion of free to paid patients On the call  the company said that approximately 225 000 new patients in the United States have been prescribed Aimovig since launch  suggesting that there remains growth potential Evenity recorded sales of  28 million in the quarter  In the United States  where Evenity was launched in April this year  sales were  3 million while international sales of  25 million came from Japan  the first country where Evenity was launched this year Amgen recorded biosimilar revenues of  82 million in the quarter  entirely from international markets compared with  55 million in the previous quarter However  Amgen s mature drugs like Enbrel  Aranesp  Epogen  Neupogen and Neulasta are facing an array of branded and generic competitors Aranesp revenues declined 8  from the prior year quarter to  436 million on lower volume due to increased competitive pressure Revenues of the other ESA  Epogen  declined 11  to  223 million due to lower selling prices as the category has become extremely competitive Neulasta revenues declined 25  from the year ago period to  824 million due to lower selling prices and biosimilar competition  However  the Neulasta Onpro kit  on body injector  continues to perform well Neupogen recorded 26  decline in sales to  75 million in the quarter due to biosimilar competition in the United States  which hurt demand and prices Enbrel delivered revenues of  1 36 billion  up 5  from the year ago quarter  driven primarily by favorable changes in inventory along with a slight price increase  which offset the unfavorable impact of lower demand Sensipar Mimpara revenues declined 71  to  122 million due to at risk small molecule generic launches Other product sales rose 11  to  79 million Operating Margins DecreaseAdjusted operating margin declined 180 basis points  bps  to 53 3   Adjusted operating expenses decreased 1  year over year in the second quarter SG A spend decreased 6  to  1 26 billion on cost control  R D expenses rose 7  year over year to  906 million due to higher spending on early stage oncology pipeline Adjusted tax rate was 15 3  for the quarter  a 1 1 points increase from the year ago quarter Amgen repurchased 13 1 million shares worth  2 3 billion in the second quarter and has  4 7 billion remaining under its stock repurchase authorization 2019 GuidanceAmgen raised the lower end of its previously issued sales and earnings guidance for 2019 for the second time this year based on its solid second quarter performance  The company expects revenues in the range of  22 4  22 9 billion versus  22 0  22 9 billion expected previously  Adjusted earnings per share are anticipated in the range of  13 75  14 30 versus  13 25    14 30 expected previously Operating costs in 2019 are expected to be flat from 2018 level on an absolute basis  R D costs are expected to rise in single digit percentage terms in 2019  However  SG A expenses are expected to decline as launch expenses normalize Operating margin is expected to be lower in the second half of the year due to the unfavorable timing of expenses  Adjusted tax rate is expected in the range of 14  to 15  Amgen still plans to invest approximately  700 million in capital expenditures in 2019 Amgen believes that higher sales of newer products should make up for the evolving competitive dynamics associated with Neulasta and other legacy products  However  recently launched products including Aimovig  Repatha and biosimilars and international expansion provide incremental growth opportunities Update on AMG 510On the call  the company said that its KRAS inhibitor for solid tumors  AMG 510 has shown responses in patients with colorectal and appendiceal cancer  Amgen also said it is enrolling patients in a NSCLC cohort in combination with a PD 1 inhibitor  It plans to initiate a registration enabling phase II study soon  
How Have Estimates Been Moving Since Then 
It turns out  estimates review flatlined during the past month 
VGM Scores
At this time  Amgen has a subpar Growth Score of D  however its Momentum Score is doing a lot better with an A  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Amgen has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-up-112-since-last-earnings-report-can-it-continue-200459875,200459875
149090,370606,AMGN,Premarket Gainers as of 9 05 am,news,CTMX  32  on teaming up with Amgen  NASDAQ AMGN  to develop EGFR targeting antibodies for cancer  CATB  27  as edasalonexent shows long term treatment effect in mid stage DMD study  CAPR  21  as its lead candidate CAP 1002 shows positive effect on heart function in young men with advanced DMD  EDAP  18  on FDA approval of Ablatherm Fusion device  MYL  16  on positive analyst action  VKTX  13  as VK0214 shows treatment effect in proof of concept study  FOLD  13  on announcement of new positive data on ATB200 AT2221 in Pompe disease  BIOP  12  on strategic investment in Coinsquare Ltd  GLBS  11   MNKD  7   DRYS  7  on right offering announcement  FCEL  7  on positive analyst action  TISA  6   Now read ,2017-10-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-gainers-as-of-905-am-536705,536705
149098,370614,AMGN,Roche s Tecentriq Combo Gets EU Nod For Critical Breast Cancer,opinion,Roche Holdings AG   OTC RHHBY   announced that the European Commission  EC  has approved its immuno oncology drug Tecentriq in combination with Celgene s   NASDAQ CELG   chemotherapy drug Abraxane for the treatment of adult patients with unresectable locally advanced metastatic triple negative breast cancer  TNBC  whose tumors express PD L1  having not received a prior chemotherapy for metastatic disease The approval was based on data from the phase III IMpassion130 study  which showed that the combo of Tecentriq   Abraxane significantly reduced the risk of disease worsening or death  PFS  by 38  compared to nab paclitaxel alone  Moreover  progression free survival  PFS  results demonstrated a statistically significant benefit for the combination Per the company  Tecentriq combination is the first cancer immunotherapy regimen to be approved for triple negative breast cancer in Europe  Notably  in July 2019  the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  recommended the approval of the Tecentriq combo for the given indication Tecentriq  for multiple indications  recorded significant growth in sales during the first half of 2019  Higher sales were mainly witnessed in the United States  Europe and Japan  This approval of Tecentriq for the above mentioned indication will further boost the drugs  sales Earlier this March  the FDA granted an accelerated approval for the same combo of Tecentriq   Abraxane for the same indication Meanwhile  last week  Roche s subsidiary Chugai obtained a regulatory nod for Tecentriq in Japan for the treatment of extensive stage small cell lung cancer  SCLC  Shares of Roche have rallied 10 4  so far this year against the  decrease of 2 1  Currently  Roche has seven ongoing phase III studies evaluating Tecentriq for TNBC including the early and advanced stages of the disease Roche has a strong presence in the oncology market  Particularly  it dominates the breast cancer space with solid demand for its HER2 franchise drugs  The HER2 franchise includes Herceptin  Perjeta and Kadcyla  Growth in Herceptin is being driven by increasing demand across the United States and Europe Approval of new drugs and label expansion of the existing drugs bode well for the company and should offset the adverse impact of biosimilar competition for some of its key drugs  such as Avastin  Rituxan and Herceptin from the likes of Novartis   NYSE NVS   and Amgen   NASDAQ AMGN   In a separate press release  Roche announced that the EC has also approved VENTANA PD L1  SP142  Assay as the first companion diagnostic to help identify the TNBC patients  who are eligible for treatment with cancer immunotherapy  and Tecentriq plus chemotherapy Zacks RankRoche currently sports a Zacks Rank  1  Strong Buy   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/roches-tecentriq-combo-gets-eu-nod-for-critical-breast-cancer-200460009,200460009
149099,370615,AMGN,Pharma Stock Roundup  JNJ s Opioid Lawsuit  Regulatory Nod For LLY  BMY  RHHBY Drugs,opinion,"This week  J J   NYSE JNJ   received an unfavorable ruling in the litigation related to abuse of its opioid based drugs  The FDA granted approval to Lilly s   NYSE LLY   psoriasis injection for active ankylosing spondylitis  AS  while the European Commission approved Bristol Myers    NYSE BMY   multiple myeloma drug  Empliciti and Roche s   OTC RHHBY   PD L1 inhibitor  Tecentriq in combination use for an expanded patient population Recap of the Week s Most Important StoriesOklahoma Judge Rules Against J J in Opioid Lawsuit  J J was ordered by a district court in to pay  572 million to the state of Oklahoma in connection with a lawsuit filed by the latter  The lawsuit claimed that J J was one of the several companies whose opioid based drugs   Duragesic  Nucynta and Nucynta ER   were responsible for fueling the state s opioid epidemic  However  the fine was much lower than Oklahoma state s demand of  17 billion to be paid over 30 years by J J  The company has decided to appeal against the ruling  The company is confident that its drugs were not responsible for the opioid crisis in the state and the ruling is inconsistent with the available facts and law  There are still a number of opioid related lawsuits pending with about 1900 suits consolidated at the federal level in the state of Ohio  with trial set to begin in October this year FDA Approves Lilly s Taltz for Ankylosing Spondylitis  Lilly gained FDA approval for its psoriasis injection for its third indication   active ankylosing spondylitis  AS   A type of spondyloarthritis  AS affects the pelvic joints and spine that can cause severe back pain  The approval was based on data from two phase III studies  COAST V and COAST W  Taltz is presently marketed for treating moderate to severe plaque psoriasis and active psoriatic arthritis Lilly s  baricitinib  met the primary endpoint in a phase III BREEZE AD7 study  evaluating it in a new indication   moderate to severe atopic dermatitis  AD   a type of eczema  Lilly is conducting five studies on baricitinib under the AD program and BREEZE AD7 is the third study to be completed this year  BREEZE AD1 and BREEZE AD2 were the other two studies wherein baricitinib 4 mg and 2 mg both met the primary endpoint  Top line data from the remaining two studies are expected to be presented later this year or early next year EU Approval for Expanded Label of Bristol Myers   Roche s Cancer Medicines  The European Commission granted approval for label expansion of Bristol Myers s multiple myeloma drug    The drug is now approved in the EU for use in combination with Celgene s Pomalyst  pomalidomide  and low dose dexamethasone for the treatment of patients with relapsed refractory multiple myeloma  r rMM  in second  or later line settings  Empliciti was approved for this combination use in the United States in November last yearThe regulatory agency also gave approval to Roche s in combination with Celgene s Abraxane for the treatment of adults with PD L1 positive  metastatic triple negative breast cancer   a difficult to treat cancer  The drug was approved for the same combination use by the FDA  on an accelerated basis  in March this year  The approval was based on encouraging data from the phase III IMpassion130 study AbbVie Ends Rova T Program  AbbVie   NYSE ABBV   discontinued development of its cancer candidate rovalpituzumab tesirine or Rova T as the third study on the candidate  MERU  also failed  The MERU study was evaluating Rova T as a first line maintenance therapy for advanced small cell lung cancer  SCLC  compared to placebo  Interim data from the study demonstrated no survival benefit for patients treated with Rova T  The lack of survival benefit led the Independent Data Monitoring Committee to recommend terminating MERU  Rova T was added to AbbVie s portfolio  following the  5 8 billion acquisition of Stemcentrx in June 2016 In December  AbbVie stopped enrollment in a pivotal phase III study  TAHOE   evaluating Rova T in second line SCLC  In March 2018  Rova T fell short of expectations in a phase II TRINITY study evaluating it in third line or later SCLC  The failure of TRINITY and the halt on TAHOE had already raised skepticism on Rova T s potential  Discontinuation of the candidate has now broughtinto question the viability of the Stemcentrx deal Several Updates from AstraZeneca  AstraZeneca s   NYSE AZN   late stage study  TULIP 2  evaluating its pipeline candidate  anifrolumab for systemic lupus erythematosus  SLE   met the primary endpoint  Top line data from the study showed that treatment with anifrolumab plus standard of care  SOC  medicine led to a statistically significant and clinically meaningful reduction of disease activity based on composite lupus assessment versus placebo  SOC  This is the second phase III study on the candidate for SLE  The first study  TULIP 1  did not meet the primary endpoint  per data announced last year The FDA assigned Fast Track designation to AstraZeneca s for chronic kidney disease  CKD   The type II diabetes drug is being evaluated in the phase III DAPA CKD study to see its effect on renal outcomes and cardiovascular  CV  mortality in patients with CKD with or without type II diabetes  DAPA CKD is part of AstraZeneca s DapaCare clinical program to explore the CV and renal profile of Farxiga in type II diabetes patients The FDA also granted orphan drug designation to AstraZeneca s respiratory biologic  for a new indication   eosinophilic esophagitis   an allergic inflammatory disease of the esophagus Meanwhile  a phase III study  evaluating AstraZeneca s fixed dose triple combination inhaler Breztri Aerosphere  PT010  in patients with moderate to very severe chronic obstructive pulmonary disease  COPD  met the primary endpoint  Breztri Aerosphere was approved in Japan in June for the treatment of COPD and is under review in the United States and EU for the same indication Bristol Myers Expects Celgene  NASDAQ CELG  Acquisition to Close by Year End  Bristol Myers moved a step closer toward the closure of its pending acquisition of Celgene this week as the latter signed a deal with Amgen  NASDAQ AMGN  to divest global commercial rights to its blockbuster psoriasis drug    Amgen will pay  13 4 billion in cash for the same to Celgene  Back in June  Bristol Myers had announced plans to divest Otezla to be able to close the acquisition of Celgene on a timely basis in light of concerns expressed by the U S  Federal Trade Commission  FTC   The sale of Otezla should now make it easier for Bristol Myers to get FTC s approval and will also fund a part of its massive  74 billion cost of buying Celgene  So  the deal looks like a win win for Bristol Myers  which expects the merger to close by the end of this year Novartis MS Candidate Meets Study Endpoints  Novartis    NYSE NVS   multiple sclerosis candidate  ofatumumab met the primary endpoints by reducing the annualized relapse rate compared to Sanofi s multiple sclerosis drug Aubagio in two phase III head to head studies  Ofatumumab is marketed by the company for oncology indications as an intravenous infusion under the brand name  Arzerra  In the studies  the key secondary endpoints of delaying time to confirmed disability progression were also met  Novartis plans to make regulatory submissions to health authorities  seeking approval of ofatumumab for relapsing forms of MS  by the end of this year The NYSE ARCA Pharmaceutical Index declined 0 3  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 
Here is how the seven major stocks performed in the last five trading sessions In the last week  while Glaxo rose the most  1 8    J J declined the most  2 3   In the past six months  AstraZeneca has been the biggest gainer  8 8   while Pfizer  NYSE PFE  lost the most  18 5    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-29,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-jnjs-opioid-lawsuit-regulatory-nod-for-lly-bmy-rhhby-drugs-200460324,200460324
149100,370616,AMGN,The Zacks Analyst Blog Highlights  J J  Eli Lilly  Bristol Myers  Roche And AbbVie,opinion,For Immediate ReleaseChicago  IL  September 3  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  J J   NYSE JNJ    Eli Lilly   NYSE LLY    Bristol Myers   NYSE BMY    Roche   OTC RHHBY   and AbbVie   NYSE ABBV   Here are highlights from Friday s Analyst Blog Pharma Stock Roundup  JNJ  LLY  BMY   MoreThis week  J J received an unfavorable ruling in the litigation related to abuse of its opioid based drugs  The FDA granted approval to Lilly s psoriasis injection for active ankylosing spondylitis  AS  while the European Commission approved Bristol Myers  multiple myeloma drug  Empliciti and Roche s PD L1 inhibitor  Tecentriq in combination use for an expanded patient population Recap of the Week s Most Important StoriesOklahoma Judge Rules Against J J in Opioid Lawsuit J J was ordered by a district court in to pay  572 million to the state of Oklahoma in connection with a lawsuit filed by the latter  The lawsuit claimed that J J was one of the several companies whose opioid based drugs   Duragesic  Nucynta and Nucynta ER   were responsible for fueling the state s opioid epidemic However  the fine was much lower than Oklahoma state s demand of  17 billion to be paid over 30 years by J J  The company has decided to appeal against the ruling  The company is confident that its drugs were not responsible for the opioid crisis in the state and the ruling is inconsistent with the available facts and law  There are still a number of opioid related lawsuits pending with about 1900 suits consolidated at the federal level in the state of Ohio  with trial set to begin in October this year FDA Approves Lilly s Taltz for Ankylosing Spondylitis  Lilly gained FDA approval for its psoriasis injection for its third indication   active ankylosing spondylitis  AS   A type of spondyloarthritis  AS affects the pelvic joints and spine that can cause severe back pain  The approval was based on data from two phase III studies  COAST V and COAST W  Taltz is presently marketed for treating moderate to severe plaque psoriasis and active psoriatic arthritis Lilly s  baricitinib  met the primary endpoint in a phase III BREEZE AD7 study  evaluating it in a new indication   moderate to severe atopic dermatitis  AD   a type of eczema  Lilly is conducting five studies on baricitinib under the AD program and BREEZE AD7 is the third study to be completed this year  BREEZE AD1 and BREEZE AD2 were the other two studies wherein baricitinib 4 mg and 2 mg both met the primary endpoint  Top line data from the remaining two studies are expected to be presented later this year or early next year EU Approval for Expanded Label of Bristol Myers   Roche s Cancer Medicines  The European Commission granted approval for label expansion of Bristol Myers s multiple myeloma drug    The drug is now approved in the EU for use in combination with Celgene s Pomalyst  pomalidomide  and low dose dexamethasone for the treatment of patients with relapsed refractory multiple myeloma  r rMM  in second  or later line settings  Empliciti was approved for this combination use in the United States in November last yearThe regulatory agency also gave approval to Roche s in combination with Celgene s Abraxane for the treatment of adults with PD L1 positive  metastatic triple negative breast cancer   a difficult to treat cancer  The drug was approved for the same combination use by the FDA  on an accelerated basis  in March this year  The approval was based on encouraging data from the phase III IMpassion130 study AbbVie Ends Rova T Program  AbbVie discontinued development of its cancer candidate rovalpituzumab tesirine or Rova T as the third study on the candidate  MERU  also failed  The MERU study was evaluating Rova T as a first line maintenance therapy for advanced small cell lung cancer  SCLC  compared to placebo  Interim data from the study demonstrated no survival benefit for patients treated with Rova T  The lack of survival benefit led the Independent Data Monitoring Committee to recommend terminating MERU  Rova T was added to AbbVie s portfolio  following the  5 8 billion acquisition of Stemcentrx in June 2016 In December  AbbVie stopped enrollment in a pivotal phase III study  TAHOE   evaluating Rova T in second line SCLC  In March 2018  Rova T fell short of expectations in a phase II TRINITY study evaluating it in third line or later SCLC  The failure of TRINITY and the halt on TAHOE had already raised skepticism on Rova T s potential  Discontinuation of the candidate has now broughtinto question the viability of the Stemcentrx deal Bristol Myers Expects Celgene  NASDAQ CELG  Acquisition to Close by Year End Bristol Myers moved a step closer toward the closure of its pending acquisition of Celgene this week as the latter signed a deal with Amgen  NASDAQ AMGN  to divest global commercial rights to its blockbuster psoriasis drug    Amgen will pay  13 4 billion in cash for the same to Celgene  Back in June  Bristol Myers had announced plans to divest Otezla to be able to close the acquisition of Celgene on a timely basis in light of concerns expressed by the U S  Federal Trade Commission  FTC   The sale of Otezla should now make it easier for Bristol Myers to get FTC s approval and will also fund a part of its massive  74 billion cost of buying Celgene  So  the deal looks like a win win for Bristol Myers  which expects the merger to close by the end of this year Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-09-02,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-jj-eli-lilly-bristolmyers-roche-and-abbvie-200461039,200461039
149101,370617,AMGN,Merck s Keytruda Combination Gets EC Nod For Kidney Cancer ,opinion,"Merck   Co   Inc    NYSE MRK   announced that the European Commission has approved the label expansion of its PD L1 inhibitor  Keytruda  in combination with Pfizer s   NYSE PFE   Inlyta  axitinib  for the first line treatment of advanced or metastatic renal cell carcinoma   RCC    the most common type of kidney cancer The approval was based on data from the pivotal phase III KEYNOTE 426 study  Data from the study showed that the Keytruda Inlyta combination led to significant improvements in the dual primary endpoints of overall survival and progression free survival   PFS   as well as a key secondary endpoint of objective response rate   ORR   compared to Pfizer s older kidney cancer treatment  Sutent  sunitinib   Data from the study showed that the combination led to a 31  reduction in the risk of progression of disease or death  PFS  and a 47  reduction in the risk of death  The ORR was 59 3  in the Keytruda Inlyta combination arm while the same was 35 7  in the Sutent arm Keytruda becomes the first PD 1 inhibitor to receive approval as part of any combination regimen for treating RCC in Europe  Keytruda Inlyta combination regimen was approved in the United States for a similar indication in April This approval marks the second label expansion for Keytruda in Europe and the eighth globally so far in 2019  Three more label expansion applications for Keytruda are under review in Europe including an expanded first line lung cancer indication So far this year  Merck s shares have outperformed the   rising 12 6  against the 0 7  decrease for the industry Keytruda is a key contributor to Merck s sales growth  In a very short span of time  Keytruda has become Merck s largest product  It is already approved for use in 15 indications across 10 different tumor types in the United States The drug generated sales of  4 9 billion in the first six months of 2019  reflecting a massive 56 6  surge year over year  Keytruda is continuously growing and expanding into new indications and markets globally Keytruda sales are gaining particularly from strong momentum in the first line lung cancer indication after being the first anti PD 1 therapy approved in the first line setting The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 1000 studies  including more than 600 combination studies  Merck has collaborated with several companies including Amgen   NASDAQ AMGN    Incyte   NASDAQ INCY    Glaxo and Pfizer separately for the evaluation of Keytruda in combination with other regimens We believe that Keytruda has strong future growth prospects based on increased utilization  approval for new indications and expectation of additional approvals worldwide Merck   Co   Inc  Price
    Zacks RankMerck currently carries a Zacks Rank  2  Buy   You can see  It s Illegal in 42 States  But Investors Will Make Billions LegallyIn addition to the companies you read about above  today you get details on the newly legalized industry that s tapping into a  habit  that Americans spend an estimated  150 billion on every year That s twice as much as they spend on marijuana  legally or otherwise Zacks special report revealing how investors can profit from this new opportunity  As more states legalize this activity  the industry could expand by as much as 15X  Zacks  has just released a Special Report revealing 5 top stocks to watch in this space ",2019-09-04,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-combination-gets-ec-nod-for-kidney-cancer-200461806,200461806
149102,370618,AMGN,Protagonist readies equity offering  shares up 1  after hours,news,Thinly traded micro cap Protagonist Therapeutics  NASDAQ PTGX  is up 1  after hours on light volume on the heels of its announced public offering of common stock  Price  volume and terms have yet to be announced Now read ,2017-10-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/protagonist-readies-equity-offering-shares-up-1-after-hours-540257,540257
149103,370619,AMGN,Amgen teams up with Boston Children s Hospital to identify new pain targets,news,Amgen  NASDAQ AMGN  enters into a neuroscience research collaboration with Boston Children s Hospital s Division of Pain Medicine that will leverage genetic analyses to identify new pain targets  The one year partnership will focus on patients with genetic abnormalities of pain sensitivity Financial terms are not disclosed Now read ,2017-10-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgen-teams-up-with-boston-childrens-hospital-to-identify-new-pain-targets-542337,542337
149109,370625,AMGN,AstraZeneca s tezepelumab shows significant treatment benefit in mid stage asthma study  shares up 1  premarket,news,AstraZeneca  NYSE AZN  and collaboration partner Amgen  NASDAQ AMGN  announce positive results from the Phase 2b PATHWAY study assessing tezepelumab in patients with severe uncontrolled asthma  The data  published today in the New England Journal of Medicine  showed treatment with tezepelumab  given as add on therapy  reduced annual asthma exacerbation rates by as much as 71  versus placebo  p 0 001  Tezepelumab is a novel anti thymic stromal lymphopoietin  TSLP  monoclonal antibody being developed by AZN s MedImmune  in collaboration with Amgen  TSLP is an upstream pro inflammatory epithelial cytokine that plays a key role in a range of diseases  including asthma  Blocking TSLP may prevent the release of pro inflammatory cytokines The development of tezepelumab is ongoing AZN is up 1  and AMGN up a fraction premarket Now read ,2017-09-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/astrazenecas-tezepelumab-shows-significant-treatment-benefit-in-midstage-asthma-study-shares-up-1-premarket-526372,526372
149110,370626,AMGN,Roche s Actemra RoActemra OK d in Europe for giant cell arteritis,news,The European Commission approves Roche s  OTCQX RHHBY  Actemra RoActemra  tocilizumab  for the treatment of giant cell arteritis  GCA   a potentially life threatening autoimmune disorder The approval was based on the Phase 3 GiACTA study that showed a weekly dose of Actemra RoActemra  initially combined with a six month steroid taper  significantly increased the proportion of patients achieving sustained remission at one year compared to the steroid taper alone The FDA approved Actemra RoActemra for GCA in May Now read ,2017-09-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/roches-actemraroactemra-okd-in-europe-for-giant-cell-arteritis-531816,531816
149112,370628,AMGN,Company News For Aug 27  2019,opinion,Shares of Amgen Inc    NASDAQ AMGN   rose 3 2  after the company announced agreement to buy Otzela  a subsidiary of Celgene Corp    NASDAQ CELG  Shares of Pitney Bowes Inc    NYSE PBI   fell 8 3  after it announced sell of its software solutions business to data company SyncsortShares of Beyond Meat  Inc    NASDAQ BYND   plunged 5 6  following the announcement that KFC will start testing its plant based chicken in an Atlanta restaurantSRC Energy Inc    NYSE SRCI   and PDC Energy  Inc  s   NASDAQ PDCE   shares rose more than 12  and 17   respectively  following the announcement of merger in a deal worth  1 7 billion,2019-08-26,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-aug-27-2019-200458990,200458990
149115,370631,AMGN,Top Ranked Momentum Stocks To Buy For August 28th,opinion,"Here are four stocks with buy rank and strong momentum characteristics for investors to consider today  August 28th Arconic Inc   ARNC   This manufacturer and seller of lightweight metals has a Zacks Rank  1  Strong Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 14 6  over the last 60 days Arconic Inc  Price and Consensus   Arconic s shares gained 0 1  over the last one month compared to S P 500 s fall of  5   The company possesses a  of A 
Arconic Inc  Price   Amgen  AMGN   This developer and manufacturer of innovative human therapeutics has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2 4  over the last 60 days 
Amgen Inc  NASDAQ AMGN   Price and Consensus   Amgen s shares gained 17 3  over the last one month  The company possesses a Momentum Score of B 
Amgen Inc  Price   Asanko Gold Inc   AKG   This explorer and developer of gold properties has a Zacks Rank  1  Strong Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100  over the last 60 days 
Asanko Gold Inc  Price and Consensus   Asanko s shares gained 35 1  over the last one month  The company possesses a Momentum Score of B 
Asanko Gold Inc  Price   Aerojet Rocketdyne Holdings  Inc   AJRD   This manufacturer of aerospace and defense products and systems has a Zacks Rank  1  Strong Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 13 8  over the last 60 days 
Aerojet Rocketdyne Holdings  Inc  Price and Consensus   Aerojet Rocketdyne s shares gained 17 1  over the last one month  The company possesses a Momentum Score of B 
Aerojet Rocketdyne Holdings  Inc  Price   See the 
Learn more about the  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-08-27,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-momentum-stocks-to-buy-for-august-28th-200459511,200459511
149117,370633,AMGN,Amgen teams up with Simcere to commercialize four biosimilars in China,news,Amgen  NASDAQ AMGN  inks an agreement with Simcere Pharmaceutical Group to co develop and commercialize four biosimilars in China  including undisclosed products in oncology and inflammation and Amgen s current biosimilar portfolio Under the terms of the partnership  Amgen will be responsible for co development  regulatory applications and manufacturing  Simcere will be responsible for distribution and commercialization while Amgen will have a limited right to co promote Financial terms are not disclosed Now read ,2017-09-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgen-teams-up-with-simcere-to-commercialize-four-biosimilars-in-china-533164,533164
149118,370634,AMGN,Wall St  edges up on healthcare  tax plan hopes,news,"By Chuck Mikolajczak  Reuters    Wall Street edged higher on Thursday  with the S P 500 poised to close at a record on gains in McDonald s and healthcare names  while investors continued to hope President Donald Trump will be able to make progress on tax reform   Shares in the world s biggest fast food chain  N MCD  rose 2 36 percent  their biggest single day percentage gain in more than two months  after Longbow Research upgraded the stock to  buy   Financials  SPSY   up 0 03 percent  and the Russell 2000 index of smallcap stocks  RUT   up 0 17 percent  which are expected to be among the beneficiaries of a tax reduction  turned higher after trading lower in the early portion of the session   But gains were tempered with equities at record highs and valuations elevated  The forward price to earnings ratio  P E  on the S P stood at 17 9 compared with its long term average of 15 1 while the forward P E on the Russell is 26 3 against an average of 21 3   The market is doing what it has been doing a lot of this year  it doesn t surge to new levels  it just crawls to new levels   said Scott Wren  senior global equity strategist at  Wells Fargo   NYSE WFC  Investment Institute in St  Louis    People are comfortable owning stocks  but for us  these valuations are pretty stretched  especially for something like smallcaps    U S  Treasury Secretary Steven Mnuchin said Trump s proposal for a cut in the corporate income tax rate to 20 percent was  not negotiable   The plan  which called for tax cuts for most Americans  also drew criticism for favoring business and the rich and potentially adding trillions of dollars to the deficit  A Commerce Department report showed the economy grew a bit faster than previously estimated in the second quarter  but the momentum probably slowed in the third as Hurricanes Harvey and Irma temporarily curbed activity  The storms also pushed up initial claims for state unemployment benefits for the week  the Labor Department said   The Dow Jones Industrial Average  DJI  rose 37 11 points  or 0 17 percent  to 22 377 82  the S P 500  SPX  gained 1 84 points  or 0 07 percent  to 2 508 88 and the Nasdaq Composite  IXIC  dropped 7 07 points  or 0 11 percent  to 6 446 19  The healthcare index  SPXHC  led S P gainers  rising by a third of a percent   AbbVie  N ABBV  was the biggest boost to the S P  rising more than 5 6 percent after announcing a global resolution of intellectual property related litigation with Amgen  O AMGN   Abbott  N ABT  also rose almost 3 percent after the U S  FDA approved the company s glucose monitoring device  The company also won U S  antitrust approval to buy  Alere Inc   N ALR  on condition that it sell two point of care medical testing businesses  
Advancing issues outnumbered declining ones on the NYSE by a 1 22 to 1 ratio  on Nasdaq  a 1 33 to 1 ratio favored advancers ",2017-09-28,Reuters,https://www.investing.com/news/stock-market-news/futures-flat-ahead-of-gdp-jobs-data-534077,534077
149122,370638,AMGN,Here s Why Merck  MRK  Is Outperforming Its Industry Of Late,opinion,Merck   Co   Inc    NYSE MRK   shares have risen 11 9  this year so far against the  s decrease of 2 1    Earnings estimates for 2019 and 2020 have risen 3 2  and 1 1   respectively over the past 30 days What s Behind the Rally A significant part of Merck s outperformance this year so far has been driven by strong performance and positive regulatory updates related to its PD 1 inhibitor  Keytruda  In a short span of time  Keytruda has become Merck s biggest product  It is now already approved for use in 20 cancer indications across 12 different tumor types in the United States  The drug generated sales of almost  5 0 billion in the first half of 2019  reflecting a massive 56 6  surge year over year Keytruda is continuously growing and expanding into new indications and markets globally  Strong momentum in first line lung cancer indication and recent launch in newer indications   renal cell carcinoma and adjuvant melanoma   are driving Keytruda sales The Keytruda development program is also progressing well with Merck spending billions for research and development of this medicine to secure more approvals in earlier lines of treatment  The drug is being studied for more than 30 types of cancer in more than 1000 studies  including more than 600 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte  NASDAQ INCY   Glaxo and Pfizer   NYSE PFE   separately for the evaluation of Keytruda in combination with other regimens  This year so far  Keytruda has gained several label expansion approvals  In July  Keytruda was approved by the FDA as a monotherapy for advanced esophageal cancer  In June  it was approved by the FDA for first line treatment of recurrent or metastatic head and neck squamous cell cancer and for previously treated advanced small cell lung cancer  In April  the FDA gave approval to Keytruda in combination with Pfizer s Inlyta for the first line treatment of advanced renal cell carcinoma as well as for an expanded first line lung cancer patient population  In the first quarter  it was approved by the FDA as an adjuvant therapy for high risk stage III melanoma and for five new cancer line extensions in Japan  All these label expansion approvals should drive sales of Keytruda higher in the future quarters Several regulatory decisions for new indications in the United States as well as in Europe are due this year  A regulatory nod will further boost sales  Other than that  this year Merck gained FDA approval for its new combination antibacterial injection  Recarbrio  MK 7655A   a fixed combination of relebactam with imipenem cilastatin  and a new indication   two types of pneumonia infections   for its antibacterial medicine  Zerbaxa  It also gained several label expansion approvals for its and partner AstraZeneca s   NYSE AZN   PARP inhibitor Lynparza including in front line ovarian cancer in EU and Japan and for advanced breast cancer in the EU Merck has also been on a strong footing as far as collaborations and M A activity are concerned  In this year  Merck bought small cancer focused biotech  Immune Design and privately held Europe s animal health technology provider  Antelliq Group  In May and June  it announced dealsto buy small private biotechs  Peloton Therapeutics and Tilos Therapeutics for around  1 05 billion and 773 million  respectively  These deals should close later in the year ConclusionMerck  which carries a Zacks Rank  2  Buy   has its share of challenges in the form of generic competition for several drugs  pricing pressure and rising competitive pressure on the diabetes franchise and on products like Isentress  HIV  and Zepatier  HCV  Nonetheless  going forward  new products like Keytruda  Lynparza  and Bridion should continue to contribute meaningfully to the top line  Animal health and vaccine products are also performing strongly and remain core growth drivers for Merck Also  Merck can gain approval for its vaccine for Ebola Zaire  V920 and further line extensions for Keytruda and Lynparza in the second half of 2019  Meanwhile  Merck is expected to continue its cost cutting initiatives  which should drive its bottom line You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-08-27,Zacks Investment Research,https://www.investing.com/analysis/heres-why-merck-mrk-is-outperforming-its-industry-of-late-200459469,200459469
149125,370641,AMGN,What Investors Need To Know About The Celgene  Amgen   Bristol Myers Deals,opinion,"On Monday  Celgene   NASDAQ CELG   announced a sale of its psoriasis drug Otezla for  13 4 billion to Amgen   NASDAQ AMGN    This deal will be all cash and is expected to clear before the end of the year  Celgene s stock climbed 3 2  the day of the announcement and has risen another 0 5  since then 
The Sale
Bristol Myers Squibb will buy Celgene contingent on Celgene s sale of its Otezla drug to Amgen 
Celgene began looking for a buyer for Otezla after U S  regulators raised antitrust concerns over a proposed acquisition of Celgene by Bristol Myers Squibb   NYSE BMY    Regulators are likely concerned about BMY s psoriasis drug in late stage development that would be similar to Otezla 
The sale is contingent on approval from regulators and the subsequent acquisition of Celgene by BMY  Amgen expects this deal to be worth about  11 2 billion after anticipated future cash tax benefits  This is much higher than the  8  10 billion range that analysts expected  However  Amgen released a statement after the announcement saying  We re doubtful investors will miss the additional cash required to bring Otezla on board from AMGN s balance sheet   Recall  AMGN finished Q2 with  22B in cash  
Impact
Last year  Otezla brought in  1 61 billion in sales for Celgene  Amgen anticipates sales to grow by low single digits over the next five years due to its compatible portfolio of other anti inflammatory drugs  Otezla has already shown impressive growth since its 2014 approval  with sales up over 300  from 2015 to 2018  and Amgen does not expect this to stop  This will boost Amgen s top line significantly and help offset recent pressure from copycats of its Neulasta and Sensipar drugs 
Currently  BMY s acquisition of Celgene is expected to be worth about  74 billion  Bristol Myers Squibb stated that it would use cash from Celgene s sale of Otezla sale to pare down debt incurred as a result of its Celgene purchase  The company will target a better debt to EBITDA ratio of 1 5x by 2023  using this sale to start  BMY also announced it would increase its already accelerated share buyback program from  5 billion to  7 billion 
Let s now look at the individual financial estimates for Bristol Myers Squibb and Celgene to gain insight into the combined company s possible future 
Celgene
Celgene stock is up 51 7  YTD  beating the large cap pharma market s performance of  2 0   Celgene is also a Zacks Rank  3  Hold  at the moment  with earnings estimates having been revised in both directions in the past 60 days 
Earnings estimates show a current quarter growth of 19 21  to  2 73 per share  Next quarter is projected to come in 18 41  above last year  along with a full year estimate of  10 87 per share  a 22 55  jump  Fiscal 2020 is predicted to see earnings continue to rise 10 14  to  11 97 for the full year 
Bristol Myers Squibb 
For Q3 2019  our Zacks Consensus Estimates show earnings shrinking by 3 67  over the year ago period  to  1 05  Investors should note that BMY crushed Q2 fiscal 2018 s  0 91 per share estimate when it posted  1 09  Meanwhile  full year earnings are projected to grow 7 54   Earnings for the following year are projected to jump another 18 67  
BMY currently holds a Zacks Rank  1  Strong Buy   due to positive earnings estimate revisions for full year fiscal 2019  It is also currently trading at a discount with a forward P E ratio of just 9 7x compared to the large cap pharma average of 14 1x 
Bottom Line
Analysts expect this deal to close by the end of the year  and for anti trust regulators to approve it after the Otezla sale  Both companies look promising financially  making it likely that the deal will create a pharma powerhouse  Investors should look for more news on this deal as it approaches completion  as it is possible to make gains if the combined company operates successfully 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/what-investors-need-to-know-about-the-celgene-amgen--bristolmyers-deals-200459615,200459615
149131,370647,AMGN,Canaccord defends Radius Health after FDA rejection of Amgen s romosozumab application,news,Canaccord Genuity says its rating  BUY  85  on Radius Health  RDUS  2 2   makes sense because its osteoporosis drug TYMLOS  abaloparatide  has a better risk benefit profile than Amgen  NASDAQ AMGN  s romosozumab which means the latter should not present a credible challenge to TYMLOS uptake  It adds that the FDA could reject romosozumab outright due to its cardiovascular risks  Amgen just received a CRL and will have to include data from the ARCH study in its resubmission  Another positive for Radius is RAD 1901  elacestrant  in breast cancer  Early stage study results are encouraging Previously  FDA rejects Amgen s marketing application for osteoporosis candidate romosozumab  resubmission to include ARCH and BRIDGE data  July 17 Previously  Late stage extension study confirms long term treatment effect of Radius Health s TYMLOS  shares up 3  after hours  May 24 Source  Briefing comNow read ,2017-07-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/canaccord-defends-radius-health-after-fda-rejection-of-amgen's-romosozumab-application-506889,506889
149132,370648,AMGN,CryoPort inks deal with Novartis for logistics support of CAR Ts  shares ahead 7  premarket,news,CryoPort  NASDAQ CYRX  is up 7  premarket on light volume in response to its announcement that it has inked a three year agreement with Novartis  NYSE NVS  for cryogenic logistics support for CTL019 CD19 CAR T cell therapy The company says its support will include the use of its Cryoport Express shippers  SmartPak II Condition Monitoring System  Cryoportal Logistics Management Platform  chain of condition and chain of custody monitoring  and around the clock logistics support Financial terms are not disclosed Now read ,2017-07-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/cryoport-inks-deal-with-novartis-for-logistics-support-of-car-ts;-shares-ahead-7-premarket-509598,509598
149135,370651,AMGN,TESARO out licenses niraparib to Takeda for up to  340M,news,TESARO  TSRO  0 3   inks an exclusive licensing agreement with Takeda Pharmaceutical Company  OTCPK TKPHF  enabling the latter to develop and commercialize the PARP inhibitor for all tumor types in Japan and all tumor types except prostate cancer in South Korea  Taiwan  Russia and Australia Under the terms of the deal  TESARO will receive  100M upfront  up to  240M in milestones and tiered double digit royalties on net sales  Additional terms are not disclosed TESARO launched Niraparib in the U S  in April under the brand name ZEJULA for the treatment of recurrent ovarian cancer Now read ,2017-07-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/tesaro-out-licenses-niraparib-to-takeda-for-up-to-$340m-511078,511078
149138,370654,AMGN,FDA accepts Amgen s application to include survival data in Kyprolis label,news,The FDA accepts for review Amgen s  NASDAQ AMGN  supplemental New Drug Application  sNDA  seeking to add overall survival data from the Phase 3 ENDEAVOR study to the package insert of KYPROLIS  carfilzomib   The data showed KYPROLIS   dexamethasone reduced the risk of death by 21  and increased overall survival by 7 6 months compared to Takeda s Velcade   dexamethasone in patients with treatment resistant multiple myeloma The agency s action date is April 30  2018 Previously  Amgen s Kyprolis beats Takeda s Velcade in late stage MM study  Feb  28 Now read ,2017-08-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-accepts-amgens-application-to-include-survival-data-in-kyprolis-label-524047,524047
149142,370658,AMGN,Amgen  AMGN  Moves To Buy  Rationale Behind The Upgrade,opinion,"Amgen  AMGN  could be a solid choice for investors given its recent upgrade to a Zacks Rank  2  Buy   This upgrade is essentially a reflection of an upward trend in earnings estimates    one of the most powerful forces impacting stock prices 
The Zacks rating relies solely on a company s changing earnings picture  It tracks EPS estimates for the current and following years from the sell side analysts covering the stock through a consensus measure    the Zacks Consensus Estimate 
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts  since these are mostly driven by subjective factors that are hard to see and measure in real time  In these situations  the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near term stock price movements 
Therefore  the Zacks rating upgrade for Amgen basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  has proven to be strongly correlated with the near term price movement of its stock  The influence of institutional investors has a partial contribution to this relationship  as these big professionals use earnings and earnings estimates to calculate the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their transaction of large amounts of shares then leads to price movement for the stock 
Fundamentally speaking  rising earnings estimates and the consequent rating upgrade for Amgen imply an improvement in the company s underlying business  Investors should show their appreciation for this improving business trend by pushing the stock higher 
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  so it could be truly rewarding if such revisions are tracked for making an investment decision  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for Amgen
This world s largest biotech drugmaker is expected to earn  14 25 per share for the fiscal year ending December  2019  which represents a year over year change of  1  
Analysts have been steadily raising their estimates for Amgen  Over the past three months  the Zacks Consensus Estimate for the company has increased 2 2  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of Amgen to a Zacks Rank  2 positions it in the top 20  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2019-08-21,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-moves-to-buy-rationale-behind-the-upgrade-200457699,200457699
149143,370659,AMGN,Top Ranked Momentum Stocks To Buy For August 26th,opinion,"Here are four stocks with buy rank and strong momentum characteristics for investors to consider today  August 26th Arbor Realty Trust  Inc   ABR   This real estate investment trust and national direct lenderhas a Zacks Rank  1  Strong Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 8 1  over the last 60 days Arbor Realty Trust Price and Consensus   Arbor Realty s shares gained 2 2  over the last one month compared to S P 500 s fall of  5 8   The company possesses a  of B 
Arbor Realty Trust Price   YAMANA GOLD INC   AUY   This precious metals producer with significant gold and silver production has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 75  over the last 60 days 
Yamana Gold Inc  Price and Consensus   YAMANA s shares gained 23 1  over the last one month  The company possesses a Momentum Score of A 
Yamana Gold Inc  Price   Amgen  AMGN   This developer and manufacturer of innovative human therapeutics has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2 4  over the last 60 days 
Amgen Inc  NASDAQ AMGN   Price and Consensus   Amgen s shares gained 13 1  over the last one month  The company possesses a Momentum Score of A 
Amgen Inc  Price   ACADIA Pharmaceuticals Inc   ACAD   This biopharmaceutical company has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6 3  over the last 60 days 
ACADIA Pharmaceuticals Inc  Price and Consensus   ACADIA s shares gained 16 5  over the last one month  The company possesses a Momentum Score of B 
ACADIA Pharmaceuticals Inc  Price   See the 
Learn more about the  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-26,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-momentum-stocks-to-buy-for-august-26th-200458664,200458664
149144,370660,AMGN,Amgen To Buy Celgene s Otezla  5 ETF Drugs,opinion,Amgen   NASDAQ AMGN   agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene   NASDAQ CELG   for  13 4 billion in cash  The deal could pave the way for one of the pharmaceutical industry s largest mergers of the past decade   Bristol Myers Squibb s   NYSE BMY   proposed acquisition of Celgene Corp   NASDAQ CELG   for  74 billion in a cash and stock deal  read    Otezla offers huge growth to Amgen as it has patent exclusivity through at least 2028 in the United States  Additionally  the drug will provide patients an innovative oral therapy for psoriasis and psoriatic arthritis that fits in well with the company s anti inflammatory injectable Enbrel  prospects of which got a boost recently after a U S  judge upheld two patents protecting the drug s active ingredient until 2029  effectively denying a biosimilar challenge by Novartis AG   NYSE NVS   Further  the acquisition of the psoriasis drug is expected to be accretive to Amgen s revenues and non GAAP EPS immediately after the completion of the deal  Otezla s sales are expected to grow at least in the low double digits over the next five years  The psoriasis drug had generated  1 61 billion in sales last year and is expected to bring in revenues of  2 71 billion in 2023  according to analysts  estimates compiled by Bloomberg  see    ETF ImpactInvestors seeking to play Amgen s strong future growth story could consider ETFs having the largest allocation to this biotech company  We have highlighted some of them in detail below VanEck Vectors Biotech ETF   LON BBH  This fund offers exposure to 25 large biotechnology corporations by tracking the MVIS US Listed Biotech 25 Index  Amgen is the top firm accounting for 9 9  share  BBH has amassed  343 5 million in its asset base and charges 35 basis points in fees per year  It sees a light volume of 15 000 shares per day on average and has a Zacks ETF Rank  2  Buy  with a High risk outlook  read    iShares Nasdaq Biotechnology ETF This fund provides exposure to 2219 firms by tracking the Nasdaq Biotechnology Index  with AMGN taking the top spot at 9 42   IBB is the most popular fund is the biotech space with AUM of  6 7 billion  Expense ratio comes in at 0 47   The product trades in average daily volume of 2 5 million shares and has a Zacks ETF Rank  2 with a High risk outlook Invesco Dynamic Biotechnology   Genome ETF This fund follows the Dynamic Biotech   Genome Intellidex Index  It holds 29 stocks in its basket with AMGN occupying the top spot at 6 11  share  It has managed  227 7 million in its asset base while trades in a light volume of 16 000 shares per day  Expense ratio comes in at 0 59   The product has a Zacks ETF Rank  3  Hold  with a High risk outlook  read   Invesco Dynamic Pharmaceuticals ETF   WA PJP  With AUM of about  367 4 million  this ETF targets the pharma corner of the broad healthcare sector and follows the Dynamic Pharmaceuticals Intellidex Index  It holds 30 stocks in its basket  with Amgen taking 6 12   The product trades in average daily volume of 37 000 shares and charges 57 bps in fees and expenses  It has a Zacks ETF Rank  3 with a High risk outlook  read    iShares Evolved U S  Innovative Healthcare ETF This actively managed ETF employs data science techniques to identify companies with exposure to the innovative healthcare sector  Holding 213 stocks in its basket  BMY takes the seventh spot at 4 45   The product has accumulated  4 8 million in its asset base and charges 18 bps in annual fees  Volume is light  trading in about 2 000 shares a day on average Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-08-26,Zacks Investment Research,https://www.investing.com/analysis/amgen-to-buy-celgenes-otezla-5-etf-drugs-200458992,200458992
149152,370668,AMGN,FDA rejects Pfizer s marketing application for Epogen biosimilar,news,Pfizer   NYSE PFE  receives a Complete Response Letter  CRL  from the FDA regarding its marketing application seeking approval of its biosimilar to Amgen s  NASDAQ AMGN  Epogen  epoetin alfa   The CRL relates to a warning letter issued in February after an on site inspection of the company s McPherson  KS facility  a potential manufacturing site for the product The company says it is working with the agency to address the issues Source  Bloomberg First WordNow read ,2017-06-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-rejects-pfizer's-marketing-application-for-epogen-biosimilar-498469,498469
149155,370671,AMGN,European Ad Com backs pediatric formulation of Amgen s Mimpara,news,The European Medicines Agency s Committee for Medicinal Products for Human Use  CHMP  adopts a positive opinion recommending approval of a pediatric formulation of Amgen s  NASDAQ AMGN  Mimpara  cinacalcet  for the treatment of secondary hyperparathyroidism  HPT  in children at least three years old with end stage renal disease on maintenance dialysis therapy whose HPT is not controlled adequately with standard of care therapy Mimpara is currently approved in Europe to treat adults with HPT and to reduce hypercalcemia  excessive amount of calcium in the blood  in adult patients with cancer of the parathyroid glands or with primary HPT A final decision from the European Commission usually takes  60 days Now read ,2017-06-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/european-ad-com-backs-pediatric-formulation-of-amgen's-mimpara-498860,498860
149156,370672,AMGN,FDA Ad Com backs Amgen s ABP 215 in unanimous vote,news,The FDA s Oncologic Drugs Advisory Committee votes 17   0 in favor of approving Amgen s  AMGN  0 6   ABP 215  a biosimilar to Roche s AVASTIN  bevacizumab  Previously  Ad Com review today for Amgen s ABP 215  July 13 Now read ,2017-07-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-ad-com-backs-amgen's-abp-215-in-unanimous-vote-505427,505427
149159,370675,AMGN,Is Amgen  AMGN  Outperforming Other Medical Stocks This Year ,opinion,"Investors interested in Medical stocks should always be looking to find the best performing companies in the group  Is Amgen  AMGN  one of those stocks right now  A quick glance at the company s year to date performance in comparison to the rest of the Medical sector should help us answer this question 
Amgen is one of 866 companies in the Medical group  The Medical group currently sits at  3 within the Zacks Sector Rank  The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors 
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months  The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks  AMGN is currently sporting a Zacks Rank of  2  Buy  
Over the past 90 days  the Zacks Consensus Estimate for AMGN s full year earnings has moved 2 19  higher  This is a sign of improving analyst sentiment and a positive earnings outlook trend 
Based on the most recent data  AMGN has returned 5 71  so far this year  Meanwhile  the Medical sector has returned an average of 2 51  on a year to date basis  This means that Amgen is outperforming the sector as a whole this year 
To break things down more  AMGN belongs to the Medical   Biomedical and Genetics industry  a group that includes 367 individual companies and currently sits at  83 in the Zacks Industry Rank  Stocks in this group have lost about 1 61  so far this year  so AMGN is performing better this group in terms of year to date returns 
AMGN will likely be looking to continue its solid performance  so investors interested in Medical stocks should continue to pay close attention to the company ",2019-08-12,Zacks Investment Research,https://www.investing.com/analysis/is-amgen-amgn-outperforming-other-medical-stocks-this-year-200454591,200454591
149160,370676,AMGN,Amgen submits regulatory filings to add OS data to Kyprolis label,news,Amgen  AMGN  0 3   files regulatory applications in the U S  and Europe seeking approval to add overall survival  OS  data to the label of multiple myeloma med KYPROLIS  carfilzomib  The results were generated in the Phase 3 ENDEAVOR study which showed almost an eight month survival benefit over Takeda s VELCADE  bortezomib  Previously  Amgen s Kyprolis beats Takeda s Velcade in late stage MM study  Feb  28 Now read ,2017-07-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgen-submits-regulatory-filings-to-add-os-data-to-kyprolis-label-505766,505766
149162,370678,AMGN,Merck s Cancer Immunotherapy Keytruda Continues To Aid Growth,opinion,The demand for checkpoint inhibitors  especially those targeting PD 1 and PD L1  has risen significantly in the past couple of years  Cancer therapies that target either PD 1 or PD L1 can stop them from attaching and prevent cancer cells from hiding PD L1 inhibitors available on the market are Merck s   NYSE MRK   Keytruda  AstraZeneca s   NYSE AZN   Imfinzi  Bristol Myers    NYSE BMY   Opdivo  Roche s Tecentriq and Pfizer s   NYSE PFE   Bavencio Keytruda continues to be a key contributor to Merck s sales  In a short span of time  Keytruda has become Merck s biggest product  It is now already approved for use in 20 indications across 12 different tumor types in the United States  The drug generated sales of almost  5 0 billion in the first half of 2019  reflecting a massive 56 6  surge year over year Keytruda is continuously growing and expanding into new indications and markets globally  Keytruda sales are gaining from strong momentum in first line lung cancer indication and recent launch in newer indications   renal cell carcinoma and adjuvant melanoma The Keytruda development program is also progressing well with Merck spending billions for research and development of this medicine to secure more approvals in earlier lines of treatment  The drug is being studied for more than 30 types of cancer in more than 1000 studies  including more than 600 combination studies  Merck is collaborating with several companies including Amgen  NASDAQ AMGN   Incyte  NASDAQ INCY   Glaxo and Pfizer separately for the evaluation of Keytruda in combination with other regimens  This year so far  Keytruda has gained several label expansion approvals  In July  Keytruda was approved by the FDA as a monotherapy for advanced esophageal cancer  In June  it was approved by the FDA for first line treatment of recurrent or metastatic HNSCC and for previously treated advanced small cell lung cancer  In April  the FDA gave approval to Keytruda in combination with Pfizer s Inlyta for the first line treatment of advanced renal cell carcinoma as well as for an expanded first line lung cancer patient population  In the first quarter  it was approved by the FDA as an adjuvant therapy for high risk stage III melanoma and for five new cancer line extensions in Japan  All these label expansion approvals should drive sales of Keytruda higher in the future quarters Several regulatory decisions for new indications in the United States as well as in Europe are pending in the rest of the year  which if approved can further boost sales  Though Keytruda has its share of side effects and has suffered some major pipeline setbacks  we believe the drug has strong growth prospects based on increased utilization  recent approvals for new indications and potential additional approvals worldwide Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-15,Zacks Investment Research,https://www.investing.com/analysis/mercks-cancer-immunotherapy-keytruda-continues-to-aid-growth-200455399,200455399
149167,370683,AMGN,Amgen Wins Enbrel U S  Patent Litigation Against Novartis,opinion,Amgen Inc    NASDAQ AMGN   announced that a district court of New Jersey has upheld the validity of its two patents on blockbuster rheumatoid arthritis drug Enbrel against Novartis    NYSE NVS   generic arm  Sandoz The two patents describe and claim Enbrel and methods for making it  Novartis said it will appeal the ruling to the US Court of Appeals for the Federal Circuit Sandoz received FDA approval for the biosimilar version of Enbrel  Erelzi in August 2016  However  Erelzi could not be launched in the United States due to the ongoing litigation with Amgen  The latest district court ruling prevents Sandoz from launching Erelzi  at least for now  and further delays its launch Amgen s shares rose almost 6  on Friday as the favorable patent ruling came as a relief to investors concerned about potential competition to Enbrel  Amgen shares have risen 0 8  this year so far against 1 3  decrease registered by the during this period   Despite lower demand hurting volumes of Enbrel  it remains the largest drug for Amgen  generating sales of  2 5 billion in the first half of 2019  Biosimilars of Enbrel are already eroding its revenues in the ex U S  market  The drug would face a rapid erosion in its sales if a biosimilar version is launched in the United States  We remind investors that Pfizer   NYSE PFE   has exclusive rights to Enbrel outside the United States and Canada Sandoz was the first company to receive FDA approval for a biosimilar version of Enbrel  The FDA had approved Erelzi for the treatment of multiple inflammatory diseases  We remind investors that the decision was not unexpected as the FDA s Arthritis Advisory Committee  AAC  had unanimously voted  20 0  in favor of Erelzi s approval in Jul 2016  In April 2019  the FDA approved a second biosimilar version of Enbrel  Eticovo made by Samsung  KS 005930  Bioepis  Amgen is also in a similar litigation with Samsung BioepisBiosimilars are having a negative impact on key products of Amgen like Neupogen  Epogen and Sensipar  Several generic versions of Neupogen have been launched  which have significantly pulled down sales  For Neulasta  two companies  Mylan   NASDAQ MYL   and Coherus launched biosimilars in the United States in mid 2018 early 2019 while three long acting biosimilar competitors were launched in the EU  These launches are hurting sales  More biosimilars are expected to be launched in 2019  which will put further pressure on Neulasta sales  Pfizer s Retacrit  the first biosimilar version of Epogen  was launched in November  Other biosimilar versions of Epogen may also receive approval in 2019  Sensipar lost patent exclusivity in March 2018 and generics have been launched  at risk Amgen currently carries a Zacks Rank  2  Buy   You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-11,Zacks Investment Research,https://www.investing.com/analysis/amgen-wins-enbrel-us-patent-litigation-against-novartis-200454278,200454278
149172,370688,AMGN,Cost controls help offset lower Amgen first quarter drug sales,news,"By Bill Berkrot  Reuters     Amgen Inc   O AMGN  on Wednesday reported higher than expected first quarter profit as cost controls helped offset a sharp drop in sales of Enbrel  its blockbuster rheumatoid arthritis and psoriasis drug  But an earnings beat based on lower expenses rather than sales growth did not please investors and Amgen shares fell more than 3 percent to  159 00 in after hours trading  Sales of Enbrel  faced with increased competition and slowing growth in the rheumatology and dermatology sectors  dropped 15 percent to  1 18 billion  below Wall Street estimates of about  1 38 billion  Enbrel has traditionally been a growth driver for Amgen  although the company had cautioned that pricing pressure would likely hit the franchise this year   The biggest weakness on the top line was definitely Enbrel  It s in decline   said Cowen and Co analyst Eric Schmidt  adding that inventory stocking in the prior quarter likely contributed to the sales drop   Total sales fell 1 percent to  5 5 billion  shy of analysts  consensus estimates of  5 6 billion  Excluding items  Amgen had adjusted earnings of  3 15 per share  topping analysts  average expectations by 15 cents  according to Thomson Reuters I B E S  Amgen maintained its full year revenue forecast of  22 3 billion to  23 1 billion  It raised the low end of its adjusted 2017 earnings forecast by 20 cents to  12 00 per share  but kept the top end of the range at  12 60  Total operating expenses fell 8 percent to  2 87 billion  helped by a 12 percent drop in research and development spending  The company s potent new cholesterol drug Repatha  faced with reimbursement barriers from insurers and pharmacy benefit managers  had sales of just  49 million  Data showing that it does indeed cut the risk of heart attacks and strokes  expected to greatly improve payer and physician acceptance of the expensive medicine  did not come out until late in the quarter and so was not reflected in the sales for the period  Still  Schmidt said   it s not good when your growth franchise is weak  even if it s early days    The world s largest biotechnology company said net profit rose to  2 07 billion  or  2 79 per share  from  1 9 billion  or  2 50 per share  a year ago  Other key medicines performed better  with sales of osteoporosis drug Prolia rising 21 percent to  425 million  ahead of Wall Street estimates of about  415 million  
Sales of infection fighter Neulasta rose 2 percent to  1 21 billion  above analyst expectations of  1 13 billion ",2017-04-26,Reuters,https://www.investing.com/news/stock-market-news/amgen-first-quarter-profit-exceeds-street-estimates-on-lower-costs-477769,477769
149175,370691,AMGN,Temasek  Yunfeng lead  75 million funding into China genomics firm,news,"SHANGHAI  Reuters    Jack Ma s private equity firm Yunfeng Capital and Singapore s Temasek have led a  75 million fund raising round into genomics company WuXi NextCODE  the firm said in a statement on Tuesday  underlining a race for medical data in China  WuXi NextCODE  a contract genomics organization with offices in Shanghai  Iceland and the United States  said it would use the funds to commercialize its products for China  and boost its capabilities in artificial intelligence and deep learning  Chinese firms are increasingly looking to boost capabilities in genomics amid a drive into higher tech medicines  where understanding and mapping DNA related data can help develop targeted medicines and treatments   We are building the world s leading genomics data platform  applying genome sequencing data at a scale to improve human health and wellness around the world   Hannes Smarason  WuXi NextCODE s chief executive  said in the statement  He added their data would support a drive to develop precision medicines  which China plans to focus on in its latest five year plan  as well as genome driven diagnostics  
The series B financing round also included Amgen Inc s  O AMGN  venture capital fund Amgen Ventures and private equity firm 3W Partners  WuXi NextCODE said ",2017-05-02,Reuters,"https://www.investing.com/news/stock-market-news/temasek,-yunfeng-lead-$75-million-funding-into-china-genomics-firm-479180",479180
149177,370693,AMGN,Galmed beats by  0 12  beats on revenue,news,Galmed  NASDAQ GLMD   Q1 EPS of   0 26 beats by  0 12 Revenue of  0 27M beats by  0 01M Press ReleaseNow read ,2017-05-15,Seeking Alpha,"https://www.investing.com/news/stock-market-news/galmed-beats-by-$0.12,-beats-on-revenue-484259",484259
149180,370696,AMGN,Majka takes yellow jersey after winning stage 2 in California,news, Reuters    Pole Rafal Majka fought strong headwinds and a late push by New Zealand s George Bennett to win a hilly stage two and earn the yellow jersey at the Tour of California on Monday  Majka took the leader s jersey from Marcel Kittel  winner of Monday s opening stage and one of the favorites at the seven day  583 mile race across the state   Bora Hansgrohe s Majka  who has an overall lead of 2 seconds  edged out Lotto NL Jumbo rider Bennett to win the stage while third place went to Ian Boswell of Sky and fourth to Lachlan Morton of Dimension Data  Daniel Jaramillo took the King of the Mountain jersey for the race s fastest climber during the 89 8 mile second stage  which included 9 276 feet of elevation gain and a grueling climb up Mt  Hamilton  Latvian rider Toms Skujins left the race after he was involved in a nasty crash during a stretch of downhill while zipping along at about 50 miles per hour  His team  Cannondale Drapac  later announced that he had a concussion  a broken left collarbone and road rash  A medical evaluation was ongoing  the team said  The seven day race continues on Tuesday with a ride from Pismo Beach to Morro Bay for stage 3  a 119 6 mile ride that includes 6 375 feet of elevation gain  This is the twelfth edition of the Amgen  NASDAQ AMGN  Tour of California and the first time the race has been staged as part of the World Tour  a designation that organizers hope will draw more top names in the sport from Europe  This year  Tour of California is being held at the same time as the Giro d Italia  now in its 100th year and one of cycling s traditional three  Grand Tours  of Europe  Many of the sport s biggest names are competing there rather California  The Tour of California wraps up in Pasadena on May 20 ,2017-05-16,Reuters,https://www.investing.com/news/general-news/majka-takes-yellow-jersey-after-winning-stage-2-in-california-484690,484690
149181,370697,AMGN,Prescription trends for Synergy s Trulance ahead of projections  shares ahead 2  premarket,news,Synergy Pharmaceuticals  NASDAQ SGYP  is up 2  premarket on modest volume on the heels of a note from BTIG Research s Timothy Chiang saying prescription trends for CIC med TRULANCE  plecanatide  are tracking ahead of projections  now more than 800 week  He adds that the company should be able to meet it 2017 sales estimate of   21 5M  Refills are also beginning to ramp Mr  Chiang reiterates his peak sales estimate of   500M by 2022 Source  StreetInsiderNow read ,2017-05-31,Seeking Alpha,"https://www.investing.com/news/stock-market-news/prescription-trends-for-synergy's-trulance-ahead-of-projections,-shares-ahead-2-premarket-490204",490204
149186,370702,AMGN,Is Amgen  AMGN  A Great Value Stock Right Now ,opinion,"Here at Zacks  our focus is on the proven Zacks Rank system  which emphasizes earnings estimates and estimate revisions to find great stocks  Nevertheless  we are always paying attention to the latest value  growth  and momentum trends to underscore strong picks 
Of these  perhaps no stock market trend is more popular than value investing  which is a strategy that has proven to be successful in all sorts of market environments  Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued  leaving room for profits 
On top of the Zacks Rank  investors can also look at our innovative Style Scores system to find stocks with specific traits  For example  value investors will want to focus on the  Value  category  Stocks with high Zacks Ranks and  A  grades for Value will be some of the highest quality value stocks on the market today 
Amgen  AMGN  is a stock many investors are watching right now  AMGN is currently sporting a Zacks Rank of  2  Buy  and an A for Value 
Investors should also note that AMGN holds a PEG ratio of 2 19  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  AMGN s PEG compares to its industry s average PEG of 4 10  Within the past year  AMGN s PEG has been as high as 2 35 and as low as 1 76  with a median of 2 05 
Value investors also use the P S ratio  The P S ratio is is calculated as price divided by sales  This is a prefered metric because revenue can t really be manipulated  so sales are often a truer performance indicator  AMGN has a P S ratio of 4 77  This compares to its industry s average P S of 12 95 
These figures are just a handful of the metrics value investors tend to look at  but they help show that Amgen is likely being undervalued right now  Considering this  as well as the strength of its earnings outlook  AMGN feels like a great value stock at the moment ",2019-08-04,Zacks Investment Research,https://www.investing.com/analysis/is-amgen-amgn-a-great-value-stock-right-now-200450764,200450764
149187,370703,AMGN,Amgen submits applications in U S  and Europe to add CVOT data to Repatha label,news,Amgen  AMGN  0 1   files supplemental applications in the U S  and Europe seeking approval to add data from the large scale cardiovascular study  FOURIER  to the label of cholesterol drug Repatha  evolocumab   The data showed that lowering bad cholesterol levels beyond what is possible with conventional therapies leads to a further reduction in major cardiovascular events Now read ,2017-06-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgen-submits-applications-in-u.s.-and-europe-to-add-cvot-data-to-repatha-label-491899,491899
149201,370717,AMGN,Roche  RHHBY  1H19 Earnings   Sales Up Y Y  View Raised,opinion,"Swiss pharma giant Roche Holding  SIX ROG  AG   OTC RHHBY   posted strong results for the first half of 2019  propelled by strong performance of new drugs  The company also raised its guidance for 2019 for the second consecutive time Shares are expected to gain on strong results  Roche s stock has gained 9 1  in the year so far against the  s decline of 0 8   The company reported sales of CHF 30 5 billion in the first half of 2019  up 8  year over year  Earnings per share came in at CHF 11 12 in the first half of 2019  up 13  from CHF 9 84 in the same period last year The company reports results under two divisions   Pharmaceuticals and Diagnostics  All growth rates mentioned below are on a year over year basis and at constant exchange rates Sales at the Pharmaceuticals division increased 10   driven by strong growth in multiple sclerosis  MS  drug Ocrevus  the new hemophilia drug Hemlibra  and cancer drugs Tecentriq  Perjeta and Avastin  The strong uptake of new drugs more than offset lower sales of Herceptin and MabThera Rituxan  Growth in the United States offset the sales decline in Europe  stemming from biosimilar competition for Herceptin and Rituxan  Diagnostics division sales increased 2   primarily on the back of strong immunodiagnostic business Results in DetailHerceptin sales declined 9   due to biosimilar competition in Europe and Japan from mid 2018  Moreover  patients switched to Kadcyla in the United States in the adjuvant setting which in turn impacted sales  The HER2 franchise  Herceptin  Perjeta and Kadcyla  was up 5  Perjeta sales grew 34  following increased demand in adjuvant early breast cancer therapy Strong Ocrevus sales further drove the top line  The drug  used to treat two forms of MS  continued to gain traction worldwide with sales of  1 7 billion Immuno oncology drug  Tecentriq  for multiple indications   recorded 141  growth in sales  Sales growth was mainly witnessed in the United States  Europe and Japan  In the United States  growth was driven by the new indications of triple negative breast cancer and extensive stage small cell lung cancer Sales of lung cancer drug  Alcenesa  surged 50  and witnessed solid growth across all regions  Oncology drug Avastin recorded 7  growth  driven by strong broad based growth  especially in China Performance of the immunology franchise was driven by increased sales of Actemra RoActemra   8   and Xolair   1    Gazyva Gazyvaro sales soared 36   due to growth in the United States  Japan and Europe Sales of ophthalmology drug  Lucentis  grew 10  However  sales of Rituxan MabThera declined 4   due to entry of biosimilars in Europe and Japan Revenues at the Diagnostics division increased 2  on the back of solid performance of the Centralised and Point of Care Solutions   3   unit  which was  in turn  propelled by immunodiagnostics   7    Tissue Diagnostics were down 3  but Molecular Diagnostics was up 6  on continued strong demand for the cobas 6800 8800 Systems  Diabetes Care sales grew 1   mainly driven by good uptake of the new Accu Chek Guide and increasing sales of Accu Chek Instant blood glucose monitoring systems  2019 Outlook Raised AgainSales in 2019 are expected to grow in the mid  to high single digit range  previous range  low to mid single digits   The company expects core earnings to grow in line with sales  Roche anticipates to raise its dividend further Pipeline Progress   The pipeline progress in the second quarter was encouraging  The FDA granted accelerated approval to Polivy  polatuzumab vedotin piiq  in combination with bendamustine plus Rituxan for the treatment of adults with relapsed or refractory diffuse large B cell lymphoma  who have received at least two prior therapies Rozlytrek  entrectinib  for the treatment of adult and pediatric patients with advanced recurrent solid tumors was approved in Japan The FDA also approved Kadcyla for adjuvant  after surgery  treatment of people with HER2 positive early breast cancer  who have residual invasive disease after neoadjuvant  before surgery  taxane and Herceptin based treatment The FDA also approved Venclexta Venclyxto in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma  The drug has been developed in collaboration with AbbVie  Inc    NYSE ABBV   The European Medicines Agency s Committee for Medicinal Products for Human Use recommended the approval of Tecentriq plus chemotherapy for the treatment of adult patients with unresectable locally advanced or metastatic  triple negative breast cancer Update on Spark AcquisitionIn February 2019  Roche announced that it will acquire Spark Therapeutics  Inc    NASDAQ ONCE    Regulatory review of the transaction is ongoing  The acquisition is expected to conclude later this year Our TakeRoche s performance in the first half of 2019 was impressive  as strong growth in Ocrevus  Perjeta  Tecentriq  Alecensa and Hemlibra combated biosimilar competition in Europe for Herceptin and MabThera from the likes of Amgen   NASDAQ AMGN    among others  In particular  MS drug Ocrevus witnessed strong growth on increased demand The consecutive increase in guidance is impressive as well  and reflects strong underlying growth from newly launched drugs Meanwhile  the company continues to progress with its pipeline  as it looks to restructure the portfolio beyond oncology into MS and haemophilia  among others  The approvals of Polivy and Rozlytrek should further boost sales in the rest of the year 
Roche carries a Zacks Rank  2  Buy   You can see  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-07-25,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-1h19-earnings--sales-up-yy-view-raised-200444602,200444602
149203,370719,AMGN,Lilly  LLY  Q2 Earnings Beat  New Drugs Drive Sales  Stock Up,opinion,Eli Lilly   Company   NYSE LLY   reported second quarter 2019 adjusted earnings per share of  1 50  which beat the Zacks Consensus Estimate of  1 46  Earnings rose 1  year over year as higher operating costs were partially offset by a lower tax rate and reduction in shares outstanding due to share repurchase Quarter in DetailLilly reported revenues of  5 64 billion  which missed the Zacks Consensus Estimate of  5 65 billion  Sales however grew 1  year over year  backed by strong demand for its newer drugs  namely Trulicity  Taltz  Jardiance  Basaglar  Olumiant and Verzenio  which compensated for lower sales of older products like Cialis Foreign exchange hurt sales growth by 2  in the quarter  Also  lower realized prices had a negative impact of 3  on sales  Volumes rose 6  New pharma products  products launched since 2014  drove 13  of volume growth and represented nearly 43  total revenues  up from 39  in the previous quarter  U S  revenues were flat at  3 25 billion while ex U S  revenues rose 2  to  2 38 billion Among the established products  Forteo sales declined 17 to  360 8million  Alimta sales rose 4 to  577 8million  Humalog sales dropped 12  to  677 6million  Humulin sales declined 7  to  322 6 million Cialis sales declined 63  to  200 2million as U S  sales were hurt by entry of generic products  Lilly lost exclusivity for Cialis in September 2018 and generic versions entered the market in the same month  resulting in rapid erosion of sales  Outside U S  sales were also hurt by generic competition  lower realized prices and currency headwinds Among the new products  Trulicity generated revenues of  1 03 billion  up 32  year over year driven by higher demand in the United States and higher volumes in ex U S  markets  which offset the impact of lower realized prices and changes in segment mix Cyramza revenues were  241 8 million  up 11  year over year driven by higher sales in both U S  and international markets  In May  Cyramza gained FDA approval for second line liver cancer  which expanded the drug s eligible patient population Jardiance sales surged 58  to  231 9 million  driven by increased demand trends within the SGLT2 class of diabetes medicines in the United States and increased volume outside the United States  which offset the negative impact of currency Basaglar recorded revenues of  290 7 million  up 44  year over year  In the United States  sales rose 48   benefiting from higher demand and the impact of higher realized prices  Outside U S  sales growth of 29  was driven by increased volume  which offset the impact of lower realized prices Taltz brought in sales of  353 8 million  up 61  year over year as U S  sales gained from higher demand  Ex U S  sales were driven by increased volume from launches in new countries  which offset the impact of currency headwinds New rheumatoid arthritis drug  Olumiant generated sales of  102 4 million in the quarter backed by increased demand  compared with  82 1 million in the previous quarter  In the United States  Olumiant recorded sales of  10 7 million  higher than  6 4 million in the previous quarter New advanced breast cancer treatment medicine  Verzenio generated sales of  133 9 million in the quarter  which was more than  109 4 million in the previous quarter  This was because of increased demand in the United States The newly launched CGRP antibody  Emgality generated revenues of  34 3million in the quarter  compared with 14 2million generated in the previous quarter  In the United States  Emgality sales were  33 8 million  In June  Emgality was granted FDA approval for the preventive treatment of episodic cluster headache in adult patients Amgen s   NASDAQ AMGN   Aimovig and Teva s   NYSE TEVA   Ajovy were two other CGRP antibodies launched last year  which pose strong competition to Emgality Adjusted gross margin of 81  in the quarter expanded 120 basis points  Operating income decreased 7  year over year to  1 58 billion on higher operating expenses 2019 Earnings Outlook UppedLilly raised its expectations for full year earnings while keeping its revenue guidance intact   The earnings forecast was increased from a range of  5 60 to  5 70 per share to  5 67 to  5 77  The revenue guidance was maintained in the range of  22 0 billion    22 5 billion Gross margin is still expected to be approximately 80   Adjusted tax rate is expected to be in the range of 13  14  versus 14  15  expected previously Marketing  selling and administrative expense are expected to be in a range of  5 9 billion to  6 1 billion versus  5 7 billion to  6 0 billion expected previously  Research and development expense is still expected to be in the range of  5 5 billion to  5 7 billion Positive Overall Survival Data from MONARCH 2 studyIn a separate press release  Lilly announced that treatment with Verzenio in combination with fulvestrant led to a statistically significant improvement in overall survival  OS  in the phase III MONARCH 2 study  The study evaluated Verzenio plus fulvestrant in HR   HER2  advanced breast cancer patients who experienced disease progression following endocrine therapy  Please note that Verzenio plus fulvestrant is already approved for the above patient population on the basis of progression free survival data from the same study  Lilly will now look to get approval for OS data from the study to be included on the drug s label Our TakeLilly beat estimates for second quarter earnings but missed the same for sales by a whisker   The stock was up around 1  in pre market trading on the second quarter earnings beat and raised earnings guidance for the full year  However  so far this year  shares of Lilly have declined 6  against the increase of 0 1    In 2019  revenue growth is expected to be driven by higher demand for its newer drugs including Trulicity  Jardiance  Taltz  Verzenio  Basaglar and Emgality  However  competitive pressure on Lilly s drugs is rising  Generic competition for several drugs including Cialis  rising pricing pressure in the United States due to rebates and legislated increases in Medicare Part D cost sharing  price cuts in some international markets  currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line We remind investors that in February  due to the failure of the ANNOUNCE confirmatory study  Lilly suspended promotion of advanced soft tissue sarcoma drug Lartruvo  Sales of the drug have declined sharply thereafter Nonetheless  Lilly has made significant pipeline progress in the past year with several positive late stage data readouts  multiple approvals and regulatory submissions  In the second quarter  Lilly gained FDA approval for Baqsimi  its glucagon nasal powder to treat severe hypoglycemia in diabetes patients and new indications for Cyramza and Emgality  Lilly regularly adds promising new pipeline assets through business development deals Zacks RankLilly currently carries a Zacks Rank  3  Hold   You can see  A better ranked large cap pharma stock is Novartis   NYSE NVS    which has a Zacks Rank  2  Buy   Novartis  earnings estimates for 2019 have gone up by 0 8  while that for 2020 have increased 2  over the past seven days  Novartis stock has rallied 7 4  so far in 2019 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-30,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-q2-earnings-beat-new-drugs-drive-sales-stock-up-200447349,200447349
149204,370720,AMGN,Amgen  AMGN  Beats Q2 Earnings And Revenue Estimates,opinion,"Amgen  AMGN  came out with quarterly earnings of  3 97 per share  beating the Zacks Consensus Estimate of  3 58 per share  This compares to earnings of  3 83 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 10 89   A quarter ago  it was expected that this world s largest biotech drugmaker would post earnings of  3 45 per share when it actually produced earnings of  3 56  delivering a surprise of 3 19  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Amgen  which belongs to the Zacks Medical   Biomedical and Genetics industry  posted revenues of  5 87 billion for the quarter ended June 2019  surpassing the Zacks Consensus Estimate by 3 43   This compares to year ago revenues of  6 06 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Amgen shares have lost about 9 6  since the beginning of the year versus the S P 500 s gain of 20 5  
What s Next for Amgen 
While Amgen has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Amgen was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  3 47 on  5 55 billion in revenues for the coming quarter and  13 89 on  22 56 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Biomedical and Genetics is currently in the top 23  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-30,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-beats-q2-earnings-and-revenue-estimates-200447558,200447558
149205,370721,AMGN,Pharma industry shuns Trump push for radical shift at FDA,news,"By Deena Beasley  Reuters    U S  President Donald Trump s vow to roll back government regulations at least 75 percent is causing anxiety for some pharmaceutical executives that a less robust Food and Drug Administration would make it harder to secure insurance coverage for pricey new medicines  The prospect of big change at the regulatory agency comes as drugmakers are under fire for high prices  including Marathon Pharmaceuticals LLC  which said Monday it was  pausing  the launch of its Duchenne muscular dystrophy drug after U S  lawmakers questioned its  89 000 a year price  Industry trade group Biotechnology Innovation Organization told Reuters that during high level discussions with Trump advisors  lobbyists urged the administration not to name a new commissioner of the Food and Drug Administration who would act rashly to speed up the agency s approval of new medicines  That sentiment was echoed by executives at more than a dozen pharmaceutical and biotechnology firms  who told Reuters that the FDA is already adopting new drug development models and warned that a looser review process would put patients at risk   People often argue that the FDA is too restrictive   said Roger Perlmutter  head of research and development at Merck  NYSE MRK    Co Inc   We have the sense that the balance is pretty right     you have to have a well characterized risk benefit profile   That stance underscores the unique position the drug industry finds itself in when it comes to regulating its products  While most sectors welcome less oversight  drugmakers say a robust review process is critical in convincing physicians and insurers that a pricey new medicine has value   Otherwise  the time and money it takes to get a new drug to market   estimates run as high as  2 6 billion   would be lost if insurers are not willing to pay for the product   It is great that the administration is seeking deregulation     to make sure the private sector can be more competitive   said John Maraganore  chief executive officer at Alnylam Pharmaceuticals Inc and co chair of BIO s regulatory committee   But payers are looking for evidence of value   He said the FDA should speed the approval of lower cost generic versions of drugs that have lost patent protection  but warned that allowing novel products to be launched without extensive testing could be dangerous   Any change at the FDA that allows drugs to be tried out on patients without clinical evidence is a damaging approach   said Jeremy Levin  chief executive officer at Ovid Therapeutics Inc   which is developing drugs for rare diseases  Health insurers are pushing back against high priced drugs  Sales of expensive new cholesterol drugs from  Amgen Inc   NASDAQ AMGN  and Regeneron Pharmaceuticals Inc  NASDAQ REGN  have stalled as insurers limit coverage until they see results of trials designed to prove that the drugs significantly lower the risk of heart attack and other cardiovascular crises   It is one thing to get a drug approved  but you have got to get reimbursed   said Paul Perreault  CEO at biotech company CSL Ltd  adding that won t happen unless payers see proof that a new drug is better than what is already available  To be sure  some pharmaceutical executives have been vocal about the need for deregulation  Reducing regulation  will help with drug prices  because it will induce more competition    Pfizer  Inc  NYSE PFE  CEO Ian Read said on a recent conference call  After top executives at Merck  Johnson   Johnson  NYSE JNJ  and others met at the White House last month with Trump  who pledged to  streamline  the FDA  industry trade group Pharmaceutical Research and Manufacturers of America said the meeting found common ground such as tax reform  and removal of outdated regulations  The trade group declined to comment on changes at the FDA  The prospect of a shake up at the FDA is being welcomed by a new class of investor with ambitions to disrupt the current drug development model  in which larger pharmaceutical players often buy or license early stage medicines  and reap the bigger rewards if they succeed   The system we have now has its roots 50  60 even 70 years ago     it has become incredibly expensive   said Tim Shannon  of venture capital firm Canaan Partners  He supports the notion that some prescription medications could reach the market  possibly at discounted prices  once testing shows they are safe  If such controlled usage indicates that they are also effective  prices could then be raised   We want to make healthcare itself more efficient   he said   Let the marketplace decide how valuable a drug is   The fate of deregulating the FDA will be driven by its next commissioner  President Trump said last month he has a  fantastic person  lined up for the role  Candidates  according to sources close to the administration  include former FDA staffer Scott Gottlieb  and Jim O Neill  a colleague of Trump supporter Peter Thiel who has advocated for allowing some medicines to reach the market once they are shown to be safe  even if there is scant evidence that they work  A recent survey of drug company executives conducted by Mizuho Securities found that 72 percent said Gottlieb should be Trump s pick to head the FDA  
 There is no groundswell of movement for change   said attorney Jim Shehan  head of Lowenstein Sandler s FDA regulatory practice   The industry likes certainty  ",2017-02-15,Reuters,https://www.investing.com/news/stock-market-news/pharma-industry-shuns-trump-push-for-radical-shift-at-fda-459982,459982
149216,370732,AMGN,Bristol Myers  Ono  Bayer Team Up For Colorectal Cancer Study,opinion,Bristol Myers Squibb Company   NYSE BMY   along with Japan s Ono Pharmaceutical and Bayer  DE BAYGN  AG   OTC BAYRY   has entered into a collaboration agreement to evaluate the combination of Bristol Myers  PD L1 inhibitor Opdivo  nivolumab  plus Bayer s Stivarga  regorafenib  for treating patients with microsatellite stable metastatic colorectal cancer  MSS mCRC   the most common type of CRC With this deal  the three companies are looking to evaluate the combination of Opdivo   Stivarga compared to Stivarga alone for treating the given indication  The financial terms of the deal have been kept under wraps Stivarga as a monotherapy demonstrated an overall survival benefit compared to placebo in the pivotal phase III CORRECT study  However  despite progress in the treatment and current approvals for the drug  MSS mCRC remains difficult to treat  As a result  combination treatment options become imperative  The combination of Opdivo   Stivarga has shown promising preliminary efficacy results in a phase Ib REGONIVO study conducted in Japan  Data from the study was recently presented at the annual meeting of American Society of Clinical Oncology Shares of Bristol Myers have lost 15 3  so far this year  underperforming the  decrease of 1 2  We remind investors that in 2011  Bayer had entered into a collaboration agreement with Onyx Pharmaceuticals  a subsidiary of Amgen  NASDAQ AMGN   under which Onyx receives royalty on global net sales of Stivarga  The drug is already approved in more than 90 countries including the United States  China and Japan and in Europe for metastatic colorectal cancer  metastatic gastrointestinal stromal tumors and hepatocellular carcinoma Notably  in 2014  Bristol Myers and Ono signed a strategic collaboration agreement to jointly develop commercialize Opdivo and Yervoy  ipilimumab  for the treatment of different tumor types  both as single agents and in combination regimens to treat several cancer indications in Japan  South Korea and Taiwan Opdivo is a blockbuster immuno oncology drug in Bristol Myers  portfolio  It is currently approved in the United States  EU  Japan and in other countries for several cancer indications  In the first quarter of 2019  Opdivo generated sales of  1 8 billion  reflecting a rise of 19  year over year However  Opdivo faces stiff competition from Merck s   NYSE MRK   PD L1 inhibitor Keytruda  Additionally  competition is rising in this category with the presence of Roche s   OTC RHHBY   Tecentriq  Both Keytruda and Tecentriq are approved for first line non small cell lung cancer  which has the largest patient population among all cancer indications As a result  Bristol Myers is working on expanding the label of Opdivo further  Label expansion into additional indications would give the product access to a higher patient population and increase its commercial potential significantly Zacks RankBristol Myers currently has a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-07-18,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-ono-bayer-team-up-for-colorectal-cancer-study-200441934,200441934
149217,370733,AMGN,Q2 Earnings Surprise In The Cards  Healthcare ETFs To Buy,opinion,The healthcare space has been on a smooth ride over the past three months thanks to the dual tailwinds of encouraging industry fundamentals including M A  and the sector s defensive tilt  Trump s move to abandon the previously proposed elimination of rebates from government drug plans also added to the strength Popular ETFs like Health Care Select Sector SPDR Fund   Vanguard Health Care ETF   ASX VHT    iShares U S  Healthcare ETF  andFidelity MSCI Health Care Index ETF   are up more than 7  each  The strength is likely to continue with some big names like Pfizer   NYSE PFE    Merck   NYSE MRK    Amgen   NASDAQ AMGN    AbbVie   NYSE ABBV    Gilead Sciences   NASDAQ GILD   and Bristol Myers Squibb   NYSE BMY   lined up to report this week and in the next  All these stocks collectively account for 23 6  share in XLV  21 8  in IYH  20 5  in VHT and 20  in FHLC  read    Let s dig deeper into the earnings picture of these companies  which will drive the performance of the above mentioned funds in the coming days According to the our methodology  a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   when combined with a positive  increases our chances of predicting an earnings beat  while Zacks Rank  4 or 5  Sell rated  stocks are best avoided  You can uncover the best stocks to buy or sell before they re reported with our  Inside Our Surprise Prediction for These StocksPfizer has a Zacks Rank  3 and an Earnings ESP of  2 91   indicating lower chance of beating estimates this quarter  The stock saw negative earnings estimate revision of a penny for to be reported quarter over the past 30 days  It delivered an average positive earnings surprise of 5 65  for the past four quarters and has a VGM Score of C  Pfizer is scheduled to report earnings on Jul 30  before the opening bell Merck is expected to report results on Jul 30 before market open  It has a Zacks Rank  2 and an Earnings ESP of  0 22   The stock delivered a positive earnings surprise in the last four quarters  with the average beat being 5 67   It witnessed positive earnings estimate revision of a penny over the past 30 days for the to be reported quarter  Merck has a VGM Score of C Amgen carries a Zacks Rank  3 and has an Earnings ESP of  1 05   indicating reasonable chance of beating estimates this quarter  The earnings surprise track over the past four quarters is strong  with the average positive surprise being 6 20   Amgen has witnessed negative earnings estimate revision of a couple of cents over the past 30 days for the quarter to be reported  The stock has a VGM Score of D  Amgen will report earnings on Jul 30 after market close  read    AbbVie has a Zacks Rank  2 and an Earnings ESP of  0 12   indicating a good chance of beating estimates this quarter  The company delivered a positive earnings surprise in the last four quarters  with the average beat being 2 58   It saw no earnings estimate revision over the past month for the to be reported quarter  The stock has a top VGM Score of A  The company is scheduled to report on Jan 26 before the opening bell     Gilead is expected to release earnings on Jul 30 after market close  It has a Zacks Rank  3 and an Earnings ESP of  3 69   Gilead delivered average positive earnings surprise of 6 86  over the last four quarters and saw positive earnings estimate revision of a penny over the past month for the to be reported quarter  It has a VGM Score of B  read    Bristol Myers will likely report earnings on Jul 25 before the opening bell  It has a Zacks Rank  3 and an Earnings ESP of  0 28   The stock delivered an average positive earnings surprise of 11 85  over the past four quarters  and witnessed positive earnings estimate revision of a penny for the to be reported quarter in a month  It has a VGM Score of A Summing UpWith earnings surprise in cards  the healthcare sector is expected to witness earnings growth of  in the second quarter  suggesting continued outperformance for healthcare ETFs  In particular  FHLC has a Zacks ETF Rank  3 while the remaining  three have a Zacks ETF Rank  2  see    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-07-21,Zacks Investment Research,https://www.investing.com/analysis/q2-earnings-surprise-in-the-cards-healthcare-etfs-to-buy-200442714,200442714
149218,370734,AMGN,Amgen s erenumab successful in second late stage migraine study  shares up 1  after hours,news,A Phase 3 clinical trial  STRIVE  assessing Amgen s  NASDAQ AMGN  erenumab  AMG 334  for the prevention of migraine met its primary endpoint of a statistically valid change from baseline in mean monthly migraine days at week 24 compared to placebo STRIVE randomized participants to receive either 70 mg or 140 mg of erenumab or placebo administered subcutaneously once per month for six months  At baseline  patients were experiencing an average of 8 3 migraine days per month  At week 24  the average reductions in migraine days per month for the 70 mg  140 mg and placebo arms were 3 2  3 7 and 1 8  respectively Erenumab s safety profile was comparable to placebo and was consistent with previous studies  The most common adverse events were nasopharyngitis  upper respiratory infection and sinusitis The analysis of the data is ongoing  Detailed results will be submitted for publication and for presentation at a future medical conference It was also successful in another Phase 3 study called ARISE  Regulatory submissions are on tap for 2017 Erenumab  a fully human monoclonal antibody  inhibits the calcitonin gene related peptide  CGRP  receptor  which is believed to transmit signals that cause incapacitating pain  It is being co developed with Novartis  NYSE NVS   Amgen retains commercial rights in the U S   Canada and Japan and Novartis has commercial rights elsewhere Shares are up 1  after hours on average volume Previously  Amgen s erenumab  AMG 334  successful in late stage study in migraine prevention  Sept  28 ,2016-11-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgen's-erenumab-successful-in-second-late-stage-migraine-study;-shares-up-1-after-hours-441590,441590
149220,370736,AMGN,Amgen  AMGN  Expected To Beat Earnings Estimates  Should You Buy ,opinion,"Amgen  AMGN  is expected to deliver a year over year decline in earnings on lower revenues when it reports results for the quarter ended June 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The earnings report  which is expected to be released on July 30  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This world s largest biotech drugmaker is expected to post quarterly earnings of  3 57 per share in its upcoming report  which represents a year over year change of  6 8  
Revenues are expected to be  5 65 billion  down 6 8  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 45  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Amgen 
For Amgen  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  1 05  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that Amgen will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Amgen would post earnings of  3 45 per share when it actually produced earnings of  3 56  delivering a surprise of  3 19  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Amgen appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-07-22,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-expected-to-beat-earnings-estimates-should-you-buy-200443198,200443198
149221,370737,AMGN,Exclusive  Novartis in talks to sell some central nervous system drugs   sources,news,"By Sophie Sassard and Arno Schuetze ZURICH  Reuters    Novartis is in talks about the sale of some older neuroscience drugs  people close to the matter said  as the Swiss drugmaker clears the decks to concentrate on promising new medicines it hopes will help to restore sales growth  The assets may be valued at more than 500 million Swiss Francs   496 million  in a potential deal  the people said  Novartis did not immediately return phone calls and emails seeking comment   Chief Executive Joe Jimenez is in the process of refreshing the group s drugs portfolio to help return the company to sales growth   The expiration of patents on Novartis s best selling medicine Glivec in the United States this year and Europe next year is putting pressure on sales as generics hit the market  But the world s biggest maker of prescription drugs has high expectations for investigational multiple sclerosis medicines including BAF312 and CJM 112  as well as ofatumumab that it bought from GlaxoSmithKline last year  Additionally  Novartis bought U S  and Australia based Spinifex Inc  in 2015 to get control of early stage treatments for neuropathic pain and is working with Amgen  NASDAQ AMGN  on a promising medicine to treat episodic and chronic migraines  As a result  Novartis is seeking to sell older medicines within its central nervous system  CNS  range to free up its workforce s capacity to introduce  manufacture and market new drugs that it sees as potential blockbusters  the sources said  Novartis has been offering its CNS portfolio  including its Exelon  NYSE EXC  Patch  to treat symptoms of Alzheimer s disease  and Ritalin against attention deficit hyperactivity disorder  since early 2016  another source said  Generic drugmakers are among the potential buyers  one of the people said  Another source said that the asset might appeal to medium sized healthcare groups such as Endo   Mallinckrodt   NYSE MNK   Recordati or Pierre Fabre  Novartis is more familiar as a potential buyer of companies in the M A arena  with Jimenez saying last month he was looking for bolt on acquisitions  The company bought U S  based Selexys Pharmaceuticals in a deal worth up to  665 million in November  But Novartis has also periodically culled its stable of drugs  including central nervous system medications  In 2001  for instance  it unloaded the rights to five older CNS medications including the insomnia medication Restoril   
Neuroscience is one of nine research and therapeutic areas where Jimenez and new research boss Jay Bradner  who heads up the Novartis Institutes for Biomedical Research  have said they will focus the Basel based company ",2016-12-06,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-novartis-in-talks-to-sell-some-central-nervous-system-drugs---sources-445913,445913
149223,370739,AMGN,AbbVie s revenue misses as Hepatitis C  cancer drugs drag,news, Reuters    AbbVie Inc s  N ABBV  quarterly adjusted revenue missed analysts  estimate as sales of its hepatitis C treatment and cancer therapy came in below Street expectations  overshadowing strong U S  sales of its flagship Humira drug  The company s shares fell 1 25 percent to  60 50 in premarket trading on Friday  Sales of the company s leukemia treatment Imbruvica  which is also sold by Johnson   Johnson  N JNJ   and its hepatitis C treatment Vikiera Pak fell short of consensus estimates  according to Evercore ISI  AbbVie acquired half ownership of Imbruvica in 2015 through the buyout of Pharmacyclics Inc as part of efforts to reduce its dependence on its arthritis treatment Humira   Sales of the drug  also used to treat Crohn s disease and psoriasis  rose 15 5 percent to  4 29 billion in the latest quarter  just ahead of the consensus estimate of  4 26 billion  according to Evercore ISI  However  sales of Humira outside the United States came in light of expectations due to a strong dollar and possibly indirect biosimilar competition in Europe  analysts said   AbbVie is trying to block the launch of Amgen Inc s  O AMGN  approved biosimilar version of Humira in the United States  citing patents that should protect the drug until at least 2022   Humira  the world s top selling drug  accounted for nearly two thirds of AbbVie s total net revenue in the latest quarter  AbbVie earlier this month promised to keep all price increases in 2017 under 10 percent amid recent political and payer scrutiny of drug pricing in the United States   The company raised Humira s gross price by 8 4 percent last week  according to Evercore analysts  AbbVie reported adjusted revenue of  6 78 billion in the fourth quarter ended Dec  31  below analysts  average estimate of  6 91 billion  according to Thomson Reuters I B E S   The company said net profit fell to  1 39 billion  or 85 cents per share  from  1 52 billion  or 92 cents per share  a year earlier  Excluding special items  the suburban Chicago drugmaker earned  1 20 per share  in line with the average analyst estimate   Net revenue rose to  6 80 billion from  6 40 billion   AbbVie said it expected 2017 adjusted earnings of  5 44 to  5 54 per share  compared with analysts  estimate of  5 47 ,2017-01-27,Reuters,https://www.investing.com/news/stock-market-news/abbvie-revenue-rises-6.2-percent-456154,456154
149236,370752,AMGN,Pfizer scraps cholesterol fighter  trims profit forecast,news,"By Ransdell Pierson  Reuters     Pfizer  Inc  N PFE  said it halted development of a costly new type of cholesterol fighter because disappointing clinical trial data and an unfavorable market for similar approved drugs bode poorly for its injectable medicine  The largest U S  drugmaker trimmed the top end of its 2016 earnings forecast on Tuesday due to costs of scrapping the experimental drug  called bococizumab  which works by blocking a protein called PCSK9  Pfizer said bococizumab gradually lost its potency in reducing  bad  LDL cholesterol and caused more irritation at the injection site than similar recently approved drugs   Shares of Pfizer were down 1 3 percent in early trading   Pfizer was trying to catch up with two other PCSK9 inhibitors approved by U S  regulators more than a year ago  Amgen Inc s  O AMGN  Repatha and Praluent from Regeneron Pharmaceuticals Inc  O REGN  and Sanofi SA  PA SASY    The drugs can slash LDL cholesterol almost 60 percent  above and beyond reductions achieved with statins  but large ongoing trials have not yet determined whether they can actually cut the incidence of heart attacks  And Repatha and Praluent each have annual sales of only about  100 million  far below initial expectations  in part because insurers have blocked reimbursement due to annual costs of more than  14 000 each    The totality of clinical information now available for bococizumab  taken together with the evolving treatment and market landscape for lipid lowering agents  indicates that bococizumab in not likely to provide value to patients  physicians or shareholders   Pfizer said in a news release  Pfizer cut the upper end of its 2016 earnings forecast to  2 43 per share from  2 48 while retaining the lower end at  2 38   The drugmaker  which in September decided not to split itself into two  said it earned 61 cents per share in the third quarter  excluding special items  The results missed the analysts  average estimate by 1 cent  according to Thomson Reuters I B E S  Quarterly sales of  13 05 billion matched Wall Street expectations  One of Pfizer s most important new drugs is breast cancer treatment Ibrance  which has a list price of about  10 000 a month and blocks two enzymes known as CDK 4 and CDK 6  Its sales of  550 million trailed forecasts of  576 million  and competition looms from similar drugs being developed by  Novartis  AG  S NOVN  and Eli Lilly and Co  N LLY    
Pfizer raised the lower end of its full year revenue forecast to  52 billion from  51 billion  while keeping the upper end at  53 billion ",2016-11-01,Reuters,https://www.investing.com/news/stock-market-news/pfizer-quarterly-profit-falls-38-percent-436438,436438
149237,370753,AMGN,California drug pricing initiative headed for defeat,news,"By Deena Beasley
LOS ANGELES  Reuters    A California ballot initiative aimed at reining in rising prices for prescription drugs was headed for defeat on Tuesday after pharmaceutical companies spent more than  100 million to fight it 
The California Drug Price Relief Act  also known as Proposition 61  sought to limit state health programs from paying more for medications than the U S  Department of Veterans Affairs  VA   which receives the steepest discounts in the country 
As of late Tuesday night  with 47 percent of precincts partially reporting  the vote was 46 percent in support of the measure and 54 percent opposed  according to California s Secretary of State 
 The pharmaceutical companies spent a lot to defeat this   said Stuart Schweitzer  professor of health policy and management at the University of California  Los Angeles Fielding School of Public Health   They wanted to draw a line in the sand  
The rising cost of prescription drugs has come under attack during the recent U S  presidential campaign  Both Democratic candidate Hillary Clinton and Republican Donald Trump have called for cost trimming measures including allowing Medicare  the federal health plan for seniors  to negotiate prices with drugmakers 
 This strong vote for Prop 61  even despite the barrage of drug company campaigning against it  provides momentum for state legislation to rein in prescription drug prices   Anthony Wright  executive director of advocacy group Health Access California  said in a statement 
Pharmaceutical companies  concerned about their bottom lines  spent heavily on ads urging  no  votes  making this California s most expensive initiative contest among the 17 in this election 
Opponents  led by global drugmakers such as  Pfizer  Inc  NYSE PFE  and  Amgen Inc   NASDAQ AMGN   spent around  106 million to fight Proposition 61  They argued that the measure would benefit only 12 percent of Californians  while putting the other 88 percent  as well as veterans across the country  at risk of higher drug costs 
Supporters  led by the AIDS Healthcare Foundation and AARP  which advocates for seniors  said only drug companies themselves can raise prices for veterans or other consumers  Vermont Independent Senator Bernie Sanders also campaigned in support of Proposition 61  calling on voters to  stand up to the greed of the pharmaceutical industry  
Proponents  who raised  17 million to support the measure  estimated it could save California taxpayers up to  5 7 billion over 10 years  although a state legislative analysis said the financial impact is not clear 
UCLA s Schweitzer said the measure would have had only a modest impact on state drug costs 
There were also questions about how Proposition 61 would be implemented  The VA s mandated prices are listed publicly  but its steepest negotiated drug price discounts are required by law to be confidential 
The VA spends some  6 1 billion a year on medicines for 6 million veterans  Proposition 61 would extend those discounts to around 4 5 million Californians  including certain members of the state s low income Medicaid plan  state employees and retirees  university teachers and prisoners 
The  Yes on Prop 61  coalition said it plans to carry its message to other states  A similar proposition has already been approved for Ohio s 2017 November ballot ",2016-11-09,Reuters,https://www.investing.com/news/politics-news/california-drug-pricing-initiative-headed-for-defeat-439032,439032
149238,370754,AMGN,Amgen and Janssen team up assessing drug combo in multiple myeloma,news,Amgen  AMGN  3 8   and Janssen Pharmaceuticals  JNJ  0 3   will collaborate in multiple clinical trials assessing the combination of KYPROLIS  carfilzomib  and DARZALEX  daratumumab  in patients with multiple myeloma  MM  Under the terms of the agreement  each company will supply its product and share development costs on a study specific basis The first trial initiated under the partnership is an open label Phase 3 study assessing the combination of KYPROLIS and DARZALEX with dexamethasone compared to KYPROLIS and dexamethasone alone in MM patients who have been previously treated with one   three prior lines of therapy  The primary endpoint is progression free survival  Secondary endpoints include overall survival  overall response rate and minimal residual disease  Enrollment should commence in April of next year ,2016-11-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgen-and-janssen-team-up-assessing-drug-combo-in-multiple-myeloma-439563,439563
149239,370755,AMGN,J J arthritis drug has mixed results against incumbents,news,Johnson   Johnson  NYSE JNJ  says experimental sirukumab treatment for rheumatoid arthritis showed mixed results against AbbVie  NYSE ABBV  top selling Humira in a large trial By one measure  patients with moderate to severe disease who took sirukumab showed significantly greater improvement in the Phase III study than those taking Humira  But another comparison showed no significant benefit of one drug over the other Results of the study were reported today at the annual meeting of the American College of Rheumatology in Washington Humira  and other older medicines such as Amgen  NASDAQ AMGN  Enbrel and J J s Remicade  works by blocking a protein called tumor necrosis factor   TNF   that is involved in inflammation  Sirukumab is a member of an emerging new class of treatments that work instead by blocking IL 6  another protein involved in the inflammation process Source,2016-11-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/j-j-arthritis-drug-has-mixed-results-against-incumbents-440199,440199
149242,370758,AMGN,Amgen s Parsabiv OK d in Europe,news,As expected  the European Commission approves Amgen s  NASDAQ AMGN  Parsabiv  etelcalcetide  for the treatment of secondary hyperparathyroidism  sHPT  in adult patients with chronic kidney disease on hemodialysis  It is the first calcimimetic agent that can be administered intravenously three times per week at the end of a hemodialysis session The company says that  88  of dialysis patients and  79  of hemodialysis patients will develop sHPT  About 2M people worldwide receive dialysis The approval follows a positive opinion by the advisory committee CHMP in September Previously  European Ad Comm backs Amgen s Parsabiv  Sept  16 ,2016-11-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgen's-parsabiv-ok'd-in-europe-440303,440303
149243,370759,AMGN,Amarin  AMRN  Issues Update On Q2 Sales  Raises  19 Guidance,opinion,"Amarin Corporation plc   NASDAQ AMRN   announced impressive preliminary second quarter sales results  which led it to raise its total sales guidance for 2019  The company estimates second quarter sales  mainly from its sole marketed drug  Vascepa  to be in the range of  97 million    101 million  The preliminary sales number indicates year over year growth of approximately 84  92   The Zacks Consensus Estimate for second quarter sales stands at  91 million Consequently  the company raised its guidance for total sales in 2019 to the range of  380 to  420 million from the previous guidance of  350 million provided on its first quarter earnings call Vascepa is approved in the United States as an adjunct to diet to reduce triglyceride levels in adult patients with severe   500 mg dL  hypertriglyceridemia Strong estimated sales in the second quarter and consequent increase in guidance led to a rally of 16 3  in shares on Jul 2  Amarin s shares have rallied 64 4  so far this year compared with the  s increase of 7   Meanwhile  a label expansion application looking to get approval for Vascepa to reduce cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL C  bad cholesterol  is under  in the United States  The FDA will provide its decision by September  If approved  Vascepa will be the first drug for the indication in the United States Along with the latest release  the company also announced its plan to double its sales force to 800 by October to support the commercialization of Vascepa in the expanded label following a potential approval  The company is also planning to start multiple promotional and educational programs to create awareness about the potential expanded label of Vascepa Vascepa demonstrated strong growth in the first half of 2019  Potential approval for its label expansion will further boost the sales of the drug  The company is planning to submit a regulatory application seeking approval of Vascepa in Europe by the end of the yearKey players in Vascepa s targeted indication are Sanofi   NASDAQ SNY   and Amgen s   NASDAQ AMGN   PCSK9 inhibitors  Praluent and Repatha  respectively Amarin Corporation PLC Price
    Zacks Rank and Stock to ConsiderAmarin currently carries Zacks Rank  3  Hold   A better ranked stock in the biotech sector is BioDelivery Sciences   NASDAQ BDSI    sporting a Zacks Rank  1  Strong Buy   You can see  BioDelivery also witnessed positive estimate revision  Estimates for 2019 have narrowed from loss of 21 cents per share to 14 cents per share while that for 2020 earnings per share has increased from 20 cents to 25 cents over the past 60 days  The stock has increased 27 3  so far this year The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-07-02,Zacks Investment Research,https://www.investing.com/analysis/amarin-amrn-issues-update-on-q2-sales-raises-19-guidance-200436827,200436827
149244,370760,AMGN,Merck s Keytruda SBLAs For 6 Week Dosing To Be Reviewed By FDA,opinion,"Merck   Co   Inc    NYSE MRK   announced that the FDA has accepted for review its supplemental Biologics License Applications  sBLAs  looking for approval of an improved dosing schedule of its blockbuster anti PD 1 therapy  Keytruda Merck is looking for approval of a six week 400 mg dosing option of Keytruda for six indications  melanoma  classical Hodgkin lymphoma  primary mediastinal large B cell lymphoma  gastric cancer  hepatocellular carcinoma and Merkel cell carcinoma  The new recommended dose will be delivered as an intravenous infusion over 30 minutes and will provide greater flexibility than the currently approved dose of 200 mg every three weeks infused over 30 minutes  The FDA will give its decision on Feb 18  2020 In March  the European Commission had approved the 400 mg six week dosing schedule of Keytruda for approved monotherapy indications in EU Merck s stock has risen 11  this year so far compared with a 1 9  increase for the    Keytruda  Merck s biggest product  is approved for use in 15 cancer indications across 10 different tumor types in the United States Keytruda generated sales of  2 27 billion in the first quarter of 2019  up around 5 6  sequentially and 55  year over year  Sales were driven by the launch of indications globally  Keytruda sales are gaining particularly from strong momentum in first line lung cancer indication both as monotherapy and with the rollout of the chemotherapy combo in both non squamous and squamous NSCLC This year so far  Keytruda has gained several label expansion approvals  Keytruda was approved by the FDA as an adjuvant therapy for high risk stage III melanoma and for five new cancer line extensions in Japan in the first quarter  In April  the FDA gave approval to Keytruda in combination with Pfizer s   NYSE PFE   Inlyta for the first line treatment of advanced renal cell carcinoma as well as for an expanded first line lung cancer patient population  In June  Keytruda was approved by the FDA for first line treatment of recurrent or metastatic HNSCC and for previously treated advanced small cell lung cancer  SCLC   All these label expansion approvals should drive sales of Keytruda higher in the future quarters The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 1000 studies  including more than 600 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte   NASDAQ INCY    Glaxo and Pfizer separately for the evaluation of Keytruda in combination with other regimens Undoubtedly  Keytruda has strong growth prospects based on increased utilization  approval for new indications and expectation of additional approvals worldwide 
Merck currently carries a Zacks Rank  2  Buy   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-07-09,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-sblas-for-6week-dosing-to-be-reviewed-by-fda-200438471,200438471
149245,370761,AMGN,Court Ruling Topples Trump Order  No Price Display In TV Ads,opinion,The pharma and the biotech sector gave investors a reason to cheer for when it received a welcoming news on Monday  A federal court passed a judgement in favour of the healthcare companies against the Trump administration in relation to drug pricing Per the ruling  pharmaceutical companies need not disclose the wholesale prices of their drugs in television advertising  The verdict comes as a blow to the US government s crackdown on drug pricing A judge in the United States District Court in the District of Columbia sentenced in support of Merck   NYSE MRK    Eli Lilly   NYSE LLY   and Amgen   NASDAQ AMGN   determining that the Department of Health and Human Services  HHS  cannot compel pharma companies to reveal the wholesale acquisition cost of drugs in adverts  The companies argued that many patients subscribe to health insurance policies that lower the prices they pay for the required drugs Last October  the Trump administration determined that drug makers should mention the prices of drugs in television commercials that cost more than  35 a month  This proposal was a step forward by the government to regulate the rising drug prices as a high list price would act as a deterrent The rule was scheduled to be effective Jul 9  2019 However  the federal judge pronounced that the HHS cannot impose any such rule as it lacked authority from the U S  Congress Drug pricing has been an overhang on the industry for long  The Trump government has been putting pressure on the pharma and biotech companies for quite some time through various means to lower the exorbitant prices of drugs and make healthcare affordable  The authorities had earlier proposed to do away with the drug rebates granted to middlemen and make the whole system more transparent Spending on drugs has reached an all time high in recent times due to cost intensive specialty drugs for complex conditions Earlier  companies like Gilead Sciences  Inc    NASDAQ GILD   were under scrutiny for the high costs of its blockbuster HCV drugs  Most recently  even Sanofi   NASDAQ SNY    Eli Lilly and Novo Nordisk   NYSE NVO   were under vigilance on account of the staggering prices of insulin drugs  Even generic companies like Teva   NYSE TEVA   and Mylan  NASDAQ MYL  are on the radar for quoting inflated prices of generic drugs While all governments vow to go for a clampdown on high drug prices and make healthcare reasonable  little has been done in this regard  Meanwhile  the pharma and biotech companies contend the high research   development costs that bump up the prices of prescription drugs  Given the slowdown in growth of legacy drugs  most companies resort to hiking the prices of drugs to combat low volume growth We expect this contentious issue to persist as a headwind to the industry for a while now Merck currently carries a Zacks Rank  2  Buy   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-07-09,Zacks Investment Research,https://www.investing.com/analysis/court-ruling-topples-trump-order-no-price-display-in-tv-ads-200438570,200438570
149246,370762,AMGN,Late stage study shows Amgen and UCB s romosozumab significantly increases bone mineral density in men with osteoporosis,news,Results from a Phase 3 clinical trial  BRIDGE  assessing Amgen  NASDAQ AMGN  and co developer UCB s  OTCPK UCBJF  OTCPK UCBJY  romosozumab  AMG 785  in men with osteoporosis showed statistically significant bone mineral density  BMD  gains compared to placebo  The data were presented at the American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting in Washington  D C The study randomized 245 men 2 1 to receive either 210 mg romosozumab or placebo subcutaneously once per month for 12 months  The primary endpoint  the increase in BMD at the lumbar spine at Month 12 versus placebo  was achieved  12 1   p 0 01   All secondary endpoints were also met Romosozumab is a monoclonal antibody that inhibits sclerostin  a protein that has anti anabolic effects on bone formation  It has a dual effect of increasing bone formation and decreasing bone breakdown Worldwide  20  of men over the age of 50 will experience an osteoporosis related fracture The companies plan to discuss the data with global regulatory authorities Previously  Amgen s romosozumab successful in late stage study in men with osteoporosis  March 21 ,2016-11-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/late-stage-study-shows-amgen-and-ucb's-romosozumab-significantly-increases-bone-mineral-density-in-men-with-osteoporosis-440308,440308
149247,370763,AMGN,Amgen s migraine drug succeeds in late stage trial,news, Reuters     Amgen Inc   O AMGN  said on Wednesday its migraine treatment met the main goal of reducing monthly migraine days in patients with episodic migraine in a second late stage study   Patients receiving 70 milligram of the drug  erenumab  experienced reduction of 3 2 days from baseline in monthly migraine days  while those on 140 milligram experienced reduction of 3 7 days  Those in the placebo experienced a 1 8 day reduction  the company said  At baseline  patients were experiencing an average of 8 3 migraine days per month  Amgen said  Amgen  which is co developing the treatment with Swiss drugmaker  Novartis  AG  S NOVN   said patients received the injectable drug once monthly for six months  Erenumab is also being tested for episodic migraine prevention and chronic migraine prevention  Worldwide  about 90 percent of people diagnosed with migraine have episodic migraine  which is characterized by up to 14 migraine days a month  the company said  Amgen s shares  which closed at  147 23 in regular trading  were up marginally after market on Wednesday ,2016-11-16,Reuters,https://www.investing.com/news/stock-market-news/amgen's-migraine-drug-succeeds-in-late-stage-trial-441580,441580
149248,370764,AMGN,Why Amgen  AMGN  Could Beat Earnings Estimates Again,opinion,"If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report  you should consider Amgen  AMGN   This company  which is in the Zacks Medical   Biomedical and Genetics industry  shows potential for another earnings beat 
This world s largest biotech drugmaker has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 4 05  
For the most recent quarter  Amgen was expected to post earnings of  3 45 per share  but it reported  3 56 per share instead  representing a surprise of 3 19   For the previous quarter  the consensus estimate was  3 26 per share  while it actually produced  3 42 per share  a surprise of 4 91  
Price and EPS Surprise

Thanks in part to this history  there has been a favorable change in earnings estimates for Amgen lately  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the stock is positive  which is a great indicator of an earnings beat  particularly when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Amgen has an Earnings ESP of  0 89  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  3  Hold   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on July 30  2019 
Investors should note  however  that a negative Earnings ESP reading is not indicative of an earnings miss  but a negative value does reduce the predictive power of this metric 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-07-11,Zacks Investment Research,https://www.investing.com/analysis/why-amgen-amgn-could-beat-earnings-estimates-again-200439349,200439349
149266,370782,AMGN,Amgen s Osteoporosis Drug Evenity Gets Adverse CHMP View,opinion,Amgen Inc    NASDAQ AMGN   and Belgian partner UCB announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has rendered a negative opinion on the marketing approval of its osteoporosis drug  Evenity  romosozumab  Amgen is seeking an approval of Evenity for the treatment of severe osteoporosis in postmenopausal women  who stand at a risk of fracture The companies are planning to submit a written notice to the regulatory agency  requesting a re evaluation of Evenity for the given indication Notably  Evenity gained an approval in the United States earlier this April for the treatment of osteoporosis in postmenopausal women  who are at high risk of fracture  However  the nod came with a boxed warning  The drug s label states that treatment with Evenity may increase the risk level of myocardial infarction  heart attack   stroke and cardiovascular death and that it should not be administered to patients  who already suffered heart attack or stroke in the preceding year  The company is required to conduct a post marketing study to evaluate the cardiovascular safety of Evenity in postmenopausal osteoporosis women The drug had received an approval for a similar indication in postmenopausal women as well as men in Japan  earlier this January This CHMP s response was based on data from three pivotal phase III studies  namely FRAME  ARCH and BRIDGE  which evaluated Evenity in postmenopausal women with osteoporosis  who are at a high risk of fracture and men with osteoporosis Evenity treats osteoporosis by increasing bone formation and reducing bone resorption simultaneously  This increases bone mineral density  BMD  and lowers the risk of fracture Shares of Amgen have decreased 5 5  so far this year versus the increase of 2 7  We remind investors that Evenity was issued a complete response letter  CRL  by the FDA in July 2017 due to a cardiovascular side effect observed in a study  Last July  Amgen and UCB re submitted the biologics license application  BLA  to the regulatory body for Evenity Notably  Evenity is likely to face stiff competition from Radius Health s   NASDAQ RDUS   Tymlos injection  which is already approved for treating postmenopausal women with osteoporosis  who are at a high risk of fracture  Novartis    NYSE NVS   Reclast is also approved for treating osteoporosis Zacks Rank   Key PickAmgen currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Acorda Therapeutics  Inc    NASDAQ ACOR    which sports a Zacks Rank  1  Strong Buy   You can see  Acorda s loss per share estimates have been narrowed 6 5  for 2019 and 6 9  for 2020 over the past 60 days Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-27,Zacks Investment Research,https://www.investing.com/analysis/amgens-osteoporosis-drug-evenity-gets-adverse-chmp-view-200435627,200435627
149267,370783,AMGN,Immunicum  Successful Large Share Issue Transforms Outlook,opinion,"Immunicum AB  ST IMMUN  s investment case has transformed over the course of 2018  The funding of SEK351m gross  in a direct and subsequent rights issue  raised in Q418 allows the company to be more ambitious and finance R D for the lead product  immune primer ilixadencel  through to 2021  The strategy stays unchanged  which is to accumulate as much clinical proof of concept data in combinations with checkpoint inhibitors and other anti cancer therapies before seeking an out licensing  2020   The fund raise ensures cash reach to late 2021  including publication of the results from the Phase II MERECA and the Phase Ib II ILIAD trials and potential updates on partnering activities  Our valuation has increased to SEK2 0bn or SEK21 7  vs SEK15 1 share previously  



Business description
Immunicum is a clinical stage immuno oncology company based in Stockholm  Sweden  It is developing an allogeneic off the shelf dendritic cell immune activator or immune primer ilixadencel for use in combination with checkpoint inhibitors and other anti cancer therapies in potentially any solid tumour indications accessible via direct injection 
Positioning ilixadencel for CPI combos
The fund raise extended the cash runway until the end of 2021 and several milestones are achievable within this period  Phase II MERECA trial top line results in Q319  initial safety data from the Phase Ib of ILIAD trial around end 2019 and then full safety data from the Phase Ib of ILIAD trial in 2020  Although final results  including efficacy endpoints  from the ILIAD trial are not likely until 2022  safety data from the Phase Ib part are key  as this will be the first time ilixadencel is combined with a checkpoint inhibitor  CPI  and will allow the company to engage in negotiations with potential partners before the full ILIAD results are available 
Focus on accumulating attractive data package
CPIs have well established safety issues  which limit combination potential  ie two CPIs can be more effective  but also increase toxicity  Therefore  when it comes to combinations  emphasis on safety is just as important as on efficacy  Immune primers tend to have benign safety profiles  so should combine with CPIs well presuming efficacy is proven  By the time safety data from the Phase Ib part of the ILIAD trial are obtained  expected in 2020   Immunicum will have gathered an attractive data package supporting ilixadencel s mechanism of action  especially immune activation data from the MERECA trial   safety and initial clinical efficacy 
Valuation  SEK2 0bn or SEK21 7 share
Our risk adjusted NPV valuation of Immunicum is increased to SEK2 0bn or SEK21 7  share compared to SEK1 4bn or SEK15 1 share previously  The changes to our model essentially reflect the fact that Immunicum is investing more in R D after the share issue in Q418 and creating more value  presuming the successful trial outcome  we use risk adjusted NPV model   The next 12 18 months will be eventful for the company with multiple R D events and potential updates on partnering 
Immunicum is a research client of Edison Investment Research Limited


Investment summary
Developing immune primer for combination cancer therapies
Immunicum is an immunooncology company listed on NASDAQ Stockholm and based in Stockholm  Sweden  which develops allogeneic DC technologies  It was formed in 2002 based on research originally carried out at Sahlgrenska University Hospital in Gothenburg  Sweden  Immunicum is developing an  off the shelf   clinical stage immune primer  ilixadencel  based on activated allogeneic DCs  The company also has two other preclinical stage  off the shelf vaccine technology platforms  IMM 2  which focuses on adenovirus transfected allogeneic DCs  and IMM 3  an optimized CAR T expansion protocol for improved anti cancer activity  The lead product  ilixadencel  is based on Immunicum s patented pro inflammatory allogeneic DC technology  which is now being explored in the Phase II MERECA trial in RCC and the Phase Ib II ILIAD trial in multiple solid tumours  The underlying rationale is to develop ilixadencel as an immune primer  which will be used in conjunction with other cancer therapies that either directly target the tumour or amplify the immune response against it  The synergy of these mechanisms is expected to boost the anti cancer immune response 
Valuation  SEK2 0bn or SEK21 7 share
Following the share issue completed in Q418  we have revised our model to reflect the fact that Immunicum will be able to create more value before the assumed out licensing  In addition  we rolled our model forward and incorporated the increased net cash position  We have postponed the deal in our model from 2019 to 2020  which is when full safety data from the ILIAD trial are expected  We reflect the improved deal terms by increasing the royalty rate from 5 0  to 7 5  and total milestone payments from  160m to  400m  supported by benchmarking as described in the valuation section below   Overall  we maintain the valuation approach described in our initiation report  where we value five of the six indications in Immunicum s R D pipeline 
Financials  Cash runway to 2021 after successful share issue
Immunicum s Q119 operating loss of SEK29 1m was in line with SEK28 8m in Q118  As expected  R D costs comprised most of Immunicum s expense  accounting for SEK23 2m  SEK22 2m in Q118   while administrative costs were SEK6 1m vs SEK6 0m a year ago  In Q418  Immunicum completed an underwritten fund raising split between a direct share issue  c SEK178m  and a rights issue  c SEK173m   which management guides will extend its cash runway to the end of 2021  To reflect a higher level of R D investment  we have amended our valuation model as described above  postponed the deal by two years and improved the terms   This means our operating loss estimates now are SEK119 9m and SEK121 6m in 2019 and 2020 respectively  This brings our model in line with management guidance on cash reach 
Sensitivities  Biotech risks apply
Ilixadencel has yet to reach a definitive proof of concept clinical stage so has significant R D risk  as is typical for a company at this stage  The clinical programmes are all testing the same therapy  therefore the investment case relies on the success of ilixadencel  CT or ultrasound is required to guide the injection to the viable part of the tumour  It is unlikely that the administration procedure is too difficult for physicians to perform since intratumourally injected products are already marketed  By the time ilixadencel is launched  the treatment landscape and  standard treatments  are likely to have developed  Ilixadencel is already being positioned as an addition to combination therapy  so potential changes in clinical practice are not prohibitive to the development of ilixadencel as a part of a combination treatment 
Efficacy data from Ph II MERECA trial in RCC in Q319
Immunicum s long term strategy is to accumulate proof of concept clinical data in multiple solid cancer indications where ilixadencel is used in combination with other anti cancer treatments  The company expects that this type of data package will be interesting to a number of potential partners and improve the prospects for a potential out licensing deal  The current R D programme focuses on six cancers  Exhibit 1  
The most advanced trial is in renal cell carcinoma  RCC   where ilixadencel is being tested in the Phase II MERECA study  n 88  in combination with Pfizer s tyrosine kinase inhibitor sunitinib versus sunitinib alone  Recruitment in this trial is completed and top line results are expected in Q319 
The other key study is the Phase Ib II ILIAD trial  estimated n 150  in multiple solid tumour indications  non small cell lung cancer  NSCLC   head and neck squamous cell carcinoma  HNSCC  or gastric adenocarcinoma in combination with CPIs  In the Phase Ib part of the trial  ilixadencel will be combined with Keytruda  pembrolizumab  Merck   Co MSD  and in the larger Phase II part with Bavencio  avelumab  Merck KGaA and Pfizer  NYSE PFE    for which Immunicum will acquire Bavencio at no cost  The trial started enrolling patients in January 2019  Interim safety toxicity results are expected around end 2019  full safety and efficacy data from the Phase Ib of ILIAD should be released in 2020 and controlled efficacy data from the Phase II of ILIAD should be obtained in 2022 
Immunicum has completed a Phase I II trial in liver cancer  HCC   with results demonstrating that ilixadencel was safe  well tolerated and showed initial signs of clinical efficacy 
Most recently  Immunicum also completed a smaller Phase I study  n 6  in patients with relatively rare gastrointestinal stromal tumours  GIST   where ilixadencel was combined with tyrosine kinase inhibitors in second or later lines of therapy  In line with previous findings  Ilixadencel was safe and well tolerated and showed clinical benefit in two out of six patients  who had all previously progressed while on TKI therapy 

Ilixadencel  an  off the shelf  immune primer
How it is different
Ilixadencel is an immune primer made up of pro inflammatory activated allogeneic DCs and intended for intratumoural administration  The DCs are activated ex vivo using a potent cocktail  denoted as COMBIG  of poly I C  TLR3 ligand   R848  TLR7 8 ligand  and IFN    Karlsson Parra et al  2018   This induces DCs to produce large amounts of chemokines and cytokines  The activated DCs can then be frozen and stored on the shelf for at least three years  expected shelf life could increase   and used in any patient  The key differences between ilixadencel and most other cell therapies or cancer vaccines are as follows 
Ilixadencel DCs are allogeneic  ie isolated from healthy donors  This allows an off the shelf product manufacturing  which is one of the most desired characteristics when considering cell therapies and allows for stockpiling  An additional benefit is the fact that around 100 ilixadencel doses can be produced from a single donor  which is expected to be sufficient for c 50 patients 
Ilixadencel DCs are not loaded with antigens  which means there is no need to obtain a patient s tumour tissue  The treatment can be simply used and administered off the shelf  which avoids the more complex logistics typical in the manufacture and administration of autologous immune primers  involving retrieval of a patient s cells and or tumour tissue  ex vivo manipulation and the administration of the product to the same patient  Exhibit 2  
Ilixadencel potentially makes the full set of cancer neoantigens accessible  Cancer vaccines in a traditional sense typically introduce one or several so called tumour associated antigens  which often can be tolerated by the immune system  so the drawback of such an approach is that it is difficult to select the right antigens  Personalized cancer vaccines can expose the whole neoantigen set  but  as discussed above  are autologous  Immunicum s approach is to introduce allogeneic  activated allogeneic DCs directly into the tumour with the aim that the patient s own tumour will become the source of neoantigens  This ensures that there is no need to predict  which neoantigens would be effective  and that the full set of immunogenic antigens will be used for immune system activation 
These features correspond to what could be called a  holy grail  immune primer  allogeneic  exposes the full set of patient specific neoantigens  simple and cost effective  The critical question as to whether it will be effective will obviously need to be addressed in clinical trials  However  the combination of these features alone is what makes ilixadencel a stand out immune primer cell therapy in R D  in our view 

How it works
Classical cancer treatment options include surgery  radiation and chemotherapy  However  improving knowledge about the immune system has led to the development of innovative therapies such as cytokines  interferon alfa  interleukin 2  and antibodies  rituximab  trastuzumab  bevacizumab   The more recent drugs in this area are checkpoint inhibitors  with Yervoy  ipilimumab  Bristol Myers Squibb  NYSE BMY   being the first launched in 2011  followed by Keytruda  pembrolizumab  Merck  and Opdivo  nivolumab  Bristol Myers Squibb   and the first virus based cancer vaccine Imlygic  talimogene laherparepvec  Amgen  NASDAQ AMGN    Adoptive T cell therapies represent the latest breakthrough in cancer treatment  with the first chimeric antigen receptor T cell therapy  Kymriah  tisagenlecleucel  Novartis   approved by the FDA in August 2017 for paediatric acute lymphoblastic leukaemia 
There are two immune system types  innate and acquired  Innate immunity is inborn  non specific ability to defend against infections  acquired  adaptive  immunity is specific to a pathogen and responsible for a long lasting effect  eg vaccination  The latter is subdivided into an antibody based immune response  humoral  and a cellular response  which involves T cells  T cells sense and can kill infections or a patient s own tissue cells if those become abnormal and cause the risk of a tumour developing  There are several subsets of T cells  but the two major ones are CD4   also called  helper   and CD8    killer    indicating which CD glycoprotein they express  CD4  cells are involved in the coordination of other immune cells that participate in the immune response  CD8  cells can directly attack and kill other cells which  for example  are infected with viruses or become malignant  Another important class of immune cells is dendritic cells  DCs  
In a malignant process  when cancer cells die and release abnormal proteins antigens  the DCs pick them up  process and present to the CD8  cells  which then initiate an attack against the cancer  Ilixadencel is made up of activated allogeneic DCs  When injected into the tumour  the ilixadencel DCs survive for 48 72 hours and release immunostimulating factors  including chemokines and cytokines  during that time period  Production of the immunostimulating factors causes local recruitment and activation of the patient s immature DCs  natural killer  NK  cells and T cells  The recognition of the injected DCs by the immune system as foreign  to the patient or host  also helps this process  which leads to cancer cell death and neoantigen release  This then leads to the initiation of the cancer immunity cycle  Exhibit 3   which is expected to mount a sustained anti cancer response  The patient s activated DCs migrate to the tumour site  pick up neoantigens and express them on the cell surface  They then travel to the lymph node  where the patient s DCs  present  these neoantigens to patient CD8  cells  which become cytotoxic CD8  cells that are able to kill tumour cells which display the same antigens as those previously presented  Importantly  in ilixadencel s case  although it is injected intratumourally  if the cancer immunity cycle is efficiently initiated  then both the primary tumour and metastases should be targeted  abscopal effect  
Combinations exploiting several steps in cancer IO cycle are needed
In a malignant process  the tumour evolves in such a way that it can escape being cleared by the immune system  This can happen because either the cancer antigens are not effectively exposed to the immune system and or the cancer develops a so called immunosuppressant environment  Checkpoint inhibitors are effective in certain cancers  however  a very significant part of the patient population is non responsive to the treatment  One suggestion for this effect is that a non responder s immune system is not efficient at carrying out the full immunity cycle in so called  cold  tumours  Chen and Mellman  2013   This is why more traditional chemotherapeutic drugs are used in combination with CPIs to hit the tumours at different targets  For the same reason  novel immuno oncology approaches are also tested in combination with CPIs with the goal of priming the immune cycle and inducing a sustained anti cancer immune response  which will then be amplified by CPIs  turning  cold  tumours to  hot    This approach is supported by emerging evidence that CPIs are more effective in tumours that are already recognized by the immune system  ie tumour specific CD8  T cells are already present before administering CPIs  Ock et al  2016  

Ilixadencel s mechanism of action is  inspired by nature 
Natural viral infection and vaccination with live attenuated viruses  eg the smallpox vaccination  mounts an immune response  which includes the development of specific cytotoxic CD8  T cells that attack and kill the cells infected with the virus  Current understanding  Karlsson Parra et al  2018  is that those DCs that are first infected with a virus lose their ability to present viral antigens to T cells  but instead start to act as an immune primer by secreting inflammatory compounds  This leads to the recruitment and maturation of non infected DCs or  bystander  DCs  The newly recruited DCs absorb the dying virus infected cells and thereby take up the viral antigens  The immune cycle follows  where the DCs migrate to lymph nodes and present the antigens to CD8  T cells that attack the virus infected cells 
The goal with ilixadencel is to recreate this initial stage of the immunity cycle  leading to local inflammation  maturation of own DCs  cancer neoantigen release and uptake by the patient s own mature DCs  Theoretically  this should also be facilitated by the fact that allogeneic DCs will still be recognized as  foreign   which should facilitate an inflammatory reaction  Since ilixadencel is injected intratumourally  the expectation is that the matured own DCs will have access to full set of cancer neoantigens  intracellular and surface  
Existing data are promising
Preclinical data
Immunicum has preclinical data supporting ilixadencel s proposed mechanism of action  which has been published in several peer reviewed articles and different conference presentations  Fotaki et al  2018  Fotaki et al  2017  and ESMO presentation 2018  
Most recent set of preclinical in vivo data was presented at the ESMO conference in October 2018  In this study the researchers used anti PD 1 resistant colon carcinoma mouse model  CT26   The co administration of ilixadencel and PD 1 inhibitor was found to overcome tumour anti PD 1 resistance  Exhibit 4A   which is exactly the proposition of ilixadencel s combination with CPIs  In survival studies researchers treated colon carcinoma mice with ilixadencel in combinations with anti PD 1 or a known immune enhancer 4 1BB  anti CD137   The results showed that combinations with ilixadencel were synergistic when compared to these drugs standalone  Exhibit 4B  

In preclinical in vitro studies ilixadencel was shown to produce pro inflammatory cytokines and chemokines in a sustained fashion  such as IL 12p70  TNF    IL 1  and MIP 1   Ilixadencel also activated co cultured allogeneic T cells  The secretion of these pro inflammatory factors during the co culture promoted the maturation of bystander DCs  which efficiently presented a model antigen to activate antigen specific CD8  T cells 
In preclinical in vivo studies  mouse models   intratumoural administration of allogeneic mouse DCs activated with an identical stimulation cocktail was shown to induce recruitment of T cells  and NK cells  into the tumour  In another study  mice were vaccinated with allogeneic DCs transfected with a virus vector  which induced the expression of a tumour antigen gp 100  This resulted in the generation of gp 100 specific CD8   T cells  ie the animal s own immune system discovered the tumour antigen 
Phase I II in RCC
The Phase I II study in RCC was completed before the MERECA trial  The study was conducted at Uppsala University Hospital  Sweden  in 12 newly diagnosed metastatic RCC patients  Patients were only enrolled if they were candidates for nephrectomy  had a tumour larger than 4cm and at least one metastasis  Following treatment with ilixadencel  patients underwent nephrectomy and only received subsequent standard of care  TKI  upon disease progression  The primary safety endpoints were adverse events  AEs   Immunicum also measured the tumour specific response as a secondary endpoint using various immunological techniques  The main findings were  Laurell et al  2017  
Ilixadencel was found to be safe and well tolerated  All AEs were mild to moderate and were fever  five patients   chills  two patients   rash  one patient  and hypotension  one patient   No dose limiting toxicity was found  SAEs were reported but were unrelated to ilixadencel and there were no signs of an autoimmune response  We believe the side effect profile is encouraging and suggests that a transformation of the immune response to the tumour was in progress 
Immunological examination showed strong to massive tumour specific immune activation with CD8  T cell infiltration in the primary tumour  in 7 out of 12 removed kidney tumours   Massive CD8  T cell infiltration was also observed in one  and the only evaluable  obtained distant metastasis  abscopal effect  
Long term follow up data  six out of 11 evaluable patients received subsequent treatment with TKIs  Three of these six patients surpassed five year survival  while the median overall survival of all 11 patients was 48 months  This compared to historical median overall survival of 14 16 months in similar patients who were treated with TKIs  Exhibit 5  
An interesting case involved one of those three patients  He had multiple liver and brain metastases that all completely regressed after the treatment with ilixadencel and Sutent  Brain metastases are not expected to respond when treated with Sutent 

Phase I II in liver cancer
Ilixadencel has completed a second clinical Phase I II study in 18 patients  17 had HCC and one had cholangiocarcinoma   The patients had an advanced or unresectable disease and received three intratumoural injections of ilixadencel in first line as monotherapy  first line in combination with sorafenib  or second line after progression on sorafenib  The primary endpoint was safety and tolerability  while secondary endpoints included immunological response and initial signs of clinical activity  Overall  ilixadencel was shown to be safe and well tolerated when given as a single treatment or in combination with Nexavar  and some evidence of tumour specific immune activation was observed in the majority of evaluable patients  Rizell et al  2019  
Safety and tolerability  The most common toxicity was grade 1 and 2 fever and chills  with one single treatment related grade 3 event  Notably  this patient was also treated with sorafenib  The patient was suspected of having sepsis  although this was not confirmed  and later recovered 
Immunological examination showed that in the majority of evaluable patients  11 15   there was an increased frequency of tumour specific CD8  T cells in circulating blood 
Initial clinical efficacy  A subgroup of 6 patients received ilixadencel in combination with sorafenib and had a median overall survival of 8 6 months that was shorter than expected when compared with historical controls receiving first line sorafenib  While this was a surprising finding  it could be explained by observations from in vitro studies  where sorafenib  but not sunitinib or anti PD 1 antibodies  inhibited so called mixed leukocyte reaction that leads to a by stander effect  In contrast  patients who received ilixadencel monotherapy as a second line treatment  n   7  had a longer median survival of 10 9 months 
The safety profile from these clinical studies appears to be very good  It appears that sorafenib may not be the best combination drug with ilixadencel due to impaired DC maturation effect  but ilixadencel monotherapy data and in vitro studies allow exploring other TKIs and anti PD 1 combinations  in our view 
Phase I II study in GIST
In June 2019  Immunicum released top line results from the Phase I II trial  which tested ilixadencel in patients with GIST  The Phase I II open label  single arm trial evaluated the safety and efficacy of ilixadencel in unresectable or metastatic GIST patients with tumour progression during ongoing second or later lines of treatment with TKI therapy  Patients were treated with two intratumoural doses of ilixadencel in combination with the ongoing TKI treatment  Ilixadencel was administered in combination with sunitinib  regorafenib or similar TKI  Initial plans were to conduct a larger study  but due to the rarity of the disease  enrolment was stopped at six patients  The released top line results include 
The primary safety endpoint was met with no life threatening  treatment related adverse events  and
The secondary endpoint exploring initial efficacy was based on tumour growth  In two out of six patients the tumour growth was stopped and partially regressed for three and six months  respectively 
GIST is a relatively rare cancer and accounts for less than 1  of all gastrointestinal  GI  tumours  and is therefore a small indication compared to others in Immunicum s R D pipeline  When diagnosed with GIST  most patients appear to have a localised disease and so surgery is the mainstay of curative treatment  but 40  of the resected tumours recur and spread  Schvartsman et al  2017   TKIs became standard of care chemotherapy  but GIST remains one of the most chemo resistant solid malignancies  Imatinib is the TKI of choice for first line treatment  but 50  of patients develop resistance within two years  Other TKIs  sunitinib or regorafenib  were shown to have a benefit in subsequent lines of therapy  but the medial survival at this stage typically is several months  Feng and Morris  2014  
The findings in this study showed that two out of six patients had partial regression  in patients who received ilixadencel in conjunction with second  or third line of standard TKIs   This could be an indication that ilixadencel helped to overcome the resistance to TKIs in these patients  but since the patient sample was small  efficacy claims would need to be investigated in a larger population  As with other trials Immunicum has done  the benefit of this study is the fact that ilixadencel will gather data in multiple tumours and more proof of mechanism of action can be accumulated  specific tumour immune response  tumour infiltration   Further details from the study will be published in a peer reviewed journal 
Ongoing R D programme
Phase Ib II ILIAD study
The ILIAD study is an open label  multi centre  Phase Ib II study in 21 and up to 150 patients  respectively  to evaluate ilixadencel when injected intratumourally in combination with CPIs  The study started enrolling patients in January 2019 and will be carried out in two parts 
The Phase Ib part will enrol a total of 21 patients in a staggered format  Exhibit 6   It will assess safety and define optimal dosing in combination with Keytruda 

The Phase II part will enrol up to 150 patients who will be grouped by indication  NSCLC  H N cancer and gastric adenocarcinoma  into three arms advancing in parallel  Each of the arms is expected to be sufficiently powered to detect clinical efficacy  Futility analyses are also included in the design 
In November 2018  Immunicum announced a collaboration and supply agreement with Merck KGaA and Pfizer  which will supply their jointly developed checkpoint inhibitor avelumab  Bavencio  anti PD L1  to Immunicum for the Phase II part of the study at no cost  costs can be substantial in the market   Immunicum will sponsor the study and retain all commercial rights to ilixadencel  Avelumab will be used to treat patients with H N cancer and gastric cancer  NSCLC patients will receive Keytruda  Although the involvement of Merck KGaA and Pfizer appears to be limited to supply only at the moment  we believe it provides a degree of external validation of the technology and rationale behind ilixadencel  as we assume that the partners conducted due diligence before committing to supply avelumab for free 
The importance of the ILIAD trial is that it will be the first study to test ilixadencel in combination with CPIs  As well as safety and efficacy data  it is also designed to gather data to demonstrate the proof of mechanism of action by showing that ilixadencel generates a systemic tumour specific immune response 
Phase II MERECA study
Patient enrolment for the Phase II MERECA study  n 88  with newly diagnosed  metastatic RCC patients completed in early 2018  The patients in the active arm were treated with ilixadencel  subsequently underwent nephrectomy  removal of the kidney  and received the tyrosine kinase inhibitor  TKI  Sutent  sunitinib  Pfizer   Patients in the comparator arm received only Sutent after nephrectomy  This is the most advanced trial in the R D pipeline and should deliver pertinent efficacy data  The primary endpoints of the study are the hard clinical endpoints of median overall survival and median survival after 18 months  in addition to other safety and efficacy endpoints  Like the ILIAD trial  intratumoural infiltration of CD8  T cells will also be measured  Top line results are expected in Q319 

Path forward  Combination with CPIs is likely key focus
The current cash position should finance operations until the end of 2021  Several milestones are achievable within this period  Phase II MERECA trial top line results in Q319  initial safety data from the Phase Ib of ILIAD trial around end 2019 and then full safety and efficacy data from the Phase Ib of ILIAD trial in 2020  Although controlled efficacy data from the Phase II of ILIAD trial are not likely until 2022  safety data from the Phase Ib part of the trial are key  as this will be the first time ilixadencel is combined with a CPI  CPIs have well established safety issues  which limit combination potential  ie two CPIs can be more effective  but also increase toxicity  Therefore  when it comes to CPI and other anti cancer therapy combinations  safety is as important as efficacy  From this perspective  immune primers tend to have benign safety profiles  so should combine with CPIs well  Specifically  ilixadencel s safety data have so far been very good 
By the time the safety results from the Phase I part of the ILIAD trial are known  expected in 2020   Immunicum will have data from the MERECA  liver cancer and GIST trials  This will also include the all important tumour infiltration and tumour specific systemic immune response results  If positive  these findings would demonstrate proof of concept of ilixadencel s mechanism of action of and we believe Immunicum would be in a strong position to reach a partnership deal without waiting for efficacy data from the ILIAD trial 
We believe that details of the pivotal trials and specific indications will be clarified in conjunction with potential partners  according to their priorities  Immunicum s current strategy is to gather as much proof of concept data in as many indications as possible with the aim of attracting the attention of potential partners 
We also believe that CPIs will be the most likely combination partner drug  In addition  given good safety profile of ilixadencel  there is potential to use it in combination with more than one other anti cancer drug  novel or established   in our view  as long as the cumulative toxicity is manageable  This is not unlike the classic chemotherapy regimens  which routinely combine anywhere from two to four and more drugs 
Historically  ilixadencel was tested in combination with targeted therapies  which made sense at that time  as it was the best standard of care  The advent of CPIs meant that  despite the side effect profile and non responder issue  the standard of care is changing  For example  in February 2019  Merck reported data from its pivotal KEYNOTE 426 trial  n 862   which showed that Keytruda in combination with Inlyta  VEGF targeted TKI axitinib  Pfizer  was more effective than standalone Sutent in extending both overall and progression free survival in first line metastatic RCC  primarily in patients that did not have metastases at diagnosis of the primary tumour  This combination is now expected to become the standard of care in this broader setting  which have a more favourable prognosis than the patients included in the MERECA study  which only included patients with metastatic disease at diagnosis of the primary tumour  intermediate or poor prognosis   In primary liver cancer  Nexavar  sorafenib  has been the standard of care for a decade  In 2017  the FDA approved Opdivo  nivolumab  for second line treatment of patients with HCC  based only on a Phase I II clinical trial  Bristol Myers Squibb has conducted a large Phase III trial CheckMate 459  which tested Opdivo as first line treatment in advanced HCC  but the results reported on 24 June 2019 showed that the overall survival endpoint did not reach statistical significance in this setting 
These developments demonstrate the importance of the ILIAD trial in Immunicum s R D programme  as ILIAD will be the first study to combine ilixadencel with CPIs  Even though the upcoming pivotal trials will have to accommodate the changing standard of care  accumulated data from the MERECA and liver cancer trials will be valuable in partnering discussions for the reasons discussed above 
Competitive landscape
So far  Dendreon s Provenge  dendritic cell vaccine  approved in 2010  and Amgen s Imlygic  oncolytic virus  approved in 2015  are the only approved cancer vaccines although there is no lack of research being conducted in this area  However  the relative lack of more successful examples could be explained by variability in the design of the vaccine  the selection of antigens and understanding of the inhibitory tumour microenvironment  In addition  an increasing number of third party studies are supporting the idea that the backbone strategy of immuno oncology should be in combination treatments exploiting different steps in the immunity cycle  Schlom and Gulley  2018  

Immunotherapy approaches that have been tried so far can be grouped into several categories based on which antigens are exposed to immune system and how the vaccines are manufactured  Exhibit 8  
 Off the shelf  vaccines based on tumour associated antigens  These vaccines contain tumour associated self antigens  typically in the form of synthetic long peptides  and are not based on the patient s own tumour  Compared to personalised vaccines they can be easier to manufacture  store and ship  However  the identification of suitable neoantigens that are conserved and expressed in the majority of patients is a significant challenge  especially due to patient to patient  and even intratumoural  variation 
Personalised cancer neoantigen vaccines  These are developed from the patient s own tissues and contain patient specific neoantigens  DCs can be isolated from the patient and modified ex vivo to express neoantigens from the patient s own tumour and administered back to the patient  Although apparently solving the problem of neoantigen variation between patients  the procedures can be complicated  expensive  time consuming and can expose the patient to infection 
 Off the shelf  personalised cancer neoantigen vaccines  These are immune primers that become personalised vaccines when injected into the patient s tumour  These vaccines offer a potential compromise between the first two approaches  They are personalised in that they exploit the patient s own tumour neoantigen release by inducing tumour cell death  and are also off the shelf  Ilixadencel falls into this category  as do oncolytic virus vaccines  eg Amgen s Imlygic  
Provenge  Dendreon Sanpower  contains a prostate specific antigen  which is a tumour associated self antigen  rather than a neoantigen  and has not been commercially successful  Because autologous DCs are used as the primer adjuvant  this concept does not easily fit into any of the three groups here  and  furthermore  is unrelated to Immunicum s DC technology 
Looking at the R D landscape  there are ongoing attempts to develop various approaches that would fall into all the above categories  Products that would fall into ilixadencel s category include oncolytic viruses  STING pathway activator and Toll like receptor  TRL  agonists  Imlygic  the oncolytic virus from Amgen  is the only marketed for several solid tumours  melanoma and prostate  respectively   Transgene s oncolytic virus Pexa Vec is in Phase III for HCC in combination with sorafenib  Viralytics  oncolytic virus Cavatak is in Phase I for NSCLC in combination with the CPI pembrolizumab 


Sensitivities
Ilixadencel has yet to reach a definitive proof of concept clinical stage  so is subject to significant R D risk  as is typical for a company at this stage  The clinical programmes are all testing the same therapy  therefore the investment case relies on the success of ilixadencel  CT or ultrasound is required to guide the injection to the viable part of the tumour  The administration procedure is unlikely to be too difficult for physicians to perform since intratumourally injected products are already marketed  However  some tumours will be more difficult to access than others  and some may be inaccessible  This may affect market uptake  but given ilixadencel can be used in many solid tumours  the overall potential is still high  In addition  ilixadencel can be injected in distant metastases  which could be easier to reach than the primary tumour  By the time ilixadencel is launched  the treatment landscape and  standard treatments  are likely to have developed  Ilixadencel is already being positioned as an addition to combination therapies  so potential changes in clinical practice are not necessarily prohibitive for ilixadencel combination development  The new trial  ILIAD  is exploring ilixadencel combinations with CPIs 
Click This Link To Read The Full Report",2019-06-28,Edison,https://www.investing.com/analysis/immunicum-successful-large-share-issue-transforms-outlook-200435511,200435511
149268,370784,AMGN,Pfizer s  PFE  Avastin Biosimilar Zirabev Gets FDA Approval,opinion,Pfizer  Inc    NYSE PFE   announced that the FDA has granted approval to Zirabev  its biosimilar version of Roche s   OTC RHHBY   blockbuster cancer drug  Avastin for several types of cancer Zirabev can be prescribed for the treatment of five types of cancer   metastatic colorectal cancer  unresectable  locally advanced  recurrent or metastatic non squamous non small cell lung cancer  recurrent glioblastoma  metastatic renal cell carcinoma and persistent  recurrent or metastatic cervical cancer This is Pfizer s second oncology biosimilar to be approved in the United States  the first being a biosimilar of Roche s breast cancer drug  Herceptin  Pfizer gained FDA approval for Trazimera  its biosimilar version of Herceptin in March this year Amgen Allergan s biosimilar version of Avastin  Mvasi was approved by the FDA in 2017 and in the EU in early 2018  However  Mvasi has not been launched yet  Several other companies like Samsung  KS 005930  Bioepis and Boehringer Ingelheim are also developing biosimilar versions of Avastin Pfizer s shares have declined 0 8  this year so far against an increase of 2 2  for the    At present  in the United States  Pfizer has six approved biosimilar products including Inflectra  its first biosimilar version of J J Merck s Remicade  which was launched in November 2016  Pfizer also markets biosimilar versions of Amgen s   NASDAQ AMGN   drugs  Neupogen and Epogen in Europe and the United States Pfizer is gradually venturing into the oncology biosimilars space  A biosimilar version of Roche s another cancer medicine  Rituxan is also under review and FDA s decision on the same is expected this year  With a biosimilar version of AbbVie s   NYSE ABBV   Humira also under review in the United States  Pfizer expects potential U S  approvals for up to four biosimilar products in 2019  Of these  the company has already received approval for Zirabev and Trazimera Biosimilar versions of Herceptin and Avastin are already approved in the EU while that of Rituxan is under review in the EU  Meanwhile  Pfizer is evaluating several biosimilar molecules in various stages of development In a separate press release  Pfizer announced that a phase III study evaluating its pulmonary arterial hypertension  PAH  drug  Revatio  sildenafil citrate   for another indication did not meet its primary efficacy endpoint  The study was evaluating intravenous sildenafil added to inhaled nitric oxide  iNO  for the treatment of newborns with persistent pulmonary hypertension  PPHN   Presently  Revatio is not approved for the treatment of PPHN  The data showed that treatment with sildenafil iNO did not result in a statistically significant reduction in treatment failure rate or time on iNO versus iNO alone  Revatio is the trade name of sildenafil citrate in EU and Japan while in the United States  Pfizer markets it by the trade name of Viagra to treat erectile dysfunction and PAH Pfizer currently carries a Zacks Rank  2  Buy   You can see  The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2019-06-30,Zacks Investment Research,https://www.investing.com/analysis/pfizers-pfe-avastin-biosimilar-zirabev-gets-fda-approval-200436097,200436097
149269,370785,AMGN,Roche s Tecentriq Gets CHMP Recommendation For Breast Cancer,opinion,"Roche   OTC RHHBY   announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has recommended the approval of immuno oncology drug  Tecentriq  for yet another indication 
The CHMP recommended approval of Tecentriq in combination with Celgene Corporation s   NASDAQ CELG   Abraxane for the treatment of adult patients with unresectable  locally advanced or metastatic triple negative breast cancer  TNBC   whose tumours have PD L1 expression    1   and who have not received prior chemotherapy for metastatic disease 
The recommendation is based on data from the phase III IMpassion130 study  wherein Tecentriq plus nab paclitaxel significantly reduced the risk of disease worsening or death by 38  compared with nab paclitaxel alone in patients who tested positive for PD L1 expression on tumour infiltrating immune cells  IC   The study will continue until the next planned analysis 
The European Commission generally takes the CHMP recommendation in consideration but is not bound by it  A decision from the commission is expected soon 
Roche has a strong presence in the oncology market  In particular  the company dominates the breast cancer space with strong demand for its HER2 franchise drugs  The HER2 franchise includes Herceptin  Perjeta and Kadcyla  Growth in Herceptin is being driven by increasing demand in the United States and Europe  A potential approval of Tecentriq for this indication will further boost the company s franchise 
In March 2019  the FDA approved the drug for the same indication 
We remind investors that Tecentriq is approved in the United States  EU and or countries  either alone or in combination with targeted therapies and or chemotherapies in various forms of non small cell and small cell lung cancer  certain types of metastatic urothelial cancer  and PD L1 positive triple negative breast cancer 
Tecentriq sales came in at CHF336 million in the first quarter of 2019  up 135  from the year ago quarter  Label expansion of the drug for other indications should further boost sales 
Currently  Roche has seven ongoing phase III studies evaluating the drug in TNBC  including early and advanced stages of the disease 
Roche s stock has gained 14  in the past six months compared with the s growth of 3 2  

 
Approval of new drugs and label expansion of existing drugs bode well for the company and should offset the adverse impact of biosimilar competition for some of its key drugs such as Avastin  Rituxan and Herceptin from the likes of Novartis   NYSE NVS   and Amgen   NASDAQ AMGN   
Zacks Rank
Roche currently carries a Zacks Rank  4  Sell   You can see  
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-07-01,Zacks Investment Research,https://www.investing.com/analysis/roches-tecentriq-gets-chmp-recommendation-for-breast-cancer-200436247,200436247
149270,370786,AMGN,Exclusive  Sanofi to unveil challenge to Medivation s board   sources,news,"By Greg Roumeliotis  Reuters    France s Sanofi SA  PA SASY  is preparing to name candidates it will put forward to replace the entire board of U S  cancer drug company  Medivation  Inc  O MDVN  as early as Wednesday  according to people familiar with the matter  Sanofi has threatened to oust the board after Medivation rejected its unsolicited  9 3 billion acquisition offer late last month  taking advantage of a so called  written consent  rule that gives Medivation shareholders the ability to act at any time to replace directors  Medivation has declined to engage in sale talks with Sanofi unless the latter raises its  52 50 per share cash offer first  sources have said  The French drugmaker has said it is willing to raise its bid only after Medivation engages with it in negotiations  Medivation shares ended trading on Tuesday in New York at  61 91   Among Sanofi s eight nominees are Michael Campbell  the former chief executive of Arch Chemicals Inc  Ronald Rolfe  a retired partner at law firm Cravath  Swaine   Moore LLP  and Barbara Deptula  a former executive vice president and chief corporate development officer of biopharmaceutical company  Shire  Plc  L SHP   one of the people said  The sources asked not to be identified because the names of the nominees have not been disclosed  Medivation and Sanofi representatives did not immediately respond to requests for comment  Medivation has signed non disclosure agreements to share confidential information with other pharmaceutical companies interested in an acquisition  including  Pfizer  Inc  N PFE  and  Amgen Inc   O AMGN   sources told Reuters earlier this month  However  no other company is close to tabling an offer for Medivation  according to the sources  Sanofi is vying for Medivation in an attempt to expand in the lucrative oncology sector  as it struggles to compensate for declining revenues from a key diabetes drug that recently lost patent protection  Medivation has argued that Sanofi s offer fails to value fairly the prospects of its recently developed prostate cancer drug XTANDI  as well as two other products currently in clinical trials  Talazoparib  for the treatment of breast cancer  and Pidilizumab  for the treatment of blood cancers  Campbell served as chairman  president and chief executive officer of Arch Chemicals  a maker of products that kill bacteria and fungi  between 1999 and 2011  Switzerland s Lonza AG  S LONN  agreed in 2011 to buy the company for  1 2 billion  Rolfe retired from Cravath s litigation department in 2010  having worked on major antitrust and securities cases  as well as U S  Securities and Exchange Commission and grand jury investigations  His clients included  IBM  Corp  N IBM   PepsiCo Inc  N PEP  and Sprint Corp  N S   
Deptula worked at Shire between 2004 and 2012  where she led efforts to expand its product portfolio  She has been a director on the board of AMAG Pharmaceuticals Inc  O AMAG   a specialty pharmaceutical company focusing on maternal health  anemia and cancer supportive care  since 2013 ",2016-05-25,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-sanofi-to-unveil-challenge-to-medivation's-board---sources-404268,404268
149271,370787,AMGN,Western Digital shares jump 4  amid CFO transition  increased outlook,news,"Investing com    Shares in  Western Digital  Corporation  NASDAQ WDC  jumped 4  in after hours after the California based computer data storage company raised its fourth quarter earnings outlook and announced a chief financial officer transition plan on Wednesday 
Western Digital shares popped shortly after the company named Mark Long as its new CFO  effective Sept  1  succeeding Olivier Leonetti  who is leaving the company to pursue other opportunities  Leonetti will remain with the company through the first of September and will oversee the company s fiscal year end reporting requirements  Western Digital said in a statement  He will also continue in an advisory role to CEO Steve Milligan until October 1 
 The company is going through a strategic and organizational transformation with the integration of our HGST and WD subsidiaries as well as integrating the recently completed acquisition of SanDisk   Milligan said in a statement   Although in the early stages  we are already seeing the benefits of these strategic steps  
 As we build on our strategy driven focus in a tightly integrated manner  it is the right time to combine the strategy and finance organizations and Mark Long is the right leader of this integrated team  with his extensive experience in financial and strategic planning  Olivier made a tremendous contribution to Western Digital in nearly two years as CFO  He played a key role through the successful planning  financing and completion of the SanDisk acquisition  
Leonetti joined Western Digital in September  2014 as CFO following a three and a half year stint as Vice President  finance  global commercial at Amgen  NASDAQ AMGN   Previously  Leonetti served in a variety of senior finance positions at Dell from July  1997 through April  2011 
 I am proud of what we have accomplished at Western Digital  particularly the successful completion of the transaction with SanDisk   Leonetti said   Western Digital has a first class executive team and I am confident that the finance and strategy organization is in good hands with Mark  
Also on Wednesday  Western Digital rose its fourth quarter earnings per share guidance to 0 72 from a previous range of 0 65 to 0 70  The company also increased its quarterly revenue estimate to  3 46 billion from a range of  3 35 to  3 45 billion 
Shares in Western Digital rose 2 02 to 4 44  to 47 48 in after hours trading ",2016-07-06,Investing.com,"https://www.investing.com/news/stock-market-news/western-digital-shares-jump-4-amid-cfo-transition,-increased-outlook-412841",412841
149272,370788,AMGN,Loeb s Third Point makes more new bets on energy  cuts stake in Dow,news,"By Svea Herbst Bayliss BOSTON  Reuters    Billionaire investor Daniel Loeb s hedge fund Third Point added new bets in the energy and information technology sectors with investments in Whiting Petroleum Corp   Facebook  NASDAQ FB  and Activision Blizzard Inc  NASDAQ ATVI   according to regulatory filings on Friday  Third Point  which invests roughly  16 billion and is widely followed because of its years of strong returns  also made new bets on Tesoro Petroleum and  Devon Energy  Corp  NYSE DVN   Last month Loeb wrote to investors that savvy bets on the energy market had helped the portfolio gain 4 6 percent in the second quarter  beating the broader Standard   Poor s stock market   We came into the year with a short credit portfolio that we reversed sharply in February  getting long over  1B in energy credit   Third Point said in its latest quarterly letter to clients  Loeb also said he sold out of Amgen  NASDAQ AMGN  because he saw better opportunities in other companies  Among Loeb s biggest holdings  he cut his stake in  Dow Chemical   NYSE DOW  Co by 20 percent as the firm sold 5 million shares  At the end of the second quarter he owned 20 million shares  Third Point made nearly two dozen new investments in U S  stocks  which were revealed in quarterly 13F filings made with the Securities and Exchange Commission  The filings show what stocks funds owned at the end of the last quarter   
Third Point also exited Signet Jewelers  a widely owned stock that fell 34 percent in the second quarter ",2016-08-12,Reuters,"https://www.investing.com/news/stock-market-news/loeb's-third-point-makes-more-new-bets-on-energy,-cuts-stake-in-dow-420101",420101
149273,370789,AMGN,UnitedHealth trims drug coverage  including Sanofi insulin,news," Reuters    UnitedHealth Group  N UNH   the largest U S  health insurer  will stop covering several brand name drugs as of next year  reinforcing a trend of payers steering prescriptions to lower priced options  In a bulletin seeking client feedback by Sept  28  UnitedHealth said it is changing reimbursement terms for long acting insulins and will no longer cover Lantus  the main insulin drug sold by Sanofi  PA SASY   The insurer said Basaglar  a cheaper biosimilar insulin sold by Eli Lilly  N LLY  would be covered as  Tier 1   meaning the lowest out of pocket costs for members  Levemir  produced by  Novo Nordisk   CO NOVOb   will move from Tier 1 to Tier 2  CVS Health  N CVS  made a similar move last month to drop Lantus in favor of Lilly s new biosimilar  Analysts at Jefferies said the sales impact of the United exclusion should be less than that from the CVS move  because the United plan covers around 15 million people while CVS covers 19 million  Sanofi shares fell more than 1 percent on Thursday after the news but had recovered by 1200 GMT  while Novo was down 1 3 percent   Sanofi reaffirmed its sales expectations despite the latest exclusion  A spokeswoman said the company was still targeting a decline in diabetes drug sales of 4 to 8 percent a year until 2018   We are disappointed with the decision  For Sanofi  it is a pity not to leave doctors a choice   she said   We had anticipated this kind of decision but we are holding discussions with other organisations in the United States to have them keep Lantus on their lists   Biosimilars are cheaper copies of protein based biotech drugs such as Lantus  which are no longer protected by patents  They cannot be precisely replicated like conventional chemical drugs but have been shown to be equivalent in terms of efficacy and side effects  United also said it will exclude from coverage Amgen s  O AMGN  white blood cell boosting drug Neupogen  in favor of Zarxio  a biosimilar sold by  Novartis   S NOVN   
UnitedHealth last year bought Catamaran for  12 8 billion  making it the nation s No  3 pharmacy benefit manager after Express Scripts Holding  O ESRX  and Caremark  which is owned by CVS ",2016-09-22,Reuters,"https://www.investing.com/news/stock-market-news/unitedhealth-trims-drug-coverage,-including-sanofi-insulin-427833",427833
149274,370790,AMGN,Pfizer set to start shipping Remicade biosimilar next month,news," Reuters     Pfizer  Inc  N PFE  said on Monday it plans to begin shipping its biosimilar version of Johnson   Johnson s  N JNJ  blockbuster rheumatoid arthritis drug Remicade in late November at a 15 percent discount to current wholesale prices  The Pfizer drug  to be sold under the name Inflectra  is already available in Europe and other overseas markets and would be the second biosimilar medicine available in the United States  As it is not possible to produce exact copies of biotech drugs made from living cells  the cheaper versions are referred to as biosimilars rather than generics  They are intended to provide cost savings as less expensive alternatives to pricey biologic medicines  Remicade is J J s biggest selling drug with U S  sales of about  5 billion a year  J J s forecasts for 2016 had assumed no competition from a Remicade biosimilar this year  Its shares slipped about half a percent to  118 49 in after hours trading  J J  in an emailed statement  said it considers any sales by Pfizer of a Remicade biosimilar to be an  at risk launch   That could entitle the company to triple damages if Pfizer is found in court to have infringed Remicade patents   Pfizer said its pricing for the drug below Remicade wholesale costs does not take into account discounts to health insurers  distributors or other purchasing organizations  J J said it expects to be competitive with the Remicade biosimilar   We intend to compete through a variety of innovative contracting options  discounts and rebates to payers  providers and pharmacy benefit managers  PBMs   to ensure Remicade remains an affordable option for patients and physicians   a J J statement said  In addition to rheumatoid arthritis Inflectra  like Remicade  is also approved to treat Crohn s disease  ulcerative colitis  psoriasis  psoriatic arthritis and the spine condition ankylosing spondylitits   Novartis   S NOVN  last year began selling the first biosimilar in the United States  a cheaper version of Amgen s  O AMGN  infection fighter Neupogen called Zarxio  
Several companies are developing biosimilar versions of the top selling biotech medicines for rheumatoid arthritis and cancer ",2016-10-17,Reuters,https://www.investing.com/news/stock-market-news/pfizer-set-to-start-shipping-remicade-biosimilar-next-month-432943,432943
149276,370792,AMGN,Amgen Q3 top line up 2   EPS up 10   earnings guidance raised  shares ease 1  after hours,news,Amgen  NASDAQ AMGN  Q3 results   M   Total Revenues  5 811   1 5    Product Sales  5 516  0   Net Income  2 017   8 3    Non GAAP Net Income  2 276   9 4    EPS  2 68   9 8    Non GAAP EPS  3 02   11 0    CF Ops  2 662   8 0   Key Product Sales  Enbrel  1 452   0 5    Neulasta  1 200   5 3    Aranesp  531   7 7    Sensipar Mimpara  415   17 6    XGEVA  394   4 2    Prolia  379   18 4    EPOGEN  335   31 5    NEUPOGEN  183   35 6    KYPROLIS  183   33 6    Vectibix  164   24 2    Nplate  151   10 2    Repatha  40  BLINCYTO  29 2016 Guidance  Total Revenues   22 6B   22 8B from  22 5B   22 6B  EPS   9 94   10 11 from  9 55   9 90  Non GAAP EPS   11 10   11 40  unch  Consensus view was EPS of  2 79 on revenues of  5 7B Shares are off 1  after hours on increased volume ,2016-10-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgen-q3-top-line-up-2;-eps-up-10;-earnings-guidance-raised;-shares-ease-1-after-hours-435403,435403
149291,370807,AMGN,Ligand Inks Oncology Drug Discovery Deal With PhoreMost,opinion,"Ligand Pharmaceuticals Incorporated   NASDAQ LGND   announced that its subsidiary  Vernalis has signed a research collaboration agreement with privately held PhoreMost Limited for an undisclosed novel oncology target We remind investors that Ligand completed the acquisition of UK based biotechnology company  Vernalis  for  43 million in October 2018  Vernalis has expertise in structure based drug discovery Per this agreement  Ligand will apply Vernalis Design Platform   VDP   for designing small molecule inhibitors for the undisclosed oncology target  PhoreMost has identified and validated the target using its next generation phenotypic screening technology  SITESEEKER  The use of VDP is expected to accelerate the discovery and design of compounds for the target cancer indication  The companies are looking to out license the resulting compounds for further development Per the terms of the agreement  Vernalis and PhoreMost will share any future revenues from the compounds including upfront payments  milestone fees and royalties  Ligand will be eligible to receive scaling interest in license economics based on its contribution and stage of development at the time of licensing related to the compounds Ligand s shares have declined 18 7  so far this year against the  s increase of 1 2  Please note that Vernalis has a broad pipeline of partnered programs and ongoing collaborations  The acquisition of Vernalis has added eight fully funded partnered programs including pipeline products for respiratory  oncology and CNS indications to Ligand s portfolio  The latestagreement demonstrates the potential of Vernalis acquisition for successful integration with Ligand s business  Ligand expects Vernalis  technology to boost the company s long term milestones and royalties potential Last month  Ligand  a novel  oral  selective  Chk1 kinase inhibitor   VER250840   discovered using VDP  Rights to the pre clinical candidate was granted to privately held UK based Cumulus Oncology for an undisclosed upfront payment  It is also expected to bring more than  76 million in milestone payments and tiered royalties Ligand is focused on strengthening and broadening its technology platform through agreements and acquisitions  Ligand s Captisol technology is the key revenue generator for the company  Key drugs developed using this technology include Novartis    NYSE NVS   Promacta  Amgen s   NASDAQ AMGN   Kyprolis  Spectrum s   NASDAQ SPPI   Evomela and Merck s Noxafil IV  In March 2019  Ligand  all rights to blockbuster drug  Promacta  to privately held Royalty Pharma for  827 million Ligand had acquired OMT  Inc  in 2016  which added an antibody generating platform  OmniAb  to its technology portfolio  The acquisition of Crystal Bioscience in 2017 added a highly complementary antibody technology to Ligand s OmniAb platform  Ligand anticipates its technology platform to generate more than  3 5 billion in potential contract payments Ligand Pharmaceuticals Incorporated Price
    Zacks RankLigand currently has a Zacks Rank  2  Buy   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-06-12,Zacks Investment Research,https://www.investing.com/analysis/ligand-inks-oncology-drug-discovery-deal-with-phoremost-200431276,200431276
149292,370808,AMGN,Roche Reports Positive Data On Rituxan For Pemphigus Vulgaris,opinion,"Roche   OTC RHHBY   announced positive top line results from the late stage study  PEMPHIX 
The study evaluated the efficacy and safety of MabThera Rituxan  rituximab  compared to mycophenolate mofetil  MMF  in adults with moderate to severe pemphigus vulgaris  PV  
The primary endpoint was the percentage of participants who achieved sustained complete remission off corticosteroid therapy  no disease activity  as evaluated by Pemphigus Disease Area Index  without the use of steroids for 16 consecutive weeks or more  at week 52  The study met the primary endpoint and demonstrated MabThera to be superior to MMF in achieving sustained complete remission 
MabThera Rituxan also met the secondary endpoints  including cumulative corticosteroid dose  number of flares  time to sustained remission and time to disease flare 
We remind investors that in June 2018  MabThera Rituxan became the first biologic therapy approved by the FDA and the European Commission for PV  an autoimmune  blistering disease  This approval was based on the Ritux 3 study  The PEMPHIX study provided additional clinical evidence on the effectiveness of MabThera Rituxan for PV  Data from the PEMPHIX study will be presented at an upcoming medical congress 
The stock has gained 11 4  in the year so far compared with the  s 3 1  growth 

 
Recently  the FDA accepted Roche s supplemental biologics license application  sBLA  and granted Priority Review status to Rituxan in children with two rare blood vessel disorders  The sBLA is for the use of the drug in combination with glucocorticoids  GCC  for the treatment of granulomatosis with polyangiitis  GPA  and microscopic polyangiitis  MPA  in children aged two years or older  If approved  this would be the first pediatric indication for MabThera Rituxan 
Rituxan is currently approved for the treatment of four autoimmune indications 
The FDA approved the drug for rheumatoid arthritis  RA  in 2006  GPA and MPA in 2011  and pemphigus vulgaris in 2018 
Roche is currently looking to diversify its portfolio in wake of stiff competition from biosimilars for key drugs such as Avastin  Rituxan and Herceptin from Novartis   NYSE NVS   and Amgen   NASDAQ AMGN    Apart from Rituxan  the company s rheumatology portfolio has a first in class anti IL 6 receptor therapy  Actemra RoActemra  which is approved for rheumatoid arthritis  RA   polyarticular and systemic juvenile idiopathic arthritis  giant cell arteritis  and chimeric antigen receptor T cell induced cytokine release syndrome 
Zacks Rank   Another Stock to Consider
Roche currently carries a Zacks Rank  2  Buy  
Another top ranked stock worth considering is Bristol Myers Squibb Company   NYSE BMY    which sports a Zacks Rank  1  Strong Buy   You can see  
Bristol Myers  earnings per share estimates increased from  4 79 to  5 03 for 2020 over the past 60 days 
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1  and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-06-13,Zacks Investment Research,https://www.investing.com/analysis/roche-reports-positive-data-on-rituxan-for-pemphigus-vulgaris-200431477,200431477
149293,370809,AMGN,Merck s Keytruda Gets 2nd Label Expansion Approval In June,opinion,"Merck   Co   Inc    NYSE MRK   announced that the FDA has granted accelerated approval for the label expansion of its PD L1 inhibitor  Keytruda  for metastatic small cell lung cancer   SCLC   in third  or later line setting  This approval marks the first label expansion for Keytruda in the SCLC indication The approval was based on pooled data from SCLC cohorts of two clinical studies   KEYNOTE 158  cohort G  and KEYNOTE 028  cohort C1    which evaluated the drug in SCLC patients whose disease has progressed after platinum based chemotherapy and at least one other prior line of therapy  Data demonstrated that treatment with Keytruda achieved an objective response rate of 19  and complete response rate of 2  in the patient population  The duration of response was six months or longer in 94  of the patients  12 months or longer in 63  of patients and 18 months or more in 56  of patients However  continued approval of the drug in this indication will depend on verification and description of clinical benefit in the confirmatory studies Merck s shares have risen 10 5  this year so far compared with the  s increase of 2 4  Keytruda generated sales of  2 27 billion in the first quarter of 2019  up around 5 6  sequentially and 55  year over year  Sales were driven by the launch of indications globally  Keytruda sales are gaining particularly from strong momentum in first line lung cancer indication both as monotherapy and with the rollout of the chemo combo in both non squamous and squamous non small cell lung cancer   NSCLC   Per the press release  SCLC occurs in 10 15  of lung cancer patients  A label expansion in this indication is likely to strengthen Keytruda s position further in the lung cancer market Keytruda is continuously growing and expanding into new indications  treatment setting or geographies and markets globally  Earlier this month  the drug received  as the first line treatment for recurrent or metastatic head and neck squamous cell cancer Moreover  the drug received approval for multiple label expansions earlier in 2019 including expansion of NSCLC patient population in the    and   A decision on the label expansion of the drug to include first line treatment of advanced or metastatic renal cell carcinoma   RCC   is  later this week However  in 2019  Keytruda faced failure in two clinical studies evaluating it as a second  or third line treatment of metastatic triple negative  or second line treatment of advanced   the most common type of liver cancer The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 900 studies  including more than 600 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte   NASDAQ INCY    Glaxo   NYSE GSK   and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens Several other regulatory decisions for new indications in the United States as well as in Europe are pending in 2019  which  if approved  can further boost sales Apart from Keytruda  Merck is also focusing on acquisitions to strengthen its oncology pipeline  The company has offered to acquire three biotech companies so far this year spending more than  2 billion   The company has completed the acquisition of   which was announced in February  to boost its capabilities in infectious diseases and cancer  In May  it entered into an agreement to buy   which will add a late stage novel late stage RCC candidate to Merck s pipeline  Earlier this month  the company announced a definitive deal to acquire   which has pre clinical oncology candidates in its pipeline Merck   Co   Inc  Price
    Zacks RankMerck currently carries a Zacks Rank  2  Buy   You can see  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-06-18,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-gets-2nd-label-expansion-approval-in-june-200432882,200432882
149298,370814,AMGN,European stocks open sharply higher  eyes on Fed  Dax up 1 69 ,news,"Investing com   European stocks opened sharply higher on Tuesday  after oil prices slightly rebounded late Monday and as markets turned their focus to this week s policy decision by the Federal Reserve 
During European morning trade  the EURO STOXX 50 jumped 1 61   France s CAC 40 advanced 1 77   while Germany s DAX 30 rallied 1 69  
Most investors expect the Fed to raise interest rates for the first time since June 2006 at its upcoming meeting due to begin later Tuesday 
Market participants also continued to focus on oil prices as they moved back above the  35 threshold after falling to the lowest levels since February 2009 on Monday amid expectations that a global supply glut will worsen next year 
Financial stocks were broadly higher  as French lenders  BNP Paribas   PA BNPP  and  Societe Generale   PA SOGN  rallied 1 93  and 1 84   while Germany s Commerzbank  DE CBKG  and  Deutsche Bank   DE DBKGn  gained 0 30  and 1 20  
Among peripheral lenders  Italy s Unicredit  MI CRDI  and  Intesa Sanpaolo   MI ISP  surged 1 79  and 2 16   while Spanish banks BBVA  MC BBVA  and  Banco Santander   MC SAN  rose 0 21  and 1 39  respectively 
Elsewhere  Sanofi  PA SASY  saw shares soar 3 85  after the French drugmaker and Boehringer Ingelheim GmbH said they are in exclusive talks to swap assets worth  18 1 billion 
Hennes   Mauritz AB  ST HMb  added to gains  with shares up 0 98   even after the retailer reported revenue below analysts  estimates as mild weather weighed on demand in North America and Europe 
In London  commodity heavy FTSE 100 jumped 1 36   boosted by sharp gains in the mining sector 
Shares in  Rio Tinto   L RIO  rallied 1 76  and  Bhp Billiton   L BLT  gained 2 76   while  Glencore   L GLEN  surged 3 19  
Financial stocks were also on the upside  as the Royal Bank of Scotland  L RBS  advanced 1 13  and  HSBC Holdings   L HSBA  climbed 2 22   while  Barclays   L BARC  and Lloyds Banking  L LLOY  surged 2 25  and 3 63  respectively 
Meanwhile  GlaxoSmithKline PLC  L GSK  shares jumped 1 37  following reports  Amgen Inc   O AMGN   will reacquire the rights to three drugs in 48 countries from the British company as part of a plan to develop its own international sales infrastructure for future products 
In the U S   equity markets pointed to a higher open  The Dow Jones Industrial Average futures pointed to a 0 40  increase  S P 500 futures signaled a 0 42  climb  while the Nasdaq 100 futures indicated a 0 39  gain ",2015-12-15,Investing.com,"https://www.investing.com/news/forex-news/european-stocks-open-sharply-higher,-eyes-on-fed;-dax-up-1.69-376056",376056
149299,370815,AMGN,Exclusive  Medivation succumbs to pressure to explore sale   sources,news,"By Greg Roumeliotis and Pamela Barbaglia  Reuters     Medivation  Inc  O MDVN  will actively seek to sell itself after the US cancer drug maker rejected a  9 3 billion takeover offer from France s Sanofi SA  PA SASY   according to people familiar with the situation  The San Francisco based company has agreed to open its books to both  Pfizer  Inc  N PFE  and  Amgen Inc   O AMGN   those people said  The move comes less than two weeks after Sanofi made its approach public by publishing a letter to Medivation s chief executive David Hung that contained details of the offer  However  there is still no certainty that Sanofi s rivals will press ahead with bids for Medivation  the people cautioned  The sources asked not to be identified because the deliberations are confidential  Medivation  Sanofi  Pfizer and Amgen declined to comment   Medivation said last week that Sanofi s  52 50 per share cash offer  substantially undervalues the company  its leading oncology franchise  and innovative late stage pipeline   Medivation shares traded on Monday around  10 above the offer price  Sanofi has said it is willing to raise its offer as long as Medivation engages in negotiations  and has threatened to go directly to shareholders to oust its board if it does not  Sanofi  which is being advised by  Morgan Stanley   NYSE MS   has a track record of pushing through unsolicited deals  after buying Genzyme for  20 billion in 2011  A sale of Medivation would mark a bittersweet moment for Hung  who founded the company in 2003  In 13 years  he built Medivation from a penny stock peddling a 20 year old Russian treatment for hay fever into a  10 billion market capitalization oncology company   In the process  he overcame numerous obstacles  including the failure of Alzheimer s treatment Dimebon  which used to be sold as an antihistamine in Russia  In 2009  Hung took a bet on a chemical compound called MDV3100  which was developed at the University of California  Los Angeles  In partnership with Japan s Astellas Pharma Inc  T 4503   Medivation turned MDV3100 into a nearly  2 billion dollar prostate cancer drug called Xtandi  Xtandi s successful progression from early stage experiments to full blown regulatory approval was one of the fastest in biopharmaceutical history  taking only seven years   At times  Hung resorted to unconventional methods to finance Medivation s research  including tapping the public markets through a 2004 reverse merger with a shell company  which he used to raise  12 million in public capital  
Prior to joining Medivation  Hung was already an experienced life sciences executive  having previously led a medical device company  Pro Duct Health  to a more than  167 million sale in 2001 ",2016-05-10,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-medivation-succumbs-to-pressure-to-explore-sale---sources-400887,400887
149307,370823,AMGN,Lilly s Emgality Gets FDA Approval For Cluster Headache,opinion,Eli Lilly and Company   NYSE LLY   announced that the FDA has granted approval to its CGRP antibody  Emgality injection  300 mg  for the preventive treatment of episodic cluster headache in adult patients Notably  Lilly gained an FDA approval for Emgality for preventive treatment of migraine late last September  The supplemental biologics license application for the cluster headache indication was based on data from a phase III study  which showed that 71 4  of patients who were given Emgality  300 mg  had their weekly cluster headache attacks reduced by half versus 52 6  of patients with placebo  Last September  the FDA granted Breakthrough Therapy status to Emgality for the same indication  The drug will be priced the same as for migraine on a per milligram basisLilly s shares have risen 1 1  this year so far against the  s decline of 0 1    Amgen s   NASDAQ AMGN   and Novartis  Aimovig and Teva s   NYSE TEVA   Ajovy were two other CGRP antibodies to be launched last year and pose strong competition to Emgality  However  Emgality now becomes the only CGRP antibody approved for two headache disorders   migraine and episodic cluster headache   which will help Lilly gain access to a broader patient population and boost sales of this promising drug  Currently  there are no approved medicines in the United States for treating episodic cluster headache In April  Lilly said that Emgality captured 33  share of market for new prescriptions in the United Statesin the first quarter of 2019  an increase of almost 13 points from end of 2018Please note that Teva discontinueda late stage study evaluating Ajovy for episodiccluster headache in April 2019 and one for chronic cluster headache in June last year According to Lilly s press release  episodic cluster headache represents 85  90  of cluster headache cases  Chronic cluster headache accounts for 10  15  of the cluster headache market Notably  Lilly s overall pain portfolio looks promising  Apart from Emgality  the company is developing lasmiditan  which is currently under review in the United States for the treatment of acute migraine in adult patients  Lilly along with partner Pfizer   NYSE PFE   is developing tanezumab  which is being evaluated in several phase III programs for treating osteoarthritis pain  chronic low back pain and cancer pain in adult patients In a separate press release  Lilly announced that the FDA has accepted its new drug application looking for approval of a triple combination tablet for type II diabetes  The tablet is a fixed dose single pill combining of Lilly s diabetes medicines  Jardiance  a SGLT 2 inhibitor  and Tradjenta  a DPP 4 inhibitor  plus with metformin extended release Lilly currently has a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-06-05,Zacks Investment Research,https://www.investing.com/analysis/lillys-emgality-gets-fda-approval-for-cluster-headache-200429227,200429227
149308,370824,AMGN,Roche Receives FTC Request For Further Data On Spark Buyout ,opinion,Roche Holding  SIX ROG s AG   OTC RHHBY   and Spark Therapeutics  Inc    NASDAQ ONCE   have received a request for additional information and documentary material from the U S  Federal Trade Commission  FTC  The request is in connection with the FTC s review of the company s pending acquisition of Spark  which was announced in February 2019  The request is issued as part of the regulatory review process under Hart Scott Rodino Act The waiting period will be extended by 10 days after Roche substantially complies with the Second Request  unless the waiting period is terminated earlier by the FTC or the parties enter into a timing agreement with it Roche has also extended the period of its previously announced tender offer to purchase all the outstanding shares of common stock of Spark at  114 50 per share till Jul 31  2019 We note that the company is looking to diversify its strong oncology portfolio through deals and acquisitions The delay in approval by regulatory authorities is disappointing  Spark s shares are trading down on the news The impending acquisition will enable Roche to have a foothold in the promising gene therapy space  Spark Therapeutics is a leader in the field of gene therapy Spark Therapeutics  lead drug  Luxturna  was approved by the FDA for the treatment of patients with viable retinal cells and confirmed biallelic RPE65 mutation associated retinal dystrophy  a genetic blinding condition caused by mutations in the RPE65 gene  Per the company  Luxturna is the first FDA approved gene therapy for a genetic disease  the first and only pharmacological treatment for an inherited retinal disease  IRD   and the first adeno associated virus  AAV  vector gene therapy approved in the United States  The company has a collaboration agreement with Novartis Pharma AG   NYSE NVS   The stock has gained 10 1  in the year so far compared with the  s 1 7  growth   The addition of Luxturna will bolster Roche s broad portfolio  as it faces stiff competition from biosimilars for key drugs such as Avastin  Rituxan and Herceptin from Novartis and Amgen   NASDAQ AMGN   Zacks RankRoche currently carries a Zacks Rank  2  Buy   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-09,Zacks Investment Research,https://www.investing.com/analysis/roche-receives-ftc-request-for-further-data-on-spark-buyout-200430204,200430204
149310,370826,AMGN,Roche s Rituxan Gets Priority Review For Blood Disorder,opinion,"Roche Holding  SIX ROG  AG s   OTC RHHBY   subsidiary  Genentech  announced that the FDA has accepted its supplemental biologics license application  sBLA  and granted Priority Review status to Rituxan  rituximab  in children with two rare blood vessel disorders  The sBLA is for the use of Rituxan in combination with glucocorticoids  GCC  for the treatment of granulomatosis with polyangiitis  GPA  and microscopic polyangiitis  MPA  in children aged two years or older 
Notably  Priority Review designation is granted to drugs that have the potential to provide significant improvements in the safety and effectiveness of the treatment  prevention or diagnosis of a serious disease 
The sBLA was submitted based on data from the PePRS study  a phase IIa  single arm study investigating the safety  pharmacodynamics pharmacokinetics and exploratory efficacy of intravenous Rituxan in 25 patients with severe GPA or MPA between six and 17 years of age  The PePRS study is the first global trial of the drug in pediatric patients with GPA or MPA  If approved  this would be the first pediatric indication for the drug 
Rituxan is currently approved for the treatment of four autoimmune indications  The FDA approved the drug for rheumatoid arthritis  RA  in 2006  GPA and MPA in 2011  and  pemphigus vulgaris in 2018 
We note that MabThera Rituxan is one of Roche s legacy drugs  However  the drug is facing biosimilar competition in Europe  which is adversely impacting sales 
Apart from Rituxan  Roche s rheumatology portfolio has a first in class anti IL 6 receptor therapy  Actemra RoActemra  The drug is approved for RA  polyarticular and systemic juvenile idiopathic arthritis  giant cell arteritis  and chimeric antigen receptor T cell induced cytokine release syndrome 
Roche s stock has gained 12 0  in year to date compared with the  s growth of 5 3  

 
The company s legacy drugs like Herceptin and MabThera are facing stiff competition from biosimilars 
Novartis   NYSE NVS   has already launched its biosimilar version of Rituxan MabThera in Europe  Amgen   NASDAQ AMGN   also obtained FDA approval for a biosimilar version of Avastin for the treatment of five types of cancers  including lung  colorectal  glioblastoma  renal cell carcinoma and cervix Roche Holding AG Price

   Zacks Rank   Stock to Consider
Roche currently carries a Zacks Rank  2  Buy  
A better ranked stock worth considering is Bristol Myers Squibb Company   NYSE BMY    which sports a Zacks Rank  1  Strong Buy   You can see  
Bristol Myers  earnings per share estimates increased from  4 79 to  5 03 for 2020 over the past 60 days  Estimates for 2020 also increased 48 cents  The company delivered a positive earnings surprise in the trailing four quarters  with average beat of 11 85  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-06-12,Zacks Investment Research,https://www.investing.com/analysis/roches-rituxan-gets-priority-review-for-blood-disorder-200431077,200431077
149313,370829,AMGN,Boost Your Portfolio s Health With These 3 Big Drug Stocks ,opinion,The spate of pharma M A deal announcements this year so far has helped drugmakers to post a recovery after a dismal run toward the end of 2018 A key announcement was Bristol Myers    NYSE BMY   offer to buy Celgene   NASDAQ CELG   for  74 billion  one of the biggest mergers in the industry  Other important acquisition announcements include Lilly s   NYSE LLY   purchase of small cancer biotech  Loxo Oncology  and Merck s   NYSE MRK   acquisition of Immune Design and pending acquisitions of small private cancer biotechs  Peloton Therapeutics and Tilos Therapeutics  Roche   OTC RHHBY   is also due to acquire Spark Therapeutics for  4 8 billion  per a deal announced in February The Zacks industry  comprising some of the biggest drugmakers in the world  has gained 1 9  in 2019 so far  Moreover  the industry features in the top 15  of the 255 Zacks ranked industries   We believe that new product sales ramp up as a result of rising demand  driven by growth in ageing population  successful innovation and product line extensions in important therapeutic areas  strong clinical study results  and frequent FDA approvals  12 new drugs approved so far in 2019   helped the big drug giants to do well this year despite broader macro issues or the industry s own challenges  The industry is likely to perform well even if the global economy slows down this year  as is widely expected  This is because it is a defensive sector  which is almost insulated from broader macroeconomic factors Meanwhile  most big pharma companies are resorting to restructuring activities  which is increasing their financial capacity  The funds can be used to re stock pipelines with promising new drug candidates bought from smaller innovative drug biotech companies However  the sector faces its share of headwinds like government scrutiny of high drug prices  pricing and competitive pressure  generic competition for blockbuster treatments  slowdown in sales of some of the most high profile older drugs and most importantly major pipeline setbacks Nonetheless  we believe pipeline success  cost cutting  share buybacks  product launches  increased M A and collaboration activity and appropriate utilization of cash should keep the sector afloat through the rest of this year In this scenario  investing in stocks with a large market cap is a prudent move  given the fact that they control a large portion of the industry Here we have highlighted three bigshot drugmakers  which may prove to be good buys  All these stocks carry a Zacks Rank  2  Buy  and have seen share price rally in the past year and positive estimate revisions in the past 60 days You can see  A chart showing the share price movement of the three stocks and the Large Cap Pharmaceuticals industry in the past one year is given below  Merck Shares of Merck have risen 32 6  in the past year  Merck s earnings estimates for 2019 and 2020 have gone up 1 7  and 0 6   respectively in the past 60 days Like 2018  a significant part of Merck s outperformance this year so far has been driven by strong performance and positive regulatory updates related to its PD 1 inhibitor  Keytruda In addition to Keytruda  Merck s other new products  Lynparza  and Bridion are contributing meaningfully to its top line  Merck has also been on a strong footing in terms of collaborations and M A activity  This year  Merck bought small cancer focused biotech  Immune Design and privately held Europe s animal health technology provider  Antelliq Group  Merck also announced definitive agreements to buy small private cancer biotechs  Peloton Therapeutic and Tilos Therapeutics Meanwhile  Merck s animal health and vaccine products are also performing strongly and remain core growth drivers  Also  Merck can gain approval for two new products this year  a vaccine for Ebola Zaire  V920 and an anti bacterial medicine  MK 7655A  which is a fixed combination of relebactam with imipenem cilastatin Roche Roche s earnings estimates have increased 2 1  for 2019 and 1 3  for 2020 over the past 60 days  The company s shares have increased 28 7  this year so far Roche has gained regulatory approvals for label expansions of its PD L1 inhibitor  Tecentriq  leukemia drug  Venclexta  rheumatoid arthritis  RA  drug  MabThera and hemophilia drug  Hemlibra this year  These approvals have expanded the eligible patient population for these drugs  mainly Tecentriq  which can drive sales of Roche higher in the future quarters Moreover  the acquisition of Spark will enable Roche to have a foothold in the promising gene therapy space as it faces stiff competition from biosimilars for key drugs such as Avastin  Rituxan and Herceptin from Novartis and Amgen  NASDAQ AMGN   Meanwhile  the company continues to progress with its pipeline  It is looking to restructure the portfolio beyond oncology into multiple sclerosis and hemophilia  among othersPfizer   NYSE PFE  Pfizer s stock has risen 17 8  in the past year  Its earnings estimates for 2019 have risen 1 05  in the past 60 days Pfizer is witnessing strong growth of key product franchises  including Ibrance  Eliquis  and Xeljanz  To offset the threat of generic competition mainly due to expected loss of exclusivity of key drug Lyrica in the United States in June  Pfizer is strengthening its pipeline as well as oncology portfolio  Pfizer looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years  which can drive long term growth In oncology  Pfizer gained FDA approval for four innovative medicines  Daurismo  Lorbrena  Vizimpro and Talzenna  in the last four months of 2018  which can boost its oncology sales in 2019  Last month  it gained key FDA approvals for Bavencio in combination with Inlyta  axitinib  for first line treatment of advanced renal cell carcinoma  RCC  and tafamidis to treat transthyretin amyloid cardiomyopathy  ATTR CM   a rare and fatal illness associated with progressive heart failure  Its biosimilar drugs are also expected to contribute to growth in 2019 The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2019-06-12,Zacks Investment Research,https://www.investing.com/analysis/boost-your-portfolios-health-with-these-3-big-drug-stocks-200430863,200430863
149315,370831,AMGN,Merck s Keytruda Wins FDA Nod For First Line Head Neck Cancer ,opinion,Merck   Co   Inc    NYSE MRK   announced that the FDA has granted approval to its blockbuster PD L1 inhibitor  Keytruda for first line treatment of recurrent or metastatic head and neck squamous cell cancer  HNSCC  With the latest approval  Keytruda can be prescribed to previously untreated patients with metastatic or with unresectable  recurrent HNSCC as monotherapy in patients whose tumors express PD L1  CPS  combined proportion score   1   or in combination with chemotherapy regardless of PD L1 expression  The sBLA was based on data from the phase III KEYNOTE 048 study  wherein Keytruda  as a monotherapy and in combination with platinum and 5 fluorouracil  5 FU  chemotherapy  demonstrated significant improvement in overall survival compared to the standard of care in the given patient population  Keytruda was approved in 2016  on an accelerated basis  for recurrent or metastatic HNSCC with disease progression on or after platinum containing chemotherapy  With the approval to include data from the KEYNOTE 048 study on Keytruda s label  the accelerated approval gets converted to a regular approval  The regular approval was contingent upon verification and description of clinical benefit  which has now been demonstrated in the KEYNOTE 048 study Merck s shares have risen 8 6  this year so far compared with the  s increase of 1 8  Keytruda  Merck s biggest product  is already approved for use in 15 cancer indications across 10 different tumor types in the United States Keytruda generated sales of  2 27 billion in the first quarter of 2019  up around 5 6  sequentially and 55  year over year  Sales were driven by the launch of indications globally  Keytruda sales are gaining particularly from strong momentum in first line lung cancer indication both as monotherapy and with the rollout of the chemo combo in both non squamous and squamous non small cell lung cancer  NSCLC  This year so far  Keytruda has gained several label expansion approvals  Keytruda was approved by the FDA as an adjuvant therapy for high risk stage III melanoma and for five new cancer line extensions in Japan in the first quarter  In April  the FDA gave approval to Keytruda in combination with Pfizer s   NYSE PFE   Inlyta for the first line treatment of advanced renal cell carcinoma as well as for an expanded first line lung cancer patient population  All these label expansion approvals should drive sales of Keytruda higher in the future quarters of 2019 Several regulatory decisions for new indications in the United States as well as in Europe are pending in 2019  which  if approved  can further boost sales of Keytruda  This month an FDA decision is expected on the regulatory application looking for label expansion of Keytruda for previously treated advanced small cell lung cancer In fact  the Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 1000 studies  including more than 600 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte   NASDAQ INCY    Glaxo and Pfizer separately for the evaluation of Keytruda in combination with other regimensMerck currently carries a Zacks Rank  2  Buy   You can see The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2019-06-12,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-wins-fda-nod-for-firstline-headneck-cancer-200430857,200430857
149317,370833,AMGN,Keytruda   4 Other Reasons To Invest In Merck s  MRK  Stock,opinion,Large cap drug stocks have done well this year so far after a dismal run toward the end of 2018  The recovery was aided by a spate of pharma M A deal announcements  successful innovations and clinical studies  results  frequent FDA approvals and new product sales ramp up as a result of rising demand Among the bigshots  Merck   Co   Inc    NYSE MRK   is well poised with products like Remicade  Zetia  Januvia Keytruda  Gardasil and others Here are five reasons to invest in the stock this year Favorable Rank  Rising Share Price and Earnings Estimates  Merck currently carries a Zacks Rank  2  Buy   You can see  Shares of Merck have risen 9 5  this year so far compared with the  s increase of 1 9   Merck s earnings estimates for 2019 and 2020 have gone up 1 7  and 0 6   respectively in the past 60 days Its earnings surpassed expectations in each of the last four quarters  with the average being 5 67   The company is expected to record earnings and sales growth of 9  and 4 9   respectively in 2019 A Star in Keytruda  PD L1 inhibitor Keytruda  Merck s biggest product  is approved for use in 15 cancer indications across 10 different tumor types in the United States Keytruda generated sales of  2 27 billion in the first quarter of 2019  up around 5 6  sequentially and 55  year over year  Sales were driven by the launch of indications globally  Keytruda sales are gaining particularly from strong momentum in first line lung cancer indication both as monotherapy and with the rollout of the chemo combo in both non squamous and squamous NSCLC Several regulatory decisions for new indications in the United States as well as in Europe are pending in 2019  If approved  the drugs can further boost sales  Earlier this week  Keytruda was approved by the FDA for first line treatment of recurrent or metastatic HNSCC while another FDA decision is expected this month for label expansion of Keytruda for previously treated advanced small cell lung cancer  SCLC The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 1000 studies  including more than 600 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte   NASDAQ INCY    Glaxo and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens Undoubtedly  Keytruda has strong future growth prospects based on increased utilization  approval for new indications and expectation of additional approvals worldwideDeals   Acquisitions This Year  Merck has also been on a strong footing in terms of collaborations and M A activity this year  It bought small cancer focused biotech  Immune Design and privately held Europe s animal health technology provider  Antelliq Group  Merck also recently announced definitive agreements to buy small private cancer biotechs  Peloton Therapeutic and Tilos Therapeutics New Products Support the Top Line  Keytruda Lynparza  Gardasil and Bridion are supporting the company s top line  Key recent approvals for Merck include Steglatro and its fixed dose combinations for type II diabetes  two new HIV drugs   Pifeltro and Delstrigo   containing doravirine and Prevymis  letermovir  for cytomegalovirus  CVM  infection  These new products coupled with successful and regular label expansions for Keytruda and PARP inhibitor  Lynparza  markets in partnership with AstraZeneca   NYSE AZN    provide incremental sales growth opportunities A Strong Pipeline  Merck has many pipeline candidates in advanced stages of development targeting multiple disease areas such as oncology  cardiovascular diseases  diabetes  infectious diseases  neurosciences  respiratory and immunology diseases and vaccines  Merck can gain approval for two new products this year  a vaccine for Ebola Zaire  V920 and an anti bacterial medicine  MK 7655A  which is a fixed combination of relebactam with imipenem cilastatin Meanwhile  Keytruda is being studied in phase III studies for breast  cervical  colorectal  esophageal  gastric  hepatocellular  nasopharyngeal  mesothelioma  ovarian  renal and small cell lung cancers while Lynparza is being evaluated for pancreatic and prostate cancer  Lenvima is being studied in combination with Keytruda for endometrial cancer Conclusion Merck has its share of challenges in the form of generic competition for several drugs  pricing pressure  rising competitive pressure on the diabetes franchise and products like Isentress  HIV   Zepatier  HCV  and Zostavax  vaccine   However  we believe that strong sales performance of pharmaceutical products like Keytruda Lynparza  Gardasil and Bridion  and animal health and vaccine products  and cost savings should drive profits Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-06-12,Zacks Investment Research,https://www.investing.com/analysis/keytruda--4-other-reasons-to-invest-in-mercks-mrk-stock-200431278,200431278
149318,370834,AMGN,Amgen profit tops Street view  boosts full year forecast,news,"By Bill Berkrot  Reuters     Amgen Inc   O AMGN  on Thursday reported higher than expected second quarter profit and revenue  helped by strong sales of its Enbrel rheumatoid arthritis drug and cost cutting  and the company raised its full year forecasts  Excluding special items  Amgen earned  2 57 per share  topping analysts  average expectations by 14 cents  according to Thomson Reuters I B E S  The strong second quarter performance led the world s largest biotechnology company to boost 2015 profit and revenue expectations  Amgen now sees adjusted earnings of  9 55 to  9 80 per share  up from its prior view of  9 35 to  9 65  It sees revenue coming in between  21 1 billion and  21 4 billion  up from  20 9 billion to  21 3 billion   The magnitude of the guidance raise was substantial   said Cowen and Co analyst Eric Schmidt   The numbers are all very good   Amgen s shares rose 1 8 percent in extended trading  The company is expecting U S  approval of what could be its next big product  a potent new type of cholesterol fighter called Repatha  by late August  It won European approval earlier this month  Regeneron  O REGN  and Sanofi  PA SASY  gained U S  approval of a similar medicine last week   We are on track to deliver on our long term objectives for patients and shareholders   Chief Executive Robert Bradway said in a statement  The company also named to its board industry veteran Fred Hassan  who has a long history of selling large companies  including Pharmacia and Schering Plough   They are making headway with expense cuts   said Bernstein analyst Geoffrey Porges   Now it s really all about the PCSK9 approval and launch   he said of Repatha  Revenue for the quarter rose to  5 37 billion  exceeding Wall Street forecasts of  5 32 billion  Unfavorable foreign exchange rates due to the strong dollar hurt revenue by 2 5 percentage points  the company said  Amgen gets about 22 percent of its sales from overseas  Enbrel sales rose 8 percent to  1 36 billion  driven by price increases despite a highly competitive market  Analysts had been looking for about  1 25 billion  Osteoporosis drug Prolia also topped expectations by about  30 million with sales of  340 million for the quarter  Sales of the infection fighting white blood cell boosters Neulasta and Neupogen  which are bracing for competition from new biosimilar versions  were in line with expectations at  1 41 billion  Amgen has been working to cut costs  Research and development expense was down 6 percent and operating expenses fell 1 percent  
Net profit rose to  1 65 billion  or  2 15 per share  from  1 55 billion  or  2 01  a year ago ",2015-07-30,Reuters,"https://www.investing.com/news/stock-market-news/amgen-profit-tops-street-view,-boosts-full-year-forecast-353752",353752
149319,370835,AMGN,European stocks open higher  recover from heavy losses  Dax up 0 79 ,news,"Investing com   European stocks were higher on Wednesday  as markets recovered from the previous session s sharp losses  although gains were expected to remain limited by sustained volatility in Asia 
During European morning trade  the EURO STOXX 50 climbed 0 67   France s CAC 40 gained 0 73   while Germany s DAX 30 advanced 0 79  
Investors remained cautious amid ongoing volatility on Asian equity markets  Shares in Shanghai plunged over 4  at the open of trading on Wednesday 
Market volatility increased after data on Tuesday showed that manufacturing activity in China contracted at its fastest rate in three years in August  while service sector activity also slowed 
The weak data fueled fears over a worsening slowdown in the world s second largest economy 
Financial stocks were broadly higher  as French lenders  BNP Paribas   PARIS BNPP  and  Societe Generale   PARIS SOGN  climbed 0 75  and 1   while Germany s  Deutsche Bank   XETRA DBKGn  and Commerzbank  XETRA CBKG  rallied 1 39  and 0 68  
Among peripheral lenders  Italy s Unicredit  MILAN CRDI  and  Intesa Sanpaolo   MILAN ISP  jumped 1 33  and 1 49  respectively  while Spanish banks BBVA  MADRID BBVA  and  Banco Santander   MADRID SAN  added 0 18  and 0 11  
Elsewhere   Novartis  AG  SIX NOVN  rallied 1 36  after the Swiss pharmaceutical company it formed a partnership with California biotechnology group  Amgen Inc   NASDAQ AMGN   to develop new drugs for Alzheimer s disease and migraines 
In London  FTSE 100 gained 0 62   boosted by gains the pharmaceutical sector  as  Astrazeneca   LONDON AZN  advanced 1 80  and rival comapny Hikma Pharmaceuticals surged 4 85  
Mining stocks added to gains  as  Fresnillo   LONDON FRES  climbed 0 67  and  Bhp Billiton   LONDON BLT  jumped 1 18   while  Rio Tinto   LONDON RIO  advanced 1 66  
In the financial sector  stocks were also mostly higher  Shares in Lloyds Banking  LONDON LLOY  and the Royal Bank of Scotland  LONDON RBS  added 0 16  and 0 27  respectively  while  Barclays   LONDON BARC  gained 0 66  and the  HSBC Holdings   LONDON HSBA  climbed 0 76  
Meanwhile  shares in  Tesco   LONDON TSCO  advanced 0 51  following reportes the retailer it had picked private equity company MBC Partners as the preferred bidder for its South Korean unit 
On the downside  British online fashion retailer ASOS  LONDON ASOS  plummeted 3 52  after announcing that Nick Robertson was stepping down as chief executive after 15 years 
In the U S   equity markets pointed to a higher open  The Dow Jones Industrial Average futures pointed to a 0 90  climb  S P 500 futures signaled a 0 93  increase  while the Nasdaq 100 futures indicated a 1 05  rally ",2015-09-02,Investing.com,"https://www.investing.com/news/stock-market-news/european-stocks-open-higher,-recover-from-heavy-losses;-dax-up-0.79-359662",359662
149335,370851,AMGN,Fight over hot new cholesterol drugs may be won in milligrams,news,"By Deena Beasley LOS ANGELES  Reuters    Two powerful and innovative cholesterol drugs likely to be approved this summer both target the same protein and have been shown to sharply lower LDL in high risk patients   But there is at least one significant difference between the two offerings  the dosages in which they will be sold  Assuming approval from the U S  Food and Drug Administration   Amgen Inc   NASDAQ AMGN   will offer its drug  Repatha  as a biweekly 140 mg injection or a monthly injection of 420 mg  while Praluent  from Regeneron Pharmaceuticals Inc  NASDAQ REGN  and Sanofi  PARIS SASY   will be offered in biweekly injections of 75 mg or 150 mg  The difference in dosages is likely to lead to very different sales strategies for the two drugs  in what could be a fierce competition for market share  Amgen s high dose monthly injection could be seen as more convenient and might appeal to doctors because of its higher potency  Regeneron and Sanofi could enjoy a significant pricing advantage with their low dose option   Both drugs belong to a new class of antibodies that target PCSK9  a protein that maintains  bad  LDL cholesterol in the blood  and are aimed at the millions of people who don t benefit from statins  Statin pills  like  Pfizer  Inc  NYSE PFE  s Lipitor  work very differently  blocking the liver s production of LDL cholesterol   Neither Amgen nor Regeneron Sanofi would talk about possible pricing of their new drugs  but some industry experts suggest that low dose Praluent will be priced significantly below Repatha to make it more attractive to health insurers who have become increasingly aggressive about keeping medication costs down   Dr Jennifer Robinson  a University of Iowa epidemiologist and lead researcher on clinical trials of Praluent  believes Sanofi and Regeneron  would be crazy not to  price its 75 mg dose below the 150 mg option   Sanofi will say you can start off at this cheaper  lower dose   Robinson said   If you don t reach the LDL goal  you can move up  to a higher dose  at the higher price  Sanford Bernstein analyst Geoffrey Porges predicts that lower dose Praluent will cost  5 000 a year  with the higher dose at  10 000  He estimates Repatha s price at  10 000 per year for both the biweekly and monthly versions  Manufacturers do not necessarily charge less for lower doses of a medication  Amgen s high dose injections could be appealing in light of recent clinical data that has shown that keeping LDL very low can better protect against heart attack and stroke in high risk patients  Trial data has shown that both drugs produce greater LDL reductions in higher doses    It goes back to the patients we are trying to serve   patients with elevated  very high LDL cholesterol   said Scott Wasserman  Amgen s head of cardiovascular and metabolic therapies   We didn t feel that a low dose option would serve those patients   The FDA is due to decide on approval for Praluent by July 24 and on Repatha by Aug  27  The agency  which has convened expert panels on June 9 and 10 to review both drugs  could also issue a joint decision  The two PCSK9 drugs are each expected to generate about  2 5 billion in annual sales by 2020  according to Wall Street estimates compiled by Thomson Reuters Cortellis  Some predict total sales for the class rising to  20 billion by 2026  PRICE MATTERS In March  new clinical trial data showed that both Repatha and Praluent  combined with statins  reduced LDL levels dramatically  cutting in half the risk for heart attack  stroke  and other major cardiovascular problems  Sanofi Regeneron and Amgen are conducting larger trials to confirm the benefits of PCSK9 drugs in reducing cardiovascular risks  Industry experts note that there are many unanswered questions about the market for the drugs  including how widely the FDA will allow them to be used  how aggressively cardiologists will seek to lower LDL and whether other differences between them will emerge from the larger trials that will yield results in 2017   Some see Sanofi having an advantage purely due to its larger marketing force among heart doctors  Another possible factor in which drug will dominate the market is the success or failure of a lawsuit Amgen has brought against Sanofi and Regeneron for alleged patent infringement  But in the meantime  with the main merits of the two drugs appearing nearly equal  their comparative dose and price will become much more important differentiators  Health insurers  are likely to view this as a class  one is the same as the other   said Les Funtleyder healthcare portfolio manager for ESquared Asset Management  which does not own shares in any of the three drugmakers   You could have a case where if payers pay  they ll only pay for one rather than the other    Express Scripts Holding Co is the largest U S  manager of pharmacy benefit plans and succ By Deena Beasley LOS ANGELES  Reuters    Two powerful and innovative cholesterol drugs likely to be approved this summer both target the same protein and have been shown to sharply lower LDL in high risk patients   But there is at least one significant difference between the two offerings  the dosages in which they will be sold  Assuming approval from the U S  Food and Drug Administration  Amgen Inc  will offer its drug  Repatha  as a biweekly 140 mg injection or a monthly injection of 420 mg  while Praluent  from Regeneron Pharmaceuticals Inc and Sanofi  will be offered in biweekly injections of 75 mg or 150 mg  The difference in dosages is likely to lead to very different sales strategies for the two drugs  in what could be a fierce competition for market share  Amgen s high dose monthly injection could be seen as more convenient and might appeal to doctors because of its higher potency  Regeneron and Sanofi could enjoy a significant pricing advantage with their low dose option   Both drugs belong to a new class of antibodies that target PCSK9  a protein that maintains  bad  LDL cholesterol in the blood  and are aimed at the millions of people who don t benefit from statins  Statin pills  like Pfizer Inc s Lipitor  work very differently  blocking the liver s production of LDL cholesterol   Neither Amgen nor Regeneron Sanofi would talk about possible pricing of their new drugs  but some industry experts suggest that low dose Praluent will be priced significantly below Repatha to make it more attractive to health insurers who have become increasingly aggressive about keeping medication costs down   Dr Jennifer Robinson  a University of Iowa epidemiologist and lead researcher on clinical trials of Praluent  believes Sanofi and Regeneron  would be crazy not to  price its 75 mg dose below the 150 mg option   Sanofi will say you can start off at this cheaper  lower dose   Robinson said   If you don t reach the LDL goal  you can move up  to a higher dose  at the higher price  Sanford Bernstein analyst Geoffrey Porges predicts that lower dose Praluent will cost  5 000 a year  with the higher dose at  10 000  He estimates Repatha s price at  10 000 per year for both the biweekly and monthly versions  Manufacturers do not necessarily charge less for lower doses of a medication  Amgen s high dose injections could be appealing in light of recent clinical data that has shown that keeping LDL very low can better protect against heart attack and stroke in high risk patients  Trial data has shown that both drugs produce greater LDL reductions in higher doses    It goes back to the patients we are trying to serve   patients with elevated  very high LDL cholesterol   said Scott Wasserman  Amgen s head of cardiovascular and metabolic therapies   We didn t feel that a low dose option would serve those patients   The FDA is due to decide on approval for Praluent by July 24 and on Repatha by Aug  27  The agency  which has convened expert panels on June 9 and 10 to review both drugs  could also issue a joint decision  The two PCSK9 drugs are each expected to generate about  2 5 billion in annual sales by 2020  according to Wall Street estimates compiled by Thomson Reuters Cortellis  Some predict total sales for the class rising to  20 billion by 2026  PRICE MATTERS In March  new clinical trial data showed that both Repatha and Praluent  combined with statins  reduced LDL levels dramatically  cutting in half the risk for heart attack  stroke  and other major cardiovascular problems  Sanofi Regeneron and Amgen are conducting larger trials to confirm the benefits of PCSK9 drugs in reducing cardiovascular risks  Industry experts note that there are many unanswered questions about the market for the drugs  including how widely the FDA will allow them to be used  how aggressively cardiologists will seek to lower LDL and whether other differences between them will emerge from the larger trials that will yield results in 2017   Some see Sanofi having an advantage purely due to its larger marketing force among heart doctors  Another possible factor in which drug will dominate the market is the success or failure of a lawsuit Amgen has brought against Sanofi and Regeneron for alleged patent infringement  But in the meantime  with the main merits of the two drugs appearing nearly equal  their comparative dose and price will become much more important differentiators  Health insurers  are likely to view this as a class  one is the same as the other   said Les Funtleyder healthcare portfolio manager for ESquared Asset Management  which does not own shares in any of the three drugmakers   You could have a case where if payers pay  they ll only pay for one rather than the other    Express Scripts Holding Co is the largest U S  manager of pharmacy benefit plans and successfully pressed for price reductions on novel hepatitis C drugs earlier this year   Its chief medical officer  Dr  Steve Miller  said in an interview that  10 000 per year for a new cholesterol drug is  an extraordinarily high price   As many as 15 million Americans are estimated to have high cholesterol that cannot be controlled by statins   We are bullish on the health benefits  but they have to bring value   Miller said  adding that pricing would be a major factor in recommending either Praluent or Repatha for coverage  Dr Steven Nissen  chairman of the department of cardiovascular medicine at the Cleveland Clinic  said he is most concerned about effectiveness   What counts is how much you can lower LDL cholesterol   he said   
But he acknowledges that if the lower dose also had a lower price   there might be some people who find that appealing   Nissen said ",2015-05-26,Reuters,https://www.investing.com/news/stock-market-news/fight-over-hot-new-cholesterol-drugs-may-be-won-in-milligrams-343450,343450
149336,370852,AMGN,AstraZeneca hit after psoriasis drug linked to suicide fears,news,"By Ben Hirschler LONDON  Reuters    AstraZeneca s  L AZN  hopes of topping  45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion dollar plus seller  Amgen  O AMGN   its partner on the project  announced late on Friday it was ending a collaboration to develop brodalumab after suicidal thoughts were observed in patients taking the medicine  Shares in AstraZeneca fell 1 percent on Tuesday in the wake of the news  following a long holiday weekend in Britain   Deutsche Bank   XETRA DBKGn  analyst Richard Parkes said the setback was a surprise and terminating the drug s development would hit long term consensus forecasts for AstraZeneca s earnings by around 2 percent  Although the British group said it was still considering whether to scrap the product or continue on its own  the drug s prospects now seem badly tarnished with Amgen declaring that safety concerns would likely result in restricted use  AstraZeneca and Amgen have been sharing development of brodalumab since 2012 as a treatment for psoriasis  psoriatic arthritis and axial spondyloarthritis  It works by blocking a molecule involved in inflammation called interleukin 17  IL 17    Novartis   VX NOVN  already markets a psoriasis drug called Cosentyx that binds to a related protein  IL 17A  without any problems involving suicidal thoughts  and Eli Lilly  N LLY  has a rival in development   Barclays   LONDON BARC  analysts said AstraZeneca might still decide to continue development on its own  but with the Novartis drug showing a clean bill of health and Eli Lilly aiming to submit its IL 17 for approval by mid year  the commercial perspectives are clearly very challenging   AstraZeneca gave its long term  45 billion sales forecast a year ago when it was fending off a takeover bid by  Pfizer   N PFE   It said at the time that estimates for annual brodalumab sales were between  500 million and  1 5 billion  
The company made  26 billion of revenues last year ",2015-05-26,Reuters,https://www.investing.com/news/stock-market-news/astrazeneca-hit-after-psoriasis-drug-linked-to-suicide-fears-343473,343473
149337,370853,AMGN,Merck  MRK  Up This Year So Far  Will The Momentum Continue ,opinion,"Merck   Co   Inc    NYSE MRK   shares have performed well this year so far   Merck s shares have risen 6 2  this year so far compared with the  s increase of 0 7  
 

 
Earnings estimates for 2019 and 2020 have risen 1 5  and 0 6   respectively  over the past 60 days 
What s Behind the Rally 
Like 2018  a significant part of Merck s outperformance this year so far has been driven by strong performance and positive regulatory updates related to its PD 1 inhibitor  Keytruda  In a short span of time  Keytruda has become Merck s biggest product  It is already approved for use in 15 indications across 10 different tumor types in the United States 
Keytruda  the largest product in Merck s portfolio  generated sales of  2 27 billion in the first quarter of 2019  up around 5 6  sequentially and 55  year over year  Sales were driven by the launch of indications globally  Keytruda sales are gaining particularly from strong momentum in first line lung cancer indication both as monotherapy and with the rollout of the chemo combo in both non squamous and squamous NSCLC 
Following approval to include data from KEYNOTE 407 study in October 2018  the company witnessed strong uptake in squamous non small cell lung cancer in the United States in the past two quarters  In March  European Commission granted marketing approval to Keytruda for the same indication  In fact  in the first quarter  Keytruda was approved by the FDA as an adjuvant therapy for high risk stage III melanoma and for five new cancer line extensions in Japan 
In April  the FDA gave approval to Keytruda in combination with Pfizer s   NYSE PFE   Inlyta for the first line treatment of advanced renal cell carcinoma  RCC  as well as for an expanded first line lung cancer patient population  All these label expansion approvals should drive sales of Keytruda higher in future quarters of 2019 
The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 1000 studies  including more than 600 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte  NASDAQ INCY   Glaxo  and Pfizer separately for the evaluation of Keytruda in combination with other regimens 
Several regulatory decisions for new indications in the United States as well as in Europe are pending in 2019  which  if approved  can further boost sales of Keytruda  In June  FDA decisions are expected on regulatory applications looking for label expansion of Keytruda for previously treated advanced small cell lung cancer  SCLC  and first line treatment of recurrent or metastatic HNSCC 
Other than that  in April  Merck and partner AstraZeneca s   NYSE AZN   Lynparza gained approval in Europe as a monotherapy for the treatment of certain adult patients with advanced breast cancer  Merck also announced positive data from several late stage studies this year  mainly evaluating Keytruda for further line extensions in 2019 so far 
Merck has also been on a strong footing was far as collaborations and M A activity is concerned  In the year  Merck bought small cancer focused biotech  Immune Design and privately held Europe s animal health technology provider  Antelliq Group  This month  Merck also announced a definitive agreement to buy small private cancer biotech  Peloton Therapeutics for an upfront payment of  1 05 billion in cash  The acquisition will add Peloton s novel late stage renal cell carcinoma  RCC  candidate  PT2977 to Merck s oncology pipeline 
Conclusion
Merck  which carries a Zacks Rank  2  Buy   has its share of challenges in the form of generic competition for several drugs  pricing pressure and rising competitive pressure on the diabetes franchise and on products like Isentress  HIV   Zepatier  HCV  and Zostavax  vaccine 
Nonetheless  going forward  new products like Keytruda  Lynparza  and Bridion should continue to contribute meaningfully to the top line  Animal health and vaccine products are also performing strongly and remain core growth drivers for Merck 
Also  Merck can gain approval for two new products this year  a vaccine for Ebola Zaire  V920 and an anti bacterial medicine  MK 7655A which is a fixed combination of relebactam with imipenem cilastatin  Meanwhile  Merck will also continue to focus on cost cutting initiatives  which should drive its bottom line 
You can see  
Will you retire a millionaire 
One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-05-29,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-up-this-year-so-far-will-the-momentum-continue-200426245,200426245
149338,370854,AMGN,Amgen  AMGN  Down 4  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Amgen  AMGN   Shares have lost about 4  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Amgen due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Amgen Q1 Earnings Top  Sales Hurt by Pricing PressureAmgen reported first quarter 2019 earnings of  3 56 per share  which beat the Zacks Consensus Estimate of  3 45  Earnings increased 3  year over year helped by a lower share count as sales were weak in the quarter Total revenues of  5 56 billion in the quarter were almost in line with the Zacks Consensus Estimate and flat year over year Quarter in DetailTotal product revenues decreased 1  from the year ago quarter to  5 29 billion  U S    3 99 billion  ex U S    1 30 billion  as increasing demand for newer products like Prolia was offset by the erosion of mature brands from biosimilar competition  Product sales growth was mostly driven by higher volumes as pricing pressure hurt sales of several drugs  mainly Repatha and Aimovig Other revenues of  271 million rose 28 4  in the quarter driven by royalty income growth Prolia revenues came in at  592 million  up 20  from the year ago quarter  attributable to 17  volume growth resulting from higher demand  However  a seasonal sales pattern with first quarter sales being lower than second quarter due to a six month dosing interval hurt Prolia sales to an extent in the quarter Xgeva delivered revenues of  471 million  up 6  from the year ago quarter mainly due to higher demand  which drove volumes Kyprolis recorded sales of  245 million  up 10  year over year driven primarily by growth in key markets including the United States Blincyto sales increased 41  from the year ago period to  69 million  reflecting rise in demand Repatha generated revenues of  141 million  up 15  year over year  as higher unit demand was offset by lower prices  Repatha volumes grew 81  globally and 90  in the United States Sales of Repatha have suffered since launch due to payer restrictions  Despite Amgen s efforts to improve access to Repatha  patients face significant hurdles due to high co pay expenses  In response  Amgen announced a cut in the U S  list price of Repatha by 60  to improve access and affordability of Repatha Vectibix revenues came in at  170 million  up 1  year over year  Nplate sales rose 6  to  189 million Parsabiv  launched in several markets including United States 2018  recorded sales of  126 million in the first quarter  higher than  120 million in the previous quarter driven by higher demand Aimovig recorded sales of  59 million in the quarter  less than  95 million in the previous quarter as discounts and rebates offered to improve coverage led to lower selling price of the drug On the call  the company said that approximately 200 000 new patients in the United States have tried Aimovig since launch  suggesting that there remains growth potential  Aimovig has captured 60  market share in total scripts and 40  of new to brand prescriptions Amgen recorded biosimilar revenues of  55 million in the quarter  entirely from international markets versus  34 million in the previous quarter  On the call  the company said that Kanjinti and Amgevita are off to a strong start in Europe  explaining the higher biosimilars revenues in the quarter  Amgen expects more biosimilars to gain approval this year with biosimilars making important contribution to total revenues  especially as drug pricing issues increase demand for lower cost treatment options However  Amgen s mature drugs like Enbrel  Aranesp  Epogen  Neupogen and Neulasta are facing an array of branded and generic competitors Aranesp revenues declined 9  from the prior year quarter to  414 million on lower demand primarily due to increased competitive pressure Revenues of the other ESA  Epogen  declined 10  to  219 million due to lower selling prices as the category has become extremely competitive  Sales in the quarter benefited from approximately  20 million of large end customer purchases  Pfizer s Retacrit  the first biosimilar version of Epogen  was launched in November 2018  Biosimilar competition coupled with Amgen s contractual pricing commitments with DaVita is expected to hurt Epogen s price significantly in 2019Neulasta revenues declined 12  from the year ago period to  1 02 billion due to lower selling prices and inventory changes Two companies  Mylan  NASDAQ MYL  and Coherus launched biosimilars of Neulasta in the United States in mid  2018 early 2019 while three long acting biosimilar competitors were launched in the EU  which are hurting sales of Neulasta  More biosimilars are expected to be launched in 2019  which will put further pressure on Neulasta sales Also  increased competition from PD 1s and other new cancer therapies are hurting demand for the class of medicines to which Neulasta belongs  However  the Neulasta Onpro kit  on body injector  continues to perform well  commanding a market share of more than 60  in the United States for all Neulasta sales Neupogen recorded 29  decline in sales to  73 million in the first quarter due to biosimilar competition in the United States  which hurt demand and prices Enbrel delivered revenues of  1 15 billion  up 4  from the year ago driven primarily by favorable changes in accounting estimates along with a slight price increase  which offset the unfavorable impact of changes in inventory  On the call  Amgen said that the slight benefit in pricing should persist through the rest of the year Sensipar Mimpara revenues declined 57  to  213 million  Though Sensipar lost patent exclusivity in March 2018  Amgen was keeping generic competition at bay  However  recently some generic drugmakers launched small molecule generic versions  at risk   which hurt Sensipar sales significantly in the first quarter  In the second quarter  U S  sales of Sensipar are expected to be lower than Q1 levels Other product sales rose 24  to  78 million Operating Margins DecreaseAdjusted operating margin declined 450 basis points  bps  to 52 4  due to higher operating costs SG A spend increased 5  to  1 15 billion on higher investments to support new products including Aimovig  Evenity  Amgevita and Kanjinti  R D expenses rose 16  year over year to  859 million due to higher spending on the early stage oncology pipeline Adjusted tax rate was 14 6  for the quarter  a 0 9 points increase from the year ago quarter Amgen repurchased 15 9 million shares worth  3 0 billion in the first quarter and has  2 1 billion remaining under its stock repurchase authorization 2019 GuidanceAmgen raised the lower end of its previously issued sales and earnings guidance for 2019  The company expects revenues in the range of  22 0  22 9 billion versus  21 8  22 9 billion previously  Adjusted earnings per share are anticipated in the range of  13 25    14 30 versus  13 10  14 30 expected previously Amgen believes that higher sales of newer products should make up for uncertainty surrounding timing and intensity of generic competition to Sensipar and biosimilar competition to Neulasta and continued competitive dynamics for Enbrel and other mature products will create pressure on the top line in 2019   However  recently launched products including Aimovig  Repatha and biosimilars and international expansion provide incremental growth opportunities Operating costs in 2019 are expected to be flat to down from 2018 on an absolute basis  R D costs are expected to rise in a single digit percentage terms in 2019  However  SG A expenses are expected to decline as launch expenses normalize Adjusted tax rate is estimated at approximately 14 Amgen plans to invest approximately  700 million in capital expenditures in 2019  
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates have trended downward during the past month 
VGM Scores
Currently  Amgen has a subpar Growth Score of D  a grade with the same score on the momentum front  However  the stock was allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Amgen has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-29,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-down-4-since-last-earnings-report-can-it-rebound-200426619,200426619
149339,370855,AMGN,Amgen  AMGN  Dips More Than Broader Markets  What You Should Know,opinion,"Amgen  AMGN  closed the most recent trading day at  166 70  moving  1 38  from the previous trading session  This change lagged the S P 500 s daily loss of 1 32   Elsewhere  the Dow lost 1 41   while the tech heavy Nasdaq lost 1 51  
Heading into today  shares of the world s largest biotech drugmaker had lost 4 23  over the past month  lagging the Medical sector s loss of 1 9  and outpacing the S P 500 s loss of 5 09  in that time 
Wall Street will be looking for positivity from AMGN as it approaches its next earnings report date  On that day  AMGN is projected to report earnings of  3 60 per share  which would represent a year over year decline of 6 01   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  5 66 billion  down 6 63  from the year ago period 
AMGN s full year Zacks Consensus Estimates are calling for earnings of  13 94 per share and revenue of  22 58 billion  These results would represent year over year changes of  3 19  and  4 94   respectively 
Any recent changes to analyst estimates for AMGN should also be noted by investors  These revisions typically reflect the latest short term business trends  which can change frequently  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 65  higher within the past month  AMGN is currently sporting a Zacks Rank of  3  Hold  
Digging into valuation  AMGN currently has a Forward P E ratio of 12 12  This represents a discount compared to its industry s average Forward P E of 25 25 
We can also see that AMGN currently has a PEG ratio of 2 23  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  Medical   Biomedical and Genetics stocks are  on average  holding a PEG ratio of 1 74 based on yesterday s closing prices 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 77  which puts it in the top 31  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow AMGN in the coming trading sessions  be sure to utilize Zacks com ",2019-05-31,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-dips-more-than-broader-markets-what-you-should-know-200427342,200427342
149340,370856,AMGN,Company News For Jun 4  2019,opinion,Shares of El Paso Electric Co    NYSE EE   climbed 13 5  following confirmation that JP Morgan controlled Infrastructure Investments Fund will acquire the company for  4 3 billionCypress Semiconductor Corp  s   NASDAQ CY   shares jumped 23 9  after Infineon Technologies AG decided to acquire the company for  10 1 billionAmgen Inc  s   NASDAQ AMGN   shares soared 3 4  after the company announced positive initial results from its experimental drug AMG 510 for the treatment of non small cell lung cancerShares of Merck   Co  Inc    NYSE MRK   gained 1 3  after the FDA approved the filling of sNDA of its antibiotic  ZERBAXA to treat hospital acquired pneumonia in patients 18 years and older,2019-06-03,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-jun-4-2019-200428227,200428227
149342,370858,AMGN,Amgen s KRAS Inhibitor Shows Impressive Anti Tumor Activity ,opinion,Amgen  Inc    NASDAQ AMGN   announced encouraging early data from a study evaluating its novel investigational KRAS inhibitor for solid tumor  AMG 510  at the annual meeting of American Society of Clinical Oncology  ASCO  In the phase I study  AMG 510  when given as a monotherapy  showed encouraging anti tumor activity in patients with locally advanced or metastatic KRASG12C mutant solid tumorsThe study enrolled 35 patients at multiple ascending dose levels  The primary treated tumor types were non small cell lung cancer  NSCLC  and colorectal cancer  CRC   which have the highest incidence of KRAS G12C mutations  KRASG12C accounts for approximately 13  of NSCLC and 3   5  of CRC cases In the NSCLC cohort  five out of 10 heavily pre treated patients experienced a partial response  PR   which means at least a 50  reduction in tumor size  Another four had stable disease  SD   which means the tumor is neither growing nor shrinking  In the CRC cohort  13 of 18 evaluable patients achieved SD  Overall  AMG510 was found to be safe and well tolerated Amgen s shares were up 3 4  in response to the positive news  However  so far this year  Amgen shares have declined 11 5  compared with 2  decrease registered by the  during this period   KRAS gene has been a target of active exploration in cancer research and is particularly common in solid tumors  Merck believes that AMG 510 has the potential to be developed into a successful targeted therapy to treat patients with the KRASG12C mutation due to its high selectivity for this mutation AMG510 enjoys orphan drugs status from the FDA for KRASG12C positive NSCLC and colorectal cancers Another company  Mirati Therapeutics Inc   NASDAQ MRTX   also has a candidate  MRTX849  which targets the KRAS G12C mutation  Mirati s shares were up almost 32  on Monday after Amgen s promising initial data on its KRAS G12C inhibitor Amgen currently carries a Zacks Rank  3  Hold   You can see  Some other top ranked large drug stocks include Bristol Myers Squibb Company   NYSE BMY   and Roche   OTC RHHBY    While Bristol Myers sports a Zacks Rank  1  Roche has a Zacks Rank  2  Buy  Bristol Myers  earnings estimates increased 5 2  for 2020 over the last 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with the average being 11 85  Roche s earnings estimates increased 2 1  for 2019 and 1 3  for 2020 over the last 60 days  The company s shares have increased 9 4  this year so far Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-06-03,Zacks Investment Research,https://www.investing.com/analysis/amgens-kras-inhibitor-shows-impressive-antitumor-activity-200428275,200428275
149344,370860,AMGN,Pfizer To Launch Several Drugs Despite Generic Headwinds,opinion,Pfizer  Inc    NYSE PFE   expects continued strong growth of key product franchises  including Ibrance  Eliquis  Xeljanz and Prevnar  However  loss of exclusivity  LOE  on key drugs in the United States is expected to hurt 2019 sales significantly  including the expected LOE of key drug Lyrica in the United States in June 2019  In fact  loss of exclusivities hurt 2017 sales by  2 1 billion and 2018 sales by  1 8 billion  It is expected to hurt 2019 sales by  2 6 billion including the expected LOE of Lyrica  Some other products like Chantix and Sutent will lose exclusivity in the country in the next couple of years Also  currency headwinds are expected to significantly pull down 2019 revenues Other top line headwinds include weak sales in the sterile injectables portfolio  pricing pressure and rising competition Pfizer s sterile injectables portfolio has been seeing lower revenues since the past few quarters due to continued legacy Hospira product shortage in the United States  Pfizer is facing supply shortages for sterile injectable products mainly due to capacity constraints and technical issues To offset the threat of generic competition as well as other headwinds  Pfizer is strengthening its pipeline as well as oncology portfolio Pfizer boasts a strong pipeline and looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years  which can drive long term growth  Pfizer expects approximately 25 to 30 drug approvals through 2022  including around 15 products that have blockbuster potential  These also include line extensions for Xtandi  Ibrance   Xeljanz XR  Half of these potential blockbusters are expected to receive approval by 2020 In oncology  Pfizer gained FDA approval for four innovative medicines in the last four months of 2018  which can boost its oncology sales  These include Daurismo  glasdegib  for previously untreated AML  Lorbrena  lorlatinib  for second line non small cell lung cancer  Vizimpro  dacomitinib  for advanced NSCLC with EGFR activating mutations and Talzenna  talazoparib   an orally available PARP inhibitor for advanced breast cancer A key candidate in the oncology pipeline is Bavencio  avelumab   which is being evaluated for different types of cancer  Bavencio is already approved in metastatic Merkel cell carcinoma in the United States  Europe and Japan  It has also received accelerated approval for second line treatment of locally advanced or metastatic urothelial carcinoma in the United States  Bavencio  though approved for two small indications currently  is being considered a key long term growth driver for Pfizer if it can gain label expansion approvals Biosimilars are also expected to contribute to growth in 2019  Pfizer launched Inflectra  its first biosimilar version of Merck J J s Remicade in November 2016  Gradually  Pfizer is venturing into the oncology biosimilars space  In Europe and United States  it markets biosimilar versions of Amgen s   NASDAQ AMGN   drugs Neupogen and Epogen  Biosimilar version of Roche s   OTC RHHBY   cancer drugs Herceptin  trade name  Trazimera  was approved by the FDA in March  Biosimilar versions of Roche s other cancer drugs Rituxan and Avastin  trade name  Zirabev  are also under review in the United States with FDA decisions on all expected in 2019 With a biosimilar version of AbbVie s   NYSE ABBV   Humira also under review in the United States  Pfizer expects potential U S  approvals for up to four biosimilar products in 2019  Biosimilar versions of Herceptin and Avastin are already approved in the EU while that of Rituxan is under review in the EU  Pfizer is evaluating several biosimilar molecules in various stages of development Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-06-04,Zacks Investment Research,https://www.investing.com/analysis/pfizer-to-launch-several-drugs-despite-generic-headwinds-200428746,200428746
149350,370866,AMGN,Cancer Fighting Stocks   ETF  What You Need To Know,opinion,"In this episode of ETF Spotlight  I speak with Brad Loncar  CEO of Loncar Investments  Brad is in Chicago to attend the annual meeting of ASCO  American Society of Clinical Oncology   It is the world s largest and most prestigious cancer conference where participants learn about the latest developments in treating the disease 
Brad explains why ASCO is so important and how he uses it as an investor  He says Amgen  NASDAQ AMGN     is the most exiting large biotech company this year at ASCO with two very promising therapies  BiTE and KRAS 
The global market for cancer drugs is estimated to be about  123 billion and big players are investing heavily to gain an edge in this increasingly competitive market   Pharmaceutical giant Bristol Myers     a pioneer in immunotherapy  is acquiring rival Celgene  NASDAQ CELG     for  74 billion 
Merck    is acquiring cancer drug developer Peloton Therapeutics for  1 05 billion  The announcement came as Peloton was preparing for its IPO  Earlier this year  Eli Lilly  NYSE LLY     bought Loxo Oncology for  8 billion 
Should we expect more M A in the space 
Brad created the index for the Loncar Cancer Immunotherapy ETF     which invests in companies at the forefront of immunotherapy research   He explains why immunotherapy  which harnesses the body s immune system to fight cancer  is often called a game changer for cancer treatment 
He also talks about important developments in the space and promising work being done by some smaller  innovative biotech companies 
Mirati Therapeutics     Iovance Biotherapeutics  formerly Lion Biotechnologies     and Nektar Therapeutics    soared this week  These are among the top holdings in CNCR  Find out more about them on the podcast 
WSJ recently reported about AstraZeneca    is planning to target early stages of the disease whereas traditionally  pharma companies focus on drugs that treat advanced forms of cancer  Will the new approach help AstraZeneca gain an edge over competitors 
Health Care is the worst performing sector this year  thanks mainly to policy concerns  Will there be a big focus on policy related issues at the conference 
Tune into the podcast to learn more 
Brad also created the index for the Loncar China BioPharma ETF    which focuses on the booming biopharma industry in China  To learn more about these ETFs  please visit  
Please also visit the  to learn about this cancer treatment and clinical trials 
Make sure to be on the lookout for the next edition of ETF Spotlight  If you have any comments or questions  please email podcast zacks com 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-06-05,Zacks Investment Research,https://www.investing.com/analysis/cancerfighting-stocks--etf-what-you-need-to-know-200428813,200428813
149353,370869,AMGN,Was ASCO Quieter For Big Drug Biotech Stocks This Year ,opinion,The world of cancer research is seeing huge developments and companies are taking great strides to find treatments for a variety of cancers The five day long ASCO conference  which is basically the most important annual cancer research event  held in Chicago concluded on Tuesday  The conference featured clinical updates from several companies about the latest developments in treating the disease  Cancer research is definitely an exciting area and one that investors will keep a close watch on in the coming years  This is because the disease is one of the leading causes of morbidity and mortality across the world preceded only by heart disease Though this year s event was labelled by many as unusually quiet as far as big drug biotech companies are concerned  still  a lot of impactful data was presented Amgen   NASDAQ AMGN   presented  for AMG 510  its novel investigational KRAS inhibitor for solid tumor  In the phase I study  AMG 510  when given as a monotherapy  showed encouraging anti tumor activity in patients with locally advanced or metastatic KRASG12C mutant solid tumors KRAS gene has been a target of active exploration in cancer research and is particularly common in solid tumors  Amgen believes that AMG 510 has the potential to be developed into a successful targeted therapy to treat patients with the KRASG12C mutation due to its high selectivity for this mutation  Amgen also presented data from an early stage study of AMG 420  a bispecific T cell engager  BiTE  molecule that binds to BCMA and CD3 Merck   NYSE MRK   and Bristol Myers   NYSE BMY   presented long term follow up data on their successful PD L1 inhibitors  Keytruda and Opdivo  respectively Merck on Keytruda in advance lung cancer  Data from the phase Ib KEYNOTE 001 study  n 550  showed that five year overall survival  OS  rates for Keytruda were 23 2  in treatment na ve patients and 15 5  in previously treated lung cancer patients  Historically  the five year survival rate in advanced lung cancer patients in the United States has been around 5   Keytruda s five year survival rates thus represent a huge improvement over these historical rates Meanwhile  follow up lung cancer data from the KEYNOTE 189 study showed that Keytruda in combination with Lilly s Alimta  pemetrexed  and platinum chemotherapy reduced the risk of death by 44  compared with chemotherapy alone as a first line treatment option for metastatic non squamous non small cell lung cancer  NSCLC  in patients with no EGFR or ALK genomic tumor aberrations Bristol Myers presented data from on Opdivo  at ASCO including the longest follow up data for the Opdivo plus Yervoy combination in advanced melanoma patients   A five year analysis of the phase I CA209 004 study showed that overall survival  OS  rates were stable at 57  in the Opdivo plus Yervoy arm  with a median follow up of 43 1 months in all patients  at four years or longer  Moreover  data presented from multiple analyses of CheckMate   067 study demonstrated that quality of life was maintained throughout the course of Opdivo plus Yervoy treatment and follow up  These data clearly reinforce the long term efficacy of the combination treatment in advanced melanoma Merck and partner AstraZeneca   NYSE AZN   announced detailed data from the phase III POLO study  evaluating their PARP inhibitor  Lynparza for germline BRCA mutated metastatic pancreatic cancer patients who did not progress on chemotherapy  The data showed that at six months  more than twice as many patients treated with Lynparza were progression free compared to those on placebo  Lynparza reduced the risk of disease progression or death by 47   Meanwhile  full data presented from phase III SOLO 3 study on Lynparza in advanced ovarian cancer demonstrated a 72  objective response rate compared to 51  of patients receiving chemotherapyWhile Bristol Myers sports a Zacks Rank  1  Strong Buy   Merck has a Zacks Rank  2  Buy   Amgen currently carries a Zacks Rank  3  Hold   You can see  Sanofi s   NASDAQ SNY   phase III data on its investigational anti CD38 monoclonal antibody isatuximab showed that isatuximab in combination with pomalidomide and dexamethasone led to an impressive 40  reduction in the risk of disease progression or death for patients with relapsed refractory multiple myeloma AstraZeneca presented from a lung cancer study on Imfinzi  which showed that more than half of the unresectable  stage III NSCLC patient population treated with Imfinzi was alive following three years of treatment  J J  NYSE JNJ  presented long term data from two pivotal studies on Imbruvica and from a couple of studies on Darzalex Roche   OTC RHHBY   presented additional results from a pre specified exploratory analysis from the phase III IMpower150 study  which was used as a basis for the regulatory approval of a combination of Tecentriq  Avastin and chemotherapy in metastatic non squamous NSCLC in December 2018  Novartis   NYSE NVS   presented data from studies on its new breast cancer drug  Kisqali and selective MET inhibitor capmatinib while Gilead  NASDAQ GILD  provided update on its CAR T cell therapy candidate  KTE X19Celgene  NASDAQ CELG  and Nektar Therapeutics also made some cancer data presentations at the meeting Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-06-05,Zacks Investment Research,https://www.investing.com/analysis/was-asco-quieter-for-big-drugbiotech-stocks-this-year-200429242,200429242
149361,370877,AMGN,Insight  Big Pharma faces up to new price pressure from aggressive insurers,news,By Deena Beasley and Caroline Humer SAN FRANCISCO  Reuters    The world s biggest drugmakers face a new reality when it comes to U S  pricing for their products as insurers use aggressive tactics to extract steep price discounts  even for the newest medications  Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J P  Morgan Healthcare conference in San Francisco  Drugmakers have long relied on their ability to charge whatever they deemed appropriate in the U S   the world s most expensive healthcare system   Industry advocates have defended those U S  prices in the past as a way to recoup the billions of dollars spent on experimental drugs that fail and to offset discounts offered overseas   There has definitely been increased price competition     if a product is viewed as a commodity   Derica Rice  chief financial officer at Eli Lilly   Co  said in an interview   Our goal is clinical differentiation   Pascal Soriot  chief executive of AstraZeneca Plc  warned investors that the pressure exerted by health insurers has expanded from medicines used to treat common maladies to the specialized fields  like cancer  where drugmakers have been able to charge their highest prices   Payers will try to leverage their strengths to try and get pricing concessions because those agents are very expensive   Soriot said  Many say the tide shifted with a campaign by insurers and pharmacy benefits companies against Gilead Sciences Inc s  84 000 hepatitis C treatment Sovaldi  The drug represented the first effective cure for hepatitis C and quickly raked in billions of dollars in sales within its first few months on the market in 2014  Sovaldi s cost is based on a 12 week treatment regime and amounts to  1 000 a pill  By contrast  the treatment costs about  57 000 in the U K  As soon as U S  regulators approved Sovaldi s competitor  a treatment from AbbVie Inc  last month  the country s largest pharmacy benefits manager Express Scripts Co dropped reimbursement for the Gilead drug   Express Scripts said it had received a substantial discount from AbbVie  a departure from industry practice of pricing new competing drugs close to the incumbent for as long as possible  It didn t say how much the discount was  Express Scripts said this week it sought similar opportunities for discounts in new cancer medications  and was looking closely at a new class of cholesterol fighting drugs aimed at millions of patients who can t tolerate or get enough benefit from widely used statins   Amgen Inc and Regeneron Pharmaceuticals Inc are two of the companies racing to bring the new cholesterol treatments  which target a protein called PCSK9  to market   It s not a worry  It s a reality that we will deal with   Regeneron CEO Len Schleifer said of Express Scripts  goals   I think there will be fair pricing and healthy competition in the marketplace     A LESS CROWDED FIELD     When pressed on how they could counter the growing pressure from insurers  large drugmakers say they are relying on strategies long employed in the marketplace  focusing research on diseases that don t have adequate treatments and finding ways to differentiate their products from competitors in terms of effectiveness and convenience  But some industry experts believe they will have to become far more selective even when entering a new treatment area  The hepatitis C example shows how insurers have been able to play just two competitors off one another to wrest a discount    Gilead Chief Operating Officer John Milligan said that in recent weeks  more health plans are asking the company to drop its hepatitis C drug price more in line with AbbVie in order to keep both drugs on their reimbursement lists   Payers are starting to move beyond hand wringing to real action   said Glen Giovannetti  head of global life sciences at Ernst   Young   We are starting to see  pharmaceutical  companies deciding which therapeutic options they want to compete in   Nils Behnke  a partner with Bain   Co s global healthcare and strategy practices  noted that even for the most new promising classes of medications  there are often three or four companies pursuing similar development programs    Companies that were heavily into specialty indications thought they were immune  but it is now clear that they are not   he said Merck   Co CEO Kenneth Frazier acknowledged that U S  prices for diabetes drugs remain under pressure   We need to identify a value proposition     show that over time we can reduce costs   he said in an interview  Smaller biotech Isis Pharmaceuticals Inc said it is already taking into account potential competition when deciding which research programs to pursue  CEO Stanley Crooke said the company abandoned its PCSK9 program when it became clear the drug would reach the market only after several others   We are working on diseases for which there are no real treatments    Parkinson s  Alzheimer s  ALS   said George Scangos  CEO at Biogen Idec   In the future  we will see more correlation between value that drugs deliver and the way they are reimbursed  ,2015-01-15,Reuters,https://www.investing.com/news/stock-market-news/insight:-big-pharma-faces-up-to-new-price-pressure-from-aggressive-insurers-323560,323560
149362,370878,AMGN,Amgen profit tops expectations on Enbrel sales  tax credit,news,"By Bill Berkrot  Reuters    Amgen Inc  O AMGN  on Tuesday reported higher than expected fourth quarter profit  driven by strong sales of its blockbuster rheumatoid arthritis drug Enbrel and a tax credit  Despite pressure on overseas sales from the strong dollar that has put a crimp in pharmaceutical company profits  Amgen reiterated the 2015 forecast it provided in October for adjusted earnings of  9 05 to  9 40 per share on revenue of  20 8 billion to  21 3 billion  Analysts are estimating earnings of  9 28 per share and revenue of  20 87 billion  Amgen is less exposed to foreign exchange fluctuations than other large drugmakers as only about 25 percent of its sales come from outside the United States  Excluding items  Amgen earned  2 16 per share  topping analysts  average expectations by 11 cents  according to Thomson Reuters I B E S  The results were helped by a research and development tax credit that came through in the quarter  adding about 10 cents per share to earnings  the company said  On the positive side  RBC Capital Markets analyst Michael Yee said  they affirmed the strong 2015 outlook   But  he added  a good chunk of the earnings beat  came from a tax credit that was not in the guidance   The world s largest biotechnology company posted a net profit of  1 29 billion  or  1 68 per share  compared with a profit of  1 02 billion  or  1 33 per share  a year ago  Revenue rose 6 percent to  5 33 billion  edging past Wall Street estimates of  5 19 billion  Enbrel sales rose 11 percent in the quarter to  1 34 billion  topping analyst expectations of  1 21 billion  The white blood cell boosters Neupogen and Neulasta had combined worldwide sales of  1 45 billion  The older Neupogen is expected to face competition this year from the first U S  approved biosimilar version  Kyprolis  the multiple myeloma drug Amgen acquired with its  10 billion purchase of Onyx Pharmaceuticals  had sales of  91 million  falling short of Wall Street estimates of  109 million  However  based on positive clinical trial data  Amgen said it filed applications with U S  and European regulators to approve Kyprolis use earlier in the disease  after one prior treatment has failed rather than two  This should boost future sales  
U S  approval decisions on two new drugs  ivabradine for heart failure and T Vec for melanoma  will be delayed by three months each as regulators asked for additional data  which Amgen said it has supplied ",2015-01-27,Reuters,"https://www.investing.com/news/stock-market-news/amgen-profit-tops-expectations-on-enbrel-sales,-tax-credit-325366",325366
149363,370879,AMGN,Shares in cholesterol drug makers mixed ahead of cardiology conference,news,"Investing com    A trio of pharmaceutical companies embroiled in a race for control of the cholesterol drug market displayed mixed results on Friday ahead of this weekend s American College of Cardiology s annual expo in San Diego 
The three day conference will feature sessions on nearly a dozen clinical learning pathways  including topics in acute coronary syndromes  congenital heart disease  critical care cardiology  sports cardiology and vascular medicine 
 Amgen Inc   NASDAQ AMGN   the world s largest independent biotechnology firm  has plans to present a lecture on Repatha  its investigational cholesterol lowering medication  at the conference 
 As we head into a milestone filled year for our cardiovascular pipeline  we are eager to share safety analyses and data exploring the effect of Repatha on LDL cholesterol   Sean E  Harper  M D   executive vice president of Research and Development at Amgen  said in a statement   We are working with regulatory agencies to bring cardiovascular therapies to patients which we believe will provide new options for those with high cholesterol  
Amgen Inc  gained 0 01 or 0 01  to 154 26 on Friday  Sanofi  PARIS SASY  SA   the world s fifth largest pharmaceutical company  gained 0 49 or 1 03  to close at 47 07  while Regeneron Pharmaceuticals Inc  NASDAQ REGN  rose more than 6 00 points to 431 00 
Last month  Sanofi and Regeneron collaborated on a nationwide Calorie Counts program that encouraged Americans to be more vigilant about their awareness of LDL C  also regarded as the more problematic form of high cholesterol  The survey of 12 000 Americans found that more than 70  of subjects were unaware of the level of LDL C in their bodies 

The U S  Food and Drug Administration could approve cholesterol drug therapies from all three companies at some point this year ",2015-03-13,Investing.com,https://www.investing.com/news/stock-market-news/stocks-in-cholesterol-drug-makers-mixed-ahead-of-cardiology-conference-332338,332338
149367,370883,AMGN,Radius  RDUS  Posts Narrower Q1 Loss  Misses On Revenues ,opinion,"Radius Health  Inc    NASDAQ RDUS   reported mixed results for the first quarter of 2019  wherein loss was narrower than expected but sales missed estimates 
The company incurred a loss of 94 cents per share in the quarter  narrower than the Zacks Consensus Estimate of a loss of 95 cents and the year ago loss of  1 11  The year over year improvement was backed by an increase in revenues 
The company reported Tymlos  sales of  29 8 million  missing the Zacks Consensus Estimate of  34 8 million 
Quarter in Detail
We remind investors that Radius Health obtained the FDA approval for Tymlos  abaloparatide  injection in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk of fracture  The company began shipments of the drug to wholesalers at the end of May 2017 
Hence  revenues recorded in the year ago quarter were  14 6 million only  Tymlos U S  net sales were negatively impacted by anabolic market seasonality that showed lower volumes in the quarter versus the fourth quarter of 2018  higher gross to net expenses due to the impact of the Medicare Part D coverage gap on manufacturers and increased support for commercial patient deductibles 
Tymlos captured  on average  30  of the U S  anabolic osteoporosis market  based on Patient Months on Therapy  TRx PMOT  in the first quarter of 2019 and 42  of new anabolic patient starts  At the end of the first quarter of 2019  the drug was covered for approximately 283 million U S  insured lives  representing approximately 99  of U S  commercial  67  of Medicare and 97  Medicaid Other insured lives  Growth in new scripts in the commercial business was also strong  with a 17  increase from the fourth quarter of 2018 
Research and development expenses for the reported quarter were  23 3 million  up 1 7  year over year due to increases in elacestrant project costs and abaloparatide patch project costs  General and administrative expenses decreased 14  to  41 2 million 
Pipeline Updates
The pipeline includes abaloparatide injection for potential use in the treatment of men with osteoporosis  abaloparatide patch for potential use in osteoporosis  and elacestrant  RAD1901  for potential use in hormone receptor positive breast cancer 
Radius Health presented a post hoc subset analysis on postmenopausal osteoporosis patients with type 2 diabetes from the phase III ACTIVExtend Study at the American Association of Clinical Endocrinologists conference in April 2019  The ACTIVE Study cohort included patients with Type 2 diabetes  The data from the study showed that use of abaloparatide SC for 18 months led to significant improvement in lumbar spine TBS  trabecular bone score  and suggested that abaloparatide SC improved bone microarchitecture 
As the incidence of both type 2 diabetes and osteoporosis increase with age  they frequently coexist and represent a high unmet medical need population with a lower diagnosis rate for osteoporosis  compromised bone quality and higher fracture risk 
The company is developing two formulations   abaloparatide Subcutaneous  SC  and abaloparatide transdermal patch  Radius Health is on track with its preparations for the phase III trial on abaloparatide patch and expects to start the study in August 2019 
2019 Sales Guidance Updated
Radius Health expects Tymlos net revenues to be  160  175 million  previous guidance was  155  175 million in 2019  
Our Take
The narrower than expected loss in the first quarter was encouraging 
The company s sales surpassed expectation in the first quarter of 2019 as Tymlos continued to gain traction 
Tymlos market share increased in April  with a 34  share of the U S  anabolic osteoporosis market and more than 44  of new anabolic patient starts 
Shares of Radius Health have gained 28 2  in the year so far  outperforming the  s growth of 8 7  

 
During the second half of 2019  Radius Health expects the drug to become the NBRx anabolic market leader by reaching more than 50  of new patient starts 
Although the osteoporosis market in the United Sates has great potential  Tymlos is expected to face significant competition from Eli Lilly   Co s   NYSE LLY   Forteo and Amgen s   NASDAQ AMGN   Prolia 
Zacks Rank   Stock to Consider
Radius Health currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is Roche Holdings   OTC RHHBY    which sports a Zacks Rank  2  Buy   You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
Roche s earnings per share estimates have increased from  2 35 to  2 40 for 2019 in the past 60 days 
This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-05-09,Zacks Investment Research,https://www.investing.com/analysis/radius-rdus-posts-narrower-q1-loss-misses-on-revenues-200419744,200419744
149368,370884,AMGN,Lilly s Cyramza Gets FDA Nod For Second Line Liver Cancer ,opinion,"Eli Lilly and Company   NYSE LLY   announced that the FDA has granted approval to its already approved cancer drug  Cyramza for the second line treatment of patients with hepatocellular carcinoma  HCC   a common form of liver cancer  Importantly  along with this approval  the FDA has also removed the boxed warning from Cyramza s label  which included warnings for hemorrhage  ruptured bowel and non healing wounds Lilly s shares have declined 1 2  this year so far compared with the  s decline of 1 6    The approval for HCC was based on data from the REACH  2 study  which evaluated the benefit of Cyramza as a single agent in HCC patients who were intolerant to or experienced disease progression after treatment with Amgen   NASDAQ AMGN   Bayer s   OTC BAYRY   Nexavar and also had elevated levels of alpha fetoprotein  AFP   The results from the REACH   2 study showed that such patients derived a survival benefit with Cyramza treatment following first line treatment with Nexavar According to Lilly s press release  approximately 40  of all advanced HCC patients have a high AFP  a marker of poor prognosis  Until now there have been only limited treatment options for HCC patients with increased AFP concentrations  indicating unmet clinical need for the latest approved indication of Cyramza Please note that Cyramza is already marketed as a single agent and in combination with another agent as a second line treatment of advanced or metastatic gastric cancer  It is also approved for use in combination with another agent as a second line treatment of metastatic non small cell lung cancer  NSCLC  and metastatic colorectal cancer  The AFP High HCC indication is the fifth FDA approval for Cyramza in an advanced or metastatic cancer Cyramza generated revenues of  198 3 million in the recently concluded first quarter of 2019  recording year over year increase of 8   Cyramza is being evaluated in several studies for additional indications  which include a phase III RELAY study for first line EGFR mutation positive NSCLC In March  Lilly announced that the study met the primary endpoint of progression free survival  PFS   The data from the study showed that treatment with Cyramza  in combination with erlotinib significantly delayed disease progression in previously untreated patients with metastatic NSCLC whose tumors have activating EGFR mutations   Detailed efficacy and safety results from the study will be presented at ASCO in June  Lilly intends to initiate global regulatory submissions in mid 2019 Lilly currently has a Zacks Rank  3  Hold   A better ranked large cap pharma stock is Merck   Co   Inc    NYSE MRK    which has a Zacks Rank  2  Buy   You can see  Shares of Merck have gained 1  so far this year while estimates for 2019 and 2020 have risen 1 5  and 1   respectively  over the past 30 days 
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-05-13,Zacks Investment Research,https://www.investing.com/analysis/lillys-cyramza-gets-fda-nod-for-secondline-liver-cancer-200421254,200421254
149369,370885,AMGN,AbbVie Settles Humira Litigation With Boehringer Ingelheim,opinion,AbbVie  Inc    NYSE ABBV   resolved its pending litigation with Boehringer Ingelheim regarding the latter s proposed biosimilar version of AbbVie s blockbuster rheumatoid arthritis drug  Humira in the United States  Per the settlement  AbbVie granted Boehringer Ingelheim a non exclusive license to launch its biosimilar Humira in the United States beginning Jul 1  2023  With this settlement  AbbVie has resolved all Humira related patent litigation in the United States Per the terms of the settlement  Boehringer Ingelheim will pay royalties to AbbVie once its cheaper version is launched  AbbVie will make no payments to Pfizer Shares of AbbVie were up more than 2  on Tuesday in response to the patent settlement announcement  AbbVie s stock has declined 14 9  this year so far compared with a decrease of 2 7  recorded by the    Humira is a key driver of AbbVie s revenues  accounting for around 61  of its total sales  Currently approved for 13 indications  Humira sales increased 8 2  in 2018 to almost  20 billion backed by robust demand trends despite new competition With Humira accounting for such a significant amount of AbbVie s total sales  the entry of biosimilars will have a huge impact on the company s financials However  AbbVie has successfully struck similar licensing deals with seven other generic manufacturers   Pfizer   NYSE PFE    Momenta  Amgen   NASDAQ AMGN    Mylan   NASDAQ MYL    Fresenius Kabi Sandoz and Biogen Samsung Bioepis   to protect its U S  revenues from the drug  Per the settlements  Humira biosimilars are expected to be launched in the United States at different times in 2023 The settlements give AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when Humira biosimilars are launched  AbbVie expects to launch several new products including yet to be launched immunology drugs Skyrizi  risankizumab  and upadacitinib or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023  Skyrizi and upadacitinib  which demonstrated differentiated clinical profiles versus Humira  are on track for launch in 2019  Skyrizi was approved by the FDA to treat plaque psoriasis last month However  AbbVie is already facing direct biosimilar competition in Europe and other countries  which account for approximately 25  of total global Humira revenues  Humira biosimilars were launched in the EU in October 2018  In 2019  AbbVie expects a decline of 30  or  2 billion in international Humira sales AbbVie currently carries a Zacks Rank  2  Buy   You can see  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-05-15,Zacks Investment Research,https://www.investing.com/analysis/abbvie-settles-humira-litigation-with-boehringer-ingelheim-200421601,200421601
149373,370889,AMGN,Facebook Has the Worst 401 k   Bloomberg,news,"By    At age 35  Daniel Baker  feels pretty set for retirement  The ConocoPhillips  NYSE COP  employee  a senior analyst in the treasury department  has logged 13 years at the oil and gas firm  His employer also offers one of the best 401 k  plans in the country  a Bloomberg News ranking released Tuesday indicates     
Meanwhile  Facebook  NASDAQ FB   which did not offer a match until this year  ranked last  In April  the company began to contribute 50 cents on the dollar   up to a maximum 3 5 percent benefit for employees who save 7 percent of their salaries   Bloomberg reported 
The ConocoPhillips plan includes a generous matching formula  employees only have to save 1 percent of their pay for the company to kick in 9 percent of their salary  For an employee who starts out making  75 000 a year  and sees pay increase of 4 percent each year   CononocoPhillips estimates that an employee could retire at 60 after 35 years of service with savings of  3 8 million   Bloomberg said 
 My wife and I have peace of mind   Baker told the news service 
Bloomberg calls the ranking a  first of its kind  examination of what the top 250 largest public companies in the United States provide for employees in terms of 401 k  retirement benefits  ConocoPhillips ranked No  1  Other companies at the top of the list include Philip Morris International  NYSE PM   Amgen  NASDAQ AMGN   Boston Scientific  NYSE BSX   and Dupont  NYSE DFT     

Retailers including Whole Foods  NASDAQ WFM  and Home Depot  NYSE HD  fall near the bottom  as do a handful of tech giants  including Amazon com  NASDAQ AMZN  
In response to the ranking  Facebook benefits manager Renee Whitney told Bloomberg   Although Facebook is a young company  we take a comprehensive approach to the benefits we offer all our people  which include a robust 401 k  match  as well as other retirement benefits  ",2014-07-22,International Business Times,https://www.investing.com/news/stock-market-news/facebook-has-the-worst-401(k):-bloomberg-296876,296876
149374,370890,AMGN,Ligand Grants Preclinical Candidate Rights To UK based Firm,opinion,"Ligand Pharmaceuticals Incorporated   NASDAQ LGND   announced that it has signed a license agreement with privately held UK based Cumulus Oncology  Per the terms of the agreement  Ligand granted Cumulus exclusive worldwide rights to develop and commercialize the novel  oral  selective  Chk1 kinase inhibitor   VER250840   discovered using Ligand s Vernalis Design Platform   VDP   The candidate is in pre clinical stage of development for cancer indications  Ligand will receive as undisclosed amount in upfront payment and is also eligible to receive more than  76 million in milestone payments and tiered royalties Shares of Ligand have declined 15 5  so far this year against the  s 1 7  increase Ligand is focused on strengthening and broadening its technology platform through agreements and acquisitions  In October 2018  Ligand had acquired Vernalis  for approximately  43 million  gaining ownership of VDP  Vernalis has collaborations with global partners for drug discovery across many therapeutic areas  including oncology  CNS  anti infectives and inflammation In 2016  Ligand added OmniAb platform with the acquisition of OMT  Inc  OmniAb and VDP platforms are new technologies  which may boost the company s major revenue generator platform  Captisol technology The Captisol technology has enabled development of several FDA approved products  which generate royalties for Ligand  In March 2019  Sage Therapeutics   NASDAQ SAGE   received approval for postpartum depression drug   Zulresso   which triggered a  3 million milestone payment to Ligand  Amgen s   NASDAQ AMGN   Kyprolis has attained blockbuster status and is a key royalty generating drug for Ligand  It was developed using Captisol technology In March  Ligand  the rights to Novartis    NYSE NVS   Promacta  which was also developed using Captisol technology  for  827 million  The drug had generated almost  100 million in revenues for Ligand in 2018  Ligand plans to use the funds to develop its technologies  acquire companies to drive growth over the next five to 10 years or beyond and continue development of its OmniAb platform The development of these technologies may increase signing of new licenses and partnerships  eventually driving revenues at Ligand Ligand Pharmaceuticals Incorporated Price
    Zacks RankLigand currently has a Zacks Rank  3  Hold   You can see  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-05-19,Zacks Investment Research,https://www.investing.com/analysis/ligand-grants-preclinical-candidate-rights-to-ukbased-firm-200423049,200423049
149375,370891,AMGN,Merck s Keytruda Fails In Late Stage Breast Cancer Study,opinion,"Merck   Co   Inc    NYSE MRK   announced that a pivotal phase III study evaluating its PD 1 inhibitor  Keytruda for the second  or third line treatment of metastatic triple negative breast cancer   TNBC   did not meet its primary endpoints of overall survival   OS   The KEYNOTE 119 study compared Keytruda monotherapy versus chemotherapy in previously treated metastatic TNBC patients  Data from the study showed that Keytruda did not achieve superiority in OS compared to chemotherapy However  the company stated that it will continue with Keytruda s development in earlier stages  including previously untreated patients of TNBC as well as in combination with chemotherapy in ongoing studies  The drug is not approved for any breast cancer indication Merck s shares lost 0 7  following the disappointing study update  Shares of the company have increased 3 2  so far in 2019 against the  s decrease of 1 2   Please note that this is the second study failure for Keytruda in 2019  In February  the drug has  to meet co primary endpoints of OS and progression free survival in the KEYNOTE 240 study  which evaluated it in advanced hepatocellular carcinoma  the most common type of liver cancer Moreover  in April  Keytruda in combination with chemotherapy failed to demonstrate superiority for OS and PFS versus chemotherapy alone in KEYNOTE 062 study  which evaluated the drug in patients with advanced gastric or gastroesophageal junction adenocarcinoma  in first line setting  However  Keytruda monotherapy demonstrated non inferiority compared to chemotherapy in similar patients in the study Meanwhile  Keytruda has become the top revenue generator for Merck in a short span of time on the back of its several label expansions  especially first line lung cancer  It is now already approved for use in 15 indications across 10 different tumor types in the United States  The drug generated sales of  2 27 billion in the first quarter of 2019  surging 55  surge year over year  Keytruda is continuously growing and expanding into new indications and markets globally The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 900 studies  including more than 500 combination studies  Merck is collaborating with several companies including Amgen  NASDAQ AMGN   Incyte   NASDAQ INCY    Glaxo   NYSE GSK   and Pfizer   NYSE PFE   separately for the evaluation of Keytruda in combination with other regimens We believe that Keytruda has strong growth prospects based on increased utilization  recent approvals for new indications and potential approvals worldwide Merck   Co   Inc  Price
    Zacks RankMerck currently carries a Zacks Rank  2  Buy   You can see  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-05-21,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-fails-in-latestage-breast-cancer-study-200423533,200423533
149377,370893,AMGN,Pricing is key for new heart drugs challenging cheap generics,news,"By Ben Hirschler BARCELONA  Reuters    Doctors looking at highly encouraging clinical trial results for new heart drugs at the world s largest cardiology meeting this week are missing one piece of data that will be critical to their success   the price 
While new treatments on show in Barcelona are certainly moving cardiovascular medicine forward after a series of setbacks in recent years  cardiologists say that cost will be key in determining how widely they are used 
 We are entering a new era of treatment and  of course  it will cost a lot of money  which is a problem   said Michel Bertrand  emeritus professor at the University of Lille and a past president of the European Society of Cardiology  ESC  
Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC s annual meeting indicated that they can save more lives than standard therapies 
The pharmaceuticals industry  however  faces a challenge because the new drugs are designed to replace or supplement a range of older medicines that have lost patent protection and are now widely available as bargain basement generics 
Novartis s new heart failure drug LCZ696  for example  was tested in a pivotal trial against enalapril  a generic drug in the so called ACE inhibitor class  a month s supply of which can be bought at Wal Mart stores for only  4 
The Swiss company has yet to say what it will charge for LCZ696  but based on the cost of recently launched drugs such as Bayer and Johnson   Johnson s anticoagulant Xarelto  analysts expect between  7 and  8 a day   or about  225 a month   with a lower price in Europe 
LARGE MARKET
It would be a big price for a big population   heart failure affects about 26 million people across the United States and Europe   and analysts have forecast peak annual sales of  5 billion plus 
Doctors  too  are keen that insurers and governments should see beyond the upfront cost to the long term benefits 
 Unfortunately  many insurance companies focus strictly on the cost of the pill   Elliott Antman  professor of medicine at Harvard Medical School and president of the American Heart Association  told Reuters 
 But if we only look at the per pill cost we have blinders on  We have to think about the impact on the health delivery system overall   and if a more expensive new drug reduces symptoms to the extent that patients aren t hospitalized as much  then that has enormous economic impact  
That chimes with the message from Novartis pharmaceuticals head David Epstein  who argues that the cost of a generic  is not the way to think about this product  
Still  with LCZ696 now in a position to replace an array of cheap medicines that have been the mainstay of heart failure treatment for more than 20 years  many cardiologists expect inevitable delays as healthcare providers haggle over access 
 A lot of payers will probably initially deny this because of costs   said Alfred Bove  emeritus professor at Temple University   Normally it takes about two years for something like this to get ingrained into routine care  
COST EFFECTIVENESS CHALLENGE
While LCZ696 may involve wholesale switching of treatment  the emerging class of PCSK9 agents present a different cost effectiveness challenge 
They are designed to complement existing drugs  such as statins  and are likely to cost about twice as much as LCZ696 because they are complex biotech products that have to be injected  according to industry analysts 
Sanofi  working with Regeneron Pharmaceuticals  is racing Amgen to bring the first PCSK9 drug to market in 2015  with Pfizer lagging slightly behind 
Once again the data is looking good  but in this case cardiologists expect uptake to be much more targeted  initially focused on people with a rare familial condition that raises their cholesterol dangerously  as well as high risk and statin intolerant patients 
 I think doctors will be quite cautious and I would expect a very stratified approach   said the University of Edinburgh s Keith Fox  who chairs the ESC s congress program committee   I don t see these drugs going out in the same broad way as statins  
However  this high risk group alone totals about 21 million in the United States and Europe  Sanofi estimates  pointing to a multibillion dollar sales opportunity 
For cardiologists  the expected launch next year of two important types of treatment is a breath of fresh air  Heart medicine has recently been eclipsed by advances in oncology  with U S  regulators approving five new cancer drugs this year against only one for cardiovascular conditions 
What is more  some heart drugs launched in recent years have not been used as widely as initially hoped  including AstraZeneca s Brilinta and Pfizer and Bristol Myers Squibb s Eliquis  a rival to Xarelto 
These drugs  however  did not offer the innovative mechanisms used with LCZ696 or PCSK9  which Freek Verheugt  of the Rotterdam Thorax Center  says should make a difference when the success stories from Barcelona finally reach patients 

 A brand new thing that saves lives should be adopted quickly   he said 
 Editing by David Goodman ",2014-09-01,Reuters,https://www.investing.com/news/stock-market-news/pricing-is-key-for-new-heart-drugs-challenging-cheap-generics-306792,306792
149378,370894,AMGN,Amgen profit tops Wall Street expectations  raises 2014 outlook,news,"By Bill Berkrot  Reuters    Amgen Inc  O AMGN  on Monday reported higher than expected third quarter earnings and revenue  even as net profit fell due to a hefty restructuring charge  and the company raised its full year forecast and the number of job cuts it expects to make 
The world s largest biotechnology company recorded a  376 million charge related to restructuring moves announced July 29 and expects to take another charge of up to  150 million in the fourth quarter  as well as additional charges next year 
Amgen shares rose 1 percent  They are up about 20 percent since the restructuring announcement that involved plant closings and job cuts  now expected to exceed 2 900  The company had previously estimated 2 400 to 2 900 job cuts as it looks to reallocate resources to prepare for the launch of new medicines  including a potential multibillion dollar cholesterol drug 
Further details of the restructuring are expected to be laid out at a business update for analysts and investors in New York on Tuesday 
Excluding items  Amgen earned  2 30 per share  exceeding analysts  average expectations by 19 cents  according to Thomson Reuters I B E S 
Amgen said it now expects 2014 adjusted earnings of  8 45 to  8 55 per share  up from the boosted forecast it provided in July of  8 20 to  8 40 per share  The company expects full year revenue of  19 8 billion to  20 billion  It previously forecast  19 5 billion to  19 7 billion 
 The numbers on the top line were a little better than we thought and on the bottom line in particular they were very strong   said Cowen and Co analyst Eric Schmidt 
 The guidance went up  It looked very conservative  but also certainly welcome   he added 
Amen posted a net profit of  1 24 billion  or  1 61 per share  down from a profit of  1 37 billion  or  1 79 per share  a year ago 
Revenue for the quarter rose 6 percent to  5 03 billion  edging past Wall Street estimates of  4 96 billion 
Sales of the white blood cell booster Neulasta rose 5 percent to  1 19 billion  topping the  1 13 billion analysts had expected 
Kyprolis  the multiple myeloma drug at the heart of Amgen s nearly  10 billion acquisition of Onyx Pharmaceuticals last year  had sales of  94 million  exceeding analysts  expectations of  87 million and the previous quarter s  78 million  Kyprolis still lags Celgene s new rival drug Pomalyst  which rang up sales of  181 million for the quarter 
Sales of the osteoporosis treatment Prolia jumped 43 percent to  255 million  topping analysts  estimates of  236 million  but down from  264 million in the prior quarter 
The blockbuster rheumatoid arthritis drug Enbrel saw sales fall three percent to  1 12 billion  shy of the  1 17 billion analysts were expecting  Inventory stocking issues hurt Enbrel in the quarter  the company said 

Amgen shares rose to  149 68 in extended trading from a Nasdaq close at  148 20 
 Reporting by Bill Berkrot  Editing by Chris Reese  Meredith Mazzilli and Nick Zieminski ",2014-10-27,Reuters,https://www.investing.com/news/stock-market-news/amgen-profit-tops-wall-street-expectations;-raises-2014-outlook-314417,314417
149379,370895,AMGN,Pfizer beats sales and profit forecasts  mum on future deals,news,"By Ransdell Pierson   Reuters    Pfizer Inc  N PFE  reported stronger than expected quarterly results  helped by growing sales of its cancer drugs and demand for its medicines in emerging markets  but did not signal any acquisition plans following its recent failed efforts to buy rival British drugmaker AstraZeneca Plc  L AZN    The largest U S  drugmaker on Tuesday said it had earned  2 67 billion  or 42 cents per share  in the third quarter  That compared with  2 59 billion  or 39 cents per share  a year earlier   Excluding special items  Pfizer earned 57 cents per share  Analysts on average expected 55 cents  according to Thomson Reuters I B E S   Sales fell 2 percent to  12 36 billion  hurt by generic competition and expiration of a longstanding deal with Amgen Inc  O AMGN  to co market its Enbrel arthritis drug  But they topped Wall Street expectations of  12 24 billion   Pfizer tightened its full year earnings forecast to between  2 23 and  2 27 per share from its prior outlook of  2 20 to  2 30   The company officially gave up its six month pursuit of AstraZeneca after its final  118 billion bid was rejected on May 26  It had hoped to base the combined company in Britain  which has lower taxes than the United States  a maneuver called tax inversion   Under UK takeover rules  Pfizer can make another run at AstraZeneca late next month  but the company did not mention its intentions in Tuesday s earnings report   U S  drugmaker AbbVie  N ABBV  two weeks ago gave up its  55 billion quest to buy Dublin drugmaker Shire  another tax inversion deal  because of new U S  Treasury tax rules that made the deal less attractive    Now that  AbbVie  has canceled its deal  it s less likely that Pfizer will move ahead  with its own attempt at AstraZeneca  said Edward Jones analyst Ashtyn Evans   But given Pfizer s predicted lack of growth over the next few years because of patent expirations  Evans said Pfizer  will still have to do something  like breaking up the company or making a big acquisition    In the next four years  generic rivals will challenge blockbuster Pfizer products such as painkiller Celebrex  nerve pain treatment Lyrica and anti impotence drug Viagra  The three drugs  with combined annual sales of almost  10 billion  generate about 20 percent of current company sales   Lyrica sales jumped 16 percent to  1 32 billion in the quarter  while Viagra sales fell 7 percent to  427 million due to generic competition in Europe  Sales of Celebrex  which goes generic in the United States in December  rose 2 percent to  764 million   Pfizer Chief Executive Ian Read on Tuesday said the company would rely on  operational and financial efficiencies and remain opportunistic regarding business development   The company stressed that its board last week had authorized a new  11 billion share repurchase program over time   
Pfizer shares rose 3 cents to  29 06 in premarket trading     Reporting by Ransdell Pierson  Editing by Bernadette Baum  Lisa Von Ahn and Meredith Mazzilli ",2014-10-28,Reuters,"https://www.investing.com/news/stock-market-news/pfizer-beats-third-quarter-forecasts,-mum-on-likely-future-deals-314490",314490
149380,370896,AMGN,Wall St  jumps 1 percent  S P ends above key level,news,"By Ryan Vlastelica  NEW YORK  Reuters    U S  stocks rose more than 1 percent on Tuesday  with the S P 500 ending above its 50 day moving average for the first time in almost a month as strong earnings eased concerns about the outlook for corporate America   The gains were broad  with all 10 primary S P 500 sectors up on the day  Energy stocks  were the day s biggest gainers  up 2 2 percent  while the Philadelphia SE Oil Service index  OSX  gained 3 4 percent   Adding to the day s positive tone was consumer confidence data  which hit its highest since 2007 in October  The report overshadowed a separate read that showed new orders for capital goods by U S  businesses fell the most in eight months in September   Amgen Inc  O AMGN  climbed 6 1 percent to  157 19  among the top boosts for the S P 500 and Nasdaq  a day after its 2015 outlook topped expectations  The Nasdaq Biotech index  NBI  rose 1 3 percent   The majority of U S  companies reporting third quarter results have beaten analysts  expectations so far  easing some worries about the impact of a stronger U S  dollar and weak global demand    We haven t seen big global companies downgrade their outlooks because of the stronger dollar or anything else  so earnings coming in so strong has been a relief   said Channing Smith  co portfolio manager of capital advisors growth fund at Capital Advisors in Tulsa  Oklahoma   There have been some high profile earnings disappointments  Twitter Inc  N TWTR  fell 9 8 percent to  43 78 after it posted a slide in a closely watched measure of engagement  even as its user base grew in the third quarter   The Dow Jones industrial average  DJI  rose 187 81 points  or 1 12 percent  to 17 005 75  the S P 500  SPX  gained 23 42 points  or 1 19 percent  to 1 985 05 and the Nasdaq Composite  IXIC  added 78 36 points  or 1 75 percent  to 4 564 29   With the day s advance  the S P 500 ended above its 50 day moving average for the first time since Sept  29  a sign that momentum is turning more positive  The Russell 2000  TOY  jumped 2 7 percent and traded above its 200 day moving average for the first time since Sept  19   After the market closed  Facebook Inc  O FB  posted revenue growth of almost 60 percent  Shares were little changed in after hours trading   Investors were awaiting clues on the outlook for the U S  economy from the Federal Reserve as the central bank commenced a two day policy meeting  It is likely to reinforce expectations it will wait a long while before rising interest rates  although the Fed is all but certain to announce the end of its massive bond buying stimulus   Advancing issues outnumbered declining ones on the NYSE by 2 582 to 501  for a 5 15 to 1 ratio on the upside  on the Nasdaq  2 171 issues rose and 526 fell for a 4 13 to 1 ratio   The benchmark S P 500 index posted 64 new 52 week highs and 2 new lows  the Nasdaq Composite recorded 133 new highs and 36 new lows   
About 6 17 billion shares traded on all U S  platforms  according to BATS exchange data  below the month to date average of 7 92 billion     Editing by Nick Zieminski ",2014-10-28,Reuters,"https://www.investing.com/news/stock-market-news/futures-rise-ahead-of-data,-twitter-tumbles-314493",314493
149384,370900,AMGN,Exclusive  Amgen s new leukemia drug to carry  178 000 price tag,news,"By Ransdell Pierson   Reuters    Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about  178 000 when it becomes available on Thursday  which would make it one of the world s most expensive cancer drugs    Company spokeswoman Danielle Bertrand said the price for the infused medicine  called Blincyto  would reflect two courses of treatment  at  89 000 per cycle    We believe the price reflects the significant clinical  economic and humanistic value of the product to patients and the healthcare system  for an ultra orphan population with a dramatic impact on a serious illness   Amgen said in an emailed statement    The world s largest biotech company also said the price reflects the complexity of developing and making innovative biotech drugs   U S  regulators on Dec  3 approved the Amgen drug more than five months ahead of the expected decision date  to treat a blood cancer called acute lyphoblastic leukemia  ALL   for which there are few options once a patient has relapsed following standard treatment   The initial approval is for patients whose cancer has returned after treatment or did not respond to previous treatment  such as a stem cell transplant or chemotherapy   In a clinical trial used for the approval decision  32 percent of patients achieved complete remission for nearly seven months after receiving the drug via infusion for four weeks   An estimated 6 020 Americans in 2014  almost half of them children  will be diagnosed with ALL and 1 440 will die from the disease  according to the National Cancer Institute  It is the most common form of leukemia affecting children   Amgen acquired Blincyto through its  1 2 billion purchase in 2012 of Micromet  a biotechnology company founded in Germany  At the time  Blincyto was known by its chemical name  blinatumomab   The drug is a so called bispecific antibody  a hot emerging technology that could prove more potent than conventional antibodies  which have become mainstay treatments for a wide array of cancers   Antibodies are proteins that look out for  foreign  invaders such as bacteria  as well as for aberrant fast growing cells like cancer  The Y shaped proteins have two arms that bind the same protein target found on cancer cells  in an attempt to neutralize the cells   With bispecific antibodies  however  one arm grasps the cancer cell  while the other takes hold of an immune system defender called a T cell  bringing the enemies into contact and leading to destruction of the cancer cell    Immuno oncology drugs  which stimulate the immune system or prevent tumor cells from hiding themselves  have become a main focus of drugmakers  following approval in 2011 of Bristol Myers Squibb Co s Yervoy treatment for melanoma  It costs about  120 000 for a complete course of four infusions   
Yervoy and members of another class of drugs called PD 1 inhibitors  including Merck   Co s recently approved Keytruda  work by removing a brake on the immune system  Keytruda costs about  150 000 for a year of treatment     Reporting by Ransdell Pierson  Editing by Lisa Von Ahn and David Gregorio ",2014-12-17,Reuters,"https://www.investing.com/news/stock-market-news/exclusive:-amgen's-new-leukemia-drug-to-carry-$178,000-price-tag-320650",320650
149385,370901,AMGN,Leaked Sony emails show Loeb influence on studio execs,news,"By Ritsuko Ando and Svea Herbst Bayliss  TOKYO BOSTON  Reuters    Sony Corp movie executives kept up a dialogue with hedge fund titan Daniel Loeb  even after rebuffing the billionaire investor s proposal to sell up to one fifth of the studio s entertainment business  leaked emails show   Loeb s New York based Third Point took a 7 percent stake in the company in May 2013 and suggested that proceeds from a sale could be used to overhaul Sony s struggling electronics business   For months  Loeb  who is closely watched in the hedge fund industry because of his fund s strong returns and pointed messages to chief executives  tried to persuade the company to do what he thought was best  Even after his proposals were official rejected in August 2013  he held the stock for roughly another year  telling investors in October 2014 that his  18 billion firm had exited the position during the third quarter   Having already forced a board room reshuffle at Yahoo Inc  Loeb has in the last few months actively pushed for change at Sotheby s   where he won board seats and the chief executive resigned in November  He has also pushed Dow Chemical Co and Amgen Inc to consider splitting themselves apart   Known for his sharp tongue  Loeb has penned pointed letters to underperforming chief executive officers and other top managers  But investors say he has worked on being more congenial in the last months        The emails  made available online following a massive hack into networks at Sony s film subsidiary Sony Pictures Entertainment  showed its executives carefully weighed how to deal with Loeb s overtures  The documents released by the hackers shed light on Sony s plans and business future   Loeb met with Sony Entertainment Chief Executive Michael Lynton in early January in Las Vegas  during the Consumer Electronics Show  CES   the emails show       In April  Lynton asked Sony Entertainment President Nicole Seligman whether he should invite Loeb to a Spider Man film premiere  or arrange a meeting          Should I try and see him when I am in NYC next Thursday   he wrote in an email in April  He also asked Jeff Blake  Sony Pictures  vice chairman at the time  whether tickets for the premiere were available for Loeb        My instinct is to stay off his radar   Seligman advised       Loeb  at times  tried to show his support for Sony  In a January 12  2014 email  Loeb sent Lynton a link to a New York Post article in which he praised Sony products       The report in what Loeb jokingly refers to as New York s  newspaper of record  quotes Loeb gushing over Sony s TVs and phones shown at CES        For the first time in a while  it feels like they re competing against Samsung again   he was quoted as saying   Activist investors like Loeb are often in close touch with executives at their target companies  sending both supportive and critical messages  industry analysts have said       Emails in September showed Loeb tried to broker a meeting between Sony and Lions Gate executives to discuss a possible merger and acquisition deal       Sony Corp Chief Executive Kazuo Hirai turned down a meeting with Lions Gate Vice Chairman Michael Burns  saying  I don t believe a meeting with me would be fruitful or a good use of your time   but refers him to Lynton and Seligman       The emails also showed pressure from Loeb influenced some decisions within Sony  including a possible appointment of media executive Strauss Zelnick to a key post  It was unclear what the position was for       A human resources official at Sony emailed Lynton in February to say a  nominating committee  would still keep Zelnick on its list  but that  the importance on entertainment background has decreased slightly according to the shift of focus interest from Dan Loeb     
    Sony declined to comment on the hacked emails  Zelnick did not immediately respond to a request for comment     Additional reporting by Svea Herbst Bayliss  James Pearson  Lisa Richwine and Jim Finkle ",2014-12-17,Reuters,https://www.investing.com/news/technology-news/leaked-sony-emails-show-loeb-influence-on-studio-execs-320682,320682
149401,370917,AMGN,Lilly  LLY  Down Despite Q1 Earnings Beat On Sales View Cut ,opinion,Eli Lilly   Company   NYSE LLY   delivered first quarter 2019 adjusted earnings per share of  1 33  beating the Zacks Consensus Estimate of  1 32 by a penny  Earnings rose 2  year over year Including asset impairment  restructuring and other special charges  first quarter earnings per share were  4 31 compared with  1 16 reported in first quarter 2018 Revenues in DetailIn the first quarter of 2019  Lilly reported revenues of  5 1 billion  Sales grew 3  year over year  backed by strong demand for its new drugs  namely Trulicity  Taltz  Jardiance and Basaglar  which compensated lower sales of older products like Cialis and Strattera Foreign exchange hurt sales growth by 2  in the quarter  Also  lower realized prices had a negative impact of 3  on sales  Volumes rose 7   U S  revenues grew 3  to  2 9 billion and ex U S  revenues inched up 2  to  2 2 billion Forteo sales were flat at  312 9 million  Humalog sales declined 8  to  730 8 million  Humulin sales fell 9  to  297 7 million Cialis sales plunged 38  to  308 2 million as U S  sales were hurt by the entry of generic products  Outside U S  sales were hit by currency headwindsAmong the new products  Trulicity generated revenues of  879 7 million  up 30  year over year  driven by higher demand Cyramza revenues were  198 3 million  up 8  year over year  attributable to higher demand Jardiance sales surged 35  to  203 6 million  boosted by increased demand trends within the SGLT2 class of diabetes medicines in the United States and an expanded volume outside the United States Basaglar recorded revenues of  251 4 million  soaring 51  year over year  In the United States  sales jumped 56   benefiting from higher demand  which offset the impact of lower realized price changes in estimates to rebates and discounts Taltz fetched in sales of  252 5 million  up 72  year over year as U S  sales gained from solid demand  which made up for lower realized prices  Ex U S  sales were aided by higher volume from launches across new countries Lartruvo generated revenues of  83 5 million in fourth quarter 2018 but did not contribute to the top line in the quarter under review  Notably  in February this year  Lilly announced that Lartruvo  which had won conditional approval two years back  failed to improve survival in patients with advanced soft tissue sarcoma in a late stage confirmatory study  ANNOUNCE  Continued approval was contingent on the verification of clinical benefit in a confirmatory study  With the ANNOUNCE study failing to confirm clinical benefit  management stated that it will stop promoting Lartruvo  The company has been working with regulatory agencies to facilitate the withdrawal of Lartruvo from the market New rheumatoid arthritis drug  Olumiant  generated sales of  82 1 million in the quarter  backed by the launch uptake across new European markets compared with  70 1 million in the previous reported quarter  In the United States  Olumiant registered sales of  6 4 million  higher than  4 2 million in the earlier reported quarter New advanced breast cancer treatment medicine  Verzenio  generated sales of  109 4 million in the quarter  which was more than  83 1 million sequentially  This is because of solid demand and to some extent  higher realized prices The newly launched CGRP antibody  Emgality  galcanezumab   generated sales of  14 2 million in the quarter  higher than  4 9 million in the sequential quarter Notably  in March this year  the FDA granted a priority review to Lilly s regulatory application looking for the label expansion of Emgality injection to address the preventive treatment of episodic cluster headache in adult patients Amgen s   NASDAQ AMGN   Aimovig and Teva s   NYSE TEVA   Ajovy were two other CGRP antibodies unveiled last year  which pose a strong competition to Emgality Meanwhile  Lilly divested its Elanco animal health unit as an independent publicly traded company   Elanco Animal Health Incorporated   NYSE ELAN     via an initial public offering  IPO  of a minority stake in 2018  Lilly sold the remaining 80 2  interest in the new company through a  tax efficient transaction  this March Gross Margin   Operating IncomeAdjusted gross margin of 80 2  in the quarter expanded 160 basis points  Operating income decreased 8  year over year to  1 33 billion on higher operating expenses  Operating expenses increased 12  year over year to  2 7 billion due to steep marketing costs to support the introduction of Emgality 2019 Sales Outlook LoweredThe earnings forecast was raised from a range of  5 55  5 65 per share to the  5 60  5 70 band  Lilly now expects revenues between  22 0 billion and  22 5 billion in 2019  down from the prior expectation of  25 1 billion  25 6 billion Despite the earnings beat  Lilly s shares declined more than 2  in pre market trading for trimming its full year revenue prediction  However  so far this year  shares of Lilly have gained 3 4  against the  dip of 0 9  Our TakeIn 2019  revenue growth is anticipated to be driven by elevated demand for the company s newer medicines including Trulicity  Jardiance  Taltz  Verzenio and Emgality besides some older drugs like Cialis  which lost patent exclusivity  However  generic competition for several drugs including Cialis  the rise in pricing pressure across the United States and some international markets  currency headwinds and the impact of the failed Lartruvo study might put pressure on the top line Eli Lilly and Company Price  Consensus and EPS Surprise   Zacks RankLilly currently carries a Zacks Rank  2  Buy   You can see  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-04-29,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-down-despite-q1-earnings-beat-on-sales-view-cut-200413167,200413167
149402,370918,AMGN,Protalix  PLX  To Report Q1 Earnings  What s In The Cards ,opinion,"Protalix BioTherapeutics  Inc    NYSE PLX   is scheduled to report first quarter 2019 results on May 6 
The company has surpassed expectations in two of the previous four quarters  the average earnings positive surprise being 22 50  
Protalix s share price has increased 36  compared with the  s growth of 4  year to date 

 
Let s see how things are shaping up for this announcement 
Factors to Consider
Protalix is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system  ProCellEx  The company is developing its lead candidate Pegunigalsidase alfa  PRX 102  for the treatment of Fabry Disease 
The company expects to provide light on the revenues of its first commercial drug product  Elelyso  which marketed for the treatment of Gaucher Disease 
The company had a very productive meeting with the FDA to discuss the potential filing of an application for accelerated approval of PRX 102 and  at the FDA s reques t the company intends to hold a follow up meeting by the end of the second quarter of 2019 to discuss the data and content of the potential filing for accelerated approval   
In 2018  the company reported positive results from its phase II study of OPRX 106 for the treatment of ulcerative colitis  
We expect the company to throw more light other pipeline updates 
What Our Model Indicates
Our proven model does not conclusively show that Protalix is likely to beat on earnings in the to be reported quarter  This is because a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  But that is not the case here  as you will see below 
Earnings ESP  Protalix has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Protalix BioTherapeutics  Inc  Price and EPS Surprise

   Zacks Rank  The company carries a Zacks Rank  3  which increases the predictive power of ESP  However  we need to have a positive Earnings ESP to be confident of an earnings beat 
Note that Sell rated stocks  Zacks Rank  4 or 5  going into an earnings announcement are best avoided 
Stocks That Warrant a Look
Here are some stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Ultragenyx Pharmaceuticals Inc    NASDAQ RARE   has an Earnings ESP of  6 36  and a Zacks Rank  2  You can see  
Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  0 12  and a Zacks Rank  3  The company is scheduled to release first quarter 2019 results on May 7 
Inovio Pharmaceuticals  Inc    NASDAQ INO   has an Earnings ESP of  13 79  and a Zacks Rank  3 
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year 
Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-05-02,Zacks Investment Research,https://www.investing.com/analysis/protalix-plx-to-report-q1-earnings-whats-in-the-cards-200416080,200416080
149403,370919,AMGN,Ligand  LGND  Q1 Earnings   Sales Fall Y Y  Stock Down,opinion,"Ligand Pharmaceuticals Incorporated   NASDAQ LGND   reported first quarter 2019 adjusted earnings of  1 16 per share  down from the year ago figure of  1 55  Adjusted earnings exclude the impact of one time tax gain of  640 million related to sales of Promacta rights  Including this gain  the company reported earnings of  31 32 per share  The Zacks Consensus Estimate was  28 42 In March  Ligand  all rights to Promacta  including royalty rights to worldwide net sales  to privately held Royalty Pharma for  827 million Shares of Ligand were down almost 5 7  in after market trading on May 2 following the news  Shares of the company have declined 51 3  so far this year compared with the  s 13 8  decrease Total revenues in the quarter decreased to  43 2 million from  56 2 million in the year ago period  However  the top line surpassed the Zacks Consensus Estimate of  38 31 million Quarterly HighlightsRoyalty revenues were  19 5 million in the reported quarter  down approximately 6 3  year over year  Ligand primarily earns royalties on sales of Novartis    NYSE NVS   Promacta  Amgen s   NASDAQ AMGN   Kyprolis and CASI Pharmaceuticals    NASDAQ CASI   Evomela  which were developed using its Captisol technology License fees  milestones and other revenues were  15 million in the first quarter compared with  30 9 million in the year ago period  The company had recorded an upfront milestone payment related to the out licensing of its glucagon receptor antagonist program to Roivant Sciences in year ago quarter Material sales were  9 million compared with  4 4 million in the year ago quarter due to the favorable timing of Captisol purchases for clinical and commercial use Ligand announced completion of enrollment in a phase I study evaluating its internal Captisol enabled Iohexol program  Top line data is expected in the third quarter of 2019 Business DevelopmentsDuring the quarter  Ligand completed six new deals related to its OmniAb and Captisol technology platforms  It also acquired a new technology company  Dianomi  Moreover  a drug developed using Ligand s technology received approval and the first OmniAb partnered program entered late stage development In March  Sage Therapeutics received approval from the FDA for its postpartum depression drug  Zulresso  Zulresso has been developed using Ligand s Captisol technology  Ligand received  3 million in milestone payment following the approval  The drug will be launched in June this year  which may generate potential royalties for Ligand 2019 Guidance MaintainedLigand reiterated its guidance for 2019 following the completion of sale of Promacta rights  It expects revenues to be approximately  118 million including royalties of nearly  48 million  material sales of roughly  27 million and license fees and milestones of almost  43 million  Adjusted earnings  excluding one time gain from Promacta sale  are estimated to be  3 20 per share for 2019 Ligand Pharmaceuticals Incorporated Price  Consensus and EPS Surprise
    Zacks RankLigand currently carries a Zacks Rank  5  Strong Sell  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-05-03,Zacks Investment Research,https://www.investing.com/analysis/ligand-lgnd-q1-earnings--sales-fall-yy-stock-down-200416669,200416669
149411,370927,AMGN,U S  futures lower on China PMI  U S  data ahead  Dow Jones down 0 53  ,news,Investing com   U S  stock futures pointed to a lower open on Wednesday  as the release of disappointing Chinese service sector data weighed on market sentiment  while expectations for the Federal Reserve to soon begin tapering its stimulus program persisted ahead of U S  data  Ahead of the open  the Dow Jones Industrial Average futures pointed to a 0 53  decline  S P 500 futures signaled a 0 58  loss  while the Nasdaq 100 futures indicated a 0 63  decline    Markets were jittery after a government report showed that China s non manufacturing purchasing managers  index inched down to 53 9 in June from 54 3 in May    Meanwhile  investors were looking ahead to a string of U S  economic reports later in the day  as well as Friday s U S  nonfarm payrolls data  for further clues on when the Fed may decide to unwind its USD85 billion a month stimulus program   Pharmaceutical companies were likely to be in focus  following reports Pfizer and Novartis may make preliminary bids for Onyx Pharmaceuticals   On Sunday  Onyx turned down a roughly USD10 billion offer from Amgen  The company s shares dropped 0 52  in pre market trade  In the tech sector  Apple slid 0 42   amid news the iPhone maker iring Paul Deneve  the former chief executive officer of luxury group Yves St Laurent  to work on special projects for CEO Tim Cook   Elsewhere in company news  SoftBank s USD21 6 billion bid for mobile carrier Sprint Nextel won the support it needs from the last U S  regulatory body reviewing the transaction  Sprint shares were down 0 56  in early trading  Auto stocks were also expected to remain active  after General Motors reported strong sales last month  Ford said the overall U S  auto industry will report its best monthly sales rate since December 2007  Across the Atlantic  European stock markets were sharply sower  The EURO STOXX 50 plunged 1 91   France s CAC 40 plummeted 1 68   Germany s DAX retreated 1 61   while Britain s FTSE 100 tumbled 1 59     During the Asian trading session  Hong Kong s Hang Seng Index dove 2 48   while Japan s Nikkei 225 Index slid 0 39     Later in the day  the U S  was to release the ADP report on nonfarm payrolls  as well as the weekly government report on initial jobless claims one day ahead of schedule  and data on the trade balance ,2013-07-03,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-futures-lower-on-china-pmi,-u.s.-data-ahead;-dow-jones-down-0.53-249808",249808
149412,370928,AMGN,U S  stocks lower after U S  employment data  Dow Jones down 0 13  ,news,Investing com   U S  stocks opened lower on Wednesday  as the release of strong U S  employment data added to expectations for the Federal Reserve to scale back its stimulus program before the year end   During early U S  trade  the Dow Jones Industrial Average fell 0 13   the S P 500 index slid 0 32   while the Nasdaq Composite index edged down 0 08    Payroll processor ADP said the U S  private sector added 188 000 jobs in June  more than expectations for an increase of 160 000 Separately  the U S  Department of Labor said of people who filed for unemployment assistance last week fell by 5 000 to a seasonally adjusted 343 000  compared to expectations for a drop of 3 000 to 345 000 Investors were looking ahead to Friday s U S  nonfarm payrolls data  for further clues on when the Federal Reserve may decide to unwind its USD85 billion a month stimulus program   Onyx Pharmaceuticals dropped 0 80  following reports Pfizer and Novartis may make preliminary bids for the company  On Sunday  Onyx turned down a roughly USD10 billion offer from Amgen  Adding to losses  Sprint Nextel saw shares slide 0 42  after SoftBank s USD21 6 billion bid for the mobile carrier won the support it needs from the last U S  regulatory body reviewing the transaction  Elsewhere  General Motors was down 0 38   even after reporting strong sales last month  In the same sector  Ford advanced 0 87  after saying the overall U S  auto industry will report its best monthly sales rate since December 2007  Also on the upside  Apple climbed 0 60   amid news the iPhone maker iring Paul Deneve  the former chief executive officer of luxury group Yves St Laurent  to work on special projects for CEO Tim Cook  Across the Atlantic  European stock markets were sharply sower  The EURO STOXX 50 tumbled 1 64   France s CAC 40 declined 1 36   Germany s DAX retreated 1 42   while Britain s FTSE 100 plummeted 1 63    During the Asian trading session  Hong Kong s Hang Seng Index dove 2 48   while Japan s Nikkei 225 Index slid 0 39    Later in the day  the Institute of Supply Management was to produce a report on U S  service sector activity ,2013-07-03,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-lower-after-u.s.-employment-data;-dow-jones-down-0.13-249823,249823
149413,370929,AMGN,AstraZeneca Cancer Drugs Seen As Draw For Pfizer,news,"By    LONDON  Reuters    Pfizer Inc  NYSE PFE  may come back to bid for British drug company Astrazeneca Plc  AZN ST  after its reported 60 billion pound   101 billion  takeover approach was rejected  since a deal could make sense for the U S  pharmaceuticals giant as it seeks to build up its cancer franchise               
In addition to adding promising   though still risky   experimental medicines known as immunotherapies that boost the body s immune system to fight tumors  acquiring AstraZeneca could also generate significant cost savings  according to industry analysts               
As a result  a deal at around a 25 percent premium to the current share price funded by cash  cheap debt and some stock could boost Pfizer earnings immediately  they believe               
Both companies have declined to comment on a report in the Sunday Times  which cited senior investment bankers and industry sources saying that Pfizer approached the British pharmaceuticals group about a deal  The newspaper said no talks were currently under way after AstraZeneca resisted the approach               
Citi analyst Andrew Baum said he believed the report was  very likely genuine  and Pfizer could return to the fray  given the attractiveness of AstraZeneca s pipeline of cancer drugs  its expertise in autoimmune diseases and the scope for taking out costs               
 We anticipate Pfizer to push aggressively ahead with a second approach   Baum wrote in a research note on Monday  adding that AstraZeneca might seek to structure any deal as a merger of equals as a defense strategy 
Betaville  a British financial blog  on Monday said AstraZeneca had hired Goldman Sachs and Morgan Stanley to act as  defense  advisors in the event Pfizer makes a new effort to acquire the London based drugmaker  The two investment banks already act as AstraZeneca s corporate brokers 
The blog also said that Pfizer may be working with JP Morgan to work on any potential bid  AstraZeneca and Pfizer declined to comment on the investment bankers  and officials at Goldman Sachs and Morgan Stanley could not immediately be reached               
Pfizer shares closed up 2 percent  while AstraZeneca shares rose 8 8 percent  both on the New York Stock Exchange               
Pfizer has a long track record of making major acquisitions  with the  68 billion purchase of Wyeth in 2009 its last major deal  after earlier acquisitions of Pharmacia and Warner Lambert               
The drugmaker has more recently been divesting certain operations and mega mergers have fallen out of fashion in the pharmaceuticals industry following skepticism about how well some of them have worked  But Chief Executive Officer Ian Read has said he would still consider a large deal that made sense               
Read also has an incentive to buy assets overseas rather than in the United States since Pfizer has tens of billions of dollars accumulated through foreign subsidiaries  which if repatriated to the U S  would be heavily taxed 
OTHER BIDDERS              
A Pfizer move on AstraZeneca might flush out other bidders  U S  biotech giant Amgen Inc  NASDAQ AMGN  already has a tie up with AstraZeneca in autoimmune medicines to treat diseases such as psoriasis and severe asthma  Novartis  NOVN SIX  and larger Glaxosmithkline  GSK LSE  have also been mentioned in the past as potential suitors  although GSK has in recent years said publicly it is not interested in making a large acquisition  while Novartis is in the middle of strategic review and already has a presence in cancer immunotherapy 
Mark Schoenebaum  an analyst at ISI  agreed cancer immunotherapy was likely the main lure for Pfizer  since the field is expected to become one of the biggest areas of modern medicine in the next few years               
However  Mark Clark at Deutsche Bank said Pfizer would be making something of a  leap of faith  since AstraZeneca s most exciting cancer drugs are still at an early stage of development               
Pfizer has a highly promising breast cancer drug in late stage development called palbociclib but otherwise its cancer portfolio is relatively weak 
 Notably  Pfizer appears to be nowhere in the important field of immuno oncology  which Bristol Myers Squibb  Roche  Merck   Co and AstraZeneca currently dominate   Schoenebaum said               
Bristol  Roche and Merck are viewed as being ahead of AstraZeneca in the new cancer field but the British firm believes it can make up ground by pioneering drug combinations  including the use of a medicine known as tremelimumab that it licensed from Pfizer               
AstraZeneca and its rivals will present the latest clinical data on promising new cancer drugs at the May 30 to June 3 annual meeting of the American Society of Clinical Oncology               
DRUG PIPELINE              
The London market was closed on Monday for Easter but the talk of Pfizer s interest in AstraZeneca is likely to overshadow dealings when trade resumes on Tuesday               
AstraZeneca Chief Executive Officer Pascal Soriot  who has been credited for progress in rebuilding the company s new drug pipeline since taking over in 2012  fuelling a rally in the shares  will also come under pressure to address the reported Pfizer approach when he presents half year results on Thursday 
Speculation over such a takeover  which would be potentially the biggest ever foreign takeover of a British company  is likely to trigger concerns about jobs in Britain s pharmaceuticals sector  which is viewed as a key industry by the government but which has been under pressure               
AstraZeneca has already laid off thousands of scientists and other staff as it shrinks its cost base to cope with a fall in sales due to patent losses on blockbuster medicines               
With heartburn treatment Nexium losing U S  patent protection next month and cholesterol fighter Crestor facing patent expiry in 2016  the decline in sales is expected to continue for several years              
In an attempt to reshape the company  Soriot is currently moving its research and corporate headquarters to Cambridge  England  Pfizer has also made the university city a research hub after shuttering a large research site in Sandwich  southern England               
The Cambridge connection is only one link between Pfizer and AstraZeneca  highlighting how the companies know each other well               
AstraZeneca s head of innovative medicines Mene Pangalos also used to work at Pfizer and the two firms are familiar with each other s products from working together on projects  such as a pioneering of a new kind of clinical trial for cancer drugs announced last week ",2014-04-21,International Business Times,https://www.investing.com/news/stock-market-news/astrazeneca-cancer-drugs-seen-as-draw-for-pfizer-278556,278556
149414,370930,AMGN,Novartis  NVS  Q1 Earnings Beat Estimates  Revenues Up Y Y,opinion,"Shares of Swiss pharma Novartis AG   NYSE NVS   are up in pre market trading after it beat on earnings in the first quarter  The company also raised its guidance First quarter 2019 core earnings  excluding one time charges  of  1 20 per share beat the Zacks Consensus Estimate of  1 11 and increased from  1 15 recorded in the year ago quarter Novartis AG Price  Consensus and EPS Surprise
    Revenues rose 2  year over year to  11 1 billion but marginally missed the Zacks Consensus Estimate of  11 2 billion All growth rates mentioned below are on a year over year basis and at constant exchange rates Quarter in DetailNovartis operates under two segments  Innovative Medicines  pharmaceuticals  and Sandoz  generics  The Innovative Medicines division recorded sales of  8 8 billion  up 10  year over year  Within this segment  Pharmaceuticals business unit grew 11   as psoriasis drug Cosentyx continues to gain traction  Cosentyx sales increased 41  to  791 million  driven by strong demand growth in all indications  Entresto sales grew 85  to  357 million  driven by increased worldwide uptake Oncology unit increased 9   driven by solid performance of Lutathera  Promacta and Kisqali  Lutathera was added to Novartis  portfolio from the Advanced Accelerator Applications  AAA  acquisition  Sales from AAA came in at  163 million  driven by the growth in sales of the drug   106 million   Kisqali sales were up 115   driven by use in first line metastatic breast cancer patients  who are independent of menopausal status or combination partner  Promacta sales grew 24  on increased use in chronic immune thrombocytopenia Sales at the Sandoz division were  2 3 billion  down 2  due to price erosion in the United States  Biopharmaceuticals sales grew 11   mainly driven by strong double digit growth in Rixathon  the biosimilar version of Roche s   OTC RHHBY   Rituxan  rituximab   Erelzi  the biosimilar of Enbrel  and Hyrimoz  filgrastim  in Europe Business RestructuringThe Alcon business was spun off as a separate public company on Apr 9  following the shareholder vote on Feb 28 Novartis expects to complete the previously announced divestment of the Sandoz US oral solids and dermatology businesses in 2019   Outlook UpdatedThe company expects net sales in 2019 to grow mid single digit  Operating income is now expected in high single digits compared to the earlier guidance of growth in mid to single digits  Innovative Medicines revenues are projected to grow mid single digit  Revenues from Sandoz are expected to be broadly in line with that in 2018 Pipeline UpdateThe pipeline progress during the first quarter was encouraging  The FDA approved Mayzent for the treatment of adults with relapsing forms of multiple sclerosis  MS   including secondary progressive multiple sclerosis  SPMS  with active disease  relapsing remitting multiple sclerosis  RRMS  and clinically isolated syndrome  CIS  Cosentyx was approved in China for moderate to severe plaque psoriasis in adult patients CAR T cell therapy Kyrmiah was approved in Japan for the treatment of relapsed or refractory  r r  DLBCL and  r r  pediatric ALL Capmatinib  INC280  was granted the Orphan Drug designation by the FDA for the treatment of non small cell lung cancer with cMET genomic tumor aberrations Sandoz recently resubmitted the application for its proposed biosimilar of Amgen s   NASDAQ AMGN   Neulasta  pegfilgrastim  to the FDA  following the complete response letter received in June 2016 Interim analyses from a phase III study  STRIVE  on gene therapy Zolgensma  AVXS 101  was presented in April at the Muscular Dystrophy Association congress Our TakeNovartis  first quarter results beat on earnings but missed on sales  While performance of key drugs like Cosentyx  Entresto  Kisqali and Promacta was encouraging  Sandoz continues to face challenging business conditions in the United States Novartis  stock has lost 9 9  in the past six months against the  s 0 1  growth The company is currently restructuring its business in order to become a core drug focused company  powered by data and digital technologies  The separation of the Alcon business is a step in the right direction  as the business was not performing as per management s expectations Zacks Rank   Stock to ConsiderNovartis currently carries a Zacks Rank  5  Strong Sell  
A better ranked stock in the large cap pharma space is GlaxoSmithKline plc   NYSE GSK    which carries a Zacks Rank  2  Buy   You can see  
Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire ",2019-04-23,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-q1-earnings-beat-estimates-revenues-up-yy-200410437,200410437
149419,370935,AMGN,Why Amgen  AMGN  Might Surprise This Earnings Season,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Amgen Inc    NASDAQ AMGN   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Amgenis seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for AMGN in this report In fact  the Most Accurate Estimate for the current quarter is currently at  3 46 per share for AMGN  compared to a broader Zacks Consensus Estimate of  3 45 per share  This suggests that analysts have very recently bumped up their estimates for AMGN  giving the stock a Zacks Earnings ESP of  0 37  heading into earnings season Amgen Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that AMGN has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Clearly  recent earnings estimate revisions suggest that good things are ahead for Amgen  and that a beat might be in the cards for the upcoming report Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-04-28,Zacks Investment Research,https://www.investing.com/analysis/why-amgen-amgn-might-surprise-this-earnings-season-200412284,200412284
149420,370936,AMGN,US STOCKS Futures drop after vote delayed on debt deal,news,"  U S  House delays vote on debt deal
   GDP on tap  economists forecast 1 8 pct growth
   Futures off  S P 5 9 pts  Dow 57 pts  Nasdaq 7 25 pts
   For up to the minute market news see  STXNEWS US 
   Adds quote  byline  updates prices 
 By Angela Moon
 NEW YORK  July 29  Reuters    U S  stock index futures fell
on Friday after lawmakers in Washington delayed a vote on a
Republican proposal to raise the U S  government s debt limit 
 U S  House of Representatives Speaker John Boehner s
failure to round up enough votes for his plan late Thursday
exposed a rift in the Republican Party that is hampering
efforts to reach a compromise to raise the U S  debt ceiling
before a Tuesday deadline  For details  see  ID nN1E76S004 
 House Republicans are due to meet at 10 a m  EDT  1400 GMT 
to discuss a way forward 
  The fear factor of the debt ceiling crisis is becoming a
major one as we near the deadline   said Peter Cardillo  chief
market economist at Avalon Partners in New York   There is a
possibility that we might the test the 1 275 level on the
S P  
 On Thursday  the S P 500 fell for a fourth straight day 
closing near 1 300 as buyers kept to the sidelines while
lawmakers struggled to hash out an agreement on the deficit and
debt ceiling 
 S P 500 futures  fell 5 9 points and were below fair
value  a formula that evaluates pricing by taking into account
interest rates  dividends and time to expiration on the
contract  Dow Jones industrial average futures  were down
57 points  and Nasdaq 100 futures  gained 7 25 points 
 The Commerce Department releases its first estimate of
second quarter gross domestic product  GDP  at 8 30 a m  EDT
 1230 GMT   Economists in a Reuters survey forecast a 1 8
percent annualized pace of growth  compared with a 1 9 percent
rate in the final first quarter estimate 
 Also at 8 30 a m   the Labor Department issues the
Employment Cost Index for the second quarter  Economists expect
a rise of 0 5 percent versus a 0 6 percent rise in the first
quarter 
 Chevron Corp   the second largest U S  based oil and
gas producer  will report second quarter earnings that are
expected to rise as higher prices for oil and robust refining
margins helped offset slightly lower total output 
 In other economic data  the Institute for Supply
Management Chicago releases July business barometer at 9 45
a m  EDT  1345 GMT   Economists forecast a reading of 60 0 in
the month  compared with 61 1 in June 
 The Thomson Reuters University of Michigan Surveys of
Consumers July final consumer sentiment index is reported at
9 55 a m  EDT  1355 GMT   Economists look for a reading of
64 0  compared with 63 8 in the preliminary July report 
 The euro zone debt crisis is also a concern to markets 
Rating agency Moody s put Spain on review for a possible
downgrade on Friday  adding to worries that a Greek rescue
package has done little to halt the spread of Europe s debt
crisis   ID nLDE76S04W 
 Amgen Inc   the world s largest biotechnology
company  is expected to post lower profit and revenue as sales
of its once top selling anemia drug Aranesp continues to
erode 
   Reporting by Angela Moon  editing by Jeffrey Benkoe ",2011-07-29,Reuters,https://www.investing.com/news/stock-market-news/us-stocks-futures-drop-after-vote-delayed-on-debt-deal-220627,220627
149421,370937,AMGN,U S  futures higher  eyes on Fed statement  Dow Jones up 0 46 ,news,Investing com   U S  stock futures were higher on Wednesday  boosted by Apple s strong first quarter earnings while investors eyed the release of a series of statements by the Federal Reserve later in the day Ahead of the open  the Dow Jones Industrial Average futures pointed to a rise of 0 46   S P 500 futures signaled a 0 62  increase  while the Nasdaq 100 futures indicated 1 93  surge Investors remained cautious as European Central Bank President Mario Draghi gave no indication  during a speech in Brussels earlier Wednesday  on whether the central bank will provide further support to banks or governments The comments came amid speculation that the Netherlands could lose its triple A credit rating following the collapse of its government on Monday after talks on the 2013 austerity budget failed Meanwhile  markets were also jittery as a string of mixed U S  data on consumer confidence  new home sales and home prices failed on Tuesday to paint a clear picture of the level of recovery of the world s largest economy Apple was expected to be active after the company s quarterly profit nearly doubled  as strong Asian sales of iPhones   five times the number from a year ago   offset recent drops in U S  orders  Apple shares soared 9 26  in pre market trade Other tech stocks were likely to be in focus  such as Baidu Inc   as the owner of China s dominant Internet search engine forecast second quarter revenue will be no more than USD867 million  falling short of the average analyst estimate of USD869 2 million  and sending shares down 9 08  in pre market trade International Game Technology  the world s biggest maker of slot machines  rose 3 90  in late trading however  after it forecast profit in 2012 of 99 cents to USD1 04 a share  compared with the average analyst estimate of 99 cents Elsewhere  maker of Post it Notes and fuel system tune up kits  3M was set to move in Wednesday s session after posting earnings per share that beat analysts  estimates by 10 cents  helped by rising domestic auto and industrial demand  Shares rose 0 34  in after hour trade In the pharmaceutical and biotech sectors  Life Technologies and Amgen Inc   were slated to be active after both groups reported better than expected first quarter profit  Amgen said it benefited from increased sales of its drugs to treat infections in cancer patients Across the Atlantic  European stock markets were higher  The EURO STOXX 50 surged 1 38   France s CAC 40 jumped 1 47   Germany s DAX advanced 1 19   while Britain s FTSE 100 added 0 15  During the Asian trading session  Hong Kong s Hang Seng Index eased down 0 15   while Japan s Nikkei 225 Index rallied 0 95  Later in the day  the U S  was to publish government data on durable goods orders and crude oil stockpiles  while the Federal Reserve was to announce its benchmark interest rate and release its rate statement ,2012-04-25,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-futures-higher,-eyes-on-fed-statement;-dow-jones-up-0.46-232973",232973
149425,370941,AMGN,Teladoc  TDOC  To Report Q1 Earnings  What s In The Cards ,opinion,"Teladoc Health  Inc    NYSE TDOC    the global leader in virtual care  will release first quarter 2019 results on Apr 30  2019  after the market closes 
The company is expected to post a loss of 44 cents per share  which is wider than the loss of 39 cents  sustained in the year ago quarter  Revenues of  128 14 million are expected to grow 43  year over year 
In the last reported quarter  the company sustained a loss of 35 cents per share  in line with the Zacks Consensus Estimate  The same was also lower than the year ago quarter s loss of 50 cents per share  The decline in losses was supported by increase in revenues  partly offset by rise in expenses 
Let s see the factors affecting Q1 results
We expect to see higher visit revenues in the first quarter of 2019  attributable to increased adoption of virtual care and benefits from the company s diversification strategy  pursuant to which it had broadened the scope of clinical services offered 
In the recent past  the company launched Teladoc Global Care that enables multinational organizations to provide expats and travelers with a single solution for convenient and easy to navigate access to quality care  regardless of geographic location  This should buoy the company s revenue from international operations  Moreover  the company has already closed meaningful cross selling expansion contracts in 2019  in sync with the aim of selling its full suite of products around the world 
The company is constantly witnessing growth in its client roster due to the addition of new clients across multiple market segments  Its emphasis is on increasing value add clients through product innovation that will also help to retain customers  In the first quarter  the company s growing clients should aid the top line 
Teladoc has been banking on acquisitions to boost growth  The buyouts of Advance Medical and Best Doctors should result in membership growth thus aiding revenues 
Per management  the first quarter is typically the least profitable quarter of the year as the company realizes the expense of on boarding millions of new members in advance of associated visit revenue  Therefore adjusted EBITDA should decline in the first quarter of 2019  compared with the fourth quarter of 2018 
Also rise in expenses primarily due by higher marketing and advertising  technology and development  and legal expenses  should compress margins 
Company s Guidance
For the first quarter  the company expects total revenues of  126  129 million and total adjusted EBITDA of  0  2 million  It projects total visits between 950 000 and 1050 000  Net loss per share  based on 70 8 million weighted average shares outstanding  is expected to range from a loss of 44 cents to 46 cents per share 
Earnings Surprise History
The company boasts an attractive earnings surprise history having surpassed estimates in three of the four reported quarters with an average positive surprise of 4 4  This is depicted in the graph below 
Teladoc  Inc  Price and EPS Surprise
    
What Our Model Says
Our proven model does not conclusively show that Teladoc is likely to beat estimates in the to be reported quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen 
Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is 0 00   You can uncover the best stocks to buy or sell before they re reported with our   
Zacks Rank  Currently  the company carries a Zacks Rank  4  Sell   We caution against stocks with a Zacks Ranks  4 or 5  Strong Sell  going into the earnings announcement  especially when the company is witnessing negative estimate revisions 
Stocks Worth a Look
Here are a few healthcare stocks worth considering as these have the right combination of elements to beat on earnings in the upcoming quarterly results 
WellCare Health Plans  Inc    NYSE WCG   has an Earnings ESP of  1  and a Zacks Rank of 3 
You can see  
Pfizer Inc    NYSE PFE   has an Earnings ESP of  0 65  and a Zacks Rank 3 
Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  0 37  and carries a Zacks  3 
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1  and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-04-29,Zacks Investment Research,https://www.investing.com/analysis/teladoc-tdoc-to-report-q1-earnings-whats-in-the-cards-200412593,200412593
149426,370942,AMGN,Pfizer  PFE  Beats On Q1 Earnings   Sales  Raises EPS View,opinion,"Pfizer  Inc    NYSE PFE   reported first quarter 2019 adjusted earnings per share of 85 cents  which beat the Zacks Consensus Estimate of 77 cents  Earnings rose 13  year over year driven by higher sales and reduced share count The pharma heavyweight recorded revenues of  13 12 billion  which beat the Zacks Consensus Estimate of  12 80 billion  Revenues rose 2  from the year ago quarter on a reported basis  Currency fluctuation hurt sales by 4  in the quarter  On an operational basis  excluding the impact of currency  revenues rose 5  year over year driven by higher sales of some key brands in Pfizer s Biopharmaceuticals group International revenues rose 5   up 12  an operational basis  to  6 94 billion  U S  revenues however declined 2  to  6 18 billion Adjusted selling  informational and administrative  SI A  expenses rose 3   operationally  in the quarter to  3 31 billion  Adjusted R D expenses declined 2  to  1 69 billion Change in Segment ReportingIn 2018  Pfizer s reporting segments were Pfizer Innovative Health  IH  and Pfizer Essential Health  EH  Beginning the first quarter of 2019  Pfizer is reporting under three new business units   Pfizer Biopharmaceuticals Group  previous IH unit except Consumer Healthcare   Upjohn  previous EH unit  and Consumer Healthcare  However  Pfizer re allocated its biosimilar portfolio and certain legacy established products into the Biopharma group from the previous EH unit We remind investors that Pfizer s Consumer Healthcare unit will merge with Glaxo s   NYSE GSK   unit to form a new joint venture  JV   Pfizer will own a stake of 32  in the JV  Pfizer had been exploring strategic options for its Consumer Healthcare unit since October 2017  The transaction is expected to close in the second half of 2019 Segment DiscussionPfizer Biopharma sales grew 3  on a reported basis  up 7  an operational basis  from the year ago period to  9 19 billion  Higher sales of Eliquis  Ibrance  Prevnar 13 Prevenar 13 and Xeljanz drove this segment s sales growth Within the Biopharma group  Oncology revenues increased 15  to  1 96 billion  Vaccine revenues rose 13  to  1 61 billion  Internal Medicine rose 10  to  2 22 billion  The Inflammation   Immunology franchise rose 8  to  1 04 billion  However  the portfolio of Rare Disease declined 9  to  470 million  The newly added Hospital sub segment s sales declined 3  to  1 9 billion  The Hospital segment includes Pfizer s global portfolio of sterile injectable and anti infective medicines and also includes revenues from its contract manufacturing operation called Pfizer CentreOne Pfizer s Upjohn group s sales declined 1  to  3 08 billion  On an operational basis  sales rose 1  in the segment as strong growth in emerging markets and Japan was offset by decline in developed markets other than Japan Revenues in the Consumer Healthcare unit declined 5   2  on an operational basis  to  858 million due to lower sales in the U S  market  which were partially offset by higher sales in international markets Performance of Key DrugsIbrance revenues rose 25  year over year to  1 13 billion as continued strong uptake in international markets made up for moderating volumes in United States Xeljanz sales rose 34  to  423 million driven by continued growth in rheumatoid arthritis  RA  revenues and contributions from the drug s recent expansion into psoriatic arthritis and ulcerative colitis in the United States and only ulcerative colitis indication in certain developed markets Global Prevnar 13 Prevenar 13 revenues rose 10  to  1 49 billion  Prevnar 13 revenues rose 6  in the United States reflecting increased government purchases for the pediatric indication  Prevenar 13 revenues rose 16  in international markets driven by higher revenues in emerging markets Enbrel revenues declined 3  to  451 million in key European markets due to continued biosimilar competition  Pfizer has exclusive rights to Amgen  Inc  s   NASDAQ AMGN   blockbuster rheumatoid arthritis  RA  drug  Enbrel  outside the United States and Canada Xalkori sales declined 16  to  123 million primarily due to competitive pressure  Sutent sales declined 6  to  232 million  Eliquis alliance revenues and direct sales rose 36  to  1 01 billion  Chantix sales rose 10  to  273 million in the quarter  Xtandi recorded alliance revenues of  168 million in the quarter  up 6  year over year Inflectra  Pfizer s biosimilar version of Johnson   Johnson   NYSE JNJ   and Merck s blockbuster RA drug  Remicade  recorded sales of  138 million globally  flat year over year In the Upjohn segment  sales of key drug Lyrica declined 1  to  1 19 billion reflecting wholesaler destocking ahead of the drug s anticipated loss of exclusivity  LOE  in June and lower sales in developed Europe due to generic launches  Viagra sales declined 19  to  145 million due to generic competition that began in December 2017 2019 GuidancePfizer maintained its sales guidance for 2019  However  the company raised the mid point of its earnings guidance by a penny as increased expectation for other income  due to a milestone payment received in the first quarter  was offset by stronger currency headwinds   The guidance includes a full year of revenues and expense contribution from the Consumer Healthcare unit Revenues are still expected in the range of  52 0 billion to  54 0 billion  Adjusted earnings per share are expected in the range of  2 83  2 93 versus the previous expectation of  2 82  2 92 Research and development expense is expected in the range of  7 8  8 3 billion while SI A spending is projected in the range of  13 5   14 5 billion  Adjusted tax rate is expected to be approximately 16  in 2019 Our TakePfizer beat estimates for first quarter earnings and sales  raised the mid point of its earnings expectations for 2019 by a penny and confirmed its previous outlook for full year sales  Shares of Pfizer rose almost 1  in pre market trading  Pfizer s shares have declined 9 3  this year so far compared with a decline of 1  for the    In 2019  Pfizer expects continued strong growth of key product franchises  including Ibrance  Eliquis  Xeljanz and Prevnar However  LOEs are expected to hurt 2019 sales significantly including the expected LOE of key drug Lyrica in the United States in June 2019  Also  currency headwinds are expected to significantly pull down 2019 revenues To offset the threat of generic competition  Pfizer is strengthening its pipeline as well as oncology portfolio  Pfizer gained FDA approval for four innovative medicines  Daurismo  Lorbrena  Vizimpro and Talzenna  in the last four months of 2018  which can boost its oncology sales in 2019  Pfizer boasts a strong pipeline and looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years  which can drive long term growth  Biosimilars are also expected to contribute to growth in 2019 Pfizer currently carries a Zacks Rank  3  Hold   You can see   Pfizer Inc  Price  Consensus and EPS Surprise
  
   Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-29,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-beats-on-q1-earnings--sales-raises-eps-view-200412909,200412909
149427,370943,AMGN,U S  stocks tumble on growth concerns  Dow Jones down 1 36 ,news,Investing com   U S  stocks opened sharply lower on Tuesday  as market sentiment remained under pressure following weak earnings reports and after Moody s lowered credit ratings on five Spanish regions late Monday   During early U S  trade  the Dow Jones Industrial Average tumbled 1 36   the S P 500 index plunged 1 37   while the Nasdaq Composite index dropped 0 97    Market sentiment weakened after ratings agency Moody s cut the credit ratings of Catalonia and four other Spanish regions late Monday  citing their worsening liquidity positions and predicting that these regions are likely to ask the central government for aid in 2013 The downgrade comes on the heels of regional elections in Spain  Prime Minister Mariano Rajoy s center right Popular Party increased its majority in his home region of Galicia on Sunday  removing a possible obstacle to formally requesting financial aid from Spain s euro zone partners   Investors were also eyeing the Federal Reserve s two day policy setting meeting  which kicks off later in the day  after the central bank announced its third round of quantitative easing last month  DuPont tumbled 6 83  after the chemical company reported a profit that fell short of expectations and announced 1 500 layoffs in an aggressive cost cutting move   Also on the downside  United Technologies dropped 0 57   as it reported a decline in third quarter earnings and cut its sales forecast for the year  citing weak demand from airlines and an uncertain economy  Elsewhere in the tech sector  Apple plunged 1 31   even as it was expected to make its biggest product move since the iPad s debut two years ago  by launching later in the day a smaller  cheaper tablet    RadioShack dove 11 72  after the consumer electronics retailer badly missed estimates due to weak margins in its smartphone business   On the upside  Yahoo surged 3 23  after the Internet company posted quarterly results that easily beat expectations on Monday   Marissa Mayer  who took over in July as the company s fifth chief executive officer in four years  said that the company will emphasize on mobile technology and personalized services in a strategy to reverse a sales decline   Other stocks in focus included Amgen  Facebook  Netflix  Gilead Sciences  due to report earnings later in the day   Across the Atlantic  European stock markets were lower  The EURO STOXX 50 plummeted 2 24   France s CAC 40 dove 2 22   Germany s DAX plunged 2 08   while Britain s FTSE 100 tumbled 1 44   During the Asian trading session  Hong Kong s Hang Seng Index climbed 0 68   while Japan s Nikkei 225 Index inched up 0 04    Markets were expected to remain subdued ahead of the release later in the week of U S  data including monthly new home sales  durable goods orders and third quarter GDP figures ,2012-10-23,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-tumble-on-growth-concerns;-dow-jones-down-1.36-239809,239809
149428,370944,AMGN,Wall Street plunges on weak earnings  Spanish fears  Dow off 1 82 ,news,Investing com   U S  stocks closed sharply lower Tuesday  as market sentiment remained under pressure following weak earnings reports and after Moody s lowered credit ratings on five Spanish regions late Monday    At the close of  U S  trade  the Dow Jones Industrial Average tumbled 1 82   the S P 500 index plunged 1 44   while the Nasdaq Composite index dropped 0 88     Triggering the sell off   ratings agency Moody s cut the credit ratings of Catalonia and four other Spanish regions late Monday  citing their worsening liquidity positions and predicting that these regions are likely to ask the central government for aid in 2013   The downgrade comes on the heels of regional elections in Spain  Prime Minister Mariano Rajoy s center right Popular Party increased its majority in his home region of Galicia on Sunday  removing a possible obstacle to formally requesting financial aid from Spain s euro zone partners    Investors were also eyeing the Federal Reserve s two day policy setting meeting  which kicks off later in the day  after the central bank announced its third round of quantitative easing last month    DuPont tumbled 6 83  after the chemical company reported a profit that fell short of expectations and announced 1 500 layoffs in an aggressive cost cutting move    Also on the downside  United Technologies dropped 0 57   as it reported a decline in third quarter earnings and cut its sales forecast for the year  citing weak demand from airlines and an uncertain economy    Elsewhere in the tech sector  Apple plunged 1 31   even as it was expected to make its biggest product move since the iPad s debut two years ago  by launching later in the day a smaller  cheaper tablet    RadioShack dove 11 72  after the consumer electronics retailer badly missed estimates due to weak margins in its smartphone business    On the upside  Yahoo surged 3 23  after the Internet company posted quarterly results that easily beat expectations on Monday    Marissa Mayer  who took over in July as the company s fifth chief executive officer in four years  said that the company will emphasize on mobile technology and personalized services in a strategy to reverse a sales decline    Other stocks in focus included Amgen  Facebook  Netflix  Gilead Sciences  due to report earnings later in the day    At the close of European trade  the EURO STOXX 50 plunged 2 10   France s CAC 40 plummeted 2 40   while Germany s DAX 30 was smacked lower by 2 11    Investors are awaiting the U S new home sales numbers and the interest rate decision on Wednesday ,2012-10-23,Investing.com,"https://www.investing.com/news/stock-market-news/wall-street-plunges-on-weak-earnings,-spanish-fears;-dow-off-1.82-239822",239822
149431,370947,AMGN,U S  futures steady  markets focus on U S  elections  Dow Jones up 0 08 ,news,Investing com   U S  stock futures pointed to a steady open on Monday  as investors remained cautious ahead of the upcoming U S  Presidential election and amid sustained euro zone debt concerns  Ahead of the open  the Dow Jones Industrial Average futures pointed to a 0 08  rise  S P 500 futures signaled a 0 03  gain  while the Nasdaq 100 futures indicated a 0 12  increase  Markets were jittery amid uncertainty over the outcome of Tuesday s U S  presidential elections  with opinion polls indicating a dead heat between President Barack Obama and Republican challenger Mitt Romney  Meanwhile  concerns over Spain s financial woes re emerged after the country s Employment Ministry said the number of unemployed people rose by a seasonally adjusted 128 200 in October  above expectations for an increase of 90 500  The number of unemployed people in Spain rose by an unrevised 79 600 in September   The financial sector was expected to be active  amid reports International Lease Finance Corp  the aircraft leasing arm of American International Group  shrugged off threats from a growing number of domestic players in China  its biggest single market  saying it has the  first mover  advantage with more than 200 planes on order   Separately  Goldman Sachs said it cut the number of employees it lists as partners to help streamline expenses  Elsewhere  drilling contractor Transocean saw shares jump 1 82  in pre market trade  after it reported a higher than expected adjusted profit for the third quarter as it made more efficient use of the world s largest offshore oil drilling fleet  Comcast and Amgen were also likely to be in focus  as they were reportedly preparing to ask the U S  Supreme Court on Monday to further limit class actions following a decision last year in the landmark Wal Mart Stores discrimination case that restricted such group litigation   Other stocks in focus included health insurer Humana and exchange operator IntercontinentalExchange  due to report earnings later in the day  Across the Atlantic  European stock markets were lower  The EURO STOXX 50 dropped 0 87   France s CAC 40 declined 0 85   Germany s DAX slid 0 50   while Britain s FTSE 100 retreated 0 55   During the Asian trading session  Hong Kong s Hang Seng Index dropped 0 47   while Japan s Nikkei 225 Index slumped 0 48    Later in the day  the Institute of Supply Management was to publish data on U S service sector activity ,2012-11-05,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-futures-steady,-markets-focus-on-u.s.-elections;-dow-jones-up-0.08-240305",240305
149440,370956,AMGN,Radius Health  RDUS  Rallies 33 4  YTD On Robust Tymlos Sales,opinion,"Shares of Radius Health  Inc    NASDAQ RDUS   have gained 35 3  in the year so far  outperforming the  growth of 12 4  

 
The company primarily focuses on the development of endocrine therapeutics in the areas of osteoporosis and oncology  
Radius Health got a significant boost with the FDA approval of Tymlos  abaloparatide  SC  injection for the treatment of postmenopausal women with high risk osteoporosis for fracture   defined as history of osteoporotic fracture   multiple risk factors for fracture  or patients  who have failed or are intolerant to other available osteoporosis therapies 
The drug was approved in 2017 and continued to gain traction in 2018  In October 2018  the FDA approved a labeling supplement for Tymlos to include additional information from the ACTIVExtend study  The labeling now reflects that after 24 months of open label alendronate therapy  the vertebral fracture risk reduction achieved with Tymlos therapy was maintained 
The drug captured  on average  20  of the U S  anabolic osteoporosis market  based on Patient Months on Therapy  TRx PMOT  in 2018  In the first six weeks of 2019  the drug captured a 29  share of the U S  anabolic osteoporosis market and more than 40  of new anabolic patient starts 
The company is also developing an abaloparatide transdermal patch  abaloparatide patch  for the treatment of postmenopausal women with osteoporosis 
Apart from Tymlos  Radius Health is working on the development of elacestrant   The company initiated the phase III EMERALD study on elacestrant in November 2018   This is the first phase III study to evaluate treatment benefit for second  and third line breast cancer patients following CDK 4 6 inhibitor therapy and compare outcomes in patients whose tumors harbor estrogen receptor 1 gene  ESR1  mutations  The study is open to enrollment  with a planned recruitment period of 18 21 months and potential data read out in 2021 
While the market for postmenopausal osteoporosis provides significant commercial potential  it is pretty crowded given the presence of products like Amgen s   NASDAQ AMGN   Prolia and Lilly s   NYSE LLY   Forteo  among others  The recent approval of Amgen s Evenity will further intensify competition for Tymlos  Novartis    NYSE NVS   Reclast is also approved for osteoporosis  Hence  it remains to be seen what the growth trajectory will be for Tymlos in 2019  Moreover  the drug has been refused approval in Europe 
Zacks Rank   Stock to Consider
Radius Health currently carries a Zacks Rank  3  Hold   You can see  
Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-04-16,Zacks Investment Research,https://www.investing.com/analysis/radius-health-rdus-rallies-334-ytd-on-robust-tymlos-sales-200407453,200407453
149443,370959,AMGN,Can Q1 Earnings Lift Healthcare ETFs Higher ,opinion,While the broader stock market has been on the rise  healthcare is the only sector that has been in the red from a year to date look  The potential adverse impact of future policy changes  more specifically  Medicare for All  push  is weighing on the sector This plan will largely eliminate private insurance and shift all Americans into a Medicare based  government run healthcare plan that Republicans have criticized as too costly and radical  The plan  if approved  could significantly hurt profits in the managed care and health services sectors UnitedHealth Group   NYSE UNH   is already facing the heat of the proposed plan as its shares fell in spite of robust first quarter 2019 results  The largest U S  health insurer breezed past the Zacks Consensus Estimate on both earnings and revenues and raised its full year forecast  read    However  broader healthcare ETFs such as Health Care Select Sector SPDR Fund  has gained 2 5 so far this year while Vanguard Health Care ETF   AX VHT    iShares U S  Healthcare ETF  and Fidelity MSCI Health Care Index ETF   are up 4 3   3 4  and 4 2   respectively  The strength is likely to continue with some big names like Pfizer   NYSE PFE    Merck   NYSE MRK    Amgen   NASDAQ AMGN    AbbVie   NYSE ABBV    and Gilead Sciences   NASDAQ GILD   lined up to report in the coming weeks  All these stocks collectively account for 22 5  share in XLV  20 8  in IYH  19 1  in VHT and 19 5  in FHLC Let s dig deeper into the earnings picture of these companies  which will drive the performance of the abovementioned funds in the coming days  see    According to our methodology  a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  when combined with a positive  increases our chances of predicting an earnings beat  while Zacks Rank  4 or 5  Sell rated  stocks are best avoided  You can uncover the best stocks to buy or sell before they re reported with our Inside Our Surprise Prediction for These StocksPfizer has a Zacks Rank  3 and an Earnings ESP of  1 94   The stock has seen positive earnings estimate revision of a penny for the to be reported quarter over the past 60 days  It delivered average four quarter positive earnings surprise of 4 07   It has a VGM Score of C  Pfizer is scheduled to report earnings on Apr 30  before the opening bell  Pfizer Inc  Price  Consensus and EPS Surprise   Merck is expected to report results on Apr 30 before market open  It has a Zacks Rank  2 and an Earnings ESP of  2 64   The stock delivered a positive earnings surprise in each of the last four quarters  with the average beat being 3 13   However  it has witnessed negative earnings estimate revision of four cents over the past 60 days for the to be reported quarter  Merck has a VGM Score of B  read    Merck   Co   Inc  Price  Consensus and EPS Surprise   Amgen carries a Zacks Rank  3 and has an Earnings ESP of  0 03   The earnings surprise track over the past four quarters is strong  with the average positive surprise being 7 26   Amgen has witnessed negative earnings estimate revision of three cents over the past 60 days for the quarter to be reported  The stock has a VGM Score of C  Amgen will report earnings on Apr 30 after market close Amgen Inc  Price  Consensus and EPS Surprise   AbbVie has a Zacks Rank  3 and an Earnings ESP of  0 89   indicating a reasonable chance of an earnings surprise  The company delivered a positive earnings surprise in the last four quarters  with the average beat being 2 58   It saw no earnings estimate revision over the past two months for the to be reported quarter  The stock has a solid VGM Score of B  The company is scheduled to report on Apr 25 before the opening bell AbbVie Inc  Price  Consensus and EPS Surprise   Gilead is expected to release earnings on May 2 after market close  It has a Zacks Rank  3 and an Earnings ESP of  1 86   Gilead delivered average positive earnings surprise of 1 99  over the last four quarters and saw negative earnings estimate revision of three cents over the past two months for the to be reported quarter  It has a VGM Score of D  read    Gilead Sciences  Inc  Price  Consensus and EPS Surprise   Summing UpWith negative earnings revisions  the healthcare sector is expected to witness earnings growth of  in the first quarter  suggesting smooth trading for healthcare ETFs  All the four ETFs have a Zacks ETF Rank  1  Strong Buy  or  2  Buy   read    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-04-17,Zacks Investment Research,https://www.investing.com/analysis/can-q1-earnings-lift-healthcare-etfs-higher-200408280,200408280
149445,370961,AMGN,US STOCKS Wall St ends up slightly in late rally led by banks,news,"  New home sales post biggest monthly gain in eight years
   Home builders  banks up after home sales data
   Amgen profit beats view  shares up after the bell
   Dow up 0 2 pct  S P up 0 3 pct  Nasdaq up 0 1 pct
  Updates to add Amgen after results  volume 
 By Rodrigo Campos
 NEW YORK  July 27  Reuters    U S  stocks rose slightly on
Monday in a late rally as investors rotated into financial
shares  which had lagged in the recent two week run up 
 Upbeat data on new home sales underpinned financial
stocks  the session s strongest sector  and prompted investors
to snap up the shares of several regional banks  which had
been among the worst hit by credit losses tied to a weak
housing market 
 Regions Financial Corp jumped 8 9 percent to  4 02 on the
New York Stock Exchange and Zions Bancorporation soared 13
percent to  12 65 on the Nasdaq  while the KBW Bank Index rose
3 1 percent 
 Financials had lagged in the previous weeks  but Friday
saw the beginning of a rotation into the sector and out of
technology  which continued Monday  according to Michael
James  senior trader at Wedbush Morgan in Los Angeles 
 The Dow Jones U S  home construction index shot up 4 3
percent after data showed U S  new home sales posted their
biggest monthly gain in eight years in June  suggesting the
housing market may be starting to recover from its worst slump
since the Great Depression of the 1930s 
 Stronger than expected earnings  coupled with upbeat
economic data  have lifted indexes recently  giving stocks
their best two week run since just after the S P 500 hit a
12 year closing low in the beginning of March  The three major
indexes rose about 11 percent each over the past two weeks 
 The Dow Jones industrial average rose 15 27 points  or
0 17 percent  to close at 9 108 51  The Standard   Poor s 500
Index gained 2 92 points  or 0 30 percent  to 982 18  The
Nasdaq Composite Index added 1 93 points  or 0 10 percent  to
end at 1 967 89 
  There was a little more willingness to bid stocks up two
weeks ago on positive earnings surprises   said Wedbush
Morgan s Michael James   You re seeing people less willing to
do that now  given the move the market has had in the last two
weeks  
 Shares of Dow component Verizon Communications fell 1 6
percent to  31 after the company reported second quarter
earnings that fell from a year ago 
 Aetna shares shed 2 7 percent to  25 72 after the company 
one of the biggest U S  providers of employer based health
insurance  cut its full year outlook  citing
higher than projected medical costs 
 AMGEN JUMPS AFTER THE BELL
 After the closing bell  shares of Amgen Inc rose 3 2
percent to  62 72 as the biotechnology company raised its
full year earnings forecast and reported a
better than expected quarterly profit  Amgen said its results
were helped by strong sales of its rheumatoid arthritis drug
and a tax benefit  The stock closed on Nasdaq at  60 77  down
0 25 percent  or 15 cents  before the release of the results 
 In the regular session  volume was light on the New York
Stock Exchange  where about 1 04 billion shares changed hands 
less than last year s estimated daily average of 1 49 billion 
On the Nasdaq  about 2 16 billion shares traded  below last
year s daily average of 2 28 billion 
 Advancers outnumbered decliners on the NYSE by a ratio of
9 to 5  while on the Nasdaq  about 13 stocks rose for every 10
that fell 
  Editing by Jan Paschal ",2009-07-27,Reuters,https://www.investing.com/news/equities-news/us-stocks-wall-st-ends-up-slightly-in-late-rally-led-by-banks-75172,75172
149446,370962,AMGN,5 Oncology Stocks Investors Should Be Watching,opinion,"Cancer is a devastating ailment that continues to be a challenge for patients and the medical professionals that dedicate their lives to treating them  Due to the difficult to treat nature of various types of cancer  many patients and physicians are left with few to no options as it relates to treatment 
If you follow news on biotechnology stocks  you ve seen that there are several companies that are working to change this  many of which have already had incredible success  both in the clinical setting and the real world setting  Moreover  these companies have driven incredible investor interest  creating market opportunities that are hard not to watch  Today  we ll talk about the top 5 companies that I believe to be presenting the strongest opportunities in the oncology space 
 1  Novartis AG  NVS    Continued Innovation Likely To Drive Further Growth
Novartis is a name that is well known in the investing community  and for good reason  While the company focuses on several disease areas  the majority of its efforts are spent within the oncology space  In fact  the company has received marketing approval for about 25 cancer fighting drugs to date  Of course  the value of this commercial stage oncology portfolio is incredible  earning the company the  220 billion  market cap that it currently enjoys 
Nonetheless  it is believed that the value of the company will continue to grow for multiple reasons  Of the most pressing are 
First and foremost  the growth in sales of the company s commercially available oncology treatments has been very strong  This shows that the team behind Novartis is highly effective when it comes to the commercialization of its drugs 
It s also worth mentioning that Novartis has an incredible oncology pipeline  In fact  the company currently has approximately 30 clinical phase programs focused on the oncology space  more than half of which are in the midst of late stage trials  Considering this  there are multiple catalysts ahead 
Finally  Novartis is actively building its pipeline  both organically and through acquisitions  In fact  the company recently acquired Advanced Accelerator Applications in a deal worth  3 9 billion as well as Endocyte in a deal worth  2 1 billion  Both of these acquisitions brought high value oncology candidates to the table 
All in all  Novartis is an oncology giant that has earned its spot at the top of the list  Moreover  the value proposition only seems to be growing as the company s work continues 
 2  Celgene  NASDAQ CELG    A Company With A Proven Record
Celgene is another company that has made a great name for themselves in the Oncology space  Currently  the company has eight treatments approved in the United States  with seven of these treatments being indicated for various forms of cancer 
Moreover  as with Novartis  Celgene has a proven ability when it comes to commercialization of these treatments  This can be seen by the strong sales growth that the company has experienced quarter over quarter and year over year for several consecutive years  On top of that  the company has greatly expanded earnings for investors over the years  In fact  in the last four quarters alone  the company has increased earnings from  1 61 per share for the quarter ending May 4  2018 to  2 20 per share for the quarter ending January 1  2019 
Key reasons to watch Celgene 
As with Novartis  Celgene has consistently produced growth in sales  leading to strong growth in revenue as well as earnings per share  With the company s positive track record in terms of sales growth  there s no reason to expect a plateau any time soon 
Also  the company has an impressive pipeline of products under development  In fact  there are 19 clinical development programs currently taking place at the company  These development programs are centered around the treatment of three of the most difficult to treat types of cancer  and many of them have already yielded positive results 
Finally  while Celgene is incredibly active in the oncology space  the company is also active among other high value indications  Two of the highest value indications in this list include Myelofibrosis and Multiple Sclerosis 
 3  Cellectar Biosciences  CLRB    A Highly Undervalued Oncology Play
Cellectar Biosciences is a relatively small company  with a market cap of just over  10 million  However  the low market cap actually provides the basis for many bullish opinions as compared to others at its level  it is highly undervalued  Nonetheless  a feeling of undervaluation isn t necessarily the motive for a decision to get involved in a stock  Nonetheless  there are several reasons to be excited here 
Cellectar Bioscience is a clinical stage oncology company that may be on the verge of a significant breakthrough  The company s claim to fame is its proprietary Phospholipid Drug Conjugates  or PDCs  This proprietary technology gives the company the ability to target cancerous tumors in a way that is unmatched elsewhere  and it is the delivery method that has proven to be effective through multiple clinical trials of its flagship candidate  CLR 131 
Key reasons to watch Cellectar Biosciences 
First and foremost  the company s proprietary PDC delivery method comes with several benefits  Due to the highly targeted nature of this delivery method  radiation is proportionately delivered to tumor cells  avoiding surrounding tissue and leading to a low risk of serious adverse events  SAEs   In fact  to date  there have been no SAEs reported in any clinical trials for the treatment  In the treatment of cancer  this is unheard of 
Another reason to keep tabs on Cellectar Biosciences is that the company has several catalysts ahead  In fact  the company is expecting to share a minimum of 7 clinical data readouts with investors in the year 2019 alone  This  combined with interim analysis announcements  potential presentations  and peer reviewed publications  means that catalysts are likely to come in droves ahead  leading to strong potential opportunities 
Finally  the company is not targeting the easy to treat populations that we see with other companies on the list  Instead  their clinical trials have included patients that have already received at least 5 prior lines of therapy  With potential efficacy dropping off of a cliff after the third line of therapy  this can be a very risky move  However  in a recent clinical trial  the company showed that even in this difficult to treat patient population  CLR 131 was able to extend overall survival by 22 months  This is an unheard of accomplishment in the addressed patient population 
 4  Amgen  NASDAQ AMGN    Taking Proactive Steps To Further Improve Shareholder Value
Next in the line  we have Amgen  This is yet another company with a proven history in oncology  Currently  Amgen has 17 therapies that are approved for commercialization in the United States  Of these  nearly half  8  have been approved for oncology related indications 
Through the years  Amgen has shown its ability to successfully commercialize treatments  earning a market cap of more than  116 billion  However  the company s previous success isn t the only reason that this oncology stock is one to keep an eye on 
Key reasons to watch Amgen 
As with many of the companies on this list  Amgen has a proven track record of solid growth in sales  As a result  the company has experienced strong revenue growth and earnings growth  providing an incredible return of value to its investors by consistently growing earnings  which have beat analyst expectations for the past four consecutive quarters 
Amgen is also making smart moves with regard to targeted indications  In fact  the company currently has a pipeline that includes 35 programs  most of which are targeting serious conditions with few to no options for patients and the physicians treating them  As a result of this focus on serious conditions with high medical need  the company has earned various Orphan Drug Designations and is well positioned to take the lion s share of various markets as these pipeline products make their way to commercialization 
Finally  Amgen is on an acquisition hunt at the moment  As generic competition starts to encroach on sales  the company is working to increase value for investors by acquiring others that have products with the potential to drive strong revenue increases  When companies of this size make proactive moves to combat potentially declining sales  we generally see strong growth in value in the long run 
 5  Exelixis  EXEL    A Blockbuster Product And A Strong Pipeline Make This Hard To Ignore
Finally  we have Exelixis  With a market cap of just over  7 billion  this is an up and coming oncology company that could quickly grow to a valuation like what we ve see with Celgene and Novartis 
The company s flagship product is known as Cabometyx  The treatment was designed as a second line option for renal cell carcinoma  also known as RCC  In both clinical and real world settings  Cabometyx has proven to be effective  improving objective response rates  progression free survival rates  and overall survival rates 
Key reasons to keep an eye on Exelixis 
First and foremost  Cabometyx is a blockbuster drug  In 2018  the treatment generated  619 million in sales  showing an impressive 77  year over year increase  Moreover  the FDA recently expanded the label of the drug to include second line advanced hepatocellular carcinoma  HCC  as an approved indication  This could lead to strong sales growth in the year ahead as the commercial rollout for this indication hits full swing 
Also  Exelixis isn t planning on putting a halt to innovation any time soon  In fact  the company recently submitted several Investigational New Drug  IND  applications to the FDA  The ultimate goal is to develop XL092 as an option for various types of cancer  Although XL092 is currently in the early stages of development  the treatment has shown promising preclinical data and could be yet another blockbuster down the line 
Finally  according to Finviz  institutional investor interest is incredibly high  with institutional investors currently holding well over 70  of shares 
Final Thoughts
The oncology space is an exciting one to follow  With a massive market opportunity in any cancer indication  and innovation taking place at a rapid rate  investor interest in the space is climbing and will likely continue to do so  With the advancements the companies above have made and are continuing to make in the space  these stocks are hard to ignore 
Original post",2019-04-18,Modest Money,https://www.investing.com/analysis/5-oncology-stocks-that-investors-should-be-watching-200408089,200408089
149447,370963,AMGN,Analysts Estimate Amgen  AMGN  To Report A Decline In Earnings  What To Look Out For,opinion,"Amgen  AMGN  is expected to deliver a year over year decline in earnings on lower revenues when it reports results for the quarter ended March 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The earnings report  which is expected to be released on April 30  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This world s largest biotech drugmaker is expected to post quarterly earnings of  3 39 per share in its upcoming report  which represents a year over year change of  2 3  
Revenues are expected to be  5 55 billion  down 0 1  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1 93  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Amgen 
For Amgen  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 06  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Amgen will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Amgen would post earnings of  3 26 per share when it actually produced earnings of  3 42  delivering a surprise of  4 91  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Amgen doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-22,Zacks Investment Research,https://www.investing.com/analysis/analysts-estimate-amgen-amgn-to-report-a-decline-in-earnings-what-to-look-out-for-200409586,200409586
149461,370977,AMGN,Pfizer s New Lung Cancer Drug Vizimpro Gets EU Approval ,opinion,Pfizer  Inc    NYSE PFE   announced that the European Commission has granted marketing approval to its tyrosine kinase inhibitor  Vizimpro  dacomitinib  for the first line treatment of metastatic non small cell lung cancer  NSCLC  in patients with EGFR activating mutations  This new lung cancer medicine was approved in the United States last September Vizimpro s  45 mg approval in EU was expected as in February the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  had granted a positive opinion recommending approval of Vizimpro  The drug holds immense sales potential as EGFR mutated NSCLC is a disease that is associated with low overall survival rates Including Vizimpro  in oncology  Pfizer gained FDA approval for four innovative medicines in the last four months of 2018  which has strengthened its oncology portfolio  These include Daurismo  glasdegib  for previously untreated AML  Lorbrena  lorlatinib  for second line non small cell lung cancer and Talzenna  talazoparib   an orally available PARP inhibitor for advanced breast cancer Shares of Pfizer have declined 1 8  so far this year against the  s 4 8  increase   Moreover  two leukemia treatments   Besponsa inotuzumab ozogamicin for relapsed refractory acute lymphoblastic leukemia  ALL  and Mylotarg for newly diagnosed CD33 positive AML   were approved in the United States in 2017 A key candidate in the oncology pipeline is Bavencio  avelumab   which is being evaluated for different types of cancer  Bavencio is already approved in metastatic Merkel cell carcinoma and for second line treatment of locally advanced or metastatic urothelial carcinoma  Bavencio  though approved for two small indications currently  could be a key long term growth driver for Pfizer if it can gain label expansion approvals Pfizer has 30 ongoing studies in the avelumab development program involving more than 9 000 patients across 15 tumor types  The studies include double triple combination studies for chemotherapy and targeted therapies and several avelumab combination therapies with immuno oncology agents are under development  Pfizer has developed Bavencio in partnership with Germany s Merck KGaA  Pfizer is als oventuring into the oncology biosimilars space  In Europe and United States  Pfizer markets biosimilar versions of Amgen s   NASDAQ AMGN   drugs  Neupogen and Epogen  A biosimilar version of Roche s   OTC RHHBY   cancer drug Herceptin  trade name  Trazimera  was approved by the FDA in March  Biosimilar versions of Roche s other cancer drugs Rituxan and Avastin  trade name  Zirabev  are also under review in the United States with FDA decisions on all expected in 2019  Biosimilar versions of Herceptin and Avastin are already approved in the EU while that of Rituxan is under review in the EU  Pfizer is evaluating several biosimilar molecules in various stages of development In fact  oncology drugs have been a key driver of Pfizer s sales  accounting for more than 13  of its total sales in 2018  Oncology revenues increased 30  to  1 91 billion in 2018  Its marketed oncology drugs are Ibrance Sutent  Inlyta  Bosulif and others  Pfizer also gets a share of profit from its alliance with Japan s Astellas Pharma for Xtandi Pfizer currently carries a Zacks Rank  3  Hold  You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-04-03,Zacks Investment Research,https://www.investing.com/analysis/pfizers-new-lung-cancer-drug-vizimpro-gets-eu-approval-200403882,200403882
149462,370978,AMGN,Why Amgen  AMGN  Is Poised To Beat Earnings Estimates Again,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering Amgen  AMGN   which belongs to the Zacks Medical   Biomedical and Genetics industry 
This world s largest biotech drugmaker has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 6 40  
For the last reported quarter  Amgen came out with earnings of  3 42 per share versus the Zacks Consensus Estimate of  3 26 per share  representing a surprise of 4 91   For the previous quarter  the company was expected to post earnings of  3 42 per share and it actually produced earnings of  3 69 per share  delivering a surprise of 7 89  
Price and EPS Surprise

Thanks in part to this history  there has been a favorable change in earnings estimates for Amgen lately  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the stock is positive  which is a great indicator of an earnings beat  particularly when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Amgen currently has an Earnings ESP of  4 31   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  3  Hold  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on April 30  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-04-04,Zacks Investment Research,https://www.investing.com/analysis/why-amgen-amgn-is-poised-to-beat-earnings-estimates-again-200404306,200404306
149464,370980,AMGN,Novartis   Amgen In Legal Dispute Over Migraine Drug Aimovig ,opinion,"Swiss pharma giant Novartis AG   NYSE NVS   announced it is suing partner Amgen   NASDAQ AMGN   Both the companies had a development and worldwide commercialization agreement for migraine drug  Aimovig  erenumab  Aimovig is designed specifically to block the calcitonin gene related peptide receptor  CRGP   Per Novartis  Aimovig is the first FDA and EMA approved CGRP targeted therapy for the prevention of migraine in adults  The drug was approved in the United States in May and EU in July 2018  Both the companies co commercialize the drug in the United States  While Amgen has exclusive rights to commercialize the drug in Japan  Novartis has exclusive commercialization rights in the rest of the world However  on Apr 2  2019  Amgen issued a notice of termination for the migraine collaboration agreements with Novartis due to an alleged material breach of the same Consequently  Novartis has filed a lawsuit asking the court to confirm that Amgen has no right to terminate the agreements CRGP are a new class of drugs  which are designed to reduce the number of migraine attacks and have fewer adverse reactions in clinical trials  and lesser warnings and precautions compared to other approved migraine therapeutics  Other drugs in this category are Teva s   NYSE TEVA   Ajovy and Eli Lilly s   NYSE LLY   Emgality The uptake of the drug has been encouraging  and more than 165 000 patients worldwide have been treated with Aimovig since launch Shares of the company have gained 12 7  in the past six months compared with the  s 2 7  growth  Last year was a transformative one for Novartis  as it restructured its business to become a core drug focused company  powered by data and digital technologies  The company acquired U S  based clinical stage gene therapy company  AveXis  Inc in 2018  Novartis also acquired Endocyte to expand expertise in radiopharmaceuticals  We expect more acquisitions in the coming months  as the company looks to further restructure its business Zacks Rank
Novartis currently carries a Zacks Rank  3  Hold    You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-04,Zacks Investment Research,https://www.investing.com/analysis/novartis--amgen-in-legal-dispute-over-migraine-drug-aimovig-200404298,200404298
149466,370982,AMGN,The Zacks Analyst Blog Highlights  Pfizer  Teva  Novartis  Merck And AstraZeneca,opinion,"For Immediate Release
Chicago  IL   April 8  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Pfizer   NYSE PFE    Teva   NYSE TEVA    Novartis   NYSE NVS    Merck   NYSE MRK   and AstraZeneca   NYSE AZN   
Here are highlights from Friday s Analyst Blog  
Pharma Stock Roundup  PFE  TEVA  NVS   More
This week Pfizer and Teva gained marketing approval from the European Commission for their new medicines  While Pfizer gained approval for its new lung cancer medicine  Vizimpro  Teva s CGRP injection  Ajovy was approved in EU  Meanwhile  Novartis announced plans to acquire IFM Tre  a subsidiary of privately held IFM Therapeutics  The acquisition will give Novartis full rights to IFM s two NLRP3 inhibitors  Meanwhile  Novartis  blockbuster psoriasis drug  Cosentyx was approved in China while Merck s Keytruda was approved in the country for first line lung cancer as a combination therapy 
Recap of the Week s Most Important Headlines
Teva   Pfizer s Medicines Get Approval in EU  Teva s CGRP injection  Ajovy was granted for the prophylaxis of migraine in adult patients who experience at least four migraine days per month  Ajovy  fremanezumab   for prevention of chronic episodic migraine  was approved in the United States in September last year and has been enjoying strong demand since launch 
Pfizer also for its new lung cancer medicine  Vizimpro  dacomitinib  that was approved in the United States last September  Vizimpro  dacomitinib   a tyrosine kinase inhibitor  is now approved in EU for the first line treatment of metastatic non small cell lung cancer  NSCLC  in patients with EGFR activating mutations 
Novartis  New Immunology Acquisition  Novartis announced plans to   a subsidiary of Boston based IFM Therapeutics  for an upfront payment of  310 million upfront  In addition  IFM will also be eligible to earn up to  1 265 billion in milestone payments  The deal will give Novartis full rights to IFM s two NLRP3 inhibitors   one clinical and two preclinical  These medicines target the NLRP3 inflammasome  a key component of the innate immune system  thereby providing a novel approach to preventing chronic inflammation that results in serious disease  The deal complements Novartis  existing pipeline of anti inflammatory medicines  The transaction is expected to close in the second quarter of 2019 
Meanwhile  Novartis  blockbuster psoriasis drug    Cosentyx  a first in class interleukin 17A  IL 17A  inhibitor  is the first biologic approved in China for moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy 
Novartis  generic arm  Sandoz announced to the FDA looking for approval of its biosimilar version of Amgen s neutropenia drug  Neulasta   Novartis had earlier in June 2016 received a complete response letter from the FDA for the same  Neutropenia is one of the most serious side effects of chemotherapy 
Novartis also notified of a dispute with Amgen  NASDAQ AMGN  relating to their collaboration agreement for the newly launched migraine medicine  Aimovig  Novartis said that Amgen issued a notice of termination of the agreement on Apr 2  Novartis strongly disputes the notice and has sued Amgen accusing the biotech of making an unjustifiable attempt to end the collaboration with Novartis 
Merck s Keytruda Gets Approval in China for First Line Lung Cancer  Merck announced that the  has granted conditional approval to Keytruda in combination with Lilly s Alimta  pemetrexed  and platinum chemotherapy for the first line treatment of metastatic non squamous non small cell lung cancer  NSCLC  with no EGFR or ALK genomic tumor aberrations  The approval was based on significant survival benefit demonstrated in a key late stage lung cancer study  KEYNOTE 189  Notably  data from the KEYNOTE 189 study is already included in Keytruda s U S  and EU label 
FDA Grants AstraZeneca Merck s Selumetinib Breakthrough Therapy Status  AstraZeneca and Merck s MEK 1 2 inhibitor   by the FDA for the treatment of neurofibromatosis type 1  NF1  related plexiform neurofibromas  an incurable genetic condition that affects newborns  Selumetinib is being evaluated in a phase II SPRINT study in pediatric patients with inoperable NF1 related PN  which formed the basis of the designation 
Pfizer Sangmo Announce Promising Data on Gene Therapy Candidate  Pfizer and its partner  Sangamo Therapeutics announced from a phase I II study evaluating their gene therapy candidate  SB 525  for treating hemophilia A  Data from the study showed that patients treated with the highest dosage of SB 525  3e13 vg kg  achieved normal factor VIII levels  Dose dependent increase in factor VIII levels was observed in eight patients treated with SB 525 gene therapy across the four dosage cohorts  Excess levels of factor VIII increase blood clotting  which is a major symptom of haemophilia  Based on the data from the study  the Safety Monitoring Committee  SMC  recommended expansion of the 3e13 vg kg cohort 
Meanwhile  Pfizer s breast cancer drug Ibrance in combination with an aromatase inhibitor or fulvestrant gained FDA s approval for the treatment of men with HR   HER2  metastatic breast cancer 
The NYSE ARCA Pharmaceutical Index declined 1  in the last five trading sessions 

All the stocks were in the red in the last five trading sessions  except Pfizer  which rose 1 1   AstraZeneca declined the most  5 7   
 See the last pharma stock roundup here   
What s Next in the Pharma World 
Watch out for pipeline and regulatory updates next week 
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year 
Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  

Media Contact
Zacks Investment Research
800 767 3771 ext  9339
 
 
Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2019-04-07,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-pfizer-teva-novartis-merck-and-astrazeneca-200404834,200404834
149468,370984,AMGN,Amgen s  AMGN  Osteoporosis Drug Evenity Gets FDA Approval,opinion,"Amgen  Inc    NASDAQ AMGN   and its partner UCB announced that the FDA has approved Evenity  romosozumab aqqg  for treating osteoporosis in postmenopausal women at high risk of fracture Evenity is the first and only approved drug for osteoporosis to increase bone mineral density   BMD   and reduce the risk of fracture  The drug had received approval for a similar indication in postmenopausal women as well as men in Japan in January  A regulatory application is under review in Europe We remind investors that a regulatory application seeking approval for Evenity in the United States was issued a complete response letter by the FDA in 2017 due to a cardiovascular side effect observed in a study Please note that the current approval for Evenity by the FDA comes with a boxed warning  The drug s label states that treatment with Evenity may increase risk of myocardial infarction  heart attack   stroke and cardiovascular death and that it should not be administered to patients who have suffered heart attack or stroke in the preceding year  The company is also required to conduct a post marketing study to evaluate the cardiovascular safety of Evenity in postmenopausal osteoporosis women Shares of the company have declined 0 9  so far this year against the  s increase of 11 4  in that period The approval for Evenity in the United States is backed by data from two late stage clinical studies   FRAME and ARCH Data from the FRAME study demonstrated that treatment with the drug led to significant reduction in new vertebral  spine  fracture compared to placebo at 12 months  A follow up treatment with Amgen s another osteoporosis drug Prolia  denosumab  maintained the reduction in fracture risk over the next 12 months  Moreover  treatment with Evenity in the first year and a follow up treatment with Prolia showed increase in bone mineral density   BMD   The ARCH study data showed that treatment with Evenity in the first year and a follow up treatment with Merck s   NYSE MRK   Fosamax  alendronate  resulted in statistically significant reduction in new vertebral fracture in patients  A similar treatment regimen in the first 24 months showed significantly increased BMD compared to a regimen consisting of Fosamax alone Per the press release  there are approximately 10 million people suffering from osteoporosis in the United States  which leads to two million fractures every year  More than 600 000 patients require hospital or nursing home admission for osteoporosis related fractures annually  The osteoporosis market is expected to reach  25 3 billion by 2025  These factors represent a good opportunity for Evenity in the country and the dual nature of efficacy  increase in BMD and reduction in fracture risk  may boost demand for the drug Radius Health s   NASDAQ RDUS   Tymlos injection  which received approval for treating postmenopausal women with osteoporosis at a high risk of fracture in 2017  had a strong 2018 with sales growing sequentially in every quarter to reach almost  100 million  Evenity is likely to face competition from Tymlos  There are several other approved drugs for osteoporosis including Novartis    NYSE NVS   Reclast Amgen Inc  Price
    Zacks RankAmgen currently carries a Zacks Rank  3  Hold   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-09,Zacks Investment Research,https://www.investing.com/analysis/amgens-amgn-osteoporosis-drug-evenity-gets-fda-approval-200405588,200405588
149469,370985,AMGN,Akebia Expands Vadadustat Licensing Deal With Vifor Pharma,opinion,"Akebia Therapeutics  Inc    NASDAQ AKBA   and Switzerland based Vifor Pharma Group amended the license agreement to sell vadadustat in the United States to include certain third party dialysis organizations The original agreement  signed in 2017  allowed Vifor Pharma to sell vadadustat  following an FDA approval  solely to dialysis clinics of Fresenius Medical Care North America  Per the amended terms of the agreement  Vifor Pharma will be eligible to sell vadadustat to certain third party dialysis organizations in the United States  which will help the drug to cover 60  of the U S  dialysis patient population Akebia is evaluating vadadustat  an oral hypoxia inducible factor   HIF   prolyl hydroxylase inhibitor  in late stage global development programs for treatment of anemia due to chronic kidney disease   CKD   Shares of the company have increased 34 9  so far this year compared with the  s rise of 16 7   The amended terms of the agreement make Akebia eligible to receive  25 million  an additional  5 million  from Vifor Pharma upon potential approval of vadadustat and determination of the reimbursement system for the drug by the Centers for Medicare   Medicaid  The license agreement  upon amendment  will remain valid for two CMS reimbursement programs   End Stage Renal Disease Prospective Payment System and Transitional Drug Add on Payment Adjustment In March  Akebia announced positive top line data from four phase III studies evaluating the candidate in patients in Japan with anemia due to CKD  Data from the studies showed that vadadustat met the primary endpoint of non inferiority to Amgen s   NASDAQ AMGN   Aranesp  darbepoetin alfa  in improving mean hemoglobin level from baseline after treatment for 20 and 24 weeks  The company plans to submit a regulatory application in Japan seeking approval for vadadustat later this year  Pivotal studies to support approval of the candidate in the United States and Europe are currently underway Vadadustat may face competition upon approval from already approved drugs for anemia in CKD patients  The already approved drugs include Amgen s Epogen and Aranesp and J J s   NYSE JNJ   Procrit and Eprex  Several other pharma companies are developing candidates with similar mechanism including FibroGen   NASDAQ FGEN   and Glaxo Akebia has one product in its marketed portfolio  Auryxia  approved for two indications   to control serum phosphorus levels in CKD patients and to treat iron deficiency anemia in patients with CKD  Sales of the drug were encouraging in 2018  increasing 72  year over year to  96 million We remind investors that in December Akebia completed its merger with Keryx Biopharmaceuticals to boost its pipeline of renal candidates Akebia Therapeutics  Inc  Price
    Zacks RankAkebia currently carries a Zacks Rank  3  Hold   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-09,Zacks Investment Research,https://www.investing.com/analysis/akebia-expands-vadadustat-licensing-deal-with-vifor-pharma-200405583,200405583
149487,371003,AMGN,Teva s Anti CGRP Injection Ajovy Gets Approval In Europe,opinion,Teva Pharmaceutical Industries Ltd    NYSE TEVA   announced that its anti calcitonin gene related peptide   CGRP   injection  Ajovy  was granted marketing approval by the European Commission for prophylaxis of migraine in adult patients who experience at least four migraine days per month With the approval  Ajovy becomes the first and the only anti CGRP treatment to secure a nod in the EU with monthly and quarterly dosing options for patients to follow The approval was expected as in February  the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  had adopted a positive opinion  recommending approval of AjovyThis generic drugmaker s shares have risen 1 9  this year so far compared with the  s increase of 9 6    Ajovy  fremanezumab   for prevention of chronic episodic migraine  was approved by the FDA in September last year  Regarding its launch uptake in the United States  Teva said  on the fourth quarter conference call in February  that Ajovy has been performing strongly  enjoying growing demand due to its flexible dosing options   quarterly and monthly  Teva said that Ajovy has captured around 30  of new to brand patients  Ajovy recorded sales of  3 million in 2018  On the call  the company guided sales of approximately  150 million in the United States in 2019  With the approval in Europe  sales of Ajovy should be higher However  Ajovy faces intense competition from Amgen   NASDAQ AMGN   Novartis   NYSE NVS   and Lilly s   NYSE LLY   CGRPs  Aimovig and Emgality  respectively  Both were also approved by the FDA in mid 2018  Both are also approved in EU Fremanezumab is also being evaluated in a late stage study for episodic cluster headache and in a mid stage study for post traumatic headache  Teva is optimistic that Ajovy could emerge as significant contributor to its long term sales growth Teva currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/tevas-anticgrp-injection-ajovy-gets-approval-in-europe-200403049,200403049
149488,371004,AMGN,Merck s Keytruda Gets Nod For First Line Lung Cancer In China,opinion,"Merck   Co   Inc    NYSE MRK   announced that its PD L1 therapy  Keytruda  has gained conditional approval for use in combination with chemotherapies for first line metastatic nonsquamous non small cell lung cancer   NSCLC   in China  The drug received approval in combination with Eli Lilly s   NYSE LLY   Alimta  pemetrexed  and platinum chemotherapy in adult lung cancer patients whose tumors have no EGFR or ALK positive mutations A confirmatory study on Chinese patients is required for continued approval in the aforementioned indication  The drug is approved for a similar indication in the United States and Europe  Keytruda is already approved for advanced melanoma in China The approval was based on data from a pivotal KEYNOTE 189 study  which demonstrated superiority of Keytruda combination regimen in improving overall survival   OS   and progression free survival   PFS   over chemotherapy  The Keytruda combination significantly improved overall survival  reducing the risk of death by half  51   compared to chemotherapy alone  Meanwhile  PFS was also significantly improved  The risk of progression or death was reduced by nearly half  48   in patients in the Keytruda combination arm versus chemotherapy alone So far this year  Merck s shares have outperformed the   rising 9  compared with a 4 9  increase for the industry Keytruda has   in a very short time  become the single largest revenue generator for the company with sales of more than  7 billion in 2018  Merck has successfully expanded Keytruda s label over the years  a significant one being for the first line lung cancer indication Meanwhile  several other pharma companies are looking to get their drugs approved in first line NSCLC  In June 2018  AstraZeneca s   NYSE AZN   Tagrisso received approval for first line NSCLC in Europe The approval in China in first line lung cancer is likely to further boost the prospects of the drug due to a huge patient population in the country  Per the press release  more than 626 000 patients die in China due to lung cancer every year The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 800 studies  including more than 400 combination studies  Merck is collaborating with several companies including Amgen  NASDAQ AMGN   Incyte  NASDAQ INCY   Glaxo   NYSE GSK   and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens  These include several lung cancer studies across multiple settings and stages of the disease  both as a monotherapy as well as a combination therapy Merck   Co   Inc  Price
    Zacks RankMerck currently has Zacks Rank  2  Buy   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-gets-nod-for-firstline-lung-cancer-in-china-200403193,200403193
149489,371005,AMGN,Novartis Resubmits BLA To FDA For Biosimilar Of Neulasta ,opinion,"Novartis AG s   NYSE NVS   generic arm  Sandoz  resubmitted its Biologics License Application  BLA  for a proposed biosimilar of Neulasta to the FDA The BLA was resubmitted to the FDA to address the issues mentioned in the complete response letter  CRL  received in June 2016  The resubmission includes new data from a pivotal pharmacokinetics  PK  and pharmacodynamics  PD  study We note that Neulasta is a long acting version of Neupogen and is used primarily to help reduce the chance of infection due to a low white blood cell count in patients with certain types of cancer  nonmyeloid   who receive anticancer medicines  chemotherapy  that can cause fever and reduce blood cell count We note that Sandoz is one of the strongest players in the biosimilars market  Ziextenzo  the biosimilar of Neulasta  has already been launched in Europe in November 2018  The company has three approved biosimilars in the United States and markets eight biosimilars in the European Economic Area  EEA  Among these  Hyrimoz  a biosimilar of Humira  was launched in the EU in October 2018  It is also approved in the United States  However  Novartis cannot launch Hyrimoz in the United States until October 2023  per a settlement with AbbVie  Inc    NYSE ABBV    Zessly  a biosimilar of Remicade  was launched in the EU in November 2018   The FDA approved Erelzi  a biosimilar of Enbrel  in 2016 but the launch is pending litigation with Amgen  Inc    NASDAQ AMGN   Meanwhile  Sandoz received a CRL from the FDA in May 2018 for a biosimilar of Rituxan and has decided thereafter not to pursue it any further as of now We remind investors that the Sandoz business has suffered significant declines in sales and profits in the United States due to increased competition in its product segments  The company has agreed to sell the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo Pharma USA Inc Shares of the company have gained 12 9  in the past six months compared with the  s 3 6  growth The last year was a transformative one for Novartis  as it restructured its business to become a core drug focused company  powered by data and digital technologies  Novartis acquired U S  based clinical stage gene therapy company  AveXis  Inc in 2018  The company also acquired Endocyte to expand expertise in radiopharmaceuticals  We expect more acquisitions in the coming months  as the company looks to further restructure its business Approval of new drugs and label expansion of existing drugs bode well for Novartis  as it looks to streamline its business  The company sold its stake in consumer healthcare joint venture to GlaxoSmithKline   NYSE GSK   for  13 billion Zacks Rank
Novartis currently carries a Zacks Rank  3  Hold    You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-04-03,Zacks Investment Research,https://www.investing.com/analysis/novartis-resubmits-bla-to-fda-for-biosimilar-of-neulasta-200403948,200403948
149509,371025,AMGN,Roche s  RHHBY  Tecentriq Gets FDA Approval For Breast Cancer,opinion,Roche Holdings AG   OTC RHHBY   announced that the FDA has granted accelerated approval to immuno oncology drug  Tecentriq in combination with Celgene Corporation s   NASDAQ CELG   Abraxane for the treatment of adults with unresectable locally advanced or metastatic triple negative breast cancer  TNBC  in patients whose tumors express PD L1  as determined by an FDA approved test The accelerated approval was based on encouraging data from the phase III IMpassion130 study  which showed that the combination significantly reduced the risk of disease worsening or death  PFS  by 40  compared with nab paclitaxel alone The FDA generally grants conditional approval to a medicine that fills an unmet medical need for a serious or life threatening disease or condition  under its Accelerated Approval Program  However  continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial s  Per Roche  Tecentriq combination is the first cancer immunotherapy regimen to be approved in breast cancer Concurrently  Roche announced that the FDA also approved VENTANA PD L1  SP142  Assay2 as the first companion diagnostic to help in identifying TNBC patients who are eligible for treatment with cancer immunotherapy  Tecentriq plus chemotherapy  Abraxane  paclitaxel protein bound particles for injectable suspension  albumin bound   nab paclitaxel   Roche has a strong presence in the oncology market  In particular  the company dominates the breast cancer space with strong demand for its HER2 franchise drugs  The HER2 franchise includes Herceptin  Perjeta and Kadcyla  Growth in Herceptin is being driven by growing demand in both the United States and Europe  The approval of Tecentriq will further boost the company s franchise Breast cancer is the one of the most common cancer among women worldwide  Per the American Cancer Society  approximately 271 000 people in the United States will be diagnosed with breast cancer with an estimated 42 000 deaths in 2019 alone Last week  the European Commission  EC  granted marketing authorization to Tecentriq in combination with Avastin  paclitaxel and carboplatin for the first line treatment of adults with metastatic non squamous non small cell lung cancer  NSCLC   Meanwhile  Tecentriq is already approved in the European Union and the United States for previously treated metastatic NSCLC and for certain types of untreated or previously treated metastatic urothelial carcinoma  mUC   The FDA had earlier approved Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with metastatic non squamous NSCLC Tecentriq sales came in at CHF772 million in 2018  up 59  from 2017  Label expansion of the drug for other indications should further boost sales Roche s stock has gained 11 2  in the past six months compared with the  growth of 3  Approval of new drugs and label expansion of existing drugs bode well for the company as biosimilars pose stiff competition for some of its key drugs such as Avastin  Rituxan and Herceptin in the long term   Novartis   NYSE NVS   has already launched its bisomilar version of Rituxan MabThera in Europe  Amgen   NASDAQ AMGN   also obtained FDA approval for a biosimilar version of Avastin for the treatment of five types of cancers  including lung cancer  colorectal cancer  glioblastoma  renal cell carcinoma and cervix cancer Zacks RankRoche currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-03-11,Zacks Investment Research,https://www.investing.com/analysis/roches-rhhby-tecentriq-gets-fda-approval-for-breast-cancer-200396936,200396936
149511,371027,AMGN,Pfizer s Herceptin Biosimilar Trazimera Gets FDA Approval,opinion,Pfizer  Inc    NYSE PFE   announced FDA approval of Trazimera  a biosimilar version Roche s   OTC RHHBY   breast cancer drug  Herceptin Trazimera is approved for the treatment of HER2 overexpressing breast cancer and HER2 overexpressing metastatic gastric cancer  We remind investors that in April last year  the FDA had given a complete response letter  CRL  to Pfizer s biologics license application  BLA  for Herceptin biosimilar  The FDA  back then  had asked for additional technical information though it was not related to safety or clinical data submitted in the application The BLA filing was based on a comprehensive data package  which included data from the REFLECTIONS B3271002 study  a comparative safety and efficacy study of Trazimera in combination with paclitaxel versus a combination of Herceptin and paclitaxel in first line patients with HER2 positive metastatic breast cancer  Data from the study showed that the primary endpoint of objective response rate  ORR  was equivalent for Trazimera and Herceptin We remind investors that in January this year  Samsung  KS 005930  Bioepis Co   Ltd and its partner  Merck received FDA approval for their Herceptin biosimilar  Ontruzant  Ontruzant was Samsung Bioepis  first oncology biosimilar to receive FDA approval  In December last year  Celltrion and Teva Pharmaceutical  NYSE TEVA  Industries  biosimilar version of Herceptin  Herzuma gained FDA s approvalPfizer s shares have declined 4 9  this year so far against an increase of 2 1  for the    Trazimera is Pfizer s first oncology biosimilar to get approved in the United States  At present  in the United States  Pfizer marketsInflectra  its first biosimilar version of J J Merck s Remicade which was launched inNovember 2016  In Europe and United States  Pfizer also markets biosimilar versions of Amgen s   NASDAQ AMGN   drugs  Neupogen and Epogen Gradually  Pfizer is venturing into the oncology biosimilars space  Biosimilar versions of Roche s other cancer drugs Rituxan and Avastin  Zirabev  arealsounder review in the United States with FDA decisions on all expected in 2019  With a biosimilar version of AbbVie s   NYSE ABBV   Humira also under review in the United States  Pfizer expects potential U S  approvals for up to four biosimilar products in 2019 Biosimilar versions of Herceptin and Avastin are already approved in the EU while that of Rituxan is under review in the EU  Meanwhile  Pfizer is evaluating several biosimilar molecules in various stages of development Pfizer currently carries a Zacks Rank  4  Sell  You can seeToday s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-03-11,Zacks Investment Research,https://www.investing.com/analysis/pfizers-herceptin-biosimilar-trazimera-gets-fda-approval-200396979,200396979
149512,371028,AMGN,Roche Receives EC Approval For Label Expansion Of Hemlibra,opinion,"Roche   OTC RHHBY   announced that the European Commission  EC  has approved a label expansion of hemophilia drug  Hemlibra  emicizumab  The drug is now approved for routine prophylaxis of bleeding episodes in patients with severe hemophilia A  congenital factor VIII deficiency  FVIII  1   without factor VIII inhibitors The approval was based on encouraging results from the HAVEN 3 and HAVEN 4 studies An approval was on the cards as the EU Committee for Medicinal Products for Human Use   CHMP   had given a positive opinion on the same We remind investors that the FDA has also approved Hemlibra to prevent or reduce the frequency of bleeding episodes in adults and children  newborn or older  without hemophilia A without factor VIII inhibitors in October 2018 The drug is already approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in people with hemophilia A with factor VIII inhibitors in more than 60 countries worldwide Hence  the drug can be used for all indicated people with hemophilia A  including those with factor VIII inhibitors with multiple dosing options  once weekly  every two weeks  or every four weeks   A label expansion of the drug should further boost sales Roche s hematology portfolio comprises approved drugs like MabThera Rituxan  Tecentriq  Gazyva and Venclexta in collaboration with AbbVie   NYSE ABBV   The pipeline includes polatuzumab vedotin and a small molecule that inhibits the interaction of MDM2 with p53  idasanutlin RG7388  In February 2019  the FDA accepted the company s Biologics License Application  BLA  for anti CD79b antibody drug conjugate  ADC  polatuzumab vedotin in combination with bendamustine plus Rituxan  BR   for the treatment of patients suffering from relapsed or refractory  R R  diffuse large B cell lymphoma  DLBCL   The FDA also granted Priority Review status to the candidate  A decision from the FDA is expected by Aug 19  2019 Roche s stock has gained 12 2  in the past six months compared with the  s growth of 3 4   Approval of new drugs and a potential label expansion of existing drugs bode well for Roche  as its legacy drugs like Herceptin and MabThera are facing competition from biosimilars Novartis   NYSE NVS   has already launched its biosimilar version of Rituxan MabThera in Europe  Amgen   NASDAQ AMGN   also obtained FDA approval for a biosimilar version of Avastin for the treatment of five types of cancers  including lung  colorectal  glioblastoma  renal cell carcinoma and cervix  Entry of biosimilars of these key drugs adversely impacted sales in Europe in 2018 Zacks Rank
Roche currently carries a Zacks Rank  3  Hold   You can see   Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-13,Zacks Investment Research,https://www.investing.com/analysis/roche-receives-ec-approval-for-label-expansion-of-hemlibra-200397729,200397729
149513,371029,AMGN,Roche Gets Approval For Label Expansion Of MabThera In Europe,opinion,"Roche Holdings AG   OTC RHHBY   announced that the European Commission has approved a label expansion of its rheumatoid arthritis  RA  drug  MabThera 
The drug is now approved in Europe for the treatment of adults with moderate to severe pemphigus vulgaris  PV  
Per Roche  MabThera is the first biologic therapy approved by the European Commission for PV 
The FDA had already approved the drug for this indication in June 2018  MabThera is known as Rituxan in the United States 
PV  a rare autoimmune disease characterized by progressive painful blistering of the skin and or mucous membranes  affects 50 000 people in Europe 
The EU approval was based on positive results form the phase III Ritux study  which evaluated MabThera plus a tapering regimen of oral corticosteroids  CS  compared to a standard dose of CS alone  as a first line treatment in patients with newly diagnosed moderate to severe pemphigus 
As a result of this approval  Rituxan is now approved to treat four autoimmune diseases like RA  granulomatosis with polyangiitis  GPA   microscopic polyangiitis  MPA  and PV in both the United States and Europe 
We note that MabThera Rituxan is one of Roche s legacy drugs  However  the drug is facing biosimilar competition in Europe  which is adversely impacting sales  Sales in 2018 came in at CHF6 7 billion  down 8  from 2017 
Apart from Rituxan  Roche s rheumatology portfolio has a first in class anti IL 6 receptor therapy  Actemra RoActemra  The drug is approved for RA  polyarticular and systemic juvenile idiopathic arthritis  giant cell arteritis and chimeric antigen receptor T cell induced cytokine release syndrome 
Roche s stock has gained 13 8  in the past six months compared with the  s growth of 3  

 
Roche s legacy drugs like Herceptin and MabThera are facing stiff competition from biosimilars 
Novartis   NYSE NVS   has already launched its biosimilar version of Rituxan MabThera in Europe  Amgen   NASDAQ AMGN   also obtained FDA approval for a biosimilar version of Avastin for the treatment of five types of cancers  including lung  colorectal  glioblastoma  renal cell carcinoma and cervix 
Zacks Rank
Roche currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Celgene Corp    NASDAQ CELG    which sports a Zacks Rank  1  Strong Buy   You can see  
Celgene s earnings per share estimates increased from  10 34 to  10 73 for 2019 over the past 30 days  Estimates for 2020 also increased 48 cents 
Is Your Investment Advisor Fumbling Your Financial Future 
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-15,Zacks Investment Research,https://www.investing.com/analysis/roche-gets-approval-for-label-expansion-of-mabthera-in-europe-200398286,200398286
149514,371030,AMGN,Spectrum Pharma  SPPI  Withdraws Rolontis BLA  Shares Down,opinion,"Spectrum Pharmaceuticals  Inc    NASDAQ SPPI   announced that it has withdrawn the biologics license application   BLA   seeking approval for its neutropenia candidate  Rolontis  The company stated that the withdrawal is due to the FDA s request for additional manufacturing related data for the drug  Moreover  though the additional data ar not likely to be a major amendment to the BLA  theexpected time to gather the requested data is likely to cross the 60 day review period ending Mar 29 Shares of Spectrum Pharma fell more than 7  in pre market trading on Mar 15  However  the company recovered most of the loss in normal trading and closed at 2 9  down on Mar 15  The company s shares are up 14 1  so far this year compared with the  s growth of 19 1  Spectrum Pharma said the FDA also did not raise any concern related to the pre clinical and clinical data submitted with the BLA or made any request to conduct additional studies  The company is in active discussion with the FDA and plans to file the updated BLA  including the requested information  as early as possible With the sale of the marketed portfolio in March  Spectrum Pharma has no steady product revenues  The company depends on the success of its pipeline development  Rolontis is the lead candidate  which has been evaluated for treating chemotherapy induced neutropenia in patients undergoing myelosuppressive chemotherapy The BLA was based on positive data from two phase III studies  namely ADVANCE and RECOVER  In both programs  Rolontis demonstrated non inferiority to Amgen s   NASDAQ AMGN   Neulasta  pegfilgrastim  in improving duration of severe neutropenia Apart from Rolontis  the company is developing poziotinib for the treatment of metastatic non small cell lung cancer with EGFR exon 20 mutations  In December 2018  the company had received a setback as the FDA did not grant Breakthrough Therapy designation to the candidate A marketing approval to pipeline candidates is necessary for future prospects of Spectrum Pharma  With the withdrawal of Rolontis BLA  commercialization of the candidate will also be delayed Spectrum Pharmaceuticals  Inc  Price
    Zacks Rank   Stocks to ConsiderSpectrum Pharma currently carries a Zacks Rank  4  Sell   Better ranked stocks in the same sector include Infinity Pharmaceuticals  Inc    NASDAQ INFI   and AIT Therapeutics  Inc    OTC AITB    both sporting a Zacks Rank  1  Strong Buy   You can see  Infinity Pharma s earnings estimates have been revised 10 5  upward for 2019 over the past 60 days  The stock has rallied 52 6  so far this year AIT Therapeutics  earnings estimates have moved 18 8  north for 2019 over the past 60 days  The stock is up 6 2  year to date Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-17,Zacks Investment Research,https://www.investing.com/analysis/spectrum-pharma-sppi-withdraws-rolontis-bla-shares-down-200398642,200398642
149516,371032,AMGN,Regeneron  Sanofi Get EC Nod For Label Expansion Of Praluent,opinion,"Regeneron Pharmaceuticals  Inc    NASDAQ REGN   announced that the European Commission  EC  has approved a label expansion of its PCSK9 inhibitor  Praluent 
The drug s label has been expanded to reduce cardiovascular  CV  risk in adults with established atherosclerotic CV disease  ASCVD  by lowering low density lipoprotein cholesterol  LDL C  levels as an adjunct to correction of other risk factors 
The trial met its primary endpoint  showing that Praluent significantly reduced the relative risk of major adverse CV events  MACE  by 15  in patients who had suffered a recent ACS   The data also showed that MACE occurred in 9 5  of patients in the Praluent group compared with 11 1  in the placebo group  Moreover  Praluent was associated with a 15  lower risk of death from any cause  Adverse events were similar in the Praluent and placebo groups  except for injection site reactions 
We note that Praluent is already approved in the EU for heterozygous familial hypercholesterolemia  HeFH  or clinical ASCVD  in adults   The drug is also approved for use as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or clinical ASCVD who require additional lowering of LDL C in the United States 
We remind investors that data from ODYSSEY OUTCOMES have also been submitted to the FDA and the regulatory body has set a target action date of Apr 28  2019 
Regeneron has a collaboration agreement with Sanofi   NASDAQ SNY   for Praluent  The label expansion of the drug should further boost sales  
Earlier  both the companies decided to implement a 60  cut in U S  list price of Praluent  following a similar action last year by rival Amgen  Inc    NASDAQ AMGN   to cut the U S  list price of its PCSK9 inhibitor  Repatha by 60  to improve access and affordability 
Regeneron inked another collaboration agreement with Sanofi  per which the latter records sales for commercialized products  Dupixent  Praluent and Kevzara  and the former has the right to co promote such products on a country by country basis  Regeneron has exercised its option to co promote Dupixent  Praluent and Kevzara in the United States 
Regeneron s stock has gained 20 7  in the past twelve months  against the  s decline of 13 2  

While the overall biotech sector was in doldrums in 2018  Regeneron s performance has been steady  backed by strong growth of two drugs   Eylea and Dupixent  Eylea continues to drive sales  and label expansion of the drug into additional indications has further boosted growth in 2018 
The company has co developed Eylea with the HealthCare unit of Bayer  DE BAYGN  AG   OTC BAYRY   
Zacks Rank
Regeneron currently carries a Zacks Rank  3  Hold   You can see  
Is Your Investment Advisor Fumbling Your Financial Future 
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-18,Zacks Investment Research,https://www.investing.com/analysis/regeneron-sanofi-get-ec-nod-for-label-expansion-of-praluent-200398855,200398855
149520,371036,AMGN,Nuevolution  Small Molecules  Big Ambitions,opinion,"Positive progress in Nuevolution s  ST NUEVOL  ROR t partnership with Almirall  LON 0O9B  has triggered a  1m milestone payment  SEK10 5m  and we continue to forecast that it will enter the clinic in 2019  FY18 was defined by the progress in the Amgen  NASDAQ AMGN  partnership as it opted in for two oncology programmes  further validating Nuevolution s Chemetics technology  In Nuevolution s BET BD1 programme  a development candidate  NUE20798  has been nominated  data in animal cancer models highlight that it may have synergistic effects in combination with immunotherapies  The FY18 net loss was down year on year to SEK99 7m  from SEK117 5m  as a result of lower R D costs  Net cash of SEK108m  FY17  SEK110 6m  should fund operations into 2020  We value Nuevolution at SEK20 7 share 

Almirall milestone achieved with positive CD data
Almirall and Nuevolution have completed significant characterisation of its candidate drug  CD  leading them to believe the program could have potential best in class attributes  Almirall will now press forward with its plans to start a clinical trial programme in moderate to severe psoriasis patients  The partnership includes  172m in development milestones and  270m in regulatory milestones  in addition to tiered royalties on future net sales  The timing and design of any clinical trial is ultimately Almirall s decision and we await further information on these elements 
Amgen opt ins proving the worth of NUEV technology
Nuevolution continues to demonstrate that it has the in house ability to execute and deliver on its partnerships  In 2018  Amgen opted in on two programmes and is now covering development costs  If Amgen exercises its option to license a candidate  Nuevolution will receive an initial licensing fee of at least  10m and potential milestone payments of up to  400m per candidate  With the collaboration spanning multiple undisclosed targets  significant financial potential exists 
Internal pipeline continues to add value
Nuevolution continues to build and strengthen its pipeline of preclinical assets and aims to monetise some of those in the near term via out licensing  We have no visibility on the timelines for potential new deals for Nuevolution  but believe the BET BD1 programme  which is the most advanced internal candidate  is well positioned and most likely to be out licensed or partnered 
Valuation  SEK20 7 share  SEK1 026m 
We value Nuevolution at SEK20 7 share  SEK1 026m   vs SEK19 7 share  SEK974m  previously  The increase in value is driven by the rolling forward of our model  and we have updated net cash and FX rates 


Business description
Nuevolution is a Copenhagen based biopharmaceutical company  Its patent protected Chemetics drug discovery platform enables the selection of drugs to an array of tough to drug disease targets  To date it has entered into 17 agreements with major pharmaceutical companies ",2019-03-19,Edison,https://www.investing.com/analysis/nuevolution-small-molecules-big-ambitions-200398950,200398950
149522,371038,AMGN,Merck s Keytruda Picks Up Pace In Thriving Anti PD L1 Market,opinion,The demand for checkpoint inhibitors  especially those targeting PD 1 and PD L1 has risen significantly in the past couple of years  Cancer therapies that target either PD 1 or PD L1 can stop them from attaching and help keep cancer cells from hiding PD L1 inhibitors available on the market are Merck s   NYSE MRK   Keytruda  AstraZeneca s   NYSE AZN   Imfinzi  Bristol Myers    NYSE BMY   Opdivo  Roche s Tecentriq and Pfizer s   NYSE PFE   Bavencio Keytruda is a key contributor to Merck s sales  In a very short span of time  Keytruda has become Merck s biggest product  It is now already approved for use in 15 indications across 10 different tumor types in the United States  The drug generated sales of  7 17 billion in 2018  reflecting a massive 88  surge year over year Keytruda is continuously growing and expanding into new indications and markets globally  Keytruda sales are gaining particularly from strong momentum in the indication of first line lung cancer as it is the only anti PD 1 approved in the first line setting in certain patients both as a monotherapy as well as combination therapy The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 900 studies  including more than 600 combination studies  Merck is collaborating with several companies including Amgen  NASDAQ AMGN   Incyte  NASDAQ INCY   Glaxo and Pfizer separately for the evaluation of Keytruda in combination with other regimens   A key recent FDA approval was for first line treatment for metastatic squamous non small cell lung cancer  NSCLC    a difficult to treat lung cancer patient population   in October last year based on data from the KEYNOTE 407 study  Following this approval  Keytruda witnessed strong uptake in this patient population in the United States in the fourth quarter  Last week  European Commission granted marketing approval to Keytruda for the same indication which can drive sales higher in 2019 In fact  in 2019 so far  Merck has announced several positive pipeline updates related to Keytruda  This included FDA approval as an adjuvant therapy for high risk stage III melanoma  Committee for Medicinal Products for Human Use  CHMP  nod for an improved six week dosing schedule  FDA s priority review for Keytruda Pfizer s Inlyta for first line advanced metastatic renal cell carcinoma  RCC  as well as first line recurrent or metastatic head and neck squamous cell carcinoma  HNSCC  and five new label expansion approvals in Japan Several regulatory decisions for new indications in the United States as well as in Europe are pending in 2019  which if approved can further boost sales   Though Keytruda has its share of side effects and suffered some major pipeline setbacks  we believe that Keytruda has strong growth prospects based on increased utilization  recent approvals for new indications and potential additional approvals worldwide Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-03-20,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-picks-up-pace-in-thriving-antipdl1-market-200399864,200399864
149537,371053,AMGN,Roche  RHHBY  To Acquire Spark Therapeutics For  4 8 Billion,opinion,Roche Holding  SIX ROG  AG   OTC RHHBY   announced that it has entered into a definitive agreement to acquire Philadelphia based gene therapy company Spark Therapeutics  Inc    NASDAQ ONCE   at a price of  114 50 per share in an all cash transaction  This price represents a premium of about 122  to Spark Therapeutics  closing price on Feb 22  2019  The total value of the deal is  4 8 billion  The boards of both the companies have unanimously approved the deal  Under the terms of the merger agreement  Roche will promptly commence a tender offer to acquire all of the outstanding shares of Spark Therapeutics  common stock  Following completion of the tender offer  Roche will acquire all remaining shares at the same price of  114 50 per share through a second step merger  The transaction is expected to close in the second quarter of 2019 Acquiring Spark Therapeutics will also give Roche the access to some hemophilia products  which will broaden its drug development pipeline  Roche will get access to the former s novel gene therapy  SPK 8011 for the treatment of hemophilia A  which is expected to start phase III in 2019  Spark Therapeuticsalso has SPK 8016 in a phase I II study  which is aimed at addressing the hemophilia A inhibitor population  Roche already sells Hemlibra  a drug against hemophilia A  With the acquisition  Roche will also get to add Luxturna to its portfolio  Luxturna is a one time gene therapy product indicated for the treatment of patients with confirmed biallelic RPE65 mutation associated retinal dystrophy  and currently marketed in the United States by Spark Therapeutics and elsewhere by Novartis   NYSE NVS   Spark Therapeutics  hemophilia A program could become a new therapeutic option for people living with this disease Additional candidates in Spark Therapeutics  portfolio include SPK 9001  an investigational gene therapy for the potential treatment of hemophilia B in phase III and SPK 7001 for choroideremia in phase I II  The portfolio also includes SPK 3006 for Pompe disease and SPK 1001 for CLN2 disease  a form of Batten disease   Both the candidates are expected to be ready for clinical development in 2019  and additional preclinical programs for Huntington s disease and Stargardt disease With this deal  Roche plans to shift from cancer treatments as it faces stiff competition for its products  Stiff competition from biosimilars looms large for some of Roche s key drugs   Novartis has already launched its bisomilar version of Rituxan MabThera in Europe  Amgen   NASDAQ AMGN   also obtained FDA approval for a biosimilar version of Avastin for treatment of five types of cancers including lung cancer  colorectal cancer  glioblastoma  renal cell carcinoma and cervix cancer  Zacks RankRoche carries a Zacks Rank 3  Hold   You can see  This Could Be the Fastest Way to Grow Wealth in 2019 Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities  These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119 and  164 gains in as little as 1 month ,2019-02-24,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-to-acquire-spark-therapeutics-for-48-billion-200392083,200392083
149538,371054,AMGN,Sanofi Regeneron Disagree With Jury Verdict In Amgen s Favor,opinion,"Sanofi   NASDAQ SNY   and partner Regeneron Pharmaceuticals  Inc    NASDAQ REGN   strongly disagreed with a Delaware jury verdict that upheld the validity of three of five asserted claims of two U S  patents owned by Amgen  Inc    NASDAQ AMGN   for its PCSK9 inhibitor  Repatha  Notably  Sanofi and Regeneron also market a PCSK9 inhibitor  Praluent  The companies believe that all Amgen s asserted U S  patent claims are invalid based on lack of written description Sanofi Regeneron intend to appeal against the jury verdict and request a new trial  The two patents describe and claim monoclonal antibodies of PCSK9 In October 2014  Amgen had filed a patent infringement lawsuit against Sanofi and Regeneron in the U S  District Court of Delaware to prevent the manufacture  use and sale of Praluent  In March 2016  a Delaware jury ruled in favor of Amgen declaring that the two patents were valid  and that Sanofi and Regeneron had failed to invalidate them due to the lack of written description and enablement  In January 2017  the U S  District Court in Delaware granted Amgen permanent injunction against infringement by Sanofi and Regeneron of two patents owned by Amgen for Repatha  Later  a federal circuit court reversed in part the judgment of the Delaware district court and demanded a new triaI We note that both Repatha and Praluent are used to inhibit a protein known as PCSK9  which lowers the liver s ability to remove  bad  cholesterol  LDL C  from the blood  While both the drugs hit the market in 2015 within a month  the companies have been working rigorously on securing deals with health insurers and pharmacy benefit managers  However  sales of both these PCSK9 inhibitors have been below expectations since launch due to payer restrictions  Despite Sanofi Regeneron and Amgen s efforts to improve access to their products  patients face significant hurdles due to high co pay expenses Earlier this month  Sanofi Regeneron announced a 60  cut in the U S  list price of Praluent  following a similar action last year by Amgen to improve access and affordability of the product  The price cuts have been taken to encourage payers to improve access to Praluent and Repatha  which will encourage use of these drugs  It goes without saying that the price cuts will significantly dent Sanofi s and Amgen s profits from their respective PCSK9 inhibitors Sanofi s shares have risen 7 7  in the past year  Sanofi currently carries a Zacks Rank  3  Hold  Sanofi Price and Consensus
    A better ranked large cap pharma stock is Glaxo   NYSE GSK    carrying a Zacks Rank  2  Buy   Shares of Glaxo have risen 16 8  in the past year while earnings estimates for 2019 have risen 1 4  in the past 30 days You can  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-02-25,Zacks Investment Research,https://www.investing.com/analysis/sanofiregeneron-disagree-with-jury-verdict-in-amgens-favor-200392600,200392600
149540,371056,AMGN,Spectrum  SPPI  Misses Earnings Estimates In Q4  Tops Sales,opinion,"Spectrum Pharmaceuticals  Inc    NASDAQ SPPI   incurred adjusted loss of 30 cents per share in the fourth quarter of 2018  wider than the Zacks Consensus Estimate of a loss of 20 cents as well as the year ago quarter loss of 23 cents per share Quarterly revenues came in at  29 4 million  up 2 9  from the year ago quarter  The top line beat the Zacks Consensus Estimate of  25 97 million Spectrum Pharma s shares have declined 48 2  in the past year Quarter in DetailTotal product sales came in at  28 million  up 0 4  year over year  Sales were generated by seven marketed products   Fusilev   0 4 million   Folotyn   12 2 million   Zevalin   0 9 million   Marqibo   2 3 million   Beleodaq   3 7 million   Evomela   7 5 million  and recently launched Khapzory   0 9 million  License fees and service revenues were  1 4 million compared with  0 6 million in the prior year quarter Adjusted research   development  R D  expenses were  33 6 million  up 57 7  from the year ago quarter due to higher costs related to regulatory application and commercial initiatives for Rolontis  Adjusted selling  general and administrative  SG A  spending was up 4 2  to  19 9 million 2018 ResultsSpectrum Pharma s total sales for the full year were down 14 8  to  109 3 million  which comprises product revenues of  104 5 million and license fees and service revenues of  4 9 million  Adjusted loss for the period was 84 cents per share  wider than the year ago loss of 61 cents per share 2019 GuidanceThe company expects SG A expenses to decrease 30  in 2019 as the company remains on track to divest its marketed portfolio  However  R D expenses are expected to increase marginally due to higher costs related to pre commercial supply and tech transfer activities for Rolontis and poziotinib  Its cash  including the amount from sale of assets  is enough to fund operations for at least three years In January 2019  the company signed an agreement to sell its portfolio of marketed drugs to privately held Acrotech Biopharma  Spectrum Pharma will receive  160 million in upfront fees and is eligible to receive  140 million in future milestone payments  The transaction is expected to close in March Pipeline UpdateSpectrum Pharma successfully completed two phase III studies on its pipeline candidate  Rolontis  which showed that the candidate was non inferior to Amgen Inc  s   NASDAQ AMGN   Neulasta in improving duration of severe neutropenia in patients with breast cancer In December 2018  Spectrum Pharma submitted a Biologics License Application   BLA   for Rolontis to the FDA The company is developing another key pipeline candidates  poziotinib  as monotherapy or in combination with other drugs for the treatment of lung cancer and breast cancer  A phase II study   ZENITH20   is evaluating poziotinib in previously treated non small cell lung cancer   NSCLC   patients with an exon 20 mutation in EGFR or HER2  Data from EGFR cohort is expected in the fourth quarter of 2019  However  in December  the FDA denied breakthrough therapy designation to poziotinib for NSCLC with EGFR exon 20 mutations Spectrum Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderSpectrum Pharma currently carries a Zacks Rank  4  Sell  Some better ranked stocks in the healthcare sector include Celgene Corporation   NASDAQ CELG   and Genomic Health  Inc    NASDAQ GHDX    While Celgene sports a Zacks Rank  1  Strong Buy   Genomic Health carries a Zacks Rank  2  Buy   You can see  Celgene s earnings estimates have been revised 5 3  upward for 2019 and 9 2  for 2020 over the past 60 days  The stock has rallied almost 29 7  so far this year Genomic Health s earnings estimates have moved north 17 9  for 2019 and 13 9  for 2020 over the past 60 days  The stock has gained 17 9  so far this year This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-02-28,Zacks Investment Research,https://www.investing.com/analysis/spectrum-sppi-misses-earnings-estimates-in-q4-tops-sales-200393942,200393942
149542,371058,AMGN,Radius  RDUS  Posts Narrower Q4 Loss On Robust Tymlos Sales ,opinion,"Radius Health  Inc  NASDAQ RDUS   reported encouraging results for the fourth quarter of 2018  wherein loss was narrower than expected and sales beat estimates Radius Health  Inc  Price  Consensus and EPS Surprise
 

   The company reported a loss of  0 66 per share in the quarter  narrower than both the Zacks Consensus Estimate of a loss of  0 82 and the year ago period s loss of  1 36   Increase in revenues led to the narrower than anticipated loss on a year over year basis 
The company reported Tymlos  sales of  34 4 million  marginally surpassing the Zacks Consensus Estimate of  34 million 
Quarter in Detail
Tymlos  sales also increased 25  sequentially  We remind investors that Radius Health obtained the FDA approval for Tymlos  abaloparatide  injection in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk of fracture  The company began shipments of the drug to wholesalers at the end of May 2017  Hence  revenues recorded in the year ago quarter were  7 7 million only 
Tymlos captured  on average  20  of the U S  anabolic osteoporosis market  based on Patient Months on Therapy  TRx PMOT  in 2018  During the fourth quarter of 2018  Tymlos  average U S  anabolic market share grew to 26  and achieved a 39  share of new anabolic patient starts 
In October 2018  the FDA approved a labeling supplement for Tymlos to include additional information from the ACTIVExtend study  The labeling now reflects that after 24 months of open label alendronate therapy  the vertebral fracture risk reduction achieved with Tymlos therapy was maintained 
As of Jan 1  2019  Tymlos was covered for approximately 283 million U S  insured lives  representing approximately 99  of U S  commercial  67  of Medicare and 96  Medicaid Other insured lives 
Research and development expenses for the reported quarter were  23 9 million  up 4  year over year  driven by increases in elacestrant project costs and abaloparatide patch project costs  General and administrative expenses decreased 13  to  43 9 million due to decreases in compensation and travel related expenses  and professional fees 
Pipeline Updates
The pipeline includes abaloparatide injection for potential use in the treatment of men with osteoporosis  abaloparatide patch for potential use in osteoporosis  and elacestrant  RAD1901  for potential use in hormone receptor positive breast cancer 
The company is developing two formulations   abaloparatide Subcutaneous  SC  and abaloparatide transdermal patch  Radius Health is on track with its preparations for the phase III trial on abaloparatide patch and expects to start the study in mid 2019 
Radius Health initiated the phase III EMERALD study of elacestrant late November 2018   This is the first phase III study to prospectively evaluate treatment benefit for second  and third line breast cancer patients following CDK 4 6 inhibitor therapy as well as to prospectively compare outcomes in patients whose tumors harbor estrogen receptor 1 gene  ESR1  mutations  The study is open to enrollment with a planned recruitment period of 18 21 months and potential data read out in 2021 
In December 2017  the company reported mature data from its multiple part phase I dose escalation and expansion study of elacestrant in postmenopausal women with ER positive and HER2 negative advanced breast cancer  These results showed that elacestrant was well tolerated with the most commonly reported adverse events being low grade nausea  dyspepsia and vomiting 
A phase I study  evaluating the safety and maximum tolerated dose of RAD140 in patients with hormone receptor positive  locally advanced or metastatic breast cancer  is currently enrolling patients and expected to continue through the first quarter of 2019  A provisional maximum tolerated dose  MTD  was identified and an additional cohort has been opened to further confirm tolerability  pharmacokinetics  and on treatment pharmacodynamics effects of RAD140 at that dose 
2019 Sales Guidance Reiterated
Radius Health expects Tymlos net revenues around  155  175 million in 2019 
Our Take
The company s narrower than expected loss in the fourth quarter was encouraging as sales of Tymlos continued to gain traction 
In the first six weeks of 2019  Tymlos has captured a 29  share of the U S  anabolic osteoporosis market and more than 40  of new anabolic patient starts 
Although the osteoporosis market in the United Sates has great potential  Tymlos is expected to face significant competition from Eli Lilly   Co s   NYSE LLY   Forteo and Amgen s   NASDAQ AMGN   Prolia 
Zacks Rank   Stock to Consider
Radius Health currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is Celgene Corp    NASDAQ CELG    which sports a Zacks Rank  1  Strong Buy   You can see   
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities 
These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-03-01,Zacks Investment Research,https://www.investing.com/analysis/radius-rdus-posts-narrower-q4-loss-on-robust-tymlos-sales-200394073,200394073
149546,371062,AMGN,Merck Gets CHMP Nod For Six Week Dosing Option Of Keytruda ,opinion,Merck   Co   Inc    NYSE MRK   announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has given a positive opinion  recommending marketing approval for an improved dosing schedule of its blockbuster anti PD 1 therapy  Keytruda The CHMP nod supports approval of a six week 400 mg dosing option of Keytruda for all eight approved monotherapy indications across five tumor types in Europe  The new recommended dose will be delivered as an intravenous infusion over 30 minutes and will provide greater flexibility than the currently approved dose of 200 mg every three weeks infused over 30 minutes  Merck s application will now be reviewed by the European Commission  which will announce its decision in the second quarter of this year Merck s stock has risen 6 5  this year so far compared with a 3 8  increase for the   In a very short span of time  Keytruda has become Merck s biggest product  It is now already approved for use in 15 indications across 10 different tumor types in the United States  The drug generated sales of  7 17 billion in 2018  reflecting a massive 88  surge year over year  Keytruda is continuously growing and expanding into new indications and markets globally The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 900 studies  including more than 500 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte   NASDAQ INCY    Glaxo   NYSE GSK   and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens We believe that Keytruda has strong growth prospects based on increased utilization  recent approvals for new indications and potential additional approvals worldwide Merck currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-03-04,Zacks Investment Research,https://www.investing.com/analysis/merck-gets-chmp-nod-for-sixweek-dosing-option-of-keytruda-200394737,200394737
149547,371063,AMGN,Ligand Sells Promacta Rights For  827M  Updates  19 View,opinion,"Ligand Pharmaceuticals Incorporated   NASDAQ LGND   announced the sale of all rights to Novartis    NYSE NVS   blockbuster drug  Promacta  eltrombopag   to privately held Royalty Phamra for  827 million  The sale also includes the royalty rights to worldwide net sales of Promacta  which generated the highest revenues  almost  100 million  for Ligand in 2018  The sale of Promacta is expected to close on Mar 6 Promacta has been the leader in its category in the past year amid competition from new drugs  Sales of Promacta have witnessed compound annual rate of 32  over the past five years  At this growth rate  the drug has generated significant revenues for Ligand in royalty payments  Novartis has paid Ligand  291 million in royalty payments over the past 11 years  Novartis is also developing the drug for label expansion in new patient population Although the majority of the current patents covering Promacta are set to expire in mid 2021 in the United States  Ligand s Captisol technology  used in drug development  is protected till 2029  The Captisol patent may limit generic competition for the drug and will help it generate significant revenues following its patent expiration after mid 2021 Investors were dismayed by the asset sale as Ligand s shares fell 7 1  in after market trading on Mar 5 following the news  Shares of the company are down 11 1  so far this year against the  s gain of 14 9  In the press release  Ligand stated that the sale has almost doubled its cash resources to  1 4 billion  which help Ligand to develop its technologies and acquire companies to drive growth over the next five to 10 years or beyond  The company will also be able to continue development of its OmniAb platform  which it expects to generate  500 million to  1 billion in annual royalties beginning 2030  Captisol and OmniAb along with LTP technology is estimated to generate over  3 5 billion in potential contract paymentsLigand will primarily use the proceeds from the sale to acquire long term revenue generating assets  fully funded Shots on Goal and technology platforms  The company will also use the proceeds to buy back shares  which will increase earnings per share   EPS   Following the sale of Promacta rights  Ligand s royalty revenues will majorly be driven by Amgen s   NASDAQ AMGN   Kyprolis and Acrotech Biopharma  Evomela  previously owned by Spectrum Pharma   NASDAQ SPPI   2019 Guidance UpdateAlong with the announcement of the asset sale  Ligand also updated its revenue and earnings guidance for 2019 The company expects its total revenues to be  118 million  down from the previously expected amount of  224 million  The decline in revenues is likely to be lower royalty revenues  which are currently expected to be  48 million compared with  154 million expected previously  However  guidance for license fees and milestones  and material sales was maintained  However  adjusted EPS is guided to be  32 25 compared with the previous guidance of  6 05 For the first quarter of 2019  total revenues are expected to be at least  38 million  approximately consisting of  19 million in royalties   12 million in license fees and milestones and  7 million in material sales  Royalty revenues will include  15 million royalty on sales in the first two months of 2019 Ligand Pharmaceuticals Incorporated Price
    Zacks RankLigand currently has a Zacks Rank  2  Buy  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-05,Zacks Investment Research,https://www.investing.com/analysis/ligand-sells-promacta-rights-for-827m-updates-19-view-200395178,200395178
149551,371067,AMGN,Lilly s Emgality Gets FDA Priority Review For Cluster Headache,opinion,Eli Lilly and Company   NYSE LLY   announced that the FDA has granted a priority review to the supplemental biologics license application  sBLA  for its calcitonin gene related peptide  CGRP  antibody  Emgality  galcanezumab   With this latest sBLA filing  Lilly is looking to get Emgality injection approved for the preventive treatment of episodic cluster headache in adult patients Notably  Lilly gained an FDA approval for Emgality  its CGRP antibody  for adult migraine in late last September Generally  the FDA provides a priority review designation to drugs with potential for driving significant improvements in the safety and effectiveness of treatment  prevention or diagnosis of a serious disease The sBLA filing was based on data from a phase III study  which evaluated the safety and efficacy of Emgality injection  300mg  in adult patients with episodic cluster headache  Last September  the FDA granted a Breakthrough Therapy status to Emgality for the same indication  Currently  there are no approved medicines in the United States for treating episodic cluster headache  Thus  a nod will help Lilly gain access to a broader patient population and boost sales for this promising drug Shares of Lilly have rallied 11  so far this year compared with the  increase of 3 3  Emgality was the third CGRP antibody to get an FDA nod in 2018 for migraine treatment  Amgen s   NASDAQ AMGN   and Novartis  CGRP antibody  Aimovig  was approved and launched in the United States during the second quarter of 2018 while Teva s   NYSE TEVA   Ajovy was also approved last September Lilly is also enrolling patients in phase III studies on Emgality for the preventive treatment of migraine in children and adolescents  aged 6 17 years Notably  Lilly s overall pain portfolio looks promising  Apart from Emgality  the company is developing lasmiditan  which is currently under review in the United States for the treatment of acute migraine in adult patients  Lilly along with partner Pfizer   NYSE PFE   is developing tanezumab  which is being evaluated in several phase III programs for treating osteoarthritis pain  OA   chronic low back pain and cancer pain in adult patients Zacks RankLilly currently carries a Zacks Rank  4  Sell  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-03-05,Zacks Investment Research,https://www.investing.com/analysis/lillys-emgality-gets-fda-priority-review-for-cluster-headache-200395074,200395074
149554,371070,AMGN,Is Amgen  AMGN  A Profitable Pick ForValue Investors Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Amgen Inc    NASDAQ AMGN   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Amgen has a trailing twelve months PE ratio of 12 6  as you can see in the chart below This level actually compares favorably with the market at large  as the PE for the S P 500 stands at about 17 4  If we focus on the long term PE trend  Amgen s current PE level puts it below its midpoint of 14 7 over the past five years  with the number having risen rapidly over the past few months Further  the stock s PE also compares pretty favorably with the Medical Market s trailing twelve months PE ratio  which stands at 20 4  At the very least  this indicates that the stock is much undervalued right now  compared to its peers We should also point out that Amgen has a forward PE ratio  price relative to this year s earnings  of 12 9  which is significantly lower than the current level  So  it is fair to say that a slightly more value oriented path may be ahead for Amgen stock in the near term too PEG RatioWhile earnings are certainly important  it is essential to know how much you are paying for the growth of earnings as well  One can easily do that with the PEG ratio  ratio of the P E to the expected future earnings growth rate   The PEG ratio gives a more complete picture of the valuation of a stock than the P E ratio Amgen s PEG ratio stands at just 2 2  compared with the Zacks Medical Biomed  Genetics industry s average of 3 8  This suggests a bit undervalued trading relative to its earnings growth potential right now Broad Value OutlookIn aggregate  Amgen currently has a Value Score of B  putting it into the top 40  of all stocks we cover from this look  This makes Amgen a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the P CF ratio for Amgen is 10  a level that is quite lower than the industry average of 14 96x  Clearly  AMGN is a solid choice on the value front from multiple angles What About the Stock Overall Though Amgen might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has Growth score of C and Momentum Scores of A  This gives AMGN a Zacks VGM score   or its overarching fundamental grade   of B   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been bearish  The current quarter has seen two upward revisions in the past sixty days compared to three downward revisions  while the full year estimate has seen three upward and ten downward revisions in the same time period This has had a negative impact on the consensus estimate as the current quarter consensus estimate has declined by 4 4  in the past two months  while the full year estimate has also dipped by 2 6   You can see the consensus estimate trend and recent price action for the stock in the chart below Amgen Inc  Price and Consensus   Despite the bearish analyst sentiments  the stock holds a Zacks Rank  3  Hold   Thus  we are looking for in line performance from the company in the near term Bottom LineAmgen is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Further  a strong industry rank  among Top 28  of more than 250 industries  instils our confidence However  with a Zacks Rank  3 it is hard to get too excited about this company overall  In fact  over the past two years  the broader industry has clearly underperformed the market at large  as you can see below So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-03-10,Zacks Investment Research,https://www.investing.com/analysis/is-amgen-amgn-a-profitable-pick-forvalue-investors-now-200396554,200396554
149574,371090,AMGN,Merck Gets Priority Review For Keytruda Combo In Kidney Cancer,opinion,Merck   Co   Inc    NYSE MRK   announced that the FDA has granted priority review to yet another supplemental biologics license application  sBLA  for its PD L1 inhibitor  Keytruda  In the latest sBLA  Merck is looking for FDA s approval of Keytruda in combination with Pfizer s   NYSE PFE   Inlyta for the first line treatment of advanced or metastatic renal cell carcinoma  RCC   the most common type of kidney cancer  With the FDA granting priority review  a decision is expected on Jun 20  2019 The sBLA filing is based on data from the pivotal phase III KEYNOTE 426 study as well as supporting data from an early stage study   KEYNOTE 035  Data from the KEYNOTE 426  study showed that the Keytruda Inlyta combination led to significant improvements in the dual primary endpoints of overall survival  OS  and progression free survival  PFS  as well as a key secondary endpoint of objective response rate  ORR  compared to Pfizer s older kidney cancer treatment  Sutent Full data from the KEYNOTE 426 study was also presented at the 2019 Genitourinary Cancers Symposium as well as published in the New England Journal of Medicine  The additional data showed that the combination led to a 31  reduction in the risk of progression of disease or death  PFS  and a 47  reduction in the risk of death  OS   The ORR was 59 3  in the Keytruda Inlyta combination arm while the same was 35 7  in the Sutent arm In the past year  Merck s shares have outperformed the   rising 41 8  compared with a 5 9  increase for the industry   This is the second priority review granted to Merck s sBLA for Keytruda in less than a fortnight  Last week  Merck announced that the FDA has granted priority review to its sBLA looking for approval of Keytruda for the first line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma  HNSCC   both as a monotherapy or in combination with platinum and 5 fluorouracil  5 FU  chemotherapy The sBLA was based on data from the phase III KEYNOTE 048 study wherein Keytruda as a monotherapy and in combination with chemotherapy  demonstrated significant improvement in OS compared to the standard of care in the given patient population whose tumors expressed PD L1 with CPS  combined proportion score   20 and CPS 1  Keytruda is a key contributor to Merck s sales growth  In a very short span of time  Keytruda has become Merck s largest product  It is already approved for use in 15 indications across 10 different tumor types in the United States The drug generated sales of  7 17 billion in 2018  reflecting a massive 88  surge year over year  Keytruda is continuously growing and expanding into new indications and markets globally Keytruda sales are gaining particularly from strong momentum in the first line lung cancer indication as it is the only anti PD 1 approved in first line setting The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 900 studies  including more than 500 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte   NASDAQ INCY    Glaxo and Pfizer separately for the evaluation of Keytruda in combination with other regimens We believe that Keytruda has strong future growth prospects based on increased utilization  approval for new indications and expectation of additional approvals worldwideMerck currently carries a Zacks Rank  3  Hold   You can see The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2019-02-17,Zacks Investment Research,https://www.investing.com/analysis/merck-gets-priority-review-for-keytruda-combo-in-kidney-cancer-200389291,200389291
149575,371091,AMGN,Merck s  MRK  Stock Up Almost 50  In A Year  Here s Why,opinion,In the past year  Merck   Co   Inc     NYSE MRK   has been one of the biggest gainers along with Eli Lilly   NYSE LLY     Merck s stock has risen 45 2  in the past year compared with a 7 4  increase for the   Merck s performance in 2018 was supported by strong quarterly results and positive pipeline and regulatory updates  It looks well poised to maintain the bullish run in 2019 Strong Sales   Earnings PerformanceMerck s full year 2018 sales rose 5  to  42 3 billion while adjusted earnings per share rose 9  to  4 34 per share  Pharmaceutical segment sales rose 6  in 2018 while that of the Animal Health unit rose 9   Importantly  Merck issued a decent earnings and sales guidance for 2019 on the fourth quarter conference call Strength in Keytruda  Bridion  Gardasil and Animal Health offset headwinds from loss of exclusivity for some products and competitive pressure for Zostavax and Zepatier  Keytruda continued its robust performance on strong demand  Animal health and vaccine products are also performing strongly and remain core growth drivers for Merck Keytruda  A Key Growth CatalystMerck s outperformance in the past year can largely be attributed to strong performance and positive regulatory updates related to its PD 1 inhibitor  Keytruda  In a very short span of time  Keytruda has become Merck s largest product  It is now already approved for use in 15 indications across 10 different tumor types in the United States  The drug generated sales of  7 17 billion in 2018  reflecting a massive 88  surge year over year  Keytruda is continuously growing and expanding into new indications and markets globally Keytruda sales are gaining particularly from strong momentum in the indication of first line lung cancer as it is the only anti PD 1 approved in the setting in certain patients both as a monotherapy as well as combination therapy The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 900 studies  including more than 500 combination studies  Merck is collaborating with several companies including Amgen  NASDAQ AMGN   Incyte   NASDAQ INCY    Glaxo and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens We believe that Keytruda has strong growth prospects based on increased utilization  recent approvals for new indications and potential additional approvals worldwide Other Pipeline Regulatory SuccessKey new drug approvals for Merck in the past year included that of Steglatro and its fixed dose combinations for type II diabetes  two new HIV drugs   Pifeltro and Delstrigo   containing doravirine and Prevymis  letermovir  for cytomegalovirus  CVM  infection Merck also gained several label expansion approvals for Keytruda and another cancer drug Lynparza  which it markets in partnership with AstraZeneca   NYSE AZN    For Keytruda  a key FDA approval in October was the label expansion as a first line treatment for metastatic squamous non small cell lung cancer  NSCLC    a difficult to treat lung cancer patient population   based on data from the phaseIII KEYNOTE 407 study Lynparza was alsoapproved by the FDA in the first line maintenance setting in December  becoming the first PARP inhibitor to be approved as a first line maintenance therapy for BRCA mutated advanced ovarian cancer  These new products and line extensions should bring in additional sales in 2019 and beyond Merck also announced positive data from several late stage studies  mainly evaluating Keytruda for further line extensions Merck also signed a co development deal with Japan s Eisai Co   Ltd for the latter s tyrosine kinase inhibitor  Lenvima  It also agreed to buy Viralytics Limited  an Australian pharmaceutical company that develops oncolytic immunotherapies for a range of cancers  which should strengthen its oncology portfolio In December  Merck announced plans to acquire privately held animal health technology provider Antelliq Group from BC Partners  Last month  Merck exercised its option to in license a once monthly insulin sensitizer  NGM313  from partner NGM Biopharmaceuticals  Inc   being developed for the treatment of NASH and type II diabetes What to Expect in 2019 For Keytruda  several regulatory decisions for new indications in the United States as well as in Europe are due in 2019  which  if approved  can further boost sales  Key FDA decisions expected in the first half will be on regulatory filings for label expansion of Keytruda as an adjuvant therapy in patients with high risk stage III melanoma and for patients with non squamous or squamous lung cancer whose tumors express PD L1 protein levels of 1 percent or greater  TPS of  1 percent  Meanwhile  Keytruda  Bridion  Lynparza  Gardasil and Animal Health should continue the strong performance  driving sales and profits in 2019  This should make up for headwinds from loss of exclusivity  LOEs   softness in the diabetes franchise  and competitive pressure on Zepatier and Zostavax Merck will also continue to focus on cost cutting initiatives  which should drive its bottom line Merck currently carries a Zacks Rank  3  Hold   You can see  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-18,Zacks Investment Research,https://www.investing.com/analysis/mercks-mrk-stock-up-almost-50-in-a-year-heres-why-200389637,200389637
149576,371092,AMGN,Roche s  RHHBY  BLA For Lymphoma Drug Gets Priority Review ,opinion,"Roche   OTC RHHBY   announced that the FDA has accepted the company s Biologics License Application  BLA  for anti CD79b antibody drug conjugate  ADC  polatuzumab vedotin in combination with bendamustine plus Rituxan  BR   for the treatment of patients suffering from relapsed or refractory  R R  diffuse large B cell lymphoma  DLBCL   and granted Priority Review status to the same 
A decision from the FDA is expected by Aug 19  2019 
We note that Priority Review designation is granted to drugs that have the potential to provide significant improvements in the safety and effectiveness of the treatment  prevention or diagnosis of a serious disease 
Polatuzumab vedotin was earlier granted Breakthrough Therapy designation by the FDA and PRIME  PRIority MEdicines  designation by the European Medicines Agency for the treatment of patients with R R DLBCL in 2017   Polatuzumab vedotin is being evaluated for the treatment of several types of non Hodgkin lymphoma  NHL  
A potential approval will boost Roche s hematology portfolio  which comprises approved drugs like MabThera Rituxan  Tecentriq  Gazyva and Venclexta in collaboration with AbbVie   NYSE ABBV   
The pipeline includes polatuzumab vedotin and a small molecule that inhibits the interaction of MDM2 with p53  idasanutlin RG7388   The company also has Hemlibra in its portfolio  a bispecific monoclonal antibody for the treatment of haemophilia A 
Concurrently  the FDA accepted the company s New Drug Applications  NDAs  and granted Priority Review status to pipeline candidate entrectinib  The candidate is being evaluated for the treatment of adult and pediatric patients with neurotrophic tropomyosin receptor kinase  NTRK  fusion positive  locally advanced or metastatic solid tumors who have either progressed following prior therapies or as an initial therapy when there are no acceptable standard therapies  and for the treatment of people with metastatic  ROS1 positive non small cell lung cancer  NSCLC    A decision from the FDA is expected by Aug 18  2019 
The candidate is being developed across a range of solid tumor types  including breast  cholangiocarcinoma  colorectal  gynaecological  neuroendocrine  non small cell lung  salivary gland  pancreatic  sarcoma and thyroid cancers 
Roche s stock has gained 12 6  in the last six months compared with the  s growth of 2 5  

 
Approval of new drugs and a potential label expansion of existing drugs bode well for Roche  as its legacy drugs like Herceptin and MabThera are facing competition from biosimilars 
Novartis   NYSE NVS   has already launched its bisomilar version of Rituxan  MabThera in Europe  Amgen   NASDAQ AMGN   also obtained FDA approval for a biosimilar version of Avastin for the treatment of five types of cancers including lung  colorectal  glioblastoma  renal cell carcinoma and cervix  Entry of biosimilars of these key drugs adversely impacted sales in Europe in 2018 
Zacks Rank
Roche currently carries a Zacks Rank  3  Hold  You can see  
Is Your Investment Advisor Fumbling Your Financial Future 
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-02-19,Zacks Investment Research,https://www.investing.com/analysis/roches-rhhby-bla-for-lymphoma-drug-gets-priority-review-200389817,200389817
149577,371093,AMGN,Merck s Keytruda Fails To Meet Endpoint In Liver Cancer Study,opinion,Merck   Co   Inc    NYSE MRK   announced that a pivotal phase III study evaluating its PD 1 inhibitor  Keytruda for the second line treatment of advanced hepatocellular carcinoma  HCC   the most common type of liver cancer  did not meet its co primary endpoints of overall survival  OS  and progression free survival  PFS  The KEYNOTE 240 study compared Keytruda plus best supportive care versus placebo plus best supportive care to treat advanced HCC patients who were previously treated with systemic therapy  Though the study did show an improvement in OS and PFS in the Keytruda arm compared to placebo  the results were not statistically significant Keytruda is presently approved for the treatment of patients with HCC who have been previously treated with Bayer   OTC BAYRY   Amgen s   NASDAQ AMGN   Nexavar  sorafenib   This approval was based on data from KEYNOTE 224 study  Had the data from the KEYNOTE 240 study been positive and eventually approved to be added to Keytruda s label  it would have expanded the drug s eligible patient population Keytruda is being evaluated in several other studies as monotherapy in second line HCC including KEYNOTE 394 phase III study In a separate press release  Merck announced that the FDA has granted approval to Keytruda to be used as an adjuvant therapy for the treatment of patients with high risk stage III melanoma The drug is already approved in the United States as a monotherapy for the treatment of adult patients with advanced melanoma  The approval in the adjuvant setting will help Merck gain access to a broader melanoma patient population in the United States  This is the first approval in United States for Keytruda in the adjuvant setting  It was approved for adjuvant melanoma in the EU in December last year The FDA approval was based on data from the pivotal phase III KEYNOTE 054 study  which was conducted in collaboration with the European Organisation for Research and Treatment of Cancer  EORTC   Data from the study showed that treatment with Keytruda led to a significant reduction in the risk of cancer returning after surgery  Melanoma patients often have a high risk of disease recurrence Merck s stock rose 45 3  in the past year compared with a 7 8  increase for the     Merck s outperformance in the past year can largely be attributed to strong performance and positive regulatory updates related to Keytruda  In a very short span of time  Keytruda has become Merck s largest product  It is now already approved for use in 15 indications across 10 different tumor types in the United States  The drug generated sales of  7 17 billion in 2018  reflecting a massive 88  surge year over year  Keytruda is continuously growing and expanding into new indications and markets globally The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 900 studies  including more than 500 combination studies  Merck is collaborating with several companies including Amgen  Incyte   NASDAQ INCY    Glaxo and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens We believe that Keytruda has strong growth prospects based on increased utilization  recent approvals for new indications and potential additional approvals worldwide Merck currently carries a Zacks Rank  3  Hold   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-19,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-fails-to-meet-endpoint-in-liver-cancer-study-200390037,200390037
149579,371095,AMGN,Merck Gets Priority Review For Keytruda In Third Line SCLC,opinion,"Merck   Co   Inc    NYSE MRK   announced that the FDA has granted priority review to yet another supplemental biologics license application  sBLA  for its PD L1 inhibitor  Keytruda  In the latest sBLA  Merck is looking for FDA s approval of Keytruda as monotherapy for advanced small cell lung cancer   SCLC   in third or later line setting  With the FDA granting priority review  a decision is expected on Jun 17  2019 The sBLA filing was based on data fromthe SCLC cohorts of the phase II KEYNOTE 158 study as well as supporting data from an early stage study   KEYNOTE 028  Data from the KEYNOTE 158 study  presented in June 2018  showed that treatment with Keytruda achieved overall response rate of 18 7  with 3  complete response in patients whose disease progressed after two or more lines of prior therapy  The median progression free survival was 2 months and median overall survival was 8 7 months The KEYNOTE 158 study is a multi cohort study evaluating Keytruda in several indications  Last year  the drug was  for treating advanced cervical cancer in second line setting based on the data from a cohort of this study The company is also evaluating Keytruda in combination with chemotherapy in a late stage study  KEYNOTE 604  for treating newly diagnosed extensive stage SCLC In the past six months  Merck s shares have outperformed the   rising 15  compared with a 1 5  increase for the industry The sBLA is the first regulatory application seeking approval of Keytruda in the difficult to treat cancer  SCLC  in any setting  It is also the third sBLA to get priority review from the FDA this month  Earlier this month  Merck announced that the FDA has granted priority review to its label expansion regulatory applications looking for approval of Keytruda as first line treatment for recurrent or metastatic    HNSCC   and advanced or metastatic    RCC   Keytruda has been the biggest revenue generator for Merck in 2018 and also a key contributor to the company s sales growth in the last few years  Keytruda is continuously growing and expanding into new indications and markets globally  It is already approved for use in 15 indications across 10 different tumor types in the United States  The drug generated sales of  7 17 billion in 2018  recording growth of 88  year over year Keytruda already commands a strong position in the non small cell lung cancer   NSCLC   segment as it is the only anti PD 1 approved in first line setting for NSCLC  An approval for treating SCLC will further strengthen Keytruda s position in the lung cancer market Merck is also progressing well with the Keytruda development program  The drug is being studied for more than 30 types of cancer in more than 900 studies  including more than 500 combination studies  Merck has collaborated with several companies including Amgen   NASDAQ AMGN    Incyte   NASDAQ INCY    Glaxo   NYSE GSK   and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens We believe that Keytruda has strong growth prospects based on increased utilization  approval for new indications and expectation of additional approvals worldwide Merck   Co   Inc  Price
    Zacks RankMerck currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-02-20,Zacks Investment Research,https://www.investing.com/analysis/merck-gets-priority-review-for-keytruda-in-thirdline-sclc-200390791,200390791
149598,371114,AMGN,Roche Submits SBLA To FDA For Label Expansion Of Kadcyla,opinion,Roche Holding  SIX ROG  AG   OTC RHHBY   announced that it has completed the submission of a supplemental Biologics License Application  sBLA  to the FDA to expand the label of its breast cancer drug Kadcyla  The company is seeking FDA approval for Kadcyla for adjuvant  after surgery  treatment of patients with HER2 positive early breast cancer  eBC  with residual disease after neoadjuvant  before surgery  treatment  Kadcyla  an antibody drug conjugate  is approved as monotherapy in second line setting for treating metastatic breast cancer in patients who have received treatment with Herceptin or and taxane Shares of Roche have gained 18  so far this year  compared with the  growth of 10 4  The application was supported by the results of the phase III study which showed that Kadcyla significantly reduced the risk of disease recurrence by 50  as adjuvant therapy in phase III KATHERINE study compared to its other breast cancer drug  Herceptin  The late stage KATHERINE study compared Kadcyla to Herceptin for risk of disease recurrence or death in HER2 positive eBC patients with residual disease following a neoadjuvant  before surgery  therapy The FDA is reviewing the application under the Real Time Oncology Review and Assessment Aid pilot programs  which aim to explore a more efficient review process to ensure the availability of safe and effective treatments for patients as early as possible Kadcyla was granted Breakthrough Therapy Designation for this indication  The Breakthrough Therapy designation is granted to speed up the development and review of drugs that target serious or life threatening conditions Roche has a strong presence in the oncology market  In particular  the company dominates the breast cancer space with strong demand for its HER2 franchise drugs  The HER2 franchise includes Herceptin  Perjeta and Kadcyla  Sales of the HER2 franchise grew 7  in 2018 We remind investors that in November 2018  the FDA accepted Roche s supplemental sBLA for the label expansion of immuno oncology drug Tecentriq The agency also granted Priority Review to Tecentriq plus chemotherapy  Abraxane  for the initial  first line  treatment of unresectable locally advanced or metastatic triple negative breast cancer  TNBC  in patients whose disease expresses the PD L1 protein  as determined by PD L1 biomarker testing Approval of new drugs and a potential label expansion of existing drugs bode well for Roche as its legacy drugs like Avastin  Herceptin and MabThera are facing competition from biosimilars  Novartis   NYSE NVS   has already launched its biosimilar version of Rituxan  MabThera in Europe  Amgen   NASDAQ AMGN   too has got its biosimilar of Avastin  Roche Holding AG Price    Zacks Rank   Stock to ConsiderRoche currently carries a Zacks Rank  3  Hold  A better ranked stock from the same space worth considering is Eli Lilly and Co    NYSE LLY   carrying a Zacks Rank  2  Buy   You can see  Lilly s earnings per share estimates have increased from  5 49 to  5 58 for 2018 and from  5 79 to  5 87 for 2019 in the past 90 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 10 03  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-04,Zacks Investment Research,https://www.investing.com/analysis/roche-submits-sbla-to-fda-for-label-expansion-of-kadcyla-200383708,200383708
149599,371115,AMGN,Lilly  LLY  Lags Q4 Earnings  Lowers 2019 View  Stock Down,opinion,Eli Lilly   Company   NYSE LLY   reported fourth quarter 2018 adjusted earnings per share of  1 33  which missed the Zacks Consensus Estimate of  1 36  and matched the lower end of the guided range of  1 33    1 38 per share Earnings rose 17  from the year ago quarter backed by robust growth in new product sales and higher operating income  A reduction in shares outstanding from shares repurchase also led to higher earnings in the quarter Including asset impairment  restructuring  and other special charges  fourth quarter earnings per share were  1 10 against a loss of  1 58 cents per share in the fourth quarter of 2017 However  as expected  earnings declined sequentially from third quarter levels due to U S  generic competition for key erectile dysfunction drug Cialis and launch costs for its newly launched CGRP antibody  Emgality Revenues in DetailQuarterly revenues of  6 44 billion beat the Zacks Consensus Estimate of  6 34 billion  Sales grew 5  year over year backed by strong demand for its new drugs led by Trulicity  Taltz  Jardiance and Basaglar  which made up for lower sales of established products like Cialis and Forteo Foreign exchange hurt sales growth by 1  in the quarter  Also  lower realized prices had a negative impact of 5  on sales  Volumes rose 11   U S  revenues grew 7  to  3 66 billion and ex U S  revenues rose 1  to  2 77 billion Pharmaceutical revenues rose 5  in the quarter driven by volume growth  Established products that recorded growth during the quarter included Strattera  up 9  to  107 2 million  and Alimta  up 6  to  556 9 million   Sales of all other established products declined in the quarter Forteo sales declined 15  to  437 1 million  Cymbalta sales declined 4  to  184 5 million  Humalog sales dropped 2  to  770 4 million  Zyprexa sales were down 27  to  110 8 million  Erbitux sales declined 5  to  159 8 million  Humulin sales declined 7  to  337 4 million Cialis sales declined 41  to  350 7 million as U S  sales were hurt by entry of generic competition  Outside U S  sales were hurt by loss of exclusivity in Europe  In September  Teva Pharmaceuticals   NYSE TEVA   announced the launch of a generic version of Cialis  which led to rapid erosion of sales in the quarter Among the new products  Trulicity generated revenues of  924 7 million  up 42  year over year driven by higher demand Cyramza revenues were  220 6 million  up 8  year over year driven by higher demand Jardiance sales surged 35  to  193 2 million  driven by increased demand trends within the SGLT2 class of diabetes medicines in the United States and increased volume outside the United States Basaglar recorded revenues of  232 2 million  up 51  year over year  In the United States  sales rose 59   benefiting from higher demand  which offset the impact of lower realized prices  due to increased volume in Medicare Part D  Taltz brought in sales of  307 0 million  up 78  year over year as U S  sales gained from higher demand  which made up for lower realized prices  Ex U S  sales were driven by increased volume from new launches  Taltz was launched for the second indication of psoriatic arthritis in late 2017 early 2018 in both the United States and Europe  which contributed to sales growth in the quarter Lartruvo generated revenues of  83 5 million in the quarter  higher than  76 9 million in the previous quarter  However  earlier this month  Lilly announced that Lartruvo  which had won conditional approval two years back  failed to improve survival in patients with advanced soft tissue sarcoma in a late stage confirmatory study  ANNOUNCE  Continued approval was contingent on verification of clinical benefit in a confirmatory study  With ANNOUNCE failing to confirm clinical benefit  Lilly said it will stop promoting Lartruvo while being in discussion with global regulators to determine the next steps for the drug  Though the negative update did not have any impact on fourth quarter results  sales of the drug should decline sharply in 2019 New rheumatoid arthritis drug  Olumiant generated sales of  70 1 million in the quarter backed by launch uptake in new European markets  compared with  55 6 million in the previous quarter  In the United States  Olumiant recorded sales of  4 2 million  higher than  0 8 million in the previous quarter  In the United States  only the lower dose of the medicine is approved for marketing Advanced breast cancer treatment  Verzenio  launched in the Unites States in late 2017  generated sales of  83 1 million in the quarter  which was less than  84 5 million in the previous quarter  This is because increased demand was more than offset by the negative impact of wholesaler buying patterns and lower realized prices The newly launched CGRP antibody  Emgality generated sales of  4 9 million in the quarter Animal Health segment sales rose 3  to  816 5 million Gross Margin   Operating Income Adjusted gross margin of 76 6  in the quarter rose 50 basis points driven by manufacturing efficiencies  which offset the negative impact of lower prices Operating income increased 15  year over year to  1 62 billion on higher revenues and lower operating costs  Total operating expenses  including research and development and marketing  selling and administrative expenses   as a percent of revenues  declined 190 basis points in the quarter to 51 1   This is because the company s cost saving efforts offset the impact of higher marketing costs to support Emgality s launch 2018 ResultsFull year 2018 sales rose 7  to  24 56 billion  marginally beating the Zacks Consensus Estimate of  24 46 billion  Revenues were slightly above the guided range of  24 3 billion to  24 5 billion Adjusted earnings for 2018 were  5 55 per share  missing the Zacks Consensus Estimate of  5 58 but up 30  year over year  Earnings came in at the lower end of the guided range of  5 55 to  5 60 per share Lowers 2019 OutlookLilly lowered its previously issued earnings and sales guidance for 2019 to account for the costs related to the pending acquisition of Loxo Oncology  Inc    NASDAQ LOXO   and the hit from the study failure for Lartruvo Earlier this year  Lilly announced a definitive deal to acquire small cancer biotech  Loxo Oncology for  8 billion in cash to broaden the scope of its oncology portfolio into precision medicines The earnings forecast was reduced from a range of  5 90 to  6 00 to  5 55 to  5 65 per share  Lilly now expects revenues to be between  25 1 billion and  25 6 billion in 2019  down from the prior expectations of  25 3 billion and  25 8 billion Our TakeLilly s fourth quarter results were mixed as it beat estimates for sales but missed the same for earnings  Shares of the drug giant declined almost 3  in pre market trading due to the guidance cut by the company  However  in the past year  Lilly s shares have risen 56 9  compared with the  s increase of 6 1    In 2019  revenue growth is expected to be driven by higher demand for its newer medicines including Trulicity  Jardiance  Taltz  Verzenio as well as newly launched migraine drug  Emgality as some older drugs like Cialis lose patent exclusivity  Lilly has launched 10 medicines over the past five years  most of which were successful  Emgality could emerge as a significant contributor to Lilly s long term growthLilly expects U S  regulatory action for nasal glucagon for hypoglycemia and lasmiditan for acute migraine in 2019 as well as line extension approvals for several medicines  which could drive revenue growth in 2019 However  competitive pressure on Lilly s drugs is expected to rise in 2019  Generic competition for several drugs including Cialis  rising pricing pressure in the United States and some international markets  currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line Also  Emgality faces strong competition from Teva and Amgen s   NASDAQ AMGN   CGRPs  Ajovy and Aimovig  respectively  which were also launched last year Lilly currently carries a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2019-02-05,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-lags-q4-earnings-lowers-2019-view-stock-down-200384304,200384304
149600,371116,AMGN,Ligand  LGND  Beats On Q4 Earnings   Sales  Raises  19 View,opinion,"Ligand Pharmaceuticals Incorporated   NASDAQ LGND   reported fourth quarter 2018 adjusted earnings of  1 70 per share  significantly up from the year ago figure of  1 31  Earnings also beat the Zacks Consensus Estimate of  1 27 Shares of the company have declined 51 3  in the past six months compared with the  s 13 8  decrease Total revenues in the quarter increased to  59 6 million from  50 5 million in the year ago period  Moreover  the top line surpassed the Zacks Consensus Estimate of  54 17 million Quarterly HighlightsRoyalty revenues were  40 2 million in the reported quarter  up approximately 42  year over year  Ligand primarily earned royalties on sales of Novartis    NYSE NVS   Promacta  Amgen s   NASDAQ AMGN   Kyprolis and Spectrum Pharmaceuticals  Evomela  which were developed using its Captisol technology  The increase in royalty revenues was mainly driven by higher sales of Promacta and Kyprolis Both the drugs sustained a strong growth rate in 2018  crossing a billion dollar in sales during the period  The positive trend for these two drugs is favorable to Ligand s growth Under the new accounting standard ASC 606  the comparable Royalties in the year ago period were  32 7 million License fees  milestones and other revenues were  9 3 million in the fourth quarter compared with  14 4 million in the year ago period  Material sales increased 31 2  to  10 1 million from the year ago quarter due to the favorable timing of Captisol purchases for clinical and commercial use Business DevelopmentsIn October  Ligand completed the acquisition of UK based biotechnology company  Vernalis  for approximately  43 million  Vernalis has a broad pipeline of partnered programs and ongoing collaborations along with  32 million of cash after deal fees  The acquisition will add eight fully funded partnered programs including pipeline products for respiratory  oncology and CNS indications  During the quarter  the company also invested in Palvella Therapeutics and Dianomi Therapeutics acquiring economic or royalty rights to their investigational products The company s partners have made significant progress with their pipeline candidates using Ligand s technology platform  An advisory committee to the FDA voted in favor of approval for Sage Therapeutics  new drug application  seeking approval for postpartum depression drug  Zulresso  A decision from the FDA is expected next month  Retrophin   NASDAQ RTRX   initiated phase III study on sparsentan for the treatment of IgA nephropathy  Melinta Therapeutics successfully completed a late stage study on Baxdela as a treatment for community acquired bacterial pneumoniaDuring the quarter  Ligand also entered into worldwide license agreements with Genagon Therapeutics AB and iMetabolic Biopharma Corporation  granting them access to OmniAb platform technologies to discover fully human antibodies  The company also entered into a platform license agreement with Fred Hutchinson Cancer Research Center  granting the latter rights to use OmniAb rodent platform technologies to develop new products  The company also signed a Captisol use agreement with Merck KGaA and reVision Therapeutics Full Year ResultsThe company reported total revenues of  251 5 million in 2018  up 78 2  year over year  Adjusted earnings were  7 15 per share compared with  3 26 per share in 2017 2019 Guidance RaisedLigand increased its guidance for 2019  It now expects revenues to be approximately  224 million higher than its previous guidance of  212 million  However  the expected revenues for 2019 are lower than 2018 revenues  which included  47 million in one time payment from WuXi for buying out China OmniAb milestones The expected revenues include royalties of nearly  154 million  material sales of roughly  27 million and license fees and milestones of almost  43 million  Adjusted earnings are estimated to be  6 05 per share for 2019 compared with  5 50 expected previously Ligand Pharmaceuticals Incorporated Price  Consensus and EPS Surprise
    Zacks RankLigand currently has a Zacks Rank  1  Strong Buy  You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-02-07,Zacks Investment Research,https://www.investing.com/analysis/ligand-lgnd-beats-on-q4-earnings--sales-raises-19-view-200385682,200385682
149601,371117,AMGN,Teva  TEVA  To Report Q4 Earnings  What s In The Cards ,opinion,"Teva Pharmaceutical Industries Ltd    NYSE TEVA   will report fourth quarter and full year earnings on Feb 13  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 23 64  
This generic drugmaker s shares have declined 1 4  this year so far compared with the  s decline of 14 2  

 
Teva s earnings surpassed expectations in all the last four quarters  with the average positive surprise being 23 28  Teva Pharmaceutical Industries Ltd  Price and EPS Surprise
 

    
Let s see how things are shaping up for this announcement 
Factors to Consider
Teva reports under two segments   North America  United States and Canada   Europe and International Markets 
Pricing erosion in U S  generics market  lower sales of key multiple sclerosis drug  Copaxone and divestiture of some non core assets in the Women s Health business are expected to hurt North America segment sales in the fourth quarter  On the third quarter call  management had said that despite generic competition for the 20 mg as well as the 40 mg formulation  Copaxone maintained its market share in the United States  Copaxone sales in the quarter were better than management expectations as pricing pressure on the 40 mg dose was less than forecast  It remains to be seen if the positive trend continues in the fourth quarter 
Importantly  sales of all other branded products Bendeka  Treanda  ProAir and Qvar declined in the past two quarters  The chances of sales trends improving in the fourth quarter are minimal 
Meanwhile  additional competition for Teva s largest product  Concerta authorized generic  will also hurt generics sales in the quarter  Importantly  on the third quarter call  the company said it is seeing signs of stabilization in U S  generic drug pricing 
The company also said that the rate of sales erosion in the North American Generic business slowed significantly in the third quarter from second quarter levels due to optimization of its generics product portfolio as well as product launches  The positive trend is expected to continue in the fourth quarter  Important generic launches in the third quarter were that of Mylan s   NASDAQ MYL   EpiPen  epinephrine  auto injector for severe allergy treatment and Lilly s   NYSE LLY   erectile dysfunction drug Cialis 
Importantly  on the call  investors will be keen to know the initial launch update of Teva s newly launched anti calcitonin gene related peptide   CGRP   drug  Ajovy  fremanezumab  injection  as a preventive treatment for migraine  Investors will also be interested to know how management plans to capture market share for Ajovy against Amgen  NASDAQ AMGN  and Lilly s CGRPs  which were also launched last year 
Meanwhile  in Europe as well as International Markets  loss of revenues from the divestiture of the women s health business and discontinued business activities are likely to hurt sales  The decline in sales of generic medicines and Copaxone is expected to continue  which can offset the positive impact of generic launches  The currency tailwind that this segment enjoyed in the first half reversed in the third quarter  which hurt revenues  Currency is expected to remain a headwind in the fourth quarter as well 
Cost savings from Teva s aggressive restructuring initiatives are likely to provide some support to the bottom line  Teva has a new organizational structure in place  is closing plants  cutting down its generics portfolio  divesting non core assets  eliminating low value R D projects  and is significantly cutting its global workforce  Teva expects to save almost  3 billion by the end of 2019 from these initiatives  
However  marketing costs are expected to be higher in the fourth quarter due to investments to support Ajovy s launch 
Earnings Whispers
Our proven model does not conclusively show that Teva is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below 
Earnings ESP  Its Earnings ESP is  0 45   The Zacks Consensus Estimate is pegged at 56 cents per share  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Teva s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat
We caution against stocks with a Zacks Rank  4  Sell  or  5  Strong Sell  going into an earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks to Consider
A generic drugmaker  which has the right combination of elements to beat on earnings this time around is Mallinckrodt Public Ltd  Company   NYSE MNK    Mallinckrodt is slated to announce financial figures on Feb 26  The company has an Earnings ESP of  2 25  and is a Zacks  2 Ranked stock  You can see  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-02-08,Zacks Investment Research,https://www.investing.com/analysis/teva-teva-to-report-q4-earnings-whats-in-the-cards-200385965,200385965
149608,371124,AMGN,AbbVie Buys Rights To Novel Immunotherapy For Multiple Myeloma,opinion,"AbbVie   NYSE ABBV   announced that it has entered into a global strategic transaction with privately held Teneobio  Inc  to develop and commercialize the latter s BCMA targeting immunotherapeutic candidate  TNB 383B  The pre clinical candidate  which acts by directing the body s immune system to kill BCMA expressing tumor cells  will be developed as a potential treatment for multiple myeloma Per the terms of the candidate  AbbVie will pay  90 million to Teneobio in upfront payments  Teneobio will remain responsible for developing the candidate in the phase I stage of clinical studies  The deal grants AbbVie right to acquire TeneoOne  Inc   an affiliate of Teneobio  and lead the subsequent stages of clinical development of TNB 383B as well as its commercialization Teneobio is expected to initiate phase I studies on TNB 383B in the first of 2019 AbbVie s shares have declined 17 6  in the past six months against the  s increase of 2 1   AbbVie s commercial portfolio of oncology drugs consists of Imbruvica and Venclexta  which generated billions of dollars in revenues in 2018  The company is focused on expanding the label of these drugs  The company is also co developing Bristol Myers    NYSE BMY   myeloma drug  Empliciti AbbVie has strengthened its oncology portfolio with the addition of TNB 383B  Successful development of the candidate will help the company to penetrate the lucrative cancer segment  With declining sales of its major revenue generator  Humira in Europe due to generic launch and patent expiry nearing in the United States  development of oncology candidates is becoming a necessity We note that TNB 383B works using a newer mechanism  which targets the B cell of the body s immune system  Although there are several companies developing similar candidates  these B cell targeting therapies are in early stages of development In December 2018  Amgen   NASDAQ AMGN   presented clinical data from its early stage study on anti BCMA T cell engager  AMG 420  bluebird bio s   NASDAQ BLUE   CAR T therapy  bb2121  also uses the anti BCMA mechanism and is being developed in several studies AbbVie Inc  Price
    Zacks RankAbbVie currently carries a Zacks Rank  3  Hold   You can see  Zacks  Best Stock Picking StrategyIt s hard to believe  even for us at Zacks  But from 2000 2018  while the market gained  4 8  per year  our top stock picking strategy averaged  54 3  per year How has that screen done lately  From 2017 2018  it sextupled the market s  15 8  gain with a soaring  98 3  return ",2019-02-11,Zacks Investment Research,https://www.investing.com/analysis/abbvie-buys-rights-to-novel-immunotherapy-for-multiple-myeloma-200386813,200386813
149609,371125,AMGN,Merck s Keytruda Gets FDA Priority Review For Head Neck Cancer,opinion,Merck   Co   Inc    NYSE MRK   announced that the FDA has granted a priority review to yet another supplemental biologics license application  sBLA  for its PD L1 inhibitor  Keytruda  With the latest sBLA filing  Merck is looking to get Keytruda approved for the first line treatment of patients suffering recurrent or metastatic head and neck squamous cell carcinoma  HNSCC   both as a monotherapy or in combination with platinum and 5 fluorouracil  5 FU  chemotherapy With the FDA granting a priority review to the sBLA  a decision is expected on Jun 10  2019  The approval will help Merck gain access to a broader patient population and boost sales for its blockbuster drug The sBLA was based on data from the phase III KEYNOTE 048 study wherein Keytruda as a monotherapy and also combined with chemotherapy demonstrated a significant improvement in overall survival  OS  as compared to the standard of care in the given patients  whose tumors expressed PD L1 with CPS combined proportion score  20 and CPS 1 Shares of Merck have surged 39 8  in the past year  outperforming the  increase of 7 1  Keytruda is already approved for many types of cancers and treatment settings including lung cancer  melanoma  head and neck cancer  classical Hodgkin s lymphoma and bladder cancer In a very short span of time  Keytruda has become the largest product in Merck s portfolio  The drug generated sales of  7 17 billion in 2018  reflecting a massive 88  surge year over year  Sales were driven by the launch of new indications globally  Keytruda sales are particularly gaining from a strong momentum in first line lung cancer indication as it is the only anti PD 1 medicine approved in first line setting The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in above 900 studies including 400 plus combination programs  Merck is collaborating with several companies  namely Amgen   NASDAQ AMGN    Incyte   NASDAQ INCY    Glaxo   NYSE GSK   and Pfizer  NYSE PFE   separately  for the evaluation of Keytruda in combination with other regimes Zacks Rank Merck currently carries a Zacks Rank  3  Hold   You can see  Zacks  Best Stock Picking StrategyIt s hard to believe  even for us at Zacks  But from 2000 2018  while the market gained  4 8  per year  our top stock picking strategy averaged  54 3  per year How has that screen done lately  From 2017 2018  it sextupled the market s  15 8  gain with a soaring  98 3  return ,2019-02-11,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-gets-fda-priority-review-for-headneck-cancer-200386812,200386812
149611,371127,AMGN,Key Takeaways From Eli Lilly s  LLY  Q4 Earnings Report,opinion,"Eli Lilly   Company s   NYSE LLY   fourth quarter and full year 2018 results were mixed as it beat estimates for sales but missed the same for earnings   While earnings of  1 33 per share rose 17  from the year ago quarter  sales rose 5  backed by strong demand for its new drugs led by Trulicity  Taltz  Jardiance and Basaglar  which made up for lower sales of established products like Cialis and Forteo 
Other than the usual top and bottom line numbers  Lilly s CEO Dave Ricks also discussed Lilly s outlook for 2019  He threw light on Lilly s excellent pipeline progress in 2018 with internal and external innovation investments yielding multiple approvals  submissions  and positive phase III readouts  along with several significant first in class additions to the company s late stage pipeline
New Drugs to Drive Top Line in 2019  Since 2014  Lilly has launched 10 medicines  the latest being its CGRP antibody for the preventive treatment of migraine  Emgality  Most of Lilly s new drugs have been successful and are expected to account for 45  of Lilly s pharmaceuticals sales in 2019  much higher than 34  in 2018  Meanwhile  most of these new drugsare also being evaluated for additional indications label expansions 
At the Q4 conference call  management highlighted that in 2019  Lilly s revenue should be driven by higher demand for its newer medicines including Trulicity  Jardiance  Taltz  Verzenio as well Emgality as some older drugs like erectile dysfunction medicine  Cialis face generic competition  Lilly lost exclusivity for Cialis in September 2018 and generic versions entered the market in the same month resulting in rapid erosion of sales 
Lilly expects U S  regulatory action for its nasal glucagon for hypoglycemia and lasmiditan for acute migraine in 2019 as well as line extension approvals for several medicines  which could drive revenue growth in 2019  Loxo s newly approved marketed drug Vitrakvi should also support the top line believes Lilly s management  In January this year  Lilly announced a definitive deal to acquire  Oncology  Inc  for  8 billion in cash 
Pipeline Successes in 2018  On the call  Dave Ricks also discussed the company s significant pipeline progress in 2018 with several positive late stage data readouts  multiple approvals and regulatory submissions  A key regulatory success for Lilly was the FDA approval of Emgality  which could emerge as a significant contributor to long term growth  Other important approvals in 2018 were that of JAK inhibitor  Olumiant  baricitinib  in the United States and breast cancer drug Verzenio in first line setting in the United States  Europe as well as Japan 
In fact  the pipeline successes were the key reason for the stock s massive outperformance in the past year  Lilly s shares have risen 55 1  compared with the  s increase of 5 2  in the said time frame 

 
New Collaboration and Loxo Acquisition Strengthens Portfolio  Lilly also added promising new pipeline assets in 2018 through business development deals  The pending acquisition of Loxo Oncology is expected to broaden the scope of Lilly s oncology portfolio into precision medicines  In addition  with the acquisition of California based immuno oncology biotech  ARMO Biosciences in June 2018  Lilly added pancreatic cancer candidate  pegilodecakin  to its pipeline 
At the recently held prestigious J P  Morgan Healthcare Conference  Ricks said that the company will continue to evaluate other potential deal targets to enhance its position in its core therapeutic areas like cancer  immunology and neuroscience 
Headwinds Remain
Though new drugs should drive the top line in 2019  generic competition for several drugs including Cialis  rising pricing pressure in the United States and some international markets  currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line  We remind investors that in early 2019  Lilly announced that its drug Lartruvo  which had won conditional approval in 2016  failed to improve survival in patients with advanced soft tissue sarcoma in a late stage confirmatory study  ANNOUNCE  With ANNOUNCE failing to confirm clinical benefit  Lilly stopped promoting Lartruvo 
In fact  the study failure and costs related to the pending acquisition of Loxo led Lilly management to lower the previously issued 2019 sales and earnings guidance  The earnings forecast was reduced from a range of  5 90 to  6 00 to  5 55 to  5 65 per share  Revenues are now expected to be between  25 1 billion and  25 6 billion in 2019  down from the prior expectation of  25 3 billion and  25 8 billion 
Importantly  all eyes will be on the performance of Emgality in 2019  It will face intense competition from other CGRP antibodies Amgen   NASDAQ AMGN   Novartis    NYSE NVS   Aimovig and Teva Pharmaceutical s   NYSE TEVA   Ajovy  Both were launched in the United States in the latter half of 2018 
Lilly currently carries a Zacks Rank  3  Hold  You can see 
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline 
So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2019-02-13,Zacks Investment Research,https://www.investing.com/analysis/key-takeaways-from-eli-lillys-lly-q4-earnings-report-200387692,200387692
149625,371141,AMGN,Amgen  AMGN  To Report Q4 Earnings  What s In The Cards ,opinion,We expect Amgen Inc    NASDAQ AMGN   to beat estimates when it reports fourth quarter and full year 2018 results on Jan 29  after market close  Amgen delivered positive earnings surprise of 7 89  last quarter Amgen shares have risen 0 4  in the past year against 23 9  decrease registered by the  during this period   Amgen s performance has been modest  with the company delivering a positive surprise in three out of the trailing four quarters  The average earnings beat over the last four quarters is 4 80  Let s see how things are shaping up for the company this quarter Factors at PlayAmgen s newer products like Prolia  Kyprolis  Xgeva  Blincyto are expected to perform well backed by higher demand  making up for lower sales of mature brands like Enbrel  Aranesp  Epogen  Neulasta and Neupogen due to competitive pressure High demand and share gains in both the United States and international markets should drive sales of Prolia  Though seasonality hurt sales of the product somewhat in the third quarter  it should not have any impact in the fourth quarter In 2018  Xgeva gained approval in both United States and EU for the prevention of skeletal related events in patients with multiple myeloma  The approval for the expanded patient population drove higher volumes of Xgeva in the past two quarters  a trend we expect will continue in the fourth quarter In the third quarter  Blincyto was approved in Japan and for the pediatric patient population in the United States  This label expansion may add significantly to sales in the fourth quarter Kyprolis sales should continue to be driven by increased demand and robust uptake in outside U S  markets  The Zacks Consensus Estimate for sales of Prolia  Xgeva  Blincyto and Kyprolis is pegged at  613 million   445 million   61 million and  260 million  respectively Sales of Amgen s PCSK9 inhibitor  Repatha  have suffered since launch due to payer restrictions  On the Q3 call  the company said that despite its efforts to improve access to Repatha  patients still face significant hurdles due to high co pay expenses  In response  Amgen cut the U S  list price of Repatha by 60  to improve access and affordability of Repatha  Though lower price may impact Repatha sales in the near term  management is optimistic about better volume growth in the fourth quarter and beyond  The Zacks Consensus Estimate for sales of Repatha is  163 million Amgen s newly launched secondary hyperparathyroidism treatment Parsabiv recorded significantly improved sales in the third quarter  We expect the drug to generate higher sales in the fourth quarter However  Amgen s mature drugs like Enbrel  Aranesp  Epogen  Neupogen and Neulasta are facing an array of branded and generic competitors  Novartis    NYSE NVS   generic arm Sandoz and Teva are marketing biosimilar versions of Neupogen in the United States  thereby hurting Neupogen s sales  Mylan s biosimilar version of Neulasta  Fulphila  which is priced at a discount of 33  to Neulasta s list price  was launched in the United States in July  This led to a sharp decline in sales of Neulasta in the third quarter with the negative trend expected to continue in the fourth  Pfizer s Retacrit  the first biosimilar version of Epogen  was launched in November 2018 and may hurt Amgen s branded drug sales in the fourth quarter Investor focus on the call will be on management s comments on sales uptake of its newly approved migraine drug  Aimovig  Aimovig erenumab for prevention of migraine was approved and launched in the United States in second quarter of 2018  Aimovig was approved in EU in July  On the Q3 conference call  the company said that Aimovig is off to a strong start  Regarding competitive pressure from Teva s and Lilly s CGRPs  which were also approved in 2018  management sounded confident of its ability to compete with Aimovig s differentiated product profile On the third quarter call  Amgen warned that operating costs in the fourth quarter are expected to increase in the range of 12  15  sequentiallyEarnings WhispersOur proven model shows that Amgen is likely to beat estimates this quarter because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate   3 27 per share  and the Zacks Consensus Estimate   3 26 per share   is  0 23   You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Amgen has a Zacks Rank  3  The combination of Amgen s Zacks Rank  3 and positive ESP makes us confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderLarge biotech stocks that have both a positive ESP and a favorable Zacks Rank include Regeneron Pharmaceuticals  Inc    NASDAQ REGN   has an Earnings ESP of  6 80  and a Zacks Rank of 3  The company is scheduled to report fourth quarter earnings on Feb 6  You can see  Celgene Corporation   NASDAQ CELG   has an Earnings ESP of  2 31  and a Zacks Rank  1  The company is slated to release results on Jan 31 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year  Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-to-report-q4-earnings-whats-in-the-cards-200379869,200379869
149627,371143,AMGN,Pfizer  PFE  Q4 Earnings Beat  2019 View Tepid  Stock Dips,opinion,"Pfizer  Inc    NYSE PFE   reported fourth quarter 2018 adjusted earnings per share of 64 cents  which beat the Zacks Consensus Estimate by a penny  Earnings rose 3  year over year The pharma heavyweight recorded revenues of  14 0 billion  which beat the Zacks Consensus Estimate of  13 77  Revenues rose 2  from the year ago quarter on a reported basis  Currency fluctuation hurt sales by 3  in the quarter due to a stronger dollar and weakening of certain emerging markets currencies and euro  On an operational basis  excluding the impact of currency  revenues rose 5  year over year  Higher sales in the IH segment were partially offset by lower sales in the EH segment International revenues rose 4   up 10  an operational basis  to  7 51 billion  U S  revenues declined 1  to  6 47 billion Revenues from the Consumer Healthcare segment  which Pfizer agreed to merge with Glaxo s   NYSE GSK   Consumer Health Unit last month to form a new joint venture  rose 5  year over year to  974 million  Global Oncology revenues increased 30  to  1 91 billion  Global Vaccine revenues rose 3  to  1 62 billion  Internal Medicine rose 10  to  2 66 billion  The Inflammation   Immunology franchise rose 7  to  1 13 billion  However  the portfolio of Rare Disease declined 3  to  561 million Segment DiscussionPfizer s reporting segments are Pfizer Innovative Health  IH  and Pfizer Essential Health  EH  Pfizer IH sales grew 8  on a reported basis  up 10  an operational basis  from the year ago period to  8 85 billion as higher sales of Eliquis and Xeljanz globally  Ibrance in international markets and Xtandi in the United States offset lower sales of Enbrel  Xalkori and Prevnar U S All growth rates mentioned below are on an operational basis Ibrance revenues rose 62  year over year to  1 13 billion as higher international sales offset a decline in the United States  Ibrance sales declined 4  in the United States in the fourth quarter due to increased rebates and rising competition in the CDK inhibitor category Xeljanz sales rose 27  to  553 million  Eliquis alliance revenues and direct sales rose 31  to  910 million  Chantix sales rose 10  to  296 million in the quarter  Lyrica sales rose 9  to  1 22 billion Xtandi recorded alliance revenues of  189 million in the quarter  up 12  year over year  Pfizer markets Xtandi in partnership with Japan s Astellas Pharma Global Prevnar 13 Prevenar 13 revenues rose 1  to  1 51 billion  Prevenar 13 revenues rose 5  in international markets  Prevnar 13 revenues declined 2  in the United States Enbrel revenues declined 11  to  524 million in key European markets due to continued biosimilar competition  Pfizer has exclusive rights to Amgen  Inc  s   NASDAQ AMGN   blockbuster rheumatoid arthritis RA  drug  Enbrel  outside the United States and Canada Pfizer s EH segment sales declined 7   3  on an operational basis  to  5 12 billion EH revenues were hurt by the loss of exclusivity  LOE  and associated generic competition for products  primarily Pristiq and Viagra in the United States and Lyrica in Europe  and lower revenues from sterile injectables portfolio due to increased competitive pressure and continued legacy Hospira product shortages in the United States  Also  lower sales of legacy Established Products in developed markets driven by industry wide pricing challenges hurt EH segment sales However  in the EH business  biosimilars and emerging markets did well in the quarter  Biosimilars revenues rose 31  operationally while emerging markets revenues grew 10  operationally Pfizer markets Inflectra  a biosimilar version of Johnson   Johnson   NYSE JNJ   and Merck s blockbuster RA drug  Remicade  While Inflectra recorded sales of  70 million in the United States and  173 million globally  other biosimilars brought in sales of  38 million  up 31   Adjusted selling  informational and administrative  SI A  expenses declined 6   operationally  in the quarter to  3 97 billion  Adjusted R D expenses rose 6  to  2 44 billion 2018 ResultsFull year 2018 sales rose 2  to  53 65 billion  beating the Zacks Consensus Estimate of  53 42 billion  Revenues were within the guided range of  53 0 billion to  53 7 Adjusted earnings for 2018 were  3 00 per share  in line with the Zacks Consensus Estimate and up 13  year over year  Earnings were within the guided range of  2 98  3 02 per share 2019 GuidancePfizer issued its earnings as well as sales guidance for 2019 Revenues are expected in the range of  52 0 billion to  54 0 billion  The Zacks Consensus Estimate is pegged at  53 8 billion Adjusted earnings per share are expected in the range of  2 82  2 92  lower than the Zacks Consensus Estimate of  2 99  At the mid point  revenues and adjusted EPS are expected to be flat from 2018 levels  Currency headwinds are expected to hurt 2019 sales and earnings by  900 million and 6 cents per share in 2019 Research and development expense is expected in the range of  7 8  8 3 billion while SI A spending is projected in the range of  13 5   14 5 billion  Adjusted tax rate is expected to be approximately 16  in 2019 In 2019  Pfizer expects to buy back shares worth approximately  9 billion Tanezumab Shows Promise in Second Late Stage Study Pfizer and partner Lilly announced top line data from the second phase III study evaluating tanezumab  2 5 mg or 5 mg  for the treatment of osteoarthritis  OA  pain Top line data from the study showed that treatment with tanezumab 5 mg led to statistically significant improvement in pain  physical function and the patients  overall assessment of their OA   the three primary endpoints   compared to placebo at 24 weeks  The 2 5 mg dose demonstrated a statistically significant improvement in pain and physical function  However for the third primary endpoint  overall assessment of their OA  a statistical difference was not observed Tanezumab is also being evaluated for chronic low back pain  CLBP  and cancer pain  due to bone metastases  Our TakePfizer beat estimates for fourth quarter earnings as well as sales  However  shares of Pfizer fell around 2  in pre market trading as the 2019 forecast disappointed investors  Pfizer s shares have risen 4 6  in the past year against a decline of 4 8  for the    In 2019  Pfizer expects continued strong growth of key product franchises  including Ibrance  Eliquis  Xeljanz and Xtandi However  LOEs are expected to hurt 2019 sales by  2 6 billion including the expected LOE of key drug Lyrica in the United States in June 2019  Also currency headwinds are expected to significantly pull down 2019 revenues To offset the threat of generic competition  Pfizer is strengthening its pipeline as well as oncology portfolio  Pfizer gained FDA approval for four innovative medicines in 2018  which can boost its oncology sales in 2019  Pfizer boasts a strong pipeline and looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years  which can drive long term growth  Bavencio  though currently approved for two small indications  is being considered a key long term growth driver for Pfizer if it can gain label expansion approvals  Pfizer Inc  Price  Consensus and EPS Surprise
    Pfizer currently carries a Zacks Rank  3  Hold   You can see Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-q4-earnings-beat-2019-view-tepid-stock-dips-200380779,200380779
149629,371145,AMGN,Amgen  AMGN  Q4 Earnings Beat Estimates  2019 Guidance Tepid,opinion,"Amgen Inc    NASDAQ AMGN   reported fourth quarter 2018 earnings of  3 42 per share  which beat the Zacks Consensus Estimate of  3 26  Earnings increased 18  year over year driven by higher revenues  lower tax rate and reduced share count Total revenues of  6 23 billion in the quarter surpassed the Zacks Consensus Estimate of  5 88 billion and increased 7  year over year Quarter in DetailTotal product revenues increased 8  from the year ago quarter to  6 0 billion  U S    4 66 billion  ex U S    1 35 billion  as increasing demand for newer products like Prolia  Repatha Kyprolis  Xgeva and Blincyto was partially offset by lower sales of mature brands like Enbrel  Aranesp  Epogen  Neulasta and Neupogen due to competitive pressure  Other revenues of  229 million declined 7  in the quarter While volumes growth added 10  to the top line  foreign exchange had a negative 1  impact on sales Prolia revenues came in at  655 million  up 14  from the year ago quarter  attributable to 12  volume growth resulting from higher demand and share gains in both the United States and international markets Xgeva delivered revenues of  456 million  up 17  from the year ago quarter mainly due to higher demand  which drove volumes  In 2018  Xgeva gained approval in both United States and EU for the prevention of skeletal related events in patients with multiple myeloma  The approval for the expanded patient population led to higher volumes of Xgeva in 2018 Vectibix revenues came in at  168 million  up 6   driven by higher demand Kyprolis recorded sales of  251 million  up 11  year over year  driven primarily by robust uptake in outside U S  markets Blincyto sales increased 37  from the year ago period to  63 million  reflecting rise in demand Amgen s PCSK9 inhibitor  Repatha  generated revenues of  159 million  up 62  year over year as higher unit demand was offset by lower prices  Sales of Repatha have suffered since launch due to payer restrictions  Despite Amgen s efforts to improve access to Repatha  patients face significant hurdles due to high co pay expenses  In response  Amgen announced the decision to cut the U S  list price of Repatha by 60  to improve access and affordability of Repatha  Though lower price may impact Repatha sales in the near term  management is optimistic about better volume growth in the long term Parsabiv  launched in several markets including United States in the first quarter  recorded sales of  120 million in the fourth quarter  much higher than  102 million in the previous quarter Amgen s newly launched CGRP inhibitor for migraine prevention  Aimovig  erenumab  recorded sales of  95 million in the quarter compared with  22 million in the previous quarter  On the call  the company said that Aimovig s launch has been strong and it reached more than 150 000 patients in 2018 Interestingly  Amgen recorded biosimilar revenues of  55 million in the quarter  entirely from international markets  In several European countries  Amgen launched Amjevita  its biosimilar version of AbbVie s blockbuster rheumatoid arthritis drug  Humira in October and Kanjinti  biosimilar of Roche s cancer drug Herceptin  in May However  Amgen s mature drugs like Enbrel  Aranesp  Epogen  Neupogen and Neulasta are facing an array of branded and generic competitors Revenues of Amgen s erythropoiesis stimulating agent  ESA   Aranesp declined 3  from the prior year quarter to  474 million on lower demand primarily due to increased competitive pressure  unfavorable changes in inventory levels and lower pricing Revenues of the other ESA  Epogen  declined 2  to  264 million due to lower selling prices as the category has become extremely competitive  Pfizer s   NYSE PFE   Retacrit  the first biosimilar version of Epogen  was launched in November 2018  Biosimilar competition coupled with Amgen s contractual pricing commitments with DaVita  Inc  is expected to hurt Epogen s price significantly in 2019Neulasta revenues rose 5  to  1 17 billion from the year ago period as a U S  government order led to higher volumes in the quarter  which offset the impact of lower selling prices due to biosimilar competition in the United States  Two companies  Mylan   NASDAQ MYL   and Coherus have launched biosimilars of Neulasta in the United States in the recent past while numerous biosimilars are marketed in Europe  which is hurting sales  More biosimilars are expected to be launched in 2019  which will put further pressure on Neulasta sales Neupogen recorded 40  decline in sales to  75 million due to biosimilar competition in the United States  which hurt demand and prices Enbrel delivered revenues of  1 32 billion  down 8  from the year ago quarter due to lower prices and increased competition  which hurt demand Sensipar Mimpara revenues rose 8  to  448 million as favorable changes in accounting estimates and higher pricing offset lower demand trends  Demand trends for Sensipar are being hurt by Parsabiv launch  which is also marketed for secondary hyperparathyroidism  Sensipar also lost patent exclusivity in March 2018 and Teva   NYSE TEVA   launched its generic version  at risk  in late 2018  However  Amgen and Teva settled their ongoing dispute earlier this month and Teva will no longer sell its generic product until its license date in mid year 2021  However  other generic drugmakers may launch a generic version  at risk  anytime Other product sales rose 6  to  73 million Operating Margins DecreaseAdjusted operating margin declined 60 basis points  bps  to 45 3  due to higher operating costs SG A spend increased 9  to  1 53 billion on higher investments to support new products as well as already marketed products  R D expenses rose 13  year over year to  1 16 billion Adjusted tax rate was 13  for the quarter  a 3 3 points decrease from the fourth quarter of 2017 Amgen repurchased 11 1 million shares worth  2 2 billion in the fourth quarter and has  5 1 billion remaining under its stock repurchase authorization 2018 ResultsFull year 2018 sales rose 4  to  23 75 billion  beating the Zacks Consensus Estimate of  23 37 billion  Revenues were slightly above the guided range of  23 2  23 5 billion  Product sales rose 3  in the quarter Adjusted earnings for 2018 were  14 40 per share  which beat the Zacks Consensus Estimate of  14 14 and rose 14  year over year  Earnings were above the guided range of  14 00  14 25 per share 2019 GuidanceAmgen issued its sales and earnings guidance for 2019  which indicates a decline from 2018 levels  The company expects revenues in the range of  21 8  22 9 billion  indicating a decline from 2018 levels  The Zacks Consensus Estimate is currently at  22 87 billion Adjusted earnings per share are anticipated in the range of  13 10  14 30 in 2019  lower than the current Zacks Consensus Estimate of  14 45  The guided range indicates a decline from 2018 Our TakeAmgen beat estimates for fourth quarter earnings as well as sales  However  shares of Amgen fell around 2 4  in after hours trading on Tuesday as the 2019 forecast disappointed investors   a trend seen at several other large drugmakers this quarter  In the past year  Amgen s stock has risen 0 4  against 23 6  decrease of its    While Amgen s newer drugs   Prolia  Xgeva  Blincyto  Kyprolis   will drive sales  generic competition to Sensipar  continued competitive dynamics for Enbrel and new competition against Aranesp and Neulasta will create pressure on the top line in 2019  Uncertainty and lack of visibility on the impact of biosimilar launches on key drugs  Neulasta  Sensipar  Epogen and Enbrel  coaxed management to issue a tepid outlook for 2019 However  Amgen is progressing with its pipeline and the approval of Aimovig was a huge boost  In the past five years  Amgen has launched nine products  including two in new therapeutic areasAmgen is also rapidly advancing its pipeline  Amgen boasts a strong biosimilars pipeline  which could be an important long term growth driver for the company  Amgen achieved several important milestones with its biosimilars portfolio last year including its first two launches   Amjevita and Kanjinti  It expects to launch additional biosimilars in 2019 Zacks RankAmgen currently carries a Zacks Rank  3  Hold   You can see  Amgen Inc  Price  Consensus and EPS Surprise
    
 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-01-29,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-q4-earnings-beat-estimates-2019-guidance-tepid-200381192,200381192
149632,371148,AMGN,Novartis  NVS  Q4 Earnings Miss Estimates  Revenues Up Y Y,opinion,"Shares of Swiss pharma Novartis AG   NYSE NVS   reported weaker than expected results for the fourth quarter  Shares were down on sluggish results  Moreover  investors weren t impressed with the outlook for 2019 
Fourth quarter 2018 core earnings of  1 25 per share missed the Zacks Consensus Estimate of  1 33 but was up from  1 21 recorded in the year ago quarter 
Revenues increased 6  year over year to  13 27 billion but missed the Zacks Consensus Estimate of  13 37 billion 
All growth rates mentioned below are on a year over year basis and at constant exchange rates 
Quarter in Detail
Novartis operates under three segments  Innovative Medicines  pharmaceuticals   Alcon  ophthalmology unit  and Sandoz  generics  
The Innovative Medicines division recorded sales of  9 billion  up 9   Both pharmaceuticals and oncology business units recorded growth  Pharmaceuticals unit was up 8   while the Oncology unit increased 11    Psoriasis drug  Cosentyx continues to gain traction  Cosentyx sales increased to  806 million  up 33   driven by strong demand growth in all indications in the United States and EU  Entresto s sales grew 76  to  318 million  driven by increased worldwide uptake 
Oncology franchise grew 11   driven by Promacta Revolade  the Tafinlar plus Mekinist combination  and contribution from the Advanced Accelerator Applications  AAA  acquisition  Sales from AAA came in at  135 million  driven by the launch of Lutathera   81 million 
Sales at the Sandoz division were  2 5 billion  down 5  due to price erosion in the United States  Sales in the United States declined due to pricing pressure  Biopharmaceuticals sales grew 29   mainly driven by launches of Rixathon  the biosimilar version of Rituxan  rituximab   Erelzi  the biosimilar of Enbrel in the EU  and Zarxio  filgrastim  in the United States 
Sales at the Alcon division were  1 8 billion  up 2   Surgical sales increased 6   driven by double digit growth of advanced technology IOLs  AT IOLs   and continued growth in consumables  Vision Care sales grew 3  on double digit growth of Dailies Total1 and strong Systane performance 
2018 Results
Sales of  51 9 billion missed the Zacks Consensus Estimate of  52 3 billion but was up 6  from 2017  Earnings per share of  5 15 also missed the Zacks Consensus Estimate of  5 21 
Business Restructuring
In September 2018  Novartis announced that it agreed to sell selected portions of its Sandoz US portfolio  specifically the Sandoz US dermatology business and the US oral solids portfolio  The divestiture is in accordance with Sandoz s strategy of focusing on complex generics  value added medicines and biosimilars to achieve sustainable and profitable growth in the United States in the long run  The transaction will be completed in 2019 
Earlier  Novartis announced that it intends to spin off its ophthalmology division  Alcon  into a separately traded standalone company to grow as a medicines company solely  The spin off will be completed in the first half of 2019 
Novartis also sold its stake in consumer healthcare joint venture to GlaxoSmithKline   NYSE GSK   for  13 billion 
Outlook Updated
The company expects net sales in 2019 to grow mid single digit  Innovative Medicines is projected to grow mid single digit  Revenues from Sandoz are expected to be broadly in line with that in 2018 
Pipeline Update
Gene therapy Luxturna was approved in EU to restore vision and prevent blindness in patients with biallelic RPE65 mutations  We remind investors that Novartis licensed ex U S  rights for Luxturna from Spark Therapeutics   NASDAQ ONCE   
The FDA approved Promacta for first line treatment of severe aplastic anemia  SAA   and Breakthrough Therapy designation was granted to the drug for the treatment of low platelet counts in people exposed to radiation 
Gilenya was approved in Europe for the treatment of multiple sclerosis  MS  in pediatric patients  based on the results of the PARADIGMS study 
Sandoz s biosimilar of Amgen s   NASDAQ AMGN   Neulasta was approved in Europe 
Our Take
Novartis  fourth quarter results missed estimates  The last year was a transformative year for Novartis as it restructured its business and plans to focus on becoming a core drug focused company  powered by data and digital technologies 
The company is looking to solidify its presence in the gene therapy space  It acquired U S  based clinical stage gene therapy company  AveXis  Inc  The company also acquired Endocyte to expand expertise in radiopharmaceuticals  We expect further acquisitions in the coming months as the company looks to further restructure its business 
Novartis  stock has gained 3 8  in the last six months far compared with the  s 9 0  growth

 
However  the generic division  Sandoz continues to face pricing pressure  The division also suffered a blow when the FDA issued a CRL to its generic of Advair Diskus 
Zacks Rank
Novartis currently carries a Zacks Rank  3  Hold   You can see  
 Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-01-31,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-q4-earnings-miss-estimates-revenues-up-yy-200382194,200382194
149635,371151,AMGN,Pfizer s  PFE  New Lung Cancer Drug Vizimpro Gets CHMP Nod ,opinion,"Pfizer  Inc    NYSE PFE   announced that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  has given a positive opinion  recommending marketing approval of its new lung cancer medicine  Vizimpro  dacomitinib  Pfizer is eyeing approval of Vizimpro  45 mg   an EGFR tyrosine kinase inhibitor  in Europe for the first line treatment of metastatic non small cell lung cancer  NSCLC  in patients with EGFR activating mutations  The CHMP s decision will now be reviewed by the European Commission  which mostly follows the same Vizimpro was approved in the United States in September last year  The drug holds immense sales potential as EGFR mutated non NSCLC is a disease that is associated with low overall survival rates Pfizer is making significant progress in its oncology pipeline portfolio  Inthe last four months of 2018  Pfizer gained FDA approval for four innovative cancer medicines including Vizimpro  which may boost its oncology sales  These include Daurismo  glasdegib  for previously untreated acute myeloid leukemia  AML   Lorbrena  lorlatinib  for second line non NSCLC and Talzenna  talazoparib   an orally available PARP inhibitor for advanced breast cancer 
Moreover  two leukemia treatments   Besponsa inotuzumab ozogamicin for relapsed refractory acute lymphoblastic leukemia  ALL  and Mylotarg for newly diagnosed CD33 positive AML   were approved in the United States in 2017 A key candidate in the oncology pipeline is Bavencio  avelumab   which is being evaluated for different types of cancer  Bavencio is already approved in metastatic Merkel cell carcinoma in the United States  Europe and Japan  It also received accelerated approval for second line treatment of locally advanced or metastatic urothelial carcinoma in the United States  Bavencio  though approved for two small indications currently  is being considered a key long term growth driver for Pfizer if it can gain label expansion approvals  Pfizer has 30 ongoing studies in the avelumab development program involving more than 9 000 patients across 15 tumor types  The studies include double triple combination studies for chemotherapy and targeted therapies and several avelumab combination therapies with immuno oncology agents  Pfizer has developed Bavencio in partnership with Germany s Merck KGaA  Pfizer is also venturing into the oncology biosimilars space  In Europe and United States  Pfizer markets biosimilar versions of Amgen s   NASDAQ AMGN   drugs Neupogen and Epogen  Biosimilar versions of Roche s  OTC RHHBY   cancer drugs  Rituxan  Avastin  trade name  Zirabev  and Herceptin are under review in the United States with FDA decisions on all expected in 2019  A biosimilar version of Herceptin was approved in the EU in July 2018 while that of biosimilar Rituxan and Avastin is under review in the EU In fact  oncology drugs have been a key driver of Pfizer s sales  accounting for more than 13  of its total sales in 2018  Oncology revenues increased 19  to  7 2billion  Its marketed oncology drugs are Ibrance Sutent  Inlyta  Bosulif and others  Pfizer also gets a share of profit from its alliance with Japan s Astellas Pharma for Xtandi Pfizer s shares have risen 23 7  in the past year compared with an increase of 7 1 for the    Pfizer currently carries a Zacks Rank  4  Sell  You can seeToday s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-02-03,Zacks Investment Research,https://www.investing.com/analysis/pfizers-pfe-new-lung-cancer-drug-vizimpro-gets-chmp-nod-200383257,200383257
149637,371153,AMGN,Teva Gains Positive CHMP Opinion For Migraine Drug Ajovy,opinion,Teva Pharmaceutical Industries Limited   NYSE TEVA   announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  adopted a positive opinion  recommending a marketing nod for its newly approved migraine injection  Ajovy  fremanezumab   Teva is looking for approval of Ajovy  its anti calcitonin gene related peptide   CGRP   medicine  for the preventive treatment of migraine in adult patients  who experience at least four migraine days per month Following CHMP s positive response  a decision in the EU is expected during the first half of 2019  If approved  Ajovy will be the first and the only anti CGRP treatment to secure a nod in the EU with monthly and quarterly dosing options for patients to follow The positive CHMP feedback was based on the efficacy and safety data from the HALO clinical development program  which evaluated Ajovy in two pivotal phase III studies  Data from these showed that patients administered with Ajovy experienced a significant higher reduction in migraine days as compared to placebo Shares of Teva have dipped 0 2  in the past year  narrower than the  decline of 13 6  We would like to remind investors that last September  Teva gained the FDA approval for Ajovy and immediately launched it as a preventive treatment for migraine  On third quarter conference call  the company stated that it is seeing signs of a strong launch Migraine has limited treatment options and anti CGRP is a new treatment mechanism  However  Amgen   NASDAQ AMGN    Novartis    NYSE NVS   Aimovig  erenumab  was approved and launched for prevention of migraine during the second quarter of 2018  Eli Lilly and Company s   NYSE LLY   CGRP antibody  Emgality  galcanezumab   was also unveiled in late 2018 for the precautionary therapy of migraine in adults Meanwhile  last December  Teva announced favorable top line results from the phase IIIb FOCUS analysis  which evaluated the efficacy and safety of Ajovy for the preventive treatment of migraine in adults  having previously experienced inadequate responses to 2 4 classes of preventive treatments  The study examined the efficacy  safety and tolerability of quarterly and monthly treatment with Ajovy as compared to placebo Ajovy is also being investigated for episodic cluster headache in a phase III program and post traumatic headache in a phase II study Zacks RankTeva currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-02-03,Zacks Investment Research,https://www.investing.com/analysis/teva-gains-positive-chmp-opinion-for-migraine-drug-ajovy-200383310,200383310
149660,371176,AMGN,Healthcare ETFs In Focus Ahead Of Q4 Earnings,opinion,Healthcare has been gathering enough investors  interest driven by its non cyclical nature  which provides a defensive tilt to the portfolio in a turbulent market The Health Care Select Sector SPDR Fund  hasgained 3 4  in the year to date timeframe  while Vanguard Health Care ETF   AX VHT    iShares U S  Healthcare ETF  and Fidelity MSCI Health Care Index ETF   are up more than 4  each  The strength is likely to continue with some big names like Pfizer   NYSE PFE    Merck   NYSE MRK    Amgen   NASDAQ AMGN    AbbVie   NYSE ABBV    and Gilead Sciences   NASDAQ GILD   lined up to report this week and in the next  All these stocks collectively account for 23 3  share in XLV  21 7  in IYH  21 3  in VHT and 20 3  in FHLC  read    Let s dig deeper into the earnings picture of these companies  which will drive the performance of the above mentioned funds in the coming days According to the our methodology  a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   when combined with a positive  increases our chances of predicting an earnings beat  while Zacks Rank  4 or 5  Sell rated  stocks are best avoided  You can uncover the best stocks to buy or sell before they re reported with our  Inside Our Surprise Prediction for These StocksPfizer has a Zacks Rank  4 and an Earnings ESP of 0 00   The stock saw negative earnings estimate revision of a penny for to be reported quarter over the past 30 days  It delivered an average positive earnings surprise of 6 35  for the past four quarters  It has a VGM Score of D  Pfizer is scheduled to report earnings on Jan 29  before the opening bell Merck is expected to report results on Feb 1 before market open  It has a Zacks Rank  3 and an Earnings ESP of 0 00   The stock delivered a positive earnings surprise in the last four quarters  with the average beat being 3 96   However  it has witnessed negative earnings estimate revision of a penny over the past 30 days for the to be reported quarter  Merck has a VGM Score of D Amgen carries a Zacks Rank  3 and has an Earnings ESP of  0 28   indicating lower chance of beating estimates this quarter  The earnings surprise track over the past four quarters is strong  with the average positive surprise being 4 80   Amgen has witnessed no earnings estimate revision over the past 30 days for the quarter to be reported  The stock has a solid VGM Score of B  Amgen will report earnings on Jan 29 after market close AbbVie has a Zacks Rank  3 and an Earnings ESP of  1 07   indicating a reasonable chance of beating estimates this quarter  The company delivered a positive earnings surprise in the last four quarters  with the average beat being 3 54   It has seen positive earnings estimate revision of a penny over the past month for the to be reported quarter  The stock has a solid VGM Score of B  The company is scheduled to report on Jan 25 before the opening bell  read        Gilead is expected to release earnings on Feb 4 after market close  It has a Zacks Rank  4 and an Earnings ESP of  4 72   Gilead delivered average positive earnings surprise of 6 99  over the last four quarters and saw no earnings estimate revision over the past month for the to be reported quarter  It has a VGM Score of D Summing UpWith lower negative earnings revisions  the healthcare sector is expected to witness earnings growth of  in the fourth quarter  suggesting continued outperformance for healthcare ETFs  In particular  all the four ETFs have a Zacks ETF Rank  1  Strong Buy  or  2  Buy   see    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-01-23,Zacks Investment Research,https://www.investing.com/analysis/healthcare-etfs-in-focus-ahead-of-q4-earnings-200379055,200379055
149682,371198,AMGN,Can Amgen  AMGN  Keep The Earnings Surprise Streak Alive ,opinion,"If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report  you should consider Amgen  AMGN   This company  which is in the Zacks Medical   Biomedical and Genetics industry  shows potential for another earnings beat 
This world s largest biotech drugmaker has an established record of topping earnings estimates  especially when looking at the previous two reports  The company boasts an average surprise for the past two quarters of 8 35  
For the last reported quarter  Amgen came out with earnings of  3 69 per share versus the Zacks Consensus Estimate of  3 42 per share  representing a surprise of 7 89   For the previous quarter  the company was expected to post earnings of  3 52 per share and it actually produced earnings of  3 83 per share  delivering a surprise of 8 81  
Price and EPS Surprise

For Amgen  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Amgen has an Earnings ESP of  0 25  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  2  Buy   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on January 29  2019 
Investors should note  however  that a negative Earnings ESP reading is not indicative of an earnings miss  but a negative value does reduce the predictive power of this metric 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-01-20,Zacks Investment Research,https://www.investing.com/analysis/can-amgen-amgn-keep-the-earnings-surprise-streak-alive-200377701,200377701
149683,371199,AMGN,What s In Store For Bristol Myers  BMY  In Q4 Earnings ,opinion,"Bristol Myers Squibb Company   NYSE BMY   is expected to report fourth quarter 2018 results on Jan 24  before market opens Bristol Myers  shares have decreased 8 9  in the past six months  against the  s growth of 7 1   Bristol Myers has an excellent track record  The company delivered positive earnings surprise in all the four quarters  Average positive earnings surprise in the last four quarters is 12   In the last reported quarter  Bristol Myers delivered a positive surprise of 19 8  Let s see how things are shaping up for this quarter What Will Drive Growth in Q4 Bristol Myers  key immuno oncology drug  Opdivo is expected to be the primary revenue driver in the fourth quarter  with several line extensions in the past year  Earlier in 2018  Opdivo was approved as a monotherapy for the treatment of metastatic small cell lung cancer  SCLC  in third line setting in patients who have received platinum based chemotherapy and at least one other line of therapy  The drug also received approval for treating microsatellite instability high or mismatch repair deficient metastatic colorectal cancer  in combination with Yervoy in second line setting in the United States The European Commission recently approved the combination of Opdivo plus Yervoy for the first line treatment of patients with intermediate  and poor risk advanced renal cell carcinoma  RCC   Opdivo has already captured 30  share of new patients in the first line RCC market The drug  which is approved for multiple indications  has generated sales of  1 8 billion in the third quarter and  4 9 billion in the first nine months of 2018  increasing 42  and 37   respectively  from the year ago period Yervoy s line extension in pediatric patients aged 12 years or older with unresectable or metastatic melanoma was approved in Europe  The FDA approved the drug in combination with Opdivo for first line treatment of RCC  Label expansion of the drug should further boost sales Oncology drug  Sprycel is also maintaining momentum  The European Commission approved a line extension of Sprycel in pediatric patients with Ph  chronic myeloid leukemia  The FDA also approved the drug for the treatment of pediatric patients aged one year or older  with newly diagnosed Philadelphia chromosome positive  Ph   acute lymphoblastic leukemia  ALL   in combination with chemotherapy  We expect the recent label expansion of the drug to boost sales  Cardiovascular drug  Eliquis also showed strong performance in the first nine months of 2018  with sales growing 35  from the year ago quarter  In fact  robust sales are expected in the fourth quarter too  driven by expansion in market share However  the Hepatitis C and HIV businesses continue to face competitive pressure  Sales for the franchise are expected to decline Investors will also focus on further updates on the company s recent announcement of acquiring Celgene Corporation   NASDAQ CELG   for  74 billion  The impending acquisition will result in a specialty biopharma company with a strong oncology portfolio and diverse pipeline in the therapeutic areas of inflammatory  immunologic and cardiovascular diseases  Bristol Myers was pursuing an acquisition for quite some time now to bolster its portfolio  While its blockbuster immuno oncology drug  Opdivo continues to perform well on the back of label expansions  pricing concerns and stiff competition in the immuno oncology space have limited market share gains The Zacks Consensus Estimate for fourth quarter sales and earnings is pegged at  5 98 billion and 85 cents  respectively Earnings WhispersOur proven model does not conclusively show that Bristol Myers will beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen 
Earnings ESP  The company s Earnings ESP is  0 12   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Bristol Myers has a Zacks Rank  3  which is favorable  However  the company s negative Earnings ESP makes surprise prediction difficult Conversely  we caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Bristol Myers Squibb Company Price  Consensus and EPS Surprise    Stocks to ConsiderHere are some stocks you might want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter 
AbbVie Inc    NYSE ABBV   is scheduled to release its results on Jan 25  The company has an Earnings ESP of  2 65  and a Zacks Rank  2  You can see  Amgen  Inc    NASDAQ AMGN   is scheduled to release its results on Jan 29  The company has an Earnings ESP of  0 25  and a Zacks Rank  2 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-01-21,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-bristolmyers-bmy-in-q4-earnings-200377590,200377590
149689,371205,AMGN,Amgen  AMGN  Stock Moves  1 52   What You Should Know,opinion,"In the latest trading session  Amgen  AMGN  closed at  188 98  marking a  1 52  move from the previous day  This move was narrower than the S P 500 s daily loss of 2 48   Elsewhere  the Dow lost 2 83   while the tech heavy Nasdaq lost 3 04  
Coming into today  shares of the world s largest biotech drugmaker had lost 2 96  in the past month  In that same time  the Medical sector lost 9 67   while the S P 500 lost 8 82  
AMGN will be looking to display strength as it nears its next earnings release  which is expected to be February 7  2019  In that report  analysts expect AMGN to post earnings of  3 25 per share  This would mark year over year growth of 12 46   Our most recent consensus estimate is calling for quarterly revenue of  5 86 billion  up 1 03  from the year ago period 
It is also important to note the recent changes to analyst estimates for AMGN  Recent revisions tend to reflect the latest near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 23  higher  AMGN is holding a Zacks Rank of  3  Hold  right now 
Valuation is also important  so investors should note that AMGN has a Forward P E ratio of 13 33 right now  Its industry sports an average Forward P E of 22 43  so we one might conclude that AMGN is trading at a discount comparatively 
We can also see that AMGN currently has a PEG ratio of 1 97  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  AMGN s industry had an average PEG ratio of 1 35 as of yesterday s close 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 55  putting it in the top 21  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
You can find more information on all of these metrics  and much more  on Zacks com ",2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-stock-moves-152-what-you-should-know-200372706,200372706
149690,371206,AMGN,Merck Buys NASH Candidate  Keytruda Wins 5 Approvals In Japan,opinion,Merck   Co   Inc    NYSE MRK   announced that it has exercised its option to in license a once monthly insulin sensitizer  NGM313  from partner NGM Biopharmaceuticals  Inc   being developed for the treatment of NASH and type II diabetes With this deal  Merck gets exclusive global rights to develop  manufacture and commercialize NGM313  now renamed as MK 3655  The company made a payment of  20 million to NGM for securing the deal Merck and NGM share a broad multi year strategic collaboration since 2015 to discover novel biologic therapies across a wide range of therapeutic areas  The latest deal is part of this collaboration Merck s one time option was triggered as NGM completed a phase Ib proof of concept study on the candidate  Data from the study presented last November showed that a single dose of the medicine led to a statistically significant reduction in liver fat content  LFC  and improvements in multiple metabolic parameters after five weeks of treatment Merck plans to initiate a phase IIb study on the candidate while NGM Biopharmaceuticals retains the option to take a 50  cost and profit sharing partnership for NGM313 once the candidate enters late stage development  In case NGM does not exercise this option  it will be entitled to future milestones and royalty payments In the past year  shares of Merck have outperformed the   The stock has rallied 29 9  compared with 1 2  increase for the industry   Meanwhile  Merck s PD 1 inhibitor  Keytruda  gained five new label expansion approvals in Japan  These included a first line treatment option for advanced non small cell lung cancer  NSCLC  as both monotherapy and in combination with chemotherapy  an adjuvant therapy for melanoma and for advanced microsatellite instability high  MSI H  tumors Keytruda is a key contributor to Merck s sales  Within a very short span  Keytruda has become Merck s largest product  It is already approved for use in 12 indications across eight different tumor types in the United States The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 850 studies including 400 plus combination studies  Merck is collaborating with several companies  namely Amgen   NASDAQ AMGN    Incyte   NASDAQ INCY    Glaxo   NYSE GSK   and Pfizer  NYSE PFE  separately for the evaluation of Keytruda combined with other regimens Merck currently carries a Zacks Rank  2  Buy   You can  The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2019-01-04,Zacks Investment Research,https://www.investing.com/analysis/merck-buys-nash-candidate-keytruda-wins-5-approvals-in-japan-200372817,200372817
149693,371209,AMGN,Amgen s Osteoporosis Candidate Evenity Gets Approval In Japan,opinion,Amgen  Inc    NASDAQ AMGN   and its partner UCB announced that its osteoporosis candidate  Evenity  romosozumab  has gained marketing approval in Japan  the first regulatory approval for the pipeline product  Evenity has been approved In Japan to reduce the risk of fractures and increase bone mineral density in men and postmenopausal women with osteoporosis at high risk of fracture Evenity is also under review in United States and Europe  In the United States  Amgen re submitted the biologics license application   BLA   in July last year  The first BLA seeking approval of Evenity for the same indication in the United States was issued a complete response letter   CRL   by the FDA in July 2017  The CRL was issued due to a cardiovascular side effect observed in the ARCH study  The first BLA included data only from FRAME study  The FDA requested a resubmission of the application with additional data from the ARCH and the BRIDGE studies  The second BLA includes data from the ARCH and BRIDGE studies In November  Amgen had informed that the FDA s Bone  Reproductive and Urologic Drugs Advisory Committee  BRUDAC  will review the BLA for Evenity on Jan 16  2019 In Japan  the development of Evenity is being led by Astellas BioPharma  a joint venture between Amgen and Japanese drug company  Astellas Pharma In the past year  Amgen s stock has risen 9 7  against 21 2  decrease of its    Separately  Amgen announced that all device options of its PCSK9 inhibitor  Repatha including pre filled syringe and the Pushtronex system are now available in the United States at a discount of 60   The products are now available at a reduced list price of  5 850 per year Amgen announced its decision to cut the U S  list price of Repatha by 60  in October last year to improve access and affordability of Repatha  Please note that Repatha SureClick autoinjector  the most popular device option of Repatha  has been available at a discounted price since Oct 24 last year Sales of the drug have suffered since launch due to payer restrictions  At the third quarter conference call held in October  Amgen had said that despite its efforts to improve access to Repatha  patients still face significant hurdles due to high co pay expenses  Though lower price may impact Repatha sales in the near term  management is optimistic about better volumes Amgen currently carries a Zacks Rank  3  Hold   You can see  Some better ranked stocks in the biotech sector are Aeterna Zentaris Inc    TO AEZS    Vanda Pharmaceuticals Inc    NASDAQ VNDA   and Inovio Pharmaceuticals  Inc    NASDAQ INO    all sporting a Zacks Rank  1 Estimates for Aeterna Zentaris have been revised from a loss of 37 cents to earnings of 2 cents for 2019 over the past 60 days  The stock has soared 48 9  in the past year Vanda s earnings estimates have moved 11 1  north for 2019 over the past 90 days  The stock has surged 106 5  in a year Inovio s loss estimates have remained unchanged in the past 60 days  The stock has risen 9 2  in a year Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2019-01-08,Zacks Investment Research,https://www.investing.com/analysis/amgens-osteoporosis-candidate-evenity-gets-approval-in-japan-200374034,200374034
149694,371210,AMGN,Big Pharma CEOs Indicate More M A Deals At JP Morgan Meeting,opinion,Several pharma and biotech companies participated in the prestigious J P  Morgan Healthcare Conference held in San Francisco  CA this week  After two big M A announcements early in the year  a key topic of discussion at the meeting was the possibility of more pharma and biotech M A activity in 2019 The year began with the announcement of the mega merger of cancer giants Bristol Myers   NYSE BMY   and Celgene   NASDAQ CELG    Bristol Myers offered  74 billion in cash and stock to acquire Celgene In another big deal  Lilly   NYSE LLY   offered to take over Loxo Oncology for  8 billion to expand its oncology portfolio into precision medicines or targeted therapies  In December 2018  Glaxo   NYSE GSK   had offered to acquire TESARO for almost  5 1 billion  which will add the latter s PARP inhibitor  Zejula  approved for ovarian cancer  to Glaxo s portfolio After these announcements  it is widely speculated that more M A activity  including mega mergers as well as strategic collaborations can happen  Chief executive officers   CEO   of some of the biggest biotech and pharma companies stressed on the same fact at the JP Morgan conference Big pharma companies are cash rich following the tax overhaul in 2017  which reduced the tax rate  The high premiums in the above deals also suggest the same  Moreover  the pullback in biotech stocks towards the end of 2018 lowered valuations of these companies  making them attractive buyout targets Albert Bourla  Pfizer s   NYSE PFE   new CEO said that the company will continue on the same track though it will stay away from any  destructive deals   Bourla showed interest in adding mid  and late stage assets to its pipeline in its six therapeutic areas of focus  Merck s   NYSE MRK   CEO Ken Frazier said that possibilities of more M A activity are high as valuations are coming down  Merck has not made a big acquisition lately  Justifying this  Frazier said that though the company tried to ink some deals  none worked out due to lack of a willing seller or because the late stage asset was too robustly competitive Lilly CEO David Ricks said that the company will continue to evaluate other potential deal targets   after the Loxo announcement   to enhance its position in its core therapeutic areas like cancer  immunology and neuroscience  Glaxo CEO Emma Walmsley also said that the company will look for early stage assets and strike partnerships Biotech giant Amgen s   NASDAQ AMGN   CEO  Robert Bradway said that the company s strong balance sheet and cash flow should allow it to expand its portfolio by  acquiring or in licensing attractive innovation   AbbVie s vice chairman and president  Mike Severino showed interest in strengthening the company s pipeline through  strategic licensing  acquisition and partnering activity  Undoubtedly  the string of M A announcements early in the year sets the tone for the rest of the year  However  it should be kept in mind that 2018 also began with a bang with expectations of record breaking activity in the year  However  the number of mergers and acquisitions dwindled after the first few months  probably because potential acquisition targets demanded a premium So  it remains to be seen if M A activity keeps up the momentum in 2019 or replicates last year s trajectory Among the large drug and biotech companies mentioned in the article  Lilly  AbbVie  NYSE ABBV  and Merck carry a Zacks Rank  2  Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-09,Zacks Investment Research,https://www.investing.com/analysis/big-pharma-ceos-indicate-more-ma-deals-at-jp-morgan-meeting-200374397,200374397
149695,371211,AMGN,What s In Store For Merck In 2019 After A Solid Run In  18 ,opinion,"After a solid run in 2018  supported by strong quarterly results and positive pipeline and regulatory updates  Merck   Co   Inc    NYSE MRK   looks well poised to continue the  momentum in 2019 Merck s shares outperformed the  in 2018  rising 35 8  compared with a 4 7  increase for the industry   Strong Sales   Earnings PerformanceMerck s sales rose 5  in first nine months of 2018 while adjusted earnings per share rose almost 10   Pharmaceutical segment sales rose 7  in nine months while that of the Animal Health unit rose 10  Strength in Keytruda  Bridion  Gardasil and Animal Health offset headwinds from loss of exclusivity for some products and competitive pressure for Zostavax and Zepatier  Keytruda continued its robust performance on strong demand Keytruda  A Key Growth CatalystA significant part of Merck s outperformance this year was driven by strong performance and positive regulatory updates related to its PD 1 inhibitor  Keytruda  In a very short span of time  Keytruda has become Merck s largest product  It is already approved for use in several indications across eight different tumor types in the United States  It is continuously growing and gaining approval for new indications and markets globally  Sales are gaining particularly from strong momentum in the indication of first line lung cancer as it is the only anti PD 1 approved in the setting both as a monotherapy as well as combination therapy In fact  the Keytruda development program is also progressing rapidly  Merck is conducting numerous studies to evaluate Keytruda for more than 30 types of cancer in more than 850 studies  including more than 500 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte   NASDAQ INCY    Glaxo and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens 
Other Pipeline Regulatory SuccessKey approvals for Merck in 2018 included that of Steglatro and its fixed dose combinations for type II diabetes  two new HIV drugs   Pifeltro and Delstrigo   containing doravirine and Prevymis  letermovir  for cytomegalovirus  CVM  infection Merck also gained several label expansion approvals for Keytruda and another cancer drug Lynparza  which it markets in partnership with AstraZeneca   NYSE AZN    For Keytruda  a key FDA approval in October was the label expansion as a first line treatment for metastatic squamous non small cell lung cancer  NSCLC    a difficult to treat lung cancer patient population   based on data from the phase III KEYNOTE 407 study Lynparza was also approved by the FDA in the first line maintenance setting in December  becoming the first PARP inhibitor to be approved as a first line maintenance therapy for BRCA mutated advanced ovarian cancer  These new products and line extensions should bring in additional sales in 2019 and beyond Merck also announced positive data from several late stage studies  mainly evaluating Keytruda for further line extensions Merck also signed a co development deal with Japan s Eisai Co   Ltd for the latter s tyrosine kinase inhibitor  Lenvima  It also agreed to buy Viralytics Limited  an Australian pharmaceutical company that develops oncolytic immunotherapies for a range of cancers  which should strengthen its oncology portfolio  In December  Merck announced plans to acquire privately held animal health technology provider Antelliq Group from BC PartnersWhat to Expect in 2019 For Keytruda  several regulatory decisions for new indications in the United States as well as in Europe are due in 2019  which if approved can further boost sales  Key FDA decisions expected in the first half will be on regulatory filings for label expansion of Keytruda as an adjuvant therapy in patients with high risk stage III melanoma and for patients with non squamous or squamous lung cancer whose tumors express PD L1 protein levels of 1 percent or greater  TPS of  1 percent  Meanwhile  Keytruda  Bridion  Lynparza  Gardasil and Animal Health should continue the strong performance  driving sales and profits in 2019  This should make up for headwinds from loss of exclusivity  LOEs   softness in the diabetes franchise  and competitive pressure on Zepatier and Zostavax Merck will also continue to focus on cost cutting initiatives  which should drive itsbottom line Merck currently carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2019-01-13,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-merck-in-2019-after-a-solid-run-in-18-200375230,200375230
149696,371212,AMGN,Is Amgen  AMGN  Stock Outpacing Its Medical Peers This Year ,opinion,"Investors focused on the Medical space have likely heard of Amgen  NASDAQ AMGN   but is the stock performing well in comparison to the rest of its sector peers  One simple way to answer this question is to take a look at the year to date performance of AMGN and the rest of the Medical group s stocks 
Amgen is one of 842 individual stocks in the Medical sector  Collectively  these companies sit at  2 in the Zacks Sector Rank  The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors 
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks  This system has a long record of success  and these stocks tend to be on track to beat the market over the next one to three months  AMGN is currently sporting a Zacks Rank of  2  Buy  
Within the past quarter  the Zacks Consensus Estimate for AMGN s full year earnings has moved 0 60  higher  This signals that analyst sentiment is improving and the stock s earnings outlook is more positive 
Based on the most recent data  AMGN has returned 3 03  so far this year  At the same time  Medical stocks have gained an average of 2 25   This shows that Amgen is outperforming its peers so far this year 
Breaking things down more  AMGN is a member of the Medical   Biomedical and Genetics industry  which includes 345 individual companies and currently sits at  58 in the Zacks Industry Rank  On average  this group has gained an average of 11 18  so far this year  meaning that AMGN is slightly underperforming its industry in terms of year to date returns 
Investors in the Medical sector will want to keep a close eye on AMGN as it attempts to continue its solid performance ",2019-01-13,Zacks Investment Research,https://www.investing.com/analysis/is-amgen-amgn-stock-outpacing-its-medical-peers-this-year-200375286,200375286
149727,371243,AMGN,Merck s Keytruda Gets FDA Approval For Rare Skin Cancer,opinion,Merck   Co   Inc    NYSE MRK   announced that the FDA has approved its anti PD 1 therapy  Keytruda  for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma  MCC   a rare form of skin cancer The approval was based on favorable data from the open label phase II KEYNOTE 017 study  initiated and conducted by the Cancer Immunotherapy Trials Network  CITN  Data from the study showed that as a monotherapy  Keytruda demonstrated an objective response rate of 56   complete response rate of 24  and a partial response rate of 32  in patients with recurrent locally advanced or metastatic MCC  who previously did not receive any systemic therapy for their disease Notably in September this year  the FDA accepted and granted a priority review to Merck s supplemental biologics license application  sBLA  for Keytruda in the given indication  The FDA s decision was expected on Dec 28 The FDA nod came under the accelerated approval pathway  The FDA generally grants an accelerated approval to a drug that fulfills an unmet medical need for a serious condition  Continued approval for this indication may be contingent upon verification and description of a clinical benefit observed in confirmatory studies Till now  chemotherapy was the only treatment option available for patients suffering MCC  This approval will help Merck gain access to a broader patient population and boost sales for its blockbuster drug Shares of Merck have surged 31 1  so far this year  outperforming the  increase of 2 4  Merck s Keytruda is already approved for use in several cancer types across different settings  Within a very short span  Keytruda has become Merck s largest product  In the first nine months of 2018  Keytruda generated sales of  5 02 billion  marking an almost 100  increase year over year  The drug is consistently growing and expanding into new indications Notably  this November  the FDA granted an approval to Merck s sBLA for expanding Keytruda s label with regard to advanced hepatocellular carcinoma  HCC   the most common type of liver cancer in patients  previously being administered with Bayer Amgen s   NASDAQ AMGN   Nexavar  sorafenib   Also  in October 2018  the FDA approved the label expansion of Keytruda as a first line treatment option for metastatic squamous non small cell lung cancer  NSCLC   a difficult to treat lung cancer Meanwhile  the Keytruda development program is also progressing well as the drug is being evaluated for more than 30 cancer types in above 850 analyses including several combination studies  Several regulatory decisions for new indications in the United States and across Europe are pending in 2019  which on approval  can further drive sales Zacks Rank   Other Key PicksMerck currently carries a Zacks Rank  2  Buy   Other top ranked stocks in the large cap pharma sector include Bristol Myers Squibb Company   NYSE BMY   and Roche Holding  SIX ROG  AG   OTC RHHBY    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Roche carries a Zacks Rank of 2  You can see  Bristol Myers  earnings estimates have been revised 6 3  upward for 2018 and 5 1  for 2019 over the past 60 days Roche s earnings estimates have moved 0 9  north for 2018 and 2 6  for 2019 over the past 60 days  The stock has rallied 11 6  in the past six months Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-12-19,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-gets-fda-approval-for-rare-skin-cancer-200370083,200370083
149728,371244,AMGN,Lilly s Shares Rise On Robust 2019 View  Dividend Hike,opinion,"Eli Lilly   Company s   NYSE LLY   provided better than expected financial outlook for 2019 at its investor meeting  This indicates that the company is poised to record another strong year 
Lilly expects revenues to be between  25 3 billion and  25 8 billion in 2019  representing mid single digit growth  Revenue growth is expected to be driven by higher demand for its newer medicines including Trulicity  Jardiance  Taltz  Verzenio as well as newly launched migraine drug  Emgality as some older drugs  like erectile dysfunction drug  Cialis  lose patent exclusivity 
Lilly has launched 10 medicines over the past five years  which were developed in house or in licensed from external partners  These new drugs are expected to account for 45  of Lilly s pharmaceuticals sales in 2019 
Earnings per share are expected to be  5 90 to  6 00 in 2019  excluding approximately 8 cents per share for the non controlling interest in Elanco Animal Health Inc    NYSE ELAN    Lilly divested its Elanco animal health unit as an independent publicly traded company   Elanco Animal Health Incorporated   via an initial public offering  IPO  of a minority stake this year 
Lilly s revenue and earnings guidance range for 2019 was above market expectations as well as the Zacks Consensus Estimate of  24 9 billion and  5 79 per share  respectively 
Shares of Lilly were up almost 3  on Wednesday in response to the encouraging forecast  Lilly s shares have rallied 29 2  this year so far compared with the  s increase of 2 4  
 

 
Lilly raised its long term revenue growth expectations as well  The company now expects annual revenue growth of at least 6  during the 2015 2020 period  up from 5  expected previously  For its Pharmaceuticals unit  Lilly expects 7  growth over the same time period  The company re affirmed its 2018 EPS expectation in the range of  5 55 to  5 60 
Lilly also reviewed its financial performance at the meeting and highlighted promising pipeline opportunities  It expects U S  regulatory action for nasal glucagon for hypoglycemia and lasmiditan for acute migraine in 2019 as well as line extension approvals for several medicines 
Separately  Lilly also announced a 15  increase in its dividend to 64 5 cents per share based on its growth prospects 
Meanwhile  Lilly s chief executive officer  CEO  Dave Ricks spoke about competition in the migraine space in an interview to CNBC  Emgality  a CGRP antibody  faces intense competition from Amgen   NASDAQ AMGN   Novartis  and Teva s   NYSE TEVA   CGRPs  Aimovig and Ajovy  respectively  Both were approved by the FDA in mid 2018 
Ricks said it will be a  horse race  between the three companies to capture market share  However  he sounded confident that some of their skills in reaching consumers will help it in this regard 
Lilly currently carries a Zacks Rank  2  Buy  You can see  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-20,Zacks Investment Research,https://www.investing.com/analysis/lillys-shares-rise-on-robust-2019-view-dividend-hike-200370059,200370059
149729,371245,AMGN,Amgen  AMGN  Stock Moves  1   What You Should Know,opinion,"In the latest trading session  Amgen  AMGN  closed at  178 40  marking a  1  move from the previous day  This change was narrower than the S P 500 s 2 71  loss on the day  Meanwhile  the Dow lost 2 91   and the Nasdaq  a tech heavy index  lost 2 21  
Coming into today  shares of the world s largest biotech drugmaker had lost 6 52  in the past month  In that same time  the Medical sector lost 8 61   while the S P 500 lost 8 68  
Wall Street will be looking for positivity from AMGN as it approaches its next earnings report date  This is expected to be February 7  2019  The company is expected to report EPS of  3 25  up 12 46  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  5 86 billion  up 1 03  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  14 24 per share and revenue of  23 35 billion  which would represent changes of  13 2  and  2 18   respectively  from the prior year 
Any recent changes to analyst estimates for AMGN should also be noted by investors  Recent revisions tend to reflect the latest near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 01  higher  AMGN is holding a Zacks Rank of  3  Hold  right now 
Digging into valuation  AMGN currently has a Forward P E ratio of 12 66  For comparison  its industry has an average Forward P E of 21 73  which means AMGN is trading at a discount to the group 
Also  we should mention that AMGN has a PEG ratio of 1 87  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  AMGN s industry had an average PEG ratio of 1 35 as of yesterday s close 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 66  which puts it in the top 26  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
You can find more information on all of these metrics  and much more  on Zacks com ",2018-12-24,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-stock-moves-1-what-you-should-know-200370803,200370803
149730,371246,AMGN,Will AbbVie  ABBV  Shares Regain Lost Momentum In 2019 ,opinion,AbbVie  Inc  s   NYSE ABBV   stock has declined 7  this year so far against an increase of 2 1  recorded by the    A couple of pipeline setbacks as well as concerns about the impact of EU biosimilar launches on sales of its blockbuster drug Humira hurt the stock this year despite several regulatory approvals and pipeline successes In early December  AbbVie   evaluating its cancer candidate rovalpituzumab tesirine or Rova T in second line small cell lung cancer  SCLC   In March  Rova T fell short of expectations in a phase II TRINITY study evaluating it in third line or later SCLC Rova T was added to AbbVie s portfolio following the  5 8 billion acquisition of Stemcentrx in June 2016  The failure of TRINITY and the clinical hold on TAHOE raised skepticism about Rova T s potential and has brought into question the viability of the Stemcentrx deal  Meanwhile  Humira has been performing well based on strong demand trends despite new competition  Though Humira sales continue to be impressive  direct biosimilar competition in Europe can erode Humira revenues in 2019 Several companies have made biosimilar versions of Humira  Per settlements  Amgen   NASDAQ AMGN    Pfizer   NYSE PFE    Mylan   NASDAQ MYL    Fresenius Kabi  Momenta  Sandoz and Samsung  KS 005930  Bioepis Biogen s Humira biosimilars are expected to be launched in the United States in 2023  In the EU  Amgen  Sandoz and Biogen s biosimilars were launched in October this year while others like Momenta  Pfizer and Fresenius Kabi will launch their versions as soon as they get EMA s approval  Direct biosimilar competition in the EU is expected to erode AbbVie s  6 billion international Humira business in 2019  With Humira accounting for around 65  of AbbVie s sales  the entry of biosimilars will have a huge impact on the company s financials Nonetheless  AbbVie looks well poised to witness a turnaround in the New Year  In October  AbbVie had said it is confident of delivering double digit earnings growth in 2019 despite negative impact from EU Humira biosimilar entry  a difficult comparison year  as HCV sales ramped up rapidly in 2018  and significant investments to support product launches Humira sales are expected to remain strong as it sees strong prescription volume growth  Meanwhile  AbbVie s oncology haematology  including Imbruvica and Venclexta  sales should remain strong AbbVie has also been successful in expanding approvals for Imbruvica and Venclexta in 2018  Regulatory applications seeking approval for Venclexta plus Rituxan for relapse refractory CLL  based on MURANO study data  were approved in the United States in June and in the EU in October 2018  Label expansion for this indication has expanded the patient population for Venclexta significantly  which will boost its commercial potential Also  in November AbbVie gained FDA approval for Venclexta in first line AML  Imbruvica was approved by the FDA in combination use with Rituxan for the treatment of Waldenstr m s macroglobulinemia  WM   a rare form of Non Hodgkin s lymphoma in AugustThese line extension approvals can bring in additional sales in 2019 AbbVie s newest HCV medicine Mavyret gained approval in the United States  EU  Canada and Japan in 2017  Mavyret performed beyond expectations in the first year of launch recording sales of almost  500 million in 2017  The drug recorded sales of  2 6 billion in the first nine months of 2018  commanding a global market share of 50   Mavyret is expected to keep up the strong performance in 2019 Meanwhile  AbbVie has a deep pipeline consisting of several interesting late stage candidates  In 2019  we expect FDA approvals for two key pipeline candidates    risankizumab for plaque psoriasis and upadacitinib for rheumatoid arthritis    both of which are under FDA s review  Meanwhile  these candidates are also being studied for additional indications  which can provide further growth opportunities AbbVie currently carries a Zacks Rank  3  Hold   You can see Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-12-27,Zacks Investment Research,https://www.investing.com/analysis/will-abbvie-abbv-shares-regain-lost-momentum-in-2019-200371571,200371571
149765,371281,AMGN,Amgen  AMGN  Gains But Lags Market  What You Should Know,opinion,"Amgen  AMGN  closed at  196 41 in the latest trading session  marking a  0 12  move from the prior day  This change lagged the S P 500 s 0 54  gain on the day  Meanwhile  the Dow gained 0 64   and the Nasdaq  a tech heavy index  added 0 95  
Prior to today s trading  shares of the world s largest biotech drugmaker had gained 2 42  over the past month  This has outpaced the Medical sector s loss of 2 71  and the S P 500 s loss of 4 97  in that time 
Investors will be hoping for strength from AMGN as it approaches its next earnings release  which is expected to be February 7  2019  The company is expected to report EPS of  3 25  up 12 46  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  5 86 billion  up 1 03  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  14 24 per share and revenue of  23 34 billion  which would represent changes of  13 2  and  2 13   respectively  from the prior year 
It is also important to note the recent changes to analyst estimates for AMGN  Recent revisions tend to reflect the latest near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 01  lower within the past month  AMGN is holding a Zacks Rank of  3  Hold  right now 
Valuation is also important  so investors should note that AMGN has a Forward P E ratio of 13 78 right now  Its industry sports an average Forward P E of 23 61  so we one might conclude that AMGN is trading at a discount comparatively 
It is also worth noting that AMGN currently has a PEG ratio of 2 04  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  The Medical   Biomedical and Genetics was holding an average PEG ratio of 1 53 at yesterday s closing price 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 66  which puts it in the top 26  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow AMGN in the coming trading sessions  be sure to utilize Zacks com ",2018-12-12,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-gains-but-lags-market-what-you-should-know-200367550,200367550
149766,371282,AMGN,Pfizer s  PFE  Biosimilar Of Avastin Gets Positive CHMP Nod,opinion,"Pfizer Inc    NYSE PFE   announced that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  has given a positive opinion recommending marketing authorization for Zirabev  bevacizumab   a biosimilar version of Roche s   OTC RHHBY   cancer drug Avastin  An application seeking approval of a biosimilar version of Avastin is under review in the United States as well 
Pfizer is looking to get Zirabev approved for the treatment of several cancer indications  for which the reference product is approved like colon cancer metastatic breast cancer  unresectable advanced  metastatic or recurrent non small cell lung cancer  NSCLC   among others 
The regulatory application is supported by positive results of the phase III REFLECTIONS B739 03 comparative study  which showed clinical equivalence and found no clinically meaningful differences between Zirabev and Avastin in patients with advanced non squamous NSCLC  Zirabev has been studied in about 400 subjects in the REFLECTIONS study  
Shares of the company have increased 25 2  compared with the  s growth of 8 4  year to date 

Zirabev is Pfizer s second therapeutic oncology biosimilar to receive a positive CHMP opinion from the EMA in 2018  A biosimilar version of Roche s Herceptin was approved in the EU in July 2018  In Europe  Pfizer already markets biosimilar versions of Amgen s   NASDAQ AMGN   drugs  Neupogen and Epogen 
In the United States  a biosimilar of Neupogen was launched in late September  while a biosimilar version of Epogen was approved in May 2018  Other than Avastin Biosimilar versions of Roche s cancer drugs  Rituxan and Herceptin are also under review in the United States  The FDA s decision on all these candidates are expected in 2019  
Separately  Pfizer also initiated a phase III study on its 20 Valent pneumococcal conjugate vaccine candidate  PF 06482077  for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults aged 18 years or older  Please note that PF 06482077 received Breakthrough Therapy Designation by the FDA in September 2018 Pfizer Inc  Price

    
Zacks Rank and Stock to Consider
Pfizer currently carries a Zacks Rank  3  Hold  
A better ranked stock worth considering is Bristol Myers Squibb Company   NYSE BMY    sporting a Zacks Rank  1  Strong Buy   You can see  
Bristol Myers  earnings per share estimates have increased from  3 64 to  3 87 for 2018 and  3 94 to  4 14 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 11 99  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-12-17,Zacks Investment Research,https://www.investing.com/analysis/pfizers-pfe-biosimilar-of-avastin-gets-positive-chmp-nod-200368867,200368867
149767,371283,AMGN,Teva Reports Positive Top Line Data For Migraine Candidate ,opinion,Teva Pharmaceutical Industries Ltd    NYSE TEVA   announced positive top line results from the phase IIIb FOCUS study that evaluated the efficacy and safety of fremanezumab for the preventive treatment of migraine in adult patients who previously experienced inadequate responses to two to four classes of preventive treatments We remind investors that fremanezumab is marketed as Ajovy injection in the United States for prevention of chronic episodic migraine  The drug is the first and only anti calcitonin gene related peptide   CGRP   treatment  which is approved with monthly  225 mg  and quarterly  675 mg  dosing options  FOCUS study is the first of its type to be conducted in chronic as well as episodic migraine patients  The study evaluated the efficacy  safety and tolerability of quarterly and monthly treatment with fremanezumab compared to placebo  In the study  838 patients were enrolled  Patients treated with fremanezumab experienced highly significant reduction in the monthly average number of migraine days versus placebo   0 6 days  over the 12 week assessment period  for both monthly and quarterly dosing regimens Further  patients treated with fremanezumab experienced significant improvement compared to placebo on all secondary endpoints  for both quarterly and monthly dosing regimens  Shares of the company have decreased 6 9  year to date compared with the  s decline of 17 8   Migraine has limited treatment options and anti CGRP is a new treatment mechanism  However  Amgen   NASDAQ AMGN    Novartis    NYSE NVS   Aimovig  erenumab  was approved and launched for prevention of migraine in the second quarter of 2018  Eli Lilly and Company s   NYSE LLY   CGRP antibody  Emgality  galcanezumab  received approval by the FDA in September for the preventive treatment of migraine in adults  Teva Pharmaceutical Industries Ltd  Price   Zacks RankTeva currently carries a Zacks Rank  2  Buy   You can see  3 Medical Stocks to Buy Now The greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-12-17,Zacks Investment Research,https://www.investing.com/analysis/teva-reports-positive-topline-data-for-migraine-candidate-200369178,200369178
149768,371284,AMGN,Merck s Keytruda Gets EU Nod As Adjuvant Therapy For Melanoma,opinion,Merck   Co   Inc    NYSE MRK   announced that the European Commission has approved its anti PD 1 therapy  Keytruda  for the treatment of high risk stage III melanoma patients in the adjuvant setting The nod was based on favorable data from the pivotal phase III KEYNOTE 054 study  The study was conducted in collaboration with the European Organization for Research and Treatment of Cancer  EORTC  Data from the study showed that as an adjuvant treatment  Keytruda significantly prolonged recurrence free survival  RFS  post surgery compared with placebo in patients  The drug reduced the risk of disease relapse or death by 44  compared with placebo in the overall patient population Keytruda is already approved in the EU as a monotherapy for treating adult patients with advanced melanoma  The approval in the adjuvant setting will help Merck gain access to a broader patient population and boost sales for this blockbuster drug Shares of Merck have surged 33 7  so far this year  outperforming the  increase of 5  Merck s Keytruda is already approved for use in several cancer types across different settings  Within a very short span  Keytruda has become Merck s largest product  In the first nine months of 2018  Keytruda generated sales of  5 02 billion  an almost 100  increase year over year  The drug is continuously growing and expanding into new indications Notably  this November  the FDA granted an approval to Merck s supplemental biologics license application  sBLA   looking to expand Keytruda s label for the treatment of advanced hepatocellular carcinoma  HCC   the most common type of liver cancer in patients  who were previously treated with Bayer Amgen s   NASDAQ AMGN   Nexavar  sorafenib   Also  in October 2018  the FDA approved the label expansion of Keytruda as a first line treatment for metastatic squamous non small cell lung cancer  NSCLC   a difficult to treat lung cancer Meanwhile  the Keytruda development program is also progressing well as the drug is being evaluated for more than 30 types of cancer in above 850 analyses including several combination studies  Several regulatory decisions for new indications in the United States and in Europe are pending in 2019  which on approval  can further boost sales Zacks Rank   Other Key PicksMerck currently carries a Zacks Rank  2  Buy   Other top ranked stocks in the large cap pharma sector include Bristol Myers Squibb Company   NYSE BMY   and Roche Holding  SIX ROG  AG   OTC RHHBY    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Roche carries a Zacks Rank of 2  You can see  Bristol Myers  earnings estimates have been revised 6 3  upward for 2018 and 5 1  for 2019 over the past 60 days Roche s earnings estimates have moved 0 9  north for 2018 and 2 6  for 2019 over the past 60 days  The stock has rallied 17  in the past six months 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-12-17,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-gets-eu-nod-as-adjuvant-therapy-for-melanoma-200369154,200369154
149769,371285,AMGN,Amgen  AMGN  Stock Sinks As Market Gains  What You Should Know,opinion,"In the latest trading session  Amgen  AMGN  closed at  187 10  marking a  1 57  move from the previous day  This move lagged the S P 500 s daily gain of 0 01   Elsewhere  the Dow gained 0 35   while the tech heavy Nasdaq added 0 45  
Coming into today  shares of the world s largest biotech drugmaker had lost 2 48  in the past month  In that same time  the Medical sector lost 5 57   while the S P 500 lost 7 29  
AMGN will be looking to display strength as it nears its next earnings release  which is expected to be February 7  2019  In that report  analysts expect AMGN to post earnings of  3 25 per share  This would mark year over year growth of 12 46   Meanwhile  our latest consensus estimate is calling for revenue of  5 86 billion  up 1 03  from the prior year quarter 
For the full year  our Zacks Consensus Estimates are projecting earnings of  14 24 per share and revenue of  23 34 billion  which would represent changes of  13 2  and  2 13   respectively  from the prior year 
Any recent changes to analyst estimates for AMGN should also be noted by investors  These revisions help to show the ever changing nature of near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate remained stagnant  AMGN is currently sporting a Zacks Rank of  3  Hold  
Valuation is also important  so investors should note that AMGN has a Forward P E ratio of 13 35 right now  For comparison  its industry has an average Forward P E of 21 42  which means AMGN is trading at a discount to the group 
Also  we should mention that AMGN has a PEG ratio of 1 97  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  Medical   Biomedical and Genetics stocks are  on average  holding a PEG ratio of 1 46 based on yesterday s closing prices 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 69  putting it in the top 27  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2018-12-18,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-stock-sinks-as-market-gains-what-you-should-know-200369299,200369299
149804,371320,AMGN,AbbVie Settles With Pfizer For Humira Biosimilar In U S ,opinion,AbbVie  Inc    NYSE ABBV   signed a non exclusive licensing deal with Pfizer   NYSE PFE   regarding the latter s proposed biosimilar version of its blockbuster rheumatoid arthritis drug  Humira  Per the deal  Pfizer will have a non exclusive license to launch its biosimilar Humira in the United States on Nov 20  2023  In the EU  Pfizer can launch Humira biosimilar when it gets approval from the European Medicines Agency Per the terms of the settlement  Pfizer will pay royalties to AbbVie once its cheaper version is launched  AbbVie will make no payments to Pfizer AbbVie made it clear that Pfizer s U S  license will not be accelerated by biosimilar launches by other companies  which have similar licensing deals AbbVie AbbVie s stock has declined 2 5  this year so far against with the  s increase of 11 3    Humira is a key driver of AbbVie s revenues  accounting for more than 60  of its total sales  Currently approved for several indications  Humira sales increased 11  in the first nine months of 2018 to  15 billion backed by robust demand trends despite new competition  The product continues to see strong growth in the dermatology and gastroenterology markets  The company expects Humira sales to approach  21 billion in 2020 With Humira accounting for such a significant amount of AbbVie s total sales  the entry of biosimilars will have a huge impact on the company s financials However  AbbVie has successfully struck similar licensing deals with several companies  which have made biosimilar versions of Humira to protect its U S  revenues from the drug  Per the settlement deals  Amgen   NASDAQ AMGN    Mylan   NASDAQ MYL    Fresenius Kabi  Momenta  Sandoz and Samsung  KS 005930  Bioepis Biogen s Humira biosimilars are expected to be launched in the United States in 2023 The settlements give AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when Humira biosimilars are launched  AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023 However  in the EU  Amgen  Sandoz and Biogen s biosimilars were launched in October this year while others like Momenta  Fresenius Kabi and Pfizer will launch their versions as soon as they get EMA s approval Direct biosimilar competition in the EU is expected to erode AbbVie s  6 billion international Humira business in 2019 AbbVie currently has a Zacks Rank  3  Hold   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-12-02,Zacks Investment Research,https://www.investing.com/analysis/abbvie-settles-with-pfizer-for-humira-biosimilar-in-us-200364465,200364465
149805,371321,AMGN,Roche s Tecentriq Combination Gets Priority Review By FDA,opinion,Roche Holding  SIX ROG  AG   OTC RHHBY   announced that the FDA has accepted the company s supplemental Biologics License Application  sBLA  for and granted Priority Review to Tecentriq  atezolizumab  in combination with carboplatin and etoposide  chemotherapy   for the initial  first line  treatment of patients with extensive stage small cell lung cancer  ES SCLC   The FDA is expected to make a decision by Mar 18  2019 Priority Review designation from the FDA is generally granted to drugs with potential to provide significant improvements in the safety and effectiveness of the treatment plus prevention or diagnosis of a serious disease We note that Tecentriq is already approved in the United States and European Union for patients with previously treated metastatic NSCLC and for patients with locally advanced or metastatic urothelial cancer  mUC  who are not eligible for cisplatin chemotherapy or who have had disease progression during or following platinum containing therapy This sBLA is based on results from the phase III IMpower133 study that met its overall survival  OS  and progression free survival  PFS co primary endpoints  per the study protocol  The results of the study showed that initial  first line  treatment with the combination of Tecentriq and chemotherapy  carboplatin and etoposide  enabled patients with ES SCLC live significantly longer compared to chemotherapy alone   The combination also reduced the risk of disease worsening or death  PFS  compared to chemotherapy alone Roche s stock has gained 4 4  so far this year compared with the  s growth of 12 6  Approval of new drugs and a potential label expansion of existing drugs bode well for Roche  as its legacy drugs like Herceptin and MabThera are facing competition from biosimilars Novartis   NYSE NVS   has already launched its biosimilar version of Rituxan MabThera in Europe   Amgen   NASDAQ AMGN   obtained FDA approval for a biosimilar version of Avastin for the treatment of five types of cancers  including lung cancer  colorectal cancer  glioblastoma  renal cell carcinoma and cervix cancer  Roche Holding AG Price    Zacks Rank and Stock to ConsiderRoche currently carries a Zacks Rank  3  Hold  A better ranked stock worth considering is Bristol Myers Squibb Company   NYSE BMY    sporting a Zacks Rank  1  Strong Buy   You can see  Bristol Myers  earnings per share estimates have increased from  3 63 to  3 87 for 2018 and  3 92 to  4 08 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 11 99  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-04,Zacks Investment Research,https://www.investing.com/analysis/roches-tecentriq-combination-gets-priority-review-by-fda-200365251,200365251
149806,371322,AMGN,Why Is Ligand  LGND  Down 14 9  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Ligand Pharmaceuticals  LGND   Shares have lost about 14 9  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Ligand due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Ligand Beats on Q3 Earnings   Revenues  Raises ViewLigand reported third quarter 2018 adjusted earnings of  1 32 per share  significantly up from the year ago figure of 69 cents  The bottom line also beat the Zacks Consensus Estimate of 99 cents Total revenues in the quarter increased to  45 7 million from  33 4 million in the year ago period  Moreover  the top line surpassed the Zacks Consensus Estimate of  42 9 million Quarterly HighlightsRoyalty revenues were  36 1 million in the reported quarter  up approximately 64 8  year over year  Ligand primarily earned royalties on sales of Novartis  Promacta  Amgen  NASDAQ AMGN  s Kyprolis and Spectrum Pharmaceuticals  Evomela  which were developed using Ligand s Captisol technology  The increase in royalty revenues was mainly driven by higher sales recorded by Promacta and Kyprolis  which are on track to achieve blockbuster status this year License fees  milestones and other revenues were  2 5 million compared with  3 8 million in the year ago quarter  Material sales decreased 9 1  to  7 million in the year ago quarter due to the unfavorable timing of Captisol purchases for clinical and commercial use Research   development  R D  expenses increased 14 6  to  5 5 million and general   administrative expenses rose 37 1  year over year to  9 6 million Business DevelopmentsDuring the quarter  Ligand also entered into a license agreement with Fred Hutchinson Cancer Research Center  granting the latter rights to use the OmniAb rodent platform technologies to develop new products  Ligand will receive a share of revenues from the sale of any product developed using this technology  The company also signed a Captisol use agreement with Sunshine Lake Pharma 2018 Guidance RaisedLigand increased its guidance for 2018 for the second consecutive quarter  It now expects full year revenues to be approximately  240 million compared with its previous guidance of  232 million  The expected revenues include royalties of nearly  122 million  material sales of roughly  25 million and license fees and milestones of almost  93 million with the potential for up to an additional  5 million in license fees and milestones  Adjusted earnings are estimated to be  6 52 per share for 2018 compared with  6 30 expected previously 
How Have Estimates Been Moving Since Then 
Fresh estimates followed a flat path over the past two months  The consensus estimate has shifted  7 48  due to these changes 
VGM Scores
Currently  Ligand has a nice Growth Score of B  however its Momentum Score is doing a bit better with an A  However  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Ligand has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-12-07,Zacks Investment Research,https://www.investing.com/analysis/why-is-ligand-lgnd-down-149-since-last-earnings-report-200366284,200366284
149807,371323,AMGN,Amgen  AMGN  Continues To Reward Shareholders  Ups Dividend ,opinion,Amgen  Inc    NASDAQ AMGN   has announced a 10  hike in its quarterly dividend  Quarterly dividend was increased from  1 32 per share to  1 45 per share  The first increased dividend will be paid on Mar 8  2019 to shareholders of record as of Feb 15  The new quarterly dividend amounts to an annual dividend of  5 80 per share  which implies a dividend yield of 3  Amgen regularly returns cash to shareholders through dividends  The company s target is to return more than 60  of adjusted net income in the form of dividends and share buybacks through 2018  The company started paying dividends in 2011 and has raised it 25  a year on average  Amgen raised its quarterly dividend for 2016 by 27  and for 2017 and 2018 by 15  each  Its free cash flow grew 9  from 2016 to  10 5 billion in 2017  driven by higher profitability  The company also bought back shares worth  3 1 billion in 2017 and  15 7 billion in the first nine months of 2018 So far this year  Amgen s stock has risen 10 1  against 19  decrease of its    Amgen has done relatively well in 2018 so far  coming up with strong quarterly results and positive pipeline and regulatory updates Amgen s newer drugs   Prolia  Xgeva  Blincyto  Repatha  Kyprolis   are performing well  This year  Amgen made rapid progress with its pipeline and line extensions The approval of migraine candidate  Aimovig this year was a huge boost  Amgen has developed Aimovig in partnership with Novartis   NYSE NVS    Aimovig was the first FDA approved treatment  specifically developed to treat migraine by blocking calcitonin gene related peptide  CGRP  Amgen has also delivered on its biosimilars pipeline so far this year  which represents significant growth opportunity  Two of its biosimilars  Kanjinti  a biosimilar of Roche s   OTC RHHBY   cancer drug Herceptin  and Amjevita  biosimilar of Abbvie s   NYSE ABBV   blockbuster RA drug  Humira  were launched in EU this year and can contribute to sales in the future quarters  Amgen s restructuring plan is making it leaner and more cost efficient  Lower taxes and share buybacks should provide some bottom line support However  Amgen faces challenges related to its more mature products such as launch of competing biosimilar versions of Neulasta and Epogen  further sales erosion of Neupogen and Aranesp and increasing competitive pressure on Enbrel  Meanwhile  uptake of key new drug  Repatha has been slow due to payer restrictions  The recent price cut is expected to hurt Repatha volumes going forward Amgen currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-09,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-continues-to-reward-shareholders-ups-dividend-200366692,200366692
149830,371346,AMGN,Roche s Tecentriq Gets Priority Review For Breast Cancer,opinion,Roche Holdings AG   OTC RHHBY   announced that the FDA has accepted the company s supplemental Biologics License Application  sBLA  for the label expansion of immuno oncology drug Tecentriq The agency also granted Priority Review to Tecentriq plus chemotherapy  Abraxane  for the initial  first line  treatment of unresectable locally advanced or metastatic triple negative breast cancer  TNBC  in patients whose disease expresses the PD L1 protein  as determined by PD L1 biomarker testing The FDA is expected to make a decision on approval by Mar 12  2019 The sBLA is based on positive data from the phase III study  Impassion 130 We note that Roche currently has seven ongoing phase III studies investigating Tecentriq in TNBC  including early and advanced stages of the disease   Assuming approval  this Tecentriq combination would be the first cancer immunotherapy regimen for the treatment of PD L1 positive  metastatic TNBC We remind investors that Tecentriq is already approved in the European Union  the United States and more than 80 countries for people with previously treated metastatic NSCLC and for certain types of untreated or previously treated metastatic urothelial carcinoma  mUC  A label expansion of the drug will further boost sales Roche has a strong presence in the oncology market  In particular  the company dominates the breast cancer space with strong demand for its HER2 franchise drugs  The HER2 franchise includes Herceptin  Perjeta and Kadcyla  Growth in Herceptin is being driven by increasing demand in both the United States and Europe due to longer treatment duration  Moreover  the subcutaneous  SC  formulation of Herceptin is being increasingly adopted  The FDA approved Perjeta in combination with Herceptin and chemotherapy  the Perjeta based regimen  for adjuvant  after surgery  treatment of HER2 positive early breast cancer  EBC  at high risk of recurrence Shares of Roche have gained 1 6  so far this year  against the  growth of 10 8   Approval of new drugs and a potential label expansion of existing drugs bode well for Roche as its legacy drugs like Avastin  Herceptin and MabThera are facing competition from biosimilars  Novartis   NYSE NVS   has already launched its biosimilar version of Rituxan  MabThera in Europe  Amgen   NASDAQ AMGN   too has got its biosimilar of Avastin Zacks Rank   Stock to ConsiderRoche currently carries a Zacks Rank  3  Hold    A better ranked stock in the healthcare sector is Gilead Sciences Inc    NASDAQ GILD    which sports a Zacks Rank  1  Strong Buy     You can see  Gilead s earnings per share estimates increased from  6 58 to  6 87 for 2018 over the past 60 days  Estimates for 2019 are also up by 27 cents 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-11-13,Zacks Investment Research,https://www.investing.com/analysis/roches-tecentriq-gets-priority-review-for-breast-cancer-200359112,200359112
149831,371347,AMGN,Merck s Keytruda Improves Survival In Esophageal Cancer Study,opinion,Merck   Co   Inc    NYSE MRK   announced that its PD L1 inhibitor  Keytruda significantly improved overall survival  OS  compared to standard chemotherapy in a phase III study evaluating it for the second line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma   Esophageal cancer is a difficult to treat cancer  It is the seventh most commonly diagnosed cancer and is estimated to be diagnosed in more than 17 000 adults in the United States this year However  statistical significance for OS was not reached in two patient groups   patients with squamous cell histology and in the entire intention to treat  ITT  study population   in the study  Merck will present the results at an upcoming medical conference and will also submit the same to regulatory authorities for approval to be included in the drug s label The study  KEYNOTE 181  was conducted in patients with advanced esophageal or esophagogastric junction carcinoma whose tumors express PD L1 with a Combined Positive Score or CPS of 10 or greater  While OS was the primary endpoint of the study  secondary endpoints of the study were progression free survival  PFS  and objective response rate  ORR   which were not formally tested Another phase III study  KEYNOTE 590  is evaluating Keytruda in combination with chemotherapy as a first line treatment for patients with esophageal carcinoma So far this year  Merck s shares have outperformed the   Merck s shares have risen 31 6  in the period compared with 7 6  increase for the industry  Keytruda is a key contributor to Merck s sales  In a very short span of time  Keytruda has become Merck s largest product  It is already approved for use in 12 indications across eight different tumor types in the United States  Additionally  earlier this week  Merck announced FDA approval of Keytruda for the treatment of advanced hepatocellular carcinoma  HCC   the most common type of liver cancer in patients  previously treated with Bayer Amgen s   NASDAQ AMGN   Nexavar  sorafenib  Keytruda generated sales of  1 89 billion in the third quarter  up 13  sequentially and 80  year over year  Sales were driven by the launch of new indications globally  Keytruda sales are gaining  particularly from strong momentum in the first line lung cancer indication  In fact  Keytruda is the only anti PD 1 approved in the first line setting for certain lung cancer patients as a monotherapy as well as a combination therapy The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 850 studies  including more than 400 combination studies  Merck is collaborating with several companies including Amgen  Incyte   NASDAQ INCY    Glaxo   NYSE GSK   and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens Keytruda is being studied in late stage studies for breast  colorectal  esophageal  gastric  head and neck  hepatocellular  nasopharyngeal  renal and small cell lung cancers This year  Merck announced positive data from several late stage studies on Keytruda for further line extensions Several regulatory decisions for new indications in the United States as well as in Europe are pending in late 2018 2019  which if approved can further boost sales  A key FDA approval last month was the label expansion of Keytruda as a first line treatment for metastatic squamous non small cell lung cancer  NSCLC    a difficult to treat lung cancer patient population   based on data from the phase 3 KEYNOTE 407 study Though Keytruda had its share of side effects and suffered some major pipeline setbacks  particularly in 2017  it is probably one of the most successful PD 1 and PD L1 inhibitors in the market now Merck currently carries a Zacks Rank  2  Buy   You can  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-11-14,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-improves-survival-in-esophageal-cancer-study-200359658,200359658
149832,371348,AMGN,Lilly Offers Updates On Progress Of Headache Disorder Drugs ,opinion,Eli Lilly   Company   NYSE LLY   announced that it has filed a new drug application with the FDA for approval of its migraine candidate  lasmiditan The NDA seeks approval of the oral 5 HT1F agonist for the treatment of acute migraine headaches   a medical condition that affects more than 30 million adults in the United States alone  Lasmiditan was added to Lilly s portfolio with the 2015 acquisition of CoLucid Pharmaceuticals Year to date  Lilly s shares have risen 30  compared with the  s increase of 7 6    Lilly also said that by the end of the year  it plans to submit a supplemental biologics license application  sBLA  to the FDA for label expansion of its newly approved migraine drug Emgality  galcanezumab  for preventive treatment of episodic cluster headache  Lilly gained FDA approval for Emgality  its CGRP antibody  for the preventive treatment of migraine in adults in late September  Lilly also said that the FDA has granted Breakthrough Therapy status to Emgality for the episodic cluster headache indication The designation from the regulatory body is intended to expedite the development and review of drugs with early evidence of substantial potential clinical benefit to patients  or benefit patients without current treatment options  At present  no medicines are approved for preventive treatment for episodic cluster headache in the United States Data from a late stage study evaluating Emgality for the prevention of episodic cluster headache in May showed that the drug  300 mg once monthly  led to  statistically significant differences in the reduction of weekly cluster headache attacks compared to placebo across weeks one to three of the two month treatment period   the primary endpoint  At week 3  a statistically significantly greater percentage of patients in the Emgality arm achieved at least 50  reduction in weekly cluster headache attacks  secondary endpoint  compared to placebo Emgality  a once monthly  self administered  subcutaneous 120 mg injection  could emerge as a significant contributor to long term growth at Lilly  However  it faces strong competition from Teva s   NYSE TEVA   and Amgen s   NASDAQ AMGN   CGRPs  Ajovy and Aimovig  respectively  which were also approved this year Lilly s pain portfolio also includes tanezumab  being evaluated  in collaboration with Pfizer  Inc    NYSE PFE    for multiple pain indications  including osteoarthritis pain  chronic low back pain  and cancer pain Lilly currently carries a Zacks Rank  2  Buy  You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-11-14,Zacks Investment Research,https://www.investing.com/analysis/lilly-offers-updates-on-progress-of-headache-disorder-drugs-200359635,200359635
149833,371349,AMGN,Drug Pricing Resurfaces  Pfizer To Raise Cost Of 41 Drugs ,opinion,Drug pricing controversy is back in news with a Wall Street report stating that Pfizer  Inc    NYSE PFE   plans to increase the list prices of its 41 prescription drugs next year  The drug giant put off such increases earlier this year as it faced criticism from President Donald Trump The 41 drugs comprise about 10  of Pfizer s drug portfolio  The company will raise the prices of most of its medicines by 5   effective Jan 15 next year  However  prices of three drugs will rise by 3  while that of one will go up by 9   Pfizer does not expect the price hikes to boost its revenues in 2019 as the move will be offset by higher rebates and discounts paid to insurance companies and pharmacy benefit managers  PBMs   Pfizer hopes that insurers and PBMs will pass on the benefits of discounts rebates to consumers so that the latter s out of pocket costs do not escalate Shares of Pfizer have rallied 20 1  so far this year compared with the  s 8 2   increase   We remind investors that in early July  this New York based company had announced an increase in list prices of several drugs  effective Jul 1  A week later  in a   the president slammed Pfizer for the price hike  Trump said that Pfizer and other U S  drugmakers should be  ashamed  that they raised drug prices for  no reason   The tweet also suggested that by raising drug prices in the United States  these drug companies were offering  bargain basement prices  overseas  He warned that the administration will respond to such actions A day after the above tweet was published  Pfizer issued a  indicating that it will defer the price increases until the president s drug pricing blueprint goes into effect or the current year ends  whichever is earlier   The drug pricing blueprint hasn t gone into effect yet Amid pressure on the industry from Trump s administration over the rising drug costs  another leading player Merck   NYSE MRK   pledged to limit its average price increases across its portfolio annually to the rate of inflation  Others like Amgen   NASDAQ AMGN   and Novartis   NYSE NVS   also showed commitment not to raise prices of its medicines through the rest of 2018 Lowering prices of prescription drugs was one of Trump s presidential campaign promises  He had committed to take on the industry bigwigs  which was also supported by his Democrat opponent Hillary Clinton Ever since  Trump has time and again criticized pharmaceutical companies for steep prices of medicines  This kept the pharma houses reeling under pressure for quite some time as they feared that Trump s pharma plan could dent their profits Pfizer currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-18,Zacks Investment Research,https://www.investing.com/analysis/drug-pricing-resurfaces-pfizer-to-raise-cost-of-41-drugs-200360633,200360633
149834,371350,AMGN,Amgen  AMGN  Gains As Market Dips  What You Should Know,opinion,"In the latest trading session  Amgen  AMGN  closed at  194 91  marking a  0 38  move from the previous day  The stock outpaced the S P 500 s daily loss of 1 66   At the same time  the Dow lost 1 56   and the tech heavy Nasdaq lost 3 03  
Coming into today  shares of the world s largest biotech drugmaker had lost 4 21  in the past month  In that same time  the Medical sector lost 1 89   while the S P 500 lost 2 43  
Wall Street will be looking for positivity from AMGN as it approaches its next earnings report date  This is expected to be February 7  2019  In that report  analysts expect AMGN to post earnings of  3 25 per share  This would mark year over year growth of 12 46   Meanwhile  our latest consensus estimate is calling for revenue of  5 86 billion  up 1 08  from the prior year quarter 
For the full year  our Zacks Consensus Estimates are projecting earnings of  14 21 per share and revenue of  23 34 billion  which would represent changes of  12 96  and  2 14   respectively  from the prior year 
Investors might also notice recent changes to analyst estimates for AMGN  These recent revisions tend to reflect the evolving nature of short term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 1 62  higher  AMGN is holding a Zacks Rank of  3  Hold  right now 
Valuation is also important  so investors should note that AMGN has a Forward P E ratio of 13 67 right now  This valuation marks a discount compared to its industry s average Forward P E of 22 8 
We can also see that AMGN currently has a PEG ratio of 2 02  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  AMGN s industry had an average PEG ratio of 1 6 as of yesterday s close 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 82  which puts it in the top 32  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-11-19,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-gains-as-market-dips-what-you-should-know-200360754,200360754
149835,371351,AMGN,Roche  AbbVie Get FDA Approval For Venclexta Label Expansion,opinion,Roche   OTC RHHBY   and partner AbbVie  Inc    NYSE ABBV   announced that the FDA has granted accelerated approval for a label expansion of Venclexta  venetoclax  The FDA granted accelerated approval to Venclexta in combination with a hypomethylating agent  azacitidine or decitabine  or low dose cytarabine  LDAC  for the treatment of patients suffering from newly diagnosed acute myeloid leukaemia  AML  who are aged 75 years or older or those ineligible for intensive induction chemotherapy due to coexisting medical conditions The approval was based on positive results from the M14 358 and the M14 387 studies  which showed durable remissions in patients suffering from newly diagnosed AML Consequently  Venclexta now is indicated for all AML patients regardless of subtypes The FDA generally grants accelerated approval to a drug that fills an unmet medical need for a serious condition  Continued approval for this indication may be contingent upon verification and description of clinical benefit observed in confirmatory trials Earlier  the FDA had granted Priority Review to the supplemental New Drug Application  sNDA  for Venclexta  The FDA had earlier granted two Breakthrough Therapy designations to Venclexta for the treatment of patients with previously untreated AML who are ineligible for intensive chemotherapy  either in combination with a hypomethylating agent or LDAC  based on results from the two studies  In June 2018  the FDA granted regular approval to Venclexta for patients with chronic lymphocytic leukemia  CLL  or small lymphocytic lymphoma  SLL   with or without 17p deletion  who have received at least one prior therapy The label expansion of the drug will expand the patient population  which  in turn  should boost sales While Roche and AbbVie commercialize the drug in the United States  the latter is responsible for the same outside the United States Shares of Roche have gained 1 3  so far this year compared with the  growth of 10 8   Roche is a leader in oncology market with a diverse portfolio  Approval of new drugs and potential label expansion of existing drugs bode well for Roche  as its legacy drugs like Avastin  Herceptin and MabThera are facing competition from biosimilars  Novartis   NYSE NVS   has already launched its biosimilar version of Rituxan  MabThera in Europe  Amgen   NASDAQ AMGN   too has got its biosimilar of Avastin Zacks RankRoche currently carries a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-11-22,Zacks Investment Research,https://www.investing.com/analysis/roche-abbvie-get-fda-approval-for-venclexta-label-expansion-200361701,200361701
149836,371352,AMGN,4 Reasons Why Lilly Is Up More Than 30  This Year So Far,opinion,Eli Lilly   Company s   NYSE LLY   stock has outperformed the industry this year so far  Lilly s shares have risen 33 7  compared with the  s increase of 6 8   Here are some reasons for the same  Impressive Pipeline Progress This Year  Lilly has been on a strong footing in terms of its pipeline this year so far with several positive late stage data readouts  These include positive data from phase III studies on pipeline candidates  tanezumab in osteoarthritis  OA  pain  ultra rapid lispro in type I and type II diabetes and flortaucipir  its tau imaging agent for Alzheimer s disease A novel diabetes candidate in Lilly s pipeline is tirzepatide  a dual GIP and GLP 1 receptor agonist  GIP GLP 1 RA   which showed impressive blood sugar reductions and weight loss in type II diabetes patients in October  In addition  Lilly also presented encouraging data from late stage label expansion studies on psoriatic arthritis drug  Taltz for another indication   ankylosing spondylitis  cancer drug  Cyramza  for the second line treatment of liver cancer and type II  diabetes drugs Trulicity for reducing cardiovascular risk and Jardiance for type I diabetes A key regulatory success for Lilly was FDA approval of Emgality galcanezumab  a calcitonin gene related peptide  CGRP  antibody for migraine prevention  which could emerge as a significant contributor to long term growth Other important approvals this year were that of JAK inhibitor  Olumiant  baricitinib  in the United States and breast cancer drug Verzenio in first line setting in the United States  Europe as well as Japan Talking about CGRP antibodies  Emgality will face intense competition from Amgen   NASDAQ AMGN   Novartis    NYSE NVS   and Teva Pharmaceutical Industries Limited s   NYSE TEVA   newly launched CGRPs  Aimovig and Ajovy respectively  Both were launched in the United States this year Several key regulatory and pipeline events are expected in 2019  which will drive the stock further Strategic Deals  Lilly also announced several business development transactions  including a licensing agreement which Chugai Pharmaceuticals for an oral GLP 1 agonist  a licensing and research collaboration with Dicerna Pharmaceuticals  utilizing its RNAi technology platform and collaboration with NextCure Inc   focused on discovery and development of novel immuno oncology cancer therapies  In addition  with the acquisition of California based immuno oncology biotech  ARMO Biosciences in June  Lilly added pancreatic cancer candidate  pegilodecakin  to its pipeline Spin Off of Animal Health Unit  Lilly divested its Elanco animal health unit as an independent publicly traded company   Elanco Animal Health Incorporated   via an initial public offering   IPO   of a minority stake this year  Elanco Animal Health started trading with the ticker symbol ELAN on NYSE from Sep 20  Lilly owns 80 2  stake in the new company  which is expected to be divested through a  tax efficient transaction  by 2019  We believe Lilly s decision to separate Elanco  which had been underperforming was prudent Aggressive Cost Cutting Initiatives  Lilly is also resorting to cost cutting and headcount reduction to drive the bottom line  The headcount reductions announced in September 2017 are expected to amass annualized savings of approximately  500 million  beginning 2018  Lilly plans to invest the savings in new drugs and overall growth of the company  Also  the company returned  1 6 billion to shareholders via dividend and share repurchases ConclusionLilly has its share of challenges  which include rising competitive pressure on its drugs this year  generic competition for several drugs including key drug  Cialis and rising pricing pressure on the diabetes franchise However  it looks like Lilly s strong pipeline  consistent outperformance of new drugs  cost cuts and regular strategic deals will keep the stock afloat through the rest of the year and the next Lilly currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-25,Zacks Investment Research,https://www.investing.com/analysis/4-reasons-why-lilly-is-up-more-than-30-this-year-so-far-200362356,200362356
149855,371371,AMGN,Amgen  AMGN  Counts On New Drugs Amid Rising Biosimilar Woes,opinion,Amgen  Inc    NASDAQ AMGN   has done relatively well in 2018 so far  coming up with strong quarterly results and positive pipeline and regulatory updates Strong Third Quarter ResultsLast month  Amgen reported impressive third quarter 2018 results  It beat estimates for both earnings and sales and also increased its guidance for the year Third quarter 2018 earnings of  3 69 per share beat the Zacks Consensus Estimate of  3 42  Earnings increased 13  year over year driven mainly by lower tax rate and share repurchases  Total revenues of  5 90 billion in the quarter surpassed the Zacks Consensus Estimate of  5 80 billion and increased 2  year over year Total product revenues increased 1  from the year ago quarter as increasing demand for newer products like Prolia  Kyprolis  Xgeva  Blincyto and Parsabiv was partially offset by lower sales of mature brands like Enbrel  Aranesp  Epogen  Neulasta and Neupogen due to competitive pressure Amgen raised its sales and earnings guidance for 2018 driven by a better than expected performance in the third quarter and an optimistic guidance for the fourth quarter  The company now expects revenues in the range of  23 2  23 5 billion compared with the previous prediction of  22 5  23 2 billion  The high end of the guidance assumes that no Sensipar generics are launched this year Pipeline   Regulatory Successes This year  Amgen made rapid progress with its pipeline and line extensions Aimovig erenumab for prevention of migraine was approved and launched in the United States in the second quarter of 2018  Aimovig was the first FDA approved treatment  specifically developed to treat migraine by blocking calcitonin gene related peptide  CGRP   Aimovig was approved in the EU in July  Amgen has developed Aimovig in partnership with Novartis   NYSE NVS   On the third quarter conference call  the company said that Aimovig is off to a strong start and 100 000 patients have started treatment with Aimovig since launch through 12 000 different prescribers  Regarding competitive pressure from Teva s   NYSE TEVA   and Lilly s   NYSE LLY   CGRPs  which were also approved this year  management sounded confident in its ability to compete with Aimovig s differentiated product profile Amgen also gained approval for several line extensions this year   Prolia and Xgeva were approved for new indications  glucocorticoid induced osteoporosis and prevention of SRE in multiple myeloma patients  respectively  in the United States and EU  Blincyto was approved in the United States for a new indication  minimal residual disease  MRD  positive B cell precursor acute lymphoblastic leukemia   ALL   The line extensions expanded the eligible patient populations of these drugs and will drive their sales higher in future quarters  Also  in 2017 early 2018  Amgen gained regulatory approvals to include overall survival data from key studies on the labels of Kyprolis and Blincyto  which added to sales of these products Biosimilars  A Long Term Growth DriverAmgen has also delivered on its biosimilars pipeline so far this year  which represents significant growth opportunity  Two of its biosimilars  Kanjinti  a biosimilar of Roche s cancer drug Herceptin  and Amjevita  biosimilar of Abbvie s blockbuster RA drug  Humira  were launched in EU this year and can contribute to sales in the future quarters  Amgen has eight biosimilars in its pipeline  which could be an important long term growth driver for the companyChallenges in StoreAmgen faces challenges related to its more mature products such as launch of competing biosimilar versions of Neulasta and Epogen  further sales erosion of Neupogen and Aranesp and increasing competitive pressures on Enbrel Novartis  generic arm Sandoz and Teva are already marketing biosimilar versions of Neupogen in the United States  which are hurting Neupogen s sales  Mylan s biosimilar version of Neulasta  Fulphila  which is priced at a discount of 33  to Neulasta s list price  was launched in the United States in July and hurt sales of Neulasta in the third quarter of 2018 More biosimilars are expected to be launched by the end of next year  which will put further pressure on Neulasta sales  Pfizer s Retacrit  the first biosimilar version of Epogen  was approved in May 2018 and may be launched soon  Sensipar lost patent exclusivity in March 2018 and generics may to be launched  at risk  this year The softness in sales of Enbrel  Amgen s largest product  is also a cause for concern  Pricing pressure and stiff competition are hurting sales of Enbrel  one of the main drivers of Amgen s revenues Meanwhile  uptake of key new drug  Repatha has been slow due to payer restrictions  On the third quarter conference call  the company said that despite its efforts to improve patient access to Repatha  patients still face significant hurdles due to high co pay expenses  In October  Amgen announced its decision to cut the U S  list price of Repatha by 60  to improve access and affordability of Repatha  Though the lower price may benefit Repatha volumes sales in the near term  sales from the drug will be lower due to the price cut Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-counts-on-new-drugs-amid-rising-biosimilar-woes-200356176,200356176
149856,371372,AMGN,Stocks Hold Midterm Gains After Fed Statement,opinion,"The November episode of the Zacks Ultimate Strategy Session is now available for viewing  Tune in to this  must see  event when Kevin Matras  Sheraz Mian  John Blank  PhD  David Borun and Kevin Cook discuss the investment landscape from several angles  Don t miss your chance to hear 

  John and David Agree to Disagree on whether the midterm elections turn around the October 2018 market correction
	  Kevin Matras answers your questions in Zacks Mailbag
	  Sheraz and Kevin Cook choose one portfolio to give feedback for improvement
	  And much more

Simply log on to Zacks com and view the November episode here  And please let us know what you think of this format  Email all feedback to mailbag zacks com 
	For the second time this week  a potentially huge market moving event played out as planned  Generally speaking  there were no big surprises in the midterm elections  and nor were there any bombshells in today s Fed statement  Stocks were a bit listless on Thursday with two of the major indices in the red for the session  but overall most of yesterday s sharp rally was maintained 
	The Dow soared nearly 550 points on Wednesday after it became clear that the new Congress would be split between the parties  The index held onto all of that today with a rise of 0 04  to 26 191 22  though it had been higher by more than 100 points earlier in the day 
	The other major indices didn t come along for the ride  Though off their lows of the session  the NASDAQ declined 0 53  to 7530 88 and the S P slipped 0 25  to 2806 83  It was another rough session for the FANGs with all of them moving lower 
	The Fed kept interest rates unchanged today  as was widely expected  However  the fourth hike of the year is almost definitely coming next month  And looking even further out  Powell   Friends plan to continue with  gradual  hikes in 2019 
	With the market protecting much of the midterm rally  stocks go into Friday s session solidly in the green for the week  Absent any sharp downturns  the major indices have a good chance to match or even beat last week s impressive returns that saw the NASDAQ climb 2 7  and the Dow and S P each rise 2 4   Fingers crossed that we have another session with no surprises tomorrow Today s Portfolio Highlights Surprise Trader  The market may have let its attention on earnings season waver a bit in the face of midterms and the Fed meeting  but Dave never did   On Thursday  the editor made his third buy of the week with a 12 5  allocation in cloud computing company NetApp  NASDAQ NTAP   The company has a positive Earnings ESP for the quarter coming after the bell on Wednesday  November 14  Furthermore  analysts are expecting earnings to grow more than 22  from last year  Dave also sold Amgen  NASDAQ AMGN  and Archer Daniels Midland  ADM  for profits of 3 7  and 2 5   respectively  Read the full write up for more Income Investor   The central bank unsurprisingly held rates steady  setting us up for a fourth and final rate hike of 2018 next month 
	 Investors were hoping that the Fed might take notice of recent volatility in financial markets and walk back its hawkish tone slightly  but the new policy statement made no mention of the selling 
	 The only noticeable tweaks to the Fed s policy statement were a mention that unemployment had declined since its last meeting  and a note acknowledging that the  growth of business fixed investment has moderated from its rapid pace earlier in the year  
	 Slowing business investment could be a concerning sign for investors  but no changes to the planned rate hike schedule and acknowledgment of our historic labor market balanced that out  and Wall Street effectively shrugged at the statement      Ryan McQueeneyCounterstrike   Markets were quiet after a couple wild days  Nothing wrong with a break in the action and I think that s what we saw today and will see tomorrow as we head into the weekend 
	 We have gotten past a lot of potential risk and the market will now digest what has happened  Most of the big earnings  the election and the Fed are all past us  so now we let the market show us the appropriate direction  I still think the highs are in for the year  but a strong Santa Claus rally fueled by positive China trade deal news is always possible      Jeremy Mullin 
	All the Best 
	Jim Giaquinto 
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy    Click here to  test drive  Zacks Ultimate for FREE   ",2018-11-08,Zacks Investment Research,https://www.investing.com/analysis/stocks-hold-midterm-gains-after-fed-statement-200357399,200357399
149857,371373,AMGN,Pharma Stock Roundup  LLY  AZN Report Q3 Earnings  PFE Gets FDA Nod For Cancer Drug,opinion,"This week Lilly   NYSE LLY   and AstraZeneca   NYSE AZN   released their third quarter 2018 results  Pfizer   NYSE PFE   gained FDA approval for a new cancer medicine  its third cancer drug approval in less than two months while Bristol Myers   NYSE BMY   got a nod from the same regulatory body for a triplet cancer combination for multiple myeloma Recap of the Week s Most Important StoriesEarnings  Lilly s third quarter  as it beat estimates for earnings but missed the same for sales  Lilly  however  raised its previously issued outlook for adjusted earnings while increasing the lower end of the total revenue guidance  Going forward  new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance  Lartruvo  Verzenio and Olumiant are expected to drive revenues AstraZeneca in the third quarter and maintained its previously issued outlook for 2018  AstraZeneca s product sales rose 9  at CER in the quarter to  5 27 billion  Higher sales of newer medicines  particularly cancer drugs  and strong performance in emerging markets  mainly China  offset lower sales of many other legacy medicines to drive product sales  With its product sales returning to growth after a long time  Pascal Soriot  AstraZeneca s chief executive officer  said this marks  the start of a period of sustained growth  for several years Pfizer Gets FDA Nod for Another Cancer Medicine  Pfizer gained FDA s accelerated approval for a cancer medicine  lorlatinib  to be marketed by the trade name of Lorbrena  Lorbrena can be prescribed for the treatment of patients with ALK positive metastatic non small cell lung cancer   NSCLC   who have received prior treatment with one or more ALK TKIs This is the third cancer medicine approval for Pfizer in less than two months  In late September  it gained FDA approval for Vizimpro  dacomitinib  for the first line treatment of metastatic non small cell lung cancer  NSCLC  in patients with EGFR activating mutations  In October  the FDA approved Talzenna  talazoparib   an orally available PARP inhibitor for advanced breast cancer Bristol Myers Cancer Combination Drugs in Focus  Bristol Myers gained FDA approval for a new immunotherapy combination   a triplet combination of Empliciti  elotuzumab   pomalidomide and dexamethasone for certain previously treated patients with multiple myeloma Pharmaceuticals to evaluate a combination of its PD 1 inhibitor  Opdivo and Infinity s investigational immunotherapy  IPI 549 for the treatment of advanced urothelial cancer  The companies plan to initiate MARIO 275  a randomized  global phase II study to evaluate the combination drugs in the first half of 2019  The combination drugs are already being evaluated in a phase I Ib study in patients with advanced solid tumors Sanofi s Dupixent Gets FDA Nod for Adolescent Patients  Sanofi   NYSE SNY   and partner Regeneron  for a supplemental Biologics License Application  sBLA  looking for approval of their atopic dermatitis drug  Dupixent for adolescent patients  12 years to 17 years of age   The FDA s decision is expected by Mar 11  2019  Dupixent is already approved in the United States and Europe for treating adult patients for the same disease  Last month  Dupixent was approved by the FDA as an add on maintenance treatment in adults and adolescents  12 years of age or older  with moderate to severe asthma Lilly s Diabetes Drug Succeeds in Reducing Cardiovascular Risk  Lilly announced data from an outcomes study  REWIND  on Trulicity  which showed that the GLP 1 receptor agonist led to superior reduction in cardiovascular events like death  non fatal myocardial infarction  heart attack  or non fatal stroke in a broad range of type II diabetes patients  Importantly  only 31  of the participants in the REWIND study had established CV disease compared to other CV outcomes studies  which have a much greater percentage of type II diabetes patients already with a heart disease  The statistically significant heart risk reduction shown by Trulicity in the study demonstrates that the drug may be able to cater to a much broader patient population if the data is approved to be included on the label Meanwhile  initial data from a real world study  EMPRISE  showed that Jardiance was associated with reduced risk for hospitalization for heart failure compared with DPP 4 inhibitors in type II diabetes patients with and without cardiovascular disease Lilly signed a multi year collaboration deal with small cancer biotech  NextCure  Inc  to develop novel cancer targets utilizing the latter s proprietary discovery platform   FIND IO  For the deal  Lilly will make an upfront payment of  25 million to NextCure and the latter will also be entitled to receive milestones and royalty payments if Lilly can successfully develop new cancer medicines under the collaboration AstraZeneca Sells Rights to Older Asthma   Rhinitis Drugs  AstraZeneca announced an agreement to divest rights to three older respirator products to a Swiss pharmaceutical group  Covis Pharma  Covis Pharma gained ex U S  marketing rights as well rights to U S  royalties for AstraZeneca s three medicines   Alvesco indicated for persistent asthma and Omnaris and Zetonna indicated for nasal symptoms associated with rhinitis  Covis Pharma already has the U S  rights for Alvesco  Omnaris and Zetonna  which it acquired from AstraZeneca in 2017  Covis Pharma will pay AstraZeneca  350 million for rights to the three drugs plus conditional sales related payments of up to  21 million over four years from 2019 AbbVie Settles With Momenta on Humira Biosimilar  AbbVie   NYSE ABBV   signed a non exclusive licensing deal with Momenta regarding the latter s proposed biosimilar version of Humira  Per the deal  Momenta will have a non exclusive license to launch its biosimilar Humira in the United States on Nov 20  2023  In Europe  Momenta can launch Humira biosimilar when it gets approval from the European Medicines Agency AbbVie has similar licensing deals with Amgen  NASDAQ AMGN   Mylan  NASDAQ MYL   Sandoz and Biogen Samsung Bioepis  Amgen  Mylan  Sandoz and Samsung  KS 005930  Bioepis Biogen s Humira biosimilars are expected to be launched in the United States in 2023 while in the EU  Amgen  Sandoz and Biogen s biosimilars were launched in October this year While Amgen  Sandoz and Samsung Bioepis  biosimilar versions are already approved by the FDA  Mylan is yet to gain FDA approval The NYSE ARCA Pharmaceutical Index rose 2 6  in the last five trading sessions  Large Cap Pharmaceuticals Industry 5YR   Return
  
 
Here is how the seven major stocks performed in the last five trading sessions   All stocks were in the green this week except Bristol Myers and Pfizer  While Bristol Myers recorded a massive decline of 15   Merck   NYSE MRK   rose the most  5 5   in the last five trading sessions In the past six months  Lilly has been the biggest gainer  36 2   while Bristol Myers recorded the lowest gain  3 3    See the last pharma stock roundup here  What s Next in the Pharma World Watch out for pipeline and regulatory updates next week The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-09,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-lly-azn-report-q3-earnings-pfe-gets-fda-nod-for-cancer-drug-200357505,200357505
149858,371374,AMGN,Ligand  LGND  Beats On Q3 Earnings   Revenues  Raises View,opinion,"Ligand Pharmaceuticals Incorporated   NASDAQ LGND   reported third quarter 2018 adjusted earnings of  1 32 per share  significantly up from the year ago figure of 69 cents  The bottom line also beat the Zacks Consensus Estimate of 99 cents Ligand s shares were up 5  on Nov 8 following the earnings release as the company beat estimates and raised 2018 guidance  Shares of the company have rallied 25  so far this year against the  s 14  decrease Total revenues in the quarter increased to  45 7 million from  33 4 million in the year ago period  Moreover  the top line surpassed the Zacks Consensus Estimate of  42 9 million Quarterly HighlightsRoyalty revenues were  36 1 million in the reported quarter  up approximately 64 8  year over year  Ligand primarily earned royalties on sales of Novartis    NYSE NVS   Promacta  Amgen s   NASDAQ AMGN   Kyprolis and Spectrum Pharmaceuticals    NASDAQ SPPI   Evomela  which were developed using Ligand s Captisol technology  The increase in royalty revenues was mainly driven by higher sales recorded by Promacta and Kyprolis  which are on track to achieve blockbuster status this year Under the new accounting standard ASC 606  adopted at the start of this year  Ligand said that third quarter 2018 royalties should be compared with fourth quarter 2017 royalties due to the timing of revenue recognition  Royalties for the fourth quarter of 2017 were  28 3 million License fees  milestones and other revenues were  2 5 million compared with  3 8 million in the year ago quarter  Material sales decreased 9 1  to  7 million in the year ago quarter due to the unfavorable timing of Captisol purchases for clinical and commercial use Research   development  R D  expenses increased 14 6  to  5 5 million and general   administrative expenses rose 37 1  year over year to  9 6 million Business DevelopmentsIn October  Ligand completed the acquisition of UK based biotechnology company  Vernalis  for approximately  43 million  Vernalis has a broad pipeline of partnered programs and ongoing collaborations along with  32 million of cash after deal fees  The acquisition will add eight fully funded partnered programs including pipeline products for respiratory  oncology and CNS indications The company s partners have made significant progress with their pipeline candidates using Ligand s technology platform  Melinta Therapeutics  Baxdela demonstrated positive results in patients with community acquired bacterial pneumonia  Viking Therapeutics and Aldeyra Therapeutics announced positive results from their mid stage studies evaluating their candidates in non alcoholic fatty liver disease and dry eye disease  respectively During the quarter  Ligand also entered into a license agreement with Fred Hutchinson Cancer Research Center  granting the latter rights to use the OmniAb rodent platform technologies to develop new products  Ligand will receive a share of revenues from the sale of any product developed using this technology  The company also signed a Captisol use agreement with Sunshine Lake Pharma 2018 GuidanceLigand increased its guidance for 2018 for the second consecutive quarter  It now expects full year revenues to be approximately  240 million compared with its previous guidance of  232 million  The expected revenues include royalties of nearly  122 million  material sales of roughly  25 million and license fees and milestones of almost  93 million with the potential for up to an additional  5 million in license fees and milestones  Adjusted earnings are estimated to be  6 52 per share for 2018 compared with  6 30 expected previously Ligand Pharmaceuticals Incorporated Price  Consensus and EPS Surprise
    Zacks RankLigand currently has a Zacks Rank  4  Sell  You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-09,Zacks Investment Research,https://www.investing.com/analysis/ligand-lgnd-beats-on-q3-earnings--revenues-raises-view-200357499,200357499
149859,371375,AMGN,Amgen  AMGN  Stock Moves  0 83   What You Should Know,opinion,"In the latest trading session  Amgen  AMGN  closed at  191 56  marking a  0 83  move from the previous day  This change was narrower than the S P 500 s daily loss of 1 97   Elsewhere  the Dow lost 2 32   while the tech heavy Nasdaq lost 2 78  
Heading into today  shares of the world s largest biotech drugmaker had lost 0 36  over the past month  outpacing the Medical sector s loss of 1 15  and the S P 500 s loss of 3 33  in that time 
Investors will be hoping for strength from AMGN as it approaches its next earnings release  which is expected to be February 7  2019  On that day  AMGN is projected to report earnings of  3 25 per share  which would represent year over year growth of 12 46   Our most recent consensus estimate is calling for quarterly revenue of  5 87 billion  up 1 16  from the year ago period 
AMGN s full year Zacks Consensus Estimates are calling for earnings of  14 21 per share and revenue of  23 34 billion  These results would represent year over year changes of  12 96  and  2 15   respectively 
It is also important to note the recent changes to analyst estimates for AMGN  Recent revisions tend to reflect the latest near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 1 74  higher  AMGN is currently sporting a Zacks Rank of  3  Hold  
Investors should also note AMGN s current valuation metrics  including its Forward P E ratio of 13 59  This valuation marks a discount compared to its industry s average Forward P E of 26 98 
We can also see that AMGN currently has a PEG ratio of 2 01  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  Medical   Biomedical and Genetics stocks are  on average  holding a PEG ratio of 1 64 based on yesterday s closing prices 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 98  putting it in the top 38  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2018-11-12,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-stock-moves-083-what-you-should-know-200358427,200358427
149881,371397,AMGN,Nuevolution  Pipeline And Partnerships Continue To Strengthen ,opinion,"With the completion of the up listing to the Nasdaq Stockholm main market and the successful gross SEK110m capital raise  Nuevolution AB  ST NUEVOL  continues to strengthen both its investor base and financial position  Amgen s opt in on the first programme in its multi target collaboration and the identification of much sought after small molecule IL 17A inhibitors continue to validate Nuevolution s Chemetics technology  Its transition to a clinical asset focused company continues with the Almirall ROR t inhibitor programme likely to enter the clinic in 2019 and additional internal programmes  ROR t and BET BD1  nearing clinical readiness  In addition to current partnerships  the company forecasts that a new deal is possible by year end  We value Nuevolution at SEK1 127m or SEK22 8 share 

Amgen  NASDAQ AMGN  opt in highlights potential of Chemetics
Amgen has exercised its opt in right for the first programme in its multi target relationship  This is the first of two programmes focused on undisclosed oncology targets that have been  fast tracked  through development  Amgen is now responsible for all further costs incurred by both parties and will work collaboratively on late stage research  It will be fully responsible for preclinical and clinical development  Should Amgen exercise its option to license a candidate before the end of Phase I  Nuevolution will receive an initial licensing fee of at least  10m and potential milestone payments of up to  410m 
To read the entire report Please click on the pdf File Below ",2018-09-26,Edison,https://www.investing.com/analysis/nuevolution-pipeline-and-partnerships-continue-to-strengthen-200345600,200345600
149882,371398,AMGN,Amgen  AMGN  Beats On Earnings   Sales In Q3  Raises View,opinion,"Amgen Inc    NASDAQ AMGN   reported third quarter 2018 earnings of  3 69 per share  which beat the Zacks Consensus Estimate of  3 42  Earnings increased 13  year over year driven mainly by lower tax rate and share repurchases Total revenues of  5 90 billion in the quarter surpassed the Zacks Consensus Estimate of  5 80 billion and increased 2  year over year So far this year  Amgen s stock has risen 8 8  against 19 8  decrease of its    Quarter in DetailTotal product revenues increased 1  from the year ago quarter to  5 51 billion  U S    4 26 billion  ex U S    1 25 billion  as increasing demand for newer products like Prolia  Kyprolis  Xgeva  Blincyto and Parsabiv was partially offset by lower sales of mature brands like Enbrel  Aranesp  Epogen  Neulasta and Neupogen due to competitive pressure Prolia revenues came in at  532 million  up 15  from the year ago quarter  attributable to 16  volume growth resulting from higher demand and share gains in both the United States and international markets Xgeva delivered revenues of  433 million  up 12  from the year ago quarter mainly due to higher demand  which drove volumes  This year  Xgeva gained approval in both United States and EU for the prevention of skeletal related events in patients with multiple myeloma  The approval for the expanded patient population drove higher volumes of Xgeva this quarter Vectibix revenues came in at  181 million  up 8   driven by higher demand  which made up for lower prices Kyprolis recorded sales of  232 million  up 12  year over year  driven primarily by robust uptake in outside U S  markets  Early this month  Amgen gained FDA approval for a once weekly dosing regimen of Kyprolis in combination with dexamethasone Blincyto sales increased 12  from the year ago period to  58 million  reflecting rise in demand  In the third quarter Blincyto was approved in Japan and for pediatric use in EU Amgen s PCSK9 inhibitor  Repatha  generated revenues of  120 million  up 30  year over year as higher unit demand was offset by lower prices  Last week  Amgen announced its decision to cut the U S  list price of Repatha by 60  to improve access and affordability of Repatha  Sales of the drug have suffered since launch due to payer restrictions  Though lower price may impact Repatha sales in the near term  management is optimistic to see better volume growth Parsabiv  launched in several markets including United States in the first quarter  recorded sales of  102 million in the third quarter  much higher than  73 million in the previous quarter Amgen s newly launched CGRP inhibitor for migraine prevention  Aimovig  erenumab  recorded sales of  22 million in the quarter  Aimovig was approved in the EU in July However  Amgen s mature drugs like Enbrel  Aranesp  Epogen  Neupogen and Neulasta are facing an array of branded and generic competitors  While Neupogen has been facing U S  biosimilar competition for some time now  Neulasta began facing the same this year  Also biosimilar versions of Epogen and Sensipar may be launched anytime soon Revenues of Amgen s erythropoiesis stimulating agent  ESA   Aranesp  declined 8  from the prior year quarter to  477 million on lower demand primarily due to increased competitive pressure Revenues of the other ESA  Epogen  declined 5  to  252 million due to lower selling prices as the category has become extremely competitive  Also Pfizer s   NYSE PFE   Retacrit  the first biosimilar version of Epogen  was approved in May 2018 and may be launched soon  With the launch of Retacrit and other biosimilars  there could be a further decline in selling price Neulasta revenues declined 6  to  1 05 billion from the year ago period on lower volumes and selling prices due to biosimilar competition in the United States  Mylan s   NASDAQ MYL   biosimilar version of Neulasta  Fulphila  which is priced at a discount of 33  to Neulasta s list price  was launched in July  which hurt sales of Neulasta in the third quarter  More biosimilars are expected to be launched by the end of next year  which will put further pressure on Neulasta sales Also increased competition from PD 1s and other new cancer therapies are hurting demand for the class of medicines to which Neulasta belongs  However  the Neulasta Onpro kit  on body injector  continues to perform well  commanding a market share of more than 60  in the United States for all Neulasta sales Neupogen recorded a 38  decline in sales to  85 million due to biosimilar competition in the United States  which hurt demand and prices  Novartis    NYSE NVS   generic arm Sandoz and Teva are marketing biosimilar versions of Neupogen   In July  Pfizer also gained FDA approval for its biosimilar version of Neupogen Enbrel delivered revenues of  1 29 billion  down 5  from the year ago quarter due to lower prices and increased competition  which hurt demand  The adverse effect was somewhat offset by some favorable accounting adjustments Sensipar Mimpara revenues declined 11  to  409 million hurt by Parsabiv launch  which is also marketed for secondary hyperparathyroidism  Sensipar also lost patent exclusivity in March 2018 and generics may be launched  at risk  this year Other product sales rose 36  to  87 million  Other revenues of  394 million rose 23  in the quarter due to a milestone payment from partner Novartis for Aimovig Operating Margins DecreaseAdjusted operating margin declined 170 basis points  bps  to 53 9  due to higher operating costs SG A spend increased 11  to  127 billion on higher investments to support new products as well as already marketed products  R D expenses rose 6  year over year to  906 million Adjusted tax rate was 13  for the quarter  a 6 4 points decrease from the third quarter of 2017 Amgen repurchased 8 7 million shares worth  1 7 billion in the third quarter and has  3 7 billion remaining under its stock repurchase authorization 2018 GuidanceAmgen raised its sales and earnings guidance for 2018  The company now expects revenues in the range of  23 2  23 5 billion compared with the previous prediction of  22 5  23 2 billion  Adjusted earnings are now anticipated in the range of  14 00  14 25 in 2018 compared with the previous projection  13 30  14 00 Hoping to achieve an improved cash position following the new tax law  Amgen plans to invest approximately  700 million this year in capital expenditures  lower than  750 expected previously Our TakeAmgen s third quarter results were impressive as it beat estimates for both earnings and sales and also increased its guidance for the year Amgen s newer drugs   Prolia  Xgeva  Blincyto  Kyprolis   are performing well on the back of volume driven growth  Amgen is also progressing with its pipeline and the approval of Aimovig was a huge boost  Amgen said on the investor call that the innovative migraine treatment is off to a  very strong start    It also boasts a strong biosimilar portfolio and launched Amjevita  its biosimilar version of Abbvie s blockbuster rheumatoid arthritis drug  Humira in several European countries this month  The company has eight additional biosimilar programs in development  which could be an important long term growth driver for the company  However  declining sales of some of the old blockbuster drugs is a concern Zacks RankAmgen currently carries a Zacks Rank  2  Buy   You can see  Amgen Inc  Price  Consensus and EPS Surprise
     
3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-10-30,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-beats-on-earnings--sales-in-q3-raises-view-200352501,200352501
149883,371399,AMGN,Radius Health  RDUS  Posts Narrower Than Expected Q3 Loss,opinion,"Radius Health  Inc    NASDAQ RDUS   reported encouraging results for the third quarter of 2018  wherein loss was narrower than expected  while sales beat estimates 
Following the announcement of the results  shares gained 12 1   However  Radius Health s shares have lost 41 9  in the year so far  compared with the  growth of 3 6  

 
The company reported a loss of  0 85 per share in the quarter  narrower than both the Zacks Consensus Estimate of a loss of  1 01 and the year ago period loss of  1 12  An increase in revenues led to the narrower than anticipated loss on a year over year basis 
The company reported Tymlos  sales of  27 6 million  marginally surpassing the Zacks Consensus Estimate of  27 3 million 
Quarter in Detail
Tymlos  sales also increased 22  sequentially  We remind investors that Radius Health obtained the FDA approval for Tymlos  abaloparatide  injection in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk of fracture  The company began shipments of the drug to wholesalers at the end of May 2017  Hence  revenues recorded in the year ago quarter were  3 5 million only 
Total prescriptions accounted for 22  of total U S  anabolic osteoporosis market  based on Patient Months on Therapy  TRx PMOT  in the quarter 
In October 2018  the FDA approved a labeling supplement for Tymlos to include additional information from the ACTIVExtend study  The labeling now reflects that after 24 months of open label alendronate therapy  the vertebral fracture risk reduction achieved with Tymlos therapy was maintained 
Research and development expenses for the reported quarter were  26 8 million  up 28  year over year  General and administrative expenses decreased 9  to  43 7 million  owing to decrease in compensation and travel related expenses 
Pipeline Updates
The pipeline includes abaloparatide injection for potential use in the treatment of men with osteoporosis  abaloparatide patch for potential use in osteoporosis  and elacestrant  RAD1901  for potential use in hormone receptor positive breast cancer 
The company is developing two formulations   abaloparatide Subcutaneous  SC  and abaloparatide transdermal patch  Radius Health is on track with its preparations for the phase III trial on abaloparatide patch and expects to start the study in mid 2019  The company is in the process of conducting development activities for the phase III trial and a potential NDA filing 
The company s Marketing Authorisation Application  MAA  for abaloparatide SC in Europe  for the treatment of postmenopausal women with osteoporosis  was under review  However  in July 2018  the company announced that the Committee for Medicinal Products for Human Use  CHMP   the scientific committee of the European Medicines Agency  EMA   has communicated a negative trend vote for the MAA  following a re examination procedure  Thereafter  the CHMP communicated that it maintained its negative opinion on the MAA at its formal final vote 
During the third quarter  Radius Health finalized the phase III study protocol for elacestrant based on regulatory feedback and additional considerations  The phase III trial will be a single  randomized  open label  active controlled study of elacestrant as a second  or third line monotherapy in approximately 460 patients with ER  HER2  advanced metastatic breast cancer who have received prior treatment with one or two lines of endocrine therapy  including a cyclin dependent kinase  CDK  4 6 inhibitor 
Patients in the study will be randomized to receive either elacestrant or the investigator s choice of an approved hormonal agent  The primary endpoint of the study will be progression free survival  PFS  
Secondary endpoints will include evaluation of overall survival  OS   objective response rate  ORR   and duration of response  DOR   Radius Health expects to submit marketing approvals for elacestrant as a second  and third line monotherapy in the U S   European Union  EU   and other markets based on results from the trial  The phase III study will be initiated in the fourth quarter of 2018 with a planned recruitment period of 18 21 months and potential data read out in 2021 
Guidance
Radius Health expects Tymlos net revenues around  95  98 million in 2018 and  155  175 million in 2019 
Our Take
The company s narrower than expected loss in the third quarter was encouraging as sales of Tymlos continue to gain traction 
Radius Health expects Tymlos to capture an average of 19 21  of the U S  anabolic osteoporosis market in 2018  while anabolic market in the United States is expected to increase 7 9  in volumes   Tymlos is expected to be covered for approximately 274 million insured lives  representing approximately 95  of U S  commercial and 64  of Medicare insured lives effective Jan 1  2019 
Although the osteoporosis market in the United Sates has great potential  Tymlos is expected to face significant competition from Eli Lilly   Co s   NYSE LLY   Forteo and Amgen s   NASDAQ AMGN   Prolia 
Zacks Rank   Stock to Consider
Radius Health currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD     which sports a Zacks Rank  1  Strong Buy   You can see  
Gilead s earnings per share estimates increased from  6 58 to  6 87 for 2018 and from  6 47 to  6 75 for 2019 over the last thirty days 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-02,Zacks Investment Research,https://www.investing.com/analysis/radius-health-rdus-posts-narrowerthanexpected-q3-loss-200354251,200354251
149884,371400,AMGN,Amgen  AMGN  Outpaces Stock Market Gains  What You Should Know,opinion,"Amgen  AMGN  closed at  189 92 in the latest trading session  marking a  1 53  move from the prior day  This change outpaced the S P 500 s 0 56  gain on the day  Elsewhere  the Dow gained 0 76   while the tech heavy Nasdaq lost 0 38  
Heading into today  shares of the world s largest biotech drugmaker had lost 8 07  over the past month  lagging the Medical sector s loss of 6 31  and the S P 500 s loss of 6 76  in that time 
Wall Street will be looking for positivity from AMGN as it approaches its next earnings report date  This is expected to be February 7  2019  On that day  AMGN is projected to report earnings of  3 25 per share  which would represent year over year growth of 12 46   Meanwhile  our latest consensus estimate is calling for revenue of  5 86 billion  up 1  from the prior year quarter 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  14 18 per share and revenue of  23 34 billion  These totals would mark changes of  12 72  and  2 15   respectively  from last year 
Investors might also notice recent changes to analyst estimates for AMGN  These revisions typically reflect the latest short term business trends  which can change frequently  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 1 61  higher within the past month  AMGN is currently a Zacks Rank  3  Hold  
Digging into valuation  AMGN currently has a Forward P E ratio of 13 19  Its industry sports an average Forward P E of 27 63  so we one might conclude that AMGN is trading at a discount comparatively 
We can also see that AMGN currently has a PEG ratio of 1 95  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  AMGN s industry had an average PEG ratio of 1 84 as of yesterday s close 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 87  which puts it in the top 34  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-outpaces-stock-market-gains-what-you-should-know-200355029,200355029
149885,371401,AMGN,Lilly  LLY  Tops Q3 Earnings  Lifts 2018 Outlook  Stock Up,opinion,"Eli Lilly   Company   NYSE LLY   reported third quarter 2018 adjusted earnings per share of  1 39  which beat the Zacks Consensus Estimate of  1 37 per share  Earnings rose 32  from the year ago quarter backed by robust growth in new product sales and higher operating income Including acquisition related in process R D charges  asset impairment  restructuring and other special charges  third quarter earnings per share were  1 12 compared with 53 cents in the third quarter of 2017 Revenues in DetailQuarterly revenues of  6 06 billion missed the Zacks Consensus Estimate of  6 11 billion  Sales grew 7  year over year backed by strong demand for its new drugs  which made up for lower sales of established products like Strattera  Cialis and Forteo Foreign exchange hurt sales growth by 1  in the quarter  Also  lower realized prices had a negative impact of 4  on sales Volumes rose 12  as increased demand for new products like Trulicity  Cyramza  Taltz  Basaglar  Jardiance and Verzenio offset lower volumes of some established products like Cialis  Strattera and Effient due to loss of exclusivityWhile U S  revenues grew 11  to  3 45 billion  ex U S  revenues rose 2  to  2 62 billion Pharmaceutical revenues rose 8  in the quarter  Established products that recorded growth during the quarter included Humulin  up 7  to  322 1 million  and Alimta  up 1  to  520 5 million   Sales of all other established products declined in the quarter Forteo sales declined 12  to  390 8 million  Cymbalta sales declined 6  to  172 0 million  Humalog sales dropped 5  to  664 6 million  Zyprexa sales were down 22  to  109 9 million  Erbitux sales declined 2  to  159 5 million Cialis  erectile dysfunction  sales declined 17  to  467 1 million as U S  sales were hurt by lower demand due to the entry of generic sildenafil while outside U S  sales were hurt by loss of exclusivity in Europe  In September  Teva Pharmaceuticals   NYSE TEVA   announced the launch of a generic version of Cialis  which means sales of the drug could be significantly lower in the future quarters Strattera sales declined 28  to  98 7 million due to loss of exclusivity Among new products  Trulicity generated revenues of  816 2 million  up 55  year over year driven by higher demand Cyramza revenues were  198 4 million  up 1  year over year as higher international sales were offset by lower U S  sales Jardiance sales surged 31  to  166 9 million  driven by increased demand trends within the SGLT2 class of diabetes medicines in the United States and increased volume outside the United States Basaglar recorded revenues of  201 2 million  up 38  year over year  In the United States  while sales benefitted from higher demand  lower realized prices and unfavorable changes to estimates for rebates and discounts hurt sales to some extent Taltz brought in sales of  263 9 million compared with  220 1 million in the previous quarter as U S  sales gained from higher demand  which made up for lower realized prices while ex U S  sales were driven by increased volume from new launches  Taltz was launched for the second indication of psoriatic arthritis in late 2017 early 2018 in both the United States and Europe  which contributed to sales growth in the quarter Lartruvo  olaratumab  generated revenues of  76 9 million in the quarter  less than  79 9 million in the previous quarter Olumiant  baricitinib   for rheumatoid arthritis  was launched in select European countries and in Japan in 2017 while in the United States  a lower dose of the medicine was launched in June 2018 The drug generated sales of  55 6 million in the quarter backed by launch uptake in new European markets  compared with  44 7 million in the previous quarter  In the United States  Olumiant recorded sales of  0 8 million  which was less than  1 7 million in the previous quarter Advanced breast cancer treatment  Verzenio  launched in the Unites States in late 2017  generated sales of  84 5 million in the quarter compared with  57 7 million in the previous quarter   In February  Verzenio gained FDA approval in first line setting while the drug was approved in Europe in October  The line extensions must have contributed to the drug s sales growth in the quarter Animal Health segment sales rose 4  to  772 7 million  Lilly divested its Elanco animal health unit as an independent publicly traded company   Elanco Animal Health Incorporated   NYSE ELAN     via an initial public offering  IPO  of a minority stake this year  Elanco Animal Health started trading on NYSE from Sep 20  Lilly owns 80 2  stake in the new company  which is expected to be divested through a  tax efficient transaction  by 2019 Gross Margin   Operating Income Adjusted gross margin of 76 7  in the quarter rose 190 basis points driven by manufacturing efficiencies  favorable product mix and the positive effect of foreign exchange rates on international inventories sold  which offset the negative impact of lower prices Operating income increased 29  year over year to  1 69 billion due to higher revenues and lower operating costs  Total operating expenses  including research and development and marketing  selling and administrative expenses   as a percent of revenues  declined 270 basis points in the quarter to 48 8  due to the company s cost saving efforts 2018 EPS Guidance UppedAdjusted earnings per share are now expected in the range of  5 55 to  5 60  higher than  5 40 to  5 50 expected previously The lower range of the revenue guidance was slightly upped to  24 3 billion to  24 5 billion from  24 0 billion to  24 5 billion expected previously The sales guidance increase was due to strong performance of pharmaceuticals products  especially Lilly s diabetes drugs Gross margin is expected to be approximately 76   same as previous expectations Adjusted tax rate is expected to be approximately 16   previously 17   Marketing  selling and administrative expense guidance was raised from a range of  6 2  6 5 billion to  6 3  6 5 billion  Research and development expense guidance was kept intact in the range of  5 2  5 4 billion Our TakeLilly s third quarter results were mixed as it beat estimates for earnings but missed the same for sales  Lilly  however  raised its previously issued outlook for adjusted earnings while increasing the lower end of the total revenue guidance  Shares of the drug giant rose almost 3  in pre market trading Year to date  Lilly s shares have risen 30 4  compared with the  sincrease of 3 9    Going forward  new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance  Lartruvo  Verzenio and Olumiant are expected to drive revenues Lilly is also having a strong year in terms of its pipeline with several positive late stage data readouts and regulatory nods  Late last month  Lilly gained FDA approval and the company launched Emgality  galcanezumab   its CGRP antibody  for the preventive treatment of migraine in adults  which could emerge as a significant contributor to long term growth Lilly has also added promising new assets through business development deals including pancreatic cancer candidate  pegilodecakin  which was added after the acquisition of California based immuno oncology biotech  ARMO Biosciences in June However  competitive pressure on Lilly s drugs is expected to rise this year  Challenges remain for the company in the form of generic competition for several drugs including Cialis and rising pricing pressure in the diabetes franchise  Also  newly approved Emgality faces strong competition from Teva s and Amgen s   NASDAQ AMGN   CGRPs  Ajovy and Aimovig  respectively  which were also approved this year Eli Lilly and Company Price and Consensus
    Lilly currently carries a Zacks Rank  2  Buy  You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-tops-q3-earnings-lifts-2018-outlook-stock-up-200355537,200355537
149900,371416,AMGN,Teva  Investors Split On Outlook,opinion,"Fremanezumab Chronic Cluster Trial Failure Seen as Non Issue  but Cluster Pathway Still Unclear
On June 15  Teva Pharma Industries Ltd ADR  NYSE TEVA  announced that they would be discontinuing its fremanezumab clinical trial for chronic cluster headaches  CCH   Investors have largely noted that the discontinuation of the clinical trial for CCH does not materially impact their thesis or estimates  However  Teva still faces a number of obstacles before fremanezumab can be filed 
To provide some background  we should first talk about the size and scope of cluster and migraine headaches  The addressable market in the US for migraine headaches is about 10 million people  that qualify for migraine preventives   and it is among the top 10 causes of global disability  Cluster headache prevalence in the US is about 350 000 people  Within that 350 000 people experiencing cluster headaches  there are two kinds of cluster headaches  episodic and chronic  Episodic cluster headaches can last from 7 days to a year  and include 1  months of pain free remission periods  These make up about 80 90  of cluster headaches  The remaining 10 20  is chronic cluster headaches  which can last longer than a year  and either have no remission or a brief remission of less than a month 
Getting positive clinical trial data for both chronic and episodic cluster headaches would have been great for a couple reasons  First  there are currently no approved therapy options for cluster headaches  Second  it s an extremely debilitating illness for many people 
However  chronic cluster headaches impact the smallest number of people within the three types of headaches  Teva still is pursuing the larger indications   episodic cluster headaches and migraine headaches  Additionally  Eli Lilly s galcenezumab had already failed a phase 3 trial for the same CCH indication  Investors already knew that there was more risk around the cluster headache indication  and therefore had not actually baked in any cluster headache sales in their consensus estimates for fremanezumab  Consensus estimates remain largely unchanged 
This does not mean that Teva is in the clear on fremanezumab  though  In particular  the filing path for episodic cluster headaches remains unclear  Teva management noted that they could potentially receive results for the episodic cluster headaches in 1H19  Even if they receive approval  it is unclear if they would need to run an additional phase 3 trial before filing with the FDA  If they do need an additional trial  submission could be pushed out by several more years 
There is also risk around the migraine headache path  Recall that the company has a PDUFA action date on September 16  Some analysts and investors have expressed reservations around the company s ability to get all inspections and resubmissions ready by that date  However  should they be able to do so  and receive approval  the company could essentially be in line with Eli Lilly s galcanezumab to market  and closely behind Amgen  NASDAQ AMGN  s Aimovig 
The company recently announced that they will be presenting more fremanezumab clinical trial data at the American Headache Society  which is occurring right now as of this writing  June 28 July 1  
Copaxone Has Proven More Resilient than Expected  but Longer Term Outlook Remains In Question
Copaxone and its rate of sales erosion remains a key topic among investors  Copaxone generated roughly 17  of total sales in 2017  Late last year  Mylan  NASDAQ MYL  received approval for both its 20mg and 40mg Copaxone generic  which caught many investors by surprise  After the approval  investors widely expected significant sales erosion for Teva  especially after Mylan was able to capture roughly 10  of the market out of the gate  Expectations for Teva s Copaxone sales lowered even further after Momenta Sandoz received approval for its 40mg generic in February this year 
However  since the beginning of the year  share gains by Mylan have slowed  as Teva notes that the generic Copaxone has only captured 15  of the market  Momenta Sandoz also struggled to launch their generic despite receiving approval over 4 months ago 

As a result  investors have raised Teva s Copaxone sales expectations for the year as the drug has proven more resilient than expected  This has been a major reason for Teva s recent stock outperformance  the stock is now up over 100  since its bottom in November of last year   One reason cited by analysts for the resilience has been aggressive discounting by Teva  which has eliminated the financial incentive for physicians to recommend switching to the generic version  Additionally  physician feedback has suggested that Teva s patient support network was much stronger than generic companies   which was a major deciding factor  Momenta Sandoz cited supply issues for its launch delay 
Moving forward  the outlook remains highly uncertain  Bulls would likely point to near term strength in Copaxone sales and its potential to outperform vs  consensus expectations  Bears would point to upcoming generics   Momenta Sandoz will likely address its supply issues  Amneal has guided to a generic Copaxone 20mg later this year and a 40mg potentially next year  and Dr  Reddy could have a generic Copaxone in 2020  In such an environment  bears believe it is inevitable that generic market share will rise more significantly 

ProAir Competition Delayed  Estimates Move Up
Similar to Copaxone  competition for Teva s ProAir has also been unexpectedly delayed  In early May  Perrigo announced a CRL for its generic ProAir  This would represent the third CRL for Perrigo s ProAir generic   the company received a CRL in 2016  and one in 2017  Perrigo management previously expected its ProAir generic to launch in 4Q18  investors are now expecting this to be a 2019 event  Lupin also has an upcoming action date this year  but given the issues in getting generic approval  investors do not expect an approval this year 
As a result of the delays  Teva s ProAir sales estimates  which previously factored in generic competition this year  are now being revised slightly upward  Should Perrigo or Lupin face any further headwinds  estimates could potentially move higher  In contrast  if they receive positive news or approval  Perrigo estimates may be revised downwards further  Consensus bakes in a more significant erosion in 2019 

Conclusion  Near Term Outlook Brighter  but 2019 Concerns Remain
Teva stock is controversial on the street  Bulls focus on the resilience of Copaxone sales  the new CEO  positive Austedo traction  indications that fremanezumab is still on track  signs of a recovery in the generic pricing environment  and the near term belief that consensus estimates will move higher 
Bears see the potential for continued weakness in the generic pricing environment  upcoming competition in Copaxone and ProAir that could lead to lower consensus estimates  uncertain details around the future of fremanezumab  and expensive valuation that leaves little room for error 
Copaxone s performance vs  consensus and the upcoming PDUFA date for fremanezumab on September 16 will be key factors for the stock ",2018-07-03,The Non-Consensus,https://www.investing.com/analysis/teva-investors-split-on-outlook-nearterm-outlook-not-as-bad-but-longerterm-con-200329012,200329012
149901,371417,AMGN,2 Reasons The Market Frowned After AbbVie s Blowout Q2,opinion,"AbbVie posts fantastic Q2 numbers but its stock falls  Here s why    and why the negative reaction is missing the bigger story 
AbbVie Inc  NYSE ABBV  did it again  The big drugmaker posted fantastic numbers in its first quarter results reported in April  AbbVie announced more great results with its second quarter earnings update on Friday 
Net revenue jumped 19  year over year to  8 28 billion  Adjusted earnings per share  EPS  soared nearly 41  in the second quarter to  2  Both numbers topped Wall Street estimates  AbbVie even boosted its full year 2018 adjusted EPS guidance from between  7 66 and  7 76 to between  7 76 and  7 86 
Despite AbbVie s blowout Q2 results  the market frowned  The big pharma company s share price declined in early trading on Friday  Here are two reasons behind this surprising response    and one big reason why investors actually should be excited about AbbVie s Q2 update 
AbbVie did it again  The big drugmaker posted fantastic numbers in its first quarter results reported in April  AbbVie announced more great results with its second quarter earnings update on Friday 
Net revenue jumped 19  year over year to  8 28 billion  Adjusted earnings per share  EPS  soared nearly 41  in the second quarter to  2  Both numbers topped Wall Street estimates  AbbVie even boosted its full year 2018 adjusted EPS guidance from between  7 66 and  7 76 to between  7 76 and  7 86 
Despite AbbVie s blowout Q2 results  the market frowned  The big pharma company s share price declined in early trading on Friday  Here are two reasons behind this surprising response    and one big reason why investors actually should be excited about AbbVie s Q2 update 
A big reason to be excited
There were actually several reasons why investors should have responded more enthusiastically to AbbVie s impressive Q2 results  However  I think I can roll the main reasons for excitement into one statement  Non Humira growth should be the big storyline for AbbVie going forward 
Of course  Mavyret will continue to be a key way that AbbVie s non Humira sales grow  But we can t leave out Imbruvica  Q2 sales for the cancer drug soared nearly 36  year over year  Approvals for more indications could be on the way 
Speaking of approvals  AbbVie just snagged a big one for Orilissa  elagolix   The FDA approved the drug in managing pain associated with endometriosis on July 24  AbbVie is also evaluating Orilissa in a late stage study targeting treatment of uterine fibroids 
In April  AbbVie submitted for FDA approval of risankizumab in treating psoriasis  The drug  along with another candidate  upadacitinib  is an important component of AbbVie s strategy to maintain its dominance in the immunology market even after Humira loses patent protection  They re also key reasons why market research firm EvaluatePharma ranks AbbVie s pipeline as No  2 in the industry 
But could sinking sales for Humira keep the spotlight off of AbbVie s other bright spots  Maybe  However  don t believe the doomsayers predicting that AbbVie is in trouble  The company recently signed an agreement to keep Mylan  NASDAQ MYL  s biosimilar to Humira off the U S  market until 2023 in a similar deal that it made last year with Amgen  NASDAQ AMGN   AbbVie should have plenty of time for its current drugs and pipeline candidates to generate growth and offset any decline in sales for Humira 
Is the negative reaction to AbbVie s second quarter warranted  I don t think so  Imbruvica  Mavyret  Orilissa  a loaded pipeline  and a great dividend should turn investors  frowns into smiles over the long run ",2018-07-30,Keith Speights,https://www.investing.com/analysis/2-reasons-the-market-frowned-after-abbvies-blowout-q2--and-1-reason-it-should-200334464,200334464
149903,371419,AMGN,How To Buy Your Favorite Stocks At 14  Off  With Yields Up To 7  ,opinion,"If you ve read the headlines about tech s woeful slump in the past couple weeks  you might think stocks are out of favor 
You d be wrong and this chart proves it 
Forget the Headlines  Stocks Are Rolling 
After February s gut wrenching plunge  the S P 500 has more than recovered and is up 6 2  year to date  If this trend continues  we re looking at a 12 4  return on the year 
But look at the orange line above that s the tech benchmark PowerShares QQQ Trust Series 1  NASDAQ QQQ   which is up 13 2  year to date  even after this latest correction in tech  That adds up to a monstrous 26 4  return for 2018 if that trend continues 
And I see these trends continuing  for both the market as a whole and for tech  as investors come back to this beleaguered sector 
Economic Strength Won t Be Denied
There are a couple reasons why I see stocks generally finishing up strong this year and a little further on I ll show you 2 great ways to pick up your favorite household names  and those of a certain Warren E  Buffett  too  at double digit discounts 
Oh  and you ll pocket cash dividends up to 7  while you do 
But first  back to where this incredible market run is headed from here 
One reason it s set to continue is that last week s report that US GDP rose a stunning 4 1  annualized in the second quarter is driving a lot of economists to raise their expectations for the full year  with 3  growth becoming increasingly expected 
This growth is largely thanks to two things  a stronger American consumer and increasingly profitable American companies 
Americans Go Back to Work   
A tighter job market means initial jobless claims have been falling at a steady rate over the last year  cutting the unemployment rate from 4 4  to 4   That s helping sales soar 
So far in the second quarter  73  of S P 500 companies are reporting sales above expectations  according to FactSet  That s also boosting stocks  earnings across all sectors 
  Sending Profits Soaring 
In normal times  a widespread earnings bonanza like this would be impressive  But expectations were already high  Going into the second quarter s earnings season  analysts forecasted a 21 3  profit increase from a year ago  so far  earnings for S P 500 companies have risen by just that  21 3  
And the good times aren t going to stop anytime soon companies have boosted expectations for next quarter  and analysts have boosted their expectations  too  Now all of 2018 is expected to provide a 20  jump in earnings  far above the S P 500 s still impressive 6 2  price gain 
That s another way of saying that stocks are actually cheaper in relation to forecast earnings than they were at the start of the year  despite their price gains and that points to more upside around the corner 
Like Rewinding the Clock 1 Year
If you ve been sitting on the sidelines watching this earnings surge  you might feel disheartened  But don t worry  you re not too late 
Because I want to show you 2 little known funds closed end funds  CEFs  to be specific that let you get into this strong stock market at a discount  Think of it as being able to buy today at prices we saw a year ago 
So let s get going  starting with 
CEF Pick No  1  Buy Like Buffett for 14  Off
Looking to get into the Oracle of Omaha s favorite stocks including his own company  Berkshire Hathaway  NYSE BRKa  at a big discount 
You can do just that with the Boulder Growth and Income Closed Fund  NYSE BIF   a value investing CEF that puts a third of its assets in Berkshire while allocating much of the rest to Buffett s top picks  like JPMorgan Chase  NYSE JPM   Wells Fargo  NYSE WFC  and Caterpillar  NYSE CAT  
By using Buffett s value investing approach  BIF has provided these returns to investors in the last year 
The Master s Strategy Delivers Nice Gains for BIF Holders 
And here s the best part BIF is far cheaper than it should be 
Thanks to a quirk in the CEF structure  BIF trades for less than the net asset value  NAV  of its portfolio  In fact  it s trading at a 13 9  discount to that NAV  which means you can buy every dollar of the shares BIF holds for about 86 cents if you buy BIF directly where you d get no discount if you bought those shares on the open market 
Plus  since BIF is diversified across dozens of strong large cap companies  you get diversification on top of a share of the Buffett style investing method that made the man famous 
And I haven t even gotten to the best part  dividends 
An Income Stream You Can Count On
BIF  like many closed end funds  pays out an attractive dividend to shareholders  Right now  BIF s yield is 3 5   or roughly double that of the S P 500 
The fund can pay those dividends because of its strong portfolio  Since BIF has earned much more than 3 5  on its investments on an annualized basis  it s able to maintain those payouts without being forced to sell stocks from its portfolio to do so 
And BIF isn t even the highest yielding CEF out there  which leads me to the next fund I want to show you now 
CEF No  2  A 7 4  Dividend and Market Beating Performance
Many CEFs pay 7  or more  and some of them even beat the S P 500 while doing it  Take  for instance  the Nuveen Core Equity Alpha Closed Fund  NYSE JCE   which trades at a small  1   discount to NAV and currently pays out a 7 4  dividend to shareholders 
That is not a typo  JCE s dividend is over 4 times bigger than that of the S P 500 
And JCE has managed to pay this out while crushing the market  Over the last decade  this fund s return has been nearly double that of the S P 500 
JCE Crushes the Index 
With market outperformance and a superior dividend yield  who wouldn t want to get into JCE 
Yet a lot of investors bypass this fund  simply because they don t know it  and CEFs generally  exist  Since JCE only has about  250 million in assets under management  it s too small to warrant being aggressively advertised like ETFs  which make up over  4 trillion in clients  money 
That means these smaller CEFs are one of Wall Street s best kept secrets and a corner of the market I cover exclusively in my CEF Insider service  Because JCE  BIF and many other CEFs provide market busting incomes and market outperformance that are impossible to find in the ETF world 
And now that stocks look set to soar even further from their current levels  it s a great time to compound your profits with a discounted fund like BIF or JCE 
My Top Secret Bonus Pick  Buy NOW for 8 5  Dividends and 276   Gains 
JCE and BIF are both strong funds  but I held off till the end to tell you about my very best CEF pick now  which has all the tools to lead the market  and JCE and BIF  higher in the critical 6 months to come 
The best part is that this unsung pick pays you a sky high 8 5  dividend today nearly 5 times as much as that of your typical S P 500 stock and more than twice as much as BIF  So a big part of the total return you haul in from this fund will be in cash 
And how has my top CEF pick performed in the long haul 
Answer  This off the radar biotech champ has obliterated the S P 500 in the last decade 
A Market Dominator 
Best of all  my top pick trades at a 5  discount to NAV  which may not sound like much  but it s traded at nice discounts in the past as recently as last September  which points to some nice upside ahead 
To sum up  here s what you re getting in this 5   markdown sale  

All the stocks in this fund s portfolio rock solid names with long histories of dividend growth  like Amgen  NASDAQ AMGN  and Gilead Sciences  NASDAQ GILD  
Market crushing outperformance  with 276  gains  and most of that return in cash  over the last decade 
1 click access to the top talent in biotech  this fund s manager  with more than two decades of experience himself  hires doctors and researchers with  boots on the ground  expertise at finding the next breakthrough treatment 

I ll give you all the details on this breakthrough income play when you click here 
And that s still not all 
You see  this fund is part of a 5 fund  mini portfolio  I crafted exclusively for members of my CEF Insider service  Now  for a limited time  I ll show it to you at no cost 
Taken together  these 5 totally ignored CEFs will hand you a safe 8 2  yield now  
And thanks to their ridiculous discounts  my team and I have each one pegged for easy 20   price upside in the next 12 months 
Don t miss out  CLICK HERE to get the names  ticker symbols  buy under prices and my complete research on these 5 income  and growth   plays now 
Disclosure  Brett Owens and Michael Foster are contrarian income investors who look for undervalued stocks funds across the U S  markets  Click here to learn how to profit from their strategies in the latest report   7 Great Dividend Growth Stocks for a Secure Retirement  ",2018-08-06,Michael Foster,https://www.investing.com/analysis/how-to-buy-your-favorite-stocks-at-14-off-with-yields-up-to-7-200336612,200336612
149907,371423,AMGN,4 Trade Ideas For Amgen  Bonus Idea,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Amgen  NASDAQ AMGN   went through a series of higher highs and higher lows culminating with a peak in January  It pulled back from there to a bottom at the end of March  A failed bounce fell back to a higher low and then another move higher confirmed a double bottom with a push over the 200 day SMA  It continued higher then to a top just short of the January high  It has consolidated that move since  Friday saw it push back to the January high 
The RSI is rising in the bullish zone with the MACD crossing up and positive  The Bollinger Bands had squeezed and are now opening to allow a move  There is no resistance over 198 50  Support lower comes at 196 60 and 190 30  Short interest is low at 1 6   The stock pays a 2 67  dividend and it begins trading ex dividend on August 16th  The company is expected to report earnings next on October 23rd 
Looking at the options chains  the August chain shows big open interest at the 190 put and bigger at the 200 call establishing a wide range of possibilities for the next 2 weeks  The September chain has biggest open interest at the 175 and 180 put strike with it rising from 190 to 210 on the call side  October has notable open interest at the 200 and 210 call  And January  the first after the next earnings report  builds to 170 on the put side and is centered around 200 on the call side 
Amgen  Ticker   AMGN 
Trade Idea 1  Buy the stock on a move over 198 50 with a stop at 195 
Trade Idea 2  Buy the stock on a move over 198 50 and add a September 195 190 Put Spread   1 70  while also selling a October 210 Call   1 89  to fund it 
Trade Idea 3  Buy a August October 200 Call Calendar for  2 95 
Trade Idea 4  Buy an October 200 210 Call Spread   3 35  and sell the October 180 Put   1 53 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which heading into the dog days of August sees the equity markets are looking poised for a move 
Elsewhere look for Gold to possibly pause in the downtrend while Crude Oil holds at support in the uptrend  The US Dollar Index is in a possible reversal higher while US Treasuries are pulling back in consolidation  The Shanghai Composite is renewing its downtrend and Emerging Markets are bouncing in a pullback 
Volatility looks to remain very low keeping the bias higher for the equity index ETF s SPY  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   Their charts also show strength with the SPY leading the charge in the short term  the IWM right behind it and the QQQ trying to reverse higher  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer ",2018-08-06,Gregory W. Harmon,https://www.investing.com/analysis/4-trade-ideas-for-amgen-bonus-idea-200336644,200336644
149921,371437,AMGN,Teva To Discontinue A Fremanezumab Study On Cluster Headache,opinion,"Teva Pharmaceutical Industries Ltd    NYSE TEVA   announced that it will discontinue the phase III study evaluating its key pipeline candidate  fremanezumab for the treatment of chronic cluster headache  This decision was based on data from a pre specified futility analysis of the study  which showed that the study is unlikely to meet its primary endpoint of mean change from baseline in the monthly average number of cluster headache attacks over a 12 week period The ENFORCE Phase III clinical development program comprised the chronic cluster headache study  an episodic cluster headache analysis and a long term safety study Notably  evaluation of the patients with chronic cluster headache in the long term safety study will also be stopped  However  the study on episodic cluster headache will not be affected and carried out as planned Fremanezumab  an anti calcitonin gene related peptide   CGRP   candidate  is currently under review in the United States and Europe for the preventive treatment of migraine in adults as a quarterly or monthly injection  However in May  the company announced that the FDA has postponed the action date from June to September Shares of the company slipped 0 8  including after hours trading on Jun 15  However  the stock has rallied 25 4  so far this year compared with the  s increase of 2 2  
 Teva is focused on developing fremanezumab beyond migraine for indications like cluster headache and post traumatic headache disorder We saw Alder Biopharmaceuticals Inc s   NASDAQ ALDR   share price rise 6 7  on Friday following the news of Teva s decision to suspend the cluster headache study  We note that Alder is also developing an anti CGRP candidate  eptinezumab  for the preventive treatment of migraine  The candidate is being evaluated in pivotal study with a Biologics License Application expected to be filed with the FDA during the first quarter of 2019 Meanwhile  several other companies are developing treatments for treating migraine  a multi billion dollar segment with high unmet need  In May  the FDA approved Amgen   NASDAQ AMGN   and its partner Novartis    NYSE NVS   anti CGRP drug  Aimovig  for treating episodic migraine  Other anti CGRP candidates under development include Eli Lilly s galcanezumab and Allergan s atogepant Galcanezumab is under review in the United States for preventive treatment of migraine  Lilly is also developing the candidate for cluster headache Teva Pharmaceutical Industries Ltd  Price
     Teva currently carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-06-17,Zacks Investment Research,https://www.investing.com/analysis/teva-to-discontinue-a-fremanezumab-study-on-cluster-headache-200325808,200325808
149922,371438,AMGN,Amgen Gets EU Nod To Add Survival Data On Blincyto s Label,opinion,Biotech major Amgen Inc    NASDAQ AMGN   announced that it has received European Commission s  EC  approval to include overall survival  OS  data from the TOWER study on the label of its BiTE antibody  Blincyto Blincyto is approved for treatment of patients with Philadelphia chromosome negative  Ph   relapsed or refractory B cell precursor acute lymphoblastic leukemia  ALL   The TOWER study was conducted to support the conversion of Blincyto s accelerated approval to full approval  The study evaluated the efficacy of Blincyto versus standard of care  SOC  chemotherapy for the treatment of Ph  relapsed or refractory B cell precursor ALL in adults Results from a late stage study showed that median overall survival for patients on Blincyto was 7 7 months compared with 4 months for standard of care  SOC  chemotherapy Blincyto s label in the United States already includes OS data from the TOWER study following the approval received from the FDA in July last year  In fact  the inclusion of the OS data has been instrumental in driving sales of the drug higher in the past two quarters  Blincyto sales surged 44  from the year ago period to  49 million in the first quarter of 2018  reflecting a rise in demandThe inclusion of the OS data on the European label of the drug should further boost sales We remind investors that Pfizer Inc  s   NYSE PFE   Besponsa was approved for the treatment of relapsed or refractory B cell precursor ALL in June last year in the EU  increasing competition for Blincyto Amgen s shares have gained 5 8  so far this year against a 7 2  decrease registered by the   Amgen currently carries a Zacks Rank  3  Hold   Better ranked stocks in the same sector include CRISPR Therapeutics AG   NASDAQ CRSP   and Genomic Health Inc   NASDAQ GHDX    both sporting a Zacks Rank  1  Strong Buy   You can see  CRISPR Therapeutics  loss per share estimates narrowed 7 8  for 2018 and 9  for 2019 in the last 60 days  The stock has skyrocketed 166 7  year to date Genomic Health s earnings estimates surged almost 47  for 2018 and 5 6  for 2019 in the past 60 days  The stock has soared 45 5  so far this year Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-06-19,Zacks Investment Research,https://www.investing.com/analysis/amgen-gets-eu-nod-to-add-survival-data-on-blincytos-label-200326477,200326477
149923,371439,AMGN,Merck  MRK  Stock Up So Far This Year On Keytruda Strength,opinion,Merck   Co   Inc    NYSE MRK   shares have performed well this year so far in contrast to its industry s performance  Merck belongs to the   which is a 14 stock group comprising some of the largest drugmakers of the world The Zacks Large Cap Pharmaceuticals industry has underperformed the S P 500 as well the   While the stocks in this industry have collectively declined 4 4   the Zacks S P 500 Composite and the Zacks Medical Sector have risen 3 7  and 0 1  year to date  respectively  However  Merck s shares have risen 8 4  this year so far against the industry s decline of 4 4   Also  earnings estimates for 2018 rose 1 2  while that for 2019 rose 4 1  over the past 60 days What s Behind the Rally A significant part of Merck s outperformance this year was driven by strong performance and positive regulatory updates related to its PD 1 inhibitor  Keytruda  In a very short span of time  Keytruda has become Merck s largest product  It is already approved for use in 10 different settings involving seven different tumor types  This year  it has already gained approval for two new indications  These include third line treatment of adult as well as pediatric patients with primary mediastinal B cell lymphoma  PMBCL   a type of non Hodgkin lymphoma and second line treatment of recurrent or metastatic cervical cancer  These label expansion approvals should drive sales of Keytruda in the future quarters The treatment generated sales of  1 5 billion in first quarter 2018  up 12 9  sequentially and 151  year over year  This upside was driven by the global launch of indications  which further boosted demand   Keytruda sales are gaining  particularly from strong momentum in the first line lung cancer indication  In fact  Keytruda is the only anti PD 1 approved in the first line setting for certain lung cancer patients both as a monotherapy as well as a combination therapy with Eli Lilly s   NYSE LLY   cancer drug  Alimta  pemetrexed  and carboplatin  pem carbo  At the recently concluded annual meeting of the American Society of Clinical Oncology  this PD L1 inhibitor stole the limelight with encouraging data from multiple clinical studies  The data presentation from Merck that garnered the most attention from physicians and investors was from a second interim analysis of a pivotal lung cancer study on Keytruda   phase III  Keytruda is also being studied for more than 30 types of cancer in more than 700 studies  including in excess of 400 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte  Glaxo and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens Other than that  this year Merck and partner AstraZeneca   NYSE AZN   gained approval in Europe and Japan for its PARP inhibitor Lynparza for advanced ovarian cancer and in the United States in metastatic breast cancer  Merck also announced positive data from several late stage studies  mainly evaluating Keytruda for further line extensions  Merck also signed a deal with Japan s Eisai Co   Ltd to jointly develop and commercialize the latter s tyrosine kinase inhibitor  Lenvima  both as a monotherapy as well as in combination with Keytruda  for several types of cancer  It also agreed to buy Viralytics Limited  an Australian pharmaceutical company that develops oncolytic immunotherapies for a range of cancers which should strengthen its oncology portfolio ConclusionMerck  which carries a Zacks Rank  3  Hold   has its share of challenges in the form of generic competition for several drugs and pricing pressure and rising competitive pressure on the diabetes franchise and on products like Isentress  HIV   Zepatier  HCV  and Zostavax  vaccine Nonetheless  going forward  new products like Keytruda  Lynparza  and Bridion should continue to contribute meaningfully to the top line in 2018  Merck s Animal Health unit is also strong and remains a core growth driver for the company  Meanwhile  Merck will also continue to focus on cost cutting initiatives  which should drive its bottom line You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-06-21,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-stock-up-so-far-this-year-on-keytruda-strength-200327391,200327391
149924,371440,AMGN,Amgen s Repatha Reduces Bad Cholestrol In Type II Diabetes,opinion,"Amgen   NASDAQ AMGN   announced new data from the phase III study   BANTING   which showed that its PCSK9 inhibitor  Repatha  significantly reduced bad cholesterol in patients with type II diabetes and hypercholesterolemia already receiving moderate high intensity statin therapy  The data was presented at Annual Scientific Sessions of the American Diabetes Association over the weekend According to the data from the BANTING study  the addition of Repatha to background statin therapy significantly reduced low density lipoprotein cholesterol  LDL C  and non high density lipoprotein cholesterol  non HDL C   Notably  LDL C was reduced by 53 1  at week 12 from baseline in the patient population So far this year  Amgen s shares have gained 6 5   comparing favorably with the  s 5 7  decrease The BANTING study evaluated monthly subcutaneous administration of a 420 mg dose of Repatha over a period of 12 weeks in patients with type II diabetes and hypercholesterolemia or mixed dyslipidemia who are on optimized background statin therapy The encouraging data from the study shows that patients with type II diabetes and hypercholesterolemia  who are already treated with a maximum tolerable dose of statin therapy  can further reduce LDL C and non HDL C by adding Repatha Data from the BANTING study also revealed that 84 5  of patients in the Repatha arm achieved LDL C levels of less than 70 mg dL  which is the recommended level by American College of Clinical Endocrinologists for patients with type II diabetes  compared with 15 4  of patients in placebo arm at week 12  The addition of Repatha too reduced various lipid parameters  including non HDL C by 47  compared with 1  for placebo High non HDL C levels can cause cardiovascular events in type II diabetes patients  which in combination with LDL C increases the risk further We remind investors that Repatha s label was expanded in Europe last month to include prevention of heart attack and stroke in adults with established cardiovascular disease  The encouraging data from BANTING study further brightens the prospect of the drug in reducing cardiovascular events in presumably larger patient population Another PCSK9 inhibitor available in the market is Sanofi   NYSE SNY    and partner Regeneron Pharmaceuticals  Inc  s   NASDAQ REGN   Praluent  Currently  both the drugs have recorded lower than expected sales due to higher pricing and re imbursement issues payer restrictions Amgen Inc  Price
    Zacks Rank   Stock to ConsiderAmgen currently carries a Zacks Rank  3  Hold   A better ranked stock in the pharma sector is Aeglea BioTherapeutics  Inc    NASDAQ AGLE   carrying a Zacks Rank  2  Buy   You can see  Aeglea s loss estimates narrowed from  1 93 to  1 67 for 2018 and from  3 86 to  3 57 for 2019 over the last 60 days  The company delivered positive earnings surprise in three of the trailing four quarters  with an average beat of 19 32   Its share price has increased 93 7  so far this year The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-06-24,Zacks Investment Research,https://www.investing.com/analysis/amgens-repatha-reduces-bad-cholestrol-in-type-ii-diabetes-200327526,200327526
149951,371467,AMGN,Abbvie s  ABBV  Upadacitinib Fifth RA Study Data Positive,opinion,AbbVie  Inc    NYSE ABBV   announced that its investigational oral JAK inhibitor  upadacitinib met all primary as well as secondary endpoints in the fifth phase III study from its SELECT program The phase III study  SELECT EARLY  evaluated the candidate for moderate to severe rheumatoid arthritis  RA  in patients who had not been previously treated with chemotherapy agent methotrexate  MTX  versus MTX monotherapy  The SELECT program evaluates more than 4 000 patients across six studies on RA After 12 weeks of treatment  the ACR50 response  primary endpoint  was achieved in 52  of the patients receiving the 15 mg oral once daily dose of upadacitinib and 56  of the patients taking the 30 mg dose versus 28  for patients receiving MTX The second primary endpoint of clinical remission was achieved by 48  of the patients in the 15 mg dose arm and 50  in the 30 mg dose arm  at week 24  versus only 18  for MTX Meanwhile  76  and 77  of patients in the 15 mg and 30 mg dose arm  respectively achieved ACR20 response at week 12 versus 54  for MTX The results clearly show that a significantly higher proportion of patients treated with upadacitinib in both doses achieved superior responses compared to MTX  This suggests that upadacitinib monotherapy has the potential to control progression of RA and reduce the risk of permanent bone and joint damage for MTX naive patients AbbVie plans to submit regulatory applications for upadacitinib in rheumatoid arthritis in the second half of the year Other than rheumatoid arthritis  upadacitinib is also being evaluated in late stage studies for Crohn s disease and psoriatic arthritis and mid stage studies for atopic dermatitis  giant cell arteritis and ulcerative colitis JAK inhibitors  also known as Janus kinase inhibitors  are emerging as a potential treatment option for RA  eczema and other inflammatory diseases  These medicines work by inhibiting the activity of one or more of the family of enzymesLast week  Eli Lilly   NYSE LLY   and partner Incyte Corporation   NASDAQ INCY   gained FDA approval for the lower dose of  2 mg  of their oral JAK inhibitor  Olumiant  While the FDA did not approve the higher dose  4 mg   the drug s label was approved with a boxed warning stating risk of serious infections  malignancies and thrombosis  Olumiant is already marketed in Europe and Japan  Another JAK inhibitor available in the market to treat RA is Pfizer s   NYSE PFE   Xeljanz Successful development of upadacitinib will boost AbbVie s RA portfolio  especially as biosimilar competition looms for its blockbuster RA drug  Humira Humira accounts for 65  of AbbVie s sales  Amgen  NASDAQ AMGN  and Samsung  KS 005930  Bioepis Biogen s Humira biosimilars will be launched in the United States in 2023 and in the EU in 2018 AbbVie s shares have gained 2 6  this year so far against the  s decline of 4 1   AbbVie currently carries a Zacks Rank  3  Hold   You can see Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-06-05,Zacks Investment Research,https://www.investing.com/analysis/abbvies-abbv-upadacitinib-fifth-ra-study-data-positive-200322606,200322606
149952,371468,AMGN,JAK Inhibitors  Prospects Strong  4 Stocks Ruling The Space,opinion,There is no approved therapy that can completely cure autoimmune or inflammatory diseases  The development of new treatment technologies is ongoing  Meanwhile  it is difficult to control autoimmune diseases in the majority of patients  The newest class of medications to treat these diseases is janus kinase   JAK   inhibitors  which are providing patients a better treatment option  This class of therapies has generated significant interest due to their better efficacy compared to tumor necrosis factor   TNF   inhibitor therapies Autoimmune DiseasesIn patients with autoimmune diseases  the body s immune system mistakenly attacks the healthy cells  Scientists are yet to find the reason behind this abnormality  However  the incidence of autoimmune diseases is on the rise  There are multiple types of autoimmune diseases including rheumatoid arthritis   RA    psoriasis  multiple sclerosis   MS    inflammatory bowel disease   IBD    etc  Several companies are dedicated to bringing better drugs for the treatment of these diseases  The symptoms include fatigue  muscle aches  swelling  and redness in the affected body parts The most common and first line treatment for autoimmune disease is disease modifying anti rheumatic drugs  DMARDs   especially methotrexate  Apart from methotrexate  there are several classes of DMARDs including TNF inhibitor therapies approved for these diseases that are performing well  AbbVie s   NYSE ABBV   Humira and Amgen s   NASDAQ AMGN   Enbrel are blockbuster TNF inhibitor drugs among others  However  these treatments have serious safety issues which include increased risk tuberculosis and lymphoma among others JAK InhibitorsSeveral pharma companies are developing JAK inhibitors  which work by blocking a particular signal of a body s immune response  cytokines  instead of suppressing the immune system as done by DMARDs  Patients treated with JAK inhibitors in clinical studies have shown faster and better response to the disease  However  the safety concern still looms large  The segment is attractive for companies as there are only two JAK inhibitors  presently approved for the treatment of autoimmune diseases  especially RA  However  several companies are developing their candidates  which is likely to increase competition going forward The segment was in news recently as Eli Lilly s   NYSE LLY   Olumiant  a JAK inhibitor  received approval in the United States and AbbVie   NYSE ABBV   announced top line data from a late stage study evaluating its JAK inhibitor candidate upadacitinib 4 Pharma Biotech Companies in FocusGiven the growing interest in JAK inhibitors  let s take a look at some pharma and biotech companies that are looking to change the way autoimmune diseases are treated Pfizer s   NYSE PFE   Xeljanz  tofacitinib  is the first approved JAK inhibitor in the United States for the treatment of RA  It has been available in the market since 2012  The drug is also approved for psoriatic arthritis  It generated sales of  326 million in the first quarter of 2018  up 30 4  year over year  A regulatory application seeking line extension of the drug in ulcerative colitis was approved late last month in the United States  Regulatory applications seeking approval in the above three indications are under review in Europe The company currently carries a Zacks Rank  3  Hold   You can see  Eli Lilly s JAK inhibitor  Olumiant  baricitinib   is the second drug to receive approval for treating RA in the United States  The drug was approved early this month  However  it was launched in certain European countries in 2017  We note that the FDA rejected the company s new drug application seeking approval of Olumiant in April 2017 citing safety concerns  Lilly develops and commercializes the drug in partnership with Incyte Corporation  The drug generated sales of  32 2 million in the first quarter  sequentially up 40   Lilly is currently evaluating the drug in another autoimmune indication  atopic dermatitis  eczema   in a late stage study The company currently carries a Zacks Rank  2  Buy  AbbVie is another company  which is focused on developing JAK inhibitor based treatments  The company s JAK inhibitor  upadacitinib  showed promising results in late stage studies evaluating the candidate in RA patients  It is also being developed for atopic dermatitis in a late stage study for which it enjoys breakthrough therapy status in the United States  Another late stage study is evaluating the candidate in Crohn s disease The company currently carries a Zacks Rank  3 Galapagos NV   NASDAQ GLPG   is developing its JAK inhibitor candidate  filgotinib  in collaboration with Gilead Sciences  Inc    NASDAQ GILD    Separate late stage studies are evaluating the candidate in RA  Crohn s disease and ulcerative colitis  Moreover  several mid stage studies are evaluating the candidate in multiple autoimmune indications including ankylosing spondylitis  psoriatic arthritis and cutaneous lupus erythematosus among others  Data from a mid stageI study evaluating filgotinib in psoriatic arthritis showed significant improvement in patients The company currently carries a Zacks Rank  3 Prospects of JAK Inhibitors With several blockbuster DMARDs nearing patent expiration  this new class of drugs holds potential to replace the existing treatments  This boosts the prospects of the companies that have these drugs candidates in their pipeline or commercial portfolio However  JAK inhibitors also have several side effects  which may delay their approval  We note that a lower dose of Lilly s Olumiant was approved along with a boxed warning stating risk of serious infections  malignancies and thrombosis The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-06-10,Zacks Investment Research,https://www.investing.com/analysis/jak-inhibitors-prospects-strong-4-stocks-ruling-the-space-200323853,200323853
149953,371469,AMGN,My No  1 Buy For 8 5  Dividends And 20  Gains  By 2019 ,opinion,"I don t want to alarm you  but if you ve got a lot of cash sitting on the sidelines right now  you re about to miss out on a double digit stock market gain in the next 6 months 
In a moment  I ll show you 5 funds you can buy today to lock in these quick  life changing profits  and dividend payouts  too   To make it even easier for you  I ve ranked these 5 popular buys from worst to first 
But first  let me tell you what I m basing this bold prediction on  The story starts in early February of this year 
You no doubt recall those wild days  after a sharp run up in stocks in January  which itself was on the heels of a 23  gain for the S P 500 in 2017  the SPDR S P 500 ETF  NYSE SPY  suddenly did this 
A Nosedive
Panic was in the air so much so that I was getting calls from worried family and friends asking me what was causing the selloff and what it meant for their retirements  I wrote about that in this article  
My response   It means nothing  
That s also what I told readers I explained how there was a bit of profit taking and a much needed break from the bull market we d enjoyed for so long  And I also said that stocks would recover long before the end of 2018 a theme I wrote about again even as the market kept falling in February and again in March 
And now the market is doing this 
The Recovery Kicks In
I don t have a crystal ball I have something better  data  A lot of it  And it s telling me you need to act now if you want to grab your share of the profits from  stage 2  of the 2018 market boom 
Your Buy Window Is Closing Fast
Whether it s corporate profits  which rose to a record high in the first quarter of 2018 and are set to rise again in Q2   falling unemployment  now at a shockingly low 3 8   or wage growth  which is reaching 3    the signs of a resurgent economy were all there in early February 
On top of that  the S P 500 s forward P E ratio was 17 lower than it s been for most of the last 30 years  even though the index is now dominated by tech companies boasting higher P E ratios 
All of that screamed  buy  
Fast forward to today  and the market has finally realized that  yes  the economy is strong  which means your window to buy into the recovery is closing fast 
But don t worry  it s not closed yet 
With continued economic strength lifting most US firms  there s plenty of reason to expect stocks to end the year up at  or at least near  double digits 
So how do we get in before it s too late 
5 Funds to Play the Rebound Ranked From Worst to First
The obvious candidate  and worst of my 5 picks  would be an index fund  You can take your pick here  SPY or the Vanguard 500 ETF  VOO   Both will get you the same thing  market matching performance and a pretty sad 1 8  dividend 
Next up is the Invesco QQQ Trust  QQQ   which gives you a growth burst through its exposure to the tech companies of the NASDAQ 100 index  including the big payment giant Visa  NYSE V   which is up a handsome 16 7  so far in 2018  QQQ is already up a nice 11 9  for 2018 after falling into negative territory in early February 
But you are sacrificing income to get that growth  the fund yields just 0 75  as I write 
A slightly better option is the iShares S P 500 Growth ETF  IVW   which goes beyond tech stocks while focusing on companies that are seeing the biggest sales growth and dodging  old economy  laggards like Xerox  NYSE XRX  and Time Warner  NYSE TWX   Its dividend  at 1 5   is above that of QQQ but still behind the index funds 
I m sure you re seeing a theme here  and it s a major downside with all 3 of these funds  if you want a meaningful income stream  you ll have to supplement their meager dividends by selling your shares 
Trouble is  you ll have to be very careful not to do so into a downturn  And that kind of market timing is beyond the reach of most mortals  which gives my top ETF pick a decided edge 
I m talking about the iShares Core High Dividend ETF  HDV   Its 3 8  yield is far ahead of the payouts on the 3 funds I just showed you  and it also offers exposure to American large cap firms boasting either a long history of growing dividends such as Johnson   Johnson  NYSE JNJ  and Pfizer  NYSE PFE  or big yields right now  like Verizon  NYSE VZ  and AT T  NYSE T  
And since HDV still hasn t recovered for 2018  it s down 5 6  year to date   it s a great bet for the contrarian who sees a market wide recovery in the future  as I do 
My  1 Pick  Buy NOW for 8 5  Dividends and 276   Gains 
But I have to tell you something here  I still have one serious reservation about HDV  it s just a little too focused on  old economy  stocks and underweight on the tech and biotech firms setting the pace for tomorrow s economy 
And that could set the stage for a steady drip lower while the rest of the market races away 
Luckily  my No  1 fund pick which I m going to tell you about now doesn t have that problem  It s got all the tools to lead the market higher in the critical 6 months to come 
This off the radar biotech champ has obliterated SPY in the last decade and that s just the start 
A Market Dominator
You see  because this chart includes dividends  most of this monstrous return was in CASH  so owners didn t have to worry about selling shares into a crash  hello  2008 09   like SPY holders did 
And those dividend payouts are still massive  this fund currently yields a mind blowing 8 5  nearly 5 TIMES as much as SPY  Oh  and it drops those fat cash payouts into your account monthly too 
I m not done yet 
The secret behind this off the radar fund lies in its very structure  it s a closed end fund  CEF  
Don t let the technical name fool you  All this really means is that this fund trades at a market price that s different than the value of its underlying holdings 
And right now  that difference amounts to a 5  discount  This is basically free money 
To sum up  here s what you re getting in this 5   markdown sale  

All the stocks in this fund s portfolio rock solid names with long histories of dividend growth  like Amgen  NASDAQ AMGN  and Gilead Sciences  NASDAQ GILD  
Market crushing outperformance  with 276  gains  and most of that return in cash  over the last decade 
1 click access to the top talent in biotech  this fund s manager  with more than two decades of experience himself  hires doctors and researchers with  boots on the ground  expertise at finding the next breakthrough treatment 

I ll give you all the details on this breakthrough income play when you click here 
And that s still not all 
You see  this fund is part of a 5 fund  mini portfolio  I crafted exclusively for members of my CEF Insider service  Now  for a limited time  I ll show it to you at no cost  Taken together  these 5 totally ignored CEFs will hand you a safe 8 2  yield now 
And  thanks to their ridiculous discounts  my team and I have each one pegged for easy 20   price upside in the next 12 months 
Don t miss out  CLICK HERE to get the names  ticker symbols  buy under prices and my complete research on these 5 income  and growth   plays now 
Disclosure  Brett Owens and Michael Foster are contrarian income investors who look for undervalued stocks funds across the U S  markets  Click here to learn how to profit from their strategies in the latest report   7 Great Dividend Growth Stocks for a Secure Retirement  ",2018-06-11,Michael Foster,https://www.investing.com/analysis/crucial-my-no-1-buy-for-85-dividends-and-20-gains-by-2019-200323756,200323756
149954,371470,AMGN,Merck s  MRK  Keytruda Gets FDA Approval For Cervical Cancer,opinion,"Merck   NYSE MRK   has received FDA s accelerated approval for label expansion of its blockbuster anti PD 1 therapy  Keytruda  to include advanced cervical cancer in second line setting  The company will need to evaluate the drug in confirmatory studies in this indication for gaining continued approval The eligible patients for the treatment in cervical cancer will be selected based on an FDA approved test for PD L1 expression in tumors with combined positive score   CPS    1 The approval comes a bit earlier than the expected date of Jun 28  The FDA had granted priority review to this label expansion regulatory application in March Keytruda is the most successful immuno oncology drug to date with approval in several cancer indications including the lucrative first line lung cancer  This is the first anti PD 1 therapy approved in advanced cervical cancer and the first indication for Keytruda in gynecologic cancer as well This year so far  Merck s shares have outperformed the   Its shares have risen 10 9  in the period against the industry s decline of 4 4    The latest FDA approval is based on data from a single cohort of a multi cohort phase II study   KEYNOTE 158   evaluating the drug in recurrent or metastatic cervical cancer  Data from a subset of patient population expressing PD L1 with a CPS  1 showed that Keytruda achieved an objective response rate of 14 3   Moreover  2 6  of the patients achieved a complete response and 11 7  of patients demonstrated partial response The drug generated no response in cervical cancer patients whose PD L1 expression in tumors had a CPS  1 Merck is evaluating the drug in a wide range of cancer indications and treatment settings in more than 750 clinical studies At the recently concluded annual meeting of the American Society of Clinical Oncology  this PD L1 inhibitor stole the limelight with encouraging data from multiple clinical studies  The data presentation  which garnered attention from physicians and investors  was from a second interim analysis of a pivotal lung cancer study on Keytruda   phase III KEYNOTE 407 study Moreover  Merck has collaborated with several pharma companies  including Amgen   NASDAQ AMGN    Glaxo   NYSE GSK    Pfizer   NYSE PFE   and Incyte  to evaluate Keytruda in combination with other regimens The drug generated worldwide sales of almost  1 5 billion in the first quarter of 2018  up 150  from the year ago period  With this line extension approval in cervical cancer and potential approvals in other indications under review  the positive momentum of the drug is expected to continue in 2018 Merck   Co   Inc  Price
    Merck currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-06-12,Zacks Investment Research,https://www.investing.com/analysis/mercks-mrk-keytruda-gets-fda-approval-for-cervical-cancer-200324610,200324610
149975,371491,AMGN,Biotech Stock Roundup  FDA Gives Nod To Amgen s Drugs  EU Approves Exelixis  Cabometyx ,opinion,"The Biotech space remained a key area of investors  focus with label expansion of a few prominent drugs and pipeline updates on a few others  While Amgen obtained the FDA approval for Prolia and Repatha  Exelixis also obtained approval for its lead drug Cabometyx for the first line treatment of kidney cancer in Europe 
Recap of Important Stories
Label Expansion of Amgen s Drugs  It is raining approvals at Amgen   NASDAQ AMGN    The FDA approved the label expansion of Prolia for the treatment of glucocorticoid induced osteoporosis  GIOP  in men and women at high risk of fracture  defined as a history of osteoporotic fracture  multiple risk factors for fracture  or patients who have failed or are intolerant to other available osteoporosis therapy  
Notably  this is the fifth indication for Proloa in men and women at high risk of fracture receiving systemic glucocorticoid therapy  The approval was based on positive data from a phase III study  which showed that patients on glucocorticoid therapy who received Prolia had greater gains in bone mineral density  BMD  compared with those who received active comparator  risedronate  
Last week  Amgen obtained approval for a label expansion of Repatha in adults with established atherosclerotic cardiovascular disease  myocardial infarction  stroke or peripheral arterial disease  to reduce cardiovascular risk by lowering low density lipoprotein cholesterol  LDL C  levels in Europe   Amgen and partner Novartis also obtained the FDA approval of migraine drug  Aimovig  erenumab    Read more       
Amgen is a Zacks Rank  3  Hold  stock  You can see  
Exelixis Gets EU Approval For Cabometyx  Exelixis   NASDAQ EXEL   announced that its partner Ipsen has obtained approval from the European Commission  EC  for kidney cancer drug  Cabometyx  cabozantinib  20 mg  40 mg and 60 mg for the first line treatment of adults with intermediate  or poor risk advanced renal cell carcinoma  RCC  in the European Union 
The approval will broaden the geographic reach of the drug as the market potential is significant for the first line treatment of kidney cancer  The approval also triggered a milestone payment of  50 million to Exelixis from Ipsen of which approximately  46 million was recognized as collaboration revenue in the first quarter of 2018  The payment will be made by Ipsen within the next 70 days   Read more   
Regeneron Announces Data on Dupixent  Regeneron   NASDAQ REGN   and partner Sanofi   NYSE SNY   announced that a pivotal phase III trial evaluating Dupixent for the treatment of moderate to severe atopic dermatitis in adolescents  ages 12 17  met its primary and key secondary endpoints  The results show that Dupixent as monotherapy significantly improved measures of overall disease severity  skin clearing  itching and certain health related quality of life measures 
The New England Journal of Medicine  NEJM  also published detailed results from two phase III trials  QUEST and VENTURE  on Dupixent for the treatment of moderate to severe asthma  The results showed that Dupixent significantly reduced the risk of severe asthma attacks  exacerbations   improved lung function and reduced dependence on oral corticosteroids  OCS  
The drug also demonstrated significant improvements in the key primary and secondary endpoints across the overall populations in both QUEST and VENTURE studies  Patients with more severe type 2 inflammatory asthma experienced the greatest benefit   Read more   
Both the companies also announced that data evaluating cemiplimab as a potential treatment for advanced non small cell lung cancer  NSCLC  from a phase I will be shared at the 2018 American Society of Clinical Oncology  ASCO  Annual Meeting 
Lexicon Sanofi s Drug Accepted by FDA  Lexicon Pharmaceuticals  Inc    NASDAQ LXRX   and partner Sanofi announced that the FDA has accepted the New Drug Application  NDA  for diabetes drug Zynquista  sotagliflozin   Zynquista is an investigational oral dual inhibitor of SGLT 1 and SGLT 2  proteins that influence how the intestines and kidneys absorb and eliminate sugar  glucose   resulting in improved glucose control and additional clinical benefits 
The FDA action date is expected to be Mar 22  2019 under the Prescription Drug User Fee Act  PDUFA   Earlier in 2018  Sanofi also submitted a regulatory application to the European Medicines Agency 
Nabriva Therapeutics Announces Positive Data on Lefamulin  Nabriva Therapeutics plc   NASDAQ NBRV   announced positive top line results from the phase III trial  LEAP  Lefamulin Evaluation Against Pneumonia  2  on lefamulin  The trial evaluated the safety and efficacy of five days of oral lefamulin compared with seven days of oral moxifloxacin in adult patients with moderate community acquired bacterial pneumonia  CABP  
Lefamulin met the FDA primary endpoint of non inferiority compared with moxifloxacin for early clinical response  ECR  assessed 72 120 hours following initiation of therapy with the intent to treat  ITT  patient population  The company plans to file a New Drug Application with the FDA in the fourth quarter of 2018  However  the stock fell as investors were wary of the rate of treatment emergent adverse events observed in the lefamulin arm 
PerformanceMedical   Biomedical and Genetics Industry 5YR   Return

The NASDAQ Biotechnology Index lost 0 74  over the last five trading sessions  Among the major biotech stocks  Gilead gained 0 41   Over the past six months  Celgene  NASDAQ CELG  lost 27 15   while Alexion gained 10 60   See the last biotech stock roundup here    

 
What s Next in Biotech 
Stay tuned for regulatory updates and pipeline development news 
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-05-23,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-fda-gives-nod-to-amgens-drugs-eu-approves-exelixis-cabometyx-200318870,200318870
149976,371492,AMGN,Merck s Keytruda Shows Survival Benefit In Squamous NSCLC,opinion,"Merck   NYSE MRK   announced that its pivotal study   KEYNOTE 407   evaluating Keytruda chemotherapy combination in first line metastatic squamous non small cell lung cancer   NSCLC   met its dual primary endpoint of overall survival   OS   and progression free survival   PFS    The drug in combination with chemotherapy demonstrated significantly longer OS and PFS versus chemotherapy alone Merck s supplemental Biologics License Application   sBLA   seeking continued approval of Keytruda combined with Eli Lilly s   NYSE LLY   Alimta and platinum chemotherapy for treating metastatic non squamous NSCLC is under review in the United States  The sBLA was filed based on encouraging data from another phase III study  KEYNOTE 189 The company plans to share data from the KEYNOTE 407 study with FDA and may expand the sBLA to include patients with squamous histology The company will present detailed data from the KEYNOTE 407 study at the upcoming annual meeting of the American Society of Clinical Oncology next month Shares of Merck were up 0 2  in after market trading after the news was announced  This year so far  Merck s shares have outperformed the   Its shares have risen 5 1  in the period against the industry s decline of 4  Notably  Keytruda is already approved as monotherapy for the first line treatment of patients with metastatic NSCLC whose tumors express PD L1 protein levels of 50  or greater  Keytruda also has accelerated approval to treat first line patients with metastatic NSCLC in combination with Alimta and chemotherapy Merck remains focused on developing Keytruda as monotherapy or combination therapy for the treatment of lung cancer with various mutation or histology in first line setting in a bid to further reinforce its position in that segment  Lung cancer is an attractive market as it is the largest cause of death among all cancer patients Moreover  Keytruda is the only immune oncology drug  which is approved for the treatment of lung cancer in the first line setting  We remind investors that Bristol Myers   NYSE BMY   is also developing its immune oncology drug  Opdivo  in first line lung cancer  However  Keytruda s early entry and positive data readouts from several phase III studies in expanded first line lung cancer patients bode well for the company s top line We note that Keytruda is marketed for many types of cancer and treatment settings including lung cancer  melanoma  head and neck cancer  classical Hodgkin s lymphoma  gastric cancer  bladder cancer and microsatellite instability high  MSI H  or mismatch repair deficient cancer Meanwhile  Keytruda is being studied for more than 30 types of cancer  in more than 700 studies  including in excess of 400 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte  Glaxo and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens Merck   Co   Inc  Price
    Merck currently carries a Zacks Rank  3  Hold   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-05-23,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-shows-survival-benefit-in-squamous-nsclc-200319182,200319182
149977,371493,AMGN,Why Is Amgen  AMGN  Up 3 7  Since Its Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Amgen Inc    NASDAQ AMGN    Shares have added about 3 7  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is AMGN due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers Amgen First Quarter Earnings   Sales BeatAmgen reported first quarter 2018 earnings of  3 47 per share  which beat the Zacks Consensus Estimate of  3 23 by 7 4   Earnings increased 10  year over year driven by higher product sales  seasonally low expenses in Q1  a lower tax rate and lower share count Total revenues of  5 55 billion in the quarter marginally surpassed the Zacks Consensus Estimate of  5 46 billion  The top line also registered an increase of 2  year over year Quarter in DetailTotal product revenues increased 3  from the year ago quarter to  5 34 billion  U S    4 15 billion  ex U S    1 20 billion  as increasing demand for newer products like Prolia  Kyprolis  Xgeva  Repatha and Blincyto  was partially offset by lower sales of mature brands like Enbrel  Aranesp  Epogen  Neulasta and Neupogen due to competitive pressure Revenues of Amgen s erythropoiesis stimulating agent  ESA   Aranesp  declined 11  from the prior year quarter to  454 million due to lower demand  primarily due to increased competitive pressures Revenues of the other ESA  Epogen  declined 10  to  244 million due to lower selling price owing to a newly negotiated contract with DaVita Inc Neulasta revenues declined 5  to  1 16 billion from the year ago period due to lower demand and unfavorable comparisons to last year s first quarter  Increased competition from PD 1s and other new cancer therapies is hurting demand for Neulasta  However  the Neulasta Onpro kit  on body injector  continues to perform well  commanding a market share of about 62  in the United States for all Neulasta sales  Amgen is optimistic that it will see more global utilization of Onpro in 2018 Neupogen recorded a 30  decline in sales to  103 million due to biosimilar competition in the United States Enbrel delivered revenues of  1 11 billion declined 6  from the year ago quarter due to lower selling prices and increased competition  which hurt demand  Unfavorable comparisons to last year s first quarter  which benefited from favorable changes in accounting estimates  also hurt Enbrel sales Prolia revenues came in at  494 million  up 16  from the year ago quarter due to higher demand  The osteoporosis drug witnessed continued growth in new patient starts and strong repeat injection rates  which drove year over year growth Xgeva delivered revenues of  445 million  up 11  from the year ago quarter mainly due to higher demand Sensipar Mimpara revenues rose 18  to  497 million  mainly riding on higher demand and some inventory build probably due to a shift in reimbursement from U S  Medicare Part D to Part B at the beginning of 2018 Vectibix revenues came in at  169 million  up 15   driven by higher demand Kyprolis recorded sales of  222 million  up 17  year over year  driven by increased demand and a robust uptake from outside U S  markets  In Europe  the majority of sales came from triplet regimens and Kyprolis continues to take market share from Velcade Blincyto sales surged 44  from the year ago period to  49 million  reflecting rise in demandRepatha generated revenues of  123 million compared with  98 million in the previous quarter driven by volume growth  On the call  the company said that access to Repatha for high risk cardiovascular patients has improved over the past few months with the outcomes data included on the Repatha label Other revenues declined 20 4  to  211 million due to lower milestone payment received than the first quarter of 2017 Parsabiv  launched in several markets including the United States  recorded sales of  41 million in the quarter  On the call  the company said that in the United States  Parsabiv has witnessed a solid uptake in the midsized dialysis providers Operating Margins DecreaseAdjusted operating margins declined 70 basis points  bps  to 56 9  due to higher operating costs SG A spend increased 6  to  1 1 billion on higher investments to support growth products as well as the pre launch preparations for Aimovig and bio similar products  R D expenses were almost flat at  739 million compared with the year ago figure The adjusted tax rate was 13 7  for the quarter  a 4 8 point decrease from the first quarter of 2017 Amgen repurchased 56 4 million shares worth  10 8 billion in the first quarter and plans to repurchase between  2 billion and  4 billion of stock in the second quarter 2018 GuidanceAmgen raised the lower end of its sales and earnings guidance for 2018  Better than expected first quarter earnings and a revised tax outlook led to the increase in the earnings guidance The company now expects its revenues in the range of  21 9  22 8 billion compared with the previous prediction of  21 8  22 8 billion  Adjusted earnings are now anticipated in the range of  12 80  13 70 in 2018 compared with the previous projection  12 60  13 70 The guidance assumes the approval and launch of migraine candidate  Aimovig and Amgevita in 2018  Also  management seems quite confident that Repatha will become an important growth driver for the company with the inclusion of outcomes data on its label  Nonetheless  other than continuing competitive dynamics for Enbrel  possible generic competition to Sensipar and new competition for Neulasta and Aranesp could be the new challenges in 2018 and are accounted for in the 2018 revenue guidance Operating margin is expected to be between 52  and 54  in 2018  Operating margin is expected to be lower in the remaining quarters of 2018 due to the timing of expenses  Operating expenses  as a percent of products sales  were seasonally low in the first quarter and the ratio is expected to be higher in the remaining quarters of the year and normalize to around 2017 levels Adjusted tax rate is now estimated at approximately 13 5  14 5   lower than the past range of 14 15   reflecting the impact of the latest tax reform Hoping to achieve an improved cash position following the new tax law  Amgen plans to invest approximately  750 million this year in capital expenditures 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates have trended downward during the past month  There have been four revisions higher for the current quarter compared to five lower 
Amgen Inc  Price and Consensus
    VGM Scores
At this time  AMGN has a nice Growth Score of B  though it is lagging a bit on the momentum front with a C  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is equally suitable for value and growth investors than momentum investors 
Outlook
Estimates have been trending downward for the stock and the magnitude of these revisions looks promising  Notably  AMGN has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-05-23,Zacks Investment Research,https://www.investing.com/analysis/why-is-amgen-amgn-up-37-since-its-last-earnings-report-200319172,200319172
149978,371494,AMGN,Novartis Gets Approval For Remicade Biosimilar In Europe ,opinion,"Novartis   NYSE NVS   announced that its generic arm  Sandoz  obtained approval for Zessly  a biosimilar version of Johnson   Johnson   NYSE JNJ   s Remicade  in Europe 
Zessly is approved for use in all indications of the branded drug including rheumatoid arthritis  adult Crohn s disease  pediatric Crohn s disease  adult ulcerative colitis  pediatric ulcerative colitis  ankylosing spondylitis  psoriatic arthritis and plaque psoriasis 
The approval from the European Commission is based on review of a comprehensive development program  including analytical  preclinical and clinical data  which confirmed Zessly matching Remicade in terms of safety  efficacy and quality 
An approval was in the cards as the CHMP had given a positive opinion on the same in March 
The approval will strengthen Sandoz s already strong biosimilar portfolio with five marketed biosimilars  Omnitrope  a human growth hormone  Binocrit  an erythropoiesis stimulating agent used to treat anemia  and filgrastim for neutropenia under the brand names Zarzio outside the United States and Zarxio in the United States  
Rixathon  biosimilar rituximab   approved in Europe in 2017 to treat blood cancers and immunological diseases  also approved in the EU as Riximyo under a duplicate marketing authorization   and Erelzi  biosimilar etanercept   approved in Europe in 2017 to treat multiple inflammatory diseases   
With Zessly s approval  Sandoz will now have six approved biosimilars in its portfolio  Zessly is the third biosimilar which has been approved by the EC in the last 12 months for Sandoz 
The FDA also approved biosimilar Erelzi in 2016  However  the launch is pending in the United States due to an ongoing litigation with Amgen   NASDAQ AMGN   
We note that Sandoz acquired the biosimilar of infliximab from Pfizer   NYSE PFE   in February 2016 for the 28 EU countries plus Norway  Iceland and Liechtenstein that form the European Economic Area 
Novartis  shares have declined 2 6  over a year  compared with the  s fall of 5 5  

 
However  Sandoz continues to face pricing pressure and sales are projected to decline in the upcoming quarters 
Zacks Rank
Novartis carries a Zacks Rank  3  Hold   You can see  
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-05-24,Zacks Investment Research,https://www.investing.com/analysis/novartis-gets-approval-for-remicade-biosimilar-in-europe-200319153,200319153
149979,371495,AMGN,FDA Confirms September Action Date For Teva s Migraine Drug,opinion,"Teva Pharmaceutical Industries Ltd    NYSE TEVA   confirmed that FDA has extended the action date of the Biologics License Application  BLA  for fremanezumab  The action date for fremanezumab is now set for September 16  2018  which was previously set for mid June  There are no additional data requests from the FDA 
Fremanezumab is an investigational therapy currently under review by the FDA as a quarterly or monthly injection for the preventive treatment of migraine in adults   It is also under review in the European Union 
Shares of Teva increased 11 6  year to date against the i s decline of 6 2  

We remind investors that the FDA accepted for review the company s BLA for fremanezumab  in December 2017 and  granted fast track designation to the candidate  However  in January 2018  Teva s partner Celltrion received a warning letter from FDA for a facility in South Korea  following an inspection of the fill finish side of the facility  thus delaying the approval of the drug  This facility manufactures active pharmaceutical ingredients  APIs  for fremanezumab 
Teva  thus  stated in its first quarter 2018 earnings call that it did not expect to receive FDA approval on its BLA for fremanezumab on the mid June date  The company was in a constructive dialogue with the FDA in close collaboration with partner Celltrion 
Recently  we note that Amgen   NASDAQ AMGN   and partner Novartis   NYSE NVS   have received FDA approval for their pipeline candidate Aimovig  erenumab  for the prevention of migraine  The drug is the first FDA approved treatment  specifically developed to treat migraine by blocking calcitonin gene related peptide   CGRP   receptor 
Another Pharma giant Eli Lilly   NYSE LLY   has anti CGRP candidate  galcanezumab  which is under review in the United States  A decision on galcanezumab is expected in the third quarter of the year 
Teva carries a Zacks Rank  3  Hold   You can see 
Teva Pharmaceutical Industries Ltd  Price
   Wall Street s Next Amazon  NASDAQ AMZN  
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-05-24,Zacks Investment Research,https://www.investing.com/analysis/fda-confirms-september-action-date-for-tevas-migraine-drug-200319127,200319127
149980,371496,AMGN,Merck s  MRK  Keytruda Lung Cancer Data In Focus At ASCO ,opinion,Merck   Co   Inc  s   NYSE MRK   PD L1 inhibitor  Keytruda ruled at the annual meeting of the American Society of Clinical Oncology  ASCO  in Chicago as the drug giant presented additional data from two pivotal lung cancer studies on the drug Merck presented additional data from the pivotal KEYNOTE 042 study in patients with locally advanced or metastatic nonsquamous or squamous non small cell lung cancer  NSCLC  whose tumors express PD L1 protein levels of 1 percent or greater   TPS of  1 percent  In April  Merck had said that in such patients  Keytruda led to a significant survival benefit compared with platinum based chemotherapy  With the latest release  the company said that in patients with TPS of  1 percent  median overall survival  OS  was 16 7 months in the Keytruda arm versus 12 1 months in chemotherapy arm  In the PD L1 TPS  50 percent patient population  median OS was 20 months while that in patients with TPS of  20 percent was 17 7 months versus 12 2 months and 13 months  respectively for chemotherapy alone Also  Merck said the risk of progression or death or progression free survival  PFS    the secondary endpoint   was 19  in the PD L1 TPS  50 percent population at the time of interim analysis  which was not statistically significant Notably  Keytruda monotherapy is already marketed for the first line treatment of patients with metastatic NSCLC whose tumors express PD L1 protein levels of 50 percent or greater  TPS of  50 percent  based on data from the KEYNOTE 024 study If the OS data from KEYNOTE 042 study are approved to be included in Keytruda s label  the drug can be prescribed to treat an expanded lung cancer patient population  further reinforcing its position in the lung cancer market  Later in the year  Merck will file regulatory application to get the OS data from the study included in the label of Keytruda Merck also announced data from a second interim analysis of a pivotallung cancer study on Keytruda   phase III KEYNOTE  407 study   which evaluated Keytruda in combination with carboplatin paclitaxel or nab paclitaxel  chemotherapy  for the first line treatment of metastatic squamous NSCLC  The data from the study showed that the combination of Keytruda plus chemotherapy led to significant improvement in both OS and PFS regardless of PD L1 expression  The risk of death  OS  was reduced by 36  compared to chemotherapy alone  The median OS was 15 9 months in the Keytruda combination group versus 11 3 months in the chemotherapy arm  The PFS improvement was nearly half for patients in the Keytruda combination group compared with chemotherapy alone  The median PFS was 6 4 months in the Keytruda combination group versus 4 1 months in the chemotherapy arm A regulatory application to include data from this study was submitted to the FDA in May  At the same time  the company had presented data from the first interim analysis of the KEYNOTE  407 study  It said that the study met a pre specified secondary endpoint of overall response rate  ORR  in an early cohort of participants  At ASCO  the company said that ORR was 57 9  in the Keytruda arm compared to 38 4  for chemotherapy aloneMetastatic squamous NSCLC is a difficult to treat population  which accounts for about 30  of lung cancer cases  If the Keytruda combination is approved to treat this difficult to treat population  lung cancer sales of the drug should improve further This year so far  Merck s shares have outperformed the   Its shares have risen 7 6  in the period against the industry s decline of 4 5  Keytruda is the second largest product in Merck s portfolio  It is marketed for many types of cancer and treatment settings including lung cancer  melanoma  head and neck cancer  classical Hodgkin s lymphoma  gastric cancer  bladder cancer and microsatellite instability high  MSI H  or mismatch repair deficient cancer The treatment fetched sales of  3 8 billion in 2017  up almost 172  year over year  This upside is driven by the global launch of new indications  which further bolstered demand   Keytruda sales are gaining  particularly from strong momentum in the first line lung cancer indication  In fact  Keytruda is the only anti PD 1 approved in the first line setting for certain lung cancer patients both as a monotherapy as well as a combination therapy with Eli Lilly s   NYSE LLY   cancer drug  Alimta  pemetrexed  and carboplatin  pem carbo  Meanwhile  Keytruda is being evaluated in several lung cancer studies across multiple settings and stages of the disease  both as a monotherapy as well as a combination therapy At ASCO  Merck also presented data from several combination studies of tyrosinekinase inhibitor  Lenvimaplus Keytruda at ASCO The studies evaluating the Lenvima Keytruda combination in four different tumor types   unresectable hepatocellular carcinoma  HCC   squamous cell carcinoma of the head and neck  SCCHN   advanced renal cell carcinoma  RCC   and advanced endometrial carcinoma  EC    demonstrated encouraging ORR as well as safety profile of this cancer combination We remind investors that in March  Merck formed a deal with Japan s Eisai to co develop and commercialize Lenvima  both as a monotherapy as well as in combination with Keytruda for several types of cancer At ASCO  Merck also presented interim data from a mid stage study  KEYNOTE 427  evaluating Keytruda monotherapy for the first line treatment of advanced clear cell RCC  The data showed that in the Keytruda arm  the ORR   the primary endpoint   was 38 2   Meanwhile  in a sub group of patients whose tumors expressed PD L1  the ORR was 50  Keytruda is being studied for more than 30 types of cancer  in more than 700 studies  including in excess of 400 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte  Glaxo   NYSE GSK   and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens Merck currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-06-03,Zacks Investment Research,https://www.investing.com/analysis/mercks-mrk-keytruda-lung-cancer-data-in-focus-at-asco-200322063,200322063
149981,371497,AMGN,Eli Lilly s Olumiant Gets FDA Nod For Rheumatoid Arthritis,opinion,"Eli Lilly and Company   NYSE LLY   along with its partner Incyte Corporation   NASDAQ INCY   announced that the FDA has approved the 2 mg dose of Olumiant  baricitinib  for treating moderately to severely active rheumatoid arthritis   RA    The once daily oral JAK inhibitor is approved as monotherapy or in combination with methotrexate for treating adult patients with inadequate response to tumor necrosis factor   TNF   inhibitor therapies The approval in the United States was not much of a surprise considering that an FDA advisory committee had recommended approval of the lower dose of the drug in April  However  the 4 mg dose of the drug was not approved Moreover  the drug s label includes a boxed warning stating risk of serious infections  malignancies and thrombosis The companies expect to launch the drug by the end of the second quarter  It will be available at a price 60  lower than the leading TNF inhibitors approved for RA  which includes AbbVie s   NYSE ABBV   Humira and Amgen s   NASDAQ AMGN   Enbrel among others We remind investors that the FDA had issued a Complete Response Letter in April 2017 for the new drug application seeking approval of Olumiant  requesting additional information to determine the most appropriate doses Olumiant is already approved in Europe and Japan and generated sales of  32 2 million in the first quarter of 2018  The U S  approval will further boost the sales of the drug Lilly s share price has increased 0 5  year to date compared with the  s decline of 4 4  The approval was based on data from RA BEACON study  which evaluated Olumiant in combination with disease modifying anti rheumatic drugs versus placebo  Data showed that 49  of the patients treated with Olumiant achieved improvement in the signs and symptoms of RA compared to placebo  27   The companies will conduct a long term safety study of Olumiant in RA patients as part of the approval Following approval in the United States  Incyte is now eligible to receive a milestone payment of  100 million from Lilly  which it expects to record in full in the second quarter of 2018 Olumiant is also being evaluated in a late stage study for the treatment of atopic dermatitis Eli Lilly and Company Price
    Lilly currently carries a Zacks Rank  2  Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-06-03,Zacks Investment Research,https://www.investing.com/analysis/eli-lillys-olumiant-gets-fda-nod-for-rheumatoid-arthritis-200322059,200322059
149982,371498,AMGN,Novartis Announces Positive Data On Kisqali And Tasigna ,opinion,"Novartis   NYSE NVS   presented positive results from the third phase III trial on breast cancer drug Kisqali  ribociclib  in advanced or metastatic breast cancer at the 54th Annual Meeting of the American Society of Clinical Oncology  ASCO  in Chicago 
The phase III trial  MONALEESA 3  showed Kisqali plus Faslodex significantly prolonged progression free survival  PFS  compared to Faslodex alone in postmenopausal women with hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   advanced breast cancer 
The median PFS was not reached in the subgroup of patients taking Kisqali plus fulvestrant in the first line setting  However  70  were estimated to remain progression free at median follow up of 16 5 months 
Moreover  results from MONALEESA 7 showed consistent treatment benefit among premenopausal women with HR  HER2  advanced breast cancer  regardless of prior chemotherapy treatment in the advanced setting 
We remind investors that Kisqali was approved by the FDA in Mar 2017 and by the European Commission in August 2017  as initial endocrine based therapy for postmenopausal women with HR  HER2  locally advanced or metastatic breast cancer in combination with an aromatase inhibitor 
Novartis is currently in discussions with the FDA to submit a supplemental New Drug Application  sNDA   seeking approval of Kisqali plus Faslodex for the treatment of postmenopausal women with HR  HER2  advanced breast cancer 
The company also presented data from two long term Treatment free Remission  TFR  studies  ENESTop and ENESTfreedom in patients with Philadelphia chromosome positive  Ph   chronic myeloid leukemia  CML  in the chronic phase  CP   The results from the open label phase II trials  ENESTop and ENESTfreedom  show sustained TFR in patients treated with both front line and second line Tasigna  nilotinib  therapy 
The 144 week trials evaluate the potential to maintain molecular response  MR  after stopping therapy in eligible adult patients with Ph  CML CP  Data showed durability and safety of TFR with Tasigna  Nearly all patients who lost TFR regained major molecular response after restarting therapy 
Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Jadenu and Kisqali  which continue to boost sales  The approval of Kymriah for acute lymphoblastic leukemia is a major boost  given the potential in the CAR T therapy space  The FDA recently expanded Kymriah s label which should boost sales 
Last week  Novartis completed the divestiture of its 36 5  stake in a consumer healthcare joint venture with GlaxoSmithKline PLC   NYSE GSK   for  13 billion 
The company also announced that its generic arm  Sandoz  obtained a positive opinion from the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency for marketing authorization of a proposed biosimilar of AbbVie s  blockbuster drug Humira  The generic division is seeking approval of the proposed biosimilar for use in all indications of the branded drug including those in rheumatology  gastroenterology and dermatology  
A tentative approval will further boost the generic division  which has been struggling with competitive pricing  Last month  Sandoz obtained approval for Zessly  a biosimilar version of Remicade  in Europe  With Zessly s approval  Sandoz now has six approved biosimilars in its portfolio  Zessly is the third biosimilar that has been approved by the EC in the last 12 months for Sandoz 
The CHMP has also recommended approval for Aimovig  erenumab  for the prevention of migraine in adults who have at least four migraine days per month  The drug was recently approved by the FDA  Novartis and Amgen   NASDAQ AMGN   are co commercializing the drug in the United States  While Amgen has exclusive commercialization rights to the drug in Japan  Novartis has exclusive rights to commercialize in the rest of the world 
Novartis  shares have declined 7 4  in the last six months compared with the  s decline of 1 9  

 
The approval of new drugs bode well for Novartis as the company is facing the loss of patent protection for some of the key drugs 
Zacks Rank
Novartis carries a Zacks Rank  3  Hold   You can see  see  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-06-04,Zacks Investment Research,https://www.investing.com/analysis/novartis-announces-positive-data-on-kisqali-and-tasigna-200322079,200322079
149986,371502,AMGN,Merck Presents Positive Melanoma Data On Keytruda At ASCO,opinion,Merck   Co   Inc    NYSE MRK   is stealing the limelight at the annual meeting of the American Society of Clinical Oncology  ASCO  in Chicago  After presenting  practice changing  lung cancer data on its PD L1 inhibitor  Keytruda  the drug giant presented encouraging data from studies evaluating the drug in advanced melanoma and small cell lung cancer  SCLC  patients Shares of Merck were up 2 4  on Monday in response to the positive news  This year so far  Merck s shares have outperformed the   Its shares have risen 10 2  in the period against the industry s decline of 4 5  Four and five years follow up data presented from two pivotal advanced melanoma studies showed that treatment with Keytruda led to long term survival benefit A new analysis of four year data from the phase III KEYNOTE 006 study showed that 86  of the advanced melanoma patients remained progression free  20 months after completing two years of treatment with Keytruda Five year data from the melanoma cohort of the phase Ib KEYNOTE 001 study demonstrated significant survival benefits in advanced melanoma patients  The five year OS rate  a secondary endpoint for the study  was 34  in all patients and 41  in previously untreated metastatic melanoma patients Interim data from a cohort of a phase II study  KEYNOTE 158  evaluating Keytruda as a monotherapy in patients with previously treated advanced small cell lung cancer  SCLC  demonstrated encouraging response rates in the overall population of SCLC patients as well as in patients whose tumors express PD L1  In the overall population of SCLC patients  overall response rate  ORR   primary endpoint  was 18 7   while in patients whose tumors expressed PD L1  ORR was 35 7  Keytruda is being evaluated in combination with chemotherapy as a first line treatment in patients with extensive stage small cell lung cancer in another phase III study  KEYNOTE 604 Earlier at ASCO  Merck presented data from two pivotal lung cancer trials   KEYNOTE 042 study evaluating Keytruda monotherapy in newly diagnosed lung cancer patients and KEYNOTE  407 study evaluating Keytruda in combination with chemotherapy in difficult to treat squamous non small cell lung cancer  NSCLC   Both the studies showed that treatment with Keytruda led to improved survival  further cementing Merck s position in the lung cancer market  which is the most lucrative oncology sector Meanwhile  Keytruda also demonstrated encouraging ORR in studies evaluating the Lenvima Keytruda combination in four different tumor types and Keytruda monotherapy for the first line treatment of advanced clear cell RCC Keytruda holds a dominant position in lung cancer as it is the only anti PD 1 approved in first line setting for certain lung cancer patients both as a monotherapy as well as a combination therapy with Eli Lilly s   NYSE LLY   cancer drug  Alimta  pemetrexed  and carboplatin  pem carbo   In fact  Keytruda sales are gaining particularly from strong momentum in the first line lung cancer indication Meanwhile  Keytruda is being evaluated in several lung cancer studies across multiple settings and stages of the disease  both as a monotherapy as well as a combination therapy Keytruda is being studied for more than 30 types of cancer in more than 700 studies  including in excess of 400 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte  Glaxo   NYSE GSK   and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens Merck currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-06-04,Zacks Investment Research,https://www.investing.com/analysis/merck-presents-positive-melanoma-data-on-keytruda-at-asco-200322348,200322348
149988,371504,AMGN, Mylan  MYL  Gets FDA Approval For Biosimilar Of Neulasta,opinion,"Mylan N V   NASDAQ MYL   and partner Biocon announced that the FDA has approved Fulphila  a biosimilar of Amgen s   NASDAQ AMGN   Neulasta 
The news comes as a significant boost for Mylan  given the potential market for Fulphilia  According to the IQVIA  Neulasta generated U S  sales of  4 2 billion for the twelve months ending Mar 31  2018 
The biosimilar has been approved to reduce the duration of febrile neutropenia  fever or other signs of infection with a low count of neutrophils  a type of white blood cells  in patients treated with chemotherapy in certain types of cancer 
Notably  this is the first FDA approved biosimilar of Neulasta  The company plans to launch the biosimilar in the coming weeks 
The approval will broaden Mylan s biosimilars portfolio  The FDA approval was based on a comprehensive package of analytical  nonclinical and clinical data  which confirmed that the biosimilar is highly similar to the branded drug  The data demonstrated that there were no clinically meaningful differences between the biosimilar product and Neulasta in terms of safety  purity and potency 
Both the companies had earlier won FDA approval for Ogivri  a biosimilar of Herceptin  The biosimilar is also approved for 30 additional countries  Mylan and Biocon are collaborating to develop 11 biologic and insulin products  While Mylan owns the commercialization rights for the product in the United States  Canada  Japan  Australia  New Zealand  the European Union and European Free Trade Association countries  Biocon has co exclusive commercialization rights with Mylan for the product in the rest of the world  In March 2018  Mylan and Biocon announced that their co developed biosimilar insulin glargine Semglee has obtained approval from the European Commission  EC  following the positive recommendation by the Committee for Medicinal Products for Human Use  CHMP  of European Medicines Agency 
We note that Mylan has one of the widest portfolios of generics and biosimilars  The company has a portfolio of 20 bioismilar and insulin analog products 
Mylan s stock has gained 11 5  in the last six months compared with the  decline of 0 6   Shares are trading up on the news 

Mylan s efforts to develop its biosimilars portfolio is impressive  Mylan also has a partnership with Momenta Pharmaceuticals   NASDAQ MNTA   for the development of biosimilars   Both the companies plan to initiate a patient clinical trial of M710   a proposed biosimilar of Regeneron Pharmaceuticals    NASDAQ REGN   Eylea   in the first half of 2018  The trial will be a randomized  double blind  active control  multicenter study in patients with diabetic macular edema to compare the safety  efficacy and immunogenicity of M710 with the reference drug  Eylea  a vascular endothelial growth factor  VEGF  inhibitor  has been approved for the treatment of neovascular  wet  age related macular degeneration  macular edema  following retinal vein occlusion  diabetic macular edema and diabetic retinopathy in patients with diabetic macular edema 
Although volatility in the United States markets is expected to continue in 2018  yet these new approvals should position Mylan better in the year ahead and help it combat the decline in EpiPen sales 
Zacks RankMylan carries a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-06-05,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-gets-fda-approval-for-biosimilar-of-neulasta-200322414,200322414
149999,371515,AMGN,Radius Health  RDUS  Incurs Narrower Than Expected Q1 Loss ,opinion,"Radius Health  Inc    NASDAQ RDUS   reported a loss of  1 37 per share in the first quarter of 2018  narrower than the Zacks Consensus Estimate of a loss of  1 43 but wider than the year ago period loss of  1 32  Increase in general and administrative expenses led to the wider than anticipated net loss year over year The company reported sales of Tymlos  abaloparatide  of  14 5 million surpassing the Zacks Consensus Estimate of  13 8 million Quarter in DetailTymlos sales of  14 5 million increased 90  from the fourth quarter of 2017  Radius Health received the FDA approval for Tymlos in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk of fracture  The company began shipments of the drug to wholesalers at the end of May 2017 Tymlos continues to gain traction with approximately 263 million covered lives and 88  coverage in commercial plans  Tymlos market share reached approximately 31  of new anabolic patients starting anabolic therapy  NBRx  and 13  of total U S  anabolic osteoporosis market  based on Patient Months on Therapy  TRx PMOT  in the first quarter of 2018 Research and development expenses for the reported quarter were  22 9 million  up 17  year over year General and administrative expenses for the reported quarter increased 26  to  48 million due to increase incompensation  travel related expenses and increase in selling   general and administrative expenses Pipeline UpdatesThe company is developing two formulations of abaloparatide SC and abaloparatide transdermal  Radius Health suffered a setback when the Committee for Medicinal Products for Human Use of the European Medicines Agency   EMA   adopted a negative opinion on the Radius Health s marketing authorization application for abaloparatide SC in March 2018  Consequently  in April 2018  Radius Health submitted a request for re examination of the CHMP s opinion Radius Health initiated the phase III study  ATOM  Abaloparatide Treatment for Osteoporosis in Males  on abaloparatide SC for the treatment of osteoporosis in men  which  if successful  will form the basis of a supplemental NDA seeking to expand the drug s label   The randomized  double blind  placebo controlled trial will enroll approximately 225 men with osteoporosis at high risk of fracture   The study will include a primary endpoint of change in lumbar spine bone mineral density at 12 months versus placebo  and specialized high resolution imaging of bone structure in a subset of the study participants   Per estimates  male osteoporosis is estimated to account for approximately 10  of the total treated osteoporotic patient population During the quarter  Radius Health finalized a development pathway for abaloparatide patch after regulatory alignment with the FDA and entered into a scale up and commercial supply agreement with 3M Company  NYSE MMM  Meanwhile  Radius Health will conduct a single  randomized  comparator controlled phase III trial of elacestrant as a third line monotherapy in approximately 300 patients with ER positive HER2 negative advanced metastatic breast cancer as per the feedback from the FDA and EMA   The results are expected to support applications for global marketing approvals if positive  Patients in the study would be randomized to receive either elacestrant or an investigator s choice of an approved hormonal agent  The primary endpoint of the study will be progression free survival  The study is planned to be initiated in the second half of 2018 A phase I study evaluating the safety and maximum tolerated dose of RAD140 in patients with hormone receptor positive  locally advanced or metastatic breast cancer is currently enrolling  Radius Health expects to provide an update on the RAD140 development program by the end of 2018 Our TakeThe company s narrower than expected loss in the first quarter was encouraging as sales of Tymlos are picking up  Radius Health saw a 103  increase in the total number of U S  physicians prescribing Tymlos in the first quarter of 2018 as compared to the fourth quarter  Tymlos  share of new prescriptions by these physicians increased from 32  in the fourth quarter of 2017 to 49  in the first quarter of 2018  The price of the drug was increased by 5 9   implemented on Feb 22  2018 Going forward  Radius Health expects Tymlos to capture on average 19 21  of the U S  anabolic osteoporosis market in 2018  while anabolic market in the United States is expected to increase by 5 7  in volume Radius Health  shares have rallied 14 7  in the last six months compared with the   gain of 7 0    Although the osteoporosis market in the United Sates has great potential as approximately 1 4 million postmenopausal women experience an osteoporotic fracture each year  Tymlos is expected to face significant competition from Eli Lilly  Co s   NYSE LLY   Forteo and Amgen s   NASDAQ AMGN   Prolia Zacks Rank   Stock to ConsiderRadius Health currently carries a Zacks Rank  4  Sell  
A better ranked stock in the healthcare sector is Exelixis   NASDAQ EXEL   which currently sports a Zacks Rank  1  Strong Buy    You can see  Exelixis  earnings per share estimates increased from 54 cents to 86 cents for 2018 over the past 30 days 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-10,Zacks Investment Research,https://www.investing.com/analysis/radius-health-rdus-incurs-narrowerthanexpected-q1-loss-200315460,200315460
150000,371516,AMGN,Trump Announces Plan To Reign In Drug Prices And Pharma Stocks Rally ,opinion,"On Friday  President Trump unveiled his much anticipated plan to control drug prices in the U S   During his presidential campaign  Trump had promised to take on the big drug companies and it was feared that the plan would include provisions that would hurt profits in the pharmaceutical industry 
As the president began speaking  the stock prices of the biggest drug companies did in fact briefly decline  only to reverse course and ended the day broadly higher 
The reason   The plan doesn t seem to be  taking them on  at all 
The biggest fear was that the new plan would include provisions for Medicare to negotiate directly with drug companies on price  Roughly 30  of the dollar value of prescriptions filled in the U S  is paid for by Medicare  making the U S  government the single biggest customer for pharmaceuticals by a wide margin   Drug companies have been staunchly opposed to the idea of direct negotiation as it would almost certainly damage profits 
Once it was clear direct negotiation wasn t on the agenda  investors snapped up shares of the biggest U S  drug makers  including Abbvie     Amgen    and Merck  NYSE MRK      each of which finished the day 2  or more above their mid speech lows 
The President Takes on Softer Targets 
Trump decried the participation of what he referred to as  middlemen   meaning primarily Pharmacy Benefit Managers   intermediaries between manufacturers and doctors and pharmacies 
 He also took aim at small pharmaceutical companies who buy up off patent generic drugs and raise the prices sharply   Because this strategy is mainly the practice of small companies  think Martin Shkreli and Turing Pharmaceutical   it won t affect the big names and Trump s plan to speed FDA approval of generic drugs could actually help big pharma 
Finally  Trump took aim at a familiar target   foreign countries   Explaining that other countries pay  a tiny fraction of what the medicine costs in the U S   Trump continued    it s time to end the global freeloading  
Drug prices in the U S  can often be three times as much as in the U K  and the E U  and the president thinks those countries should pay their fair share of the costs of research and development of U S  manufactured pharmaceuticals  It s not immediately clear how exactly the administration could go about raising drug prices off of U S  soil  but the mere suggestion of concentrating on higher prices elsewhere as a catalyst to lower prices here at home was wind in the sales of the drug makers 
 Cancer Drugs are Attractive
In the large cap drug space  investors should consider Eli Lilly      Having just reported a strong quarter with  1 34 share in earnings  beating the Zacks Consensus Estimate of   1 11 share  LLY has seen 7 upwards estimates for 2018 in the past 30 days and earns a Zacks rank  1  Strong Buy  
Eli Lilly also recently announced its planned acquisition of Armo Biosciences  bolstering its position in the hot field of immunotherapies for cancer treatment In the Biomedical and Genetics sector  Excelixis Inc    shares have been moving lower lately despite a blowout earnings beat in Q1  topping estimates by 131    In the report EXEL highlighted several promising cancer treatments in its research pipeline and reaffirmed revenue guidance of  430M to  460M for 2018 
Six recent upward revisions in earnings for 2018 and a Zacks Consensus Estimate of  0 86 share  up from  0 54 just 30 days ago get EXEL a Zacks Rank  1  Strong Buy    The recent downturn in stock price  despite a 5  rally on Friday  make the stock an excellent value proposition  trading at a forward P E of 23 2X  considerably cheaper than its peer group which averages 48 1X  
 
Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-11,Zacks Investment Research,https://www.investing.com/analysis/trump-announces-plan-to-reign-in-drug-prices-and-pharma-stocks-rally-200315657,200315657
150001,371517,AMGN,Pfizer Gets FDA Nod For Amgen  J J s Anemia Drug Biosimilar,opinion,"Pfizer Inc    NYSE PFE   announced that the FDA has granted approval to Retacrit  a biosimilar version of two blockbuster drugs   Amgen Inc  s   NASDAQ AMGN   Epogen and Johnson   Johnson s   NYSE JNJ   Procrit   Pfizer already markets the biosimilar in EuropeRetracrit is indicated for the treatment of anemia due to chronic kidney disease  anemia due to Zidovudine in HIV infected patients and anemia due to the effects of concomitant myelosuppressive chemotherapy  anemia post chemotherapy   The drug is also approved for the reduction of allogeneic red blood cell  RBC  transfusions in patients undergoing elective  noncardiac  nonvascular surgery Retacrit becomes the first biosimilar erythropoiesis stimulating agent approved in the United States Procrit generated sales of  972 million while Epogen s sales were  1 1 billion in 2017  The sales numbers suggest bright prospects for Retacrit as it will be a lower cost alternative treatment option for patients using Procrit Epogen  However  Procrit already faces biosimilar competition from drugs like Novartis    NYSE NVS   Binocrit in Europe Pfizer s shares have declined 1 5  so far this year  comparing favorably with a fall of 3  recorded by the  The approval was supported by a comprehensive data package that demonstrated a high level of similarity of Retacrit with Epogen and Procrit  In May last year  the FDA sadvisory committee had recommended approval of RetacritPfizer has entered into collaboration with Switzerland based Vifor Pharma for the commercialization of Retacrit in certain channels Retacrit is the third approved biosimilar in Pfizer s commercial portfolio which includes Inflectra  a biosimilar version of J J s Remicade  The company is also developing 11 different biosimilar candidates in several mid to late stage studies As the Trump administration continues to rally against exorbitantly high drug prices  the FDA has been actively approving generics biosimilar of expensive branded drugs in a bid to bring down prices through competition  We saw several such approvals in 2017 and expect the trend to continue this year Pfizer Inc  Price
    Zacks RankPfizer currently carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-05-15,Zacks Investment Research,https://www.investing.com/analysis/pfizer-gets-fda-nod-for-amgen-jjs-anemia-drug-biosimilar-200316803,200316803
150007,371523,AMGN,Migraine Space In Focus As AMGN NVS  Aimovig Gets FDA Nod,opinion,Migraine is a serious neurological disease  which has significant effects on patients  daily life  Patients suffer from debilitating pain and physical impairment along with fear of the next attack  It is estimated that patients with frequent migraine attacks may lose more than half of their life to the disease Last week  Amgen   NASDAQ AMGN   and partner Novartis   NYSE NVS   announced FDA approval for their drug  Aimovig  erenumab  for the prevention of migraine  Aimovig is the first FDA approved drug specifically developed for the treatment of migraine by blocking calcitonin gene related peptide   CGRP   receptor The approval was based on positive data from several mid  and late stage studies The drug achieved significant reduction in monthly migraine days and use of acute migraine medications compared to placebo  per data from these studies  Moreover  Aimovig showed three times higher probability in reducing migraine days by half compared to placebo in patients with  episodic migraine patients and who failed two to four prior treatments With the approval of Aimovig  investors  focus has shifted to CGRP drugs candidates for the treatment of migraine  Eli Lilly   NYSE LLY   and Teva Pharmaceutical Industries Limited s   NYSE TEVA   respective anti CGRP candidates  galcanezumab and fremanezumab  are under review in the United States  Alder BioPharmaceuticals  Inc    NASDAQ ALDR   is also developing its anti CGRP candidate  eptinezumab  for treating migraine Alder  in its first quarter regulatory filing  stated that there are approximately 36 million people living with this serious neurological disease in the United States alone  including five to six million with episodic and chronic migraine  Migraine is ranked among the top 10 causes of years lived with disability worldwide However  the traditional preventive therapies have tolerability limitations along with several side effects  This represents a huge unmet need for new anti CGRP therapies like Aimovig and other under review candidates  Per a CNBC  and Alder s regulatory filing  the migraine market will be worth  1    2 billion in the next few years Amgen has priced Aimovig at  575 for a once monthly 70 or 140 mg single use prefilled SureClick autoinjector or  6 900 annually  The price will certainly pinch patients and thus the acceptance of the drug remains to be seen  However  insurance coverage along with Aimovig copay program may significantly bring down the cost  Moreover  potential approval to galcanezumab and fremanezumab in the coming months will increase competition  which may put downward pressure on pricing Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-05-20,Zacks Investment Research,https://www.investing.com/analysis/migraine-space-in-focus-as-amgnnvs-aimovig-gets-fda-nod-200318098,200318098
150008,371524,AMGN,Company News For May 21  2018,opinion,PayPal Holdings  Inc  s   NASDAQ PYPL   shares jumped 2 2  on news of the company acquiring European technology company iZettle Shares of Amgen Inc    NASDAQ AMGN   rose 1  on news of the company winning Food and Drug Administration approval for its migration prevention drug Aimovig The Trade Desk  Inc  s   NASDAQ TTD   shares increased 6 5  after reporting first quarter earnings of  0 34 per share  surpassing the Zacks Consensus Estimate of  0 10 per shareShares of CBS Corporation   NYSE CBS   surged 0 3  on news that the company s board was voting to issue a special dividend that reduces the voting power of the Redstone family from 80  to 20 ,2018-05-20,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-may-21-2018-200318041,200318041
150009,371525,AMGN,Roche  RHHBY  Announces Positive Data On Hemophilia Drug ,opinion,"Roche   OTC RHHBY   announced full results from the phase III study  HAVEN 3  evaluating haemophilia A drug Hemlibra  emicizumab  
The randomized multicenter  open label  phase III study evaluated the efficacy  safety and pharmacokinetics of Hemlibra prophylaxis versus no prophylaxis  episodic on demand factor VIII treatment  in patients with hemophilia A without factor VIII inhibitors   
The trial results show that Hemlibra reduced treated bleeds by 96  compared to no prophylaxis in HAVEN 3 study in haemophilia A without factor VIII inhibitors  Moreover  in a subset of patients included in the study  who previously received factor VIII prophylaxis  which is the standard of care  Hemlibra reduced bleeds by 68  compared to their prior therapy 
Almost 55 6  of patients treated with Hemlibra every week and 60  of patients treated with Hemlibra every two weeks experienced zero treated bleeds  compared to none of patients treated with no prophylaxis 
Additionally  results from another phase III study  HAVEN 4  showed Hemlibra administered every four weeks provides clinically meaningful control of bleeding in people with or without factor VIII inhibitors 
We remind investors that the FDA granted Breakthrough Therapy Designation to Hemlibra in April 2018 for patients with hemophilia A without factor VIII inhibitors  based on data from the HAVEN 3 study  The drug is already approved by the FDA for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors 
Hemlibra was also approved by the European Commission in February 2018 for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors 
Roche s hematology portfolio includes approved drugs like MabThera Rituxan  Gazyva Gazyvaro  Tecentriq and Venclexta 
We note that Roche is developing Venclexta in collaboration with AbbVie   NYSE ABBV    Both companies are jointly commercializing the drug in the United States  AbbVie is commercializing the drug outside the United States as well 
Approval of new drugs and a potential label expansion of existing drugs bode well for Roche as its legacy drugs like Herceptin  MabThera are facing competition from biosimilars 
Roche s stock has lost 7 3  in the last six months compared with  gain of 0 5  

 
Novartis   NYSE NVS   has already launched its biosimilar version of Rituxan  MabThera in Europe  Amgen   NASDAQ AMGN   has also obtained FDA approval for a biosimilar version of Avastin for treatment of five types of cancers including lung cancer  colorectal cancer  glioblastoma  renal cell carcinoma and cervix cancer 
Zacks Rank
Roche currently carries a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-21,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-announces-positive-data-on-hemophilia-drug-200318036,200318036
150034,371550,AMGN,4 Trade Ideas For Amgen  Bonus Idea,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Amgen  NASDAQ AMGN   has traded in a range between 165 and 195 for nearly a year  Back and forth  So how does this offer opportunity to profit  Range Trading  The stock is currently turning up off of the bottom of the range  heading towards the top  The RSI is trending higher toward the bullish zone with the MACD approaching zero  The Bollinger Bands  are also turned to the upside 
There is resistance at 178 and 181 then 188 and 192 before the top of the range at 198  Support lower sits at 174 and 171 then 166  Short interest is low at 1 4   The company is expected to report earnings next in late July so that will not get in the way of a trade  The stock does pay a dividend at a nearly 3  yield though and the stock trades ex dividend beginning May 16th 
The weekly options show more calls than puts and they are spread from 170 to 187 50  The puts are spread from 165 to 177 50  Next week expiry options are similar but with lower open interest  ranging from 172 50 to 185 on the call side and from 165 to 177 50 on the put side  The May monthly options have the biggest open interest and show more on the put side  ranging from 155 to 180  Calls span from 170 to 200 
Amgen Inc  NASDAQ AMGN 

Trade Idea 1  Buy the stock on a move over 178 with a stop at 174 looking for a move to 196 
Trade Idea 2  Buy the May 11 Expiry 177 50 Calls for  3 55 
Trade Idea 3  Buy the May 18 Expiry 177 50 185 Call Spread for  2 55 
Trade Idea 4  Buy the May 18 Expiry 165 177 5 185 Call Spread Risk Reversal for  2 00 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which with the calendar about to turn from April to May sees the equity markets are floundering  They could sure use some May flowers after all the spring rain  Elsewhere look for Gold to continue its broad consolidation while Crude Oil remains in an uptrend  The US Dollar Index is showing signs of life and attempting to reverse higher while US Treasuries are bouncing in their downtrend 
The Shanghai Composite looks weak and possibly on the verge of a big move lower while Emerging Markets continue to churn at the highs  Volatility looks to drip lower and out of the nearly 3 month range  which would be a positive for equities  The equity index ETF s SPDR S P 500  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   all seem stuck in tightening consolidation and holding over important support on the longer timeframe  Use this information as you prepare for the coming week and trad em well 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2018-04-30,Gregory W. Harmon,https://www.investing.com/analysis/4-trade-ideas-for-amgen-bonus-idea-200310747,200310747
150035,371551,AMGN,Spectrum  SPPI  Earnings And Sales Beat Estimates In Q1,opinion,"Spectrum Pharmaceuticals  Inc    NASDAQ SPPI   incurred a loss of 16 cents per share in the first quarter of 2018  narrower than the Zacks Consensus Estimate of a loss of 24 cents and the year ago quarter loss of 30 cents per share  However  adjusted loss came in at 15 cents  wider than the year ago loss of 14 cents Quarterly revenues came in at  30 5 million  up 4 8  from the year ago quarter  The top line also beat the Zacks Consensus Estimate of  26 1 million Spectrum Pharma s shares have underperformed the  so far this year  The stock has lost 16 5  against the industry s decline of 5  Quarter in DetailTotal product sales came in at  28 1 million  down 8 8  year over year  Sales were generated by six marketed products   Fusilev   0 6 million   Folotyn   12 7 million   Zevalin   3 million   Marqibo   0 9 million   Beleodaq   2 7 million  and Evomela   8 1 million   Evomela is facing pricing pressure due to generic entry License fees and service revenues were  2 4 million  down 26 8  from the prior year quarter Adjusted research   development expenses were  17 1 million  up 15 7  from the year ago quarter  Adjusted selling  general and administrative spending was up 30 1  to  20 4 million due to higher legal fees related to the termination of its former chief executive officer  The company is focused on the development of its two pipeline candidates  poziotinib and Rolontis 2018 Outlook RaisedThe company increased its revenue guidance for 2018 to the range of  95  115 million  previously  90  110 million   The company expects to have enough liquid funds to continue its operations into 2020 Pipeline UpdateSpectrum Pharma is evaluating poziotinib in two separate phase II studies for the treatment of lung cancer and a phase II study for breast cancer  In April 2018  the company published results from an analysis of the first 11 patients from the lung cancer study being conducted with MD Anderson  The candidate achieved an objective response rate of 64  in patients with EGFR exon 20 insertion mutations  The company is planning to evaluate poziotinib in several solid tumors with exon 20 mutations In February 2018  the company announced the successful completion of the phase III ADVANCE study on Rolontis  The candidate demonstrated non inferiority to Amgen Inc  s   NASDAQ AMGN   Neulasta in improving duration of severe neutropenia in patients with breast cancer It has completed enrolling patients for an additional phase III study  RECOVER  Data from this study will be included in the biologics license application   BLA   along with ADVANCE study data to be filed with the FDA The company expects to file a BLA for Rolontis in the fourth quarter of 2018 Spectrum Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderSpectrum Pharma carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the biotech sector are Ligand Pharmaceuticals   NASDAQ LGND    and Protagonist Therapeutics   NASDAQ PTGX    Both the stocks sport a Zacks Rank  1  Strong Buy  You can see  Ligand s earnings per share estimates moved up from  4 24 to  4 43 for 2018 and remained stable at  5 32 for 2019 over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 88   The company s shares have rallied 14 6  year to date Protagonist Therapeutics  loss estimates narrowed from  1 68 to 66 cents for 2018 and from  2 43 to  1 26 for 2019 over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 95  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-05-03,Zacks Investment Research,https://www.investing.com/analysis/spectrum-sppi-earnings-and-sales-beat-estimates-in-q1-200313097,200313097
150036,371552,AMGN,Ligand  LGND  Beats On Q1 Earnings   Revenues  Keeps View,opinion,"Ligand Pharmaceuticals Incorporated   NASDAQ LGND   reported first quarter 2018 adjusted earnings of  1 55 per share  significantly up from the year ago figure of 57 cents  The bottom line also beat the Zacks Consensus Estimate of  1 28 Shares of the company have outperformed the year to date  The stock has rallied 14 9  versus the industry s 12 3  decrease  Total revenues in the quarter under review surged 91 9  year over year to  56 2 million  Moreover  the top line surpassed the Zacks Consensus Estimate of  32 million Quarterly HighlightsRoyalty revenues were  20 8 million in the reported quarter  down approximately 14 1  year over year  Royalties comprise royalties from the sales of Novartis    NYSE NVS   Promacta  Amgen s   NASDAQ AMGN   Kyprolis and Spectrum Pharmaceuticals    NASDAQ SPPI   Evomela  Under the new accounting standard ASC 606  adopted at the start of this year  first quarter 2018 royalties should be compared with second quarter 2017 royalties due to the timing of revenue recognition  Royalties for the second quarter of 2017 were  14 2 million License fees  milestones and other revenues were  30 9 million compared with  3 9 million in the year ago quarter  mainly owing to a  20 million upfront payment received upon the licensing of Ligand s glucagon receptor antagonist  GRA  program and other milestones received Material sales increased to  4 4 million from  1 1 million in the year ago quarter riding on the timing of Captisol purchases for clinical and commercial use Research   development  R D  expenses declined 14 9  to  7 4 million  backed by lower spending on the GRA program partnered in the first quarter 2018  Moreover  general   administrative expenses rose 4 1  year over year to  7 6 million Pipeline and Other UpdatesLigand out licensed its GRA program  LGD 6972  now named RVT 1502   to Roivant Sciences  Per the terms of the agreement  Ligand received a  20 million upfront license fee and is entitled to receive up to additional  528 8 million of milestone payments and tiered royalties ranging from low double digits to the mid teens with the top tier applying to annual net sales above  3 billion  Roivant is responsible for all costs related to the program Ligand also announced worldwide license agreements with venBio Partners  Ferring Pharmaceuticals and Glenmark Pharmaceuticals to use the OmniAb platform technologies to discover fully human antibodies Additionally  Ligand initiated an internally funded program to develop through proof of concept contrast agents with reduced renal toxicity for diagnostic imaging procedures  This development program will leverage Ligand s Captisol technology as well as the intellectual property obtained through its acquisition of Verrow Pharmaceuticals for  2 million in cash plus earn outs The company made a significant progress with several of its leading partnered assets  Melinta Therapeutics launched newly approved intravenous Baxdela in the United States for the treatment of adult patients with acute bacterial skin and skin structure infections caused by a designated susceptible bacteria and its partners made regulatory filings in new European Union and Argentina Sage Therapeutics filed a new drug application for intravenous brexanolone for the treatment of postpartum depression and Retrophin initiated a phase III study with sparsentan for treating focal segmental glomerulosclerosis  2018 OutlookLigand reaffirmed its previous guidance for 2018 and expects the full year revenues to be approximately  184 million including royalties of nearly  116 million  material sales of roughly  23 million and license fees and milestones of almost  45 million with the potential for up to an additional  20 million in license fees and milestones  Adjusted earnings are estimated at  4 85 per share for 2018 Zacks Rank Ligand is a Zacks Rank  1  Strong Buy  stock  You can see   Ligand Pharmaceuticals Incorporated Price  Consensus and EPS Surprise
    The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-05-08,Zacks Investment Research,https://www.investing.com/analysis/ligand-lgnd-beats-on-q1-earnings--revenues-keeps-view-200314799,200314799
150048,371564,AMGN,J J  Novartis  Q1 Earnings Impress  Will Others Follow Suit ,opinion,Johnson   Johnson   NYSE JNJ   kicked off pharma earnings season on a strong note beating the Zacks Consensus Estimate for both earnings and sales in the first quarter 2018  J J s performance was driven by continued positive momentum since the second half of 2017 and improvement in Consumer segment sales How Did J J Perform in Q1 J J s earnings of  2 06 per share beat the Zacks Consensus Estimate of  2 01  Quarterly revenues were  20 billion  which also beat the consensus mark of  19 48 billion  Buoyed by its strong performance  the company upped its previously issued sales outlook for 2018   Read More    J J s Pharmaceutical segment sales grew 19 4  year over year in the first quarter of 2018 due to strong sales in both domestic and international markets and favorable currency impact  Sales in the U S  market rose 9 9  in the quarter while international sales grew 33 1  New products like Imbruvica  cancer  and Darzalex  multiple myeloma  continued to perform well  Oncology sales increased 45  during the quarter to  2 3 billion  constituting almost a quarter of the pharmaceutical sales  Core products like Xarelto  Stelara  Zytiga  Simponi Simponi Aria and Invega Sustenna also contributed to growth  Imbruvica sales rose 43 5   The drug is marketed by J J in partnership with AbbVie  Inc    NYSE ABBV   Edurant sales rose 40 9  while Prezista sales increased 11 2  However  Concerta sales continue to decline due to generic competition  Sales of Risperdal Consta also fell 5 3   Sales of Invokana Invokamet declined 12 7  due to higher managed care discounting  while blockbuster rheumatoid arthritis drug  Remicade  marketed in partnership with Merck   Co   Inc    NYSE MRK   fell 16 9  J J s Pharma segment achieved some clinical milestones during the quarter including FDA approvals of prostate cancer drug  Erleada for the treatment of men with non metastatic castration resistant prostate cancer and line extension of already marketed prostate cancer drug  Zytiga in combination with prednisone in the first line setting These will certainly boost sales in 2018  J J now expects revenues in the range of  81 0 to  81 8 billion  higher than  80 6 billion to  81 4 billion expected previously Overall  in 2018  J J expects the Pharmaceutical segment to remain strong while the Consumer and Medical Device segments will continue to improve  We expect other companies like Merck  Amgen  Inc    NASDAQ AMGN    Pfizer  NYSE PFE  and Lilly to follow suit Novartis Reports Encouraging Q1 ResultsNovartis AG   NYSE NVS   also reported this week  The Swiss pharma giant beat earnings and revenue estimates driven by strong performance of key drugs  Cosentyx and Entresto  Novartis reported core earnings of  1 28 per share  beating the Zacks Consensus Estimate of  1 25 and up from  1 13 recorded in the year ago quarter  Revenues increased 10  to  12 7 billion  beating the Zacks Consensus Estimate of  12 3 billion   Read more   Sales of the Innovative Medicines division grew 6  to  8 4 billion driven by volume growth of Cosentyx and Entresto  However  entry of generics for Gleevec in the United States and Europe impacted sales unfavorably Cosentyx sales increased to  580 million  up 35  driven strong growth in all indications and expanded access  Entresto s sales increased 126  to  200 million driven by increased uptake Oncology franchise  excluding Gleevec  grew 6  driven by Promacta Revolade  Tafinlar   Mekinist  Jakavi and recent launches  However  sales at the Sandoz division were  2 5 billion  down 4  due to price erosion in the Unites States However  this year so far  J J s shares have lost 8 8  and Novartis  shares are down 6  against 4 3  decrease witnessed by the  Will Other Pharma Bigwigs Report Solid Results Too PfizerPfizer s top line is expected to be favorably impacted by new products like Xeljanz  rheumatoid arthritis  and Ibrance  breast cancer  as well as older products like Lyrica  neuropathic pain   Chantix  smoking cessation  and Eliquis  blood thinner  in the soon to be reported quarter  Moreover  line extension of Xeljanz  Sutent and Bosulif received in the fourth quarter of 2017 is also expected to bring in more sales However  loss of exclusivity and associated generic competition for Pristiq in the United States and Lyrica in Europe  and product shortages for legacy Hospira will likely affect sales negatively  Blockbuster drug Enbrel sales should continue to decline in the quarter due to biosimilar competition In 2018  the company s sales are expected to increase in low single digits from 2017 levels  The Zacks Consensus Estimate for sales and earnings for Q1 is pegged at  13 03 billion and 73 cents  respectively  The Zacks Consensus Estimate for sales in 2018 currently stands at  54 52 billion  representing year over year growth of 3 7   Pfizer carries a Zacks Rank  2  Buy  MerckMerck s blockbuster drug  Keytruda  along with Lynparza and Bridion Injection is expected to boost revenues in the first quarter  Keytruda sales are gaining momentum through approval and launch of Keytruda in new indications  especially in first line lung cancer However  rising competitive and pricing pressure are expected to hurt sales of Zostavax  Zepatier  Januvia and Isentress Animal health franchise sales are likely to remain strong in the first quarter Merck carries a Zacks Rank  2  You can see  The Zacks Consensus Estimate for sales and earnings for Q1 is pegged at  10 11 billion and 99 cents  respectively  The Zacks Consensus Estimate for 2018 sales is  41 81 billion  representing a 4 2  year over year increase Eli Lilly  LLY Sales of Lilly s diabetes drugs  Trulicity and Jardiance are expected to grow driven by market share gains  Other new drugs such as Cyramza  Taltz  and Lartruvo are also expected to boost the top line due to continued strong demand  Verzenio is also expected to generate higher sales in the first quarter However  patent expiry in some countries for Cymbalta  Strattera  Effient  Axiron  Zyprexa  Evista and competitive pressure mainly from immuno oncology agents for Alimta will hurt sales of these drugs We expect strong uptake of new products to offset decline in sales of established products this quarter too The Zacks Consensus Estimate for sales and earnings for Q1 is pegged at  5 52 billion and  1 13  respectively  The Zacks Consensus Estimate for 2018 sales stands at  23 43 billion  representing a rise of 2 4  year over year  Lilly carries a Zacks Rank  2 Bristol Myers Squibb Company  NYSE BMY Several label expansions of Bristol Myers  blockbuster cancer drug  Opdivo  drove the company s sales last year and is expected do so this year as well  Moreover  cardiovascular drug  Eliquis  also demonstrated strong performance in 2017  We expect this trend to continue this quarter  Label expansion of leukemia drug  Sprycel  approved in November 2017 should bring in more sales for the drug  Moreover  continued strong performance of Yervoy and Orencia will have a favorable impact However  genericization of Plavix  Avapro Avalide and Baraclude in the United States due to loss of exclusivity is significantly hurting the company s top line  The company also faces stiff competition in the immuno oncology space  The HIV business continues to face competitive pressure The Zacks Consensus Estimate for sales and earnings for Q1 is pegged at  5 17 billion and 84 cents  respectively  The Zacks Consensus Estimate for 2018 sales is pegged at  21 69 billion  representing a rise of 12 7  year over year  Bristol Myers carries a Zacks Rank  3 ConclusionThe new products of the majority of these companies are doing well and are expected to offset declining sales of legacy drugs due to loss of exclusivity  Moreover  most of these companies boast a deep and promising pipeline  Also  the new tax law boosts the prospects of strategic mergers and acquisitions and in licensing deals collaboration with smaller companies  which will strengthen the companies  product portfolio Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-04-19,Zacks Investment Research,https://www.investing.com/analysis/jj-novartis-q1-earnings-impress-will-others-follow-suit-200307488,200307488
150049,371565,AMGN,Q1 Earnings Surprise Well In Cards  Healthcare ETFs To Buy,opinion,Healthcare space has been on a tough journey this year  The popular ETF like Health Care Select Sector SPDR Fund  has shed 0 4  so farwhile Vanguard Health Care ETF   AX VHT   and Fidelity MSCI Health Care Index ETF  have gained at least 0 8   Meanwhile  iShares U S  Healthcare ETF  has added 0 1  The mixed trend is likely to continue heading into the Q1 earnings season as some big names like Pfizer   NYSE PFE    Merck   NYSE MRK    Amgen   NASDAQ AMGN    AbbVie   NYSE ABBV    Gilead Sciences   NASDAQ GILD   and Bristol Myers Squibb   NYSE BMY   are lined up to report this week and in the next  All these stocks collectively account for 26 3  share in XLV  24 6  in IYH  23 9  in VHT and 22 5  in FHLC  read    Let s dig deeper into the earnings picture of these companies that would drive the performance of the above mentioned funds in the coming days According to the our methodology  a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   when combined with a positive  increases our chances of predicting an earnings beat  while a Zacks Rank  4 or 5  Sell rated  are best avoided  You can uncover the best stocks to buy or sell before they re reported with our  Inside Our Surprise Prediction of These StocksPfizer has a Zacks Rank  2 and an Earnings ESP of  1 36   indicating a higher chance of beating estimates this quarter  The stock has seen positive earnings estimate revision of seven cents for to be reported quarter and delivered an average positive earnings surprise of 4 97  for the past four quarters  It has a VGM Score of B  Pfizer is scheduled to report earnings on May 1  before the opening bell Merck is expected to report results on May 1 before the market opens  It has a Zacks Rank  2 and an Earnings ESP of 0 00   The stock delivered a positive earnings surprise in the last four quarters  with an average beat of 8 54  but witnessed a positive earnings estimate revision of eight cents over the past 90 days for the to be reported quarter  Merck has a VGM Score of C Amgen carries a Zacks Rank  3 and has an Earnings ESP of  3 34   indicating a reasonable chance of beating estimates this time around  The earnings surprise track over the past four quarters is strong with an average positive surprise of 2 94   In addition  Amgen witnessed positive earnings estimate revision of three cents over the past 90 days for the quarter to be reported  The stock has a solid VGM Score of A  Amgen will report earnings on Apr 26 after market close  read    AbbVie has a Zacks Rank  3 and an Earnings ESP of  0 06   The company delivered a positive earnings surprise in the last four quarters  with an average beat of 1 81  and saw solid earnings estimate revision of 31 cents over the past three months for the to be reported quarter  The stock has a solid VGM Score of B  The company is scheduled to report on Apr 26 before the opening bell     Gilead is expected to release earnings on May 1 after market close  It has a Zacks Rank  2 and an Earnings ESP of  0 32   Gilead delivered positive earnings surprises of 7 47  over the last four quarters but saw negative earnings estimate revision of a penny over the past three months for the to be reported quarter  It has a VGM Score of C Bristol Myers will likely report earnings on Apr 26 before the opening bell  It has a Zacks Rank  3 and an Earnings ESP of  0 82   The stock delivered an average positive earnings surprise of 4 23  over the past four quarter  and witnessed positive earnings estimate revision of 10 cents for the to be reported quarter  It has a VGM Score of C Summing UpWith earnings surprises well in the cards  the healthcare sector is expected to witness earnings growth of 9 4  in the first quarter  suggesting some upside for healthcare ETFs  In particular  all the four ETFs have a Zacks ETF Rank  3  see    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2018-04-22,Zacks Investment Research,https://www.investing.com/analysis/q1-earnings-surprise-well-in-cards-healthcare-etfs-to-buy-200308026,200308026
150050,371566,AMGN,Company News For Apr 26  2018,opinion,Anthem  Inc  s   NYSE ANTM   shares rose 6 2  after reporting first quarter 2018 adjusted earnings of  5 41 per share  surpassing the Zacks Consensus Estimate of  4 76 per shareShares of Viacom  Inc    NASDAQ VIAB   increased 0 8  after reporting first quarter 2018 adjusted earnings of  0 92per share  surpassing the Zacks Consensus Estimate of  0 80 per shareFord Motor Company s   NYSE F   shares rose 1 4  after reporting first quarter 2018 earnings of  0 43 per share  surpassing the Zacks Consensus Estimate of  0 41 per shareShares of Amgen Inc    NASDAQ AMGN   increased 1 7  after reporting first quarter 2018 earnings of  3 47 per share  surpassing the Zacks Consensus Estimate of  3 23 per share,2018-04-25,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-apr-26-2018-200309494,200309494
150051,371567,AMGN,Roche  RHHBY  Q1 Earnings  Ocrevus  Perjeta Drive Sales Beat,opinion,"Roche Holding  SIX ROG  AG   OTC RHHBY   posted strong sales number for the first quarter of 2018 propelled by demand for new drugs amid biosimilar competition for legacy drugs 
Sales came in at  14 5 billion  beating the Zacks Consensus Estimate of  13 8 billion  The Swiss pharma giant reported sales of CHF13 6 billion in the first quarter  up 6  from the year ago period 
The company reports results under two divisions  Pharmaceuticals and Diagnostics  All growth rates mentioned below are on a year over year basis and at constant exchange rates 
Sales at the Pharmaceuticals division increased 7  driven by strong growth in Ocrevus and Perjeta  which more than offset lower sales of MabThera Rituxan  Tarceva and Avastin  Diagnostics division sales climbed 5  primarily on the back of strong immunodiagnostic business 
Results in Detail
Herceptin sales grew 2  due to increasing demand in the United States  Perjeta sales grew 18  following increased demand in the neoadjuvant and metastatic settings  Sales also got a boost from the FDA approval of Perjeta for use in combination with Herceptin and chemotherapy for adjuvant  after surgery  treatment of HER2 positive early breast cancer at high risk of recurrence in late 2017  Sales of Kadcyla   6   were driven by increasing demand in international markets 
Strong Ocrevus sales further boosted the top line  The drug  used to treat two forms of multiple sclerosis  continued to gain traction in the United States  The company also launched it in Europe and other countries worldwide during the first quarter 
Recently launched drugs  Tecentriq and Alecensa for lung cancer have also had an encouraging start  Immuno oncology drug  Tecentriq  recorded 29  growth in sales  Alcenesa sales were up 81  as it witnessed solid demand in the United States  Europe and in Japan 
Performance of the immunology franchise was driven by increased sales of Actemra RoActemra  13   and Xolair  7    Gazyva Gazyvaro sales were up 27  due to growth in the United States and Europe 
Ophthalmology drug Lucentis  sales were up 6   The growth was driven by increased demand for 0 5 mg prefilled syringes in wet age related macular degeneration and continued growth in diabetic retinopathy 
However  sales of Avastin fell 2  due to increasing use of cancer immunotherapy medicines in lung cancer  Sales of Rituxan MabThera were also down 8  due to entry of biosimilars in the market 
However  sales of Tarceva declined  32   due to growing use of other therapeutic options  Sales of Xeloda  2   continue to be hit by generic competition 
Revenues at the Diagnostics division climbed 5  on the back of solid performance of the Centralised and Point of Care Solutions   4   unit  which was in turn  propelled by Immunodiagnostics   5    Tissue Diagnostics   7   and Molecular Diagnostics   6   also performed impressively   Diabetes Care sales increased 5  
2018 Outlook Raised
Roche s sales expected to grow in low single digits compared to the earlier guidance of being stable or grow in low single digits  The company expects core earnings to grow in high single digits  The company intends to further increase dividend in 2018 in local currency 
Pipeline Progress
In January 2018  the European Medicines Agency   EMA   approved Ocrevus for the treatment of relapsing and primary progressive forms of multiple sclerosis  In February 2018  the EMA also granted approval for Hemlibra for people with haemophilia A with inhibitors to factor VIII  In March 2018  the FDA approved Lucentis 0 3 mg prefilled syringe as a new method of administering the medicine to treat all forms of diabetic retinopathy 
In April 2018  the FDA granted Hemlibra a Breakthrough Therapy Designation for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A without inhibitors to factor VIII 
During the quarter  Roche acquired Flatiron Health and Ignyta  Inc  While Flatiron Health will enable accelerate development and delivery of breakthrough medicines for oncology patients  Ignyta s lead molecule entrectinib targets tumors with one of two genetically defined gene rearrangements  ROS1 fusions in NSCLC  and NTRK fusions across a broad range of solid tumors 
Our Take
Roche beat estimates in the first quarter of 2018 driven by contribution from newly launched drugs  The label expansion of key drugs  Perjeta  Tecentriq and Alecensa will further drive growth  Ocrevus and Hemlibra have been successfully launched  However  sales of Avastin and Tarceva continue to decline 

Roche s stock has lost 12 9  in the last 12 months compared with  s gain of 8 4  
Approval of new drugs and a potential label expansion of existing drugs bode well for Roche as its legacy drugs like Herceptin  MabThera are facing competition from biosimilars  Novartis   NYSE NVS   has already launched its biosimilar version of Rituxan  MabThera in Europe  Amgen   NASDAQ AMGN   also obtained FDA approval for a biosimilar version of Avastin for treatment of five types of cancers including lung cancer  colorectal cancer  glioblastoma  renal cell carcinoma and cervix cancer 
Zacks Rank   Stock to Consider
Roche carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is Ligand Pharmaceuticals Inc    NASDAQ LGND   with a Zacks Rank  1  Strong Buy   You can see  
Ligand s earnings per share estimates have moved up from  3 92 to  4 40 for 2018 and from  4 75 to  5 32 for 2019 in the last 60 days  The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24 88   Share price of the company has soared 39 1  over a year 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-04-27,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-q1-earnings-ocrevus-perjeta-drive-sales-beat-200310341,200310341
150073,371589,AMGN,Rigel  RIGL  Sinks On Failure Of Mid Stage Study On Lead Drug ,opinion,"Shares of Rigel Pharmaceuticals  Inc    NASDAQ RIGL   crashed 13 6  after the company announced disappointing top line data from a mid stage study on lead candidate  fostamatinib  an oral spleen tyrosine kinase   SYK   inhibitor Rigel s stock has lost 21 8  in the last six months as against the  gain of 3 2    The company was evaluating the candidate in a proof of concept phase II study in patients with IgA nephropathy  IgAN   an orphan autoimmune disease of the kidneys Patients enrolled in the trial were required to have a diagnosis of IgAN verified by biopsy and proteinuria greater than 500 mg day  Patients were randomized into one of the three groups  placebo  fostamatinib at 100 mg bid or fostamatinib at 150 mg bid for 24 weeks  The study evaluated the safety and efficacy as measured by change in proteinuria and renal function However  the trial did not achieve statistical significance for its primary endpoint  which was mean change in proteinuria comparing fostamatinib dose groups to placebo controls in all patients studied  The mean change in proteinuria  sPCR  was  177   577  and  158 mg g for the placebo  100 mg bid and 150 mg bid dose groups  respectively Nevertheless  the initial data showed a greater reduction in proteinuria in fostamatinib treated patients relative to placebo patients  this finding did not reach statistical significance  in a pre specified subgroup analysis of patients with greater than 1 gram day of proteinuria at baseline   Patients with greater than 1 gram day of proteinuria have an increased risk of disease The company also expects to provide further analysis  including histology  data later in the year    As a result of these data  Rigel will now seek a partner to collaborate for conducting follow on clinical studies in IgAN  for funding  The concerned partner will be responsible for the subsequent commercialization of fostamatinib in an ex US territory Rigel is also evaluating fostamatinib for a number of other indications  While the failure of IgAN study was disappointing for investors  they do have something to look forward to  Rigel s NDA for fostamatinib in patients with chronic immune thrombocytopenia   ITP   is currently under review with an expected action date of Apr 17  2018  Since the IgAN study failed  Rigel is now pinning hopes on this review  A tentative approval of the study will boost investor sentiment given the market potential  Chronic ITP affects an estimated 65 000 adult patients in the United States  However  it might not be easy for the company to gain market share for this indication given the presence of Novartis    NYSE NVS   Promacta and Amgen s   NASDAQ AMGN   Nplate Rigel is also evaluating fostamatinib in a phase II study for autoimmune hemolytic anemia Zacks Rank   Key PickRigel currently carries a Zacks Rank  4  Sell  A better ranked stock from the same space is Regeneron Pharmaceuticals   NASDAQ REGN    which sports a Zacks Rank  1  Strong Buy   You can see  Regeneron s earnings per share estimates have moved up from  18 65 to  18 68 for 2018 in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters  with an average beat of 9 15  
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-04-03,Zacks Investment Research,https://www.investing.com/analysis/rigel-rigl-sinks-on-failure-of-midstage-study-on-lead-drug-200303107,200303107
150074,371590,AMGN,Lilly s Cyramza Shows Survival Benefit In Liver Cancer Study,opinion,Eli Lilly and Company s   NYSE LLY   announced that a late stage study evaluating its already approved cancer drug  Cyramza for the second line treatment of liver cancer met the primary as well as secondary endpoint While the primary endpoint was overall survival  OS    the percentage of patients who are alive after a certain length of time    the secondary endpoint was progression free survival  PFS   the amount of time the patients live without their tumors growing larger The phase III REACH  2 study evaluated the benefit of Cyramza as a single agent in patients with hepatocellular carcinoma  HCC   also known as liver cancer  who were intolerant to or experienced disease progression after treatment with Bayer   OTC BAYRY   Amgen s   NASDAQ AMGN   Nexavar and also had elevated levels of alpha fetoprotein  AFP   According to Lilly s press release  approximately half of all advanced HCC patients have a high AFP  a marker of poor prognosis The results from the REACH   2 study showed that such patients derived a survival benefit with Cyramza treatment following first line treatment with Nexavar Please note that Cyramza is already marketed as a single agent and in combination with another agent as a second line treatment of advanced or metastatic gastric cancer  It is also approved for use in combination with another agent as a second line treatment of metastatic non small cell lung cancer and metastatic colorectal cancer Lilly plans to file regulatory applications seeking label expansion of Cyramza for the specified subgroup of liver cancer patient population by mid 2018 Many cancer drugs are being approved based on progression free survival without evidence of benefit in survival or quality of life  However  OS data  once available  sometimes shows that the drug does not help people live longer  The fact that Cyramza offered an overall survival benefit in the REACH  2 study probably impressed investors  which led the stock to rise 1 4  on Wednesday  However  this year so far  Lilly s shares have declined 6 2   comparing unfavorably with the  s decrease of 3 1  Cyramza generated revenues of  758 3 million in 2017  recording a year over year increase of 23   Meanwhile  Cyramza is being evaluated in several studies for additional indicationsPhase III studies of Cyramza in advanced urothelial carcinoma and first line EGFR mutation positive NSCLC are ongoing  While OS data from urothelial carcinoma study is expected in the first half of the year  PFS data from the EGFR mutation positive NSCLC study is expected to be released in late 2018 In December  Lilly announced top line data from a phase III study   RAINFALL   evaluating Cyramza as first line treatment for patients with advanced gastric cancer  The study met its primary endpoint of PFS but failed to improve OS  Lilly decided not to seek regulatory approval in the first line setting based on the data from this study Lilly carries a Zacks Rank  2  Buy   You can see    Another large cap stock carrying the same Zacks Rank as Lilly is GlaxoSmithKline   NYSE GSK   Glaxo s stock has returned 14 5  this year so far while earnings estimates for 2018 and 2019 went up 5  and 4 8   respectively  in the past 60 days Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-04-04,Zacks Investment Research,https://www.investing.com/analysis/lillys-cyramza-shows-survival-benefit-in-liver-cancer-study-200303451,200303451
150075,371591,AMGN,Novartis Announces Data On Cardiovascular Drug Entresto ,opinion,"Novartis AG   NYSE NVS   announced results from a post hoc analysis from the PARADIGM HF trial on cardiovascular drug Entresto  The results were published in JAMA Cardiology The results demonstrated that treatment with Entresto significantly improved seven out of 10 types of physical and social activities at eight months in heart failure patients with reduced ejection fraction  HFrEF  versus previous standard of care Moreover  the improvement in combined physical and social activity of patients treated with Entresto versus enalapril was equivalent to a difference of nine years of aging Notably  these improvements were visible from the eight month visit and were sustained during the study s three year follow up period Hence  these positive results will further prove that Entresto not only reduces the risk of death but also has a positive impact on the quality of life of heart failure patients We remind investors that Entresto is indicated for the treatment of symptomatic chronic heart failure with HFrEF  The drug was approved in Europe and the United States in 2015  Both the European Society of Cardiology heart failure guidelines and US heart failure guidelines have given a class I recommendation to the drug for the use of sacubitril valsartan in patients with HFrEF Currently  Novartis is conducting multiple studies on Entresto as part of the FortiHFy clinical program  This includes two large outcome studies  PARAGON HF is the first phase III trial of Entresto in patients with chronic heart failure with preserved ejection fraction  Meanwhile  Novartis continues recruitment in PARADISE MI  a phase IIIb trial for patients at high risk for heart failure after an acute myocardial infarction  with results expected in 2020 The drug is projected as one of the key growth drivers of Novartis along with Cosentyx  Total Entresto sales came in at  507 million in 2017  up 195   Entresto s sales benefited from continued access improvements and expansion of sales force in the United States   Novartis  shares have gained 13 8  over a year  compared with the  s rally of 9 8  Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Jadenu  and Kisqali  The approval of Kymriah for acute lymphoblastic leukemia is a major boost given the potential in the CAR T therapy space  Strong performance from new drugs like Cosentyx and Entresto should propel growth going forward  The generic division  Sandoz also combatted pricing pressure strongly buoyed by biosimilar launches of Rixathon  biosimilar of Roche s   OTC RHHBY   Rituxan and Erelzi  biosimilar of Amgen s   NASDAQ AMGN   Enbrel The company recently entered into an agreement with GlaxoSmithKline   NYSE GSK   to divest its 36 5  stake in its consumer healthcare joint venture with the latter for  13 0 billion  The proceeds from the sale will be used according to capital allocation priorities  including bolt on acquisitions Zacks RankNovartis carries a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-04-04,Zacks Investment Research,https://www.investing.com/analysis/novartis-announces-data-on-cardiovascular-drug-entresto-200303437,200303437
150076,371592,AMGN,What s In Store For Novartis  NVS  This Earnings Season  ,opinion,"Novartis AG   NYSE NVS   is scheduled to report first quarter 2018 results on Apr 19 The Swiss pharmaceutical company s stock has rallied 14 7  in the last 12 months compared with the  s 10 6  gain    Novartis has an excellent track record  In the last quarter  Novartis delivered a positive earnings surprise of 3 4   The company posted an average positive earnings surprise of 3 42  in the trailing four quarters  Let s see how things are shaping up for this announcement Factors at PlayConcurrent with the 2017 results  Novartis provided guidance for 2018  Novartis expects net sales in 2018 to grow low to mid single digit  Novartis operates under three segments  Innovative Medicines  Pharmaceuticals   Alcon and Sandoz  Generics    Innovative Medicines is projected to grow in mid single digit  Revenues from Sandoz is expected to be broadly in line or decline slightly  Alcon sales are estimated to grow in low to mid single digits The Innovative Medicines division recorded sales of  8 8 billion in 2017 as it combatted generic and pricing pressure  Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Jadenu  and Kisqali   Growth products   Cosentyx  Entresto  Promacta Revolade  Jakavi  Tafinlar   Mekinist and Gilenya continues to drive the top line Psoriasis Cosentyx achieved multi blockbuster drug status in 2017 on the back of strong growth in its three approved indications while Entresto s sales benefited from continued access improvements and expansion of sales force in the United States   The approval of Kymriah for acute lymphoblastic leukemia is a major boost for Novartis  given the potential in the CAR T therapy space Additionally  Novartis  generic arm  Sandoz  is making efforts to strengthen its biosimilars portfolio  The launches of Rixathon  the biosimilar version of Roche s   OTC RHHBY   Rituxan  rituximab  and Erelzi  the biosimilar of Amgen s   NASDAQ AMGN   Enbrel in EU has boosted the company s portfolio However  sales from this division is projected to decline due to continued industry wide pricing pressures in the United States Meanwhile  the loss of exclusivity of some of the key drugs in Novartis  portfolio will continue to hurt the company s top line   The company s blockbuster drug  Diovan  is facing stiff generic competition in the United States  the EU and Japan  Gleevec lost exclusivity in the United States in February 2016 and in the EU in December 2016  thereby leading to generic competition  Exforge is also facing generic competition in the United States and the EU  Further  the oncology drugs are facing new competition in the form of immuno oncology therapies The ophthalmology division  Alcon was struggling and consequently  Novartis took a few steps to revive the business  The turnaround has been encouraging and management believes creating a standalone company via a capital markets exit could create additional shareholder value  A decision is expected in the first half of 2019  depending on Alcon s performance in the future Earnings WhispersOur proven model does not conclusively show that Novartis will beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Unfortunately  that is not the case here  as you will see below Zacks ESP  Earnings ESP for Novartis is 0 00    This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  1 25  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Novartis currently carries a Zacks Rank  3  Although the rank is favorable  the company s 0 00  ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Novartis AG Price  Consensus and EPS Surprise
     
Stock to ConsiderHere is one stock in the healthcare sector that you may want to consider  as our model shows that it has the right combination of elements to post earnings beat this quarter Pfizer Inc    NYSE PFE   has an Earnings ESP of  2 62  and a Zacks Rank  2  The company is scheduled to release first quarter results on May 1  You can see     
Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-04-16,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-novartis-nvs-this-earnings-season-200306297,200306297
150106,371622,AMGN,Amgen Stock In Trouble  Despite Strong Results ,opinion,"Amgen Inc  NASDAQ AMGN  reported its full year 2017 results on February 1st  On a non GAAP basis  the California based biotech giant earned  12 58 per share  an 8  increase from 2016  But instead of celebrating another year of strong business performance  investors punished Amgen stock  which fell from an all time high of  201 22 to  168 45 between January 29th and February 9th 
The selloff was probably driven by the company s earnings miss in the fourth quarter  Or maybe it was the poor guidance for 2018  In our opinion  investors only used these as an excuse to get rid of the stock  The real reason for the decline  we believe  was the market itself  which was already anticipating bad news by the time Amgen s report became public  Trouble is  the  suggests this was just the beginning of an even bigger pullback   The weekly price chart of Amgen stock shows that the uptrend from  39 16 to  201 22  which has been under construction for almost 10 years since March 2008  took the shape of a five wave   labeled  1   2   3   4   5   Wave  3  is extended  but the five sub waves of the  pattern in wave  5  are also visible 
The bad news for Amgen stock investors is that according to the Wave principle  this pattern should be followed by a three wave decline  whose targets lie near the support area of wave  4   Wave  4  ended at  130 09 in late September  2015  With the stock currently at  182  we can expect another  50 to disappear from the share price  To reinforce the negative outlook  the MACD indicator shows a bearish divergence between waves  5  and  3   Now let s take a closer look at Amgen stock s post earnings drop  
Unfortunately  the hourly chart only tilts the table even more in the bears  favor  by revealing the impulsive structure of the plunge to  168 45  Impulses point in the direction of the larger sequence  which in this case tell us that Amgen stock s weakness is likely to continue  The weekly and hourly charts point in the same direction  so as long as the top of wave 5 of  5  at 201 22 holds  the bulls  resistance remains futile ",2018-03-22,EWM Interactive,https://www.investing.com/analysis/amgen-stock-in-trouble-despite-strong-results-200299836,200299836
150107,371623,AMGN,Radius Health Down On Negative CHMP Opinion For Lead Drug,opinion,"Shares of Radius Health   NASDAQ RDUS   fell 4  after the company suffered a setback once again in Europe 
Overall  Radius Health s shares have lost 7  in the last six months as against the   gain of 3 2  
  The scientific committee of the European Commission  Committee for Medicinal Products for Human Use   CHMP    rendered a negative trend vote on the benefit risk balance for the marketing authorization application   MAA   for abaloparatide SC in an oral explanation  The CHMP will therefore adopt a negative opinion on the same  The company was planning to get abaloparatide SC approved for the treatment of osteoporosis in postmenopausal women at increased risk for fracture Radius Health plans to seek a re examination of the CHMP opinion In December 2017  the CHMP issued a third Day 180 List of Outstanding Issues and informed the company that it intends to refer the MAA to a scientific advisory group for additional advice  The company has earlier issued a second Day 180 List of Outstanding Issues  The delay in getting approval in Europe is disappointing given the market potential We note that abaloparatide injection was approved by the FDA in April 2017 under the brand name Tymlos for the treatment of postmenopausal women with osteoporosis at high risk for fracture  multiple risk factors for fracture  or patients who have failed or are intolerant to other available osteoporosis therapy Tymlos continues to gain traction with approximately 259 million covered lives and 93  coverage in commercial plans  Tymlos market share reached approximately 32  of new patients starting anabolic therapy  NBRx  and 13  of total prescriptions in the anabolic market Although the osteoporosis market in the United Sates has great potential as approximately 1 4 million postmenopausal women experience an osteoporotic fractur each year  Tymlos is expected to face significant competition from Eli Lilly   Co s   NYSE LLY   Forteo and Amgen s   NASDAQ AMGN   Prolia Radius Health s pipeline includes an abaloparatide patch for potential use in osteoporosis  elacestrant  RAD1901  for the treatment of hormone receptor positive breast cancer and RAD140  a non steroidal  selective androgen receptor modulator which is being evaluated for use in hormone receptor positive breast cancer Zacks Rank   Key PickRadius Health currently carries a Zacks Rank  3  Hold  A better ranked stock in the health care sector is Regeneron Pharmaceuticals   NASDAQ REGN   which sports a Zacks Rank  1  Strong Buy   You can see  Regeneron s earnings per share estimates have moved up to  18 68 from  18 65 in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters with an average beat of 9 15  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-03-22,Zacks Investment Research,https://www.investing.com/analysis/radius-health-down-on-negative-chmp-opinion-for-lead-drug-200300234,200300234
150108,371624,AMGN,Novartis Gets Positive CHMP Opinion On Biosimilar Remicade,opinion,Novartis AG   NYSE NVS   announced that the Committee for Medicinal Products for Human Use   CHMP   of the European Medicines Agency   EMA   adopted a positive opinion for the marketing authorization of the proposed biosimilar of Johnson   Johnson s   NYSE JNJ   Remicade  infliximab  The CHMP recommended the approval of the biosimilar for all the indications of the branded drug across gastroenterology  rheumatology and dermatology  We note that Remicade is approved to treat Crohn s Disease in adults and children  ulcerative colitis  rheumatoid arthritis and psoriatic arthritis  ankylosing spondylitis and plaque psoriasis The positive opinion was based on a comprehensive data package that is expected to confirm the biosimilarity of infliximab to the original drug with analytical  preclinical and clinical data matching across quality  efficacy and safety Earlier  the phase III confirmatory study in rheumatoid arthritis  REFLECTIONS B537 02  met its primary endpoint  demonstrating equivalent efficacy of proposed Sandoz biosimilar infliximab to the reference medicine as measured by the American College of Rheumatology 20  ACR20  response at week 14   Novartis  shares have declined 4 5  over a year  compared with the  s fall of 3 7  Novartis generic arm  Sandoz  is a leader in biosimilars with five marketed products  The marketed biosimilars include   Omnitrope  a human growth hormone  Binocrit  an erythropoiesis stimulating agent used to treat anemia  filgrastim for neutropenia under the brand names Zarzio outside the United States and Zarxio in the United States  Rixathon  biosimilar rituximab   approved in Europe in 2017 to treat blood cancers and immunological diseases  also approved in the EU as Riximyo under a duplicate marketing authorization   and Erelzi  biosimilar etanercept   approved in Europe in 2017 to treat multiple inflammatory diseases   The FDA also approved biosimilar Erelzi in 2016  However  the launch is pending in the United States due to an ongoing litigation with Amgen   NASDAQ AMGN   EMA is due to review CHMP s opinion   We note that Sandoz acquired the biosimilar of infliximab from Pfizer   NYSE PFE   in February 2016 for the 28 EU countries plus Norway  Iceland and Liechtenstein that form the EEA  Per the terms  Pfizer retains commercialization and manufacturing rights to infliximab  PF 06438179  in countries outside the EEA Meanwhile  Sandoz has quite a number of biosimilars in its pipeline  A tentative approval will further boost the company s generic division  The company has also filed for approval of a biosimilar of adalimumab and pegfilgrastim in the EU Apart froma strong generic portfolio  Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Jadenu  and Kisqali  The recent approval of Kymriah for acute lymphoblastic leukemia is a major boost for Novartis given the potential in the CAR T therapy space Zacks RankNovartis carries a Zacks Rank  3  Hold   You can see  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-03-25,Zacks Investment Research,https://www.investing.com/analysis/novartis-gets-positive-chmp-opinion-on-biosimilar-remicade-200300715,200300715
150109,371625,AMGN,Merck  Eisai Get Japanese Nod For Lenvima Label Expansion,opinion,"Merck and Co    NYSE MRK   along with its Japanese partner Eisai Co   Ltd  announced that the latter s anti cancer drug Lenvima has received approval in Japan for an expanded indication  The tyrosine kinase inhibitor  Lenvima has been approved in Japan for the first line treatment of unresectable hepatocellular carcinoma  HCC   a type of liver cancer 
The approval was based on positive data from a phase III clinical study  Study 304 REFLECT study  which showed that Lenvima demonstrated statistically significant non inferiority of overall survival  OS   13 6 months  compared to Bayer  DE BAYGN  AG s   OTC BAYRY   Nexavar  12 3 months   The study also showed that Lenvima demonstrated highly statistically significant and clinically meaningful improvements as compared to Nexavar in the secondary endpoints of progression free survival  Regulatory applications seeking approval of Lenvima for HCC are also in the United States and EU 
Following the approval in Japan  Eisai will receive a development milestone payment from Merck 
Over the past year  Merck s shares have declined 14 9  as against the  s 2 8  gain 

 
This is the first approval for Lenvima after the two companies struck a global strategic collaboration last month to jointly develop and commercialize the drug both as a monotherapy as well as in combination with Merck s anti PD 1 therapy  Keytruda  for several types of cancer 
Lenvima  developed by Eisai  is presently approved for the treatment of thyroid cancer as a monotherapy and second line treatment of renal cell carcinoma  RCC    a type of kidney cancer   in combination with Novartis    NYSE NVS   Afinitor  everolimus   Also  late stage studies are already ongoing to evaluate Lenvima in separate combination studies with Keytruda and Afinitor for RCC  Meanwhile  the Keytruda Lenvima combination enjoys Breakthrough Therapy Designation from FDA in RCC 
Merck and Eisai plan to jointly develop Lenvima across six cancer types and 11 potential indications  The companies will share global development and marketing costs  as well as gross profits from Lenvima equally  However  Eisai will book Lenvima worldwide product sales both as a monotherapy and in combination 
Meanwhile  Keytruda is being studied for more than 30 types of cancer  exceeding 700 studies  including in excess of 400 combination studies  Merck is collaborating with companies like Amgen  Inc    NASDAQ AMGN    Incyte  Glaxo and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens Merck   Co   Inc  Price
 

   Zacks Rank 
Merck carries a Zacks Rank  3  Hold   You can see  
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia and other conditions  New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-03-26,Zacks Investment Research,https://www.investing.com/analysis/merck-eisai-get-japanese-nod-for-lenvima-label-expansion-200300878,200300878
150123,371639,AMGN,Merck To Pay  300M Upfront To Co Develop Eisai s Cancer Drug,opinion,Merck   Co   Inc    NYSE MRK   announced an oncology collaboration with Japan s Eisai Co   Ltd to jointly develop and commercialize the latter s tyrosine kinase inhibitor  Lenvima  both as a monotherapy as well as in combination with Merck s anti PD 1 therapy  Keytruda  for several types of cancer  For the deal  Merck will pay Eisai an upfront amount of  300 million Lenvima  developed by Eisai  is presently approved for the treatment of thyroid cancer as a monotherapy and second line treatment of renal cell carcinoma  RCC    a type of kidney cancer   in combination with Novartis    NYSE NVS   Afinitor  everolimus   Meanwhile  Lenvima monotherapy is under review in the United States  EU and Japan for hepatocellular carcinoma  a type of liver cancer  Also  late stage studies are already ongoing to evaluate Lenvima in separate combination studies with Keytruda and Afinitor for RCC  Meanwhile  the Keytruda Lenvima combination enjoys Breakthrough Therapy Designation from FDA in RCC Merck and Eisai plan to jointly develop Lenvima across six cancer types and 11 potential indications  The companies will share global development and marketing costs  as well as gross profits from Lenvima equally  However  Eisai will book Lenvima worldwide product sales both as a monotherapy and in combination Other than the upfront payment  Merck will also pay up to  650 million for certain option rights through 2020  as well as  450 million as reimbursements for R D costs  Other than these  Eisai will be entitled to regulatory sales milestone payments of up to  4 36 billion So far this year  Merck s shares have underperformed the   Merck s shares have declined 3 2  in the period compared with a 1 9  decrease for the industry Keytruda is the second largest product in the Merck portfolio  It is marketed for many types of cancer and treatment settings including lung cancer  melanoma  head and neck cancer  classical Hodgkin s lymphoma  gastric cancer  bladder cancer and microsatellite instability high  MSI H  or mismatch repair deficient cancer The treatment fetched sales of  3 8 billion in 2017  up almost 172  year over year  This upside is driven by the global launch of new indications  further boosting demand  Keytruda sales are gaining  particularly from a strong momentum in the indication of first line lung cancer  as it is the only anti PD 1 approved in the first line setting both as a monotherapy as well as a combination therapy with Eli Lilly s   NYSE LLY   cancer drug Alimta  pemetrexed  and carboplatin  pem carbo  The Keytruda development program also significantly advanced in 2017 with several regulatory approvals in the United States  Europe and Japan  The new approvals expanded the patient population  driving up sales last year  The positive momentum is expected to continue in 2018 as well Meanwhile  Keytruda is being studied for more than 30 types of cancer  exceeding 700 studies  including in excess of 400 combination studies  Merck is collaborating with several companies including Amgen  Inc    NASDAQ AMGN    Incyte  Glaxo and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens We expect Merck to present data from several key Keytruda studies this year  including a combination study with Incyte s epacadostat in first line metastatic melanoma  Also  Keytruda could get an approval for the relapsed or refractory primary mediastinal large B cell lymphoma indication this year with FDA action expected in April Merck carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-08,Zacks Investment Research,https://www.investing.com/analysis/merck-to-pay-300m-upfront-to-codevelop-eisais-cancer-drug-200296635,200296635
150124,371640,AMGN,Regeneron And Sanofi Announce Positive Data On Praluent ,opinion,Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and partner Sanofi   NYSE SNY   announced positive results from the ODYSSEY OUTCOMES trial on Praluent during a late breaker session at the American College of Cardiology s 67th Annual Scientific Session in Orlando  FL The study was evaluating the long term clinical benefit of Praluent initiation in patients with post acute coronary syndrome The trial met the primary endpoint as results showed  that Praluent significantly reduced the risk of major adverse cardiovascular events   MACE   in patients with a recent acute coronary syndrome   ACS   event such as a heart attack Praluent reduced the overall risk of MACE by 15   HR 0 85  CI  0 78 0 93  p 0 0003   The MACE composite endpoint includes patients who experienced a heart attack  ischemic stroke  death from coronary heart disease  or unstable angina requiring hospitalization  The results from a pre specified analysis also showed that the patients with baseline LDL C levels at or above 100 mg dL  2 6 mmol L  experienced a more pronounced effect from Praluent  reducing their risk of MACE by 24   HR 0 76  CI  0 65 0 87  Moreover  no new safety signals emerged from the trial  with injection site reactions experienced more commonly in the Praluent group compared to patients on maximally tolerated statins alone  3 8  Praluent  2 1  placebo  In June 2017  Regeneron and Sanofi announced that two phase IIIb IV ODYSSEY DM trials in patients with diabetes met their primary endpoints  While the uptake of the drug hasn t been encouraging  we note that the cholesterol management market represents huge commercial potential We remind investors that Regeneron received a major boost when Praluent became the first PCSK9 inhibitor to be approved  July 2015  in the United States  The drug was also approved in the EU  September 2015   The FDA recently approved the companies  new supplemental Biologics License Application  sBLA  for a once monthly  300 mg dose of Praluent alirocumab  Injection for the treatment of adults with high low density lipoprotein  LDL  cholesterol  The approval will expand the drug s dosing options Meanwhile  a phase III study evaluating Praluent in homozygous familial hypercholesterolemia was initiated in the fourth quarter of 2017  The sBLA for use of Praluent with apheresis was filed with the FDA  which has set a target action date of Aug 24  2018  In October 2017  the U S  Court of Appeals for the Federal Circuit ordered a new trial on the issues of written description and enablement and vacated the permanent injunction in the ongoing PCSK9 litigation   Regeneron s stock has lost 22  in the last six months compared with the  s 8 2  decline Regeneron s fourth quarter results were impressive as both earnings and sales beat estimates driven by strong Eylea sales  The   potential label expansion of Eylea  Dupixent and Praluent will further boost results However  although Praluent is the first PCSK9 drug for hypercholesterolemia to get FDA approval  Amgen s   NASDAQ AMGN   Repatha is also approved in the United States  the EU and Japan and poses significant competition Regeneron and Sanofi announced a reduction in net price for Praluent in alignment with a new value assessment for high risk patients from the Institute for Clinical and Economic Review  The companies will take a precision medicine approach to address the burden of CV disease  focusing efforts on high risk patients most vulnerable to future CV events  such as those who have suffered a previous coronary event and are unable to reduce their LDL cholesterol  LDL C  below 100 mg dL despite maximally tolerated statin therapy Zacks Rank   Another Stock to ConsiderRegeneron sports a Zacks Rank  1  Strong Buy   You can see the  Another top ranked stock in the healthcare sector is Ligand Pharmaceuticals   NASDAQ LGND   which carries a Zacks Rank  2  Buy  Ligand s earnings per share estimates have moved up  3 78 to  4 15 from  4 75 to  5 75 for 2018 and 2019 respectively over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 24 88  The Hottest Tech Mega Trend of All Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-11,Zacks Investment Research,https://www.investing.com/analysis/regeneron-and-sanofi-announce-positive-data-on-praluent-200297338,200297338
150125,371641,AMGN,Is Amgen Inc   AMGN  A Great Stock For Value Investors  ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Amgen Inc    NASDAQ AMGN   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Amgen has a trailing twelve months PE ratio of 15 1  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 21 5x  If we focus on the long term PE trend  Amgen s current PE level puts it above its midpoint over the past five years  with the number having increased rapidly over the past few months Further  the stock s PE also compares unfavorably with the broader industry s trailing twelve months PE ratio  which stands at 34 9  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Amgen has a forward PE  ratio  price relative to this year s earnings  of just 14 3  so it is fair to say that a slightly more value oriented path may be ahead for Amgen stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Amgen has a P S ratio of about 6  This is higher than the S P 500 average  which comes in at 3 5x right now  Also  as we can see in the chart below  this is well above the lows for this stock in particular over the past few years Broad Value OutlookIn aggregate  Amgen currently has a Zacks Value Style Score of  B   putting it into the top 40   of all stocks we cover from this look  This makes Amgen a solid choice for value investors What About the Stock Overall Though Amgen might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of  B  and a Momentum score of  A   This gives AMGN a Zacks VGM score or its overarching fundamental grade of  A    You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been upbeat  The current quarter has seen two estimates go higher in the past sixty days compared to four lower  while the full year estimate has seen nine up and three down in the same time period This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has risen by 1 9  in the past two months  while the full year estimate has increased 3 9   You can see the consensus estimate trend and recent price action for the stock in the chart below Amgen Inc  Price and Consensus    The stock has a Zacks Rank  3  Hold  and we are looking for in line performance from the company in the near term Bottom LineAmgen is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a sluggish industry rank  among Bottom 27  of more than 250 industries  and a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past two years  the broader industry has clearly underperformed the market at large  as you can see below So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks  has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-03-13,Zacks Investment Research,https://www.investing.com/analysis/is-amgen-inc-amgn-a-great-stock-for-value-investors-200297973,200297973
150126,371642,AMGN,Merck s Keytruda Gets Priority Review For Cervical Cancer,opinion,Merck   Co   Inc    NYSE MRK   announced that a supplemental Biologics License Application  sBLA  for its anti PD 1 therapy  Keytruda  has been accepted under priority review by the FDA With the latest application  Merck is looking to expand the label of Keytruda for the treatment of advanced cervical cancer with disease progression on or after chemotherapy  With the FDA granting priority review  a decision is expected on Jun 28 This is the first time that the FDA has accepted a filing for an anti PD 1 therapy in cervical cancer  Meanwhile  this is the fourteenth regulatory submission for Keytruda accepted by the FDA  The sBLA was based in part on data from phase II KEYNOTE 158 study This year so far  Merck s shares have underperformed the   Merck s shares have declined 1 6  in the period against 1 4  increase for the industry Keytruda is the second largest product in the Merck portfolio  It is marketed for many types of cancer and treatment settings including lung cancer  melanoma  head and neck cancer  classical Hodgkin s lymphoma  gastric cancer  bladder cancer and microsatellite instability high  MSI H  or mismatch repair deficient cancer The treatment fetched sales of  3 8 billion in 2017  up almost 172  year over year  This upside is driven by the global launch of new indications  which further boosted demand   Keytruda sales are gaining  particularly from strong momentum in the first line lung cancer indication  It is the only anti PD 1 approved in the first line setting both as a monotherapy as well as a combination therapy with Eli Lilly s   NYSE LLY   cancer drug Alimta  pemetrexed  and carboplatin  pem carbo  The Keytruda development program also significantly advanced in 2017 with several regulatory approvals in the United States  Europe and Japan  The new approvals expanded the patient population  driving up sales last year  The positive momentum is expected to continue in 2018 as well Meanwhile  Keytruda is being studied for more than 30 types of cancer  in more than 700 studies  including in excess of 400 combination studies  Merck is collaborating with several companies including Amgen   NASDAQ AMGN    Incyte  Glaxo   NYSE GSK   and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens Merck carries a Zacks Rank  3  Hold   You can see  Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-03-13,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-gets-priority-review-for-cervical-cancer-200298042,200298042
150127,371643,AMGN,Nuevolution  Pipeline And Strategic Execution Drives Prospects  ,opinion,"Nuevolution s  ST NUEVOL  2017 was defined by internal progress of the ROR t inhibitor and BET BD1 programmes  expected to be clinically ready in 2019   In 2018 we anticipate value will be driven by new and existing partners  for example we expect Almirall to initiate a ROR t inhibitor Phase I trial in late 2018  making it the first Nuevolution product candidate to enter the clinic  In addition to existing collaborations  a new partnership is anticipated by Nuevolution in the next three to nine months  If achieved  revenue from these events will aid Nuevolution s strategy of transitioning into a clinical stage biotech  We value Nuevolution at SEK21 0 share or SEK901m from SEK21 4 share  SEK917m  previously 

Major year for Almirall and Amgen  NASDAQ AMGN  partnerships
In 2018  we anticipate significant newsflow from partnerships with Almirall s ROR t inhibitor  licensed from NUE in Psoriatic arthritis and dermatology  potentially entering the clinic  while Amgen could exercise its option this year to further develop one of the partnered oncology programmes  Both events would likely trigger substantial milestone payments  Additionally  a new deal is expected shortly  potentially focused on the BET BD1 or ROR t inhibitor programmes 
To read the entire report Please click on the pdf File Below ",2018-03-15,Edison,https://www.investing.com/analysis/nuevolution-pipeline-and-strategic-execution-drives-prospects-200298337,200298337
150148,371664,AMGN,Radius Health  RDUS  To Disappoint Investors In Q4 Earnings ,opinion,"Radius Health  Inc    NASDAQ RDUS   is scheduled to report fourth quarter 2017 results on Mar 1   Radius Health s shares have lost 7 9  over a year compared with the  0 9   slip Radius Health has a disappointing track record  The company has reported wider than expected loss in the trailing four trailing quarters with an average negative earnings surprise of 8 37  Let s see how things are shaping up for this quarter  Radius Health  Inc  Price and Consensus
     
Factors at Play  Radius Health develops therapeutics for the treatment of osteoporosis  oncology and endocrine diseases The company s lead drug  Tymlos  was approved in the United States in April 2017  The drug was approved for treating postmenopausal women with osteoporosis at high risk for fracture  defined as history of osteoporotic fracture and multiple risk factors for fracture  The drug can also be used for patients who have failed or are intolerant to other available osteoporosis therapies The company reported sales of Tymlos  abaloparatide  of  3 5 million in third quarter 2017 Hence  we expect investors to focus on the uptake of the drug during the upcoming earnings call Although the osteoporosis market in the United States has great potential as approximately 1 4 million postmenopausal women experience osteoporotic fractures each year  Tymlos is expected to face significant competition from Eli Lilly  Co s   NYSE LLY   Forteo and Amgen s   NASDAQ AMGN   Prolia Meanwhile  the company s Marketing Authorisation Application for Eladynos  abaloparatide SC  in Europe for the treatment of postmenopausal women with osteoporosis was under review   However  in December 2017  Radius Health announced that the Committee for Medicinal Products for Human Use   CHMP   will issue a third Day 180 List of Outstanding Issues in its regulatory review of abaloparatide SC  The CHMP informed the company that it will refer the marketing authorisation application to a scientific advisory group for additional advice as part of its ongoing risk benefit assessment  Hence  the CHMP expects to give an opinion on the same during the first half of 2018  In July 2017  the CHMP provided a second Day 180 List of Outstanding Issues and requested additional data analyses related to the safety and efficacy of abaloparatide SC for their ongoing regulatory review  The delay in approval in Europe is disappointing given the potential the market holds Meanwhile  the FDA granted Fast Track designation to pipeline candidate elacestrant  an experimental selective estrogen receptor down regulator degrader for the treatment of women with ER  and HER2  advanced or metastatic breast cancer  The elacestrant clinical development program is currently ongoing with two phase I studies in patients with ER   HER2  advanced or metastatic breast cancer who have been heavily pre treated  median of three prior lines of therapy  and have evaluable disease   In December 2017  Radius Health provided encouraging data from the phase I 005 clinical study of elacestrant  RAD1901  in patients with estrogen receptor positive  ER   breast cancer at the 2017 San Antonio Breast Cancer Symposium Approximately 40 patients were treated at the 400 mg dose in the elacestrant phase I dose escalation and expansion cohorts  Of the enrolled patients  22 patients met the RECIST measurable disease criteria at baseline and there were six confirmed partial responses in this group  Elacestrant was well tolerated with the most common adverse events being low grade nausea  dyspepsia and vomiting  Consequently  Radius Health plans to initiate a phase II study of elacestrant monotherapy  a potentially pivotal study  for women suffering from advanced or metastatic ER  HER2  breast cancer early in 2018  Hence  we expect the management to throw light on pipeline progress Earnings WhispersOur proven model does not conclusively show that Radius Health is likely to beat estimates this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here  as you will see below Zacks ESP  Earnings ESP for Radius Health is currently pegged at  1 22   This is because both the Most Accurate estimate is pegged at a loss of  1 50 while the Zacks Consensus Estimate stands at a loss of  1 48  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Radius Health has a Zacks Rank  3  Although the rank is favorable  the company s negative ESP makes surprise prediction difficult  Note that we caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stock to ConsiderHere is a pharma company that you may consider  as our model shows that it has the right combination of elements to deliver an earnings beat this quarter Gemphire Therapeutics   NASDAQ GEMP   is expected to release fourth quarter results on Mar 21  The company has an Earnings ESP of  8 01  and a Zacks Rank  2  You can see   Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-02-25,Zacks Investment Research,https://www.investing.com/analysis/radius-health-rdus-to-disappoint-investors-in-q4-earnings-200294162,200294162
150149,371665,AMGN,4 Buy Ranked Large Cap Pharma Stocks To Boost Your Portfolio,opinion,After rising 16 3  last year  the  industry has risen 1 9  this year so far  It has however underperformed the 4  gain for the S P 500 in the same time frame Though the sector was off to a strong start in 2018  it struggled a little thereafter probably on broader market correction  Also  the mention of high drug prices by President Donald Trump in his State of the Union address hurt investor sentiment  However  the sector is largely expected to rebound as the year progresses 2017 was a good year for pharma and biotech stocks with the sector witnessing some positive developments that led to a much awaited recovery The NYSE ARCA Pharmaceutical Index gained 11 8  in 2017  in sharp contrast to the decline witnessed in 2016  which was a tough year for pharma stocks given the furor over rising drug prices A key reason for the sector s improved performance was the willingness of investors to look beyond the drug pricing controversy and focus more on fundamentals instead  Although the drug pricing controversy will remain a headline risk  investors appear more comfortable with the issue  Moreover  a significantly higher number of FDA approvals in 2017 restored investor confidence in the sector  The approval of the first gene cell therapy last year was a major breakthrough for the sector Coming back to 2018  we believe that new product sales ramp up with rising demand  successful innovation and product line expansion  strong clinical study results  more frequent FDA approvals  continued strong performance from key products  growing demand for drugs especially for rare to treat diseases  an aging population and increased health care spending are some of the factors that should keep the sector on track  A faster drug approval process and the proposed removal of outdated regulations that drive up costs and slow down innovation should also provide benefits Possibilities of more mergers and acquisitions  M As  are also high now that the tax reform is in place and big players are on the lookout for companies with innovative pipelines technology  There has already been quite a bit of M A buzz this year about potential deals  Sanofi   NYSE SNY   and Celgene   NASDAQ CELG   have already announced two deals each Meanwhile  with the Large Cap Pharma industry being among the top 30  of the 256 Zacks ranked industries  it would make sense to look at some Buy ranked stocks in the space Investing in stocks with a large market cap is a much more reliable investment because of the fact that they control a large portion of their given industry  Also companies with a larger market cap have performed well in 2017 and look well poised to earn higher profits in 2018 Here is a look at four large cap pharma companies that sport a favorable Zacks Rank     1  Strong Buy  or  2  Buy  H  Lundbeck A S   OTC HLUYY  Denmark based Lundbeck specializes in psychiatric and neurological disorders  The company s key areas of focus include depression  schizophrenia  Parkinson s disease and Alzheimer s disease  According to Lundbeck  about 700 million people across the world suffer from psychiatric and neurological disorders with many receiving inadequate treatment YTD  Lundbeck has outperformed the Large Cap Pharmaceutical industry with shares gaining 4 7   In addition to delivering revenue growth of 12   in local currencies  in 2017  Lundbeck issued an upbeat outlook for 2018  Estimated earnings growth for the current year is 31 2   Meanwhile  earnings estimates for 2019 are up 8 5  over the past 30 days AbbVie  Inc    NYSE ABBV  AbbVie beat estimates for both earnings and sales in the fourth quarter  It also raised its earnings expectations for 2018 based on continued strong operational performance  AbbVie s key drug  Humira has been performing well based on strong demand trends  despite new competition  AbbVie s shares have outperformed the industry in the past year  supported by a series of positive news including promising data from several pivotal studies  regulatory nods  including approval for its competitive HCV medicine Mavyret and two approvals for Imbruvica  and settlement of its Humira patent disputes with biotech major  Amgen   NASDAQ AMGN   AbbVie s shares are up an impressive 22 3  this year so far  outperforming the industry Estimated earnings growth for the current year is 33 9   Meanwhile  estimates for 2018 and 2019 are up 8 4  and 7  respectively  over the past 30 days Pfizer Inc    NYSE PFE  New York based  Pfizer is one of the most well known names in the pharmaceutical sector not just for its medicines and vaccines but also for its consumer healthcare products Pfizer reported better than expected fourth quarter 2017 results as it beat estimates for earnings as well as sales and provided an upbeat outlook for 2018  We believe that Pfizer snew products like Ibrance  contribution from acquisitions  cost cuts and share buybacks should help the company earn profits in the future quarters  Pfizer s shares have risen 1 6  this year so far Estimated earnings growth for the current year is 11 3   Meanwhile  estimates for 2018 and 2019 are up 6 1  and 4 1   respectively  over the past 30 days Novo Nordisk  CO NOVOb  A S   NYSE NVO  The year 2017 was eventful for this Denmark based pharma giant as it gained regulatory approvals for some key pipeline drugs candidates including fast acting insulin aspart   Fiasp  once daily pre filled pen   Ozempic and hemophilia B treatment Rebinyn  Meanwhile  strong performance of Victoza is driving top line growth  We believe these new products and a solid pipeline will pave the way for growth this year for the company Over the past 30 days  earnings estimates have risen 1 5  and 4 9   respectively  for 2018 and 2019  Estimated earnings growth for the current year is 13 7  While Pfizer  AbbVie and Novo Nordisk are all Zacks Rank  2  Buy  stocks  Lundbeck is a Zacks Rank  1  Strong Buy  stock  You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-02-27,Zacks Investment Research,https://www.investing.com/analysis/4-buyranked-large-cap-pharma-stocks-to-boost-your-portfolio-200295077,200295077
150150,371666,AMGN,Radius  RDUS  Q4 Loss Wider Than Expected On Higher Expenses,opinion,Radius Health  Inc    NASDAQ RDUS   reported a loss of  1 59 per share in the fourth quarter of 2017  wider than the Zacks Consensus Estimate loss of  1 48 and the year ago quarter loss of  1 22  Increase in general and administrative expenses led to the wider than anticipated net loss year over year Radius Health  Inc  Price and Consensus   The company reported sales of Tymlos  abaloparatide  of  7 7 million surpassing the Zacks Consensus Estimate of  6 7 million Quarter in DetailResearch and development expenses for the reported quarter were  22 9 million  down 10 5  year over year due to the reduction in R D expenses associated with the elacestrant projects and the development of Tymlos   Radius Health received FDA approval for Tymlos in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk of fracture and began shipments to wholesalers at the end of May 2017 Tymlos continues to gain traction with approximately 259 million covered lives and 93  coverage in commercial plans  Tymlos market share reached approximately 32  of new patients starting anabolic therapy  NBRx  and 13  of total prescriptions in the anabolic market General and administrative expenses for the reported quarter jumped to  50 7 million from  27 5 million primarily due to personnel  promotional  and consulting expenses related to the launch of Tymlos Pipeline UpdatesThe company is developing two formulations of abaloparatide SC and abaloparatide transdermal  A labeling supplement for Tymlos was submitted to the FDA in the fourth quarter with the positive 43 month data from the ACTIVExtend study  which showed continued significant risk reduction in fractures in patients who were transitioned to receive an additional 24 months of bisphosphonate therapy  In January 2018  Radius Health met with the FDA to discuss the regulatory development path for the abaloparatide patch  The FDA agreed that  depending on the study results  a single  randomized  open label  active controlled  non inferiority  to abaloparatide SC  study of up to 500 patients with postmenopausal osteoporosis at high risk of fracture would be sufficient to gain approval for the abaloparatide patch  The primary endpoint in the study will be change in lumbar spine bone mineral density at 12 months  Radius Health expects to initiate this pivotal trial in mid 2019 Meanwhile  Radius Health  Marketing Authorisation Application   MAA   for Eladynos  abaloparatide SC  for the treatment of postmenopausal women with osteoporosis in Europe is under review by the Committee for Medicinal Products for Human Use   CHMP   of the European Medicines Agency   EMA    The company however suffered a setback when the CHMP issued a second Day 180 List of Outstanding Issues  In December 2017  the CHMP issued a third Day 180 List of Outstanding Issues and informed the company that it intends to refer the MAA to a scientific advisory group for additional advice  The Company expects an opinion from the CHMP regarding the MAA in the first half of 2018   Radius Health and the FDA have also agreed on the design of a clinical trial in men with osteoporosis  which  if successful  will form the basis of an sNDA seeking to expand the use of Tymlos to treat men with osteoporosis at high risk for fracture  The study is expected to be initiated in the first quarter of 2018 The company also plans to initiate a clinical trial in men with osteoporosis  which  if successful  will form the basis of an sNDA seeking to expand the label to treat men with osteoporosis at high risk for fracture  The study is expected to be initiated in the first quarter of 2018 Meanwhile  the company presented positive data on elacestrant for breast cancer in December 2017  The FDA also granted Fast Track designation to elacestrant in October 2017  In February 2018  Radius Health obtained scientific advice from the EMA regarding a potential single arm monotherapy phase II trial of elacestrant in patients with ER positive HER2 negative advanced or metastatic breast cancer  Based on feedback from the EMA and the FDA  the company will conduct a single  randomized  controlled phase II trial of elacestrant as a third line monotherapy in approximately 300 patients with ER positive HER2 negative advanced metastatic breast cancer Our TakeThe company s wider than expected loss in the fourth quarter was due to escalated expenses with the commercialization of Tymlos  The drug continues to gain traction and grab further market share Radius Health  shares have gained 0 2  in the last six months compared with the   gain of 2 7  Although the osteoporosis market in the United Sates has great potential as approximately 1 4 million postmenopausal women experience an osteoporotic fractur each year  Tymlos is expected to face significant competition from Eli Lilly  Co s   NYSE LLY   Forteo and Amgen s   NASDAQ AMGN   Prolia Moreover  the approved label carries a boxed warning of osteosarcoma  a malignant bone tumor   The company also a setback when the CHMP issued a third Day 180 List of Outstanding Issues Zacks Rank   Key PickRadius Health currently carries a Zacks Rank  3  Hold  A better ranked stock in the health care sector is Regeneron Pharmaceuticals   NASDAQ REGN   which sports a Zacks Rank  1  Strong Buy   You can see  Regeneron s earnings per share estimates have moved up from  17 13 to  18 65 and from  20 38 to  21 56 for 2018 and 2019  respectively  in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters with an average beat of 9 15  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-03-01,Zacks Investment Research,https://www.investing.com/analysis/radius-rdus-q4-loss-wider-than-expected-on-higher-expenses-200295652,200295652
150151,371667,AMGN,Profit From Share Buyback Boom With These ETFs,opinion,President Donald Trump s biggest tax overhaul in decades has raised the appeal of buyback ETFs  This is especially true as a massive  1 4 trillion tax cut and the repatriation policy have prompted companies from almost every sector to boost their multi billion dollar share buyback program this year Notably  approximately  2 6 trillion in American corporate profits are sitting in overseas bank accounts  about half of that being in cash  The new tax law encourages these companies to bring this cash back home at much reduced rates  read    U S  companies have announced  209 billion worth of share buyback since the beginning of this year  according to the latest report from Senate Democrats  A California based research firm TrimTabs stated that the pace of buybacks had exploded in February to a record  billion from  59 9 billion in January  Among the largest share repurchases so far  Cisco   NASDAQ CSCO   has been on the forefront  with its additional  25 billion buyback plan  This was followed by  22 6 billion for Wells Fargo   NYSE WFC     15 billion for Pepsico   NASDAQ PEP     10 billion for Abbvie   NYSE ABBV   and  10 billion for Amgen   NASDAQ AMGN   Given this optimism  2018 is expected to be the second busiest year for buybacks since the bull market began in 2009 as U S  companies are on track to return a record  1 trillion to their shareholders  An analyst at J P  Morgan   NYSE JPM   expects companies on the S P 500 index to buy back as much as  800 billion in shares of their own stock this year  representing a whopping jump of 51   i e   300 billion  from  530 billion repurchased last year About  100 billion of additional buybacks is the result of the tax savings and stronger earnings while  200 billion will be generated from the repatriation bonanza  Another analyst at Goldman Sachs   NYSE GS   projects that buybacks will rise 23  this year to  650 billion  read    As a result  investors should take advantage of the ongoing boom in share buybacks through the following three ETFs SPDR S P 500 Buyback  NYSE SPYB  ETF This fund focuses on the 101 top companies in the S P 500 with the highest buyback ratio in the last 12 months  It follows the S P 500 Buyback Index  charging investors 35 bps in annual fees  From a sector look  financials and consumer discretionary take the largest share with 28 8  and 23 9  allocation  respectively  while information technology and healthcare round off the next spots  The product has a lower AUM of  15 7 million and trades in a paltry volume of around 3 000 shares a day on average  read     PowerShares Buyback Achievers Portfolio  This ETF tracks the NASDAQ US Buyback Achievers Index  which comprises companies that have repurchased 5  or more of their common stock in the trailing 12 months  It holds 131 stocks in its basket and charges a higher annual fee of 63 bps  Here also  financials and consumer discretionary are the top two sectors  with at least 29  share each  closely followed by consumer staples  15 3    PKW is the popular fund in the buyback space  managing an asset base of nearly  1 4 billion and trading in an average daily volume of 67 000 shares AdvisorShares Wilshire Buyback ETF This is an actively managed fund that seeks to generate long term capital appreciation by investing in stocks with liquidity and fundamental characteristics that are historically associated with superior long term performance  This approach results in a basket of 101 securities with financials and consumer discretionary as the top two sectors accounting for 19  of assets each  This was followed by industrials  18    information technology  13   and healthcare  13    The product has amassed  113 7 million in its asset base while sees low volume of nearly 6 000 shares a day  The fund charges 90 bps in annual fees iShares U S  Dividend and Buyback ETF This fund offers exposure to a broad basket of 379 U S  companies that return capital to shareholders by paying dividends or buying back their stock  Information technology  financials  consumer discretionary  health care and industrials are the top five sectors with double digit exposure each  The ETF has newly debuted in the space and accumulated  6 5 million within three months  It trades in a paltry volume of under 7 000 shares a day on average and charges 25 bps in annual fees  read    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2018-03-05,Zacks Investment Research,https://www.investing.com/analysis/profit-from-share-buyback-boom-with-these-etfs-200296165,200296165
150152,371668,AMGN,Spectrum  SPPI  Q4 Loss Widens Y Y  Sales Miss  Stock Falls,opinion,"Spectrum Pharmaceuticals  Inc    NASDAQ SPPI   incurred a loss of 29 cents per share in the fourth quarter of 2017  wider than the Zacks Consensus Estimate of a loss of 25 cents and in line with the year ago loss  Moreover  adjusted loss came in at 23 cents  wider than the year ago loss of 10 cents Quarterly revenues came in at  28 6 million  down almost 18 9  from the year ago quarter  The top line also missed the Zacks Consensus Estimate of  34 million Shares of the company were down almost 9 3  in after hours trading on Mar 6  presumably due to wider loss and lower sales However  Spectrum Pharma s shares have significantly outperformed the  in the past year  The stock has gained 235 9  compared with the industry s increase of 2 1    Quarter in DetailTotal product sales came in at  27 9 million  down 13 2  year over year  Sales were generated by six marketed products   Fusilev   0 9 million   Folotyn   11 million   Zevalin   3 9 million   Marqibo   1 2 million   Beleodaq   2 7 million  and Evomela   8 3 million   Evomela is facing pricing pressure due to generic entry License fees and service revenues were  0 6 million  down 79 4  from the prior year quarter Adjusted research   development expenses were  21 3 million  up 38 1  from the year ago quarter  Adjusted selling  general and administrative spending was up 22 1  to  19 1 million  The company is focused on the development of its two pipeline candidates  poziotinib and Rolontis 2017 ResultsTotal product sales came in at  116 2 million  down 9 7  year over year Adjusted research   development  R D  expenses were  63 4 million  up 17 2  from year ago period  Adjusted selling  general and administrative spending was up 2  to  65 4 million The company reported adjusted loss of 61 cents for the period  wider than the year ago loss of 23 cents 2018 OutlookThe company provided revenue guidance for 2018 in the range of  90  110 million  The company expects R D expenses to increase due to higher investment related to its pipeline Pipeline UpdateSpectrum Pharma is evaluating poziotinib in two separate phase II studies for the treatment of lung cancer and a phase II study for breast cancer  In October 2017  the company presented results from a preliminary analysis of the lung cancer study  The candidate achieved an objective response rate of 73  in patients with EGFR exon 20 insertion mutations A phase III study  ADVANCE  was conducted under a Special Protocol Assessment   SPA   agreement with the FDA evaluating Rolontis for treatment of chemotherapy induced neutropenia in patients with breast cancer  Last month  the company announced the successful completion of the ADVANCE study on Rolontis  The candidate demonstrated non inferiority to Amgen Inc  s   NASDAQ AMGN   Neulasta in improving duration of severe neutropenia It has completed enrolling patients for an additional phase III study  RECOVER  Data from this study will be included in the biologics license application   BLA   along with ADVANCE study data  to be filed with the FDA The company expects to file a BLA for Rolontis in the fourth quarter of 2018 Spectrum Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
     Zacks Rank   Stocks to ConsiderSpectrum Pharma carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the healthcare sector are Ligand Pharmaceuticals Incorporated   NASDAQ LGND   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Both the stocks sport a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates have moved up from  3 78 to  4 15 for 2018 over the last 30 days  The company pulled off positive earnings surprises in three of the trailing four quarters with an average beat of 24 88   Share price of the company has soared 53 4  over a year Regeneron s earnings per share estimates have been revised from  17 13 to  18 65 and from  20 37 to  21 56 for 2018 and 2019  respectively  in the last 30 days  The company delivered a positive surprise in three of the last four quarters with an average beat of 9 15  Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks  has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-03-06,Zacks Investment Research,https://www.investing.com/analysis/spectrum-sppi-q4-loss-widens-yy-sales-miss-stock-falls-200296408,200296408
150178,371694,AMGN,4 Trade Ideas For A Move Higher In Amgen  Bonus Idea ,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Amgen  NASDAQ AMGN    AMGN  has been making a series of higher highs and higher lows since staring to move up at the beginning of 2017  It took until February 2017 to make the first new high and since then there have been 3 additional new highs  All of this action has left the stock marginally higher that the channel it spent 2016 in 
Last week it pulled back into its earnings report and then after reporting Thursday held in place and printed a bullish engulfing candle Friday  This with the broad market falling over 3  for the week  mostly the last 2 days  Momentum has stopped falling with the RSI halting at the mid line while the MACD continues lower  but remains positive 
A Measured Move to the upside would give a target to 207 with the October high and the high last week as the only resistance along the way  Support lower sits at 183 then 180 and 173 50  with a reversal of the uptrend on a move under 168 75  Short interest is low at 1 3  and the stock begins trading ex dividend on February 14th 
The February 9 Expiry options chain show the biggest open interest at the 180 and 177 5 Put strikes with a cluster from 195 to 202 5 on the Call side  The February monthly options range from 175 to 190 on the Put side and are bigger at 185 and 200 on the call side with good size in between  March options are focused from 175 to 185 on the Put side and build from 185 to a big top at 200 on the call side  April options are much bigger on the Call side and rise from 185 to 200 but are biggest at 240 
Amgen  Ticker   AMGN
Trade Idea 1  Buy the stock now  over 183  with a stop at 180 
Trade Idea 2  Buy the stock and add a February monthly 185 175 Put Spread for protection   2 60  while selling an April 200 Call   2 30  to pay for the protection 
Trade Idea 3  Buy the March 180 190 200 Call Spread Risk Reversal   0 20  buying the 190 200 call spread and selling the 180 put  
Trade Idea 4  Buy the February April 195 Call Calendar   3 30  
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which as February starts sees equities have experienced their first pullback of more than 3  since what feels like forever  with technicals suggesting the pain may not be over yet 
Elsewhere look for Gold to consolidate in its uptrend while Crude Oil pauses in its uptrend as well  The US Dollar Index downtrend has hit new lows but may be ready for a bounce while US Treasuries are accelerating lower  The Shanghai Composite and Emerging Markets are are pulling back in their uptrends 
Volatility looks to continue higher keeping the pressure on the equity index ETF s SPY  NYSE SPY   IWM and QQQ  Their charts show pauses in the uptrend in the longer timeframe with pullbacks in the shorter one ready to continue next week  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2018-02-05,Gregory W. Harmon,https://www.investing.com/analysis/4-trade-ideas-for-a-move-higher-in-amgen-bonus-idea-200286935,200286935
150179,371695,AMGN,Novartis  Cosentyx Label Expanded To Include Scalp Psoriasis,opinion,"Novartis   NYSE NVS   announced that the FDA has approved a line extension for its IL 17A inhibitor drug  Cosentyx  in moderate to severe scalp psoriasis  The FDA approval comes on the back of positive efficacy and safety outcomes from a dedicated phase III study   SCALP   in patients with scalp psoriasis We note that the drug was approved for a similar indication in Europe in June 2017  It is already approved for the treatment of plaque psoriasis  psoriatic arthritis  PsA  and ankylosing spondylitis   AS   Per the press release  scalp psoriasis is one of the difficult to treat forms of psoriasis  which affects about half of the approximately 125 million patients with the disease  The line extension of the drug is an important achievement as treatment of scalp psoriasis with topical agents or phototherapy is challenging due to the presence of hair and other factors Novartis  shares have returned 13 7  in the past year  compared to the  s gain of 14 1  in the same period  The SCALP study evaluated the subcutaneous administration of Cosentyx  300 mg  for 12 weeks  Data showed significant improvement in patients compared to placebo Cosentyx s performance was impressive in 2017  It achieved multi blockbuster drug status on the back of strong growth in all the approved indications  Sales of the drug increased 82  in 2017 to surpass the  2 billion mark The drug has shown superiority in clinical studies to Johnson   Johnson s   NYSE JNJ   Stelara and Amgen s   NASDAQ AMGN   Enbrel in treating psoriasis  Novartis is also conducting head to head clinical trials   EXCEED and SURPASS   to evaluate the superiority of Cosentyx versus AbbVie s   NYSE ABBV   Humira in PsA and to a proposed biosimilar of Humira in AS  respectively The superiority of the drug over Stelara and Enbrel has helped it gain market share  Potential superiority over Humira and its biosimilar along with this line extension in scalp psoriasis will certainly boost the prospect of the drug Novartis AG Price
    Zacks RankNovartis carries a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/novartis-cosentyx-label-expanded-to-include-scalp-psoriasis-200288619,200288619
150180,371696,AMGN,ImmunoGen  IMGN  Q4 Loss Wider  Revenues Rise Y Y ,opinion,Waltham  MA based ImmunoGen  Inc    NASDAQ IMGN   is a development stage biotechnology company  which focuses on developing targeted anticancer therapeutics using its antibody drug conjugate technology  ADC   The company s ADC technology is used in Roche s marketed product  Kadcyla  in four other development stage candidates in its own pipeline  and in programs in development by its partners Amgen  NASDAQ AMGN  and Bayer  DE BAYGN  among others With ImmunoGen not having any approved products in its portfolio  the company earns revenues from royalties  license and milestone payments  and research and development support fees paid by its partners ImmunoGen has moved to reporting on a calendar year basis  effective Jan 1  2017 ImmunoGen s track record has been mixed with the company beating expectations in two of the past four quarters  posting in line results in one and missing in the other  Overall  the company has posted an average positive surprise of 10 22  ImmunoGen  Inc  Price and EPS Surprise   Currently  ImmunoGen has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings ImmunoGen posted wider than expected loss in the fourth quarter of 2017  Our consensus called for a loss of 7 cents per share  and the company reported a loss of 9 cents per share  However  loss in the quarter is significant narrower than year ago figure of 39 cents Revenues ImmunoGen posted revenues of  39 4 million compared with the Zacks Consensus Estimate of  41 million  The top line missed expectations for the quarter  However  revenue almost doubled from year ago figure of  13 8 million Key Stats  R D expenses increased 18 4  from the year ago level to  39 8 million  Selling  general and administrative  SG A  expenses were also up 5 9  to  9 million in the fourth quarter of 2017 2018 Guidance  The company expects revenues in the range of  60  65 million for 2018  The Zacks Consensus Estimate for the metric is pegged at  64 8 million for the year Operating expenses are expected in the range of  185  190 million during the same period Moreover  the company expects cash and cash equivalents by Dec  2018 end in the range of  115 million to  120 million Share Price Impact  Shares are up almost 3  in pre market trading Check back later for our full write up on IMGN earnings report later The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/immunogen-imgn-q4-loss-wider-revenues-rise-yy-200288972,200288972
150181,371697,AMGN,Can ImmunoGen s Key Ovarian Cancer Candidate Drive Growth ,opinion,On February 14  2018  we issued an updated report on ImmunoGen  Inc    NASDAQ IMGN   ImmunoGen reported fourth quarter results on Feb 9  2018  The company posted wider than expected loss in the reported quarter with revenues missing estimates  However  with the loss being significantly narrower than the year ago figure  sales show a massive increase during the period  This top line improvement was mainly driven by substantially higher license and milestone fees related to divestment of the company s non core B cell assets  IMGN529  in November 2017 to Debiopharm International  On fourth quarter conference call  focus was mainly on the progress related to the company s pipeline development Shares of ImmunoGen have significantly outperformed the in a year s time  The stock has soared 300  against the industry s decline of 0 8   ImmunoGen has significantly progressed with respect to its lead pipeline candidate  mirvetuximab soravtansine  The candidate is under evaluation in a phase III study  FORWARD I  as a single agent therapy for treating patients with platinum resistant ovarian cancer  whose tumors express high or medium levels of FR alpha Notably  combo therapies with mirvetuximab soravtansine for ovarian cancer are being evaluated in the phase Ib II FORWARD II study  The study consists of cohorts assessing mirvetuximab soravtansine in combination with Roche s   OTC RHHBY   Avastin and Merck s   NYSE MRK   Keytruda  Initial data from the study demonstrated that the candidate has potential to complement all available therapies for the indication  Updated data from the program is expected in the first half of 2018 Notably  mirvetuximab soravtansine enjoys an Orphan Drug status in both the United States and the EU for treatment of ovarian cancer Apart from mirvetuximab soravtansine  ImmunoGen works upon developing a couple of other candidates including IMGN779 and IMGN632  In December 2017  ImmunoGen released positive findings from the ongoing phase I study  evaluating IMGN779 on patients with relapsed or refractory adult acute myeloid leukemia  AML   Earlier  this January  the company initiated a phase I program  analyzing IMGN632 to treat hematological malignancies including AML ImmunoGen has agreements with several big healthcare companies including Amgen   NASDAQ AMGN    Bayer  DE BAYGN   Eli Lilly  Novartis  Roche  Sanofi  PA SASY  and Takeda  These contracts in turn allow other companies to use ImmunoGen s ADC technology and provide it with funds in the form of license and milestone fees  royalties  clinical materials revenues and R D  research and development  support fees Zacks RankImmunoGen carries a Zacks Rank  3  Hold   You can see  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-02-13,Zacks Investment Research,https://www.investing.com/analysis/can-immunogens-key-ovarian-cancer-candidate-drive-growth-200290426,200290426
150182,371698,AMGN,Roche s Rituxan Gets Priority Review For Label Expansion,opinion,"Roche Group s   OTC RHHBY   member Genentech announced that the FDA accepted Supplemental Biologics License Application  sBLA  and granted Priority Review for the label expansion of the company s leukemia drug Rituxan  rituximab   The company is seeking to get Rituxan approved for the treatment of pemphigus vulgaris  which is a life threatening condition characterized by progressive painful blistering of the skin and mucous membranes 
Rituxan is already approved for treating blood cancers including non Hodgkin s lymphoma  follicular lymphoma and diffuse large B cell lymphoma  and chronic lymphocytic leukemia as well as immunological diseases like rheumatoid arthritis 
Priority Review designation from the FDA is generally granted to drugs that have the potential to provide significant improvements in the safety and effectiveness of the treatment  prevention or diagnosis of a serious disease  
Over a year  shares of Roche have declined 3  as against the  s growth of 10 1  

The sBLA submission was based on data from a Roche supported randomized trial conducted in France which evaluated Rituxan plus a tapering regimen of low dose oral corticosteroid   CS   treatment compared with a standard dose of CS alone as a first line treatment in patients with newly diagnosed moderate to severe pemphigus  The study showed that Rituxan provides considerable improvement in pemphigus vulgaris remission rates and successful tapering and or cessation of CS therapy 
However  we remind investors that competition from Amgen s   NASDAQ AMGN   and Novartis    NYSE NVS   biosimilars loom large on Rituxan Roche Holding  SIX ROG  AG Price

   Zacks Rank   Stock to Consider
Roche carries a Zacks Rank  3  Hold  
A better ranked stock from the health care space is Exelixis   NASDAQ EXEL    carrying a Zacks Rank  2  Buy   You can see  
Exelixis  earnings per share estimates have moved up from 72 cents to 77 cents for 2018 in the last 60 days  The company delivered positive earnings surprise in the last four quarters  with an average beat of 572 92   Share price of the company surged 30 8  over a year 
Don t Even Think About Buying Bitcoin Until You Read This 
The most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 
Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ",2018-02-14,Zacks Investment Research,https://www.investing.com/analysis/roches-rituxan-gets-priority-review-for-label-expansion-200290596,200290596
150207,371723,AMGN,Roche Gets Breakthrough Therapy Designation For ASD Drug,opinion,Roche Holdings AG   OTC RHHBY   announced that the FDA has granted Breakthrough Therapy Designation for its experimental drug oral medicine balovaptan  previously known as RG7314   a vasopressin 1a  V1a  receptor antagonist for individuals with autism spectrum disorder  ASD  The designation from the FDA is intended to expedite the development and review of drugs with early evidence of substantial potential clinical benefit to patients  or benefit patients without current treatment options The designation for balovaptan is primarily based on efficacy findings in the phase II trial  VANILLA  Vasopressin ANtagonist to Improve sociaL communication in Autism  study  in adults with ASD Meanwhile  a phase II trial balovaptan in children and adolescents with ASD is ongoing and other trials in ASD are also being planned We note that ASD is approximately four times more prevalent in boys than in girls  As per estimates  1 in 42 boys and 1 in 189 girls suffer from ASD in the United States  The World Health Organization estimates that the global prevalence of ASD is approximately one in every 160 people and 0 3  of the global burden of disease Roche has more than a dozen pipeline candidates in the neuroscience portfolio for diseases that include multiple sclerosis  Alzheimer s disease  spinal muscular atrophy  Parkinson s disease and autism Earlier in the month  the European Commission granted marketing authorization to multiple sclerosis drug Ocrevus  The approval boosts Roche s neuroscience portfolio   Roche s stock has rallied 5 1  over a year compared with  s gain of 30 6  Approval of new drugs and a potential label expansion of existing drugs bode well for Roche as its legacy drugs like Herceptin  MabThera are facing competition from biosimilars Novartis AG   NYSE NVS   has already launched its biosimilar version of Rituxan  MabThera in Europe  Amgen   NASDAQ AMGN   has also obtained FDA approval for a biosimilar version of Avastin for treatment of five types of cancers including lung cancer  colorectal cancer  glioblastoma  renal cell carcinoma and cervix cancer Zacks Rank   Key PickRoche carries a Zacks Rank  3  Hold  A better ranked stock in the healthcare sector is Exelixis  Inc    NASDAQ EXEL   with a Zacks Rank  1  Strong Buy   You can see  Exelixis  earnings per share estimates have moved up from 72 cents to 77 cents for 2018 over the last 60 days  The company delivered a positive earnings surprise in the last four quarters  with an average beat of 572 92  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-01-29,Zacks Investment Research,https://www.investing.com/analysis/roche-gets-breakthrough-therapy-designation-for-asd-drug-200284974,200284974
150208,371724,AMGN,Pfizer  PFE  Stock Falls Despite Q4 Earnings   Sales Beat,opinion,Pfizer  Inc    NYSE PFE   reported fourth quarter 2017 adjusted earnings per share of 62 cents  which beat the Zacks Consensus Estimate of 56 cents by 10 7   Earnings also rose 32  year over year driven by higher international sales and lower costs and share count The pharma heavyweight delivered revenues of  13 70 billion  which also beat the Zacks Consensus Estimate of  13 61 billion  Revenues rose 1  from the year ago quarter on a reported basis  On an operational basis  revenues were flat year over year Sales in DetailCurrency movement benefited Pfizer s fourth quarter revenues by 1   In February 2017  Pfizer divested its Hospira infusion systems  HIS  business to ICU Medical  Excluding currency headwinds and HIS revenues in the prior year quarter  sales rose 2  operationally Strong performance of newer products like Ibrance  breast cancer   Xtandi  prostate cancer  and Xeljanz  rheumatoid arthritis  somewhat offset lower sales of Enbrel and Viagra  loss of exclusivity for some products and supply shortages in legacy Hospira products International revenues rose 5   up 4  an operational basis  to  7 19 billion  Meanwhile  U S  revenues declined 4  to  6 51 billion Segment DiscussionPfizer s reporting segments are Pfizer Innovative Health  IH  and Pfizer Essential Health  EH  Pfizer IH sales grew 6  on a reported basis  up 5  an operational basis  from the year ago period to  8 22 billion  Pfizer IH revenues were driven by persistently strong momentum of Eliquis globally and Xeljanz Lyrica  Ibrance and Chantix Champix  all primarily in the United States Ibrance revenues rose 11  to  716 million in the quarter driven by strong U S  revenues  However  Ibrance sales were softer than the prior quarter as a one time price adjustment hurt international sales Xeljanz sales rose 47  to  410 million  Lyrica sales rose 8  to  1 13 billion  Eliquis alliance revenues and direct sales rose 43  to  710 million  Chantix sales rose 28  to  271 million in the quarter Revenues from the blockbuster prostate cancer drug  Xtandi  added to Pfizer s portfolio following the September 2016 Medivation acquisition  also contributed to U S  revenues  Xtandi recorded alliance revenues of  168 million in the quarter compared with  150 million in the third quarter This was partially offset by continued decline in revenues from Prevnar 13 in the United States and lower revenues of Enbrel and Viagra Enbrel revenues declined 13  to  634 million in key European markets due to biosimilar competition  Pfizer has exclusive rights to Amgen  Inc  s   NASDAQ AMGN   blockbuster rheumatoid arthritis RA  drug  Enbrel  outside the United States and Canada  Total Viagra  IH EH  sales declined 46  to  209 million due to generic competition that began in December 2017 Global Prevnar 13 Prevenar 13 revenues rose 7  to  1 53 billion as higher international sales made up for the decline in the United States  Prevnar 13 revenues tanked 7  in the United States due to continued decline in revenues for the eligible adult patient population  However  Prevenar 13 revenues rose 27  in international markets due to favorable timing of government purchases in some emerging markets for the pediatric indication Consumer Healthcare revenues declined 2  to  950 million  Global Oncology revenues increased 10  to  1 51 billion  Global Vaccine revenues rose 7  to  1 62 billion  Internal Medicine rose 6  to  2 44 billion  The Inflammation   Immunology franchise rose 6  to  1 10 billion  Additionally  the portfolio of Rare Disease declined 2  to  603 million Pfizer is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin off  sale or other transaction  A decision is expected this year  which could also be to retain the business Pfizer EH segment sales recorded a decline of 7   down 8  operationally  to  5 48 billion  Excluding HIS revenues  EH sales declined 3  EH revenues were hurt by the loss of exclusivity and associated generic competition for products  primarily Pristiq in the United States and Lyrica in Europe  lower revenues from legacy Hospira products due to product shortages and divesture of HIS  However  in the EH business  biosimilars and emerging markets did well in the quarter  Biosimilars revenues rose 72  operationally while emerging markets revenues grew 10  operationally Pfizer launched Inflectra  a biosimilar version of Johnson   Johnson   NYSE JNJ   and Merck s   NYSE MRK   blockbuster RA drug Remicade  in November last year  While Inflectra recorded sales of  44 million in the United States and  135 million globally  all other biosimilars brought in sales of  30 million  down 7   from outside the U S  markets Adjusted selling  informational and administrative  SI A  expenses declined 3   operationally  in the quarter to  4 32 billion  Adjusted R D expenses also declined 9  to  2 3 billion 2017 ResultsFull year sales were  52 55 billion  flat year over year on an operational basis  Sales marginally beat the Zacks Consensus Estimate of  52 50 billion and were in line with the guidance range of  52 4 billion to  53 1 billion Adjusted earnings of  2 65 per share for the full year exceeded the Zacks Consensus Estimate of  2 60 as well as the guided range of  2 58    2 62  Earnings rose 11  year over year 2018 GuidanceRevenues are expected in the range of  53 5 billion to  55 5 billion  The Zacks Consensus Estimate is pegged at  53 72 billion Adjusted earnings per share are expected in the range of  2 90    3 00  above the Zacks Consensus Estimate of  2 77 per share At the mid point  adjusted EPS is expected to increase 11  while revenues are expected to increase 4  Research and development expenses are expected in the range of  7 4  7 9 billion while SI A spending is projected in the range of  14 0  15 0 billion Adjusted tax rate is expected to be 17  in 2018 Our TakePfizer s fourth quarter results were above expectations as it beat estimates for both earnings and revenues  Meanwhile  it issued an upbeat guidance for 2018  Also Pfizer said that it plans to invest approximately  5 billion in capital projects in the United States over the next five years on increased access to foreign cash following the U S  tax reforms However  after initial gains  shares of Pfizer fell around 1 9  in premarket trading  We believe that lower sales in the United States and a sequentially softer performance of Ibrance in the quarter hurt investor sentiment  In the past year  Pfizer s shares have increased 24 6   comparing unfavorably with an increase of 29  for the Despite top line headwinds in the form of genericization of key drugs  supply shortages in legacy Hospira products  pricing pressure and rising competition  Pfizer achieved 11  adjusted earnings growth in 2017  New products like Ibrance  contribution from acquisitions  cost cutting efforts  a lower tax rate and share buybacks helped the company achieve its 2017 guidance  Meanwhile  Pfizer looks well poised to record profit growth in 2018 Pfizer carries a Zacks Rank  3  Hold   You can see  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-01-29,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-stock-falls-despite-q4-earnings--sales-beat-200284963,200284963
150209,371725,AMGN,Why Earnings Season Could Be Great For Amgen  AMGN ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Amgen Inc    NASDAQ AMGN   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Amgenis seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for AMGN in this report In fact  the Most Accurate Estimate for the current quarter is currently at  3 06 per share for AMGN  compared to a broader Zacks Consensus Estimate of  3 04 per share  This suggests that analysts have very recently bumped up their estimates for AMGN  giving the stock a Zacks Earnings ESP of  0 55  heading into earnings season Amgen Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that AMGN has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Amgen  and that a beat might be in the cards for the upcoming report The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/why-earnings-season-could-be-great-for-amgen-amgn-200285373,200285373
150210,371726,AMGN,Amgen Gets CHMP Nod To Add ENDEAVOR Data On Kyprolis Label,opinion,Amgen   NASDAQ AMGN   announced that it received a positive opinion from the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  recommending addition of an updated overall survival  OS  data from a phase III head to head study on the label of its multiple myeloma drug  Kyprolis  carfilzomib  The phase III ENDEAVOR study was conducted on 929 patients  Data from the trial demonstrated that a combination of Kyprolis plus dexamethasone  Kd  led to superior overall survival when compared with Takeda Pharmaceutical s Velcade plus dexamethasone  Vd  in second line multiple myeloma setting  Findings showed that the combination therapy reduced the risk of death by 21  and increased OS by 7 6 months compared with Vd in the given patients  population Importantly  in January 2018  Amgen announced that the FDA has approved its supplemental New Drug Application  sNDA  to include OS data from the ENDEAVOR program on Kyprolis  label  The FDA s decision comes much earlier than expected  initially expected in April this year Note that the Kd regimen is already approved in the United States  EU and other countries based on the primary analysis of a progression free survival in the ENDEAVOR study  This overall survival data  if approved  can help drive the usage of Kyprolis and boost its sales We remind investors that Kyprolis is also approved in the United States as a single agent for treating patients with multiple myeloma  who have received at least two prior therapies including Velcade and an immunomodulatory agent Significantly  Amgen collaborated with Johnson   Johnson   NYSE JNJ   in November 2016 to study the combination of Kyprolis and J J s Darzalex in multiple clinical studies for addressing the case of multiple myeloma  Under the terms of the agreement  the first study   a phase III registrational trial  evaluating the combo therapy of Kyprolis Darzalex and dexamethasone compared with Kyprolis and dexamethasone alone on patients with multiple myeloma  having undergone one  two or three prior lines of therapy   has been initiated Amgen s shares have outperformed the in a year s time  The stock has rallied 22 1   comparing favorably with the industry s increase of 8   Incidentally  Kyprolis  which became part of Amgen s portfolio following its acquisition of Onyx  registered sales of  608 million in the first nine months of 2017  up 18 9  compared with the year ago figure  The drug s label expansion would immensely expand the patient population as well as its commercial potential Per the company s press release  multiple myeloma is an aggressive disease  accounting for approximately one percent of all cancers  Moreover  around 39 000 patients are annually diagnosed with multiple myeloma in Europe  of which  almost 61 5  of the cases proves to be fatal  Hence  the market opportunity of the combination therapy is huge in the EU to cater to the unmet need of patients with an additional option to apprehend the life threatening disease Amgen Inc  Price    Zacks Rank   Key PicksAmgen carries a Zacks Rank  3  Hold   Two better ranked stocks in the health care sector are XOMA Corporation   NASDAQ XOMA   and Exelixis  Inc    NASDAQ EXEL    While XOMA sports a Zacks Rank  1  Strong Buy   Exelixis carries a Zacks Rank  2  Buy   You can see  XOMA s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 over the last 60 days  The company came up with an average beat of 47 92   The stock has skyrocketed 678 3  in the last 12 months Exelixis  earnings per share estimates have been revised upward from 72 cents to 77 cents for 2018 over the last 60 days  The company pulled off a positive surprise in all the trailing four quarters with an average beat of 572 92   Share price of the company has soared 68 4  in a year s time The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/amgen-gets-chmp-nod-to-add-endeavor-data-on-kyprolis-label-200285450,200285450
150211,371727,AMGN,Roche  RHHBY  Posts Solid 2017 Sales On Tecentriq   Alecensa,opinion,Roche Holding  SIX ROG  AG s   OTC RHHBY   reported sales of CHF13 8 billion in the fourth quarter of 2017  up 5  from the year ago period   Roche s stock has moved up 7 7  in the last twelve months compared with  s gain of 24 7  The company reports results under two divisions  Pharmaceuticals and Diagnostics  All growth rates mentioned below are on a year over year basis and at constant exchange rates Sales in 2017 came in at CHF 53 3 billion  up 5   Earnings per share came in at CHF 15 34 in 2017  up from CHF 14 53 in 2016   Sales at the Pharmaceuticals division increased 5  driven by strong growth in Tecentriq  Ocrevus  Alecensa and Perjeta  Diagnostics division sales climbed 5  primarily on the back of strong immunodiagnostic business Results in DetailHerceptin sales improved 3  due to increasing demand in the United States and Brazil  Perjeta sales grew 19  following increased demand in the neoadjuvant and metastatic settings  Sales of Kadcyla   10   were driven by increasing demand in the international markets Meanwhile  sales of Avastin decreased due to increasing use of cancer immunotherapy medicines in lung cancer Sales of Rituxan MabThera  1   were driven by growth in the immunology segments  Growth in Gazyva Gazyvaro  41   was strong despite increasing competition in chronic lymphocytic leukemia Recently launched drugs  Tecentriq and Alecensa for lung cancer are off to a strong start  Tecentriq  Ocrevus and Alecensa contributed CHF1 4 billion of new sales Performance of the immunology franchise was driven by increased sales of Actemra RoActemra  14    and strong uptake of Esbriet  13   and Xolair  16    Increasing use of Actemra RoActemra in the subcutaneous formulation drove sales However  sales of Tarceva declined  18   due to growing use of other therapeutic options  Sales of Xeloda  10   continue to be hit by generic competition  Sales of Tamiflu also declined 33  Revenues at the Diagnostics division climbed 5  on the back of solid performance of the Centralised and Point of Care Solutions  7   unit  which was in turn  propelled by Immunodiagnostics  13    Tissue Diagnostics  13   and Molecular Diagnostics  11   also performed impressively However  Diabetes Care sales declined 4  as sales continue to be impacted by challenging market conditions  particularly in North America 2018 OutlookRoche now expect sales to remain stable or grow in low single digits  The company expects core earnings to grow in high single digits  The company intends to further increase its dividend in 2017 in local currency Pipeline ProgressThe company won FDA approvals for two new drugs in 2017   Ocrevus for the treatment of relapsing and primary progressive forms of multiple sclerosis and Hemlibra for haemophlia A with factor VIII inhibitors The company continues to expand the label for its existing drugs   Perjeta for adjuvant  after surgery  treatment of HER2 positive early breast cancer at high risk of recurrence  in combination with Herceptin and chemotherapy as well as full approval of Perjeta for neoadjuvant use During the fourth quarter  Roche obtained FDA approval of a label expansion of a few drugs  Alecensa for first line treatment in ALK positive non small cell lung cancer   NSCLC    Zelboraf in Erdheim Chester disease  Gazyva for untreated advanced follicular lymphoma and Avastin for glioblastoma in adult patients whose cancer has progressed after prior treatment Alecensa was also approved as a monotherapy for the first line treatment of adult patients with anaplastic lymphoma kinase  ALK  positive  advanced NSCLC in Europe  In January 2018  EMA approved Ocrevus for the treatment of both the relapsing and the primary progressive forms of multiple sclerosis and Hemlibra was granted a positive opinion by the CHMP Meanwhile  Tecentriq in combination with Avastin showed positive study results in lung cancer and kidney cancer On the diagnostics front  Roche entered into a strategic  long term partnership with GE Healthcare to jointly develop and co market digital clinical decision support solutions Our TakeRoche performance in 2017 was strong driven by contribution from newly launched drugs  The label expansion of key drugs  Perjeta  Tecentriq and Alecensa will further drive growth  Ocrevus and Hemlibra have been successfully launched  However  sales of Avastin and Tarceva continue to decline Approval of new drugs and a potential label expansion of existing drugs bode well for Roche as its legacy drugs like Herceptin  MabThera are facing competition from biosimilars Novartis AG   NYSE NVS   has already launched its biosimilar version of Rituxan  MabThera in Europe  Amgen   NASDAQ AMGN   also obtained FDA approval for a biosimilar version of Avastin for treatment of five types of cancers including lung cancer  colorectal cancer  glioblastoma  renal cell carcinoma and cervix cancer Zacks Rank   Key PickRoche carries a Zacks Rank  3  Hold  A better ranked stock in the healthcare sector is Exelixis   NASDAQ EXEL   with a Zacks Rank  1  Strong Buy   You can see   Exelixis  earnings per share estimates have moved up from 72 cents to 77 cents for 2018 over the last 60 days  The company delivered a positive earnings surprise in the last four quarters  with an average beat of 572 92  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-01-31,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-posts-solid-2017-sales-on-tecentriq--alecensa-200286189,200286189
150212,371728,AMGN,Amgen  AMGN  Q4 Earnings   Sales Lag  2018 Sales View Soft,opinion,"Biotech major Amgen Inc    NASDAQ AMGN   reported fourth quarter 2017 earnings of  2 89 per share  which missed the Zacks Consensus Estimate of  3 04 by 4 9   Earnings were flat year over year as lower sales and higher operating costs offset the benefit of a lower tax rate Including a  6 1 billion charge related to U S  tax reform  fourth quarter 2017 loss per share was  5 89 against earnings of  2 59 per share in the fourth quarter of 2016 Total revenues of  5 80 billion in the quarter missed the Zacks Consensus Estimate of  5 86 billion  Revenues declined 3  year over year Quarter in DetailTotal product revenues declined 2  from the year ago quarter to  5 57 billion  U S    4 35 billion  ex U S    1 22 billion  as increasing demand for newer products like Prolia  Kyprolis  Xgeva and Blincyto was not enough to make up for lower sales of some of Amgen s largest products like Enbrel  Aranesp  Epogen  Neulasta and Neupogen due to competitive pressure Revenues of Amgen s erythropoiesis stimulating agent  ESA   Aranesp  declined 7  from the year ago quarter to  491 million due to lower demand and unfavorable changes in currency rates Revenues of the other ESA  Epogen  declined 15  to  270 million due to lower selling price owing to a newly negotiated contract with DaVita Inc Neulasta revenues were flat at  1 14 billion from the year ago period as lower demand was offset by changes in accounting estimates Increased competition from PD 1s and other new cancer therapies is hurting demand for Neulasta  However  the Neulasta Onpro kit  on body injector  continues to perform well  commanding a market share of about 60  in the United States for all Neulasta sales Please note that Neulasta and Epogen could start facing biosimilar competition in the United States this year  which will hurt sales further Neupogen recorded a 27  decline in sales to  126 million due to biosimilar competition in the United States  Zarxio  Sandoz s  Novartis    NYSE NVS   generic arm  biosimilar version of Neupogen  was launched in the United States in September 2015 and is hurting sales Enbrel delivered revenues of  1 42 billion  down 13  from the year ago quarter due to lower selling prices and increased competition  which hurt demand  Amgen launched the Enbrel AutoTouch  an autoinjector device in November last year Prolia revenues came in at  574 million  up 24  from the year ago quarter due to higher demand  The osteoporosis drug witnessed continued growth in new patient starts and strong repeat injection rates  which drove year over year growth Meanwhile  Xgeva delivered revenues of  391 million  up 4  from the year ago quarter mainly due to higher demand and favorable changes in inventory levels Earlier this year  Amgen gained FDA approval for an expanded label for Xgeva to include prevention ofskeletal related events  SREs  inpatients with multiple myeloma  Until now Xgeva was only approved for the prevention of SREs in solid tumors in patients with bone metastases  The approval for the expanded patient population may drive sales of Xgeva in future quarters Sensipar Mimpara revenues were flat at  411 million as higher price increases were offset by unfavorable inventory changes Vectibix revenues came in at  159 million  up 11   driven by higher demand Kyprolis recorded sales of  227 million  up 24  year over year driven by higher demand and robust uptake from outside U S  markets Amgen s regulatory application in the United States to include overall survival data from the ENDEAVOR study on the label of Kyprolis was granted approval by the FDA earlier this month  Also  earlier this week Amgen announced that the Committee for Medicinal Products for Human Use  CHMP  has given a positive opinion recommending addition of ENDEAVOR on Kyprolis label in the EU  The study demonstrated that a combination of Kyprolis plus dexamethasone led to superior overall survival when compared to Takeda s Velcade plus dexamethasone  This overall survival data  if approved  can help drive usage and boost sales of Kyprolis Blincyto sales surged 59  from the year ago period to  46 million  reflecting higher demand Amgen s PCSK9 inhibitor  Repatha generated revenues of  98 million compared with  89 million in the third quarter Uptake of the drug  which gained FDA approval in August 2015  has not been very encouraging so far due to pricing and re imbursement issues payer restrictions  Sanofi   NYSE SNY   and partner Regeneron Pharmaceuticals also faced similar issues with their PCSK9 inhibitor  Praluent  The priority for Amgen right now is to improve patient access to Repatha In December  Amgen gained FDA approval to include a new indication   risk reduction of major cardiovascular events data   on Repatha s label based on data from the phase III cardiovascular outcomes study  FOURIER This makes Repatha the first PCSK9 inhibitor to prevent heart attacks  strokes and coronary revascularizations in adults with established cardiovascular disease  With the cardiovascular indication approved to be included in Repatha s label  patient access to Repatha is expected to improve Operating Margins DecreaseAdjusted operating margins declined 460 basis points  bps  to 45 9  due to higher operating costs and  79 million in expenses related to Hurricane Maria recovery efforts R D expenses declined 3  in the quarter due to lower late stage pipeline related costs and lower payments for in licensing transactions  SG A spend increased 8  due to higher investments to support new product launches  which partially offset the impact of October 2016 expiration of Enbrel residual royalty payments This month  Amgen s board of directors approved a new share buyback plan of  10 billion  bringing the total existing share repurchase authorization to  14 4 billion 2017 ResultsFull year 2017 sales of  22 85 billion missed the Zacks Consensus Estimate of  22 90 billion  Revenues were within the guidance range of  22 7 billion to  23 0 billion  Sales declined 1  year over year Adjusted earnings for 2017 were  12 58 per share  also missing the Zacks Consensus Estimate of  12 69 per share  Earnings were within the guidance range of  12 50 to  12 70  Earnings rose 8  year over year 2018 GuidanceThe company expects total revenues in the range of  21 8 billion to  22 8 billion  which fell short of the Zacks Consensus Estimate of  22 90 billion  Adjusted earnings are now expected in the range of  12 60 to  13 70 in 2018  The Zacks Consensus Estimate was pegged at  12 65 per share Adjusted tax rate is expected to be approximately 14  15   much lower than 18  in 2017 reflecting the impact of tax reform On expectation of an improved cash position following the tax reform  Amgen plans to invest approximately  3 5 billion over the next five years in capital expenditures  Approximately 75  of this investment will be made in the United States including setting up a new drug substance manufacturing plant in the country Our TakeAmgen had a rather poor quarter as it missed expectations for both earnings and sales and also issued a lower than expected sales guidance for 2018  Shares lost 1 7  in after market trading in response  However  in the past year  Amgen s shares have returned 10 7   better than the 4 6  increase registered by the  Though Amgen s newer products   Prolia  Xgeva  Vectibix  Nplate and Sensipar   are all performing well  their volume growth is not enough to offset the decline in mature brands like Enbrel due to competitive pressure  However  Amgen is also progressing with its pipeline and expects approval and launch of migraine candidate  Aimovig this year  Also  Amgevita  Amgen s biosimilar version of AbbVie s   NYSE ABBV   blockbuster rheumatoid arthritis drug  Humira is expected to be launched in Europe later this year  Parsabiv  a specialty product for kidney disease  was launched in the United States last month  Also  management seems quite confident that Repatha will become an important growth driver for the company with the inclusion of outcomes data on its label  Nonetheless  other than continuing competitive dynamics for Enbrel  possible generic competition to Sensipar and new competition for Neulasta and Aranesp could be the new challenges in 2018 Amgen carries a Zacks Rank  3  Hold   You can see Amgen Inc  Price  Consensus and EPS Surprise
    Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-q4-earnings--sales-lag-2018-sales-view-soft-200286485,200286485
150232,371748,AMGN,AstraZeneca s PARP Inhibitor Lynparza Gets Approval In Japan,opinion,"AstraZeneca   NYSE AZN   and partner Merck   NYSE MRK   announced that the Japanese Ministry of Health  Labour and Welfare has granted approval to its PARP inhibitor  Lynparza  as a maintenance therapy for relapsed ovarian cancer  irrespective of BRCA mutation status in patients who have responded to their last platinum based chemotherapy Lynparza becomes the first PARP inhibitor approved for any indication in Japan We remind investors that Lynparza s prospects got a boost with its line expansion in breast cancer earlier this month in the United States  The expansion of label and geography will certainly boost sales of the drug  Meanwhile  the label expansion application to include breast cancer is under review in Europe AstraZeneca s shares have increased 30 7  in the last year  while shares of Merck are down 0 9  in that period  Meanwhile  the  moved up 23 9  in the same time period The approval was granted based on encouraging data from phase II study   Study 19   and phase III study   SOLO 2  Both the studies evaluated Lynparza monotherapy in maintenance setting against placebo Data from SOLO 2 study showed that Lynparza improved median progression free survival   PFS   to 19 1 months compared to 5 5 months for placebo  Similarly  data from Study 19 trial demonstrated that the drug achieved a PFS of 8 4 months versus 4 8 months for placebo  The drug also achieved a median overall survival   OS   of 29 8 months against 27 8 months for placebo  Median OS is yet to be reached in SOLO 2 study Clovis Oncology  Inc  s   NASDAQ CLVS   Rubraca and Tesaro  Inc  s   NASDAQ TSRO   Zejula are the other PARP inhibitors  which give competition to Lynparza in the United States In a separate press release  AstraZeneca announced that Fasenra  benralizumab  was also granted approval as an add on treatment for bronchial asthma in Japan  The drug was approved in patients who continue to experience asthma exacerbations despite receiving treatment with high dose inhaled corticosteroid and other asthma controllers The approval was based on data from the WINDWARD program  which included three phase III studies   SIROCCO  CALIMA and ZONDA Data from SIROCCO and CALIMA showed that Fasenra achieved significant reductions in exacerbations and improvements in lung function  Meanwhile  data from ZONDA study showed that Fasenra alone or in combination with standard of care  glucocorticoid  led to statistically significant and clinically relevant reduction in daily maintenance oral corticosteroid   OCS   compared with placebo Other severe asthma candidates in AstraZeneca s portfolio are tralokinumab and tezepelumab   in partnership with Amgen  NASDAQ AMGN  Astrazeneca  LON AZN  PLC Price
    Zacks RankAstraZeneca carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-21,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-parp-inhibitor-lynparza-gets-approval-in-japan-200282259,200282259
150233,371749,AMGN,Merck Reports Positive Phase III Liver Cancer Data On Keytruda,opinion,Merck   Co   Inc    NYSE MRK   announced data from the phase II KEYNOTE 224 study evaluating the use of its anti PD 1 therapy  Keytruda in patients with advanced hepatocellular carcinoma  HCC  a form of liver cancer  who were previously treated with systemic therapy  sorafenib   The data showed that treatment with Keytruda monotherapy led to an overall response rate  ORR  of 16 3   The data also showed complete response rate of 1  and a partial response rate of 15 4  on treatment with KeytrudaThe data also included six month overall survival  OS  and progression free survival  PFS  rates  The median PFS in the Keytruda arm was 4 8 months with a six month PFS rate of 43 1 percent  However  the data showed that the median OS was not reached at the time of analysis and the six month OS rate was 77 9  The data was presented presented at the 2018 American Society of Clinical Oncology Gastrointestinal  ASCO GI  Cancers Symposium in San Francisco  Notably  Keytruda is already marketed for several cancer indications  including lung cancer  melanoma  head and neck cancer  classical hodgkin lymphoma and bladder cancer Last week  Merck announced that Keytruda  in combination with Lilly s    NYSE LLY   Alimta  pemetrexed  and acisplatin or carboplatin  met dual primary endpoints in a phase III KEYNOTE 189 study  The combination was evaluated for the first line treatment of patients with metastatic non squamous NSCLC  The study met both its primary endpoints  progression free survival  PFS  and OS  co primary endpoint  We remind investors at the third quarter 2017 call  Merck had mentioned that it is including the overall survival  OS  as a co primary endpoint in the KEYNOTE 189 study  which could defer the readout from the study to 2019  It was then estimated that the study would complete in February 2019 Therefore the one year earlier than expected positive read out of KEYNOTE 189 study was a big boost to the company Shares of Merck have lost 0 9  in the past one year compared unfavorably with the  s 23 9  increase  We remind investors that Keytruda is a key top line driver for Merck and it brought in  1 5 billion sales in third quarter 2017  up 18 8  sequentially and 194  year over year  Sales continue to be driven by a launch of new indications globally Significantly  Keytruda sales in the United States have gained particularly from a strong momentum in the new indication of first line lung cancer  Meanwhile  the Keytruda development program also significantly advanced in 2017 with regulatory approvals for four new indications in the United States and two additional diseases in Europe Keytruda is continuously growing and expanding into new indications and markets globally  It is under trial for more than 30 types of cancer in above 650 studies including excess of 300 combination studies Merck is collaborating separately with several companies namely Amgen  Inc    NASDAQ AMGN    Incyte  Glaxo and Pfizer  Inc    NYSE PFE   for the evaluation of Keytruda in combination with other regimens  Merck   Company  Inc  Price    Zacks RankMerck carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-01-21,Zacks Investment Research,https://www.investing.com/analysis/merck-reports-positive-phase-iii-liver-cancer-data-on-keytruda-200282344,200282344
150234,371750,AMGN,Healthcare ETFs To Watch As Q4 Earnings Unfold,opinion,Healthcare is performing well with the start of the New Year thanks to encouraging industry trends and a favorable policy environment  Notably  popular ETFs like Health Care Select Sector SPDR Fund   Vanguard Health Care ETF   AX VHT    iShares U S  Healthcare ETF  and Fidelity MSCI Health Care Index ETF  have gained nearly 7  so far The bullish trend is likely to continue heading into the Q4 earnings season as some big names like Johnson and Johnson   NYSE JNJ    Pfizer   NYSE PFE    Merck   NYSE MRK    Amgen   NASDAQ AMGN    AbbVie   NYSE ABBV    Gilead Sciences   NASDAQ GILD   and Bristol Myers Squibb   NYSE BMY   are lined up to report this week and in the next  All these stocks collectively account for 38 4  share in XLV  36 9  in IYH  33 2  in VHT and 33 2  in FHLC  read    Let s dig deeper into the earnings picture of these companies that would drive the performance of the above mentioned funds in the coming days According to the our methodology  a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   when combined with a positive  increases our chances of predicting an earnings beat  while a Zacks Rank  4 or 5  Sell rated  are best avoided  You can uncover the best stocks to buy or sell before they re reported with our  Inside Our Surprise Prediction of These StocksJNJ has a Zacks Rank  3 and an Earnings ESP of  0 09   indicating a lower chance of beating estimates this quarter  The stock has seen no earnings estimate revision for the yet to be reported quarter but delivered an average negative earnings surprise of 3 12  for the past four quarters  It has an impressive Momentum Style Score of B and a Value and Growth Style Score of C each  Johnson and Johnson is slated to release its earnings on Jan 23 before the opening bell  see    Pfizer has a Zacks Rank  3 and an Earnings ESP of  0 67   indicating a reasonable chance of beating estimates this quarter  The stock has seen positive earnings estimate revision of a penny for to be reported quarter but delivered an average negative earnings surprise of 0 79  for the past four quarters  It has an impressive Growth  Value and Momentum Style Score of B  A and A  respectively  Pfizer is scheduled to report earnings on Jan 30 before the opening bell Merck is expected to report results on Feb 2 before the market opens  It has a Zacks Rank  3 and an Earnings ESP of  1 06   The stock delivered a positive earnings surprise in the last four quarters  with an average beat of 7 76  but witnessed a negative earnings estimate revision of couple of cents over the past 90 days for the to be reported quarter  Merck has a Value  Growth and Momentum Style Score of C  F and D  respectively Amgen carries a Zacks Rank  3 and has an Earnings ESP of  0 41   indicating less chances of beating estimates this quarter  Though the earnings surprise track over the past four quarters is robust with an average positive surprise of 5 25   Amgen witnessed negative earnings estimate revision of four cents over the past 90 days for the quarter to be reported  The stock has a solid Value Style Score of B but the Growth and Momentum Style Score of D each looks dull  Amgen will report earnings on Feb 1 after market close  read    AbbVie has a Zacks Rank  3 and an Earnings ESP of  1 30   The company delivered a positive earnings surprise in the last four quarters  with an average beat of 1 12  and saw no earnings estimate revision over the past three months for the to be reported quarter  The stock has a solid Value and Growth Style Score of B each but a Momentum Style Score of D is unimpressive  The company is scheduled to report on Jan 26 before the opening bell     Gilead is expected to release earnings on Feb 6 after market close  It has a Zacks Rank  4 and an Earnings ESP of  1 37   Gilead delivered positive earnings surprises of 9 07  over the last four quarters and saw negative earnings estimate revision of 28 cents over the past three months for the to be reported quarter  Though it has a solid Value Style Score of A  a Growth and Momentum Style Score of F each looks ugly Bristol Myers will likely report earnings on Feb 5 before the opening bell  It has a Zacks Rank  3 and an Earnings ESP of  1 64   The stock delivered average positive earnings surprises of 2 72  over the past four quarter  and witnessed positive earnings estimate revision of three cents for the to be reported quarter  It has a solid Momentum and Growth Style Score of A and B  respectively  but an unfavorable Value Style Score of C Summing UpWith earnings surprises well in the cards  the healthcare sector is expected to witness earnings growth of 3  in the fourth quarter  suggesting some upside for healthcare ETFs  In particular  all the four ETFs have a Zacks ETF Rank  3 Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2018-01-21,Zacks Investment Research,https://www.investing.com/analysis/healthcare-etfs-to-watch-as-q4-earnings-unfold-200282431,200282431
150235,371751,AMGN,Novartis Announces Positive Results On Migraine Candidate ,opinion,"Novartis AG   NYSE NVS   announced positive results from the phase IIIb study  LIBERTY  which assessed the efficacy and safety of erenumab  AMG 334  140mg in patients with episodic migraine who had experienced two to four previous preventive treatment failures  due to lack of efficacy or intolerable side effects 
The study met its primary endpoint  with significantly more patients taking erenumab experiencing at least a 50  reduction from baseline in their monthly migraine days as compared to placebo  The trial met all secondary endpoints including reduction of monthly migraine days  lowering in days needing acute  rescue  medication  improvement in scores on the Migraine Physical Function Impact Diary  MPFID  tool  and 75  and 100  responder rates  number of patients experiencing at least a 75  or 100  reduction in monthly migraine days compared to placebo   The safety data are consistent with previous studies of erenumab to date  showing a placebo like safety profile 
Novartis will present full data at an upcoming scientific meeting 

 
Novartis  stock has rallied 3 2  in the last six months compared with the  s 10   gain 
Erenumab  an investigational fully human monoclonal antibody is designed to selectively block the calcitonin gene related peptide  CGRP  receptor  which plays a critical role in migraine activation  The candidate is being developed by Novartis in collaboration with Amgen  Inc    NASDAQ AMGN   
The candidate is the first investigational therapy targeting the CGRP pathway to have received Food and Drug Administration and European Medicines Agency  EMA  regulatory filing acceptance 
Upon approval  Novartis and Amgen will co commercialize erenumab in the United States  Amgen has exclusive commercialization rights to the drug in Japan and Novartis has exclusive rights to commercialize in the rest of the world 
Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Jadenu  and Kisqali  The recent approval of Kymriah for acute lymphoblastic leukemia is a major boost for Novartis given the potential in the CAR T therapy space  New products like Cosentyx and Entresto are expected to boost the top line  Cosentyx has been strong and the company has grabbed market shares from rivals like AbbVie  Inc  s   NYSE ABBV   Humira and Amgen s Enbrel 
Zacks Rank   Key Pick
Novartis currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is Exelixis  Inc    NASDAQ EXEL   with a Zacks Rank  1  Strong Buy   You can see  
Exelixis  earnings per share estimates have moved up from 72 cents to 73 cents for 2018 over the last 60 days  The company delivered a positive earnings surprise in the last four quarters  with an average beat of 572 92  
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-23,Zacks Investment Research,https://www.investing.com/analysis/novartis-announces-positive-results-on-migraine-candidate-200282839,200282839
150236,371752,AMGN,Novartis Gets Spark Therapeutics  Luxterna License Outside US,opinion,Novartis AG   NYSE NVS   entered into a licensing agreement with Spark Therapeutics to develop  register and commercialize Luxturna  voretigene neparvovec  in markets outside the United States We note Luxturna was approved in the United States on Dec 19  2017 as one time gene therapy to restore functional vision in children and adult patients with biallelic mutations of the RPE65  retinal pigment epithelial 65 kDa protein  gene The market authorization application was filed with the European Medicines Agency on July 31  2017 Novartis will make an upfront payment as well as pay milestones and royalties to Spark Therapeutics  Meanwhile  Spark Therapeutics will retain exclusive rights for Luxturna in the United States and will retain responsibility for obtaining approval in Europe  Spark Therapeutics will also be responsible for the supply of Luxturna under a separate manufacturing and supply agreement with Novartis We remind investors that the FDA approved Novartis  breakthrough gene transfer treatment  Kymriah suspension for the treatment of patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse   Kymriah has been launched in the United States Earlier in the week  Novartis reported encouraging results for the fourth quarter wherein results beat both earnings and sales estimates on strong performance of Cosentyx and Entresto  Psoriasis Cosentyx achieved multi blockbuster drug status in 2017 on the back of strong growth of three approved indications while Entresto s sales benefited from continued access improvements and expansion of sales force in the United States The generic division  Sandoz also combatted pricing pressure strongly buoyed by launches of Rixathon  the biosimilar version of Roche Holdings  Inc  s   OTC RHHBY   Rituxan  rituximab  and Erelzi  the biosimilar of Amgen  Inc  s   NASDAQ AMGN   Enbrel in EU  The proposed biosimilar version of AbbVie  Inc  s   NYSE ABBV   Humira  adalimumab  has also been accepted for review by the FDA Meanwhile  the strategic decision on Alcon to retain the business or separation via capital market transactions such as a spin off or an initial public offering has been postponed  The company believes that the Alcon division has revived well for now and hence a decision on a possible spin off will be taken in 2019  The recent approvals of Kymriah and Kisqali will further boost the oncology portfolio and drive growth Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-01-25,Zacks Investment Research,https://www.investing.com/analysis/novartis-gets-spark-therapeutics-luxterna-license-outside-us-200284045,200284045
150256,371772,AMGN,Here s Why Nektar Stock Skyrocketed Almost 500  In A Year,opinion,Shares of Nektar Therapeutics   NASDAQ NKTR   have increased a massive 483 7  in a year s time  substantially outperforming the  s gain of 11 9   Let s analyze the factors that led to this massive rally Nektar s rapid progress on a robust pipeline in a year accompanied with several study initiations  positive readouts and strategic collaborations has driven its share price consistently The company s PEGylation technology also facilitated development of several approved products in the United States and the EU through partnerships with healthcare companies namely AstraZeneca s   NYSE AZN   Movantik  UCB s Cimzia and Amgen s   NASDAQ AMGN   Neulasta  among others Furthermore  it has a robust pipeline of early and late stage candidates  Nektar has made a significant progress with its lead candidate Onzeald  formerly known as NKTR 102   which is currently under accelerated assessment in the EU  for treating adults with advanced breast cancer as well as brain metastases  A response is anticipated within the first half of 2018 Meanwhile  a randomized phase III confirmatory study  ATTAIN  began on Onzeald  late last year  The study compares Onzeald with the single agent chemotherapy of physician s choice on patients with advanced breast cancer having brain metastases of late  Positive results from the program are likely to support a regulatory filing in the United States Apart from Onzeald  Nektar is working on developing other candidates  In September 2017  the company announced initiation of phase I II PROPEL study to evaluate the efficacy and safety of its immuno oncology candidate  NKTR 214  in combination with Roche s Tecentriq  atezolizumab  and Merck s   NYSE MRK   Keytruda  pembrolizumab  A phase I II PIVOT study  evaluating NKTR 214 as a potential combination treatment regimen with Bristol Myers Squibb s Opdivo  is also underway across five tumor types  melanoma  kidney  colorectal  bladder and non small cell lung cancer  and eight potential indications In November 2017  the company announced positive data from PIVOT study for treating patients with melanoma  renal cell carcinoma and non small cell lung cancers Also  Nektar entered into a research collaboration with Takeda Pharmaceuticals to explore the combination of NKTR 214 with five oncology compounds from Takeda s cancer portfolio in May 2017 Another candidate  NKTR 181  is being examined in a phase III program for treatment of chronic pain  In July 2017  the company reported positive top line findings from an oral human abuse potential study  analysing NKTR 181  to assess the opioid abuse potential compared with oxycodone  It is planning to submit a new drug application for the candidate by April 2018 In March 2017  the company initiated a phase I clinical study  evaluating NKTR 358  to treat a wide range of auto immune diseases and inflammatory disorders Subsequently  in July 2017  Nektar sealed a co development deal with Elly Lilly and Company for NKTR 358  Pursuant to this agreement  the company will own responsibility for completing the ongoing phase I study on the candidate  Both the companies will share phase II development costs with Lilly acquiring the lion share  75   of the total expenses This year looks extremely favorable for the stock with several updates lined up  The expected approval of Onzeald in the EU for breast cancer and the submission of NDA for NKTR 181 should act as a catalyst to further drive the stock in 2018 Nektar Therapeutics Price   Zacks RankNektar carries a Zacks Rank  4  Sell  You can see  Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-01-18,Zacks Investment Research,https://www.investing.com/analysis/heres-why-nektar-stock-skyrocketed-almost-500-in-a-year-200281916,200281916
150274,371790,AMGN,Novartis Starts Trial On Psoriasis Drug Cosentyx Biosoimilar,opinion,"Novartis AG   NYSE NVS   initiated a head to head trial  SURPASS  on psoriasis drug  Cosentyx  The drug will be compared to its proposed biosimilar for the treatment of ankylosing spondylitis  AS  The trial is the first head to head clinical trial in AS investigating superiority of Cosentyx in slowing spinal bone damage compared with proposed biosimilar adalimumab We note that SURPASS and EXCEED are part of a larger rheumatology program for Cosentyx   In the head to head EXCEED trial  Cosentyx is being compared to AbbVie  Inc  s   NYSE ABBV   Humira in psoriatic arthritis  PsA   This trial is currently recruiting patients The trial is the first large double blinded head to head clinical trial versus Humira in PsA investigating superiority of Cosentyx on ACR 20 at 52 weeks as the primary endpoint   Novartis  stock have rallied 22 4  over a year compared with the  s 22  gain Cosentyx is the first targeted biologic that specifically inhibits IL 17A  cornerstone cytokine involved in the inflammation of entheses in spondyloarthritis  which plays a major role in PsA and AS The drug was approved for the treatment of active AS and PsA  The drug was approved for the treatment of moderate to severe plaque psoriasis The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals  Humira and and Amgen  Inc  s   NASDAQ AMGN   Enbrel  Cosentyx achieved blockbuster status in 2016 recording over  1 billion of sales  Novartis expects  2 billion of sales from Cosentyx in 2017 We note that Novartis has a strong oncology portfolio  The company s breast cancer portfolio includes drugs like Afinitor  Kisqali and Tykerb   Approval of new drugs and label expansion of existing drugs will further enhance its portfolio In March 2015  Novartis acquired certain oncology products and pipeline compounds from GlaxoSmithKline plc   NYSE GSK   for  16 billion  In exchange  the company sold its non influenza Vaccines business to Glaxo for  7 1 billion Meanwhile  Sandoz  the generic arm of Novartis  continues to advance its portfolio of biosimilars and generics Zacks RankNovartis currently carries a Zacks Rank  3  Hold   You can see 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-01-09,Zacks Investment Research,https://www.investing.com/analysis/novartis-starts-trial-on-psoriasis-drug-cosentyx-biosoimilar-200279157,200279157
150275,371791,AMGN,AstraZeneca s Asthma Drug Benralizumab Gets Approval In EU,opinion,AstraZeneca  plc   NYSE AZN   announced that the European Commission   EC   has granted approval to its asthma disease candidate  benralizumab  It is approved as an add on maintenance treatment for severe eosinophilic asthma in adult patients  It will be marketed by the trade name of Fasenra With this approval  Fasenra is the first respiratory biologic drug to have an 8 week maintenance dosing schedule  The drug will be available in a fixed dose subcutaneous injection via a prefilled syringe We remind investors that Fasenra received approval in the same indication in the United States in November last year  It is also under review in JapanAstraZeneca s shares have gained 25 1  in the past year  comparing favorably with the  s growth of 18 4  in that period The EC approved Fasenra based on data from the WINDWARD program  which included three phase III studies   SIROCCO  CALIMA and ZONDA Data from SIROCCO and CALIMA showed that Fasenra achieved significant reductions in exacerbations and improvements in lung function  Meanwhile  data from ZONDA study showed that Fasenra alone or in combination with standard of care  glucocorticoid  led to statistically significant and clinically relevant reduction in daily maintenance oral corticosteroid   OCS   compared with placebo Severe asthma patients whose disease is driven by inflammation of eosinophils  a type of white blood cell  have until now had only limited treatment options  mostly oral steroids  Fasenra  which distinctively targets and rapidly depletes eosinophils  has shown potential to reduce oral steroid use in such patients GlaxoSmithKline s   NYSE GSK   Nucala  subcutaneous administration  and Teva Pharmaceutical Industries    NYSE TEVA   Cinqair  intravenous infusion  are presently marketed for the same indication but administered once every four weeks Asthma is a chronic inflammatory disease of breathlessness and has a significant unmet medical need  This affects 315 million individuals worldwide and up to 10  of patients who have severe asthma  which can become uncontrolled despite receiving high doses of standard of care medicines and require the use of chronic OCS Benralizumab is also being evaluated for the treatment of chronic obstructive pulmonary disease   COPD   in late stage studies  Other severe asthma candidates in AstraZeneca s portfolio are tralokinumab and tezepelumab   in partnership with Amgen  Inc    NASDAQ AMGN   AstraZeneca s respiratory portfolio accounted for 23  of total product sales in the first nine months of 2017  The segment saw a decline in sales in the period due to competition and other market conditions  However  addition of another drug in the portfolio will certainly boost performance Astrazeneca  LON AZN  PLC Price   AstraZeneca carries a Zacks Rank  3  Hold   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-01-10,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-asthma-drug-benralizumab-gets-approval-in-eu-200279546,200279546
150276,371792,AMGN,Merck s Keytruda On A Roll  Can It Retain The Spark In 2018 ,opinion,With the rise in demand for immuno oncology drugs and their combinations  Merck   Co   Inc  s   NYSE MRK   anti PD 1 therapy  Keytruda  is fast becoming the key top line driver of the pharma giant Keytruda is marketed for many types of cancers and treatment settings including lung cancer  melanoma  head and neck cancer  classical Hodgkin s lymphoma and bladder cancer Having crossed the  1 billion mark in sales during the third quarter of 2017  Keytruda became the second largest product in the Merck portfolio  The treatment fetched in sales of  2 51 billion in the first nine months of 2017  up 174  year over year  This upside is driven by the global launch of new indications  which further boosts demand  Keytruda sales are gaining particularly from a strong momentum in the indication of first line lung cancer as the therapy is the only anti PD 1 approved in the first line setting The Keytruda development program also significantly advanced in 2017with regulatory approvals secured for six new indications in the United States  four in Europe and three in Japan  Key approvals for indications included advanced bladder cancer  advanced microsatellite instability high cancers and the first approval of a combination therapy with Eli Lilly s   NYSE LLY   cancer drugs Alimta  pemetrexed  and carboplatin  pem carbo  for first line lung cancer The new approvals expanded the patient population  driving up sales in the third quarter  This momentum should be maintained in the fourth quarter and in 2018 as well Meanwhile  Keytruda is being studied for more than 30 types of cancer in above 600 studies including excess of 400 combination trials  Merck is collaborating with several companies including Amgen  Inc    NASDAQ AMGN    Incyte  Glaxo and Pfizer  Inc    NYSE PFE    separately for the evaluation of Keytruda in combination with other regimens  Data from several programs on Keytruda were presented at medical conferences in 2017 We expect Merck to present data from several key Keytruda studies this year including a combination study with Incyte s epacadostat in first line metastatic melanoma  Also  Keytruda could get an approval for the relapsed or refractory primary mediastinal large B cell lymphoma indication this year with FDA action expected in April ConclusionMerck did witness some setbacks regarding Keytruda s pipeline program in 2017  In October  the company announced a delay in the readout from an important lung cancer study and postponed it to 2019  This was due to the inclusion of overall survival as a co primary endpoint in the KEYNOTE 189 phase III study of Keytruda in first line lung cancer  This in turn raised investor concern as the delay in the readout can give competitors a chance to gain traction in the lung cancer market Also  three combination studies of Keytruda on multiple myeloma were put on clinical hold  following reports of death in Keytruda groups last July Also Merck s top line has been lately hurt by a generic competition from several drugs and pricing pressure  We believe  Keytruda has immense commercial potential and coupled with some other newer drugs  can ease the impact of genericization  Although rivalry in the immuno oncology market has risen following FDA approval of newer oncology treatments like Pfizer s Bavencio  avelumab  for Merkel cell carcinoma  MCC  and bladder cancer indications and AstraZeneca s Imfinzi  durvalumab  for bladder cancer  we believe that Keytruda can give these drugs a tough run for money as there is ample scope for growth in the immuno oncology space Merck carries a Zacks Rank  3  Hold   You can see  Shares of Merck have declined 6 5  in a year against the  rally of 18 1    Zacks Editor in Chief Goes   All In   on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2018-01-11,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-on-a-roll-can-it-retain-the-spark-in-2018-200279910,200279910
150277,371793,AMGN,Ligand  LGND  Inks Deal With Glenmark For OmniAb Platform,opinion,Ligand Pharmaceuticals Incorporated   NASDAQ LGND   announced that it has inked a worldwide license agreement with global innovative pharmaceutical company  Glenmark Pharmaceuticals  Per the agreement  Glenmark will be able to use the full OmniAb platform for producing mono  and bispecific human therapeutic antibodies Ligand will be entitled to receive to receive annual platform access payments  development and regulatory milestone payments and tiered royalties for each product incorporating an OmniAb antibody  Meanwhile  Glenmark will be responsible for all costs related to the programs  With the latest deal  Glenmark will also be able to access a technology that includes three separate species in a single license Notably  this is the first new OmniAb deal to include OmniChicken in addition to OmniRat  OmniMouse and OmniFlic OmniAb includes three transgenic animal platforms consisting of four different technologies  OmniRat  OmniMouse OmniFlic and OmniChicken   for producing mono  and bispecific human therapeutic antibodies Ligand s shares have gained 39  in a year s time compared with the  s growth of 1 1  We remind investors that OmniAb  an antibody generating platform  became a part of Ligand s technology portfolio following its OMT  Inc  acquisition in January 2016 Ligand is focused on the development and licensing of biopharmaceutical assets  In fact  its Captisol formulation technology has allowed the company to enter into several licensing deals and generate royalties  Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility  stability  and bioavailability or lessen the volatility  irritation  smell or taste of drugs Other technology platforms at Ligand include LTP technology and Selexis technology  All these technologies along with Captisol and OmniAb have created a strong platform for the company to seek new licenses and partnerships  Also  Ligand has partnership agreements with leading healthcare companies like Novartis   NYSE NVS    Amgen  NASDAQ AMGN   Merck   NYSE MRK    Pfizer   NYSE PFE    Celgene  NASDAQ CELG   Gilead and Lilly  among others Ligand Pharmaceuticals Incorporated Price    Zacks Rank Ligand has a Zacks Rank  5  Strong Sell  You can see  Zacks Editor in Chief Goes  All In  on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2018-01-11,Zacks Investment Research,https://www.investing.com/analysis/ligand-lgnd-inks-deal-with-glenmark-for-omniab-platform-200279866,200279866
150278,371794,AMGN,Novartis  NVS  Announces Acceptance Of Humira BLA By The FDA,opinion,"Novartis AG   NYSE NVS   generic arm  Sandoz announced that the FDA accepted its Biologics License Application  BLA  for the proposed biosimilar of AbbVie  Inc    NYSE ABBV   Humira The biosimilar was submitted under the 351  k  pathway The drug is already approved for the treatment of a number of inflammatory diseases including rheumatoid arthritis  plaque psoriasis  Crohn s disease and ulcerative colitis The data package submitted to the FDA comprises analytical  preclinical and clinical data and is expected to demonstrate that Sandoz proposed biosimilar adalimumab matches the reference biologic in terms of safety  efficacy and quality  It also included a pharmacokinetic study in healthy volunteers and a phase III confirmatory safety and efficacy study in patients with moderate to severe chronic plaque type psoriasis   Novartis  stock has rallied 4  in the past one year compared with the  s 9 1  gain The biosimilar version of Humira is also under review in the EU  We note Sandoz holds a leading position in the biosimilars space with a portfolio of five marketed biosimilars currently and a deep pipeline The biosimilar version of rituximab  Rixathon  was approved by the European Commission in June 2017  It is currently under review in the United States Meanwhile  Sandoz witnessed strong growth outside the United States buoyed by launches of Rixathon and Erelzi  the biosimilars of Amgen  Inc  s   NASDAQ AMGN   Enbrel in Europe  However  pricing pressure intensified in the United States   The company expects low single digit sales decline at Sandoz in the fourth quarter  mainly due to seasonal shipment phasing and continued pricing pressures in the United States Meanwhile  Novartis is mulling strategic options for Alcon which includes retaining the business separation via capital market transactions such as a spin off or an initial public offering  The company believes that the Alcon division has revived well for now even though a separation via capital markets will create value for shareholders  On the other hand  Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Jadenu  and Kisqali  The recent approval of Kymriah for acute lymphoblastic leukemia is a major boost for Novartis given the potential in the CAR T therapy space Zacks Rank   Key PickNovartis currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is Exelixis  Inc    NASDAQ EXEL   with a Zacks Rank  1  Strong buy   You can see  Exelixis  earnings per share estimates have moved up from 72 cents to 73 cents for 2018 over the last 60 days  The company delivered a positive earnings surprise in the last four quarters  with an average beat of 572 92  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-01-15,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-announces-acceptance-of-humira-bla-by-the-fda-200280695,200280695
150282,371798,AMGN,Can AbbVie  ABBV  Stock Keep The Momentum Alive In 2018 ,opinion,AbbVie Inc    NYSE ABBV   shares are expected to be northbound in 2018  carrying on the momentum achieved last year  The stock was up 54 4  in 2017  comparing favorably with a gain of 16 3  recorded by the  AbbVie carries a Zacks Rank  2  Buy   You can see  Last year s share price surge was supported by a series of positive news  AbbVie met primary endpoints in several pivotal studies   the key phase III MURANO study of Venclexta plus Roche s   OTC RHHBY   Rituxan in relapse refractory chronic lymphocytic leukemia  three phase III studies evaluating oral JAK 1 selective inhibitor  upadacitinib for rheumatoid arthritis and also a phase IIb study in atopic dermatitis  and four pivotal head to head phase III studies evaluating risankizumab versus Johnson   Johnson s   NYSE JNJ   Stelara and Humira  for moderate to severe chronic plaque psoriasis Meanwhile  AbbVie gained regulatory approvals in the United States  Europe  and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for cancer drug Imbruvica in 2018 AbbVie also settled its patent disputes with Amgen   NASDAQ AMGN    which delayed the launch of the latter s biosimilar version of AbbVie s blockbuster arthritis drug  Humira in the United States to 2023 and in most countries in the EU to October 2018 This agreement has removed a major overhang on AbbVie s shares  Moreover  the agreement gave AbbVie ample time to focus on developing its pipeline and launching new products that will help make up for the loss of revenues once biosimilar Humira enters the market Factors Likely to Support the Rally in 2018With several pivotal data readouts and regulatory milestones expected in 2018  the bullish run of the stock should continue in 2018  An important catalyst for the stock will be data from a pivotal phase III  TRINITY  study on Rova T in third line or later small cell lung cancer  SCLC  in the first half of the year  An important regulatory milestone will be the FDA decision on elagolixin the second quarter  Please note that the new drug application  NDA  for elagolix for endometriosis was granted priority review by the FDA in October last year Importantly Humira has been generating strong sales  Despite new competition  AbbVie raised its long term target for Humira sales in October based on strong demand trends for the drug  Imbruvica  AbbVie s second most important drug  is also doing consistently well and has multibillion dollar potential  AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases  All these factors bode well for the stock Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-01-03,Zacks Investment Research,https://www.investing.com/analysis/can-abbvie-abbv-stock-keep-the-momentum-alive-in-2018-200277648,200277648
150283,371799,AMGN,3 Large Cap Pharma Stocks To Watch Out For This New Year,opinion,"The year 2017 has turned out to be pretty impressive for the pharma biotech stocks  Though the industry was hampered by drug pricing issues in 2016  it bounced back and made a considerable headway in 2017  courtesy of a slew of FDA approvals  The regulatory body approved 46 novel drugs last year  easily surpassing 2016 s total tally of 22 
Particularly  large cap players in the industry raked in stellar returns  up 15 8  in the last 12 months  Nonetheless  the same space also posted a 5 2  decline in 2016 
Upbeat quarterly results  rise in demand for new product sales  successful innovation and product line expansion  strong clinical study results as well as a continued strong performance of legacy products propelled the large cap drug sector to scale new highs in 2017  Moreover  these tailwinds are expected to drive the sector s growth in 2018 
Meanwhile  jubilant Republicans have of late passed the tax overhaul bill for the first time in 30 years  The bill slashes corporate tax rates from 35  to 21   Such tax reduction is likely to further boost profit margins of these companies with more cash left in hand  This  in turn can also be used for striking strategic deals this year  which were relatively fewer in 2017 
Notably  the  sub industry carries a Zacks Industry Rank of  104  placing it among the top 39  of the 265 plus Zacks industries  Our backtesting shows that the top 50  of the Zacks ranked industries outperforms the bottom half by a factor of more than two to one 
Banking on such positive trends  investing in sound large cap pharma stocks this year seems judicious  We have therefore identified three Large Cap stocks based on a favorable combination of a solid Zacks Rank  1  Strong Buy  or 2  Buy  and a strong VGM Score of A or B  These stocks are backed by sound fundamentals and ensure a steady stream of cash inflows 
Back tested results show that only stocks with an impressive  of A or B when combined with a bullish Zacks Rank of 1 or 2  offer the best upside potential 
Below are the selected three companies  poised to continue their winning streak this year 
AbbVie Inc    NYSE ABBV  
This Illinois based biopharmaceutical company is a lucrative option  The stock has a Zacks Rank  2  Buy  and a VGM Score of B  Shares of the company have soared 57 9  in a year s time  Moreover  the stock s earnings and sales are further estimated to increase 18 2  and 11 8   respectively  in 2018 

 
These positive trends were supported by a series of positive news in the past few months  AbbVie presented promising data from several pivotal studies  gained key regulatory approvals and settled its Humira patent disputes with Amgen   NASDAQ AMGN   
With several pivotal data readouts and regulatory milestones expected in 2018  the bullish run of the stock is expected to continue this year 
Novo Nordisk A S   NYSE NVO  
We also recommend Novo Nordisk  CO NOVOb   the Denmark based global healthcare company and a leader in the worldwide diabetes market   Shares of the company have surged 51 2  in a year s time  Moreover  the stock s earnings and sales are further estimated to increase 5 3  and 1 5   respectively  in 2018 
Currently the stock  with VGM Score of B  carries a Zacks Rank of 2  You can see  

 
Novo Nordisk has been in news for the past few months based on the encouraging progress of its diabetes pipeline  In December 2017  Novo Nordisk announced that the FDA has approved its semaglutide once daily pre filled pen to improve glycaemic control in type II diabetes patients  It will be marketed by the trade name of Ozempic 
The company expects to launch Ozempic in the United States in the beginning of 2018  Meanwhile  in September  the FDA had approved Fiasp  fast acting insulin aspart  for treating adults with diabetes 
In August  the FDA had approved label expansion of the company s diabetes drug  Victoza  now approved to reduce the risk of major adverse cardiovascular events in adults with type II diabetes 
The company s label expansion efforts and the corresponding approvals bode well for its growth 
Roche Holding  SIX ROG  AG   OTC RHHBY  
Investors can count on Switzerland based Roche Holding with a VGM Score of B  The company is a Zacks  2 Ranked player with its shares having gained 10 1  in the last 12 months 

 
Roche dominates the breast cancer space with strong demand for its HER2 franchise drugs like Herceptin  Perjeta and Kadcyla  The company also has a dominant position in lung cancer market 
The company is looking for a label expansion of drugs namely  Actemra  which was approved for the treatment of giant cell arteritis last May  This is the sixth FDA approval for Actemra since the medicine was launched in 2010 
Moreover  the recent FDA approval of Hemlibra for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with haemophilia A is encouraging  Also  the potential acquisition of Ignyta   announced a couple of weeks earlier   is likely to strengthen Roche  s pipeline as the integration will add a mid stage cancer candidate entrectinib to its portfolio 
Continuous label expansions of key drugs  regular approvals and a robust pipeline are expected to drive the stock in 2018 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-04,Zacks Investment Research,https://www.investing.com/analysis/3-largecap-pharma-stocks-to-watch-out-for-this-new-year-200277843,200277843
150285,371801,AMGN,ImmunoGen Starts Phase I Study On Leukemia Candidate IMGN632,opinion,ImmunoGen  Inc    NASDAQ IMGN   announced that it has initiated a phase I study to evaluate its anti CD123 antibody drug conjugates  ADCs   IMGN632  for treating patients with hematological malignancies including acute myeloid leukemia  AML  and blastic plasmacytoid dendritic cell neoplasm Notably  IMGN632 uses the company s indolino benzodiazepine cancer killing agents known as IGNs This is ImmunoGen s second IGN ADC to move into clinical development  the first being IMGN779  a CD33 targeting ADC  already evaluated in a phase I study for the treatment of AML We remind investors that the FDA has completed the safety review of the investigational new drug  IND  application for IMGN632 in October last year  which was filed by the company in mid September for the aforementioned indications  The IND application was supported by positive data from preclinical studies  which demonstrated IMGN63 s promising activity against AML cells while sparing normal bone marrow cells ImmunoGen s shares have significantly outperformed the  year to date  The stock has skyrocketed 185 6  compared with the industry s 8 1  increase during the same time frame The phase I study will follow a dose regime of IMGN632 once every three weeks  Thereafter  the selected dose will be evaluated in expansion cohorts in patients with the above mentioned hematologic malignancies We remind investors that ImmunoGen had earlier entered into a strategic collaboration and option agreement with Jazz Pharmaceuticals PLC   NASDAQ JAZZ   in August for the development and commercialization of IMGN632  The collaboration also includes IMGN779 Notably  ImmunoGen is focused on developing targeted cancer therapeutics using its proprietary ADC technology  In fact  this innovative technology of the company is also used in Roche s   OTC RHHBY   marketed product  Kadcyla  and in three other development stage candidates in its pipeline Additionally  the ADC technology is used in development programs by ImmunoGen s partners Amgen   NASDAQ AMGN    Bayer AG  DE BAYGN   Biotest  CytomX  Eli Lilly  Novartis  Sanofi  PA SASY  and Takeda ImmunoGen  Inc  Price   Zacks RankImmunoGen carries a Zacks Rank  3  Hold   You can see  Zacks Editor in Chief Goes  All In  on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2018-01-05,Zacks Investment Research,https://www.investing.com/analysis/immunogen-starts-phase-i-study-on-leukemia-candidate-imgn632-200278020,200278020
150289,371805,AMGN,Merck s  MRK  Keytruda Succeeds In High Risk Melanoma Study,opinion,Merck   Co   Inc    NYSE MRK   announced that a phase III study evaluating its anti PD 1 therapy  Keytruda as monotherapy for the treatment of high risk melanoma met the primary endpoint of recurrence free survival  RFS  Keytruda is already approved for many types of cancers and treatment settings including lung cancer  melanoma  head and neck cancer  classical Hodgkin s lymphoma and bladder cancer Interim data from the KEYNOTE 054 study showed that treatment with Keytruda  as an adjuvant therapy in surgically resected high risk melanoma patients  led to significantly improved RFS compared to placebo  In other words  Keytruda showed the potential to extend the duration before the disease recurs in high risk melanoma patients The study will continue to evaluate other key endpoints  including overall survival  Results from the study will be submitted to regulatory authorities and also be presented at a future medical meeting Merck is conducting the study in collaboration with The European Organisation for Research and Treatment of Cancer  EORTC  Shares of Merck have declined 5 4  in the past year against the  surge of 16 9  Keytruda  the second largest product in the Merck portfolio  is a key top line driver for Merck  In fact  Keytruda is continuously growing and expanding into new indications and markets globally  The Keytruda development program also significantly advanced in 2017 with several key regulatory approvals  which should further drive sales in 2018 Keytruda is being studied for more than 30 types of cancer in more than 550 studies  including over 300 combination studies  Merck is collaborating with several companies including Amgen  Inc    NASDAQ AMGN    Incyte  Glaxo   NYSE GSK   and Pfizer  Inc    NYSE PFE   separately for the evaluation of Keytruda in combination with other regimens In another press release  Merck announced that the FDA has accepted the new drug application  NDA  for its investigational candidate  doravirine  a non nucleoside reverse transcriptase inhibitor  NNRTI   for the treatment of HIV 1 infection Merck is looking to get doravirine approved as a once daily single tablet in combination with other antiretroviral agents and also as a once daily fixed dose combination regimen containing doravirine  lamivudine  3TC  and tenofovir disoproxil fumarate  TDF   DOR 3TC TDF   The FDA is expected to give its decision on both the applications on Oct 23  2018 Merck carries a Zacks Rank  3  Hold   You can see    Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2018-01-08,Zacks Investment Research,https://www.investing.com/analysis/mercks-mrk-keytruda-succeeds-in-highrisk-melanoma-study-200278907,200278907
150292,371808,AMGN,Amgen Announces Acceptance Of MAA For Evenity In Europe,opinion,"Amgen   NASDAQ AMGN   and its partner UCB announced that the marketing authorization application   MAA   seeking approval of Evenity for treating osteoporosis has been accepted by the European Medicine Agency   EMA    Amgen is looking to get Evenity approved for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture in Europe Shares of the company have increased 13 7  in the past year  outperforming the  s decline of 3 4  in that period The MAA included data from three pivotal phase III studies   FRAME  ARCH and BRIDGE   in postmenopausal women with osteoporosis  postmenopausal women with osteoporosisat high risk for fracture and men who have osteoporosis Evenity treats osteoporosis by increasing bone formation and reducing bone resorption simultaneously  which increases bone mineral density   BMD   and reduces the risk of fracture In the ARCH study  Evenity showed statistically significant superior fracture risk reduction in postmenopausal women compared to current standard of care for osteoporosis  Merck   Co   Inc  s   NYSE MRK   Fosamax The EMA will review the potential of Evenity in increasing BMR as well as reducing risk of fracture and also cardiovascular safety signal from ARCH study We remind investors that the biologics license application   BLA   seeking approval of Evenity for the same indication in the United States was issued a complete response letter   CRL   by the FDA in July 2017  The CRL was issued due to a cardiovascular side effect observed in the ARCH study  The BLA included data only from FRAME study and the FDA has requested a resubmission of the application with additional data from ARCH and BRIDGE study In a separate press release  Amgen reported that Mechelen  Belgium based Biocartis Group has signed a development agreement with Amgen for developing the former s Idylla TM  CDx biomarker tests for analyzing novel oncology compound  which can be used for the treatment of certain solid tumors Amgen Inc  Price
    Zacks Rank   Stocks to ConsiderAmgen currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the pharma sector include Celldex Therapeutics  Inc    NASDAQ CLDX   and Catabasis Pharmaceuticals  Inc    NASDAQ CATB    Both the stocks carry a Zacks Rank  2  Buy   You can see  Celldex s loss estimates remained stable at 93 cents for 2017 and at 90 cents for 2018 in the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15 36  Catabasis s loss estimates narrowed from  1 39 to  1 37 for 2017 and from  1 09 to 89 cents for 2018 over the last 30 days  The company delivered a positive earnings surprise in the trailing four quarters with an average beat of 9 94  Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2018-01-08,Zacks Investment Research,https://www.investing.com/analysis/amgen-announces-acceptance-of-maa-for-evenity-in-europe-200278906,200278906
150293,371809,AMGN,Merck s Keytruda Combo Gets Breakthrough Therapy Status,opinion,"Merck   NYSE MRK   and Japanese partner Easai Co   Ltd announced that the FDA has granted breakthrough therapy designation   BTD   to the combination regimen of Merck s anti PD 1 therapy  Keytruda  and Easai s multiple receptor tyrosine kinase inhibitor  Lenvima The companies are developing the combination as a potential treatment for advanced and or metastatic renal cell carcinoma   RCC   or kidney cancer This is the 12th BTD for Keytruda and second for Lenvima The designation aims to expedite the development and review of drugs intended to treat serious or life threatening conditions and provide patients access to these as soon as possible Merck s shares have decreased 5 2  in the past year  underperforming the  s gain of 16 8  during that period The FDA granted the BTD to the combination regimen based on data from the RCC arm of the open label phase Ib II study  Study 111  which is currently evaluating Keytruda Lenvima in six cancer indications While Keytruda is Merck s blockbuster immunotherapy drug approved for several cancer indications  Easai s Lenvima is approved as a single agent for treating differentiated thyroid cancer and in combination with Novartis    NYSE NVS   chemo drug  Afinitor  everolimus   for advanced RCC following one prior anti angiogenic therapy Apart from Lenvima  Merck has collaborated with several companies including Amgen  Inc    NASDAQ AMGN    Incyte  Glaxo and Pfizer  Inc    NYSE PFE   separately for the evaluation of Keytruda in combination with other regimens Merck   Company  Inc  Price
    Merck carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-01-09,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-combo-gets-breakthrough-therapy-status-200279190,200279190
150315,371831,AMGN,Pfizer s Arthritis Drug Gets FDA Nod For Label Expansion,opinion,Pfizer Inc    NYSE PFE   announced that the FDA has approved a label expansion for its janus kinase  JAK  inhibitor  Xeljanz  tofacitinib   for two doses   5 mg twice daily and 11 mg once daily extended release  XR  formulation With this latest approval  Xeljanz can now be administered for treating adult patients with active psoriatic arthritis  PsA   who had an inadequate response to conventional synthetic disease modifying antirheumatic drugs  csDMARDs  and tumor necrosis factor inhibitors  respectively Notably  Xeljanz  5 mg twice daily  is approved in the United States as a second line treatment option for patients with moderate to severely active rheumatoid arthritis   RA    who have had an inadequate response to or cannot tolerate methotrexate  MTX   The drug was approved in Europe and China in March for RA  Significantly  this is the first and only JAK inhibitor approved in the United States for both moderate to severe RA and an active PsA Shares of Pfizer have gained 12 3  so far this year  underperforming the  s rally of 16 5  A supplemental new drug application  sNDA  for Xeljanz was filed with the FDA in May this year for the aforementioned indication  The approval was based on encouraging data from two phase III OPAL  Oral Psoriatic Arthritis TriaL  studies   Broaden and Beyond   on Xeljanz Both OPAL Broaden and OPAL Beyond trials evaluated the efficacy and safety of Xeljanz on adult patients with PsA  The programs achieved the primary efficacy endpoint of a statistically significant improvement with twice daily Xeljanz 5 mg compared with placebo at three months as per measurement by American College of Rheumatology 20 response and the change from baseline in the Health Assessment Questionnaire Disability Index score Overall safety results from these studies were found to be consistent with those observed in the broader rheumatology development program for Xeljanz We remind investors that the company is also looking to get the drug s label expanded to include treatment of adult patients suffering from moderate to severe active ulcerative colitis  A response from the FDA is expected in March next year Additionally  Pfizer is conducting a phase IIIb IV head to head study comparing Xeljanz with AbbVie s   NYSE ABBV   Humira  In February  the company announced top line results from the assessment  Outcomes from the trial demonstrated non inferiority of combo therapy comprising Xeljanz plus MTX compared with the other combo agents Humira plus MTX  thus meeting the primary endpoint We are encouraged by Pfizer s label expansion efforts  Xeljanz s U S  sales surged 44  year over year to  935 million in the first nine months of 2017  The drug s label expansion should boost further the sales Blockbuster drugs approved to treat PsA and RA include Johnson   Johnson s   NYSE JNJ   Remicade and Amgen  Inc  s   NASDAQ AMGN   Enbrel that Pfizer markets outside the United States and Canada In another Pfizer press release  the company announced that it has started a phase III study  evaluating the efficacy and safety of its once daily janus kinase 1  JAK1  inhibitor  PF 04965842  for treatment of moderate to severe atopic dermatitis  This initiation surfaces as the first trial in the JAK1 Atopic Dermatitis Efficacy and safety global development program Pfizer  Inc  Price   Zacks RankPfizer carries a Zacks Rank  3  Hold   You can see  Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ,2017-12-15,Zacks Investment Research,https://www.investing.com/analysis/pfizers-arthritis-drug-gets-fda-nod-for-label-expansion-200273714,200273714
150316,371832,AMGN,Merck s Keytruda Misses Primary End Point For Gastric Cancer,opinion,Merck   NYSE MRK   announced disappointing results from a pivotal phase III KEYNOTE 061 study  evaluating its anti PD 1 therapy  Keytruda  pembrolizumab   as a second line treatment for patients with advanced gastric or gastroesophageal junction   GEJ   adenocarcinoma Notably  Keytruda is already approved in the United States as a monotherapy for third line treatment of advanced gastric or GEJ  Additionally  it is approved for many types of cancers and treatment settings including lung cancer  melanoma  head and neck cancer  classical hodgkin lymphoma and bladder cancer Shares of Merck has lost 4 9  this year so far compared unfavorably with the  s 16 5  increase The phase III study failed to meet its primary endpoint of overall survival  OS   Notably  the progression free survival  PFS  showed no statistical significance in the PD L1 positive patient population However  the company said that it will continue to evaluate Keytruda in two other phase III studies  both as a monotherapy as well as in combination with chemotherapy as a first line treatment for patients with GEJ We remind investors that Keytruda is a key top line driver for Merck and it brought in  1 5 billion sales in third quarter 2017  up 18 8  sequentially and 194  year over year  Sales continue to be driven by a launch of new indications globally Significantly  Keytruda sales in the United States have gained particularly from a strong momentum in the new indication of first line lung cancer  The drug s sales were primarily driven by melanoma outside the United States Meanwhile  the Keytruda development program also significantly advanced this year with regulatory approvals for four new indications in the United States and two additional diseases in Europe Important approvals include nods for advanced bladder cancer in both the United States and the EU  advanced microsatellite instability high cancers and the first sanction for a combination therapy with Eli Lilly   Company s   NYSE LLY   cancer drug Alimta  pemetrexed  and carboplatin  pem carbo   a commonly used chemo regimen in lung cancer Keytruda is continuously growing and expanding into new indications and markets globally  It is under trial for more than 30 types of cancer in above 650 studies including excess of 300 combination studies Merck is collaborating separately with several companies namely Amgen  Inc    NASDAQ AMGN    Incyte  Glaxo and Pfizer  Inc    NYSE PFE   for the evaluation of Keytruda in combination with other regimens Merck   Company  Inc  Price   Zacks RankMerck carries a Zacks Rank  3  Hold   You can see  Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ,2017-12-15,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-misses-primary-end-point-for-gastric-cancer-200273713,200273713
150317,371833,AMGN,Why Is Nektar  NKTR  Stock Up More Than 350  This Year ,opinion,Shares of Nektar Therapeutics   NASDAQ NKTR   have skyrocketed almost 368  this year so far  substantially outperforming the  s increase of 8 2   Let s analyze the factors that led to this massive rally Nektar s rapid progress on a robust pipeline this year including several study initiations with positive readouts and strategic collaborations has driven its share price consistently The company s PEGylation technology has facilitated development of its several approved products in the United States and the EU through partnerships with healthcare companies namely  AstraZeneca s   NYSE AZN   Movantik  UCB s Cimzia and Amgen s   NASDAQ AMGN   Neulasta among others Notably  a randomized phase III confirmatory study  ATTAIN  began on the company s lead candidate  Onzeald  late last year  The trial compares Onzeald with the single agent chemotherapy of physician s choice in patients with advanced breast cancer having brain metastases shortly  Positive results from the program could support a regulatory filing in the United States Apart from Onzeald  Nektar is working on developing other candidates  In September  the company announced initiation of phase I II PROPEL study to evaluate the efficacy and safety of NKTR 214 in combination with Roche s Tecentriq  atezolizumab  and Merck s   NYSE MRK   Keytruda  pembrolizumab  A phase I II trial  evaluating NKTR 214 as a potential combination treatment regimen with Bristol Myers Squibb s Opdivo  is also underway  The candidate is being examined across five tumor types  melanoma  kidney  colorectal  bladder and non small cell lung cancer  and eight potential indications In November  the company announced positive data from the study for treating patients with melanoma  renal cell carcinoma and non small cell lung cancers Significantly in May  the company entered into a research collaboration with Takeda Pharmaceuticals to explore the combination of NKTR 214 with five oncology compounds from Takeda s cancer portfolio Another candidate  NKTR 181  is being examined in a phase III program for treatment of chronic pain  In July  the company reported positive top line findings from an oral human abuse potential study  analysing NKTR 181  to assess the opioid abuse potential compared with oxycodone  The company is planning to submit a new drug application for the candidate by April 2018 Meanwhile  in March  the company initiated a phase I clinical study  evaluating NKTR 358  to treat a wide range of auto immune diseases and inflammatory disorders Subsequently  in July  Nektar sealed a co development deal with Elly Lilly and Company for NKTR 358  Pursuant to this agreement  the company will own responsibility for completing the ongoing phase I study on the candidate  Both the companies will share phase II development costs with Lilly acquiring the lion share  75   of the total expenses Successful development and commercialization of undertrial candidates will boost the company s top line  considering the lucrative markets they are targeting Nektar carries a Zacks Rank  3  Hold  You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-12-21,Zacks Investment Research,https://www.investing.com/analysis/why-is-nektar-nktr-stock-up-more-than-350-this-year-200275413,200275413
150318,371834,AMGN,Watch This Biotech Play For A Possible Short Trade,opinion,"Shares of Amgen  NASDAQ AMGN  have almost formed a head and shoulder pattern  which is a bearish setup  If when the neck line breaks to the downside  the head and shoulder pattern has serious downside  In Amgen s case  if the stock breaks the neck line  price could fall within weeks to below  150 
Hurry Up And Wait
Just remember that Amgen is not yet a short because it hasn t broken the trend line  I m watching this pattern formation in case it breaks  That s when I may step in to AMGN ",2017-12-27,Gareth Soloway,https://www.investing.com/analysis/watch-this-biotech-play-for-a-possible-short-200276146,200276146
150335,371851,AMGN,AbbVie Stock Up More Than 30  So Far In 2H17  Here s Why,opinion,AbbVie Inc    NYSE ABBV   shares have gained 32 1  so far in the second half of the year  comparing favorably with a gain of only 3 8   recorded by the  The share price surge was supported by a series of positive news in the past few months  AbbVie presented promising data from several pivotal studies  gained key regulatory approvals and settled its Humira patent disputes with Amgen Resolution of Amgen LawsuitAbbVie announced the resolution of a patent dispute with Amgen Inc    NASDAQ AMGN   in September  which has delayed the launch of the latter s biosimilar version of AbbVie s blockbuster arthritis drug  Humira in the United States to 2023 and in most countries in the EU to October 2018 This agreement has removed a major overhang on AbbVie s shares though the company is still facing a patent challenge from Boehringer Ingelheim  which gained approval for its biosimilar version of Humira  Cyltezo  in August  Moreover  the agreement gives AbbVie ample time to focus on developing its pipeline and launching new products that will help make up for the loss of revenues once biosimilar Humira enters the market Key Regulatory ApprovalsAbbVie s 8 week  pan genotypic  ribavirin free  once daily HCV treatment  Mavyret Maviret  gained approval in the United States  EU and Canada in the third quarter of 2017  Mavyret  AbbVie s next generation HCV program  is a combination of glecaprevir  a potent protease inhibitor and pibrentasvir  a NS5A inhibitor  Maviret has the potential to rejuvenate growth in the HCV franchise  According to AbbVie  Mavyret may be used in up to 95  of HCV patients  depending on the stage of liver disease and prior treatment history In August  AbbVie gained approval for the sixth indication for Imbruvica  The drug was approved for chronic graft versus host disease  GVHD   a serious and potentially life threatening condition with high unmet medical need  cGVHD is the first indication of Imbruvica outside of cancer  Also  Imbruvica is the first treatment specifically approved for cGVHD Positive Data from StudiesAbbVie announced positive data from the phase III MURANO study of Venclexta plus plus Roche s   OTC RHHBY   Rituxan in relapse refractory CLL last month  The data showed that Venclexta plus Rituxan met the primary endpoint of prolonged progression free survival compared with Treanda  bendamustine  plus Rituxan in patients with relapsed refractory chronic lymphocytic leukemia   CLL     Label expansion for this indication should expand the patient population for Venclexta significantly and boost its commercial potential AbbVie s oral JAK 1 selective inhibitor  upadacitinib  ABT 494  met primary endpoints in a phase III study for the treatment of RA with highly statistically significant and clinically meaningful results for both the doses  15 mg and 30 mg  of upadacitinib compared to placebo  Upadacitinib also met primary endpoints in a phase IIb study for the treatment of adult patients with atopic dermatitis  also known as eczema  The company plans to advance the candidate into phase III studies next year  Data from both the upadacitinib studies were announced in September In October  AbbVie announced that three pivotal head to head phase III studies evaluating risankizumab versus Johnson   Johnson s   NYSE JNJ   Stelara and Humira  for the treatment of moderate to severe chronic plaque psoriasis  met all co primary and secondary endpoints ConclusionWith several pivotal data readouts and regulatory milestones expected in 2018  the bullish run in the stock should continue next year  Importantly Humira has been generating strong sales  Despite new competition  AbbVie raised its long term target for Humira sales in October based on strong demand trends for the drug  Imbruvica  AbbVie s second most important drug  is also doing consistently well and has multibillion dollar potential  AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases  All these factors bode well for the stock AbbVie carries a Zacks Rank  3  Hold   You can see The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2017-11-29,Zacks Investment Research,https://www.investing.com/analysis/abbvie-stock-up-more-than-30-so-far-in-2h17-heres-why-200269450,200269450
150336,371852,AMGN,Amgen s PCSK9 Inhibitor Gets FDA Nod For Stroke Prevention,opinion,"Amgen  Inc    NASDAQ AMGN   announced that the FDA has approved its regulatory application seeking approval to include data from the cardiovascular outcomes study  FOURIER  on the label of its PCSK9 inhibitor  Repatha With the label expansion  Repatha can now be prescribed to prevent heart attacks  strokes and coronary revascularizations in patients with established cardiovascular disease This year so far  Amgen s shares are up 21 2   better than 2 6  increase registered by the    Data from the phase IIIFOURIER study  presented in the first quarter  had revealed significant reduction in myocardial infarctions and strokes on treatment with Repatha compared with the current best therapy alone Repatha significantly reduced risk of hard MACE  heart attack  stroke or cardiovascular death  by 20  compared to the standard treatment with statin therapy  For individual components  risks of heart attack  stroke and coronary revascularization were nominally reduced by 27   21  and 22   respectively  with Repatha However  Repatha did not show any improvement in cardiovascular death risk  which had raised investor concerns then Notably  Repatha gained an FDA approval in August 2015  for the treatment of patients  incapable of managing their LDL cholesterol at acceptable levels  It is approved in over 50 countries  including the United States  Japan  Canada and overall  28 member countries of the European Union for the given indication However  uptake of the drug has not been very encouraging so far due to higher pricing and re imbursement issues payer restrictions  Sanofi   NYSE SNY   and partner Regeneron Pharmaceuticals  Inc    NASDAQ REGN   also faced similar issues with their PCSK9 inhibitor  Praluent The FOURIER data holds the key to the commercial success of Repatha as it will broaden the use of the drug  With the cardiovascular indication approved to be included in Repatha s label  patient access to the drug should improve Amgen filed regulatory applications in both the United States and EU to include FOURIER data on Repatha s label in June 2017  In July  the FDA had granted priority review forthe regulatory application Amgen currently carries a Zacks Rank  3  Hold   You can see A better ranked large cap pharma stock is Johnson   Johnson   NYSE JNJ    which has a Zacks Rank  2  Buy  Shares of J J have risen 21 5  this year so far while 2018 earnings estimates have gone up 0 7  in the past 60 days 
Zacks  Best Private Investment Ideas
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public 
Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-12-03,Zacks Investment Research,https://www.investing.com/analysis/amgens-pcsk9-inhibitor-gets-fda-nod-for-stroke-prevention-200270275,200270275
150337,371853,AMGN,Mylan Up On FDA Approval   Amazon s Rumored Pharmacy Interest,opinion,Mylan N V    NASDAQ MYL   and its India based partner Biocon announced that the FDA has approved their biosimilar version of Roche s   OTC RHHBY   Herceptin  trastuzumab   The biosimilar will be available under the tradename of Ogivri and will include all indications of Herceptin in its label including HER 2 positive breast cancer and metastatic stomach cancer Mylan is also seeking approval for Herceptin s biosimilar in Europe  The company announced the acceptance of Marketing Authorization Application   MAA   for the biosimilar on Friday by the European Medicines Agency   EMA    Another MAA is looking to get approval for a biosimilar to Amgen Inc  s   NASDAQ AMGN   neutropenia drug  Neulasta  However  the FDA has issued a complete response letter to the biologics license application seeking approval for a biosimilar version of Neulasta in the United States Meanwhile  Amazon  NASDAQ AMZN  is exploring its options to enterthe pharmaceutical segment  per a report by CNBC  Amazon may first focus on distributing generics   It is reportedly in preliminary talks with generic makers like Mylan and Sandoz  Novartis    NYSE NVS   generic arm Mylan s shares were up 4 45  on Friday on rumours about Amazon s plan to enter pharmacy segment  Meanwhile  shares of the company have declined 0 1  so far this year  outperforming the  s fall of 29 7  in that period Ogivri is the first approved biosimilar of Herceptin in the United States  Earlier in March  Mylan received global license to trastuzumab product from Roche allowing it to commercialize the biosimilar worldwide Mylan is already a leading supplier of cancer medications  The company s supply network may help Ogivri reach patients quickly  boosting its prospects  A potential approval in Europe will provide a further boost In a separate press release  Mylan announced that the FDA has approved its generic version of for blood thinner  Heparin  Mylan is focused on developing generics biosimilars of popular drugs with 16 biosimilars in its portfolio  Per the press release  Mylan currently has 211 abbreviated new drug applications under review  which represent  93 2 billion in annual brand sales Mylan N V  Price   Mylan carries a Zacks Rank  3  Hold   You can see  Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-12-03,Zacks Investment Research,https://www.investing.com/analysis/mylan-up-on-fda-approval--amazons-rumored-pharmacy-interest-200270200,200270200
150338,371854,AMGN,AbbVie Psoriasis Candidate Succeeds In 4th Phase III Study,opinion,AbbVie  Inc    NYSE ABBV   announced that a fourth pivotal phase III study evaluating its investigational IL 23 inhibitor  risankizumab for the treatment of moderate to severe chronic plaque psoriasis  met all co primary and secondary endpoints Top line data from the IMMhance study showed that a significant portion of patients treated with risankizumab achieved high levels of skin clearance  Nearly half  47   of the patients treated with risankizumab achieved complete skin clearance versus placebo  1   after 16 weeks of treatment On continuous treatment with risankizumab  at week 28  87  of the risankizumab patients maintained this response for one year  This data shows that patients can achieve better disease improvement over time on continuous treatment with risankizumab rather than withdrawing from the therapy after an initial response  Results from this study will support regulatory filings for the candidate The 16 week results from this study were presented at the 8th International Congress of Psoriasis from Gene to Clinic meeting in London AbbVie had in licensed risankizumab from Boehringer Ingelheim in 2016  AbbVie is responsible for the future development and commercialization of the candidate We remind investors that in October  AbbVie had announced that three pivotal head to head phase III studies evaluating risankizumab versus Johnson   Johnson s   NYSE JNJ   Stelara and AbbVie s Humira  for the treatment of moderate to severe chronic plaque psoriasis  met all co primary and secondary endpoints  Top line data presented from the studies showed that risankizumab achieved significantly greater response of clear or almost clear skin versus Stelara and Humira or placebo after 16 weeks of treatment Risankizumab is also being evaluated in phase II studies for other immunological disorders like Crohn s disease and psoriatic arthritis AbbVie s shares have gained 52  so far this year  comparing favorably with a gain of only 16 5   recorded by the  The share price surge was supported by a series of positive news in the past few months  AbbVie presented promising data from several pivotal studies  gained regulatory approvals in the United States  Europe  and Japan for its competitive HCV medicine  Mavyret  received FDA approval for the sixth indication for Imbrivicaand settled its Humira patent disputes with Amgen  Inc    NASDAQ AMGN   AbbVie carries a Zacks Rank  3  Hold   You can see A better ranked large cap pharma stock is H  Lundbeck A S   OTC HLUYY    carrying a Zacks Rank  2  Buy  Shares of Lundbeck have risen 21 7  so far this year while 2018 earnings estimates have gone up 3 2  in the past 30 days Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-12-04,Zacks Investment Research,https://www.investing.com/analysis/abbvie-psoriasis-candidate-succeeds-in-4th-phase-iii-study-200270738,200270738
150339,371855,AMGN,AbbVie J J s Imbruvica Succeeds In Combo Study With Rituxan,opinion,AbbVie Inc    NYSE ABBV   and partner Janssen  Johnson   Johnson s   NYSE JNJ   pharmaceuticals subsidiary  announced that a combination study evaluating their key cancer drug Imbruvica in Waldenstr m s macroglobulinemia  WM   a rare form of non Hodgkin s lymphoma  met the primary endpoint Interim data from the phase III iNNOVATE study showed that a combination of Imbruvica and Roche s   OTC RHHBY   Rituxan led to improved progression free survival  PFS  in treatment naive and previously treated patients with WM compared to Rituxan alone  Based on the early positive results  the Independent Data Monitoring Committee  IDMC  recommended an unblinded study  AbbVie and J J plan to discuss the positive interim data with regulatory authoritiesImbruvica is already approved as a monotherapy for the treatment of WM  In fact  including WM  Imbruvica is presently approved for six distinct patient populations including mantle cell lymphoma  MCL   small lymphocytic lymphoma  SLL   chronic lymphocytic leukemia  CLL   marginal zone lymphoma  MZL  and chronic graft versus host disease  GVHD  Imbruvica was added to AbbVie s pipeline with the May 2015 acquisition of Pharmacyclics  It has become a key revenue driver for AbbVie  In 2017  AbbVie expects to record Imbruvica global revenues of more than  2 4 billion with sales in the United States expected to cross  2 billion  In the first nine months of 2017  Imbruvica had recorded sales of  1 87 billion  representing growth of 41 2  year over year   In fact  AbbVie expects Imbruvica peak sales of more than  7 billion and revenues of about  5 billion in 2020At present  the CLL segment is the largest revenue contributor to Imbruvica s growth while expansion into non Hodgkin s lymphoma  NHL  and other indications will be major growth drivers in the future Imbruvica has multi billion dollar potential and AbbVie is exploring the potential to expand its label into solid tumors and autoimmune diseases  Imbruvica is in phase III studies for diffuse large B cell lymphoma and follicular lymphoma  AbbVie is positioning Imbruvica as a  pipeline in a molecule  with the treatment featuring in several company sponsored studies AbbVie s shares have gained 52 3  so far this year  comparing favorably with a gain of only 15  recorded by the  The share price surge was supported by a series of positive news in the past few months  AbbVie presented promising data from several pivotal studies  gained regulatory approvals in the United States  Europe  and Japan for its competitive HCV medicine  Mavyret  received FDA approval for the sixth indication for Imbruvicaand settled its Humira patent disputes with Amgen  Inc    NASDAQ AMGN   AbbVie carries a Zacks Rank  3  Hold   You can see Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-12-05,Zacks Investment Research,https://www.investing.com/analysis/abbviejjs-imbruvica-succeeds-in-combo-study-with-rituxan-200270983,200270983
150340,371856,AMGN,Sanofi Begins Combo Studies On Multiple Myeloma Candidate,opinion,Sanofi  PA SASY   Inc    NYSE SNY   announced the start of two new phase III studies evaluating its investigational biologic  isatuximab in combination with other cancer medicines for the treatment of multiple myeloma  a rare blood cancer While the first study   IKEMA  n 325    will compare a combination of isatuximab  Amgen s   NASDAQ AMGN   Kyprolis  carfilzomib  and dexamethasone to Kyprolis and dexamethasone  the second study IMROZ  n 425  will evaluate a combination of isatuximab  dexamethasone  Celgene s   NASDAQ CELG   multiple myeloma drug Revlimid   lenalidomide  and Japanese firm Takeda s Velcade  bortezomib  against a combination of Velcade  Revlimid and dexamethasone While the IKEMA study will include patients with relapsed refractory multiple myeloma that have been previously been treated with one to three lines of therapy  IMROZ will evaluate the cancer combinations in newly diagnosed multiple myeloma patients not eligible for transplant The primary endpoint will be progression free survival in both the studiesPlease note that isatuximab is already being evaluated as a monotherapy in phase III studies for relapsed refractory multiple myeloma and in phase II for acute lymphoblastic leukemia Sanofi s shares have risen 7  so far this year  comparing unfavorably with a gain of 14 7  recorded by the  Sanofi carries a Zacks Rank  4  Sell  A better ranked large cap pharma stock is Johnson   Johnson   NYSE JNJ    carrying a Zacks Rank  2  Buy   You can see Shares of J J have risen 21 5  this year so far while 2018 earnings estimates have gone up 1 7  in the past 60 days Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-12-07,Zacks Investment Research,https://www.investing.com/analysis/sanofi-begins-combo-studies-on-multiple-myeloma-candidate-200271784,200271784
150342,371858,AMGN,3 Stocks In Focus As Biotech M A Hopes For 2018 Rise,opinion,"At the beginning of 2017  expectations were pretty high that the pharma and biotech sector would finally see lots of mergers and acquisitions  M As   However  that did not happen  While a few high value deals were announced  the focus was mostly on small bolt on acquisitions and licensing deals and agreements According to Mergermarket s Global Pharma  Medical   Biotech trend report for Q317  M A in the global pharma  medical and biotechnology sector was in the range of  207 6 billion spanning 1 040 deals so far this year  declining 9 9  from the year ago period  The dip was mostly attributable to the pharma and medical sectors Key deals announced this year include the Gilead   NASDAQ GILD   Kite and the Johnson   Johnson   NYSE JNJ   Actelion acquisitions  which boosted the value of M A transactions in the biotech sector  Biotech stocks continue to command hefty premiums where M A is concerned The key question now facing the sector is   will M A activity remain sluggish in 2018 or will there be a surge in M A deals   With tax reform in the works  M A activity is expected to increase in the upcoming quarters  Tax reform and cash repatriation are expected to lead to a boost in this area with biotech remaining a highly sought after sector  Companies with innovative technologies and pipelines remain in demand with disease areas like nonalcoholic steatohepatitis   NASH    immuno oncology  gastrointestinal and central nervous system diseases seeing quite a bit of activity  Treatments for orphan diseases and gene editing technology are also in demand There are several large drugmakers that are on the lookout for deals   while some of these companies are looking to replace sales of blockbuster products that are facing loss of patent exclusivity  others are looking to build their pipelines both through acquisitions as well as licensing agreements Expectations are high that big players like Sanofi   NYSE SNY    Pfizer  NYSE PFE   Merck  NYSE MRK  and Amgen   NASDAQ AMGN   will announce M A deals in 2018  Companies like J J and Gilead are also expected to be on the lookout for additional acquisition targets  A major deterrent  however  could be high valuations and bidding wars which could keep some of the key players on the sidelines    In this backdrop  here is a look at three biotech stocks that could find themselves on the radar of companies on the lookout for acquisition targets in 2018 Incyte Corporation   NASDAQ INCY    Wilmington  DE based Incyte is a company that is often considered an attractive acquisition target thanks to its flagship product  Jakafi  and a promising pipeline  Jakafi   a JAK1 JAK2 inhibitor   looks well positioned for growth  Jakafi revenues are expected in the range of  1 125  1 135 million in 2017  Incyte is also working on expanding Jakafi s label into additional indications including steroid refractory acute graft versus host disease   GVHD    data expected in the first half of 2018  and essential thrombocythemia   ET    a rare blood cancer that can lead to life threatening complications The company has several catalysts lined up for 2018 including the potential approval of baricitinib  resubmission of the new drug application for moderate to severe rheumatoid arthritis expected by January 2018  as well as the advancement of its immuno oncology pipeline 
The company s immuno oncology pipeline includes IDO1 inhibitors  epacadostat   PI3K delta inhibitors  INCB50465   and JAK inhibitors  itacitinib  INCB52793  among others  Epacadostat  which is in late stage development for melanoma with data due in the first half of 2018  has immense commercial potential  Epacadostat is being evaluated for several other types of cancer as well 
Juno Therapeutics  Inc    NASDAQ JUNO    Biopharmaceutical company  Juno s shares have been on an upward trend following the Gilead Kite acquisition announcement earlier this year  With Juno being focused on the development of innovative cellular immunotherapies for the treatment of cancer  the company is considered a potential acquisition target  Juno s cell based cancer immunotherapies are based on chimeric antigen receptor and high affinity T cell receptor technologies  The company has several cell based candidates in its pipeline targeting a variety of B cell malignancies as well as multiple solid tumors and multiple myeloma Although the company suffered a major setback with the development of its erstwhile lead pipeline candidate due to safety issues  including patient deaths   Juno is now focusing on JCAR017  a next generation CAR T cell product that targets CD19  JCAR017 is currently in a registrational study for non Hodgkin s lymphoma   NHL    The company expects to file for approval in the second half of 2018   Juno s shares are up 211 1  year to date  compared to the 2 7  gain recorded by the  it belongs to 

bluebird bio  Inc    NASDAQ BLUE    bluebird is another clinical stage company working on developing gene therapies for serious genetic diseases and T cell based immunotherapies for cancer  The company s pipeline includes Lenti D  currently in a phase II III study  for the treatment of cerebral adrenoleukodystrophy  and LentiGlobin  currently in five studies for the treatment of transfusion dependent   thalassemia and severe sickle cell disease  The company s lead oncology programs  bb2121 and bb21217  are anti BCMA CAR T programs which are being developed in collaboration with Celgene  NASDAQ CELG  
While Incyte  Juno and bluebird are all Zacks Rank  3  Hold  stocks  you can see  
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-12-10,Zacks Investment Research,https://www.investing.com/analysis/3-stocks-in-focus-as-biotech-ma-hopes-for-2018-rise-200272126,200272126
150366,371882,AMGN,AstraZeneca s  AZN  Asthma Drug Benralizumab Approved By FDA,opinion,AstraZeneca  plc   NYSE AZN   announced that the FDA has granted approval to its asthma disease candidate  benralizumab  Benralizumab  approved as an add on maintenance treatment for severe eosinophilic asthma in patients aged 12 years and older  will be marketed by the trade name of Fasenra Shares of this London  United Kingdom based pharma giant were up more than 1  on Tuesday  So far this year  AstraZeneca s shares have gained 21 7   comparing favorably with the  s growth of 14 4  Fasenra will be given as a fixed dose subcutaneous injection via a prefilled syringe  once in every eight weeks  making it the first respiratory biologic medicine to be approved with the convenient 8 week maintenance dosing schedule  GlaxoSmithKline s   NYSE GSK   Nucala  subcutaneous administration  and Teva Pharmaceutical Industries    NYSE TEVA   Cinqair  intravenous infusion  are presently marketed for the same indication but administered once every four weeksThe FDA approval of Fasenra was based on positive data from pivotal studies  SIROCCO and CALIMA  which showed significant reductions in exacerbations and improvements in lung function on treatment with benralizumab  Meanwhile  another phase III study  ZONDA  showed that adding benralizumab to standard of care led to statistically significant and clinically relevant reduction in daily maintenance oral corticosteroid  OCS  use with two benralizumab dosing regimens compared with placebo Severe asthma patients whose disease is driven by inflammation of eosinophils  a type of white blood cell  have until now had only limited treatment options  mostly oral steroids  Fasenra  which distinctively targets and rapidly depletes eosinophils  has shown the potential to reduce oral steroid use in such patients Fasenra is under regulatory review in the EU  Japan and many other countries  Earlier this week  AstraZeneca said that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  has recommended marketing approval of benralizumab Asthma is a chronic inflammatory disease of breathlessness and has a significant unmet medical need  This is because it affects 315 million individuals worldwide and up to 10  of patients who have severe asthma  which can become uncontrolled despite receiving high doses of standard of care medicines and require the use of chronic OCS Benralizumab is also being evaluated for the treatment of chronic obstructive pulmonary disease  COPD  in late stage studies  Other severe asthma candidates in AstraZeneca s portfolio are tralokinumab and tezepelumab   in partnership with Amgen  Inc    NASDAQ AMGN    AstraZeneca carries a Zacks Rank  3  Hold   You can see The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2017-11-14,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-azn-asthma-drug-benralizumab-approved-by-fda-200265455,200265455
150367,371883,AMGN,Pfizer s Cancer Drug Sutent Gets FDA Nod For Label Expansion,opinion,"Pfizer Inc    NYSE PFE   announced that the FDA has approved a label expansion for its cancer drug Sutent  sunitinib malate   With this latest approval  Sutent s label has been expanded as an adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma   RCC   following surgery  This approval makes it the first and only adjuvant therapy for recurrent RCC  the most common type of kidney cancer 
Sutent is marketed for the first line treatment of advanced renal cell carcinoma  RCC  
We remind investors that the supplemental new drug application  sNDA  for the drug was accepted by the FDA earlier in May  Subsequently  in September  the drug s label for the expanded indication got a mixed response from the FDA s Oncologic Drug Advisory Committee  ODAC   The committee voted six in favor and six against the benefit risk profile for Sutent for the expanded indication  However  the drug s label expansion was approved earlier than the target action date in January 2018 
Pfizer s shares have underperformed the  so far this year  The stock has gained 9 5   comparing unfavorably with the industry s 14 7  rally during the period 

Notably  the FDA approval was based on positive data from a phase III study  S TRAC   evaluating Sutent as an adjuvant treatment in patients at high risk of recurrent RCC  following nephrectomy  surgical removal of the cancer containing kidney   Full data presented in October last year  showed that the trial met the primary endpoint of improving disease free survival   DFS    determined by a blinded independent central review in such patients  Data demonstrated that Sutent extended DFS by 6 8 years compared with 5 6 years in the placebo arm  resulting in an overall risk reduction of 24  
An application for use in the same patient population is also under review in the EU 
Significantly  the kidney cancer market is already pretty crowded  The drug faces stiff competition from Bristol Myers Squibb s   NYSE BMY   Opdivo  Novartis    NYSE NVS   Afinitor and Votrient  Bayer  DE BAYGN  s and Amgen  NASDAQ AMGN  s Nexavar  Roche s   OTC RHHBY   Avastin and Tecentriq among others 
Sutent generated sales of  805 million year to date  down 2  year over year due to competitive pressure  However  with this approval for the expanded patient population  sales of the drug should improve 
Per information provided by the company  RCC accounts for around 90  of all kidney cancers  Also  those at high risk of recurrence represent approximately 15  of all patients  It is estimated that 60  of high risk patients will have RCC recurrence within five years  Hence  the potential market opportunity for the drug is huge for this additional indication Pfizer  Inc  Price

   Zacks Rank
Pfizer carries a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-11-17,Zacks Investment Research,https://www.investing.com/analysis/pfizers-cancer-drug-sutent-gets-fda-nod-for-label-expansion-200266375,200266375
150368,371884,AMGN,Amgen  AMGN  Unveils Auto Injector Device For Enbrel In US,opinion,Amgen  Inc    NASDAQ AMGN   announced the launch of its Enbrel Mini with AutoTouch  a new auto injector device for Enbrel in the United States The Enbrel Mini single dose prefilled cartridges  used with the AutoTouch reusable autoinjector device  provide an additional administration option for rheumatoid arthritis drug Enbrel  The Enbrel Mini with AutoTouch device was approved by the FDA in September Amgen s shares have rallied 16 2  this year so far  better than the  s growth of 1 5  Sales of Amgen s largest product Enbrel have been soft for quite some time now  Pricing pressure and stiff competition are hurting sales of Enbrel  one of the main drivers of Amgen s revenues  Enbrel has recorded sales of  4 01 billion in 2017 so far  a decline of 7  year over year The RA market is extremity crowded  given the presence of treatments like AbbVie s   NYSE ABBV   Humira and Pfizer s   NYSE PFE   Xeljanz among others It remains to be seen if this new device for Enbrel can lead to some improvement in sales  However  on the Q3 conference call  Amgen had said that the declining trends in price and market share will continue in 2018 In Europe  while biosimilar versions of Enbrel are available  in the United States  Sandoz  the generic arm of Novartis   NYSE NVS    has received FDA approval for its biosimilar version of Enbrel  Erelzi  Notably  Erelzi is yet to be launched in the United States Currently  Amgen has a Zacks Rank  3  Hold   You can see Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-19,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-unveils-auto-injector-device-for-enbrel-in-us-200266718,200266718
150370,371886,AMGN,This Biotech Stock Struggles To Hold Key Level  AMGN,opinion,"This morning  many of the leading biotechnology stocks are trading lower to start the day  The highly followed and traded iShares Nasdaq Biotechnology  NASDAQ IBB  is trading lower by  2 70 to  308 51 a share  One of the most important components of the IBB is Amgen Inc  NASDAQ AMGN  
This leading biotechnology stock has been pulling back since September 14th when it traded as high as  191 09 a share  Today  the biotech giant is trading at  168 46 a share  The stock is currently holding its 50 week moving average  but a weekly chart close below  167 00 level should trigger further declines  The  160 00 level is going to be the next major support area in the stock  This level is where the stock was defended in June 2017 and should be solid support when retested ",2017-11-21,Nicholas Santiago,https://www.investing.com/analysis/this-biotech-stock-struggles-to-hold-key-level-200267015,200267015
150371,371887,AMGN,J J Seeks Darzalex s Label Expansion In First Line Setting,opinion,"Johnson   Johnson   NYSE JNJ   announced the submission of regulatory applications to the FDA and the European Medicines Agency   EMA   seeking label expansion of its multiple myeloma   MM   drug Darzalex in the first line setting A potential approval will allow Darzalex to be used in combination with J J s proteasome inhibitor MM drug Velcade  bortezomib   melphalan and prednisone to treat MM in treatment na ve patients who cannot have autologous stem cell transplantation in bone marrow  If approved  this will be the fifth indication for the drug We are encouraged by J J s efforts to expand Darzalex s label further  a drug which generated one sixth of the company s total oncology sales in the first nine months of 2017  We note that Darzalex was first approved in November 2015 as monotherapy for MM in patients treated with at least three prior lines of therapy  followed by approvals in the past two years as combination therapy in second and third line settings J J s shares have outperformed the  so far this year  The company s shares have gained 20 1  compared with the industry s gain of 14 8  J J has submitted top line data from the phase III ALCYONE study to support its regulatory applications in both the geographies  Data from the study showed that the Darzalex combination therapy reduced the risk of disease progression or death by 50  when compared to treatment with bortezomib  melphalan and prednisone  standard of care  alone J J will present the data at the Annual Meeting of the American Society of Hematology scheduled to be held between Dec 9 and Dec 12 We note that J J licensed Darzalex from Genmab through its subsidiary  Janssen  in 2012  J J holds the worldwide rights to develop  manufacture and commercialize the drug and has to pay milestone payments to Genmab Per the National Cancer Institute  30 280 new patients are likely to be diagnosed with MM and it will cause 12 590 deaths in the United States in 2017 alone Darzalex competes with other approved and marketed treatments for MM  which include Celgene Corporation s   NASDAQ CELG   Revlimid  Amgen Inc  s   NASDAQ AMGN   Kyprolis and Bristol Myers    NYSE BMY   Emplicti Johnson   Johnson Price
    J J carries a Zacks Rank  2  Buy   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-11-21,Zacks Investment Research,https://www.investing.com/analysis/jj-seeks-darzalexs-label-expansion-in-firstline-setting-200267555,200267555
150372,371888,AMGN,Nuevolution  On The Road To Becoming A Clinical Company  ,opinion,"July to September 2017 results highlight the continued progression of Nuevolution AB  ST NUEVOL  into a clinical company  Ongoing partnerships with Almirall  Amgen  NASDAQ AMGN  and Janssen continue to advance as we expect and we anticipate that Almirall s ROR t inhibitor programme will be the first Nuevolution asset to enter the clinic  in dermatology and psoriatic arthritis   which we forecast for H218 H119  Lead assets in the internal pipeline are nearing clinical readiness and Nuevolution anticipates a new partnership in the next three to 12 months  In the near term  up listing to Nasdaq Stockholm s Main Market and expansion of the investor base will position the company for future development  We value Nuevolution at SEK917m 

Collaborations continue to provide validation
Nuevolution s core collaborations continue to progress as expected  In vivo proof of concept is expected in two cancer programmes in the Amgen Inc   NASDAQ AMGN  collaboration within the next three to six months  In the Almirall collaboration we expect Nuevolution to give a detailed update on the programme in H118  we forecast that it will enter the clinic in H218 H119  Nuevolution s unpartnered assets are progressing well to clinical readiness  the ROR t inhibitor  outside Almirall licensed indications  is in ongoing API production and the company expects to select the optimal indication for clinical development by year end  The BET BD1 programme is following closely behind with API production expected to start in H118  Nuevolution expects to announce a new collaboration licensing deal in the next 3 12 months 
To read the entire report Please click on the pdf File Below ",2017-11-24,Edison,https://www.investing.com/analysis/nuevolution-on-the-road-to-becoming-a-clinical-company-200267976,200267976
150374,371890,AMGN,Why Is ImmunoGen  IMGN  Stock Up More Than 150  This Year ,opinion,Shares of ImmunoGen  Inc    NASDAQ IMGN   have been massively up 192 7  this year so far  outperforming the  s registered 4 3  increase  Let s analyze the factors that led to this rally ImmunoGen s rapid pipeline progress along with positive readouts and strategic collaborations has pushed its share price up consistently ImmunoGen has made a significant progress with regard to its lead pipeline candidate  mirvetuximab soravtansine this year  The candidate is being evaluated in a phase III study  FORWARD I  on as a single agent therapy for treating patients with platinum resistant ovarian cancer  The company has presently activated over 90 sites for enrolment under the trial  which it aims to complete by the middle of 2018  Also  the candidate is being evaluated in three phase I expansion cohorts on 113 ovarian cancer patients  In May  the company reported positive data from the study which demonstrated promising safety and efficacy profile of the candidate Meanwhile  combination regimens with mirvetuximab soravtansine in ovarian cancer are also being evaluated in phase Ib II FORWARD II study  The FORWARD II trial consists of cohorts assessing mirvetuximab soravtansine in combination with Roche s   OTC RHHBY   Avastin and Merck s   NYSE MRK   Keytruda  In May  ImmunoGen had reported initial data from this study  showing mirvetuximab soravtansine with potential to complement the currently available therapies for the indication  Approval for any of these combination regimes will significantly expand the eligible patient population for mirvetuximab soravtansine An approval of mirvetuximab soravtansine would be a huge boost to ImmunoGen  given its immense commercial potential in the target market  Ovarian cancer results in maximum annual deaths among gynecologic cancers with majority of the patients diagnosed at an advanced stage  Per data provided by the American Cancer Society  approximately 22 440 new cases of ovarian cancer will be diagnosed in the United States in 2017  resulting in more than 14 080 deaths Apart from mirvetuximab soravtansine  ImmunoGen is working on developing a couple of other clinical pre clinical candidates including IMGN779 and IMGN632  Notably  IMGN779 is being evaluated in a phase I study for treating acute myeloid leukemia   AML   with data expected later this year  On the other hand  the company plans to move IMGN632 into clinical development before the year end to treat hematological malignancies including AML ImmunoGen has agreements with several big healthcare companies including Amgen  NASDAQ AMGN   Bayer  DE BAYGN   Eli Lilly   NYSE LLY    Novartis  Roche  Sanofi  PA SASY  and Takeda  These contracts allow other companies to use ImmunoGen s ADC technology and provide it with funds in the form of license and milestone fees  royalties  clinical materials revenues and R D support fees   Notably  in August  ImmunoGen had announced a strategic collaboration and option agreement with Jazz Pharmaceuticals for development and commercialization of the two candidates under ADC programs  IMGN779 and IMGN632  Pursuant to the deal  ImmunoGen would be eligible to receive milestone payments based on certain pre decided conditions Though the platinum resistant ovarian cancer market offers an immense commercial potential  ImmunoGen is notably set to face intense competition  upon approval  However  mirvetuximab soravtansine looks promising at this juncture and its approval will be a big lift to the company ImmunoGen carries a Zacks Rank  3  Hold   You can see   Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-11-27,Zacks Investment Research,https://www.investing.com/analysis/why-is-immunogen-imgn-stock-up-more-than-150-this-year-200268563,200268563
150392,371908,AMGN,Sanofi  SNY  Q3 Earnings In Line  Sales Lag  Diabetes Weak,opinion,"Sanofi  PA SASY    NYSE SNY   reported third quarter 2017 earnings of  1 00 per American depositary share  which were in line with the Zacks Consensus Estimate  Earnings declined 4 5  on a reported basis  However at constant currency rates  CER   earnings rose 1 1  Third quarter net sales rose 0 3  on a reported basis and 4 7  at CER to almost  10 59 billion   8 05 billion   Sales  however  missed the Zacks Consensus Estimate of  10 93 billion  Unfavorable exchange rate movements hurt sales by 4 4  In January 2017  the French drug maker swapped its Merial Animal Health businesses with Boehringer Ingelheim s Consumer Healthcare  CHC  business  Reflecting this exchange and full consolidation of Sanofi s European vaccines operations  sales declined 0 2  at constant structure  CS  and CER Sales declined 2 4  at CER in the United States  However  sales rose 11 4  in Emerging Markets  8 2  in Europe and 9 1  in the Rest of the World  Japan  South Korea  Canada  Australia  New Zealand  Puerto Rico  All growth rates mentioned below are on a year on year basis and at CER Segmental PerformancePharmaceuticals sales  including emerging markets  increased 3 2  to  7 14 billion  However  at CS and CER  Pharmaceuticals sales declined 1 2  as double digit growth of multiple sclerosis drugs and vaccines franchises and robust growth in emerging markets was offset by a decline in diabetes  established products and generics sales Sanofi reports through five Global Business Units  GBUs    Sanofi Genzyme  Specialty Care   Diabetes   Cardiovascular  General Medicines   Emerging Markets  Consumer Healthcare and Sanofi Pasteur  Vaccines  Sanofi Genzyme Specialty Care GBU sales  including emerging markets  increased 12 5  to  1 63 billion  driven by strong U S  launch of Dupixent and higher sales of multiple sclerosis  MS  drugs Sales of MS drugs Aubagio rose 19 2  to  382 million while sales of Lemtrada went up 5 4  to  113 million  However  sales of both these drugs declined sequentially in the quarter Meanwhile  sales of rare disease drugs like Myozyme Lumizyme improved 5 9  to  191 million while Fabrazyme sales were  175 million  up 4 5   Cerdelga sales came in at  31 million  up 14 3  while Cerezyme sales rose 1 6  to  178 million Oncology sales rose 5  to  363 million driven mainly by higher sales of Jevtana and Thymoglobulin  Jevtana sales were up 6 8  to  90 million while Thymoglobulin recorded sales of  71  up 5 7   Taxotere sales rose 2 2  to  42 million  Eloxatine sales were up 11 6  to  45 million Sanofi and Regeneron Pharmaceuticals  Inc  s   NASDAQ REGN   rheumatoid arthritis  RA  drug Kevzara  sarilumab  was launched in the United States in June and in Netherlands and Germany in Europe in the third quarter   Kevzara recorded sales of  2 million in the third quarter compared with  1 million in the previous quarter Meanwhile  Dupixent dupilumab for treating atopic dermatitis was launched in the United States in March  Dupixent generated sales of  75 million in the third quarter compared with  26 million in the previous quarter  Management is pleased with the drug s uptake and said that in the United States  the drug has been prescribed by over 7 100 physicians  Meanwhile  Dupixent was approved in the EU in September and is expected to be launched in Germany by the end of this year  Kevzara and Dupixent generated total immunology sales of  77 million in the third quarter Diabetes and Cardiovascular GBU  including emerging markets  declined 9 1  to  1 68 billion  The Diabetes franchise  including emerging markets  declined 10  to  1 55 billion due to lower sales of key drug Lantus Sales of diabetes drugs in the United States declined 22 4  to  725 million due to a tough U S  payer environment  Sales of diabetes drugs in Emerging Markets were up 17 3  while in Europe it declined 3 1  Lantus sales declined 15 5  to  1 12 billion in the quarter  Lantus sales declined 25 4  in the United States due to lower average net price and exclusion from the CVS and United Health formulary plans while Europe sales declined 14  due to biosimilar competition and patient switching to Toujeo Toujeo generated sales of  198 million in the reported quarter  which  though up 23 4  on a year over year basis  declined 5 7  sequentially Soliqua  a once daily titratable fixed ratio combination of Lantus and Lyxumia  was launched in the United States in January and in Netherlands  trade name   Suliqua  recently  Soliqua Suliqua generated sales of  8 million in the quarter compared with  5 million in the previous quarter Management warned that U S  diabetes franchise sales will decline at an accelerated rate in the fourth quarter due to CVS United Health formulary exclusion plans and difficult comparisons with the last year  Considering recent market trends  Sanofi now expects its global Diabetes sales to decline in the range of 6 8  CAGR over the 2015 2018 timeframe  Previously  Sanofi had guided sales decline in the range of 4  to 8  In the cardiovascular franchise  Sanofi s anti PCSK9 therapy  Praluent garnered worldwide sales of  42 million in the reported quarter  flat sequentially  Incidentally  Amgen   NASDAQ AMGN    which reported last week  also did not report a very significant sequential improvement in sales of its PCSK9 inhibitor  Repatha  Uptake of these drugs has not been very encouraging so far due to pricing and re imbursement issues payer restrictions General Medicines   Emerging Markets GBU sales came in at  3 31 billion  down 2 7   Sales of Established products were  2 26 billion  down 6 5  as strong performance in emerging markets was offset by lower sales in Europe and generic competition for Plavix in Japan and Renvela Renagel in the United States Sales of Generics declined 0 9  to  433 million due to lower sales in Europe  Consumer Healthcare GBU sales were  1 13 billion  up 48 5   However  sales were up only 1  excluding acquisition of Boehringer Ingelheim s Consumer Healthcare business due to increased competition in developed markets Third quarter consolidated Sanofi Pasteur  Vaccines  sales increased 11  to  1 92 billion due to the strong performance of pediatric combinations and booster vaccine  Menactra  Vaccines sales reflect the termination of the Sanofi Pasteur MSD joint venture with Merck   NYSE MRK   in Europe from December 2016 Costs RiseSelling general and administrative expenses  SG A  increased 5 9  at CER in the quarter  reflecting launch costs of Dupixent and Kevzara  R D expenses were up 12 9  at CER  reflecting higher pipeline development costs in oncology  isatixumab  PD 1  and sotagliflozin 2017 OutlookSanofi maintained its previously issued financial outlook Sanofi expects 2017 business earnings to be broadly flat at CER  It anticipates a negative currency impact in the range of 1  2  on business earnings in 2017  This compares unfavorably with the prior expectations of a positive currency impact of 1  Our TakeSanofi s third quarter 2017 results mixed as it reported in line earnings and missed sales expectations  Strong performances of multiple sclerosis and vaccines franchises  successful launch of Dupixent and robust emerging market sales could not make up for the weak performance in the diabetes and cardiovascular unit  Shares of Sanofi  were down slightly more than 1  in pre market trading So far this year  Sanofi s share price has risen 14 9   slightly worse than a 15 1  increase for the  However  despite greater than previously expected headwinds from currency  the company maintained its earnings forecast  which was encouraging We are encouraged by the strong performance of MS drugs like Aubagio and Lemtrada  We are also optimistic on sales prospects of Dupixent  which could prove to be an important growth driver for the company However  headwinds include a bleak outlook for the Diabetes franchise  generic competition for many drugs and slower than expected uptake of new products like Praluent Sanofi Price  Consensus and EPS Surprise
    Sanofi currently carries a Zacks Rank  4  Sell  You can see  Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/sanofi-sny-q3-earnings-in-line-sales-lag-diabetes-weak-200257833,200257833
150393,371909,AMGN,5 Biotech Stocks Well Poised To Surpass Expectations In Q3,opinion,"The Q3 earnings season is approaching its end with 81 2  of the S P 500 companies having already released results  The majority of players within the medical space have already reported their performance  Per the latest   total earnings for the medical sector are up 6 5  from the same period last year on 4 6  higher revenues This year  biotech stocks bounced back strongly after the drug pricing issue affected last year s performance  The pharma and biotech industry has demonstrated strength despite challenges like rising competition  pipeline setbacks  slowdown in growth of mature products and generic competition for certain key drugs  Although drug pricing risk persists  investors look comfortable with the scenario and are focused on the fundamentals to drive the stocks Many factors were responsible for the recovery of the sector this year including ramp up of new product sales  R D success and innovation  strong clinical study results  regular FDA approvals and a consistently strong performance of legacy products On a broader spectrum  the proposed tax reforms  if approved  will leave more cash in hand for these companies  The cash can be invested for mergers acquisitions  which have been relatively few this year compared with the last Among the big biotech pharma companies that have already reported earnings results  Biogene  BIIB   Gilead  GILD   Amgen  NASDAQ AMGN  and Vertex  VRTX  beat both earnings and revenue estimates  On the other hand  Celgene  NASDAQ CELG  reported mixed results in the quarter with earnings beating expectations but sales missing the same  While Gilead raised its earnings guidance  Celgene increased only the lower end of its earnings outlook While most key players have reported quarterly numbers  some small biotech companies are yet to come up with solid figures How to Pick Prospective Q3 WinnersGiven the enormity of the healthcare space  selecting stocks with potential to beat estimates appears to be a daunting task  But our simple proprietary methodology helps choosing stocks with the right combination of two key ingredients   a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    and a positive   which indicates higher chances of an earnings beat  More often than not  a positive earnings surprise delivered by a company leads to stock price appreciation An Earnings ESP determines the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate  Our research shows that chances of a positive earnings surprise for stocks with an ideal combination of elements are pegged as high as 70    You can uncover the best stocks to buy or sell before they re reported with our  
Here are five best biotech stocks that hold promise to beat estimates in the third quarter Cidara Therapeutics Inc    is a San Diego  CA based company with an Earnings ESP of  16 06  and a Zacks Rank  2  You can see  
The Zacks Consensus Estimate for the third quarter is pegged at a loss of 97 cents per share  The company has a mixed earnings surprise record with earnings having surpassed expectations in only one of the last four quarters with an average negative surprise of 4 96  Cidara is scheduled to report results on Nov 8 Inovio Pharmaceuticals  Inc     has an Earnings ESP of  41 79  and carries a Zacks Rank  3  The Zacks Consensus Estimate for the third quarter is pegged at a loss of 22 cents per share  The Pennsylvania based Inovio has a mixed earnings track record  The average negative earnings surprise over the trailing four quarters is 0 41  Inovio is scheduled to announce results on Nov 8 Puma Biotechnology Inc    has an impressive track record with the company beating expectations in three of the last four quarters with an average positive surprise of 39 46   It looks poised to beat expectations in the third quarter as well  This Los Angeles  CA based company carries a Zacks Rank of 3 and has an Earnings ESP of  18 47   The Zacks Consensus Estimate is pegged at a loss of  2 75 cents per share Puma is scheduled to report results on Nov 9 Strongbridge Biopharma PLC    is another solid bet this season  This Zacks  2 Ranked stock has an Earnings ESP of  8 80   The Pennsylvania based company delivered an average positive earnings surprise of 15 42  over the trailing four quarters Strongbridge is scheduled to release results on Nov 14 with the Zacks Consensus Estimate for the third quarter being pegged at a loss of 42 cents per share Waltham  MA based Repligen Corporation    also enters the list of likely outperformers in the third quarter by virtue of its Earnings ESP of  31 58  and is  3 Ranked as well  The Zacks Consensus Estimate is pegged at 11 cents per share Repligen is expected to release results on Nov 9     Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-11-06,Zacks Investment Research,https://www.investing.com/analysis/5-biotech-stocks-well-poised-to-surpass-expectations-in-q3-200263367,200263367
150394,371910,AMGN,Novartis  NVS  Arm s Biosimilars Study Results Encourage ,opinion,"Novartis AG s   NYSE NVS   generic arm  Sandoz  reported data from four clinical studies  The studies compared proposed biosimilar adalimumab and biosimilar rituximab to reference drugs  AbbVie  Inc  s   NYSE ABBV   Humira and Roche Holdings   OTC RHHBY   MabThera respectively The studies included two innovative trials involving switching and two pharmacokinetic  PK  and pharmacodynamic  PD  studies A phase III confirmatory efficacy and safety study met its primary endpoint in the proportion of patients who achieved a 75  improvement at week 16   The study confirmed that there were no meaningful clinical differences in efficacy  safety and immunogenicity in patients who continuously received adalimumab  those who continuously received the reference drug and those who switched between biosimilar adalimumab and reference drug on multiple occasion In addition  a phase III study evaluated rituximab retreatment in patients with rheumatoid arthritis  RA   who had already received reference rituximab for treatment of RA in the past  The study evaluated the biosimilar and the reference drug in terms of safety and immunogenicity in patients who switched from the reference drug to biosimilar rituximab and in those who continued treatment with the reference drug In addition  the PK and PD data demonstrated equivalence as the phase I PK study met its primary endpoint as bioequivalence was demonstrated between the biosimilar adalimumab and the reference drug  We note Sandoz holds a leading position in the biosimilars space with a portfolio of five marketed biosimilars currently and a deep pipeline The biosimilar version of rituximab  Rixathon  was approved by the European Commission in June 2017  It is currently under review in the United States  The biosimilar version of Humira is also under review in the EU Meanwhile  Sandoz witnessed strong growth outside the United States buoyed by biosimilar launches of Rixathon and Erelzi  the biosimilar of Amgen  Inc  s   NASDAQ AMGN   Enbrel in Europe  However  pricing pressure intensified in the United States   The company expects low single digit sales decline at Sandoz in the fourth quarter  mainly due to seasonal shipment phasing and continued pricing pressures in the United States   Novartis  stock has rallied 17  year to date compared with the  s 17 6  gain  In the first half of 2017  Novartis announced that it is mulling strategic options for Alcon which includes retaining the business separation via capital market transactions such as a spin off or an initial public offering  The company believes that the Alcon division has revived and hence a decision on a possible spin off will be taken in 2019  The recent approvals of Kymriah and Kisqali will further boost the oncology portfolio and drive growth 
Zacks Rank
Novartis currently carries a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-11-13,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-arms-biosimilars-study-results-encourage-200264957,200264957
150401,371917,AMGN,Amgen  AMGN  Q3 Earnings Top  Sales Decline Y Y  Stock Falls,opinion,"Biotech major Amgen Inc    NASDAQ AMGN   reported third quarter 2017 earnings of  3 27 per share  which beat the Zacks Consensus Estimate of  3 09 by 5 8   Earnings increased 8  from the year ago period backed by lower operating costs  which offset the year over year sales decline Including costs related to discontinuation of a pipeline candidate  AMG 899  an oral CETP inhibitor   reported earnings were  2 76 per share  up 3  year over year Total revenue of  5 77 billion in the quarter slightly beat the Zacks Consensus Estimate of  5 74 billion  Revenues declined 1  year over year  An unfavorable impact of foreign exchange hurt sales by 1  in the quarter While U S  revenues declined 2   ex U S  sales grew 5   excluding currency headwinds Quarter in DetailTotal product revenue declined 1   including negative currency impact of 1   from the year ago quarter to  5 45 billion  U S    4 3 billion  ex U S    1 16 billion  as strong demand for newer products like Prolia  Kyprolisand Blincyto was not enough to make up for lower sales of mature brands like Enbrel  Epogen  Neulasta and Neupogen due to competitive pressure Revenues of Amgen s erythropoiesis stimulating agent  ESA   Aranesp  declined 3  from the year ago quarter to  516 million due to lower demand Revenues of the other ESA  Epogen  declined 21  to  264 million due to lower selling price owing to a recently negotiated contract with DaVita Inc  Unfavorable changes in inventory also hurt Epogen sales Neulasta revenues declined 6  to  1 12 billion from the year ago period dueto unfavorable shift in timing of purchases by some large customersand increased competition from PD 1s and other new cancer therapies  However  the Neulasta Onpro kit  on body injector  continues to perform well  commanding a market share of about 56  in the United States for all Neulasta sales Neupogen recorded a 25  decline in sales to  138 million due to biosimilar competition in the United States  Zarxio  Sandoz s  Novartis    NYSE NVS   generic arm  biosimilar version of Neupogen  was launched in the United States in September 2015 and is hurting sales Enbrel delivered revenues of  1 36 billion  down 6  from the year ago quarter due to lower selling prices and increased competition  which hurt demand Enbrel lost market share by less than 1 point in both the rheumatology and dermatology segments Prolia revenues came in at  464 million  up 22  from the year ago quarter due to higher demand  The osteoporosis drug witnessed market share gains in both the United States and international markets Meanwhile  Xgeva delivered revenues of  387 million  down 2  from the year ago quarter mainly due to unfavorable shift in timing of purchases by some large customers Sensipar Mimpara revenues increased 10  to  457 million due to higher price increases Vectibix revenues came in at  168 million  up 2   driven by higher demand Kyprolis recorded sales of  207 million  up 13  year over year driven by higher demand and robust uptake from outside U S  markets Amgen s regulatory applications in the United States and EU to include overall survival data from the ENDEAVOR study on the label of Kyprolis are under review  The study demonstrated that a combination of Kyprolis plus dexamethasone led to superior overall survival when compared to Velcade plus dexamethasone  This overall survival data  if approved  can help drive usage and boost sales of Kyprolis  The FDA is expected to give its decision on Apr 30 next year Blincyto sales surged 79  from the year ago period to  52 million  reflecting higher demand  In July  the FDA approved the inclusion of overall survival data from the TOWER study on the label of Blincyto to convert the accelerated approval to a full approval  The addition of the data must have boosted sales Amgen s PCSK9 inhibitor  Repatha generated revenues of  89 million  not a very significant improvement from  83 million in the second quarter  Changes in inventory and accounting adjustments that favourably affected second quarter sales were missing in the third quarter Uptake of the drug  which gained FDA approval in August 2015  has not been very encouraging so far due to pricing and re imbursement issues payer restrictions  Sanofi   NYSE SNY   and partner Regeneron Pharmaceuticals   NASDAQ REGN   also faced similar issues with their PCSK9 inhibitor  Praluent  The priority for Amgen right now is to improve patient access to Repatha Amgen s regulatory applications to include data from the phase III cardiovascular outcomes study  FOURIER  on Repatha s label is under priority review with a decision from the FDA expected on Dec 2  We remind investors that data from the FOURIER study  presented in the first quarter  had revealed significant reduction in myocardial infarctions and strokes  The data is key to commercial success of Repatha as it will broaden the use of the drug  Though data from the study looks good  it is not very clear if payers will be willing to improve access to Repatha based on this data Operating Margins IncreaseAdjusted operating margins rose 270 basis points  bps  to 55 6  due to lower operating costs  reflecting continued benefits from transformation and process improvement efforts R D expenses declined 11  in the quarter due to lower late stage pipeline related costs and lower upfront payments for in licensing transactions than third quarter of last year  SG A spend declined 6  due to the October 2016 expiration of Enbrel residual royalty payments  which offset investments to support new product launches Amgen bought back shares worth  0 8 billion in the quarter  This month  Amgen s board of directors approved a new share buyback plan of  5 billion 2017 GuidanceWhile Amgen slightly raised the lower end of the previously issued sales outlook  it raised the earnings guidance on the back of effective cost management The company expects total revenue in the range of  22 7 billion to  23 0 billion compared with  22 5 billion to  23 0 billion expected previously  Adjusted earnings are now expected in the range of  12 50 to  12 70 in 2017 compared with  12 15 to  12 65 per share expected previously However  the company tightened its reported earnings guidance to a range of  10 96  11 20 per share from  10 79  11 37 to account for the costs related to the hurricane recovery efforts at its Puerto Rico manufacturing facility  Though the company does not expect any negative impact on product supply  the expenses related to Hurricane Maria are expected to hurt earnings per share by 15 18 cents Operating expenses are expected to be higher in the fourth quarter than the third Our TakeThough Amgen beat expectations for both earnings and sales and raised its earnings guidance for the full year  shares lost more than 1  in after market trading due to the decline in sales and probably due to disappointing sales of Repatha  a key new drug  However  so far this year  Amgen s shares are up 21 4   better than the 6 9  increase registered by the  Though Amgen s newer products   Prolia  Xgeva  Vectibix  Nplate and Sensipar   are all performing well  their volume growth may not be enough to offset the decline in mature brands like Enbrel due to competitive pressure  However  Amgen s restructuring plan should make it leaner and more cost efficient  Amgen is also progressing with its pipeline  including biosimilar drugs Amgen currently carries a Zacks Rank  3  Hold   You can see Amgen Inc  Price  Consensus and EPS Surprise
    Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-25,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-q3-earnings-top-sales-decline-yy-stock-falls-200221293,200221293
150410,371926,AMGN,AbbVie  ABBV  Q3 Earnings Top  Revenues In Line  View Up,opinion,"AbbVie Inc    NYSE ABBV   reported mixed results in the third quarter of 2017  The company surpassed earnings estimates  while posted in line revenues during the period  Importantly  the company raised its long term sales expectations of its blockbuster rheumatoid arthritis drug Humira  despite rising competition in the market  In response  shares nudged up almost 2  in pre market trading 
In the year so far  AbbVie s shares have surged 48 6   significantly outperforming the  s 16 1  rally 

The biopharmaceutical company reported third quarter 2017 earnings of  1 41 per share  beating the Zacks Consensus Estimate of  1 39 by 1 4   The bottom line grew 16 5  year over year 
The company posted revenues of  7 billion in the reported quarter  having met the Zacks Consensus Estimate  Revenues also increased 9 5  year over year  Excluding a 0 7  favorable impact from foreign exchange rate fluctuations  operational revenues climbed 8 8  
Quarter in Detail
Key drug Humira recorded sales growth of 14 8   on an operational basis  with revenues coming in at  4 7 billion  Sales in the United States rallied 19 1  to  3 2 billion  Humira sales in the ex U S  market were up 6 8  on operational basis and 9 7  on reported basis to  1 55 billion  Growth across all three major market categories drove the upside  despite increasing competition from new classes of drugs as well as an indirect biosimilar competition in international markets 
Third quarter net revenue from Imbruvica stood at  688 million  up 37 3  year over year  U S  sales of Imbruvica were  574 million  up 31  compared with the year ago figure  AbbVie recorded  114 million of international profit sharing with Johnson   Johnson   NYSE JNJ   
Other products that delivered an impressive performance include Duodopa  showing revenue growth of 22  on operational and 26 3  on reported basis  Another product called Creon witnessed an increase of 14 8  in revenues on both operational and reported basis 
HCV  chronic hepatitis C virus  product recorded sales of  276 million  down 27 7  and 26 8  on operational and reported basis  respectively  The downside can be attributable to intense pricing and competitive pressure in the HCV market 
Adjusted SG A expenses were up 5 8  to  1 45 billion  while R D expenses escalated 13 3  to  1 19 billion in the quarter  Adjusted operating margin was 43 1  of sales in the reported quarter 
AbbVie announced an 11  hike in quarterly dividend to 71 cents per share from 64 cents per share  The increased payment will begin with the dividend payable in February next year 
2017 Outlook
AbbVie raised its adjusted earnings for 2017 in the range of  5 53  5 55 compared with  5 44  5 54  expected previously  The earnings guidance reflects year over year growth of 14 9  at the mid point  The Zacks Consensus Estimate is currently pegged at  5 53 per share 
Long Term Guidance
AbbVie projects adjusted EPS in the range of  6 37  6 57 for 2018  showing an approximate 15 19  rally from the mid point of the revised range of 2017 outlook 
AbbVie estimates Humira to generate global sales of  21 billion in 2020  higher than  18 billion  predicted previously in 2015 
Several companies are working on biosimilar versions of Humira  Though Amgen s   NASDAQ AMGN   Humira biosimilar received an FDA approval in September 2016  its launch is delayed to 2023 due to settlement of its patent dispute with AbbVie  This will make Humira free from competition for a few more years  Also  AbbVie has a robust intellectual property  which is expected to generate positive sentiments among the investors 
Zacks Rank   Key Picks
AbbVie currently carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Eli Lilly and Company   NYSE LLY    carrying a Zacks Rank  2  Buy   You can see  
Eli Lilly s earnings per share estimates increased from  4 15 to  4 19 for 2017 and from  4 57 to  4 61 for 2018 over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters with an average beat of 1 68  
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-27,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-q3-earnings-top-revenues-in-line-view-up-200221549,200221549
150411,371927,AMGN,Pfizer  PFE  Beats On Q3 Earnings  Raises 2017 EPS View,opinion,"Pfizer  Inc    NYSE PFE   reported third quarter 2017 adjusted earnings per share of 67 cents  which beat the Zacks Consensus Estimate of 65 cents by 3 1   Earnings also rose 10  year over year driven by slightly higher sales and lower costs and share count 
The pharma heavyweight delivered revenues of  13 17 billion  which were in line with the Zacks Consensus Estimate  Revenues rose 1  from the year ago quarter on a reported as well as operational basis 
Sales in Detail
Currency movement hurt Pfizer s third quarter revenues slightly   54 million  while the divestiture of Hospira infusion systems business hurt sales by 2  in the quarter  In February 2017  Pfizer divested its Hospira infusion systems  HIS business to ICU Medical  Inc    NASDAQ ICUI    Excluding currency headwinds and HIS revenues  sales rose 4  
Strong performance of newer products like Ibrance  breast cancer   Xtandi  prostate cancer  and Xeljanz  rheumatoid arthritis  offset lower sales of Enbrel  Viagra and the Prevnar Prevenar 13 vaccines franchise and loss of exclusivity for some products 
International revenues rose 2   up 3  an operational basis  to  6 63 billion  Meanwhile  U S  revenues were flat at  6 53 billion 
Segment Discussion
Pfizer s reporting segments are Pfizer Innovative Health  IH  and Pfizer Essential Health  EH  
Pfizer IH sales grew 11  on a reported and operational basis from the year ago period to  8 12 billion  Pfizer IH revenues were driven by persistently strong momentum of Ibrance and Eliquis globally and growth of Lyrica and Xeljanz primarily in the United States 
While Ibrance revenues rose 60  to  878 million in the quarter  Xeljanz rose 48  to  348 million  Lyrica sales rose 10  to  1 15 billion  Eliquis alliance revenues and direct sales rose 43  to  644 million 
Revenues from the blockbuster prostate cancer drug  Xtandi  added to Pfizer s portfolio following the September 2016 Medivation acquisition  also contributed to U S  revenues  Xtandi recorded alliance revenues of  150 million in the quarter compared with  141 million in the second quarter 
This was partially offset by continued decline in revenues from Prevnar 13 in the United States and lower revenues of Enbrel and Viagra 
Enbrel revenues declined 13  to  613 million in key European markets due to biosimilar competition  Pfizer has exclusive rights to Amgen  Inc  s   NASDAQ AMGN   blockbuster rheumatoid arthritis  RA  drug  Enbrel  outside the United States and Canada  Total Viagra  IH EH  sales declined 20  to  308 million  Lower demand and wholesaler destocking ahead of the potential generic competition in December hurt sales of Viagra 
Global Prevnar 13 Prevenar 13 revenues declined 1  to  1 52 billion  Prevnar 13 revenues tanked 4  in the United States due to continued decline in revenues for the eligible adult patient population  However  Prevenar 13 revenues rose 5  in international markets due to favorable timing of government purchases in some emerging markets 
Consumer Healthcare revenues rose 4  to  829 million  Global Oncology revenues surged 46  to  1 62 billion driven by Ibrance  Global Vaccine revenues rose 1  to  1 65 billion  Internal Medicine rose 9  to  2 46 billion  The Inflammation   Immunology franchise rose 4  to  1 billion  Additionally  the portfolio of Rare Disease declined 3  to  569 million 
Earlier this month  Pfizer said that it is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin off  sale or other transaction  A decision is expected next year 
Pfizer EH segment sales recorded a decline of 12   down 11  operationally  to  5 05 billion  Excluding HIS revenues  EH sales declined 7  
EH revenues were hurt by the loss of exclusivity and associated generic competition for products primarily Pristiq in the United States and Vfend and Lyrica in Europe  lower revenues from legacy Hospira products due to product shortages and divesture of HIS  However  in the EH business  biosimilars and emerging markets did well in the quarter 
Pfizer launched Inflectra  a biosimilar version of Johnson   Johnson   NYSE JNJ   and Merck s blockbuster RA drug Remicade  in November last year  While Inflectra recorded sales of  34 million in the United States and  112 million globally  all other biosimilars brought in sales of  28 million  down 16   from outside the U S  markets  Emerging markets revenues grew 7  operationally 
Adjusted selling  informational and administrative  SI A  expenses declined 1   operationally  in the quarter to  3 48 billion  Adjusted R D expenses also declined 1  to  1 85 billion 
2017 Guidance Updated
While Pfizer raised its adjusted earnings guidance  it tightened the revenue expectations for the year  Revenues are expected in the range of  52 4 billion to  53 1 billion compared with  52 billion to  54 billion expected previously  The Zacks Consensus Estimate is pegged at  52 65 billion 
Adjusted earnings per share are expected in the range of  2 58    2 62 compared with  2 54    2 60 expected previously  The Zacks Consensus Estimate is pegged at  2 56 per share 
At the mid point  adjusted EPS is expected to increase 8   previously 7   
Research and development expenses are expected in the range of  7 5  7 8 billion  previously  7 5  8 0 billion   while SI A spending is projected in the range of  14 0  14 5 billion  previously  13 7  14 7 billion  
Our Take
Pfizer s third quarter results were mixed as it beat earnings estimates but delivered in line sales  However  the company raised its adjusted earnings guidance for the year  Shares were down 0 5  in pre market trading  So far this year  Pfizer s shares are up 8 2   comparing unfavorably with an increase of 14 6  for the 

 
Pfizer continues to face headwinds in the form of genericization of key drugs  lost alliance revenues  pricing pressure and rising competition  which are hurting the top line  Nonetheless  we believe that new products like Ibrance  contribution from acquisitions  cost cutting efforts and share buybacks should help the company achieve its guidance 
Pfizer also boasts a strong pipeline and expects a  multiyear wave of potential new product launches and product line extensions   Bavencio is being considered a key long term growth driver for Pfizer 
Bavencio avelumab received FDA approval for metastatic Merkel cell carcinoma  MCC  in March this year and for advanced bladder cancer in May  Bavencio was also approved in EU and Japan in September for MCC 
Two other leukemia treatments   Besponsa inotuzumab ozogamicin for relapsed refractory acute lymphoblastic leukemia  ALL  and Mylotarg for newly diagnosed CD33 positive acute myeloid leukemia  AML    were also approvedby the FDA in the third quarter  Besponsa was also approved in the EU in June 
Pfizer carries a Zacks Rank  3  Hold   You can see  Pfizer  Inc  Price  Consensus and EPS Surprise

   Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-30,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-beats-on-q3-earnings-raises-2017-eps-view-200257407,200257407
150431,371947,AMGN,ImmunoGen To Push Leukemia Candidate Into Phase I Trial,opinion,"ImmunoGen  Inc    NASDAQ IMGN   announced that it is planning to move its leukemia candidate  IMGN632  into phase I study before the year end  The company said that the FDA has completed the safety review of its investigational new drug  IND  application for IMGN632  filed in mid September for treating patients with CD123 positive hematological malignancies  including acute myeloid leukemia  AML  and blastic plasmacytoid dendritic cell neoplasm  BPDCN  
Notably  IMGN632 uses the company s indolino benzodiazepine cancer killing agents known as IGNs 
ImmunoGen s shares have significantly outperformed the  year to date  The stock has soared 194 1  compared with the industry s increase of 2  during the same time 

 
The IND application for IMGN632 was supported by positive data from preclinical studies  which demonstrated IMGN63 s selective activity against AML cells  while sparing normal bone marrow cells 
We remind investors that ImmunoGen had earlier entered into a strategic collaboration and option agreement with Jazz Pharmaceuticals PLC   NASDAQ JAZZ   in August for the development and commercialization of IMGN632  The collaboration also included another program s IMGN779   a CD33 targeting ADC   already in phase I stage for the treatment of AML 
Notably  ImmunoGen is focused on developing targeted cancer therapeutics using its proprietary ADC technology  In fact  this innovative technology of the company is also used in Roche s   OTC RHHBY   marketed product  Kadcyla and in three other development stage candidates in its pipeline 
Additionally  the ADC technology is used in development programs by ImmunoGen s partners Amgen   NASDAQ AMGN    Bayer AG  DE BAYGN   Biotest  CytomX  Eli Lilly  Novartis  Sanofi  PA SASY  and Takeda 
Per the company s press release  approximately 21 380 patients are expected to be diagnosed with AML this year in the United States  Among them  around 10 590 patients are anticipated to succumb to the disease  Hence  IMGN632 s potential market opportunity is huge in the country  if successfully developed ImmunoGen  Inc  Price

   Zacks Rank
ImmunoGen currently carries a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside  
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-17,Zacks Investment Research,https://www.investing.com/analysis/immunogen-to-push-leukemia-candidate-into-phase-i-trial-200219408,200219408
150432,371948,AMGN,Teva Submits BLA To FDA For Migraine Candidate Fremanezumab,opinion,"Teva Pharmaceutical Industries Ltd   NYSE TEVA   announced the submission of a biologics license application   BLA   to the FDA seeking approval for its monoclonal antibody candidate  fremanezumab  as a preventive treatment for migraine The BLA submission was supported by positive data from two phase III studies under HALO program  which evaluated the candidate in patients with episodic migraine   EM   and chronic migraine   CM   Fremanezumab was subcutaneously administered once a month for two months  quarterly dose regimen   either in high  675mg  or low doses  225 mg  monthly dose regimen  in the study on CM patients  The data demonstrated statistically significant reduction in the number of monthly headache days when treated with fremanezumabcompared to a placebo  The study also met its secondary endpoints and showed significant improvement over placebo Data from the study on EM patients showed that patients who were treated with monthly as well as quarterly dosing regimens of fremanezumab experienced clinically and statistically significant improvements in monthly average number of migraine days and 12 pre specified analyses 
Given the limited treatment options  fremanezumab represents significant commercial potential  According to Teva s press release  more than a billion people suffer from migraine across the world including 38 million in the United States We remind investors that the BLA from Amgen  Inc    NASDAQ AMGN   and partner Novartis AG   NYSE NVS   for approval of their CGRP receptor  erenumab  for the prevention of migraine was accepted by the FDA in July  Eli Lilly   Company   NYSE LLY   is also planning to file for FDA approval of its investigational migraine drug  galcanezumab  in the second half of the year Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-18,Zacks Investment Research,https://www.investing.com/analysis/teva-submits-bla-to-fda-for-migraine-candidate-fremanezumab-200219828,200219828
150433,371949,AMGN,Can ImmunoGen s Key Pipeline Cancer Candidate Drive Growth ,opinion,On Oct 18  2017  we issued an updated report on ImmunoGen  Inc    NASDAQ IMGN   ImmunoGen is a development stage biotechnology company  focused on developing targeted cancer therapeutics  using its proprietary antibody drug conjugate  ADC  technology ImmunoGen has made significant progress with regard to its lead pipeline candidate  mirvetuximab soravtansine  The candidate is currently in a phase III study  FORWARD I  as a single agent therapy for treating patients with platinum resistant ovarian cancer  whose tumors express high or medium levels of FR alpha  Additionally  they have received up to three prior treatment regimens  Successful development and subsequent approval will be a huge boost to the company as ovarian cancer market represents a huge potential Notably  combination regimens with mirvetuximab soravtansine in ovarian cancer are in the phase Ib II FORWARD II study  The trial consists of cohorts assessing mirvetuximab soravtansine in combination with Roche s Avastin and Merck s Keytruda  ImmunoGen reported initial data from the FORWARD II study in May  demonstrating the candidate to have potential to complement currently available therapies for the indication Notably  mirvetuximab soravtansine enjoys an Orphan Drug status in both the United States and the EU for treatment of ovarian cancer Although the platinum resistant ovarian cancer market provides immense commercial potential  ImmunoGen is set to face intense competition upon approval from established products like Roche s Avastin and Johnson   Johnson s   NYSE JNJ   Doxil  Also  several companies are working on to introduce treatments to the market  targeting this disease Apart from mirvetuximab soravtansine  ImmunoGen is working to develop a couple of other candidates  including IMGN779 and IMGN632  Notably  IMGN779 is being evaluated in a phase I study for treating acute myeloid leukemia with data expected later this year  On the other hand  the company plans to move IMGN632 into clinical development before the year end to treat hematological malignancies including acute myeloma leukemia  AML  ImmunoGen has agreements with several big healthcare companies including Amgen Inc  NASDAQ AMGN    Bayer  DE BAYGN   Eli Lilly and Company   NYSE LLY    Novartis   NYSE NVS    Roche  Sanofi  PA SASY  and Takeda  These contracts in turn allow other companies to use ImmunoGen s ADC technology and provide it with funds in the form of license and milestone fees  royalties  clinical materials revenue and R D  research and development  support fees Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-18,Zacks Investment Research,https://www.investing.com/analysis/can-immunogens-key-pipeline-cancer-candidate-drive-growth-200219808,200219808
150450,371966,AMGN,Regeneron And Sanofi Get Favorable Ruling Against Amgen ,opinion,"Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and partner Sanofi  PA SASY   Inc    NYSE SNY   received a favorable ruling from the Court of Appeals for the Federal Circuit relating to Praluent  The court ordered a new trial and vacated the permanent injunction in the dispute concerning Amgen  Inc   s   NASDAQ AMGN   asserted patent claims for antibodies targeting PCSK9  proprotein convertase subtilisin kexin type 9   As a result  Sanofi and Regeneron will continue to commercialize Praluent in the United States We note that Praluent was the first PCSK9 antibody to be approved as adjunct to diet and maximally tolerated statin therapy  It is used for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease  who require additional lowering of  bad   LDL  cholesterol in the United States  Amgen s Repatha was introduced much later in the market We remind investors that Amgen asserted a number of U S  patents  which were subsequently narrowed to patent Nos  8 829 165  the  165 Patent  and 8 859 741  the  741 Patent   and sought a permanent injunction to prevent Regeneron and the Sanofi defendants from commercializing Praluent It was found that the trial court erred on multiple grounds without any substantial evidence regarding written description and enablement  The jury also claimed that the law requires  a written description of the invention   and concluded that Amgen s patents were non obvious  The lack of evidence helped Regeneron and Sanofi to win a favorable ruling The date for the new trial has not been decided by the court yet  Both Regeneron and Sanofi do not anticipate any new trial proceedings to start in 2017 The news should relieve Regeneron and Sanofi  Earlier  Amgen was granted a permanent injunction prohibiting Sanofi and Regeneron from selling Praluent during the term of two of Repatha patents  However  Regeneron and Sanofi appealed against the ruling in a higher court  Following the news  shares of Regeneron have moved up  In fact  shares of the company have outperformed the  year to date  The stock has surged 26 2  compared with the industry s 16  rally during the period Prospects of PCSK9 inhibitors  a new class of cholesterol lowering treatments with blockbuster potential  gained instant popularity even before hitting the market  However  sales of Praluent have failed to impress as the drug is facing significant payer utilization management restrictions in the United States and limited market access in Europe  which are resulting in a low volume of prescriptions 
Zacks Rank   Key Pick
Regeneron currently sports a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is Aduro Biotech   NASDAQ ADRO   which carries a Zacks Rank  2  Buy   You can see  
Aduro s loss estimates per share have narrowed from  1 36 to  1 29 for 2017 over the last 60 days  The company delivered positive earnings surprises in two of the trailing four quarters  the average being 2 53  
5 Trades Could Profit  Big League  from Trump Policies
 If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-10-05,Zacks Investment Research,https://www.investing.com/analysis/regeneron-and-sanofi-get-favorable-ruling-against-amgen-200217469,200217469
150451,371967,AMGN,Mylan Gets Complete Response Letter For Biosimilar Neulasta,opinion,Mylan N V    NASDAQ MYL   suffered a setback following the FDA s Complete Response Letter  CRL  for the company s Biologics License Application  BLA  for MYL 1401H  a proposed biosimilar of Amgen s Inc    NASDAQ AMGN   Neulasta The CRL relates to the pending update of the BLA with certain CMC data from facility requalification activities post recent plant modifications However  the CRL did not raise any questions on biosimilarity  pharmacokinetic pharmacodynamic data  clinical data or immunogenicity Mylan is exploring the world of biosimilars  a market that has the potential to grow to  20 billion in 2020  A partnership with Biocon  and additional collaborations has helped Mylan develop a wide portfolio of biosimilar insulin analog generic products  representing a total brand market value of more than  75 billion in worldwide sales Earlier  the FDA notified Mylan and partner Biocon that the target action date for a biosimilar version of Roche Holding  SIX ROG  AG s   OTC RHHBY   Herceptin  trastuzumab  has been extended to Dec 3  2017  A decision from the FDA was expected by Sep 3 but the review period was extended due to some of the clarificatory information that were needed to be submitted to the agency as part of the process Last week the FDA approved the generic version of Teva Pharmaceutical Industries Limited s   NYSE TEVA   multiple sclerosis drug Copaxone  glatiramer acetate  40 mg mL  thrice weekly    The news boosted investors  sentiment and the company s shares surged on the same  Mylan s stock has increased 1 1  in the last six months compared with the s decline of 17 4  Notably  this is the first generic of Copaxone that has been approved  The FDA also approved a generic for Copaxone 20 mg mL once daily  Since Mylan was one of the first applicants to submit a substantially complete ANDA for glatiramer acetate Injection  40 mg mL  containing a Paragraph IV certification  the company and other first filers may be eligible for 180 days of generic drug exclusivity  According to QuintilesIMS  sales of Copaxone 20mg mL dose was approximately  700 million and  3 64 billion for the 40 mg mL dose for the 12 months period ending July 31  2017  Hence  the generic approval is expected to provide a significant boost to Mylan Zacks RankMylan currently carries a Zacks Rank  2  Buy   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-10,Zacks Investment Research,https://www.investing.com/analysis/mylan-gets-complete-response-letter-for-biosimilar-neulasta-200218274,200218274
150474,371990,AMGN,Merck s Keytruda Gets FDA Nod For Advanced Gastric Cancer,opinion,"Merck   Co   Inc    NYSE MRK   announced that the FDA has approved its anti PD 1 therapy  Keytruda as a monotherapy for third line treatment of advanced gastric or gastroesophageal junction adenocarcinoma Keytruda is already approved for many types of cancers and treatment settings including lung cancer  melanoma  head and neck cancer  classical hodgkin lymphoma and bladder cancer The drug s label has now been expanded to include treatment of heavily pre treated patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumors express PD L1  as determined by an FDA approved test  However  the approval for this tenth new indication for Keytruda comes on an accelerated basis with continued approval dependent on further benefit demonstrated from clinical studies The FDA approval was based on data from the KEYNOTE 059 study Keytruda is key top line driver for Merck and it brought in sales of  881 million in second quarter 2017  up 51  sequentially and 180  year over year Sales continue to be driven by launch of new indications globally  Keytruda sales in the U S  gained particularly from strong momentum in the new indication of first line lung cancer  Outside U S  Keytruda sales were primarily driven by the melanoma indication Meanwhile  the Keytruda development program also significantly advanced this year with regulatory approvals for four new indications in the U S  and two additional indications in Europe  Important approvals include that for advanced bladder cancer in both United States and the EU  advanced microsatellite instability high cancers and first approval as a combination therapy with Eli Lilly   Company s   NYSE LLY   cancer drug Alimta  pemetrexed  and carboplatin  pem carbo     a commonly used chemo regimen  in lung cancer  Further Keytruda data readouts are pending this year Keytruda is continuously growing and expanding into new indications and markets globally  Keytruda is being studied for more than 30 types of cancer in more than 550 studies  including more than 300 combination studies Merck is collaborating with several companies including Amgen  Inc    NASDAQ AMGN    Incyte  Glaxo and Pfizer  Inc    NYSE PFE   separately for the evaluation of Keytruda in combination with other regimens Merck carries a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-09-24,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-gets-fda-nod-for-advanced-gastric-cancer-200215178,200215178
150475,371991,AMGN,Ligand s Captisol Deals Set To Drive Growth In The Long Run,opinion,On Sep 26  2017  we issued an updated report on Ligand Pharmaceuticals Incorporated   NASDAQ LGND   Ligand s leading Captisol formulation technology platform has allowed it to enter into partnerships with several leading drug companies like Novartis AG   NYSE NVS    Merck   Co   Inc    NYSE MRK   and Amgen Inc    NASDAQ AMGN    thus in turn providing it with funds in the form of milestone and royalty payments Ligand receives royalties and milestone payments for several FDA approved products that use its Captisol technology  Ligand s major royalty revenues comes from sales of two key partnered assets   Novartis  Kyprolis and Amgen s Promacta  other latest product approvals include Spectrum s Evomela  Lundbeck s Carnexiv and Melinta Therapeutics  Baxdela  Apart from these  several candidates are in late stage development and expected to bring in royalties to the company once commercialized Regarding the company s internal pipeline  various candidates are under observation and development for indications like diabetes  One such extremely advanced candidate is LGD 6972  presently undergoing a phase II study for treating type II diabetes  This month  the company reported positive top line results from the study  It further expects LGD 6972 to bring in future licensing opportunities Nonetheless  Ligand s entry into the Medical Devices Segment with acquisition of multiple programs owned by CorMatrix is also encouraging However  Ligand obtains Captisol from a single supplier  Hovione   a major global supplier of active pharmaceutical ingredients and drug product intermediates  located in Portugal  Any interruption in Captisol s supply would hit the company s results Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-09-28,Zacks Investment Research,https://www.investing.com/analysis/ligands-captisol-deals-set-to-drive-growth-in-the-long-run-200216198,200216198
150476,371992,AMGN,How Will Trump s Proposed Tax Reform Impact Drug Companies ,opinion,During his presidential campaign  Donald Trump had stressed on tax reforms and promised that bringing down corporate tax would be his top priority as the President of the United States  Keeping his words  Trump proposed changes in tax rates for both individuals and corporates to stimulate economic growth as well as employment growth Tax ReformsThe plan proposes to lower the current corporate tax rate of 35   one of the highest in the world  to 15   This is expected to favorably impact the post tax earnings of companies  A territorial tax system  tax on only domestic income  has also been proposed for American companies so as to create a level playing field  It also suggests the elimination of special tax breaks for companies  Another major reform proposed is the repatriation of trillions of dollars held as cash reserve overseas by the companies with global operations for one time tax  reportedly 10    A similar tax move was made for bringing in overseas cash reserves by the Bush administration in 2004 for one time tax of 5 25   A number of companies repatriated an amount exceeding  300 billion The current tax code allows tax repatriation at 35  rate  However  it gives tax credit for the amount of tax paid in overseas country Anticipated ImpactThe reforms have been proposed to create new jobs and aid economic growth through expanded investment as more cash will available to companies through tax cuts and repatriation  However  the extent to which these steps will be successful is uncertain  A large portion of the repatriated cash in 2004 was used to fund share buybacks and dividend payments  Though the buybacks fueled a stock rally  there was no actual economic growth The tax reforms are expected to benefit companies which have operations around the globe  A similar buyback this time is also expected to help the stocks grow   Large cap pharma companies based in the United Sates with major operations worldwide including J J  Amgen Inc    NASDAQ AMGN    Gilead Sciences and others are sitting on huge pile of cash reserves stashed in overseas countries  The repatriation will benefit these large drug biotech companies more than the tax savings due to rate cutsMoreover  repatriation of cash held overseas will create a surplus in domestic cash reserve  which may fuel merger   acquisition  M A  in the sector  The industry has seen only two major acquisitions this year  Actelion by Johnson   Johnson   NYSE JNJ   and Kite Pharma  Inc    NASDAQ KITE   by Gilead Sciences  Inc    NASDAQ GILD    which is expected to close by 2017 end Let s discuss the impact of tax reform on the some drug biotech giants Johnson   JohnsonJohnson   Johnson is a well known brand all over the world catering to a wide variety of medical needs  The company has paid tax at an effective rate of 16 5   19 7  and 20 6  for 2016  2015 and 2014  respectively  Therefore  a revision of tax rate to 15  will not bring a huge positive change in post tax earnings  As of June end  J J had  12 9 billion in cash reserve  down almost 70  from 2016 year end  The company has used a major chunk of its cash reserves in 2017  Hence  J J is expected to be least impacted by these reforms AmgenThe company has a strong presence in the oncology hematology  cardiovascular disease  inflammation  bone health and nephrology markets  The effective tax rate for Amgen in 2016  2015 and 2014 were 15 7   13  and 7 6   respectively  Hence  a tax rate cut will have minimal effect  Amgen had nearly  35 billion in overseas cash as of 2016 fiscal end  per a Bloomberg report  The total cash reserve of the company has changed minimally in the first six months of 2017  So  the repatriation reform may initiate a buyback  Moreover  after 10  tax  it will have more than  30 billion in domestic cash reserve  if the total overseas cash is repatriated  This increase in domestic cash can also be used in acquiring new drug technologies like CAR T therapy Gilead SciencesGilead recently announced its plan to acquire Kite Pharma for nearly  12 billion  adding the latter s CAR T therapy candidate to its pipeline  Gilead is planning to complete the acquisition through a combination of cash and debt  Per a Bloomberg report  Gilead had  29 3 billion of cash reserves in overseas countries at the end of 2016  A repatriation will help the company to pay off the debt quickly  The effective tax rate has been between 16  and 21   which suggests a minimal impact due to tax rate cut Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-09-28,Zacks Investment Research,https://www.investing.com/analysis/how-will-trumps-proposed-tax-reform-impact-drug-companies-200216195,200216195
150477,371993,AMGN,Radius  RDUS  Enrols First Patient In Breast Cancer Study,opinion,"Radius Health  Inc    NASDAQ RDUS   announced that the first patient has been enroled in the phase I study on pipeline candidate  RAD140 RAD140 is a nonsteroidal selective androgen receptor modulator  SARM  which is being evaluated for the treatment of hormone receptor positive breast cancer  The phase I trial is a safety and dose ranging study in approximately 40 patients suffering from progressive metastatic or locally advanced or metastatic breast cancer  Postmenopausal women with metastatic hormone receptor positive breast cancer will receive escalating doses of RAD140 by oral administration over a period of 28 days in part A of the study  The primary safety outcomes include rate of dose limiting toxicities  adverse events related to treatment and tolerability as measured by dose interruptions or adjustments  In addition  pharmacokinetics  pharmacodynamics and tumor response will also be evaluated The SARM mechanism of action is differentiated from both selective estrogen receptor modulators  SERMs  and selective estrogen receptor degraders  SERDs   Consequently  RAD140 has significant potential to complement future applications of elacestrant  RAD1901  by targeting distinct mechanisms of endocrine resistance We note that an investigational new drug application submitted to the FDA for RAD140 has been accepted  Radius  share price has increased 1 4  year to date compared with the  4 6  gain In April the FDA approved Tymlos  abaloparatide SC  for the treatment of postmenopausal women with high risk osteoporosis for fracture   defined as history of osteoporotic fracture   multiple risk factors for fracture  or patients who have failed or are intolerant to other osteoporosis therapies  Although the osteoporosis market in the United States holds great promise as approximately 1 4 million postmenopausal women suffer osteoporotic fracture each year  Tymlos is expected to face significant competition from Eli Lilly  Co s   NYSE LLY   Forteo and Amgen Inc s   NASDAQ AMGN   Prolia  Moreover  the approved label carries a boxed warning of osteosarcoma  a malignant bone tumor   The company  however  suffered a setback when the CHMP issued a second Day 180 List of Outstanding Issues 
Meanwhile  Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant  RAD1901  for potential use in hormone driven and or hormone resistant breast cancer  and vasomotor symptoms in postmenopausal women 
Zacks Rank   Key Pick
Radius Health currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Aduro Biotech   NASDAQ ADRO    carrying a Zacks Rank  2  Buy   You can see  
Aduro Biotech s loss per share estimates narrowed from  1 46 to  1 29 for 2017 and from  1 41 to  1 26 for 2018 over the last 60 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-01,Zacks Investment Research,https://www.investing.com/analysis/radius-rdus-enrols-first-patient-in-breast-cancer-study-200216482,200216482
150500,372016,AMGN,OncoSec Medical Inc   ONCS   Seeks Accelerated Approval To Treat,opinion,"The fight against cancer has always been at the forefront of the biotech industry  As the methods of attacking and healing cancer can vary greatly between different companies  researchers are always searching for newer and more effective ways to combat the disease  Likewise  experienced biotech investors are always on the lookout for emerging opportunities that show promise in bringing a new treatment to the table  OncoSec Medical Incorporated  NASDAQ ONCS  is maturing as one of those niche companies that has earned significant interest from investors and sector partners alike  thanks to its robust and differentiated approach to cancer treatment 
ONCS Advances With Novel Platform
OncoSec  a San Diego based biotechnology company  is combining over two decades of research and development processes that may very well define a new chapter in how disease gets treated  The company s mission is laser focused on developing new and effective ways of treating various types of cancer  specifically through their innovative and proprietary immunotherapy treatments  OncoSec s focus is intent on developing immunotherapy benefits designed to address an unmet medical need in the market by providing a proven safe and clinically effective treatment for anti PD 1 relapse refractory patients  alongside other cancer indications 
Immunotherapy  as biotech investors know  has become an industry buzz word  and in its simplest form  works by using the body s immune system to engage its war against cancer  The therapy attempts to increase the uptake and absorption of DNA based treatments directly into the tumor  OncoSec is well on their way to demonstrating best in class potential built out by compelling proof of concept clinical trials  Data published by ONCS is impressive  showing a 48  BORR  Best Overall Response Rate  in patients diagnosed with immunologically  cold  tumors   Cold  tumors are those designated as difficult for the body s immune system to treat on its own  and carries a high likelihood of relapse 
Recognizing its value  immunotherapy is now considered a primary option for tumor treatment  and scientists are looking toward innovative and combination therapies to treat these diseases  To address that need  OncoSec has established its use of electroporation technology to deliver a safe and targeted method of gene transmission  Additionally  ONCS is working to broaden its deliverables by building upon multi gene plasmid constructs to meet next generation treatment strategies  OncoSec has secured Fast Track Designation from the FDA  and alongside an Orphan Drug Status for additional pipeline candidates  the company sits on the verge of earning an FDA review for accelerated approval for their lead program in 2019  Furthermore  ONCS has in place a drug supply and clinical collaboration agreement with Merck  NYSE MRK   a globally recognized player in the pharmaceutical industry  Overall  the convincing clinical capability built out by OncoSec may indeed provide them with a sizable advantage amongst competitors in securing a valuable and competitive place in the market 
OncoSec s Approach Makes A Difference
Although OncoSec may be a relatively small company at the moment  the company s targeted strategy has allowed them to not only keep pace with their competitors but in several clinical aspects surpasses them  supported by published and compelling clinical data  While most competitors  programs are still in Phase 1 or 2 studies  OncoSec is now advancing its Phase 2 registration enabling clinical trials in an expedited manner  Additionally  the company s projected milestone for treatment approval in early 2019 suggests that OncoSec may further distance themselves from market competitors and emerge as a market leader in targeted cancer treatment  enjoying licensing and partnership opportunities intended to exploit the multi billion dollar market potential 
Being a disruptor may be an advantage  and the innovative technology within OncoSec s pipeline is a key factor that sets the company apart from its competitors  potentially leading to ONCS s ability to alter the course of cancer treatment  OncoSec s flagship treatment  ImmunoPulse  IL 12  is an innovative  non viral gene delivery platform designed to utilize the power of the human immune system to target and attack tumors in the body  The non viral treatment works by introducing a controlled amount of IL 12 in the tumor s microenvironment  which allows the immune system to recognize the tumor and assemble an army of killer t cells to eliminate the diseased target  In clinical trials  the ImmunoPulse  IL 12 system was shown to deliver equal gene transmission rates  while maintaining a higher safety profile than other currently available viral and non viral therapies  ImmunoPulse  IL 12 benefits are proven and validated through multiple human clinical trials across multiple disease types  and as there is no limit on size or number of genes delivered to the patient  the therapy can be specifically targeted to address multiple disease indications  With this advantage  the device carries the opportunity to be the first of its kind on the market  putting OncoSec in a potentially lucrative and enviable position by cementing a landscape for both a strategic and partnership opportunity 
The ImmunoPulse  Effect  A Key Advantage
As stated earlier  the ImmunoPulse  IL 12 system works by delivering a certain amount of IL 12 into the patient s tumor  IL 12  or Interleukin 12  is a powerful and pro inflammatory cytokine  and tavokinogene teslaplasmid  or  Tavo   is a plasmid DNA encoding for IL 12  The process plays out by Tavo getting injected into the microenvironment of the tumor  then delivering the Tavo inside the cells  which in turn secretes the IL 12 inside the tumor  Subsequently  the body s T cells can better identify and determine how to fight against the cancerous cells  leading to a proficient anti tumor response from the body  The intratumoral delivery made possible by the ImmunoPulse  device carries a notably low toxicity level for any immunotherapeutic treatment  making it a safe yet powerful treatment unlike anything currently on the market  Another important feature of the ImmunoPulse  system is its flexibility  The platform allows for precisely measurable variability in the number of genes delivered to a targeted area  which allows physicians to adjust the treatment to bring out the best possible anti tumor immune response in patients  Finally  and intrinsically important  is that the device has proven effective in its ability to deliver multiple genes into the tumor simultaneously  which may significantly reduce the likelihood for the tumor to avoid the internal defenses of the body s immune system after treatment 
And  while industry limitations exist in overcoming the tumors ability to challenge an immune response  the strategy in place by OncoSec  utilizing the ImmunoPulse  platform  aims to target and defeat that limitation  Currently  the majority of patients with solid tumors do not respond to anti PD 1 therapy  regardless of the cancer type  This occurrence  of course  begs the question  what is causing these patients to not receive any benefit from this kind of therapy  Scientists have found that in general  patients who DO respond to anti PD 1 therapies have what is known as a  hot  or  inflamed  tumor  meaning that the tumor already has a high expression of PD L1 in its cells  along with a higher density of tumor infiltrating lymphocytes  A  hot  tumor is more easily detected by the body s immune system  thus more responsive to anti PD 1 therapies  opening the door to OncoSec s novel technology  Complimented by the ImmunoPulse  platform  interim clinical studies have shown that the ONCS treatment has the potential to convert  cold  tumors to  hot   actually increasing the patient s odds of responding positively to anti PD 1 therapies  During these clinical trials  ImmunoPulse  IL 12 was shown to have a noticeable response in patients that were confirmed to have  cold  tumors  After the treatment regimen  results showed a 48  Best Overall Response Rate  BORR  in patients provided with ImmunoPulse  IL 12 combined with anti PD 1  proving the value in patients who initially had a lower chance of benefiting from the anti PD 1 treatment alone  The published data suggests that people who were unable to receive healing treatment are now able to significantly increase their chances at responding to the same therapy after using ImmunoPulse  IL 12  If these test results prove to be durable throughout the upcoming clinical trials  OncoSec could be very well positioned to introduce a lucrative and game changing cancer treatment technology to a receptive market 
All Signs Point To Yes
Alongside the development of their ImmunoPulse  IL 12 treatment  OncoSec is strategizing on how to best take advantage of the company s expected developments and market opportunities  Primarily  ONCS has set their target patient population to those with a pathological diagnosis of unresectable or metastatic melanoma  stage III IV  that fail anti PD1 therapy  Currently  there are over 10 200 of these patients in the United States that could potentially benefit from ImmunoPulse  IL 12 therapy in combination with anti PD 1  For example  there are an estimated 9 900 patients currently undergoing anti PD 1 therapy in the U S  Of these 9 900 people  around 6 400 have shown poor response rates to anti PD 1 therapy alone  demonstrating that a significant subset of individuals could receive a tremendous benefit from treatment via the ImmunoPulse  IL 12 platform  And  with over 80 000 new cases of melanoma diagnosed in the U S  per year  OncoSec s ImmunoPulse  device  utilizing combination therapies  could prove to be a revolutionary treatment for those who are unresponsive to current procedures  And  researchers within the company have expressed that their early proof of concept in melanoma patients indicates a potential for the ImmunoPulse  IL 12 platform to work on other ailments with similar characteristics  For instance  diseases such as triple negative breast cancer and head and neck cancers are known to have accessible tumors  and similar to melanoma  also carry a very high rate of non response to anti PD 1 therapy alone  The characteristics of both of these cancers point to a likely possibility of patients responding to the ImmunoPulse  IL 12 platform similarly to how it works in patients with melanoma  and OncoSec has established plans to investigate additional ways of broadening the device s reach  From the inhibition of a tumor s immunosuppressive environment to cell signaling and trafficking  OncoSec researchers are already aware of many potential applications of Interleukin 12 delivered through the ImmunoPulse  device  and company management acknowledges that the application s power may be an extremely profitable opportunity 
Investors will be pleased to know that the market and medical community interest in melanoma and immunotherapy treatments are significant and that a gap in the market is waiting to get filled by a responsive company  like ONCS  who is demonstrating the ability to provide a reliable  safe  and curable treatment to cancer patients  In the past  companies have spent vast sums of money on earlier programs that dealt with the same issues focused on by OncoSec  For example  Amgen s 2011 acquisition of BioVex demonstrated the proof of interest and need for an effective melanoma treatment  BioVex was a company that had been researching and developing a treatment against melanoma called Imlygic  also known as T VEC  T VEC was an oncolytic viral therapy that aimed to promote a similar anti tumor response to OncoSec s ImmunoPulse   The company showed promise  and in 2011  was purchased by Amgen  NASDAQ AMGN  for  1 billion in hopes that the treatment would prove revolutionary  Unfortunately  as additional clinical data continued to become available  it was found that the treatment was not as effective as initially hoped  and as of 2016  there is little evidence that the treatment was able to extend the life of people with melanoma  Additionally  T VEC was known to cause a myriad of undesirable side effects  including fever  nausea  and other flu like symptoms in over 30  of those treated  Although the treatment proved unsuccessful  the BioVex deal was still one of the largest deals in the immunotherapy field at the time and signaled a voracious interest in bringing to market a more effective product  And  keeping this goal in mind  OncoSec may hold the potential to provide the treatment that T VEC was unable to deliver 
ONCS On The Fast Track
OncoSec  in some respects  is in a similar position to BioVex before their acquisition by Amgen   the company has robust clinical data to date  and as their Phase 2 data continues to unfold  the company is sure to spark the interest of respected players within the biotech industry  Not only has the initial testing of their ImmunoPulse  IL 12 platform brought positive results  but it is also doing so without causing many of the uncomfortable side effects caused by earlier and similar treatments  Additionally  the FDA s granting of Orphan Drug Status and Fast Track Approval to the company will allow them to more quickly develop and undergo research trials for their products  removing many of the restrictions that may be faced by competitors  Finally  as stated earlier  OncoSec has indicated that their ImmunoPulse  system is likely able to work on multiple tumor types  allowing the company to expand their label across different kinds of diseases  rather than simply melanoma 
As for what s currently in store for OncoSec  the company plans to initiate their enrollment for a phase 2 trial and collaboration with Merck  referred to as PISCES  by the end of 2017  The company also intends to hold an End of Phase 2  EOP2  meeting with the FDA during the 1H of 2018  which is anticipated to grant ONCS with an accelerated approval path for anti PD 1 non responders in melanoma  along with an approval of their plans for phase 3 trials  This phase 3 confirmatory study is expected to run throughout 2018 and carry on into late 2019  where the company has set milestone goals to obtain a marketing authorization to penetrate a market in need of a viable and responsive cancer treatment 
OncoSec may be considered by some to be a small company  but what can t get overlooked is that they have built an enviable foundation and scientific infrastructure  And  from a position of clinical strength  ONCS may be ideally placed to reap enormous benefit from the development of their promising immunotherapy treatment system  If ImmunoPulse  IL 12  with combination therapy  continues to deliver positive results  OncoSec may very well be the company the market has been waiting to embrace  providing game changing cancer treating technology that may alter the therapeutic landscape and fill a void to address unmet medical needs 
Disclaimer   The author has no positions in any stock mentioned herein nor plans to open a position within the next 72 hours ",2017-09-12,Modest Money,https://www.investing.com/analysis/oncosec-medical-inc-oncs-stock-seeks-accelerated-approval-to-treat-200212684,200212684
150501,372017,AMGN,Novartis Announces Positive Data On Urticaria Drug Xolair ,opinion,"Novartis AG   NYSE NVS   announced new data on chronic spontaneous urticaria  CSU  drug Xolair at the 26th European Academy of Dermatology and Venereology Congress in Geneva  Switzerland from a phase IIIb study  OPTIMA 
OPTIMA is a phase IIIb international  multicenter  randomized  open label  non comparator study  314 patients with CSU symptoms despite treatment with H1 antagonists were initially randomized 4 3 to Xolair 150 or 300 mg for 24 weeks in the first dosing period  Thereafter  patients who responded well to the treatment were given a break and then  if symptoms returned were retreated 
Per the data  90  of CSU patients who responded well to initial treatment with Xolair regained symptom control within 12 weeks following a treatment interruption based on Weekly Urticaria Activity Score  UAS7  criteria  UAS7  6   Data from the study re confirmed that almost two thirds of patients treated with Xolair 300 mg for 6 months are well controlled 
We note that Xolair is approved for the treatment of CSU in the EU and the United States  chronic idiopathic urticaria   Xolair is also approved for the treatment of moderate to severe or severe persistent allergic asthma 
Novartis has a collaboration agreement with Roche Holdings AG   OTC RHHBY   to develop and co promote Xolair in the United States 
We note that Novartis is a global leader in Immunology   Dermatology with drugs like Cosentyx  Xolair  Zortress and Myfortic and Ilaris 

 
Novartis  stock has rallied 20 3  in the year so far compared with the  s 19 4  gain 
Novartis is currently going through a transitional stage  The company s blockbuster drug  Diovan  is facing stiff generic competition in the United States  EU and Japan  Gleevec lost exclusivity in the United States in February 2016  The company also lost patent protection for the drug in EU in December 2016 leading to generic competition 
The loss of patent protection for these top selling drugs continue to hurt sales  Hence  Novartis expects the next growth phase to begin in 2018 driven by Cosentyx  in psoriasis  psoriatic arthritis and ankylosing spondylitis indications   Entresto  Kisqali and a deep pipeline with candidates like BAF312  AMG 334  RTH258 
Moreover  with the recent approval of Kymriah  Novartis is the first company to bring CAR T cell therapy for cancer treatment  Going forward  we expect that the approval of new drugs and label expansion of existing ones to bode well for Novartis 
On the other hand  generic division  Sandoz is a leader in biosimilar market with five marketed biosimilars  Omnitrope  a human growth hormone  Binocrit  an erythropoiesis stimulating agent used to treat anemia  and filgrastim for neutropenia under the brand names Zarzio outside the United States and Zarxio in the United States   
The company plans to launch five major oncology and immunology biosimilars between 2017 and 2020  This includes a biosimilar version of Rituxan  rituximab   which was approved by the European Commission in June 2017  marketed as Rixathon   In August 2016  Sandoz s Erelzi  a biosimilar version of Amgen  Inc  s   NASDAQ AMGN   blockbuster drug Enbrel gained approval in the United States for five indications  Erelzi was also approved by the European Commission in 2017 
Zacks Rank   Stock to Consider
Novartis currently carries a Zacks Rank  3  Hold  
Aduro Biotech  Inc    NASDAQ ADRO   is a better ranked biomedical company with a Zacks Rank  2  Buy   You can see  
Aduro s loss estimates narrowed 9 6  to  1 32 for 2017 and 20  to  1 24 for 2018 over the last 60 days  The company delivered an average earnings beat of 2 53  for the four trailing quarters 
New Report  An Investor s Guide to CybersecurityCyberattacks have become more frequent and destructive than ever  In fact  they re expected to cause  6 trillion per year in damage by 2020  The cybersecurity industry is expanding quickly in response to these threats  In fact  a projected  170 billion per year will be spent to protect consumer and corporate assets  Zacks has just released Cybersecurity  An Investor s Guide to Locking Down Profits  which reveals 4 promising investment candidates ",2017-09-18,Zacks Investment Research,https://www.investing.com/analysis/novartis-announces-positive-data-on-urticaria-drug-xolair-200213987,200213987
150502,372018,AMGN,Pfizer Sues J J  Accuses It Of Preventing Inflectra Uptake,opinion,Pfizer  Inc    NYSE PFE   has filed a lawsuit in a U S  district court alleging that Johnson   Johnson   NYSE JNJ   is resorting to unfair practices to prevent sale of Inflectra   Pfizer s biosimilar version of J J and Merck  Co   Inc  s   NYSE MRK   blockbuster rheumatoid arthritis drug  Remicade  Pfizer s biosimilar version is available at a Wholesale Acquisition Cost  WAC   which is 19  lower than J J s referenced product Pfizer s shares were up 1 6  on Wednesday while J J s shares were down 1 5   However  Pfizer s shares have underperformed the  this year so far  The stock has returned 10 8  during this period  comparing unfavorably with an increase of 16 7  for the industry Pfizer alleged in a complaint filed in the U S  District Court for the Eastern District of Pennsylvania that J J has entered into  biosimilar exclusion  contracts with U S  insurers  These contracts encourage insurers not to cover Inflectra  thereby making it non easily accessible to patients and protecting its referenced product  Pfizer also claimed that anticompetitive contracts were being offered to hospitals  which encouraged discounts on purchase of Remicade on the condition that they do not buy the biosimilar versions  Pfizer claims these unfair practices benefit sales of J J s referenced product  which is a key revenue generator for the latter We remind investors that at the second quarter conference call held in August  Pfizer had said that Inflectra penetration in the United States has been slower than expected as it was experiencing access challenges among national commercial payers On the other hand  J J had said at its second quarter conference call held in July that the rate of penetration of Inflectramay be modest  The latest lawsuit suggests that J J could be responsible for the slow sales of Inflectra Please note that in April this year  Samsung  KS 005930  Bioepis  biosimilar version of Remicade also received FDA approval Pfizer had launched Inflectra in the United States in November last year and the biosimilar is also marketed in ex U S  markets  Inflectra generated sales of  23 million in the United States and  94 million globally in second quarter Biosimilars are essentially cheaper versions of expensive biologic drugs but are complex to make unlike traditional generic drugs  While biosimilars have been available in the EU for quite a while  there was no regulatory pathway for biosimilars in the United States for a long time  However  this changed with the passing of The Biologics Price Competition and Innovation Act of 2009  BPCI Act  as part of the Affordable Care Act that President Obama signed into law in March 2010 Several pharma as well as biotech companies are involved in the development of biosimilars The first biosimilar to gain approval in the United States was Sandoz s Zarxio  a biosimilar version of Amgen Inc  s   NASDAQ AMGN   Neupogen  Zarxio was launched in the United States in September 2015  Inflectra was the second biosimilar to gain approval Other approved biosimilars in the country  include Sandoz s Erelzi  a biosimilar to Amgen s Enbrel  etanercept  and Amgen s Amjevita  a biosimilar version of Abbvie s Humira  However  these have not been launched yet due to ongoing litigation Earlier this month  FDA approved the first cancer biosimilar  Amgen and Allergan s Mvasi  a biosimilar version of Roche s blockbuster cancer drug  Avastin Biosimilars were expected to reduce health care costs and provide a large number of patients with access to much needed biologic treatments  However  so far biosimilars have not seen much commercial success and are yet to make a significant dent in referenced product sales in the United States The fight between these two drug giants is likely to aid efforts to lower drug prices through increased biosimilar availability Pfizer carries a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge  With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ,2017-09-20,Zacks Investment Research,https://www.investing.com/analysis/pfizer-sues-jj-accuses-it-of-preventing-inflectra-uptake-200214731,200214731
150503,372019,AMGN,4 Sell Ranked Biotech Stocks With Falling Estimates To Avoid,opinion,"The biotech industry witnessed a rebound in 2017 despite facing some odds in the previous year  The industry faced some challenges like rising competition  pipeline setbacks  slowdown in growth of mature products and generic competition for certain key drugs in 2016 
However  we have seen the trend reversing in 2017 with more FDA approvals  new product sales ramp up  R D success and innovation  strong clinical study results and continued strong performance of some legacy products  These positive factors are expected to continue to contribute to the sector s growth through the rest of this year and maybe the next 
The NASDAQ Biotechnology Index has gained 25 6  so far this year  This is in sharp contrast to last year s performance when the index was down 22  
Some major recent events that contributed to the rally were the announcement by Gilead Sciences   NASDAQ GILD   to acquire immunotherapy focused company Kite Pharma   NASDAQ KITE    and the second was the FDA approval of the first gene therapy in the United States   Novartis AG s   NYSE NVS   Kymriah 
Recently  the FDA also approved the first cancer biosimilar   Amgen   NASDAQ AMGN   and Allergan s Mvasi  a biosimilar version of Roche s   OTC RHHBY   blockbuster cancer drug  Avastin 
Though the momentum in the biotech sector is likely to continue  it s a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio 
4 Sell Rated Stocks to Avoid
Getting rid of underperforming stocks at the right time helps maximize portfolio returns  It will be tricky to avoid stocks from an industry which is doing well  However  we have taken the help of the to shortlist the stocks that should be dumped from the vast universe of biotech sector  We have picked stocks that carry a Zacks Rank  4  Sell  or 5  Strong Sell   You can see  
Further we narrowed down the list  and selected those which have a  of D or F  Under no circumstance should one buy a stock with a Zacks Rank  4  Sell  or  5  Strong Sell  and a VGM Score of D or F We have also taken into consideration stocks that witnessed negative estimate revisions for the current year as well as the next year over the last 60 days as these are likely to see further negative estimate revisions and should be dumped 
Clearside BioMedical  Inc    NASDAQ CLSD    a late stage clinical biopharmaceutical company is developing first in class drug therapies to treat back of the eye diseases  The company has been incurring losses since its inception and also expects to incur losses over the next few years  Currently  this Alpharetta  GA based company carries a Zacks Rank  4 and has a VGM Score of F 
Further  over the last 60 days  the Zacks Consensus loss Estimate has widened by 19 8  for 2017 and 15  for 2018  Shares of the company have declined 14 4  year to date  underperforming the  s gain of 16 4  

Abeona Therapeutics Inc    NASDAQ ABEO   a clinical stage biopharmaceutical company focused on developing novel therapies for life threatening rare genetic diseases   The company currently carries a Zacks Rank  4 and has a VGM Score of F  Over the last 60 days  the Zacks Consensus loss Estimate has widened by 24 5  for 2017 and 21 7  for 2018 
Reata Pharmaceuticals  Inc    NASDAQ RETA   a biopharmaceutical company currently carries a Zacks Rank  4 and has a VGM Score of F  Over the last 60 days  the Zacks Consensus loss Estimate has widened by 39 5  for 2017 and 23 8  for 2018 
Urogen Pharma Ltd    NASDAQ URGN   is a clinical stage biopharmaceutical company developing treatments to address unmet needs in the field of urology  The company currently carries a Zacks Rank  4 and has a VGM Score of D  Over the last 60 days  the Zacks Consensus loss Estimate has widened by 43 3  for 2017 and 21 9  for 2018 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-09-21,Zacks Investment Research,https://www.investing.com/analysis/4-sellranked-biotech-stocks-with-falling-estimates-to-avoid-200214752,200214752
150537,372053,AMGN,Immunogen Inks Deal With Jazz Pharma To Develop ADC Molecule,opinion,ImmunoGen Inc    NASDAQ IMGN   announced a strategic collaboration and option agreement   with Jazz Pharmaceuticals PLC   NASDAQ JAZZ   for the development and commercialization of two early stage  hematology related antibody drug conjugate  ADC  programs  and also another l program which will be designated during the term of the agreement The programs include IMGN779   a CD33 targeting ADC and which is in phase I study for the treatment of acute myeloid leukemia  AML  and IMGN632 also being evaluated in a preclinical study for treating hematological malignancies including AML   IMGN632 is expected to enter the clinic before the end of 2017 Consequently  ImmunoGen s shares rose by almost 17  following the news  The shares  have also outperformed the  year to date  The stock has skyrocketed 288 7  against the industry s decline of 1 2  in the same time frame Per the agreement  Immunogen will take care of the the development of the three ADC programs prior to any potential opt in by Jazz  Following any opt in  Jazz will be responsible for any further development as well as for potential regulatory submissions and commercialization Per the deal  Jazz will make an upfront payment of  75 million to ImmunoGen  Additionally  it will also pay up to  100 million in development funding over seven years to support the three ADC programs  For each program  Jazz may exercise its opt in right at any time prior to a pivotal study or any time prior to a biologics license application  BLA   For each program for which Jazz elects to opt in  ImmunoGen would be eligible to receive milestone payments based on certain pre decided conditionsImmunogen believes that the deal with Jazz will enable it to advance and speed up the development of its early stage novel ADC assets  The deal also provides Immunogen with sufficient funding to support these programs  and gives the right to co commercialize one of these assets On the other hand  Jazz believes that this collaboration will help it to expand its oncology portfolio with the potential addition of multiple innovative antibody drug conjugates ImmunoGen is focused on the development of targeted cancer therapeutics using its proprietary ADC technology  ImmunoGen s ADC technology is also used in Roche s   OTC RHHBY   marketed product  Kadcyla  in three other development stage candidates  in its own pipeline  and in development programs by its partners Amgen   NASDAQ AMGN    Bayer AG  DE BAYGN   Biotest  CytomX  Eli Lilly  Novartis  Sanofi  PA SASY  and Takeda  ImmunoGen  Inc  Price    Zacks RankImmunoGen currently carries a Zacks Rank  3  Hold   You can see  4 Surprising Tech Stocks to Keep an Eye OnTech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really take off ,2017-08-29,Zacks Investment Research,https://www.investing.com/analysis/immunogen-inks-deal-with-jazz-pharma-to-develop-adc-molecule-200210505,200210505
150538,372054,AMGN,Amgen AstraZeneca Asthma Candidate Tezepelumab Shows Promise,opinion,"Amgen Inc    NASDAQ AMGN   and AstraZeneca plc   NYSE AZN   announced that their pipeline candidate tezepelumab reduced annual asthma exacerbation rate   AAER    a measure of deterioration of asthma  in PATHWAY study in patients with severe  uncontrolled asthma  Tezepelumab  an anti thymic stromal lymphopoietin monoclonal antibody  is being studied in the phase IIb PATHWAY study The results from the study were also published by the New England Journal of Medicine and will be presented at the European Respiratory Society  ERS  International Congress 2017 in Milan Amgen s shares are up 22  so far this year  outperforming the  s gain of 15 7  in that period AstraZeneca s shares have underperformed its  so far this year  The company rose 11  while the industry gained 12 6  in the period The PATHWAY study compared three doses of the candidate   70 mg or 210 mg every four weeks or 280 mg every two weeks   to a placebo  Tezepelumab was administered as an add on therapy in patients who have experienced asthma exacerbations and uncontrolled asthma despite treatment with asthma controllers like corticosteroids  Data from the study demonstrated that tezepelumab achieved significant reduction in AAER when compared to placebo  In fact  the candidate showed a reduction of 61   71  and 66  for 70 mg  210 mg and 280 mg doses  respectively Tezepelumab has also achieved significant and clinically meaningful reductions in the exacerbation rate irrespective of baseline blood eosinophil count  It also improved lung function at all doses and in asthma control at the two higher doses Per the press release  around 315 million people are affected with asthma globally with up to 10  of them having severe asthma  which can become uncontrolled despite receiving high doses of standard of care medicines  These uncontrolled asthma patients then can  in addition  be treated with chronic oral corticosteroids  Tezepelumab can help these patients to control further deterioration of the disease However  the asthma market is crowded with treatments like GlaxoSmithKline plc s   NYSE GSK   Nucala and Teva Pharmaceutical Industries Limited s   NYSE TEVA   Cinqair available  Moreover  AstraZeneca itself is developing benralizumab for treating asthma Amgen Inc  Price and Consensus
    Amgen and AstraZeneca currently have a Zacks Rank  3  Hold   You can see  Astrazeneca  LON AZN  PLC Price and Consensus
    One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-09-06,Zacks Investment Research,https://www.investing.com/analysis/amgenastrazeneca-asthma-candidate-tezepelumab-shows-promise-200211946,200211946
150539,372055,AMGN,OncoSec Medical Seeks Accelerated Approval,opinion,"The fight against cancer has always been at the forefront of the biotech industry  As the methods of attacking and healing cancer can vary greatly between different companies  researchers are always searching for newer and more effective ways to combat the disease  Likewise  experienced biotech investors are always on the lookout for emerging opportunities that show promise in bringing a new treatment to the table  OncoSec Medical  NASDAQ ONCS  is maturing as one of those niche companies that has earned significant interest from investors and sector partners alike  thanks to its robust and differentiated approach to cancer treatment 
ONCS Advances With Novel Platform
OncoSec  a San Diego based biotechnology company  is combining over two decades of research and development processes that may very well define a new chapter in how disease gets treated  The company s mission is laser focused on developing new and effective ways of treating various types of cancer  specifically through their innovative and proprietary immunotherapy treatments  OncoSec s focus is intent on developing immunotherapy benefits designed to address an unmet medical need in the market by providing a proven safe and clinically effective treatment for anti PD 1 relapse refractory patients  alongside other cancer indications 
Immunotherapy  as biotech investors know  has become an industry buzz word  and in its simplest form  works by using the body s immune system to engage its war against cancer  The therapy attempts to increase the uptake and absorption of DNA based treatments directly into the tumor  OncoSec is well on their way to demonstrating best in class potential built out by compelling proof of concept clinical trials  Data published by ONCS is impressive  showing a 48  BORR  Best Overall Response Rate  in patients diagnosed with immunologically  cold  tumors   Cold  tumors are those designated as difficult for the body s immune system to treat on its own  and carries a high likelihood of relapse 
Recognizing its value  immunotherapy is now considered a primary option for tumor treatment  and scientists are looking toward innovative and combination therapies to treat these diseases  To address that need  OncoSec has established its use of electroporation technology to deliver a safe and targeted method of gene transmission  Additionally  ONCS is working to broaden its deliverables by building upon multi gene plasmid constructs to meet next generation treatment strategies  OncoSec has secured Fast Track Designation from the FDA  and alongside an Orphan Drug Status for additional pipeline candidates  the company sits on the verge of earning an FDA review for accelerated approval for their lead program in 2019  Furthermore  ONCS has in place a drug supply and clinical collaboration agreement with Merck  NYSE MRK   a globally recognized player in the pharmaceutical industry  Overall  the convincing clinical capability built out by OncoSec may indeed provide them with a sizable advantage amongst competitors in securing a valuable and competitive place in the market OncoSec s Approach Makes A DifferenceAlthough OncoSec may be a relatively small company at the moment  the company s targeted strategy has allowed them to not only keep pace with their competitors but in several clinical aspects surpasses them  supported by published and compelling clinical data  While most competitors  programs are still in Phase 1 or 2 studies  OncoSec is now advancing its Phase 2 registration enabling clinical trials in an expedited manner  Additionally  the company s projected milestone for treatment approval in early 2019 suggests that OncoSec may further distance themselves from market competitors and emerge as a market leader in targeted cancer treatment  enjoying licensing and partnership opportunities intended to exploit the multi billion dollar market potential 
Being a disruptor may be an advantage  and the innovative technology within OncoSec s pipeline is a key factor that sets the company apart from its competitors  potentially leading to ONCS s ability to alter the course of cancer treatment  OncoSec s flagship treatment  ImmunoPulse  IL 12  is an innovative  non viral gene delivery platform designed to utilize the power of the human immune system to target and attack tumors in the body  The non viral treatment works by introducing a controlled amount of IL 12 in the tumor s microenvironment  which allows the immune system to recognize the tumor and assemble an army of killer t cells to eliminate the diseased target  In clinical trials  the ImmunoPulse  IL 12 system was shown to deliver equal gene transmission rates  while maintaining a higher safety profile than other currently available viral and non viral therapies  ImmunoPulse  IL 12 benefits are proven and validated through multiple human clinical trials across multiple disease types  and as there is no limit on size or number of genes delivered to the patient  the therapy can be specifically targeted to address multiple disease indications  With this advantage  the device carries the opportunity to be the first of its kind on the market  putting OncoSec in a potentially lucrative and enviable position by cementing a landscape for both a strategic and partnership opportunity The ImmunoPulse  Effect  A Key
Advantage
As stated earlier  the ImmunoPulse  IL 12 system works by delivering a certain amount of IL 12 into the patient s tumor  IL 12  or Interleukin 12  is a powerful and pro inflammatory cytokine  and tavokinogene teslaplasmid  or  Tavo   is a plasmid DNA encoding for IL 12  The process plays out by Tavo getting injected into the microenvironment of the tumor  then delivering the Tavo inside the cells  which in turn secretes the IL 12 inside the tumor  Subsequently  the body s T cells can better identify and determine how to fight against the cancerous cells  leading to a proficient anti tumor response from the body  The intratumoral delivery made possible by the ImmunoPulse  device carries a notably low toxicity level for any immunotherapeutic treatment  making it a safe yet powerful treatment unlike anything currently on the market  Another important feature of the ImmunoPulse  system is its flexibility  The platform allows for precisely measurable variability in the number of genes delivered to a targeted area  which allows physicians to adjust the treatment to bring out the best possible anti tumor immune response in patients  Finally  and intrinsically important  is that the device has proven effective in its ability to deliver multiple genes into the tumor simultaneously  which may significantly reduce the likelihood for the tumor to avoid the internal defenses of the body s immune system after treatment 
And while industry limitations exist in overcoming the tumors ability to challenge an immune response  the strategy in place by OncoSec  utilizing the ImmunoPulse  platform  aims to target and defeat that limitation  Currently  the majority of patients with solid tumors do not respond to anti PD 1 therapy  regardless of the cancer type  This occurrence  of course  begs the question  what is causing these patients to not receive any benefit from this kind of therapy  Scientists have found that in general  patients who DO respond to anti PD 1 therapies have what is known as a  hot  or  inflamed  tumor  meaning that the tumor already has a high expression of PD L1 in its cells  along with a higher density of tumor infiltrating lymphocytes  A  hot  tumor is more easily detected by the body s immune system  thus more responsive to anti PD 1 therapies  opening the door to OncoSec s novel technology  Complimented by the ImmunoPulse  platform  interim clinical studies have shown that the ONCS treatment has the potential to convert  cold  tumors to  hot   actually increasing the patient s odds of responding positively to anti PD 1 therapies  During these clinical trials  ImmunoPulse  IL 12 was shown to have a noticeable response in patients that were confirmed to have  cold  tumors  After the treatment regimen  results showed a 48  Best Overall Response Rate  BORR  in patients provided with ImmunoPulse  IL 12 combined with anti PD 1  proving the value in patients who initially had a lower chance of benefiting from the anti PD 1 treatment alone  The published data suggests that people who were unable to receive healing treatment are now able to significantly increase their chances at responding to the same therapy after using ImmunoPulse  IL 12  If these test results prove to be durable throughout the upcoming clinical trials  OncoSec could be very well positioned to introduce a lucrative and game changing cancer treatment technology to a receptive market All Signs
Point To Yes
Alongside the development of their ImmunoPulse  IL 12 treatment  OncoSec is strategizing on how to best take advantage of the company s expected developments and market opportunities  Primarily  ONCS has set their target patient population to those with a pathological diagnosis of unresectable or metastatic melanoma  stage III IV  that fail anti PD1 therapy  Currently  there are over 10 200 of these patients in the United States that could potentially benefit from ImmunoPulse  IL 12 therapy in combination with anti PD 1  For example  there are an estimated 9 900 patients currently undergoing anti PD 1 therapy in the U S  Of these 9 900 people  around 6 400 have shown poor response rates to anti PD 1 therapy alone  demonstrating that a significant subset of individuals could receive a tremendous benefit from treatment via the ImmunoPulse  IL 12 platform  And  with over 80 000 new cases of melanoma diagnosed in the U S  per year  OncoSec s ImmunoPulse  device  utilizing combination therapies  could prove to be a revolutionary treatment for those who are unresponsive to current procedures  And  researchers within the company have expressed that their early proof of concept in melanoma patients indicates a potential for the ImmunoPulse  IL 12 platform to work on other ailments with similar characteristics  For instance  diseases such as triple negative breast cancer and head and neck cancers are known to have accessible tumors  and similar to melanoma  also carry a very high rate of non response to anti PD 1 therapy alone  The characteristics of both of these cancers point to a likely possibility of patients responding to the ImmunoPulse  IL 12 platform similarly to how it works in patients with melanoma  and OncoSec has established plans to investigate additional ways of broadening the device s reach  From the inhibition of a tumor s immunosuppressive environment to cell signaling and trafficking  OncoSec researchers are already aware of many potential applications of Interleukin 12 delivered through the ImmunoPulse  device  and company management acknowledges that the application s power may be an extremely profitable opportunity 
Investors will be pleased to know that the market and medical community interest in melanoma and immunotherapy treatments are significant and that a gap in the market is waiting to get filled by a responsive company  like ONCS  who is demonstrating the ability to provide a reliable  safe  and curable treatment to cancer patients  In the past  companies have spent vast sums of money on earlier programs that dealt with the same issues focused on by OncoSec  For example  Amgen  NASDAQ AMGN  s 2011 acquisition of BioVex demonstrated the proof of interest and need for an effective melanoma treatment  BioVex was a company that had been researching and developing a treatment against melanoma called Imlygic  also known as T VEC  T VEC was an oncolytic viral therapy that aimed to promote a similar anti tumor response to OncoSec s ImmunoPulse   The company showed promise  and in 2011  was purchased by Amgen for  1 billion in hopes that the treatment would prove revolutionary  Unfortunately  as additional clinical data continued to become available  it was found that the treatment was not as effective as initially hoped  and as of 2016  there is little evidence that the treatment was able to extend the life of people with melanoma  Additionally  T VEC was known to cause a myriad of undesirable side effects  including fever  nausea  and other flu like symptoms in over 30  of those treated  Although the treatment proved unsuccessful  the BioVex deal was still one of the largest deals in the immunotherapy field at the time and signaled a voracious interest in bringing to market a more effective product  And  keeping this goal in mind  OncoSec may hold the potential to provide the treatment that T VEC was unable to deliver 
ONCS On The Fast Track
OncoSec  in some respects  is in a similar position to BioVex before their acquisition by Amgen   the company has robust clinical data to date  and as their Phase 2 data continues to unfold  the company is sure to spark the interest of respected players within the biotech industry  Not only has the initial testing of their ImmunoPulse  IL 12 platform brought positive results  but it is also doing so without causing many of the uncomfortable side effects caused by earlier and similar treatments  Additionally  the FDA s granting of Orphan Drug Status and Fast Track Approval to the company will allow them to more quickly develop and undergo research trials for their products  removing many of the restrictions that may be faced by competitors  Finally  as stated earlier  OncoSec has indicated that their ImmunoPulse  system is likely able to work on multiple tumor types  allowing the company to expand their label across different kinds of diseases  rather than simply melanoma 
As for what s currently in store for OncoSec  the company plans to initiate their enrollment for a phase 2 trial and collaboration with Merck  referred to as PISCES  by the end of 2017  The company also intends to hold an End of Phase 2  EOP2  meeting with the FDA during the 1H of 2018  which is anticipated to grant ONCS with an accelerated approval path for anti PD 1 non responders in melanoma  along with an approval of their plans for phase 3 trials  This phase 3 confirmatory study is expected to run throughout 2018 and carry on into late 2019  where the company has set milestone goals to obtain a marketing authorization to penetrate a market in need of a viable and responsive cancer treatment OncoSec may be considered by some to be a small company  but what can t get overlooked is that they have built an enviable foundation and scientific infrastructure  And  from a position of clinical strength  ONCS may be ideally placed to reap enormous benefit from the development of their promising immunotherapy treatment system  If ImmunoPulse  IL 12  with combination therapy  continues to deliver positive results  OncoSec may very well be the company the market has been waiting to embrace  providing game changing cancer treating technology that may alter the therapeutic landscape and fill a void to address unmet medical needs 
Disclaimer   The author has no positions in any stock mentioned herein nor plans to open a position within the next 72 hours  
This article was originally featured on  ",2017-09-11,CNA Finance,https://www.investing.com/analysis/oncosec-medical-inc-oncs-stock-seeks-accelerated-approval-to-treat-m-200212571,200212571
150567,372083,AMGN,Can Ligand s Captisol Deals Boost Growth In The Long Run ,opinion,On Aug 14  2017  we issued an updated report on Ligand Pharmaceuticals Incorporated   NASDAQ LGND   Ligand s Captisol formulation technology platform has allowed it to enter into partnerships with several leading drug companies like Novartis AG   NYSE NVS    Merck   Co   Inc    NYSE MRK   and Amgen Inc    NASDAQ AMGN    providing it with funds in the form of milestone and royalty payments  Royalties depend on the sales of its two key partnered assets   Novartis  Kyprolis and Amgen s Promacta Ligand receives royalties and milestone payments for several FDA approved products that uses its Captisol technology  Latest product approvals include Spectrum s Evomela  Lundbeck s Carnexiv and Melinta Therapeutics  Baxdela  Apart from these  several other candidates are in late stage development and is expected to bring in royalties for the company once commercialized In July  the company announced that it has entered into another commercial license and supply agreement with Amgen  granting it with rights to use Captisol in the formulation of its anti CD33 x anti CD3  BiTE  bispecific antibody  AMG 330  Under the agreement terms  Ligand is entitled to potential milestone payments  royalties and revenues from the future sales of AMG 330 Regarding the company s internal pipeline  various candidates are being developed for indications like diabetes  One of the most advanced candidates is LGD 6972  presently undergoing a phase II study for treatment of type II diabetes  Data from this trial is awaited in the second half of 2017 with potential to bring in future licensing opportunities Nonetheless  Ligand s entry into the Medical Devices Segment with the acquisition of multiple programs owned by CorMatrix is also encouraging However  Ligand obtains Captisol from a single supplier  Hovione   a major global supplier of active pharmaceutical ingredients and drug product intermediates  located in Portugal  Any interruption in Captisol s supply would hit the company s results Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ,2017-08-14,Zacks Investment Research,https://www.investing.com/analysis/can-ligands-captisol-deals-boost-growth-in-the-long-run-200207296,200207296
150568,372084,AMGN,Watch These Swing Trades,opinion,"Long HollyFrontier Corporation  NYSE HFC 



Long Trinity Industries  NYSE TRN 



Short Amgen  NASDAQ AMGN ",2017-08-16,Ryan Mallory,https://www.investing.com/analysis/watch-these-swing-trades-200207675,200207675
150569,372085,AMGN,Can Sanofi  SNY  Sustain The Solid 1H Momentum In 2H17 ,opinion,Sanofi  PA SASY   Inc    NYSE SNY   performed quite well in the first half of 2017 and looks well poised to carry on the momentum in the second half While earnings per share beat the Zacks Consensus Estimate in the first quarter  it met the same in the second  Earnings rose 4 9  on a reported basis in the first half of 2017 and 2 7  at constant currency rates  CER  on a year over year basis First halfnet sales rose 8 7  on a reported basis and 5 5  at CER   In Jan 2017  Sanofi swapped its Merial Animal Health businesses with Boehringer Ingelheim s Consumer Healthcare  CHC  business  Reflecting this exchange and full consolidation of Sanofi s European vaccines operations  sales rose 2  at constant structure and CER  We remind investors that Sanofi terminated its Sanofi Pasteur MSD joint venture with Merck  Co   Inc    NYSE MRK   in Europe in December last year A strong performance by Genzyme s Specialty Care  Genzyme  and Vaccines units is making up for an accelerated decline in the diabetes franchise to support the top line In fact  at the second quarter conference call  Sanofi raised its previously issued profit outlookbacked by a better than expected performance in the first half and cost discipline despite a tough U S  payer environment hurting sales in theDiabetesunit Sanofi expects 2017 business earnings to be broadly flat at CER  This outlook compares favorably with the previous expectation of flat to down 3  at CER So what will work in Sanofi s favor in the second half Continued strong performance of the Genzyme unit  especially the multiple sclerosis drugs  Aubagio and Lemtrada and the rare disease drugs like Myozyme Lumizymeand Fabrazyme is a positive  The Vaccines unit is also expected to perform well  Sales  including emerging markets  rose 14 3  at CER in the Genzyme unit and 24 5  at CER in the Vaccines unit in the first half of 2017 Meanwhile  Sanofi  at the second quarter conference call  sounded quite optimistic about the sales prospects of its newly launched drug Dupixent for treating atopic dermatitis  The drug  which was launched in the U S in March 2017  generated sales of  26 million in the second quarter  backed by strong demand Management waspleased with the drug s uptake  We are optimistic on sales prospects of Dupixent  which could prove to be an important growth driver for the company  Other than Dupixent  other new drugs like Kevzara  launched in the U S  in June 2017 and Soliqua  a once daily titratable fixed ratio combination of Lantus and Lyxumia  launched in the U S  in January 2017 should also bring in higher sales in the back half of the year However  management expects U S  diabetes franchise sales to decline faster in the second half due to the impact of formulary exclusion at CVS Health Corporation   NYSE CVS   and UnitedHealth Group  NYSE UNH  and difficult comparisons from last year U S  diabetes sales declined 19 1  in the first half of 2017 Sanofi s Diabetes franchise is under significant pressure with key product  Lantus  facing increasing competitive pressure at the payor level and biosimilar competition in several European markets and Japan In the cardiovascular franchise  it also remains to be seen if sales trends of Sanofi s anti PCSK9 therapy  Praluent improve in the second half  Uptake of PCSK9 inhibitors like Praluent and Amgen  Inc  s   NASDAQ AMGN   Repatha have been slower than expected due to significant payer utilization management restrictions in the U S  and limited market access in Europe  Praluent s uptake could remain limited until guidelines supporting broader use of the treatment are issued and phase III cardiovascular outcome study data are out Also generic competition will continue to hurt sales of many key drugs in Sanofi s portfolio including its blockbuster drug  Plavix Despite these challenges  we believe that new drug approvals  a solid pipeline and aggressive savings will pave the way for growth in the second half What Do the Numbers Say So far this year  Sanofi s share price has risen 22   better than a 7 8  increase for the  The strong quarterly results and the back to back product approvals this year have led to an uptick in estimates as well  Sanofi s earnings estimates for 2017 went up 2 5  while that for 2018 moved up 1 5  in the past 30 days  Sanofi s earnings performance has also been pretty impressive  with the company reporting positive surprises consistently  The average earnings beat over the last four quarters is 5 10  Sanofi carries a Zacks Rank  3  Hold   You can see One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-08-23,Zacks Investment Research,https://www.investing.com/analysis/can-sanofi-sny-sustain-the-solid-1h-momentum-in-2h17-200209368,200209368
150570,372086,AMGN,Amgen Presents New Repatha Analysis From FOURIER Study,opinion,Amgen  Inc    NASDAQ AMGN   announced a new analysis from the phase III cardiovascular outcomes study  FOURIER  on its PCSK9 inhibitor  Repatha This analysis of a large cohort of patients with established atherosclerotic cardiovascular disease showed that there was a strong progressive relationship between lower achieved levels of LDL C or  bad  cholesterol and a lower risk of cardiovascular events rates  This analysis suggests that the use of intensive LDL C therapies such as Repatha in high risk cardiovascular patients can safely reduce the risk of another cardiovascular event like heart attack  stroke or cardiovascular death This year so far  Amgen s shares are up 17 5   better than the 7 2  increase registered by the  The results were presented at the European Society of Cardiology  ESC  Congress held in Spain and also published in The Lancet We remind investors that data presented from FOURIER in March this year had revealed that treatment with Repatha led to a significant reduction in myocardial infarctions and strokes Uptake of the drug  which gained FDA approval in Aug 2015  has not been very encouraging so far due to pricing and re imbursement issues payer restrictions  The FOURIER data holds the key to the commercial success of Repatha as it will broaden the use of the drug  Though data from the study looks good  it is not very clear if payers will be willing to improve access to Repatha based on this data Encouragingly  at the second quarter conference call  management said that Repatha holds 58  share of the PCSK9 segment in the U S  and Europe  with share trends improving sequentially in both the markets in the quarter  Meanwhile  in the U S   the new to brand share for Repatha was 70  in the second quarter  Management said that the presentation of the outcomes study data had a positive impact on Repatha share trends Amgen filed regulatory applications in both the U S  and EU to include FOURIER data on Repatha s label in Jun 2017  Last month  Amgen announced that the FDA has granted priority review foritsregulatory application seeking approval to include FOURIER data on its label  A decision from the agency is expected on Dec 2  2017 Sanofi   NYSE SNY   and partner Regeneron Pharmaceuticals  Inc    NASDAQ REGN   also faced similar issues with their PCSK9 inhibitor  Praluent Amgen currently carries a Zacks Rank  3  Hold   You can see A better ranked pharma biotech stock is Gilead Sciences  Inc    NASDAQ GILD   with a Zacks Rank  2  Buy  Shares of Gilead are up 4 3  so far this year while estimates for 2017 and 2018 have inched up almost 07  and 0 1   respectively over the last 30 days Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ,2017-08-28,Zacks Investment Research,https://www.investing.com/analysis/amgen-presents-new-repatha-analysis-from-fourier-study-200210258,200210258
150598,372114,AMGN,Amgen  AMGN  Stock Falls Despite Q2 Earnings   Sales Beat,opinion,"Biotech major Amgen Inc    NASDAQ AMGN   reported second quarter 2017 earnings of  3 27 per share  which beat the Zacks Consensus Estimate of  3 09 by 5 8  and increased 15  from the year ago period  Better revenues and lower operating costs drove the bottom line  A lower tax rate and share count also pulled up profits 
Total revenue rose 2  to  5 81 billion in the quarter  beating the Zacks Consensus Estimate of  5 67 billion by 2 5   An unfavorable impact of foreign exchange hurt sales by 1  in the quarter 
While U S  revenues rose 2  and ex U S  sales grew 8   excluding currency headwinds 
Quarter in Detail
Total product revenue rose 2  from the year ago quarter to  5 57 billion  U S    4 39 billion  ex U S    1 19 billion  as strong demand for newer products like Prolia  Xgeva  Kyprolisand Blincyto somewhat made up for lower sales of mature brands like Enbrel  Epogen  Neulasta and Neupogen due to competitive pressure 
Revenues of Amgen s erythropoiesis stimulating agent  ESA   Aranesp  rose 6  from the year ago quarter to  535 million due to higher unit demand in the U S 
Revenues of the other ESA  Epogen  declined 12  to  292 million due to lower selling price owing to a recently negotiated contract with DaVita Inc 
Neulasta revenues declined 5  to  1 09 billion from the year ago period due to lower unit demand following competition from PD 1s and other new cancer therapies  Neupogen recorded a 30  decline in sales to  137 million due to biosimilar competition in the U S  Zarxio  Sandoz s  Novartis AG s   NYSE NVS   generic arm  biosimilar version of Neupogen  was launched in the U S  in Sep 2015 and is hurting sales 
The company expects Neulasta and Neupogen sales to continue to be hurt by competitive dynamic through the rest of 2017  However  management did specify on the call  that  no new U S  biosimilar competition  is expected this year  This suggests that Neulasta and Epogenmay not start facing any biosimilar competition in the U S  this year  contrary to previous expectations 
However  the Neulasta Onpro kit  on body injector  continues to perform well commanding a market share of about 55  in the U S  for all Neulasta sales 
Enbrel delivered revenues of  1 47 billion  down 1  from the year ago quarter due to increased competition  which offset favorable changes in inventory and price 
However  in the quarter  market volume growth improved in the rheumatology dermatology segments compared with the first quarter with Enbrel experiencing relatively stable unit share in these markets 
Prolia revenues came in at  505 million  up 15  from the year ago quarter due to higher demand  The osteoporosis drug witnessed market share gains in both the U S  and our international markets 
Meanwhile  Xgeva delivered revenues of  395 million  up 4  from the year ago quarter mainly due to higher demand 
Sensipar Mimpara revenues increased 10  to  427 million due to higher price increases 
Vectibix revenues came in at  168 million  up 5   driven by higher demand 
Kyprolis recorded sales of  211 million  up 23  year over year driven by higher demand 
In the quarter  Amgen submitted regulatory applications in the U S  and EU to include overall survival data from the ENDEAVOR study on the label of Kyprolis  The study demonstrated that a combination of Kyprolis plus dexamethasone led to superior overall survival when compared to Velcade plus dexamethasone
This overall survival data  if approved  can help drive usage and boost sales of Kyprolis 
Amgen also announced final data from the phase III ASPIRE study of Kyprolis this month  which showed that a triple combination regimen of Kyprolis plus Celgene Corporation s   NASDAQ CELG   Revlimid  lenalidomide  and dexamethasone  KRd   significantly improved overall survival  OS  in patients with relapsed multiple myeloma compared to Revlimidand dexamethasone Rd  
Blincyto sales surged 43  from the year ago period to  43 million  reflecting higher demand  Earlier this month  the FDA approved the inclusion of overall survival data from the TOWER study on the label of Blincyto  The addition of the data should help boost sales 
Amgen s PCSK9 inhibitor  Repatha generated revenues of  83 million  higher than  49 million in the first quarter driven by higher demand 
Uptake of the drug  which gained FDA approval in Aug 2015  has not been very encouraging so far due to pricing and re imbursement issues payer restrictions  Sanofi   NYSE SNY   and partner Regeneron Pharmaceuticals also faced similar issues with their PCSK9 inhibitor  Praluent 
We remind investors that a phase III cardiovascular outcomes study  FOURIER  on Repatha had revealed significant reduction in myocardial infarctions and strokes in the first quarter  The data is key to commercial success of Repatha as it would broaden the use of the drug  Though data from the study looks good  it is not very clear if payers will be willing to improve access to Repatha based on this data  Amgen filed regulatory applications in both the U S  and EU to include FOURIER data on Repatha s label in Jun 2017 
Operating Margins Increase
Adjusted operating margins rose 380 basis points  bps  to 55 2  due to lower operating costs  reflecting continued benefits from transformation and process improvement efforts 
R D expenses declined 3  in the quarter due to lower late stage pipeline related costs  SG A spend declined 7  due to the Oct 2016 expiration of Enbrel residual royalty payments  which offset investments to support new product launches 
Amgen bought back shares worth  1 billion in the quarter  At the end of the second quarter  Amgen had  2 5 billion remaining under its  5 billion stock repurchase plan 
2017 Guidance
While Amgen slightly cut the lower end of the previously issued sales outlook  it raised the earnings guidance to account for strong first half profits 
The company expects total revenue in the range of  22 5 billion to  23 0 billion versus  22 3 billion to  23 1 billion expected previously  Adjusted earnings are now expected in the range of  12 15 to  12 65 in 2017 compared with  12 00 to  12 60 per share  expected previously  The Zacks Consensus Estimate for earnings and revenues in 2017 is pegged at  12 40 per share and  22 62 billion  respectively 
Operating expenses are expected to be higher in the second half 
Our Take
It was a rather strong quarter for Amgen as it beat expectations for both earnings and sales and raised its earnings guidance  Shares  however  lost 2 4  in after market trading probably due to concerns related to the tightened revenue guidance  However  so far this year  Amgen s shares are up 23 7   better than the 12 7  increase registered by the  
Though Amgen s newer products   Prolia  Xgeva  Vectibix  Nplate and Sensipar   are all performing well  their volume growth may not be enough to offset the decline in mature brands like Enbrel due to competitive pressure  However  Amgen s restructuring plan should make it leaner and more cost efficient  Amgen is also progressing with its pipeline  including biosimilar drugs  given quite a few regulatory and data updates scheduled for the second half 
Amgen currently carries a Zacks Rank  3  Hold   You can see Amgen Inc  Price  Consensus and EPS Surprise
    The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2017-07-25,Zacks Investment Research,https://www.investing.com/analysis/amgen-(amgn)-stock-falls-despite-q2-earnings---sales-beat-200203682,200203682
150599,372115,AMGN,Radius  RDUS  Q2 Loss Wider Than Expected On Higher Expenses,opinion,"Radius Health  Inc    NASDAQ RDUS   posted a loss of  1 58 per share in the second quarter of 2017  wider than the loss of  1 01 per share in the year ago quarter and wider than the Zacks Consensus Estimate loss of  1 35  The year over year increase in net loss was attributable to an increase in general and administrative expenses 

Radius  share price increased 13 3  year to date against the  gain of 1  
The company reported sales of Tymlos  abaloparatide  of  1 0 million from the first four weeks of launch  missing the Zacks Consensus Estimate of  1 96 million 
Quarter in Detail
Research and development expenses for the reported quarter were  19 6 million  down 27  year over year due to a decrease in regulatory and professional fees associated with abaloparatide SC regulatory applications  decrase in elacestrant  RAD1901  project costs and a decrease in development costs associated with abaloparatide TD 
General and administrative expenses for the reported quarter jumped to  50 1 million from  17 2 million  The increase was attributed to growth in professional support costs  including the costs associated with increasing headcount for the commercialization of Tymlos  Higher compensation expenses  including stock based compensation  due to an increase in headcount were also responsible for increased costs Radius Health  Inc  Price and EPS Surprise
 

   Pipeline Updates
On Apr 28  the FDA approved Radius Health s lead candidate Tymlos injection for the treatment of postmenopausal women with high risk osteoporosis for fracture   defined as history of osteoporotic fracture   multiple risk factors for fracture  or patients who have failed or are intolerant to other available osteoporosis therapy 
The company is developing two formulations of abaloparatide  abaloparatide SC and abaloparatide transdermal 
Meanwhile  Radius Health  Marketing Authorisation Application  MAA  for Eladynos  abaloparatide SC  for the treatment of postmenopausal women with osteoporosis in Europe is under review by the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  The company however suffered a setback when the CHMP issued a second Day 180 List of Outstanding Issues  Consequently  Radius is working with the CHMP to address these issues and the company expects a response prior to the end of 2017 
In May  Radius Health announced positive top line results from the completed 24 month ACTIVExtend clinical trial on Tymlos  which met all of its primary and secondary endpoints  The company expects to submit a sNDA to the FDA in connection with the ACTIVExtend results by year end 
The company reported positive data from its ongoing phase I dose escalation and expansion study on elacestrant in advanced metastatic breast cancer  The company discussed these data from the ongoing phase I studies with the FDA to determine the next steps for elacestrant breast cancer program  including the design of a phase II trial 
Following this discussion  the FDA agreed that a single arm monotherapy phase II study of under 200 patients is appropriate  The agency also provided additional feedback on the proposed clinical protocol  including confirmation that the primary endpoint will be objective response rate  along with durability of response  The FDA also stated that if the study results demonstrate superiority to the then available therapies  the single arm phase II trial could be considered a pivotal study for accelerated approval as long as the company has also commenced a confirmatory study by the time of its new drug application  NDA  submission 
In addition  elacestrant is also being evaluated at low doses as an estrogen receptor ligand for the potential relief of the frequency and severity of moderate to severe hot flashes in postmenopausal women with vasomotor symptoms  The company expects to report results from its phase IIb clinical study of elacestrant for the potential treatment of postmenopausal vasomotor symptoms in the second half of 2017 
Our Take
The company s wider than expected loss in the second quarter was disappointing as expenses continue to increase with the launch of Tymlos  The company is moving ahead with its plans in contracting with managed care organizations with access to over 133 million covered lives across Commercial and Medicare Part D plans 
Although the osteoporosis market in the U S  has great potential as approximately 1 4 million postmenopausal women in the U S  experience an osteoporotic fracture each year  Tymlos is expected to face significant competition from Eli Lilly  Co s   NYSE LLY   Forteo and Amgen Inc s   NASDAQ AMGN   Prolia  Moreover  the approved label carries a boxed warning of osteosarcoma  a malignant bone tumor   The company  however  suffered a setback when the CHMP issued a second Day 180 List of Outstanding Issues 
Zacks Rank   Key Pick
Radius Health currently has a Zacks Rank  4  Sell  
A better ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD   which currently carries a Zacks Rank  2  Buy   You can see  
Gilead s earnings per share estimates increased from  7 92 to  8 53 for 2017  over the last 30 days following strong results in the second quarter  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 8 18  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-08-04,Zacks Investment Research,https://www.investing.com/analysis/radius-rdus-q2-loss-wider-than-expected-on-higher-expenses-200205442,200205442
150600,372116,AMGN,Ligand  LGND  Q2 Earnings   Revenues Top  2017 View Raised,opinion,Ligand Pharmaceuticals Incorporated   NASDAQ LGND   reported second quarter 2017 earnings of 54 cents per share  including the after tax impact of stock based compensation expenses   significantly up 157 1  from the year ago figure of 21 cents  Earnings also beat the Zacks Consensus Estimate of 25 cents per share  Lower costs and higher revenues boosted earnings in the quarter Ligand s stock has outperformed the year to date  The company s shares have rallied 25  compared with the industry s increase of 9 7  Total revenue in the quarter surged 40  year over year to  28 million on the back of higher royalty revenues  Revenues also surpassed the Zacks Consensus Estimate of  24 million Quarterly HighlightsRoyalty revenues were  14 2 million in the reported quarter  up approximately 46  year over year  Higher royalties on sales of Novartis AG s   NYSE NVS   Promacta and Amgen Inc  s   NASDAQ AMGN   Kyprolis as well as Spectrum Pharmaceuticals    NASDAQ SPPI   Evomela drove this upside  Ligand licenses its platform technologies such as Captisol or OmniAb to partners for use in their proprietary programs Material sales also soared by 43 6  to  5 6 million owing to the favorable timing of Captisol purchases for clinical and commercial use License and milestone revenues were  8 2 million  thus registering a massive rise of 39 5  compared with  5 9 million in the year ago period  This increase was courtesy the favorable timing of milestones and license fees earned Research   development  R D  expenses marginally decreased by 2  to  4 8 million  General   administrative expenses reduced 9 7  year over year to  6 5 million Other UpdatesIn July  the company announced that it has entered into a commercial license and supply agreement with Amgen  granting it rights to use Captisol in the formulation of its anti CD33 x anti CD3  BiTE  bi specific antibody  AMG 330  Under the deal terms  Ligand is entitled to potential milestone payments  royalties and revenues from the future sales of AMG 330 Also in June  Ligand announced that it has entered into a worldwide omniab platform license agreement with Surface oncology  Under this license  Surface will be able to use the OmniRat  OmniMouse and OmniFlic platforms to discover fully human mono and bi specific antibodies The company is entitled to receive annual platform access payments  development and regulatory milestone payments along with tiered royalties for each product incorporating an OmniAb antibody  Surface will be responsible for all costs related to the programs In April  Ligand announced a commercial license and supply agreement with Marinus Pharmaceuticals  Inc   granting the latter with rights to use the company s Captisol in the formulation of its intravenous  IV  ganaxolone  This license agreement replaces the prior research contract which allowed Marinus to evaluate ganaxolone IV with Captisol in preclinical and phase I clinical studies 2017 OutlookLigand raised its 2017 revenue and earnings outlook  The company now expects earnings of approximately  2 93 per share in 2017 compared with  2 70  expected previously  The company anticipates its revenues to be  133 million for 2017 compared with  130 million  estimated previously  The core revenues are projected to comprise royalties of approximately  87 million  material sales of approximately  23 million and contract payments of at least  23 million  old guidance   20 million  The company is expected to receive additional contract revenues of approximately  9 million in 2017 Ligand Pharmaceuticals Incorporated Price  Consensus and EPS Surprise   Zacks RankLigand currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana   Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-08-07,Zacks Investment Research,https://www.investing.com/analysis/ligand-lgnd-q2-earnings--revenues-top-2017-view-raised-200206061,200206061
150630,372146,AMGN,Amgen  AMGN  Gets CRL For Osteoporosis Drug Evenity s BLA,opinion,Amgen Inc    NASDAQ AMGN   and partner UCB SA  announced that the FDA has issued a complete response letter  CRL  for the biologics license application  BLA  for Evenity  romosozumab   Amgen is looking to get Evenity approved for the treatment of postmenopausal women with osteoporosis The original BLA included data from the pivotal FRAME study However  the FDA now requires safety and efficacy data from the other two pivotal phase III studies   ARCH and BRIDGE   to be included in the application  The agency has asked for a resubmission of the BLA  which will be considered as an extension of the current review We remind investors that in May  Amgen had presented data from ARCH fracture study of romosozumab compared to Merck   Co   Inc  s   NYSE MRK   Fosamax  alendronate  in postmenopausal women with osteoporosis  Data from the study showed that Evenity romosozumab led to a statistically significant superior fracture risk reduction than Fosamax  alendronate   which is the current standard of care in osteoporosis  However  a cardiovascular side effect was observed in the study The company then said that the safety data from the ARCH data will now be considered in the regulatory review as agreed with the FDA  Following the heart related safety issue that emerged from the otherwise successful ARCH results  Amgen warned that it did not expect Evenity to be approved this year The CRL  thus  does not come as a surprise So far this year  Amgen s shares are up 21 1   better than the 9 0  increase registered by the Zacks categorized  industry The FRAME study evaluated the effectiveness of Evenity in reducing the risk of new vertebral fractures over 12 months  It also compared the effectiveness of 12 months of Evenity administration  followed by another 12 months of Xgeva to placebo followed by Xgeva administration The BRIDGE study evaluated Evenity in older men with osteoporosis and a history of fragility fracture or vertebral fracture  The study evaluated the effectiveness of Evenity in increasing bone mineral density  BMD  at the lumbar spine and its effect on BMD at the femoral neck and total hip The company is working along with the FDA and is in a process to re submit the BLA with the requested data In a separate press release  Amgen announced the submission of a supplemental New Drug Application  sNDA  to the FDA and a variation to the marketing application to the European Medicines Agency  EMA  for its myeloma drug  Kyprolis  The submission of the regulatory applications was done to expand the drug s label to include overall survival  OS  data from phase III ENDEAVOR study We remind investors that Kyprolis  twice weekly  is already approved for use in combination with dexamethasone or with Celgene Corporations    NASDAQ CELG   Revlimid  lenalidomide  plus dexamethasone based on the primary analysis of progression free survival  PFS  data from the ASPIRE study The submissions include data from the pivotal ENDEAVOR study  which compared Kyprolis and J J s Velcade in combination with dexamethasone in patients with relapsed or refractory multiple myeloma  The data demonstrated that Kyprolis reduced the risk of death by 21  compared to Velcade and increased the median OS by 7 6 months  47 6 months vs  40 months  Kyprolis is the first and only therapy to achieve superior OS in a head to head comparison with a current standard of care  Velcade Last week  Amgen announced OS data from the ASPIRE study  Overall survival data from the study showed that patients with relapsed or refractory multiple myeloma lived 7 9 months longer when treated with Kyprolis plus Revlimid and dexamethasone  KRd  compared to those treated with Revlimid and dexamethasone  Rd   median OS of 48 3 months for KRd versus median OS of 40 4 months for Rd    Kyprolis is also being evaluated in a couple of other studies for potential label expansion  Amgen is evaluating a weekly dosing regimen of Kyprolis in a phase III study  ARROW  in relapsed and refractory multiple myeloma patients  Data is expected to be out in 2019 Amgen Inc  Price and Consensus   Zacks RankAmgen currently has a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-07-16,Zacks Investment Research,https://www.investing.com/analysis/amgen-(amgn)-gets-crl-for-osteoporosis-drug-evenity's-bla-200201605,200201605
150631,372147,AMGN,Why Did Radius Health  RDUS  Stock Plummet Today ,opinion,Shares of Radius Health    NASDAQ RDUS    dropped more than 7 8  in early morning trading hours Monday after the company announced that Jesper H iland  a former top ranking executive at Novo Nordisk  CO NOVOb     NYSE NVO     has been appointed its new president and chief executive officer   H iland joins Radius at an integral moment for the company  which recently received approval for its once daily  injectable osteoporosis treatment  Tymlos    We are pleased to welcome Jesper to Radius Health at this important time  and believe that he is uniquely qualified to lead Radius through the successful launch of TYMLOS   and the advancement of our exciting clinical stage assets including elacestrant   said Radius Chairman Kurt Graves  H iland replaces Bob Ward  who served as Radius  CEO since 2013 and helped lead the company through its IPO in 2014  Not long after its market debut  shares of Radius reached a peak of more than  80 during the summer of 2015  but the stock has struggled to maintain momentum since then   I am delighted to be joining Radius in the exciting  early stages of the commercialization of TYMLOS    said Jesper H iland   and I look forward to guiding the continued development of its strong pipeline   The new appointment comes in the wake of Radius Health rival Amgen s    NASDAQ AMGN    announcement that its own osteoporosis drug did not receive FDA approval  For now  the list of approved treatments for building bone strength to fight this degenerative condition remains at just two  with Eli Lilly s    NYSE LLY    Forteo remaining the market leader  For Radius investors  today s appointment will likely lead to some short term volatility  but a fresh face at the top of the company s management could be the much needed ignition source for this Zacks Rank  4  Sell  stock  Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively   And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-07-17,Zacks Investment Research,https://www.investing.com/analysis/why-did-radius-health-(rdus)-stock-plummet-today-200201592,200201592
150632,372148,AMGN,Novartis Tops Q2 Earnings  Sandoz Faces Pricing Pressure ,opinion,Novartis AG   NYSE NVS   reported second quarter 2017 core earnings of  1 22 per share  beating the Zacks Consensus Estimate of  1 16 but the recorded figure was a penny lower than the year ago figure of  1 23 Revenues declined 2  to  12 2 billion as volume growth was offset by the negative impact of generic competition and pricing but beat the Zacks Consensus Estimate of  12 1 billionA look at Novartis  share price movement in the last three months shows that the stock outperformed the Zacks classified  industry  Its shares have rallied 14 5  compared with the 7 2  gain recorded by the industry All growth rates mentioned below are on a year over year basis and at constant exchange rates The Quarter in DetailNovartis operates under three segments  Innovative Medicines  Pharmaceuticals   Alcon  Ophthalmology unit  and Sandoz  Generics  The Innovative Medicines division recorded sales of  8 3 billion  up 1   Generic competition and pricing pressure impacted sales at the segment  primarily due to the entry of generics for Gleevec in the U S and Europe  Nevertheless  growth products   Cosentyx  Entresto  Promacta Revolade  Jakavi  Tafinlar   Mekinist and Gilenya boosted sales Psoriasis Cosentyx sales surged 90  on the back of strong growth in its three approved indications while Entresto too had solid quarter as sales benefited from continued access improvements  expansion of sales force in the U S and reimbursement in Europe  Oncology franchise grew 9  driven mainly by Promacta Revolade  Jakavi  Tafinlar   Mekinist Sales at the Sandoz division were  2 5 billion  down 4  as volume growth was offset by price erosion mainly in the U S  Sales in the U S  declined 15  due to pricing pressure in retail generics and prior year launch timing  Biopharmaceuticals sales grew 6  to  260 million mainly driven by Zarxio in the U S Sales at the Alcon division were  1 5 billion  up 3   Surgical sales increased 3  driven by growth in cataract consumables and vitreoretinal  intraocular lenses returning to growth globally  Vision Care sales were up 2  fuelled by the continued double digit growth of Dailies Total1 2017 Outlook ReiteratedNovartis expects net sales to be broadly in line with the 2016 levels after including the impact of continued genericization of Gleevec Glivec in the U S  and Europe  Management had earlier estimated the impact of generic competition on sales to be approximately  2 5 billion in 2017 Pipeline UpdateNovartis  pipeline candidates  progress has been encouraging  The oncology portfolio continues to gain traction  Breast cancer drug Kisqali received a positive CHMP opinion as a first line option for HR  HER2  advanced or metastatic breast cancer in combination with any aromatase inhibitor in Europe  The drug is already approved in the U S  The company also received FDA approval of Rydapt for the treatment of newly diagnosed FLT3 mutated acute myeloid leukemia  AML  and three types of systemic mastocytosis  In addition  Zykadia received FDA and EMA approval for first line use in ALK positive advanced non small cell lung cancer  NSCLC  while Tafinlar   Mekinist received FDA approval for treatment of BRAF V600E mutant metastatic NSCLC CTL019 was unanimously recommended for approval by an FDA Oncologic Drugs Advisory Committee in July for the treatment of pediatric and young adult patients with relapsed or refractory  r r  B cell acute lymphoblastic leukemia Meanwhile  Cosentyx was granted approval in Europe for a label update to include 52 week data from CLEAR study demonstrating long term superiority of Cosentyx compared to Johnson   Johnson s   NYSE JNJ   Stelara in psoriasis Sandoz received approval and launched two major biosimilars in the EU  Erelzi  the biosimilar of Amgen  Inc  s   NASDAQ AMGN   Enbrel and Rixathon  the biosimilar version of Roche Holdings   OTC RHHBY   MabThera to treat blood cancers and immunological diseases  The EMA also accepted proposed biosimilars of adalimumab and infliximab  Sandoz  generic version of asthma drug Advair Diskus was accepted by FDA Novartis AG Price and EPS Surprise   Our TakeNovartis second quarter results were encouraging as the company beat both earnings and sales estimates  However  Sandoz s performance was disappointing as it battles pricing pressure In the first half of 2017  Novartis announced that it is mulling strategic options for Alcon which includes retaining the business separation via capital market transactions such as a spin off or an initial public offering  The company will throw more light on its plans for Alcon by the end of 2017 On a positive note  growth drivers like Cosentyx and Entresto  more than offset the impact of generic erosion  mainly due to Glivec  Cosentyx hit blockbuster status in 2016  The recent approval of Kisqali in the U S  and FDA panel recommendation for CTL019 also bodes well for the company s portfolio Zacks RankNovartis currently carries a Zacks Rank  3  Hold  You can see  5 Trades Could Profit  Big League  from Trump Policies If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-07-17,Zacks Investment Research,"https://www.investing.com/analysis/novartis-tops-q2-earnings,-sandoz-faces-pricing-pressure-200201902",200201902
150633,372149,AMGN,Ligand Signs Agreement With Amgen  Grants Rights To Captisol,opinion,Ligand Pharmaceuticals Incorporated   NASDAQ LGND   announced that it has signed a commercial license and supply agreement with Amgen Inc    NASDAQ AMGN    Per the deal  Amgen was granted exclusive worldwide rights to use Ligand s Captisol technology for the development of its pipeline candidate AMG 330 for a wide variety of therapeutic indications Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility  stability  and bioavailability or lessen the volatility  irritation  smell or taste of drugs  Amgen is developing its early stage candidate  AMG 330  as an anti CD33 x anti CD3  BiTE  bispecific antibody for the treatment of acute myeloid leukemia Shares of Ligand have outperformed the Zacks classified  industry so far this year  The stock has rallied 14 9  compared with the broader industry s increase of 8 7  The company already had an agreement with Amgen for using Captisol for developing AMG 330 in preclinical and early clinical studies  Under the terms of the recent agreement  Amgen is liable to pay an undisclosed upfront payment along with potential milestone payments  royalties and revenues from future sales of AMG 330 formulated using Captisol Ligand s Captisol formulation technology platform has allowed it to enter into partnerships with several leading drug companies like Novartis AG   NYSE NVS   and Merck   Co   Inc    NYSE MRK   that provide it with funds in the form of milestone and royalty payments  Ligand also derives revenues by selling Captisol material to its partners who have either licensed the company s Captisol enabled drugs or have licensed Captisol for their internal programs Ligand Pharmaceuticals Incorporated Price and Consensus   Zacks RankLigand currently carries a Zacks Rank  3  Hold   You can see  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-07-17,Zacks Investment Research,"https://www.investing.com/analysis/ligand-signs-agreement-with-amgen,-grants-rights-to-captisol-200201849",200201849
150634,372150,AMGN,Surprise In Store For Healthcare In Q2  Buy Top Ranked ETFs,opinion,Despite the hurdles in Trump s plans to repeal and replace Obamacare  healthcare is the second best performing sector this year lagging technology  The optimism comes especially from encouraging industry trends and hopes of a favorable policy environment The Trump administration plans to focus on easing regulatory hurdles rather than lowering drug prices  and expedite new drug approvals  Additionally  the shift in investors  sentiment to defensive sectors like healthcare  which generally outperform during periods of low to moderate growth and rising geopolitical uncertainty  has led to a rally in healthcare stocks  read    As such  popular funds   Health Care Select Sector SPDR Fund   Vanguard Health Care ETF   AX VHT    iShares U S  Healthcare ETF  and Fidelity MSCI Health Care Index ETF    have gained at least 18  so far this year  The trend is likely to continue heading into the Q2 earnings season as some big names like Pfizer   NYSE PFE    Merck   NYSE MRK    Amgen   NASDAQ AMGN    AbbVie   NYSE ABBV    Gilead Sciences   NASDAQ GILD   and Bristol Myers Squibb   NYSE BMY   are lined up to report this week and in the next  All these stocks collectively account for 26 3  share in XLV  25 2  in IYH  22 8  in VHT and 22 5  in FHLC Let s dig deeper into the earnings picture of these companies that would drive the performance of the above mentioned funds in the coming days According to the our methodology  a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  when combined with a positive  increases our chances of predicting an earnings beat  while a Zacks Rank  4 or 5  Sell rated  are best avoided  You can uncover the best stocks to buy or sell before they re reported with our  Inside Our Surprise Prediction of These StocksPfizer has a Zacks Rank  3 and an Earnings ESP of  1 54   indicating a reasonable chance of beating estimates this quarter  The stock saw no earnings estimate revision for the yet to be reported quarter and delivered negative earnings surprise of 0 35  over the past four quarters  Additionally  it has an impressive Growth and Momentum Style Score of C and F  respectively  though a Value Style Score of B is favorable  Pfizer is scheduled to report earnings on August 1 before the opening bell  read    Pfizer  Inc  Price  Consensus and EPS Surprise   Merck is expected to report results on July 28 before the market opens  It has a Zacks Rank  2 and an Earnings ESP of 0 00   which makes surprise prediction difficult  The stock witnessed a positive earnings estimate revision of a penny over the past 90 days for the to be reported quarter and delivered positive earnings surprises in the last four quarters  with an average beat of 4 36   Merck has a strong Value and Momentum Style Score of B each and an unfavorable Growth Style Score of D Merck   Company  Inc  Price  Consensus and EPS Surprise   Amgen has a Zacks Rank  3 and an Earnings ESP of  0 32   indicating less chances of beating estimates this quarter  Though the earnings surprise track over the past four quarters is robust with an average positive surprise of 5 31   Amgen witnessed negative earnings estimate revision of a couple of cents over the past 90 days for the yet to be reported quarter  The stock has a solid Value and Momentum Style Score of B and A  respectively  but the Growth Style Score of C looks dull  Amgen will report earnings on July 25 after market close Amgen Inc  Price  Consensus and EPS Surprise   AbbVie has a Zacks Rank  3 and an Earnings ESP of  0 71   indicating less chance of beating estimates this quarter  The company delivered positive earnings surprises in the last four quarters  with an average beat of 1 65  and saw positive earnings estimate revision by a couple of cents over the past three months for the to be reported quarter  The stock has a solid Value Style Score of B while the Growth and Momentum Style Score of C and F  respectively  is unimpressive  The company is scheduled to report on July 28 before the opening bell  read        AbbVie Inc  Price  Consensus and EPS Surprise   Gilead is expected to release earnings on July 26 after market close  It has a Zacks Rank  3 and an Earnings ESP of  3 32   indicating reasonable chance of beating estimates  Gilead delivered positive earnings surprises in three of the last four quarters  with an average beat of 3 52  but saw no earnings estimate revision over the past three months for the to be reported quarter  Though it has a solid Value and Momentum Style Score of A and B  respectively  the Growth Style Score of F looks ugly Gilead Sciences  Inc  Price  Consensus and EPS Surprise   Bristol Myers will likely report earnings on July 27 before the opening bell  It has a Zacks Rank  3 and an Earnings ESP of 0 00   which makes surprise prediction difficult  The stock delivered positive earnings surprises in three of the past four quarters with an average beat of 8 39  and witnessed positive earnings estimate revision of three cents for the to be reported quarter  It has an unfavorable Value  Growth and Momentum Style Score of C  C  and F respectively  see    Bristol Myers Squibb Company Price  Consensus and EPS Surprise   Summing UpThough the healthcare sector is expected to post an earnings decline of 0 1  in the second quarter and has a dismal Zacks Rank in the   some surprises may well be in the cards  suggesting upside for healthcare ETFs  In particular  XLV  VHT and IYH have a Zacks ETF Rank  1 while FHLC has a Zacks ETF Rank  3 Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2017-07-23,Zacks Investment Research,https://www.investing.com/analysis/surprise-in-store-for-healthcare-in-q2:-buy-top-ranked-etfs-200203030,200203030
150665,372181,AMGN,Teva s  TEVA  Filing For Biosimilar Rituxan Accepted By FDA,opinion,Teva Pharmaceutical Industries Ltd    NYSE TEVA   and Korean partner Celltrion  Inc   announced that the FDA has accepted for review their Biologics License Application  BLA  for CT P10  a proposed biosimilar to Roche Holding  SIX ROG  AG s   OTC RHHBY   Rituxan  rituximab   The regulatory action by the FDA is expected by the first quarter of 2018 Teva s shares have lost 9 1  so far this year against the Zacks classified  industry s loss of 0 5  CT P10 is a monoclonal antibody  mAb  designed to target CD20  which is found on the surface of most B cells  B cells are involved in immune related diseases such as rheumatoid arthritis  and hematological cancers  The proposed indications are for the treatment of non Hodgkin s lymphoma  NHL   chronic lymphocytic leukemia  CLL   rheumatoid arthritis  RA   granulomatosis with polyangiitis and microscopic polyangiitis  CT P10  is approved in the EU for these indications We remind investors that Teva bought exclusive rights to commercialize biosimilar versions  CT P10 and CT P6  of two Roche drugs  Rituxan and Herceptin in October last year  Once the mAb biosimilars are commercialized  Teva and Celltrion Healthcare will share profits from the same  Both candidates have met their primary endpoints in the respective late stage phase III studies CT P6 is submitted to the European Medicines Agency  EMA  for product approval in all indications of the reference Herceptin including HER2 positive breast cancer and HER2 positive metastatic stomach cancer There are few biosimilars approved and launched in the U S  Sandoz  a Novartis AG   NYSE NVS   company  was the first to gain approval for and launch a biosimilar in the U S  The company launched Zarxio  filgrastim sndz   a biosimilar version of Amgen Inc  s   NASDAQ AMGN   Neupogen in 2015  The second biosimilar which was launched in the U S  in Nov 2016 was Pfizer  NYSE PFE  and Celltrion s Inflectra  infliximab dyyb  with the reference product being Remicade This was followed by the FDA approval of biotech giant Amgen s Amjevita  adalimumab atto   a biosimilar to AbbVie s Humira  However  Amjevita is yet to be launched due to ongoing litigation Last year  Sandoz received approval for a biosimilar version of Enbrel  called Erelzi in August  Erelzi is still to be launched in the U S The market for biosimilars is huge and highly lucrative  Several other blockbuster biologics including Humira and Lantus will lose patent protection by 2020  Biosimilars are expected to reduce healthcare costs and provide a large number of patients with access to much needed biologic treatments  Teva Pharmaceutical Industries Limited Price and Consensus    Zacks RankTeva currently carries a Zacks Rank  3  Hold   You can see  5 Trades Could Profit  Big League  from Trump Policies If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course  Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-06-30,Zacks Investment Research,https://www.investing.com/analysis/teva's-(teva)-filing-for-biosimilar-rituxan-accepted-by-fda-200198566,200198566
150666,372182,AMGN,Pfizer s  PFE  Leukemia Candidate Receives Approval In EU,opinion,Pfizer Inc    NYSE PFE   announced that its leukemia candidate  Besponsa  has been approved by the European Commission The drug is approved as a monotherapy for relapsed or refractory CD22 positive B cell precursor acute lymphoblastic leukemia  ALL   including patients with either Philadelphia chromosome positive  Ph   or Philadelphia chromosome negative  Ph    Besponsa is the first and only approved therapy in the EU for ALL  which acts by binding anticancer agents to an antibody to target cancerous cells Shares of Pfizer have risen 3 4  since the beginning of this year  underperforming the Zacks classified  industry  which increased 12  in the same period The approval is based on data from a pivotal study  INO VATE ALL  which demonstrated that patients treated with Besponsa showed significant improvement in complete response and also significantly extended progression free survival  PFS  compared to chemotherapy  Moreover  the overall survival  OS  rate over two years was almost double for the candidate versus chemotherapy The current standard of care of intensive chemotherapy is associated with poor long term survival  high toxicities  lengthy inpatient stays and continuous infusions  Treatment with Besponsa was found to achieve complete remission without excessive toxicity  The company claims that this will help patients to proceed for additional therapeutic intervention to prolong patient survivalWe remind investors that Besponsa enjoys breakthrough therapy designation in the U S  with FDA granting priority review to its biologics license application  BLA  in Mar 2017  A decision is expected in Aug 2017 Meanwhile  Kite Pharma  Inc    NASDAQ KITE   is developing its lead candidate  axicabtagene ciloleucel for treatment of ALL patients  Amgen Inc    NASDAQ AMGN   also submitted a supplemental biologics license application in Feb 2017 to expand Blincyto s label to include ALL patients with Ph   Blicynto is already approved in Ph  patients Pfizer  Inc  Price and Consensus   Zacks Rank   Stock to ConsiderPfizer currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare industry is Sanofi   NYSE SNY    which carries a Zacks Rank  2  Buy   You can see  Sanofi s earnings estimates moved up from  3 00 to  3 18 for 2017 and from  3 25 to  3 30 for 2018  over the last 30 days  The company delivered positive earnings surprises in two of the last four quarters  with an average beat of 5 10   The stock is up 22 98  so far this year 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-07-02,Zacks Investment Research,https://www.investing.com/analysis/pfizer's-(pfe)-leukemia-candidate-receives-approval-in-eu-200198901,200198901
150667,372183,AMGN,Key FDA Events To Watch Out For In Jul 2017,opinion,"Halfway into the year and the FDA has already crossed its total tally of 22 approvals in 2016  So far in 2017  the FDA has given its nod to 23 novel drugs including 2 in June  Key approvals so far in 2017 include Regeneron Sanofi s Kevzara  rheumatoid arthritis   Roche s multiple sclerosis treatment  Ocrevus  Regeneron and Sanofi s eczema treatment  Dupixent  Tesaro s PARP inhibitor  Zejula  Portoloa s Bevyxxa  prophylaxis of venous thromboembolism  VTE  in adult patients hospitalized for an acute medical illness  and BioMarin s Brineura  treatment of a specific form of Batten disease  among others  Some of these drugs have blockbuster potential With the drug development process being lengthy and time consuming and requiring the utilization of a lot of funds and resources  key pipeline events including data readouts and regulatory updates are of paramount importance and could act as major catalysts  Here is a look at a few important regulatory events scheduled for the month of July Puma s Neratinib Set for FDA Approval Puma Biotechnology  Inc    NASDAQ PBYI   looks set to gain FDA approval for its first drug  neratinib  Neratinib is under review for the extended adjuvant treatment of HER2  early stage breast cancer based on a favorable risk benefit profile  According to information provided by Puma  about 36k patients in the U S  and 34k in the EU suffer from early stage HER2  breast cancer  If approved  neratinib would be used in year 2 after adjuvant Herceptin  which generated adjuvant revenues of about  4 5  5 billion in 2015  year 1  Currently  chances of gaining FDA approval look pretty good considering neratinib got support from the FDA s Oncologic Drugs Advisory Committee  The panel voted 12   4 in favor of approving neratinib based on a favorable risk benefit profile  While the FDA is not required to follow the advice of its advisory panels  it usually does so  A response from the agency is expected this month Puma s shares are up 184 7  YTD  outperforming the Zacks categorized  industry which is up 6 5  so far in 2017 
Second Time Lucky for Ocular s Dextenza Eye disease focused Ocular Therapeutix  Inc    NASDAQ OCUL   is awaiting a response from the FDA for Dextenza for the treatment of ocular pain following ophthalmic surgery this month  A decision is expected on Jul 19  Ocular had initially submitted a new drug application  NDA  for the treatment in Sep 2015    however  the FDA responded with a complete response letter  CRL  in Jul 2016 following which the company resubmitted the NDA  Ocular got an FDA Form 483 following a re inspection of manufacturing operations that was completed in early May 2017 Ocular s shares are up 10 8  so far in 2017  performing better than the Zacks categorized  industry which is up 5 6  year to date  YTD   Dextenza s approval would be a major boost for the stock  Once approval comes for the post surgery ocular pain indication  Ocular intends to seek FDA approval for post surgical ocular inflammation  Dextenza is being evaluated for the treatment of allergic conjunctivitis as well 
Another Indication for Eagle s Ryanodex Eagle Pharmaceuticals  Inc    NASDAQ EGRX   is currently seeking FDA approval for the use of Ryanodex for external heat stroke  EHS   There is significant unmet medical need for EHS with many patients facing long term neurological damage as well as organ damage  The FDA granted priority review to Ryanodex    currently  no approved drug is available for the treatment of EHS The FDA is expected to deliver a decision on Jul 23  Eagle Pharma is preparing for the potential launch with the company building a 50 person sales team to support the launch  The company is working on expanding the label of Ryanodex further Eagle Pharma s YTD performance has been disappointing with shares declining 0 6  while the Zacks categorized  industry has gained 20 9  
CRL for Amgen UCB Drug Amgen   NASDAQ AMGN   and partner UCB s  experimental osteoporosis drug  Evenity  is under FDA review with a response expected on Jul 19  However  the companies  plans for the treatment have stumbled with a new safety signal emerging in a late stage study  Although Evenity met both the primary endpoints and the key secondary endpoint in the study  the companies said that an imbalance in positively adjudicated cardiovascular serious adverse events was observed  Based on the new safety event  Amgen said that it does not expect FDA approval in 2017  Given this development  the FDA will most likely issue a CRL on the PDUFA date Amgen s shares are up 17 8  YTD  outperforming the Zacks categorized Medical Biomedical industry while UCB s shares are up 13 6  
FDA Advisory Panel Meetings for Pfizer  NYSE PFE   Novartis  Amgen  Intellipharmaceutics   Mylan  NASDAQ MYL  DrugsApart from the above decisions  there are quite a few advisory panel meetings scheduled for this month The FDA s Oncologic Drugs Advisory Committee  ODAC  will be meeting on Jul 11 to discuss Pfizer s regulatory application for Mylotarg    the company is looking to get the product approved for use in combination therapy with daunorubicin  DNR  and cytarabine  AraC  for the treatment of adult patients with previously untreated  de novo acute myeloid leukemia  AML  Meanwhile  all eyes will be on the outcome of the Jul 12 meeting of the ODAC when Novartis    NYSE NVS   CAR T treatment  tisagenlecleucel T  will be reviewed for the treatment of pediatric and young adult patients 3 to 25 years of age with relapsed refractory B cell acute lymphoblastic leukemia  ALL  Jul 13 will see the ODAC discussing regulatory applications for the biosimilar versions of Roche s cancer drugs Avastin  bevacizumab  and Herceptin  trastuzumab  submitted by Amgen and Mylan  respectively    Intellipharmaceutics    TO IPCI   Rexista abuse deterrent oxycodone hydrochloride extended release tablets will be reviewed on Jul 26 in a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee  A final decision from the FDA is expected on Sep 25 Intellipharmaceutics is a Zacks Rank  2  Buy  stock    you can see  And then later this month  on Jul 28  the Vaccines and Related Biological Products Committee  VRBPAC  will meet to discuss and make recommendations regarding the safety and efficacy of Dynavax  hepatitis B vaccine 
5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-07-03,Zacks Investment Research,https://www.investing.com/analysis/key-fda-events-to-watch-out-for-in-jul-2017-200198880,200198880
150668,372184,AMGN,Merck Falls As FDA Puts Hold On 3 Keytruda Myeloma Studies,opinion,"Merck   Co   Inc    NYSE MRK   shares were down more than 1  in after hours trading on Wednesday after the company announced that the FDA has placed a clinical hold on three combination studies of Keytruda in multiple myeloma  a form of blood cancer While the KEYNOTE 183 and KEYNOTE 185 phase III studies have been placed on full clinical hold  cohort 1 of KEYNOTE 023 phase I study has been placed on partial clinical hold Shares of Merck have underperformed the Zacks Classified  industry so far this year  The company has gained 9  while the industry rose 12 1  in the period We remind investors that last month  Merck was recommended by an external Data Monitoring Committee to stop new enrolment in the KEYNOTE 183 and KEYNOTE 185 phase III studies to allow investigation of death of patients taking Keytruda  However  Merck had then said that patients enrolled in the two studies would continue to receive the treatment While the KEYNOTE 183 study was evaluating a combination of Keytruda  Celgene Corporation s   NASDAQ CELG   Pomylast and dexamethasone  KEYNOTE 185 was studying a combination of Keytruda  Celgene s Revlimid and dexamethasoneWith KEYNOTE 183 and KEYNOTE 185 now under full clinical hold  all patients enrolled in the two studies will discontinue treatment with Keytruda The latest decision by the FDA was taken based on data currently available from the studies  which showed that the risks of the combination therapy outweigh any potential benefit for patients with multiple myeloma KEYNOTE 023 is evaluating Keytruda in combination with backbone treatments in multiple myeloma patients  Cohort 1 of the study was evaluating a combination of the drug with Revlimid and dexamethasone in patients who have received anti multiple myeloma treatment with an immunomodulatory drug  Patients enrolled in this cohort will also discontinue treatment  The other cohorts of the study will continue Keytruda is presently marketed for the treatment of first line as well as second line non small cell lung cancer  NSCLC   advanced melanoma and previously treated recurrent or metastatic head and neck cancer  HNSCC  Keytruda registered sales of  1 4 billion in 2016  It is expected to grow with a series of regulatory approvals for label expansion received this year  the most important being for classical Hodgkin lymphoma  the first label expansion in a type of haematological cancer  and in combination with Eli Lilly and Company s   NYSE LLY   Alimta for first line lung cancerThe latest clinical hold is a setback for Keytruda  which has otherwise been on a roll this year and is touted as a significant top line driver for Merck Meanwhile  Keytruda is also being studied for more than 30 types of cancer in 500 trials  Almost 50  of these trials are in combination with other cancer drugs  Merck is collaborating with several companies including Amgen  Inc    NASDAQ AMGN    Incyte  Glaxo and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens Merck   Company  Inc  Price and Consensus   Zacks Rank
Merck currently carries a Zacks Rank  2  Buy   You can see Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-07-05,Zacks Investment Research,https://www.investing.com/analysis/merck-falls-as-fda-puts-hold-on-3-keytruda-myeloma-studies-200199541,200199541
150669,372185,AMGN,Novartis  Cosentyx Superior To Stelara In Psoriasis Study ,opinion,Novartis AG   NYSE NVS   announced that the Committee for Medicinal Products for Human Use  CHMP  has approved a label update for psoriasis drug Cosentyx  The label update includes 52 week data from the CLEAR study which demonstrated the long term superiority of Cosentyx over Johnson   Johnson s   NYSE JNJ   Stelara  ustekinumab  in psoriasis The study revealed that Cosentyx was superior to Stelara in achieving and sustaining a PASI 90 response  76  versus 61   and was significantly better in achieving a PASI 100  clear skin  response  46  versus 36   at week 52 Psoriasis drug  Cosentyx  was also approved for the treatment of two new indications   ankylosing spondylitis  AS  and psoriatic arthritis  PsA    in the EU in 2016  Moreover  the FDA approved Cosentyx for AS and PsA in Jan 2016   The uptake ofCosentyx has been strong and the company has grabbed market shares from rivals AbbVie s   NYSE ABBV   Humira and Amgen s   NASDAQ AMGN   Enbrel  Cosentyx achieved the blockbuster status in 2016 recording over  1 billion of sales Approximately 60 million patients globally are impacted by psoriasis  The addition of the study data in the product label reflects the benefit of Cosentyx for patients living with this chronic condition Novartis expects the next growth phase to begin in 2018 driven by Cosentyx  in all three indications psoriasis  psoriatic arthritis and ankylosing spondylitis  Entresto  and Kisqali and a deep pipeline with candidates like CTL019  BAF312  AMG 334  RTH258 Novartis has outperformed the Zacks classified industry in the last six months  The stock has rallied 13 0  compared with the  industry s 11 1  gain Going forward  we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis  Also  strong performance of growth products should be able to offset the impact of generic competition for Gleevec Zacks RankNovartis currently carries a Zacks Rank  4  Sell  You can see  Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-07-09,Zacks Investment Research,https://www.investing.com/analysis/novartis'-cosentyx-superior-to-stelara-in-psoriasis-study-200200103,200200103
150670,372186,AMGN,What Lies Ahead For Pharma ETFs In Second Half 2017,opinion,"We are halfway through 2017 and pharma stocks have recovered nicely with their performance representing a sharp contrast to 2016 when the sector was under immense pressure due to the drug pricing issue  Another factor that weighed on pharma stocks last year was the noticeably lower number of FDA approvals  2016 saw only 22 treatments gaining FDA approval  well below 45 approvals in 2015 and 41 in 2014  The industry was also hit by some high profile R D failures as well as mixed results  slower than expected new product launches and increasing competition 
 
However  the sector has fared better this yearand the NYSE ARCA Pharmaceutical Index is up 10 1  year to date  YTD   New product sales ramp up  R D success and innovation  strong results  a higher number of FDA approvals and continued strong performance from legacy products are some of the factors that could contribute to a sustained recovery in the sector  Tax reforms and cash repatriation would support a recovery as well   Read   
 
Importantly  investors now seem to be more comfortable with the drug pricing scenario and are willing to look at the fundamentals of the sector  Although the drug pricing issue will remain a headwind this year as well  expectations are that steps taken by the Trump administration to drive down drug prices will not be as draconian as previously expected  
 
Deregulation and increased competition seem to be some of the ways that will be used to control drug prices  FDA Commissioner Scott Gottlieb recently said that the agency is working on a plan to lower healthcare costs by speeding up the development of next generation treatments  especially for rare diseases or targeted cancer therapies 
 
Faster Drug Approval Process 
 
At a meeting with pharma majors earlier this year  President Trump spoke about speeding up the FDA approval process  The President said that the FDA will be streamlined and the drug approval process will be much faster  The 21st Century Cures Act is a step in this direction 
 
With the passing of this Act  expectations are that there will be more innovation in the sector and  maybe  a surge in new drug approvals  According to an IMSQuintiles report  the late phase R D pipeline for the industry indicates that there should be about 40 45 new brand launches every year through 2021 
 
Meanwhile  the FDA has already surpassed last year s total tally with 23 drugs being approved so far in 2017    Read   
 
Will M As Pick Pace 
 
There has been a lot of consolidation in the pharma industry over the last few years with quite a few deals being announced completed in 2016  Expectations are high that M As will increase as the year progresses    potential tax reform and cash repatriation are expected to lead to a boost in this area  While not too many deals have been announced so far in 2017  we could see several M A agreements being announced in the coming quarters though companies are wary of bidding wars leading to over priced deals 
 
Companies with innovative technologies and pipelines are highly sought after  Niche disease areas like nonalcoholic steatohepatitis  NASH   immuno oncology and multiple sclerosis are in demand  Treatments for orphan diseases are also much sought after with quite a few deals being signed in these areas   Read   
 
Innovative Pipelines   Catalyst Rich 2017 
 
Pharma companies continue to work on bringing innovative new treatments to market  and there could be significant catalysts in the coming quarters in the form of important new product approvals as well as major data read outs especially in key therapeutic areas like immuno oncology  Alzheimer s  central nervous system disorders  and immunology inflammation 
 
Cancer remains a key focus area  According to IMSQuintiles  68 new cancer drugs were approved for 22 indications from 2011 to 2016 while worldwide costs for cancer therapeutics and supportive care drugs shot up from  91 billion in 2012 to  113 billion in 2016  More than 600 molecules are in late stage development with the majority being targeted therapy 
 
Meanwhile  sales of products that gained approval over the last two years as well as line extensions should ramp up and boost growth 
 
Pharma ETFs in Focus
 
Highlighted below are some pharma ETFs   ETFs present a low cost and convenient way to get a diversified exposure to the sector 
 
Powershares Dynamic Pharmaceuticals ETF   
 
PJP  launched in Jun 2005 by Invesco PowerShares  tracks the Dynamic Pharmaceuticals Intellidex Index  The fund covers healthcare stocks  The top 3 holdings include Celgene Corporation  NASDAQ CELG   5 24    Amgen Inc  NASDAQ AMGN    5 14   and AbbVie Inc  NYSE ABBV    5 01    The total assets of the fund as of Jul 6  2017 were  742 1 million representing 30 holdings  The fund s expense ratio is 0 57  while dividend yield is 0 81   The trading volume is roughly 53 041 shares per day 
 
SPDR S P Pharmaceuticals  NYSE XPH  ETF   
 
XPH  launched inJun 2006  tracks the S P Pharmaceuticals Select Industry Index  This ETF primarily covers pharma stocks with the top 3 holdings being Akorn  Inc   5 27    Jazz Pharmaceuticals plc  5 19    and Endo International  plc  4 7   
 
Total assets as of Jul 6  2017 were  458 5 million representing 38 holdings  The fund s expense ratio is 0 35  and dividend yield is 0 62  The trading volume is roughly 58 019 shares per day 
 
iShares U S  Pharmaceuticals   
 
IHE  launched in May 2006  seeks investment results that correspond generally to the price and yield performance of the Dow Jones U S  Select Pharmaceuticals Index  The fund mainly consists of pharma companies  89 8    Biotech companies account for about 10 1  of the fund 
 
The top 3 holdings of this fund are Johnson   Johnson  NYSE JNJ   9 95    Pfizer Inc   NYSE PFE   8 21   and Merck  NYSE MRK    Co  Inc   7 58    The total assets of the fund as of Jul 6  2017 were  693 7 million representing 41 holdings  The fund s expense ratio is 0 44  with the dividend yield being 1 25   The trading volume is roughly 19 527 shares per day 
 
Market Vectors Pharmaceutical   
 
PPH was launched in Dec 2011 and tracks the Market Vectors U S  Listed Pharmaceutical 25 Index  This ETF covers healthcare stocks  While the expense ratio is 0 35   dividend yield is 1 95   The trading volume is roughly 39 357 shares per day  The total assets of the fund as of Jul 6  2017 were  276 8 million representing 26 holdings  The top 3 holdings of this fund are Johnson   Johnson  8 63    Novartis AG  6 4   and AbbVie Inc   5 17   
 
Conclusion
 
Although fears regarding the drug pricing issue have waned  it will nevertheless remain a headwind until the Trump administration comes out with a policy for controlling drug prices  Meanwhile  increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector 
 
Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-07-10,Zacks Investment Research,https://www.investing.com/analysis/what-lies-ahead-for-pharma-etfs-in-second-half-2017-200200111,200200111
150704,372220,AMGN,Roche s  RHHBY  Combination Cancer Remedy Wins FDA Approval,opinion,Roche   OTC RHHBY   announced that the FDA has granted approval to the subcutaneous injection of its marketed lymphoma drug MabThera Rituxan as Rituxan Hycela for the treatment of adults with different types of blood cancers The injection used Halozyme Therapeutics    NASDAQ HALO   proprietary Hycela  hyaluronidase   an FDA approved enzyme that facilitates the delivery of a large volume of medicine under the skin Note that  MabThera Rituxan is already approved in the U S  for healing relapsed indolent non Hodgkin Lymphoma  NHL   It is also sanctioned in the EU for treating patients with previously untreated and relapsed refractory chronic lymphocytic leukaemia  CLL   Note that MabThera is traded by its brand name Rituxan in the U S   Japan and Canada The approval was based on three phase III clinical studies and one phase Ib study in different types of blood cancers  The studies demonstrated that the combination of Rituxan and Hycela  resulted in non inferior levels of rituximab in the blood and showed positive clinical efficacy outcomes compared with the intravenous Rituxan alone One of the studies also showed that 77  of patients preferred the combination therapy over Rituxan as treatment with Rituxan Hycela can be administered in just five to seven minutes compared with the prolonged procedure of 1 5 hours under the influence of intravenous Rituxan Notably  Rituxan Hycela received an FDA approval for treating three most common types of blood cancers  including follicular lymphoma  diffuse large B Cell lymphoma  DLBCL  and chronic lymphocytic leukaemia  CLL  Per the company s press release  approximately 198 000 patients worldwide are estimated to be annually diagnosed with the two types of above mentioned lymphoma  Leukaemias are estimated to affect around 3 5 million people each year globally  Hence  patients suffering from the above mentioned blood cancers now have a new treatment option which provides efficacy comparable with intravenous Rituxan  Moreover  it can be administered in lesser time compared to IV infusion We remind investors that competition from Amgen   NASDAQ AMGN   and Novartis   NYSE NVS   biosimilars loom large on Rituxan  However  the biosimilar versions of Rituxan are expected to enter Europe in the second half of 2017 In a separate press release  the company has announced presentation of results from a new post hoc phase III study evaluating its marketed drug Ocrevus  ocrelizumab  at the European Academy of Neurology  EAN   Ocrevus is indicated for treating patients with relapsing and primary progressive forms of multiple sclerosis The post hoc analyses revealed that Ocrevus has increased disease control in patients with relapsing multiple sclerosis  RMS  and primary progressive multiple sclerosis  PPMS   A higher proportion of RMS patients  75   achieved No Evidence of Disease Activity  NEDA  when applied with Ocrevus compared with the interferon beta 1a  Rebif  arm  Also a higher proportion of PPMS patients  47   achieved No Evidence of Progression  NEP  with Ocrevus compared with placebo Notably in Mar 2017  Ocrevus had passed the FDA approval test for treatment of both RMS and PPMS The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ,2017-06-25,Zacks Investment Research,https://www.investing.com/analysis/roche's-(rhhby)-combination-cancer-remedy-wins-fda-approval-200197477,200197477
150705,372221,AMGN,Gold Bounces At Long Term Support  The Nikkei Probes Higher,opinion,"VIX continues to challenge both Short term and Intermediate term resistance before closing beneath them  A rally above Long term resistance at 12 60 implies that VIX may challenge its Ending Diagonal trendline at 17 50 in the following move 
Despite calls from investment banks that market tumult is on the horizon  Wall Street traders seemed to be taking it easy this Friday  A measure of expected volatility hit a two week low  while major stock market indices meandered modestly higher 
The Vix index  which tracks expected S P 500 volatility over the next month  slipped as much as 0 5 point to 9 98 per cent  the lowest level in two weeks  and well below the long term average of about 20 
SPX caught between support and resistance 

SPX appears to be caught between the upper trendline of its larger Ending Diagonal and the lower trendline of the smaller Ending diagonal  A break of the lower Diagonal trendline and Short term support at 2406 29 may be the star of a decline that completely retraces the rally from the February 2016 low 
U S  stocks were mostly lower on Friday  dragged lower by healthcare and consumer staples shares 
Health stocks had rallied on Thursday after Senate Republicans unveiled legislation that would replace Obamacare 
However  the bill faced skepticism from the Democrats  who attacked the legislation as a callous giveaway to the rich that would leave millions without coverage 
UnitedHealth was down about 1 percent and was the biggest drag on the Dow  Other major health stocks  including Regeneron and Amgen  NASDAQ AMGN   were down between 1 percent and 3 percent 
NDX retraces two thirds of its loss 

NDX retraced 67  of its loss from the June 9 decline The next move to look for is a challenge of the trendline and supports beneath it  A decline beneath the rally trendline and Cycle Top support at 5614 79 may suggest a deeper correction is in order 
 BusinessInsider  Technology stocks suffered from a little anxiety attack in the markets last week 
It didn t last long and really wasn t all that serious   Yet   It was nothing worse than what everyone called  normal volatility  10 years ago 
But the lack of concern it generated this time    
High Yield Bond Index puts in a secondary high 

The High Yield Bond Index rallied until Tuesday  then tested Intermediate term support at 166 29 before a small bounce into the weekly close  The sell signal may be reinstated beneath that support level  The Cycles Model suggests weakness may continue 
High yield corporate bonds have been a remarkably resilient asset class throughout the post crisis period  This included emerging from the rising default wave that spread across the asset class in 2015 and 2016  And  while high yield bonds continue to hover near all time highs  a renewed threat that first emerged for the category back in the spring is continuing to pick up steam  It remains to be seen how much longer high yield bonds can resist the pressure 
USB continues higher 

The Long Bond continues to rally aboveLong term support at 154 60  signaling more strength ahead  The operative formation is the Head   Shoulders which may require the completion of the right shoulder near 165 00 before plunging through the neckline 
Lots of hand wringing these days about the flattening yield curve   We still maintain our position that the signal from the bond market is significantly distorted due to the global central bank intervention  QE  into the bond markets  See  
Most of what is happening with the U S  yield curve is technical  Sure  traders can get a wild hair up their arse  believing the economy is slowing and try and game duration by punting in the cash or futures markets  Given the small relative float of the U S  Treasury bond market  however  it doesn t take much buying to move yields  In the words of economists  the supply curve of outstanding Treasuries is very inelastic 
The euro testing support 

The euro attempted a test of Short term support at 110 81  making a probable Master Cycle low  The follow up appears to be a potential probe to the weekly Cycle Top resistance at 115 32 over the next three weeks 
You may think the reflation trade is dead  Actually  it s simply traveled across the Atlantic 
Instead of betting on the dollar and better economic growth in the U S   currency investors are coming to terms with the possibility that the dollar s best days are behind it after three years of record breaking strength  More and more  traders are starting to count on the euro to take the dollar s place as the overarching trade of the  5 1 trillion market 
Euro Stoxx bounces at Intermediate term support 

The Euro Stoxx 50 Index probed Intermediate term support at 3522 64 before a bounce  There may be a brief period of strength lasting up to a week before Euro Stoxx plunges through that support 
European stocks closed lower on Friday as investors monitored oil prices and business activity in Germany dipped to a four year low 
The pan European Stoxx 600 slipped 0 23 percent with most sectors and major bourses in negative territory  For the week  bourses were little changed 
Europe s food and beverages sector was among the worst performers on Friday  down about 0 7 percent  Britain s pizza delivery business Domino s slipped towards the bottom of the benchmark after Berenberg bank lowered its outlook for the stock to  hold  from  buy   Its shares fell more than 2 percent on the news 
The yen tests Intermediate term support 

The yen challenged Intermediate term support at 89 64 closing above it  This week s pullback appears to be an important test of support prior to launching higher  It is probable that the rally may resume in the next week  A breakout above Long term resistance at 90 70 may alter the pace of the rally 
The Nikkei probes higher 

The Nikkei may have made the final probe of its rally from mid Cycle support  although another week of strength cannot be ruled out  The Cycles Model suggests areversal may be developing  but a sell signal may not be generated until the NIKK declines beneath Short term support at 19785 60 Further confirmation of the decline lies at Intermediate term support at 19444 10 
US dollar uppressed at mid Cycle resistance 

USD continues to be suppressed at mid cycle resistance at 97 47 for the past five weeks  The Cycles Model does allow for a potential false breakout to challenge Short term resistance at 97 85 in the next week or so before a plunge lower 
Speculators boosted net long positions on the U S  dollar  after slashing them the previous week to their lowest level since last August  according to calculations by Reuters and data from Commodity Futures Trading Commission released on Friday 
The value of the dollar s net long position rose to  7 82 billion in the week ended June 20  from  6 48 billion the previous week  The previous week s net long dollar position was the lowest since the third week of August last year 
Last week s interest rate hike by the Federal Reserve along with its hawkish statement have spurred speculators buy back dollars again 
Gold bounces at Long term support 

Gold declined to Long term support at 1241 38 before bouncing to Short term resistance at 1256 57  The Cycles Model suggests that the expected Master Cycle low may not have occurred yet  This next week may see a decline beneath Long term support to challenge mid Cycle support at 1212 25 with a minimum target of 1220 00 1224 00 
Crude slips beneath the Head   Shoulders neckline 

Crude slipped beneath the Head   Shoulders neckline at 44 00 this week and may be ready for the next leg of its decline  There are now three formations indicating the probable target for the coming decline this Summer 
Crude oil has officially entered a bear market  and Commodities king Dennis Gartman told CNBC the pain is far from over 
In a recent interview  the editor and founder of The Gartman Letter said oil conglomerate OPEC was losing the war on oil  especially in light of the ascension of Saudi Arabia s new crown prince  Mohammed bin Salman  Crude oil is down nearly 20 percent in 2017  and is tracking for its biggest six month drop since the late 1990s 
Gartman said 

He understands that crude oil  over the course of the next 20 to 40 years  is going to be a worthless commodity  It will be supplanted by something else 

Shanghai Index challenges Intermediate term resistance 

The Shanghai Index attempted a challenge of Intermediate term resistance at 3175 48  but closed beneath it  The Shanghai Index appears to have completed a rather flat correction  The potential for a sharp sell off is rising 
For the 10th day in a row  China s bond yield curve remains inverted  the longest in history  
With yields at 3 year highs  corporate bond issuance is evaporating  and has now emerged as the latest major  and most imminent  threat facing China s financial sector and  10 trillion corporate debt market 
However  it appears Chinese authorities have reached their max pain point 
In a very symbolic move overnight  China s Ministry of Finance bought 1 26 billion yuan of 1 year bonds for the first time in history via the secondary market 
The Banking Index completes its correction 

BKX appears to have made its final rally high on Monday before declining beneath Intermediate term support at 92 11  The sell signal has been activated again  The expected weakness may develop as BKX declines beneath its Short term support at 91 43 
Vermont Senator Bernie Sanders and his wife Jane have lawyer d up amid an FBI investigation into a loan obtained to expand Burlington College while she was its president 
As we noted just over a year ago  Burlington College  a small Vermont private school once led by the wife of Democratic presidential candidate Bernie Sanders  said Monday it will close later this month  citing  the crushing weight  of debt incurred during the presidency of Jane Sanders who was in charge of the college until 2011 
ECB shuts down Veneto Banca and Banca Popolare di Vicenza 
When banks fail and regulators decide to liquidate them  it happens on Friday evening so that there is a weekend to clean up the mess  And this is what happened in Italy   with two banks 
It s over for the two banks that have been prominent zombies in the Italian banking crisis  Veneto Banca and Banca Popolare di Vicenza  in northeastern Italy 
The banks have combined assets of  60 billion  a good part of which are toxic and no one wanted to touch them  They already received a bailout but more would have been required  and given the uncertainty and the messiness of their books  nothing was forthcoming  and the ECB which regulates them lost its patience 
Australian bankers are furious after the country s smallest state levied a  surprise  tax on the country s five biggest banks that could siphon off  280 million in profits during its first four years on the books  according to Reuters  The tax was imposed by South Australia  which is struggling with the country s highest unemployment rate and thanks the banks should be doing more to pitch in 
Major central banks should press ahead with interest rate increases  the Bank for International Settlements said on Sunday  while recognizing that some turbulence in financial markets will have to be negotiated along the way 
The BIS  an umbrella body for leading central banks  said in one of its most upbeat annual reports for years that global growth could soon be back at long term average levels after a sharp improvement in sentiment over the past year 
Though pockets of risk remain because of high debt levels  low productivity growth and dwindling policy firepower  the BIS said policymakers should take advantage of the improving economic outlook and its surprisingly negligible effect on inflation to accelerate the  great unwinding  of quantitative easing programs and record low interest rates ",2017-06-26,Anthony M. Cherniawski,"https://www.investing.com/analysis/weekend-update-june-23,-2017-200197437",200197437
150706,372222,AMGN,Amgen Gets Positive CHMP Opinion For Mimpara Label Expansion,opinion,Amgen Inc    NASDAQ AMGN   announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has rendered a positive opinion recommending marketing approval of a pediatric formulation  granules in capsule for opening  of Mimpara for the treatment of secondary hyperparathyroidism  HPT   Upon approval  the drug s label will be expanded to include use for children aged three years and older with end stage renal disease  ESRD  on maintenance dialysis therapy where standard of care therapy cannot adequately control secondary HPT We note that the European Commission generally follows the recommendation of the CHMP but is not bound to do so  An approval will grant marketing authorization with unified labeling for Mimpara in 28 EU countries Amgen s shares have outperformed the Zacks classified  industry so far this year  The stock gained 18 8  compared with the industry s increase of 11 5  during the period The positive opinion is based on data from studies assessing the use of Mimpara in pediatric secondary HPT patients that have been conducted by Amgen since 2007 Mimpara is already approved and marketed in EU as an oral therapy for secondary HPT patients and for the reduction of hypercalcemia in adult patients with parathyroid carcinoma Per the data from the press release  of the two million people receiving dialysis worlwide  the majority are affected by secondary HPT  The disease also occurs in patients with chronic kidney disease on hemodialysis Mimpara generated sales of  84 million in the first quarter of 2017  down 6  year over year  and  342 million in full year 2016  down 1  year over year in Europe  The label expansion  if approved  is expected to boost sales of the drug  which are currently witnessing a downside We remind investors that Mimpara is set to face generic competition soon in the U S  Zydus Pharmaceuticals  USA  Inc  and Cadila Healthcare Ltd  are looking to bring generic version of Sensipar  Mimpara  in the U S  Amgen has filed a patent litigation lawsuit against both the companies seeking restraint on approval of any generic version of Mimpara by the FDA before the expiration of the drug s patent Amgen Inc  Price and Consensus   Zacks Rank   Stocks to ConsiderAmgen currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the healthcare sector include Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Sanofi   NYSE SNY   and Enzo Biochem  Inc    NYSE ENZ    Regeneron sports a Zacks Rank  1  Strong Buy  while Sanofi and Enzo Biochem carry a Zacks Rank  2  Buy   You can see  Regeneron s earnings estimates moved up from  10 16 to  10 52 for 2017 and from  10 90 to  12 10 for 2018  over the last 60 days  The company came up with positive earnings surprises in two of the last four quarters  with an average beat of 0 45   Its share price is up 40 6  so far this year Sanofi s earnings estimates moved up from  3 08 to  3 18 for 2017 and from  3 26 to  3 30 for 2018  over the last 30 days  The company delivered positive earnings surprises in two of the last four quarters  with an average beat of 5 10   The stock is up 22 8  so far this year Enzo Biochem s loss estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018  over the last 30 days  The company came up with positive earnings surprises each of the last four quarters  with an average beat of 55 83   Its shares are up 65  so far this year Sell These Stocks  Now Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ,2017-06-26,Zacks Investment Research,https://www.investing.com/analysis/amgen-gets-positive-chmp-opinion-for-mimpara-label-expansion-200197721,200197721
150707,372223,AMGN,Alder s Shares Dip Despite Positive Migraine Trial Results,opinion,Alder Biopharmaceuticals  Inc  s   NASDAQ ALDR   shares plummeted almost 28  despite the announcement of positive top line results from phase III PROMISE I study  evaluating its lead pipeline candidate eptinezumab  ALD403  for prevention of frequent episodic migraine Though the study has met both is primary and secondary endpoints  the safety profile of eptinezumab was almost in line with placebo and consistent with the previously reported eptinezumab trials The PROMISE 1 study evaluated the efficacy and safety of eptinezumab across three doses  300mg  100mg or 30mg   administered by intravenous infusion once every 12 weeks through week 24  The study has met its primary endpoint  inducing a mean change in monthly migraine days from baseline for weeks 1 through 12 Patients who were applied with eptinezumab had experienced a 4 3 monthly migraine days reduction for 300mg and 3 9 days for 100mg compared with an average 3 2 days under the effect of placebo Good news is that a significant decrease in proportion of patients suffering from migraine was observed from day one  after the first dose was administered  In the opening month under trial  31 5  and 30 8  of patients administered with eptinezumab dosages of 300mg and 100mg respectively  had experienced an above 75  drop in monthly migraine days from baseline versus 20 3  with placebo  As it is evident  the results were not substantially better than placebo  causing the shares to inevitably downslide Shares of Alder have underperformed the Zacks classified  industry so far this year  The stock has lost 35 2  compared with the broader industry s progress of 8 9  Notably in Nov 2016  the company had initiated another pivotal phase III study  PROMISE 2  on eptinezumab for treatment of chronic migraine  Enrollment for the study is underway and the top line data is expected to be issued in the first half of 2018 Based on the outcomes from two pivotal phase III studies and a single open label phase III study  the company plans to file a Biologics License Application  BLA  in the second half of 2018 It is important to remind investors that eptinezumab uses calcitonin gene related peptide  CGRP  antibody for prevention of migraine  Amgen Inc  s   NASDAQ AMGN   erenumab  Eli Lilly and Company s   NYSE LLY   galcanezumab and Teva Pharmaceutical Industries Limited s   NYSE TEVA   fremanezumab TEV 48125 are also being evaluated for treating the same disease using anti CGRP Per the company s release  migraine is a serious neurological disease affecting about 36 million people in the U S  Among them  around 13 million adults live with migraines  occurring four or more days a month  Approximately 90  of them doesn t resort to any preventive therapy  Hence  approval of the drug would provide the company with an access to a market having immense commercial potential We expect investors  focus to remain on the updates related to further development of eptinezumab Alder BioPharmaceuticals  Inc  Price   Zacks RankAlder currently carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-06-27,Zacks Investment Research,https://www.investing.com/analysis/alder's-shares-dip-despite-positive-migraine-trial-results-200198079,200198079
150708,372224,AMGN,Amgen s Colorectal Cancer Drug Gets FDA Nod To Expand Label,opinion,Amgen  Inc    NASDAQ AMGN   announced that the FDA has approved a label expansion of its colorectal cancer drug  Vectibix Vectibix is now approved for use as first line treatment of wild type RAS metastatic colorectal cancer  mCRC  patients in combination with Folfox and as monotherapy following disease progression after prior treatment with fluoropyrimidine  oxaliplatin  and irinotecan containing chemotherapy So far this year  Amgen s shares are up 18   better than the 11 6  increase registered by the Zacks classified industry Wild type RAS is defined as wild type in both KRAS and NRAS as determined by an FDA approved test for this use  Presently  Vectibix is approved as a treatment for patients with wild type KRAS mCRC only  The approval of a refined indication of wild type RAS mCRC was based on a retrospective analysis from the PRIME study and prospective  pre defined analyses from the phase III  0007 study  Data from a key secondary endpoint of the  0007 study showed that patients with wild type RAS  absence of mutations in exons 2  3 and 4 of KRAS and NRAS  mCRC achieved median overall survival  OS  of 10 months when treated with Vectibix plus best supportive care  BSC  versus 6 9 months for BSC alone We believe the approval for an additional patient population can lead to improved sales of this cancer drug  The drug recorded sales of  147 million in the last reported quarter   first quarter of 2017   representing growth of 2  year over year  driven by higher demand We remind investors that in 2015 Amgen re acquired rights for Vectibix in select regions from GlaxoSmithKline   NYSE GSK   Amgen carries a Zacks Rank  3  Hold  Better ranked stocks in the sector include Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and VIVUS  Inc    NASDAQ VVUS    both sporting a Zacks Rank  1  Strong Buy   You can see  Regeneron s earnings estimates have risen 3 4  for 2017 and 11  for 2018 over the last 60 days  Shares of the company have risen 38 9  so far this year VIVUS  loss per share estimates narrowed 22  for 2017 in the last 60 days  The company delivered positive earnings surprises in all four trailing quarters with an average beat of 233 69    Shares of VIVUS have risen 5 3  this year so far 5 Trades Could Profit   Big League   from Trump Policies If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-06-29,Zacks Investment Research,https://www.investing.com/analysis/amgen's-colorectal-cancer-drug-gets-fda-nod-to-expand-label-200198510,200198510
150737,372253,AMGN,Is Amgen  AMGN  A Great Stock For Value Investors ,opinion,"Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Amgen Inc    NASDAQ AMGN   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Amgen has a trailing twelve months PE ratio of 13 79  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 compares in at about 20 37  If we focus on the stock s long term PE trend  the current level puts Amgen s current PE ratio below its midpoint over the past five years  with the number having trended roughly downwards over the past few months Further  the stock s PE also compares favorably with the Zacks classified Medical   Biomedical and Genetic sector s trailing twelve months PE ratio  which stands at 32 26  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Amgen has a forward PE ratio  price relative to this year s earnings  of just 13 35  so it is fair to say that a slightly more value oriented path may be ahead for Amgen stock in the near term too PEG RatioWhile earnings are certainly important  it is essential to know how much you are paying for the growth of earnings as well  One can easily do that with the PEG ratio  ratio of the P E to the expected future earnings growth rate  The PEG ratio gives a more complete picture of the valuation of a stock than the P E ratio Amgen s PEG ratio stands at just 2 18  compared with the Zacks Medical   Biomedical and Genetics average of 2 75  This suggests a decent undervalued trading relative to its earnings growth potential right now Broad Value OutlookIn aggregate  Amgen currently has a Zacks Value Style Score of  B   putting it into the top 40  of all stocks we cover from this look  This makes Amgen a solid choice for value investors What About the Stock Overall Though Amgen might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of  C  and a Momentum score of  F   This gives AMGN a Zacks VGM score or its overarching fundamental grade of  C    You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter has seen two estimates go higher in the past sixty days compared to five lower  while the full year estimate has seen eight up and five down in the same time period This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has inched down by almost 1  in the past two months  while the full year estimate has inched upper by 0 9   You can see the consensus estimate trend and recent price action for the stock in the chart below Amgen Inc  Price and Consensus
     This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineAmgen is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a sluggish industry rank  among Bottom 36  of more than 250 industries  and a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past two years  the Zacks Medical   Biomedical and Genetics industry has clearly underperformed the broader market  as you can see below So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick 3 Top Picks to Ride the Hottest Tech TrendZacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for those who make the right trades early ",2017-06-15,Zacks Investment Research,https://www.investing.com/analysis/is-amgen-(amgn)-a-great-stock-for-value-investors-200195644,200195644
150738,372254,AMGN,Amgen s Xgeva Myeloma Label Expansion SBLA Accepted By FDA ,opinion,Amgen Inc    NASDAQ AMGN   announced that the FDA has accepted its supplemental Biologics License Application  sBLA  to expand the label of its key drug  Xgeva Xgeva is currently approved for the prevention of skeletal related events  SREs  in solid tumors in patients with bone metastases  Amgen is looking to expand the label to include patients with multiple myeloma The FDA is expected to deliver a decision on the sNDA on Feb 3  2018 Xgeva is a fully human monoclonal antibody that inhibits bone breakdown by binding itself with RANK ligand and neutralizing it  Amgen s shares have outperformed the Zacks classified  industry so far this year  The stock gained 12 9  compared with the industry s increase of 6 4  during the period The company had submitted the sBLA in April this year backed by data from a pivotal  482 study  which compared Xgeva to Novartis AG s   NYSE NVS   Zometa  zoledronic acid   The study met its primary endpoint and demonstrated that Xgeva is non inferior to zoledronic acid in delaying the time to first on study skeletal related event  SRE  in patients with multiple myeloma  Xgeva also achieved a median increase of 10 7 months in progression free survival  PFS  compared with Zometa  Moreover  secondary endpoints of superiority in delaying time to first SRE and delaying time to first and subsequent SRE were not met The company will also apply for changes to its already submitted marketing authorization application to the European Medicines Agency  EMA   based on the data from  482 study In the phase III  482 study  120 mg dosage of Xgeva was administered subcutaneously along with an intravenous placebo every four weeks  This administration was compared with 4 mg intravenous dose of Zometa and subcutaneous placebo every four weeks Per the press release  an estimated 114 000 new patients are diagnosed with multiple myeloma worldwide every year and there are more than 80 000 related deaths  The disease is characterized by osteolytic bone lesions and renal impairment  However  currently available treatments are associated with renal toxicity and the majority of the patients face the risk of renal impairment over the course of the disease  Upon approval  Xgeva will provide a way of treatment without affecting renal functions and may boost revenues by expanding market share Xgeva sales contributed more than 7 5  to Amgen s total product revenue in the first quarter of 2017 and its label expansion is expected to boost sales further Amgen Inc  Price and Consensus   Zacks RankAmgen currently carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the healthcare sector include VIVUS  Inc    NASDAQ VVUS   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Both the stocks sport a Zacks Rank  1  Strong Buy   You can see  VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017 in the last 60 days  The company delivered positive earnings surprises in all four trailing quarters with average beat of 233 69  Regeneron s earnings estimates moved up from  10 16 to  10 52 for 2017 and from  10 90 to  12 10 for 2018  over the last 60 days  The company came up with positive earnings surprise in two of the last four quarters  with an average beat of 0 45  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-06-19,Zacks Investment Research,https://www.investing.com/analysis/amgen's-xgeva-myeloma-label-expansion-sbla-accepted-by-fda-200196399,200196399
150739,372255,AMGN,Small Cancer Biotech Space In Focus  3 Stocks Up 100    More,opinion,"The oncology space has always been keenly watched by investors interested in the pharma biotech sector  Cancer is the second most common cause of death in the U S  preceded only by heart disease  According to a report by the American Cancer Society  almost 1 7 million cancer cases are expected to be diagnosed in 2017  which creates significant need for effective cancer medication  While there are various types of cancer treatments including surgery  radiation  targeted therapy and chemotherapy  immuno oncology or immunotherapy is presently a hot therapeutic area with huge commercial potential   Immuno oncology or immunotherapy is a new class of cancer therapies that utilize certain parts of the immune system to fight the disease  This can be done by stimulating the immune system to attack cancer cells or by introducing immune system components into the body   Immuno oncology drugs and their combinations are in great demandWith big pharma and biotech companies like Merck   Co  Inc    NYSE MRK    Pfizer  Inc    NYSE PFE    Amgen  Inc    NASDAQ AMGN   and others in trouble due to generic competition for their key drugs  drug pricing issues and rising competition  focus is gradually shifting to smaller innovative biotechs  mainly the ones making cancer drugs  These companies are in the limelight on account of important advances in clinical studies of their experimental cancer drugs and are fast approaching the path to FDA EU approval  These stocks are also hot targets for acquisitions 
Let s discuss three of these smaller companies making cancer drugs whose shares are up 100  and more so far this year  All the three companies have a Zacks Rank  3  Hold   You can see Kite Pharma  Inc    NASDAQ KITE  Santa Monica  CA based Kite Pharma  focused on the development of immuno oncology treatments  has a market cap of  5 05 billion  Shares of the company are up 103 4  so far this year Kite Pharma s lead drug axicabtagene ciloleucel  previously KTE C19  is an anti CD19 CAR based therapy currently under priority review in the U S  for treating aggressive non Hodgkin lymphoma  NHL  with a FDA decision expected on Nov 29  The Biologics License Application  BLA  filing was based on data from the ZUMA 1 study  In Europe  a regulatory application is expected to be filed in the third quarter of this year  We believe that the solid efficacy profile demonstrated by the pivotal ZUMA 1 study should support the drug s approval this year Meanwhile other studies with axicabtagene ciloleucel and additional candidates including KITE 585 and KITE 718 are also advancing  A number of key data readouts are expected in 2017  which should keep investors glued to the stock Clovis Oncology  Inc    NASDAQ CLVS  Boulder  CO based Clovis Oncology develops treatments targeting specific subsets of cancer population  The company has a market cap of  3 93 billion  Shares of the company are up 99 6  so far this year Clovis got a huge boost with the FDA granting accelerated approval to its advanced ovarian cancer treatment  Rubraca last December  Rubraca has bright prospects  given the tremendous demand for PARP inhibitors  Successful commercialization will significantly boost Clovis  sales  Rubraca is also under review in the EU for a comparable ovarian cancer indication Importantly  the stock shot up this week after it announced promising progression free survival and safety results from the pivotal maintenance study  ARIEL3  earlier this week  The study data showed that Rubraca has a meaningful impact in delaying disease recurrence in advanced ovarian cancer patients  Overall  the study results suggest that advanced ovarian cancer patients can stay on Rubraca treatment for a longer time while gaining benefit  irrespective of their tumor genetics  The positive results may expand Rubraca s label  which could improve the commercial uptake of the drug Several studies on Rubraca  targeting different types of ovarian cancer patients  are currently underway  Also  Clovis is also looking to expand Rubraca s label into additional indications like prostrate  breast and pancreatic cancers  among others  either as monotherapy or in combination with other agents Puma Biotechnology  Inc    NASDAQ PBYI  This Los Angeles  CA based cancer focused company has a market cap of  2 97 billion  Shares of the company are up 155 9  so far this year Puma got a huge boost last month after an FDA advisory committee recommended the approval of its lead pipeline candidate  neratinib for the extended adjuvant treatment of HER2 positive early stage breast cancer as a single agent  The recommendation was mainly based on a favourable benefit demonstrated by neratinib in reducing the risk of disease recurrence in a phase III two year ExteNET study The positive vote significantly raised the chances of neratinib gaining FDA approval  While it is not mandatory for the FDA to go by the suggestions of its advisory panels  it usually does so  With Puma being a development stage company  neratinib s approval would be a major milestone for the stock Neratinib is also under review in the EU for the same indication  Meanwhile  several additional studies on neratinib targeting different types of breast cancer patient populations are currently underwayA couple of other cancer focused companies like Bluebird Bio  Inc    NASDAQ BLUE   and Incyte Corporation   NASDAQ INCY   also deserve a mention Earlier this month at ASCO  Bluebird Bio presented promising results from an early stage refractory multiple myeloma study on its investigational anti BCMA CAR T cell therapy  bb2121  which it is developing in collaboration with Celgene Corporation   NASDAQ CELG    Data from the study showed that 100  of the 15 evaluable patients in active dose cohorts achieved an objective response  Overall response rate  ORR  across all cohorts  n 18  is 89   The investment community believes that the data  though early stage  bodes well for the candidate s future development  While shares of the company are up 83 2  this year so far  the stock has gained more than 150  since Jun 5  when the data were presented Coming to Incyte  a promising immune therapy in its pipeline is epacadostat   a novel  potent and selective inhibitor of the enzyme IDO1  The candidate is being studied in combination with other immuno oncology agents  Incyte has collaboration agreements with Merck  Bristol Myers  AstraZeneca MedImmune and Roche Genentech to evaluate epacadostat with their respective anti PD 1 and anti PD L1 agents  At ASCO  Incyte also presented encouraging data from several combination studies  Shares of the company are up 24 2  this year ConclusionMounting competition in the cancer market  mainly in immuno oncology  is a significant concern  Several bigwigs are looking to develop and bring cancer treatments to market  Merck is conducting numerous studies to evaluate its anti PD 1 therapy  Keytruda for more than 30 types of cancer in 500 trials  Almost half of these trials are in combination with other cancer drugs  Recently approved cancer drugs like AstraZeneca s Imfinzi  durvalumab  and Pfizer s Bavencio avelumab are being evaluated for multiple cancers  either alone or in combination with other regimens  and have bright long term prospects  Meanwhile  many cancer drugs  already approved for quite a few indications like J J and AbbVie s Imbruvica  Pfizer s Ibrance  Bristol Myers  Opdivo  Celgene s Revlimid are being evaluated in several studies for label expansion  Several of these pharma biotech giants have significant financial resources at their disposal and have even collaborated with each other to pool their resources and technology  This makes it all the more difficult for smaller biotechs to match up to them However  these smaller companies can give their bigger counterparts a tough run as there is ample scope for growth in the immuno oncology space  be it in terms of revenues or patient outcomes  Any breakthroughs achieved by them will take the stocks to new highs 
Zacks  Hidden Trades
While we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them 
Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-06-20,Zacks Investment Research,"https://www.investing.com/analysis/small-cancer-biotech-space-in-focus,-3-stocks-up-100---more-200196554",200196554
150740,372256,AMGN,Novartis Migraine Drug Accepted  AMD Positive In Phase III,opinion,Novartis AG   NYSE NVS   announced that the European Medicines Agency  EMA  accepted its Marketing Authorization Application  MAA  for migraine candidate AMG 334  erenumab  Erenumab  an anti CGRP monoclonal antibody  is being developed for the prevention of migraine The MAA includes data from four phase II and phase III studies involving more than 2 600 patients experiencing four or more migraine days per month The data from the study showed erenumab demonstrated clinically meaningful  statistically significant and sustained efficacy compared with placebo in reducing the number of migraine days per month  The candidate also showed significant improvements on the impact migraine had on patients  disability and quality of life compared with placebo The safety profile of erenumab was comparable with placebo  Additionally  an extension trial is ongoing which is evaluating its long term safety in migraine patients for up to five years We remind that Novartis will co commercialize erenumab in the U S  with Amgen  Inc    NASDAQ AMGN   Both the companies entered into a global collaboration in Aug 2015 whereby they jointly agreed to develop and commercialize pioneering treatments in the field of migraine and Alzheimer s disease   The collaboration includes experimental candidates erenumab and AMG 301  currently in phase I development   We remind investors that the Biologics License Application  BLA  for erenumab has been submitted both in the U S  and EMA in May 2017 The companies expanded the agreement to include co commercialization of erenumab in the U S While Amgen retains the sole commercialization rights in Japan for the candidate  Novartis has commercialization rights in Europe  Canada and the rest of world 2017 is also expected to be a challenging year for the company   Novartis has outperformed the Zacks classified industry in the last six months  The stock has rallied 13 7  compared with the Large Cap Pharma industry s gain of 12 8  Going forward  we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis given the stiff existing generic competition for key drugs like Gleevec Meanwhile  Novartis also reported that ophthalmology candidate RTH258  brolucizumab  6 mg met the primary and key secondary endpoints in two phase III studies  HAWK and HARRIER  The studies enrolled more than 1 800 patients with neovascular age related macular degeneration  nAMD  in the trials  The primary and key secondary efficacy endpoints were non inferiority of RTH258 to Regeneron Pharmaceuticals s  NASDAQ REGN   Eylea in mean change in best corrected visual acuity  BCVA  from baseline to week 48  and average mean change over the period of week 36 48  respectively The candidate demonstrated long lasting efficacy compared with Eylea dosed every eight weeks   The successful development and commercialization of the candidate will significantly boost Novartis position in the ophthalmology market The performance of its eye care business  Alcon  has been quite disappointing due to lower surgical equipments sales  Hence  Novartis is mulling strategic options for Alcon which includes retaining the business to separation via a capital markets transaction such as a spin off or an initial public offering  The company will throw light on its plans for Alcon later in 2017 Zacks Rank   Key PickNovartis currently carries a Zacks Rank  3  Hold  A better ranked stock in the healthcare sector worth considering is VIVUS  Inc    NASDAQ VVUS   which currently sports a Zacks Rank  1  Strong Buy   You can see   VIVUS  loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days  The company posted positive earnings surprises in each of the trailing four quarters  with an average beat of 233 69  Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-06-20,Zacks Investment Research,"https://www.investing.com/analysis/novartis-migraine-drug-accepted,-amd-positive-in-phase-iii-200196659",200196659
150741,372257,AMGN,Ligand Gets Milestone Payment On Partner Drug FDA Approval,opinion,"Ligand Pharmaceuticals Incorporated   NASDAQ LGND   announced receipt of a milestone payment of  1 5 million after its partner Melinta Therapeutics  pipeline candidate Baxdela  delafloxacin  was approved by the FDA  Baxdela was approved to treat acute bacterial skin and skin structure infections  ABSSSI   caused by susceptible bacteria Melinta leveraged Ligand s Captisol technology to develop the IV formulation of Baxdela  In addition to the milestone payment  Ligand is entitled to earn a 2 5  royalty on Baxdela IV sales Shares of Ligand have outperformed the Zacks classified  industry so far this year  The stock rallied 13 9  compared with the broader industry s increase of 6 4  Notably  Melinta had submitted New Drug Applications  NDAs  to FDA for Baxdela in Oct 2016  Subsequently  the drug was accepted by the same in Jan 2017 under priority review  Eventually  the FDA has sanctioned both the intravenous and oral versions of Baxdela for treatment of ABSSSI The FDA approval was supported by positive results from two phase III studies in patients with ABSSSI  Baxdela met the primary endpoint of non inferiority in reducing lesion size at the primary infection site at 48 to 72 hours to a combination regimen of vancomycin plus aztreonam in both the phase III studies Ligand s Captisol formulation technology platform has allowed it to enter into partnerships with several leading drug companies like Novartis AG   NYSE NVS    Merck   Co   Inc    NYSE MRK    and Amgen Inc    NASDAQ AMGN   that provide it with funds in the form of milestone and royalty payments  Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility  stability  and bioavailability or lessen the volatility  irritation  smell or taste of drugs  Ligand derives revenues by selling Captisol material to its partners who have either licensed the company s Captisol enabled drugs or have licensed Captisol for their internal programs Ligand Pharmaceuticals Incorporated Price

   Zacks Rank   Key Picks
Ligand currently carries a Zacks Rank  5  Strong Sell   You can see  
Zacks  Hidden Trades
While we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them 
Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-06-21,Zacks Investment Research,https://www.investing.com/analysis/ligand-gets-milestone-payment-on-partner-drug-fda-approval-200196713,200196713
150742,372258,AMGN,Merck s Keytruda On A Roll  Can It Retain The Momentum ,opinion,As demand for immuno oncology drugs and their combinations rises  Merck   Co   Inc  s   NYSE MRK   anti PD 1 therapy  Keytruda  is being touted as a significant top line driver for this Kenilworth  NJ based pharma giant Keytruda is presently marketed for the treatment of first line as well as second line non small cell lung cancer  NSCLC   advanced melanoma and previously treated recurrent or metastatic head and neck cancer  HNSCC  Keytruda brought in sales of  584 million in first quarter 2017  up 20 9  sequentially and 134 5  year over year  Sales were driven by label as well as geographical expansion  Keytruda sales gained from launches in new indications like first line lung cancer  approved in Oct 2016   and recurrent or metastatic head and neck cancer  approved in Aug 2016  in the U S   and second line and first line NSCLC across the world At the first quarter conference call held in May  the company said that the  significant acceleration  in PD L1 testing for first line NSCLC patients experienced in the fourth quarter of 2016 had started to translate into higher demand  Meanwhile  Merck also mentioned at the call that it was working on securing reimbursement for the drug in first as well as second line NSCLC indication outside U S  and lung cancer sales should become a much larger contributor outside the U S  as the year progresses In fact  Keytruda uptake in the first line lung cancer indication and potential label expansion   with FDA action pending on multiple regulatory applications   are catalysts for the stock in 2017 In the last couple of months  there were a series of regulatory approvals for label expansion of Keytruda that should drive sales going forward Importantly  last month  the FDA granted accelerated approval to Keytruda for use in combination with Eli Lilly   Company s   NYSE LLY   cancer drug Alimta  pemetrexed  and carboplatin  pem carbo   a commonly used chemo regimen  in first line NSCLC  Note that this is the first FDA approval for Keytruda as a combination therapy  which can significantly expand its access in the lung cancer market Also  last month  Keytruda was approved for the first as well as second line treatment of certain patients with locally advanced or metastatic urothelial carcinoma  a type of bladder cancer Also  the drug gained FDA approval last month for use in adult and pediatric patients with unresectable or metastatic  microsatellite instability high  MSI H  or mismatch repair deficient  dMMR  solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or colorectal cancer that has progressed following treatment with a fluoropyrimidine  oxaliplatin  and irinotecan  This makes Keytruda the first cancer therapy approved for use based on a biomarker regardless of tumor type In Mar Apr 2017  Keytruda received FDA and EU approval for refractory classical Hodgkin lymphoma  cHL    the first Keytruda approval for hematologic malignancy indication Keytruda is continuously growing and expanding into new indications and markets globally Meanwhile  Keytruda is also being studied for more than 30 types of cancer in 500 trials  Almost 50  of these trials are in combination with other cancer drugs  Merck is collaborating with several companies including Amgen  Inc    NASDAQ AMGN    Incyte  Glaxo and Pfizer  Inc    NYSE PFE   separately for the evaluation of Keytruda in combination with other regimens ConclusionMerck s top line has been lately hurt by generic competition for several drugs and pricing pressure  We believe Keytruda has immense commercial potential and it coupled with some other newer drugs can ease the impact of genericization  Meanwhile  though competition in the immuno oncology market is rising following recent FDA approval of Pfizer s Bavencio  avelumab  in MCC and bladder cancer indications and AstraZeneca s Imfinzi  durvalumab  for bladder cancer  we believe Keytruda can give these drugs a tough run as there is ample scope for growth in the immuno oncology space Merck carries a Zacks Rank  3  Hold   You can see  Merck s shares are up 11 2  year to date  comparing unfavorably with an increase of 12 3  witnessed by the Zacks classified industry Looking for Ideas with Even Greater Upside  Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-06-21,Zacks Investment Research,https://www.investing.com/analysis/merck's-keytruda-on-a-roll:-can-it-retain-the-momentum-200196950,200196950
150774,372290,AMGN,Teva Migraine Candidate Succeeds In Second Phase III Study,opinion,Teva Pharmaceutical Industries Ltd    NYSE TEVA   announced that its experimental migraine prevention drug  fremanezumab  met all the primary and secondary endpoints in a second late stage study Pivotal data from the second phase III HALO study in episodic migraine prevention showed that patients who were treated with monthly as well as quarterly dosing regimens of fremanezumab experienced clinically and statistically significant improvements in all endpoints and 12 pre specified analyses Teva s shares have lost 20 7  so far this year compared with the Zacks classified industry s decline of 7 0  Coming back to fremanezumab  it is an anti calcitonin gene related peptide  CGRP  subcutaneous injection developed for the prevention of episodic and chronic migraine Last week  Teva presented positive results from another HALO late stage study in chronic migraine which also showed that the monthly and quarterly dosing regimens of fremanezumab met all primary and secondary endpoints Detailed findings from both the studies will be presented at future medical meetings Teva intends to seek FDA approval for fremanezumab later this year based on the HALO studies for both episodic and chronic migraine and expects approval in the second half of next year Given the limited treatment options  fremanezumab represents significant commercial potential  According to Teva s press release  more than a billion people suffer from migraine across the world including 38 million in the U S We remind investors that Teva is not the only company working on a migraine drug  Amgen  Inc    NASDAQ AMGN   and partner Novartis AG   NYSE NVS   recently filed for FDA approval of their CGRP receptor  erenumab  for the prevention of migraine  Meanwhile  Eli Lilly   Company   NYSE LLY   plans to file for FDA approval of its investigational migraine drug  galcanezumab  in the second half of the year Teva carries a Zacks Rank  3  Hold   You can see 3 Top Picks to Ride the Hottest Tech Trend Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for those who make the right trades early ,2017-06-07,Zacks Investment Research,https://www.investing.com/analysis/teva-migraine-candidate-succeeds-in-second-phase-iii-study-200194077,200194077
150775,372291,AMGN,AbbVie  ABBV  Announced Positive Phase III RA Candidate Data,opinion,AbbVie Inc    NYSE ABBV   announced positive top line results from a phase III study on rheumatoid arthritis candidate  upadacitinib  ABT 494   Upadacitinib is an investigational oral JAK1 selective inhibitor being studied as a once a day oral therapy AbbVie s shares have rallied 13 2  in the past one year  outperforming the Zacks classified  industry s 1 7  rise The multi center  randomized  double blind  placebo controlled parallel group SELECT NEXT study evaluated the efficacy and safety of two doses  15 mg and 30 mg  of upadacitinib versus placebo over 12 weeks in adult patients with moderate to severe rheumatoid arthritis  RA  who are on a stable dose of conventional synthetic DMARDs and have had an inadequate response to them The study met its primary endpoint and all secondary endpoints with highly statistically significant and clinically meaningful results for both the doses compared to placebo The results showed that 64  of patients  receiving 15 mg and 66  of patients  administered 30 mg dose once daily  achieved ACR20 responses after 12 weeks of treatment compared to 36  of patients receiving placebo  Low disease activity was achieved by 48  of the patients receiving either dose of upadacitinib compared to 17  for placebo Upadacitinib is also being investigated in a pivotal study for psoriatic arthritis  Other studies are also ongoing for the treatment of Crohn s disease  ulcerative colitis and atopic dermatitis AbbVie s flagship RA drug Humira brought in sales of  4 1 billion  However  the RA market is extremely crowded including drugs like Johnson   Johnson s Simponi and UCB s Cimzia among others We note that upadacitinib is a JAK1 inhibitor as second line treatment for RA patients where drugs like Humira have inadequate response  However  Eli Lilly and Company s   NYSE LLY   JAK inhibitor  Olumiant was recently approved in the EU and Pfizer Inc  s   NYSE PFE   Xeljanz is marketed in the U S  for treating RA by inhibiting JAK enzyme Meanwhile  Amgen Inc    NASDAQ AMGN   has already received approval to market a Humira biosimilar but the drug has not been launched due to ongoing litigation  If upadacitinib is approved  it may reduce the potential negative impact of Humira generics on the company s top line AbbVie Inc  Price   Zacks Rank AbbVie currently carries a Zacks Rank  3  Hold   You can see  3 Top Picks to Ride the Hottest Tech TrendZacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ,2017-06-07,Zacks Investment Research,https://www.investing.com/analysis/abbvie-(abbv)-announced-positive-phase-iii-ra-candidate-data-200194074,200194074
150776,372292,AMGN,4 Trades To Ride Amgen Higher  Bonus Idea,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Amgen  NASDAQ AMGN  started to run higher in November reaching a peak in March  It held there for 1 day before a gap down and then a drift lower to a low in May  Since that low the stock price has been moving higher and ended the week at resistance  It is now over the 50 and 200 day SMA s  and sees the Bollinger Bands  opening to the upside  Continuation triggers an AB CD pattern that gives a target to 202 50 in late September 
The RSI is back in the bullish zone while the MACD has crossed up and is moving into positive territory  Both support more upside price action  There is resistance at 165 30 and 170 and hen a gap to fill to 180 then the all time high at 184 21  Support lower comes at 160 and 156 followed by 152 50  Short interest is low at 1 2   The company is expected to report earnings next on July 26th 
Options chains show the majority of open interest this week below the current price and on the Put side  but with size at 160 and 165 on the Call side as well  In the July monthly chain open interest is spread around a cent at 155 on the Put side and focused from 160 to 165 on the Call side  The July 28 Expiry only opened last week and open interest is still building  To find bets on earnings we need to look at the September chain  That shows open interest spread from 150 to 160 on the Put side and then again large at 170  On the Call side it is spread from 160 to 175 
Amgen
Trade Idea 1  Buy the stock on a move over 165 50 with a stop at 160 
Trade Idea 2  Buy the stock on a move over 165 50 and add a July 28 Expiry 162 5 155 Put Spread   3 76  for protection through earnings  selling the July 28 Expiry 170 Calls   2 00  to lower the cost 
Trade Idea 3  Buy the July September 170 Call Calendar   2 60  
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which showed equities mixed heading into the June Options Expiration Week  with the iShares Russell 2000  NYSE IWM  and SPY  NYSE SPY  looking strong but the PowerShares QQQ Trust Series 1  NASDAQ QQQ  weak as there was rotation out of the QQQ and into IWM 
Elsewhere look for Gold to continue lower while Crude Oil also looks better to the downside  The US Dollar Index continues to be biased lower while US Treasuries pullback in the uptrend  The Shanghai Composite is back to its upward drift and Emerging Markets are biased to continue higher 
Volatility looks to remain at very low levels keeping the bias higher for the equity index ETF s SPDR S P 500  NYSE SPY   IWM and QQQ  Their charts show strength in the IWM and consolidation in the SPY short term with the QQQ looking diseased  Longer term all trends remain higher with real strength returning to the IWM  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2017-06-12,Gregory W. Harmon,https://www.investing.com/analysis/4-trades-to-ride-amgen-higher:-bonus-idea-200194531,200194531
150777,372293,AMGN,Amgen s Multiple Myeloma Drug Receives NICE Recommendation,opinion,Amgen Inc    NASDAQ AMGN   announced that Kyprolis gained recommendation from National Institute for Health and Care Excellence  NICE  in combination with dexamethasone for the treatment of relapsed multiple myeloma  RMM  in patients who have received at least one prior therapy excluding Johnson   Johnson s   NYSE JNJ   Velcade The drug  in combination with Celgene Corporation s   NASDAQ CELG   Revlimid  lenalidomide  and dexamethasone  is already approved in the EU for the treatment of multiple myeloma in patients who have received at least one prior therapy  Moreover  the recommendation for label expansion from NICE  a public body of the Department of Health in the United Kingdom  will allow Amgen to market the drug with expanded label in England and Wales Amgen s shares have outperformed the Zacks classified  industry so far this year  The stock gained 12 8  compared with the industry s increase of 2 3  during the period  The recommendation was based on data from the pivotal ENDEAVOR study  which compared Kyprolis and Velcade in combination with dexamethasone in patients with RMM  The data demonstrated superiority of Kyprolis over Velcade by doubling progression free survival  PFS   18 7 months vs  9 4 months  and significantly improving overall survival in patients Moreover  data from ASPIRE study showed that Kyprolis in combination with Revlimid and dexamethasone achieved better PFS than combination therapy with Revlimid and dexamethasone  26 3 months vs 17 6 months  According to the company press release  there are approximately 17 500 patients with myeloma in the UK with news cases of approximately diagnosed every year Kyprolis posted sales of  190 million in the first quarter 2017  up 23  year over year  driven by higher demand  At the call  the company said that in the second line multiple myeloma market  despite triplet regimens being used in approximately one third of patients  Kyprolis gained 50  market share for new patient starts  With the approval of label expansion in the U K   sales of this drug are likely to witness an increase Amgen Inc  Price   Zacks Rank   Stock to ConsiderAmgen currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is VIVUS  Inc    NASDAQ VVUS    sporting a Zacks Rank  1  Strong Buy   You can see  VIVUS  loss per share estimates declined from 50 cents to 39 cents for 2017 in the last 60 days  The company posted positive earnings surprises in the four trailing quarters with an average beat of 233 69  Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ,2017-06-12,Zacks Investment Research,https://www.investing.com/analysis/amgen's-multiple-myeloma-drug-receives-nice-recommendation-200194831,200194831
150778,372294,AMGN,Merck Stalls Enrolment In Two Myeloma Studies Of Keytruda,opinion,Merck   Co   Inc    NYSE MRK   announced that it is pausing two late stage studies evaluating its anti PD 1 therapy  Keytruda  as a combination therapy for the treatment of multiple melanoma  a form of blood cancer  Shares were down more than 1  in after hours trading Merck s shares are up 9 2  year to date  comparing unfavorably with an increase of 10 8  witnessed by the Zacks classified industry The decision to stop new enrollment in the KEYNOTE 183 and KEYNOTE 185 phase III studies was taken at the recommendation of an external Data Monitoring Committee  The break in enrollment is meant to allow investigation of death of patients taking Keytruda  However  patients presently enrolled in the two studies would continue to receive the treatment While the KEYNOTE 183 study was evaluating a combination of Keytruda  Celgene Corporation s   NASDAQ CELG   Pomylast and dexamethasone  KEYNOTE 185 was studying a combination of Keytruda  Celgene s Revlimid and dexamethasonePresently  Keytruda is marketed in the U S  and EU for the treatment of previously untreated metastatic non small cell lung cancer  NSCLC  in patients whose tumors express high levels of PD L1 and previously treated metastatic NSCLC in patients whose tumors express PD L1  as well as advanced melanoma  In the U S   it is also approved for previously treated recurrent or metastatic head and neck cancer  HNSCC  However  in the last couple of months  there were a series of regulatory approvals for the label expansion of Keytruda that should drive sales going forward  Keytruda brought in sales of  584 million in first quarter 2017  up 20 9  sequentially and 134 5  year over year Last month  Keytruda was approved for the first  as well as second line treatment of certain patients with locally advanced or metastatic urothelial carcinoma  a type of bladder cancer The drug gained FDA approval last month for use in adult and pediatric patients with unresectable or metastatic  microsatellite instability high  MSI H  or mismatch repair deficient  dMMR  solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or colorectal cancer that has progressed following treatment with a fluoropyrimidine  oxaliplatin  and irinotecan  This makes Keytruda the first cancer therapy approved for use based on a biomarker regardless of tumor type Also  last month  the FDA granted accelerated approval to Keytruda for use in combination with Eli Lilly   Company s   NYSE LLY   cancer drug Alimta  pemetrexed  and carboplatin  pem carbo   a commonly used chemo regimen  for the first line treatment of metastatic NSCLC  irrespective of PD L1 expression  Note that this is the first FDA approval for Keytruda as a combination therapy In Mar Apr 2017  Keytruda received FDA and EU approval for refractory classical Hodgkin lymphoma  cHL    the first Keytruda approval for hematologic malignancy indication Keytruda is continuously growing and expanding into new indications and markets globally and is considered to be one of Merck s key growth drivers  Especially  its sales received a boost with the approval in the first line lung cancer setting  With the recent label expansions  sales should pick up further in the upcoming quarters Meanwhile  Keytruda is being studied for more than 30 types of cancer in 500 trials  Almost 50  of these trials are in combination with other cancer drugs  Merck is collaborating with several companies including Amgen  Inc    NASDAQ AMGN    Incyte  Glaxo and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimens Merck carries a Zacks Rank  2  Buy   You can see  Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ,2017-06-12,Zacks Investment Research,https://www.investing.com/analysis/merck-stalls-enrolment-in-two-myeloma-studies-of-keytruda-200194827,200194827
150779,372295,AMGN,Why Is ImmunoGen  IMGN  Stock Up 131  This Year ,opinion,"Shares of ImmunoGen  Inc    NASDAQ IMGN   are massively up 130 9  this year so far  outperforming the the Zacks classified  industry s registered 3 6  increase during this period  Let s analyze the factors that led to the rally Waltham  MA based ImmunoGen is a development stage biotechnology company  focused on developing targeted cancer therapeutics using proprietary antibody drug conjugate  ADC  technology  ImmunoGen has agreements with several big healthcare companies including Amgen Inc    NASDAQ AMGN    Bayer  DE BAYGN   Eli Lilly and Company   NYSE LLY    Novartis   NYSE NVS    Roche  Sanofi  PA SASY  and Takeda  These agreements allow other companies to use ImmunoGen s ADC technology and provide it with funds in the form of license and milestone fees  royalties  clinical materials revenue and R D support fees ImmunoGen has made a significant progress with regard to the lead pipeline candidate  mirvetuximab soravtansine  The candidate is currently in a phase III study  FORWARD I  as a single agent therapy for treating patients with platinum resistant ovarian cancer whose tumors express high or medium levels of FR alpha and who have received up to three prior treatment regimens In Jan 2017  the company has announced the first patient to have been dosed in the study  Data from the study is anticipated in 2019 Combination regimens with mirvetuximab soravtansine in ovarian cancer in the phase Ib II FORWARD II study aim to expand the eligible patient population  Following the successful completion of dose escalation  a phase II expansion cohort in combination with Roche Holding  SIX ROG  AG s Avastin is also ongoing Last month  IMGN announced some encouraging data from the FORWARD I and FORWARD II study which was presented at the American Society of Clinical Oncology  ASCO  in June A pooled analysis of data from the FORWARD I phase II study was announced to show a consistent clinical profile of mirvetuximab soravtansine with an overall response rate  ORR  of 47  and a progression free survival  PFS  of 6 7 months in 36 patients The data meets the eligibility criteria for enrolment in the phase III FORWARD I study  Data from the FORWARD II combinations studies  though early  also looked favorable An approval of mirvetuximab soravtansine would be a huge boost for ImmunoGen  given the immense commercial potential in the target market  Ovarian cancer results in maximum deaths per year among gynecologic cancers  with majority of the patients diagnosed at an advanced stage Per data provided by the American Cancer Society  approximately 22 440 new cases of ovarian cancer will be diagnosed in the U S  in 2017  resulting in over 14 080 deaths Apart from mirvetuximab soravtansine  ImmunoGen is working on developing a couple of other candidates  These include IMGN779 and IMGN632  IMGN779 is being evaluated in a phase I study for treating acute myeloid leukemia with data expected later this year  The company plans to file an investigational new drug application  INDA  for IMGN632 to treat hematological malignancies in the third quarter of 2017 Though the platinum resistant ovarian cancer market provides an immense commercial potential  ImmunoGen is notably set to face intense competition  upon approval  However  mirvetuximab soravtansine looks promising at this juncture and its approval will be a huge boost to the company ImmunoGen  Inc  Price and Consensus

   ImmunoGen carries a Zacks Rank  3  Hold   You can see  
3 Stocks to Ride a 588  Revenue Explosion
At Zacks  we re mostly focused on short term profit cycles  but the hottest of all technology mega trends is starting to take hold   
By last year  it was already generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ",2017-06-15,Zacks Investment Research,https://www.investing.com/analysis/why-is-immunogen-(imgn)-stock-up-131-this-year-200195517,200195517
150780,372296,AMGN,Novartis  NVS  Announced Positive Data On Psoriasis Cosentyx ,opinion,"Novartis AG   NYSE NVS   announced positive data on arthritis drug Cosentyx from two phase III studies at the Annual European Congress of Rheumatology  EULAR 2017   in Madrid 
Cosentyx  fully human monoclonal antibody  is already approved in the U S  and EU for the treatment of moderate to severe plaque psoriasis  The drug is also approved in the EU for the treatment of adults with ankylosing spondylitis  AS  who have responded inadequately to conventional therapy  such as non steroidal anti inflammatory drugs  The drug is also instrumental for the treatment of active psoriatic arthritis  PsA  in adults when the response to disease modifying anti rheumatic drug therapy is unsatisfactory 
In Jan 2016  Cosentyx obtained the FDA approval for the treatment of adults with active ankylosing spondylitis and for the treatment of adults with active psoriatic arthritis 
The data shows sustained improvement in the signs and symptoms for active AS at three years  The new data also revealed that Cosentyx provides rapid and sustained pain relief in patients with PsA out to 2 years 
Data from the phase III study  MEASURE 1 extension study  showed 80  of AS patients consistently achieved an ASAS 20 response at 3 years  in tandem with previous findings from the FUTURE 1 study on Cosentyx for active PsA  Additionally  a 2 year post hoc analysis of the FUTURE 2 study evaluated Cosentyx in PsA  where 99  patients reported moderate to extreme pain or discomfort before initiating treatment  At week 3  half of the treated with Cosentyx reported clinically meaningful improvements in pain of over 20   as measured by Visual Analogue Scale 
Meanwhile  patient recruitment is underway for the new head to head clinical trial  EXCEED  to evaluate the superiority of Cosentyx versus AbbVie s   NYSE ABBV   Humira in PsA 
Novartis  has outperformed the Zacks classified industry over the last six months  The stock has rallied 12 2  compared with the  industry s gain of 4 5  
The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals  Humira and Amgen s   NASDAQ AMGN   Enbrel  Cosentyx achieved blockbuster status in 2016 recording over  1 billion of sales 
Novartis expects the next growth phase to begin in 2018 driven by Cosentyx  in all three indications psoriasis  psoriatic arthritis and ankylosing spondylitis  Entresto  and Kisqali and a deep pipeline with candidates like CTL019  BAF312  AMG 334  RTH258  Going forward  we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis 
Zacks Rank   Key Pick
Novartis currently carries a Zacks Rank  3  Hold  
A better ranked stock in healthcare sector include VIVUS  Inc    NASDAQ VVUS   which sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS s loss per share estimates lessened from 50 cents to 39 cents for 2017 in the last 30 days  The company posted positive earnings surprises in all four trailing quarters with average beat of 233 69  
3 Stocks to Ride a 588  Revenue Explosion 
At Zacks  we re mostly focused on short term profit cycles  but the hottest of all technology mega trends is starting to take hold 
By last year  it was already generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ",2017-06-15,Zacks Investment Research,https://www.investing.com/analysis/novartis-(nvs)-announced-positive-data-on-psoriasis-cosentyx-200195528,200195528
150822,372338,AMGN,Amgen Evenity Approval Derailed On Cardiovascular Side Effect,opinion,A late stage study at Amgen  Inc    NASDAQ AMGN   showed that its pipeline candidate Evenity romosozumab led to a statistically significant superior fracture risk reduction in postmenopausal women with osteoporosis than Merck   Co   Inc  s   NYSE MRK   Fosamax  alendronate   which is the current standard of care in osteoporosis  However  a cardiovascular side effect was observed in the study  following which Amgen does not expect Evenity to get FDA approval this year The phase III ARCH study compared 12 months of treatment with the subcutaneous injection of Evenity monthly followed by 12 months of Fosamax compared to Fosamax alone in postmenopausal women with osteoporosis at a high risk for fractureAt the primary analysis  the Evenity Fosamax arm significantly reduced the incidence of new vertebral fractures through 24 months  clinical fractures  primary endpoints  and non vertebral fractures  key secondary endpoint  in the above mentioned patients  compared to Fosamax alone However  an imbalance in cardiovascular safety signal was observed in the study  which management said will be assessed as part of the overall benefit risk profile for Evenity The incidence of positively adjudicated cardiovascular serious adverse events at 12 months was 2 5  in the Evenity arm compared with 1 9  in the Fosamax arm Evenity romosozumab is presently under review in the U S  for the treatment of osteoporosis in postmenopausal women at increased risk for fracture with a decision expected on Jul 19  2017  This regulatory application was based on the FRAME study result  It is also under review in Canada and Japan for the same indication However  the safety data from the ARCH data will now be considered in the regulatory review as agreed with the FDA  Following the new heart related safety issue that emerged from the otherwise successful ARCH results  Amgen does not expect Evenity to be approved this year Shares of Amgen were down 1  on Friday  However  so far this year  Amgen s shares are up 7   better than the 0 4  increase registered by the Zacks classified industry Amgen carries a Zacks Rank  3  Hold   Better ranked stocks in the pharmaceutical sector are Akari Therapeutics  Plc   NASDAQ AKTX   and VIVUS  Inc    NASDAQ VVUS    both with a Zacks Rank  1  Strong Buy   You can see  Shares of Akari Therapeutics have risen 1 6  this year so far Loss estimates for Vivus for 2017 have narrowed by 22  over the past 30 days  The company has delivered an average positive earnings surprise of 233 63  over the past four quarters Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ,2017-05-22,Zacks Investment Research,https://www.investing.com/analysis/amgen-evenity-approval-derailed-on-cardiovascular-side-effect-200190598,200190598
150823,372339,AMGN,Merck s  MRK  Keytruda Gets FDA Nod For Solid Tumor Cancers,opinion,Merck   Co   Inc    NYSE MRK   announced that its anti PD 1 therapy  Keytruda  has received accelerated approval for the treatment of microsatellite instability high  MSI H  or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options  Also  the label will be expanded to include MSI H or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine  oxaliplatin  and irinotecan In a separate press release  Merck announced that the FDA has granted priority review to its supplemental biologics license application  sBLA  for label expansion of Keytruda for the treatment of recurrent or advanced gastric or gastroesophageal junction adenocarcinoma  The FDA is expected to give its decision on Sep 22 Presently  Keytruda is approved in the U S  and EU for the treatment of previously untreated metastatic non small cell lung cancer  NSCLC  in patients whose tumors express high levels of PD L1 and previously treated metastatic NSCLC in patients whose tumors express PD L1  as well as advanced melanoma  In the U S  it is also approved for previously treated recurrent or metastatic head and neck cancer  HNSCC  Merck s shares are up 9 8  year to date  comparing unfavorably with an increase of 10 2  witnessed by the Zacks classified industry The last few months witnessed a series of regulatory approvals for label expansion of Keytruda that should drive sales going forward  Keytruda brought in sales of  584 million in first quarter 2017  up 20 9  sequentially and 134 5  year over year Earlier this month  the company announced that FDA has approved two new bladder cancer indications for Keytruda  Also  this month  the FDA granted accelerated approval to Keytruda for use in combination with Eli Lilly   Company s   NYSE LLY   cancer drug Alimta  pemetrexed  and carboplatin  pem carbo   a commonly used chemo regimen  for the first line treatment of metastatic NSCLC  irrespective of PD L1 expression  Note that this is the first FDA approval for Keytruda as combination therapy In Mar Apr 2017  Keytruda received FDA and EU approval for refractory classical Hodgkin lymphoma  cHL    the first Keytruda approval for hematologic malignancy indication Keytruda is the first anti PD 1 therapy to gain FDA approval and is continuously growing and expanding into new indications and markets globally  Especially  its sales received a boost with the approval in the first line lung cancer setting  With the recent label expansions  sales should pick up further in the upcoming quarters Meanwhile  Keytruda is being studied for more than 30 types of cancer in 500 trials  Almost 50  of these trials are in combination with other cancer drugs  Merck is collaborating with several companies including Amgen  Inc    NASDAQ AMGN    Incyte  GlaxoSmithKline plc   NYSE GSK     and Pfizer  NYSE PFE  separately for the evaluation of Keytruda in combination with other regimensMerck carries a Zacks Rank  2  Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana   Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-05-23,Zacks Investment Research,https://www.investing.com/analysis/merck's-(mrk)-keytruda-gets-fda-nod-for-solid-tumor-cancers-200191144,200191144
150824,372340,AMGN,Radius Health Osteoporosis Drug Positive In Phase III Study,opinion,Radius Health  Inc    NASDAQ RDUS   announced positive data from the ACTIVExtend study on Tymlos  The 24 month ACTIVExtend study on Tymlos enrolled patients who had completed 18 months of treatment with Tymlos  abaloparatide  injections or placebo in the phase III trial  ACTIVE  These patients were then transitioned to receive 24 additional months of open label alendronate Data from the study revealed that Tymlos  80 mcg   when dosed daily for 43 months  18 months in ACTIVE study   24 months in ACTIVExtend study   led to a significant reduction  84   in the incidence of new vertebral fractures in postmenopausal women with osteoporosis  compared to placebo  Results also demonstrated a 39  reduction in the risk of nonvertebral fractures  a 34  risk reduction in clinical fractures and 50  reduced risk in major osteoporotic fractures compared with women who received placebo followed by Merck   Co   Inc  s   NYSE MRK   Fosamax Radius Health s share price has outperformed the Zacks categorized  industry in the past one year  The stock increased 18 3  compared with an increase of 12 3  for the broader industry We remind investors that Tymlos was recently approved in the U S  for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture  multiple risk factors for fracture  or patients who have failed or are intolerant to other available osteoporosis therapy  The drug is under review in the EU The company is planning to file a supplemental New Drug Application  sNDA  for Tymlos based on the ACTIVExtend study An opinion from the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  for the marketing application is expected in Jul 2017 Although the osteoporosis market in the U S  has great potential as approximately 1 4 million postmenopausal women in the U S  experience osteoporotic fractures each year  Tymlos is expected to face significant competition from Eli Lilly and Company s   NYSE LLY   Forteo and Amgen Inc  s   NASDAQ AMGN   Prolia In addition  the company is developing abaloparatide transdermal  abaloparatide TD  for potential use as a treatment for osteoporosis As per the company s press release  approximately 2 million osteoporotic fractures take place annually in the U S  This number is likely to grow to 3 million by 2025 According to the National Osteoporosis Foundation  NOF   an estimated 8 million women are already affected by osteoporosis  while an estimated 44 million individuals have demonstrated low bone mass  placing them at high risk for osteoporosis Radius Health  Inc  Price   Radius Health currently has a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-05-24,Zacks Investment Research,https://www.investing.com/analysis/radius-health-osteoporosis-drug-positive-in-phase-iii-study-200191392,200191392
150825,372341,AMGN,Pfizer s Epogen Biosimilar Gets Positive FDA Committee Vote,opinion,"Pfizer  Inc    NYSE PFE   announced that an FDA advisory committee has recommended approval of its biosimilar version of Amgen Inc  s   NASDAQ AMGN   erythropoiesis stimulating agent  ESA  Epogen and Procrit The Oncologic Drugs Advisory Committee  ODAC  recommended approval across all indications of the reference product  which includes treatment of anemia and chronic kidney disease  CKD  
Pfizer s shares are down 1  so far this year against an increase of 10 8  for the Zacks classified  industry 
This marks the first time a biosimilar version of an ESA has been recommended for approval by an FDA advisory committee  Epogen generated revenues of  1 28 billion in 2016 for Amgen We note that Pfizer s biosimilar capabilities were significantly boosted by the Hospira acquisition in 2015  The company launched Inflectra  a biosimilar version of Johnson   Johnson   NYSE JNJ   Merck   Co   Inc  s   NYSE MRK   blockbuster drug Remicade in the U S  in November last year  Inflectra is the first and only biosimilar monoclonal antibody  mAb  therapy and the second biosimilar to be approved in the U S   Inflectra recorded sales of  17 million in the U S  and  78 million globally in the first quarter of 2017 Pfizer s biosimilars in late stage development include biosimilar versions of Roche s Herceptin  Rituxan and Avastin  and AbbVie s Humira Pfizer believes that the market for biosimilars is huge and can grow to  17  20 billion by 2020  In the first quarter of 2017  Pfizer recorded biosimilars revenues of  105 million In fact  the pharmaceutical industry is awaiting a string of biosimilars  which are essentially generic versions of expensive biologic drugs Several pharma as well as biotech companies are involved in the development of biosimilars  The first biosimilar to gain approval in the U S  was Sandoz s Zarxio  a biosimilar version of Amgen s Neupogen  Zarxio was launched in the U S  in Sep 2015 Other approved biosimilars in the U S  include Sandoz s Erelzi  a biosimilar to Amgen s Enbrel  etanercept   Amgen s Amjevita is an approved biosimilar version of Abbvie s Humira  However  these have not been launched yet due to ongoing litigation Pfizer carries a Zacks Rank  3  Hold   You can see  Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-05-25,Zacks Investment Research,https://www.investing.com/analysis/pfizer's-epogen-biosimilar-gets-positive-fda-committee-vote-200191622,200191622
150826,372342,AMGN,Amgen  AMGN  Presents Positive Clinical Data On Cancer Drugs,opinion,Amgen  Inc    NASDAQ AMGN   presented encouraging results from a phase III study  evaluating its marketed drug Xgeva  denosumab  for an expanded indication at the American Society of Clinical Oncology  ASCO   The company is looking to expand Xgeva s label for treating patients with multiple myeloma  blood cancer  We remind investors that in Apr 2017  Amgen announced submission of a supplemental biologics license application  sBLA  to FDA to expand the label of Xgeva for the aforesaid indication  Additionally  the company has tendered a request to modify the marketing authorization to European Medicines Agency  EMA  Xgeva is already approved in the U S  and the EU for prevention of skeletal related events  SREs  in patients with bone metastases from solid tumors  However  same is not the case for multiple myeloma  Xgeva is also approved in the U S  for treatment of giant cell tumor of bone  GCTB  that cannot be cured through surgery in adults and skeletally mature adolescents Amgen s share price movement shows the stock to outperform the Zacks classified  industry so far this year  The stock gained 8 9  compared to industry s increase of 2 8  during the period The phase III 482 study compared Xgeva to Novartis AG s   NYSE NVS   Zometa  zoledronic acid   It  met the primary endpoint of analyzing the drugs  non inferiority in delaying the time to first on study SRE in patients with multiple myeloma The secondary endpoints involved assessing the superiority of Xgeva versus zoledronic acid  regarding delaying the time to first on study SRE as well as first and subsequent SRE of the study The overall survival  OS  was in favour of Xgeva  albeit statistically insignificant  While the progression free survival  PFS  rate improved by 10 7 months  when treated with Xgeva versus Zometa In a separate press release  the company had announced positive results from a phase II study of its marketed drug Imlygic  talimogene laherparepvec  in combination with Bristol Myers Squibb Company s   NYSE BMY   Yervoy  ipilimumab  for treating patients with unresectable stage IIIB IV melanoma  skin cancer   The results were presented at the annual meeting of ASCO Imlygic is already approved by FDA for local treatment of unresectable cutaneous  subcutaneous and nodal lesions in patients with melanoma  recurrent after initial surgery The phase II 264 study met its primary end points and demonstrated a higher objective response rate for the combination therapy  Data showed that 38 8  of patients treated with combination of Imlygic and Yervoy  achieved an objective response compared to 18  of patients treated with Yervoy alone Per the company s press release  myeloma is the second most common hematologic cancer  affecting nearly 114 000 new patients worldwide and causing 80 000 deaths every year  Whereas  patients with melanoma has drastically increased in the past 40 years  with 132 000 cases annually occurring worldwide  Hence  there is a huge potential market opportunity for the company to tap into and address the unmet needs of patients in both areas Amgen Inc  Price   Zacks Rank   Key PicksAmgen currently carries a Zacks Rank  3  Hold   A better ranked stock in healthcare sector includes VIVUS  Inc    NASDAQ VVUS    sporting a Zacks Rank  1  Strong Buy   You can see  VIVUS s loss per share estimates lessened from 50 cents to 39 cents for 2017 in last 30 days  The company posted positive earnings surprises in all four trailing quarters with average beat of 233 69  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-06-05,Zacks Investment Research,https://www.investing.com/analysis/amgen-(amgn)-presents-positive-clinical-data-on-cancer-drugs-200193312,200193312
150827,372343,AMGN,Amgen Files For Repatha In The U S   EU For Expanded Use,opinion,"Biotech major Amgen  Inc    NASDAQ AMGN   announced that it submitted regulatory applications for its PCSK9 inhibitor  Repatha in both the U S  and EU  The submissions seek to include data from a phase III cardiovascular outcomes study  FOURIER  showing significant reductions in myocardial infarctions and strokes compared with the current best therapy alone The company submitted a supplemental biologics license application  sBLA  to FDA and a variation to the marketing authorization at European Medicines Agency  EMA  for Repatha  Data from the study showed that Repatha lowers LDL C or bad cholesterol to unprecedented low levels  resultsing in meaningful cardiovascular benefit in patients with clinically evident atherosclerotic cardiovascular disease 
The study demonstrated that Repatha treatment led to a 15  reduction in primary endpoints of risk of major adverse cardiovascular events  MACE   including hospitalization for unstable angina  coronary revascularization  heart attack  stroke or cardiovascular death Notably  Repatha gained an FDA approval in Aug 2015  for treatment of patients  incapable of managing their LDL cholesterol at acceptable levels  It is approved in over 50 countries  including the U S   Japan  Canada and overall  28 member countries of the European Union for the given indication Amgen s share price movement shows the stock to outperform the Zacks classified  industry so far this year  The stock gained 9 6  compared to industry s increase of 2 8  during the period 
Regarding the FOURIER study data  Repatha significantly reduced risk of hard MACE  heart attack  stroke or cardiovascular death  by 20  compared to the standard treatment with statin therapy  For individual components  risks of heart attack  stroke and coronary revascularization were nominally reduced by 27   21  and 22   respectively  with Repatha However  Repatha did not show any improvement in cardiovascular death risk  which has raised investor concerns Meanwhile  a monthly administration of single dosing option for Repatha  Pushtronex  is approved in the U S  and the EU  thus making it the first and only PCSK9 inhibitor to have a monthly single dose delivery option Better to remind investors that in Jan 2017  Amgen has announced granting of permanent injunction by the U S  District Court in Delaware against infringement by Sanofi   NYSE SNY   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN   for two patents that it owned for Repatha This decision bans Sanofi and Regeneron from selling Praluent during the term of the two patents  which describe and claim monoclonal antibodies of PCSK9  Regeneron and Sanofi however have appealed against the ruling in a higher court The appeals court granted their request to stay  suspend  the permanent injunction  pending the outcome of the appeal  Praluent s ban could in turn drive sales for Repatha Amgen Inc  Price

   Zacks Rank   Key Picks
Amgen currently carries a Zacks Rank  3  Hold   A better ranked stock in healthcare sector includes VIVUS  Inc    NASDAQ VVUS    that flaunts a Zacks Rank  1  Strong Buy   You can see  
VIVUS  loss per share estimates diminished from 50 cents to 39 cents for 2017 in last 30 days  The company posted positive earnings surprises in all four trailing quarters with an average beat of 233 69  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-06-06,Zacks Investment Research,"https://www.investing.com/analysis/amgen-files-for-repatha-in-the-u.s.,-eu-for-expanded-use-200193569",200193569
150828,372344,AMGN,Merck s Cancer Drug Keytruda Positive In Clinical Studies ,opinion,"Merck   Co   Inc    NYSE MRK   announced positive data from a phase III study KEYNOTE 024  evaluating its anti PD 1 therapy  Keytruda  pembrolizumab  for first line treatment of patients with metastatic non small cell lung cancer  NSCLC  with high levels of PD L1 In Aug 2016  Keytruda was approved in the EU for second line treatment of advanced or metastatic NSCLC in patients with tumors expressing PD L1 and who have received at least one prior chemotherapy regimen Incidentally  the drug is already approved in the U S  for first line NSCLC indication  In fact  its sales figures are projected to sharply improve  following the latest approval which would allow Keytruda to be marketed in all 28 member countries of the EU apart from Iceland  Lichtenstein and Norway Investors must be reminded that in addition to healing lung cancer   Keytruda is approved in the U S  for treating patients with unresectable or metastatic melanoma  The drug can be administered until the disease progresses or the toxicity level reaches an unacceptable point Also  the medicine comes handy for patients whose previously treated metastatic head and neck cancer  HNSCC  relapses Merck s share price movement shows the stock to outperform the Zacks classified  industry in the last year  The stock climbed 14 1  compared to industry s 2 4  increase during the period With approximately eight additional months of follow up  data from the KEYNOTE 024 study demonstrated a superior overall survival  OS  and progression free survival  PFS  of Keytruda compared to chemotherapy The study showed an 18 month OS rate of 61 2  in the Keytruda group  compared to 43  in chemotherapy segment  Also a 12 month OS rate of 70 3  in Keytruda group is pitted against 54 8  in chemotherapy  These results injected more confidence in Keytruda as a first line curative agent for patients with NSCLC In a separate press release  the company announced some encouraging results from a phase II study I SPY 2  evaluating Keytruda in combination with a standard therapy as a neoadjuvant treatment for in patients suffering from triple negative breast cancer  TNBC  Data from the study showed that an addition of Keytruda has increased the estimated pathologic complete response  pCR  rate nearly 60  in patients with TNBC  compared to a modest 20  in standard therapy  While in patients with HR  HER2  breast cancer  the pCR increased by 34  compared to a 13  in standard therapy Keytruda is the first anti PD 1 therapy to gain an FDA approval  The drug is being studied in over 30 types of cancer  Merck is collaborating with several companies like Amgen  Inc    NASDAQ AMGN    Incyte  GlaxoSmithKline plc   NYSE GSK   and Pfizer Inc    NYSE PFE   for evaluating Keytruda in combination with other regimens Merck   Company  Inc  Price

   Zacks Rank
Merck currently carries a Zacks Rank  2  Buy   You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana     
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-06-06,Zacks Investment Research,https://www.investing.com/analysis/merck's-cancer-drug-keytruda-positive-in-clinical-studies-200193597,200193597
150869,372385,AMGN,Ligand Pharmaceuticals  LGND  Q1 Earnings Miss Estimates,opinion,Ligand Pharmaceuticals Incorporated   NASDAQ LGND   reported first quarter 2017 earnings of 31 cents per share  including the impact of stock based compensation expenses   down 32 5  from the year ago figure  The bottom line also missed the Zacks Consensus Estimate of 55 cents per share However  Ligand s stock outperformed the Zacks classified  industry year to date  The company s shares gained 13 3  compared with the industry s increase of 2  Including one time and special items  earnings in the reported quarter came in at 22 cents per share compared with 30 cents a year ago Total revenue in the quarter dipped 1  year over year to  29 3 million and also fell short of the Zacks Consensus Estimate of  34 million Quarter HighlightsRoyalty revenues were  24 2 million in the reported quarter  up approximately 68 1  year over year  Higher royalties on sales of Novartis AG s   NYSE NVS   Promacta and Amgen Inc  s   NASDAQ AMGN   Kyprolis as well Spectrum Pharmaceuticals    NASDAQ SPPI   Evomela drove the upside Material sales plunged to  1 1 million from the year ago figure of  5 3 million due to the unfavorable timing of Captisol purchases for clinical and commercial use License and milestone revenues were  3 9 million compared with  9 9 million in the year ago period  The decrease was due to a  6 million milestones payment the company received in the first quarter of 2016 as a result of the Evomela approval  which was absent in the first quarter of 2017 Research   development expenses increased to  8 7 million from  4 million a year ago  primarily due to the completion of enrollment in its ongoing phase II study with Ligand s novel  small molecule GRA program  LGD 6972  for the treatment of type 2 diabetes mellitus General   administrative expenses increased 2 8  year over year to  7 3 million 2017 OutlookLigand continues to expect 2017 earnings of approximately  2 70 per share on revenues of  130 million  The core revenues are expected to comprise of royalties of approximately  87 million  material sales of approximately  23 million and contract payments of at least  20 million The company mentioned that this amount is expected to increase if additional contract revenues are received in 2017 Ligand Pharmaceuticals Incorporated Price  Consensus and EPS Surprise    Zacks RankLigand currently carries a Zacks Rank  3  Hold   You can see  Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-05-09,Zacks Investment Research,https://www.investing.com/analysis/ligand-pharmaceuticals-(lgnd)-q1-earnings-miss-estimates-200188390,200188390
150870,372386,AMGN,Mylan  MYL  Beats On Q1 Earnings  Revenues Miss Estimates,opinion,"Mylan N V    NASDAQ MYL   reported first quarter 2017 results wherein earnings of 93 cents per share beat the Zacks Consensus Estimate by a penny and was up from 76 cents reported in the year ago quarter 

We note that shares of Mylan have outperformed the Zacks categorized  industry in the year so far with the stock dipping 2 2  compared with the industry s decline of 3 4  
First quarter revenues of  2 72 billion missed the Zacks Consensus Estimate of  2 83 billion  Nevertheless  the top line recorded 24  year over year growth on the back of acquisitions 
Quarter in Detail
The company report results in three segments on a geographic basis   North America  Europe and Rest of the World 
North America segment third party net sales came in at  1 21 billion  up 5  due to contribution from the acquisitions of Meda AB and the non sterile  topicals focused business of Renaissance Acquisition Holdings  LLC which more than offset the decline in sales of new products and  negative impact of lower pricing and reduced volumes of existing products due to increased competition  Sales of the EpiPen Auto Injector declined in the current quarter as a result of increased competition and the impact of the authorized generic launch 
Third party net sales from Europe were  892 million  up 53   propelled by the acquisition of Meda which was partially offset by a net decrease in net sales from new products and lower volume and pricing on existing products   Unfavorable foreign currency translation had an impact of 4  within Europe 
Rest of World segment third party net sales of  580 5 million was up 34  fueled by the Meda acquisition  Moreover  net sales from existing products increased due to higher sales from the anti retroviral franchise while sales from new products and higher volumes on existing products more than offset lower pricing  Foreign currency translation had a favorable impact of 3  in the Rest of the World segment 
Adjusted gross margin declined to 53  from 54  in the year ago quarter due to lower gross profit from the sales of existing products in North America  including the EpiPen Auto Injector  partially offset by the contributions from the acquired businesses 
2017 Outlook Reiterated
Mylan expects revenues between  12 25 and  13 75 billion in 2017  The company projects earnings in the range of  5 15  5 55 per share for 2017 
Our Take
Mylan s first quarter results beat on earnings but missed the top line due to decline in EpiPen sales as a result of increased competition and entry of generics  Pricing continues to impact results and the company projects mid single digit price erosion globally for the year  The company recent suffered a few setbacks 
Mylan received a complete response letter from the FDA regarding its abbreviated new drug application  ANDA  for the generic version of GlaxoSmithKline s   NYSE GSK   asthma drug Advair Diskus  In Apr 2017  Mylan received a warning letter from the FDA for its manufacturing facility in India 
The FDA cited significant violations of current good manufacturing practice  CGMP  regulations for finished pharmaceuticals in the warning letter  The violations relate to the agency s inspection in Sep 2016 and even though the company had responded to the same  the agency deemed them inadequate  The FDA warned that until Mylan redresses the violations completely and confirms its compliance with CGMP  the approval of new applications and the listing of the company as a drug manufacturer may be withheld 
The FDA has earlier accepted biologics license application for a biosimilar version of Amgen s   NASDAQ AMGN   Neulasta  pegfilgrastim  and a biosimilar version of Roche s   OTC RHHBY   Herceptin Mylan N V  Price and Consensus 
   Zacks Rank 
Mylan currently carries a Zacks Rank  3  Hold   You can see  
Looking for Ideas with Even Greater Upside 
Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-05-10,Zacks Investment Research,"https://www.investing.com/analysis/mylan-(myl)-beats-on-q1-earnings,-revenues-miss-estimates-200188366",200188366
150871,372387,AMGN,Lilly s Migraine Drug Phase III Trials Meet Primary Endpoint,opinion,"Eli Lilly and Company   NYSE LLY   recently announced that its migraine candidate  galcanezumab  met primary endpoint in phase III studies  The data from the evaluation demonstrated that the galcanezumab led to statistically significant reduction in the number of migraine headaches days per month as compared with a placebo 
Lilly s shares have outperformed the Zacks classified  industry so far this year  Shares of the company rallied 9 0   while the industry registered gain of 8 6  

Coming back to galcanezumab  it is being evaluated for the prevention of episodic migraine in EVOLVE 1 and EVOLVE 2 as well as chronic migraines in REGAIN phase III studies in two subcutaneously injection dosages of 120 mg and 240 mg  On one hand  the EVOLVE 1 study showed an average reduction of 4 7 days for 120 mg dosage and 4 6 days for 240 mg dosage in comparison with a reduction of 2 8 days for placebo for both the doses 
On the other hand  the EVOLVE 2 study showed an average reduction of 4 3 days for 120 mg dosage and 4 2 days for 240 mg dosage in comparison with a reduction of 2 3 days for placebo  Notably  both the studies evaluated the drug over a six month period 
The REGAIN study treated patients over a three month period with galcanezumab and showed an average reduction of 4 8 days for 120 mg dosage and 4 6 days for 240 mg dosage in comparison with a reduction of 2 7 days for placebo 
All these three studies reported that the most common side effects of galcanezumab were pain and other reactions at the injection site  Detailed data from these studies are likely to be presented in scientific meetings and published in peer reviewed journals  later this year 
Based on the positive data from the studies  Lilly plans to submit a Biologics License Application  BLA  to the FDA in the second half of 2017 and to other regulatory agencies internationally  later 
Additionally  the company is planning to evaluate the candidate for the treatment of cluster headache based on the results from the phase III study expected next year  Lilly s migraine pipeline also includes lasmiditan for oral treatment of acute migraine in a phase III study  We note that Lilly added lasmiditan in its pipeline with the acquisition of Cambridge  MA based biotech firm  CoLucid Pharmaceuticals in March 
In fact  Lilly s galcanezumab uses calcitonin gene related peptide  CGRP  antibody for the prevention of migraine  Moreover  Amgen Inc  s   NASDAQ AMGN   erenumab  Alder Biopharmaceuticals Inc s   NASDAQ ALDR   eptinezumab and Teva Pharmaceutical Industries Limited s   NYSE TEVA   TEV 48125 are being evaluated for treatment of the same diseases using anti CGRP Eli Lilly and Company Price and Consensus
   Zacks Rank
Lilly currently carries a Zacks Rank  3  Hold   You can see  
5 Trades Could Profit  Big League  from Trump Policies
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course 
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-05-15,Zacks Investment Research,https://www.investing.com/analysis/lilly's-migraine-drug-phase-iii-trials-meet-primary-endpoint-200189301,200189301
150872,372388,AMGN,Celgene s  CELG  Revlimid Looks Solid On Label Expansion,opinion,"We issued an updated research report on Celgene Corporation   NASDAQ CELG   on May 15  2017 
Celgene is a biopharmaceutical company focused on the discovery  development and commercialization of drugs targeting cancer and inflammatory diseases through next generation solutions in protein homeostasis  immuno oncology  epigenetic  immunology and neuro inflammation 
Celgene s key growth engine is Revlimid  Revlimid  an oral immunomodulatory drug  is currently approved for several indications including MM  myelodysplastic syndromes  MDS  and mantle cell lymphoma  MCL   The drug performed well in the first quarter and combated the deterrents of uneven buying patterns and coverage gap challenges  Continued momentum in the core indication  label expansion and global launches are likely to help the product to boost the top line 
Market share gains in key markets and longer treatment duration are contributing to the drug s growth  Meanwhile  Celgene is working on expanding Revlimid s label further  Revlimid received FDA approval for use as a maintenance treatment in NDMM patients after they receive an autologous stem cell transplant  The drug was also approved in the EU for the same  NDMM market share continues to grow outside of the U S   with a positive uptake both in the EU and in Japan 

Celgene s share price movement shows that the stock outperformed the Zacks classified  industry in the past year  Specifically  the stock gained 18 7   during this period  compared with a decline of 4 4  for the industry 
Celgene is also currently working on label expansion of drugs like Pomalyst Imnovid  Abraxane and Otezla among others  which is encouraging  Pomalyst Imnovid is being evaluated in multiple combination studies in relapsed refractory MM 
Meanwhile  Celgene has a robust pipeline  Interesting candidates include GED 0301  phase III   Crohn s disease  phase II   UC   CC 486  phase III   high risk MDS  phase II   NSCLC   enasidenib  phase III   relapsed refractory AML   regulatory application filed in the U S   and luspatercept  phase III   lower risk MDS and beta thalassemia  
Successful development and subsequent approval of these candidates will be a huge boost for the company  The NDA for Idhifa was granted Priority Review with a Prescription Drug User Fee Act  PDUFA  action date of Aug 30 
While Revlimid sales continue to be impressive  we are concerned about the company s dependence on the product for growth  Lower than expected sales of the drug could adversely impact the company s growth prospects  On the other hand  Otezla sales in the first quarter were impacted by managed care dynamics that drove lower total marketplace prescriptions for psoriasis therapies in the first quarter 
Higher gross to net adjustment related to new contracts with several large payers that were implemented in January and a modest decline in inventory levels also impacted sales  Moreover  the hematology  oncology  inflammation and immunology markets are dominated by several major players like AbbVie   NYSE ABBV   and Amgen   NASDAQ AMGN    among others 
Zacks Rank   Key Pick
Celgene currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is VIVUS  Inc    NASDAQ VVUS   which currently sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS  loss per share estimates narrowed from 502 cents to 39 cents for 2017 over the last 60 days  The company posted positive earnings surprises in all of the four trailing quarters  with an average beat of 233 69  
5 Trades Could Profit  Big League  from Trump Policies
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course 
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-05-16,Zacks Investment Research,https://www.investing.com/analysis/celgene's-(celg)-revlimid-looks-solid-on-label-expansion-200189576,200189576
150873,372389,AMGN,Merck s  MRK  Keytruda Gets FDA Nod For Two New Indications,opinion,"Merck   Co   Inc     NYSE MRK    announced that the FDA has approved two new indications for Keytruda  pembrolizumab   the company s anti PD 1 therapy   The drug is now approved for the first line treatment of patients with locally advanced or metastatic urothelial carcinoma  who are ineligible for cisplatin containing chemotherapy 
The first indication is approved under the accelerated approval based on tumor response rate and duration of response  The approval is based on data from a single arm study  KEYNOTE 052  investigating Keytruda in 370 patients with locally advanced or metastatic urothelial carcinoma who were not eligible for cisplatin containing chemotherapy 
The second approval came in for patients in second line setting for the treatment of patients with locally advanced or metastatic urothelial carcinoma  who have disease progression during or following platinum containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy  The second line approval is based on data from a KEYNOTE 045 study  evaluating Keytruda in patients with locally advanced or metastatic urothelial carcinoma with disease progression on or after platinum containing chemotherapy 
Notably  Keytruda is approved for use in these indications at a fixed dose of 200 mg every three weeks until disease progression or unacceptable toxicity  or up to 24 months in patients without disease progression Merck s shares has rallied 8 5  year to date  comparing favorably with the Zacks classified  industry s gain of 8 4  
 We note that Keytruda is already approved in the U S  for the treatment of previously untreated metastatic non small cell lung cancer  NSCLC  in patients whose tumors express high levels of PD L1 and previously treated metastatic NSCLC in patients whose tumors express PD L1  as well as advanced melanoma  and previously treated recurrent or metastatic head and neck cancer  HNSCC  
In fact  Keytruda is the first anti PD 1 therapy to gain the FDA approval and is being studied for more than 30 types of cancer in 500 trials  half in combination with other cancer drugs  Also  Merck is collaborating with several companies including Amgen  Inc    NASDAQ AMGN    Incyte  GlaxoSmithKline plc   NYSE GSK   and Pfizer Inc    NYSE PFE   separately for the evaluation of Keytruda in combination with other regimens  The last few months too witnessed a series of positive news on Keytruda  thereby raising sales expectations for the drug  Further  label expansion of the drug is expected to significantly boost Merck s top line  going forward 
 Merck   Company  Inc  Price
    Zacks Rank
Merck currently carries a Zacks Rank  3  Hold   You can see  
Zacks  Hidden Trades
While we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-05-18,Zacks Investment Research,https://www.investing.com/analysis/merck's-(mrk)-keytruda-gets-fda-nod-for-two-new-indications-200190255,200190255
150912,372428,AMGN,Pfizer  PFE  Q1 Earnings  Will It Pull Off A Surprise ,opinion,"Pfizer  Inc    NYSE PFE   will report first quarter 2017 earnings on May 2  before market open  Last quarter  the company delivered a negative earnings surprise of 6 0  The pharma giant has a mixed record of earnings surprises  The company s earnings surpassed expectations in two of the last four quarters while missing in the other two  with an average positive surprise of 4 36  Pfizer s shares rose 4  in the past one year compared with an increase of 5 4  for the Zacks classified industry Factors to ConsiderNew products like Xalkori  lung cancer   Xeljanz  rheumatoid arthritis  and Ibrance  breast cancer  as well as older products like Lyrica  neuropathic pain  should contribute to the top line meaningfully  Also  revenues from the blockbuster prostate cancer drug Xtandi  added to Pfizer s portfolio following the Sep 2016 Medivation acquisition  should propel U S  revenues Meanwhile  the Hospira acquisition should continue to be an important growth driver as well  Also  Pfizer launched Inflectra  a biosimilar version of Johnson   Johnson   NYSE JNJ   and Merck s blockbuster drug Remicade in Nov 2016  which should generate more sales in the first quarter of 2017  Also  Eucrisa  crisaborole  topical ointment  added to Pfizer s portfolio with the Jun 2016 Anacor acquisition  was approved by the FDA in Dec 2016 for the treatment of eczema  The product should also contribute to the top line in the first quarter However  Pfizer will continue to face headwinds in the form of loss of exclusivity on key products like Zyvox and Celebrex and the expiration of a few co promotion agreements  which will continue to hamper top line growth  Blockbuster drug Enbrel s sales will continue to be hurt in the quarter due to biosimilar competition  The Prevnar Prevenar 13 vaccines franchise should also continue to see lower sales Meanwhile  the bottom line should be driven by cost savings and share buybacks  However  new product launch expenses and R D investments are expected to hurt profits On the first quarter call  investor focus is expected to remain on the company s performance along with that of new products and pipeline progress including biosimilars and immuno oncology In March  Pfizer announced marketing approvals for its RA drug Xeljanz in the EU and China  said that its breast cancer drug Ibrance s accelerated approval was converted to regular approval and announced accelerated FDA approval for avelumab for the treatment of metastatic Merkel cell carcinoma  MCC   a rare and aggressive form of skin cancer  Though these positive regulatory updates will not have any impact on first quarter sales  these should add to the top line in later quarters Earnings WhispersOur proven model does not conclusively show that Pfizer is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  The Earnings ESP is 0 00  as both the Most Accurate estimate as well as the Zacks Consensus Estimate stand at 67 cents  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Pfizer s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Pfizer  Inc  Price and EPS Surprise
    Stocks to ConsiderStocks in the pharma sector that have both a positive ESP and a favorable Zacks Rank are Amgen  Inc    NASDAQ AMGN   has an Earnings ESP of  2 33  and a Zacks Rank  3  The company is scheduled to release results on Apr 26 Scheduled to release results on May 2  Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  2 77  and a Zacks Rank  3  You can see   Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-04-25,Zacks Investment Research,https://www.investing.com/analysis/pfizer-(pfe)-q1-earnings:-will-it-pull-off-a-surprise-200185364,200185364
150913,372429,AMGN,What s In Store For Merck  MRK  This Earnings Season ,opinion,"Merck   Co   Inc    NYSE MRK   will be reporting first quarter 2017 earnings on May 2  before market opens  Last quarter  the company delivered a positive earnings surprise of 1 14  Merck s performance has been pretty impressive  with the company exceeding earnings expectations consistently  The average positive earnings surprise over the last four quarters is 4 03 Merck s shares rose 5 8  this year so far compared with 5 3  for the Zacks classified industry Factors to ConsiderMerck s new products like Keytruda  cancer  and Zepatier  HCV  have been doing well  We believe strong uptake  launches in new countries and expansion into additional indications  especially first line NSCLC indication  should drive Keytruda s sales  At the fourth quarter conference call  management guided that lung cancer sales are expected to accelerate sharply in the first quarter of 2017  Keytruda received FDA approval for the first line NSCLC setting in Oct 2016 and EU approval in Jan 2017  That apart  continued strength in the melanoma indication and rapid penetration of head and neck cancer indication should boost Keytruda sales Meanwhile  ongoing launches in the U S  supported by launches in the EU and Japan late in the fourth quarter should boost Zepatier s sales this quarter Zinplava  bezlotoxumab   launched for the prevention of Clostridium difficile  C  difficile  infection recurrence  in the U S  in Feb 2017 should bring in some sales this quarter However  the company faces headwinds in the form of genericization of key drugs as well as increasing competition and the negative impact of currency exchange Sales of Remicade  lost exclusivity in Europe and facing stiff biosimilar competition in the region   Nasonex  generic version launched in the U S  in Mar 2016   Cubicin  lost patent protection in the U S  in Jun 2016  and Zetia  lost market exclusivity in the U S  in Dec 2016  are likely to decline in the quarter Sluggish growth of the integrase class and continued competitor dynamics in the U S  and Europe will affect Isentress  sales It should be noted that at the fourth quarter conference call  management had warned that while sales of drugs that have lost patent exclusivity will continue to decline rapidly  the full benefit of the ramp from new product launches  such as Keytruda and Zepatier  will be realized only from the second half of 2017  Meanwhile  operating expenses are expected to be higher in the first half of 2017 largely due to higher promotional expense for Keytruda and the phasing of clinical spend At the call  investors will look for update on the performance of Merck s DPP 4 inhibitor   Januvia   including the effect of pricing pressure and whether it is losing any share to SGLT2 Earnings WhispersOur proven model does not conclusively show that Merck is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP   Its Earnings ESP is 0 00  as both the Most Accurate estimate as well as the Zacks Consensus Estimate stand at 83 cents  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Merck s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderStocks in the pharma sector that have both a positive ESP and a favorable Zacks Rank are 
Proteostasis Therapeutics  Inc    NASDAQ PTI    which is expected to release results on May 12  has an Earnings ESP of  5 17  and a Zacks Rank  1  Strong Buy   You can see   
Amgen  Inc    NASDAQ AMGN   with an Earnings ESP of  2 33  and a Zacks Rank  3  The company is scheduled to release results on Apr 26 
Scheduled to release results on May 2  Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  2 77  and a Zacks Rank  3 Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-04-25,Zacks Investment Research,https://www.investing.com/analysis/what's-in-store-for-merck-(mrk)-this-earnings-season-200185362,200185362
150914,372430,AMGN,Amgen  AMGN  Q1 Earnings Top  Sales Miss  Shares Decline,opinion,"Biotech major Amgen Inc    NASDAQ AMGN   reported first quarter 2017 earnings of  3 15 per share  beating the Zacks Consensus Estimate of  3 00 by 5  and increasing 9  from the year ago period  Higher operating margins offset a weak top line performance to drive the bottom line  Total revenue declined 1  to  5 46 billion in the first quarter of 2017  missing the Zacks Consensus Estimate of  5 68 billion by 3 8   Excluding the impact of foreign exchange  sales were flat year over year While U S  revenues declined 1   ex U S  sales grew 3   excluding currency headwinds Quarter in DetailTotal product revenue declined 1  from the year ago quarter to  5 2 billion  U S    4 10 billion  ex U S    1 10 billion  as strong demand for newer products like Prolia  Xgeva  and Blincyto was offset by lower sales of mature brands like Enbrel  Aranesp  Epogen  Neulasta and Neupogen Revenues of Amgen s erythropoiesis stimulating agent  ESA   Aranesp  declined 4  from the year ago quarter to  511 million as higher unit demand in the U S was offset by currency headwinds and lower inventory and selling price Revenues of the other ESA  Epogen  declined 10  to  270 million due to lower selling price Neulasta revenues rose 2  to  1 21 billion from the year ago period as a favorable accounting benefit and higher price offset lower unit demand  Neupogen recorded a 31  decline in sales to  148 million due to biosimilar competition in the U S  Zarxio  Sandoz s  Novartis AG s   NYSE NVS   generic arm  biosimilar version of Neupogen  was launched in the U S  in Sep 2015 and is hurting sales The company expects Neulasta to face biosimilar competition in the U S  from the fourth quarter of 2017  Neupogen is expected to face continued competitive pressure in 2017 from existing and potentially new biosimilars However  the Neulasta Onpro kit  on body injector  continues to perform well commanding a market share of more than 50  in the U S  for all Neulasta sales Enbrel delivered revenues of  1 18 billion  down 15  from the year ago quarter due to increased competition and soft demand trends in the rheumatology dermatology market  Enbrel s market share in both rheumatology and the dermatology segments declined sequentially in the first quarter  Meanwhile  lower inventory levels also hurt Enbrel sales in the quarter On the call  management maintained that it expects minimal net price growth for Enbrel in 2017 while volume trends this year will be similar to 2016 levels Prolia revenues came in at  425 million  up 21  from the year ago quarter due to higher demand  Prolia volume growth continued to improve as the company continues to capture share across U S  and EU Meanwhile  Xgeva delivered revenues of  402 million  up 6  from the year ago quarter mainly due to higher demand Sensipar Mimpara revenues increased 15  to  421 million due to higher price and volume growth Vectibix revenues came in at  147 million  up 2   driven by higher demand  which offset the negative impact of foreign currency Kyprolis posted sales of  190 million  up 23  year over year driven by higher demand Blincyto sales surged 26  from the year ago period to  34 million  reflecting higher demand Amgen s PCSK9 inhibitor  Repatha generated revenues of  49 million  lower than  58 million in the fourth quarter  At the call  management said that Repatha s sequential performance was hurt by a booking of a Middle East tender in the previous quarter  which was not repeated in the first quarter of 2017 Uptake of the drug  which gained FDA approval in Aug 2015  has not been very encouraging so far due to pricing and re imbursement issues payer restrictions  Sanofi   NYSE SNY   and partner Regeneron Pharmaceuticals  Inc    NASDAQ REGN   also faced similar issues with their PCSK9 inhibitor Praluent We remind investors that a phase III cardiovascular outcomes study  FOURIER  on Repatha reported positive data in the first quarter of 2017 The outcomes data is considered the key to the commercial success of Repatha as it would broaden the use for the drug  Though data from the study looks good  it is not very clear if payers will be willing to improve access to Repatha based on this data Operating Margins IncreaseAdjusted operating margins rose 300 basis points  bps  to 57 6  due to lower operating costs  reflecting continued benefits from transformation and process improvement efforts R D expenses declined 13  in the quarter due to lower late stage pipeline related costs  while SG A spend declined 6  due to the Oct 2016 expiration of Enbrel residual royalty payments  which offset investments to support new product launches Amgen bought back shares worth  555 million in the quarter  At the end of the first quarter  Amgen had  3 5 billion remaining under its  5 billion stock repurchase plan 2017 GuidanceWhile Amgen retained the previously issued sales outlook  it raised the earnings guidance to account for the first quarter earnings beat The company expects total revenue in the range of  22 3 billion to  23 1 billion  same as the previous guidance  However  adjusted earnings are now expected in the range of  12 00 to  12 60 in 2017 compared with  11 80 to  12 60 per share expected previously Meanwhile  operating margin is expected to be lower in the rest of the quarters this year due to the timing of expenses Our TakeIt was a rather mixed quarter for Amgen as it beat earnings expectations while missing the same for sales  Shares lost 3 1  in after market trading  However  so far this year  Amgen s shares are up 8 7   better than the 4 7  increase registered by the Zacks classified industry Though Amgen s newer products   Prolia  Xgeva  Vectibix  Nplate and Sensipar   are all performing well  investors are concerned that their volume growth may not be enough to offset the decline in mature brands like Enbrel  Meanwhile  Neulasta and Epogen could start facing biosimilar competition this year while minimal sales price increases  Stiff competition is beginning to hurt sales of Enbrel  However  Amgen s restructuring plan should make it leaner and more cost efficient  Amgen is also progressing with its pipeline given quite a few regulatory and data updates scheduled for the coming quartersAmgen currently carries a Zacks Rank  3  Hold   You can see  Amgen Inc  Price  Consensus and EPS Surprise
    The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1   Strong Buys   free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5   Strong Sells    Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ",2017-04-26,Zacks Investment Research,"https://www.investing.com/analysis/amgen-(amgn)-q1-earnings-top,-sales-miss,-shares-decline-200185718",200185718
150915,372431,AMGN,Sanofi  SNY  Q1 Earnings Top  Sales Rise Y Y  Shares Up,opinion,"Sanofi  PA SASY    NYSE SNY   reported first quarter 2017 earnings of 75 cents per American depositary share  which beat the Zacks Consensus Estimate of 73 cents by 2 7   Earnings rose 6  on a reported basis and 3  at constant currency rates  CER  First quarter 2017 net sales rose 11 1  on a reported basis and 8 6  at CER to almost  8 65 billion  Sales benefitted from favorable exchange rate movements of 2 5   In Jan 2017  the French drugmaker swapped its Merial Animal Health businesses with Boehringer Ingelheim s Consumer Healthcare  CHC  business  Reflecting this exchange and full consolidation of Sanofi s European vaccines operations  sales rose 3 5  at constant structure and CER Sales rose 3  at CER in the U S   11 3  in Emerging Markets  10 4  in Europe and 14 9  in the Rest of the World  Japan  South Korea  Canada  Australia  New Zealand  Puerto Rico  market All growth rates mentioned below are on a year on year basis and at CER Segmental PerformancePharmaceuticals sales  including emerging markets  increased 7 4  to  7 86 billion driven by growth in multiple sclerosis  rare disease  oncology and consumer healthcare franchises  which offset a decline in diabetes sales Sanofi reports through five Global Business Units  GBUs    Sanofi Genzyme  Specialty Care   Diabetes   Cardiovascular  General Medicines   Emerging Markets  Consumer Healthcare and Sanofi Pasteur  Vaccines   Please note that in Emerging Markets  Specialty Care and Diabetes and Cardiovascular sales are included in the General Medicines and Emerging Markets GBU Sanofi Genzyme Specialty Care GBU sales  including emerging markets  increased 15 6  to  1 62 billion  driven mainly by strong uptake of multiple sclerosis drugs  Aubagio  up 29 7  to  371 million  and Lemtrada  up 40 9  to  125 million  Meanwhile  sales of rare disease drugs like Myozyme Lumizyme improved 12 7  to  190 million while Fabrazyme sales were  177 million  up 15 4   Cerdelga sales came in at  31 million  up 30 4   However  Cerezyme sales declined this quarter by 4 9  to  176 million due to lower sales in emerging markets Oncology sales rose 12 8  to  412 million driven mainly by higher sales of Jevtana and boosted by a U S  government order for Leukine  Jevtana sales were up 5 6  to  97 million  Taxotere sales rose 2 2  as higher sales in emerging markets offset generic competition in Japan  Eloxatin sales rose 7 1  as higher sales in China offset generic competition in Canada Diabetes and Cardiovascular GBU  including emerging markets  declined 4  to  1 80 billion  The Diabetes franchise  including emerging markets  declined 6  to  1 66 billion due to slowing trends of newly launched Toujeo and continued weakness in Lantus Sales of diabetes drugs in the U S  declined 14 7  to  839 million  Sales of diabetes drugs in Emerging Markets were up 12 1  while in Europe it declined 3  Sales of key diabetes drugs  Lantus and Toujeo in the quarter were hurt by exclusion from various CVS commercial formularies Lantus sales declined 14 1  to  1 23 billion in the quarter  Lantus sales declined 20 9  in the U S  due to lower average net price  patient switching to Toujeo and CVS formulary exclusion while in Europe sales declined 14 8  due to biosimilar competition and patient switching to Toujeo Toujeo generated sales of  192 million  down 19 3  sequentially in the reported quarter Management warned that the U S  diabetes franchise sales decline will accelerate through the rest of the year due to exclusion from the United Health formulary plans  which started on Apr 1  2017 Soliqua  a once daily titratable fixed ratio combination of Lantus and Lyxumia  was launched in the U S  in Jan 2017  Soliqua sales were  4 million in the first quarter In the cardiovascular franchise  Sanofi s anti PCSK9 therapy Praluent garnered worldwide sales of  34 million in the reported quarter  down 8 1  sequentially due to significant payer utilization management restrictions in the U S  Amgen  Inc    NASDAQ AMGN    which reported earlier this week  also reported a sequential decline in sales of its PCSK9 inhibitor  Repatha General Medicines   Emerging Markets GBU sales came in at  3 73 billion  up 2 2   Sales of Established products were  2 64 billion  up 0 69  as strong performance in emerging markets offset generic competition of Plavix in Japan  Plavix lost exclusivity in Japan in 2015  Sales of Generics declined 2  to  468 million as lower sales in Europe offset higher sales in Emerging Markets  Sanofi plans to initiate a carve out process in order to divest the European generics business  which is expected to be completed by the end of 2018 Consumer Healthcare GBU sales were  1 34 billion  up 42 7   up 4 7  excluding acquisition of Boehringer Ingelheim s Consumer Healthcare business   as higher sales in Europe due to an early cough and cold season and in the U S  due to the launch of Xyzal Allergy 24HR offset lower sales in Russia due to a challenging economic environment First quarter consolidated Sanofi Pasteur  Vaccines  sales increased 22 2  to  784 million due to the strong performance of pediatric combinations and influenza vaccines  Vaccines sales reflect the termination of the Sanofi Pasteur MSD joint venture in Europe from Dec 2016 New Products and Pipeline UpdateSanofi and Regeneron Pharmaceuticals  Inc  s   NASDAQ REGN    rheumatoid arthritis  RA  drug Kevzara  sarilumab  was approved in Canada in Feb 2017 while in the U S   PDUFA date  May 22  2017  and EU  the drug is under review  Meanwhile  Dupixent dupilumab was approved by the FDA for treating atopic dermatitis in Mar 2017 and is now available to adult patients in the U S  The drug is under review in the EU for the same indication Costs RiseSelling general and administrative expenses  SG A  increased 9 5  at CER in the quarter  reflecting launch costs of Dupixent  Kevzara and Xyzal  R D expenses were up 4  at CER  reflecting higher pipeline development costs2017 OutlookSanofi maintained its previously issued financial outlook Sanofi expects 2017 business earnings to be flat to down 3  at CER  It anticipates positive currency impact in a range of 3  4  on business earnings in 2017 Our TakeSanofi s first quarter 2017 sales and profits were better than expected  Both earnings and sales increased year over year backed by strong specialty care  Genzyme  and vaccines sales  Shares of Sanofi rose 1 5  in pre market trading  In fact  so far this year  Sanofi s share price has risen 15 8   better than a 5 9  increase for the Zacks classified industry  We are encouraged by the strong performance of MS drugs like Aubagio and Lemtrada  We are also optimistic on sales prospects of Dupixent  which could prove to be an important growth driver for the company However  headwinds include a bleak outlook for the Diabetes franchise  generic competition for many drugs and slower than expected uptake of new products like Praluent Sanofi Price  Consensus and EPS Surprise
    Sanofi currently carries a Zacks Rank  3  Hold   You can see A better ranked pharma biotech stock worth considering is Heska Corporation   NASDAQ HSKA   which sports a Zacks Rank  1  Strong Buy   Heska s earnings estimates increased almost 8  for 2017 over the last 60 days  The company posted positive surprises all the four trailing quarters with an average beat of 291 54   Its share price has increased 47 2  this year so far Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-04-27,Zacks Investment Research,"https://www.investing.com/analysis/sanofi-(sny)-q1-earnings-top,-sales-rise-y-y,-shares-up-200186007",200186007
150916,372432,AMGN,Radius Health  RDUS  Posts Wider Q1 Loss  Tymlos Approved ,opinion,"Radius Health  Inc    NASDAQ RDUS   posted a loss of  1 32 per share in the first quarter of 2017  compared with a loss of 94 cents per share in the year ago quarter and wider than the Zacks Consensus Estimate loss of  1 25  The year over year increase in net loss was attributable to an increase in general and administrative expenses 

Radius  share price decreased 9 7  year to date compared with the Zacks classified  industry s gain of 5 3  
Quarter in Detail 
Research and development expenses for the reported quarter were  19 5 million  down 28 9  year over year  The decline was attributed to a decrease in Tymlos abaloparatide SC  abaloparatide TD and elacestrant program development costs  partially offset by an increase in RAD140 development costs 
General and administrative expenses for the reported quarter jumped to  38 1 million from  13 6 million  The increase came on the back of growth in professional support costs  including the costs associated with increasing headcount for the commercialization of Tymlos  including the completion of the build out of the commercial organization in the first quarter of 2017  This increase was also driven by an increase in compensation expenses  including stock based compensation  due to an increase in headcount 
Pipeline Update
On Apr 28  the FDA approved Radius Health s lead candidate Tymlos  abaloparatide  injection for the treatment of postmenopausal women with high risk osteoporosis for fracture   defined as history of osteoporotic fracture   multiple risk factors for fracture  or patients who have failed or are intolerant to other available osteoporosis therapy  It is currently under review in the EU  The company expects an opinion from the European Medicines Agency s Committee for Medicinal Products for Human Use in Jul 2017 
The company is also developing abaloparatide transdermal as a short wear time transdermal patch  The company posted positive results from the trial in Sep 2016  The company is currently focused on completing the manufacturing  scale up  and other required activities needed to initiate a pivotal study to evaluate bioequivalence to abaloparatide SC 
The company also completed enrolment in its ongoing phase I studies of elacestrant in advanced metastatic breast cancer  Radius Health reported encouraging results from its ongoing phase I studies  The company plans to take the next steps for the program in the first half of 2017  which would include the design of a phase II trial  Additionally  it anticipates reporting results from its completed phase IIb trial in vasomotor symptoms in the first half of 2017 
Furthermore  the company submitted an investigational new drug application to the FDA for RAD140  which is a selective androgen receptor modulator   The application has been accepted  Moving ahead  it expects to commence a first in human phase I study in women with hormone receptor positive breast cancer in 2017 Radius Health  Inc  Price and EPS Surprise

   Our take
The FDA s approval of Radius Health s lead candidate  Tymlos  is a significant boost for the company  However  shares were down 9 6  on the company s wider than expected loss in the first quarter as expenses continues to rise  Although the osteoporosis market in the U S  has great potential as approximately 1 4 million postmenopausal women in the U S  experience an osteoporotic fracture each year  Tymlos is expected to face significant competition from Eli Lilly   Co s   NYSE LLY   Forteo and Amgen Inc s   NASDAQ AMGN   Prolia  Moreover  the approved label carries a boxed warning of osteosarcoma  a malignant bone tumor  
Hence  we expect investors to focus on the drug s pricing and uptake post launch 
Zacks Rank   Stock to Consider
Radius Health currently has a Zacks Rank  4  Sell  
A better ranked stock in the healthcare sector is Heska Corporation   NASDAQ HSKA   which sports a Zacks Rank  1  Strong Buy   Heska s earnings estimates for 2017 have increased to  1 65 from  1 53 over the last 60 days  The company posted positive surprises all the four trailing quarters with an average beat of 291 54   Its share price has increased 47 2  this year so far 
You can see 
5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-05-02,Zacks Investment Research,"https://www.investing.com/analysis/radius-health-(rdus)-posts-wider-q1-loss,-tymlos-approved-200186632",200186632
150917,372433,AMGN,ImmunoGen  IMGN  Reports Narrower than Expected Loss,opinion,Waltham  MA based ImmunoGen  Inc    NASDAQ IMGN   is a development stage biotechnology company  which focuses on developing targeted anticancer therapeutics using its antibody drug conjugate technology  ADC   The company s ADC technology is used in Roche s marketed product  Kadcyla  in four other development stage candidates in its own pipeline  and in programs in development by its partners Amgen  NASDAQ AMGN  and Bayer  DE BAYGN  among others With ImmunoGen not having any approved products in its portfolio  the company earns revenues from royalties  license and milestone payments  and research and development support fees paid by its partners ImmunoGen has moved to reporting on a calendar year basis  effective Jan 1  2017 ImmunoGen s track record has been disappointing with the company missing expectations in all the past four quarters  Overall  the company has posted an average negative miss of 17 85  ImmunoGen  Inc  Price and EPS Surprise   Currently  ImmunoGen has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings  ImmunoGen posted narrower than expected loss in the first quarter of 2017  Our consensus called for a loss of 36 cents per share  and the company reported a loss of 20 cents per share  excluding restructuring charge  Revenues  Revenues also beat expectations  ImmunoGen posted revenues of  28 7 million  compared to our consensus estimate of  18 million Key Stats  R D expenses decreased 8 3  from the year ago level to  33 1 million  Selling  general and administrative  SG A  expenses were significantly down 27 7  to  8 1 million due decreased personnel expenses in the first quarter of 2017 Guidance Updated  The company maintained its financial guidance for 2017  Revenues are expected in the range of  70 million and  75 million  which includes  28 million of expected upfront and milestone fees from partners Operating expenses are projected in the range of  175 million and  180 million for 2017 Share Price Impact  Shares were up 8  in pre market trading Check back later for our full write up on IMGN earnings report later Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ,2017-05-04,Zacks Investment Research,https://www.investing.com/analysis/immunogen-(imgn)-reports-narrower-than-expected-loss-200187389,200187389
150950,372466,AMGN,Gilead  GILD  Q1 Earnings  Stock Likely To Beat Estimates ,opinion,"Gilead Sciences Inc    NASDAQ GILD   is scheduled to report first quarter 2017 results on May 2  after the market closes  Last quarter  the company beat expectations by 14 3  
Gilead s track record is mixed  with the company beating estimates in two of the last four trailing and missing in the other two  Overall  the company recorded an average positive earnings surprise of 2 88  

Shares of Gilead lost 33 7  in the last one year  underperforming the Zacks classified  industry s decline of 12 0  
Let s see how things are shaping up for this biotech major for this announcement 
Earnings Whispers
Our proven model shows that Gilead is likely to beat on earnings because it has the right combination of two key ingredients  a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  
Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is at  2 77   This is because the Most Accurate estimate is  2 23 while the Zacks Consensus Estimate is pegged lower at  2 17  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Gilead currently carries a Zacks Rank  3  The combination of Zacks Rank  3 and a positive ESP makes us confident of an earnings beat at Gilead in the upcoming release 
On the other hand  Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions 
Factors at Play
Concurrent with the fourth quarter earnings call  Gilead provided guidance for annual guidance for 2017  Gilead expects net product sales in the range of  22 5  24 5 billion  Non HCV product sales are projected between  15 billion and  15 5 billion   HCV product sales are projected between  7 5 billion and  9 0 billion 
Adjusted R D expenses and adjusted SG A expenses are projected in the range of  3 1  3 4 billion and  3 1  3 4 billion  respectively  Adjusted product gross margin is estimated in the range of 86 88  
2016 witnessed strong performance from HIV and other antiviral product sales driven by continued uptake of its tenofovir alafenamide  TAF  based products   Genvoya  Descovy and Odefsey  We expect the trend to continue in the first quarter as well  Genvoya has already become the most prescribed regimen for both treatment na ve and switch patients since its launch 
By the end of 2016  the TAF based regimens made up 37  of Gilead s HIV prescription volume in the treatment market  Strong uptake for Truvada for use in the pre exposure prophylaxis setting should also boost sales   However  Gilead will lose exclusivity for Viread in 2017 in some countries outside the U S  which should impact sales 
However  the HCV franchise continues to be under competitive and pricing pressure leading to a massive decline in Harvoni and Sovaldi sales in 2016  Harvoni and Sovaldi face competition from AbbVie s   NYSE ABBV   Viekira Pak and Viekira XR among others  Higher discounts and payer mix continue to impact sales adversely  Total HCV treatment starts in the U S  were an estimated 231 000 in 2016  approximately 25 000 less than 2015  The company expects a further decline in patients starts in 2017 
On a positive note  the HCV portfolio was boosted when Epclusa gained approval in 2016 to become the first and only all oral  pan genotypic  STR consisting of Sovaldi and velpatasvir  an NS5A inhibitor   for the treatment of adults with genotype 1 6 chronic HCV infection  Initial uptake of Epclusa has been encouraging while formulary reviews are on track 
The recently approved HBV drug Vemlidy should also start contributing meaningfully to the top line 
On the first quarter call  investors should keep an eye on Gilead s performance while pipeline updates will also be keenly awaited  Focus would also be on the performance of Epclusa and TAF based regimens 
Stocks to Consider
Here are some other health care stocks that you may want to consider  as our model shows that they too have the right combination of elements to post an earnings beat this quarter 
Intercept Pharmaceuticals  Inc    NASDAQ ICPT   has an Earnings ESP of  9 13  and a Zacks Rank  3   The company is expected to release results on May 4  You can see  
Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  2 33  and a Zacks Rank  3  The company is scheduled to release results on Apr 26 
Zacks  Best Private Investment Ideas 
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public 
Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-04-25,Zacks Investment Research,https://www.investing.com/analysis/gilead-(gild)-q1-earnings:-stock-likely-to-beat-estimates-200185075,200185075
150951,372467,AMGN,Drug Stocks Q1 Earnings Releases On Apr 26  AMGN  GSK   More,opinion,The Q1 earnings season is in full swing and we believe this quarter is on track to see the highest growth in almost three years  According to the report  95 S P 500 members  accounting for 24 9  of the index s total market capitalization  have reported results as of Apr 21  2017 Total earnings for these 95 index members were up 14 3  from the year ago quarter on a 4 6  improvement in revenues  The beat ratio was 72 6  for earnings and 62 1  for revenues The positive earnings growth momentum is expected to continue through the season  Per the report  total earnings for S P 500 companies are expected to grow 9 1  year over year on 6  higher revenues  Note that estimates for the current period  second quarter 2017  are also looking up However  with regard to the broader medical sector  which includes the pharma biotech as well as medical device companies  the overall scenario does not look that positive  Total earnings for medical companies are expected to grow only 0 8  year over year on 6 3  higher revenues Among the pharma bigwigs  only Johnson   Johnson   NYSE JNJ   has reported so far  J J reported mixed first quarter results  beating on earnings but missing on sales   This was the second consecutive sales miss for J J due to a slowdown in pharmaceutical product sales  J J s lower than expected performance has left the investment community worrying about how the rest of the sector will perform Here we have four pharma companies that are set to report first quarter results on Apr 26  Let s see how things are shaping up for this quarter Amgen  Inc    NASDAQ AMGN   Amgen  which is scheduled to release earnings after market hours  had delivered a positive earnings surprise of 4 33  in the last quarter  Amgen s performance has been pretty impressive  with the company reporting positive surprises consistently  The average earnings beat over the last four quarters is 7 38  For this quarter  Amgen has an  of  2 33  and a Zacks Rank  3  Hold   indicating a likely positive surprise  The Zacks Consensus Estimate is pegged at  3 00 per share You can uncover the best stocks to buy or sell before they re reported with our Amgen s growth products like Prolia  Xgeva  Vectibix  Nplate  Sensipar  should continue to perform well  However  volume growth of recently launched products may not be enough to offset the decline in mature brands   Read More   GlaxoSmithKline   NYSE GSK  Glaxo is scheduled to announce results before the opening bell  Last quarter  the company delivered a positive earnings surprise of 14 04   Glaxo s performance has been pretty good so far  with earnings beating expectations thrice in the four trailing quarters  Overall  the company has delivered an average positive surprise of 11 03  The company has an Earnings ESP of 0 00  and a Zacks Rank  3  You can see  The Zacks Consensus Estimate is pegged at 63 cents per share The Brentford  UK based pharma giant should continue to see strong performance at all of its business segments   Pharmaceuticals  Vaccines and Consumer Healthcare in the to be reported quarter  However  pricing dynamics and competitive pressure are hurting sales of its top selling drug Advair   Read More    United Therapeutics Corporation   NASDAQ UTHR  The company is also expected to report before market opens  In the last reported quarter  United Therapeutics recorded a negative earnings surprise of 27 07   Overall  the company has posted an average positive earnings surprise of 15 39  in the four trailing quarters The company has an Earnings ESP of  4 24  and a Zacks Rank  3  indicating a likely positive surprise  The Zacks Consensus Estimate is pegged at  3 54 per share The Medicines Company   NASDAQ MDCO  The Medicines Company is also expected to report before the opening bell  In the last reported quarter  Medicines Company recorded a positive earnings surprise of 9 79   Overall  the company has posted an average positive earnings surprise of 13 13  in the four trailing quarters The company has an Earnings ESP of 0 00  and a Zacks Rank  3  The Zacks Consensus Estimate is pegged at a loss of  1 13 per share Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public   Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-04-25,Zacks Investment Research,"https://www.investing.com/analysis/drug-stocks-q1-earnings-releases-on-apr-26:-amgn,-gsk---more-200184946",200184946
150986,372502,AMGN,Is Shinhan Financial A Great Stock For Value Investors ,opinion,"Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Shinhan Financial Group Co Ltd   NYSE SHG   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Shinhan Financial has a trailing twelve months PE ratio of 4 13  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 compares in at about 20 06  If we focus on the stock s long term PE trend  the current level puts Shinhan Financial s current PE ratio above its midpoint over the past five years  with the number remaining roughly stable over the past few months Further  the stock s PE also compares favorably with the Zacks classified Banks Foreign sector s trailing twelve months PE ratio  which stands at 13 90  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Shinhan Financial has a forward PE ratio  price relative to this year s earnings  of just 12 86  so it is fair to say that a slightly more value oriented path may be ahead for Shinhan Financial stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Shinhan Financial has a P S ratio of about 0 87  This is way lower than the S P 500 average  which comes in at 3 04 right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  Shinhan Financial currently has a Zacks Value Style Score of  A   putting it into the top 20  of all stocks we cover from this look  This makes Shinhan Financial a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for Shinhan Financial is just 0 47  a level that is far lower than the industry average of 1 72  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate Additionally  its P CF ratio  another great indicator of value  comes in at 3 38  which is lower than the industry average of 5 77  Clearly  SHG is a solid choice on the value front from multiple angles What About the Stock Overall Though Shinhan Financial might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of  C  and a Momentum score of  A   This gives SHG a Zacks VGM score or its overarching fundamental grade  of  B    You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been encouraging  Both the current year and next year have seen one estimate go higher in the past thirty days compared to no movement in the opposite direction This has had just a small impact on the consensus estimate though as the current year consensus estimate has risen by 2 6  in the past one month  while the full year estimate has inched upper by 2 7   You can see the consensus estimate trend and recent price action for the stock in the chart below Shinhan Financial Group Co Ltd Price and Consensus
    Buoyed by the bullish analyst sentiments  the stock has a Zacks Rank  1  Strong Buy  and we are looking for outperformance from the company in the near term Bottom LineShinhan Financial is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Furthermore  a strong industry rank  among Top 19  of more than 250 industries  and a Zacks Rank  1 increases our confidence on the stock However  on the flipside over the past two years  the Zacks Banks Foreign industry has clearly underperformed the broader market  as you can see below Despite the poor past performance of the industry  a good industry rank signals that the stock is likely to benefit from favorable broader factors in the immediate future  Add to this the solid Zacks rank  favorable estimate revisions and robust value metrics  and we believe that we have a strong value contender in Amgen  NASDAQ AMGN  5 Trades Could Profit   Big League   from Trump Policies If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-04-17,Zacks Investment Research,https://www.investing.com/analysis/is-shinhan-financial-a-great-stock-for-value-investors-200183418,200183418
150987,372503,AMGN,Novartis  NVS  Up 7 7  Since Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Novartis AG   NYSE NVS    Shares have added about 7 7  in that time frame  outperforming the market 
Will the recent positive trend continue leading up to the stock s next earnings release  or is it due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers Novartis Beats Q4 Earnings  Might Spin Off AlconNovartis reported fourth quarter 2016 core earnings of  1 12 per share  above the Zacks Consensus Estimate of  1 09 but below than the year ago figure of  1 14  Moreover  revenues declined 2  to  12 3 billion and were marginally below the Zacks Consensus Estimate of  12 4 billion as volume growth was offset by the negative impact of generic competition All growth rates mentioned below are on a year over year basis and at constant exchange rates The Quarter in DetailNovartis operates under three segments  Innovative Medicines  Pharmaceuticals   Alcon  Ophthalmology unit  and Sandoz  Generics  The Innovative Medicines division recorded sales of  8 3 billion  down 1   Generic competition and pricing pressure dented sales at the segment primarily attributed to entry of generics for Gleevec in the U S  Growth products   Gilenya  Tasigna  Cosentyx  Tafinlar   Mekinist  Promacta Revolade  Jakavi and Entresto   surged 20  to  4 0 billion  and comprised 48  of net division sales Sales at the Sandoz division were  2 6 billion  up 3  as volume growth was offset by price erosion  Biopharmaceuticals sales surged 28  to  277 million Sales at the Alcon division were  1 4 billion  flat y y  Surgical sales were down due to lower sales of cataract and refractive equipment along with competitive pressures   in intraocular lenses  IOLs   The supply levels and customer service has improved in the surgical department  Vision care sales were up 5  fueled by strong performance of the daily contact lens portfolio  including continued double digit growth of Dailies Total1 globally 2016 ResultsRevenues for 2016 came in at  48 5 billion  marginally below the Zacks Consensus Estimate of  48 6 billion  Earnings per share came in at  4 75  down from   5 01 in 2015 but surpassed the Zacks Consensus Estimate of  4 71 2017 OutlookNovartis expects net sales to be broadly in line with the 2016 levels after including the impact of continued genericization of Gleevec Glivec in the U S  and Europe  The impact of generic competition on sales is expected to be approximately  2 5 billion in 2017  Moreover  unfavorable currency movement is anticipated to hurt sales by 2  in 2016 Pipeline UpdateNovartis  pipeline progress has been encouraging  The company received EU approval for a label expansion of ophthalmology drug Lucentis  The drug is now approved to treat patients with visual impairment due to rare conditions causing choroidal neovascularization  CNV   The European Commission  EC  also approved Arzerra in combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed chronic lymphocytic leukemia On the other hand  Novartis got positive opinion from CHMP for Votubia as an adjunctive treatment for patients aged two years and older whose refractory partial onset seizures  with or without secondary generalization  are associated with tuberous sclerosis complex  TSC  The CHMP also recommended the approval of Ilaris to treat three rare and distinct Periodic Fever Syndromes   Quite a few drugs candidates received Priority Review status from the FDA  The FDA granted priority review to LEE011  ribociclib  in combination with letrozole as first line treatment for post menopausal women with HR  HER2  advanced or metastatic breast cancer  The application for the same was also accepted for review in the EU   The FDA also granted Priority Review to Tafinlar   Mekinist combination therapy for the treatment of BRAF mutant non small cell lung cancer  NSCLC  and PKC412  midostaurin  for the treatment of newly diagnosed FLT3 mutation positive acute myeloid leukemia and advanced systemic mastocytosis Novartis is also looking to expand Zykadia s label in the U S  and EU as a first line treatment for patients with ALK  NSCLC  The company has submitted applications for the same in the U S  and EU Meanwhile  BACE inhibitor CNP520 was granted Fast Track designation in the U S  We note that Novartis is developing CNP520 is being co developed with Amgen  Inc   NASDAQ AMGN  On the other hand  Sandoz continues to strengthen its biosimilars portfolio  The ASSIST FL trial met its primary endpoint wherein biosimilar version of MabThera demonstrated equivalent efficacy in addition to safety  pharmacokinetics and pharmacodynamics to the reference product while the data from the EGALITY trial showed that there are no clinically meaningful differences between biosimilar version of Enbrel and reference drug 
How Have Estimates Been Moving Since Then 
Following the release  investors have witnessed a downward trend in fresh estimates  There has been one revision lower for the current quarter Novartis AG Price and Consensus
    VGM Scores
At this time  Novartis  stock has an average Growth Score of  C   though it is lagging a bit on the momentum front with a  D   However  the stock was allocated a grade of  D  on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of  D   If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is solely suitable for growth investors 
Outlook
Estimates have been broadly trending downward for the stock  The magnitude of this revision also indicates a downward shift   Notably  the stock has a Zacks Rank  5  Strong Sell   We are expecting below average return from the stock in the next few months ",2017-04-18,Zacks Investment Research,https://www.investing.com/analysis/novartis-(nvs)-up-7.7-since-earnings-report:-can-it-continue-200183299,200183299
150988,372504,AMGN,Is J J s Pharma Sales Slowdown A Warning For Other Players ,opinion,"Johnson   Johnson   NYSE JNJ   reported mixed first quarter 2017 earnings results on Tuesday  While earnings beat the Zacks Consensus Estimate  sales missed due to a slowdown in pharmaceutical product sales 
For the first quarter  J J s earnings of  1 83 per share beat the Zacks Consensus Estimate of  1 77  Quarterly revenues were  17 8 billion  which missed the consensus mark of  18 0 billion   Read More    
This was the second consecutive sales miss for the Zacks Rank  3  Hold  company  Shares of the drug and consumer products giant declined 3  in response 
This year so far  J J s share price is up 6 4   However  this compares unfavorably with the 6 9  increase witnessed by the Zacks classified  industry 

The impact of J J earnings caused the NYSE ARCA Pharmaceutical Index to decline 1 32  on Tuesday 
About the Pharmaceutical Division
Johnson   Johnson has several multi million dollar drugs within its pharmaceutical division covering a broad range of therapeutic areas such as neuroscience  cardiovascular and metabolism  immunology  oncology and infectious diseases vaccines  Pharmaceutical sales account for more than 45  of J J s total revenue  However  several products in this segment are facing generic competition 
How Did the Segment Perform in Q1 
J J s Pharmaceutical segment sales grew only 0 8  year over year in the first quarter of 2017 due to weaker sales in the domestic markets  Sales in the U S  market declined 1 3  in the quarter 
New products like Imbruvica  cancer  and Darzalex  multiple myeloma  continued to perform well  Other growth drivers were Stelara  Invega Sustenna and Simponi 
However  Concerta declined 9 5  due to generic competition while Zytiga sales fell 6 3  due to higher utilization of independent patient assistance foundations 
In the cardiovascular metabolic space  pricing pressure and competitive payer dynamics hurt sales of Invokana and Xarelto  Sales of Xarelto declined 9 5  due to the timing of Medicare Part D costs and higher drug access discounts while Invokana Invokamet sales declined 12 6  due to lower price  Some analysts fear these issues are not isolated for J J and other pharma biotech companies may also feel the impact of these pricing payer issues this year 
Importantly  sales of the blockbuster rheumatoid arthritis drug Remicade  marketed in partnership with Merck   Co   Inc    NYSE MRK    declined 6  in the quarter with U S  sales declining 2 4  and international sales declining 3  due to biosimilar competition in Europe 
In this regard  we would like to mention that Pfizer Inc    NYSE PFE   launched its Inflectra injection  a biosimilar version of Remicade in the U S  late last November at risk  which did not have any significant impact on Remicade sales in the first quarter of 2017  Nonetheless  we believe that though the rate of penetration of a biosimilar entrant may be modest  the launch brings a certain element of uncertainty to the Pharma segment as there may be an additional impact as the year progresses 
J J s Pharma segment is expected to see slower growth this year as a number of key growth drivers like Remicade and Concerta have slowed down and are facing generic competition  Meanwhile  HCV sales continue to decline in the face of intense competition 
What s With Other Pharma Giants 
J J is not the only large pharma company facing a slowdown in sales of its drugs  Many others like Merck  Amgen  Inc    NASDAQ AMGN    Pfizer and others are facing loss of exclusivity and generic biosimilar competition for key revenue generators  slowdown in sales of mature drugs and competitive and pricing pressure  mainly in the U S  which is hurting their top line 
We discuss here a few companies facing similar issues 
Pfizer
Pfizer s top line is being impacted by the loss of patent exclusivity on products like Celebrex  Lipitor  Norvasc  Protonix  Camptosar  and Zoloft  Meanwhile  products like Lyrica and Chantix will lose exclusivity in the coming years  Other than that  pricing pressure and rising competition and expiry of certain key contracts are also hampering top line growth  New products like cancer drug Ibrance and contribution from acquisitions like Hospira and Medivation are expected to provide some top line support  going forward 
In 2017  the company s sales are expected to increase only slightly from 2016 levels  The Zacks Consensus Estimate for sales in 2017 is  53 1 billion  representing year over year growth of only 0 54   Pfizer carries a Zacks Rank  3  Hold  
Merck
Merck is facing generic competition for several drugs including Singulair  Maxalt  Propecia  Temodar  Cozaar Hyzaar  Zocor and Fosamax  All these drugs have recorded rapid and steep declines in revenues due to the presence of generics  In 2016  key drugs like Nasonex  Cubicin and Zetia lost patent exclusivity  which is hurting sales  In 2017  Merck will lose market exclusivity in the U S  for Vytorin  Sales of the drug are expected to decline sharply in the U S  thereafter  In addition  Isentress is facing competitive pressure and is being impacted by slowing growth of the integrase class 
While sales of drugs that have lost patent exclusivity will continue to decline rapidly  the full benefit of the ramp from new product launches such as Keytruda and Zepatier will be realized only from the second half of 2017 
Merck carries a Zacks Rank  3  You can see  
The Zacks Consensus Estimate for 2017 sales is  39 78 billion  representing a slight year over year decline 
Amgen
While biotech major Amgen s results impressed in 2016  concerns remain about the sustainability of the performance  considering the presence of biosimilar competition and slowdown in sales of mature products  Biosimilars are already having a negative impact on key products like Neupogen and Neulasta in the EU 
Meanwhile  Neupogen sales are also being hurt by biosimilar competition in the U S  We expect competition to increase as additional biosimilars receive approval  Neulasta and Epogen could start facing biosimilar competition in the U S  this year  Moreover  minimal sales price increases and stiff competition can hurt blockbuster Enbrel sales in 2017 
Volume growth of relatively newer products   Prolia  Xgeva  Vectibix  Nplate and Sensipar   may not be enough to offset the decline in mature brands 
Amgen carries a Zacks Rank  3  The Zacks Consensus Estimate for 2017 sales is pegged at  30 billion  flat year over year 
Sanofi   NYSE SNY  
Sanofi has faced significant loss of revenues in the last couple of years as several of its key products went off patent including its blockbuster drug  Plavix  Although the company is now past its patent cliff  sales of new products are yet to pick up  Meanwhile  drugs like Lantus  Lovenox  Aprovel Avapro  Renagel and Taxotere  among others  are expected to face further generic competition in 2017  which will continue to have a negative impact on revenues in the coming quarters  Additionally  the company is facing increased genericization in Japan due to new policies 
Sanofi s Diabetes franchise is under significant pressure with key product  Lantus  facing increasing competitive pressure at the payer level  Sanofi s outlook for its Diabetes franchise is bleak  Meanwhile  the uptake of new products like its PCSK9 inhibitor Praluent has been slower than expected due to pricing and reimbursement issues 
Bristol Myers Squibb Company   NYSE BMY  
Genericization of Plavix  Avapro Avalide and Baraclude in the U S  due to loss of exclusivity is significantly hurting the company s top line  The company also faces stiff competition in the immuno oncology space  Meanwhile  shares are under pressure with investors expressing disappointment over the company s failed efforts to expand its key product Opdivo s label to include the first line treatment of lung cancer  which could give an edge over competitors 
Bristol Myers carries a Zacks Rank  3 
Conclusion
Most of these companies boast a deep and promising pipeline while their new products are doing relatively well  Also  these companies are looking at strategic mergers and acquisitions  in licensing deals collaboration with smaller companies to boost their product portfolio  It remains to be seen how far these efforts offset the negative impact of genericization and pricing  payer and competitive pressure in the U S 
Sell These Stocks  Now 
Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-04-19,Zacks Investment Research,https://www.investing.com/analysis/is-j-j's-pharma-sales-slowdown-a-warning-for-other-players-200183798,200183798
150989,372505,AMGN,Novartis  NVS  Q1 Earnings  Will The Stock Disappoint ,opinion,"Swiss pharmaceutical company Novartis AG   NYSE NVS   is scheduled to report first quarter 2017 results on Apr 25 
A look at Novartis  share price movement year to date shows that the stock has underperformed the Zacks classified  industry  Its shares have declined 0 2   as against the industry s gain of 4 2  

In the last reported quarter  Novartis recorded a positive earnings surprise of 2 75   Overall  the company has posted an average positive earnings surprise of 2 38  in the four trailing quarters  Let s see how things are shaping up for this announcement 
Factors to Impact the Quarter
Novartis operates under three segments  Innovative Medicines  Pharmaceuticals   Alcon and Sandoz  Generics  
In fact  loss of exclusivity of some of the key drugs in Novartis  portfolio is hurting the top line  We expect the negative trend to continue in the first quarter of 2017 
While on one hand  the company s blockbuster drug  Diovan  is facing stiff generic competition in the U S   the EU and Japan  On the other hand  Gleevec lost exclusivity in the U S  in Feb 2016 and inthe EU in Dec 2016  thereby leading to generic competition  Exforge is also facing generic competition in the U S  and the EU  Furthermore  the oncology drugs are facing new competition in the form of immuno oncology therapies  The negative impact of generic competition is expected to impact sales by  2 5 billion in 2017 as well 
The company s ophthalmologic division  Alcon  continues to face challenges due to lower surgical equipments sales as a result of competition faced by intraocular lens and a slowdown in demand for equipment purchases We do not expect any improving trends in the division s sales in the to be reported quarter 
Novartis suffered quite a few pipeline setbacks in the quarter  The FDA issued a Complete Response Letter  CRL  to RLX030  Recently  the company also reported disappointing data from a late stage study on the candidate for the treatment of acute heart failure  Furthermore  RELAX AHF 2 did not meet its primary endpoints of reduction in cardiovascular death through day 180 or reduced worsening heart failure through day five   
We expect management to discuss the issues at the conference call Additionally  Novartis  generic arm  Sandoz  is making efforts to strengthen the biosimilars portfolio generics  The company plans to launch five biosimilars of major oncology and immunology biologics across key geographies by 2020 
In the quarter  Novartis received FDA approval of Kisqali  formerly known as ribociclib  LEE011   for use in combination with an aromatase inhibitor for the first line treatment of postmenopausal women with hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   advanced or metastatic breast cancer  We expect the company to throw light on the commercialization plans of the drug at the first quarter conference call 
Earnings Whispers
Our proven model does not conclusively show that Novartis will beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Unfortunately  that is not the case here  as you will see below 
Zacks ESP  The Earnings ESP for Novartis is 0 00    This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  1 10  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Novartis has a Zacks Rank  5  Strong Sell  
Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Novartis AG Price and EPS Surprise
    Stocks to Consider
Here are some other pharma stocks that you may want to consider  as our model shows that they too have the right combination of elements to post an earnings beat this quarter Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  1 99  and a Zacks Rank  3  The company is scheduled to release results on Apr 26  You can see  
Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  4 63  and a Zacks Rank  3  The company is scheduled to release results on May 2 
Intercept Pharmaceuticals  Inc    NASDAQ ICPT   has an Earnings ESP of  9 13  and a Zacks Rank  3   The company is expected to release results on May 4 Zacks  2017 IPO Watch List
Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time  One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-04-19,Zacks Investment Research,https://www.investing.com/analysis/novartis-(nvs)-q1-earnings:-will-the-stock-disappoint-200183990,200183990
150990,372506,AMGN,Eli Lilly  LLY  To Report Q1 Earnings  What s In The Cards ,opinion,"Eli Lilly and Company   NYSE LLY   will report first quarter 2017 results on Apr 25  before the market opens  Last quarter  the company delivered a negative earnings surprise of 4 04  So far this year  Lilly s share price has risen 10 7  compared with an increase of 5 6  for the Zacks classified  industry Lilly s performance has been rather poor with earnings missing expectations in three of the last four quarters  while beating in only one  bringing the average negative surprise to 3 39  Let s see how things are shaping up for this quarter Factors at PlayNew products like Trulicity  Cyramza  Taltz and Jardiance supported the top line in the past two quarters  We expect the trend to continue in the first quarter of 2017 as well  While Trulicity sales are being driven by growth in the GLP 1 market and market share gains  Jardiance sales should continue to be driven by increased market share within the growing SGLT2 class  In Dec 2016  the FDA approved Jardiance for the CV indication while the American Diabetes Association updated its diabetes treatment guidelines  Management believes that both these factors will drive growth of Jardiance and the SGLT 2 class However  sales of Alimta  Cymbalta and Zyprexa are expected to continue to decline due to the loss of exclusivity  Cymbalta has lost exclusivity in Europe and Canada  Zyprexa in Japan and Alimta in several countries outside the U S  Meanwhile  lower demand in the U S  due to competitive pressure mainly from immuno oncology agents is hurting sales of key drug Alimta in the U S Tthe Animal Health segment should continue to do well and so do older products like Humalog  Trajenta and Forteo Newly launched drugs like Basaglar and Lartruvo should add to the top line  Basaglar   Lilly and partner Boehringer Ingelheim s follow on insulin to Sanofi s   NYSE SNY   blockbuster drug  Lantus   was launched in the U S  in mid Dec 2016  Lartruvo was launched in the U S  in late Oct 2016  In Europe  Lartruvo was launched in mid Nov 2016 Last week  Lilly and partner Incyte announced the receipt of a CRL from the FDA for baricitinib  denying approval to the NDA in its present form  The FDA requires additional clinical data  which could delay the approval of the drug  The announcement took the investor community by surprise and further clarity is expected on the conference call What Our Model IndicatesOur proven model does not conclusively show that Lilly is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  The Earnings ESP is 0 00  as both the Most Accurate estimate as well as the Zacks Consensus Estimate are pegged at 96 cents  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Lilly s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Eli Lilly and Company Price and EPS Surprise
    
Stocks to ConsiderStocks in the pharmaceuticals sector that have both a positive ESP and a favorable Zacks Rank are Amgen  Inc    NASDAQ AMGN   is scheduled to release results on Apr 26  The company has an Earnings ESP of  1 99  and a Zacks Rank  3  You can see  Celldex Therapeutics  Inc    NASDAQ CLDX   has an Earnings ESP of  7 14  and a Zacks Rank  3  The company is expected to release results early next month Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-04-19,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-(lly)-to-report-q1-earnings:-what's-in-the-cards-200183989,200183989
151024,372540,AMGN,Nuevolution  Chemetics Proof Is In The Deal Making ,opinion,"Nuevolution s  ST NUEVOL  proprietary Chemetics DNA encoded screening platform technology enables fast and accurate small molecule drug discovery  The technology has received powerful external validation  including two recent collaborations  Amgen  NASDAQ AMGN  and Almirall  LON 0O9B   that could generate significant value in the coming years  In addition  we expect Nuevolution to progress at least one internally generated asset into clinical development in the near future  We value the company s recent deals with Amgen and Almirall  plus its cash position alone  at SEK901m   102m   our valuation does not include the technology  other pipeline assets and future deal opportunities 

Existing deals validate the technology
Chemetics  a DNA encoded screening platform  is designed to rapidly select drugs for an array of tough to drug disease targets  the technology has been validated by multiple collaborative deals  17 since inception   Notably  deals with Amgen  multi target  value up to  410m per target and a tiered royalty on sales  and Almirall  up to  442m plus tiered royalties for RORyt inverse agonist  dermatology and psoriatic arthritis indications  programme  are pivotal in defining near term value 
To read the entire report Please click on the pdf File Below",2017-02-16,Edison,https://www.investing.com/analysis/nuevolution---chemetics-proof-is-in-the-deal-making-200175953,200175953
151025,372541,AMGN,ANTH s  ANTH  Blisibimod Completes Dosing In Phase III Study,opinion,Anthera Pharmaceuticals  Inc    NASDAQ ANTH   recently announced the completion of dosing in a phase II study  BRIGHT SC  The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy  IgAN   Please note that blisibimod was acquired from Amgen  Inc    NASDAQ AMGN   in Dec 2007 Anthera s share price movement shows that the stock has significantly underperformed the Zacks classified industry so far this year  Specifically  the stock lost 37 5  during this period compared with the industry s increase of 2 8  The BRIGHT SC study is a randomized  double blind  placebo controlled study that was initiated in Jun 2013  The study was initiated to evaluate the efficacy  safety  tolerability and immunogenicity of blisibimod in IgA nephropathy  In Jun 2016  an interim analysis of the BRIGHT SC study was conducted and the results showed a tendency toward lower proteinuria in blisibimod versus placebo treated patients However  the study did  not  meet  the  pre defined  statistical  primary endpoint  of  complete  or  partial  response at  Week  48  Subsequently  there was again a tendency toward slowing proteinuria progression with blisibimod  Hence  the company elected to continue the study until the majority of patients had the opportunity to complete two years of treatment  The study was conducted in a total of 57 patients  In fact  42 of 57 patients completed at least 60 weeks of evaluation and 21 completed assessments through at least 104 weeks  Anthera is likely to report top line data in the third quarter of 2017 We note that Anthera is also developing blisibimod for the treatment of systemic lupus erythematosus in a phase III program We remind investors that the company has a mid stage development candidate  Sollpura  which it acquired from Eli Lilly and Company   NYSE LLY   in Jul 2014  The candidate is being developed for the treatment of patients suffering from low digestive enzyme levels or exocrine pancreatic insufficiency  EPI  due to cystic fibrosis or other potential diseases  The company initiated a phase III SOLUTION study on Sollpura in the third quarter of 2015  In Dec 2016  the company announced that the study narrowly missed the primary endpoint of a change in the Coefficient of Fat Absorption  CFA  non inferiority margin  However  Sollpura achieved the statistical criterion for nitrogen absorption  However  Anthera reported positive data from the extension phase of the SOLUTION study in Mar 2017 The company currently has no approved products  Hence  the successful development of these candidates is crucial for it Anthera Pharmaceuticals  Inc  Price    Zacks Rank   Other Stocks to ConsiderAnthera currently carries a Zacks Rank  1  Strong Buy   Investors may also consider another stock in the health care sector is Heska Corporation   NASDAQ HSKA    which has the same Zacks Rank as Anthera  You can see  Heska s earnings per share estimates increased from  1 53 to  1 65 for 2017 and from  1 90 to  2 01 for 2018  over the last 60 days  The company posted positive surprises in three of the four trailing quarters with an average beat of 291 54  Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-04-10,Zacks Investment Research,https://www.investing.com/analysis/anth's-(anth)-blisibimod-completes-dosing-in-phase-iii-study-200182302,200182302
151055,372571,AMGN,3 Reasons Why AMGN Is A Strong Buy,opinion,"The stock market is at all time highs  but biotechnology stocks like Amgen  Inc   NASDAQ AMGN  are near their 52 week lows  What gives  There are multiple reasons why the biotechnology stocks have under performed  but based on my analysis  that is starting to change  In fact  they are going to play catch up very quickly  Below are the 3 reasons why every investor should by Amgen  Inc 
1  As a majority of stocks are at all time highs  investors are looking for value  Valuations on financial stocks and many other sectors are in bubble territory  The ONLY sector that is near its 52 week lows is the biotechnology sector  Capital rotation is likely to occur as investors realize there is value here  Amgen  Inc  is one of the leaders that is most secure safe  It will see a lot of capital flow 
2  Over the last two weeks  Amgen  Inc  has seen a gentle slow grind lower known as bullish consolidation  This tells investors that big money is accumulating heavily  In addition  just yesterday price filled a gap fill to the downside  It is major support and a trigger for a move up  Today  Amgen  Inc  is already popping over  3  There is huge upside based on the stock chart  with a target to  160 00 
3  The fear of price caps on drugs is way overblown  First  it was Hillary Clinton that biotech investors were scared of  now it is Donald Trump  We know Donald Trump is extremely pro business  He is not going to kill the biotechnology sector with massive price caps  He just won t  In this case  the bark is worse than the bite ",2016-12-09,Jenny Rebekka,https://www.investing.com/analysis/3-reason-why-$amgn-is-a-strong-buy-200169156,200169156
151056,372572,AMGN,The Week Ahead  New Year  New Highs  New List Of Worries,opinion,"There is a normal dose of economic data this week  but we are entering a quiet  pre holiday period  As the rally faltered a bit  the Dow 20K talk yielded to a discussion of what could go wrong  I expect this discussion to continue in the coming week  and perhaps the next one as well  The punditry will be asking 
What can derail the rally  
Last Week
In a reversal from the last month  most of the economic news was soft  There was little apparent market effect 
Theme Recap
In my last WTWA  I predicted a week long fixation on the Dow 20K story  That was very accurate  with the closest call coming just as I arrived at Chicago s NBC tower for a  on my Dow 20K forecast back in 2010  I think it represents a delay rather than a jinx 
Some might attribute the selling to the Fed and Chair Yellen s press conference  an  effect  that was reversed the next day  It must have been me   I ll stay at the office for the rest of the year 
The Story in One Chart
I always start my personal review of the week by looking at this  of the S P 500 from Doug Short  He captures the continuing rally and the move to new highs 

Doug has a special knack for pulling together all the relevant information  His charts save more than a thousand words  Read his entire post where he adds analysis grounded in data and several more charts providing long term perspective 
Personal
I will have several year end posts planned for the next two weeks  but will probably skip WTWA next weekend  I am planning a Weighing the Year Ahead installment  probably in two weeks 
The News
Each week I break down events into good and bad  Often there is an  ugly  and on rare occasion something very positive  My working definition of  good  has two components  The news must be market friendly and better than expectations  I avoid using my personal preferences in evaluating news   and you should  too  
This week s news was quite good almost all positive  I make objective calls  which means not stretching to achieve a false balance  If I missed something for the  bad  list  please feel free to suggest it in the comments 
The Good 
Framing lumber prices are higher  year over year   sees this as an important leading indicator for housing  so we should  too 
Initial jobless claims edged lower  to 254K 
Hotels are close to an occupancy record     
The Fed provided the expected increase in rates with almost no market reaction   That is the good part    some insight  See also  Davidson  via  
The Philly Fed showed a big gain to 21 5  7 6 prior  and trouncing expectations  I am not very interested in the Empire State survey  but it mirrored the Philly result  Business and consumer confidence have both strengthened since the election  Confidence is essential for spending  investment  and economic strength 
Inflation is still tame  even as it creeps toward the Fed s target 
Household balance sheets are much stronger  Scott Grannis regularly produces this chart  It is far more valuable than material from those focusing exclusively on debt  and ignoring assets 

Homebuilder confidence hits the highest level since 2005     

The Bad 
Industrial production declined by 0 4  from October to November 
The rail contraction continues   continues his coverage with multiple takes and time frames  Check it out 
China drone incident  The drone seizure coincided with Friday selling  a hint of market reaction to sensitive international issues  China will  and claims that the story was  hyped up  
High frequency indicators edge lower  NDD s  shows continuing strength in short leading indicators  neutral in the coincident group  and some weakness in the long term  He is downplaying the effects due to seasonality  but it bears watching 
Housing starts dropped by 18 7   This was a very bad headline number  Various sources suggest that it emphasizes multi family while single family is strong  This is a shift that is quite acceptable  so we should follow it closely  Calculated Risk  our go to source on all things housing  has a great analysis and this chart 

The Ugly 
The Young   from helping credit card companies  The choices are frequently worse than the student could find otherwise 
The Old   that cost of living adjustments may soon end  Already the inflation rate for seniors  mostly because of medical costs  exceeds the standard CPI calculation 

The Silver Bullet 
I occasionally give the Silver Bullet award to someone who takes up an unpopular or thankless cause  doing the real work to demonstrate the facts  No award this week  but opportunities abound and nominations are welcome 
The Week Ahead 
We would all like to know the direction of the market in advance  Good luck with that  Second best is planning what to look for and how to react  That is the purpose of considering possible themes for the week ahead  You can make your own predictions in the comments 
The Calendar 
We have a normal week for data  loaded into the latter part of the week  Things will get very quiet after Friday s opening 
The  A  List 
Michigan sentiment  F   Confidence is important right now  Will the mid month preliminary high hold up 
New home sales  F   Not much change expected in this important sector 
Leading indicators  Th   This widely followed measure is likely to be flat 
Personal income and spending  Th   This important read on the economy is expected to show solid growth 
Initial claims  Th   The best concurrent indicator for employment trends 
The  B  List 
Existing home sales  W   A small decline is expected  Less important than new construction  but still relevant 
PCE price index  Th   The Fed s favorite inflation indicator   still very tame at a touch over 1  
Q3 GDP third estimate  Th   Little change expected in what is now viewed as  old news  
Durable goods orders  Th   This volatile series is expected to be much weaker than the October data 
Crude inventories  W   Recently showing even more impact on oil prices  Rightly or wrongly  that spills over to stocks 
Despite the end of the FOMC quiet period  we have little FedSpeak  Chair Yellen makes an early week appearance  and that is all I see 
Next Week s Theme 
Last week attention focused on Dow 20K  This was true even though it is a rather meaningless round number in a flawed index  It shows the power of symbolism to attract attention  When the rally fizzled out  the story swiftly turned  Everyone questions rapid  short term moves  so it is a natural for the punditry 
I expect it to carry over into a quiet week  with plenty of focus on 2017  The popular question will be about what could stop the rally  What should we worry about  It is time to rebuild the wall or worry 
What could go wrong  
Pundits were already hard at work last week 
You should  the lists or 2017 winners 
Trump s policies might not get enacted  disappointing markets   are in line for  871 billion 
Trump s policies might be enacted     Think trade matters  
Trump might make a bad decision in a crisis  An ill timed tweet 
 are still excessive  Stocks are  
The Fed and a strong dollar  
Stocks  for dividend reinvestment   You can t make this up  
Bonds are  
Or maybe we should look at the bright side  
A nice reversal from the negativity of last January  the worst start to a year ever     

The rally is real   valuation model showed stocks as 30  under valued on election day 
20  upside for next year  Brian Gilmartin sticks to the facts  This is an earnings based conclusion 
What should investors conclude from these sharply conflicting ideas  As usual  I ll have a few ideas of my own in today s  Final Thoughts  
Quant Corner 
We follow some regular great sources and the best insights from each week 
Risk Analysis 
Whether you are a trader or an investor  you need to understand risk  Think first about your risk  Only then should you consider possible rewards  I monitor many quantitative reports and highlight the best methods in this weekly update 
The Indicator Snapshot 

The increased yield on the 10 year note has lowered the risk premium a bit  I suspect much more to come  By this I mean that the relative attractiveness of stocks and bonds will continue to narrow 
The Featured Sources  
Bob Dieli  The  C Score  which is a weekly estimate of his Enhanced Aggregate Spread  the most accurate real time recession forecasting method over the last few decades   His subscribers get  including both an economic overview of the economy and employment 
Holmes  Our cautious and clever watchdog  who sniffs out opportunity like a great detective  but emphasizes guarding assets 
Brian Gilmartin  Analysis of  for the overall market as well as coverage of many individual companies 
RecessionAlert  Many  for both economic and market analysis  While we feature his recession analysis  Dwaine also has several interesting approaches to asset allocation  Try out his new public   His most recent research update suggests some    from labor markets 
Georg Vrba  The  and much more   for an array of interesting methods  Georg  Bob Dieli s enhanced aggregate spread  considering when it might first give a recession signal  Georg thinks it is still a year away  It is interesting to watch this approach along with our weekly monitoring of the C Score 
Doug Short  The World Markets Weekend Update  and much more   Jill Mislinski   noting that their public leading index is at the highest point since 2010  Surprisingly  the ECRI public statements remain bearish on the U S  economy  the global economy  and stocks  It is as if they never recovered from the bad recession call in 2011  They have been out of step ever since 
James Picerno highlights an important  oft ignored relationship  Many worry about higher interest rates  He notes the relationship between higher rates and stronger economic growth 
How to Use WTWA  especially important for new readers  
In this series  I share my preparation for the coming week  I write each post as if I were speaking directly to one of my clients  Most readers can just  listen in   If you are unhappy with your current investment approach  we will be happy to talk with you  I start with a specific assessment of your personal situation  There is no rush  Each client is different  so I have six different programs ranging from very conservative bond ladders to very aggressive trading programs  A key question 
Are you preserving wealth  or like most of us  do you need to create more wealth  
My objective is to help all readers  so I provide several free resources  Just write to info at newarc dot com  We will send whatever you request  We never share your email address with others  and send only what you seek   Like you  we hate spam   Free reports include the following 
Understanding Risk   what we all should know 
Income investing   better yield than the standard dividend portfolio  and less risk 
Holmes and friends   the top artificial intelligence techniques in action 
Why it is a great time to own for Value Stocks   finding cheap stocks based on long term earnings 
You can also check out my website for   and a discussion of the    I welcome questions on this subject  What scares you now  
Best Advice for the Week Ahead 
The right move often depends on your time horizon  Are you a trader or an investor 
Insight for Traders 
We consider both our models and the top sources we follow 
Felix and Holmes 
We continue with a strongly bullish market forecast  Felix is fully invested  Oscar is fully invested in aggressive sectors  The more cautious Holmes also remains fully invested  but with continued profit taking and position switching  The group meets weekly for a discussion they call the    This week we had a great topic   whether the focus on Dow20K had an effect on technical analysis  The prior two segments were on limiting risk and maximizing returns   We report exits from announced Holmes positions if you ask to be on that list  Write to holmes at newarc dot com  
Top Trading Advice 
Brett Steenbarger continues to provide almost daily insights for traders  Sometimes the ideas draw upon his expertise in psychology  Sometimes they emphasize his skills in training traders  Sometimes there are specific trading themes  They all deserve reading  This week I especially liked the following 
More    and a good idea from that noted trader  Bertrand Russell 
A clever method for generating new trading ideas    
 has an excellent piece on finding ideas  You must be experienced  but also avoid confirmation bias   gives a HT and follows up 
Brendan Mullooly takes one of my favorite approaches   drawing a lesson from outside trading  especially from sports  This approach helps rid us of confirmation bias  providing a fresh look  Check out the  for data on the impact from overtrading  And the sports analogy  Teams that keep switching quarterbacks 

 This chart was approved by Mrs  OldProf  a native of Green Bay and a knowledgeable football fan  
Insight for Investors 
Investors have a longer time horizon  The best moves frequently involve taking advantage of trading volatility 
Best of the Week 
If I had to pick a single most important source for investors to read this week it would be advice from legendary investor Peter Lynch  Instead of finding something from the last week  I wanted to find the best choice for current conditions   did the Peter Lynch report about two years ago  starting with this very relevant quotation 

Far more money has been lost by investors preparing for corrections  or trying to anticipate corrections  than has been lost in corrections themselves 

And also  

Now no one seems to know when they are gonna happen  At least if they know about  em  they re not telling anybody about  em  I don t remember anybody predicting the market right more than once  and they predict a lot  So they re gonna happen  If you re in the market  you have to know there s going to be declines  And they re going to cap and every couple of years you re going to get a 10 percent correction  That s a euphemism for losing a lot of money rapidly  That s what a  correction  is called  And a bear market is 20 25 30 percent decline 


They re gonna happen  When they re gonna start  no one knows  If you re not ready for that  you shouldn t be in the stock market  I mean the stomach is the key organ here  It s not the brain  Do you have the stomach for these kinds of declines  And what s your timing like  Is your horizon one year  Is your horizon ten years or 20 years 


What the market s going to do in one or two years  you don t know  Time is on your side in the stock market 

Stock Ideas 
Lee Jackson has an interesting screen that produced    We screened the Merrill Lynch research data base for stocks that are rated Buy  pay a dividend and haven t gone parabolic this year  We found five that make good sense for investors  
Wind energy stocks have been  in the  Trump rally   Buying opportunity or victim of policy changes 
But keep in mind that solar is now cheaper than wind energy  Tom Randall    has a helpful analysis of how much and why 
Our trading model  Holmes  has joined our other models in a weekly market discussion  Each one has a different  personality  and I get to be the human doing fundamental analysis  We have an enjoyable discussion every week  including four or five specific ideas that we are buying   Holmes likes Amgen  NASDAQ AMGN    for my own reaction  and more information about the trading models 

While we cannot verify the suitability of specific stocks for everyone who is a reader  the ideas have worked well so far  My hope is that it will be a good starting point for your own research  Holmes may exit a position at any time  If you want more information about the exits  just sign up via holmes at newarc dot com  You will get an email update whenever we sell an announced position 

Some Merrill Lynch top picks for 2017  via   
Ben Levisohn    sees 23  upside for FedEx  NYSE FDX  
Interested in REITs  Try  
Get ready for Eddy Elfenbein s   This annual event is a great source of ideas for investors who like to think in a time frame of at least a year  You can also join in the whole list via Eddy s new ETF     It is both convenient and inexpensive 
Personal Finance 
Professional investors and traders have been making Abnormal Returns a daily stop for over ten years  If you are a serious investor managing your own account  you should join us in adding this to your daily reading  Every investor should make time for a weekly trip on Wednesday  Tadas always has first rate links for investors in his  There are always several great choices worth reading  My personal favorite this week is the important  on your personal risk free rate  It is not the T Bill or T Note from financial analysis  but your own most costly loan  This may seem obvious  but many people fail to consider it in their financial calculations 
Seeking Alpha Editor Gil Weinreich s Financial Advisors  Daily Digest is a must read for financial professionals  The topics are frequently important for active individual investors  so the series is worth following regularly  This week I especially liked the   Even active investors are unable to answer basic questions  WTWA readers would get them all right  so it may seem very surprising 
Watch out for  
Bonds cratering while stocks rally   a telling chart of the SPDR S P 500 ETF  NYSE SPY  vs iShares 20  Year Treasury Bond Fund  NASDAQ TLT  



Final Thoughts 
My biggest reason for the 2010 Dow20K post was to alert investors to the idea of  upside risk   There is always   always   a list of plausible worries  These dominate the news and the financial discussions  The other side is difficult  It is boring to say repeatedly that things are normal and promising  Talking about some new development seems smart   attracting viewers  page views  more gigs to make you famous  and even investors who seek confirmation 
The natural process leads to a focus on problems  These are easy to see  while solutions are not  Therefore  most investors do not understand the ill named concept of the  
The new list of worries  all well known and reflected in current market prices  is a replacement for those listed on my current  investor fears  page  which replaced those from the 2010 era  It seems smart to study world events and use that knowledge to guide your investment decisions  But it is not  
You cannot make these calls as well as the market does  You are almost certain to over react 
The investor mistakes I highlighted in 2010 are still with us 
Excessive attention to headline events 
Reliance on poor forecasts of the economy  especially recessions   James Picerno has a  of typical forecasts 
Too much reliance on backward looking earnings  reflective of unusual events and times 
Ignoring the long term economic forces putting idle assets to work    on 24K 
Emphasizing politics instead of investing  In 2008 many investors hated the prospects and principles of the Obama administration  They sat out the start  and never found an entry point 
It is more profitable to accept a measure of uncertainty  rely upon the best recession and earnings indicators  and remain agnostic about politics ",2016-12-18,Jeff Miller,"https://www.investing.com/analysis/weighing-the-week-ahead:-new-year,-new-highs,-and-a-new-list-of-worries-200170028",200170028
151057,372573,AMGN,Progenics Pharmaceuticals  Inc Shares Climb On Trial Announcement News,opinion,"Progenics Pharmaceuticals Inc  NASDAQ PGNX 
Progenics Pharmaceuticals  Inc   PGNX   a global oncology company yesterday announced that an independent company has recommended continuation of its phase 3 trial of PSMA targeted SPECT CT imaging 
Progenics Pharmaceuticals  Inc  CEO s Comments

 The growing acceptance of active surveillance among men with lower grade prostate cancer presents a significant opportunity for 1404 to enable clinicians and patients to accurately and non invasively visualize and manage their disease   said Mark Baker  Chief Executive Officer of Progenics 
 We are pleased that the DMC has determined that the trial should continue  The decision to undergo more invasive treatments  such as radical prostatectomy  is a difficult one for both patients and their families given the severity of potential side effects  and we look forward to the completion of this study as we work to introduce new and effective surveillance options   Mr  Baker continued   Our modification to the protocol reflects emerging trends among men with low grade disease to increasingly favor the use of active surveillance versus more aggressive measures  consistent with treatment guidelines  We believe that this shift underscores the potential for agents such as 1404 to address the growing active surveillance market  In addition  we expect that the protocol modification will allow for a better balance in the enrollment of subjects with clinically significant disease versus those with indolent disease  with the goal of evaluating the specificity of 1404 imaging to identify patients without clinically significant prostate cancer and the sensitivity of 1404 imaging to identify patients with clinically significant disease  

PGNX Technical Analysis

PGNX opened trading yesterday at  8 93 which was up from the previous day s trading close of  8 88  PGNX closed trading yesterday at  8 86 and spiked up after market to  9 55  equivalent to a 8  increase from the closing price  Taking a look at the daily chart we can see that the last time PGNX traded above these levels we have to go back to July 29th  2015 when it traded at  9 61 
Taking a closer look at the daily chart we can see that before the spike up PGNX had already been in an overall upward trend dating back to November 3rd when it traded at  4 92  PGNX has a float of 56 28 million shares and traded below the normal daily trading volume on Thursday  For trading purposes  I would like to see PGNX open trading on Friday above  9 30 and if it does I would be looking to take a long position at the bell  My stop loss would be  0 20 from my entry position fearing anything more than that and the stock would start to fill in the gap up  Check out Ross over at where he is applying his  to these types of stocks 
Company Profile
Progenics Pharmaceuticals  Inc  develops medicines for oncology in the United States and internationally  The company s primary clinical stage product candidates include Azedra  a radiotherapeutic product candidate  which is in Phase IIb clinical trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma  1404  a technetium 99m labeled small molecule that has completed Phase II testing  as well as acts as an imaging agent to diagnose and detect prostate cancer  and PyL  a fluorinated prostate specific membrane antigen  PSMA  targeted PET imaging agent for prostate cancer  Its clinical stage product candidates also comprise 1095  a PSMA targeted Iodine 131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration resistant prostate cancer  PSMA antibody drug conjugate  which has completed Phase II testing in chemotherapy experienced patients and is ongoing second cohort in chemotherapy na ve patients for the treatment of prostate cancer  and EXINI Bone BSI  an analytical tool for analysis of bone scan index from bone scintigraphy images 
The company also offers Relistor subcutaneous injection for the treatment of opioid induced constipation  OIC  in advanced illness patients receiving palliative care when laxative therapy has not been sufficient  and for treatment of OIC inpatients with non cancer pain  In addition  it develops Relistor oral that has completed Phase III testing for the treatment of OIC  and PRO 140  which is in Phase III testing for HIV treatment  The company has license agreement with Salix Pharmaceuticals  Inc  for the development and commercialization of Relistor worldwide  and with Amgen  NASDAQ AMGN  Fremont  Inc  to use its XenoMouse technology for generating human antibodies to PSMA  as well as has collaboration agreement with Seattle Genetics  Inc  Progenics Pharmaceuticals  Inc  was founded in 1986 and is based in Tarrytown  New York ",2016-12-25,Warrior Trading,"https://www.investing.com/analysis/progenics-pharmaceuticals,-inc.-$pgnx-stock-shares-climb-on-announce-200170722",200170722
151058,372574,AMGN,Nuevolution  Delivering On Promises ,opinion,"The Almirall  LON 0O9B  deal announced on 12 December tops a defining year for Nuevolution AB  ST NUEVOL   it has delivered on two key IPO promises  signing at least one licensing agreement  Almirall  and one risk sharing collaboration  Amgen  NASDAQ AMGN   within 12 18 months of IPO  The Almirall deal focuses on the development and commercialisation of ROR t inverse agonist for dermatological diseases and psoriatic arthritis  An upfront of  11 2m  SEK109 4m  contributes to a total potential deal value of  453 2m  SEK4 4bn   Added to a strong cash balance and existing deals with Amgen and Janssen  Nuevolution is well placed to generate significant value 
Almirall  A good deal for all
The strategic collaboration with Almirall gives Nuevolution a strong potential revenue stream  while allowing Almirall access to a differentiated product candidate  Almirall has multiple dermatology products  both on the market and in late stage development  and is well placed to advance the ROR t inverse agonist platform in dermatology and psoriatic arthritis  Nuevolution retain ownership of other indications   Combined potential future revenue of up to  442m  SEK4 3bn  from development  regulatory and sales milestones in addition to tiered royalties on future sales could generate significant revenue for Nuevolution  Almirall is responsible for both funding and undertaking all research and commercial activities 
2017  Onwards to the clinic
While the development of Nuevolution s lead candidate  the ROR t inverse agonist  will transfer completely to Almirall  potential IND filing in H217   we expect Nuevolution to continue to progress the rest of its pipeline  particularly BRD BD1 and Cytokine X   Nuevolution s second most advanced programme is an inhibitor of Bet Bromodomain 1  BRD BD1   it recently demonstrated positive preliminary toxicology and efficacy data in an animal mouse model for Systemic Lupus Erythematosus  Additionally  we anticipate the collaboration with Amgen to be of focus in the short to medium term as Nuevolution generates drug candidates which  if successful in preclinical development  will be taken to the clinic by Amgen 
To read the entire report Please click on the pdf File Below",2017-01-04,Edison,https://www.investing.com/analysis/nuevolution---delivering-on-promises-200171440,200171440
151091,372607,AMGN,Merck s Keytruda Gets Priority Review For Hodgkin Lymphoma,opinion,"Another Merck   Co   Inc  s   NYSE MRK   supplemental Biologics License Application  sBLA    the second this week   for its anti PD 1 therapy  Keytruda  has been accepted for priority review by the FDA This time  the company is looking to expand the label for the treatment of patients with refractory classical Hodgkin lymphoma  cHL  or who had relapsed after three or more prior lines of therapy Merck s shares are up 15  this year comparing favorably with a decline of 8 1  for the Zacks classified Large Cap Pharma industry backed by consistently strong earnings results and regular positive news flow and regulatory updates MERCK   CO INC Price
    Coming back to the latest news story  with the FDA granting priority review  a response should be out by Mar 15  2017  In April  the FDA granted Breakthrough Therapy designation to the drug for the indication  The sNDA submission was based on positive data from KEYNOTE 087 and KEYNOTE 013 trials  The sBLA  which is seeking approval for a fixed dose of 200 mg of Keytruda given intravenously every three weeks  will be reviewed under the FDA s Accelerated Approval program  This is the first time that Merck is seeking approval for hematologic malignancy Earlier this week  a sBLA from Merck to expand the label of Keytruda for the treatment of previously treated patients with advanced microsatellite instability high  MSI H  cancer was accepted for priority review by the FDA  also on an accelerated approval basis   PDUFA date  Mar 8  2017 Keytruda is currently approved in the U S  for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy  ipilimumab  and  if BRAF V600 mutation positive  a BRAF inhibitor  It is also approved for the first line treatment of patients with unresectable or metastatic melanoma in patients refractory to Yervoy It is also approved for the treatment of metastatic lung cancer  NSCLC  in patients whose tumors express PD L1 as determined by an FDA approved test and whose disease progressed on or after platinum containing chemotherapy  In October  Keytruda received an earlier than expected FDA approval for the first line treatment of metastatic lung cancer  This is an important milestone for the company and Keytruda sales should improve sharply with the first line NSCLC indication  Additionally  in August  Keytruda was approved for previously treated recurrent or metastatic head and neck cancer  HNSCC  New products like Keytruda have been contributing meaningfully to Merck s top line  somewhat making up for the generic competition for several drugs  Keytruda is the first anti PD 1 therapy to gain FDA approval and is being studied for more than 30 types of cancer  Merck is collaborating with several companies including Amgen  Inc    NASDAQ AMGN    Incyte  GlaxoSmithKline plc   NYSE GSK   and Pfizer Inc    NYSE PFE   among others separately for the evaluation of Keytruda in combination with other regimens  The last few months have seen a series of positive news regarding Keytruda  raising sales expectations for the drug  Further  label expansion of the key drug should significantly boost sales of Merck Merck currently carries a Zacks Rank  3  Hold   You can see  Zacks  Best Private Investment Ideas In addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ",2016-12-01,Zacks Investment Research,https://www.investing.com/analysis/merck's-keytruda-gets-priority-review-for-hodgkin-lymphoma-200167962,200167962
151092,372608,AMGN,AbbVie  ABBV  Presents Impressive Imbruvica Data At ASH,opinion,"AbbVie Inc    NYSE ABBV   and partner Janssen  Johnson   Johnson s   NYSE JNJ   pharmaceuticals subsidiary  presented encouraging results on their cancer drug Imbruvica at the annual meeting of the American Society of Hematology  ASH  AbbVie s share price has risen 3 3  in the past one month  comparing favorably with a decline of 1 3  for the Zacks classified Large Cap Pharma industry Data from a phase II study  n 63  showed that nearly half of the patients with relapsed refractory marginal zone lymphoma  MZL  had a complete or partial response when treated with the company s hematological cancer drug Imbruvica  In the study  79  of patients experienced some tumor reduction and overall response rates  ORR  was 48   Safety data from the study was consistent with previous Imbruvica studies We remind investors that AbbVie submitted a supplemental New Drug Application  sNDA  for a label expansion of Imbruvica to include the treatment of MZL in September Imbruvica became part of AbbVie s portfolio following the Pharmacyclics acquisition last March Imbruvica is presently approved for quite a few indications  The drug is currently approved in the U S  for the treatment of mantle cell lymphoma  MCL  or chronic lymphocytic leukemia  CLL  patients  who have received at least one previous therapy and for CLL patients with deletion 17p  It is also approved for the treatment of Waldenstrom s macroglobulinemia Imbruvica has multi billion dollar potential and AbbVie is exploring the potential to expand its label into solid tumors and autoimmune diseases  Imbruvica is in phase III studies for diffuse large B cell lymphoma and follicular lymphoma  AbbVie is positioning Imbruvica as a  pipeline in a molecule  with the treatment featuring in several company sponsored studies  A registrational study for graft versus host disease  GVHD  is also underway In separate press releases  AbbVie announced five year cancer research collaborations with Johns Hopkins University School of Medicine and Northwestern University s Lurie Cancer Center AbbVie carries a Zacks Rank  3  Hold   You can see  ABBVIE INC Price and Consensus
    AbbVie s key drug Humira has been performing well  However  quite a few companies are working on bringing Humira biosimilars to the market  Amgen  Inc  s   NASDAQ AMGN   Humira biosimilar Amjevita received FDA approval in Sep 2016  Momenta Pharmaceuticals Inc  s   NASDAQ MNTA   biosimilar version of Humira  M923  is in a phase III study Zacks  Top Investment Ideas for Long Term Profit How would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ",2016-12-05,Zacks Investment Research,https://www.investing.com/analysis/abbvie-(abbv)-presents-impressive-imbruvica-data-at-ash-200168385,200168385
151093,372609,AMGN,Time To Buy American Funds Investment Co Of America A Fund  AIVSX ,opinion,"American Funds Investment Co of America A Fund     principally invests in common stocks  it s hold securities convertible into common stocks  as well as bonds  U S  government securities  nonconvertible preferred stocks  and cash and equivalents  AIVSX seeks long term growth of capital and income  placing greater emphasis on future dividends than on current income  AIVSX invests in securities of issuers domiciled outside the United States   typically not to exceed 15  of assets 

	This Large Blend product has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 8  and 5 year 12 9   To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds   

	AIVSX s performance  as of the last filing  when compared to funds in its category was in the top 12  over the past 1 year  in the top 11  over the past 3 years  and in the 17  over the past 5 years 

	The American Funds Investment Co of America A fund  as of the last filing  allocates their fund in six major groups  Large Value  Large Growth  Intermediate Bond  Emerging Market  Foreign Stock and Precious Metal  Further  as of the last filing  Amgen Inc  NASDAQ AMGN   Abbvie Inc and Verizon Communications Inc  NYSE VZ  were the top holdings for AIVSX 

	This Zacks Rank  2  Buy  was incepted in December 1973 and is managed by    AIVSX carries an expense ratio of 0 58  and requires a minimal initial investment of  250 

Want key mutual fund info delivered straight to your inbox 

	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ",2016-12-06,Zacks Investment Research,https://www.investing.com/analysis/time-to-buy-american-funds-investment-co-of-america-a-fund-(aivsx)-200168632,200168632
151094,372610,AMGN,Time To Buy American Funds Capital World Growth   Income A Fund  CWGIX ,opinion,"American Funds Capital World Growth   Income A Fund     invests primarily in blue chip stocks issued by companies in the world s largest stock markets  CWGIX seeks long term growth of capital with current income by investing in established  growing companies all over the world  including the United States  CWGIX is conservatively managed and focuses on established companies that pay regular dividends  CWGIX invests in common stocks  government and corporate bonds  and cash and equivalents 

	This Global   Equity product has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 3  and 5 year 9   To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds   

	CWGIX s performance  as of the last filing  when compared to funds in its category was in the top 47  over the past 1 year  in the top 43  over the past 3 years  and in the 37  over the past 5 years 

	The American Funds Capital World Growth   Income A fund  as of the last filing  allocates their fund in six major groups  Foreign Stock  Large Growth  Emerging Market  Large Value  High Yield Bond and Intermediate Bond  Further  as of the last filing  Amgen Inc  NASDAQ AMGN   Novartis AG ADR and Abbvie Inc were the top holdings for CWGIX 

	This Zacks Rank  2  Buy  was incepted in March 1993 and is managed by   CWGIX carries an expense ratio of 0 77  and requires a minimal initial investment of  250 

Want key mutual fund info delivered straight to your inbox 

	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ",2016-12-07,Zacks Investment Research,https://www.investing.com/analysis/time-to-buy-american-funds-capital-world-growth---income-a-fund-(cwgix)-200168934,200168934
151124,372640,AMGN,Aegerion s Juxtapid Gets Pricing Authorization In Japan,opinion,"Aegerion Pharmaceuticals  Inc    NASDAQ AEGR   announced that Japan s Ministry of Health  Labor   Welfare  MHLW  has approved the pricing authorization of its first product  Juxtapid  The product was approved in Japan in September for the treatment of homozygous familial hypercholesterolemia  HoFH   In Sep 2013  MLHW granted orphan drug status to Juxtapid 
Notably  HoFH is a rare genetic lipid disorder that impairs the function of the receptor responsible for removing LDL C   bad  cholesterol  from the body 
Juxtapid was launched in the U S  in late Jan 2013  as an adjunct to a low fat diet and other lipid lowering treatments  including low density lipoprotein  LDL  apheresis where available  to reduce LDL cholesterol  LDL C   total cholesterol  TC   apolipoprotein B and non high density lipoprotein cholesterol  non HDL C  for the treatment of adult patients suffering from HoFH  In the U S   the drug carries a boxed warning for the risk of hepatotoxicity 
Juxtapid gained EU approval under the trade name Lojuxta in Aug 2013 
Sales of Juxtapid declined 45 5  in the second quarter and 62 6  in the third quarter of 2016 from the year ago levels due to a reduction in patients on therapy in the U S   as a result of increased competition from PCSK9 inhibitors  The launch of Amgen  Inc  s   NASDAQ AMGN   Repatha and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Sanofi s   NYSE SNY   Praluent in the U S  market dampened Juxtapid sales and will continue to do so in the forthcoming quarters 
In July  Aegerion announced plans to withdraw Juxtapid from the EU and certain other global markets by the end of 2016  unless it finds suitable partners as part of the company s strategy to lower operating expenses  improve cash position amid stiff competition for Juxtapid  and increase cash generation from operations in 2017 AEGERION PHARMA Price
 

   Aegerion currently carries a Zacks Rank  3  Hold   You can see the  
Confidential from Zacks 
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-18,Zacks Investment Research,https://www.investing.com/analysis/aegerion's-juxtapid-gets-pricing-authorization-in-japan-200165558,200165558
151125,372641,AMGN,Novartis  NVS  Reports Favorable Data On Enbrel Biosimilar,opinion,Novartis AG s   NYSE NVS   generic arm  Sandoz announced the publication of results from EGALITY study in the British Journal of Dermatology  The study showed that its biosimilar version of Amgen Inc  s   NASDAQ AMGN   blockbuster drug  Enbrel  Erelzi  is equivalent to the originator product in more than 500 adult patients over 52 weeks Erelzi was approved by the FDA in August this year for the treatment of various inflammatory conditions including rheumatoid arthritis  plaque psoriasis and psoriatic arthritis  The biosimilar candidate is under review in the EU where the submission was accepted last year  Notably  Erelzi is still to be launched in the U S EGALITY included both the switched and continuous treatment arms  Patients were treated with Erelzi and Enbrel alternatively and it was seen that no clinically meaningful difference in safety and efficacy were observed between Erelzi and the originator product over the duration of the study  In addition the three treatment switches had no impact on the safety and efficacy of the biosimilar candidate Sandoz currently markets Zarxio in the U S  a biosimilar version of Amgen Inc  s  AMGN  Neupogen  In addition  it has a strong pipeline of biosimilars including that of Roche Holding  SIX ROG  AG s   OTC RHHBY   Rituxan  The company plans to launch five biosimilars for major oncology and immunology biologics across key geographies by 2020  Sandoz is well positioned in the biosimilars space based on its experience and capabilities in development  manufacturing and commercialization Novartis currently carries a Zacks Rank  3  Hold  A Stock to ConsiderA better ranked stock in the healthcare sector is Arbutus Biopharma Corporation   NASDAQ ABUS    which sports a Zacks Rank  1  Strong Buy   You can see  Arbutus s loss estimates narrowed from  2 15 to  1 74 for 2016 and from  1 96 to  1 51 for 2017 over the last 60 days  The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59 31  NOVARTIS AG ADR Price   Zacks  Best Private Investment IdeasIn addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ,2016-11-20,Zacks Investment Research,https://www.investing.com/analysis/novartis-(nvs)-reports-favorable-data-on-enbrel-biosimilar-200165892,200165892
151126,372642,AMGN,Nuevolution Amgen Deal  A Significant Step Forward ,opinion,"The strategic collaboration with Amgen  NASDAQ AMGN  provides further validation of Nuevolution s Chemetics drug discovery platform  With up to  410m per development programme and a tiered royalty rate  the deal could generate significant value in the coming years  Cash of c SEK176m   19 4m  at 30 September 2016  along with revenue from collaborations and licensing agreements  will enable Nuevolution to continue to expand its internal pipeline  We anticipate its lead internal candidate ROR t and possibly another internal candidate to be out licensed in the next six months  while one further Amgen style partnership could be formed by the end of 2017 
Amgen deal holds significant value
In October  2016  Nuevolution announced a risk sharing collaboration with Amgen focused on oncology and neuroscience  Per target  the company can receive up to  410m  specific targets and diseases were undisclosed  Under the terms of the deal  Nuevolution will carry out the initial research work before working collaboratively with Amgen in the later stage research  Amgen is responsible for all preclinical and clinical development  in addition to worldwide commercialisation 
Capital to deliver on goals
On 17 December 2015  Nuevolution completed its initial public offering and raised net proceeds of SEK230 1m   25 5m   Funds are being used to mature its pipeline through application of its Chemetics platform  Since Nuevolution s inception in 2001  it has generated SEK395m   43 5m  in revenues through collaborations with global pharmaceutical companies  Cash as of 30 September 2016 was SEK176m 
To read the entire report Please click on the pdf File Below",2016-11-24,Edison,https://www.investing.com/analysis/nuevolution---amgen-deal:-a-significant-step-forward-200166409,200166409
151127,372643,AMGN,Pfizer Merck KGaA  Priority Review For Cancer Drug Avelumab,opinion,"Pfizer  Inc    NYSE PFE   and German partner Merck KGaA  announced that the Biologics License Application  sBLA  for their experimental anti PD L1 monoclonal antibody  avelumab  has been accepted for priority review by the FDA Pfizer shares rose 0 7  in the past one month comparing favorably with a decline of the same magnitude for the Zacks classified Large Cap Pharma industry PFIZER INC Price
    Coming back to the latest press release  the companies are looking to get avelumab approved for the treatment of metastatic Merkel cell carcinoma  a rare type of skin cancer  With the FDA granting priority review  a response should be out within six months from the day of filing The U S  filing was based on positive data from the phase II study  JAVELIN Merkel 200  If approved by the FDA  avelumab could be the first immunotherapy option for the treatment of metastatic MCC  Avelumab enjoys Breakthrough Therapy  Fast Track and Orphan Drug status in the U S  for the MCC indication  This is an aggressive disease with less than 20  of patients surviving beyond five years  thereby creating a vital need for treatment options Avelumab is under review in EU for the indication We note that in Nov 2014  Merck KGaA entered into a strategic collaboration with Pfizer to co develop and co commercialize avelumab  Currently  avelumab is being developed for more than 15 types of tumors including breast  gastric gastroesophageal junction  head and neck  Hodgkin s lymphoma  melanoma  mesothelioma  non small cell lung  ovarian  renal cell carcinoma and urothelial  primarily bladder   Previously  the companies had said they intend to commercially launch avelumab in 2017  assuming successful development and a subsequent approval of the candidate  Thereafter  they aim to make at least one additional launch every year through 2022 Interest in immunotherapy is building up fast  The basic concept of cancer immunotherapy or immuno oncology is to utilize certain parts of the immune system to fight the disease  This can be done by stimulating the immune system to attack cancer cells or by introducing immune system components into the body Merck   Co   Inc  s   NYSE MRK   anti PD 1 therapy  Keytruda  is being studied for more than 30 types of cancers  Amgen  Inc  s   NASDAQ AMGN   Blincyto  a BiTE antibody  gained earlier than expected FDA approval in Dec 2014  Blincyto has the potential to be developed for other hematologic malignancies as well Smaller biotechs like Juno Therapeutics and Kite Pharma are also developing immuno oncology treatments Pfizer carries a Zacks Rank  3  Hold   You can see  Zacks  Top Investment Ideas for Long Term Profit How would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ",2016-11-29,Zacks Investment Research,https://www.investing.com/analysis/pfizer-merck-kgaa:-priority-review-for-cancer-drug-avelumab-200167389,200167389
151128,372644,AMGN,Momenta Shire s Humira Biosimilar Meets Study Objective,opinion,Momenta Pharmaceuticals  Inc    NASDAQ MNTA   announced positive data from a confirmatory phase III study on its biosimilar candidate  M923  Shares inched up 1 1  on the news The company s share price has gained 28 9  ever since the company released its third quarter results on Nov 2  The share price rally was even better than the Zacks classified Medical Biomed Genetics market of 9 1  M923  a biosimilar version of AbbVie Inc  s   NYSE ABBV   flagship drug  Humira  adalimumab   is being developed for the treatment of patients with moderate to severe chronic plaque psoriasis The study evaluated the safety  efficacy and immunogenicity of M923 in adult patients with moderate to severe chronic plaque psoriasis  who received M923  Humira or Humira alternating with M923 for up to 48 weeks Results demonstrated that the proportion of patients who met the primary endpoint was equivalent on the M923 and Humira arm  The primary endpoint was at least 75  reduction on an index of psoriasis severity  following 16 weeks of treatment Momenta expects to present full data from this study at future conferences and in publications Humira is approved for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis  juvenile idiopathic arthritis  psoriatic arthritis  ankylosing spondylitis  Crohn s disease  ulcerative colitis and plaque psoriasis  In the first nine months of 2016  Humira raked in worldwide sales of  11 8 billion  up 14 6  Note that in September  Amgen Inc  s   NASDAQ AMGN   biosimilar version of Humira  Amjevita  was approved in the U S  for the same indications as the reference product  Amjevita is the first biosimilar version of Humira to be approved by the FDA  However  Amgen is unlikely to launch Amjevita in 2017 due to the ongoing litigation with AbbVie We remind investors that Momenta had a collaboration agreement with Shire plc s   NASDAQ SHPG   Baxalta for the development and commercialization of M923  However  in Sep 2016  Shire exercised its right to terminate their collaboration agreement and is currently in the process of transitioning M923 to Momenta MOMENTA PHARMA Price    Momenta currently carries a Zacks Rank  3  Hold   You can see  Zacks  Top Investment Ideas for Long Term ProfitHow would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ,2016-11-29,Zacks Investment Research,https://www.investing.com/analysis/momenta-shire's-humira-biosimilar-meets-study-objective-200167499,200167499
151129,372645,AMGN,5 Top Performing Biotechnology Stocks Of November,opinion,"November was a great month for pharma biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices 
The pharma biotech industry responded favorably to Donald Trump s victory in the Presidential election last month on anticipation of fewer drug pricing headwinds  This is because Trump has not been as vocal as Hillary Clinton about rising drug prices and excessive cost of treatments  Trump and the Republican Congress are expected to be more lenient on the drug industry s pricing practices than Clinton would have been 
We note that post elections  biotech stocks have recovered from the sharp selloff witnessed over the past one year  The Zacks classified Drugs industry gained 1 7  since the elections but declined 16 3  on a year to date basis  In November  the Drugs industry rose 2 0  
Companies like Celgene  NASDAQ CELG   9 3    Merck  NYSE MRK   1 1    Pfizer  NYSE PFE   7 1    Amgen  NASDAQ AMGN   4 1    Bristol Myers  6 2    Endo  10 3   and Regeneron  3 1   were in the positive territory post elections  However  most of these companies  shares declined on a year to date basis Medical Sector Price Index
 

Notably  Trump s intentions to repeal ObamaCare and free up cash currently held overseas for tax reasons are expected to boost the pharma biotech industry further  With the presidential election over  a group of investors believe that biotechs are geared for an extraordinary comeback 
Also  healthcare mergerand acquisition activity has gathered steam this year  In licensing activities and collaborations for the development of pipeline candidates have also increased significantly  Several pharma companies are focusing on in licensing  mid to late stage pipeline candidates that look promising instead of developing a product from scratch that take a lot of funds and time Merger and acquisitions  especially small bolt on acquisitions as well as aggressive in licensing activities and collaborations are expected to increase  going forward  This is expected to act as a huge catalyst for biotech stocks 
Our Picks
Given such positive trends for biotech stocks  investment in this sector might be prudent at the moment  With the help of the Zacks   we have zeroed in on the following drug stocks that have a favorable Zacks Rank and a  of  A  or  B   Share price of all these companies rose in the month of November 
Enzo Biochem Inc    NYSE ENZ   is an integrated life science and biotechnology company  The company has a Zacks Rank  2  Buy  and a VGM Score of  A   You can see   The Zacks Consensus Estimate for its current year earnings improved 5 6  over the last 60 days  The company s expected growth rate for the current year is 15 0   The company s shares rose 11 8  in November 
Exelixis  Inc    NASDAQ EXEL   is a biopharmaceutical company that engages in the discovery  development  and commercialization of new medicines  The company has a Zacks Rank  2 and a VGM Score of  B   The Zacks Consensus Estimate for its current year earnings rose 25 4  over the last 60 days  The company s expected growth rate for the current year is 42 4   Last month  the company s shares soared 59 8  
Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Tarrytown  NY based Regeneron is also a Zacks Rank  2 stock and has a VGM Score of  A   The company surpassed earnings expectations in all three quarters of 2016  The Zacks Consensus Estimate for the current year earnings rose 3 8  over the last 60 days  The company s expected growth rate for the current year is 5 62   In November  the company s shares rose 9 9  
Regeneron  known for its flagship eye drug   Eylea   has several candidates in its pipeline for a wide range of therapeutic areas  including rheumatoid arthritis  RA   asthma  atopic dermatitis  pain  cancer  and infectious diseases 
Genmab A S  is a biotech company that develops antibody therapeutics for the treatment of cancer  The company has a Zacks Rank  2 and a VGM Score of  B   The Zacks Consensus Estimate for the current year earnings soared 305 9  over the last 60 days  The company s expected growth rate for the current year is a 10 70   In November  the stock rose 3 8  
VIVUS  Inc    NASDAQ VVUS   focuses on the development of compounds to treat obesity  sleep apnea  diabetes and sexual health  The company has a Zacks Rank  2 and a VGM Score of  A   The Zacks Consensus Estimate for its current year earnings scaled around 35  over the last 60 days  The company s expected growth rate for the current year is 34   Its shares rose 27 6  in November 
Conclusion
In remains to be seen what s in store for the biotech industry going forward  We expect some action on drug prices  given the massive focus on the issue this year  Nonetheless  the aforementioned bullish factors call for investment in the space 
Confidential from Zacks
This week  Zacks researchers have named 7 other stocks that look to break out even sooner than today s Bull of the Day  You can see these time sensitive tickers free  and access additional trades that are not available to the public ",2016-12-01,Zacks Investment Research,https://www.investing.com/analysis/5-top-performing-biotechnology-stocks-of-november-200167796,200167796
151151,372667,AMGN,Top Trade Ideas For The Week November 14  2016  AMGN,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Amgen  NASDAQ AMGN   made a top in August 2015 and fell back  finding a bottom nearly 30  lower at the end of September that year  It bounced around from there for a while until rising back to that August 2015 high in August this year  It tagged it again later in the month and then pulled back to a higher low at the 50 day SMA 
Another run up to resistance in September failed to make a new high and it fell back again  This time it dropped all the way back to the rising trend support line going back to 2014  Two weeks ago it bounced up off of that level and quickly ran to the 20 day SMA  It found resistance there and has pulled back in a bull flag  A measured move out of the flag to the upside would target 157 if it continues out of the flag to the upside Monday 
The RSI is pausing at the mid line  but rising  and the MACD is crossed up and rising  There is a lot of run higher within the wide Bollinger Bands   The company pays a  1 dividend Monday  already trading ex dividend  and the company is not expected to report earnings again until January 26th as they recently reported  The stock has a small 1  short float 
The November options chain show large open interest from the 139 to 160 strikes on the put side and at 145  152 5 and 160 on the call side  No overwhelming draw this week  December options are centered at 150 on the call side with a longer tail to the upside  The December puts are biggest higher but spread more to the downside  January sees the distribution centered around 170 on the call side but at 145 on the put side 

Trade Idea 1  Buy the stock on a move over 151 40 with a stop at 146 
Trade Idea 2  Buy the stock on a move over 151 40 with a December 150 140 Put Spread   3 85  and selling the January 155 Calls   3 30  for a low cost Collar 
Trade Idea 3  Buy the December 150 160 Call Spread   3 00  and sell the December 140 Puts   1 80  
Trade Idea 4  Buy the November December 30 Expiry 152 5 Call Calendar   2 75  selling the November 145 Puts   1 08  
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which with the election in the rearview mirror and heading into the last full week before Thanksgiving and the holiday season begins  sees equity markets looking a bit mixed but positive 
Elsewhere look for Gold to continue lower while Crude Oil moves lower in the short term as well  The US Dollar Index looks strong and ready to challenge the 2015 highs while US Treasuries are biased continue lower  The Shanghai Composite is looking strong as it continues higher while Emerging Markets are at key support and looking weak if it does not hold 
Volatility looks to remain at lower normal levels now that the election has passed keeping the bias higher for the equity index ETF s SPY  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   Their charts are a bit mixed though with the IWM leading a charge higher towards new all time highs while the SPY stalls just below highs and the QQQ struggles in consolidation  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2016-11-14,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-november-14,-2016:-bonus-idea-200164444",200164444
151152,372668,AMGN,Is Immunotherapy The Next Hot Industry For Biotech Stock Investors ,opinion,"Biotechnology can be a tough market for investors to break in to  The jargon is intimidating  the volatility is incredible  while there are political concerns to be cognizant of as well 
But in this edition of the Dutram Report  I take a closer look at this market  and in particular the immunotherapy world  in order to shine some light on this promising space for investors  In order to do this  I talk with Brad Loncar  the CEO of Loncar Investments  who developed a benchmark of such companies called the Loncar Cancer Immunotherapy Index  which is the underlying benchmark for the Loncar Cancer Immunotherapy ETF  CNCR  
In the interview  we discuss the basics of immunotherapy  and why this technique might be a real gamechanger for the treatment of cancer  The approach looks to harness the power of someone s immune system in order to fight disease  which may help some patients improve their quality of life while still achieving great outcomes  This only scratches the surface though  as we discuss some of the more innovative and groundbreaking treatments under development in this market too 
We also discuss how someone might go about investing in this market with stocks  and why a broad biotechnology ETF like IBB or XBI might not get you exposure to this corner of the sector  We also take a deeper look at the Loncar index  and what exactly an  immunotherapy stock  means 
In particular  I note some of the large caps which find their way into the benchmark  such as Amgen  NASDAQ AMGN   Merck  NYSE MRK   or AstraZeneca  AZN   But we also discuss some of the more growth oriented names that might be more in line with investors  initial assumptions about the market  such as KITE Pharma  KITE  or Juno Therapeutics  JUNO   These all fit into the theme in their own way though  and we dive into the key trends taking place in these companies  and others  that have business in this important market   
Lastly  I also wanted to note that Loncar has partnered with the   and will be giving part of its fee to the charity  Loncar Investments looks to give four basis points of the fee from assets under management to the CRI on a regular basis  in an effort to help support this basic research institution  This is definitely something that could be more of a trend in the future  and especially among the many socially conscious ETFs out there 
This was certainly an informative podcast  and I definitely learned something about this often overlooked corner of the biotechnology world  I think you will as well  so make sure to listen to this edition of the Dutram Report for additional information  And for more news and insights into the world of ETFs  make sure to be on the lookout for the next edition of the Dutram Report  and check out the 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2016-11-16,Zacks Investment Research,https://www.investing.com/analysis/is-immunotherapy-the-next-hot-industry-for-biotech-stock-investors-200165078,200165078
151175,372691,AMGN,5 Healthcare Stocks Poised To Trump Q3 Earnings,opinion,"The past few months have been pretty rough for the healthcare sector  with the drug pricing issue taking the center stage once again  This time  it was the massive price hike of Mylan N V  s  NASDAQ MYL  severe allergy treatment  EpiPen that sparked controversies  With no possibility of dying down any time soon  the company has drawn flak from lawmakers  consumers and the common people alike 

Presidential candidate Hillary Clinton s tweet on the issue made matters worse  which was followed by her proposal of a health care plan to keep drug prices under control  protect consumers from unjustified drug price hikes and increase the accountability of drug manufacturers 
Deals  Product Approvals   Zika Virus

Despite all these negative developments  mergers and acquisitions  and licensing deals continued to make it to the headlines  German drug maker  Bayer AG  DE BAYGN  and U S  seed behemoth Monsanto Company  NYSE MON  have finally reached an agreement under which the latter will be acquired by the former in an all cash deal valued at about  66 billion  While biotech company Horizon Pharma plc acquired California based Raptor Pharmaceuticals Corp   Pfizer Inc   NYSE PFE  took over oncology focused company Medivation  Inc  for approximately  14 billion 

Allergan  NYSE AGN pa  plc  AGN  continued with its acquisition spree  In Oct 2016  Allergan announced the intention to acquire Motus Therapeutics  Inc   a wholly owned subsidiary of Rhythm Holding Company  The acquisition should be completed by the year end  Note that Allergan announced a string of small bolt on acquisitions in Sep 2016 to expand its presence in the highly lucrative non alcoholic steatohepatitis space 

Collaborations between large cap and development stage companies are being seen mostly in the immuno oncology space  and to some extent in other therapeutic areas like autoimmune and cardiovascular 

Additionally  new product approvals  along with the label expansion of existing drugs and regular pipeline updates kept investors glued to the sector  While Eli Lilly and Company  NYSE LLY  gained accelerated approval in the U S  for Lartruvo  in combination with doxorubicin  for the first line treatment of soft tissue sarcoma  Sarepta Therapeutics  Inc  received a huge boost with the same for Exondys 51 for the treatment of Duchenne muscular dystrophy 

Meanwhile  Roche Holding  SIX ROG  AG s immuno oncology drug Tecentriq was granted FDA approval for an additional indication  this time for the treatment of metastatic non small cell lung cancer 

Let us now come to biosimilars  which are being touted as the next big thing in the health care sector  Among the approved biosimilars in the U S  are Novartis AG s Erelzi  a biosimilar version of Amgen Inc  NASDAQ AMGN   s Enbrel   Amgen s Amjevita  a biosimilar version of AbbVie Inc  NYSE ABBV   s Humira  and Celltrion  and Pfizer s Inflectra  a biosimilar version of Johnson   Johnson s Remicade   In late November  Pfizer is expected to launch Inflectra in the U S 

Meanwhile  the widespread outbreak of the deadly Zika virus has brought companies focused on the disease  such as Inovio Pharmaceuticals  Inc  and Intrexon Corporation  to the forefront 

With this backdrop  let s take a look at some companies in the health care space that have the potential to beat expectations in their upcoming releases  Although the  is well underway  it s not too late to cash in on the bountiful opportunities in the health care space  These stocks are well positioned in today s market environment  and could see considerable upside on the aforementioned trends 
Medical s Performance So Far

With several pharma and major biotech companies having released their Q3 earnings results  Medical is one of the many sectors that is witnessing earnings and revenue growth this quarter  Our Q3 scorecard shows that 54 7  of the companies in the Medical sector have reported results so far  with earnings increasing 14 9  on 8 1  higher revenues  The blended beat  which represents the percentage of companies that have beaten both earnings and revenue estimates  stands at 48 3  

Quite a few pharma and biotech companies are slated to report results in this week and next  Per our Earnings Trends report  Medical is one of the eight broader sectors that are anticipated to record positive earnings growth in Q3  with projections of 6  earnings growth on a 7 3  increase in revenues  Notably  this could be the first quarter to record positive earnings growth after five quarters of back to back declines 

So far  performance of the sector has been mixed  While it was a  beat and raise  quarter for some like Johnson   Johnson  NYSE JNJ   Bristol Myers Squibb Company  NYSE BMY  and Celgene Corporation  NASDAQ CELG   Eli Lilly and Roche s quarterly numbers fell short of expectations 
Grab the Prospective Q3 Winners

With the enormity of stocks in the healthcare space  selecting stocks that have the potential to beat estimates could appear daunting  But the proprietary Zacks methodology makes it fairly simple  One way to narrow down the list of choices this earnings season is by looking at stocks that sport the combination of a favorable Zacks Rank   Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold    and a positive   More often than not  a positive earnings surprise delivered by a company leads to stock price appreciation 

The Earnings ESP is our proprietary methodology for identifying stocks that have high chances of surprising with their upcoming earnings announcement  It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate  Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70   Please check our  that enables you to find stocks that are expected to come out with earnings surprises  

Going by this criterion  here are five healthcare stocks that we believe are poised to beat estimates this quarter 

Our first choice is Dublin  Ireland based pharma company  Allergan     which has a Zacks Rank  3 and an Earnings ESP of  0 56   The Zacks Consensus Estimate is pegged at  3 56  The company has consistently beaten earnings expectations  In fact  Allergan s earnings have surpassed expectations in each of the last four quarters  with an average positive surprise of 3 44  

Allergan is slated to report Q3 results on Nov 2  before the opening bell 
A well known name in the attention deficit hyperactivity disorder market  Shire plc    has made it to our list of the likely Q3 winners  thanks to its Zacks Rank  2 and  1 57  Earnings ESP  The Zacks Consensus Estimate is  3 18  Also based in Dublin  Ireland  Shire has beaten expectations in all of the past four quarters  bringing the average earnings surprise to 8 41  
Shire is scheduled to report Q3 results on Nov 1  before the opening bell 

One of the leading global animal health companies  Zoetis Inc  NYSE ZTS      has an impressive track record with the company consistently beating earnings expectations  Can Zoetis keep the earnings streak alive  Its Zacks Rank  3 and Earnings ESP of  2 17  sure indicate an earnings beat in Q3  The average positive earnings surprise over the last four trailing quarters is 15 92   The Zacks Consensus Estimate currently stands at 46 cents 

Zoetis is scheduled to report Q3 results on Nov 2  before the market opens 

Oncology focused biotech company  TESARO  Inc     is focused on the development of treatments targeting cancer  Based in Waltham  MA  TESARO has a disappointing track record with the company surpassing estimates only in one of the trailing four quarters  However  its prospects for Q3 look pretty good  The stock currently has an Earnings ESP of  2 08  and a Zacks Rank  3  You can see  

TESARO is slated to release Q3 results on Nov 3  after the market closes  The Zacks Consensus Estimate currently pegged at a loss of  1 92 

Our last pick is QIAGEN N V      with a Zacks Rank  3 and an Earnings ESP of  3 70   Its Zacks Consensus Estimate currently stands at 27 cents  Based in Netherlands  QIAGEN is one of the leading providers of sample to insight solutions that transform biological samples into valuable molecular insights  The company has recorded an average positive surprise of 0 20  over the trailing four quarters 

QIAGEN is set to release Q3 results on Nov 2  after the market closes 
The Bottom Line
Despite challenges like growing political pressure on drug prices in the U S   biosimilar and generic competition  European pricing pressure  stressed balance sheets and other broad based factors  newer therapies  licensing agreements  partnership acquisition deals and restructuring initiatives should help support growth  We expect investors to keep an eye on these potential outperformers given their solid Zacks Rank and positive Zacks Earnings ESP Looking for Ideas with Even Greater Upside 
Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2016-10-31,Zacks Investment Research,https://www.investing.com/analysis/5-healthcare-stocks-poised-to-trump-q3-earnings-200161765,200161765
151176,372692,AMGN,Zacks Industry Outlook Highlights  Mylan  Lilly  Pfizer  Novartis And Amgen,opinion,"For Immediate Release

	Chicago  IL   November 01  2016   Today  Zacks Equity Research discusses the Pharmaceuticals  part 1  including Mylan  NASDAQ MYL     NASDAQ          Lilly   NYSE          Pfizer  NYSE PFE     NYSE      Novartis    NYSE       and Amgen  NASDAQ AMGN     NASDAQ        

	Industry  Pharmaceuticals  part 1

	Link  

	It s been a rough year for pharma and biotech stocks with several factors weighing on the sector including media and political focus on the high price of drugs  mixed performance results  slower than expected new product launches and increasing competition 

	The impact of these issues is more evident on biotech stocks  with the NASDAQ Biotechnology Index declining 20 9  year to date  YTD  while the NYSE ARCA Pharmaceutical Index has lost 10 9  YTD 

Drug Pricing to Remain in Focus

	Right now  the biggest issue that is weighing on the sector is the political rhetoric regarding drug pricing  With presidential candidates  policymakers  the media and the general public focusing on the high price tags for drugs  the drug pricing controversy is not likely to die down easily 

	In fact  the drug pricing issue heated up recently given the price hikes taken by Mylan    NASDAQ         for its life saving combination product EpiPen  Democratic Presidential candidate Hillary Clinton announced a health care plan that will address the excessive price hikes of treatments that have been around for years and also reaffirmed her earlier broader plan  announced in Sep 2015  with the aim to lower drug prices for all Americans 

	Insulin drugmakers like Lilly   NYSE         and Novo Nordisk  CO NOVOb  are also under attack with Senator Bernie Sanders posting a series of tweets questioning the prices of their insulin drugs 

Will M As Pick Up Pace 

	With the major price correction resulting in reasonable valuations  expectations are high that more M A deals will be announced in the coming quarters  So far in 2016  some of the announced completed acquisitions include Shire Baxalta  Bristol Myers Padlock  and Pfizer   NYSE       Medivation  among others 

	In fact  the Pfizer Medivation deal  valued at approximately  14 billion  has raised hopes that major M As will pick pace once elections are over while licensing deals and small bolt on acquisitions will continue 

	Several pharma companies are focusing on in licensing mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time  Small biotech companies are open to such deals  with most of them finding it challenging to raise cash  thereby making it difficult to survive and continue with the development of promising pipeline candidates  Therefore  it makes sense to seek deals with pharma companies sitting on huge piles of cash 

Divestment of Non Core Assets   Restructuring Activities

	Another trend being witnessed is the divestment of non core business segments  Companies like Pfizer  UCB  Novartis    NYSE         Glaxo and AstraZeneca have all been a part of this trend  More recently  Sanofi  PA SASY  is looking to divest its generics portfolio in Europe while Valeant is in discussions for various divestitures including the Salix business  The monetization of non core assets allows these companies to focus on their areas of expertise 

	Restructuring activities are also gaining momentum as large pharma companies look to cut costs and streamline operations  Most of these companies are re evaluating their pipelines and discontinuing programs with an unfavorable risk benefit profile 

New Products Should Gain Traction

	Highly awaited new products that gained approval last year should contribute significantly to revenues  Some of the important new product approvals include Vertex s cystic fibrosis treatment  Orkambi  Amgen s    NASDAQ       heart failure treatment  Corlanor  Pfizer s cancer treatment  Ibrance  Novartis  psoriasis treatment  Cosentyx  PCSK9 inhibitors   Amgen s Repatha and Sanofi Regeneron s Praluent  Roche s advanced melanoma treatment  Cotellic and Gilead s Genvoya  HIV  

	Meanwhile  so far in 2016  the FDA has approved 19 new drugs including Zinplava  c  difficile infection   Lartruvo  soft tissue carcinoma   Exondys 51  Duchenne muscular dystrophy   Epclusa  HCV   Ocaliva  rare  chronic liver disease   Zinbryta  multiple sclerosis   Tecentriq  urothelial cancer   Venclexta  chronic lymphocytic leukemia in patients with a specific chromosomal abnormality   Taltz  moderate to severe plaque psoriasis   Cinqair  severe asthma  and Zepatier  HCV  among others  The FDA also expanded the label of cancer drugs like Kyprolis  Imbruvica and Xalkori 

Biosimilars Gaining Importance

	With the FDA approving the first biosimilar in the U S   Zarxio  a biosimilar version of Amgen s blockbuster drug  Neupogen   the floodgates have opened  While biosimilars have been available in the EU for quite a while  there was no regulatory pathway for biosimilars in the U S 

	The second biosimilar to gain approval in the U S  was Pfizer and Celltrion s Inflectra  infliximab dyyb  with the reference product being Remicade 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-11-03,Zacks Investment Research,"https://www.investing.com/analysis/zacks-industry-outlook-highlights:-mylan,-lilly,-pfizer,-novartis-and-amgen-200162874",200162874
151200,372716,AMGN,Healthcare ETFs  Gain Or Pain Ahead In Q3 Earnings ,opinion,The Q3 earnings season is in full swing with the healthcare sector showing the third highest growth at this stage  trailing materials and business services  Earnings from 22  of the sector s market capitalization that have reported so far are up 15 9  with a beat ratio of 83 3  on revenue growth of 8 8  and revenue surprise of 66 7   as per the  In particular  robust earnings reports from the leading drug maker Johnson   Johnson   NYSE JNJ   and the largest U S  health insurer UnitedHealth Group   NYSE UNH   spread strong optimism in the sector last week    As a result  healthcare ETFs saw smooth trading  with the popular funds   Health Care Select Sector SPDR Fund   Vanguard Health Care ETF   iShares U S  Healthcare ETF  and Fidelity MSCI Health Care Index ETF    gaining nearly 0 2  over the past five days  Will the positive trend continue in the weeks ahead given that the sector is expected to post Q3 earnings growth of 3 7  and revenue growth of 7 4  Let s delve into the earnings picture of some of the other largest companies in the healthcare space that would drive the performance of the above mentioned funds in the coming days  Some of the big names include Pfizer   NYSE PFE    Merck   NYSE MRK    Amgen   NASDAQ AMGN    AbbVie   NYSE ABBV    Gilead Sciences   NASDAQ GILD   and Bristol Myers Squibb Company   NYSE BMY   that dominate these fund s portfolio  All these stocks collectively account for the maximum portion  with 28 6  share in XLV  27 4  in IYH  25  in VHT and 24 6  in FHLC Inside Our Surprise Prediction of These StocksPfizer has a Zacks Rank  3  Hold  and an Earnings ESP of  1 59   indicating a lower probability of beating estimates this quarter  According to the our surprise prediction methodology  a Zacks Rank  1  Strong Buy    2 or  3 when combined with a positive Earnings ESP has chances of an earnings beat  while a Zacks Rank  4 or  5  Sell rated  are best avoided  Pfizer delivered positive earnings surprises in the last four quarters  with an average beat of 11 16  Additionally  the Zacks Consensus Estimate for third quarter 2016 is 63 cents  up a penny over the past three months  Further  the stock has a solid Value and Momentum Style Score of B and A  respectively  while a Growth Style Score of C looks unimpressive  Pfizer is scheduled to report its earnings on November 1 before the opening bell Merck is expected to report its results on October 25 before market open  It has a Zacks Rank  2  Buy  and an Earnings ESP of 0 00   which makes surprise prediction difficult  The stock saw no earnings estimate revision over the past 90 days for the to be reported quarter  The drug maker delivered positive earnings surprises in the last four quarters  with an average beat of 3 37   The stock has an unfavorable Value and Growth Style Score of C and D  respectively  while a Momentum Style Score of B looks good  read    Amgen has a Zacks Rank  3 and an Earnings ESP of  1 08   indicating a good chance of beating estimates this quarter  The earnings surprise track over the past four quarters is robust with an average positive surprise of 11 55   The stock also witnessed positive earnings estimate revision of a penny over the past 90 days for the yet to be reported quarter  Additionally  the stock has a solid Value Style Score of B but an unfavorable Growth and Momentum Style Score of C and D  respectively  Amgen will reports its earnings on October 27 after market close AbbVie has a Zacks Rank  3 and an Earnings ESP of  0 83   indicating a reasonable chance of beating estimates this quarter  The company delivered positive earnings surprises in the last four quarters  with an average beat of 3 32   Moreover  it saw solid positive earnings estimate revision of three cents over the past three months for the to be reported quarter  Further  the stock has a top Momentum Style Score of A and a Value Style Score of B while the Growth Style Score is unimpressive at C  The company is schedule to report on October 28 before market open Gilead is expected to release its earnings on November 1 after market close  It has a Zacks Rank  5  Strong Sell  and an Earnings ESP of  0 36   Gilead saw a negative earnings estimate revision of 19 cents over the past three months for the to be reported quarter but delivered positive earnings surprises in three of the last four quarters  with an average beat of 4 08   Though it has a solid Value and Growth Style Score of B each  the Momentum Style Score of F is an eyesore  read    Bristol Myers will likely report its earnings on October 27 before the opening bell  It has an unfavorable Zacks Rank  4 but an Earnings ESP of  3 08   The stock delivered positive earnings surprises over the past four quarters with an average beat of 15 56  and saw positive earnings estimate revision of a penny for the to be reported quarter  However  it has an unfavorable Value  Growth and Momentum Style Score of C  F and C  respectively Summing UpGiven that some companies have an unfavorable Zacks Rank and a lower probability of beating this quarter  healthcare ETFs might struggle to hold onto gains in the coming days  However  the above mention ETFs have a favorable Zacks ETF Rank of  1  Strong Buy  in case of XLV  VHT and IYH and  2 for FHLC  see    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2016-10-23,Zacks Investment Research,https://www.investing.com/analysis/healthcare-etfs:-gain-or-pain-ahead-in-q3-earnings-200160324,200160324
151201,372717,AMGN,Can AbbVie  ABBV  Sustain Earnings Beat Trend In Q3 ,opinion,"We expect pharma company AbbVie Inc    NYSE ABBV   to beat expectations when it reports third quarter earnings results on Oct 28 before market open  AbbVie had delivered a positive earnings surprise of 5 00  in the second quarter 
AbbVie s performance has been pretty impressive  with consistent positive surprises  The average earnings beat over the last four quarters is 3 32  ABBVIE INC Price and EPS Surprise
 

   Let s see how things are shaping up for the company this quarter 
Factors at Play
At the second quarter conference call  management had said that it expects third quarter earnings in the range of  1 18 to  1 20 per share  Revenues were guided to see high single digit operational growth  excluding a modest negative foreign exchange impact 
Key drug Humira should remain the main growth driver in the third quarter  Growing awareness  strong underlying demand  favorable clinical data  additional indications and market share gains should help the product to continue contributing significantly to the top line 
However  a factor to be considered for international Humira sales is the impact of Remicade and Enbrel biosimilars 
Another area of focus is the performance of Imbruvica which was added to AbbVie s portfolio following its May 2015 acquisition of Pharmacyclics  Imbruvica has multi billion dollar potential that the company is exploring to expand Imbruvica s label into solid tumors and autoimmune diseases 
The drug recorded strong sales and share gains in the second quarter  a trend we expect to continue 
AbbVie is positioning Imbruvica as a  pipeline in a molecule     a treatment that is currently used in a wide range of studies  Imbruvica is partnered with Johnson   Johnson   NYSE JNJ    which recorded third quarter Imbruvica sales of  349 million 
Other drugs like Duopa and Creon should also do well in the quarter to be reported 
However  Abbvie s Hepatitis C virus  HCV  treatment  Viekira  will continue to be impacted by the addition of liver injury warnings to the labels of AbbVie s HCV treatments as well as new competition in the market 
What Our Model Indicates
Our proven model shows that AbbVie is likely to beat on earnings because it has the right combination of the two key ingredients 
Positive Zacks ESP    which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  0 83   This is a meaningful indicator of a likely positive earnings surprise 
Zacks Rank  3  Hold   Note that stocks with Zacks Ranks of  1   2 and  3 have a significantly higher chance of beating earnings  The Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement 
The combination of ABbVie s Zacks Rank  3 and  0 83  ESP makes us confident in looking for an earnings beat in the upcoming release 
Other Stocks to Consider
Some other stocks in the large cap healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are 
Amgen Inc    NASDAQ AMGN    which is scheduled to report results on Oct 27  The company has an Earnings ESP of  1 08  and a Zacks Rank  3  You can see 
Novartis AG   NYSE NVS   with an Earnings ESP of  2 54  and a Zacks Rank  3  The company is scheduled to release results on Oct 25 
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-24,Zacks Investment Research,https://www.investing.com/analysis/can-abbvie-(abbv)-sustain-earnings-beat-trend-in-q3-200160409,200160409
151202,372718,AMGN, Gilead Sciences  GILD  Q3 Earnings  Stock To Disappoint ,opinion,Gilead Sciences Inc    NASDAQ GILD   is scheduled to report third quarter 2016 results on Nov 1  after the market closes  Last quarter  the company had surpassed expectations with a positive earnings surprise of 0 33  Gilead s track record has been encouraging so far  with the company beating estimates in three of the last four trailing quarters  Overall  the company has recorded an average positive earnings surprise of 4 08  Let s see how things are shaping up for this biotech major for this announcement Factors at PlayIn the second quarter of 2016  Gilead s hepatitis C virus  HCV  franchise  which consists of Harvoni  Sovaldi and the recently launched Epclusa  recorded a year over year decline of 18 4  mainly due to lower sales of Harvoni  down almost 29  year over year   Performance of the HCV franchise was disappointing in both the U S  and Europe Thus  during the last quarterly earnings call  Gilead lowered its net product sales outlook for 2016  keeping in mind the current trends in payer and patient flow dynamics for HCV  The company now expects net product sales in the range of  29 5  30 5 billion  old guidance   30  31 billion  Management had stated that the trimmed outlook was due to a number of factors including lower HCV revenue per patient as a result of a mix shift toward the more heavily discounted payer segment in the U S  and a lower net average price in Europe  slowing patient starts in the U S  commercial segment and some earlier launch markets of Europe  continued preference for shorter duration treatment  and the loss of market share to competition Nevertheless  the company s HIV business has been performing well and should continue to do so in the to be reported quarter  thanks to the recently launched tenofovir alafenamide  TAF  based regimens  Genvoya  Odefsey and Descovy  Genvoya has already become the most prescribed regimen for both treatment na ve and switch patients since its launch last November On the third quarter call  investors should keep an eye on the company s performance while business development plans will also be keenly awaited  Focus would also be on the performance of Epclusa and TAF based regimens GILEAD SCIENCES Price and EPS Surprise    What Our Model IndicatesOur proven model does not conclusively show that Gilead is likely to beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to likely post an earnings beat  But that is not the case here  as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is at  0 36   This is because the Most Accurate estimate is  2 74 while the Zacks Consensus Estimate is pegged higher at  2 75 Zacks Rank  Gilead currently carries a Zacks Rank  5  Strong Sell   As it is  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Please check our  that enables you to find stocks that are expected to come out with earnings surprises Stocks That Warrant a LookHere are some health care stocks that you may want to consider instead  as our model shows that they have the right combination of elements to post an earnings beat this quarter Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  1 08  and a Zacks Rank  3  The company is scheduled to release third quarter results on Oct 27 Bristol Myers Squibb Company   NYSE BMY   has an Earnings ESP of  3 08  and a Zacks Rank  3  It is scheduled to report third quarter results on Oct 27 Shire plc   NASDAQ SHPG   is scheduled to report third quarter results on Nov 1  It has an Earnings ESP of  1 26  and a Zacks Rank  2  You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-25,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-(gild)-q3-earnings:-stock-to-disappoint-200160865,200160865
151203,372719,AMGN,Here s Why Amgen  AMGN  Stock Slid Over 10  Today,opinion,"On Friday  shares of therapeutics company Amgen Inc    NASDAQ AMGN   are sliding  down over 10  in afternoon trading after the company  its third quarter earnings results 
Earnings per share came in at  3 02  beating the Zacks Consensus Estimate of  2 79 and increasing 11  year over year Total revenues gained 2  to  5 81 billion  beating our consensus estimate of  5 74 billion by 1 2  
However  lower sales of its established product brands like Epogen  Aranesp  Neulasta  Neupogen  and especially Enbrel  have hit shares of AMGN hard  Sales of Enbrel  used to treat moderate to severe rheumatoid arthritis and moderate to severe plaque psoriasis  were flat when compared to the year ago period  And  Amgen said it expects sales of the drug will see only minimal net price growth in 2017 
Amgen has depended on its legacy products for many years now Enbrel  Neulasta  and the rest of the above mentioned treatments make up  15 billion of the company s  22 8 billion total revenue this year but this reliance is now become a thorn in its side  according to   who cite Leerink s Geoffrey Porges and Bradley Canino  The analysts believe this slowdown in growth will affect AMGN stock  and it  is likely to come under pressure from both negative estimate revisions and multiple compression  
Looking ahead  Amgen management raised its full year 2016 earnings range  as well as the lower end of its revenue guidance  The company now expects earnings of  11 40 to  11 55 per share  and revenue of  22 6 billion to  22 8 billion  The Zacks Consensus Estimate for earnings and sales stand at  11 34 per share and  22 74 billion  respectively 
Interested in the other top stories of the week  Listen to Zacks Friday Finish Line to catch up on the week s financial and investment news 


Stocks that Aren t in the News Yet
You are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street  They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015  with a stellar average gain of  26  per year ",2016-10-28,Zacks Investment Research,https://www.investing.com/analysis/here's-why-amgen-(amgn)-stock-slid-over-10-today-200161452,200161452
151234,372750,AMGN,Bristol Myers Squibb  BMY  Q3 Earnings  What s In Store ,opinion,Bristol Myers Squibb Company   NYSE BMY   is scheduled to report third quarter 2016 results on Oct 27  before the market opens  Last quarter  the company posted a positive earnings surprise of 2 99  Bristol Myers has an impressive track record so far  The company s earnings surpassed expectations in each of the four trailing quarters  with an average positive surprise of 15 56   Will Bristol Myers be able to beat estimates this time around as well  Let s see how things are shaping up for this quarter Factors to Consider This QuarterBristol Myers  high profile immuno oncology drug  Opdivo  continues to demonstrate robust performance globally driven by strong demand  Opdivo sales in the U S  are being driven by the lung cancer and renal cell carcinoma indications  In the melanoma indication  robust performance of the Opdivo Yervoy  Bristol Myers  other immuno oncology drug  regimen is contributing to growth of both the products  Securing reimbursement for the combination regimen across Europe should further aid revenues  Meanwhile  international sales of Yervoy are expected to be under pressure due to competition from PD 1 agents Another oncology drug  Sprycel  should continue to keep up its performance in the third quarter of 2016  Meanwhile  multiple myeloma drug  Empliciti s initial sales have been encouraging despite stiff competition Anticoagulant Eliquis  performance should continue to accelerate  It is well on its way to become the number one novel anticoagulant globally on the back of strong demand trends from key markets globally  Rheumatoid arthritis drug  Orencia  should also contribute significantly to the company s top line on the back of high demand With key products performing well  Bristol Myers raised its 2016 earnings guidance  primarily for Opdivo and Eliquis  at the time of announcing second quarter 2016 results  For 2016  the company expects earnings in the range of  2 55 to  2 65 per share  old guidance   2 50 to  2 60 per share  Bristol Myers expects the HIV and HCV franchises to remain under competitive pressure During the third quarter  Bristol Myers remained active on the deal making and acquisition front in the immuno oncology space  It collaborated with companies like Johnson   Johnson   NYSE JNJ   and AbbVie Inc    NYSE ABBV   for the evaluation of Opdivo in combination with their cancer treatments On the expense front  while marketing  selling and administrative expenses are expected to decrease in the low single digit range  research and development expenses will increase in the mid teen range in 2016 due to investments in Opdivo and the immuno oncology programs On the third quarter call  investors are expected to focus on the company s performance and label expansion efforts  along with updates on business development activities Earnings WhispersOur proven model does not conclusively show that Bristol Myers is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  Unfortunately  that is not the case here  as elaborated below Zacks ESP  The Earnings ESP for Bristol Myers is  3 08  since the Most Accurate Estimate stands at 67 cents  higher than the Zacks Consensus Estimate of 65 cents Zacks Rank  Bristol Myers carries a Zacks Rank  4  Sell   As it is  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions BRISTOL MYERS Price and EPS Surprise    A Stock to ConsiderHere is a health care stock that you may want to consider  as our model shows that it has the right combination of elements to post an earnings beat this quarter Amgen Inc    NASDAQ AMGN   is slated to release third quarter results on Oct 27  The company has an Earnings ESP of  1 79  and a Zacks Rank  3  You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-20,Zacks Investment Research,https://www.investing.com/analysis/bristol-myers-squibb-(bmy)-q3-earnings:-what's-in-store-200160064,200160064
151235,372751,AMGN,GlaxoSmithKline  GSK  Q3 Earnings  What s In The Cards ,opinion,"GlaxoSmithKline plc   NYSE GSK   is scheduled to report third quarter 2016 results on Oct 26  Last quarter  the company delivered a positive earnings surprise of 27 27   Let s see how things are shaping up for this quarter Factors at PlayGlaxo focuses on its three core business   Pharmaceuticals  Vaccines and Consumer Healthcare  On the second quarter conference call  the company lifted its outlook for 2016  At constant exchange rates  the core earnings growth rate is now expected in the range of 11 12   previous projections  10 12   The Pharmaceuticals segment is expected to continue being driven by strong sales of new HIV products  Tivicay and Triumeq  Sales of newly launched respiratory drugs  Relvar Breo  Incruse  Anoro  Arnuity and Nucala are expected to offset the declines in Seretide  Advair and Avodart The Vaccines segment will benefit from continued uptake of meningitis vaccines  Bexsero and Menveo  acquired from Novartis AG   NYSE NVS    are expected to witness growth during the quarter as well  However  the segment is expected to remain volatile on a quarterly basis  particularly in the emerging markets  due to factors like the timing of government tenders In the second quarter  Consumer Healthcare saw strong performance across the Oral health and Wellness power brands in all regions  particularly the International market  Moreover  strong growth in Flonase  which was backed by the launch of a number of innovative line extensions  drove results in the last quarter  The trend is expected to continue in the to be reported quarter as well Notably  currency movement is expected to provide tailwinds to third quarter sales We expect investors to focus on the company s performance  sales ramp up of newly launched drugs and pipeline updates on Glaxo s third quarter call Surprise HistoryGlaxo s performance has been pretty good so far  with the company s earnings beating expectations thrice in the four trailing quarters  Overall  the company has delivered an average positive surprise of 11 59  GLAXOSMITHKLINE Price and EPS Surprise
    Earnings WhispersOur proven model does not conclusively show that Glaxo is likely  to beat earnings this quarter  This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  But that is not the case here  as you will see below Zacks ESP  The Earnings ESP for Glaxo is  4 00  as the Most Accurate estimate stands at 72 cents while the Zacks Consensus Estimate is higher at 75 cents Zacks Rank  Although Glaxo s Zacks Rank  3 increases the predictive power of ESP  its negative ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a couple of health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter Amgen Inc    NASDAQ AMGN   is scheduled to report results on Oct 27  The company has an Earnings ESP of  1 79  and a Zacks Rank  3  You can see  The Earnings ESP for ImmunoGen  Inc    NASDAQ IMGN   is  5 41  and it carries a Zacks Rank  3  The company is scheduled to release earnings on Oct 28 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-20,Zacks Investment Research,https://www.investing.com/analysis/glaxosmithkline-(gsk)-q3-earnings:-what's-in-the-cards-200160060,200160060
151236,372752,AMGN,The Zacks Analyst Blog Highlights  Pfizer  Novartis AG  Amgen  Merck And Momenta Pharmaceuticals,opinion,"For Immediate Release

	Chicago  IL   October 21  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Pfizer  NYSE PFE   Inc   NYSE     Novartis AG  NYSE     Amgen Inc  NASDAQ AMGN    NASDAQ     Merck  NYSE MRK    Co   Inc   NYSE     and Momenta Pharmaceuticals Inc   NASDAQ      

	Today  Zacks is promoting its   Buy   stock recommendations    

Here are highlights from Thursday s Analyst Blog  

Drug Stocks to Consider as Biosimilars Pick Up Pace

	Interest in biosimilars has picked up considerably with Pfizer  Inc  s  NYSE      announcement this week regarding its plans to launch a biosimilar version of Johnson   Johnson s blockbuster drug  Remicade  in late November 

What are Biosimilars 

	A biosimilar is a biologic product whose approval is based on evidence that it is highly similar to an approved biologic  known as the reference product  Moreover  there should be no clinically meaningful differences between the biosimilar and the reference product where safety and effectiveness is concerned 
	While biosimilars have been available in the EU for quite a while  they are a new entrant in the U S  where a regulatory pathway was implemented recently 
	Sandoz  a Novartis AG  NYSE      company  was the first to gain approval for and launch a biosimilar in the U S  The company launched Zarxio  filgrastim sndz   a biosimilar version of Amgen Inc  s  NASDAQ      Neupogen last year 
	The second biosimilar to gain approval in the U S  was Pfizer and Celltrion s Inflectra  infliximab dyyb  with the reference product being Remicade 
	This was followed by the FDA approval of biotech giant Amgen s Amjevita  adalimumab atto   Amjevita is approved for use in all eligible indications of the reference product  Humira  adalimumab   which is used for a wide range of inflammatory diseases Biosimilars Set to Change the Competitive Landscape
	The market for biosimilars is huge and highly lucrative  Several blockbuster biologics including Humira and Lantus will lose patent protection by 2020  Biosimilars are expected to reduce healthcare costs and provide a large number of patients with access to much needed biologic treatments  According to new research released by the IMS Institute for Healthcare Informatics earlier this year  increasing acceptance of biosimilars across different therapeutic areas plus an active pipeline of 56 candidates are expected to lead to total savings of about  110 billion to health systems across Europe and the U S  through 2020 
	The report further says that by 2020  biosimilars will start competing with biologics that currently have annual sales of  50 billion  About 30 companies are developing biosimilars of 16 molecules   most of the biosimilars in development are for reference products like Remicade  Enbrel  etanercept   Rituxan  rituximab  and Humira  adalimumab  What about Formulary Coverage 
	Biosimilars are also gaining acceptance across formularies  CVS Health  NYSE CVS  announced that biosimilars and follow on biologics will be a key part of its 2017 standard formulary strategy  replacing higher cost drugs within the categories  The company said that its formulary list will include Zarxio  replacing Neupogen  to decrease the risk of infection in patients receiving treatment for certain forms of cancer  and the follow on product Basaglar  replacing Lantus  for the treatment of diabetes 

	Meanwhile  UnitedHealth Group  NYSE UNH  will be moving Basaglar from Tier 3 to Tier 1 effective Apr 1  2017  Basaglar is expected to enter the market in mid December  Sanofi s Lantus SoloStar and Lantus Vials will remain on Tier 3 untilMar 31  2017 after which they will be excluded  Zarxio will be on Tier 2  Pharmacy benefit manager Express Scripts said that the basal insulins category may be reassessed later in the year to reflect anticipated product launches Stocks to Consider
	With biosimilars picking up pace  it makes sense to zero in on companies that are in the biosimilars business  Here is a mix of pharma  generic and biotech stocks that should benefit from the biosimilars opportunity especially given the current scenario of increased political  media and public pressure on drug pricing  the growing interest in developing biosimilars and the potential of biosimilars to reduce healthcare costs 
	Sandoz  a Novartis company  has a strong presence in the biosimilars market being the first to launch a biosimilar  Omnitrope  in the EU way back in 2006  in Japan  Somatropin BS S C   2009  as well as in the U S   Zarxio  2015   Earlier this year  Sandoz announced that it will launch 5 biosimilars of major cancer and immunology biologics in key geographies by 2020  Some of the biosimilars that Sandoz is working on include biosimilar versions of Enbrel  Humira  Neulasta  Remicade and Rituxan   these biologics generated global sales of approximately  43 6 billion in 2015  Novartis is a Zacks Rank  3  Hold  stock 

   

Pfizer   also has a strong presence in the biosimilars market  The acquisition of Hospira significantly expanded Pfizer s biosimilar capabilities and gave the company access to Hospira s lucrative biosimilar portfolio of both marketed and pipeline assets  The company has three marketed products in Europe and several programs including four in late stage development  Rituxan  Humira  Herceptin  and Avastin   The Zacks Rank  3 stock will be launching Inflectra in late November and has decided to price it at a 15  discount to the current wholesaler acquisition cost of Remicade 

   

Merck   Co   Inc   NYSE      has an agreement with Samsung  KS 005930  Bioepis for the development and commercialization of multiple biosimilar candidates in certain partnered territories  Earlier this year  Merck announced the filing of a Biologics License Application  BLA  for SB2  infliximab   a biosimilar version of Remicade  Moreover  Merck recently launched a website to provide clarity on and increase awareness about biosimilars  Merck is a Zacks Rank  2  Buy  stock  You can see   

   

	Cambridge  MA based Momenta Pharmaceuticals Inc   NASDAQ      is a biotech company with a focus in three areas   complex generics  biosimilars and novel drugs for autoimmune diseases  The most advanced biosimilars in the company s pipeline include M923  reference drug  Humira  and M834  reference drug  Orencia   The Zacks Rank  3 stock has a collaboration agreement with Mylan  NASDAQ MYL  for the development  manufacture and commercialization of six biosimilar candidates including M834 

   

	Although Amgen itself is a major target of biosimilar competition  the company has been quick to recognize the commercial potential of the biosimilars market and has already made significant progress in this field with quite a few late stage biosimilar candidates in its pipeline  Last month  Amgen got FDA approval for its biosimilar version of AbbVie s multi billion dollar drug  Humira  The Zacks Rank  3 stock is developing biosimilar versions of Avastin  Herceptin  Rituxan  and Remicade as well 

   

Where Do Zacks  Investment Ideas Come From 
	You are welcome to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buy  stocks free of charge  There is no better place to start your own stock search  Plus you can access the full list of must avoid Zacks Rank  5  Strong Sells  and other private research  

	You can find all of today s stock research reports   

	Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-10-20,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-pfizer,-novartis-ag,-amgen,-merck-and-momenta-pharmaceuticals-200160045",200160045
151237,372753,AMGN,Intro Guide To The American Funds American Mutual C  AMFCX  Fund,opinion,"American Funds American Mutual C Fund     a Zacks Rank  1  Strong Buy  was incepted in February 1950 and is managed by Capital Research and Management Company  The objective of AMFCX is to provide for the balanced accomplishment of three objectives current income  capital growth and conservation of principal  AMFCX invests primarily in common stocks  securities convertible into common stocks  non convertible preferred stocks  U S  government securities  bonds rated A or better and cash 

	This Large Value product  as of the last filing  allocates their fund in four major groups  Large Value  Intermediate Bond  Large Growth and Emerging Market  Further  as of the last filing  Verizon Communications Inc  NYSE VZ   Amgen Inc  NASDAQ AMGN  and Texas Instruments  NASDAQ TXN  Inc were the top holdings for AMFCX 

	The American Funds American Mutual C fund  managed by   carries an expense ratio of 1 38   Moreover  AMFCX requires a minimal initial investment of  250 

	AMFCX has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 8 6  and 5 year 13 1   To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds   

	AMFCX s performance  as of the last filing  when compared to funds in its category was in the top 13  over the past 1 year and in the top 42  over the past 3 years 

Want key mutual fund info delivered straight to your inbox 

	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ",2016-10-20,Zacks Investment Research,https://www.investing.com/analysis/intro-guide-to-the-american-funds-american-mutual-c-(amfcx)-fund-200160039,200160039
151238,372754,AMGN,Amgen s  AMGN  Xgeva Meets Endpoint In Phase III Study,opinion,"Amgen Inc   NASDAQ AMGN   announced that a phase III study on its marketed drug  Xgeva for the prevention of skeletal related events  SRE  in patients with multiple myeloma met the primary endpoint Xgevais is approved in the U S and the EU for the prevention of SREs in patients with bone metastases from solid tumors  However  it is not indicated for the prevention of SREs in patients with multiple myeloma  Xgeva is also approved in the U S for the treatment of giant cell tumor of bone  GCTB   in adults and skeletally mature adolescents  which cannot be treated with surgery The study  n 1 718   comparing Xgeva to zoledronic acid met the primary endpoint of non inferiority in delaying the time to first on study SRE in patients with multiple myeloma AMGEN INC Price
    However  the secondary endpoints  delaying time to first SRE and delaying time to first and subsequent SRE of the study have not met Patients treated with Xgeva were observed to have some side effects which are common with the well known safety profile of the drug  Diarrhea and nausea were the most familiar side effects seen in the Xgeva arm of the study Notably  Xgeva delivered revenues of  381 million in the second quarter of 2016  up 15  from the year ago quarter mainly due to higher demand Other than Xgeva  Amgen is also evaluating currently marketed products like Prolia Vectibix and Aranesp for additional indications  Results from several pivotal programs are expected in the upcoming quarter Amgen currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Bioblast Pharma Ltd    NASDAQ ORPN    Geron Corporation   NASDAQ GERN   and Exelixis  Inc    NASDAQ EXEL    All the companies sport a Zacks Rank  1  Strong Buy  You can see the  Bioblast Pharma recorded an average positive surprise of 51 66  for the last four quarters Geron has an average positive surprise of 20 78  for the last four quarters Exelixis has an average positive surprise of 9 10  for the trailing four quarters  Its share price has surged more than 100  year to date Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-20,Zacks Investment Research,https://www.investing.com/analysis/amgen's-(amgn)-xgeva-meets-endpoint-in-phase-iii-study-200160029,200160029
151239,372755,AMGN,Will Amgen  AMGN  Sustain Its Earnings Beat Trend In Q3 ,opinion,"We expect biotech major Amgen Inc    NASDAQ AMGN   to beat expectations when it reports third quarter earnings results on Oct 27 after market close  Amgen had delivered a positive earnings surprise of 3 65  in the second quarter Amgen s performance has been pretty impressive  with consistent positive surprises  The average earnings beat over the last four quarters is 11 55  AMGEN INC Price and EPS Surprise
    Let s see how things are shaping up for the company this quarterFactors at PlayAmgen s growth products like Enbrel  Xgeva  Vectibix  Sensipar  Prolia and Nplate should continue to perform well  While new patient adoption and repeat injections should drive Prolia  Xgeva should benefit from its superior clinical profile versus competition However  Enbrel is facing increasing competition in the dermatology segment which could hurt sales Moreover  Kyprolis sales fell below expectations in the second quarter due to increased competition in the multiple myeloma market  It remains to be seen if sales pick up in the third quarter Meanwhile  Epogen will continue to be impacted by further share decline at Fresenius Medical Care and the potential for additional switching to Aranesp The bottom line will continue to be driven by the company s overall cost cutting efforts and share buyback  The company s restructuring plan should make it leaner and more cost efficient Investor focus will remain on the performance of the company s PCSK9 inhibitor  Repatha  its acceptance in the physician community  the formulary scenario for the product and its performance in other territories where it is being launched  We expect Repatha sales to pick up once positive outcomes data is available and added to the label  The impact of the launch of Zarxio  biosimilar  on Neupogen sales will also be in focus What Our Model IndicatesOur proven model shows that Amgen is likely to beat on earnings because it has the right combination of the two key ingredients Positive Zacks ESP    which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  1 79   This is a meaningful indicator of a likely positive earnings surprise Zacks Rank  3  Hold   Note that stocks with Zacks Ranks of  1  2 or 3 have a significantly higher chance of beating earnings  The Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement The combination of Amgen s Zacks Rank  3 and  1 79  ESP makes us confident in looking for an earnings beat in the upcoming release Other Stocks to ConsiderSome other stocks in the healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are AbbVie Inc    NYSE ABBV   is scheduled to report results on Oct 28  The company has an Earnings ESP of  0 83  and a Zacks Rank  3  You can see  Achillion Pharmaceuticals  Inc    NASDAQ ACHN   has an Earnings ESP of  12 5  and a Zacks Rank  2  It is expected to report its results on Nov 3 Novartis AG   NYSE NVS   has an Earnings ESP of  2 54  and a Zacks Rank  3  The company is scheduled to release results on Oct 25 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-20,Zacks Investment Research,https://www.investing.com/analysis/will-amgen-(amgn)-sustain-its-earnings-beat-trend-in-q3-200160106,200160106
151240,372756,AMGN,Agenus  AGEN   What s Ahead For The Stock In Q3 Earnings ,opinion,"Agenus Inc    NASDAQ AGEN   is scheduled to report third quarter 2016 results on Oct 27  before the opening bell  Last quarter  Agenus delivered a positive earnings surprise of 29 41   Let s see how things are shaping up for the company this quarter Factors at PlayAgenus is an immuno oncology company focused on the discovery and development of revolutionary new treatments that engage the body s immune system to fight cancer The company earns revenues primarily through fees received under collaboration and license agreements  which not only provide it with funds in the form of upfront and milestone payments and future royalties  but also validate the company s proprietary product platform  Collaboration revenues should continue to drive the top line in the third quarter as well Agenus is currently evaluating AGEN1884 in a phase I study for the treatment of advanced or refractory cancer  and INCAGN1876  in partnership with Incyte Corporation   NASDAQ INCY    in a phase I II study for the treatment of solid tumors  Consequently  research and development expenses are expected to increase sequentially In its third quarter conference call  investor should remain focus on the company s update on the initiation of combination studies on these antibodies as well as the advancement of additional checkpoint modulator antibodies and vaccines into the clinic in the coming quarters We remind investors that Agenus  lead candidate and several backup antibodies were selected by Merck   Co   Inc    NYSE MRK   for an undisclosed checkpoint target  Under the terms of the agreement  Agenus is eligible to receive up to  100 million in milestone payments  in addition to royalties on worldwide product sales Surprise HistoryAgenus  track record has been disappointing so far  The company has surpassed estimates in only once in the trailing four quarters and missed the same in all the other occasions  bringing the average negative surprise to 1 04  AGENUS INC Price and EPS Surprise
    Earnings WhispersOur proven model does not conclusively show that Agenus is likely to beat estimates this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  Unfortunately  this is not the case here as you will see below Zacks ESP  The Earnings ESP for Agenus is 0 00  since the Most Accurate estimate stands in line with the Zacks Consensus Estimate of a loss of 30 cents Zacks Rank  Agenus currently carries a Zacks Rank  3  which when combined with a 0 00  ESP  makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions A Stock That Warrants a LookHere is a health care stock that you may want to consider  as our model shows that it has the right combination of elements to post an earnings beat this quarter Amgen Inc    NASDAQ AMGN   is scheduled to report results on Oct 27  The company has an Earnings ESP of  1 08  and a Zacks Rank  3  You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-23,Zacks Investment Research,https://www.investing.com/analysis/agenus-(agen):-what's-ahead-for-the-stock-in-q3-earnings-200160355,200160355
151267,372783,AMGN,Abbott Labs  ABT  Q3 Earnings  What s Ahead For The Stock ,opinion,"Abbott Laboratories   NYSE ABT   is scheduled to report third quarter 2016 results before the opening bell on Oct 19 Last quarter  Abbott Labs delivered a positive earnings surprise of 3 77   Let s see how things are shaping up for this quarter Factors at PlayAbbott Labs operates under four segments   Established Pharmaceuticals Division  EPD   Medical Devices  Diagnostics and Nutrition  Continued outperformance at the Medical Devices and Diagnostics businesses should drive sales in the third quarter The Diagnostics segment should see persistent above market performance in Core Laboratory and Point of Care Diagnostics  The second quarter launch of AlinIQ should also add to the company s top line  Segment sales are anticipated to grow in the mid single digits in the third quarter Sales in the Nutrition business are projected to increase in the low to mid single digit range in the to be reported quarter  Continued uptake of the recently launched products in Pediatric Nutrition should bode well At EPD  sales are expected to grow in the high single digits in the third quarter  Realignment of the division through acquisitions in Latin America and Russia  along with business divestitures in developed markets  has positioned the company advantageously for the coming quarters At Medical Devices  Vascular is expected to grow in the low single digits in the third quarter  while Diabetes sales are expected to increase in the high single digit band  Medical Optics is envisioned to improve in the low to mid single digit range  The Medical Devices segment got a significant boost with the Jul 2016 FDA approval of Absorb bioresorbable stent and TECNIS Symfony intraocular lenses For the third quarter  earnings have been estimated to be in the range of 57 to 59 cents per share  Operational sales growth at the current exchange rates is expected to be in the mid single digits  Third quarter sales are  however  expected to be hurt by negative currency impact of around 1 5  We expect sluggish growth in the Venezuelan market to persist in the third quarter  During the quarterly call  investor focus should remain on the company s performance and sales ramp up of the newly launched products Surprise HistoryAbbott Labs has an impressive track record  The company surpassed estimates in each of the trailing four quarters with an average earnings surprise of 3 11  ABBOTT LABS Price and EPS Surprise
    What Our Model IndicatesOur proven model does not conclusively show that Abbott Labs is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to beat earnings  However  that is not the case here  as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 58 cents Zacks Rank  Abbott Labs has a Zacks Rank  4  Sell   As it is  we caution against stocks with a Zacks Rank  4 and  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are some health care stocks that you may want to consider instead  as our model shows that they have the right combination of elements to post an earnings beat this quarter Johnson  Johnson   NYSE JNJ   is scheduled to report third quarter results on Oct 18  The company has an Earnings ESP of  4 88  and a Zacks Rank  3  You can see  Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  1 79  and a Zacks Rank  3  The company is expected to report results on Oct 26 The Earnings ESP for Bristol Myers Squibb Company   NYSE BMY   is  7 81  and it carries a Zacks Rank  3  The company is scheduled to release earnings on Oct 27 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-12,Zacks Investment Research,https://www.investing.com/analysis/abbott-labs-(abt)-q3-earnings:-what's-ahead-for-the-stock-200158587,200158587
151268,372784,AMGN,J J  JNJ  Likely To Beat Earnings Estimates In Q3 Again,opinion,"Johnson   Johnson   NYSE JNJ    the bellwether of healthcare companies  is scheduled to report third quarter 2016 results on Oct 18  before the opening bell  Last quarter  the company reported a positive earnings surprise of 4 19  
J J has consistently surpassed earnings expectations  The company s earnings beat expectations in each of the last four quarters  with an average positive surprise of 2 88   Will J J be able to beat estimates this time as well 
Let s see how things are shaping up for this announcement 
Why a Likely Positive Surprise  For the third quarter of 2016  our proven model shows that J J is again likely to beat earnings estimates because it has the right combination of two key ingredients  Positive Zacks ESP    which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  4 88   This is a meaningful and leading indicator of a likely positive earnings surprise for the shares  Zacks Rank  3  Hold   Note that stocks with Zacks Ranks  1  Strong Buy    2  Buy  and  3 have a significantly higher chance of beating earnings However  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions  The combination of J J s Zacks Rank  3 and  4 88  ESP makes us reasonably confident of an earnings beat this season 
JOHNSON   JOHNS Price and EPS Surprise   Will the Pharma Segment Continue to Drive Results 
J J s Pharmaceutical segment has been performing well and should continue the same this quarter as well on the back of strong sales of new products as well as core growth products  Robust market growth and increased share should boost sales of Simponi and Stelara  Imbruvica should benefit from increased patient uptake  New cancer treatment  Darzalex  has been off to an encouraging start in the U S  It gained EU approval in May 2016  which should further add to the drug s sales 
Xarelto and Invokana Invokamet should keep up their performance thanks to growth in prescription share  Invega Sustenna should also benefit due to strong sales 
However  Olysio sales will keep declining due to increased competition while Invega continues to face a decline in sales due to generic competition J J continues to assume no biosimilar competition for Procrit or Remicade in the U S  even though the FDA approved a Remicade biosimilar  Inflectra  earlier this April  The company also does not expect generic competition for Zytiga  Risperdal Consta  and Invega Sustenna this year 
The Medical Device business will continue to be affected by soft global market conditions and pricing challenges  The company is working on driving growth in this segment through new product launches and by transforming its commercial models 
Meanwhile  the Consumer business is slowly recovering from the impact of the manufacturing issues that had affected this segment 
The company has been quite active on the deal making front  In Sep 2016  J J announced its intention to acquire Abbott Laboratories    NYSE ABT   Abbott Medical Optics for  4 325 billion in cash  With this proposed acquisition  J J is looking to strengthen its eye care segment  The acquisition is slated to close in the first quarter of 2017 
In Jul 2016  J J acquired privately held company Vogue International in a deal worth  3 3 billion in cash  The acquisition is expected to strengthen its position in hair care and contribute to the profitability of the company s Consumer business 
J J s share buyback program  worth up to  10 billion  should boost the bottom line  Currency movement and operations in Venezuela will remain headwinds 
Stocks That Warrant a Look
J J is not the only company looking up this earnings season  Here are a couple of health care stocks that you may want to consider as our model shows that they too have the right combination of elements to post an earnings beat this quarter 
Amgen Inc    NASDAQ AMGN   is expected to report third quarter results on Oct 26  It has an Earnings ESP of  1 79  and a Zacks Rank  3  You can see  
Bristol Myers Squibb Company   NYSE BMY   has an Earnings ESP of  7 81  and a Zacks Rank  3  It is scheduled to report third quarter results on Oct 27 
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-12,Zacks Investment Research,https://www.investing.com/analysis/j-j-(jnj)-likely-to-beat-earnings-estimates-in-q3-again-200158656,200158656
151269,372785,AMGN,ETFs To Play As Biotech Juggles Election   Earnings ,opinion,Biotech stocks had a tumultuous ride in the first half of 2016  Though the sector bounced back in July and recovered half of the losses  the rally fizzled again in late September due to worries over the upcoming election This is especially true as iShares Nasdaq Biotechnology ETF   which tracks the Nasdaq Biotechnology Index  shed 8 3  over the past one month compared with losses of 3 4  for the broad healthcare fund  XLV  and 0 5  for the broad market fund  SPY  NYSE SPY    The presidential debate so far has confirmed Clinton s lead in the race  The  after the second presidential debate showed Clinton leading Trump by 9 points  read    Inside The SlideThreats of a Hillary Clinton White House have eroded confidence in the sector as she has promised to curb the fast rising prices of specialized drug treatments and has called for increased regulatory scrutiny that will likely pressure profits margins of biotech and drug companies  Just a year ago  Clinton s tweet on  price gouging  led to a blood bath in biotech stocks and eroded about  40 billion in market value in a single trading day Several other factors have added to the weakness  The most notable among them is genomic sequencing company Illumina s slashing of its third quarter revenue guidance last week and its warning of a revenue miss  This news sent its share price down more than 25  in just one day  leading to sell off in the biotech sector Stable OutlookThe steep decline has made biotech stocks cheaper given that IBB is down 21 2  in the year to date time frame  Additionally  the Q3 earnings outlook seems decent for healthcare  which is one of the eight sectors expecting growth  The sector is expected to post 2 7  earnings growth on 7 4  higher revenues  as per the  report  see    Further  investors continue to pour money into biotech ETFs despite the recent weakness  In fact  IBB pulled in over  248 million in capital over the past one month  This suggests that investors still have an appetite for biotech stocks and ETFs  Moreover  the med biomed gene industry has a solid Zacks Rank in the top 41   suggesting that the industry could outperform in the months to come How to Play Given a good earnings trend and uncertainty surrounding the election  biotech will likely see choppy trading in the near term  Investors could capitalize this opportune moment and could play the quick moves with ETFs Trade ElectionClinton maintains her lead over Trump ahead of the third presidential debate to be held on October 19  as per number of   A recent ABC News Washington Post poll showed Clinton ahead of Trump by four percentage points while NBC News Wall Street Journal survey found Clinton s lead much wider at 11   As a result  investors could easily tap this trend with the help of inverse ETFs   Direxion Daily S P Biotech Bear 1x Shares This ETF provides inverse exposure to the performance of the S P Biotechnology Select Industry Index  It has attracted  6 million in AUM and trades in paltry volume of about 1 000 shares on average  Expense ratio comes in at 0 45   The fund added 6 6  over the past one month ProShares UltraShort Nasdaq Biotechnology ETF   AX BIS  This fund seeks two times  2x  inverse exposure to the NASDAQ Biotechnology Index  charging 95 bps in fees  It has amassed  79 4 million in its asset base and trades in a solid volume of more than 316 000 shares per day on average  BIS gained 18 2  over the past one month Direxion Daily S P Biotech Bear 3x Shares Investors having a more bearish view and higher risk appetite could find LABD interesting  This product provides three times  3x  inverse exposure to the S P Biotechnology Select Industry Index  It charges an annual fee of 95 bps and trades in volume of more than 2 4 million shares  The fund has accumulated AUM of  89 4 million and gained 22  in the same period  read    ProShares UltraPro Short Nasdaq Biotechnology Like LABD  this fund also provides three times inverse exposure to the biotech sector but tracks the NASDAQ Biotechnology Index  It charges a similar fee but trades in moderate volume of about 60 000 shares a day on average  ZBIO attracted  11 4 million in AUM and was up nearly 28  in the same period Trade EarningsMost of the biotech companies are expected to come up with earnings surprises that would give a boost to their stock price  In particular  the top player in the industry Amgen  NASDAQ AMGN   has a Zacks Rank  3  Hold  and an Earnings ESP of  1 79   suggesting a reasonable chance of beating the estimate  Additionally  Ultragenyx Pharmaceutical  and Sarepta Therapeutics  have a Zacks Rank  3 each with an Earnings ESP of  1 92  and  0 74   respectively  while Exelixis  has a Zacks Rank  1  Strong Buy  and an Earnings ESP of  15 38  In order to tap this  investors could bet on biotech ETFs cautiously or take advantage of the quick turn in sentiment with the help of leveraged ETFs VanEck Vectors Biotech ETF   CM BBH  This fund offers exposure to 26 large biotechnology corporations by tracking the MVIS US Listed Biotech 25 Index  Amgen occupies the top position in the basket with 12 4  share  The fund has amassed  548 7 million in its asset base while sees moderate trading volume of nearly 75 000 shares a day  It charges a reasonable 35 bps fee per year  The ETF shed 9 5  over the past month and has a Zacks Rank  3 with a High risk outlook SPDR S P Biotech ETF With AUM of  2 4 billion and average daily volume of around 6 7 million shares  XBI is extremely liquid and an easily traded fund  It tracks the S P Biotechnology Select Industry Index and provides exposure to 87 stocks with no concentration issue  Sarepta  Amgen  Ultragenyx and Exelixis collectively account for 11 6  of assets  It charges a relatively low fee of 35 bps a year for the exposure  The ETF lost about 8  in the same time frame and has a Zacks ETF Rank  3 with a High risk outlook  read    ProShares Ultra Nasdaq Biotechnology ETF BIB is an excellent pick for investors seeking to make large profits in a short span  The fund creates a double leveraged long position in the NASDAQ Biotechnology Index while charging 95 bps in fees a year  It has  413 9 million in its asset base and sees solid volume of more than 672 000 shares a day in average  The ETF lost 17 3  over the past one month ProShares UltraPro Nasdaq Biotechnology ETF This product follows the same index as that of BIB but offers three times inverse exposure with the same expense ratio  It has AUM of  33 2 million and average daily volume of 163 000 shares  UBIO was down 25 3  in the same period Direxion Daily S P Biotech Bull 3x Shares This fund provides three times inverse exposure to the S P Biotechnology Select Industry Index  It charges an annual fee of 95 bps and is more liquid than UBIO trading in volume of more than 3 8 million shares  The fund has accumulated AUM of  240 8 million and lost 24  in the same period Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2016-10-16,Zacks Investment Research,https://www.investing.com/analysis/etfs-to-play-as-biotech-juggles-election---earnings-200159134,200159134
151270,372786,AMGN,Can Merck  MRK  Keep The Earnings Streak Alive In Q3 ,opinion,"Merck   Co   Inc    NYSE MRK   is set to report third quarter 2016 results on Oct 25  before the market opens  Last quarter  the company delivered a positive earnings surprise of 1 09  Merck s performance has been pretty impressive  with the company beating earnings expectations consistently  The average earnings beat over the last four quarters is 3 37  MERCK   CO INC Price and EPS Surprise
    Let s see how things are shaping up for this announcement Factors to ConsiderMerck s new products have been doing well  with their performances being driven by products like Keytruda  cancer  and Zepatier  HCV   Strong uptake  launches in new countries and expansion into additional indications should drive Keytruda s sales However  the company will continue to face headwinds in the form of genericization as well as increasing competition and the negative impact of currency exchange Investors will also be focused on the performance of Merck s DPP 4 inhibitor   Januvia   including the effect of pricing pressure and whether it is losing any share to SGLT2 Meanwhile  Remicade will continue to feel the pressure of biosimilar competition in Europe  with sales expected to decline at a rapid pace in the coming quarters  Sluggish growth of the integrase class and continued competitor dynamics in the U S  and Europe will affect Isentress  sales  Cubicin and Nasonex will be under pressure given the loss of exclusivity  Cubicin lost patent protection in Jun 2016 and sales are anticipated to fall significantly However  Merck s cost cutting efforts  share buybacks and other strategic initiatives should support the bottom line  Like the previous quarters  higher R D expenses will be partially offset by lower marketing and administrative expenses Earnings WhispersOur proven model does not conclusively show that Merck is likely to beat earnings this quarter  That is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  The Earnings ESP is  1 02  as the Most Accurate estimate stands at 97 cents while the Zacks Consensus Estimate is pegged higher at 98 cents Zacks Rank  Merck s Zacks Rank  2 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about a positive earnings surprise We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderSome stocks in the large cap healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank include Amgen Inc    NASDAQ AMGN   with an Earnings ESP of  1 79  and carries a Zacks Rank  3  It will be reporting results on Oct 27 Bristol Myers Squibb Company   NYSE BMY   with an Earnings ESP of  4 69  and carries a Zacks Rank  3  It will be reporting results on Oct 27 Novartis AG   NYSE NVS   with an Earnings ESP of  0 84  and a Zacks Rank  3  The company is scheduled to release results on Oct 25  You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-18,Zacks Investment Research,https://www.investing.com/analysis/can-merck-(mrk)-keep-the-earnings-streak-alive-in-q3-200159575,200159575
151271,372787,AMGN,Can Eli Lilly  LLY  Pull A Surprise This Earnings Season  ,opinion,"Eli Lilly and Company   NYSE LLY   is set to report third quarter 2016 results on Oct 25  before the market opens  Last quarter  the company posted a positive earnings surprise of 1 18  The company s performance has been pretty strong so far with earnings surpassing expectations in three of the last four quarters  the average positive surprise being 4 31  LILLY ELI   CO Price and EPS Surprise
    Let s see how things are shaping up for this announcement Factors to ConsiderNew products like Trulicity and Cyramza as well as strong performance by the company s older products like Trajenta  Cialis  Forteo  Humalog Strattera and Erbitux drove significant top line growth in the second quarter of 2016  The animal health business and the diabetes franchise did reasonably well in the quarter  We expect the trend to continue in the third quarter as well  Revenues from other new products like Taltz  Jardiance  Portrazza and Basaglar should also contribute However  sales of Alimta  Cymbalta and Zyprexa are likely to decline further  Lower demand in the U S  due to competitive pressure from immuno oncology agents has mainly hurt Alimta sales  Meanwhile  loss of exclusivity is affecting sales of Cymbalta and Zyprexa Further  we expect marketing  selling and administrative as well as R D expenses to continue to increase  which will again exert pressure on margins Earnings WhispersOur proven model does not conclusively show that Lilly is likely to beat earnings this quarter  That is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  The Earnings ESP for the company is 0 00  as both the Most Accurate estimate as well as the Zacks Consensus Estimate stand at 96 cents Zacks Rank  Lilly s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about a positive earnings surprise Meanwhile  we caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderSome stocks in the large cap healthcare sector that have a positive Earnings ESP and a favorable Zacks Rank include Amgen Inc    NASDAQ AMGN    with an Earnings ESP of  1 79  and a Zacks Rank  3  The company will be reporting results on Oct 27 Bristol Myers Squibb Company   NYSE BMY     slated to report on Oct 27   has an Earnings ESP of  4 69  and a Zacks Rank  3  You can see Novartis AG   NYSE NVS    with an Earnings ESP of  0 84  and a Zacks Rank  3  The company is scheduled to release results on Oct 25 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-18,Zacks Investment Research,https://www.investing.com/analysis/can-eli-lilly-(lly)-pull-a-surprise-this-earnings-season-200159570,200159570
151272,372788,AMGN,Celgene  CELG  Q3 Earnings  What s In Store For The Stock ,opinion,Celgene Corporation   NASDAQ CELG   is scheduled to report third quarter 2016 results on Oct 27  before the opening bell  Celgene s track record has been decent with the company beating earnings estimates on three occasions over the trailing four quarters  Overall  the company has delivered an average positive earnings surprise of 4 10  In the last reported quarter  Celgene reported a positive earnings surprise of 3 23   Let s see how things are shaping up at the company ahead of this announcement Will Core Products Drive Results During its second quarter 2016 call  Celgene has raised its 2016 outlook for both earnings and revenues  buoyed by the performance of core products and operating expense discipline  The company now expects earnings in the range of  5 70  5 75 per share  old guidance   5 60  5 70 per share   while net product sales are anticipated to be approximately  11 billion  old guidance   10 75  11 billion  Key drug  Revlimid  should continue acting as the main growth driver in the third quarter driven by new patient market share gains and increased duration  Meanwhile  the drug s launch in the newly diagnosed multiple myeloma  NDMM  indication across geographies is well on track  While the U S  NDMM launch is resulting in significant share and duration gains  NDMM share continues to grow in the reimbursed markets in Europe with additional reimbursement expected by the end of 2016 Encouraged by the strong uptake  Celgene projects net sales of Revlimid to be approximately  6 8 billion  old guidance  around  6 7 billion  in 2016 Meanwhile  Pomalyst Imnovid continues to grow globally on the back of strong market share and treatment duration  Additionally  securing reimbursement in additional countries  particularly in Japan  should continue to drive the drug s sales in the international markets Commercialization of Otezla  on the other hand  continues to be encouraging with physician and consumer campaigns fuelling brand awareness and patient requests for the drug  particularly in the U S  The company is also working on expanding its footprint in the EU by gaining reimbursement for the drug Abraxane continued to enjoy a leadership position in the U S  for pancreatic cancer in the second quarter  while its share grew in the reimbursed markets outside the U S  Its market share remained same in the breast and lung cancer markets  despite competition from other agents Meanwhile  the company s share buyback program should boost the bottom line On the third quarter call  investors are expected to focus on the company s performance and label expansion efforts  along with updates on the pipeline front  Note that during the quarter  Jul 2016   Celgene decided that it will not seek marketing approval for an expanded label of Revlimid as a maintenance treatment for a certain type of diffuse large B cell lymphoma Earnings WhispersOur proven model does not conclusively show that Celgene is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  Unfortunately  that is not the case here  as elaborated below Zacks ESP  The Earnings ESP for Celgene is  0 76  since the Most Accurate Estimate stands at  1 30  lower than the Zacks Consensus Estimate of  1 31 Zacks Rank  Celgene carries a Zacks Rank  3  You can see  Celgene s Zacks Rank  3  when combined with a negative ESP  makes surprise prediction difficult  Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions CELGENE CORP Price and EPS Surprise    Stocks That Warrant a LookHere are some health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter Novartis AG   NYSE NVS   has an Earnings ESP of  0 84  and carries a Zacks Rank  3  The company is scheduled to report third quarter results on Oct 25 United Therapeutics Corporation   NASDAQ UTHR   has an Earnings ESP of  5 46  and carries a Zacks Rank  3  It is scheduled to announce third quarter results on Oct 27 Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  1 79  and a Zacks Rank  3  The company is slated to release third quarter results on Oct 27 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-19,Zacks Investment Research,https://www.investing.com/analysis/celgene-(celg)-q3-earnings:-what's-in-store-for-the-stock-200159792,200159792
151273,372789,AMGN,Novartis  NVS  Q3 Earnings  Stock To Beat Estimates Again ,opinion,"Novartis AG   NYSE NVS   is scheduled to report third quarter 2016 results on Oct 25 In the last reported quarter  it recorded a positive earnings surprise of 3 39   Overall  Novartis has posted an average negative earnings surprise of 2 38  in the four trailing quarters  Let s see how things are shaping up for this announcement Why a Likely Positive Surprise Our proven model shows that Novartis is likely to beat earnings because it has the right combination of two key ingredients Zacks ESP  The Earnings Surprise Prediction or   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  stands at  0 84   This is very meaningful and a leading indicator of a likely positive earnings surprise for shares Zacks Rank  Novartis carries a Zacks Rank  3  Hold   Note that stocks with a Zacks Rank  1  Strong Buy    2  Buy  and  3 have a significantly higher chance of beating earnings  The sell rated stocks   4 or  5   on the other hand  should never be considered going into an earnings announcement  especially when the company is witnessing negative estimate revisions The combination of Novartis  favorable Zacks Rank and positive ESP makes us reasonably confident of a positive earnings beat on Oct 25 Factors to Impact the QuarterNovartis operates under three segments  Innovative Medicines  Pharmaceuticals   Alcon and Sandoz  Generics   Although the company expects 2016 to be a transformative year  it has been facing challenging conditions over the past few quarters Innovative Medicines is expected to continue being impacted by generic competition due to the genericization of Gleevec Glivec in the U S  The company s ophthalmologic division  Alcon  continues to face challenges due to a slowdown in cataract equipment placements and weak sales of intraocular lenses  Going forward  we expect these factors to dampen sales at the segment  On the other hand  Novartis  generic arm  Sandoz  in its efforts to strengthen the biosimilars portfolio and pipeline  should offset weakness in Alcon Last quarter  the company s heart failure drug  Entresto  obtained a strong Class I recommendation in both the U S  and the EU as per the heart failure treatment guidelines  These guidelines establish Entresto as the standard of care for symptomatic patients with heart failure with reduced ejection fraction  HFrEF   The company s decision to increase spending on Entresto to build a U S  primary care field force and add incremental medical support will drive expenses in the third quarter  Entresto sales are expected to be approximately  200 million in 2016 In the third quarter  unfavorable movements in foreign exchange rates are estimated to impact sales by 1  and earnings by 2  Meanwhile  investor focus should remain on the sales ramp up of newly launched drugs Entresto  Glatopa and Cosentyx  Main growth drivers at the oncology segment will include Jakavi  Tasigna  Promacta Revolade  Tafinlar Mekinist and the improved formulation of Exjade  Multiple sclerosis drug  Gilenya  should also perform well NOVARTIS AG ADR Price and EPS Surprise
    Stocks to ConsiderHere are some other health care stocks that you may want to consider  as our model shows that they too have the right combination of elements to post an earnings beat this quarter Amgen Inc    NASDAQ AMGN   is expected to report results on Oct 26  The company has an Earnings ESP of  1 79  and a Zacks Rank  3   The Earnings ESP for ImmunoGen  Inc    NASDAQ IMGN   is  5 41  and it carries a Zacks Rank  3  The company is scheduled to release earnings on Oct 28 Infinity Pharmaceuticals  Inc    NASDAQ INFI   has an Earnings ESP of  5 81  and a Zacks Rank  1  The company is expected to report quarterly numbers on Nov 3 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-19,Zacks Investment Research,https://www.investing.com/analysis/novartis-(nvs)-q3-earnings:-stock-to-beat-estimates-again-200159789,200159789
151297,372813,AMGN,Momenta To Regain Rights To Humira Biosimilar From Shire,opinion,"Momenta Pharmaceuticals Inc    NASDAQ MNTA   announced that Shire plc   NASDAQ SHPG   has exercised its right to terminate their collaboration agreement for the development and commercialization of M923  a biosimilar version of AbbVie Inc  s   NYSE ABBV   flagship drug  Humira  adalimumab  Currently  M923 is in a phase III study for the treatment of chronic plaque psoriasis  The study is evaluating the safety  efficacy and immunogenicity of the candidate in comparison to Humira  Top line data from the study are expected in late 2016 As per terms of the agreement  the collaboration will end in 12 months of the termination notice  Shire will continue to fund the program till termination  We remind investors that Shire had acquired the rights to M923 following the acquisition of Baxalta Incorporated in Jun 2016 MOMENTA PHARMA Price
    Humira is approved for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis  juvenile idiopathic arthritis  psoriatic arthritis  ankylosing spondylitis  Crohn s disease  ulcerative colitis and plaque psoriasis  In 2015  Humira had raked in worldwide sales of  14 billion Note that several pharma and biotech companies are involved in the development of biosimilars  Late last week  Amgen Inc  s   NASDAQ AMGN   Amjevita  adalimumab atto   a biosimilar of Humira  was approved in the U S  across all eligible indications of the reference product   Read more    Going forward  we expect investor focus to remain on the successful development of M923 by Momenta  Investors should also keep an eye on further updates related to the termination of the agreement with Shire Both Momenta and Shire carry a Zacks Rank  3  Hold   You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-27,Zacks Investment Research,https://www.investing.com/analysis/momenta-to-regain-rights-to-humira-biosimilar-from-shire-200156032,200156032
151298,372814,AMGN,Pfizer To Sell Hospira Infusion Unit To ICU Medical For  1B,opinion,Pfizer  Inc   NYSE PFE   has entered into a definitive agreement to sell its Hospira infusion systems business to medical device maker ICU Medical Inc    NASDAQ ICUI   for  1 billion in cash and stock  Shares of ICU Medical were up almost 15  on Thursday With the addition of Hospira infusion systems business which includes IV pumps  solutions  and devices  ICU Medical will become a leading pure play infusion therapy company  The deal extends the company s global presence with direct operations in more than 20 countries  Hospira Infusion Systems business is presently ICU Medical s largest single customer Per terms of the deal  Pfizer will receive approximately  400 million in freshly issued ICU Medical shares and have a 16 6  stake in the company  The purchase consideration also includes 600 million in cash Additionally  as long as Pfizer keeps a 10  stake in ICU Medical s common equity  it will have the right to nominate one director to ICU Medical s board of directors PFIZER INC Price     The transaction is expected to close in the first quarter of 2017  subject to regulatory approvals  Pfizer bought Hospira infusion systems business as part of its Sep 2015 acquisition of Hospira  a leading sterile injectable drugs and biosimilars manufacturer  for about  17 billion The Hospira acquisition has significantly expanded Pfizer s sterile injectable and biosimilar capabilities  This takeover provided Pfizer with Hospira s lucrative biosimilar portfolio of both marketed and pipeline assets  Biosimilars of Herceptin  Rituxan MabThera  Avastin and AbbVie Inc  s   NYSE ABBV   Humira are in phase III development  while biosimilars of Amgen Inc  s   NASDAQ AMGN   Neupogen and Neulasta are in phase I  Pfizer believes that the market for biosimilars is huge and can grow to  17  20 billion by 2020 Hospira added  1 13 billion to Pfizer s top line in the last reported quarter   second quarter of 2016 While Pfizer carries a Zacks Rank  3  Hold   ICU Medical has a Zacks Rank  2  Buy   You can see the  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-06,Zacks Investment Research,https://www.investing.com/analysis/pfizer-to-sell-hospira-infusion-unit-to-icu-medical-for-$1b-200157736,200157736
151328,372844,AMGN,Novartis Reports Positive Phase II Data On Migraine Drug,opinion,Novartis AG   NYSE NVS   announced results from a phase II study on migraine candidate AMG334 Data from the study were presented at the fifth European Headache and Migraine Trust International Congress  EHMTIC  in Glasgow  Scotland The study enrolled 667 patients who had a mean baseline of approximately 18 migraine days per month  The study showed that AMG334 led to a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine NOVARTIS AG ADR Price and Consensus     Moreover  a significantly higher number of patients receiving monthly subcutaneous administration of AMG334 70mg or 140mg  experienced a reduction of 50  or more in the number of monthly migraine days  compared with placebo We note that Novartis is developing AMG334 in collaboration with Amgen  Inc    NASDAQ AMGN    Under the collaboration agreement dated 2015  the companies agreed to jointly develop and commercialize treatments in the field of Alzheimer s disease and migraine  Amgen retained commercialization rights for AMG334 in the U S   Canada and Japan  while Novartis owns the rights to Europe and the rest of world Meanwhile  Novartis expects results from phase III studies on AMG 334 in episodic migraine later this year Another migraine candidate being developed under this collaboration is AMG301  currently in a phase I study  We expect investors to keep an eye on the approval of new drugs and label expansion of existing ones at Novartis  given that the company has been facing stiff generic competition for some of its key drugs like Diovan and Gleevec Novartis currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Ligand Pharmaceuticals   NASDAQ LGND   and Pacira Pharmaceuticals   NASDAQ PCRX    Both these stocks sport a Zacks Rank  1  Strong Buy   You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-09-15,Zacks Investment Research,https://www.investing.com/analysis/novartis-reports-positive-phase-ii-data-on-migraine-drug-200153982,200153982
151329,372845,AMGN,Guide To American Funds American Mutual F1 Fund  AMFFX ,opinion,"American Funds American Mutual F1 Fund     a Zacks Rank  2  Buy  as incepted in February 1950 and is managed by Capital Research and Management Company  The objective of AMFFX is to provide for the balanced accomplishment of three objectives current income  capital growth and conservation of principal  AMFFX invests primarily in common stocks  securities convertible into common stocks  non convertible preferred stocks  U S  government securities  bonds rated A or better and cash 

	This Large Value product  as of the last filing  allocates their fund in five major groups  Large Value  Intermediate Bond  Large Growth  Foreign Stock and Precious Metal  Further  as of the last filing  Verizon Communications Inc  NYSE VZ   Amgen Inc  NASDAQ AMGN  and Texas Instruments  NASDAQ TXN  Inc were the top holdings for AMFFX 

	The American Funds American Mutual F1 fund  managed by   carries an expense ratio of 0 66   Moreover  AMFFX requires a minimal initial investment of  250 

	AMFFX has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 10 51  and 5 year 12 85   To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds   

	AMFFX s performance  as of the last filing  when compared to funds in its category was in the top 8  over the past 1 year  in the top 28  over the past 3 years  and in the 42  over the past 5 years 

Want key mutual fund info delivered straight to your inbox 

	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ",2016-09-15,Zacks Investment Research,https://www.investing.com/analysis/guide-to-american-funds-american-mutual-f1-fund-(amffx)-200153946,200153946
151330,372846,AMGN,Amgen  AMGN  Parsabiv Gets Positive CHMP Opinion In EU,opinion,"Amgen  Inc    NASDAQ AMGN   announced that the European Medicines Agency s Committee for Medicinal Products for Human Use  CHMP  has rendered a positive opinion for its secondary hyperparathyroidism  SHPT  candidate Parsabiv  etelcalcetide  Amgen is looking to get Parsabiv approved in the EU for the treatment of secondary hyperparathyroidism in adult chronic kidney disease  CKD  patients on dialysis  Amgen had submitted the Marketing Authorisation Application for Parsabiv last September The marketing authorization and the positive CHMP opinion were based on encouraging data from three phase III trials  including two placebo controlled trials in more than 1 000 patients  and a head to head study comparing Parsabiv to Sensipar  All the three trials met their primary endpoints We note that Parsabiv is also under review in the U S  In August  Amgen received a Complete Response Letter  CRL  from the FDA for its New Drug Application  NDA  for Parsabiv in the indication  The company is currently reviewing the letter and expects to meet with the agency later this year to discuss the next step AMGEN INC Price and Consensus
    Parsabiv became part of Amgen s portfolio following its Jul 2012 acquisition of privately held KAI Pharmaceuticals SHPT  a chronic and serious condition  is estimated to affect two million individuals in the world who receive dialysis  Approximately 88  of dialysis patients and 79  of patients on hemodialysis are expected to develop SHPT In a separate press release  Amgen and partner UCB S  A   announced that data from the phase III FRAME study were published in the New England Journal of Medicine and were also presented at a medical meeting in Atlanta  Results from the FRAME study  which evaluated Amgen s romosozumab for the treatment of postmenopausal women with osteoporosis  were announced this February  In July  Amgen and UCB submitted a Biologic License Application to the FDA seeking an approval in this indication based on the data from the study Amgen currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Geron Corporation   NASDAQ GERN   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    Both these stocks sport a Zacks Rank  1  Strong Buy   You can see the  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-18,Zacks Investment Research,https://www.investing.com/analysis/amgen-(amgn)-parsabiv-gets-positive-chmp-opinion-in-eu-200154333,200154333
151331,372847,AMGN,As Humira Alternative Gets FDA Approval  Is Abbvie In Trouble ,opinion,"On Friday  the  to a Humira  adalimumab  alternative called Amjevita  adalimumab atto    Amjevita is one of nine programs in Amgen s   NASDAQ AMGN   pipeline of biosimilar drugs   Biosimilars are a relatively new frontier in the biotech space  and Amjevita is just the fourth one to receive FDA approval 
Biosimilars are not the same as interchangeable products such as generic drugs   Rather  a biosimilar is a biological product that gets approved if it is shown to be highly similar to an already approved product   This means that there should not be meaningful differences in clinical studies that measure the drug s safety  purity  and potency 
Humira vs  Amjevita
In the years following Humira s approval in 2002  the FDA has expanded the number of conditions that it can be used to treat   Now that Amjevita has been given the green light by the FDA  it can be used for most of the conditions which Humira treats   Amjevita is approved to treat multiple conditions afflicting adults  such as moderate to severely active rheumatoid arthritis  active psoriatic arthritis  active ankylosing spondylitis  moderate to severely active Crohn s disease  moderate to severely active ulcerative colitis  and moderate to severe plaque psoriasis   Amjevita is also approved to treat moderately to severely active polyarticular juvenile idiopathic arthritis in patients who are four years of age and older 
Is Abbvie   NYSE ABBV   in Trouble 
Biosimilars are supposed to cost less than the original product which they are based off of  but there is no clear indication of how much Amjevita will cost when it is launched   On the other hand  Humira often costs about  2000 per month   Amjevita is expected to be a cheaper option than Humira  so Abbvie could see some of its dominant share in the arthritis market contract when Amgen s new drug is launched 
This could be a major concern for Abbvie  who saw Humira revenues account for over  14 billion of its total sales   22 8 billion  in 2015   Humira is ABBV s top product  and revenues generated from the drug are close to ten times higher than any of the company s other products   In the first six months of fiscal 2016  Humira generated 62 3  of Abbvie s total sales   Since Friday s announcement of Amjevita s approval  Abbvie s stock has dropped by about 1 3  
Bottom Line
Since a direct competitor is set to take on Humira in the future  Abbvie s long term cash flows will become more difficult to forecast   If you are invested in ABBV for the long run  you may want to reassess your position as more news comes out about when and how much Amjevita will cost 
Amgen looks poised to take advantage of the biosimilars market that has emerged in recent history   As mentioned earlier  the company has nine biosimilar programs in its pipeline   If you are looking to cap in on this technology which is meant to reduce drug costs for patients  then Amgen looks like a solid stock to bet on over the long run 
The Zacks Rank is a truly marvelous trading tool   Our ranking system has beaten the S P 500  yielding an average return of 25  per year for the last 29 years   Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-09-26,Zacks Investment Research,"https://www.investing.com/analysis/as-humira-alternative-gets-fda-approval,-is-abbvie-in-trouble-200155639",200155639
151332,372848,AMGN,Top Trade Ideas For The Week September 26  2016  Bonus Idea,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Amgen  NASDAQ AMGN   moved higher out of a 2011 consolidation rising for more than 3 years before running out of steam  The move increased the stock by more than 240  from a low of 50 to over 170  Since December 2014 the stock price has done nothing  Or at least that is how it appears 
When an Andrews  Pitchfork is applied a different story emerges  With this view the stock has settled at the Lower Median Line and started riding it higher again  The run higher from the late June low had it moving toward the Median Line and it seems to have bogged down between the two for now  This shows a positive trend higher 
Looking left into 2015 sees the current pause is coming at prior resistance  With a touch there in August it had a shallow pullback and then jumped back last week  A push through would give a target to 200 
The momentum indicators support more movement higher too  The RSI is bullish and rising while the MACD is turning back up  avoided a cross down  It has resistance above at 177 and then just free air above  Support lower comes at 167 and 164 before 152 and 145  Short interest is low at 1 1  and the company is expected to report earnings next October 27th  The stock currently pays a  4 00 dividend  a 2 29  yield 
Options open interest in between now and that report show a bias to the upside  The October 28 Expiry options show light open interest  November options show an upward bias but also light open interest  In January 2017 the picture is mixed 
Amgen

Trade Idea 1  Buy the stock on a move over 177 with a stop at 167 
Trade Idea 2  Buy the stock on a move over 177 and add a October 28 Expiry 175 165 Put Spread   3 00  for protection and sell a November 180 Covered Call   3 00  for a free Collar 
Trade Idea 3  Buy the November 165 175 180 Call Spread Risk Reversal  20 cent credit  
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which heading into the last week of September sees the Equity Indexes looking strong  especially on the longer timeframe 
Elsewhere look for Gold to move higher short term in consolidation while Crude Oil consolidates  The US Dollar Index also looks to continue to move sideways while US Treasuries are biased higher  The Shanghai Composite looks to drift higher while Emerging Markets are biased to the downside in the short term 
Volatility looks to remain at abnormally low levels keeping the bias higher for the equity index ETF s SPY  NYSE SPY   IWM and QQQ  Their charts show strength in moving higher at the end of the week  especially in the longer timeframe  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2016-09-26,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-september-26,-2016:-bonus-idea-200155470",200155470
151343,372859,AMGN,Merck s Lung Cancer Drug Keytruda Under Priority Review ,opinion,"Merck   Co   Inc  s   NYSE MRK   supplemental Biologics License Application  sBLA  for its anti PD 1 therapy  Keytruda has been accepted for priority review by the FDA The company is looking to expand the label into the first line treatment of patients with advanced non small cell lung cancer  NSCLC  whose tumors express PD L1 With the FDA granting priority review  a response should be out by Dec 24  2016  Additionally  the FDA granted Breakthrough Therapy designation to the drug for this indication  The sNDA submissions were based on positive data from pivotal phase 3 KEYNOTE 024 study  which showed that Keytruda led to significant improvement in survival in patients with high PD L1 expression compared to chemotherapy  The drug is also under review in the EU for this indication Price and Consensus
    Keytruda is currently approved in the U S  for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy  ipilimumab  and  if BRAF V600 mutation positive  a BRAF inhibitor  It is also approved for the treatment of metastatic NSCLC patients whose tumors express PD L1 as determined by an FDA approved test and whose disease has progressed on or after platinum containing chemotherapy  It is also approved for the first line treatment of patients with unresectable or metastatic melanoma advanced melanoma in patients refractory to Yervoy Keytruda is being studied for more than 30 forms of cancers including melanoma  NSCLC  head and neck  bladder  gastric  colorectal  esophageal  breast  ovarian  Hodgkin lymphoma  non Hodgkin lymphoma  multiple myeloma  nasopharyngeal  and others  Merck is collaborating with several companies including Amgen  Inc    NASDAQ AMGN    Incyte  GlaxoSmithKline plc   NYSE GSK   and Pfizer Inc    NYSE PFE   among others separately for the evaluation of Keytruda in combination with other regimens Keytruda also has Breakthrough Therapy Designation for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma  cHL   specific patients with advanced melanoma  advanced non small cell lung cancer  NSCLC   and advanced colorectal cancer Merck currently carries a Zacks Rank  3  Hold   You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-07,Zacks Investment Research,https://www.investing.com/analysis/merck's-lung-cancer-drug-keytruda-under-priority-review-200152521,200152521
151347,372863,AMGN,5 Biotech Stocks That Are Broker Favorites,opinion,"It s been a pretty rough year for the biotech sector with the NASDAQ Biotechnology index tumbling 18 7  over the last 12 months and 12 3  year to date  YTD   Factors like a changing competitive scenario and more importantly  the drug pricing issue  have been weighing on the sector The drug pricing issue has heated up in recent times given the price hikes taken by Mylan   NASDAQ MYL   for its life saving combination product EpiPen  Democratic Presidential candidate Hillary Clinton recently announced a health care plan that will address the excessive price hikes of treatments that have been around for years and also reaffirmed her earlier broader plan  announced last September  with the aim to lower drug prices for all Americans However  the sector s fundamentals remain strong   strong pipelines  innovative treatments  impressive results  growing demand for drugs especially for rare to treat diseases  an aging population and increased health care spending should support growth  With Pfizer   NYSE PFE   recently announcing its intention to acquire cancer focused biopharma company Medivation for approximately  14 billion  expectations are high that mergers and acquisitions  M As  will pick up pace while licensing deals will continue Picking Winners Could Be a ChallengeAnyone interested in biotech stocks will know that it could be challenging to pick winners in this  high risk   high returns  industry which is constantly growing and changing  Companies which hit the bull s eye become overnight success stories with shares even doubling or tripling on positive news  However  negative outcomes have an equally strong effect on the shares and failure may very well spell doom for these companies In such a scenario  let s take a look at stocks preferred by analysts who have a deep knowledge and understanding of the industry and its companies  We have zeroed in on 5 stocks with the help of our    these stocks have been given a Strong Buy or Buy rating by 80  or more brokers and sport a favorable Zacks Rank  1  Strong Buy  or  2  Buy  Ligand Pharmaceuticals Incorporated   NASDAQ LGND    San Diego  CA based Ligand is a biotech company whose business model is based on developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure  The company is focused on the development and licensing of biopharmaceutical assets  Ligand s Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties  The company s partners include big names like Novartis and Amgen  NASDAQ AMGN   One of Ligand s partners  Retrophin  recently reported positive mid stage data on a treatment being developed for a rare kidney disorder that often leads to end stage renal disease  Read more    Ligand is a Zacks Rank  1 stock with 80  Strong Buy or Buy broker rating 
Price and Consensus   AVEO Pharmaceuticals  Inc    NASDAQ AVEO    Cambridge  MA based AVEO is focused on bringing targeted treatments for cancer and other areas of unmet medical need to market  The company s lead pipeline candidate  tivozanib  is being evaluated for the treatment of renal cell cancer and other types of cancer This Zacks Rank  2 stock enjoys 100  Strong Buy or Buy broker rating 
Price and Consensus Fate Therapeutics  Inc    NASDAQ FATE    San Diego  CA based Fate is focused on the development of programmed cellular immunotherapies for cancer and immune disorders  The company recently announced a partnership with Memorial Sloan Kettering Cancer Center for the development of off the shelf T cell product candidates using engineered pluripotent cell lines Fate is also a Zacks Rank  2 stock with 100  Strong Buy or Buy broker rating  You can see  
Price and Consensus   ImmunoCellular Therapeutics  Ltd    NYSE IMUC    ImmunoCellular is a Los Angeles based clinical stage company focused on developing immune based therapies for the treatment of brain and other types of cancer  The company s lead pipeline candidate  ICT 107  is in a late stage study   ICT 107 is a patient specific  dendritic cell based immunotherapy targeting multiple tumor associated antigens on glioblastoma stem cells ImmunoCellular is a Zacks Rank  2 stock with 100  Strong Buy or Buy broker rating 
Price and Consensus   Argos Therapeutics  Inc    NASDAQ ARGS    Durham  NC based Argos is an immuno oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform  Lead pipeline candidate  AGS 003  is in a late stage study for the treatment of metastatic renal cell carcinoma Argos is also a Zacks Rank  2 stock with 100  Strong Buy or Buy broker rating 
Price and Consensus
Zacks  Best Investment Ideas for Long Term ProfitToday you can gain access to long term trades with double and triple digit profit potential rarely available to the public  Starting now  you can look inside our stocks under  10  home run and value stock portfolios  plus more  Want a peek at this private information ",2016-09-12,Zacks Investment Research,https://www.investing.com/analysis/5-biotech-stocks-that-are-broker-favorites-200153238,200153238
151370,372886,AMGN,Regeneron Sanofi Present Positive Phase III Praluent Data,opinion,Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Sanofi   NYSE SNY   announced detailed results from a completed placebo controlled phase III study  ODYSSEY ESCAPE  which evaluated its PCSK9 inhibitor  Praluent  in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia  HeFH   who required regular weekly or bi weekly apheresis treatment Data from the study showed that Praluent  when added to existing therapy  reduced low density lipoprotein cholesterol  LDL C  roughly 50  from baseline in comparison to a 2  increase in the placebo arm  In addition  Praluent significantly reduced the need for apheresis treatment by 75  compared to placebo  thereby meeting the primary endpoint of the study Other key results of the study indicated that throughout the study  patients on Praluent witnessed significant reductions in their LDL C starting week 6  55  greater reduction compared to placebo   continuing until week 18  46  greater reduction compared to placebo   On the safety front  a similar proportion of patients experienced adverse events in both the Praluent and placebo arms  76  for both groups  ODYSSEY ESCAPE study data were presented at the European Society of Cardiology  ESC  Congress and were concurrently published in the European Heart Journal Considering that apheresis therapy is an invasive  time consuming and expensive treatment for some of the most difficult to treat patients with very high cholesterol unable to achieve their cholesterol lowering goals on any other therapy  the phase III study data are encouraging  These results indicate that Praluent can used for overall management of patients with HeFH undergoing regular apheresis therapy  with the potential to minimize the need for difficult apheresis treatments REGENERON PHARM Price     Meanwhile  Praluent s potential to demonstrate cardiovascular  CV  benefit in patients who have experienced an acute coronary syndrome is being evaluated in the ongoing ODYSSEY OUTCOMES study Amgen Inc    NASDAQ AMGN   also presented data on its PCSK9 inhibitor  Repatha  at the ESC Congress  Data presented showed that Repatha consistently reduced LDL C in patients across CV risk subgroups or with HeFH We note that sales of both Repatha and Praluent are yet to pick up with the drugs facing a difficult access and reimbursement environment among other factors  Nevertheless  positive CV outcomes data should help boost the drugs  sales  Amgen expects to report top line data from its Repatha outcomes study in the first quarter of 2017 Regeneron is a Zack Rank  2  Buy  stock  while Sanofi carries a Zack Rank  4  Sell   ANI Pharmaceuticals  Inc    NASDAQ ANIP   is a well placed stock in the health care sector  sporting a Zacks Rank  1  Strong Buy  ,2016-08-28,Zacks Investment Research,https://www.investing.com/analysis/regeneron-sanofi-present-positive-phase-iii-praluent-data-200150581,200150581
151371,372887,AMGN,Top Trade Ideas For The Week Of August 29  2016  Amgen,opinion,"Amgen  NASDAQ AMGN  has had a long term trend sideways in a broad range since late 2014  In the intermediate term it broke to a higher range at the end of July and has been consolidating in the short term in a narrow range since then  That consolidation is occurring at the top of the broad long term range  The spike down in late 2015 touched a 38 2  retracement of the long move higher from 2011 
As it spins its wheels there  the RSI is pulling back in the bullish zone while the MACD is rising and positive  Notice that the recent consolidation started when the price hit the upper Bollinger Bands   After two years of sideways grind  is it ready to move higher again 
There is resistance at 176 and then nothing to stop it  Support comes lower at 170 and 165 before 150  Short interest is low at 1 1   It does carry a big 2 33  dividend yield  but just went ex dividend August 15th 
Options chains show open interest spread this week from 165 to 175 on the put side and then from 170 to 180 on the call side  The monthly September options chain shows open interest spread on the put side at 160  170 and 175  On the call side it is tighter and large  from 175 to 182 50 
October monthly options show a long tail building from 120 to biggest open interest at 170 on the put side  while the call side again is more focused and big  from 170 to 180  Finally looking at January 2017 chains  the first beyond the next earnings report October 27th  shows a distribution with a peak at 145 on the put side and 170 on the call side  No big bets to move out of the range 
Trade Idea 1  Buy the stock on a move over 177 with a stop at 168 
Trade Idea 2  Buy the September October 175 Call Calendar   2 30  
Trade Idea 3  Buy the September January 175 Call Calendar   7 70  
The first trade gives the upside with a stop that takes effect should it fall below the current flag  The second looks for the open interest in September to hold it near 175 until then and allows upside participation after  The third trade is similar to the second but allows for a sale of calls in October  November and December as well to lower the cost of a longer term trade 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday  Heading into the unofficial last week of summer ahead of the Labor Day holiday the equity markets are tired  consolidating at their highs and even pulling back 
Elsewhere look for gold to continue lower while crude oil extends to the upside  The US Dollar Index looks to continue higher short term in its broad range while US Treasuries are biased lower in consolidation  The Shanghai Composite and Emerging Markets are both looking like they will continue lower in the short run  more damaging for the Emerging Markets than the Chinese 
Volatility looks to remain subdued but back at more normal levels  keeping the bias higher for the equity index ETFs SPDR S P 500  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   Their charts have lost all their strength though and suggest they may continue to pause or pullback in the short run 
Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the blog  please see my  page for my full disclaimer ",2016-08-29,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-august-29,-2016:-bonus-idea-200150525",200150525
151372,372888,AMGN,The Medicines Co  Offers Update On Dyslipidemia Programs,opinion,The Medicines Company   NASDAQ MDCO   came up with important announcements related to its pipeline  The company provided an update on its dyslipidemia programs   MDCO 216  which contains APoA 1 Milano  and PCSK9si  PCSK9 synthesis inhibitor  MDCO 216 Misses Early Termination CriteriaThe Medicines Co  reported that a planned  interim analysis of the first 40 randomized patients  who completed treatment in the MILANO PILOT study on MDCO 216  has been reviewed by an Independent Data Monitoring Committee  IDM Committee   Based on the protocol and pre defined criteria  the IDM Committee recommended the continuation of the MILANO PILOT study The 40 patient data from the MILANO PILOT study failed to meet the pre defined  upper statistical boundary efficacy threshold for early termination  Since only a limited number of patients were involved in the first interim analysis  summary data received by the company from the IDM Committee are inconclusive at this moment We note that MILANO PILOT is a proof of concept  double blind  placebo controlled  randomized study that aims to improve cardiovascular outcomes by reducing plaque burden in patients with atherosclerotic disease  The Medicines Co  has completed enrollment of the planned 120 patients  Data from the study will be presented at the American Heart Association  AHA  Scientific Sessions in Nov 2016 MEDICINES CO Price     PCSK9 Synthesis Inhibitor Study Fully EnrolledConcurrently  The Medicines Co  announced that it has completed enrollment in the ORION 1 phase II study on PCSKsi  also known as ALN PCSsc  ahead of schedule  An interim analysis with a day 90 follow up for all patients will be conducted and presented at the AHA Scientific Sessions this November  The company anticipates the day 180 follow up for all patients to be completed  analyzed and presented by the year end ORION 1 is a placebo controlled  double blind  randomized study that is being conducted on single or multiple subcutaneous injections of PCSK9si in patients with atherosclerotic cardiovascular disease  ASCVD  or ASCVD risk equivalents  like diabetes and familial hypercholesterolemia  and elevated LDL C despite maximum tolerated doses of LDL C lowering therapies The Medicines Co  believes that PCSK9si is a first in class experimental treatment that acts by turning off PCSK9 synthesis in the liver in contrast to anti PCSK9 monoclonal antibodies that bind to PCSK9 in blood  Currently  there are two PCSK9 inhibitors available in the market   Amgen Inc  s   NASDAQ AMGN   Repatha and Regeneron Pharmaceuticals  Inc    NASDAQ REGN   Sanofi s   NYSE SNY   Praluent The Medicines Co  currently carries a Zacks Rank  3  Hold   Regeneron is a better ranked stock in the healthcare sector  with a Zacks Rank  2  Buy  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-08-30,Zacks Investment Research,https://www.investing.com/analysis/the-medicines-co.-offers-update-on-dyslipidemia-programs-200151050,200151050
151374,372890,AMGN,Novartis  NVS  Gets FDA Nod For Biosimilar Version Of Enbrel,opinion,"Novartis AG   NYSE NVS   received a major boost when its generic arm  Sandoz obtained FDA approval for Erelzi  the biosimilar version of Amgen s   NASDAQ AMGN   blockbuster drug Enbrel  etanercept  The FDA has approved Erelzi for all indications stated in Enbrel s label   rheumatoid arthritis  RA   plaque psoriasis  PsO   psoriatic arthritis  PsA   ankylosing spondylitis  AS  and polyarticular juvenile idiopathic arthritis  JIA  However  the decision was not unexpected as the FDA s Arthritis Advisory Committee  AAC  had unanimously voted  20 0  in favor of Erelzi s approval in Jul 2016 We remind investors that Erelzi is Sandoz s second biosimilar to be approved through the FDA biosimilars pathway established under the Biologics Price Competition and Innovation Act In Sep 2015  Sandoz launched Zarxio in the U S   the biosimilar version of Amgen s blockbuster drug  Neupogen  Zarxio became the first FDA approved biosimilar to be launched in the country  Zarxio was followed by the FDA approval for Pfizer s   NYSE PFE   Inflectra  a biosimilar version of Remicade in Apr 2016  It was approved for multiple indications including AS  arthritis of the spine   PsA and chronic severe PsO among others Meanwhile  a regulatory application for Erelzi was accepted by the European Medicines Agency in 2015 and is currently under review NOVARTIS AG ADR Price
    Sandoz is a global leader in biosimilars and currently markets three products   Omnitrope  a human growth hormone  Binocrit  an erythropoiesis stimulating agent  and Zarxio   in the U S  Backed by its deep pipeline of biosimilars  the company plans to make 11 regulatory filings over the 2015 2017 time frame  of which six applications have already been submitted  Further  Sandoz plans to launch five biosimilars of major oncology and immunology biologics across key geographies by 2020 Enbrel generated sales of  2 9 billion in the first half of 2016  up 16  from the year ago period  The entry of biosimilar will adversely impact Amgen s sales  although both the companies are presently involved in a lawsuit for the same Novartis currently carries a Zacks Rank  3  Hold   Investors interested in the healthcare sector may consider Actelion Ltd   OTC ALIOF   with a Zacks Rank  1  Strong Buy  Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-08-31,Zacks Investment Research,https://www.investing.com/analysis/novartis-(nvs)-gets-fda-nod-for-biosimilar-version-of-enbrel-200151107,200151107
151395,372911,AMGN,Kite Pharma  KITE  Q2 Loss Wider But Focus Is On KTE C19,opinion,"Kite Pharma  Inc    NASDAQ KITE   reported a loss of  1 31 per share in the second quarter of 2016  wider than the Zacks Consensus Estimate of a loss of  1 28 per share and the year ago loss of 48 cents 
Second quarter revenues came in at  4 8 million  slightly above the Zacks Consensus Estimate of  4 7 million and up 8 9  from the year ago period 
Revenues consisted entirely of the amortization of deferred collaboration revenues related to the  60 million upfront payment received under the collaboration agreement with Amgen Inc    NASDAQ AMGN   in the first quarter of 2015 KITE PHARMA INC Price  Consensus and EPS Surprise   KTE C19 Year End Filing Plan Remains on TrackWhile Kite s research and development expenses shot up 185 5  from the year ago period to  47 4 million in the reported quarter  general and administrative expenses were  23 5 million  up 140 6  from the year ago period Kite continues to expect cash burn of  235  250 million in 2016 including both operating expenses and about  20 million of capital expenditures but excluding the impact of business development activities With no approved product in its portfolio at the moment  focus remains on KTE C19  Kite s lead pipeline candidate  which is currently in the pivotal phase of a phase I II study  ZUMA 1  in patients with refractory diffuse large B cell lymphoma  DLBCL  including primary mediastinal B cell lymphoma  PMBCL  and transformed follicular lymphoma  TFL   All these are types of aggressive non Hodgkin s lymphoma  NHL   Interim results from the phase II part of this study are expected late in the third quarter of 2016  Depending on these results  the company expects to file for approval in late 2016 and potentially launch KTE C19 next year Kite is also evaluating KTE C19 in a phase II study  ZUMA 2  in patients with relapsed refractory mantle cell lymphoma  MCL  and in two additional pivotal studies  phase I II  for acute lymphoblastic leukemia  ALL    ZUMA 3 for adult ALL and ZUMA 4 for pediatric ALL  with results from all these studies due in 2017 Kite plans to move KTE C19 into a second series of studies for additional indications and earlier lines of therapy in DLBCL patients in 2017  KTE C19 studies will be initiated in Europe later this year A phase Ib II combination study evaluating KTE C19 plus Genentech s Tecentriq  atezolizumab  in patients with chemorefractory DLBCL is scheduled to commence later in the third quarter Investor focus will remain on KTE C19 interim results and the company s Investor Day on Oct 18  2016 where an update will be provided on the ZUMA studies  other pipeline programs as well as an overview of commercial and manufacturing preparations 
Kite is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the healthcare sector include Cambrex Corporation   NYSE CBM   and Heska Corporation   NASDAQ HSKA    Both are Zacks Rank  1  Strong Buy  stocks Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-09,Zacks Investment Research,https://www.investing.com/analysis/kite-pharma-(kite)-q2-loss-wider-but-focus-is-on-kte-c19-200146888,200146888
151415,372931,AMGN,The Zacks Analyst Blog Highlights  Facebook  Amgen  Whole Foods And Groupon,opinion,"For Immediate Release

	Chicago  IL   July 28  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include   Facebook  NASDAQ FB      Amgen  NASDAQ AMGN      Whole Foods      and Groupon     

	Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Wednesday s Analyst Blog  

Facebook  FB  Owns Q2 Earnings on Huge Beat  Plus Groupon Blasts Off 

	Plenty to chew on in the after market round of Q2 earnings releases Wednesday  with Facebook      which has been priced to near perfection  delivering on that very high bar  We also see results for Amgen     Whole Foods    and Groupon     hitting the tape this afternoon 

	Facebook just posted a monster Q2 earnings report  trouncing analyst estimates on both top and bottom lines  Earnings of 76 cents per share  accounting for stock based compensation and other BNRI  beat the Zacks consensus of 62 cents  Quarterly sales reached  6 44 billion  far ahead of the  6 01 billion expected and up 59  year over year  Daily active users  DAU   monthly active users  MAU  and average revenue per user were all better than expected  Mobile revenue was as well  and went up 81  year over year  Shares shot up 6 6  immediately after the news  
	Groupon shares shot up 24  on a strong Q2 in both sales and loss per share  The bottom line figure of  0 06 cents  accounting for stock based compensation and other BNRI  improved on the Zacks consensus of  0 07 per share  Revenues of  756 million easily beat the  712 million expected  The company also revised guidance upward for fiscal 2016  
	Biotech major Amgen topped expectations on both Q2 sales and earnings  The maker of Enbrel and Neulasta beat earnings expectations of  2 74 by 10 cents  Revenues of  5 69 billion beat the Zacks consensus estimate of  5 60 billion  The company also raised guidance for fiscal 2016 from  11 20 per share to  11 40 per share  Shares have slipped about a quarter post report  but AMGN stock was up roughly 18  over the past month 
	Whole Foods met top and bottom line Q3 estimates exactly  37 cents per share on  3 7 billion in revenues  Gross margins were slightly better than expected  but a same store sales read of  2 6  was worse than expected  The company expects same store sales to go positive next quarter  though guided a penny lower for Q4 earnings  

	Want more insight on Q2 earnings  Check out Zacks Director of Research Sheraz Mian s latest 

	Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days   

	Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

	Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-07-27,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-facebook,-amgen,-whole-foods-and-groupon-200144704",200144704
151416,372932,AMGN, Company News For July 29  2016,opinion,"  Shares of Celgene Corporation  NASDAQ CELG     advanced 2 9  after reporting second quarter adjusted earnings of  1 28 per share  higher than the Zacks Consensus Estimate of  1 24


	  MasterCard Incorporated s    shares rose 2 4  after declaring second quarter earnings per share of  0 96  beating the Zacks Consensus Estimate of  0 90


	  Shares of Harley Davidson  Inc     increased 0 9  after announcing second quarter earnings per share of  1 55  outpacing the Zacks Consensus Estimate by a couple of cents


	  Amgen  NASDAQ AMGN  Inc s    shares gained 0 4  after posting second quarter earnings of  2 84 per share  better than the Zacks Consensus Estimate of  2 74",2016-07-28,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-july-29,-2016-200144973",200144973
151417,372933,AMGN,Ligand  LGND  Beats Q2 Earnings  Revenues Up Y Y,opinion,La Jolla  CA based Ligand Pharmaceuticals Incorporated   NASDAQ LGND   is a biotechnology company with a focus on drug discovery  reformulation and partnering  Ligand s Captisol formulation technology has allowed it to enter into several licensing deals with companies like Amgen  NASDAQ AMGN  and Novartis among others and generate royalties  Ligand generates revenues in the form of royalties  license and milestone payments and sale of Captisol material In Jan 2016  Ligand acquired OMT  Inc  in a deal valued at about  178 million  The acquisition has added an antibody generating platform  OmniAb  to the company s technology portfolio In this scenario  investor focus remains on the company s major pipeline assets apart from the usual top and bottom line numbers Ligand has an impressive earnings track record with the company surpassing expectations in each of the last four quarters delivering an average positive surprise of 44 33  Currently  Ligand has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings  Ligand s second quarter 2016 earnings surpassed expectations    the company reported EPS of 30 cents  including stock based compensation expense  while our consensus called for EPS of 22 cents Revenues  Revenues in the reported quarter increased 6  from the year ago period to  19 5 million Key Stats  Royalty revenues increased from the year ago period reflecting higher royalties from Promacta and Kyprolis The company continues to expect total revenues of  115 million    119 million in 2016 and earnings per share of  3 41    3 46  The Zacks Consensus Estimate for earnings is  2 72 per share on revenues of  116 8 million Second half total revenues are expected in the range of  66 million    70 million  while earnings per share are expected in the range of  1 94    1 99 LIGAND PHARMA B Price   Check back later for our full write up on this LGND earnings report later Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-08-03,Zacks Investment Research,"https://www.investing.com/analysis/ligand-(lgnd)-beats-q2-earnings,-revenues-up-y-y-200146102",200146102
151428,372944,AMGN,Celgene  CELG  Q2 Earnings  Can The Stock Pull A Surprise ,opinion,"Celgene Corporation   NASDAQ CELG   is scheduled to report second quarter 2016 results on Jul 28  before the market opens  Last quarter  the company reported a positive earnings surprise of 12 38  
Celgene s track record has been mixed with the company beating earnings estimates on two occasions while missing in one and posting in line results in another  Overall  the company has delivered an average positive surprise of 3 29   Let s see how things are shaping up for the company this quarter 
Will Strong Product Sales Continue to Drive Q2 Results 
At the time of reporting first quarter 2016 results  Celgene raised the low end of its 2016 guidance range for both earnings and revenues with the company s products performing well  The company anticipates earnings in the range of  5 60  5 70 per share  old guidance   5 50  5 70 per share   Net product sales for 2016 are expected in the range of  10 75  11 0 billion  old guidance   10 5  11 0 billion  
Key drug  Revlimid  should continue to remain the main growth driver in the second quarter as well  Increases in duration of use and market share gains in the U S   and ongoing global launches in the newly diagnosed multiple myeloma indication should continue to be an important driver of growth and help the drug contribute significantly to the top line  Reimbursement across EU and Japan should further support revenues  For 2016  Revlimid sales are anticipated to be approximately  6 7 billion  at the high end of the previous guidance of  6 6  6 7 billion 
Meanwhile  Celgene continues to expect Pomalyst Imnovid and Otezla to generate sales greater than  1 billion in 2016  Pomalyst Imnovid growth should continue to be strong in 2016 on the back of the first full year of product sales in Japan and increase in duration of treatment along with market share gains across the world  On the first quarter call  the company noted that Pomalyst Imnovid holds a strong global position in relapsed refractory myeloma 
Commercialization of Otezla  on the other hand  continues to be encouraging with physician and consumer campaigns driving increases in brand awareness and patient requests for the drug  particularly in the U S  On the first quarter call  the company mentioned that Otezla continues to lead all other therapies in new to brand share  with approximately 40  of both the psoriasis and psoriatic arthritis markets  The company is also working on expanding its footprint in the EU by gaining reimbursement for the drug 
However  the company had lowered Abraxane s outlook for 2016  Abraxane sales are expected in the range of  950 million to  1 billion  previous guidance  greater than  1 billion  due to a highly competitive U S  market for lung and breast cancer therapy 
Meanwhile  Celgene s share buyback program should boost the bottom line 
On the second quarter call  investor focus is expected to remain on the company s performance and label expansion efforts along with pipeline updates 
Earnings Whispers
Our proven model does not conclusively show that Celgene is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  Unfortunately  that is not the case here  as elaborated below 
Zacks ESP  The Earnings ESP for Celgene is 0 00  since the Most Accurate estimate stands in line with the Zacks Consensus Estimate of  1 25 
Zacks Rank  Celgene carries a Zacks Rank  3  which when combined with an ESP of 0 00   makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions CELGENE CORP Price and EPS Surprise   Stocks That Warrant a Look
Here are a few health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  1 10  and a Zacks Rank  3  It is scheduled to report second quarter results on Jul 27 
United Therapeutics Corporation   NASDAQ UTHR   has an Earnings ESP of  2 51  and a Zacks Rank  3  It is scheduled to report second quarter results on Jul 28 
Sanofi   NYSE SNY   has an Earnings ESP of  1 33  and a Zacks Rank  3  It is scheduled to report second quarter results on Jul 29 ",2016-07-24,Zacks Investment Research,https://www.investing.com/analysis/celgene-(celg)-q2-earnings:-can-the-stock-pull-a-surprise-200144007,200144007
151429,372945,AMGN,Bristol Myers  BMY   Stock To Beat Earnings Again In Q2,opinion,"Bristol Myers Squibb Company   NYSE BMY   is scheduled to report second quarter 2016 results on Jul 28  before the opening bell  Last quarter  the company reported a positive earnings surprise of 12 12  Bristol Myers has been seen to consistently beat earnings expectations  The company s earnings surpassed expectations in each of the last four quarters  with an average positive surprise of 27 67   Will Bristol Myers be able to beat estimates this time around as well  Let s see how things are shaping up for this announcement 
Factors Driving Q2 ResultsBristol Myers  high profile immuno oncology drug  Opdivo  continues to demonstrate strong performance across three tumors  It is the most prescribed drug for new patients in lung cancer  The renal cell carcinoma indication has also seen strong early adoption  In the melanoma indication  robust performance of the Opdivo Yervoy  Yervoy is Bristol Myers  other immuno oncology drug  regimen is contributing to growth in both Opdivo and Yervoy Opdivo should continue to contribute to top line growth on the back of continued approvals and label expansions globally  Pricing and reimbursement in additional EU countries should further aid revenues  Other oncology drugs like Sprycel should also continue to perform well in the second quarter of 2016  Meanwhile  multiple myeloma drug  Empliciti  has been off to an encouraging start in the U S  It gained EU approval during the second quarter  May 2016  Apart from cancer drugs  anticoagulant Eliquis  performance should continue to accelerate growth across the key markets globally where its uptake has been strong across cardiology  hospitals  and in the community setting  Eliquis is well on its way to become the number one novel anticoagulant globally  The rheumatoid arthritis drug  Orencia  also contributes significantly to the company s top line With key products performing well  Bristol Myers raised both its 2016 earnings and revenue guidance driven by strong trends across the business at the time of announcing first quarter 2016 results  For 2016  the company expects earnings in the range of  2 50 to  2 60 per share  old guidance   2 30 to  2 40 per share   On the other hand  Bristol Myers expects worldwide revenues to increase in the low double digit range in 2016  Previously  the company had guided worldwide revenues to increase in the mid single digit range However  the company expects the HIV and HCV franchises to remain under competitive pressure for the remainder of the year During the second quarter  Bristol Myers continued to actively build its partnership portfolio by striking a couple of immuno oncology focused collaborations 
On the second quarter call  investor focus is expected to remain on the company s performance and updated possible revision in the guidance along with an update on business development activities 
Why a Likely Positive Surprise 
For the second quarter of 2016  our proven model also shows that Bristol Myers is likely to beat earnings estimates because it has the right combination of two key ingredients 
Positive Zacks ESP    which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  1 49   This is a meaningful and leading indicator of a likely positive earnings surprise for the shares 
Zacks Rank  1  Strong Buy   Note that stocks with a Zacks Ranks  1   2  Buy  or  3  Hold  have a significantly higher chance of beating earnings  However  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
The combination of Bristol Myers  Zacks Rank  1 and  1 49  ESP makes us reasonably confident of an earnings beat this season BRISTOL MYERS Price and EPS Surprise   Other Stocks That Warrant a Look
Bristol Myers is not the only company looking up this earnings season  Here are some other health care stocks that you may want to consider as our model shows that they too have the right combination of elements to post an earnings beat this quarter 
Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  1 10  and a Zacks Rank  3  It is scheduled to report second quarter results on Jul 27 
United Therapeutics Corporation   NASDAQ UTHR   has an Earnings ESP of  2 51  and a Zacks Rank  3  It is scheduled to report second quarter results on Jul 28 
Sanofi   NYSE SNY   has an Earnings ESP of  1 33  and a Zacks Rank  3  It is scheduled to report second quarter results on Jul 29 ",2016-07-24,Zacks Investment Research,https://www.investing.com/analysis/bristol-myers-(bmy):-stock-to-beat-earnings-again-in-q2-200143999,200143999
151433,372949,AMGN,Biotech Earnings Battle  Gilead  GILD  Vs  Amgen  AMGN  ,opinion,"In this video  we take a look at two of the biggest and most important companies in the biotech space  Both are reporting earnings this week  and given the volatile nature of the sector lately  it will definitely be in investors  best interest to see how two of the top dogs in this market fare in their quarterly reports 
After all  the space is likely to face some political risks with the upcoming election  while there are definitely valuation concerns  And given a top 30  industry rank  there are going to be plenty of stocks to buy in this space  but also a few to avoid too 
First  let s take a quick look at Gilead Sciences  NASDAQ GILD   a California based giant with a market cap over  100 billion  The stock currently has a Zacks Rank  2  buy   while it has an  A  Score for its VGM  so fundamentals are pretty impressive  However  it did just miss estimates to break its impressive streak  while growth rates aren t that inspiring  making this a real mixed bag heading into earnings GILEAD SCIENCES Price  Consensus and EPS Surprise   
Next up we have Amgen  NASDAQ AMGN   another large cap company which reports this week  The company is riding an impressive streak at earnings season which includes beats meets in every quarter since early 2013  It is seeing solid growth projections  but it has been stuck in a narrow range in recent months  Add in a Zacks Rank  3  hold  and a  B  VGM score  and some of its fundamentals aren t quite as good as GILD heading into the report AMGEN INC Price  Consensus and EPS Surprise   
The biotech industry is promising overall and it currently has an Industry Rank in the top 30   so either could be intriguing  though we discuss the better pick in the video  Make sure to watch for the selection  as well as more insights on both of these companies  including a more thorough discussion of their charts  And if you d like more information on how to trade earnings reports  make sure to check out our podcast below ",2016-07-25,Zacks Investment Research,https://www.investing.com/analysis/biotech-earnings-battle:-gilead-(gild)-vs.-amgen-(amgn)-200143982,200143982
151440,372956,AMGN,Facebook  FB  Owns Q2 Earnings On Huge Beat  Plus GRPN  GPRO And More,opinion,"Plenty to chew on in the after market round of Q2 earnings releases this Wednesday  with Facebook   NASDAQ FB    which has been priced to near perfection  delivering on that very high bar  We also see results for Amgen   NASDAQ AMGN    Whole Foods   NASDAQ WFM   and Groupon   NASDAQ GRPN   hitting the tape this afternoon Facebook just posted a monster Q2 earnings report  trouncing analyst estimates on both top and bottom lines  Earnings of 76 cents per share  accounting for stock based compensation and other BNRI  beat the Zacks consensus of 62 cents  Quarterly sales reached  6 44 billion  far ahead of the  6 01 billion expected and up 59  year over year  Daily active users  DAU   monthly active users  MAU  and average revenue per user were all better than expected  Mobile revenue was as well  and went up 81  year over year  Shares shot up 6 6  immediately after the news  Groupon shares shot up 24  on a strong Q2 in both sales and loss per share  The bottom line figure of  0 06 cents  accounting for stock based compensation and other BNRI  improved on the Zacks consensus of  0 07 per share  Revenues of  756 million easily beat the  712 million expected  The company also revised guidance upward for fiscal 2016  Biotech major Amgen topped expectations on both Q2 sales and earnings  The maker of Enbrel and Neulasta beat earnings expectations of  2 74 by 10 cents  Revenues of  5 69 billion beat the Zacks consensus estimate of  5 60 billion  The company also raised guidance for fiscal 2016 from  11 20 per share to  11 40 per share  Shares have slipped about a quarter post report  but AMGN stock was up roughly 18  over the past month Whole Foods met top and bottom line Q3 estimates exactly  37 cents per share on  3 7 billion in revenues  Gross margins were slightly better than expected  but a same store sales read of  2 6  was worse than expected  The company expects same store sales to go positive next quarter  though guided a penny lower for Q4 earnings  
Want more insight on Q2 earnings  Check out Zacks Director of Research Sheraz Mian s latest",2016-07-27,Zacks Investment Research,"https://www.investing.com/analysis/facebook-(fb)-owns-q2-earnings-on-huge-beat,-plus-grpn,-gpro-and-more-200144496",200144496
151447,372963,AMGN,Amgen And Daiichi Sankyo Team Up For Biosimilars In Japan,opinion,"Amgen Inc    NASDAQ AMGN   announced an exclusive agreement with Daiichi Sankyo Company  Limited for the commercialization of nine biosimilars in Japan including biosimilars of AbbVie s   NYSE ABBV   Humira and Roche Holding  SIX ROG  AG s   OTC RHHBY   Avastin and Herceptin 
The deal with Daiichi Sankyo will see Amgen taking responsibility for the development and manufacturing of the biosimilars  While Daiichi Sankyo will file for marketing approval and will also be responsible for the distribution and commercialization in Japan  Amgen will have a limited right to co promote the products  However  Amgen will hold all additional distribution and commercialization rights for the biosimilar programs outside Japan  Specific financial terms of the agreement were undisclosed 
We note that the FDA s Arthritis Advisory Committee has voted in favor of an approval of Amgen s ABP 501  a biosimilar version of Humira  The recommendation did not come as a surprise given the favorable briefing documents that were released by the FDA ahead of the panel meeting  The advisory panel s opinion will now be reviewed by the FDA  with a final response on the approval status of ABP 501 expected by Sep 25 AMGEN INC Price   The approval of ABP 501 would be a huge boost for Amgen considering the commercial potential of Humira and the fact that Amgen itself is facing biosimilar competition for a few of its key products  like Neupogen   However  patents covering Humira should protect the drug from competition through at least 2022 
Biosimilar threats facing Amgen have gotten more intense with the FDA s Arthritis Advisory panel backing Sandoz s biosimilar version of Amgen s blockbuster drug  Enbrel  Sandoz is Novartis AG s   NYSE NVS   generic arm 
The race to develop biosimilars is heating up with a host of pharmaceutical and biotech companies in fierce competition 
Amgen is a Zacks Rank  3  Hold  stock  Roche is a better ranked stock in the health care sector  carrying a Zacks Rank  2  Buy  ",2016-07-13,Zacks Investment Research,https://www.investing.com/analysis/amgen-and-daiichi-sankyo-team-up-for-biosimilars-in-japan-200141853,200141853
151448,372964,AMGN,Novartis  Enbrel Biosimilar Gets FDA Panel Recommendation ,opinion,Novartis AG   NYSE NVS   announced that the FDA s Arthritis Advisory Committee has recommended an approval of the company s proposed biosimilar of Amgen s   NASDAQ AMGN   blockbuster drug  Enbrel  etanercept  The committee voted unanimously  20 0  for an approval of a biosimilar version of Enbrel for all five indications of the reference product  The indications include rheumatoid arthritis  RA   plaque psoriasis  PsO   psoriatic psoriasis  PsA   ankylosing spondylitis  AS  and polyarticular juvenile idiopathic arthritis  JIA  Novartis  generic arm  Sandoz  presented data from a global development program comprising analytical  pre clinical and clinical studies  which demonstrated biosimilarity to the reference product  These studies included four comparative pharmacokinetic  PK  studies and a confirmatory efficacy and safety similarity study in patients with chronic PsO We note that the FDA generally takes the recommendation of its advisory committees into account when it reviews the applications  but is not bound to follow it Meanwhile  the European Medicines Agency  EMA  accepted Sandoz s Marketing Authorisation Application  MAA  in Dec 2015 for its biosimilar version of Enbrel  which sought an approval of the product for the same indications as the reference product NOVARTIS AG ADR Price   We are encouraged by the company s efforts to develop its biosimilars portfolio  Sandoz currently markets three biosimilars   Omnitrope  a human growth hormone  Binocrit  an erythropoiesis stimulating agent  and Zarxio   in the U S  Sandoz also has a deep pipeline with several biosimilars in late stage development  including assets in the fields of immunology and oncology We believe investors should watch out for an approval of new drugs and label expansion of existing ones at Novartis as the company has been facing stiff generic competition for some of its key drugs like Diovan and Gleevec Besides  its oncology drugs are facing competition from immuno oncology therapies  Further  Alcon is witnessing a decline in surgical equipment sales in the U S  and emerging markets Novartis currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Roche Holdings   OTC RHHBY   and Johnson   Johnson   NYSE JNJ    All three carry a Zacks Rank  2  Buy  ,2016-07-14,Zacks Investment Research,https://www.investing.com/analysis/novartis'-enbrel-biosimilar-gets-fda-panel-recommendation-200141924,200141924
151454,372970,AMGN,Gilead  GILD  Stock Likely To Beat This Earnings Season,opinion,"Gilead Sciences Inc    NASDAQ GILD   is scheduled to report second quarter 2016 results on Jul 25  after the market closes  Last quarter  the company had missed expectations with a negative earnings surprise of 1 65  
Gilead otherwise has an impressive track record  with earnings  The company s earnings surpassed expectations in three of the last four quarters  with an average positive surprise of 6 39   Will this biotech major be able to beat estimates this time  Let s see how things are shaping up for this announcement 
Factors Likely to Impact Q2 Results
In the first quarter of 2016  Gilead s hepatitis C virus  HCV  franchise  consisting of blockbuster drugs Sovaldi and Harvoni  registered both sequential  12 2   and year over year  5 6   decline  The year over year decline was mainly due to lower sales of Harvoni in the U S   down 53 3  year over year to  1 4 billion   reflecting lower patient starts and the full quarter impact of higher commercial rebates  which were entered into during the first quarter of 2015 
The sequential decline was primarily due to lower revenues in the U S  and Japan  However  Sovaldi had recorded growth in the first quarter of 2016  Performance of the HCV franchise was also disappointing in Europe 
Nevertheless  Gilead noted on the first quarter call that there was an uptick in new patients in the first quarter of 2016 and the company expects new patient starts to remain consistent through 2016  The company expects its HCV business to remain strong and sustainable 
Good news came in for the HCV franchise during second quarter 2016  Gilead was successful in its efforts to expand its HCV franchise  Late last month  the company gained FDA approval for Epclusa  the first all oral  pan genotypic  single tablet regimen for the treatment of adults with genotype 1 6 chronic HCV  It is also approved for use in certain other patient populations  Subsequently  Epclusa gained EU approval earlier this month 
As far as the HIV business is concerned  Genvoya  the company s first tenofovir alafenamide  TAF  based single tablet regimen for the treatment of HIV 1 infection uptake  has been strong both in the U S  and EU since the drug s launch in Nov 2015  Genvoya may soon be among the most prescribed products for patients new to treatment 
While Descovy was launched both in the U S  and EU during the quarter  Odefsey gained approval in the EU  Both Descovy and Odefsey are the two other TAF based regimens in the company s HIV franchise  TAF based regimens are expected to drive the HIV franchise s sales 
Given the launch of these TAF based regimens  the company expects switches out of tenofovir disoproxil fumarate  TDF  based single tablet regimens into the TAF regimens to grow significantly  The company at the same time believes it can maintain its ability to retain switch patients  implying fewer patients to switch from Gilead s TDF containing regimens to non Gilead products   The company noted on the first quarter call that 82  of Genvoya s prescriptions came from switches while 49  of the switches have come from Stribild  another HIV 1 drug belonging to Gilead  
Other antivirals and products are expected to perform well  For 2016  Gilead continues to expect net product sales in the range of  30  31 billion 
Meanwhile  Gilead is actively pursuing partnerships acquisitions to strengthen its product portfolio as well as pipeline  During the quarter  the company acquired Nimbus Apollo  Inc  and its acetyl CoA carboxylase inhibitor program in a deal worth up to  1 2 billion 
On the second quarter call  investors should keep an eye on the guidance based on the company s performance while deals acquisitions are also something to look out for 
Why a Likely Positive Surprise For the second quarter of 2016  our proven model also shows that Gilead is likely to beat earnings estimates because it has the right combination of two key ingredients Positive Zacks ESP    which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  6 91   This is a meaningful and leading indicator of a likely positive earnings surprise for the shares Zacks Rank  2  Buy   Note that stocks with Zacks Ranks of  1  Strong Buy    2 and  3  Hold  have a significantly higher chance of beating earnings  However  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
The combination of Gilead s Zacks Rank  2 and  6 91  ESP makes us reasonably confident of an earnings beat this season GILEAD SCIENCES Price and EPS Surprise   Other Stocks That Warrant a Look
Gilead is not the only company looking up this earnings season  Here are a couple of other health care stocks that you may want to consider as our model shows that they too have the right combination of elements to post an earnings beat this quarter 
Eli Lilly and Co    NYSE LLY   has an Earnings ESP of  1 18  and a Zacks Rank  3  The company is scheduled to release second quarter results on Jul 26 
Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  1 10  and a Zacks Rank  3  It is scheduled to report second quarter results on Jul 27 
Bristol Myers Squibb Co    NYSE BMY   has an Earnings ESP of  1 49  and a Zacks Rank  1  It is scheduled to report second quarter results on Jul 28 ",2016-07-21,Zacks Investment Research,https://www.investing.com/analysis/gilead-(gild)-stock-likely-to-beat-this-earnings-season-200143370,200143370
151457,372973,AMGN,Eli Lilly  LLY  May Beat Q2 Earnings  Will The Stock Gain ,opinion,Eli Lilly and Company   NYSE LLY   is set to report second quarter 2016 earnings results on Jul 26 before the market opens  The company s performance has been pretty good with earnings surpassing expectations in three of the last four quarters with an average positive earnings surprise of 9 42  during this period  However  Lilly delivered a negative earnings surprise of  2 35  in the first quarter of 2016 Let s see how things are shaping up for the company this quarter What Our Model IndicatesOur proven model shows that Lilly is likely to beat estimates this quarter because it has the right combination of two key ingredients Positive Zacks ESP  Earnings Surprise Prediction or   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  1 18   This is very meaningful and a leading indicator of a likely positive earnings surprise for shares Zacks Rank  3  Hold   Note that stocks with Zacks Ranks of  1   2 and  3 have a significantly higher chance of beating earnings  The sell rated stocks   4 and  5  should never be considered going into an earnings announcement The combination of Lilly s Zacks Rank  3 and  1 18  ESP makes us very confident in looking for a positive earnings beat on Jul 26 LILLY ELI   CO Price and EPS Surprise   Factors at PlayProducts like Trajenta  Cialis  Forteo  Strattera  Erbitux  and animal health products should drive growth while revenues from new products like Cyramza  Trulicity  Jardiance  Portrazza and Basaglar will increase  The company had upped its outlook earlier this year to reflect currency rates and a lower tax rate resulting from the recognition of a discrete tax benefit in the first quarter Meanwhile  the modification of the company s agreement with Incyte Corporation   NASDAQ INCY   provides Lilly with an upfront payment of  35 million that will be recognized as other income in the second quarter  The takeback of North American rights for Erbitux will also boost sales Investors will also be focused on the performance of recently launched Taltz for the treatment of moderate to severe plaque psoriasis However  price revisions in Japan  effective Mar 1  will impact sales  Other headwinds include generic competition being faced by drugs like Alimta and Cialis in certain territories  Meanwhile  Humalog sales declined in the U S  in the first quarter  Moreover  Alimta may continue to experience some softening in later lines of therapy  second line and beyond  reflecting the launch of Cyramza in the second line setting as well as competition from immuno oncology agents Stocks That Warrant a LookHere are some health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Gilead Sciences Inc    NASDAQ GILD   has an Earnings ESP of  6 91  and carries a Zacks Rank  2  It will be reporting results on Jul 25 Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  1 10  and carries a Zacks Rank  3  It will be reporting results on Jul 27 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-21,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-(lly)-may-beat-q2-earnings:-will-the-stock-gain-200143222,200143222
151471,372987,AMGN,5 Best Performing Biotech Stocks Of June,opinion,"The biotech sector has been under a bit of a cloud  with stocks feeling the pressure of macroeconomic issues as well as sector specific issues like increasing political and media focus on high price tags for new drugs  a changing competitive scenario  and mixed earnings reports The performance of this once impressive sector has been dismal in 2016 with the NASDAQ Biotechnology index declining 22 1  in the first half of 2016 and 7 5  in Jun 2016 MEDICAL BIOMED GENETICS Industry Price IndexBut not all biotech stocks had a bad run in June  Here is a look at 5 biotech stocks that managed to beat the downward trend and shot up more than 20  in the month of Jun 2016  All are Zacks Rank  2  Buy  stocks Ontario  Canada based Transition Therapeutics Inc    NASDAQ TTHI   shot up 70 9  in June  The company has agreed to be acquired by OPKO Health  Inc  in an all stock deal worth about  60 million  Read more     This clinical stage biotech company is focused on advancing novel therapeutics for central nervous system  CNS   metabolic diseases and androgen deficiency indications TRANSITN THERAP Price   Opexa Therapeutics  Inc    NASDAQ OPXA   saw its shares gain 27 1  in June  The company is developing personalized immunotherapies for major illnesses including multiple sclerosis  MS  as well as other autoimmune diseases such as neuromyelitis optica  NMO   Lead pipeline candidate  Tcelna  is a personalized T cell immunotherapy that is in mid stage development for the treatment of secondary progressive MS OPEXA THERAPEUT Price   Austin  TX based XBiotech  Inc    NASDAQ XBIT   is focused on the discovery  development and commercialization of therapeutic antibodies based on its True Human proprietary technology  The company s shares gained 32 9  in June  XBiotech is currently seeking EU approval for its lead pipeline candidate  Xilonix   approval could come as early as the fourth quarter of 2016 XBIOTECH INC Price   Anavex Life Sciences Corp  s   NASDAQ AVXL   shares surged almost 37  in June  The clinical stage company is focused on the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer s disease  other CNS diseases  pain and different types of cancer 
Lead pipeline candidate  ANAVEX 2 73  is being developed to treat Alzheimer s disease and other CNS diseases  including rare diseases  such as Rett syndrome  In Jun 2016  the FDA granted orphan drug status to ANAVEX 2 73 for the treatment of infantile spasms  Read more     ANAVEX 2 73 already had orphan drug status for the treatment of Rett syndrome ANAVEX LIFE SCI Price   Xencor  Inc  s   NASDAQ XNCR   shares were up 34 9  in June  The Monrovia  CA based company develops engineered monoclonal antibodies for the treatment of asthma and allergic diseases  autoimmune diseases and cancer  Xencor has quite a few partnerships including with big names like Amgen  NASDAQ AMGN   Merck  NYSE MRK   Alexion and Novo Nordisk  CO NOVOb  among others  In Jun 2016  the clinical stage company signed up with another big player    Novartis    for the development and commercialization of a couple of pipeline candidates focused on cancer 
The deal will see Xencor getting an upfront payment of  150 million and sharing development costs with Novartis  Importantly  Xencor could earn up to  2 41 billion in the form of milestone payments as well as royalties  Read more    XENCOR INC Price    
Will the Sector Bounce Back Given the overall performance of the sector so far in 2016  the big question weighing on investor s minds is will the sector bounce back We note that interest in biotech stocks remains high despite the poor performance  Shares should be driven by factors like mergers and acquisitions  positive pipeline and regulatory updates and strong earnings results Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-07-05,Zacks Investment Research,https://www.investing.com/analysis/5-best-performing-biotech-stocks-of-june-200140078,200140078
151474,372990,AMGN,Amgen s Kyprolis Gains Approval In EU For Label Expansion,opinion,"Amgen Inc    NASDAQ AMGN   received encouraging news with the European Commission  EC  approving a variation to the company s marketing authorization for Kyprolis to include its use in combination with dexamethasone alone for the treatment of adults with multiple myeloma who have received at least one prior therapy 
EU approval was largely expected as the Committee for Medicinal Products for Human Use had issued a favorable opinion this May 
We note that this is the second approval for Kyprolis by the EC in less than a year  In Nov 2015  Kyprolis had gained approval in the EU in combination with Celgene Corporation s   NASDAQ CELG   Revlimid  lenalidomide  and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy  based on the ASPIRE study data 
The latest approval in the EU follows the FDA approval of a supplemental new drug application for Kyprolis earlier this year  based on the ENDEAVOR study data  In Jan 2016  Kyprolis  accelerated approval was converted to full approval in the U S  In addition  the FDA expanded Kyprolis  label to allow its use as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy 
We remind investors that Kyprolis became a part of Amgen s portfolio following its acquisition of Onyx  The drug has registered total sales of  512 million in 2015  Kyprolis  label expansion would expand the patient population and increase its commercial potential significantly 
Other approved drugs for the treatment of multiple myeloma include the recently approved AbbVie Inc    NYSE ABBV   Bristol Myers Squibb Company s   NYSE BMY   Empliciti among others ",2016-07-05,Zacks Investment Research,https://www.investing.com/analysis/amgen's-kyprolis-gains-approval-in-eu-for-label-expansion-200140327,200140327
151475,372991,AMGN,Amgen s Repatha Gains FDA Approval For New Dosing Option,opinion,Amgen Inc    NASDAQ AMGN   announced that the FDA has approved a new  monthly single dose administration option for its PCSK9 inhibitor  Repatha  The Repatha Pushtronex system  an on body infusor with a prefilled cartridge  is a hands free device intended to provide 420 mg in a single dose Approval makes Repatha the first and only PCSK9 inhibitor to have a monthly single dose delivery option We note that the recommended dosage of Repatha is either 140 mg every two weeks or 420 mg once monthly  The 420 mg monthly dosing requires three 140 mg injections to be administered consecutively within 30 minutes using the single use prefilled autoinjector  SureClick  or syringe AMGEN INC Price   The latest approval will now provide patients with an additional and convenient dosing option Per Amgen s press release  the device has been priced at  14 100 annually  wholesale acquisition cost   similar to the twice weekly administration  The company expects to launch the Pushtronex system in the U S  early next month We are pleased with Repatha becoming the first and only one with a monthly single dose administration  which could most likely give the company an advantage over its competitors We note that Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Sanofi   NYSE SNY   are also looking to seek FDA approval for the once monthly dosing regimen of their PCSK9 inhibitor  Praluent However  sales of both Repatha and Praluent are yet to pick up with the drugs facing a difficult access and reimbursement environment among other things  Nevertheless  positive cardiovascular outcomes data once available should help boost these drugs  sales Amgen expects to report top line data from its Repatha outcomes study in the first quarter of 2017  Moreover  Amgen received a favorable ruling in its patent infringement lawsuit against Regeneron and Sanofi related to PCSK9 inhibitors in Mar 2016 Amgen is a Zacks Rank  3  Hold  stock  Innoviva  Inc    NASDAQ INVA   is a better ranked stock in the health care sector sporting a Zacks Rank  1  Strong Buy  ,2016-07-11,Zacks Investment Research,https://www.investing.com/analysis/amgen's-repatha-gains-fda-approval-for-new-dosing-option-200141315,200141315
151477,372993,AMGN,3 Top Rated Healthcare Mutual Funds To Invest In,opinion,Investors often rely on the healthcare sector to safeguard their investments  This is because demand for healthcare services does not vary so much with market conditions and investments in the sector provide sufficient protection to the capital invested  Many pharma companies also generate regular dividends  Companies that pay consistent dividends are financially stable and generate consistent cash flows irrespective of market conditions  Mutual funds are perfect choices for investors looking to enter this sector since they possess the advantages of wide diversification and analytical insight Below we share with you three   Each has earned a  and is expected to outperform its peers in the future  Investors can   their Zacks Rank and past performance Live Oak Health Sciences Fund  invests a large portion of its assets in equity securities of health companies that are involved in the research  development  production  or distribution of products or services related to health care  medicine  or the life sciences  LOGSX generally invests in common stocks of U S  companies  The fund may also invest in common stocks of foreign companies and American Depositary Receipts   ADRs    LOGSX seeks long term growth of capital   Live Oak Health Sciences Fund has a three year annualized return of 16 9  As of March 2016  LOGSX held 29 issues with 7 23  of its assets invested in Amgen Inc  NASDAQ AMGN  Delaware Healthcare A  seeks long term capital growth  DLHAX invests a large portion of its assets in the equity securities of health care companies  These companies produce and distribute products that are required in medical industries  Delaware Healthcare A is non diversified and has a three year annualized return of 13 8  Liu Er Chen is the lead manager and has managed DLHAX since 2007 Fidelity Select Medical Equipment   Systems  invests a major portion of its assets in companies that are primarily involved in medical equipment and devices and related technologies sector  FSMEX focuses on acquiring common stocks of companies by analyzing factors including financial strength and economic condition  FSMEX invests in both U S  and non U S  companies  Fidelity Select Medical Equipment   Systems has a three year annualized return of 22 9  As of May 2016  FSMEX held 57 issues with 22 43  of its assets invested in Medtronic  NYSE MDT  PLC To view the Zacks Rank and past performance of all healthcare mutual funds  investors can  About Zacks Mutual Fund RankBy applying the Zacks Rank to mutual funds  investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward  Pick the  with the Zacks Rank ,2016-07-13,Zacks Investment Research,https://www.investing.com/analysis/3-top-rated-healthcare-mutual-funds-to-invest-in-200141626,200141626
151481,372997,AMGN,The Zacks Analyst Blog Highlights  Juno  Amgen  AbbVie  Gilead And CytRx,opinion,"For Immediate Release 

Chicago  IL   July 14  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include   Juno     Amgen  NASDAQ AMGN      AbbVie     Gilead      and CytRx    

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Wednesday s Analyst Blog  

Biotech Stock Roundup

This week there were the usual regulatory and pipeline updates from the biotech sector  Juno      a company focused on immuno oncology treatments  was in the news with the FDA first placing a clinical hold on a pivotal study and then lifting it  Amgen     also got some positive news flow on the regulatory front with the FDA approving a new dosing option for its PCSK9 inhibitor and its biosimilar version of Humira getting a positive recommendation from an FDA advisory panel 

Recap of the Week s Most Important Stories
	1  It s been quite a week for immuno oncology focused Juno which first saw its shares slump on a FDA clinical hold and is now looking at a recovery with the hold being lifted  Last week  shares fell 31 9  when the company s pivotal phase II study  ROCKET  was placed on clinical hold by the FDA due to two deaths  Read more      But with the FDA lifting the clinical hold yesterday and the company resuming the study under a revised protocol  Juno should recover most of the lost ground  Read more     
	2  Amgen also got some good news on the regulatory front   firstly  the company s biosimilar version of AbbVie s     Humira got a positive FDA advisory panel vote and secondly  the company s monthly single dose administration option for its PCSK9 inhibitor  Repatha  gained FDA approval  This makes Repatha the first and only PCSK9 inhibitor to offer a monthly single dose delivery option  thereby giving it an edge over Regeneron and Sanofi s Praluent  Read more     
	Meanwhile  the FDA s advisory panel voting in favor of Amgen s Humira biosimilar  ABP 501  is not surprising considering the favorable FDA briefing documents that were released earlier  Read more      A decision from the FDA regarding the approval status of ABP 501 should be out bySep 25  2016 
	3  Shortly after gaining FDA approval for its latest hepatitis C virus  HCV  treatment  Epclusa  Gilead     gained EU approval as well for the drug  Read more      Meanwhile  the EMA s Pharmacovigilance Risk Assessment Committee  PRAC  has completed its review of Gilead s blood cancer drug  Zydelig  Earlier this year  safety concerns related to the use of the drug had surfaced 

While the PRAC confirmed that Zydelig s benefits outweigh its risks in the treatment of chronic lymphocytic leukemia  CLL  and follicular lymphoma  the risk of serious infections with Zydelig was also confirmed  The PRAC has provided some recommendations related to the use of Zydelig which will be passed on to the EMA s Committee for Medicinal Products for Human Use  CHMP  for adoption of the agency s final position 
	4  CytRx s    shares plunged on initial results from a late stage study which showed that aldoxorubicin failed to achieve the primary endpoint compared to investigator s choice therapy in patients with relapsed or refractory soft tissue sarcomas  STS   Although the company pointed out that enrollment was interrupted by a clinical hold and a second analysis will take place later  shares were down 59 8  on the news 
	5  AbbVie got Rare Pediatric Disease Designation from the FDA for its experimental cancer treatment  ABT 414  The designation is for the treatment of pediatric patients with EGFR amplified diffuse intrinsic pontine glioma  DIPG   highly aggressive and difficult to treat brain tumors found at the base of the brain  Read more     

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days  

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact

Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-07-13,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-juno,-amgen,-abbvie,-gilead-and-cytrx-200141874",200141874
151508,373024,AMGN,Intro Guide To The PRIMECAP Odyssey Growth Fund  POGRX ,opinion,"PRIMECAP Odyssey Growth Fund     a Zacks Rank  2  Buy  was incepted in Nov 2004  The objective of POGRX is to seek long term growth of capital  POGRX invests in common stocks of domestic companies with stable earnings growth potential  POGRX focuses on investing in stocks of companies from different sectors  POGRX invests not only in large cap and mid cap companies  but also in small cap companies 

This Large Growth fund  as of the last filing  allocates their fund in three major groups  Small Growth  Large Value and Large Growth  Further  as of the last filing  Eli Lilly and Company  NYSE LLY   Amgen Inc  NASDAQ AMGN  and Seattle Genetics  Inc were the top holdings for POGRX 

The PRIMECAP Odyssey Growth Fund  managed by   carries an expense ratio of 0 64   Moreover  POGRX requires a minimal initial investment of  2 000 

POGRX has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 10 31  and 5 year 10 14   To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds   

POGRX s performance  as of the last filing  when compared to funds in its category was in the top 32  in 1 year  top 32  over the past 3 years  and in the 20  over the past 5 years 

About Zacks Mutual Fund Rank

By applying the Zacks Rank to mutual funds  investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward  Pick the  with the Zacks Rank 

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-06-07,Zacks Investment Research,https://www.investing.com/analysis/intro-guide-to-the-primecap-odyssey-growth-fund-(pogrx)-200134751,200134751
151509,373025,AMGN,Novartis  NVS  Announces Positive Results On Migraine Drug,opinion,"Novartis AG   NYSE NVS   reported positive first results from the global phase II study  20120295 on pipeline candidate  AMG 334  erenumab  
The study evaluated AMG 334 at two doses  70mg and 140mg  administered subcutaneously once a month for the treatment of chronic migraine 
The data from the randomized  12 week  double blind  placebo controlled study showed that treatment with the candidate resulted in a statistically significant reduction in the number of monthly migraine days compared with placebo  Overall  patients had a mean baseline of 18 migraine days per month  The data also showed that safety and tolerability profile of AMG 334 was similar to placebo in both treatment groups 
We remind investors that Novartis is developing AMG334 in collaboration with Amgen  Inc    NASDAQ AMGN    As part of the agreement  Amgen owns commercialization rights in the U S   Canada and Japan  while Novartis has rights in Europe and rest of world  Both companies entered into a global collaboration agreement in 2015 to commercialize and develop pioneering neuroscience treatments for Alzheimer s and migraine 
Novartis is also planning to assess the benefit of AMG 334 in two ongoing phase III studies in episodic migraine  Initial data from the studies are expected later in 2016 
Approval of new drugs and label expansion of existing ones bode well for Novartis as it has been facing stiff generic competition for some of its key drugs like Diovan and Gleevec  This apart  its oncology drugs are facing competition from immuno oncology therapies  Moreover  its Alcon segment is witnessing a decline in surgical equipment sales in the U S  and emerging markets 
Novartis currently carries a Zacks Rank  4  Sell   A couple of better ranked stocks in the health care sector are Pfizer Inc    NYSE PFE   and Bristol Myers Squibb Company   NYSE BMY    Both the stocks sport a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-06-09,Zacks Investment Research,https://www.investing.com/analysis/novartis-(nvs)-announces-positive-results-on-migraine-drug-200135113,200135113
151510,373026,AMGN,Amgen s Biosimilar Of AbbVie s Humira To Face FDA Panel,opinion,"Amgen Inc    NASDAQ AMGN   announced that the FDA s Arthritis Advisory Committee will review data supporting the company s biologics license application for ABP 501  a biosimilar version of AbbVie Inc  s   NYSE ABBV   best selling drug  Humira 
A final decision regarding the approval status of ABP 501 is expected by Sep 25  2016  It is also under review in the EU 
Humira  an anti TNF   monoclonal antibody  is approved in many countries for the treatment of a wide range of inflammatory diseases  The drug recorded worldwide sales of  14 billion in 2015 and was one of the top selling products in the U S  in 2014 
Currently  Amgen has nine biosimilar candidates in its portfolio representing annual revenues of more than  3 billion  The company plans to launch its first biosimilar in 2017 followed by four others through 2019  subject to approval 
We note that Amgen itself is facing biosimilar competition in the U S  Zarxio  the first FDA approved biosimilar  was launched by Novartis AG s   NYSE NVS   generic arm  Sandoz  in Sep 2015  Zarxio is the biosimilar version of Amgen s blockbuster drug  Neupogen  A couple of key drugs from Amgen s portfolio   Neulasta and Enbrel   could also start facing biosimilar competition soon 
Notably  Sandoz s biosimilar version of Enbrel is expected to come up before the FDA s Arthritis Advisory Committee next month 
Considering that the market for biosimilars is highly lucrative  competition in this space is intensifying with pharmaceutical and biotech companies racing to develop the same 
Amgen is a Zacks Rank  3  Hold  stock  Bristol Myers Squibb Company   NYSE BMY   is a better ranked stock in the health care sector  carrying a Zacks Rank  1  Strong Buy  ",2016-06-13,Zacks Investment Research,https://www.investing.com/analysis/amgen's-biosimilar-of-abbvie's-humira-to-face-fda-panel-200135920,200135920
151511,373027,AMGN,Pfizer s PCSK9 Inhibitor Tops Two Additional Phase III Studies,opinion,Pfizer Inc    NYSE PFE   announced that two additional phase III studies  SPIRE HR and SPIRE FH  on its PCSK9 inhibitor  bococizumab  have met the primary endpoint in patients at high and very high risk of cardiovascular events The SPIRE HR study was conducted on adults with primary hyperlipidemia or mixed dyslipidemia at high and very high risk of cardiovascular events  receiving a maximally tolerated dose of statin therapy whose LDL C  70 mg dL  On the other hand  the SPIRE FH study involved adults with heterozygous familial hypercholesterolemia  HeFH  who were at high and very high risk of cardiovascular events  receiving a maximally tolerated dose of statin Data from the studies demonstrated a significant reduction in the percent change from baseline in LDL C at 12 weeks compared to placebo  In both the studies  bococizumab was found to be generally safe and well tolerated SPIRE HR and SPIRE FH are the third and fourth successful studies in Pfizer s phase III program  SPIRE   Studies of PCSK9 Inhibition and the Reduction of vascular Events  on bococizumab  The SPIRE program consists of six lipid lowering studies   SPIRE SI  SPIRE AI  SPIRE HR  SPIRE FH  SPIRE LL and SPIRE LDL   and two cardiovascular outcomes studies   SPIRE 1 and SPIRE 2 Two of the remaining SPIRE lipid lowering studies are expected to be completed later this year  Meanwhile  full results from SPIRE HR and SPIRE FH studies will be presented at an upcoming scientific meeting and will be used for regulatory filing for bococizumab We note that PCSK9 is a protein that lowers the liver s ability to remove  bad  cholesterol  LDL C  from the blood  Although the market represents huge commercial potential  Pfizer will be a late entrant in the market given the presence of Regeneron Pharmaceuticals  Inc    NASDAQ REGN   Sanofi s   NYSE SNY   Praluent and Amgen Inc  s   NASDAQ AMGN   Repatha Currently  Pfizer carries a Zacks Rank  1  Strong Buy  while Amgen is a Zacks Rank  2  Buy  stock in the health care sector Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-28,Zacks Investment Research,https://www.investing.com/analysis/pfizer's-pcsk9-inhibitor-tops-two-additional-phase-iii-studies-200139076,200139076
151512,373028,AMGN,Xencor Stock Up On Cancer Drugs Partnership With Novartis,opinion,"Shares of Xencor  Inc    NASDAQ XNCR   rallied 32 06  after the company announced that it has entered into a collaboration and license agreement with Swiss major  Novartis AG   NYSE NVS   
Terms of the Agreement
As per the agreement terms  the companies will collaborate to develop and commercialize two pipeline candidates   XmAb14045  expected to enter clinical development for acute myeloid leukemia in 2016  and XmAb13676  to enter clinical development for B cell malignancies in 2016   The companies will share the cost of the development of the candidates  While Xencor will retain commercialization rights in the U S   Novartis will own the marketing rights in the rest of the world 
Additionally  Novartis will receive worldwide rights to Xencor s bispecific technology to develop and commercialize four targets  These targets will be selected by Novartis and Xencor may elect to co detail one of these targets in the U S  Novartis will also receive a worldwide non exclusive license to use Xencor s XmAb Fc technologies in up to 10 molecules 
Financial Details of the Transaction
Novartis will pay an upfront fee of  150 million to Xencor along with potential milestone payments totalling up to  2 41 billion  as and when milestones are achieved   Xencor is also entitled to low double digit royalties on potential sales of XmAb14045 and XmAb13676 outside the U S  mid single digit tiered royalties on global sales of the four proprietary Novartis bi specific molecules  subject to conditions  and low single digit royalties on Novartis molecules incorporating Xencor s XmAb Fc technology 
Our Take
The deal is a major positive for the clinical stage biopharmaceutical company Xencor both strategically and financially  Not only the agreement provides Xencor with the much needed funds through the upfront fee along with potential milestone payments  the company also gets to own the commercialization rights for the drugs upon approval in the U S 
Moreover  Novartis  expertise in drug development will significantly boost the growth prospects of the candidates  We note that Xencor currently has nine candidates developed through its XmAb technology and collaborations with leading companies like Amgen  Inc    NASDAQ AMGN   among others XENCOR INC Price
   On the other hand  the agreement provides Novartis with rights to Xencor s bispecific technology to develop four additional targets thereby strengthening its pipeline which has a few leukemia candidates in its pipeline 
Both Xencor and Novartis currently carry a Zacks Rank  3  Hold   A better ranked stock in the healthcare stock is Pfizer  Inc    NYSE PFE   which currently sports a Zacks Rank  1  Strong Buy  ",2016-06-29,Zacks Investment Research,https://www.investing.com/analysis/xencor-stock-up-on-cancer-drugs-partnership-with-novartis-200139105,200139105
151531,373047,AMGN,Vanguard PRIMECAP Core Investor Funds  VPCCX  In Focus,opinion,"Vanguard PRIMECAP Core Investor Funds     a Zacks Rank  2  Buy  was incepted in Dec 2004  VPCCX s main objective is to offer capital growth over the long run  VPCCX invests in stocks that are expected to provide impressive growth prospect and are favorably priced  VPCCX invests in stocks across all sectors irrespective of their market capitalizations 

	This Large Bend product  as of the last filing  allocates their fund in four major groups  Large Value  Large Growth  Intermediate Bond and Small Growth  Further  as of the last filing  Southwest Airlines Co   Amgen Inc  NASDAQ AMGN   and Eli Lilly and Company  NYSE LLY  were the top holdings for VPCCX 

	Vanguard PRIMECAP Core Investor  managed by   carries an expense ratio of 0 47   Moreover  VPCCX requires a minimal initial investment of  3 000 

	VPCCX has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 12 06  and 5 year 11 1   To see how this fund performed compared in its category and other  1 and  2 Ranked Mutual Funds   

	VPCCX s performance  as of the last filing  when compared to funds in its category was in the top 27  in 1 year  top 9  over the past 3 years  and in the 7  over the past 5 years 

About Zacks Mutual Fund Rank

	By applying the Zacks Rank to mutual funds  investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward  Pick the  with the Zacks Rank ",2016-05-24,Zacks Investment Research,https://www.investing.com/analysis/vanguard-primecap-core-investor-funds-(vpccx)-in-focus-200132118,200132118
151532,373048,AMGN,Regeneron Reports Interim Data On Cholesterol Lowering Drug,opinion,"Regeneron Pharmaceuticals  Inc    NASDAQ REGN   announced that positive preliminary results from an ongoing  single arm  open label  phase II proof of concept study on evinacumab in patients suffering from homozygous familial hypercholestrolemia  HoFH  were presented at the European Atherosclerosis Society Congress  Evinacumab is an experimental monoclonal antibody to angiopoietin like protein 3 
Interim data showed that evinacumab in combination with other lipid lowering therapies resulted in a mean reduction in low density lipoprotein cholesterol  LDL C  in the first 4 patients by an additional 55  at week 4 compared to baseline  which was also the primary endpoint of the study  Between these 4 patients  the percent reductions in LDL C ranged from 25 90   Overall  the patients enrolled in the study saw their mean LDL C levels decrease from 331mg dL at baseline to 175mg dL at week 4 
On the safety front  evinacumab was found to be well tolerated with no adverse event being reported leading to discontinuation  Meanwhile  the study is targeting to enrol up to 8 patients with HoFH 
We are encouraged by the company s progress with the candidate  The cholesterol management market represents a huge commercial potential 
We note that Regeneron received a huge boost when Praluent became the first PCSK9 inhibitor to gain approval in the U S  The drug is also approved in the EU  Regeneron has co developed Praluent with Sanofi   NYSE SNY    The current payer restrictions are limiting the product s uptake though the companies expect a gradual uptick in sales 
PCSK9 inhibitors work by inhibiting PCSK9  a protein that reduces the liver s ability to remove  bad  cholesterol from the blood  Amgen Inc  s   NASDAQ AMGN   PCSK9 inhibitor  Repatha  is also approved both in the U S and EU 
Regeneron is a Zack Rank  3  Hold  stock  ANI Pharmaceuticals  Inc    NASDAQ ANIP   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy  ",2016-05-31,Zacks Investment Research,https://www.investing.com/analysis/regeneron-reports-interim-data-on-cholesterol-lowering-drug-200133369,200133369
151564,373080,AMGN,Kite Pharma  KITE  Posts Narrower than Expected Loss In Q1,opinion,Kite Pharma  Inc    NASDAQ KITE   reported a loss of 90 cents per share in the first quarter of 2016  narrower than the Zacks Consensus Estimate of a loss of  1 22 per share but wider than the year ago loss of 36 cents First quarter revenues came in at  5 1 million  in line with the Zacks Consensus Estimate and up 78  from the year ago period  Revenues consisted entirely of the amortization of deferred collaboration revenues related to the  60 million upfront payment received under the collaboration agreement with Amgen   NASDAQ AMGN   in the first quarter of 2015 KTE C19 Year End Filing Remains on TrackWhile Kite s research and development expenses shot up 271 6  from the year ago period to  34 4 million in the reported quarter  general and administrative expenses were  16 5 million  up 79 8  from the year ago period Kite continues to expect cash burn of  235  250 million in 2016 including both operating expenses and about  20 million of capital expenditures but excluding the impact of business development activities With no approved product in its portfolio at the moment  focus remains on KTE C19  Kite s lead pipeline candidate  which is currently in the pivotal phase of a phase I II study  ZUMA 1  in patients with refractory diffuse large B cell lymphoma  DLBCL  including primary mediastinal B cell lymphoma  PMBCL  and transformed follicular lymphoma  TFL   All these are types of aggressive non Hodgkin s lymphoma  NHL  Initial NCI conducted study results for these indications have been promising  If the study generates positive data  top line data from the phase I portion presented at ASH in December  interim results expected in the second half of 2016   Kite intends to seek accelerated FDA approval for the treatment of refractory DLBCL  PMBCL and TFL by year end  If all goes well  KTE C19 could be launched as early as 2017 Kite is also evaluating KTE C19 in a phase II study  ZUMA 2  in patients with relapsed refractory mantle cell lymphoma  MCL  and in two additional pivotal studies  phase I II  for acute lymphoblastic leukemia  ALL    ZUMA 3 for adult ALL and ZUMA 4 for pediatric ALL  with results from all these studies due in 2017 Kite plans to move KTE C19 into a second series of studies for additional indications and earlier lines of therapy in DLBCL patients in 2017 A phase Ib II combination study evaluating KTE C19 plus Genentech s atezolizumab in patients with chemorefractory DLBCL is scheduled to commence in the second half of 2016 Meanwhile  the company expects to file an IND application this year for a T cell receptor  TCR  candidate targeting MAGE in a solid tumor study Kite is a Zacks Rank  4  Sell  stock  Some better ranked stocks in the healthcare sector include Cambrex Corporation   NYSE CBM   and Heska Corporation   NASDAQ HSKA    Both are Zacks Rank  1  Strong Buy  stocks Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-05-09,Zacks Investment Research,https://www.investing.com/analysis/kite-pharma-(kite)-posts-narrower-than-expected-loss-in-q1-200129101,200129101
151565,373081,AMGN,Drug Stocks Q1 Earnings Slated On May 11  ACRS  EARS   More,opinion,With the Q1 cycle nearing its end  the earnings picture is becoming increasingly clear  While the going looked tough at the onset of the last month  that scenario has changed over the past few weeks  The earnings scorecard  as per our  report  shows that a large number of companies have posted better than expected bottom line numbers for the quarter  thereby lifting investor spirits substantially  The unforeseen number of earnings beats could perhaps be attributed to already lowered investor expectations at the start of the earnings cycle  The recent decline in the U S  dollar could have also aided matters  Amid an improved commodity price backdrop  although estimates for the second quarter are still witnessing downward revisions  the decline is not as severe as last quarter Notwithstanding headwinds like currency rates  biosimilars and generic competition  the Medical sector has surely put up a positive picture this season  Dissecting the scorecard further  65 3  of the pharma companies have surpassed both revenues and earnings estimates in the first quarter so far  as of May 6  2016   Johnson   Johnson   NYSE JNJ   kick started the earnings season on an encouraging note and quite a few followed suit even though there were laggards like Novartis   NYSE NVS    Meanwhile  results at the biotech sector have been mixed so far with Amgen   NASDAQ AMGN   topping expectations while bigwigs like Gilead Sciences   NASDAQ GILD   disappointing There are still quite a few companies that are yet to report results  Let s take a peek at a few drug stocks that will report quarterly results on May 11 Aclaris Therapeutics  Inc    NASDAQ ACRS    a clinical stage specialty pharmaceutical company  is scheduled to report first quarter results on May 11  With its focus on dermatology  this Zacks Rank  3  Hold  stock s track record has been mixed  as it beat earnings estimates in one of the last two quarters and missed the same in the other  The combination of its Zacks Rank  3  Hold  and  of 0 00  makes surprise prediction difficult Switzerland based Auris Medical Holding AG   NASDAQ EARS   is also scheduled to report first quarter results on May 11  The company is developing therapeutics to address unmet medical needs in otolaryngology  This Zacks Rank  3 stock has a mixed track record  as it beat earnings estimates in two of the last four quarters and missed the same in other two  The combination of its Zacks Rank  3 and Earnings ESP of 0 00  makes surprise prediction difficult Bio Path Holdings  Inc    NASDAQ BPTH   is scheduled to report first quarter results on May 11 as well  Bio Path s lead candidate  BP1001  Liposomal Grb2 antisense   is currently in a phase II study for blood cancers  Hence  we expect investor focus on the company s pipeline  This clinical stage biotechnology company currently carries a Zacks Rank  3 and has an Earnings ESP of 0 00  which makes it difficult for us to predict an earnings beat for this quarter Biotie Therapies Corp    NASDAQ BITI   is expected to report first quarter results on May 11  The company is set to be acquired by Acorda Therapeutics  Inc    NASDAQ ACOR    Given the company s dismal track record and the combination of its Zacks Rank  3 and an Earnings ESP of 0 00   we are uncertain of an earnings surprise this quarter Cardiome Pharma Corp    NASDAQ CRME   is expected to report first quarter results on May 11  2016  The specialty pharmaceutical company primarily focuses on the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease  However  the company has a disappointing track record  having missed estimates in three out of the last four quarters  The combination of its Zacks Rank  3 and Earnings ESP of 0 00  makes surprise prediction difficult Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-05-09,Zacks Investment Research,"https://www.investing.com/analysis/drug-stocks-q1-earnings-slated-on-may-11:-acrs,-ears---more-200129100",200129100
151566,373082,AMGN,Guide To American Funds Capital World Growth And Income A Fund  CWGIX  ,opinion,"American Funds Capital World Growth and Income A     a Zacks Ranked  2  Buy  was incepted in March 1993 and is managed by Capital Research and Management Company  CWGIX s main objective is to provide long term growth of capital with current income by investing in established  growing companies all over the world  including the United States  CWGIX invests primarily in blue chip stocks issued by companies in the world s largest stock markets  CWGIX is conservatively managed and focuses on established companies that pay regular dividends  CWGIX invests in common stocks  government and corporate bonds  and cash and equivalents 

	This Global Equity product  as of the last filing  allocates their fund in six major groups  Foreign Stock  Large Value  Large Growth  Emerging Market  Small Growth and Precious Metal  Further  as of the last filing  Amgen Inc  NASDAQ AMGN   Novartis AG and Alphabet Inc were the top holdings for CWGIX 

	American Funds Capital World Growth and Income A  managed by   carries an expense ratio of 0 77   Moreover  CWGIX requires a minimal initial investment of  250 

	CWGIX has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 5 90  and 5 year 6 08   To see how this fund performed compared in its category   

	CWGIX s performance  as of the last filing  when compared to funds in its category was in the top 47  in 1 year  top 46  over the past 3 years  and in the 41  over the past 5 years 

Zacks Premium

	To see the Zacks Mutual Fund Rank for the funds you re interested in  plus  gain access to the Zacks Rank for your stocks and ETFs  Premium Screens  Equity Research Reports  Focus List portfolio of 50 longer term stocks and more   ",2016-05-11,Zacks Investment Research,https://www.investing.com/analysis/guide-to-american-funds-capital-world-growth-and-income-a-fund-(cwgix)-200129304,200129304
151567,373083,AMGN,Bristol Myers AbbVie Empliciti Gets Approved In The EU,opinion,Bristol Myers Squibb Company   NYSE BMY   and AbbVie Inc    NYSE ABBV   announced that Empliciti was approved in the EU  in combination with Celgene Corp  s   NASDAQ CELG   Revlimid plus dexamethasone  for the treatment of multiple myeloma in patients who have received at least one prior therapy  This makes Empliciti the first and the only immunostimulatory antibody to be approved in the EU for the treatment of multiple myeloma The approval was quite expected as the European Medicine Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  issued a favorable opinion this January We note that Empliciti is approved in the U S   in combination with Revlimid plus dexamethasone  for the treatment of patients with multiple myeloma who have received one to three prior therapies Another drug approved in the EU in this indication is Amgen Inc  s   NASDAQ AMGN   Kyprolis  in combination with Revlimid and dexamethasone  Currently  Amgen is working on expanding its label  The company has filed a regulatory application seeking an approval for Kyprolis  in combination with dexamethasone  for the same indication According to information provided by the company  it is estimated that more than 114 200 new cases of multiple myeloma are diagnosed every year  and over 80 000 people die from the disease worldwide In a separate press release  Bristol Myers announced that the European Commission  EC  has approved Opdivo in combination with Yervoy for the treatment of adults with advanced  unresectable or metastatic  melanoma  The approval was based on data from two studies  CheckMate  067  phase III  and CheckMate  069  phase II  We remind investors that last month  the EC approved Opdivo monotherapy in two indications   locally advanced or metastatic non small cell lung cancer after prior chemotherapy in adults  and advanced renal cell carcinoma after prior therapy in adults It is estimated that 100 000 new cases of melanoma are diagnosed every year in the EU  with over 20 000 deaths occurring from the disease AbbVie currently carries a Zacks Rank  3  Hold   Bristol Myers  with a Zacks Rank  1  Strong Buy   is a better ranked stock in the health care sector ,2016-05-12,Zacks Investment Research,https://www.investing.com/analysis/bristol-myers-abbvie-empliciti-gets-approved-in-the-eu-200129644,200129644
151568,373084,AMGN,The Zacks Analyst Blog Highlights  Medivation  Juno  Kite  ARIAD And AbbVie,opinion,"For Immediate Release 

Chicago  IL   May 13  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include   Medivation     Juno     Kite     ARIAD      and AbbVie    

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Thursday s Analyst Blog  

Biotech Stock Roundup  MDVN Rumors Continue

Earnings remained in focus this week as well with several small and mid sized biotech companies reporting results  Meanwhile  Medivation     remains in the news as the acquisition saga continues with more companies rumored to be interested in buying the firm 

Other updates include data presentations as well as label expansions and product approvals Recap of the Week s Most Important Stories
	1  With first quarter earnings season drawing to a close  several small and mid sized biotech companies reported results over the last five trading days  Most of these are companies like Juno     Kite     and Repros which have no approved products in their portfolios and are still in the development stage  In such a scenario  investors are more focused on the pipelines and cash burn 

Kite and Juno are key names in the immuno oncology space with both looking to bring their lead candidates to market in 2017  While Juno s JCAR015 is in a registrational phase II study  ROCKET  in adult patients with relapsed refractory acute lymphoblastic leukemia  Read more      Kite s KTE C19 is in the pivotal phase of a phase I II study  ZUMA 1  in patients with refractory diffuse large B cell lymphoma including primary mediastinal B cell lymphoma and transformed follicular lymphoma  Read more     
	2  Medivation  which had rejected an unsolicited offer from French drugmaker Sanofi  PA SASY   continues to be in the news as speculation increases about other companies being interested in acquiring Medivation  The latest rumor is that the company is now interested in selling itself  According to a Reuters article  Pfizer  NYSE PFE  and Amgen  NASDAQ AMGN  are some of the companies that have signed non disclosure agreements with Medivation 
	3  As part of its ongoing strategic review  ARIAD    has decided to divest its European operations and out license Iclusig in Europe and a few other countries to Incyte  This deal will allow ARIAD to focus its efforts in the U S  and it also provides the company with a non dilutive source of funds  Under this agreement  ARIAD stands to receive up to  275 million including an upfront payment of  140 million plus tiered royalties starting from 32  that could go up to 50  
	4  The FDA expanded the label of AbbVie s    cancer treatment  Imbruvica  The label now includes new data from two late stage studies supporting its expanded use in patients with chronic lymphocytic leukemia  CLL  and small lymphocytic lymphoma  SLL  
	AbbVie and Bristol Myers also gained EU approval for their blood cancer treatment  Empliciti making it the first and only immunostimulatory antibody approved for multiple myeloma in the EU 

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research    Find out What is happening in the  on zacks com ",2016-05-12,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-medivation,-juno,-kite,-ariad-and-abbvie-200129793",200129793
151600,373116,AMGN,The Zacks Analyst Blog Highlights  Amgen  Johnson   Johnson  Pfizer  Mylan And Mallinckrodt,opinion,"For Immediate Release 

Chicago  IL   May 02  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include the Amgen Inc     NASDAQ AMGN     Johnson   Johnson    NYSE JNJ     Pfizer Inc     NYSE PFE     Mylan N V     NASDAQ MYL    and Mallinckrodt plc     NYSE MNK    

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Friday s Analyst Blog  

3 Drug Stocks Reporting Earnings Next Week

As the first quarter 2016 earnings season is well under way  results have not been as disappointing as widely apprehended  Are   

With several pharma and major biotech companies having already reported their earnings results  the spotlight shifts to the Medical sector  which is anticipated to be one of the seven sectors to record earnings growth  Earnings in the Medical sector are expected to grow 2 3  on revenue growth of 9 1  from the year ago period  per our  report 

Beats and Misses So Far

Several biotech stocks including Amgen Inc     NASDAQ AMGN    and pharma stocks like Johnson   Johnson    NYSE JNJ     Abbott Laboratories  NYSE ABT   and Bristol Myers Squibb Company  NYSE BMY  have not only managed to beat earnings estimates  but some among these have also raised their outlook for the year  There were misses as well 

Though label expansion and cost cutting initiatives were catalysts to growth  unfavorable currency movements and macroeconomic factors held back performances 

Eli Lilly and Company  NYSE LLY  raised its outlook for the year despite an earnings miss while Glaxo expects core earnings growth of 10 12  at constant exchange rate in 2016 

Meanwhile  a number of pharma and biotech companies are yet to report first quarter results  Let s see what awaits these three major drug stocks when they report on May 3  before the opening bell  Investors interested in the Medical sector will be keenly watching for beats and misses 

What to Expect from These Drug Stocks 

New York based Pfizer Inc     NYSE PFE    was recently in the news when it terminated its  160 billion deal to combine with Botox maker Allergan  NYSE AGN pa  plc  Focus will now be on the company s cash utilization plans  Meanwhile  the company continues to face headwinds in the form of genericization  unfavorable currency movement including the impact of the Venezuelan financial crisis and the expiration of a few co promotion agreements  However  its share buyback program should boost the bottom line  However  its share buyback program should boost the bottom line 

Pfizer has been seen to consistently beat earnings expectations  Will this pharma giant be able to beat estimates this time around as well  This Zacks Rank  3  Hold  stock has an  of 0 00  for the first quarter thereby making it difficult to predict a beat  read more     

Generic drug maker  Mylan N V  s    NASDAQ MYL    Zacks Rank  3 increases the predictive power of the ESP  but it also has an ESP of  2 67   making a surprise prediction difficult  Mylan s track record has however been decent with the company surpassing expectations in two of the last four quarters 
	Though the company s Generics and Specialty segments should perform well in the first quarter  pricing dynamics that existed throughout 2015 would also continue in 2016  Mylan anticipates first quarter earnings to be relatively flat with the year ago period  Considering that Mylan is set to acquire a leading international specialty pharmaceutical company  Meda  focus will be on the deal  read more     

Specialty pharmaceutical and biopharmaceutical products manufacturer  Mallinckrodt plc s     NYSE MNK    track record has been pretty good with the company consistently beating earnings estimates  However  Mallinckrodt s Zacks Rank  4  Sell  which when combined with an ESP of  1 74  makes it difficult to predict an earnings beat when it reports its second quarter fiscal 2016 results 

Though the company will benefit from the Sep 2015 Therakos acquisition  this is the first full quarter in which Therakos will contribute to results   seasonality is expected to continue in fiscal 2016  which will hurt gross profit  read more     

Stay tuned  Check later on our full write up on earnings releases of these stocks 

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days   

About Zacks Equity Research 

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research    Find out What is happening in the  on zacks com ",2016-05-01,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-amgen,-johnson---johnson,-pfizer,-mylan-and-mallinckrodt-200127256",200127256
151601,373117,AMGN,Kite  KITE  To Report Q1 Earnings  Will The Stock Disappoint ,opinion,"Kite Pharma  Inc    NASDAQ KITE   is scheduled to report first quarter 2016 results on May 9  after the market closes  The company  which started trading from Jun 2014  posted a negative earnings surprise in the last quarter  Let s see how things are shaping up for this announcement Factors at PlayKite Pharma  a development stage biopharmaceutical company  is looking to transform the paradigm of treating cancer which involves using the body s immune system to recognize and destroy cancer cells  The company uses its engineered autologous cell therapy  eACT  to genetically modify T cells to express either chimeric antigen receptors  CARs  or T cell receptors  TCRs   These modified T cells are designed to recognize and destroy cancer cells Kite Pharma s revenues comprise the amortization of deferred collaboration revenues related to the  60 million upfront payment received under its collaboration agreement with Amgen  Inc    NASDAQ AMGN   in the first quarter of 2015 With no approved products in its portfolio  investor focus will be primarily on the company s cash burn and pipeline updates At the time of releasing fourth quarter results  Kite had guided towards 2016 net cash burn of  235    250 million and net loss of  295    310 million KTE C19  Kite s lead pipeline candidate  is currently in the pivotal phase of a phase I II study  ZUMA 1  in patients with refractory diffuse large B cell lymphoma  DLBCL  including primary mediastinal B cell lymphoma  PMBCL  and transformed follicular lymphoma  TFL   All these are types of aggressive non Hodgkin s lymphoma  NHL   If the study generates positive data  top line data from the phase I portion presented at ASH in December  interim results expected in the second half of 2016   Kite intends to seek accelerated FDA approval for the treatment of patients with refractory DLBCL  PMBCL and TFL by year end  If all goes well  KTE C19 could be launched as early as 2017  Kite intends to file for EU approval in 2017 Kite is also evaluating KTE C19 in a phase II study  ZUMA 2  in patients with relapsed refractory mantle cell lymphoma  MCL  and in two additional pivotal studies  phase I II  for acute lymphoblastic leukemia  ALL    ZUMA 3 for adult ALL and ZUMA 4 for pediatric ALL  with results from all these studies due in 2017 Kite plans to move KTE C19 into a second series of studies for additional indications and earlier lines of therapy in DLBCL patients Apart from updates on KTE C19  investor focus will remain on the company s progress with its collaboration agreements with several companies including Amgen Meanwhile  the bottom line will also reflect the impact of the issuance of shares in Dec 2015 Surprise HistoryKite s performance over the last four quarters is mostly disappointing with the company surpassing expectations in just one quarter and missing in the remaining three  Overall  the company posted an average earnings surprise of  34 52  over the past four quarters 
Earnings Whispers Our proven model does not conclusively show that Kite Pharma is likely to beat earnings this quarter  That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat earnings  That is not the case here as you will see below Zacks ESP   for Kite Pharma is  11 48   This is because the Most Accurate estimate is a loss of  1 36 per share while the Zacks Consensus Estimate is a loss of  1 22 per share Zacks Rank  Kite Pharma carries a Zacks Rank  4  Kite Pharma s Zacks Rank  4 when combined with an ESP of  11 48  makes surprise prediction difficult We caution against stocks with a Zacks Rank  4 and 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are some health care stocks you may want to consider as our model shows that they have the right combination of elements to post a beat this quarter The Earnings ESP for OvaScience  Inc    NASDAQ OVAS   is  6 67  and it carries a Zacks Rank  3  The company is expected to release first quarter results on May 5 Jazz Pharmaceuticals   NASDAQ JAZZ   has an Earnings ESP of  6 11  and carries a Zacks Rank  3  It will be reporting first quarter results on May 10 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-05-03,Zacks Investment Research,https://www.investing.com/analysis/kite-(kite)-to-report-q1-earnings:-will-the-stock-disappoint-200127945,200127945
151602,373118,AMGN,Ligand  LGND  Beats Q1 Earnings And Revenue Estimates,opinion,"La Jolla  CA based Ligand Pharmaceuticals Incorporated   NASDAQ LGND   is a biotechnology company with a focus on drug discovery  reformulation and partnering  Ligand s Captisol formulation technology has allowed it to enter into several licensing deals with companies like Amgen  NASDAQ AMGN  and Novartis among others and generate royalties  Ligand generates revenues in the form of royalties  license and milestone payments and sale of Captisol material In Jan 2016  Ligand acquired OMT  Inc  in a deal valued at about  178 million  The acquisition has added an antibody generating platform  OmniAb  to the company s technology portfolio In this scenario  investor focus remains on the company s major pipeline assets apart from the usual top and bottom line numbers Ligand has an impressive earnings track record with the company surpassing expectations in each of the last four quarters delivering an average positive surprise of 44 15  Currently  Ligand has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings  Ligand s first quarter 2016 earnings surpassed expectations by a wide margin  The company reported EPS of 79 cents  including stock based compensation expense  while our consensus called for EPS of 46 cents 
Revenues  Revenues in the reported quarter also came in above expectations  Ligand posted revenues of  29 6 million  compared to our consensus estimate of  26 million Key Stats  Once again  Ligand delivered higher royalty revenues on the back of Promacta and Kyprolis sales  Meanwhile  Ligand announced the acquisition of economic rights to multiple programs owned by CorMatrix  Ligand will pay  17 5 million and in exchange will receive a portion of revenue  synthetic royalty  from CorMatrix s existing marketed products and will have the right to receive future synthetic royalties from potential future products Updates 2016 Guidance  Ligand updated its guidance for 2016  Including the effects of the synthetic royalty acquisition from CorMatrix  Ligand now expects to earn  3 41  3 46 per share  old guidance   3 37  3 42 per share  on total revenues of  115  119 million  old guidance   114  118 million  in 2016  The Zacks Consensus Estimate for earnings is  2 70 per share on revenues of  117 million Check back later for our full write up on this LGND earnings report later 
Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-05-04,Zacks Investment Research,https://www.investing.com/analysis/ligand-(lgnd)-beats-q1-earnings-and-revenue-estimates-200127896,200127896
151628,373144,AMGN,Amgen  Looking For More Upside,opinion,"Big pharma companies are known as defensive plays when the market is unsteady  but they have been cruising along with the rest of healthcare the last few years  One that has had a rough 2015  moving sideways until the August and September swoons  is Amgen Inc  O AMGN   After moving in a channel for the first 7 months of 2015  it broke out to the upside to start August  That break out didn t even last a week  though  and followed into a rout to the downside 
From the spike to the bottom in September  the stock had dropped over 25   Since then it has rebounded and has been consolidating under 165 as resistance for 2 months  with tightening support  An ascending triangle  The chart below shows this action as price presses against 165  A break over the top would give a target from 180 to 195 depending on how aggressive you want to be about that triangle 

Both targets sound pretty good  Maybe too good for the short run  Looking left there is that prior channel with a top at 173  But even a move to 173 and a stall there is good for 6  in short order  You can sit and watch for the break out to join in and see how far it goes  Another way to participate would be to use options  With the stock set to report earnings January 26  using the January 22 expiry options chain is a good place to look for a possible run up into earnings 
The structure is then dependent upon your options knowledge and risk tolerance  A straight January 22 Expiry 165 Call for about  3 00 is a defined risk way to participate  For less cost sell the January 22 Expiry 172 5 Calls for about 65 cents  shaving about 20  of your cost but capping the return at the prior channel top  An aggressive trade could also sell the January 22 Expiry 155 Puts for about  1 30  This adds risk of being assigned the stock at 155  but there has been good support at that level 
This is my last trade idea of 2015  I hope all of you have found some of them useful and profitable and learned something about trading  technical analysis or options  Happy New Year ",2015-12-30,Gregory W. Harmon,https://www.investing.com/analysis/amgen:-looking-for-more-upside-378231,378231
151629,373145,AMGN,Medigene  Recent Deals Enable Greater Focus On The Core ,opinion,"Recent non core  business related newsflow has proved highly beneficial to Medigene  DE MDG1k   The full and final transference of EndoTAG 1 rights to SynCore and the sale of its Catherex subsidiary to Amgen  O AMGN  for  10 5m  40  to Medigene  tidies up its legacy pipeline and IP assets  while providing a decent revenue stream  Medigene s core focus remains on its immune oncology franchise  and we look forward to significant progress in 2016  Our rNPV based valuation increases to  216m or  10 98 per share 

To read the entire report Please click on the pdf File Below",2016-02-08,Edison,https://www.investing.com/analysis/medigene---recent-deals-enable-greater-focus-on-the-core-383683,383683
151630,373146,AMGN,ABBV  A Cheap Dividend Aristocrat Yielding Over 4 ,opinion,"AbbVie Inc  NYSE ABBV  is one of the more controversial  for several reasons  As a relatively new spin off  2013   the company has a much shorter dividend growth track record than traditional aristocrats 
The bigger challenge  however  is AbbVie s profit drivers  Most dividend aristocrats possess the characters we desire when   They have entrenched market positions  compete in slow changing industries  and generate cash flow from many different products and industries 
In AbbVie s case  over half of its business is concentrated in one product  While this can work for some companies that have powerful brands  e g  Clorox or Coca Cola   it s a risk in AbbVie s market of branded pharmaceutical drugs and makes the stock less desirable for  
However  the stock s safe 4 1  dividend yield  relatively cheap forward earnings multiple of 11 1  and above average earnings growth prospects over the next few years make it worth a closer look Business OverviewAbbVie was spun off from Abbott Laboratories  NYSE ABT  on January 1  2013  as a standalone biopharmaceutical company  Approximately 61  of the company s revenue comes from sales of Humira  a drug that treats arthritis  Some of its other major drugs are Imbruvica  which treats leukemia  and Viekira  which treats hepatitis C  The company reported nearly  23 billion in sales last year and sells its drugs in over 170 countries Business AnalysisThe branded pharmaceuticals industry has extremely high barriers to entry and offers potential for juicy profit margins   AbbVie generated a 33  operating margin last year and targets a 50  margin by 2020  Major pharma players invest billions of dollars and years of time in research and development to commercialize breakthrough drugs 
While the success rate is low  a successful drug can generate billions in profits that are protected for many years as a result of the intellectual property owned by the manufacturer  As seen below  AbbVie s primary markets combine to reach nearly  200 billion in size  providing the company with many different opportunities for growth 
Source  AbbVie Investor Presentation
AbbVie s management team expects the company to reach  37 billion in sales by 2020  which would represent more than a 60  increase from 2015 s revenue level  Of this total  roughly half of total sales would come from the company s arthritis drug Humira  and another 13 5  would come from sales of leukemia drug Imbruvica 
AbbVie also expects to launch over 20 new products by 2020 to reach to its goals and believes that its current pipeline has potential to achieve revenues of nearly  30 billion by 2024  As growth continues  operating margins are expected to expand by 100 200 basis points per year to drive double digit earnings growth 
The company s success will hinge on the success of its drug pipeline and its ability to protect cash flows from Humira for as long as possible from biosimilar competitors AbbVie s Key RisksWe prefer to invest in pharmaceuticals that have diversified streams of income from their drugs  It s very hard for a complete outsider to forecast the timing and profitability of a company s drug pipeline  so finding businesses with enough diversification helps reduce this risk 
Johnson   Johnson  NYSE JNJ  is a great example  While pharmaceuticals drive over half of the company s profits  it is well diversified by drug and gets reliable cash flows from its consumer products and medical devices segments  The flop of any one drug will not endanger the business 
On the other hand  AbbVie is much more concentrated  Sales of Humira accounted for over 60  of sales last year and are expected to represent nearly 50  of revenue by 2020 as well  AbbVie s composition of matter patents for Humira expire in the U S  and Europe in December 2016 and October 2018  respectively 
However  the company hopes that it can litigate against biosimilar manufacturers of Humira for at least four or five years based on industry norms and its non composition of matter patents  These patents covers area such as manufacturing and formulation and do not begin to expire until 2022 
The company obviously hopes to use these patents to litigate against new biosimilar competition for Humira  and it was successful earlier this year in defending against a patent review case filed by Amgen  NASDAQ AMGN  last year  If successful  AbbVie believes it can maintain strong profitability in the U S  through 2022  but there is plenty of skepticism surrounding the matter 
Regardless of the ultimate timing  branded drugs cannot maintain their high profit margins forever  As patents expire  lower cost competition emerges with knock offs that quickly erode sales and margins  If new drugs have not been successful in the pipeline  earnings can erode very quickly 
This is a key point of controversy surrounding the stock  While management believes Humira sales can exceed  18 billion in 2020  some analysts see Humira revenue coming up at least 30  short of management s ambitions  AbbVie s forecast assumes that biosimilar versions of Humira will stay out of the U S  until 2022  whereas some analysts see competition emerging in 2019 
In addition to the risk posed by Humira s large contribution to company profits  the Food and Drug Administration  FDA  can also pose unexpected challenges  For example  during one week in October 2015  AbbVie s stock fell by more than 10  after the FDA warned that AbbVie s Viekira treatment caused liver injury to a small number of patients 
You just never know what might crop up any given week as it relates to new competition  unexpected developments in the drug pipeline  litigation  or other issues with existing treatments  For these reasons  we generally prefer to invest elsewhere in the market Dividend Analysis  AbbVieWe analyze 25  years of dividend data and 10  years of fundamental data to understand the safety and growth prospects of a dividend  Dividend Safety ScoreOur Safety Score answers the question   Is the current dividend payment safe   We look at factors such as current and historical EPS and FCF payout ratios  debt levels  free cash flow generation  industry cyclicality  ROIC trends  and more  Scores of 50 are average  75 or higher is very good  and 25 or lower is considered weak 
For the time being  AbbVie s dividend payment is extremely safe  The company received a Dividend Safety Score of 78  which is excellent and places it in the top quartile of dividend paying stocks 
AbbVie s free cash flow payout ratio over the last 12 months is a healthy 49   which is roughly in line with the company s payout ratios realized since it was spun off in 2013  Given AbbVie s strong outlook over the next few years for continued growth  we think its payout ratio is very healthy for the time being Source  Simply Safe Dividends
In addition to its healthy payout ratio  AbbVie has generated sales growth in each of the last five years  We don t have data that goes back to the last recession  but pharma companies are generally recession resistant because consumers still need to treat their illnesses regardless of how the economy is doing  The bigger risk to sales cyclicality is patent expirations of major drugs such as Humira  AbbVie needs to develop new drugs that can eventually replace those sales or else it could see a steep revenue decline that could endanger the dividend Source  Simply Safe Dividends
As we mentioned earlier  pharma manufacturers generate excellent free cash flow when they successfully commercial a major drug  Years of research and development spending has already been realized  so the company gets to enjoy healthy profits  AbbVie has generated nice free cash flow in each of the last six years  which has provided plenty of cushion to keep paying and growing the dividend Source  Simply Safe Dividends
Few businesses can generate operating margins in the teens  much less in the 30  range like AbbVie has done  Management expects margins to hit 50  by 2020  highlighting the extreme profitability enjoyed by pharma companies  High returns allow companies to compound their earnings faster and are usually a sign of competitive advantage  intellectual property and drug development expertise  in this case  Source  Simply Safe Dividends
Some investors have expressed concern about AbbVie s balance sheet  At first glance  the company s  31 7 billion debt burden  largely resulting from AbbVie s  21 billion acquisition of Pharmacyclics in 2015  does raise some eyebrows 
However  AbbVie could cover all of its debt using the  8 4 billion it has in cash and about 3 1 years  worth of earnings before interest and taxes  EBIT   which is reasonably healthy  Standard   Poor s and Morningstar have given the company A and A  credit ratings  respectively  We would like to see AbbVie reduce its debt over the next few years while it is generating strong free cash flow from Humira  If Humira s revenue unexpectedly shrinks over the next five years  the balance sheet could become strained Source  Simply Safe Dividends
Overall  AbbVie s dividend looks very safe at the moment  The company has a healthy payout ratio  generates plenty of free cash flow  and is enjoying double digit earnings growth 
However  the trajectory that Humira s revenue takes beyond the next few years  coupled with developments in AbbVie s drug pipeline  will significantly impact the safety of the dividend from 2020 and beyond Dividend Growth ScoreOur Growth Score answers the question   How fast is the dividend likely to grow   It considers many of the same fundamental factors as the Safety Score but places more weight on growth centric metrics like sales and earnings growth and payout ratios  Scores of 50 are average  75 or higher is very good  and 25 or lower is considered weak 
AbbVie s Dividend Growth score of 89 is excellent  The company last increased its dividend by 12  in October 2015 and is included on the dividend aristocrats list despite being spun off at the start of 2013  when it continued its dividend growth streak as an independent business 
Abbott Laboratories  which spun off AbbVie  has a dividend growth streak of more than 40 consecutive years and is the reason why AbbVie is considered a dividend aristocrat  With that said  AbbVie has increased its dividend by 42  since 2013 with increases each year 
We believe AbbVie will continue recording at least a high single dividend growth rate for the next few years  Growth will be fueled by the company s reasonable free cash flow payout ratio of 49  and strong business fundamentals as drug sales and margins are expected to increase significantly through 2020 
The main wild card impacting future dividend growth beyond the next few years is the rise of Humira competition  which could come as early as 2019 or as late as 2022  We will re evaluate AbbVie s dividend growth potential as that time draws nearer ValuationABBV s stock trades at 11 1x forward earnings estimates and has a dividend yield of 4 1   For a stock with above average growth prospects over the next few years  it appears to be very reasonably priced 
The seemingly low expectations attached to the stock are a reflection of investors  concerns about AbbVie s concentration in its Humira drug  which is set to experience competition in the U S  market sometime over the next three to six years  With its European patent set to expire in 2018 as well  growth in international markets could also slow 
However  Evercore ISI s analyst Mark Schoenebaum estimated that AbbVie s 2020 guidance for sales and margins implies adjusted earnings per share of approximately  8 80  He applied a 16x P E ratio to his estimate of 2020 earnings and discounted it back to 2015 using a 9  discount rate  The stock price resulting from his analysis was about  100 per share  which is nearly 100  higher than AbbVie s most recent closing price 
With expectations for double digit earnings growth through 2020  AbbVie s total return potential certainly looks attractive at first glance  However  dividend investors must be willing to accept the higher uncertainty surrounding the company s cash flows beyond 2020 ConclusionWhile the market s expectations seem to bake in a good amount of caution today  it s still hard to get comfortable with AbbVie s competitive landscape over the next five years  The key issue is how long the company s Humira drug can profit in the U S  before biosimilar competition emerges  The difference of just a few years could really make or break the stock s performance over the coming years 
Unfortunately  we don t have an edge when it comes to analyzing this risk  nor do we have a comfortable method of evaluating AbbVie s large pipeline of new drugs that will launch over the next five years  The stock looks set to be a big winner if it delivers on management s 2020 goals  it trades for less than 7x implied 2020 earnings per share today   but we would ultimately prefer to stick with other blue chip dividend stocks that offer greater profit diversification and a slower pace of industry change ",2016-03-02,Brian Bollinger,https://www.investing.com/analysis/abbv:-a-cheap-dividend-aristocrat-yielding-over-4-200120181,200120181
151631,373147,AMGN,How Should You Handle Johnson   Johnson ,opinion,"Johnson   Johnson  NYSE JNJ  posted a mixed 4Q2015 in which EPS beat and topline disappointed but anagement guided positively for 2016 despite the risk of adverse currency shifts and slowdown in the global market  Solid perform of new products also continued to drive growth in Johnson   Johnson 
Can Johnson   Johnson s diversified business model and solid financial position help it dodge the rough market conditions and for how long  This Johnson   Johnson analysis article examines the efforts the management is making to fuel more growth in the future and the risks that the company could run into that could potentially change the direction of its business  But first  here is a quick recap of last quarter s earnings 
4Q2015 highlight
Johnson   Johnson  NYSE JNJ  posted 4Q2015 EPS of  1 44  up 5 1  YoY and ahead of the consensus estimate of  1 42  But revenue reading of  17 8 billion disappointed  Revenue fell 2 4  YoY and missed the consensus estimate of  17 9 billion  Negative forex movement and pricing pressures in some markets took a heavy toll on the topline metric 
Segmentally  Pharmaceutical segment sales rose 0 8  YoY to  8 1 billion and Medical Devices sales fell 3 3  to come in at  6 4 billion  Consumer segment sales declined 7 9  to come in at  3 3 billion 
The chart below captures Johnson   Johnson s segmental revenue contribution 

2016 guidance
Johnson   Johnson  NYSE JNJ  is looking for 2016 EPS in the band of  6 43 to  6 58  Revenue is modeled in the range of  70 8 to  71 5 billion 
What s exciting about Johnson   Johnson 
Rich pipeline 
Johnson   Johnson  NYSE JNJ  has a rich portfolio of new drug candidates and candidates for label extension  Between 2015 and 2019  the management of Johnson   Johnson outlined plans to seek marketing approval of more than 10 new products  The management further emphasized that all of those new products have blockbuster potential 
Since 2009 until 2015  Johnson   Johnson had launched 14 new products  More than half of those products have already reached blockbuster status are have blockbuster potential 
To squeeze more money from its existing portfolio and also guard against generic threat  Johnson   Johnson is looking to for label extension opportunities  At least 40 drugs already launched or soon to be launched are candidates for label extension 
Growth themed deals
Johnson   Johnson boasts a well oiled R D department  which explains its solid portfolio of internally developed products  but the company leaves nothing to chance when it comes to pursuing new growth opportunities  The company has inked a number of growth focused deals including two acquisitions that particularly strengthen its play in the advanced prostate cancer market 
Acquisition of Cougar Biotechnology added to Johnson   Johnson s prostate cancer portfolio portfolio by bringing in Zytiga to the mix  Zytiga is approved for prostate cancer treatment and generated  2 2 billion in sales in 2015  An additional approval of Zytiga for chemona ve prostate cancer victims nearly tripled its addressable market 
The acquisition of Aragon also added a key prostate cancer drug candidate to Johnson   Johnson s pipeline  JNJ 927  the drug compound that Johnson   Johnson acquired through Aragon  is in Phase 3 development and is targeting pre metastatic prostate cancer  CRPC  market 
Johnson   Johnson could use JNJ 927 as a defensive product in the prostate cancer market when Zytiga s marketing exclusivity expires 
Besides outright acquisition deals  Johnson   Johnson is also fond of pairing efforts with strategic partners  The company is working with Achillion Pharmaceuticals Inc  NASDAQ ACHN  to develop a treatment for hepatitis C 
Solid new products launch record
Johnson   Johnson  NYSE JNJ  has recently launched a number of new drug products that are quickly gaining blockbuster status  The company s recent new launches include Stelara and Simponi  These products are not only doing well on the market  but comparison tests have shown them to be more effective than rival therapies from other companies  For example  Stelara beat Amgen  Inc   NASDAQ NASDAQ AMGN  s Enbrel in a measure of effectiveness on patients afflicted by plaque psoriasis 
To strike while the iron is still hot  Johnson   Johnson is working to expand the treatment mandate of these drugs by testing them for other indications  As for Simponi  the drug recently received EU approval for the treatment of rheumatoid arthritis 
Zytiga  which raked in  2 2 billion in sales last year  has also had its label expanded to include treatment of chemona ve prostate cancer  The label expansion significantly widened the drug s patient population 
Attention on emerging markets
Every multinational pharmaceutical company these days has some plans for the emerging and developing markets and Johnson   Johnson is no exception  The reason emerging markets have become attractive in the recent times is the increased emphasis on healthcare access with insurance overage expanding to cover more population  The widening healthcare market in the emerging economies is seeing Johnson   Johnson double down in markets such as India  China and Brazil 
Huge addressable market
A huge growth opportunity lies ahead for Johnson   Johnson  NYSE JNJ  in the pharmaceutical segment  Predictions by IMS Health show that the global pharmaceutical market will increase at compound annual growth rate of about 3  from 2014 to 2019  The market was worth more than  1 trillion at the end of 2014 
What s worrying about Johnson   Johnson 
Generic threat
A number of Johnson   Johnson  NYSE JNJ  s key drugs are set to lose their marketing exclusivity  thus getting exposed to generic competition  For example  Remicade is already battling competition from copycats called biosimilars in the EU market  Invega is another product struggling to overcome generic competition  In the U S   patents for Zytiga and Xarelto are being challenged 
Although only a small number of Johnson   Johnson s blockbuster products are facing generic threat or might soon face generic competition  the fact that they are large revenue contributor means that Johnson   Johnson s revenue flow could be greatly hampered 
Negative forex movement
Johnson   Johnson has a significant portion of its operations abroad  which means massive exposure to unfavorable currency movements  A stronger U S  dollar is offsetting Johnson   Johnson s gains abroad as international sales are worth less when converted to the reporting currency which is USD 
Slowdown in China
Johnson   Johnson  NYSE JNJ  s consumer business is facing growing pressure in China  Demand in the market has slowed down as economic cold spreads and a rise of new rivals is also limiting the sale of Johnson   Johnson s consumer products 
Pipeline disappointment
Johnson   Johnson invests huge amounts of money and time to develop a drug  but the company also has a history of failed drug developments  A number of its candidates have failed to secure regulatory approval at the last minute  In some other cases the company has been forced to terminate work on certain candidates  As much as the management is optimistic that they will launch 10 new products in the next five years  there is no guarantee all of the candidates it will be seeking regulatory approval for will be cleared  Failure to get a product that has cost so much money to develop usually comes as a major setback and Johnson   Johnson is prone to that risk with its ambitious rollout plan for the next five years 
Label warning
After a box warning was added to the label of Johnson   Johnson  NYSE JNJ  s Procrit  sales of the drug contracted nearly 14  to just  1 1 billion in 2015  Label warning ensures increased safety for users of a particular product  but it hurt sales like in the sale of Procrit  There is no knowing which of Johnson   Johnson s existing products  especially blockbusters  could fall victim to negative label edit 
Takeaway
Johnson   Johnson  NYSE JNJ  s new product launches have been a huge success and its growth streak could accelerate if the coming launches also become success ",2016-04-11,InvestCorrectly,https://www.investing.com/analysis/how-should-you-handle-johnson---johnson-(nyse:jnj)-200124702,200124702
151660,373176,AMGN,Sliding Into The Close,opinion,"DOW   23   16 374
SPX   2   1951
NASDAQ   16   4733
10 YR YLD    03   2 17 
Oil    12   46 63
Gold   8 70   1126 00
Silver    03   14 83
Wall Street started the session on a high note  but could not hold it  Stocks slipped into the close and the Nasdaq turned red for the day  The stakes couldn t be higher for the Friday morning s August employment report  even though the month has typically been cursed by disappointment  The consensus guesstimate calls for about 215 000 to 220 000 new jobs created in August  with the unemployment rate holding at 5 3   but August is notorious for misses  From 2005 to 2014  forecasters have over estimated the initial August payrolls print seven times  including in each of the past four years 
What s more  the Labor Department  excluding annual and benchmark revisions  has marked up its first estimate in subsequent months in eight of the past 10 years  Part of the puzzle of forecasting August payrolls is the difficulty in adjusting for annual changes in the school year calendar  Financial market turmoil  at least  probably did little to impact hiring decisions in August  The government surveys households and businesses in the week that contains the 12th of the month  so the data will reflect responses covering the Aug  9 15 period  that was a few days before the market rollercoaster ride began 
Short dated Treasury debt yields  which are tied most closely to monetary policy forecasts  rose in August  with the two year note yield logging its fifth straight monthly increase  That was its longest winning streak since 2006 when the Fed last raised interest rates  Long dated Treasury yields  often seen as a safe haven from stock market volatility  are virtually unchanged on the year  suggesting that bond investors are brushing off the panic about slowing global growth  This would suggest that bond traders are bracing for an imminent rate hike 
The European Central Bank will continue its 60 billion euro a month asset purchase plan  that s the Euro version of QE  The stimulus is intended to help get consumer price inflation back toward the ECB s target of just below 2   In the year to August  it stood at 0 2   ECB President Mario Draghi today said it could go negative in the coming months following recent oil price falls  Draghi said   The risks to the euro area growth outlook remain on the downside   And if things actually do get worse  Draghi emphasized he is willing to do even more  The euro dropped against the dollar and Eurozone stock markets enjoyed a nice bounce 
Chinese markets are closed today and tomorrow to mark the 70th anniversary of the end of World War II  The holiday is officially called  The 70th Anniversary of Victories in the Chinese people s War of Resistance Against Japanese Aggression and the World Against Fascism   and right there we have a glimpse into the problems in China  Presiding over the extravaganza  President Xi Jinping said China would remain committed to  the path of peaceful development  and unexpectedly pledged to slash 300 000 troops from the country s 2 3 million strong military  The announcement came before a huge military parade  At the same time  the U S  government reported that five Chinese Navy ships were sailing in international waters off Alaska for the first time 
Treasury Secretary Jack Lew criticized China s handling of its currency devaluation  In a CNBC interview  Lew said   there s an economic and a political reality to things like exchange rates   and  how they manage their exchange rate is a matter of great concern to us and that they need to be willing to let market forces drive the value up  not just drive it down   Lew  will be participating in a meeting of G 20 financial ministers and central bankers Friday in Turkey  The treasury secretary s remarks come ahead of the Chinese premier s visit to the U S  later this month 
Tomorrow brings the big monthly jobs report for August  This will be the data that the Fed will use at their FOMC meeting September 16   17  the question is whether the report will be weak enough to keep the Fed from hiking rates or strong enough to allow a hike 
Also tomorrow  the G 20 will be meeting in Turkey  The International Monetary Fund has prepared a report for G20 finance chiefs  and the IMF says the turmoil in China and other factors like capital flow reversals were increasing the risks to economic growth around the world  It warned that advanced and emerging economies need to continue to support demand with reforms and investment to ensure that the turbulence in markets and China s troubles do not stall economic activity in the rest of the world 
The report expressed continued confidence that growth is picking up  modestly  in advanced economies in the second half of 2015 and in 2016  helped by the impact of cheaper oil  But the oil price plunge  along with other commodities  is hurting emerging market economies  and they are also being buffeted by the impact on their currencies of China s yuan devaluation and the strong dollar  The dollar s strength  the Fund warned  could take a toll on companies with dollar liabilities  The Fund highlighted an increase in risks to overall global growth  that China would not confront its slowdown with growth supporting policies  that commodity prices would slide further  that the US dollar would continue to rise  and that companies would suffer from higher debts 
Of course  writing a report doesn t make it so  The reality on the ground is that gauging China s economy is a guessing game  the Chinese simply don t measure their economy in familiar ways and they certainly run their economy a bit differently  And most analysis overlooks the fact that China s economy is changing  the service sector is now the driver of growth  so it makes sense that industrial growth is slowing down  but it doesn t necessarily mean the economy has gone over a cliff  Beijing s economic policy makers know that even though structural overhauls will moderate growth in the near term  they ll also bolster long term growth and help stave off a major deceleration 
The U S  trade deficit fell in July to its lowest level in five months as exports rose  The Commerce Department said the trade gap narrowed 7 4 percent to  41 9 billion  the smallest since February  The smaller deficit implied a modest contribution to gross domestic product from trade early in the third quarter 
The Institute for Supply Management said its services index slipped in August  to 59  from 60 3  in July  but still a very strong reading indicating growth in the sector  Ahead of Friday s payrolls report  the ISM services employment index fell 3 6 points to 56  
 today on the gross domestic product broken out for each state for 2014  Just 16 states outperformed the country as a whole last year  In 32 states  gross domestic product advanced at the same or slower pace than the 2 2  economic growth recorded for the U S  And the economies in two other states  Alaska and Mississippi  contracted last year  Among those 16 were the four largest state economies  California  Texas  New York and Florida  The fastest growing state was North Dakota  thanks to a booming oil patch  it is unlikely to repeat in 2015  Arizona came in at  37  with anemic 1 4  growth in GDP 
Jobless claims increased by 12 000 to 282 000 in the week ended Aug  29  Since the beginning of March claims have held below 300 000  indicating employers in the U S  are confident in their outlook 
Sony Pictures has reached a settlement with former employees in a lawsuit related to the massive data breach it suffered almost a year ago  The federal lawsuit  which is still pending class action status  is a combination of seven different cases brought by nearly 50 000 current and former employees whose personal  financial and medical information were posted online  Additional details about Sony s settlement are expected to be filed by mid October 
Novartis AG  NYSE NVS  said it will begin selling the first biosimilar drug in the U S  after an appeals court in Washington rejected a request to block the Swiss drug maker s sale of its copycat version of Amgen s NASDAQ AMGN  blockbuster remedy  Neupogen  Zarxio was the first biosimilar a copy of a biotechnology drug approved by the FDA  In Europe  where biosimilars have been available for several years  they typically cost 15  to 30  less than the original brands 
Royal Dutch Shell s  NYSE RDSa  proposed  58 billion merger with BG Group  LONDON BG  has received unconditional clearance from the European Commission  the third of five key markets needed to clear the deal  The EU s top antitrust regulator concluded that the acquisition would not allow Shell to influence prices for oil and natural gas  and that the markets would remain competitive after the transaction 
Pimco Total Return saw another  1 8 billion in net outflows in August  down from  2 5 billion in July and  3 billion in June  Total assets under management at the former giant of mutual funds have now fallen below  100 billion for the first time since 2007  the fund neared  300 billion at its peak   As for the performance scorecard  Pimco Total Return s year to date gain is 0 72  vs  the benchmark of 0 45   It s also outperformed the benchmark over 3 year  5 year  and 10 year periods  as well as since its inception 
Meanwhile  Bill Ackman has joined a string of high profile hedge fund managers in reporting deep losses for August  The firm s Pershing Square Holdings portfolio dropped 9 2   and is now down 0 1  since January  Last year the fund gained 40   beating the S P 500 s 13 7  gain  Other hedge fund losses for August  Greenlight Capital  5 3   Third Point  5 2   Jana Partners  4 3   Viking Global  2 1   Omega Advisors  6   Andor Capital  4 5  ",2015-09-04,Marvin Clark,https://www.investing.com/analysis/sliding-into-the-close-264054,264054
151661,373177,AMGN,S P 500 Earnings Outlook  Sell Healthcare  Buy Energy ,opinion,"By next Friday  October 2nd  2015  readers will know what the September  15 jobs report looked like  and what the new  forward 4 quarter  estimate is for the S P 500 
Primarily because of the nature of capitalism  and expense control  there is typically an upward bias to S P 500 earnings estimates and cash flow over long periods of time  That pattern plays out quarterly as well  as each quarter  beginning the first day of January  April  July and October  sees a quarterly bump to the S P 500 forward estimate typically between  3  5 per share 
2015 has been a tougher scenario for earnings estimates watchers  given the 50  60  quarterly decline in Energy earnings  but with the October 1  15 print  expect the  forward 4 quarter  estimate to reach  125  127 per share 
From a bigger picture perspective  here are the current bottom up estimates for the S P 500 as of 9 25 15 
2014  actual    118 78
2015  est    118 44
2016  est    130 80
2015 will likely be a positive year for earnings growth  given that Q4  15 will see very easy comps for the Energy sector and the US dollar  However  1  3  S P 500 earnings growth isn t much to get excited about  This could explain why the S P 500 is flat this year 
2016 earnings growth remains the question but  minimum  mid single digit  S P 500 earnings growth in 2016 
Analysis   conclusion  Healthcare and Biotech had a brutal week this past week  with many names trading near their 8 24 lows and Amgen  NASDAQ AMGN  trading below its 8 24 lows  while Energy  despite the negative sentiment and bad news around Brazil and China  looks to be trading better 
As discussed here  Energy and the US dollar start to lap much easier comps starting October 1  15  That could start to make a difference in forward estimates and guidance for Energy  Industrials  and   depending on China exposure   even Basic Materials 
During 2014 s August   September 10  correction  the S P 500 bottomed in early October  14 and   despite the collapse in crude oil   had a decent Q4  14 return 
Energy  like Financials in 2015  could be a sector to hold in 2016  if only from a  less risk  perspective  The sector might show tepid earnings growth in 2016  but it is hard to fathom how any quarter in 2016 could be worse than the 55    60  y y Energy earnings declines we saw in 2015 ",2015-09-26,Brian Gilmartin,"https://www.investing.com/analysis/sp-500-earnings-update:-sell-health-care,-buy-energy--266242",266242
151662,373178,AMGN,Bullish  Cup And Handle  Formation On AMGN Shares,opinion,"Bullish  cup and handle  formation on AMGN shares 
O AMGN  daily ",2015-11-26,Petros Steriotis,https://www.investing.com/analysis/amgn-(nov-26)-272649,272649
151681,373197,AMGN,Dow Jones   April 28  2015,opinion,Dow JonesThe Dow Jones industrial average fell 42 17 points or 0 23  to 18 037 97 as the U S  stocks ended down on Monday  led by losses in biotech shares after disappointing news from several companies including Amgen  NASDAQ AMGN  ,2015-04-28,ICM Brokers,"https://www.investing.com/analysis/dow-jones-:-april-28,-2015-249829",249829
151684,373200,AMGN,MannKind Corporation Disappoints With Afrezza Sales,opinion,"By Sarah Roden
MannKind Corporation  NASDAQ MNKD  reported first quarter 2015 results on May 7  revealing underwhelming sales and a mediocre Afrezza launch  Shares of MannKind last closed at  4 02  just above the 52 week low of  3 52  Some analysts are beginning to doubt if the company can make a comeback 
The biotechnology company posted a net loss per share of   0 08   slightly narrower loss than the consensus of   0 09  and an improvement from   0 14  in the same quarter of last year  MannKind did not provide a revenue figure but the analyst consensus for quarterly revenue was  6 29 million 
The focus of the earnings report was Afrezza  a rapid acting inhalable insulin for adults with diabetes produced by both MannKind and Sanofi  PARIS SASY   Though Afrezza is just beginning its commercial launch  Sanofi s recent quarterly earnings revealed that the inhalable insulin only brought in  1 1 million in the first quarter far below the analyst estimate of  3 million to  4 million  MannKind anticipated the weak sales were due to the low number of prescriptions  However  MannKind executive chairman Alfred Mann pointed out that Sanofi s reported revenue for Afrezza  really covered only a portion of the quarter  since the launch only started in February  
Mann acknowledged that Afrezza s launch  may be getting off to a slower start  than anticipated  but MannKind expects to see an acceleration in sales  Mann added that  the potential diabetes market is enormous and Afrezza will fill a substantial need   Analysts and executives pointed to the positive response from people with diabetes who have used Afrezza 
Now  MannKind owes  12 4 million as its portion of the loss arrangement with Sanofi  MannKind financed the loss under Sanofi s loan facility and there is  15 4 million outstanding under the loan facility 
According to   analyst  of Piper Jaffray maintained a Neutral rating on MannKind on May 8 and lowered his price target from  7 00 to  3 50  Though MannKind revealed that Afrezza s launch fell below expectations  Schimmer pointed out that  Afrezza is well received by patients who are able to get it  but access is a limiting step   Schimmer commented    MannKind  is optimistic that measures to improve access and initiating therapy without hassle will lead to an acceleration of uptake and that deploying its technology for new pipeline programs will create value  which will be needed for shares to stabilize and or appreciate   However  the analyst is lowering his price target due to concerns regarding MannKind s  financial position increase  On average  the top analyst consensus for MannKind on is Hold Joshua Schimmer has rated MannKind 7 times since January 2010  though he has only given Sell and Hold ratings  Schimmer has earned a 50  success rate recommending the stock with a  8 1  average return when measured over a three month period  Schimmer has rated many biotechnology stocks in the past such as Amgen Inc  NASDAQ AMGN  and Gilead Sciences  NASDAQ GILD  
Schimmer has rated Amgen 12 times since October 2009  earning a 67  success rate recommending the company with a  5 7  average return per AMGN rating when measured over three months  Separately  Schimmer has rated Gilead Sciences 9 times since February 2011  earning a 67  success rate recommending the stock with a  5 1  average return per GILD rating when measured over three months 
Overall  Schimmer has a 60  overall success rate recommending stocks with a  13 2  average return per rating when measured over one year To see more ratings made by Joshua Schimmer  visit today ",2015-05-11,Sarah Roden,https://www.investing.com/analysis/mannkind-corporation-disappoints-with-afrezza-sales;-analysts-lower-expe-251317,251317
151685,373201,AMGN,Bottoms In For Continued Chop,opinion," Seize the day  and put the least possible trust in tomorrow     Horace
Markets bounced today and ran into resistance 
Great action but I ll give things a bit before I buy into the indexes 
I just need a little more proof  like heavier volume  for me to buy this bounce but as I ve talked about a lot this summer  I really expect chop until the fall which means trades of a week or so in most cases 
I did buy some Amgen Inc  NASDAQ AMGN  today but that s all I m holding for now 
Twitter Inc  NYSE TWTR  reported tonight and w as up large  but then it fell and is now off some 7   Let s see how the overnight goes but earnings moves remain very volatile and roller coaster I m not riding 

The Doji bar yesterday was confirmed today so we should have a low in here but we may only move back up to test 213 as the summer rolls on 
We may need a couple more days below 210 to push past that level ",2015-07-29,Warren Bevan,https://www.investing.com/analysis/bottoms-in-for-continued-chop-259837,259837
151708,373224,AMGN,3 Pharma Stocks That Soared Past Pfizer In 2014,opinion,"Pfizer Inc  NYSE PFE   one of the most well known large cap pharma companies in the world  had a challenging year with its top line remaining under pressure and not too many updates on the regulatory pipeline front 

Although Pfizer s earnings track record was better than expected in the last three quarters  the top line remains under pressure with several erstwhile blockbuster drugs facing generic competition 

The company ended 2014 with yet another blockbuster drug  Celebrex  losing patent protection  The impact of Celebrex generics  which entered the market in Dec 2014  will be felt in the upcoming quarters  Alliance revenues are also under pressure with the expiry of certain agreements including one withAmgen Inc  NASDAQ AMGN  for Enbrel 

Meanwhile  significant pipeline or regulatory updates were missing last year  Apart from label expansions and approval of vaccines like Trumenba  a key update was the FDA s decision to grant priority review to the company s new drug application for its experimental cancer treatment  Ibrance  palbociclib  

Pfizer was also in the news last year due to its attempt to acquire Astrazeneca Plc  NYSE AZN   Although AstraZeneca made it clear it was not interested in Pfizer s offer  rumors regarding acquisition talks surfaced again later in 2014  While the AstraZeneca deal did not happen  Pfizer did complete a few small acquisitions and entered into collaboration agreements mainly targeting immuno oncology  a key focus area for pharma and biotech companies 

A Look at Some Pharma Stocks That Fared Better than Pfizer

With Pfizer gaining just 5 88  in 2014  here s a look at some peers that fared better in 2014 and look well positioned this year 

Indianapolis based Eli Lilly and Company  NYSE LLY   which has been facing headwinds in the form of generic competition and pricing pressure  looks positioned to return to earnings growth in 2015  The Zacks Rank  3  Hold  stock  which saw its shares gain 40 51  in 2014  surpassed earnings expectations in two of the last three quarters and is also slated to report better than expected earnings in the fourth quarter 

Even though Lilly will be facing several headwinds this year    including foreign exchange  products like Cialis  Forteo  Strattera and Effient  the diabetes franchise  and the ex U S  animal health segment    should perform well  New products    Cyramza  Trulicity and Jardiance    should also do well  2015 will be eventful on the pipeline and regulatory front as well with several phase III data readouts and multiple regulatory actions expected 

UK based AstraZeneca  a Zacks Rank  3 stock  is another company that fared better than Pfizer in 2014  The company s track record was pretty decent with earnings surpassing expectations in two of the last three quarters  AstraZeneca was up 25 23  last year  Apart from being in the news related to Pfizer s interest in acquiring the company  AstraZeneca also gained approval for quite a few products last year and provided positive pipeline updates  The company s immuno oncology pipeline also looks interesting 

Swiss pharma company Novartis N  NYSE NVS   a Zacks Rank  3 stock with a strong presence in the oncology and ophthalmology markets  gained 21 68  in 2014  The company  which is facing generic competition for quite a few products  is working on reorganizing its portfolio so that it can focus on core therapeutic areas  Novartis has a deep pipeline and is also progressing with the development of biosimilars especially its biosimilar version of Amgen s Neupogen  Its experimental heart failure treatment  LCZ696  also represents huge commercial potential ",2015-01-11,Zacks Investment Research,https://www.investing.com/analysis/3-pharma-stocks-that-soared-past-pfizer-in-2014-238007,238007
151709,373225,AMGN,Biotech Stock Roundup  Shire To Acquire NPSP  Celgene   Pharmacyclics,opinion,"Acquisitions and deals continue to be in focus with yet another pharma company announcing its intention to acquire a biotech company  Meanwhile  interest in the immuno oncology area shows no signs of slowing down with another deal being announced 

Many companies also provided a peek at preliminary fourth quarter results and outlook and plans for 2015 

Recap of the Week s Most Important Stories

1 NPS Pharmaceuticals   NASDAQ NPSP  rare disease portfolio helped the company enter into an acquisition agreement with Shire under which NPSP will be acquired by Shire for about  5 2 billion   a hefty premium of 51  to NPS Pharma s unaffected share price on Dec 16  2014  With this acquisition  Shire will add short bowel syndrome treatment  Gattex  to its portfolio 

2  Several companies attended the J P  Morgan Healthcare Conference and provided an update on their pipelines and business  preliminary fourth quarter results and guidance for 2015  Companies like Celgene Corporation  NASDAQ CELG  and Pharmacyclics  NASDAQ PCYC  stood out with both providing robust outlooks  Celgene guided well above expectations for 2015 with Revlimid set to continue with its strong performance  Read more    

Another company that provided a bright outlook and better than expected fourth quarter preliminary results is Pharmacyclics  Imbruvica is expected to become a blockbuster in 2015  Meanwhile  AbbVie s 2015 EPS guidance could prove to be conservative depending on the sales ramp of the recently approved hepatitis C treatment  Viekira Pak 

3  Agenus Incs   NASDAQ AGEN  shares shot up 28 7  on an immuno oncology focused deal with Incyte  NASDAQ INCY   The agreement terms look good and provide Agenus with upfront payments and the opportunity to earn significant milestone payments and royalties  Incyte has immuno oncology focused agreements with several other companies like Merck and Bristol Myers Squibb as well 

4  Regeneron Pharmaceuticals Inc  NASDAQ REGN  and partner Sanofi continue to move ahead with their PCSK9 inhibitor  The companies said that Praluent has been accepted for review in the EU  With several companies developing PCSK9 inhibitors  it remains to be seen which company will be the first to gain approval for their product in this lucrative blockbuster market  Amgen Inc  NASDAQ AMGN  PCSK9 inhibitor  evolocumab  is currently under FDA review for dyslipidemia with a response expected by Aug 27 

5  Biogen  which has a strong presence in the multiple sclerosis market  is looking to expand and diversify its pipeline  The company has signed a deal to acquire Convergence Pharmaceuticals  The deal will allow Biogen to expand its neuropathic pain portfolio  Read more    

Performance

Over the last five trading days  Gilead s shares declined slightly  0 45   among major biotechs  Celgene was the highest gainer  8 57   during this period thanks to its strong growth outlook 

Celgene recorded the highest gain  34 52   among major biotechs over the last six months as well 

Overall  the NASDAQ Biotechnology Index was up  4 77   over the last five trading days 


What s Next in the Biotech World 
With biotech companies yet to start reporting fourth quarter results  watch out for preliminary results and pipeline updates ",2015-01-15,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-shire-to-acquire-npsp,-celgene---pharmacyclics-238503",238503
151710,373226,AMGN,Premium Earnings Trades For Amgen And United Rentals,opinion,"Two names today that report after the close tonight Amgen Inc  NASDAQ AMGN   and United Rentals Inc  NYSE URI  
Amgen
Amgen  has been slowly trending higher  making higher lows  Since December those have met resistance at 172 and consolidated  Heading into earnings it is pushing towards the top of the range with the RSI in the bullish range and rising  while the MACD is also rising  There is support lower at 162 and 155 followed by 149 50  There is no resistance above 172 but a Measured Move to 214  The reaction to the last 6 earnings reports has been a move of about 3 48  on average or  5 90 making for an expected range of 161 75 to 173 75  The at the money weekly April Straddles suggest a smaller  5 20 move by Expiry with Implied Volatility at 39  above the May at 25   Short interest is low at 1 4   Open interest is focused here between the 165 and 170 Strikes 
Trade Idea 1  Buy the April 167 5 170 Call Spread for  1 30 
Trade Idea 2  Buy the April 167 5 170 1 2 Call Spread for a  0 30 credit 
Trade Idea 3  Sell the April 162 5 172 5 Strangle for a  1 65 credit 
Trade Idea 4  Buy the April May 172 5 Call Calendar   1 44  and sell the May 155 Put  90 cent credit  for 54 cents 
 1  and  2 give the short term upside  with  2 using margin   3 gives a good range with it profitable from 160 85 to 174 15   4 gives the longer term upside and uses leverage to lower the cost  I prefer  3 or  4 
United Rentals
United Rentals  made a double top in November and pulled back  Since then it has been trending higher with consecutive higher lows  The short term consolidation into earnings is occurring at the same time spread as the last short term top and same distance measured higher  The RSI is bullish but pulling back while the MACD is leveling  There is support lower at 95 40 and 86 70 followed by 82  There is resistance higher at 99 70 and 105 50 followed by 114 and 119  The reaction to the last 6 earnings reports has been a move of about 3 05  on average or  3 00 making for an expected range of 94 75 to 101  The at the money weekly April Straddles suggest a larger  5 25 move by Expiry with Implied Volatility at 66  above the May at 33   Short interest is high at over 10   Open interest favors the 95 Strike should it fall and the 100 to 105 range if it rises 
Trade Idea 1  Buy the April 97 5 95 Put Spread for  1 20
Trade Idea 2  Buy the April 97 5 95 1 2 Put Spread for a 30 cent credit 
Trade Idea 3  Buy the May 95 100 Call Spread for  3 00 
Trade Idea 4  Buy the May 95 100 Call Spread and sell the May 95 Puts for 65 cents 
Trade Idea 5  Buy the May 97 5 100 Call Spread and sell the April May 95 Put Calendars for 50 cents
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2015-04-22,Gregory W. Harmon,https://www.investing.com/analysis/premium-earnings-trades-for-amgen-and-united-rentals-249234,249234
151732,373248,AMGN,NASDAQ Biotechnology Index Tops  Amgen  Gilead Exhaustion,opinion,"Just a couple months ago  Janet Yellen issued a warning that biotechnology may be in a bubble  Tuesday  the iShares NASDAQ Biotechnology Index ETF  NASDAQ IBB  was 20  higher  While Janet Yellen was wrong at the time  we should all remember that Alan Greenspan issued the same warning on Dot com companies in the late 1990s  He was early on that call but ultimately right Based on technical analysis  it appears biotechnology may have reached a top Tuesday  Why 
First  the daily chart put in a significant top signal  doji   Yesterday  the move confirmed as the index declined  This came on the back of an explosive move known to traders and investors as a blow off top  previous 2 weeks   In addition  stocks like Amgen  Inc   NASDAQ AMGN  and Gilead Sciences  Inc   NASDAQ GILD  reported earnings  Significant distribution appears to be taking hold on these names  Ultimately  while timing is not Fed Chair Janet Yellen s forte  nor was it Greenspan s  It is important to take it as an important heads up  Combining their viewpoint and the charts could yield a significant shorting opportunity worth 30  or more ",2014-10-30,Gareth Soloway,"https://www.investing.com/analysis/nasdaq-biotechnology-index-tops:-amgen,-gilead-exhaustion-230745",230745
151733,373249,AMGN,Energy Sector Rains On Bulls  Parade  But Skies May Clear Soon,opinion,"Stocks have needed a reason to take a breather and pull back in this long standing ultra bullish climate  with strong economic data and seasonality providing impressive tailwinds    and plummeting oil prices certainly have given it to them  But this minor pullback was fully expected and indeed desirable for market health  The future remains bright for the U S  economy and corporate profits despite the collapse in oil  and now the overbought technical condition has been relieved  While most sectors are gathering fundamental support and our sector rotation model remains bullish  the Energy sector looks fundamentally weak and continues to rank at the bottom of our forward looking sector rankings 
In this weekly update  I give my view of the current market environment  offer a technical analysis of the S P 500 chart  review our weekly fundamentals based SectorCast rankings of the ten U S  business sectors  and then offer up some actionable trading ideas  including a sector rotation strategy using ETFs and an enhanced version using top ranked stocks from the top ranked sectors 
Market overview 
The fear of broader fallout from issues like Ebola  ISIS  Russian aggression  European malaise  and slowdown in China had subsided  so the market has been waiting for next big worry to spike the fear gauge and cause a selloff to test support levels  The Dow Industrials suffered its biggest weekly percentage loss in three years  After all  it is hard to break out to new highs when bullish conviction has not been recently tested and reconfirmed  Well  it found its next big worry in the fall of oil prices and all that it might be foretelling  such as defaults in the high yield bond segment of the Financial sector and recession in global economies 
Crude oil fell another 3  on Friday to 5 year lows and 46  below the June highs after the International Energy Agency cut its outlook for 2015  and it expects prices to fall further  Tremendous increases in domestic production through enhanced recovery techniques and the prospect of energy independence in the U S   which once was considered an impossibility  has led to a global glut  but OPEC has decided not to reduce production  The U S  dollar has gained 77  year to date against the Russian ruble 
As a result  Energy sector investments are likely dead money for the near term  although the downside might be less onerous  Moreover  those investors who sought to leverage the easy money of high oil prices and enhanced production through the high yield market are no concerned more about their return OF capital rather than a return ON capital  Any surge in defaults could be a game changer  but for the moment it appears that prices will remain above the profitability thresholds  Eventually  the search for higher returns through risk assets will shift away from leveraged plays and back to unleveraged investments like Technology and Industrial stocks  and that will be bullish for the broader markets 
To be sure  the Fed s monetary policies of zero interest rates and quant easing gave the U S  economy of tremendous boost  but now the economy has its own momentum that can t be stopped with anything the Fed might have in store  As it stands  leading economic indicators are strong  GDP forecasts are being raised  job growth is the strongest since the  90s  and corporate profits sit at all time highs 
But there is no denying the cautious behavior of investors at the moment  The US 10 Year Treasury bond yield closed Friday at 2 09  as capital flowed out of equities  Its 52 week range is 1 86 3 06  The CBOE Volatility Index  a k a  fear gauge  closed at 21 08 on Friday after reaching as high as 23 06 intraday  This is still well below the October highs that spiked above 30  Also  year to date  the Healthcare and Utilities sectors  which are traditionally defensive or all weather  are the clear leaders  And then there is the condition of Europe s economy and the imminent expiration of the ECB s long term refinancing operations  which will result in a whole bunch of assets rolling off balance sheet just when it needs to expand it 
All of this warrants a degree of caution  In addition  keep in mind that this is an option expiration week  and a lack of put open interest could result in delta hedge selling that exacerbates the downside in equities and spike in VIX 
Nevertheless  2015 seems to be shaping up to indicate more of what has worked this year  i e   owning large cap equities  particularly the NASDAQ 100   longer term bonds  and a flattening yield curve   and the U S  dollar 
But simply buying a portfolio of stocks you like probably is not the right strategy  Rather  a thoughtful approach to creating a diversified portfolio of high potential stocks is more appropriate  For example  Sabrient s annual Baker s Dozen portfolio employs a  quantamental  approach that starts with a GARP  Growth At Reasonable Price  quantitative model and then applies a fundamental overlay  including a forensic accounting review by our subsidiary Gradient Analytics to help avoid the landmines among stocks with strong apparent growth prospects but poor earnings quality and sustainability  The portfolio is completing its sixth straight year  since inception in 2009  of  
SPY chart review 
The SPDR S P 500 Trust  SPY  closed Friday at 200 89  which is  3 6  below its all time highs from the previous Friday  This is the minor  but still significant  pullback that I projected  which is allowing the severely overbought technical condition to cycle back down to oversold  test support levels  and reconfirm bullish conviction  Oscillators RSI  MACD  and Slow Stochastic appear have a little further to go to the downside  but could begin a reversal at any time  I think the 50 day simple moving average will provide good support this week and the market will stabilize  Otherwise  additional levels of strong support should come from the 100 day SMA at 199  the bottom of the bullish rising channel approaching 198  and the 200 day SMA around 195 

The Russell 2000 small cap index held up much better than the large caps on Friday  which is bullish for the market at this point  and in fact it might find support from the lower line of 1 month sideways channel that appears to be forming  Both the NASDAQ 100 and Composite indexes also held up better than the S P 500 on Friday  Looking at the weak Energy sector  the price chart hardly could be uglier  but the oscillators look more promising  RSI is showing a positive divergence versus the October lows  and MACD and Slow Stochastic easily could bounce strongly from their severely oversold levels 
I am hopeful that this was the minor technical pullback the market needed in order to avoid a more dramatic event in early January 
Latest sector rankings  
Relative sector rankings are based on our proprietary SectorCast model  which builds a composite profile of each equity ETF based on bottom up aggregate scoring of the constituent stocks  The Outlook Score employs a forward looking  fundamentals based multifactor algorithm considering forward valuation  historical and projected earnings growth  the dynamics of Wall Street analysts  consensus earnings estimates and recent revisions  up or down   quality and sustainability of reported earnings  forensic accounting   and various return ratios  It helps us predict relative performance over the next 1 3 months 
In addition  SectorCast computes a Bull Score and Bear Score for each ETF based on recent price behavior of the constituent stocks on particularly strong and weak market days  High Bull score indicates that stocks within the ETF recently have tended toward relative outperformance when the market is strong  while a high Bear score indicates that stocks within the ETF have tended to hold up relatively well  i e   safe havens  when the market is weak 
Outlook score is forward looking while Bull and Bear are backward looking  As a group  these three scores can be helpful for positioning a portfolio for a given set of anticipated market conditions  Of course  each ETF holds a unique portfolio of stocks and position weights  so the sectors represented will score differently depending upon which set of ETFs is used  We use the iShares that represent the ten major U S  business sectors  Financials  NYSE IYF   Technology  NYSE IYW   Industrials  NYSE IYJ   Healthcare  NYSE IYH   Consumer Goods  NYSE IYK   Consumer Services  NYSE IYC  Energy  NYSE IYE   Basic Materials  IYM   Telecommunications  NYSE IYZ   and Utilities  NYSE IDU   Whereas the Select Sector SPDR  ARCA SPY  only contain stocks from the S P 500  I prefer the iShares for their larger universe and broader diversity  Fidelity also offers a group of sector ETFs with an even larger number of constituents in each 
 Here are some of my observations on this week s scores 
1  The rankings continue to remain stable  as Technology and Healthcare stay at the top  Technology is in the top spot with a robust Outlook score of 90  Tech stocks display the best return ratios  a good forward long term growth rate  a reasonably good forward P E  and solid support among insiders  buying activity   Healthcare scores a 73 and displays good sell side analyst support  recent upward revisions to earnings estimates   a strong forward long term growth rate  solid insider sentiment  buying activity   and good return ratios  although its forward P E is on the high side  Financial remains in third with a score of 65  and it continues to display one of the best  lowest  forward P Es  Next in the rankings  Industrial has vaulted into fourth with a more attractive forward P E  followed by Utilities and Consumer Goods Staples  a k a   Non cyclicals   Notably  prices for Consumer Services Discretionary  a k a   Cyclicals  have held up well during market weakness on the strength of strong retail sales  but this made it fall in the rankings due to a relative weaker forward P E  but the sector continues to get solid support from both analysts and insiders and boasts the best forward long term growth rate 
2  Price weakness and an improving forward long term growth rate in Basic Materials stocks has allowed its Outlook score to rise  as its forward P E is now much more attractive  But Wall Street analysts  downward earnings revisions in the Energy sector  as oil prices plummet  have kept Energy at the bottom of the rankings  Even the insiders have reduced their buying activity in this beleaguered sector  Joining Energy in the bottom two again is Telecom  which generally scores poorly across the board in most factors in the Outlook model 
3  Looking at the Bull scores  Industrial  Energy  and Basic Materials all come in with the highest score of 58  Telecom scores the lowest at 48  The top bottom spread is only 10 points  reflecting high sector correlations during particularly strong market days  i e   highly correlated risk on action  But it is generally desirable in a healthy market to see low correlations and a top bottom spread of at least 20 points  which indicates that investors have clear preferences in the stocks they want to hold  rather than the all boats lifted in a rising tide  risk on  mentality 
4  Looking at the Bear scores  Utilities again displays the highest score of 65 this week  as one would expect for this traditionally defensive sector  Utilities stocks have been the preferred safe havens on weak market days  and it is followed closely by Consumer Goods Staples  Consumer Services Discretionary  and Healthcare  Energy displays the lowest score of 36  followed by Basic Materials  The top bottom spread is a wide 29 points  which continues to reflect low sector correlations on particularly weak market days  In other words  certain sectors are holding up relatively well while others are selling off  Again  it is generally desirable in a healthy market to see low correlations and a top bottom spread of at least 20 points 
5  Technology displays the best all around combination of Outlook Bull Bear scores  followed closely by Healthcare  while Energy is the worst  Looking at just the Bull Bear combination  Utilities and Healthcare are the clear leaders  indicating superior relative performance  on average  in extreme market conditions  whether bullish or bearish   Energy is still the worst  indicating general investor avoidance  no surprise here  
6  Overall  this week s fundamentals based Outlook rankings still look bullish to me  Downward earnings revisions from Wall Street have subsided  with the exception of Energy  and in fact some sectors are getting increasingly positive revisions  The top four sectors are all economically sensitive  or in the case of Healthcare  all weather   and they also display some of the highest Bull scores  Furthermore  Basic Materials and Consumer Services Discretionary are also scoring fairly well  Keep in mind  the Outlook Rank does not include timing or momentum factors  but rather is a reflection of the fundamental expectations of individual stocks aggregated by sector 
Stock and ETF Ideas 
Our Sector Rotation model  which appropriately weights Outlook  Bull  and Bear scores in accordance with the overall market s prevailing trend  bullish  neutral  or defensive   continues to indicate a bullish bias this week  and it suggests holding Healthcare  Industrial  and  surprise   Basic Materials  in that order  for those portfolios that might be due for rebalance    Note  In this model  we consider the bias to be bullish from a rules based trend following standpoint because SPY is above both its 50 day and 200 day simple moving averages   
Other highly ranked ETFs from the Healthcare  Industrial  and Basic Materials sectors include SPDR   Health Care  ARCA XLV   iShares DJ Transport Average Index  ARCA IYT   and PowerShares Dynamic Basic Mat   NYSE PYZ  
For an enhanced sector portfolio that enlists some top ranked stocks  instead of ETFs  from within the top ranked sectors  some long ideas from Healthcare  Industrial  and Basic Materials sectors include Celgene  NASDAQ CELG   Amgen Inc  NASDAQ AMGN   Alaska Air Group  NYSE ALK   United Parcel Service  NYSE UPS   Valspar Corporation  NYSE VAL   and Westlake Chemical  NYSE WLK   All are highly ranked in the Sabrient Ratings Algorithm and also score within the top two quintiles  lowest accounting related risk  of our   a pure accounting based risk assessment signal based on the forensic accounting expertise of our subsidiary Gradient Analytics  We have found EQR quite valuable for helping to avoid performance offsetting meltdowns in our model portfolios 
However  if you prefer to maintain a neutral bias  the Sector Rotation model suggests holding Technology  Healthcare  and Financial  in that order   And if you prefer a defensive stance on the market  the model suggests holding Healthcare  Utilities  and Financial  in that order  
IMPORTANT NOTE  Some readers have been asking for more specifics on how to trade our sector rotation strategy based solely on what I discuss in my weekly newsletter  Thus  I feel compelled to remind you that I post this information each week as a free look inside some of our institutional research and as a source of some trading ideas for your own further investigation  It is not intended to be traded directly as a rules based strategy in a real money portfolio  I am simply showing what a sector rotation model might suggest if a given portfolio was due for a rebalance  and I may or may not update the information each week  There are many ways for a client to trade such a strategy  including monthly or quarterly rebalancing  perhaps with interim adjustments to the bullish neutral defensive bias when warranted    but not necessarily on the days that I happen to post this weekly article  The enhanced strategy seeks higher returns by employing individual stocks  or stock options  that are also highly ranked  but this introduces greater risks and volatility  I do not track performance of the ETF and stock ideas mentioned here as a managed portfolio 
Disclosure  Author has no positions in stocks or ETFs mentioned Disclaimer  This newsletter is published solely for informational purposes and is not to be construed as advice or a recommendation to specific individuals  Individuals should take into account their personal financial circumstances in acting on any rankings or stock selections provided by Sabrient  Sabrient makes no representations that the techniques used in its rankings or selections will result in or guarantee profits in trading  Trading involves risk  including possible loss of principal and other losses  and past performance is no indication of future results ",2014-12-15,Scott Martindale,"https://www.investing.com/analysis/energy-sector-rains-on-bulls-parade,-but-skies-may-clear-soon-235796",235796
151735,373251,AMGN,Amgen And Kite Partner For Cancer Therapy,opinion,On January 5th  biopharmaceutical company Amgen Inc   NASDAQ AMGN  announced plans to collaborate with Kite Pharma  NASDAQ KITE  on cancer treatments  The two pharmaceutical companies will join forces to research  develop  and commercialize a cancer therapy using existing drugs and research from both companies Sean E  Harper  M D   executive vice president at Amgen  stated   The intersection of immunology and oncology represents one of the most promising approaches to delivering significant impact for patients with cancer  With our existing immuno oncology portfolio of cutting edge technologies and expertise  we believe joining forces with Kite Pharma will leverage our targets and their leading CAR T cell platform to advance another new promising therapeutic approach to fight cancer  In other news  Amgen shares hit an all time high of  173 14 in October  A few weeks later on December 17th  Amgen announced a 30  dividend increase declared at  0 79  available to all stock holders as of February 12th A handful of analysts rated Amgen in light of the announcement to partner with Kite Pharma  along with forward looking statements toward 2015 On January 6th  analyst Anthony Butler of Barclays  LONDON BARC  initiated coverage of Amgen with an Equal weight rating and a  180 price target  Butler noted that Amgen will have a hard time sustaining momentum going forward in 2015 Anthony Butler has an 83  overall success rate recommending stocks from the past year with a  32 4  average return per recommendation Separately on January 5th  analyst Cory Kasimov of J P  Morgan reiterated a Neutral rating on Amgen with a price target of  163  Kasimov noted   Given  Amgen s  capital allocation strategy  we believe AMGN offers investors a differentiated investment opportunity vs  other biotechs  which likely contributed to its outperformance in 2014   He continued   At this point  however  we believe the near term potential of new drugs  is largely appreciated by investors  We do believe that recent cost cutting will help the bottom line  and the  company s  position as the only dividend issuing biotech should continue to attract generalist interest   Kasimov concluded   Bottom line  we believe AMGN s pipeline and future business mix  are attractive  but with shares meaningfully higher in 2014  we have a hard time finding additional near term levers for relative upside  Thus  we are maintaining a Neutral rating  but increasing our YE15 PT to  163 from  130  Cory Kasimov has a 50  success rate rating stocks over the past year with a  16 6  average return per recommendation On January 5th  analyst Matthew Harrison of Morgan Stanley  NYSE MS  downgraded Amgen from Overweight to Equal weight with a price target of  177  The rating was based on valuation  and Harrison claims that that Amgen doesn t have any near term catalysts Matthew Harrison has an 81  success rate recommending stocks over the past year with a  24 2  average return per recommendation On average  the top analyst consensus for AMGN on TipRanks is Hold ,2015-01-07,Uri Gruenbaum,https://www.investing.com/analysis/amgen-and-kite-partner-for-cancer-therapy-237709,237709
151750,373266,AMGN,Top Trade Ideas For The Week Of July 15  2013  The Rest,opinion,Here are the Rest of the Top 10  Amgen  Ticker  AMGNAmgen  AMGN  is moving higher out of resistance with support of a rising and bullish Relative Strength Index  RSI  and a Moving Average Convergence Divergence indicator  MACD  that is also rising  These support further upward price action  Boston Scientific  Ticker  BSXBoston Scientific  BSX  is approaching the top of a consolidation channel  tightest between 8 92 and 9 45 but up to 9 75  The RSI is bullish and making a new high as it rises with a MACD that is about to cross to positive  Diamond Offshore Drilling  Ticker  DODiamond Offshore Drilling   DO  is in a Deep Crab Harmonic with a Potential Reversal Zone  PRZ  at 82 52  The RSI and the MACD are bullish and rising to support further upward price action  Movado  Ticker  MOVMovado  MOV  is also rising in a Deep Crab pattern with a PRZ to 43 60  It has a RSI that is bullish and verging on technically overbought with a bullish and rising MACD  Nationstar Mortgage  Ticker  NSMNationstar Mortgage  NSM  is moving higher through the 50 day Simple Moving Average  SMA  and previous resistance  It has support for more upside form a bullish and rising RSI and MACD After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Saturday which  heading into next week  sees the markets looking strong but maybe a bit extended  Look for Gold to continue higher in the downtrend  Crude Oil slows at resistance in the uptrend  The U S  Dollar Index looks to continue lower along with U S  Treasuries  The Shanghai Composite and Emerging Markets are biased to the upside in their downtrends  and have potential to reverse those trends with continued strong moves  Volatility looks to remain low and drifting lower  keeping the bias higher for the equity index ETF s SPY  IWM and QQQ  All are biased higher with the QQQ looking the strongest  The IWM and SPY may have extended a little in their uptrends  Use this information as you prepare for the coming week and trad em well The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2013-07-14,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-july-15,-2013:-the-rest-175350",175350
151751,373267,AMGN,Solid Q2  14 Earnings So Far  Stock Price Reaction Less So,opinion,"Per Thomson Reuters  the  forward 4 quarter  estimate for the S P 500 this past week was  127 07  exactly the same as the past week 
The P E on the forward estimate remained at 15 5 x   given the flat S P 500  which closed this week at 1 978 34 versus last week s 1978 22 
The PEG ratio remains at 1 76 x  
The S P 500  earnings yield  also remained flat at 6 42  versus last week s 6 42  
But  the year over year  y y  growth rate on the forward estimate rose to 8 85  versus last week s 8 51  
Good news   that forward growth rate is so key  in my opinion  
Analysis   commentary  with a little less than half the S P 500 having reported Q2  14 earnings   229 companies per Thomson   the y y growth rate in Q2  14 earnings is  6 5   or excluding the Citigroup  NYSE C  charge   8 2   Personally  I would have been surprised with 10  earnings growth for Q2  14  but I m surprised we are at 8 2  with half the S P 500 having reported to date  The bulk of earnings will have been reported by mid August  14 or another 3 weeks from now 
By sector  here is how the actual earnings growth has evolved by sector  from what was estimated July 1  2014   The first column is the Q2  14 earnings growth rate as of Friday  July 25th  the 2nd column is what was estimated for Q2  14 on July 1   14  

Cons Disc   4 4    6 2 
Cons Spls   6 8    5 1 
Energy   9 4    10 8 
Fincls   8    2 6   Citigroup charge was huge   a 1 7  reduction to the S P 500 per Thomson 
Hlth Care   15 8    8 2 
Industrials   11 3    8 3 
Basic Mat   10 9    9 
Technology   14 6    12 3 
Telco   6 5    9 2 
Utes   0 9    0 4 
S P 500   6 5    6 2    8 2  currently if Citi s 98  earnings decline is excluded 

Ranking from highest y y earnings growth to lowest for Q2  14  

Health Care   15 8 
Technology   14 6 
Industrials   11 3 
Basic Mat   10 9 
Energy   9 4 
S P 500   8 2 
Cons Spls   6 8 
Telco   6 5 
Cons Disc   4 4 
Utes   0 9 
Fincl s   8 
Consumer Discretionary  i e  retail and auto s  has been lagging all year  Financials are likely bottoming from an earnings perspective 

Health Care is still the king though  in terms of earnings growth  Expected full year 2014 earnings growth is still the tops in the S P 500 at  14 5   and it has only improved as the calendar has unfolded  while full year 2014 for the S P 500 is still expected in the 8 8    9  range  Pfizer  NYSE PFE  and Merck  NYSE MRK  report this week  along with Amgen  NASDAQ AMGN   We sold Merck and Amgen earlier in 2014  Still long PFE and Johnson   Johnson  NYSE JNJ   We would need to see a decent correction to biotech to add to the sector via an ETF  Amgen is the most reasonably valued biotech name  but it is more  pharma like  at this point  AMGN is trying to make the transition from a value company to a growth company  The huge run in AMGN from  50 in late 2011  to over  100 was driven by mediocre operating results and a huge share buyback plan  The Onyx acquisition was done for the pipeline  Share repos and the dividend increases will be more modest going forward  It isn t as easy as it looks to change a company from a capital return driven theme to a growth company driven by revenue growth 
A number of Dow 30 stocks were down 3    5  this past week  per our technical software provider  Worden 
Given the stocks  reaction to earnings reports this week  a lot of this news could be discounted in current prices already  Facebook  NASDAQ FB  reported a stellar quarter on just about every metric  and while the stock made a new all time high  the reaction was tepid given the magnitude of the upside surprise   Long FB ",2014-07-27,Brian Gilmartin,"https://www.investing.com/analysis/solid-q2-14-earnings-so-far,-stock-price-reaction-less-so-220676",220676
151752,373268,AMGN,Healthcare Enjoys Growth Trends  3 Medical Stocks To Buy,opinion,"The 2014 Q2 earnings season has been impressive for the Medical sector with 16 1  year over year earnings growth on 12 5  increase in revenues  Also  among the 94  sector participants reported so far  78 7  delivered positive earnings surprises  Favorable industry trends in pharma and biotech primarily contributed to this robust growth 
Impressive Growth Trends in Pharma and Biotech
Pharmaceutical companies have been affected by genericization over the past few years  However  the worst of patent cliff is over and several companies are now on the recovery path 
Johnson   Johnson  NYSE JNJ  was the first major company from the drug manufacturing industry to post impressive second quarter earnings  Other major drug manufacturers such as Pfizer Inc  NYSE PFE  and Merck   Company Inc  NYSE MRK  also reported upbeat results 
Earnings growth in biotechnology firms such as Gilead Sciences Inc  NASDAQ GILD  and Amgen Inc  NASDAQ AMGN  became a yardstick for other stocks in the same segment 
The NYSE ARCA Pharmaceutical Index is up almost 20 1  in the last year  So far in 2014  the index increased10   As of Aug 11  2014  the Standard   Poor s biotechnology index soared 13 6  since January  compared to the S P 500 s gain of 5 1  
Pharma and bio tech space witnessed a slew of IPOs in the last few quarters  Fifty three pharmaceutical and biotech firms launched IPOs this year  The segment also witnessed a flurry of new deals in therecent months  All these boosted investors  sentiment and thus pushed the stock prices up 
New Drugs   Increased Spending Boost Growth 
Development of new drugs and an increase in healthcare spending also fueled growth of pharma and bio tech stocks 
Throughout the first half of 2014  several important products gained approval by the Food and Drug Administration  FDA   Shares of Achillion Pharmaceuticals Inc  NASDAQ ACHN  had skyrocketed  gained 83 3   after the FDA lifted the clinical hold on Achillion s lead drug sovaprevir  Merck was also immensely benefitted after the U S  health regulator approved the drug  vorapaxar 
A number of new drugs are also in the pipeline  Many companies have already announced FDA acceptance for filing of New Drug Application  NDA  
Amid all these  the Ebola outbreak is also making headlines  This has brought biotech companies such as Tekmira Pharmaceuticals Corporation  TO TKM  into the spotlight for their experimental Ebola disease treatments 
Meanwhile  Americans are currently in a better position to meet medical costs thanks to the rebound in the U S  economy  This recovery has propelled healthcare spending  According to PricewaterhouseCoopers s  PwC  Health Research Institute  healthcare spending is expected to rise 6 8  in 2015  up from 6 5  increase forecasted for this year 
The Affordable Care Act  ACA   or  Obamacare   also pushed healthcare spending upward  An aging population also significantly contributed to healthcare spending  Most of the baby boomers are expected to turn 65 and older between 2012 and 2030  Further  U S  Census Bureau stated the nation s 65 and older population is anticipated to reach 83 7 million in 2050 
Banking on these encouraging factors along with ever increasing demand in emerging markets  drug manufacturing and biotech companies are poised to grow in the coming quarters 
3 Medical Stocks to Buy Now
Gilead Sciences Inc  is a biopharmaceutical company that develops and commercializes medicines for treatment of life threatening diseases  Gilead Sciences posted second quarter earnings per share of  2 32  surpassing the Zacks Consensus Estimate of  1 61  Moreover  the Zacks Consensus Estimate for the company s current year earnings increased 18 4  to  7 26 per share in the 30 days ago 
Last Friday  Gilead won a dispute with Roche related to rights of its hepatitis C drug  Sovaldi  Shares of the Gilead rose sharply and touched a new high of  99 49  It s good news for Gilead since IMS Health revealed that prescriptions for Sovaldi amount to more than all other Hepatitis C treatments combined 
This Zacks Rank  1  Strong Buy  stock has an attractive PEG ratio of 0 46  In the last three months  the stock gained 23 4  
Allergan Inc  NYSE AGN  operates as a multi specialty health care company  Allergan reported second quarter 2014 earnings of  1 51 per share  above the Zacks Consensus Estimate of  1 44  Earnings also climbed 23 8  from the year ago quarter 
The company expects third quarter earnings in the range of  1 44  1 47 per share  The Zacks Consensus Estimate currently stands at  1 44  The company also expects 2014 earnings to increase  5 74  5 80 per share  well above the Zacks Consensus Estimate of  5 70 per share 
Expected earnings growth rate for this Zacks Rank  1  Strong Buy  stock is 21 4  for this year  much above the industry growth rate of 0 5  
Supernus Pharmaceuticals Inc  NASDAQ SUPN  is a specialty pharmaceutical company which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the U S 
Supernus posted second quarter 2014 earnings per share of 6 cents  which compared favorably with the Zacks Consensus Estimate of a loss of 18 cents and the year ago loss of 57 cents  Revenues were  29 7 million  up 10 5  from the year ago quarter  Revenues were well above the Zacks Consensus Estimate of  19 million 
Supernus has raised its annual revenue guidance to  105 million  previous guidance   75 million    85 million  
Expected earnings growth rate for this Zacks Rank  2  Buy  stock is 100 7  for 2014  significantly higher than the industry growth rate of 24 3  
Bottom Line
These stocks with strong fundamentals and growth prospects are poised to gain in the near future  While it is expected that most of the stocks in the pharma and bio tech space will gain  those with a favorable Zacks Rank may ensure outperformance ",2014-08-21,Zacks Investment Research,https://www.investing.com/analysis/healthcare-enjoys-growth-trends:-3-medical-stocks-to-buy-223354,223354
151771,373287,AMGN,Top Trade Ideas  Week Of June 3  2013   Bonus Idea,opinion,Here is your Bonus Idea with links to the full Top Ten  Amgen  AMGNAmgen  AMGN  broke support lower on Friday with a near Marubozu candle lower  The Relative Strength Index  RSI  is making a new lower low  and under the 40 level with a Moving Average Convergence Divergence indicator  MACD  that is continuing lower after what could have been a reversal set up  Both support more downside  Short interest is light at less than 2   There is support lower at 93 75 and 90 25 before 89 and a gap to fill to 86 50  Resistance higher comes at 103 75 and 108  followed by 111 50 and 113 60  Trade Idea 1  Sell the stock short now using 103 75 as a stop Trade Idea 2  Buy the June 100 Puts  offered at  2 20 late Friday  Trade Idea 3  Buy the July 100 90 Put Spreads   2 85  Trade Idea 4  Buy the July 100 90 Bearish Put Spread Risk Reversal selling the July 110 Calls   2 65  After reviewing over 1 000 charts  I have found some good setups for the week  These should be viewed in the context of the broad Market Macro picture reviewed Saturday  Heading into June  the markets seem ready to take a breather and perhaps pullback  Gold is biased higher in the short term in its downtrend  while Crude Oil is heading toward the bottom of its range  The U S Dollar Index and Treasuries both look to continue lower  The Shanghai Composite maintains an upward bias  but may consolidate first while Emerging Markets continue being in a downside bias  Volatility looks low but drifting higher  keeping the long term bias higher for the equity index ETF s SPY  IWM and QQQ  but maybe a drag in the short run  The index ETF s themselves appear to be weakening in their uptrends  The SPY is the weakest followed by the IWM  The QQQ is still showing some strength in longer charts  Use this information as you prepare for the coming week and trad em well The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2013-06-03,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas:-week-of-june-3,-2013---bonus-idea-169597",169597
151774,373290,AMGN,Market Primer  Futures Rise Despite Weak China Data ,opinion,Futures Rise Despite Weak China Data U S  equity futures rose in early pre market trade despite weak manufacturing data out of China  The official manufacturing PMI fell to a four month low of 50 1 in June from 50 8 in May  in line with expectations  However  the HSBC manufacturing PMI  which surveys smaller companies who are more likely to be hit by the recent liquidity crunch  dropped to a nine month low of 48 2  below the flash reading and estimate of 48 3 and also below May s 49 2  Top News In other news around the markets  The eurozone s manufacturing PMI unexpectedly showed less contraction than expected in June  rising to 48 8 from 48 7 in May on expectations of a flat reading  Notably  Spain s manufacturing sector improved a flat reading of 50 in the month from 48 1  better than the forecast 48 5  Italy and France posted strong figures despite slight weakness in Germany Onyx Pharmaceuticals  ONXX  confirmed Sunday night that the company had rejected a takeover bid from Amgen  AMGN  for  120  Shares closed Friday at  86 82 The eurozone s unemployment rate dropped in May to 12 1 percent  below the expected 12 3 percent  Further  April s figure was revised downwards to 12 0 percent from 12 2 percent  easing the currency bloc s unemployment woes S P 500 futures gained 4 5 points to 1 603 80 The EUR USD was higher at 1 3051 Spanish 10 year government bond yields rose 1 basis point to 4 77 percent Italian 10 year government bond yields rose 1 basis point to 4 55 percent Gold gained 1 39 percent to  1 240 70 per ounce Asian Markets Asian shares were mostly higher overnight save for Australian shares while Hong Kong s market was closed for the day  The Japanese Nikkei 225 Index gained 1 28 percent on strong economic data while the Topix Index gained 1 49 percent  In China  the Shanghai Composite Index rose 0 81 percent and the CSI 300 Index gained 0 58 percent  Also  the Korean Kospi fell 0 41 percent and Australian shares declined 1 92 percent  European Markets European shares were mixed following better than expected manufacturing data as markets await the European Central Bank s and the Bank of England s much anticipated interest rate decisions on Thursday  The Spanish Ibex Index fell 0 15 percent and the Italian FTSE MIB Index gained 0 17 percent  Meanwhile  the German DAX fell 0 59 percent and the French CAC 40 Index dropped 0 28 percent while U K  shares gained 0 06 percent  Commodities Commodities were mostly stronger overnight  boosted by a weakening of the dollar  WTI Crude futures rose 0 02 percent to  96 58 per barrel and Brent Crude futures gained 0 13 percent to  102 29 per barrel  Copper futures bounced sharply  rising 1 64 percent to  310 75 per pound  Gold was higher sharply and silver futures gained 0 87 percent to  19 64 per ounce  Currencies Currency markets were on the move overnight as the yen and the dollar led declines  showing a slight risk on tone  The EUR USD was higher at 1 3051 and the dollar gained against the yen by 0 45 percent to 99 59  Overall  the Dollar Index fell 0 1 percent on weakness against the euro  the pound  and the Canadian dollar  Earnings Reported Yesterday Key companies that reported earnings Friday include  AZZ Inc     reported first quarter EPS of  0 57 vs  0 63 expected on revenue of  183 2 million vs   197 08 million expected Blackberry  BBRY  reported a first quarter loss of  0 13 vs  EPS of  0 08 expected on revenue of  3 07 billion vs   3 37 billion expected  Also  gross margins fell a full six percentage points and smartphone shipments below expectations while cash flow from operations rose and so did the total cash position Emmis Communication  EMMS  reported first quarter EPS of  0 08 on revenue of  50 6 million The Finish Line  FINL  reported first quarter EPS of  0 20 vs   0 16 expected on revenue of  351 1 million vs   344 22 million expected Pre Market Movers Stocks moving in the pre market included  Onyx Pharmaceuticals  ONXX  shares gained 46 28 percent to  127 00 pre market after the company received and rejected a takeover offer from Amgen  AMGN  for  120 per share Hewlett Packard  HPQ  shares rose 0 6 percent pre market on a positive recommendation from Barron s on the stock Earnings Notable companies expected to report earnings Monday include  MSC Industrial  MSM  is expected to report third quarter EPS of  0 98 vs   1 10 a year ago on revenue of  637 07 million vs   611 97 million a year ago Shulman A Inc   SHLM  is expected to report third quarter EPS of  0 65 vs   0 69 a year ago on revenue of  576 1 million vs   569 11 million a year ago Economics On the economics calendar  the Markit Manufacturing PMI and the ISM Manufacturing Index are due out as well as construction spending data  Also  New York Fed President William Dudley is expected to speak at 8 am eastern and the Treasury will hold its weekly 3  and 6 month bill auctions  Overnight  the Reserve Bank of Australia s interest rate decision is expected as well as eurozone PPI BY Matthew Kanterman,2013-07-01,Benzinga ,https://www.investing.com/analysis/market-primer:-futures-rise-despite-weak-china-data-173586,173586
151775,373291,AMGN,Stocks Rise  But Finish Off Session Highs ,opinion,The U S  stock market continued its near term rally on Monday as the major averages look to make back losses from two weeks ago   The Dow came close to re taking the 15 000 level on a closing basis  but a late day sell off sent the widely watched blue chip average out just below that mark  The leader on the day was the Nasdaq  which registered a gain of just under one percent   The greenback was slightly lower on the session while bonds closed slightly higher   Major Averages The Dow rose around 65 points  or 0 44 percent  to 14 975   The S P 500 added almost 9 points  or 0 54 percent  to close at 1 615   The Nasdaq rose 31 points  or 0 92 percent  to 3 434   ISM Index The ISM Index rose to 50 9 in June from 49 0 in May  This compared to consensus expectations which expected the ISM Index to rise to 50 5  Construction Spending Construction spending rose 0 5 percent in May compared to an increase of 0 1 percent in April  This was in line with consensus estimates   Commodities The energy complex rose along with stocks on Monday  NYMEX crude futures climbed 1 42 percent to  97 93 while Brent crude contracts added 0 79 percent to  102 97  Natural gas rose 0 42 percent to  3 58   Precious metals also rose on Monday  COMEX gold futures jumped 2 29 percent to  1 251 70 while silver was last up 0 49 percent to  19 57  Copper surged 3 24 percent to  3 1565 on Monday   The grains complex was largely lower to start the week  Heading into the closing bell  corn futures were down almost 2 percent while wheat had lost 0 42 percent  Movers in soft commodities included sugar and cotton  Sugar futures were last trading down 1 36 percent while cotton had risen a little less than 2 percent   Bonds Bonds were slightly higher to start the trading week  Near the close of equity trading  the iShares Barclays 20  Year Treasury Bond ETF  TLT  was up 0 20 percent to  110 41   At last check  yields were as follows  The 2 Year Note was yielding 0 35 percent while the 5 Year yield was at 1 38 percent  The 10 Year Note and 30 Year Bond were yielding 2 48 percent and 3 48 percent  respectively   Currencies The U S  Dollar was slightly lower on Monday  Heading into the closing bell  the PowerShares DB US Dollar Index Bullish ETF  UUP   which tracks the performance of the greenback versus a basket of foreign currencies  has lost 0 24 percent to  22 50   The closely watched EUR USD pair was last up 0 31 percent to  1 3059  Other movers included the USD JPY  which rose 0 54 percent and the AUD USD  which added 0 81 percent on the session   Volatility and Volume The VIX was lower late on Monday  but not my much  At last check  the widely watched barometer of volatility expectations had lost around 2 percent to 16 51   Volume was lighter than usual on the day  Around 108 million SPDR S P 500 ETF  SPY  shares traded hands compared to a 3 month daily average of 144 million   Stock Movers Onyx Pharmaceuticals  ONYX  jumped almost 51 percent after the company said that it had rejected a bid which valued Onyx at a 38 percent premium to Friday s closing price from Amgen  Onyx said that it is seeking potential buyers in the wake of the unsolicited bid from Amgen   Best Buy  BBY  climbed almost 9 percent after Credit Suisse resumed coverage on the stock with a Outperform rating  The firm also hiked its price target by 25 percent to  40   Acura Pharmaceuticals  ACUR  added better than 16 percent late on Monday after the company said that Pfizer will expand commercialization of a pain drug that uses Acura s tamper resistant technology   Endologix  ELGX  had risen nearly 6 percent late on Monday after the company raised its full year revenue outlook   Zynga  ZNGA  climbed better than 11 percent intra day on Monday after a report surfaced that the company could name a new CEO   Steinway Musical Instruments  LVB  rose around 16 percent on Monday after the company agreed to be acquired by private equity firm Kohlberg   Co  in a  438 million cash deal   InterDigital  IDCC  lost almost 13 percent on Monday after an administrative judge overseeing patent infringement claims against Nokia  Huawei Technologies  and ZTE Corp  ruled that only one of the company s patents had been infringed  but that the patent was invalid   Insemed  INSM  fell around 20 percent after Phase III data showed that a once daily dose of the company s drug Arikace for pseudomonas aeruginosa in cystic fibrosis patients was not inferior to a twice daily dosage of another drug  Investors  however  were hoping that the treatment would show superiority to the alternative medication BY Scott Rubin,2013-07-01,Benzinga ,"https://www.investing.com/analysis/stocks-rise,-but-finish-off-session-highs-173642",173642
151776,373292,AMGN,U S  Stocks Start Half To The Upside,opinion,Stocks began the second half of 2013 with broad gains  weakening near the close after earlier lifting the Dow Jones Industrial Index past the 15 000 mark  Gains were supported by positive economic data at home as well as in Europe  Nine of the 10 industry sectors in the S P 500 ended with gains  with utilities the lone group to finish in the red  Industrial and materials stocks were the day s best performers  with metals leading commodities to solid gains  Manufacturing GrowthU S  manufacturing as measured by the Institute for Supply Management monthly index grew in June  led by a pickup in new orders  exports and production  The ISM factory index increased to 50 9 in June  up from a four year low of 49 in May  Readings above 50 suggests growth  while scores below that point indicate contraction  European financial markets also were buoyed by better than expected manufacturing data  Monday  across the continent including Spain  Italy  France and the U K  PMI MissesBut a separate survey of U S  factory activity showed a slight slowdown during June  trailing estimates but remaining in expansionary mode  The PMI Manufacturing Index came in with a 51 9 reading for June  missing the consensus call looking for a 52 3 score  New orders for export dipped  possibly reflecting a slowdown in demand from China  On the positive end of the ledger  production picked up moderately from May levels  Construction spending similarly was mixed in May with private sector continuing its upward trend  offset by weak public sector growth  Overall  construction outlays advanced 0 5  month over month during in May  up 0 1 percentage point from April but lagging market expectations for a 0 6  gain  Private sector residential spending rose 1 2   rebounding from a 0 1  decline the prior month  Commodities were higher  Crude oil for August delivery settled  1 43 higher at  97 99 per barrel while September natural gas was up a penny to  3 57 per 1 mln BTU  August gold rose  31 00 to finish at  1255 40 per ounce while September silver climbed 12 cents to  19 57 per ounce  September copper added 11 cents to  3 16 per pound  Here s Where The U S  Markets Stood At Day s EndDow Jones Industrial Index up 65 36  0 44   to 14 974 96S P 500 up 8 68  0 54   to 1 614 96Nasdaq Composite Index up 31 24  0 92   to 3 434 49GLOBAL SENTIMENTHang Seng Index up 1 78 Shanghai China Composite Index up 0 81 FTSE 100 up 1 40 UPSIDE MOVERS    P  Morgan Stanley upgrade to Overweight from Equalweight     ONXX  Rejects  10 bln takeover bid by Amgen Inc  AMGN   saying the  120 a share offer  significantly undervalues  the company but also saying it is talking with at least one other firm about a potential merger     ACUR  Pfizer  PFE  says it will expand commercialization of pain drug that uses Acura s tamper resistant Aversion technology DOWNSIDE MOVERS    IDCC  Administrative judge rejects company s claims of patent infringement by Nokia  NOK   Huawei and ZTE  IDCC will appeal to the full U S  International Trade Commission  a final decision due Oct  28     INSM  Said U S  regulators have granted Fast Track designation for its Arikace drug candidate after the drug met its primary endpoint of similar efficacy with existing treatments in Phase III testing in cystic fibrosis patients with non tuberculosis lung infections     BBRY  Four analyst downgrades Monday following last week s disappointing earnings  including rating cuts by Societe Generale  Deutsche Bank and Needham   Co   among others After Hours Stock News From  Copyright   2013 MT Newswires  a Division of MidnightTrader  Inc ,2013-07-01,Midnight Trader,https://www.investing.com/analysis/u.s.-stocks-start-half-to-the-upside-173625,173625
151795,373311,AMGN,S P 500 Trades At All Time High  Forward Earnings Hit All Time High,opinion,According to ThomsonReuter s weekly  This Week in Earnings  missive  the  forward 4 quarter  estimate for the S P 500 as of Friday  April 12th  2013 was  115 14  down  0 11 from last week s record high print of  115 25 The S P 500 forward earnings estimate is still above the previous record high estimate of  113 88 estimate from the week of January 4th  2013 The p e ratio on the S P 500 as of Friday s close was 13 8 x  the forward estimate The  earnings yield  on the S P 500  inverse of p e  ratio  is still a lofty 7 25  The year over year growth of the forward estimate has fallen to 5  from the recent high of 6 1  as of 3 1 13  and is a bit of yellow flag We like to see the year over year growth rate of the forward estimate continue to grow  since that is what results in p e expansion for the market Full year 2013 is still expecting 8 1  full year earnings growth for the S P 500  versus the 13 8 x  current p e multiple 29 companies have reported q1  13 financial results  with the flood of earnings to start this week  The current consensus per the ThomsonReuters data is for  1 1  earnings growth and 1  revenue growth  Our own expectation is that earnings growth will be closer to 4    5   when Wal Mart  WMT  concludes earnings season in mid May  while revenue growth could be a push given dollar strength 75 S P 500 companies are scheduled to report this week  and almost half of those will be Thursday before and after the bell  23 Financials are scheduled to report this week  of the 75 on tap Stat of the Week   expected q1  13 earnings and revenue growth Here is how current consensus stands for each sector of the S P 500 in terms of expected q1  13 earnings  first column  and revenue growth  second column  Financials  10 6    2 8 Consumer discretionary  7 5    5 1 Telco  5 8    1 6 Consumer staples  3 3    1 6 Basic Materials  2 1    0 1 Utilities  1 2    6 7 S P 500  1 1    1 0 Industrials  2 0    0 5 Health Care  3 6    6 7 Technology  3 8    4 5 Energy  4 0    9 8 Commentary  The best sector performance in q1  13 was not necessarily the sectors with the best earnings growth  but the best revenue growth  such as Healthcare  and Utilities  What is driving the Healthcare sector is not the large cap pharma sector  which are some of our best performers  such as Pfizer  PFE   Merck  MRK  and Amgen  AMGN   but  according to ThomsonReuters   the revenue growth is coming from HealthCare Services and Healthcare Managed Care   Long MRK  PFE  AMGN My own opinion is that Financials will continue to be a sector to put your money in 2013  as the recovery in housing and bank balance sheets  not to mention a Fed that will probably keep rates low through the end of 2013  at least   will continue to aid and drive sector earnings growth Despite the pessimism around S P 500 earnings in general  expect a decent quarter for q1  13  as results are released  We expect that q1  13 will see at least 4    5  when all is said and done by mid May  The big surprise in Q1  13 was not the record high estimate of  113 88 on January 4th  2013  but the fact that we saw less erosion in the forward estimate as the first quarter progressed from early January through March It should be getting harder and harder for Street analysts to be negative  as Corporate America has to push forward with investment and capex  despite the anti business and the  tax anything that moves or breathes  environment in Washington Our one and only market comment this week  will come from Bespoke  which noted that bullish sentiment in the AAII survey fell from 35  to 19 1  this week  Amazing  given the breakout of the S P 500 above the March  2000  and October  2007 highs ,2013-04-15,Brian Gilmartin,"https://www.investing.com/analysis/s-p-500-trades-at-all-time-high,-forward-earnings-hit-all-time-high-162903",162903
151796,373312,AMGN,Small Cap Biotech Hot Again  Here s How To Play It ,opinion,Biotech has been a hot area in this market  Whether large cap or small cap  Wall Street and Main Street have watched as biotech companies have surged  This is partly due to the safety of drug stocks  along with the optimism of future drugs  Large cap biotech Amgen  Inc   AMGN  continues to trade near its all time highs at  112 54   1 16  1 04   Today we are seeing many small cap biotech stocks surging dramatically higher  Anytime this is seen  former runners must be put on high alert as they could take off at any minute  Yesterday  stocks like Catalyst Pharmaceutical Partners  Inc   CPRX   Arca Biopharma Inc  ABIO   Opexa Therapeutics Inc  OPXA  were all jumping higher Any small cap biotech stock that ran a huge amount in the last few months and has pulled back significantly without negative news is a possible play  They should all be on your watchlist  Some former runners include CombiMatrix Corporation  CBMX   OXiGENE Inc  OXGN   and Rosetta Genomics Ltd   USA   ROSG   I am in the process of slowly accumulating some Rosetta Genomics as a swing trade long in the  3 00  3 20 area ,2013-04-23,Nicholas Santiago,https://www.investing.com/analysis/small-cap-biotech-hot-again:-here's-how-to-play-it-164024,164024
151797,373313,AMGN,Top Trade Ideas  Week Of May 13  2013   Bonus Idea,opinion,Here is your Bonus Idea with links to the full Top Ten  Amgen  Ticker  AMGNAmgen  AMGN   pulled back from a touch at 115 and found support back at the 103 90 level  There is support lower at 94 20 and 90 30 before the previous channel at 83 to 89 40  The Relative Strength Index  RSI  is holding in bullish territory through the pullback  and the MACD is starting to level after a big drop  Maybe it is time for a turn back higher  A move over the top of the descending triangle at 107 carries a target to 115 60  with resistance at 110 and 112 50 along the way  Trade Idea 1  Buy the stock on a move over 107 with a stop at 103 75 Trade Idea 2  Buy the June 110 Calls  offered at  1 72 late Friday  on the same trigger Trade Idea 3  Buy the 105 115 Call Spreads   3 27  on the same trigger Trade Idea 4  Sell the June 100 Puts   1 03  on a move over 107 Trade Idea 5  Buy the 105 115 Call Spreads selling the June 100 Puts   2 24  on a move over 107 After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Saturday  The equity markets remaining strong as we head into the options expiration week for May  Look for Gold to continue its correction  while Crude Oil could consolidate with an upside bias  The U S  Dollar Index seems content to move sideways  but an upward bias as U S Treasuries move lower in the broad consolidation zone  The Shanghai Composite is building towards a break of consolidation higher  Emerging Markets look to pullback in their uptrend  Volatility looks to remain subdued  keeping the wind at the backs of the equity index ETF s SPY  IWM and QQQ  despite their moves to new highs  Their charts agree with a continued upward bias  but with the IWM the strongest on the short term basis and the QQQ strongest on the intermediate term  Rotation into small caps may result  Use this information as you prepare for the coming week and trad em well The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2013-05-13,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas:-week-of-may-13,-2013---bonus-idea-166720",166720
151810,373326,AMGN,Amgen s Dividend Policy Has Ignited Their Stock ,opinion,Founded in 1980  Amgen  AMGN  is the world s largest biotechnology company with a current market cap of just under  68 billion  However  in spite of its already large size  we believe that Amgen has ample room to continue growing their earnings at above average rates into the foreseeable future  Our optimism for future growth is predicated on several factors  First and foremost  Amgen has a strong pipeline of potential blockbuster medicines  many of which are already in Phase III trials  We will highlight some of the major candidates later In addition to a strong pipeline  Amgen is utilizing its strong cash position  cash flow generation capability and its pristine balance sheet towards making strategic acquisitions that will expand its geographic reach and bring additional candidates into its pipeline  On December 10  2012 Amgen announced that they acquired deCODE Genetics  a global leader in human genetics headquartered in Reykjavik  Iceland in an all cash transaction of  415 million On July 5  2012  Amgen announced the completion of the acquisition of KAI Pharmaceuticals  a privately held company based in South San Francisco acquiring candidate KAI 4169  a novel agent for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis  And on June 12  2012  Amgen announced the completion of the acquisition of Mustafa Nevzat Pharmaceuticals  a privately held Turkish company expanding their reach into promising markets of Turkey and surrounding regions In addition to acquisitions and a strong pipeline  Amgen also recently announced that they will buy back  2 billion in shares as part of a total  10 billion authorized buyback program  Added to these catalysts for growth is Amgen s commitment to intensifying its research and development program under the leadership of new CEO Robert Bradway  Therefore  we believe Amgen is well positioned to continue growing their earnings which we believe is a key component for increasing shareholder value However  in our opinion the major catalyst attributed to its recently improving share price has been the initiation of a dividend in 2011  which is a rarity for biotechnology companies  Furthermore  on January 3  2013  Amgen announced that they will increase their dividend by 31  to   47 per share  Consequently  Amgen s PE ratio has expanded from approximately 11 times earnings prior to the initiation of their dividend to over 13 times earnings today  we see this as the beginning of a longer term trend  Therefore  an increasing earnings base coupled with PE expansion and a rapidly increasing dividend all indicate above average future returns for both the short term to the long term time horizon F A S T  Graphs  Historical Analysis of AmgenAn analysis of Amgen s historical business success utilizing the fundamentals analyzer software tool  F A S T  Graphs   reveals a great deal about Amgen and how the market has treated its operating results  Our first graph plots Amgen s earnings per share growth  the orange line  and dividends only since calendar year 1993  Here we discover that Amgen has been able to consistently grow its earnings at the high rate of 17  per annum  The green shaded area represents cumulative earnings  and the light blue shaded area represents dividends paid out of those earnings  Consequently  the initiation of a dividend policy is vividly expressed  Note  All F A S T  Graphs  include one year of forecasting for 2013  This next graph brings in monthly closing stock prices  the black line  in order to reveal the earnings and price correlation and relationship  There are several important aspects regarding how the market has treated Amgen shares over this two decade history that we believe are very interesting  First we discover that from 1993 to 1998  Amgen s stock price closely tracked and correlated to its earnings justified valuation  the orange line   Then as we entered what was dubbed the irrational exuberant period commencing in 1999  Amgen s share price became disconnected from its earnings  Interestingly  Amgen s stock price remained overvalued until the Great Recession of 2008 brought its shares back to economic reality and then to below intrinsic value From 2008 to 2011  Amgen share price languished in undervalued territory  even though operating results continued their upward trajectory  This quickly changed after they initiated their first dividend  the blue shaded area   Since that time  Amgen s share price has been rapidly moving back towards alignment with its earnings justified value  Consequently  we believe that the dividend is serving as the primary catalyst behind Amgen s strong share price performance in 2011 and 2012  We will calculate and reveal these results later in this analysis Whenever we analyze a business utilizing the dynamic F A S T  Graphs   fundamentals analyzer software tool   we always start with our longest time frame of 20 years  and then continue to run graphs with progressively shorter time periods  This process allows us to ascertain whether a given company s growth rate is accelerating  decelerating or staying the same  Although we believe that the most relevant information will be found within the shorter time frames  we also believe that there is a lot of value in analyzing the company s long term historical results as well With that said  our next graph looks at Amgen since calendar year end 1999  It s important to note that 1999 and 2000 represented the pinnacle of irrational pricing by Mr  Market  Therefore  we discovered that Amgen s stock price was virtually range bound for the better part of seven consecutive years  Excessive valuation kept the stock from advancing even though the company s earnings were growing rather nicely  However  the most important takeaway from graphing this shorter time frame is that Amgen still averaged 14 6  per annum compounded annual earnings growth This next graphic looks at Amgen over the past decade  Here we discover that the company s earnings growth had re accelerated to 16 5   which is very close to its 20 year average of 17   We believe this is a remarkable achievement by what has now become a very large enterprise At this point  we thought it would be interesting to evaluate Amgen s performance since calendar year 2003  Remarkably  even though the company was significantly overvalued at the beginning of 2003  shareholders were able to closely mirror the performance of the S P 500 thanks to the company s strong earnings growth rate overcoming its high valuation  This is true even though we would classify the shares as currently undervalued  In other words  this fast growing company s performance generated a positive rate of return even though the shares are overvalued at the beginning of the time period and undervalued at the end As we continue our process of reviewing shorter and shorter time frames  it is interesting to see how Amgen performed since the throes of the Great Recession of 2008  Amazingly  Amgen was capable of generating an average 11  compounded annual earnings growth rate  However  the most interesting aspect of this time period analysis is that the company s shares were moderately undervalued  thanks to the Great Recession  during most of this time frame  However  share price did trend upwards along with earnings When you evaluate the performance of Amgen when the company s stock price was not impaired with the headwinds of overvaluation  shareholders were able to harvest the company s exceptional earnings growth achievement  Moreover  strong earnings growth coupled with attractive valuation allowed shareholders to earn a very attractive 14  per annum compounded rate of return during a time when the S P 500 s performance was very weak  Thereby illustrating that a strong above average company purchased at a sound valuation can dramatically outperform the averages Our final set of graphics looks at Amgen since the company instituted a dividend policy  Once the dividend was established  the gap between the company s stock price and its earnings justified valuation has been rapidly closing  Moreover  we believe there is still room for Amgen s shares to run over the short to intermediate term based on accelerated earnings growth and the announcement of the 31  increase in the quarterly dividend  We feel it is more than coincidental that Amgen s performance has accelerated to such a great extent after it started paying its dividend  Clearly  as depicted by the performance results and dividend cash flow table below  much of Amgen s significant outperformance can be attributed to undervaluation and strong earnings growth  However  we would argue that now that the company is paying a dividend  it is beginning to broaden its appeal to other sets of potential shareholders  Currently  we contend that Amgen offers attractive valuation  above average potential growth and an above market and rapidly growing dividend  representing a nice kicker to its total return potential The Near and Longer Term FutureWe believe that fair value based on capitalizing earnings at a reasonable 15 PE ratio implies that Amgen s stock is worth approximately  99 a share  Furthermore  we believe there is a high probability that Amgen s PE ratio could easily expand beyond our 15 PE target  But more importantly  we think the recently instituted dividend  representing an above market yield  greatly minimizes downside risk The following estimated earnings and return calculator is based on the consensus five year earnings estimate of 59 analysts reporting to Standard   Poor s Capital IQ  We consider these estimates on the conservative side and somewhat biased towards expectations for calendar year 2013  Longer term  we believe that Amgen has the potential to grow earnings at low to mid double digit rates into the foreseeable future  Amgen s strong pipeline and intensified commitment to research and development  coupled with a pristine balance sheet capable of funding acquisitions and share buybacks supports our thesis for strong future growth Biotech  A Brief IntroductionAmgen is a biotechnology superstar engaging in pioneering science with the potential for delivering vital medicines  According to Amgen  in 1919 Karl Ereky  a Hungarian engineer  coined the term  biotechnology  to describe the interaction of biology and human technology  The biotechnology industry differs from its chemical pharmaceutical counterparts because it is based on living organisms  The pharmaceutical industry has traditionally manufactured drugs which were synthesized from chemical compounds  The biotechnology revolution created a new class of drugs referred to as the biologic Biologics are therapies derived from living organisms and include proteins  DNA vaccines  monoclonal antibodies  peptides and experimental modalities such as gene therapy  stem cell therapy  antisense nucleotides and RNA viruses  At the core  all cells have common processes they perform in order to survive  and biotechnology harnesses these processes to make products to treat illnesses and improve people s health Amgen s Products and PipelineAmgen has built their franchise on the strength of their 10 marketed products  Originally  EPOGEN and NEUPOGEN  their two important blockbuster erythropoiesis stimulating agents  ESAs  generated most of their revenues and profitability  However  they have significantly expanded on this franchise thereby generating significantly greater revenues and profitability  The following slides taken from Amgen presentations summarize the company s view of the future  First and foremost is their commitment to expanding their core business and current product portfolios In addition to expanding their current product portfolios  Amgen has several promising candidates in late stages of development in their pipeline  As we will soon address  developing biologic therapeutic compounds is a very expensive and time consuming process  Commercial success is highest for candidates in Phase 3  As can be seen from the following slide  Amgen has several promising compounds in Phase 3  as well as several that are moving through Phase 2 testing AcquisitionsAmgen s recent acquisitions provide them multiple opportunities for growth and expansion  In addition to enlarging their geographical reach  the company is also acquiring promising candidates and R D capabilities and opportunities Returning Capital to ShareholdersIn the beginning  Amgen was a pure growth stock that required all of their capital to fund their long term growth initiatives  However  in recent years  as the company has grown they are becoming a much more shareholder friendly enterprise  The following corporate slide summarizes Amgen s current commitment to returning capital to shareholders  Their focus on growing the dividend is a significant milestone in the company s maturity and development  Consequently  we believe that Amgen is evolving from a pure growth stock to an above average growth and income investment  Therefore  we believe the company is attractive for investors seeking growth as well as investors seeking current income Amgen s Moats One of Amgen s strongest moats is their size and scale  According to a BIOFACT that they present in their pamphlet  An Introduction to Biotechnology  Amgen states as follows   To bring a new drug to market  from discovery through clinical trials and FDA approval  cost an estimated  1 billion and can take 10 to 15 years or longer  Only one in 10 new drugs that makes it into human testing actually makes it to market  Given this high failure rate and the tremendous cost of bringing a new therapy to market  companies depend on successful drugs to produce enough revenue to compensate for both the R D cost of the successful therapies and the expense of the failed ones   Clearly  Amgen is one of the few companies in the biotechnology industry that is capable of investing the levels of capital and resources necessary to bring a candidate to market  Consequently  many smaller firms are often forced to partner with Amgen because they lack the resources necessary to commercialize their candidates  Advancing Science through Strategic Partnerships  With more than 100 active collaborations  Amgen is well suited to be a partner of choice in the human therapeutics business  With the capabilities and financial strength of a large company  Amgen can offer partners the resources to support a potential new medicine as it advances from lab to clinic to marketplace  At the same time  Amgen retains the agility and decisiveness of a smaller biotech  with an unwavering commitment to science and patients  Furthermore  Amgen has the capabilities to manufacture and distribute compounds that they and partners develop  The following is a brief summary of their manufacturing locations  A Pioneer in Biotechnology Manufacturing Assuring that Amgen medicines rapidly  reliably  and safely reach patients is the charge of Amgen s manufacturing  process development  quality  and distribution teams  Manufacturing therapies based on proteins found in the human body is a complex and highly specialized activity  From process development and clinical manufacturing to full scale therapeutic protein production  Amgen has built one of the industry s largest and most reliable operations  Amgen operates manufacturing facilities in California  Colorado  Rhode Island  Washington  and Puerto Rico   Summary  Amgen s legacy has been that of a fast growing biotechnology growth stock  However  more recently the company is evolving into a high quality blue chip dividend paying growth and income stock  On the other hand  since we are early in this process  the growth attributes of Amgen remain intact  Nevertheless  we believe that its recent posturing as a more shareholder friendly enterprise is serving as a catalyst for the market s desire towards capitalizing Amgen shares at higher valuations going forward  Therefore  the combination of reasonably well defined continued growth  low valuation and more shareholder friendly attitude by management are strong positives auguring well for short and long term profits  Moreover  the company s recent settlement with the US government  49 states and the District of Columbia removes a negative that we feel had been holding the stock price down  The following headlines and link provide more information  Amgen Finalizes Agreement Resolving Previously Announced Federal Investigations  For those interested in researching Amgen deeper and faster   to a live fully functional F A S T  Graphs  on Amgen  For more information on how to interpret   Conclusions Our short term target price for Amgen is  99 a share  or approximately 12  above current quotations  Our intermediate term forecast is approximately  115 a share  and longer term we expect double digit compounded returns in excess of 13  per annum  including dividends  Disclosure  No position at the time of writing  Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ,2013-01-13,Chuck Carnevale,https://www.investing.com/analysis/amgens-dividend-policy-has-ignited-their-stock-150642,150642
151811,373327,AMGN,UCB  Phase III Trials Help Maintain Price Momentum ,opinion,Investment summary  Wherefore art thou romoMuch attention rests on UCB s three recently launched drugs but forthcoming news regarding its Phase III  Amgen partnered antibody  romosozumab  could help to maintain the current share price momentum  Phase II data show a rapid increase in bone mineral density  BMD  in women with post menopausal osteoporosis  PMO  that is superior to existing therapies  with no concerning safety signals  Data from the ongoing Phase III trials assessing c 10 000 women with PMO are not expected until 2015  However  new fracture healing data  expected in H113 and Phase III trial initiations  expected this year could provide further indication of its potential Better efficacy over competitors   Top line Phase II data show a rapid increase in BMD over 12 months at the lumbar spine and hip of women with PMO treated with the anti sclerostin antibody  romosozumab  that is significantly superior to alendronate  Fosamax  or teriparatide  Forteo   In a meta analysis  12 month BMD increases at the lumbar spine compared favourably to increases with 36 month denosumab  Prolia  and zoledronic acid  Reclast  treatment  11 3  vs 8 8  and 6 7  respectively   and 24 month odanacatib treatment  2 3    Merck s Phase III bone resorption inhibitor    with no significant safety signalsAnti resorptive agents  largely bisphosphonates  eg Fosamax   dominate the c  8bn global osteoporosis market  However  their prolonged use has been associated with osteonecrosis of the jaw  severe pain and hypocalcaemia  The only FDA approved bone builder  Forteo  carries a black box warning against osteosarcoma  So far  the only significant side effect associated with romosozumab is mild injection site reactions  although further studies will assess longer term safety risks including the possibility of abnormal bone formation seen in patients naturally lacking sclerostin New Phase III trials to highlight potentialData from the current Phase III trial is not expected until 2015  However  new data and new Phase III trials should support the anti sclerostin approach  Positive data on two Phase II romosozumab studies in tibial and hip fracture healing could trigger the start of Phase III trial s  in this indication this year  Eli Lilly s direct competitor  blosozumab  at least 12 months behind  could start major Phase III trials this year in PMO  and data from Phase II with this antibody could also be presented Valuation  Romosozumab newsflow should buoy sharesUCB shares have risen c 37  in the last year  largely because of rising expectations for three new products  Cimzia  Vimpat and Neupro  UCB now trades on a one year forward P E of 24x  a 72  premium to its peer group  However  we believe that 2013 romosozumab related newsflow still represents important catalysts for the shares To Read the Entire Report Please Click on the pdf File Below ,2013-01-27,Edison,https://www.investing.com/analysis/ucb:-phase-iii-trials-help-maintain-price-momentum-152614,152614
151813,373329,AMGN,Top Trade Ideas For The Week Of February 4  Bonus,opinion,Here is your Bonus Idea with links to the full Top Ten  Amgen  Ticker  AMGNAmgen is consolidating after a move higher off of the pull back to 82  A break of the flag higher gives a target on a Measured Move to 90  The Relative Strength Index  RSI  is stalling after rising to the mid line and a push higher supports more upside complementing the Moving Average Convergence Divergence indicator  MACD  that is positive and already support higher prices  Resistance comes at 87 and 90 followed by 90 81  Support lower is found at 85 and 83 75 and then 82 and 80 50  Trade Idea 1  Buy the stock on a move over 87 with a stop at 86  Trade Idea 2  Buy the February 87 5 Calls  offered at 91 cents late Friday  on a move over 87  Trade Idea 3  Buy the February 87 5 90 Call Spread  60c cents  on a move over 87  Trade Idea 4  Buy the February March 90 Call Calendar  53 cents  on a move over 87  Trade Idea 5  Sell the March 82 5 80 Put Spreads  48 cents  on a move over 87  Trade idea 6  Buy the February March 90 Call Calendar selling the March 82 5 80 Put Spreads  5 cents  on a move over 87  After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Saturday which heading into the first full week of February sees that the markets have their bull on  Gold looks to have stayed off a fall and will consolidate while Crude Oil continues higher  The US Dollar Index is moving lower again and US Treasuries are joining it to the downside  The Shanghai Composite is racing higher again after some consolidation and Emerging Markets are biased to the upside but consolidating  Volatility remains near historic lows and showing no signs of rising elevated keeping the bias higher for the equity index ETF s SPY  IWM and QQQ  The weakening US Dollar and Treasuries support higher equity prices as well  And the charts of these ETF s agree  with the QQQ looking to finally join the party higher  Use this information as you prepare for the coming week and trad em well Disclosure  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2013-02-05,Gregory W. Harmon,https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-february-4:-bonus-153866,153866
151815,373331,AMGN,Zeltia  A Quick Look ,opinion,Investment Summary  Turning A CornerZeltia is approaching a material catalyst this year in the form of the read out from its Phase II study of lurbinectedin  PM01183  in platinum resistant ovarian cancer  If positive  this could form the basis of a licensing deal that could transform Zeltia s fortunes  This  and the more positive sales outlook for Yondelis  trabectedin   which has been hampered by recent Doxil supply shortages  should support further pipeline development and ultimately help Zeltia transition into a cancer pure play  A Safer And More Efficacious Yondelis   Lurbinectedin is  like Yondelis  a minor groove DNA binder  but it has improved pharmacokinetics that confer less cumulative toxicity with a more convenient dosing schedule  In a cross trial comparison of various agents in platinum resistant ovarian cancer  some 27  patients achieved an overall response on lurbinectedin  vs 7  for Yondelis   and 73  achieved disease control  vs 50  for Yondelis      Competitive vs  Next Generation ProductsThere are just three agents in Phase III studies for platinum resistant ovarian cancer  vintafolide  Endocyte Merck   Co   Avastin  bevacizumab  Roche  and trebananib  Amgen   In this same cross trial comparison  vintafolide showed a 17  overall response rate and Avastin  a partial response rate of 16   Should its superior efficacy be replicated in Phase III  lurbinectedin may have a competitive advantage provided it is better tolerated than Yondelis  However  recent failures  eg Eisai s farletuzumab  highlight the challenge of developing novel agents for ovarian cancer  Phase II Data Could Be A Major CatalystThe drug met its primary endpoint in stage one of the Phase II study  with 27  of the 22 patients achieving an overall response  with a median PFS of 4 0 months   60 patients are randomised 1 1  with crossover  to either lurbinectedin or topotecan in stage two  These data are due in H213 and could be the catalyst for a partnership that should support mid  to late stage development in other solid tumour types  activity has already been demonstrated in breast  lung and pancreatic cancers  Two Phase II studies in lung cancer  non small cell and small cell lung cancer  are due to start in mid 2013  and a Phase II trial in breast cancer is due to read out in 2015  Valuation  Hinges On Positive DataZeltia stock has fallen c 30  in the last year largely due to declining sales of Yondelis and the Phase II failure of Alzheimer s drug tideglusib  Nypta   This has given it a lower profile  just at a time when the Doxil issues are being resolved and its debt situation is improving  Thus a material pipeline catalyst and the chance of a licensing deal could give new impetus to a recovery in the shares this year ,2013-02-25,Edison,https://www.investing.com/analysis/zeltia:-a-quick-look-156617,156617
151816,373332,AMGN,Soaring Stocks  Look At The Leveraged ETFs ,opinion,Another day  another intraday record for the Dow Jones Industrial Average  Buoyed by a stronger than expected February jobs report  U S  stocks continue to grind higher   Friday s action is of the modesty variety  perhaps disappointing eager bulls that were expecting more on the back of the jobs report   Despite the Friday lethargy  nearly 300 ETFs tracking a variety of asset classes and sectors are close to or have already made new highs   That can be interpreted as a positive sign and perhaps open the door for aggressive traders to embrace some bullish leveraged ETFs   With the benefit of the SPDR S P 500  SPY  rising nearly nine percent year to date  plenty of leveraged bull ETFs have soared as well and now look overbought   When it comes to using these funds over the next few weeks  the key for traders is focusing on situations  meaning identification of leveraged ETFs that are or close to a potential sweet spot that can lead to further near term upside  Consider the following   ProShares Ultra Financials  UYG  Plenty of traders are talking about the recent bullishness in the Financial Select Sector SPDR  XLF   the largest ETF tracking financial services stocks   With good reason  too  The stress results released on Thursday were mostly positive and that was enough to extend XLF s impressive year to date performance which has the ETF hovering near a new 52 week high   Bringing the conversation back to UYG  this double leveraged ETF is not a play on XLF  Rather  UYG attempts to deliver two times the daily performance of the index tracked by the iShares Dow Jones U S  Financial Sector Index Fund  IYF   an ETF that has slightly outpaced XLF this year   As was noted on Thursday  the Comprehensive Capital Analysis and Review stress test results are due out next week   That is when the Federal Reserve can approve or reject banks  capital plans such as dividends and share buybacks  In other words  a significant catalyst could be looming over the next few days for UYG   ProShares Ultra Nasdaq Biotechnology  BIB  The ProShares Ultra Nasdaq Biotechnology is the double leveraged answer to the  2 37 billion iShares Nasdaq Biotechnology Index Fund  IBB    That means that IBB and its holdings such as Gilead Sciences  GILD   Amgen  AMGN  and Celgene  CELG  are the names traders in BIB will want to keep an eye on   One of the more obvious reasons to embrace BIB is that IBB is not just making new 52 highs  it is making all time highs  So are the other major non leveraged biotech ETFs such as the First Trust NYSE Arca Biotech Index Fund  FBT  and the SPDR S P Biotechnology ETF  XBI    Another reason to consider BIB is that biotech stocks have proven resilient to global macroeconomic headwinds  In other words  the sector s relatively low correlation to the S P 500 can be a good thing   ProShares UltraShort Yen  YCS  Alright  so we fibbed a bit because the ProShares UltraShort Yen is a bearish play on the yen  However  that means it is a bullish play on the U S  dollar against the Japanese currency   Technicalities aside  USD JPY is trading at its highest levels in nearly four years and the yen is battling with the British pound for the dubious honor of the world s worst performing developed market currency in 2013   Here is the lingering catalyst for YCS  though it will require hanging onto the ETF for a few weeks  The next Bank of Japan meeting is in early April and that will be the first with  presumably  Haruhio Kuroda at the helm  Prime Minister Shinzo Abe nominated Kuroda because the latter favors higher inflation and a weaker yen   Along those lines  it would not be surprising to see BoJ announce new monetary stimulus measures that go into effect soon after the April meeting  That means the yen likely falls and YCS keeps going higher By The ETF Professor,2013-03-08,Benzinga ,https://www.investing.com/analysis/soaring-stocks:-look-at-the-leveraged-etfs-158337,158337
151849,373365,AMGN,Top Trade Ideas For The Week Of August 20  2012  Bonus Idea,opinion,Here is your Bonus Idea with links to the full Top Ten  Amgen   AMGN Amgen  AMGN  is breaking resistance of a bull flag with a top at 84  The Measured move higher takes it to 92  The Relative Strength Index  RSI  that is bullish and holding supports more upside but the Moving Average Convergence Divergence indicator  MACD  that is negative is not as bullish  Holding at a shallow level it could sway either way  The Simple Moving Average  SMA  break the tie with a bias higher  There is no resistance higher and support lower is found at 80 40 and 76 followed by 73 40  71 and 67 60  Trade Idea 1  Buy the stock on a move over 84 with a  1 60 trailing stop Trade Idea 2  Buy the September 85 Calls  offered at  1 11 late Friday  on the same trigger Trade Idea 3  Buy the October 85 90 Call Spreads   1 42  on the same trigger Trade Idea 4  Sell the October 75 Puts   0 55  on the same trigger Trade idea 5  Buy the October 85 90 Call Spreads selling the October 75 Puts   0 87  on the same trigger Trade Idea 6  Buy the September October 87 5 Call Calendar   0 67  on the same trigger Trade Idea 7  Buy the September October 87 5 Call Calendar selling the October 75 Puts   0 12  on the same trigger After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Saturday which  heading into the back half of August has the markets looking very similar to last week s view  Gold and Crude Oil look best to continue higher  with a chance that Gold consolidates further The US Dollar Index looks to consolidate  but with an upward bias and Treasuries look to continue lower  The Shanghai Composite looks to set new multi year lows while Emerging Markets consolidate further before another upside move  Volatility looks to continue towards historic lows allowing for the Equity Index ETF s SPY  IWM and QQQ to continue their rise to multi year highs  The SPY looks the best  followed by the QQQ and then the IWM  which is still among some previous congestion  It seems only a hard reversal by Treasuries could derail this market now  Use this information as you prepare for the coming week and trade m well Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2012-08-21,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-august-20,-2012:-bonus-idea-133595",133595
151850,373366,AMGN,3 Biopharma Trades Poised For Strong Short Term Gains,opinion,Zogenix  ZGNX  engages in the development and commercialization of products for the treatment of central nervous system disorders and pain  Its commercial product includes Sumavel DosePro  sumatriptan injection   a delivery system that offers needle free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache  The company s lead product candidate  Zohydro  is a single entity extended release hydrocodone  which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around the clock opioid therapy  Zogenix is facing an FDA Advisory Committee  for its drug  Zohydro ER  hydrocodone bitartrate extended release capsules  on December 7  2012  with an assigned PDUFA date of March 1  2013 Zohydro ER could be the first hydrocodone product to offer the benefit of less frequent dosing and the ability to treat chronic pain patients without the risk of liver injury associated with the use of acetaminophen in high dosages or over long periods of time  Zohydro ER would also be the first long acting hydrocodone based solution that is not combined with another pain relieving drug  Currently  hydrocodone is only available in immediate release  combination products  most commonly with the prior mentioned analgesic acetaminophen  These products require dosing every 4 to 6 hours  In early September  Endo Health Solutions  ENDP  announced that a subsidiary issued a  for one lot of its hydrocodone bitartrate and acetaminophen tablets  saying it s possible that some tablets exceed the weight specification and could be super potent  The increased acetaminophen content could result in liver toxicity  especially in patients on other medications containing acetaminophen  patients with liver dysfunction  or people who consume more than 3 alcoholic beverages a day  Endo s drug here clearly had an issue with liver toxicity as I mentioned prior as a concern with acetaminophen  This is all the more reason I feel Zohydro could be a potential large revenue generator for the company  Zalicus Inc   ZLCS  announced on August 27th that the FDA approved the supplemental new drug application  SNDA  filed by Mallinckrodt Inc   a subsidiary of Covidien plc  for the 32 mg dose strength of Exalgo  hydromorphone HCl  Extended Release Tablets  This drug is for the management of moderate to severe pain in patients requiring continuous  around the clock opioid analgesia for an extended period of time  Exalgo provides time release of hydromorphone throughout the day once a steady state is achieved after three to four days  I like Zalcius s pain killing solution here  but unfortunately for the company  it receives a very small royalty from Covidien  Both Zohydro and Exalgo represent a time released solution for patients with pain who are opioid tolerant  Existing hydrocodone containing pain relievers generate about  3 5 billion in U S  sales  Even taking a small slice of this large market  Zohydro s sales could reach  500M to  800M in my estimation  if ultimately approved by the FDA The chart above shows that the stock has strong mid term up trend support and is currently in a near term up channel making higher highs and higher lows  The price should at least touch  2 85  the 61 8  retrace point and up channel resistance   and a move over  3 is within reach as traders anticipate this Friday s FDA s Advisory Committee  Adcomm  meeting in which committee members will vote whether or not to recommend Zohydro for approval  Cyclacel Pharma  CYCC  engages in developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases  Its core area of expertise is in cell cycle biology where the company focuses primarily on the development of orally available anticancer agents that target the cell cycle with the aim of slowing progression or shrinking the size of tumors  In addition  the company looks to enhance the quality of life while improving survival rates of cancer patients  Cyclacel s lead drug candidate is Sapacitabine  a drug undergoing research for potential use in treating blood and other types of cancers  The company s other product is Seliciclib  CYC202   a CDK  cyclin dependent kinase  inhibitor that is in a Phase IIb clinical trial for the treatment of NSCLC  The drug is also in Phase II clinical trials to treat nasopharyngeal cancer as well as Phase I clinical trials in combination with Sapacitabine to treat cancer  Sapacitabine is an oral nucleoside analog pro drug that acts through a dual mechanism  I find this oral dosing to be a big benefit if proven effective as most everyone understands the terrible side effects common from typical chemotherapy and other cancer treatments  The compound interferes with DNA synthesis by causing single strand DNA breaks and induces arrest of the cell division cycle at the G2 phase  Sapacitabine has demonstrated potent anti tumor activity in both blood and solid tumors in preclinical studies  In a liver metastatic mouse model  Sapacitabine was shown to be superior to Gemcitabine  marketed as Gemzar by Eli Lilly  LLY   in delaying the onset and growth of liver metastasis  Sapacitabine oral capsules are currently involved in the following  The SEAMLESS Phase III trial being conducted under a special protocol assessment with the FDA as front line treatment of acute myeloid leukemia  AML  in the elderly Phase II studies for myelodysplastic syndromes  MDS  and solid tumors including lung cancer Investigator led studies such as a Phase II III comparing sapacitabine to low dose cytarabine as front line treatment of elderly patients with AML or high risk MDS unfit for intensive chemotherapy  and a Phase II study in chronic lymphocytic leukemia In an   Cyclacel announced positive Phase II study results from Sapacitabine  The company reported that the drug nearly doubled the expected survival rate in elderly patients with MDS after front line therapy failure  One of these front line treatment examples is Azacitidine  marketed as Vidaza by Celgene  CELG   I looked at what the sales were for Vidaza since it can demonstrate the opportunities out there for Cyclacel  In the third quarter alone  Vidaza  had sales of  220 million  which obviously translates to close to a billion dollars when averaged out over the course of an entire year  Another example of a front line treatment is Dacogen from Astex Pharmaceuticals  ASTX   Prior to the press release  the data was discussed at The Eighth Annual Hematologic Malignancies 2012 Conference being held on October 10 14  2012  in Houston  Texas  Median overall survival to date for all 63 patients in the Phase II study is 252 days or approximately 8 months  Median overall survival for 41 out of 63 patients with 10  or more blasts in their bone marrow is 274 days or approximately 9 months  Median survival for patients with intermediate 2 or high risk disease  as defined by the International Prognostic Scoring System  IPSS   is 4 3 to 5 6 months  I thought The Life Sciences Report  TLSR  had an excellent  with John McCamant   JM  editor of the Medical Technology Stock Letter  During this interview  questions were raised related to blood cancers and potential investments in this area as well as highlighting this landscape as an unmet medical need  John believes MDS and AML represent nice opportunities for investors  One exchange from the interview in particular between John  JM  and The Life Sciences Report  TLSR  highlights Cyclacel from a valuation perspective and related to the press release I mentioned earlier  TLSR  We just got some news from Cyclacel  It announced data in an ongoing Phase II trial with sapacitabine for older patients with MDS who had failed azacitidine and or decitabine  Expected survival rates were doubled  What is your opinion on this study  JM  We looked at some of the data  and the data looks solid  particularly with the Phase III trial ongoing in AML  That makes a difference for us  The key is the larger Phase III trial with AML  The potential gives the Street and analysts a little more confidence  The Phase II MDS trial does not use a placebo as the control arm  as it would be unethical to not use standard of care in elderly and frail patients  We also know that other trials are coming  using the Cyclacel compound in similar cancers  The data have been good to date  and the stock has responded nicely  We look forward to viewing the Phase III data in AML  TLSR  Do you cover Cyclacel in your newsletter  JM  No  but we ve followed Cyclacel over the years  Frankly  it has been slow in development  but things seem to be accelerating  and the valuation looks pretty attractive right now  The company is a little low on cash  so we would not be surprised to see it trying to raise some capital  Also  it does not yet have a partner  which would help validate the technology  But it has a pretty good development team and a very nice pedigree  with Christopher Henney  a co founder of Dendreon Corp   DNDN  and Immunex Corp   acquired by Amgen  AMGN  for  16 billion in 2002   as a board member  We re going to do a little more homework on Cyclacel  We are trying to sit down with management and get its take on what s going on as the company moves forward  TLSR  Because of the recent data  Cyclacel s stock is up sharply over the last month  However  even with its performance  the company only has a  46 million   46M  market cap  JM  That s the key number  We can talk about share prices and all these other numbers  but that market cap really dials us in  For a Phase III cancer company  that s an unusual valuation  The recent price rise probably increases the odds that the company can go out and raise some money  But Wall Street is skeptical when it comes to unpartnered small biotech companies  It is hard for these types of companies to gain traction or get any visibility  At the end of the day  if Cyclacel keeps doing its job and delivering good data  valuation will take care of itself  TLSR  Can you speak to Astex Pharmaceuticals  formerly SuperGen Inc    It is also heavily involved in the heme onc space  JM  Astex is a different type of company  It has been around for quite some time under a different name  It made a good move when it merged with a British company and acquired a platform technology  Now Astex appears to be making some moves forward in the heme onc space  That being said  we re looking at a much different valuation  TLSR  A  276M market cap  right  JM  The market cap is five times that of Cyclacel  But Astex has an approved MDS product    decitabine   and it generates some revenue with that product  Management is solid  Generally  investors want an exciting molecule rather than a revenue producing  older cancer drug  It can be difficult running two different companies at the same time   one having a sales organization out there marketing  and the other focusing on research and development  It is a lot for a smaller company to manage effectively  TLSR  Dacogen is a DNA methyltransferase inhibitor used in MDS and AML  If Cyclacel gets sapacitabine approved for those indications  how much would that eat into Dacogen revenues  JM  Quite possibly a good bit  because we are talking about a novel oral compound from Cyclacel  Safety is more important in these elderly patients  but efficacy is needed  TLSR  Would you consider following Astex in your newsletter  JM  We have been tracking it off and on  We ve known the company as SuperGen  from back in the day  But we have learned to never say never  The acquisition of Astex Pharmaceuticals  the British company mentioned above  SuperGen changed its name to Astex following the merger   with its discovery platform  is intriguing to us  It looks like the lead molecules make sense and are in the right cancer space  But the company has a different valuation than Cyclacel  We ll do some work here  but it looks like the more exciting molecule might be at Cyclacel  I think the above speaks rather clearly on the potential Cyclacel offers here  However  as with most small cap biopharmas  there is no guarantee of success    with larger risk comes larger reward  and I think Cyclacel might offer such a reward for those willing to take the longer term buy and hold risk   The chart above shows the stock is sitting between the 50  and 61 8  retrace points after coming down from a very strong up channel  It now appears to have found new footing with a new uptrend line  I believe the stock is poised to test the  6 50 level soon  after yesterday s big move up  MEI Pharma  MEIP  MEI focuses on the clinical development of therapeutics for the treatment of cancer  It develops various lead drug candidates  including ME 143 that has completed Phase I clinical trials in patients with refractory solid tumors  ME 344  an active metabolite of NV 128  which is in Phase I clinical trials in patients with solid refractory tumors  and Pracinostat  an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders  On 11 6 12  the company  it will be presenting data on Pracinostat  in combination with Azacitidine in patients with advanced myelodysplastic syndrome at a poster presentation at the American Society of Hematology Annual Meeting on December 10  2012  The company also recently  that its lead mitochondrial inhibitor drug candidate  ME 344  has been named one of the Top 10 most licensable oncology products to watch for in 2012 by Elsevier Business Intelligence and Campbell Alliance  MEI has some interesting things going on for it  the most important being the poster presentation coming up on Monday  December 10th  at 6 PM eastern time  An abstract of the presentation  entitled   Very high rates of clinical and cytogenetic response with the combination of the histone deacetylase inhibitor Pracinostat  SB939  and 5 azacitidine in high risk myelodysplastic syndrome   submitted by Dr  Quintas Cardama and Dr  Garcia Manero of the MD Anderson Cancer Center  is available online at   Pracinostat has been tested in more than 150 patients in multiple Phase I and signal seeking Phase II clinical trials and found to be generally well tolerated with readily manageable side effects often associated with drugs of this class  including fatigue  The results of these studies suggest that Pracinostat has potential  when compared to other oral HDAC inhibitors  Pracinostat has demonstrated clinical evidence of single agent activity  including studies in patients with advanced hematologic disorders such as acute myeloid leukemia and myelodysplastic syndrome  The results of these studies were presented at the 2010 American Society of Hematology Annual Meeting  In addition  data from a Phase II clinical trial of oral Pracinostat showed activity in heavily pre treated patients with intermediate or high risk myelofibrosis  with two patients showing a clinical improvement  These results were published in the September 2012 issue of   Pracinostat has also shown evidence of activity when used in combination with a wide range of therapies in clinical and pre clinical studies  Recently published pre clinical data in the May 2012 issue of  demonstrated synergistic activity when Pracinostat was combined with Pacritinib  an experimental Janus kinase 2  JAK2  inhibitor  Daniel P  Gold  Ph D   President and Chief Executive Officer of MEI Pharma  We are very encouraged not only by the response rates reported to date  but also by the rapid appearance of the responses with the combination of Pracinostat and Azacitidine  These data are particularly compelling given that most patients in the study had treatment related MDS and expressed high risk cytogenetic abnormalities  both of which carry a poor prognosis  With these data in hand  combined with the capital raise we announced yesterday  11 5 12   we expect to be in a position to rapidly advance to the next stage of development and initiate a randomized Phase II trial of Pracinostat in combination with Azacitidine in patients with MDS by the second quarter of next year  The American Society of Hematology Annual Meeting is sure to get MEI some coverage here  and potentially positive data could rally the stock significantly higher than its current price level  Therefore  I bought some shares of it as a catalyst trade   The stock appears to consolidating in a pennant  which indicates it can make another nice run  It hasn t gone parabolic yet  and it still remains in a nice up channel  I would expect volume to pick up as the company nears the 12 10 12 trade catalyst event  with a move in the stock to around  2 25  Disclosure  I am long  MEIP  Disclaimer  This article is intended for informational and entertainment use only  and should not be construed as professional investment advice  They are my opinions only  Trading stocks is risky    always be sure to know and understand your risk tolerance  You can incur substantial financial losses in any trade or investment  Always do your own due diligence before buying and selling any stock  and or consult with a licensed financial adviser ,2012-12-04,Scott Matusow,https://www.investing.com/analysis/3-biopharma-trades-poised-for-strong-short-term-gains-145998,145998
151851,373367,AMGN,Cytos Biotechnology  Investment Case Hinges On Phase IIB Trial ,opinion,A new dawning   Cytos Biotechnology s  CYTN SW  investment case hinges on how its main asset  CYT003  progresses through a Phase IIb trial in allergic asthma  The company navigated its way through a funding crunch and now has sufficient cash to conduct the trial  Initial data from the study is expected in H114  Convertible notes and bonds are due for repayment in February 2015  However  if the trial is positive  we believe that current financing structures should mean that debt will be converted or repaid without difficulty  and that Cytos will have sufficient time to out license the product CYT003 set to start Phase IIb trialCytos s lead compound CYT003 is poised to start a 360 patient Phase IIb study in allergic asthma  CYT003 modifies the T cell immune response and targets asthma patients who are poorly controlled on existing therapies  An earlier 60 patient randomised and placebo controlled Phase IIa trial produced sufficiently encouraging results to interest new investors into refinancing the company Investor confidence being restoredThe past year has seen the company restructured  costs were slashed and new management introduced  with new investors brought in  The February 2012 convertible expiry was a major concern during 2011  despite the positive CYT003 Phase IIa data presented in 2010  but the convertible debt has been restructured Funded through to key value inflection pointA total of CHF35m in debt and equity has been raised  in H112  so that Cytos should have sufficient capital to complete the Phase IIb trail and have time to out license CYT003 if the trial is positive  Much of the new investments have come from a consortium of new investors including Amgen  The structuring of the combination of equity  warrants and convertible loan notes is such that Cytos s potential efforts to out license CYT003 should not be hindered by the convertible debt that needs to be repaid in February 2015 Valuation  Undervalued on most scenariosWe currently value Cytos at CHF98m  CHF4 36 per share   This centres on CYT003  worth CHF75m in our model  together with net cash of CHF6 0m  If CYT003 makes suitable progress  the value of Cytos s pipeline would rise to between CHF209m and CHF297m in FY14  which equates to between CHF4 89 and CHF6 79 per share depending on the conversion of loan notes and exercising of outstanding warrants To Read the Entire Report Please Click on the pdf File Below ,2012-12-13,Edison,https://www.investing.com/analysis/cytos-biotechnology:-investment-case-hinges-on-phase-iib-trial-147503,147503
151865,373381,AMGN,Best And Worst ETFs  And Mutual Funds   Health Care Sector,opinion,The Health Care sector ranks 2nd out of the ten sectors as detailed in my   It gets my Neutral rating  which is based on aggregation of ratings of 22 ETFs and 86 mutual funds in the Health Care sector as of April 13  2012    Figures 1 and 2 show the five best and worst rated ETFs and mutual funds in the sector  The best ETFs and mutual funds allocate more value to Attractive or better rated stocks than the worst ETFs and mutual funds  which allocate too much value to Neutral or worse rated stocks    To identify the best and avoid the worst ETFs and mutual funds within the Health Care sector  investors need a predictive rating based on  1  stocks ratings of the holdings and  2  the all in expenses of each ETF and mutual fund  Investors need not rely on backward looking ratings    Investors seeking exposure to the Health Care sector should buy one of the Attractive or better rated ETFs or mutual funds from Figures 1 and 2  My ratings and free reports on all ETFs and mutual funds in this sector are available on my free ETF and mutual fund screener    Figure 1  ETFs with the Best   Worst Ratings   Top 5 Best ETFs exclude ETFs with TNA s less than 100 million for inadequate liquidity Sources  New Constructs  LLC and company filingsFocus Morningstar Health Care Index ETF  s  FHC  is excluded from Figure 1 because its total net assets  TNA  are below  100 million so it does not meet our liquidity standards Figure 2  Mutual Funds with the Best   Worst Ratings   Top 5 Best mutual funds exclude funds with TNA s less than 100 million for inadequate liquidity    Sources  New Constructs  LLC and company filings   Icon Funds  ICON Healthcare Funds  s  ICHCX  and  s  ICHEX  are excluded from Figure 2 because their total net assets  TNA  are below  100 million so they do not meet our liquidity standards    Health Care Select Sector SPDR  s  XLV  is my top rated Health Care ETF and Vanguard World Funds  Vanguard Health Care Index Fund  s  VHCIX  is my top rated Health Care mutual fund  Both earn an Attractive or better rating  In fact  XLV is the only ETF I cover to earn my Very Attractive rating    Amgen Inc  s  AMGN  is one of my favorite stocks held by Health Care ETFs and mutual funds and earns my Very Attractive rating  AMGN offers a strong business model with a ROIC above 14  for the last 7 years  an achievement matched by less than 4  companies in the Russell 3000 over the same time  AMGN s current valuation at  66 92 implies a permanent 40  decline in profits  Strong profits and low expectations for future profitability offer appealing risk reward to investors    First Trust NYSE Arca Biotechnology Index Fund  s  FBT  is my worst rated Health Care ETF  and Fidelity Advisor Series VII  Fidelity Advisor Biotechnology Fund  s  FBTAX  is my worst rated Health Care mutual fund  Both earn a Dangerous or worse rating    Amylin Pharmaceuticals  Inc  s  AMLN  is one of my least favorite stocks held by Health Care ETFs and mutual funds  It gets my Dangerous rating  The company is a value destroyer  Not once  over the 14 years I ve covered the company  has it generated a return on invested capital  ROIC  that meets its weighted average cost of capital  WACC   To justify its current valuation of   23 7 share  the company would have to grow its revenues by 20  compounded annually for 20 years while also raising its ROIC from 3  to over 11   With so much profit growth already baked into the current valuation  I find it difficult to believe the stock has much upside    Figure 3 shows that 89 out of the 353 stocks  over 57  of the total net assets  held by Health Care ETFs and mutual funds get an Attractive or better rating  However  only 4 out of 22 Health Care ETFs  45  of total net assets  and 5 out of 86 Health Care mutual funds  less than 56  of total net assets  get an Attractive or better rating    The takeaway is  most mutual fund managers allocate too much capital to low quality stocks but investors do a great job identifying the Health Care ETFs and mutual funds with great portfolio management and low costs  Figure 3 shows that 45  of the value of ETFs and 56  of the value of mutual funds are allocated to Attractive or better rated ETFs and mutual funds    Figure 3  Health Care Sector Landscape For ETFs  Mutual Funds   Stocks  Sources  New Constructs  LLC and company filings   Investors need to tread carefully when considering Health Care ETFs and mutual funds  The sector does offer 9 investments worthy ETFs and mutual funds but is flooded with 99 ETFs and mutual funds that should be avoided  Figures 4 and 5 show the rating landscape of all Health Care ETFs and mutual funds    As detailed in     the fund industry offers many cheap funds but very few funds with high quality stocks  or with what I call good portfolio management    Figures 4 and 5 show the rating landscape of all Health Care ETFs and mutual funds    Our sector roadmap report ranks all sectors and highlights those that offer the best investments    Figure 4  Separating the Best ETFs From the Worst ETFs Sources  New Constructs  LLC and company filingsFigure 5  Separating the Best Mutual Funds From the Worst Mutual Funds Sources  New Constructs  LLC and company filings   Disclosure  I receive no compensation to write about any specific stock  sector or theme ,2012-04-18,David Trainer,https://www.investing.com/analysis/best-and-worst-etfs-(and-mutual-funds):-health-care-sector-120482,120482
